Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-Protein
conjugation	O
pathway	O
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
that	B-X
can	B-X
be	B-X
covalently	B-X
conjugated	B-X
to	B-X
a	B-X
limited	B-X
number	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Cdc53/cullin	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
NEDD8	B-X
is	B-X
efficiently	B-X
processed	B-X
to	B-X
expose	B-X
Gly-76	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
conjugation	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
Human	B-X
UBA3	B-X
could	B-X
be	B-X
precipitated	B-X
with	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-NEDD8	B-X
,	B-X
but	B-X
not	B-X
with	B-X
GST-ubiquitin	B-X
or	B-X
GST-sentrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
human	B-X
UBA3	B-X
could	B-X
form	B-X
a	B-X
beta-mercaptoethanol-sensitive	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
APP-BP1	B-X
,	B-X
a	B-X
protein	B-X
with	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
N-terminal	B-X
half	B-X
of	B-X
ubiquitin-activating	B-X
enzyme	B-X
.	B-X
We	B-X
have	B-X
also	B-X
cloned	B-X
human	B-X
UBC12	B-X
and	B-X
demonstrated	B-X
that	B-X
it	B-X
could	B-X
form	B-X
a	B-X
thiol	B-X
ester	B-X
linkage	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
activating	B-X
enzyme	B-X
complex	B-X
.	B-X
Identification	B-X
of	B-X
the	B-X
activating	B-X
and	B-X
conjugating	B-X
enzymes	B-X
of	B-X
the	B-X
NEDD8	B-X
conjugation	B-X
pathway	B-X
should	B-X
allow	B-X
for	B-X
a	B-X
more	B-X
detailed	B-X
study	B-X
of	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X

NEDD8	B-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
that	O
can	O
be	O
covalently	O
conjugated	O
to	O
a	O
limited	O
number	O
of	O
cellular	O
proteins	O
,	O
such	O
as	O
Cdc53	B-Protein
/	O
cullin	O
.	O
<EOS>	B-X
NEDD8	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
that	B-X
can	B-X
be	B-X
covalently	B-X
conjugated	B-X
to	B-X
a	B-X
limited	B-X
number	B-X
of	B-X
cellular	B-X
proteins	B-X
,	B-X
such	B-X
as	B-X
Cdc53/cullin	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
NEDD8	B-X
is	B-X
efficiently	B-X
processed	B-X
to	B-X
expose	B-X
Gly-76	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
conjugation	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
Human	B-X
UBA3	B-X
could	B-X
be	B-X
precipitated	B-X
with	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-NEDD8	B-X
,	B-X
but	B-X
not	B-X
with	B-X
GST-ubiquitin	B-X
or	B-X
GST-sentrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
human	B-X
UBA3	B-X
could	B-X
form	B-X
a	B-X
beta-mercaptoethanol-sensitive	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
APP-BP1	B-X
,	B-X
a	B-X
protein	B-X
with	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
N-terminal	B-X
half	B-X
of	B-X
ubiquitin-activating	B-X
enzyme	B-X
.	B-X
We	B-X
have	B-X
also	B-X
cloned	B-X
human	B-X
UBC12	B-X
and	B-X
demonstrated	B-X
that	B-X
it	B-X
could	B-X
form	B-X
a	B-X
thiol	B-X
ester	B-X
linkage	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
activating	B-X
enzyme	B-X
complex	B-X
.	B-X
Identification	B-X
of	B-X
the	B-X
activating	B-X
and	B-X
conjugating	B-X
enzymes	B-X
of	B-X
the	B-X
NEDD8	B-X
conjugation	B-X
pathway	B-X
should	B-X
allow	B-X
for	B-X
a	B-X
more	B-X
detailed	B-X
study	B-X
of	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
health	B-X
and	B-X
disease	B-X
.	B-X

We	O
have	O
previously	O
reported	O
that	O
the	O
C	O
terminus	O
of	O
NEDD8	B-Protein
is	O
efficiently	O
processed	O
to	O
expose	O
Gly	O
-	O
76	O
,	O
which	O
is	O
required	O
for	O
conjugation	O
to	O
target	O
proteins	O
.	O

A	O
combination	O
of	O
data	O
base	O
searches	O
and	O
polymerase	O
chain	O
reaction	O
cloning	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
human	O
UBA3	B-Protein
,	O
which	O
is	O
38	O
%	O
identical	O
to	O
the	O
yeast	O
homologue	O
,	O
22	O
%	O
identical	O
to	O
human	O
UBA2	B-Protein
,	O
and	O
19	O
%	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
region	O
of	O
human	O
UBE1	B-Protein
.	O

The	O
human	O
UBA3	B-Protein
gene	O
is	O
located	O
on	O
chromosome	O
3p13	O
and	O
gave	O
rise	O
to	O
a	O
2	O
.	O
2	O
-	O
kilobase	O
pair	O
transcript	O
that	O
was	O
detected	O
in	O
all	O
tissues	O
.	O
<EOS>	B-X
A	B-X
combination	B-X
of	B-X
data	B-X
base	B-X
searches	B-X
and	B-X
polymerase	B-X
chain	B-X
reaction	B-X
cloning	B-X
was	B-X
used	B-X
to	B-X
identify	B-X
a	B-X
cDNA	B-X
encoding	B-X
human	B-X
UBA3	B-X
,	B-X
which	B-X
is	B-X
38	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
yeast	B-X
homologue	B-X
,	B-X
22	B-X
%	B-X
identical	B-X
to	B-X
human	B-X
UBA2	B-X
,	B-X
and	B-X
19	B-X
%	B-X
identical	B-X
to	B-X
the	B-X
C-terminal	B-X
region	B-X
of	B-X
human	B-X
UBE1	B-X
.	B-X
The	B-X
human	B-X
UBA3	B-X
gene	B-X
is	B-X
located	B-X
on	B-X
chromosome	B-X
3p13	B-X
and	B-X
gave	B-X
rise	B-X
to	B-X
a	B-X
2.2-kilobase	B-X
pair	B-X
transcript	B-X
that	B-X
was	B-X
detected	B-X
in	B-X
all	B-X
tissues	B-X
.	B-X
Human	B-X
UBA3	B-X
could	B-X
be	B-X
precipitated	B-X
with	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-NEDD8	B-X
,	B-X
but	B-X
not	B-X
with	B-X
GST-ubiquitin	B-X
or	B-X
GST-sentrin-1	B-X
.	B-X
Moreover	B-X
,	B-X
human	B-X
UBA3	B-X
could	B-X
form	B-X
a	B-X
beta-mercaptoethanol-sensitive	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
APP-BP1	B-X
,	B-X
a	B-X
protein	B-X
with	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
N-terminal	B-X
half	B-X
of	B-X
ubiquitin-activating	B-X
enzyme	B-X
.	B-X
We	B-X
have	B-X
also	B-X
cloned	B-X
human	B-X
UBC12	B-X
and	B-X
demonstrated	B-X
that	B-X
it	B-X
could	B-X
form	B-X
a	B-X
thiol	B-X
ester	B-X
linkage	B-X
with	B-X
NEDD8	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
activating	B-X
enzyme	B-X
complex	B-X
.	B-X

Human	O
UBA3	B-Protein
could	O
be	O
precipitated	O
with	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
NEDD8	B-Protein
,	O
but	O
not	O
with	O
GST	B-Protein
-	O
ubiquitin	B-Protein
or	O
GST	B-Protein
-	O
sentrin	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Sentrin	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
that	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
death	B-X
domains	B-X
of	B-X
Fas	B-X
and	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
1	B-X
(	B-X
TNFR1	B-X
)	B-X
,	B-X
PML	B-X
,	B-X
Rad51	B-X
,	B-X
Rad52	B-X
,	B-X
and	B-X
RanGAP1	B-X
.	B-X
We	B-X
have	B-X
reported	B-X
previously	B-X
that	B-X
sentrin	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
other	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
protein	B-X
ubiquitination	B-X
(	B-X
Kamitani	B-X
,	B-X
T.	B-X
,	B-X
Nguyen	B-X
,	B-X
H.	B-X
P.	B-X
,	B-X
and	B-X
Yeh	B-X
,	B-X
E.	B-X
T.	B-X
H.	B-X
(	B-X
1997	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
272	B-X
,	B-X
14001-14004	B-X
)	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
conserved	B-X
C-terminal	B-X
Gly-Gly	B-X
residues	B-X
are	B-X
required	B-X
for	B-X
sentrinization	B-X
to	B-X
occur	B-X
.	B-X
To	B-X
identify	B-X
enzymes	B-X
which	B-X
play	B-X
a	B-X
role	B-X
in	B-X
sentrinization	B-X
,	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
human	B-X
placenta	B-X
cDNA	B-X
library	B-X
using	B-X
sentrin	B-X
as	B-X
bait	B-X
.	B-X
A	B-X
strong	B-X
positive	B-X
interacting	B-X
clone	B-X
was	B-X
found	B-X
to	B-X
contain	B-X
a	B-X
cDNA	B-X
insert	B-X
encoding	B-X
the	B-X
ubiquitin-conjugating	B-X
enzyme	B-X
,	B-X
Ubc9	B-X
.	B-X
The	B-X
interaction	B-X
between	B-X
sentrin	B-X
and	B-X
Ubc9	B-X
required	B-X
the	B-X
ubiquitin	B-X
domain	B-X
and	B-X
the	B-X
C-terminal	B-X
Gly-Gly	B-X
residues	B-X
of	B-X
sentrin	B-X
.	B-X
This	B-X
interaction	B-X
appears	B-X
to	B-X
be	B-X
specific	B-X
because	B-X
sentrin	B-X
could	B-X
only	B-X
interact	B-X
weakly	B-X
with	B-X
UbcH5B	B-X
,	B-X
but	B-X
could	B-X
not	B-X
interact	B-X
with	B-X
HHR6B	B-X
,	B-X
UbcH6	B-X
nor	B-X
E2-EPF	B-X
.	B-X
In	B-X
vitro	B-X
translated	B-X
sentrin	B-X
could	B-X
be	B-X
precipitated	B-X
by	B-X
a	B-X
GST-Ubc9	B-X
fusion	B-X
protein	B-X
,	B-X
but	B-X
not	B-X
by	B-X
glutathione	B-X
S-transferase	B-X
.	B-X
A	B-X
beta-mercaptoethanol-sensitive	B-X
Ubc9-sentrin	B-X
conjugate	B-X
could	B-X
also	B-X
be	B-X
identified	B-X
in	B-X
the	B-X
in	B-X
vitro	B-X
binding	B-X
assay	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
conserved	B-X
cysteine	B-X
residue	B-X
of	B-X
Ubc9	B-X
by	B-X
serine	B-X
abolished	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
Ubc9-sentrin	B-X
conjugate	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
Ubc9	B-X
is	B-X
a	B-X
strong	B-X
candidate	B-X
to	B-X
be	B-X
the	B-X
key	B-X
conjugating	B-X
enzyme	B-X
in	B-X
the	B-X
sentrinization	B-X
pathway	B-X
.	B-X

Moreover	O
,	O
human	O
UBA3	B-Protein
could	O
form	O
a	O
beta	O
-	O
mercaptoethanol	O
-	O
sensitive	O
conjugate	O
with	O
NEDD8	B-Protein
in	O
the	O
presence	O
of	O
APP	B-Protein
-	I-Protein
BP1	I-Protein
,	O
a	O
protein	O
with	O
sequence	O
homology	O
to	O
the	O
N	O
-	O
terminal	O
half	O
of	O
ubiquitin	O
-	O
activating	O
enzyme	O
.	O

We	O
have	O
also	O
cloned	O
human	O
UBC12	B-Protein
and	O
demonstrated	O
that	O
it	O
could	O
form	O
a	O
thiol	O
ester	O
linkage	O
with	O
NEDD8	B-Protein
in	O
the	O
presence	O
of	O
the	O
activating	O
enzyme	O
complex	O
.	O

Identification	O
of	O
the	O
activating	O
and	O
conjugating	O
enzymes	O
of	O
the	O
NEDD8	B-Protein
conjugation	O
pathway	O
should	O
allow	O
for	O
a	O
more	O
detailed	O
study	O
of	O
the	O
role	O
of	O
NEDD8	B-Protein
modification	O
in	O
health	O
and	O
disease	O
.	O

Correlation	O
between	O
MRI	O
and	O
clinico	O
-	O
pathological	O
manifestations	O
in	O
Lewis	O
rats	O
protected	O
from	O
experimental	O
allergic	O
encephalomyelitis	O
by	O
acylated	O
synthetic	O
peptide	O
of	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
.	O
<EOS>	B-X
Experimental	B-X
allergic	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
which	B-X
constitutes	B-X
an	B-X
accepted	B-X
animal	B-X
model	B-X
for	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
neuroinflammation	B-X
associated	B-X
with	B-X
the	B-X
acute	B-X
form	B-X
can	B-X
be	B-X
detected	B-X
with	B-X
T2-weighted	B-X
,	B-X
T1-weighted	B-X
and	B-X
diffusion	B-X
MRI	B-X
,	B-X
and	B-X
blood-brain	B-X
barrier	B-X
changes	B-X
can	B-X
be	B-X
investigated	B-X
with	B-X
Gd-DTPA-enhanced	B-X
T1-weighted	B-X
imaging	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
MS	B-X
patients	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
of	B-X
myelin	B-X
basic	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
encephalitogenic	B-X
for	B-X
the	B-X
Lewis	B-X
rat	B-X
(	B-X
MBP	B-X
68-86	B-X
)	B-X
was	B-X
acylated	B-X
by	B-X
the	B-X
attachment	B-X
of	B-X
a	B-X
palmitoyl	B-X
residue	B-X
(	B-X
PAL68-86	B-X
)	B-X
,	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
confer	B-X
almost	B-X
complete	B-X
protection	B-X
against	B-X
EAE	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rats	B-X
before	B-X
and	B-X
after	B-X
an	B-X
encephalitogenic	B-X
challenge	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
treatment	B-X
of	B-X
Lewis	B-X
rats	B-X
with	B-X
PAL68-86	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
clinical	B-X
signs	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
after	B-X
challenge	B-X
with	B-X
the	B-X
native	B-X
peptide	B-X
(	B-X
p68-86	B-X
)	B-X
in	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
(	B-X
CFA	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
considerably	B-X
the	B-X
MRI	B-X
and	B-X
histopathological	B-X
signs	B-X
of	B-X
the	B-X
disease	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
quantitative	B-X
MRI	B-X
measurements	B-X
correlate	B-X
very	B-X
well	B-X
with	B-X
the	B-X
reduced	B-X
cellular	B-X
infiltration	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
signs	B-X
in	B-X
the	B-X
EAE-protected	B-X
animal	B-X
.	B-X

Experimental	O
allergic	O
encephalomyelitis	O
(	O
EAE	O
)	O
is	O
an	O
autoimmune	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
which	O
constitutes	O
an	O
accepted	O
animal	O
model	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O
<EOS>	B-X
Experimental	B-X
allergic	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
which	B-X
constitutes	B-X
an	B-X
accepted	B-X
animal	B-X
model	B-X
for	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
disease	B-X
can	B-X
take	B-X
an	B-X
acute	B-X
or	B-X
chronic	B-X
form	B-X
depending	B-X
on	B-X
the	B-X
injection	B-X
route	B-X
,	B-X
animal	B-X
strain	B-X
and	B-X
nature	B-X
of	B-X
the	B-X
disease-inducing	B-X
antigen	B-X
administered	B-X
.	B-X
The	B-X
neuroinflammation	B-X
associated	B-X
with	B-X
the	B-X
acute	B-X
form	B-X
can	B-X
be	B-X
detected	B-X
with	B-X
T2-weighted	B-X
,	B-X
T1-weighted	B-X
and	B-X
diffusion	B-X
MRI	B-X
,	B-X
and	B-X
blood-brain	B-X
barrier	B-X
changes	B-X
can	B-X
be	B-X
investigated	B-X
with	B-X
Gd-DTPA-enhanced	B-X
T1-weighted	B-X
imaging	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
MS	B-X
patients	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
of	B-X
myelin	B-X
basic	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
encephalitogenic	B-X
for	B-X
the	B-X
Lewis	B-X
rat	B-X
(	B-X
MBP	B-X
68-86	B-X
)	B-X
was	B-X
acylated	B-X
by	B-X
the	B-X
attachment	B-X
of	B-X
a	B-X
palmitoyl	B-X
residue	B-X
(	B-X
PAL68-86	B-X
)	B-X
,	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
confer	B-X
almost	B-X
complete	B-X
protection	B-X
against	B-X
EAE	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rats	B-X
before	B-X
and	B-X
after	B-X
an	B-X
encephalitogenic	B-X
challenge	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
treatment	B-X
of	B-X
Lewis	B-X
rats	B-X
with	B-X
PAL68-86	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
clinical	B-X
signs	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
after	B-X
challenge	B-X
with	B-X
the	B-X
native	B-X
peptide	B-X
(	B-X
p68-86	B-X
)	B-X
in	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
(	B-X
CFA	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
considerably	B-X
the	B-X
MRI	B-X
and	B-X
histopathological	B-X
signs	B-X
of	B-X
the	B-X
disease	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
quantitative	B-X
MRI	B-X
measurements	B-X
correlate	B-X
very	B-X
well	B-X
with	B-X
the	B-X
reduced	B-X
cellular	B-X
infiltration	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
signs	B-X
in	B-X
the	B-X
EAE-protected	B-X
animal	B-X
.	B-X

The	O
disease	O
can	O
take	O
an	O
acute	O
or	O
chronic	O
form	O
depending	O
on	O
the	O
injection	O
route	O
,	O
animal	O
strain	O
and	O
nature	O
of	O
the	O
disease	O
-	O
inducing	O
antigen	O
administered	O
.	O
<EOS>	B-X
Diverticular	B-X
disease	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
conditions	B-X
in	B-X
the	B-X
Western	B-X
world	B-X
and	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
findings	B-X
identified	B-X
at	B-X
colonoscopy	B-X
.	B-X
Recently	B-X
,	B-X
there	B-X
has	B-X
been	B-X
a	B-X
significant	B-X
paradigm	B-X
shift	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
diverticular	B-X
disease	B-X
and	B-X
its	B-X
management	B-X
.	B-X
The	B-X
pathogenesis	B-X
of	B-X
diverticular	B-X
disease	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
multifactorial	B-X
and	B-X
include	B-X
both	B-X
environmental	B-X
and	B-X
genetic	B-X
factors	B-X
in	B-X
addition	B-X
to	B-X
the	B-X
historically	B-X
accepted	B-X
etiology	B-X
of	B-X
dietary	B-X
fiber	B-X
deficiency	B-X
.	B-X
Symptomatic	B-X
uncomplicated	B-X
diverticular	B-X
disease	B-X
(	B-X
SUDD	B-X
)	B-X
is	B-X
currently	B-X
considered	B-X
a	B-X
type	B-X
of	B-X
chronic	B-X
diverticulosis	B-X
that	B-X
is	B-X
perhaps	B-X
akin	B-X
to	B-X
irritable	B-X
bowel	B-X
syndrome	B-X
.	B-X
Antibiotic	B-X
use	B-X
for	B-X
acute	B-X
diverticulitis	B-X
and	B-X
elective	B-X
prophylactic	B-X
resection	B-X
surgery	B-X
are	B-X
considered	B-X
more	B-X
individualized	B-X
treatment	B-X
modalities	B-X
that	B-X
take	B-X
into	B-X
account	B-X
the	B-X
clinical	B-X
status	B-X
,	B-X
comorbidities	B-X
and	B-X
lifestyle	B-X
of	B-X
the	B-X
patient	B-X
.	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
pathogenesis	B-X
of	B-X
diverticular	B-X
disease	B-X
continues	B-X
to	B-X
evolve	B-X
and	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
diverse	B-X
and	B-X
multifactorial	B-X
.	B-X
Paradigm	B-X
shifts	B-X
in	B-X
several	B-X
areas	B-X
of	B-X
the	B-X
pathogenesis	B-X
and	B-X
management	B-X
of	B-X
diverticular	B-X
disease	B-X
are	B-X
explored	B-X
in	B-X
this	B-X
review	B-X
.	B-X

The	O
neuroinflammation	O
associated	O
with	O
the	O
acute	O
form	O
can	O
be	O
detected	O
with	O
T2	O
-	O
weighted	O
,	O
T1	O
-	O
weighted	O
and	O
diffusion	O
MRI	O
,	O
and	O
blood	O
-	O
brain	O
barrier	O
changes	O
can	O
be	O
investigated	O
with	O
Gd	O
-	O
DTPA	O
-	O
enhanced	O
T1	O
-	O
weighted	O
imaging	O
,	O
similar	O
to	O
that	O
of	O
MS	O
patients	O
.	O
<EOS>	B-X
Experimental	B-X
allergic	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
which	B-X
constitutes	B-X
an	B-X
accepted	B-X
animal	B-X
model	B-X
for	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
disease	B-X
can	B-X
take	B-X
an	B-X
acute	B-X
or	B-X
chronic	B-X
form	B-X
depending	B-X
on	B-X
the	B-X
injection	B-X
route	B-X
,	B-X
animal	B-X
strain	B-X
and	B-X
nature	B-X
of	B-X
the	B-X
disease-inducing	B-X
antigen	B-X
administered	B-X
.	B-X
The	B-X
neuroinflammation	B-X
associated	B-X
with	B-X
the	B-X
acute	B-X
form	B-X
can	B-X
be	B-X
detected	B-X
with	B-X
T2-weighted	B-X
,	B-X
T1-weighted	B-X
and	B-X
diffusion	B-X
MRI	B-X
,	B-X
and	B-X
blood-brain	B-X
barrier	B-X
changes	B-X
can	B-X
be	B-X
investigated	B-X
with	B-X
Gd-DTPA-enhanced	B-X
T1-weighted	B-X
imaging	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
MS	B-X
patients	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
treatment	B-X
of	B-X
Lewis	B-X
rats	B-X
with	B-X
PAL68-86	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
clinical	B-X
signs	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
after	B-X
challenge	B-X
with	B-X
the	B-X
native	B-X
peptide	B-X
(	B-X
p68-86	B-X
)	B-X
in	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
(	B-X
CFA	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
considerably	B-X
the	B-X
MRI	B-X
and	B-X
histopathological	B-X
signs	B-X
of	B-X
the	B-X
disease	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Measurement	B-X
of	B-X
the	B-X
gadolinium	B-X
leakage	B-X
due	B-X
to	B-X
neuroinflammation	B-X
revealed	B-X
a	B-X
significant	B-X
decrease	B-X
in	B-X
permeability	B-X
from	B-X
4.09	B-X
+/-	B-X
2.1	B-X
to	B-X
2.95	B-X
+/-	B-X
1.79	B-X
%	B-X
pixels	B-X
>	B-X
mean	B-X
+	B-X
2	B-X
SD	B-X
(	B-X
p	B-X
=	B-X
0.011	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
quantitative	B-X
MRI	B-X
measurements	B-X
correlate	B-X
very	B-X
well	B-X
with	B-X
the	B-X
reduced	B-X
cellular	B-X
infiltration	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
signs	B-X
in	B-X
the	B-X
EAE-protected	B-X
animal	B-X
.	B-X

A	O
synthetic	O
peptide	O
of	O
myelin	B-Protein
basic	I-Protein
protein	I-Protein
(	O
MBP	B-Protein
)	O
encephalitogenic	O
for	O
the	O
Lewis	O
rat	O
(	O
MBP	O
68	O
-	O
86	O
)	O
was	O
acylated	O
by	O
the	O
attachment	O
of	O
a	O
palmitoyl	O
residue	O
(	O
PAL68	O
-	O
86	O
)	O
,	O
and	O
was	O
shown	O
to	O
confer	O
almost	O
complete	O
protection	O
against	O
EAE	O
,	O
when	O
administered	O
to	O
rats	O
before	O
and	O
after	O
an	O
encephalitogenic	O
challenge	O
.	O
<EOS>	B-X
Experimental	B-X
allergic	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
which	B-X
constitutes	B-X
an	B-X
accepted	B-X
animal	B-X
model	B-X
for	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
disease	B-X
can	B-X
take	B-X
an	B-X
acute	B-X
or	B-X
chronic	B-X
form	B-X
depending	B-X
on	B-X
the	B-X
injection	B-X
route	B-X
,	B-X
animal	B-X
strain	B-X
and	B-X
nature	B-X
of	B-X
the	B-X
disease-inducing	B-X
antigen	B-X
administered	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
of	B-X
myelin	B-X
basic	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
encephalitogenic	B-X
for	B-X
the	B-X
Lewis	B-X
rat	B-X
(	B-X
MBP	B-X
68-86	B-X
)	B-X
was	B-X
acylated	B-X
by	B-X
the	B-X
attachment	B-X
of	B-X
a	B-X
palmitoyl	B-X
residue	B-X
(	B-X
PAL68-86	B-X
)	B-X
,	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
confer	B-X
almost	B-X
complete	B-X
protection	B-X
against	B-X
EAE	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rats	B-X
before	B-X
and	B-X
after	B-X
an	B-X
encephalitogenic	B-X
challenge	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
treatment	B-X
of	B-X
Lewis	B-X
rats	B-X
with	B-X
PAL68-86	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
clinical	B-X
signs	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
after	B-X
challenge	B-X
with	B-X
the	B-X
native	B-X
peptide	B-X
(	B-X
p68-86	B-X
)	B-X
in	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
(	B-X
CFA	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
considerably	B-X
the	B-X
MRI	B-X
and	B-X
histopathological	B-X
signs	B-X
of	B-X
the	B-X
disease	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
quantitative	B-X
MRI	B-X
measurements	B-X
correlate	B-X
very	B-X
well	B-X
with	B-X
the	B-X
reduced	B-X
cellular	B-X
infiltration	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
signs	B-X
in	B-X
the	B-X
EAE-protected	B-X
animal	B-X
.	B-X

In	O
this	O
study	O
,	O
treatment	O
of	O
Lewis	O
rats	O
with	O
PAL68	O
-	O
86	O
prevented	O
the	O
appearance	O
of	O
clinical	O
signs	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
after	O
challenge	O
with	O
the	O
native	O
peptide	O
(	O
p68	O
-	O
86	O
)	O
in	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)	O
,	O
and	O
reduced	O
considerably	O
the	O
MRI	O
and	O
histopathological	O
signs	O
of	O
the	O
disease	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Measurement	O
of	O
the	O
gadolinium	O
leakage	O
due	O
to	O
neuroinflammation	O
revealed	O
a	O
significant	O
decrease	O
in	O
permeability	O
from	O
4	O
.	O
09	O
+	O
/	O
-	O
2	O
.	O
1	O
to	O
2	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
79	O
%	O
pixels	O
>	O
mean	O
+	O
2	O
SD	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Therefore	O
,	O
quantitative	O
MRI	O
measurements	O
correlate	O
very	O
well	O
with	O
the	O
reduced	O
cellular	O
infiltration	O
in	O
the	O
CNS	O
and	O
the	O
absence	O
of	O
clinical	O
signs	O
in	O
the	O
EAE	O
-	O
protected	O
animal	O
.	O
<EOS>	B-X
Experimental	B-X
allergic	B-X
encephalomyelitis	B-X
(	B-X
EAE	B-X
)	B-X
is	B-X
an	B-X
autoimmune	B-X
disease	B-X
of	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
which	B-X
constitutes	B-X
an	B-X
accepted	B-X
animal	B-X
model	B-X
for	B-X
multiple	B-X
sclerosis	B-X
(	B-X
MS	B-X
)	B-X
.	B-X
The	B-X
disease	B-X
can	B-X
take	B-X
an	B-X
acute	B-X
or	B-X
chronic	B-X
form	B-X
depending	B-X
on	B-X
the	B-X
injection	B-X
route	B-X
,	B-X
animal	B-X
strain	B-X
and	B-X
nature	B-X
of	B-X
the	B-X
disease-inducing	B-X
antigen	B-X
administered	B-X
.	B-X
The	B-X
neuroinflammation	B-X
associated	B-X
with	B-X
the	B-X
acute	B-X
form	B-X
can	B-X
be	B-X
detected	B-X
with	B-X
T2-weighted	B-X
,	B-X
T1-weighted	B-X
and	B-X
diffusion	B-X
MRI	B-X
,	B-X
and	B-X
blood-brain	B-X
barrier	B-X
changes	B-X
can	B-X
be	B-X
investigated	B-X
with	B-X
Gd-DTPA-enhanced	B-X
T1-weighted	B-X
imaging	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
MS	B-X
patients	B-X
.	B-X
A	B-X
synthetic	B-X
peptide	B-X
of	B-X
myelin	B-X
basic	B-X
protein	B-X
(	B-X
MBP	B-X
)	B-X
encephalitogenic	B-X
for	B-X
the	B-X
Lewis	B-X
rat	B-X
(	B-X
MBP	B-X
68-86	B-X
)	B-X
was	B-X
acylated	B-X
by	B-X
the	B-X
attachment	B-X
of	B-X
a	B-X
palmitoyl	B-X
residue	B-X
(	B-X
PAL68-86	B-X
)	B-X
,	B-X
and	B-X
was	B-X
shown	B-X
to	B-X
confer	B-X
almost	B-X
complete	B-X
protection	B-X
against	B-X
EAE	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rats	B-X
before	B-X
and	B-X
after	B-X
an	B-X
encephalitogenic	B-X
challenge	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
treatment	B-X
of	B-X
Lewis	B-X
rats	B-X
with	B-X
PAL68-86	B-X
prevented	B-X
the	B-X
appearance	B-X
of	B-X
clinical	B-X
signs	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
after	B-X
challenge	B-X
with	B-X
the	B-X
native	B-X
peptide	B-X
(	B-X
p68-86	B-X
)	B-X
in	B-X
complete	B-X
Freund	B-X
's	B-X
adjuvant	B-X
(	B-X
CFA	B-X
)	B-X
,	B-X
and	B-X
reduced	B-X
considerably	B-X
the	B-X
MRI	B-X
and	B-X
histopathological	B-X
signs	B-X
of	B-X
the	B-X
disease	B-X
(	B-X
p	B-X
<	B-X
0.0001	B-X
)	B-X
.	B-X
Therefore	B-X
,	B-X
quantitative	B-X
MRI	B-X
measurements	B-X
correlate	B-X
very	B-X
well	B-X
with	B-X
the	B-X
reduced	B-X
cellular	B-X
infiltration	B-X
in	B-X
the	B-X
CNS	B-X
and	B-X
the	B-X
absence	B-X
of	B-X
clinical	B-X
signs	B-X
in	B-X
the	B-X
EAE-protected	B-X
animal	B-X
.	B-X

Synthesis	O
of	O
the	O
palmitoylated	O
and	O
prenylated	O
C	O
-	O
terminal	O
lipopeptides	O
of	O
the	O
human	O
R	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
.	O

For	O
the	O
study	O
of	O
biological	O
phenomena	O
influenced	O
by	O
the	O
R	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
,	O
characteristic	O
peptides	O
which	O
embody	O
the	O
correct	O
lipid	O
modifications	O
of	O
their	O
parent	O
proteins	O
(	O
palmitoyl	O
thioesters	O
,	O
geranylgeranyl	O
thioethers	O
,	O
and	O
farnesyl	O
thioethers	O
)	O
,	O
as	O
well	O
as	O
analogues	O
thereof	O
,	O
may	O
serve	O
as	O
efficient	O
tools	O
.	O

For	O
the	O
construction	O
of	O
such	O
acid	O
-	O
and	O
base	O
labile	O
peptide	O
conjugates	O
the	O
allyl	O
ester	O
was	O
developed	O
as	O
C	O
-	O
terminal	O
protecting	O
group	O
.	O

Allyl	O
esters	O
are	O
cleaved	O
selectively	O
and	O
in	O
high	O
yields	O
from	O
lipidated	O
peptides	O
by	O
Pd	O
(	O
0	O
)	O
-	O
mediated	O
allyl	O
transfer	O
to	O
accepting	O
N	O
-	O
or	O
C	O
-	O
nucleophiles	O
like	O
morpholine	O
and	O
N	O
,	O
N	O
'	O
-	O
dimethylbarbituric	O
acid	O
.	O

This	O
protecting	O
group	O
technique	O
formed	O
the	O
key	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
characteristic	O
S	O
-	O
palmitoylated	O
and	O
S	O
-	O
isoprenylated	O
C	O
-	O
terminus	O
of	O
human	O
R	B-Protein
-	I-Protein
Ras	I-Protein
and	O
human	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
,	O
as	O
well	O
as	O
several	O
analogues	O
thereof	O
.	O

Deprotections	O
are	O
so	O
mild	O
that	O
no	O
undesired	O
side	O
reactions	O
of	O
the	O
lipid	O
conjugates	O
are	O
observed	O
.	O
<EOS>	B-X
For	B-X
the	B-X
study	B-X
of	B-X
biological	B-X
phenomena	B-X
influenced	B-X
by	B-X
the	B-X
R-	B-X
and	B-X
N-Ras	B-X
proteins	B-X
,	B-X
characteristic	B-X
peptides	B-X
which	B-X
embody	B-X
the	B-X
correct	B-X
lipid	B-X
modifications	B-X
of	B-X
their	B-X
parent	B-X
proteins	B-X
(	B-X
palmitoyl	B-X
thioesters	B-X
,	B-X
geranylgeranyl	B-X
thioethers	B-X
,	B-X
and	B-X
farnesyl	B-X
thioethers	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
analogues	B-X
thereof	B-X
,	B-X
may	B-X
serve	B-X
as	B-X
efficient	B-X
tools	B-X
.	B-X
For	B-X
the	B-X
construction	B-X
of	B-X
such	B-X
acid-	B-X
and	B-X
base	B-X
labile	B-X
peptide	B-X
conjugates	B-X
the	B-X
allyl	B-X
ester	B-X
was	B-X
developed	B-X
as	B-X
C-terminal	B-X
protecting	B-X
group	B-X
.	B-X
Allyl	B-X
esters	B-X
are	B-X
cleaved	B-X
selectively	B-X
and	B-X
in	B-X
high	B-X
yields	B-X
from	B-X
lipidated	B-X
peptides	B-X
by	B-X
Pd	B-X
(	B-X
0	B-X
)	B-X
-mediated	B-X
allyl	B-X
transfer	B-X
to	B-X
accepting	B-X
N-	B-X
or	B-X
C-nucleophiles	B-X
like	B-X
morpholine	B-X
and	B-X
N	B-X
,	B-X
N'-dimethylbarbituric	B-X
acid	B-X
.	B-X
Deprotections	B-X
are	B-X
so	B-X
mild	B-X
that	B-X
no	B-X
undesired	B-X
side	B-X
reactions	B-X
of	B-X
the	B-X
lipid	B-X
conjugates	B-X
are	B-X
observed	B-X
.	B-X

HIV	O
-	O
1	O
Nef	B-Protein
alters	O
the	O
expression	O
of	O
betaII	O
and	O
epsilon	O
isoforms	O
of	O
protein	O
kinase	O
C	O
and	O
the	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
promoter	O
in	O
human	O
astrocytoma	O
cells	O
.	O

In	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
-	O
infected	O
brain	O
,	O
the	O
virus	O
does	O
not	O
replicate	O
in	O
astrocytes	O
,	O
but	O
a	O
synthesis	O
of	O
viral	O
regulatory	O
proteins	O
occurs	O
in	O
these	O
cells	O
,	O
leading	O
to	O
accumulation	O
of	O
Nef	B-Protein
.	O
<EOS>	B-X
Despite	B-X
efficient	B-X
combination	B-X
of	B-X
the	B-X
antiretroviral	B-X
therapy	B-X
(	B-X
cART	B-X
)	B-X
,	B-X
which	B-X
significantly	B-X
decreased	B-X
mortality	B-X
and	B-X
morbidity	B-X
of	B-X
HIV-1	B-X
infection	B-X
,	B-X
a	B-X
definitive	B-X
HIV	B-X
cure	B-X
has	B-X
not	B-X
been	B-X
achieved	B-X
.	B-X
Hidden	B-X
HIV-1	B-X
in	B-X
cellular	B-X
and	B-X
anatomic	B-X
reservoirs	B-X
is	B-X
the	B-X
major	B-X
hurdle	B-X
toward	B-X
a	B-X
functional	B-X
cure	B-X
.	B-X
Microglial	B-X
cells	B-X
,	B-X
the	B-X
Central	B-X
Nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
resident	B-X
macrophages	B-X
,	B-X
are	B-X
one	B-X
of	B-X
the	B-X
major	B-X
cellular	B-X
reservoirs	B-X
of	B-X
latent	B-X
HIV-1	B-X
.	B-X
These	B-X
cells	B-X
are	B-X
believed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
emergence	B-X
of	B-X
drugs	B-X
resistance	B-X
and	B-X
reseeding	B-X
peripheral	B-X
tissues	B-X
.	B-X
Moreover	B-X
,	B-X
these	B-X
long-life	B-X
reservoirs	B-X
are	B-X
also	B-X
involved	B-X
in	B-X
the	B-X
development	B-X
of	B-X
HIV-1-associated	B-X
neurocognitive	B-X
diseases	B-X
(	B-X
HAND	B-X
)	B-X
.	B-X
Clearing	B-X
these	B-X
infected	B-X
cells	B-X
from	B-X
the	B-X
brain	B-X
is	B-X
therefore	B-X
crucial	B-X
to	B-X
achieve	B-X
a	B-X
cure	B-X
.	B-X
However	B-X
,	B-X
many	B-X
characteristics	B-X
of	B-X
microglial	B-X
cells	B-X
and	B-X
the	B-X
CNS	B-X
hinder	B-X
the	B-X
eradication	B-X
of	B-X
these	B-X
brain	B-X
reservoirs	B-X
.	B-X
Better	B-X
understandings	B-X
of	B-X
the	B-X
specific	B-X
molecular	B-X
mechanisms	B-X
of	B-X
HIV-1	B-X
latency	B-X
in	B-X
microglial	B-X
cells	B-X
should	B-X
help	B-X
to	B-X
design	B-X
new	B-X
molecules	B-X
and	B-X
new	B-X
strategies	B-X
preventing	B-X
HAND	B-X
and	B-X
achieving	B-X
HIV	B-X
cure	B-X
.	B-X
Moreover	B-X
,	B-X
new	B-X
strategies	B-X
are	B-X
needed	B-X
to	B-X
circumvent	B-X
the	B-X
limitations	B-X
associated	B-X
to	B-X
anatomical	B-X
sanctuaries	B-X
with	B-X
barriers	B-X
such	B-X
as	B-X
the	B-X
blood	B-X
brain	B-X
barrier	B-X
(	B-X
BBB	B-X
)	B-X
that	B-X
reduce	B-X
the	B-X
access	B-X
of	B-X
drugs	B-X
.	B-X

As	O
an	O
approach	O
to	O
understand	O
the	O
effects	O
of	O
Nef	B-Protein
on	O
astrocyte	O
functional	O
activity	O
,	O
we	O
analyzed	O
whether	O
intracellular	O
Nef	B-Protein
interferes	O
with	O
the	O
expression	O
and	O
activation	O
of	O
the	O
enzyme	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
astroglial	O
functions	O
and	O
HIV	O
-	O
1	O
replication	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
-infected	B-X
brain	B-X
,	B-X
the	B-X
virus	B-X
does	B-X
not	B-X
replicate	B-X
in	B-X
astrocytes	B-X
,	B-X
but	B-X
a	B-X
synthesis	B-X
of	B-X
viral	B-X
regulatory	B-X
proteins	B-X
occurs	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
accumulation	B-X
of	B-X
Nef	B-X
.	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
Nef	B-X
and	B-X
its	B-X
membrane	B-X
localization	B-X
were	B-X
essential	B-X
for	B-X
these	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

Astrocytoma	O
clones	O
(	O
U251	O
MG	O
)	O
not	O
expressing	O
Nef	B-Protein
(	O
Neo	O
)	O
,	O
or	O
expressing	O
wild	O
-	O
type	O
Nef	B-Protein
(	O
Bru	O
)	O
or	O
nonmyristoylated	O
Nef	B-Protein
(	O
TH	O
)	O
were	O
used	O
to	O
monitor	O
the	O
expression	O
and	O
activation	O
of	O
10	O
PKC	O
isoforms	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
-infected	B-X
brain	B-X
,	B-X
the	B-X
virus	B-X
does	B-X
not	B-X
replicate	B-X
in	B-X
astrocytes	B-X
,	B-X
but	B-X
a	B-X
synthesis	B-X
of	B-X
viral	B-X
regulatory	B-X
proteins	B-X
occurs	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
accumulation	B-X
of	B-X
Nef	B-X
.	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
Nef	B-X
and	B-X
its	B-X
membrane	B-X
localization	B-X
were	B-X
essential	B-X
for	B-X
these	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

The	O
same	O
clones	O
were	O
used	O
to	O
evaluate	O
the	O
effect	O
of	O
Nef	B-Protein
on	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
after	O
activation	O
of	O
PKC	O
with	O
the	O
phorbol	O
ester	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
-infected	B-X
brain	B-X
,	B-X
the	B-X
virus	B-X
does	B-X
not	B-X
replicate	B-X
in	B-X
astrocytes	B-X
,	B-X
but	B-X
a	B-X
synthesis	B-X
of	B-X
viral	B-X
regulatory	B-X
proteins	B-X
occurs	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
accumulation	B-X
of	B-X
Nef	B-X
.	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
Nef	B-X
and	B-X
its	B-X
membrane	B-X
localization	B-X
were	B-X
essential	B-X
for	B-X
these	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

PKC	O
intracellular	O
distribution	O
and	O
activation	O
were	O
evaluated	O
by	O
Western	O
blot	O
analysis	O
of	O
cytosolic	O
and	O
membrane	O
fractions	O
of	O
control	O
and	O
Nef	B-Protein
-	O
expressing	O
clones	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
-infected	B-X
brain	B-X
,	B-X
the	B-X
virus	B-X
does	B-X
not	B-X
replicate	B-X
in	B-X
astrocytes	B-X
,	B-X
but	B-X
a	B-X
synthesis	B-X
of	B-X
viral	B-X
regulatory	B-X
proteins	B-X
occurs	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
accumulation	B-X
of	B-X
Nef	B-X
.	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
Nef	B-X
and	B-X
its	B-X
membrane	B-X
localization	B-X
were	B-X
essential	B-X
for	B-X
these	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

PMA	O
-	O
induced	O
LTR	O
activation	O
was	O
analyzed	O
in	O
clones	O
transfected	O
with	O
a	O
plasmid	O
encoding	O
for	O
the	O
CAT	B-Protein
reporter	O
gene	O
controlled	O
by	O
the	O
LTR	O
promoter	O
,	O
by	O
using	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
to	O
measure	O
CAT	B-Protein
expression	O
.	O
<EOS>	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

Nef	B-Protein
selectively	O
downregulated	O
the	O
expression	O
and	O
activation	O
of	O
betaII	B-Protein
and	O
epsilon	B-Protein
PKC	I-Protein
isoforms	O
in	O
astrocytoma	O
cells	O
.	O
<EOS>	B-X
In	B-X
the	B-X
human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
(	B-X
HIV-1	B-X
)	B-X
-infected	B-X
brain	B-X
,	B-X
the	B-X
virus	B-X
does	B-X
not	B-X
replicate	B-X
in	B-X
astrocytes	B-X
,	B-X
but	B-X
a	B-X
synthesis	B-X
of	B-X
viral	B-X
regulatory	B-X
proteins	B-X
occurs	B-X
in	B-X
these	B-X
cells	B-X
,	B-X
leading	B-X
to	B-X
accumulation	B-X
of	B-X
Nef	B-X
.	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
Nef	B-X
and	B-X
its	B-X
membrane	B-X
localization	B-X
were	B-X
essential	B-X
for	B-X
these	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

Such	O
downregulation	O
correlated	O
with	O
an	O
inhibition	O
of	O
LTR	O
activation	O
after	O
PMA	O
stimulation	O
.	O
<EOS>	B-X
As	B-X
an	B-X
approach	B-X
to	B-X
understand	B-X
the	B-X
effects	B-X
of	B-X
Nef	B-X
on	B-X
astrocyte	B-X
functional	B-X
activity	B-X
,	B-X
we	B-X
analyzed	B-X
whether	B-X
intracellular	B-X
Nef	B-X
interferes	B-X
with	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
kinase	B-X
C	B-X
(	B-X
PKC	B-X
)	B-X
,	B-X
which	B-X
is	B-X
an	B-X
important	B-X
regulator	B-X
of	B-X
astroglial	B-X
functions	B-X
and	B-X
HIV-1	B-X
replication	B-X
.	B-X
Astrocytoma	B-X
clones	B-X
(	B-X
U251	B-X
MG	B-X
)	B-X
not	B-X
expressing	B-X
Nef	B-X
(	B-X
Neo	B-X
)	B-X
,	B-X
or	B-X
expressing	B-X
wild-type	B-X
Nef	B-X
(	B-X
Bru	B-X
)	B-X
or	B-X
nonmyristoylated	B-X
Nef	B-X
(	B-X
TH	B-X
)	B-X
were	B-X
used	B-X
to	B-X
monitor	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
10	B-X
PKC	B-X
isoforms	B-X
.	B-X
The	B-X
same	B-X
clones	B-X
were	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
Nef	B-X
on	B-X
the	B-X
viral	B-X
long	B-X
terminal	B-X
repeat	B-X
(	B-X
LTR	B-X
)	B-X
promoter	B-X
after	B-X
activation	B-X
of	B-X
PKC	B-X
with	B-X
the	B-X
phorbol	B-X
ester	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
PMA	B-X
)	B-X
.	B-X
PKC	B-X
intracellular	B-X
distribution	B-X
and	B-X
activation	B-X
were	B-X
evaluated	B-X
by	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cytosolic	B-X
and	B-X
membrane	B-X
fractions	B-X
of	B-X
control	B-X
and	B-X
Nef-expressing	B-X
clones	B-X
.	B-X
PMA-induced	B-X
LTR	B-X
activation	B-X
was	B-X
analyzed	B-X
in	B-X
clones	B-X
transfected	B-X
with	B-X
a	B-X
plasmid	B-X
encoding	B-X
for	B-X
the	B-X
CAT	B-X
reporter	B-X
gene	B-X
controlled	B-X
by	B-X
the	B-X
LTR	B-X
promoter	B-X
,	B-X
by	B-X
using	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
to	B-X
measure	B-X
CAT	B-X
expression	B-X
.	B-X
Nef	B-X
selectively	B-X
downregulated	B-X
the	B-X
expression	B-X
and	B-X
activation	B-X
of	B-X
betaII	B-X
and	B-X
epsilon	B-X
PKC	B-X
isoforms	B-X
in	B-X
astrocytoma	B-X
cells	B-X
.	B-X
Such	B-X
downregulation	B-X
correlated	B-X
with	B-X
an	B-X
inhibition	B-X
of	B-X
LTR	B-X
activation	B-X
after	B-X
PMA	B-X
stimulation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
Nef	B-X
may	B-X
alter	B-X
astrocytic	B-X
functions	B-X
by	B-X
interfering	B-X
with	B-X
PKC	B-X
expression	B-X
and	B-X
activation	B-X
and	B-X
contribute	B-X
to	B-X
the	B-X
restriction	B-X
of	B-X
HIV-1	B-X
replication	B-X
in	B-X
astrocytes	B-X
.	B-X

The	O
myristoylation	O
of	O
Nef	B-Protein
and	O
its	O
membrane	O
localization	O
were	O
essential	O
for	O
these	O
effects	O
.	O
<EOS>	B-X
Human	B-X
immunodeficiency	B-X
virus	B-X
type	B-X
1	B-X
Nef	B-X
protein	B-X
is	B-X
N-terminally	B-X
myristoylated	B-X
,	B-X
a	B-X
modification	B-X
reported	B-X
to	B-X
be	B-X
required	B-X
for	B-X
the	B-X
association	B-X
of	B-X
Nef	B-X
with	B-X
cytoplasmic	B-X
membranes	B-X
.	B-X
As	B-X
myristate	B-X
alone	B-X
is	B-X
not	B-X
sufficient	B-X
to	B-X
anchor	B-X
a	B-X
protein	B-X
stably	B-X
into	B-X
a	B-X
membrane	B-X
,	B-X
it	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
N-terminal	B-X
basic	B-X
residues	B-X
contribute	B-X
to	B-X
Nef	B-X
membrane	B-X
association	B-X
via	B-X
electrostatic	B-X
interactions	B-X
with	B-X
acidic	B-X
phospholipids	B-X
.	B-X
Here	B-X
,	B-X
data	B-X
are	B-X
presented	B-X
pertaining	B-X
to	B-X
the	B-X
role	B-X
of	B-X
the	B-X
myristate	B-X
and	B-X
basic	B-X
residues	B-X
in	B-X
Nef	B-X
membrane	B-X
association	B-X
,	B-X
subcellular	B-X
localization	B-X
and	B-X
function	B-X
.	B-X
Firstly	B-X
,	B-X
by	B-X
using	B-X
a	B-X
biochemical	B-X
assay	B-X
for	B-X
membrane	B-X
association	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
,	B-X
whereas	B-X
myristoylation	B-X
of	B-X
Nef	B-X
was	B-X
not	B-X
essential	B-X
,	B-X
mutation	B-X
of	B-X
a	B-X
cluster	B-X
of	B-X
four	B-X
arginines	B-X
between	B-X
residues	B-X
17	B-X
and	B-X
22	B-X
reduced	B-X
membrane	B-X
association	B-X
dramatically	B-X
.	B-X
Mutation	B-X
of	B-X
two	B-X
lysines	B-X
at	B-X
residues	B-X
4	B-X
and	B-X
7	B-X
had	B-X
negligible	B-X
effect	B-X
alone	B-X
,	B-X
but	B-X
when	B-X
combined	B-X
with	B-X
the	B-X
arginine	B-X
substitutions	B-X
,	B-X
abrogated	B-X
membrane	B-X
association	B-X
completely	B-X
.	B-X
By	B-X
using	B-X
indirect	B-X
immunofluorescence	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
mutation	B-X
of	B-X
either	B-X
of	B-X
the	B-X
two	B-X
basic	B-X
clusters	B-X
altered	B-X
the	B-X
subcellular	B-X
distribution	B-X
of	B-X
Nef	B-X
dramatically	B-X
.	B-X
Thirdly	B-X
,	B-X
the	B-X
requirement	B-X
of	B-X
the	B-X
arginine	B-X
and	B-X
lysine	B-X
clusters	B-X
for	B-X
Nef-mediated	B-X
CD4	B-X
down	B-X
modulation	B-X
was	B-X
shown	B-X
to	B-X
correlate	B-X
precisely	B-X
with	B-X
membrane	B-X
association	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
membrane	B-X
localization	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
Nef	B-X
are	B-X
controlled	B-X
by	B-X
a	B-X
complex	B-X
interplay	B-X
of	B-X
signals	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X

These	O
results	O
suggest	O
that	O
Nef	B-Protein
may	O
alter	O
astrocytic	O
functions	O
by	O
interfering	O
with	O
PKC	O
expression	O
and	O
activation	O
and	O
contribute	O
to	O
the	O
restriction	O
of	O
HIV	O
-	O
1	O
replication	O
in	O
astrocytes	O
.	O

Farnesyl	O
protein	O
transferase	O
:	O
identification	O
of	O
K164	O
alpha	O
and	O
Y300	O
beta	O
as	O
catalytic	O
residues	O
by	O
mutagenesis	O
and	O
kinetic	O
studies	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

Farnesyl	O
protein	O
transferase	O
(	O
FPT	O
)	O
is	O
an	O
alpha	O
/	O
beta	O
heterodimeric	O
zinc	O
enzyme	O
that	O
catalyzes	O
posttranslational	O
farnesylation	O
of	O
many	O
key	O
cellular	O
regulatory	O
proteins	O
,	O
including	O
oncogenic	O
Ras	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

On	O
the	O
basis	O
of	O
the	O
recently	O
reported	O
crystal	O
structure	O
of	O
FPT	O
complexed	O
with	O
a	O
CVIM	O
peptide	O
and	O
alpha	O
-	O
hydroxyfarnesylphosphonic	O
acid	O
,	O
site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
FPT	O
active	O
site	O
was	O
performed	O
so	O
key	O
residues	O
that	O
are	O
responsible	O
for	O
substrate	O
binding	O
and	O
catalysis	O
could	O
be	O
identified	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

Eight	O
single	O
mutants	O
,	O
including	O
K164N	O
alpha	O
,	O
Y166F	O
alpha	O
,	O
Y166A	O
alpha	O
,	O
Y200F	O
alpha	O
,	O
H201A	O
alpha	O
,	O
H248A	O
beta	O
,	O
Y300F	O
beta	O
,	O
and	O
Y361F	O
beta	O
,	O
and	O
a	O
double	O
mutant	O
,	O
H248A	O
beta	O
/	O
Y300F	O
beta	O
,	O
were	O
prepared	O
.	O

Steady	O
-	O
state	O
kinetic	O
analysis	O
along	O
with	O
structural	O
evidence	O
indicated	O
that	O
residues	O
Y200	O
alpha	O
,	O
H201	O
alpha	O
,	O
H248	O
beta	O
,	O
and	O
Y361	O
beta	O
are	O
mainly	O
involved	O
in	O
substrate	O
binding	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

In	O
addition	O
,	O
biochemical	O
results	O
confirm	O
structural	O
observations	O
which	O
show	O
that	O
residue	O
Y166	O
alpha	O
plays	O
a	O
key	O
role	O
in	O
stabilizing	O
the	O
active	O
site	O
conformation	O
of	O
several	O
FPT	O
residues	O
through	O
cation	O
-	O
pi	O
interactions	O
.	O

Two	O
mutants	O
,	O
K164N	O
alpha	O
and	O
Y300F	O
beta	O
,	O
have	O
moderately	O
decreased	O
catalytic	O
constants	O
(	O
kcat	O
)	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

Pre	O
-	O
steady	O
-	O
state	O
kinetic	O
analysis	O
of	O
these	O
mutants	O
from	O
rapid	O
quench	O
experiments	O
showed	O
that	O
the	O
chemical	O
step	O
rate	O
constant	O
was	O
reduced	O
by	O
41	O
-	O
and	O
30	O
-	O
fold	O
,	O
respectively	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
product-releasing	B-X
rate	B-X
for	B-X
each	B-X
dropped	B-X
approximately	B-X
10-fold	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

The	O
product	O
-	O
releasing	O
rate	O
for	O
each	O
dropped	O
approximately	O
10	O
-	O
fold	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
product-releasing	B-X
rate	B-X
for	B-X
each	B-X
dropped	B-X
approximately	B-X
10-fold	B-X
.	B-X

In	O
pH	O
-	O
dependent	O
kinetic	O
studies	O
,	O
Y300F	O
beta	O
was	O
observed	O
to	O
have	O
both	O
acidic	O
and	O
basic	O
pKa	O
values	O
shifted	O
1	O
log	O
unit	O
from	O
those	O
of	O
the	O
wild	O
-	O
type	O
enzyme	O
,	O
consistent	O
with	O
a	O
possible	O
role	O
for	O
Y300	O
beta	O
as	O
an	O
acid	O
-	O
base	O
catalyst	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
Pre-steady-state	B-X
kinetic	B-X
analysis	B-X
of	B-X
these	B-X
mutants	B-X
from	B-X
rapid	B-X
quench	B-X
experiments	B-X
showed	B-X
that	B-X
the	B-X
chemical	B-X
step	B-X
rate	B-X
constant	B-X
was	B-X
reduced	B-X
by	B-X
41-	B-X
and	B-X
30-fold	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
product-releasing	B-X
rate	B-X
for	B-X
each	B-X
dropped	B-X
approximately	B-X
10-fold	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

K164N	O
alpha	O
had	O
a	O
pKa	O
shift	O
from	O
6	O
.	O
0	O
to	O
5	O
.	O
3	O
,	O
which	O
suggests	O
it	O
may	O
function	O
as	O
a	O
general	O
acid	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
along	O
with	O
structural	O
evidence	O
,	O
a	O
possible	O
FPT	O
reaction	O
mechanism	O
is	O
proposed	O
with	O
both	O
Y300	O
beta	O
and	O
K164	O
alpha	O
playing	O
key	O
catalytic	O
roles	O
in	O
enhancing	O
the	O
reactivity	O
of	O
the	O
farnesyl	O
diphosphate	O
leaving	O
group	O
.	O
<EOS>	B-X
Farnesyl	B-X
protein	B-X
transferase	B-X
(	B-X
FPT	B-X
)	B-X
is	B-X
an	B-X
alpha/beta	B-X
heterodimeric	B-X
zinc	B-X
enzyme	B-X
that	B-X
catalyzes	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
many	B-X
key	B-X
cellular	B-X
regulatory	B-X
proteins	B-X
,	B-X
including	B-X
oncogenic	B-X
Ras	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
crystal	B-X
structure	B-X
of	B-X
FPT	B-X
complexed	B-X
with	B-X
a	B-X
CVIM	B-X
peptide	B-X
and	B-X
alpha-hydroxyfarnesylphosphonic	B-X
acid	B-X
,	B-X
site-directed	B-X
mutagenesis	B-X
of	B-X
the	B-X
FPT	B-X
active	B-X
site	B-X
was	B-X
performed	B-X
so	B-X
key	B-X
residues	B-X
that	B-X
are	B-X
responsible	B-X
for	B-X
substrate	B-X
binding	B-X
and	B-X
catalysis	B-X
could	B-X
be	B-X
identified	B-X
.	B-X
Eight	B-X
single	B-X
mutants	B-X
,	B-X
including	B-X
K164N	B-X
alpha	B-X
,	B-X
Y166F	B-X
alpha	B-X
,	B-X
Y166A	B-X
alpha	B-X
,	B-X
Y200F	B-X
alpha	B-X
,	B-X
H201A	B-X
alpha	B-X
,	B-X
H248A	B-X
beta	B-X
,	B-X
Y300F	B-X
beta	B-X
,	B-X
and	B-X
Y361F	B-X
beta	B-X
,	B-X
and	B-X
a	B-X
double	B-X
mutant	B-X
,	B-X
H248A	B-X
beta/Y300F	B-X
beta	B-X
,	B-X
were	B-X
prepared	B-X
.	B-X
Steady-state	B-X
kinetic	B-X
analysis	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
indicated	B-X
that	B-X
residues	B-X
Y200	B-X
alpha	B-X
,	B-X
H201	B-X
alpha	B-X
,	B-X
H248	B-X
beta	B-X
,	B-X
and	B-X
Y361	B-X
beta	B-X
are	B-X
mainly	B-X
involved	B-X
in	B-X
substrate	B-X
binding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
biochemical	B-X
results	B-X
confirm	B-X
structural	B-X
observations	B-X
which	B-X
show	B-X
that	B-X
residue	B-X
Y166	B-X
alpha	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
stabilizing	B-X
the	B-X
active	B-X
site	B-X
conformation	B-X
of	B-X
several	B-X
FPT	B-X
residues	B-X
through	B-X
cation-pi	B-X
interactions	B-X
.	B-X
Two	B-X
mutants	B-X
,	B-X
K164N	B-X
alpha	B-X
and	B-X
Y300F	B-X
beta	B-X
,	B-X
have	B-X
moderately	B-X
decreased	B-X
catalytic	B-X
constants	B-X
(	B-X
kcat	B-X
)	B-X
.	B-X
In	B-X
pH-dependent	B-X
kinetic	B-X
studies	B-X
,	B-X
Y300F	B-X
beta	B-X
was	B-X
observed	B-X
to	B-X
have	B-X
both	B-X
acidic	B-X
and	B-X
basic	B-X
pKa	B-X
values	B-X
shifted	B-X
1	B-X
log	B-X
unit	B-X
from	B-X
those	B-X
of	B-X
the	B-X
wild-type	B-X
enzyme	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
possible	B-X
role	B-X
for	B-X
Y300	B-X
beta	B-X
as	B-X
an	B-X
acid-base	B-X
catalyst	B-X
.	B-X
K164N	B-X
alpha	B-X
had	B-X
a	B-X
pKa	B-X
shift	B-X
from	B-X
6.0	B-X
to	B-X
5.3	B-X
,	B-X
which	B-X
suggests	B-X
it	B-X
may	B-X
function	B-X
as	B-X
a	B-X
general	B-X
acid	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
along	B-X
with	B-X
structural	B-X
evidence	B-X
,	B-X
a	B-X
possible	B-X
FPT	B-X
reaction	B-X
mechanism	B-X
is	B-X
proposed	B-X
with	B-X
both	B-X
Y300	B-X
beta	B-X
and	B-X
K164	B-X
alpha	B-X
playing	B-X
key	B-X
catalytic	B-X
roles	B-X
in	B-X
enhancing	B-X
the	B-X
reactivity	B-X
of	B-X
the	B-X
farnesyl	B-X
diphosphate	B-X
leaving	B-X
group	B-X
.	B-X

Cloning	O
and	O
characterization	O
of	O
a	O
mammalian	O
N	O
-	O
acetylglucosamine	O
-	O
6	O
-	O
sulfotransferase	O
that	O
is	O
highly	O
restricted	O
to	O
intestinal	O
tissue	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
sequences	B-X
of	B-X
a	B-X
galactose	B-X
6-O-sulfotransferase	B-X
and	B-X
an	B-X
N-acetylglucosamine	B-X
6-O-sulfotransferase	B-X
as	B-X
probes	B-X
in	B-X
an	B-X
EST	B-X
approach	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
highly	B-X
related	B-X
cDNA	B-X
in	B-X
human	B-X
and	B-X
an	B-X
apparent	B-X
orthologue	B-X
in	B-X
mouse	B-X
.	B-X
The	B-X
cDNAs	B-X
predict	B-X
type	B-X
II	B-X
transmembrane	B-X
proteins	B-X
that	B-X
constitute	B-X
new	B-X
members	B-X
of	B-X
the	B-X
Gal/GalNAc/GlcNAc	B-X
6-O-sulfotransferase	B-X
(	B-X
GST	B-X
)	B-X
family	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
newly	B-X
identified	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
sulfate	B-X
to	B-X
C-6	B-X
of	B-X
GlcNAc	B-X
in	B-X
an	B-X
acceptor	B-X
glycoprotein	B-X
.	B-X
The	B-X
tissue	B-X
expression	B-X
of	B-X
transcripts	B-X
corresponding	B-X
to	B-X
the	B-X
cDNA	B-X
was	B-X
highly	B-X
restricted	B-X
to	B-X
the	B-X
small	B-X
intestine	B-X
and	B-X
colon	B-X
in	B-X
humans	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
characteristics	B-X
,	B-X
the	B-X
novel	B-X
sulfotransferase	B-X
is	B-X
designated	B-X
I-GlcNAc6ST	B-X
for	B-X
intestinal	B-X
GlcNAc	B-X
6-O-sulfotransferase	B-X
.	B-X

Using	O
the	O
sequences	O
of	O
a	O
galactose	O
6	O
-	O
O	O
-	O
sulfotransferase	O
and	O
an	O
N	O
-	O
acetylglucosamine	O
6	O
-	O
O	O
-	O
sulfotransferase	O
as	O
probes	O
in	O
an	O
EST	O
approach	O
,	O
we	O
have	O
identified	O
a	O
highly	O
related	O
cDNA	O
in	O
human	O
and	O
an	O
apparent	O
orthologue	O
in	O
mouse	O
.	O

The	O
cDNAs	O
predict	O
type	O
II	O
transmembrane	O
proteins	O
that	O
constitute	O
new	O
members	O
of	O
the	O
Gal	O
/	O
GalNAc	O
/	O
GlcNAc	O
6	O
-	O
O	O
-	O
sulfotransferase	O
(	O
GST	O
)	O
family	O
.	O
<EOS>	B-X
Using	B-X
the	B-X
sequences	B-X
of	B-X
a	B-X
galactose	B-X
6-O-sulfotransferase	B-X
and	B-X
an	B-X
N-acetylglucosamine	B-X
6-O-sulfotransferase	B-X
as	B-X
probes	B-X
in	B-X
an	B-X
EST	B-X
approach	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
highly	B-X
related	B-X
cDNA	B-X
in	B-X
human	B-X
and	B-X
an	B-X
apparent	B-X
orthologue	B-X
in	B-X
mouse	B-X
.	B-X
The	B-X
cDNAs	B-X
predict	B-X
type	B-X
II	B-X
transmembrane	B-X
proteins	B-X
that	B-X
constitute	B-X
new	B-X
members	B-X
of	B-X
the	B-X
Gal/GalNAc/GlcNAc	B-X
6-O-sulfotransferase	B-X
(	B-X
GST	B-X
)	B-X
family	B-X
.	B-X
Members	B-X
of	B-X
this	B-X
family	B-X
have	B-X
previously	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
sulfation	B-X
of	B-X
GAG	B-X
chains	B-X
within	B-X
proteoglycans	B-X
and	B-X
the	B-X
sulfation	B-X
of	B-X
O-linked	B-X
chains	B-X
within	B-X
sialomucin	B-X
ligands	B-X
for	B-X
l-selectin	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
newly	B-X
identified	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
sulfate	B-X
to	B-X
C-6	B-X
of	B-X
GlcNAc	B-X
in	B-X
an	B-X
acceptor	B-X
glycoprotein	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
characteristics	B-X
,	B-X
the	B-X
novel	B-X
sulfotransferase	B-X
is	B-X
designated	B-X
I-GlcNAc6ST	B-X
for	B-X
intestinal	B-X
GlcNAc	B-X
6-O-sulfotransferase	B-X
.	B-X

Members	O
of	O
this	O
family	O
have	O
previously	O
been	O
implicated	O
in	O
the	O
sulfation	O
of	O
GAG	O
chains	O
within	O
proteoglycans	O
and	O
the	O
sulfation	O
of	O
O	O
-	O
linked	O
chains	O
within	O
sialomucin	O
ligands	O
for	O
l	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Expression	O
of	O
the	O
newly	O
identified	O
cDNA	O
in	O
COS	O
cells	O
led	O
to	O
the	O
addition	O
of	O
sulfate	O
to	O
C	O
-	O
6	O
of	O
GlcNAc	O
in	O
an	O
acceptor	O
glycoprotein	O
.	O

The	O
tissue	O
expression	O
of	O
transcripts	O
corresponding	O
to	O
the	O
cDNA	O
was	O
highly	O
restricted	O
to	O
the	O
small	O
intestine	O
and	O
colon	O
in	O
humans	O
.	O

Based	O
on	O
these	O
characteristics	O
,	O
the	O
novel	O
sulfotransferase	O
is	O
designated	O
I	B-Protein
-	I-Protein
GlcNAc6ST	I-Protein
for	O
intestinal	B-Protein
GlcNAc	I-Protein
6	I-Protein
-	I-Protein
O	I-Protein
-	I-Protein
sulfotransferase	I-Protein
.	O
<EOS>	B-X
Using	B-X
the	B-X
sequences	B-X
of	B-X
a	B-X
galactose	B-X
6-O-sulfotransferase	B-X
and	B-X
an	B-X
N-acetylglucosamine	B-X
6-O-sulfotransferase	B-X
as	B-X
probes	B-X
in	B-X
an	B-X
EST	B-X
approach	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
a	B-X
highly	B-X
related	B-X
cDNA	B-X
in	B-X
human	B-X
and	B-X
an	B-X
apparent	B-X
orthologue	B-X
in	B-X
mouse	B-X
.	B-X
The	B-X
cDNAs	B-X
predict	B-X
type	B-X
II	B-X
transmembrane	B-X
proteins	B-X
that	B-X
constitute	B-X
new	B-X
members	B-X
of	B-X
the	B-X
Gal/GalNAc/GlcNAc	B-X
6-O-sulfotransferase	B-X
(	B-X
GST	B-X
)	B-X
family	B-X
.	B-X
Expression	B-X
of	B-X
the	B-X
newly	B-X
identified	B-X
cDNA	B-X
in	B-X
COS	B-X
cells	B-X
led	B-X
to	B-X
the	B-X
addition	B-X
of	B-X
sulfate	B-X
to	B-X
C-6	B-X
of	B-X
GlcNAc	B-X
in	B-X
an	B-X
acceptor	B-X
glycoprotein	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
characteristics	B-X
,	B-X
the	B-X
novel	B-X
sulfotransferase	B-X
is	B-X
designated	B-X
I-GlcNAc6ST	B-X
for	B-X
intestinal	B-X
GlcNAc	B-X
6-O-sulfotransferase	B-X
.	B-X

Inhibition	O
of	O
protein	O
palmitoylation	O
,	O
raft	O
localization	O
,	O
and	O
T	O
cell	O
signaling	O
by	O
2	O
-	O
bromopalmitate	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
ability	O
of	O
the	O
Src	O
family	O
kinases	O
Fyn	B-Protein
and	O
Lck	B-Protein
to	O
participate	O
in	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
is	O
critically	O
dependent	O
on	O
their	O
dual	O
fatty	O
acylation	O
with	O
myristate	O
and	O
palmitate	O
.	O

Here	O
we	O
identify	O
a	O
palmitate	O
analog	O
,	O
2	O
-	O
bromopalmitate	O
,	O
that	O
effectively	O
blocks	O
Fyn	B-Protein
fatty	O
acylation	O
in	O
general	O
and	O
palmitoylation	O
in	O
particular	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lck	B-X
to	B-X
participate	B-X
in	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
their	B-X
dual	B-X
fatty	B-X
acylation	B-X
with	B-X
myristate	B-X
and	B-X
palmitate	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
a	B-X
palmitate	B-X
analog	B-X
,	B-X
2-bromopalmitate	B-X
,	B-X
that	B-X
effectively	B-X
blocks	B-X
Fyn	B-X
fatty	B-X
acylation	B-X
in	B-X
general	B-X
and	B-X
palmitoylation	B-X
in	B-X
particular	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
long	B-X
chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
to	B-X
inhibit	B-X
protein	B-X
fatty	B-X
acylation	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

Treatment	O
of	O
COS	O
-	O
1	O
cells	O
with	O
2	O
-	O
bromopalmitate	O
blocked	O
myristoylation	O
and	O
palmitoylation	O
of	O
Fyn	B-Protein
and	O
inhibited	O
membrane	O
binding	O
and	O
localization	O
of	O
Fyn	B-Protein
to	O
detergent	O
-	O
resistant	O
membranes	O
(	O
DRMs	O
)	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lck	B-X
to	B-X
participate	B-X
in	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
their	B-X
dual	B-X
fatty	B-X
acylation	B-X
with	B-X
myristate	B-X
and	B-X
palmitate	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
a	B-X
palmitate	B-X
analog	B-X
,	B-X
2-bromopalmitate	B-X
,	B-X
that	B-X
effectively	B-X
blocks	B-X
Fyn	B-X
fatty	B-X
acylation	B-X
in	B-X
general	B-X
and	B-X
palmitoylation	B-X
in	B-X
particular	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
PUFAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
signaling	B-X
by	B-X
excluding	B-X
Src	B-X
family	B-X
kinases	B-X
from	B-X
DRMs	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

In	O
Jurkat	O
T	O
cells	O
,	O
2	O
-	O
bromopalmitate	O
blocked	O
localization	O
of	O
the	O
endogenous	O
palmitoylated	O
proteins	O
Fyn	B-Protein
,	O
Lck	B-Protein
,	O
and	O
LAT	B-Protein
to	O
DRMs	O
.	O

This	O
resulted	O
in	O
impaired	O
signaling	O
through	O
the	O
T	O
cell	O
receptor	O
as	O
evidenced	O
by	O
reductions	O
in	O
tyrosine	O
phosphorylation	O
,	O
calcium	O
release	O
,	O
and	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

We	O
also	O
examined	O
the	O
ability	O
of	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
to	O
inhibit	O
protein	O
fatty	O
acylation	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lck	B-X
to	B-X
participate	B-X
in	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
their	B-X
dual	B-X
fatty	B-X
acylation	B-X
with	B-X
myristate	B-X
and	B-X
palmitate	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
a	B-X
palmitate	B-X
analog	B-X
,	B-X
2-bromopalmitate	B-X
,	B-X
that	B-X
effectively	B-X
blocks	B-X
Fyn	B-X
fatty	B-X
acylation	B-X
in	B-X
general	B-X
and	B-X
palmitoylation	B-X
in	B-X
particular	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
This	B-X
resulted	B-X
in	B-X
impaired	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
as	B-X
evidenced	B-X
by	B-X
reductions	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
calcium	B-X
release	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
long	B-X
chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
to	B-X
inhibit	B-X
protein	B-X
fatty	B-X
acylation	B-X
.	B-X
PUFAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
signaling	B-X
by	B-X
excluding	B-X
Src	B-X
family	B-X
kinases	B-X
from	B-X
DRMs	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

PUFAs	O
have	O
been	O
reported	O
to	O
inhibit	O
T	O
cell	O
signaling	O
by	O
excluding	O
Src	O
family	O
kinases	O
from	O
DRMs	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lck	B-X
to	B-X
participate	B-X
in	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
their	B-X
dual	B-X
fatty	B-X
acylation	B-X
with	B-X
myristate	B-X
and	B-X
palmitate	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
This	B-X
resulted	B-X
in	B-X
impaired	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
as	B-X
evidenced	B-X
by	B-X
reductions	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
calcium	B-X
release	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
long	B-X
chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
to	B-X
inhibit	B-X
protein	B-X
fatty	B-X
acylation	B-X
.	B-X
PUFAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
signaling	B-X
by	B-X
excluding	B-X
Src	B-X
family	B-X
kinases	B-X
from	B-X
DRMs	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

Here	O
we	O
show	O
that	O
the	O
PUFAs	O
arachidonic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
inhibit	O
Fyn	B-Protein
palmitoylation	O
and	O
consequently	O
block	O
Fyn	B-Protein
localization	O
to	O
DRMs	O
.	O
<EOS>	B-X
The	B-X
ability	B-X
of	B-X
the	B-X
Src	B-X
family	B-X
kinases	B-X
Fyn	B-X
and	B-X
Lck	B-X
to	B-X
participate	B-X
in	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
is	B-X
critically	B-X
dependent	B-X
on	B-X
their	B-X
dual	B-X
fatty	B-X
acylation	B-X
with	B-X
myristate	B-X
and	B-X
palmitate	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
a	B-X
palmitate	B-X
analog	B-X
,	B-X
2-bromopalmitate	B-X
,	B-X
that	B-X
effectively	B-X
blocks	B-X
Fyn	B-X
fatty	B-X
acylation	B-X
in	B-X
general	B-X
and	B-X
palmitoylation	B-X
in	B-X
particular	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
long	B-X
chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
to	B-X
inhibit	B-X
protein	B-X
fatty	B-X
acylation	B-X
.	B-X
PUFAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
signaling	B-X
by	B-X
excluding	B-X
Src	B-X
family	B-X
kinases	B-X
from	B-X
DRMs	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

We	O
propose	O
that	O
inhibition	O
of	O
protein	O
palmitoylation	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
PUFAs	O
exert	O
their	O
immunosuppressive	O
effects	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
identify	B-X
a	B-X
palmitate	B-X
analog	B-X
,	B-X
2-bromopalmitate	B-X
,	B-X
that	B-X
effectively	B-X
blocks	B-X
Fyn	B-X
fatty	B-X
acylation	B-X
in	B-X
general	B-X
and	B-X
palmitoylation	B-X
in	B-X
particular	B-X
.	B-X
Treatment	B-X
of	B-X
COS-1	B-X
cells	B-X
with	B-X
2-bromopalmitate	B-X
blocked	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
Fyn	B-X
and	B-X
inhibited	B-X
membrane	B-X
binding	B-X
and	B-X
localization	B-X
of	B-X
Fyn	B-X
to	B-X
detergent-resistant	B-X
membranes	B-X
(	B-X
DRMs	B-X
)	B-X
.	B-X
In	B-X
Jurkat	B-X
T	B-X
cells	B-X
,	B-X
2-bromopalmitate	B-X
blocked	B-X
localization	B-X
of	B-X
the	B-X
endogenous	B-X
palmitoylated	B-X
proteins	B-X
Fyn	B-X
,	B-X
Lck	B-X
,	B-X
and	B-X
LAT	B-X
to	B-X
DRMs	B-X
.	B-X
This	B-X
resulted	B-X
in	B-X
impaired	B-X
signaling	B-X
through	B-X
the	B-X
T	B-X
cell	B-X
receptor	B-X
as	B-X
evidenced	B-X
by	B-X
reductions	B-X
in	B-X
tyrosine	B-X
phosphorylation	B-X
,	B-X
calcium	B-X
release	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
mitogen-activated	B-X
protein	B-X
kinase	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
ability	B-X
of	B-X
long	B-X
chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
(	B-X
PUFAs	B-X
)	B-X
to	B-X
inhibit	B-X
protein	B-X
fatty	B-X
acylation	B-X
.	B-X
PUFAs	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
inhibit	B-X
T	B-X
cell	B-X
signaling	B-X
by	B-X
excluding	B-X
Src	B-X
family	B-X
kinases	B-X
from	B-X
DRMs	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
PUFAs	B-X
arachidonic	B-X
acid	B-X
and	B-X
eicosapentaenoic	B-X
acid	B-X
inhibit	B-X
Fyn	B-X
palmitoylation	B-X
and	B-X
consequently	B-X
block	B-X
Fyn	B-X
localization	B-X
to	B-X
DRMs	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
inhibition	B-X
of	B-X
protein	B-X
palmitoylation	B-X
represents	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
PUFAs	B-X
exert	B-X
their	B-X
immunosuppressive	B-X
effects	B-X
.	B-X

Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
into	O
rabbit	O
cornea	O
induces	O
HSV	O
-	O
1	O
reactivation	O
:	O
evidence	O
that	O
neuronal	O
signaling	O
changes	O
after	O
infection	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

PURPOSE	O
:	O
Lysophosphatidic	O
acid	O
induces	O
neurite	O
retraction	O
;	O
it	O
is	O
also	O
present	O
in	O
tears	O
and	O
aqueous	O
humor	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

We	O
determined	O
whether	O
lysophosphatidic	O
acid	O
induces	O
HSV	O
-	O
1	O
reactivation	O
in	O
latently	O
infected	O
rabbits	O
and	O
whether	O
the	O
nerve	O
growth	O
associated	O
protein	O
GAP	B-Protein
-	I-Protein
43	I-Protein
undergoes	O
posttranslational	O
modification	O
during	O
the	O
course	O
of	O
HSV	O
-	O
1	O
infection	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

METHODS	O
:	O
Rabbits	O
were	O
infected	O
with	O
HSV	O
-	O
1	O
and	O
acute	O
infection	O
was	O
documented	O
by	O
slit	O
lamp	O
examination	O
.	O
<EOS>	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

Corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
treated	O
with	O
lysophosphatidic	O
acid	O
or	O
lysophosphatidylserine	O
(	O
structurally	O
similar	O
but	O
lacking	O
biological	O
potency	O
)	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

For	O
application	O
to	O
the	O
cornea	O
,	O
these	O
compounds	O
were	O
impregnated	O
into	O
collagen	O
shields	O
,	O
applied	O
as	O
topical	O
drops	O
,	O
or	O
iontophoresed	O
.	O
<EOS>	B-X
None	B-X
of	B-X
the	B-X
12	B-X
patients	B-X
who	B-X
had	B-X
two-stage	B-X
revision	B-X
with	B-X
iontophoresed	B-X
allografts	B-X
had	B-X
further	B-X
infection	B-X
after	B-X
a	B-X
mean	B-X
period	B-X
of	B-X
47	B-X
months	B-X
(	B-X
14	B-X
to	B-X
78	B-X
)	B-X
.	B-X
Topical	B-X
creams	B-X
such	B-X
as	B-X
lidocaine/	B-X
prilocaine	B-X
(	B-X
EMLA	B-X
)	B-X
or	B-X
tetracaine	B-X
,	B-X
iontophoresed	B-X
lidocaine	B-X
,	B-X
or	B-X
buffered	B-X
lidocaine	B-X
subcutaneously	B-X
injected	B-X
with	B-X
fine	B-X
needles	B-X
can	B-X
make	B-X
intravenous	B-X
catheter	B-X
placement	B-X
virtually	B-X
'painless	B-X
'	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
opioids	B-X
to	B-X
modulate	B-X
other	B-X
transmitters	B-X
was	B-X
determined	B-X
using	B-X
microiontophoretically	B-X
applied	B-X
ligands	B-X
and	B-X
extracellular	B-X
recordings	B-X
of	B-X
VP	B-X
neurons	B-X
from	B-X
chloral	B-X
hydrate-anesthetized	B-X
rats	B-X
.	B-X
With	B-X
neurons	B-X
that	B-X
responded	B-X
to	B-X
iontophoresed	B-X
opioid	B-X
agonists	B-X
,	B-X
the	B-X
ejection	B-X
current	B-X
was	B-X
reduced	B-X
to	B-X
a	B-X
level	B-X
that	B-X
was	B-X
below	B-X
that	B-X
necessary	B-X
to	B-X
alter	B-X
spontaneous	B-X
firing	B-X
.	B-X
This	B-X
``	B-X
subthreshold	B-X
''	B-X
current	B-X
was	B-X
used	B-X
to	B-X
determine	B-X
the	B-X
ability	B-X
of	B-X
mu	B-X
opioid	B-X
receptor	B-X
(	B-X
microR	B-X
)	B-X
agonists	B-X
to	B-X
alter	B-X
VP	B-X
responses	B-X
to	B-X
endogenous	B-X
(	B-X
released	B-X
by	B-X
electrical	B-X
activation	B-X
of	B-X
afferents	B-X
)	B-X
and	B-X
exogenous	B-X
(	B-X
iontophoretically	B-X
applied	B-X
)	B-X
transmitters	B-X
.	B-X

In	O
another	O
experiment	O
,	O
corneas	O
of	O
latently	O
infected	O
rabbits	O
were	O
either	O
untreated	O
or	O
treated	O
iontophoretically	O
with	O
lysophosphatidic	O
acid	O
,	O
lysophosphatidylserine	O
,	O
or	O
saline	O
.	O
<EOS>	B-X
Nasal	B-X
irrigation	B-X
or	B-X
nebulizing	B-X
aerosol	B-X
of	B-X
isotonic	B-X
or	B-X
hypertonic	B-X
saline	B-X
is	B-X
a	B-X
traditional	B-X
method	B-X
for	B-X
respiratory	B-X
or	B-X
nasal	B-X
care	B-X
.	B-X
We	B-X
therefore	B-X
analyzed	B-X
pharmacological/pharmacodynamic	B-X
effects	B-X
of	B-X
isotonic	B-X
or	B-X
hypertonic	B-X
saline	B-X
,	B-X
relevant	B-X
to	B-X
SARS-CoV-2	B-X
infection	B-X
and	B-X
respiratory	B-X
care	B-X
.	B-X
Both	B-X
saline	B-X
and	B-X
lactated	B-X
Ringer	B-X
's	B-X
solutions	B-X
are	B-X
commonly	B-X
given	B-X
to	B-X
surgical	B-X
patients	B-X
.	B-X
However	B-X
,	B-X
hyperchloremic	B-X
acidosis	B-X
consequent	B-X
to	B-X
saline	B-X
administration	B-X
may	B-X
provoke	B-X
complications	B-X
.	B-X
The	B-X
authors	B-X
therefore	B-X
tested	B-X
the	B-X
primary	B-X
hypothesis	B-X
that	B-X
a	B-X
composite	B-X
of	B-X
in-hospital	B-X
mortality	B-X
and	B-X
major	B-X
postoperative	B-X
complications	B-X
is	B-X
less	B-X
common	B-X
in	B-X
patients	B-X
given	B-X
lactated	B-X
Ringer	B-X
's	B-X
solution	B-X
than	B-X
normal	B-X
saline	B-X
.	B-X

Ocular	O
swabs	O
detected	O
shedding	O
of	O
infectious	O
virus	O
.	O
<EOS>	B-X
Mature	B-X
laying	B-X
chickens	B-X
were	B-X
inoculated	B-X
intratracheally	B-X
with	B-X
a	B-X
field	B-X
strain	B-X
of	B-X
infectious	B-X
laryngotracheitis	B-X
(	B-X
ILT	B-X
)	B-X
virus	B-X
.	B-X
Tracheal	B-X
swabs	B-X
were	B-X
collected	B-X
regularly	B-X
from	B-X
all	B-X
birds	B-X
for	B-X
virus	B-X
culture	B-X
.	B-X
At	B-X
various	B-X
times	B-X
post-inoculation	B-X
,	B-X
pairs	B-X
of	B-X
birds	B-X
were	B-X
killed	B-X
and	B-X
tissues	B-X
removed	B-X
for	B-X
detection	B-X
of	B-X
virus	B-X
products	B-X
using	B-X
conventional	B-X
tissue	B-X
homogenization	B-X
and	B-X
culture	B-X
,	B-X
organ	B-X
culture	B-X
,	B-X
indirect	B-X
immunofluorescence	B-X
(	B-X
IF	B-X
)	B-X
and	B-X
also	B-X
the	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
.	B-X
The	B-X
latter	B-X
was	B-X
used	B-X
to	B-X
detect	B-X
a	B-X
DNA	B-X
sequence	B-X
from	B-X
the	B-X
ILT	B-X
virus	B-X
thymidine	B-X
kinase	B-X
gene	B-X
.	B-X
Trachea	B-X
and	B-X
turbinate	B-X
tissues	B-X
were	B-X
virus-positive	B-X
as	B-X
determined	B-X
by	B-X
virus	B-X
isolation	B-X
,	B-X
organ	B-X
culture	B-X
,	B-X
IF	B-X
and	B-X
PCR	B-X
on	B-X
day	B-X
4	B-X
post-inoculation	B-X
.	B-X
After	B-X
recovery	B-X
from	B-X
the	B-X
acute	B-X
phase	B-X
,	B-X
virus	B-X
shedding	B-X
initially	B-X
ceased	B-X
,	B-X
then	B-X
intermittent	B-X
,	B-X
low	B-X
level	B-X
shedding	B-X
was	B-X
recorded	B-X
for	B-X
five	B-X
of	B-X
the	B-X
six	B-X
remaining	B-X
birds	B-X
.	B-X
Virus	B-X
was	B-X
not	B-X
detected	B-X
in	B-X
upper	B-X
respiratory	B-X
tract	B-X
or	B-X
ocular	B-X
tissues	B-X
by	B-X
conventional	B-X
techniques	B-X
,	B-X
or	B-X
in	B-X
the	B-X
trigeminal	B-X
,	B-X
proximal	B-X
and	B-X
distal	B-X
ganglia	B-X
.	B-X
All	B-X
PCR-positive	B-X
birds	B-X
had	B-X
previously	B-X
shed	B-X
ILT	B-X
virus	B-X
intermittently	B-X
between	B-X
days	B-X
19	B-X
and	B-X
59	B-X
post-inoculation	B-X
.	B-X
As	B-X
we	B-X
did	B-X
not	B-X
detect	B-X
viral	B-X
DNA	B-X
in	B-X
any	B-X
of	B-X
the	B-X
other	B-X
tissues	B-X
sampled	B-X
from	B-X
clinically	B-X
recovered	B-X
birds	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
trigeminal	B-X
ganglion	B-X
is	B-X
the	B-X
main	B-X
site	B-X
of	B-X
latency	B-X
of	B-X
ILT	B-X
virus	B-X
.	B-X

Western	O
blot	O
and	O
immunoprecipitation	O
identified	O
GAP	B-Protein
-	I-Protein
43	I-Protein
in	O
corneal	O
extracts	O
and	O
densitometry	O
of	O
silver	O
-	O
stained	O
isoelectric	O
focusing	O
gels	O
measured	O
changes	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
isoform	O
abundance	O
.	O
<EOS>	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

RESULTS	O
:	O
Iontophoresis	O
of	O
lysophosphatidic	O
acid	O
induced	O
HSV	O
-	O
1	O
shedding	O
more	O
frequently	O
than	O
lysophosphatidylserine	O
or	O
saline	O
.	O
<EOS>	B-X
Patients	B-X
with	B-X
severe	B-X
(	B-X
serum	B-X
sodium	B-X
≤120	B-X
mEq/L	B-X
)	B-X
,	B-X
symptomatic	B-X
hyponatremia	B-X
can	B-X
develop	B-X
life-threatening	B-X
or	B-X
fatal	B-X
complications	B-X
from	B-X
cerebral	B-X
edema	B-X
if	B-X
treatment	B-X
is	B-X
inadequate	B-X
and	B-X
permanent	B-X
neurologic	B-X
disability	B-X
from	B-X
osmotic	B-X
demyelination	B-X
if	B-X
treatment	B-X
is	B-X
excessive	B-X
.	B-X
Nasal	B-X
irrigation	B-X
or	B-X
nebulizing	B-X
aerosol	B-X
of	B-X
isotonic	B-X
or	B-X
hypertonic	B-X
saline	B-X
is	B-X
a	B-X
traditional	B-X
method	B-X
for	B-X
respiratory	B-X
or	B-X
nasal	B-X
care	B-X
.	B-X
A	B-X
recent	B-X
small	B-X
study	B-X
in	B-X
outpatients	B-X
with	B-X
COVID-19	B-X
without	B-X
acute	B-X
respiratory	B-X
distress	B-X
syndrome	B-X
suggests	B-X
substantial	B-X
symptom	B-X
resolution	B-X
.	B-X
We	B-X
therefore	B-X
analyzed	B-X
pharmacological/pharmacodynamic	B-X
effects	B-X
of	B-X
isotonic	B-X
or	B-X
hypertonic	B-X
saline	B-X
,	B-X
relevant	B-X
to	B-X
SARS-CoV-2	B-X
infection	B-X
and	B-X
respiratory	B-X
care	B-X
.	B-X

Viral	O
shedding	O
induced	O
by	O
collagen	O
shield	O
and	O
topical	O
drop	O
administration	O
was	O
low	O
and	O
not	O
significantly	O
different	O
for	O
lysophosphatidic	O
acid	O
and	O
lysophosphatidylserine	O
.	O

Five	O
discrete	O
GAP	B-Protein
-	I-Protein
43	I-Protein
isoforms	O
predominated	O
in	O
the	O
IEF	O
gels	O
.	O
<EOS>	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

Most	O
abundant	O
were	O
the	O
pI	O
4	O
.	O
7	O
band	O
in	O
uninfected	O
cornea	O
and	O
the	O
pI	O
5	O
.	O
05	O
band	O
in	O
latently	O
-	O
infected	O
cornea	O
.	O
<EOS>	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

Compared	O
to	O
latently	O
-	O
infected	O
cornea	O
,	O
there	O
was	O
no	O
significant	O
change	O
in	O
isoform	O
abundance	O
1	O
h	O
after	O
lysophosphatidic	O
acid	O
iontophoresis	O
,	O
but	O
24	O
and	O
72	O
h	O
later	O
,	O
the	O
pI	O
5	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

05	O
band	O
was	O
diminished	O
.	O
<EOS>	B-X
Considering	B-X
the	B-X
enamel	B-X
chemical	B-X
structure	B-X
,	B-X
especially	B-X
carbonate	B-X
band	B-X
,	B-X
which	B-X
has	B-X
a	B-X
major	B-X
role	B-X
in	B-X
the	B-X
caries	B-X
prevention	B-X
,	B-X
the	B-X
objective	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
assess	B-X
the	B-X
chemical	B-X
alterations	B-X
on	B-X
the	B-X
enamel	B-X
irradiated	B-X
with	B-X
CO	B-X
(	B-X
2	B-X
)	B-X
laser	B-X
by	B-X
means	B-X
of	B-X
FTIR	B-X
spectroscopy	B-X
and	B-X
SEM	B-X
analysis	B-X
.	B-X
Phase	B-X
locking	B-X
in	B-X
the	B-X
gamma-band	B-X
range	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
diminished	B-X
in	B-X
patients	B-X
with	B-X
schizophrenia	B-X
.	B-X
Moreover	B-X
,	B-X
there	B-X
have	B-X
been	B-X
reports	B-X
of	B-X
positive	B-X
correlations	B-X
between	B-X
phase	B-X
locking	B-X
in	B-X
the	B-X
gamma-band	B-X
range	B-X
and	B-X
positive	B-X
symptoms	B-X
,	B-X
especially	B-X
hallucinations	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
the	B-X
present	B-X
study	B-X
was	B-X
to	B-X
use	B-X
a	B-X
new	B-X
methodological	B-X
approach	B-X
in	B-X
order	B-X
to	B-X
investigate	B-X
gamma-band	B-X
phase	B-X
synchronization	B-X
between	B-X
the	B-X
left	B-X
and	B-X
right	B-X
auditory	B-X
cortex	B-X
in	B-X
patients	B-X
with	B-X
schizophrenia	B-X
and	B-X
its	B-X
relationship	B-X
to	B-X
auditory	B-X
hallucinations	B-X
.	B-X
Current	B-X
source	B-X
density	B-X
of	B-X
the	B-X
40	B-X
ASSR	B-X
response	B-X
was	B-X
significantly	B-X
diminished	B-X
in	B-X
SZ	B-X
in	B-X
comparison	B-X
to	B-X
HC	B-X
in	B-X
the	B-X
right	B-X
superior	B-X
and	B-X
middle	B-X
temporal	B-X
gyrus	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Interhemispheric	B-X
phase	B-X
locking	B-X
was	B-X
reduced	B-X
in	B-X
SZ	B-X
in	B-X
comparison	B-X
to	B-X
HC	B-X
for	B-X
the	B-X
primary	B-X
auditory	B-X
cortices	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
)	B-X
but	B-X
not	B-X
in	B-X
the	B-X
secondary	B-X
auditory	B-X
cortices	B-X
.	B-X
A	B-X
significant	B-X
positive	B-X
correlation	B-X
was	B-X
found	B-X
between	B-X
auditory	B-X
hallucination	B-X
symptom	B-X
scores	B-X
and	B-X
phase	B-X
synchronization	B-X
between	B-X
the	B-X
primary	B-X
auditory	B-X
cortices	B-X
(	B-X
p	B-X
<	B-X
0.05	B-X
,	B-X
corrected	B-X
for	B-X
multiple	B-X
testing	B-X
)	B-X
but	B-X
not	B-X
for	B-X
the	B-X
secondary	B-X
auditory	B-X
cortices	B-X
.	B-X

CONCLUSIONS	O
:	O
Lysophosphatidic	O
acid	O
can	O
induce	O
HSV	O
-	O
1	O
reactivation	O
and	O
changes	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
pI	O
suggest	O
that	O
posttranslational	O
modifications	O
,	O
possibly	O
related	O
to	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
,	O
are	O
occurring	O
during	O
HSV	O
-	O
1	O
latency	O
and	O
after	O
LPA	O
is	O
iontophoretically	O
applied	O
to	O
the	O
cornea	O
.	O

How	O
lysophosphatidic	O
acid	O
-	O
induced	O
signaling	O
,	O
HSV	O
-	O
1	O
reactivation	O
,	O
and	O
GAP	B-Protein
-	I-Protein
43	I-Protein
pI	O
are	O
related	O
remains	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
Lysophosphatidic	B-X
acid	B-X
induces	B-X
neurite	B-X
retraction	B-X
;	B-X
it	B-X
is	B-X
also	B-X
present	B-X
in	B-X
tears	B-X
and	B-X
aqueous	B-X
humor	B-X
.	B-X
We	B-X
determined	B-X
whether	B-X
lysophosphatidic	B-X
acid	B-X
induces	B-X
HSV-1	B-X
reactivation	B-X
in	B-X
latently	B-X
infected	B-X
rabbits	B-X
and	B-X
whether	B-X
the	B-X
nerve	B-X
growth	B-X
associated	B-X
protein	B-X
GAP-43	B-X
undergoes	B-X
posttranslational	B-X
modification	B-X
during	B-X
the	B-X
course	B-X
of	B-X
HSV-1	B-X
infection	B-X
.	B-X

Nedd8	B-Protein
modification	O
of	O
cul	B-Protein
-	I-Protein
1	I-Protein
activates	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

Regulation	O
of	O
NF	O
-	O
kappaB	O
occurs	O
through	O
phosphorylation	O
-	O
dependent	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
,	O
which	O
is	O
degraded	O
by	O
the	O
26S	O
proteasome	O
.	O
<EOS>	B-X
Alternative	B-X
redox	B-X
stimuli	B-X
such	B-X
as	B-X
pervanadate	B-X
or	B-X
hypoxia/reoxygenation	B-X
,	B-X
induce	B-X
transcription	B-X
factor	B-X
NF-κB	B-X
by	B-X
phospho-tyrosine-dependent	B-X
and	B-X
proteasome-independent	B-X
mechanisms	B-X
.	B-X
While	B-X
considerable	B-X
attention	B-X
has	B-X
been	B-X
paid	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
proteasomal	B-X
regulation	B-X
of	B-X
tyrosine	B-X
phosphorylated	B-X
IκBα	B-X
,	B-X
there	B-X
is	B-X
a	B-X
paucity	B-X
of	B-X
information	B-X
regarding	B-X
proteasomal	B-X
regulation	B-X
of	B-X
signaling	B-X
events	B-X
distinct	B-X
from	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
IκBα	B-X
.	B-X
To	B-X
delineate	B-X
roles	B-X
for	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
in	B-X
the	B-X
phospho-tyrosine	B-X
dependent	B-X
mechanism	B-X
of	B-X
NF-κB	B-X
induction	B-X
,	B-X
we	B-X
employed	B-X
the	B-X
proteasome	B-X
inhibitor	B-X
,	B-X
Aclacinomycin	B-X
,	B-X
and	B-X
the	B-X
phosphotyrosine	B-X
phosphatase	B-X
inhibitor	B-X
,	B-X
pervanadate	B-X
(	B-X
PV	B-X
)	B-X
.	B-X
Correspondingly	B-X
,	B-X
proteasome	B-X
inhibition	B-X
had	B-X
no	B-X
discernable	B-X
effect	B-X
on	B-X
the	B-X
key	B-X
signaling	B-X
intermediaries	B-X
,	B-X
Src	B-X
and	B-X
ERK1/2	B-X
,	B-X
involved	B-X
in	B-X
the	B-X
phospho-tyrosine	B-X
mechanisms	B-X
regulating	B-X
PV-mediated	B-X
activation	B-X
of	B-X
NF-κB	B-X
.	B-X
Consistent	B-X
with	B-X
previous	B-X
reports	B-X
,	B-X
a	B-X
significant	B-X
redox	B-X
imbalance	B-X
leading	B-X
to	B-X
the	B-X
activation	B-X
of	B-X
tyrosine	B-X
kinases	B-X
,	B-X
as	B-X
occurs	B-X
with	B-X
pervanadate	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
NF-κB	B-X
.	B-X
Strikingly	B-X
,	B-X
our	B-X
studies	B-X
demonstrate	B-X
that	B-X
proteasome	B-X
inhibition	B-X
can	B-X
potentiate	B-X
oxidative	B-X
stress	B-X
associated	B-X
with	B-X
PV-stimulation	B-X
without	B-X
impacting	B-X
kinase	B-X
activation	B-X
,	B-X
however	B-X
,	B-X
other	B-X
cellular	B-X
implications	B-X
for	B-X
this	B-X
increase	B-X
in	B-X
intracellular	B-X
oxidation	B-X
remain	B-X
to	B-X
be	B-X
fully	B-X
delineated	B-X
.	B-X

Recent	O
studies	O
have	O
shown	O
that	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
is	O
carried	O
out	O
by	O
a	O
ubiquitin	B-Protein
-	O
ligase	O
enzyme	O
complex	O
called	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

Here	O
we	O
show	O
that	O
Nedd8	B-Protein
modification	O
of	O
the	O
Cul	B-Protein
-	I-Protein
1	I-Protein
component	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
is	O
important	O
for	O
function	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
in	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

In	O
cells	O
,	O
Nedd8	B-Protein
-	O
conjugated	O
Cul	B-Protein
-	I-Protein
1	I-Protein
was	O
complexed	O
with	O
two	O
substrates	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
,	O
phosphorylated	O
IkappaBalpha	B-Protein
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
indicating	O
that	O
Nedd8	B-Protein
-	O
Cul	B-Protein
-	I-Protein
1	I-Protein
conjugates	O
are	O
part	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
in	O
vivo	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

Although	O
only	O
a	O
minute	O
fraction	O
of	O
total	O
cellular	O
Cul	B-Protein
-	I-Protein
1	I-Protein
is	O
modified	O
by	O
Nedd8	B-Protein
,	O
the	O
Cul	B-Protein
-	I-Protein
1	I-Protein
associated	O
with	O
ectopically	O
expressed	O
betaTrCP	B-Protein
was	O
highly	O
enriched	O
for	O
the	O
Nedd8	B-Protein
-	O
conjugated	O
form	O
.	O

Moreover	O
,	O
optimal	O
ubiquitination	O
of	O
IkappaBalpha	B-Protein
required	O
Nedd8	B-Protein
and	O
the	O
Nedd8	B-Protein
-	O
conjugating	O
enzyme	O
,	O
Ubc12	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

The	O
site	O
of	O
Nedd8	B-Protein
ligation	O
to	O
Cul	B-Protein
-	I-Protein
1	I-Protein
is	O
essential	O
,	O
as	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
containing	O
a	O
K720R	O
mutant	O
of	O
Cul	B-Protein
-	I-Protein
1	I-Protein
only	O
weakly	O
supported	O
IkappaBalpha	B-Protein
ubiquitination	O
compared	O
to	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
containing	O
WT	O
Cul	B-Protein
-	I-Protein
1	I-Protein
,	O
suggesting	O
that	O
the	O
Nedd8	B-Protein
ligation	O
of	O
Cul	B-Protein
-	I-Protein
1	I-Protein
affects	O
the	O
ubiquitination	O
activity	O
of	O
SCF	O
(	O
beta	B-Protein
(	I-Protein
TrCP	I-Protein
)	I-Protein
)	O
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

These	O
observations	O
provide	O
a	O
functional	O
link	O
between	O
the	O
highly	O
related	O
ubiquitin	B-Protein
and	O
Nedd8	B-Protein
pathways	O
of	O
protein	O
modification	O
and	O
show	O
how	O
they	O
operate	O
together	O
to	O
selectively	O
target	O
the	O
signal	O
-	O
dependent	O
degradation	O
of	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
Regulation	B-X
of	B-X
NF-kappaB	B-X
occurs	B-X
through	B-X
phosphorylation-dependent	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
which	B-X
is	B-X
degraded	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
is	B-X
carried	B-X
out	B-X
by	B-X
a	B-X
ubiquitin-ligase	B-X
enzyme	B-X
complex	B-X
called	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
Cul-1	B-X
component	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
is	B-X
important	B-X
for	B-X
function	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
Nedd8-conjugated	B-X
Cul-1	B-X
was	B-X
complexed	B-X
with	B-X
two	B-X
substrates	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
,	B-X
phosphorylated	B-X
IkappaBalpha	B-X
and	B-X
beta-catenin	B-X
,	B-X
indicating	B-X
that	B-X
Nedd8-Cul-1	B-X
conjugates	B-X
are	B-X
part	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
in	B-X
vivo	B-X
.	B-X
Although	B-X
only	B-X
a	B-X
minute	B-X
fraction	B-X
of	B-X
total	B-X
cellular	B-X
Cul-1	B-X
is	B-X
modified	B-X
by	B-X
Nedd8	B-X
,	B-X
the	B-X
Cul-1	B-X
associated	B-X
with	B-X
ectopically	B-X
expressed	B-X
betaTrCP	B-X
was	B-X
highly	B-X
enriched	B-X
for	B-X
the	B-X
Nedd8-conjugated	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
optimal	B-X
ubiquitination	B-X
of	B-X
IkappaBalpha	B-X
required	B-X
Nedd8	B-X
and	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
,	B-X
Ubc12	B-X
.	B-X
The	B-X
site	B-X
of	B-X
Nedd8	B-X
ligation	B-X
to	B-X
Cul-1	B-X
is	B-X
essential	B-X
,	B-X
as	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
a	B-X
K720R	B-X
mutant	B-X
of	B-X
Cul-1	B-X
only	B-X
weakly	B-X
supported	B-X
IkappaBalpha	B-X
ubiquitination	B-X
compared	B-X
to	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
containing	B-X
WT	B-X
Cul-1	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
Nedd8	B-X
ligation	B-X
of	B-X
Cul-1	B-X
affects	B-X
the	B-X
ubiquitination	B-X
activity	B-X
of	B-X
SCF	B-X
(	B-X
beta	B-X
(	B-X
TrCP	B-X
)	B-X
)	B-X
.	B-X
These	B-X
observations	B-X
provide	B-X
a	B-X
functional	B-X
link	B-X
between	B-X
the	B-X
highly	B-X
related	B-X
ubiquitin	B-X
and	B-X
Nedd8	B-X
pathways	B-X
of	B-X
protein	B-X
modification	B-X
and	B-X
show	B-X
how	B-X
they	B-X
operate	B-X
together	B-X
to	B-X
selectively	B-X
target	B-X
the	B-X
signal-dependent	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X

v	B-Protein
-	I-Protein
Src	I-Protein
suppresses	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
via	O
the	O
Ras	O
-	O
MAP	O
kinase	O
pathway	O
to	O
promote	O
the	O
oncogenic	O
growth	O
of	O
cells	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

We	O
investigated	O
the	O
effect	O
of	O
cell	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
on	O
the	O
expression	O
and	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
,	O
a	O
putative	O
docking	O
protein	O
for	O
SHP	B-Protein
-	I-Protein
1	I-Protein
and	O
SHP	B-Protein
-	I-Protein
2	I-Protein
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

We	O
found	O
that	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
virtually	O
inhibited	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
at	O
mRNA	O
level	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

While	O
nontransforming	O
Src	O
kinases	O
including	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
nonmyristoylated	O
forms	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
had	O
no	O
inhibitory	O
effect	O
on	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
,	O
transforming	O
Src	O
kinases	O
including	O
wild	O
-	O
type	O
v	B-Protein
-	I-Protein
Src	I-Protein
and	O
chimeric	O
mutant	O
of	O
c	B-Protein
-	I-Protein
Src	I-Protein
bearing	O
v	B-Protein
-	I-Protein
Src	I-Protein
SH3	O
substantially	O
suppressed	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

In	O
cells	O
expressing	O
temperature	O
sensitive	O
mutant	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
,	O
suppression	O
of	O
the	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
was	O
temperature	O
-	O
dependent	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

In	O
contrast	O
,	O
tyrosine	O
phosphorylation	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
was	O
rather	O
activated	O
in	O
cells	O
expressing	O
c	B-Protein
-	I-Protein
Src	I-Protein
or	O
nonmyristoylated	O
forms	O
of	O
v	B-Protein
-	I-Protein
Src	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
used	B-X
anti-phosphotyrosine	B-X
antibodies	B-X
to	B-X
identify	B-X
a	B-X
large	B-X
number	B-X
of	B-X
tyrosine	B-X
phosphoproteins	B-X
in	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
(	B-X
RSV	B-X
)	B-X
-transformed	B-X
chicken	B-X
embryo	B-X
fibroblasts	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
the	B-X
100,000	B-X
X	B-X
g	B-X
supernatant	B-X
when	B-X
cells	B-X
were	B-X
separated	B-X
into	B-X
soluble	B-X
and	B-X
particulate	B-X
fractions	B-X
;	B-X
however	B-X
,	B-X
one	B-X
group	B-X
of	B-X
proteins	B-X
,	B-X
of	B-X
115-120	B-X
kDa	B-X
,	B-X
was	B-X
found	B-X
in	B-X
the	B-X
particulate	B-X
fraction	B-X
.	B-X
The	B-X
phosphotyrosine	B-X
content	B-X
of	B-X
the	B-X
115-	B-X
to	B-X
120-kDa	B-X
proteins	B-X
was	B-X
greatly	B-X
reduced	B-X
in	B-X
chicken	B-X
embryo	B-X
fibroblasts	B-X
infected	B-X
with	B-X
mutants	B-X
of	B-X
RSV	B-X
(	B-X
NY314	B-X
and	B-X
SD10	B-X
)	B-X
encoding	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
the	B-X
viral	B-X
src	B-X
gene	B-X
product	B-X
that	B-X
do	B-X
not	B-X
associate	B-X
with	B-X
cellular	B-X
membranes	B-X
.	B-X
Since	B-X
RSV	B-X
mutants	B-X
NY314	B-X
and	B-X
SD10	B-X
do	B-X
not	B-X
transform	B-X
cells	B-X
,	B-X
phosphorylation	B-X
of	B-X
this	B-X
group	B-X
of	B-X
115-	B-X
to	B-X
120-kDa	B-X
membrane	B-X
proteins	B-X
may	B-X
be	B-X
related	B-X
to	B-X
the	B-X
process	B-X
of	B-X
transformation	B-X
.	B-X

SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
in	O
SR3Y1	O
was	O
restored	O
by	O
treatment	O
with	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
,	O
or	O
by	O
the	O
expression	O
of	O
dominant	O
negative	O
form	O
of	O
Ras	O
.	O
<EOS>	B-X
Upregulated	B-X
signal	B-X
flow	B-X
through	B-X
RAS	B-X
and	B-X
the	B-X
mitogen-associated	B-X
protein	B-X
kinase	B-X
(	B-X
MAPK	B-X
)	B-X
cascade	B-X
is	B-X
the	B-X
unifying	B-X
mechanistic	B-X
theme	B-X
of	B-X
the	B-X
RASopathies	B-X
,	B-X
a	B-X
family	B-X
of	B-X
disorders	B-X
affecting	B-X
development	B-X
and	B-X
growth	B-X
.	B-X
Pathogenic	B-X
variants	B-X
in	B-X
more	B-X
than	B-X
20	B-X
genes	B-X
have	B-X
been	B-X
causally	B-X
linked	B-X
to	B-X
RASopathies	B-X
,	B-X
the	B-X
majority	B-X
having	B-X
a	B-X
dominant	B-X
role	B-X
in	B-X
promoting	B-X
enhanced	B-X
signaling	B-X
.	B-X
Homozygosity	B-X
for	B-X
three	B-X
different	B-X
variants-c.187C	B-X
>	B-X
T	B-X
(	B-X
p.Arg63	B-X
The	B-X
dynein	B-X
motor	B-X
protein	B-X
complex	B-X
is	B-X
required	B-X
for	B-X
retrograde	B-X
transport	B-X
but	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
intermediate-light	B-X
chains	B-X
that	B-X
form	B-X
the	B-X
cargo-binding	B-X
complex	B-X
are	B-X
not	B-X
elucidated	B-X
and	B-X
the	B-X
importance	B-X
of	B-X
individual	B-X
subunits	B-X
in	B-X
maintaining	B-X
cellular	B-X
homeostasis	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
using	B-X
mRNA	B-X
arrays	B-X
and	B-X
protein	B-X
analysis	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
dynein	B-X
subunit	B-X
,	B-X
DYNC1LI2	B-X
(	B-X
dynein	B-X
,	B-X
cytoplasmic	B-X
1	B-X
light	B-X
intermediate	B-X
chain	B-X
2	B-X
)	B-X
is	B-X
downregulated	B-X
in	B-X
cystinosis	B-X
,	B-X
a	B-X
lysosomal	B-X
storage	B-X
disorder	B-X
caused	B-X
by	B-X
genetic	B-X
defects	B-X
in	B-X
CTNS	B-X
(	B-X
cystinosin	B-X
,	B-X
lysosomal	B-X
cystine	B-X
transporter	B-X
)	B-X
.	B-X
Reconstitution	B-X
of	B-X
DYNC1LI2	B-X
expression	B-X
in	B-X

Contrary	O
,	O
active	O
form	O
of	O
Mekl	B-Protein
markedly	O
suppressed	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
.	O
<EOS>	B-X
We	B-X
investigated	B-X
the	B-X
effect	B-X
of	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
on	B-X
the	B-X
expression	B-X
and	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
,	B-X
a	B-X
putative	B-X
docking	B-X
protein	B-X
for	B-X
SHP-1	B-X
and	B-X
SHP-2	B-X
.	B-X
We	B-X
found	B-X
that	B-X
transformation	B-X
by	B-X
v-src	B-X
virtually	B-X
inhibited	B-X
the	B-X
SHPS-1	B-X
expression	B-X
at	B-X
mRNA	B-X
level	B-X
.	B-X
While	B-X
nontransforming	B-X
Src	B-X
kinases	B-X
including	B-X
c-Src	B-X
,	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
had	B-X
no	B-X
inhibitory	B-X
effect	B-X
on	B-X
SHPS-1	B-X
expression	B-X
,	B-X
transforming	B-X
Src	B-X
kinases	B-X
including	B-X
wild-type	B-X
v-Src	B-X
and	B-X
chimeric	B-X
mutant	B-X
of	B-X
c-Src	B-X
bearing	B-X
v-Src	B-X
SH3	B-X
substantially	B-X
suppressed	B-X
the	B-X
SHPS-1	B-X
expression	B-X
.	B-X
In	B-X
cells	B-X
expressing	B-X
temperature	B-X
sensitive	B-X
mutant	B-X
of	B-X
v-Src	B-X
,	B-X
suppression	B-X
of	B-X
the	B-X
SHPS-1	B-X
expression	B-X
was	B-X
temperature-dependent	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
SHPS-1	B-X
was	B-X
rather	B-X
activated	B-X
in	B-X
cells	B-X
expressing	B-X
c-Src	B-X
or	B-X
nonmyristoylated	B-X
forms	B-X
of	B-X
v-Src	B-X
.	B-X
SHPS-1	B-X
expression	B-X
in	B-X
SR3Y1	B-X
was	B-X
restored	B-X
by	B-X
treatment	B-X
with	B-X
herbimycin	B-X
A	B-X
,	B-X
a	B-X
potent	B-X
inhibitor	B-X
of	B-X
tyrosine	B-X
kinase	B-X
,	B-X
or	B-X
by	B-X
the	B-X
expression	B-X
of	B-X
dominant	B-X
negative	B-X
form	B-X
of	B-X
Ras	B-X
.	B-X
Contrary	B-X
,	B-X
active	B-X
form	B-X
of	B-X
Mekl	B-X
markedly	B-X
suppressed	B-X
SHPS-1	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
overexpression	B-X
of	B-X
SHPS-1	B-X
in	B-X
SR3Y1	B-X
led	B-X
to	B-X
the	B-X
drastic	B-X
reduction	B-X
of	B-X
anchorage	B-X
independent	B-X
growth	B-X
of	B-X
the	B-X
cells	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
suppression	B-X
of	B-X
SHPS-1	B-X
expression	B-X
is	B-X
a	B-X
pivotal	B-X
event	B-X
for	B-X
cell	B-X
transformation	B-X
by	B-X
v-src	B-X
,	B-X
and	B-X
the	B-X
Ras-MAP	B-X
kinase	B-X
cascade	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
suppression	B-X
.	B-X

Finally	O
,	O
overexpression	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
in	O
SR3Y1	O
led	O
to	O
the	O
drastic	O
reduction	O
of	O
anchorage	O
independent	O
growth	O
of	O
the	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
SHPS	B-Protein
-	I-Protein
1	I-Protein
expression	O
is	O
a	O
pivotal	O
event	O
for	O
cell	O
transformation	O
by	O
v	B-Protein
-	I-Protein
src	I-Protein
,	O
and	O
the	O
Ras	O
-	O
MAP	O
kinase	O
cascade	O
plays	O
a	O
critical	O
role	O
in	O
the	O
suppression	O
.	O

A	O
Nedd8	B-Protein
conjugation	O
pathway	O
is	O
essential	O
for	O
proteolytic	O
targeting	O
of	O
p27Kip1	B-Protein
by	O
ubiquitination	O
.	O
<EOS>	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

Temporal	O
control	O
of	O
p27	B-Protein
(	I-Protein
Kip1	I-Protein
)	I-Protein
(	O
p27	B-Protein
)	O
degradation	O
imposes	O
periodicity	O
in	O
its	O
activity	O
during	O
cell	O
cycle	O
progression	O
and	O
its	O
accumulation	O
during	O
cell	O
cycle	O
exit	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X

Degradation	O
of	O
p27	B-Protein
is	O
initiated	O
by	O
phosphorylation	O
of	O
p27	B-Protein
at	O
Thr	O
-	O
187	O
,	O
which	O
marks	O
the	O
protein	O
for	O
ubiquitination	O
by	O
SCF	O
(	O
Skp2	B-Protein
)	O
and	O
subsequent	O
proteolysis	O
by	O
the	O
26S	O
proteasome	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X

Here	O
we	O
show	O
that	O
the	O
p27	B-Protein
ubiquitination	O
activity	O
in	O
cell	O
extracts	O
depends	O
on	O
the	O
presence	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
and	O
enzymes	O
that	O
catalyze	O
Nedd8	B-Protein
conjugation	O
to	O
proteins	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

Moreover	O
,	O
we	O
show	O
that	O
reconstitution	O
of	O
the	O
p27	B-Protein
ubiquitination	O
activity	O
of	O
recombinant	O
SCF	O
(	O
Skp2	B-Protein
)	O
also	O
requires	O
Nedd8	B-Protein
conjugation	O
pathway	O
components	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

Inactivation	O
of	O
the	O
Nedd8	B-Protein
conjugation	O
pathway	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
the	O
Nedd8	B-Protein
-	O
conjugating	O
enzyme	O
Nce1	B-Protein
/	O
Ubc12	B-Protein
blocks	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
p27	B-Protein
in	O
cell	O
extracts	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

Consistent	O
with	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
Nedd8	B-Protein
is	O
expressed	O
in	O
proliferating	O
cells	O
and	O
is	O
itself	O
down	O
-	O
regulated	O
upon	O
cellular	O
differentiation	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

These	O
results	O
suggest	O
that	O
the	O
Nedd8	B-Protein
conjugation	O
pathway	O
may	O
regulate	O
the	O
turnover	O
of	O
p27	B-Protein
(	I-Protein
Kip1	I-Protein
)	I-Protein
,	O
independently	O
of	O
p27	B-Protein
phosphorylation	O
,	O
and	O
further	O
establishes	O
the	O
identity	O
of	O
protein	O
components	O
involved	O
in	O
p27	B-Protein
ubiquitination	O
.	O
<EOS>	B-X
Temporal	B-X
control	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
(	B-X
p27	B-X
)	B-X
degradation	B-X
imposes	B-X
periodicity	B-X
in	B-X
its	B-X
activity	B-X
during	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
its	B-X
accumulation	B-X
during	B-X
cell	B-X
cycle	B-X
exit	B-X
.	B-X
Degradation	B-X
of	B-X
p27	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
p27	B-X
at	B-X
Thr-187	B-X
,	B-X
which	B-X
marks	B-X
the	B-X
protein	B-X
for	B-X
ubiquitination	B-X
by	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
and	B-X
subsequent	B-X
proteolysis	B-X
by	B-X
the	B-X
26S	B-X
proteasome	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
in	B-X
cell	B-X
extracts	B-X
depends	B-X
on	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
and	B-X
enzymes	B-X
that	B-X
catalyze	B-X
Nedd8	B-X
conjugation	B-X
to	B-X
proteins	B-X
.	B-X
Moreover	B-X
,	B-X
we	B-X
show	B-X
that	B-X
reconstitution	B-X
of	B-X
the	B-X
p27	B-X
ubiquitination	B-X
activity	B-X
of	B-X
recombinant	B-X
SCF	B-X
(	B-X
Skp2	B-X
)	B-X
also	B-X
requires	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
components	B-X
.	B-X
Inactivation	B-X
of	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
by	B-X
a	B-X
dominant	B-X
negative	B-X
mutant	B-X
of	B-X
the	B-X
Nedd8-conjugating	B-X
enzyme	B-X
Nce1/Ubc12	B-X
blocks	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
p27	B-X
in	B-X
cell	B-X
extracts	B-X
.	B-X
Consistent	B-X
with	B-X
a	B-X
role	B-X
in	B-X
cell-cycle	B-X
progression	B-X
,	B-X
Nedd8	B-X
is	B-X
expressed	B-X
in	B-X
proliferating	B-X
cells	B-X
and	B-X
is	B-X
itself	B-X
down-regulated	B-X
upon	B-X
cellular	B-X
differentiation	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
may	B-X
regulate	B-X
the	B-X
turnover	B-X
of	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
independently	B-X
of	B-X
p27	B-X
phosphorylation	B-X
,	B-X
and	B-X
further	B-X
establishes	B-X
the	B-X
identity	B-X
of	B-X
protein	B-X
components	B-X
involved	B-X
in	B-X
p27	B-X
ubiquitination	B-X
.	B-X
Finally	B-X
,	B-X
these	B-X
findings	B-X
provide	B-X
a	B-X
direct	B-X
demonstration	B-X
of	B-X
a	B-X
function	B-X
for	B-X
Nedd8	B-X
in	B-X
a	B-X
biological	B-X
process	B-X
.	B-X

Finally	O
,	O
these	O
findings	O
provide	O
a	O
direct	O
demonstration	O
of	O
a	O
function	O
for	O
Nedd8	B-Protein
in	O
a	O
biological	O
process	O
.	O

Isoprenylation	O
/	O
methylation	O
and	O
transducin	O
function	O
.	O
<EOS>	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
This	B-X
result	B-X
is	B-X
readily	B-X
understandable	B-X
in	B-X
light	B-X
of	B-X
the	B-X
role	B-X
of	B-X
methylation	B-X
in	B-X
selectively	B-X
enhancing	B-X
hydrophobicity	B-X
of	B-X
farnesylated	B-X
proteins	B-X
as	B-X
opposed	B-X
to	B-X
geranyl-geranylated	B-X
proteins	B-X
.	B-X

Freshly	O
prepared	O
proteolyzed	O
(	O
deprenylated	O
)	O
T	O
beta	O
gamma	O
and	O
material	O
isolated	O
from	O
retina	O
are	O
inert	O
with	O
respect	O
to	O
activating	O
T	O
alpha	O
in	O
the	O
presence	O
of	O
R	O
*	O
in	O
detergent	O
and	O
in	O
disk	O
membranes	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
)	B-X

In	O
addition	O
,	O
proteolyzed	O
T	O
beta	O
gamma	O
is	O
also	O
incapable	O
of	O
supporting	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
T	O
alpha	O
-	O
GDP	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

These	O
experiments	O
show	O
that	O
isoprenylation	O
/	O
methylation	O
is	O
essential	O
for	O
the	O
fruitful	O
interactions	O
between	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
at	O
the	O
membrane	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
support	O
GTP	O
-	O
for	O
-	O
GDP	O
exchange	O
catalyzed	O
by	O
R	O
*	O
,	O
demethylated	O
T	O
beta	O
gamma	O
proved	O
to	O
be	O
approximately	O
50	O
%	O
as	O
active	O
as	O
methylated	O
T	O
beta	O
gamma	O
in	O
photoreceptor	O
disk	O
membranes	O
(	O
Fig	O
.	O
3	O
)	O
and	O
in	O
reconstituted	O
liposomes	O
containing	O
rhodopsin	B-Protein
.	O

In	O
detergent	O
,	O
no	O
difference	O
was	O
observed	O
between	O
methylated	O
and	O
demethylated	O
T	O
beta	O
gamma	O
,	O
suggesting	O
no	O
role	O
at	O
all	O
for	O
the	O
methyl	O
group	O
in	O
functional	O
interactions	O
between	O
T	O
alpha	O
,	O
T	O
beta	O
gamma	O
,	O
and	O
R	O
*	O
.	O

The	O
twofold	O
activity	O
difference	O
observed	O
in	O
membranes	O
can	O
be	O
accounted	O
for	O
by	O
the	O
twofold	O
lessened	O
affinity	O
of	O
the	O
demethylated	O
T	O
beta	O
gamma	O
,	O
compared	O
with	O
its	O
methylated	O
counterpart	O
,	O
for	O
membranes	O
in	O
the	O
presence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
a	O
substantially	O
larger	O
difference	O
(	O
>	O
10	O
-	O
fold	O
)	O
in	O
the	O
relative	O
binding	O
of	O
methylated	O
versus	O
demethylated	O
T	O
beta	O
gamma	O
to	O
membranes	O
is	O
observed	O
in	O
the	O
absence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
.	O

However	O
,	O
R	O
*	O
has	O
a	O
substantial	O
affinity	O
for	O
T	O
alpha	O
beta	O
gamma	O
,	O
and	O
the	O
influence	O
of	O
R	O
*	O
and	O
T	O
alpha	O
greatly	O
reduces	O
any	O
differences	O
resulting	O
from	O
the	O
presence	O
or	O
absence	O
of	O
a	O
methyl	O
group	O
on	O
T	O
beta	O
gamma	O
.	O

The	O
results	O
from	O
studies	O
of	O
demethylated	O
T	O
beta	O
gamma	O
demonstrate	O
that	O
specific	O
lipid	O
-	O
receptor	O
interactions	O
are	O
unlikely	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
rhodopsin	B-Protein
-	O
transducin	O
system	O
,	O
and	O
further	O
show	O
that	O
the	O
effect	O
of	O
methylation	O
is	O
probably	O
due	O
to	O
the	O
increased	O
hydrophobicity	O
of	O
methylated	O
T	O
beta	O
gamma	O
versus	O
its	O
unmethylated	O
counterpart	O
.	O

These	O
studies	O
are	O
,	O
of	O
course	O
,	O
relevant	O
to	O
heterotrimeric	O
G	O
proteins	O
,	O
and	O
specifically	O
to	O
the	O
interactions	O
of	O
receptor	O
(	O
R	O
*	O
)	O
with	O
T	O
alpha	O
and	O
T	O
beta	O
gamma	O
.	O

If	O
a	O
hydrophobic	O
lipid	O
-	O
lipid	O
mechanism	O
is	O
operative	O
,	O
the	O
state	O
of	O
methylation	O
would	O
be	O
expected	O
to	O
have	O
a	O
more	O
profound	O
effect	O
on	O
the	O
membrane	O
-	O
associative	O
properties	O
of	O
farnesylated	O
proteins	O
,	O
but	O
not	O
on	O
those	O
of	O
geranylgeranylated	O
proteins	O
.	O

The	O
increased	O
hydrophobicity	O
of	O
the	O
C20	O
geranylgeranyl	O
group	O
relative	O
to	O
the	O
C15	O
farnesyl	O
group	O
will	O
compensate	O
for	O
the	O
loss	O
of	O
the	O
methyl	O
substituent	O
.	O

The	O
results	O
obtained	O
in	O
the	O
transducin	O
-	O
rhodopsin	B-Protein
system	O
can	O
be	O
contrasted	O
with	O
the	O
effect	O
of	O
gamma	O
-	O
subunit	O
methylation	O
on	O
effector	O
enzyme	O
activation	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
3	B-X
)	B-X
and	B-X
in	B-X
reconstituted	B-X
liposomes	B-X
containing	B-X
rhodopsin	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
This	B-X
result	B-X
is	B-X
readily	B-X
understandable	B-X
in	B-X
light	B-X
of	B-X
the	B-X
role	B-X
of	B-X
methylation	B-X
in	B-X
selectively	B-X
enhancing	B-X
hydrophobicity	B-X
of	B-X
farnesylated	B-X
proteins	B-X
as	B-X
opposed	B-X
to	B-X
geranyl-geranylated	B-X
proteins	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

In	O
the	O
case	O
of	O
the	O
geranylgeranylated	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
,	O
methylation	O
proved	O
to	O
have	O
only	O
a	O
small	O
effect	O
on	O
PIPLC	O
beta	O
activation	O
(	O
Fig	O
.	O
4B	O
)	O
.	O

An	O
approximately	O
25	O
%	O
diminution	O
in	O
efficacy	O
,	O
but	O
not	O
potency	O
,	O
was	O
observed	O
for	O
the	O
demethylated	O
geranylgeranylated	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
versus	O
its	O
methylated	O
counterpart	O
.	O
<EOS>	B-X
Four	B-X
hundred	B-X
and	B-X
twenty-three	B-X
alcohol	B-X
dependent	B-X
subjects	B-X
were	B-X
enrolled	B-X
into	B-X
a	B-X
12-week	B-X
randomized	B-X
,	B-X
double-blind	B-X
,	B-X
placebo-controlled	B-X
study	B-X
to	B-X
determine	B-X
the	B-X
safety	B-X
and	B-X
efficacy	B-X
of	B-X
the	B-X
5-HT2	B-X
receptor	B-X
antagonist	B-X
,	B-X
ritanserin	B-X
(	B-X
2.5	B-X
mg/day	B-X
or	B-X
5	B-X
mg/day	B-X
)	B-X
,	B-X
in	B-X
reducing	B-X
alcohol	B-X
intake	B-X
and	B-X
craving	B-X
.	B-X
All	B-X
subjects	B-X
received	B-X
1	B-X
week	B-X
of	B-X
single-blind	B-X
placebo	B-X
prior	B-X
to	B-X
randomization	B-X
into	B-X
the	B-X
11-week	B-X
double-blind	B-X
phase	B-X
.	B-X
Comparing	B-X
the	B-X
single-blind	B-X
period	B-X
with	B-X
endpoint	B-X
,	B-X
there	B-X
was	B-X
approximately	B-X
a	B-X
23	B-X
%	B-X
reduction	B-X
in	B-X
drinks/day	B-X
;	B-X
34	B-X
%	B-X
fall	B-X
in	B-X
the	B-X
total	B-X
number	B-X
of	B-X
drinking	B-X
days/week	B-X
;	B-X
22	B-X
%	B-X
decrease	B-X
in	B-X
drinks/drinking	B-X
day	B-X
;	B-X
and	B-X
a	B-X
37	B-X
%	B-X
diminution	B-X
in	B-X
alcohol	B-X
craving	B-X
for	B-X
all	B-X
treatment	B-X
groups	B-X
.	B-X

This	O
again	O
shows	O
that	O
specific	O
lipid	O
-	O
protein	O
interactions	O
are	O
unimportant	O
.	O
<EOS>	B-X
The	B-X
autoimmunity	B-X
hypothesis	B-X
fails	B-X
to	B-X
explain	B-X
why	B-X
genetic	B-X
and	B-X
environmental	B-X
risk	B-X
factors	B-X
linked	B-X
to	B-X
the	B-X
disease	B-X
in	B-X
one	B-X
population	B-X
tend	B-X
to	B-X
be	B-X
unimportant	B-X
in	B-X
other	B-X
populations	B-X
.	B-X
I	B-X
propose	B-X
a	B-X
new	B-X
framework	B-X
for	B-X
understanding	B-X
MS	B-X
as	B-X
a	B-X
dysfunction	B-X
of	B-X
the	B-X
metabolism	B-X
of	B-X
lipids	B-X
.	B-X
Specifically	B-X
,	B-X
the	B-X
homeostasis	B-X
of	B-X
lipid	B-X
metabolism	B-X
collapses	B-X
during	B-X
acute-phase	B-X
inflammatory	B-X
response	B-X
triggered	B-X
by	B-X
a	B-X
pathogen	B-X
,	B-X
trauma	B-X
,	B-X
or	B-X
stress	B-X
,	B-X
starting	B-X
a	B-X
feedback	B-X
loop	B-X
of	B-X
increased	B-X
oxidative	B-X
stress	B-X
,	B-X
inflammatory	B-X
response	B-X
,	B-X
and	B-X
proliferation	B-X
of	B-X
cytoxic	B-X
foam	B-X
cells	B-X
that	B-X
cross	B-X
the	B-X
blood	B-X
brain	B-X
barrier	B-X
and	B-X
both	B-X
catabolize	B-X
myelin	B-X
and	B-X
prevent	B-X
remyelination	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
This	B-X
again	B-X
shows	B-X
that	B-X
specific	B-X
lipid-protein	B-X
interactions	B-X
are	B-X
unimportant	B-X
.	B-X
This	B-X
result	B-X
is	B-X
readily	B-X
understandable	B-X
in	B-X
light	B-X
of	B-X
the	B-X
role	B-X
of	B-X
methylation	B-X
in	B-X
selectively	B-X
enhancing	B-X
hydrophobicity	B-X
of	B-X
farnesylated	B-X
proteins	B-X
as	B-X
opposed	B-X
to	B-X
geranyl-geranylated	B-X
proteins	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

The	O
effect	O
of	O
methylation	O
on	O
membrane	O
binding	O
would	O
be	O
expected	O
to	O
be	O
small	O
,	O
given	O
that	O
beta	B-Protein
1	I-Protein
gamma	B-Protein
2	I-Protein
is	O
geranylgeranylated	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
the	B-X
C20	B-X
geranylgeranyl	B-X
group	B-X
relative	B-X
to	B-X
the	B-X
C15	B-X
farnesyl	B-X
group	B-X
will	B-X
compensate	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
methyl	B-X
substituent	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
This	B-X
result	B-X
is	B-X
readily	B-X
understandable	B-X
in	B-X
light	B-X
of	B-X
the	B-X
role	B-X
of	B-X
methylation	B-X
in	B-X
selectively	B-X
enhancing	B-X
hydrophobicity	B-X
of	B-X
farnesylated	B-X
proteins	B-X
as	B-X
opposed	B-X
to	B-X
geranyl-geranylated	B-X
proteins	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

It	O
is	O
of	O
interest	O
to	O
compare	O
these	O
results	O
with	O
those	O
found	O
with	O
methylated	O
and	O
unmethylated	O
T	O
beta	O
gamma	O
as	O
activators	O
of	O
PIPLC	O
beta	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

In	O
this	O
instance	O
there	O
was	O
a	O
large	O
effect	O
noted	O
,	O
with	O
methylated	O
T	O
beta	O
gamma	O
being	O
at	O
least	O
10	O
-	O
fold	O
more	O
potent	O
than	O
its	O
unmethylated	O
counterpart	O
with	O
respect	O
to	O
activating	O
either	O
enzyme	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
4A	B-X
)	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

This	O
result	O
is	O
readily	O
understandable	O
in	O
light	O
of	O
the	O
role	O
of	O
methylation	O
in	O
selectively	O
enhancing	O
hydrophobicity	O
of	O
farnesylated	O
proteins	O
as	O
opposed	O
to	O
geranyl	O
-	O
geranylated	O
proteins	O
.	O
<EOS>	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
the	B-X
C20	B-X
geranylgeranyl	B-X
group	B-X
relative	B-X
to	B-X
the	B-X
C15	B-X
farnesyl	B-X
group	B-X
will	B-X
compensate	B-X
for	B-X
the	B-X
loss	B-X
of	B-X
the	B-X
methyl	B-X
substituent	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
This	B-X
result	B-X
is	B-X
readily	B-X
understandable	B-X
in	B-X
light	B-X
of	B-X
the	B-X
role	B-X
of	B-X
methylation	B-X
in	B-X
selectively	B-X
enhancing	B-X
hydrophobicity	B-X
of	B-X
farnesylated	B-X
proteins	B-X
as	B-X
opposed	B-X
to	B-X
geranyl-geranylated	B-X
proteins	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

Similar	O
results	O
were	O
obtained	O
for	O
the	O
activation	O
of	O
PI3K	O
,	O
further	O
strengthening	O
the	O
conclusion	O
that	O
it	O
is	O
lipid	O
-	O
lipid	O
interactions	O
that	O
direct	O
beta	O
gamma	O
subunit	O
membrane	O
association	O
.	O
<EOS>	B-X
Freshly	B-X
prepared	B-X
proteolyzed	B-X
(	B-X
deprenylated	B-X
)	B-X
T	B-X
beta	B-X
gamma	B-X
and	B-X
material	B-X
isolated	B-X
from	B-X
retina	B-X
are	B-X
inert	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
T	B-X
alpha	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
in	B-X
detergent	B-X
and	B-X
in	B-X
disk	B-X
membranes	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
proteolyzed	B-X
T	B-X
beta	B-X
gamma	B-X
is	B-X
also	B-X
incapable	B-X
of	B-X
supporting	B-X
the	B-X
pertussis	B-X
toxin-catalyzed	B-X
ADP	B-X
ribosylation	B-X
of	B-X
T	B-X
alpha-GDP	B-X
.	B-X
These	B-X
experiments	B-X
show	B-X
that	B-X
isoprenylation/methylation	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
fruitful	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
at	B-X
the	B-X
membrane	B-X
.	B-X
When	B-X
tested	B-X
for	B-X
its	B-X
ability	B-X
to	B-X
support	B-X
GTP-for-GDP	B-X
exchange	B-X
catalyzed	B-X
by	B-X
R	B-X
*	B-X
,	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
proved	B-X
to	B-X
be	B-X
approximately	B-X
50	B-X
%	B-X
as	B-X
active	B-X
as	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
in	B-X
photoreceptor	B-X
disk	B-X
membranes	B-X
(	B-X
Fig	B-X
.	B-X
In	B-X
detergent	B-X
,	B-X
no	B-X
difference	B-X
was	B-X
observed	B-X
between	B-X
methylated	B-X
and	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
suggesting	B-X
no	B-X
role	B-X
at	B-X
all	B-X
for	B-X
the	B-X
methyl	B-X
group	B-X
in	B-X
functional	B-X
interactions	B-X
between	B-X
T	B-X
alpha	B-X
,	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
R	B-X
*	B-X
.	B-X
The	B-X
twofold	B-X
activity	B-X
difference	B-X
observed	B-X
in	B-X
membranes	B-X
can	B-X
be	B-X
accounted	B-X
for	B-X
by	B-X
the	B-X
twofold	B-X
lessened	B-X
affinity	B-X
of	B-X
the	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
,	B-X
compared	B-X
with	B-X
its	B-X
methylated	B-X
counterpart	B-X
,	B-X
for	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
It	B-X
is	B-X
interesting	B-X
to	B-X
note	B-X
that	B-X
a	B-X
substantially	B-X
larger	B-X
difference	B-X
(	B-X
>	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
relative	B-X
binding	B-X
of	B-X
methylated	B-X
versus	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
to	B-X
membranes	B-X
is	B-X
observed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
.	B-X
However	B-X
,	B-X
R	B-X
*	B-X
has	B-X
a	B-X
substantial	B-X
affinity	B-X
for	B-X
T	B-X
alpha	B-X
beta	B-X
gamma	B-X
,	B-X
and	B-X
the	B-X
influence	B-X
of	B-X
R	B-X
*	B-X
and	B-X
T	B-X
alpha	B-X
greatly	B-X
reduces	B-X
any	B-X
differences	B-X
resulting	B-X
from	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
a	B-X
methyl	B-X
group	B-X
on	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
The	B-X
results	B-X
from	B-X
studies	B-X
of	B-X
demethylated	B-X
T	B-X
beta	B-X
gamma	B-X
demonstrate	B-X
that	B-X
specific	B-X
lipid-receptor	B-X
interactions	B-X
are	B-X
unlikely	B-X
to	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
the	B-X
rhodopsin-transducin	B-X
system	B-X
,	B-X
and	B-X
further	B-X
show	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
methylation	B-X
is	B-X
probably	B-X
due	B-X
to	B-X
the	B-X
increased	B-X
hydrophobicity	B-X
of	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
versus	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
.	B-X
These	B-X
studies	B-X
are	B-X
,	B-X
of	B-X
course	B-X
,	B-X
relevant	B-X
to	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
,	B-X
and	B-X
specifically	B-X
to	B-X
the	B-X
interactions	B-X
of	B-X
receptor	B-X
(	B-X
R	B-X
*	B-X
)	B-X
with	B-X
T	B-X
alpha	B-X
and	B-X
T	B-X
beta	B-X
gamma	B-X
.	B-X
If	B-X
a	B-X
hydrophobic	B-X
lipid-lipid	B-X
mechanism	B-X
is	B-X
operative	B-X
,	B-X
the	B-X
state	B-X
of	B-X
methylation	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
have	B-X
a	B-X
more	B-X
profound	B-X
effect	B-X
on	B-X
the	B-X
membrane-associative	B-X
properties	B-X
of	B-X
farnesylated	B-X
proteins	B-X
,	B-X
but	B-X
not	B-X
on	B-X
those	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
.	B-X
The	B-X
results	B-X
obtained	B-X
in	B-X
the	B-X
transducin-rhodopsin	B-X
system	B-X
can	B-X
be	B-X
contrasted	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
gamma-subunit	B-X
methylation	B-X
on	B-X
effector	B-X
enzyme	B-X
activation	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
the	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
,	B-X
methylation	B-X
proved	B-X
to	B-X
have	B-X
only	B-X
a	B-X
small	B-X
effect	B-X
on	B-X
PIPLC	B-X
beta	B-X
activation	B-X
(	B-X
Fig	B-X
.	B-X
An	B-X
approximately	B-X
25	B-X
%	B-X
diminution	B-X
in	B-X
efficacy	B-X
,	B-X
but	B-X
not	B-X
potency	B-X
,	B-X
was	B-X
observed	B-X
for	B-X
the	B-X
demethylated	B-X
geranylgeranylated	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
versus	B-X
its	B-X
methylated	B-X
counterpart	B-X
.	B-X
This	B-X
again	B-X
shows	B-X
that	B-X
specific	B-X
lipid-protein	B-X
interactions	B-X
are	B-X
unimportant	B-X
.	B-X
The	B-X
effect	B-X
of	B-X
methylation	B-X
on	B-X
membrane	B-X
binding	B-X
would	B-X
be	B-X
expected	B-X
to	B-X
be	B-X
small	B-X
,	B-X
given	B-X
that	B-X
beta	B-X
1	B-X
gamma	B-X
2	B-X
is	B-X
geranylgeranylated	B-X
.	B-X
It	B-X
is	B-X
of	B-X
interest	B-X
to	B-X
compare	B-X
these	B-X
results	B-X
with	B-X
those	B-X
found	B-X
with	B-X
methylated	B-X
and	B-X
unmethylated	B-X
T	B-X
beta	B-X
gamma	B-X
as	B-X
activators	B-X
of	B-X
PIPLC	B-X
beta	B-X
.	B-X
In	B-X
this	B-X
instance	B-X
there	B-X
was	B-X
a	B-X
large	B-X
effect	B-X
noted	B-X
,	B-X
with	B-X
methylated	B-X
T	B-X
beta	B-X
gamma	B-X
being	B-X
at	B-X
least	B-X
10-fold	B-X
more	B-X
potent	B-X
than	B-X
its	B-X
unmethylated	B-X
counterpart	B-X
with	B-X
respect	B-X
to	B-X
activating	B-X
either	B-X
enzyme	B-X
(	B-X
Fig	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
PI3K	B-X
,	B-X
further	B-X
strengthening	B-X
the	B-X
conclusion	B-X
that	B-X
it	B-X
is	B-X
lipid-lipid	B-X
interactions	B-X
that	B-X
direct	B-X
beta	B-X
gamma	B-X
subunit	B-X
membrane	B-X
association	B-X
.	B-X

(	O
ABSTRACT	O
TRUNCATED	O
)	O
<EOS>	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
250	B-X
WORDS	B-X
)	B-X
(	B-X
ABSTRACT	B-X
TRUNCATED	B-X
AT	B-X
400	B-X
WORDS	B-X
)	B-X

A	O
dominant	O
-	O
negative	O
UBC12	B-Protein
mutant	O
sequesters	O
NEDD8	B-Protein
and	O
inhibits	O
NEDD8	B-Protein
conjugation	O
in	O
vivo	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

NEDD8	B-Protein
,	O
a	O
novel	O
ubiquitin	B-Protein
-	O
like	O
protein	O
,	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

Recently	O
,	O
human	O
UBC12	B-Protein
was	O
identified	O
as	O
a	O
putative	O
NEDD8	B-Protein
conjugation	O
enzyme	O
(	O
E2	O
)	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

While	O
investigating	O
the	O
in	O
vivo	O
function	O
of	O
UBC12	B-Protein
,	O
we	O
found	O
that	O
the	O
point	O
mutant	O
,	O
UBC12	B-Protein
(	O
C111S	O
)	O
,	O
showed	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-Protein
conjugation	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

This	O
mutant	O
,	O
with	O
a	O
single	O
Cys	O
-	O
to	O
-	O
Ser	O
substitution	O
at	O
the	O
conserved	O
Cys	O
residue	O
in	O
the	O
E2	O
family	O
,	O
could	O
specifically	O
inhibit	O
NEDD8	B-Protein
conjugation	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

We	O
observed	O
the	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	B-Protein
conjugation	O
to	O
substrates	O
,	O
including	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
cullin	B-Protein
-	I-Protein
2	I-Protein
(	O
Cul	B-Protein
-	I-Protein
2	I-Protein
-	O
DeltaN	O
)	O
,	O
full	O
-	O
length	O
cullin	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
also	O
other	O
uncharacterized	O
target	O
proteins	O
.	O

Interestingly	O
,	O
UBC12	B-Protein
(	O
C111S	O
)	O
formed	O
a	O
heterodimeric	O
conjugate	O
with	O
NEDD8	B-Protein
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
This	B-X
conjugate	B-X
was	B-X
stable	B-X
under	B-X
stringent	B-X
conditions	B-X
,	B-X
including	B-X
6	B-X
m	B-X
guanidine	B-X
HCl	B-X
,	B-X
8	B-X
m	B-X
urea	B-X
,	B-X
2	B-X
%	B-X
SDS	B-X
,	B-X
or	B-X
5	B-X
%	B-X
beta-mercaptoethanol	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

This	O
conjugate	O
was	O
stable	O
under	O
stringent	O
conditions	O
,	O
including	O
6	O
m	O
guanidine	O
HCl	O
,	O
8	O
m	O
urea	O
,	O
2	O
%	O
SDS	O
,	O
or	O
5	O
%	O
beta	O
-	O
mercaptoethanol	O
.	O
<EOS>	B-X
Isolated	B-X
individual	B-X
components	B-X
of	B-X
the	B-X
triplet	B-X
of	B-X
neurofilaments	B-X
from	B-X
bovine	B-X
brain	B-X
can	B-X
reassemble	B-X
to	B-X
make	B-X
filaments	B-X
with	B-X
a	B-X
specific	B-X
structure	B-X
,	B-X
contrary	B-X
to	B-X
the	B-X
already	B-X
reported	B-X
result	B-X
that	B-X
NF-H	B-X
and	B-X
NF-M	B-X
can	B-X
not	B-X
make	B-X
filaments	B-X
alone	B-X
but	B-X
can	B-X
only	B-X
make	B-X
filaments	B-X
by	B-X
co-polymerization	B-X
with	B-X
NF-L.	B-X
2	B-X
.	B-X
The	B-X
triplet	B-X
components	B-X
of	B-X
neurofilaments	B-X
are	B-X
reduced	B-X
to	B-X
a	B-X
monomeric	B-X
form	B-X
in	B-X
8	B-X
M	B-X
urea	B-X
and	B-X
1	B-X
%	B-X
beta-mercaptoethanol	B-X
(	B-X
beta-ME	B-X
)	B-X
solution	B-X
.	B-X
However	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
beta-ME	B-X
,	B-X
a	B-X
part	B-X
of	B-X
each	B-X
component	B-X
of	B-X
the	B-X
triplet	B-X
was	B-X
preserved	B-X
as	B-X
oligomeric	B-X
forms	B-X
.	B-X
Among	B-X
them	B-X
,	B-X
a	B-X
stable	B-X
tetramer	B-X
of	B-X
NF-L	B-X
was	B-X
isolated	B-X
by	B-X
DE-52	B-X
column	B-X
chromatography	B-X
using	B-X
6	B-X
M	B-X
urea	B-X
solution	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
beta-ME	B-X
.	B-X
5	B-X
.	B-X

Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
UBC12	B-Protein
(	O
C111S	O
)	O
sequesters	O
the	O
NEDD8	B-Protein
monomer	O
by	O
forming	O
a	O
UBC12	B-Protein
(	O
C111S	O
)	O
-	O
NEDD8	B-Protein
conjugate	O
and	O
,	O
in	O
turn	O
,	O
inhibits	O
the	O
subsequent	O
transfer	O
of	O
NEDD8	B-Protein
to	O
its	O
targets	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
This	B-X
conjugate	B-X
was	B-X
stable	B-X
under	B-X
stringent	B-X
conditions	B-X
,	B-X
including	B-X
6	B-X
m	B-X
guanidine	B-X
HCl	B-X
,	B-X
8	B-X
m	B-X
urea	B-X
,	B-X
2	B-X
%	B-X
SDS	B-X
,	B-X
or	B-X
5	B-X
%	B-X
beta-mercaptoethanol	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

To	O
examine	O
the	O
biological	O
role	O
of	O
NEDD8	B-Protein
conjugation	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-Protein
was	O
applied	O
to	O
a	O
cell	O
growth	O
assay	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

Overexpression	O
of	O
UBC12	B-Protein
(	O
C111S	O
)	O
led	O
to	O
inhibition	O
of	O
growth	O
in	O
U2OS	O
and	O
HEK293	O
cells	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

Thus	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	B-Protein
could	O
be	O
useful	O
in	O
defining	O
the	O
role	O
of	O
NEDD8	B-Protein
modification	O
in	O
other	O
biological	O
systems	O
.	O
<EOS>	B-X
NEDD8	B-X
,	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
protein	B-X
,	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
conjugate	B-X
to	B-X
proteins	B-X
in	B-X
a	B-X
manner	B-X
analogous	B-X
to	B-X
ubiquitination	B-X
and	B-X
sentrinization	B-X
.	B-X
Recently	B-X
,	B-X
human	B-X
UBC12	B-X
was	B-X
identified	B-X
as	B-X
a	B-X
putative	B-X
NEDD8	B-X
conjugation	B-X
enzyme	B-X
(	B-X
E2	B-X
)	B-X
.	B-X
While	B-X
investigating	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
UBC12	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
point	B-X
mutant	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
,	B-X
showed	B-X
a	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
This	B-X
mutant	B-X
,	B-X
with	B-X
a	B-X
single	B-X
Cys-to-Ser	B-X
substitution	B-X
at	B-X
the	B-X
conserved	B-X
Cys	B-X
residue	B-X
in	B-X
the	B-X
E2	B-X
family	B-X
,	B-X
could	B-X
specifically	B-X
inhibit	B-X
NEDD8	B-X
conjugation	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
dominant-negative	B-X
effect	B-X
on	B-X
NEDD8	B-X
conjugation	B-X
to	B-X
substrates	B-X
,	B-X
including	B-X
the	B-X
C-terminal	B-X
fragment	B-X
of	B-X
cullin-2	B-X
(	B-X
Cul-2-DeltaN	B-X
)	B-X
,	B-X
full-length	B-X
cullin-1	B-X
,	B-X
and	B-X
also	B-X
other	B-X
uncharacterized	B-X
target	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
formed	B-X
a	B-X
heterodimeric	B-X
conjugate	B-X
with	B-X
NEDD8	B-X
.	B-X
Our	B-X
results	B-X
are	B-X
consistent	B-X
with	B-X
the	B-X
hypothesis	B-X
that	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
sequesters	B-X
the	B-X
NEDD8	B-X
monomer	B-X
by	B-X
forming	B-X
a	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
-NEDD8	B-X
conjugate	B-X
and	B-X
,	B-X
in	B-X
turn	B-X
,	B-X
inhibits	B-X
the	B-X
subsequent	B-X
transfer	B-X
of	B-X
NEDD8	B-X
to	B-X
its	B-X
targets	B-X
.	B-X
To	B-X
examine	B-X
the	B-X
biological	B-X
role	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
was	B-X
applied	B-X
to	B-X
a	B-X
cell	B-X
growth	B-X
assay	B-X
.	B-X
Overexpression	B-X
of	B-X
UBC12	B-X
(	B-X
C111S	B-X
)	B-X
led	B-X
to	B-X
inhibition	B-X
of	B-X
growth	B-X
in	B-X
U2OS	B-X
and	B-X
HEK293	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
this	B-X
dominant-negative	B-X
form	B-X
of	B-X
UBC12	B-X
could	B-X
be	B-X
useful	B-X
in	B-X
defining	B-X
the	B-X
role	B-X
of	B-X
NEDD8	B-X
modification	B-X
in	B-X
other	B-X
biological	B-X
systems	B-X
.	B-X

Heterogeneity	O
of	O
cardiac	O
rat	O
and	O
human	O
elongation	B-Protein
factor	I-Protein
2	I-Protein
.	O
<EOS>	B-X
Elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
catalyses	B-X
the	B-X
last	B-X
step	B-X
of	B-X
the	B-X
elongation	B-X
cycle	B-X
,	B-X
translocation	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
protein	B-X
biosynthesis	B-X
.	B-X
A	B-X
system	B-X
for	B-X
analyzing	B-X
post-translational	B-X
modifications	B-X
of	B-X
EF-2	B-X
,	B-X
which	B-X
is	B-X
a	B-X
single	B-X
polypeptide	B-X
of	B-X
857	B-X
amino	B-X
acids	B-X
,	B-X
is	B-X
reported	B-X
and	B-X
its	B-X
application	B-X
to	B-X
cytosolic	B-X
extracts	B-X
of	B-X
cultured	B-X
neonatal	B-X
rat	B-X
heart	B-X
myocytes	B-X
,	B-X
neonatal	B-X
and	B-X
adult	B-X
rat	B-X
cardiac	B-X
tissue	B-X
,	B-X
and	B-X
extracts	B-X
of	B-X
human	B-X
left	B-X
ventricular	B-X
myocardium	B-X
is	B-X
described	B-X
.	B-X
Comparing	B-X
different	B-X
pH	B-X
ranges	B-X
in	B-X
immobilized	B-X
pH	B-X
gradient-isoelectric	B-X
focusing	B-X
(	B-X
IPG-IEF	B-X
)	B-X
,	B-X
a	B-X
range	B-X
of	B-X
pH	B-X
3	B-X
-	B-X
10	B-X
and	B-X
4	B-X
-	B-X
9	B-X
resulted	B-X
in	B-X
a	B-X
highly	B-X
defined	B-X
and	B-X
reproducible	B-X
resolution	B-X
of	B-X
six	B-X
different	B-X
EF-2	B-X
variants	B-X
of	B-X
all	B-X
extracts	B-X
in	B-X
the	B-X
first	B-X
dimension	B-X
.	B-X
These	B-X
six	B-X
variants	B-X
were	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
imaging	B-X
plate	B-X
''	B-X
(	B-X
phosphor	B-X
radiation	B-X
image	B-X
sensor	B-X
)	B-X
after	B-X
specific	B-X
labeling	B-X
with	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
catalyzed	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylation	B-X
.	B-X
Using	B-X
two-dimensional	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
2-D-PAGE	B-X
)	B-X
,	B-X
five	B-X
to	B-X
six	B-X
EF-2	B-X
variants	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
extracts	B-X
.	B-X
By	B-X
application	B-X
of	B-X
a	B-X
second	B-X
IPG	B-X
indicator	B-X
strip	B-X
to	B-X
the	B-X
2-D	B-X
gel	B-X
,	B-X
they	B-X
could	B-X
be	B-X
aligned	B-X
with	B-X
corresponding	B-X
spots	B-X
in	B-X
a	B-X
silver-stained	B-X
2-D	B-X
separation	B-X
of	B-X
human	B-X
myocardial	B-X
tissue	B-X
,	B-X
revealing	B-X
that	B-X
the	B-X
EF-2	B-X
variants	B-X
belong	B-X
to	B-X
the	B-X
group	B-X
of	B-X
low-abundance	B-X
proteins	B-X
.	B-X

Elongation	B-Protein
factor	I-Protein
2	I-Protein
(	O
EF	B-Protein
-	I-Protein
2	I-Protein
)	O
catalyses	O
the	O
last	O
step	O
of	O
the	O
elongation	O
cycle	O
,	O
translocation	O
,	O
in	O
the	O
course	O
of	O
protein	O
biosynthesis	O
.	O
<EOS>	B-X
Elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
catalyses	B-X
the	B-X
last	B-X
step	B-X
of	B-X
the	B-X
elongation	B-X
cycle	B-X
,	B-X
translocation	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
protein	B-X
biosynthesis	B-X
.	B-X
A	B-X
system	B-X
for	B-X
analyzing	B-X
post-translational	B-X
modifications	B-X
of	B-X
EF-2	B-X
,	B-X
which	B-X
is	B-X
a	B-X
single	B-X
polypeptide	B-X
of	B-X
857	B-X
amino	B-X
acids	B-X
,	B-X
is	B-X
reported	B-X
and	B-X
its	B-X
application	B-X
to	B-X
cytosolic	B-X
extracts	B-X
of	B-X
cultured	B-X
neonatal	B-X
rat	B-X
heart	B-X
myocytes	B-X
,	B-X
neonatal	B-X
and	B-X
adult	B-X
rat	B-X
cardiac	B-X
tissue	B-X
,	B-X
and	B-X
extracts	B-X
of	B-X
human	B-X
left	B-X
ventricular	B-X
myocardium	B-X
is	B-X
described	B-X
.	B-X
Comparing	B-X
different	B-X
pH	B-X
ranges	B-X
in	B-X
immobilized	B-X
pH	B-X
gradient-isoelectric	B-X
focusing	B-X
(	B-X
IPG-IEF	B-X
)	B-X
,	B-X
a	B-X
range	B-X
of	B-X
pH	B-X
3	B-X
-	B-X
10	B-X
and	B-X
4	B-X
-	B-X
9	B-X
resulted	B-X
in	B-X
a	B-X
highly	B-X
defined	B-X
and	B-X
reproducible	B-X
resolution	B-X
of	B-X
six	B-X
different	B-X
EF-2	B-X
variants	B-X
of	B-X
all	B-X
extracts	B-X
in	B-X
the	B-X
first	B-X
dimension	B-X
.	B-X
These	B-X
six	B-X
variants	B-X
were	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
imaging	B-X
plate	B-X
''	B-X
(	B-X
phosphor	B-X
radiation	B-X
image	B-X
sensor	B-X
)	B-X
after	B-X
specific	B-X
labeling	B-X
with	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
catalyzed	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylation	B-X
.	B-X
Using	B-X
two-dimensional	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
2-D-PAGE	B-X
)	B-X
,	B-X
five	B-X
to	B-X
six	B-X
EF-2	B-X
variants	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
extracts	B-X
.	B-X
By	B-X
application	B-X
of	B-X
a	B-X
second	B-X
IPG	B-X
indicator	B-X
strip	B-X
to	B-X
the	B-X
2-D	B-X
gel	B-X
,	B-X
they	B-X
could	B-X
be	B-X
aligned	B-X
with	B-X
corresponding	B-X
spots	B-X
in	B-X
a	B-X
silver-stained	B-X
2-D	B-X
separation	B-X
of	B-X
human	B-X
myocardial	B-X
tissue	B-X
,	B-X
revealing	B-X
that	B-X
the	B-X
EF-2	B-X
variants	B-X
belong	B-X
to	B-X
the	B-X
group	B-X
of	B-X
low-abundance	B-X
proteins	B-X
.	B-X

A	O
system	O
for	O
analyzing	O
post	O
-	O
translational	O
modifications	O
of	O
EF	B-Protein
-	I-Protein
2	I-Protein
,	O
which	O
is	O
a	O
single	O
polypeptide	O
of	O
857	O
amino	O
acids	O
,	O
is	O
reported	O
and	O
its	O
application	O
to	O
cytosolic	O
extracts	O
of	O
cultured	O
neonatal	O
rat	O
heart	O
myocytes	O
,	O
neonatal	O
and	O
adult	O
rat	O
cardiac	O
tissue	O
,	O
and	O
extracts	O
of	O
human	O
left	O
ventricular	O
myocardium	O
is	O
described	O
.	O
<EOS>	B-X
Elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
catalyses	B-X
the	B-X
last	B-X
step	B-X
of	B-X
the	B-X
elongation	B-X
cycle	B-X
,	B-X
translocation	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
protein	B-X
biosynthesis	B-X
.	B-X
A	B-X
system	B-X
for	B-X
analyzing	B-X
post-translational	B-X
modifications	B-X
of	B-X
EF-2	B-X
,	B-X
which	B-X
is	B-X
a	B-X
single	B-X
polypeptide	B-X
of	B-X
857	B-X
amino	B-X
acids	B-X
,	B-X
is	B-X
reported	B-X
and	B-X
its	B-X
application	B-X
to	B-X
cytosolic	B-X
extracts	B-X
of	B-X
cultured	B-X
neonatal	B-X
rat	B-X
heart	B-X
myocytes	B-X
,	B-X
neonatal	B-X
and	B-X
adult	B-X
rat	B-X
cardiac	B-X
tissue	B-X
,	B-X
and	B-X
extracts	B-X
of	B-X
human	B-X
left	B-X
ventricular	B-X
myocardium	B-X
is	B-X
described	B-X
.	B-X
Comparing	B-X
different	B-X
pH	B-X
ranges	B-X
in	B-X
immobilized	B-X
pH	B-X
gradient-isoelectric	B-X
focusing	B-X
(	B-X
IPG-IEF	B-X
)	B-X
,	B-X
a	B-X
range	B-X
of	B-X
pH	B-X
3	B-X
-	B-X
10	B-X
and	B-X
4	B-X
-	B-X
9	B-X
resulted	B-X
in	B-X
a	B-X
highly	B-X
defined	B-X
and	B-X
reproducible	B-X
resolution	B-X
of	B-X
six	B-X
different	B-X
EF-2	B-X
variants	B-X
of	B-X
all	B-X
extracts	B-X
in	B-X
the	B-X
first	B-X
dimension	B-X
.	B-X
These	B-X
six	B-X
variants	B-X
were	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
imaging	B-X
plate	B-X
''	B-X
(	B-X
phosphor	B-X
radiation	B-X
image	B-X
sensor	B-X
)	B-X
after	B-X
specific	B-X
labeling	B-X
with	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
catalyzed	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylation	B-X
.	B-X
Using	B-X
two-dimensional	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
2-D-PAGE	B-X
)	B-X
,	B-X
five	B-X
to	B-X
six	B-X
EF-2	B-X
variants	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
extracts	B-X
.	B-X
By	B-X
application	B-X
of	B-X
a	B-X
second	B-X
IPG	B-X
indicator	B-X
strip	B-X
to	B-X
the	B-X
2-D	B-X
gel	B-X
,	B-X
they	B-X
could	B-X
be	B-X
aligned	B-X
with	B-X
corresponding	B-X
spots	B-X
in	B-X
a	B-X
silver-stained	B-X
2-D	B-X
separation	B-X
of	B-X
human	B-X
myocardial	B-X
tissue	B-X
,	B-X
revealing	B-X
that	B-X
the	B-X
EF-2	B-X
variants	B-X
belong	B-X
to	B-X
the	B-X
group	B-X
of	B-X
low-abundance	B-X
proteins	B-X
.	B-X

Comparing	O
different	O
pH	O
ranges	O
in	O
immobilized	O
pH	O
gradient	O
-	O
isoelectric	O
focusing	O
(	O
IPG	O
-	O
IEF	O
)	O
,	O
a	O
range	O
of	O
pH	O
3	O
-	O
10	O
and	O
4	O
-	O
9	O
resulted	O
in	O
a	O
highly	O
defined	O
and	O
reproducible	O
resolution	O
of	O
six	O
different	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
of	O
all	O
extracts	O
in	O
the	O
first	O
dimension	O
.	O

These	O
six	O
variants	O
were	O
detected	O
by	O
the	O
"	O
imaging	O
plate	O
"	O
(	O
phosphor	O
radiation	O
image	O
sensor	O
)	O
after	O
specific	O
labeling	O
with	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
catalyzed	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylation	O
.	O
<EOS>	B-X
Comparing	B-X
different	B-X
pH	B-X
ranges	B-X
in	B-X
immobilized	B-X
pH	B-X
gradient-isoelectric	B-X
focusing	B-X
(	B-X
IPG-IEF	B-X
)	B-X
,	B-X
a	B-X
range	B-X
of	B-X
pH	B-X
3	B-X
-	B-X
10	B-X
and	B-X
4	B-X
-	B-X
9	B-X
resulted	B-X
in	B-X
a	B-X
highly	B-X
defined	B-X
and	B-X
reproducible	B-X
resolution	B-X
of	B-X
six	B-X
different	B-X
EF-2	B-X
variants	B-X
of	B-X
all	B-X
extracts	B-X
in	B-X
the	B-X
first	B-X
dimension	B-X
.	B-X
These	B-X
six	B-X
variants	B-X
were	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
imaging	B-X
plate	B-X
''	B-X
(	B-X
phosphor	B-X
radiation	B-X
image	B-X
sensor	B-X
)	B-X
after	B-X
specific	B-X
labeling	B-X
with	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
catalyzed	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylation	B-X
.	B-X
This	B-X
finding	B-X
could	B-X
be	B-X
confirmed	B-X
in	B-X
Western	B-X
blot	B-X
analysis	B-X
with	B-X
a	B-X
specific	B-X
polyclonal	B-X
rabbit	B-X
antibody	B-X
.	B-X
Using	B-X
two-dimensional	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
2-D-PAGE	B-X
)	B-X
,	B-X
five	B-X
to	B-X
six	B-X
EF-2	B-X
variants	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
extracts	B-X
.	B-X
By	B-X
application	B-X
of	B-X
a	B-X
second	B-X
IPG	B-X
indicator	B-X
strip	B-X
to	B-X
the	B-X
2-D	B-X
gel	B-X
,	B-X
they	B-X
could	B-X
be	B-X
aligned	B-X
with	B-X
corresponding	B-X
spots	B-X
in	B-X
a	B-X
silver-stained	B-X
2-D	B-X
separation	B-X
of	B-X
human	B-X
myocardial	B-X
tissue	B-X
,	B-X
revealing	B-X
that	B-X
the	B-X
EF-2	B-X
variants	B-X
belong	B-X
to	B-X
the	B-X
group	B-X
of	B-X
low-abundance	B-X
proteins	B-X
.	B-X

This	O
finding	O
could	O
be	O
confirmed	O
in	O
Western	O
blot	O
analysis	O
with	O
a	O
specific	O
polyclonal	O
rabbit	O
antibody	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
described	B-X
the	B-X
production	B-X
of	B-X
a	B-X
polyclonal	B-X
peptide	B-X
antibody	B-X
against	B-X
the	B-X
adenylyl	B-X
cyclase-associated	B-X
protein	B-X
(	B-X
ACAP	B-X
)	B-X
of	B-X
A.	B-X
castellanii	B-X
,	B-X
and	B-X
evaluated	B-X
its	B-X
differential	B-X
diagnostic	B-X
potential	B-X
.	B-X
Enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
revealed	B-X
high	B-X
titers	B-X
of	B-X
A.	B-X
castellanii-specific	B-X
IgG	B-X
and	B-X
IgA	B-X
antibodies	B-X
being	B-X
present	B-X
in	B-X
low	B-X
dilutions	B-X
of	B-X
immunized	B-X
rabbit	B-X
serum	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
ACAP	B-X
antibody	B-X
specifically	B-X
interacted	B-X
with	B-X
A.	B-X
castellanii	B-X
,	B-X
while	B-X
not	B-X
interacting	B-X
with	B-X
human	B-X
corneal	B-X
epithelial	B-X
(	B-X
HCE	B-X
)	B-X
cells	B-X
and	B-X
other	B-X
causes	B-X
of	B-X
keratitis	B-X
such	B-X
as	B-X
Fusarium	B-X
solani	B-X
,	B-X
Pseudomonas	B-X
aeruginosa	B-X
,	B-X
and	B-X
Staphylococcus	B-X
aureus	B-X
.	B-X
Immunocytochemistry	B-X
(	B-X
ICC	B-X
)	B-X
results	B-X
confirmed	B-X
the	B-X
specific	B-X
detection	B-X
of	B-X
trophozoites	B-X
and	B-X
cysts	B-X
of	B-X
A.	B-X
castellanii	B-X
co-cultured	B-X
with	B-X
HCE	B-X
cells	B-X
.	B-X
The	B-X
ACAP	B-X
antibody	B-X
also	B-X
specifically	B-X
interacted	B-X
with	B-X
the	B-X
trophozoites	B-X
and	B-X
cysts	B-X
of	B-X
5	B-X
other	B-X
Acanthamoeba	B-X
species	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
ACAP	B-X
antibody	B-X
of	B-X
A.	B-X
castellanii	B-X
can	B-X
specifically	B-X
detect	B-X
multiple	B-X
AK-causing	B-X
members	B-X
belonging	B-X
to	B-X
the	B-X
genus	B-X
Acanthamoeba	B-X
and	B-X
may	B-X
be	B-X
useful	B-X
for	B-X
differentially	B-X
diagnosing	B-X
Acanthamoeba	B-X
infections	B-X
.	B-X

Using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
2	O
-	O
D	O
-	O
PAGE	O
)	O
,	O
five	O
to	O
six	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
could	O
be	O
demonstrated	O
in	O
all	O
extracts	O
.	O
<EOS>	B-X
Elongation	B-X
factor	B-X
2	B-X
(	B-X
EF-2	B-X
)	B-X
catalyses	B-X
the	B-X
last	B-X
step	B-X
of	B-X
the	B-X
elongation	B-X
cycle	B-X
,	B-X
translocation	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
protein	B-X
biosynthesis	B-X
.	B-X
A	B-X
system	B-X
for	B-X
analyzing	B-X
post-translational	B-X
modifications	B-X
of	B-X
EF-2	B-X
,	B-X
which	B-X
is	B-X
a	B-X
single	B-X
polypeptide	B-X
of	B-X
857	B-X
amino	B-X
acids	B-X
,	B-X
is	B-X
reported	B-X
and	B-X
its	B-X
application	B-X
to	B-X
cytosolic	B-X
extracts	B-X
of	B-X
cultured	B-X
neonatal	B-X
rat	B-X
heart	B-X
myocytes	B-X
,	B-X
neonatal	B-X
and	B-X
adult	B-X
rat	B-X
cardiac	B-X
tissue	B-X
,	B-X
and	B-X
extracts	B-X
of	B-X
human	B-X
left	B-X
ventricular	B-X
myocardium	B-X
is	B-X
described	B-X
.	B-X
Comparing	B-X
different	B-X
pH	B-X
ranges	B-X
in	B-X
immobilized	B-X
pH	B-X
gradient-isoelectric	B-X
focusing	B-X
(	B-X
IPG-IEF	B-X
)	B-X
,	B-X
a	B-X
range	B-X
of	B-X
pH	B-X
3	B-X
-	B-X
10	B-X
and	B-X
4	B-X
-	B-X
9	B-X
resulted	B-X
in	B-X
a	B-X
highly	B-X
defined	B-X
and	B-X
reproducible	B-X
resolution	B-X
of	B-X
six	B-X
different	B-X
EF-2	B-X
variants	B-X
of	B-X
all	B-X
extracts	B-X
in	B-X
the	B-X
first	B-X
dimension	B-X
.	B-X
These	B-X
six	B-X
variants	B-X
were	B-X
detected	B-X
by	B-X
the	B-X
``	B-X
imaging	B-X
plate	B-X
''	B-X
(	B-X
phosphor	B-X
radiation	B-X
image	B-X
sensor	B-X
)	B-X
after	B-X
specific	B-X
labeling	B-X
with	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
catalyzed	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylation	B-X
.	B-X
This	B-X
finding	B-X
could	B-X
be	B-X
confirmed	B-X
in	B-X
Western	B-X
blot	B-X
analysis	B-X
with	B-X
a	B-X
specific	B-X
polyclonal	B-X
rabbit	B-X
antibody	B-X
.	B-X
Using	B-X
two-dimensional	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
2-D-PAGE	B-X
)	B-X
,	B-X
five	B-X
to	B-X
six	B-X
EF-2	B-X
variants	B-X
could	B-X
be	B-X
demonstrated	B-X
in	B-X
all	B-X
extracts	B-X
.	B-X
By	B-X
application	B-X
of	B-X
a	B-X
second	B-X
IPG	B-X
indicator	B-X
strip	B-X
to	B-X
the	B-X
2-D	B-X
gel	B-X
,	B-X
they	B-X
could	B-X
be	B-X
aligned	B-X
with	B-X
corresponding	B-X
spots	B-X
in	B-X
a	B-X
silver-stained	B-X
2-D	B-X
separation	B-X
of	B-X
human	B-X
myocardial	B-X
tissue	B-X
,	B-X
revealing	B-X
that	B-X
the	B-X
EF-2	B-X
variants	B-X
belong	B-X
to	B-X
the	B-X
group	B-X
of	B-X
low-abundance	B-X
proteins	B-X
.	B-X

By	O
application	O
of	O
a	O
second	O
IPG	O
indicator	O
strip	O
to	O
the	O
2	O
-	O
D	O
gel	O
,	O
they	O
could	O
be	O
aligned	O
with	O
corresponding	O
spots	O
in	O
a	O
silver	O
-	O
stained	O
2	O
-	O
D	O
separation	O
of	O
human	O
myocardial	O
tissue	O
,	O
revealing	O
that	O
the	O
EF	B-Protein
-	I-Protein
2	I-Protein
variants	O
belong	O
to	O
the	O
group	O
of	O
low	O
-	O
abundance	O
proteins	O
.	O

Heteronuclear	O
NMR	O
studies	O
of	O
the	O
specificity	O
of	O
the	O
post	O
-	O
translational	O
modification	O
of	O
biotinyl	O
domains	O
by	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

The	O
lipoyl	O
domains	O
of	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
and	O
the	O
biotinyl	O
domains	O
of	O
biotin	O
-	O
dependent	O
enzymes	O
have	O
homologous	O
structures	O
,	O
but	O
the	O
target	O
lysine	O
residue	O
in	O
each	O
domain	O
is	O
correctly	O
selected	O
for	O
posttranslational	O
modification	O
by	O
lipoyl	B-Protein
protein	I-Protein
ligase	I-Protein
and	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

We	O
have	O
applied	O
two	O
-	O
dimensional	O
heteronuclear	O
NMR	O
spectroscopy	O
to	O
investigate	O
the	O
interaction	O
between	O
the	O
apo	O
form	O
of	O
the	O
biotinyl	O
domain	O
of	O
the	O
biotin	B-Protein
carboxyl	I-Protein
carrier	I-Protein
protein	I-Protein
of	I-Protein
acetyl	I-Protein
-	I-Protein
CoA	I-Protein
carboxylase	I-Protein
and	O
the	O
biotinyl	B-Protein
protein	I-Protein
ligase	I-Protein
(	O
BPL	B-Protein
)	O
from	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

Heteronuclear	O
multiple	O
quantum	O
coherence	O
NMR	O
spectra	O
of	O
the	O
15N	O
-	O
labelled	O
biotinyl	O
domain	O
were	O
recorded	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
ligase	O
and	O
backbone	O
amide	O
1H	O
and	O
15N	O
chemical	O
shifts	O
were	O
evaluated	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

Small	O
,	O
but	O
significant	O
,	O
changes	O
in	O
chemical	O
shift	O
were	O
found	O
in	O
two	O
regions	O
,	O
including	O
the	O
tight	O
beta	O
-	O
turn	O
that	O
houses	O
the	O
lysine	O
residue	O
targetted	O
for	O
biotinylation	O
,	O
and	O
the	O
beta	O
-	O
strand	O
2	O
and	O
the	O
loop	O
that	O
precedes	O
it	O
in	O
the	O
domain	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

When	O
compared	O
with	O
the	O
three	O
-	O
dimensional	O
structure	O
,	O
sequence	O
alignments	O
of	O
other	O
biotinyl	O
and	O
lipoyl	O
domains	O
,	O
and	O
mutagenesis	O
data	O
,	O
these	O
results	O
give	O
a	O
clear	O
indication	O
of	O
how	O
the	O
biotinyl	O
domain	O
is	O
both	O
recognised	O
by	O
BPL	B-Protein
and	O
distinguished	O
from	O
the	O
structurally	O
related	O
lipoyl	O
domain	O
to	O
ensure	O
correct	O
posttranslational	O
modification	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domains	B-X
of	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
and	B-X
the	B-X
biotinyl	B-X
domains	B-X
of	B-X
biotin-dependent	B-X
enzymes	B-X
have	B-X
homologous	B-X
structures	B-X
,	B-X
but	B-X
the	B-X
target	B-X
lysine	B-X
residue	B-X
in	B-X
each	B-X
domain	B-X
is	B-X
correctly	B-X
selected	B-X
for	B-X
posttranslational	B-X
modification	B-X
by	B-X
lipoyl	B-X
protein	B-X
ligase	B-X
and	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
,	B-X
respectively	B-X
.	B-X
We	B-X
have	B-X
applied	B-X
two-dimensional	B-X
heteronuclear	B-X
NMR	B-X
spectroscopy	B-X
to	B-X
investigate	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
apo	B-X
form	B-X
of	B-X
the	B-X
biotinyl	B-X
domain	B-X
of	B-X
the	B-X
biotin	B-X
carboxyl	B-X
carrier	B-X
protein	B-X
of	B-X
acetyl-CoA	B-X
carboxylase	B-X
and	B-X
the	B-X
biotinyl	B-X
protein	B-X
ligase	B-X
(	B-X
BPL	B-X
)	B-X
from	B-X
Escherichia	B-X
coli	B-X
.	B-X
Heteronuclear	B-X
multiple	B-X
quantum	B-X
coherence	B-X
NMR	B-X
spectra	B-X
of	B-X
the	B-X
15N-labelled	B-X
biotinyl	B-X
domain	B-X
were	B-X
recorded	B-X
in	B-X
the	B-X
presence	B-X
and	B-X
absence	B-X
of	B-X
the	B-X
ligase	B-X
and	B-X
backbone	B-X
amide	B-X
1H	B-X
and	B-X
15N	B-X
chemical	B-X
shifts	B-X
were	B-X
evaluated	B-X
.	B-X
Small	B-X
,	B-X
but	B-X
significant	B-X
,	B-X
changes	B-X
in	B-X
chemical	B-X
shift	B-X
were	B-X
found	B-X
in	B-X
two	B-X
regions	B-X
,	B-X
including	B-X
the	B-X
tight	B-X
beta-turn	B-X
that	B-X
houses	B-X
the	B-X
lysine	B-X
residue	B-X
targetted	B-X
for	B-X
biotinylation	B-X
,	B-X
and	B-X
the	B-X
beta-strand	B-X
2	B-X
and	B-X
the	B-X
loop	B-X
that	B-X
precedes	B-X
it	B-X
in	B-X
the	B-X
domain	B-X
.	B-X
When	B-X
compared	B-X
with	B-X
the	B-X
three-dimensional	B-X
structure	B-X
,	B-X
sequence	B-X
alignments	B-X
of	B-X
other	B-X
biotinyl	B-X
and	B-X
lipoyl	B-X
domains	B-X
,	B-X
and	B-X
mutagenesis	B-X
data	B-X
,	B-X
these	B-X
results	B-X
give	B-X
a	B-X
clear	B-X
indication	B-X
of	B-X
how	B-X
the	B-X
biotinyl	B-X
domain	B-X
is	B-X
both	B-X
recognised	B-X
by	B-X
BPL	B-X
and	B-X
distinguished	B-X
from	B-X
the	B-X
structurally	B-X
related	B-X
lipoyl	B-X
domain	B-X
to	B-X
ensure	B-X
correct	B-X
posttranslational	B-X
modification	B-X
.	B-X

Alternative	O
O	O
-	O
glycosylation	O
/	O
O	O
-	O
phosphorylation	O
of	O
the	O
murine	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
beta	B-X
,	B-X
a	B-X
homologue	B-X
to	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
steroid	B-X
hormone	B-X
receptor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
documented	B-X
that	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
like	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
is	B-X
modified	B-X
by	B-X
O-linked	B-X
N-acetylglucosamine	B-X
(	B-X
O-GlcNAc	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
transitory	B-X
posttranslational	B-X
modification	B-X
on	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
Lectin	B-X
chromatography	B-X
of	B-X
in	B-X
vitro	B-X
translated	B-X
protein	B-X
first	B-X
suggested	B-X
that	B-X
murine	B-X
estrogen	B-X
receptor	B-X
beta	B-X
(	B-X
mER-beta	B-X
)	B-X
is	B-X
O-GlcNAcylated	B-X
.	B-X
Structural	B-X
characterization	B-X
of	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
insect	B-X
Sf9	B-X
cells	B-X
,	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
O-GlcNAc	B-X
.	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
is	B-X
also	B-X
O-GlcNAcylated	B-X
.	B-X
The	B-X
major	B-X
site	B-X
of	B-X
O-GlcNAc	B-X
on	B-X
mER-beta	B-X
from	B-X
Sf9	B-X
cells	B-X
is	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
near	B-X
the	B-X
N-terminus	B-X
.	B-X
Concomitant	B-X
analyses	B-X
also	B-X
documented	B-X
the	B-X
O-phosphorylation	B-X
of	B-X
mER-beta	B-X
at	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

Estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
,	O
a	O
homologue	O
to	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
,	O
is	O
a	O
new	O
member	O
of	O
the	O
steroid	O
hormone	O
receptor	O
family	O
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
beta	B-X
,	B-X
a	B-X
homologue	B-X
to	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
steroid	B-X
hormone	B-X
receptor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
documented	B-X
that	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
like	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
is	B-X
modified	B-X
by	B-X
O-linked	B-X
N-acetylglucosamine	B-X
(	B-X
O-GlcNAc	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
transitory	B-X
posttranslational	B-X
modification	B-X
on	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
Lectin	B-X
chromatography	B-X
of	B-X
in	B-X
vitro	B-X
translated	B-X
protein	B-X
first	B-X
suggested	B-X
that	B-X
murine	B-X
estrogen	B-X
receptor	B-X
beta	B-X
(	B-X
mER-beta	B-X
)	B-X
is	B-X
O-GlcNAcylated	B-X
.	B-X
Structural	B-X
characterization	B-X
of	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
insect	B-X
Sf9	B-X
cells	B-X
,	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
O-GlcNAc	B-X
.	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
is	B-X
also	B-X
O-GlcNAcylated	B-X
.	B-X
The	B-X
major	B-X
site	B-X
of	B-X
O-GlcNAc	B-X
on	B-X
mER-beta	B-X
from	B-X
Sf9	B-X
cells	B-X
is	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
near	B-X
the	B-X
N-terminus	B-X
.	B-X
Concomitant	B-X
analyses	B-X
also	B-X
documented	B-X
the	B-X
O-phosphorylation	B-X
of	B-X
mER-beta	B-X
at	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

Recently	O
,	O
we	O
documented	O
that	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
,	O
like	O
other	O
transcription	O
factors	O
,	O
is	O
modified	O
by	O
O	O
-	O
linked	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
,	O
a	O
ubiquitous	O
transitory	O
posttranslational	O
modification	O
on	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
beta	B-X
,	B-X
a	B-X
homologue	B-X
to	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
steroid	B-X
hormone	B-X
receptor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
documented	B-X
that	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
like	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
is	B-X
modified	B-X
by	B-X
O-linked	B-X
N-acetylglucosamine	B-X
(	B-X
O-GlcNAc	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
transitory	B-X
posttranslational	B-X
modification	B-X
on	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
Lectin	B-X
chromatography	B-X
of	B-X
in	B-X
vitro	B-X
translated	B-X
protein	B-X
first	B-X
suggested	B-X
that	B-X
murine	B-X
estrogen	B-X
receptor	B-X
beta	B-X
(	B-X
mER-beta	B-X
)	B-X
is	B-X
O-GlcNAcylated	B-X
.	B-X
Structural	B-X
characterization	B-X
of	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
insect	B-X
Sf9	B-X
cells	B-X
,	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
O-GlcNAc	B-X
.	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
is	B-X
also	B-X
O-GlcNAcylated	B-X
.	B-X
The	B-X
major	B-X
site	B-X
of	B-X
O-GlcNAc	B-X
on	B-X
mER-beta	B-X
from	B-X
Sf9	B-X
cells	B-X
is	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
near	B-X
the	B-X
N-terminus	B-X
.	B-X
Concomitant	B-X
analyses	B-X
also	B-X
documented	B-X
the	B-X
O-phosphorylation	B-X
of	B-X
mER-beta	B-X
at	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
showed	B-X
alternative	B-X
occupancy	B-X
of	B-X
this	B-X
locus	B-X
by	B-X
these	B-X
two	B-X
abundant	B-X
and	B-X
dynamic	B-X
posttranslational	B-X
modifications	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
is	O
alternatively	O
modified	O
by	O
either	O
O	O
-	O
GlcNAc	O
or	O
O	O
-	O
phosphate	O
.	O
<EOS>	B-X
Several	B-X
methods	B-X
have	B-X
been	B-X
used	B-X
for	B-X
removal	B-X
of	B-X
phosphates	B-X
in	B-X
water	B-X
and	B-X
these	B-X
include	B-X
biological	B-X
treatment	B-X
,	B-X
membrane	B-X
filtration	B-X
processes	B-X
,	B-X
chemical	B-X
precipitation	B-X
,	B-X
and	B-X
adsorption	B-X
.	B-X
Adsorption	B-X
technology	B-X
is	B-X
highly	B-X
effective	B-X
in	B-X
the	B-X
removal	B-X
of	B-X
phosphate	B-X
from	B-X
wastewater	B-X
even	B-X
at	B-X
low	B-X
phosphate	B-X
concentrations	B-X
.	B-X
Nanomaterials/nanoparticles	B-X
,	B-X
carbon-based	B-X
materials	B-X
(	B-X
activated	B-X
carbon	B-X
and	B-X
biochar	B-X
)	B-X
,	B-X
and	B-X
their	B-X
composites	B-X
have	B-X
been	B-X
widely	B-X
employed	B-X
for	B-X
the	B-X
adsorptive	B-X
removal	B-X
and	B-X
recovery	B-X
of	B-X
phosphate	B-X
from	B-X
wastewater	B-X
due	B-X
to	B-X
their	B-X
exceptional	B-X
properties	B-X
such	B-X
as	B-X
high	B-X
surface	B-X
area	B-X
and	B-X
high	B-X
phosphate	B-X
adsorption	B-X
properties	B-X
.	B-X
This	B-X
article	B-X
is	B-X
a	B-X
review	B-X
of	B-X
the	B-X
recently	B-X
reported	B-X
literature	B-X
in	B-X
the	B-X
field	B-X
of	B-X
nanotechnology	B-X
and	B-X
activated	B-X
carbon	B-X
for	B-X
the	B-X
adsorption	B-X
of	B-X
phosphate	B-X
from	B-X
wastewater	B-X
.	B-X

Lectin	O
chromatography	O
of	O
in	O
vitro	O
translated	O
protein	O
first	O
suggested	O
that	O
murine	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
(	O
mER	B-Protein
-	I-Protein
beta	I-Protein
)	O
is	O
O	O
-	O
GlcNAcylated	O
.	O

Structural	O
characterization	O
of	O
the	O
carbohydrate	O
moieties	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
,	O
overexpressed	O
in	O
insect	O
Sf9	O
cells	O
,	O
confirmed	O
the	O
presence	O
of	O
O	O
-	O
GlcNAc	O
.	O

mER	B-Protein
-	I-Protein
beta	I-Protein
,	O
overexpressed	O
in	O
mammalian	O
cells	O
,	O
is	O
also	O
O	O
-	O
GlcNAcylated	O
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
beta	B-X
,	B-X
a	B-X
homologue	B-X
to	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
steroid	B-X
hormone	B-X
receptor	B-X
family	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
Lectin	B-X
chromatography	B-X
of	B-X
in	B-X
vitro	B-X
translated	B-X
protein	B-X
first	B-X
suggested	B-X
that	B-X
murine	B-X
estrogen	B-X
receptor	B-X
beta	B-X
(	B-X
mER-beta	B-X
)	B-X
is	B-X
O-GlcNAcylated	B-X
.	B-X
Structural	B-X
characterization	B-X
of	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
insect	B-X
Sf9	B-X
cells	B-X
,	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
O-GlcNAc	B-X
.	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
is	B-X
also	B-X
O-GlcNAcylated	B-X
.	B-X
The	B-X
major	B-X
site	B-X
of	B-X
O-GlcNAc	B-X
on	B-X
mER-beta	B-X
from	B-X
Sf9	B-X
cells	B-X
is	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
near	B-X
the	B-X
N-terminus	B-X
.	B-X
Concomitant	B-X
analyses	B-X
also	B-X
documented	B-X
the	B-X
O-phosphorylation	B-X
of	B-X
mER-beta	B-X
at	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

The	O
major	O
site	O
of	O
O	O
-	O
GlcNAc	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
from	O
Sf9	O
cells	O
is	O
Ser	O
(	O
16	O
)	O
near	O
the	O
N	O
-	O
terminus	O
.	O

Concomitant	O
analyses	O
also	O
documented	O
the	O
O	O
-	O
phosphorylation	O
of	O
mER	B-Protein
-	I-Protein
beta	I-Protein
at	O
Ser	O
(	O
16	O
)	O
.	O
<EOS>	B-X
Estrogen	B-X
receptor	B-X
beta	B-X
,	B-X
a	B-X
homologue	B-X
to	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
is	B-X
a	B-X
new	B-X
member	B-X
of	B-X
the	B-X
steroid	B-X
hormone	B-X
receptor	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
we	B-X
documented	B-X
that	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
like	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
is	B-X
modified	B-X
by	B-X
O-linked	B-X
N-acetylglucosamine	B-X
(	B-X
O-GlcNAc	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
transitory	B-X
posttranslational	B-X
modification	B-X
on	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
Lectin	B-X
chromatography	B-X
of	B-X
in	B-X
vitro	B-X
translated	B-X
protein	B-X
first	B-X
suggested	B-X
that	B-X
murine	B-X
estrogen	B-X
receptor	B-X
beta	B-X
(	B-X
mER-beta	B-X
)	B-X
is	B-X
O-GlcNAcylated	B-X
.	B-X
Structural	B-X
characterization	B-X
of	B-X
the	B-X
carbohydrate	B-X
moieties	B-X
on	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
insect	B-X
Sf9	B-X
cells	B-X
,	B-X
confirmed	B-X
the	B-X
presence	B-X
of	B-X
O-GlcNAc	B-X
.	B-X
mER-beta	B-X
,	B-X
overexpressed	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
is	B-X
also	B-X
O-GlcNAcylated	B-X
.	B-X
The	B-X
major	B-X
site	B-X
of	B-X
O-GlcNAc	B-X
on	B-X
mER-beta	B-X
from	B-X
Sf9	B-X
cells	B-X
is	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
near	B-X
the	B-X
N-terminus	B-X
.	B-X
Concomitant	B-X
analyses	B-X
also	B-X
documented	B-X
the	B-X
O-phosphorylation	B-X
of	B-X
mER-beta	B-X
at	B-X
Ser	B-X
(	B-X
16	B-X
)	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
showed	O
alternative	O
occupancy	O
of	O
this	O
locus	O
by	O
these	O
two	O
abundant	O
and	O
dynamic	O
posttranslational	O
modifications	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
documented	B-X
that	B-X
estrogen	B-X
receptor	B-X
alpha	B-X
,	B-X
like	B-X
other	B-X
transcription	B-X
factors	B-X
,	B-X
is	B-X
modified	B-X
by	B-X
O-linked	B-X
N-acetylglucosamine	B-X
(	B-X
O-GlcNAc	B-X
)	B-X
,	B-X
a	B-X
ubiquitous	B-X
transitory	B-X
posttranslational	B-X
modification	B-X
on	B-X
nuclear	B-X
and	B-X
cytoplasmic	B-X
proteins	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
estrogen	B-X
receptor	B-X
beta	B-X
is	B-X
alternatively	B-X
modified	B-X
by	B-X
either	B-X
O-GlcNAc	B-X
or	B-X
O-phosphate	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
showed	B-X
alternative	B-X
occupancy	B-X
of	B-X
this	B-X
locus	B-X
by	B-X
these	B-X
two	B-X
abundant	B-X
and	B-X
dynamic	B-X
posttranslational	B-X
modifications	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
a	B-X
major	B-X
O-GlcNAc/O-phosphate	B-X
site	B-X
in	B-X
proximity	B-X
of	B-X
the	B-X
transactivation	B-X
domain	B-X
and	B-X
as	B-X
part	B-X
of	B-X
a	B-X
PEST	B-X
region	B-X
(	B-X
target	B-X
sequences	B-X
for	B-X
rapid	B-X
protein	B-X
degradation	B-X
)	B-X
on	B-X
mER-beta	B-X
suggests	B-X
that	B-X
these	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
estrogen	B-X
receptor	B-X
beta	B-X
transactivation	B-X
and	B-X
turnover	B-X
.	B-X

The	O
localization	O
of	O
a	O
major	O
O	O
-	O
GlcNAc	O
/	O
O	O
-	O
phosphate	O
site	O
in	O
proximity	O
of	O
the	O
transactivation	O
domain	O
and	O
as	O
part	O
of	O
a	O
PEST	O
region	O
(	O
target	O
sequences	O
for	O
rapid	O
protein	O
degradation	O
)	O
on	O
mER	B-Protein
-	I-Protein
beta	I-Protein
suggests	O
that	O
these	O
modifications	O
may	O
play	O
a	O
role	O
in	O
regulating	O
estrogen	B-Protein
receptor	I-Protein
beta	I-Protein
transactivation	O
and	O
turnover	O
.	O

Inhibitors	O
of	O
prenylation	O
of	O
Ras	O
and	O
other	O
G	O
-	O
proteins	O
and	O
their	O
application	O
as	O
therapeutics	O
.	O
<EOS>	B-X
Anchoring	B-X
of	B-X
small	B-X
G-proteins	B-X
to	B-X
cellular	B-X
membranes	B-X
via	B-X
a	B-X
covalently	B-X
bound	B-X
lipophylic	B-X
prenyl	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
functioning	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X
Their	B-X
current	B-X
and	B-X
possible	B-X
future	B-X
application	B-X
as	B-X
therapeutics	B-X
in	B-X
cancer	B-X
,	B-X
restenosis	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
osteoporosis	B-X
is	B-X
briefly	B-X
discussed	B-X
.	B-X

Anchoring	O
of	O
small	O
G	O
-	O
proteins	O
to	O
cellular	O
membranes	O
via	O
a	O
covalently	O
bound	O
lipophylic	O
prenyl	O
group	O
is	O
essential	O
for	O
the	O
functioning	O
of	O
these	O
proteins	O
.	O

For	O
example	O
,	O
the	O
farnesylation	O
of	O
Ras	O
by	O
the	O
action	O
of	O
the	O
enzyme	O
protein	O
:	O
farnesyl	O
transferase	O
(	O
PFT	O
)	O
is	O
pivotal	O
for	O
its	O
signalling	O
function	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O
<EOS>	B-X
Anchoring	B-X
of	B-X
small	B-X
G-proteins	B-X
to	B-X
cellular	B-X
membranes	B-X
via	B-X
a	B-X
covalently	B-X
bound	B-X
lipophylic	B-X
prenyl	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
functioning	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
developed	B-X
several	B-X
analogues	B-X
of	B-X
the	B-X
two	B-X
substrates	B-X
of	B-X
PFT	B-X
,	B-X
i.e	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Although	B-X
other	B-X
analogues	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
,	B-X
they	B-X
affected	B-X
neither	B-X
ERK1	B-X
activation	B-X
nor	B-X
p38/stress-activated	B-X
protein	B-X
kinase	B-X
2	B-X
or	B-X
Jun	B-X
N-terminal	B-X
kinase	B-X
1	B-X
activation	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

The	O
development	O
of	O
inhibitors	O
of	O
PFT	O
was	O
triggered	O
by	O
the	O
role	O
of	O
mutated	O
Ras	O
in	O
certain	O
types	O
of	O
cancer	O
and	O
by	O
the	O
observation	O
that	O
non	O
-	O
farnesylated	O
Ras	O
is	O
inactive	O
.	O

Besides	O
the	O
screening	O
of	O
existing	O
compounds	O
for	O
PFT	O
inhibition	O
,	O
rational	O
drug	O
design	O
has	O
also	O
led	O
to	O
new	O
inhibitors	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
We	B-X
and	B-X
others	B-X
have	B-X
developed	B-X
several	B-X
analogues	B-X
of	B-X
the	B-X
two	B-X
substrates	B-X
of	B-X
PFT	B-X
,	B-X
i.e	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
Less	B-X
charged	B-X
derivatives	B-X
were	B-X
designed	B-X
to	B-X
circumvent	B-X
this	B-X
problem	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

Our	O
research	O
is	O
in	O
the	O
field	O
of	O
atherosclerosis	O
and	O
concerns	O
the	O
development	O
of	O
inhibitors	O
of	O
the	O
growth	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

The	O
latter	O
process	O
gives	O
rise	O
to	O
reocclusion	O
of	O
the	O
coronary	O
artery	O
(	O
restenosis	O
)	O
after	O
balloon	O
angioplasty	O
.	O
<EOS>	B-X
The	B-X
latter	B-X
process	B-X
gives	B-X
rise	B-X
to	B-X
reocclusion	B-X
of	B-X
the	B-X
coronary	B-X
artery	B-X
(	B-X
restenosis	B-X
)	B-X
after	B-X
balloon	B-X
angioplasty	B-X
.	B-X
Their	B-X
current	B-X
and	B-X
possible	B-X
future	B-X
application	B-X
as	B-X
therapeutics	B-X
in	B-X
cancer	B-X
,	B-X
restenosis	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
osteoporosis	B-X
is	B-X
briefly	B-X
discussed	B-X
.	B-X

We	O
and	O
others	O
have	O
developed	O
several	O
analogues	O
of	O
the	O
two	O
substrates	O
of	O
PFT	O
,	O
i	O
.	O
e	O
.	O
farnesyl	O
pyrophosphate	O
(	O
FPP	O
)	O
and	O
the	O
so	O
-	O
called	O
CAAX	O
peptide	O
consensus	O
sequence	O
,	O
which	O
were	O
tested	O
in	O
vitro	O
for	O
the	O
inhibition	O
of	O
PFT	O
and	O
of	O
other	O
enzymes	O
involved	O
in	O
protein	O
prenylation	O
,	O
such	O
as	O
protein	O
:	O
geranylgeranyl	O
transferase	O
-	O
1	O
(	O
PGGT	O
-	O
1	O
)	O
.	O

The	O
FPP	O
analogue	O
TR006	O
,	O
a	O
strong	O
inhibitor	O
of	O
PFT	O
(	O
IC	O
(	O
50	O
)	O
of	O
67	O
nM	O
)	O
,	O
blocked	O
the	O
proliferation	O
of	O
cultured	O
human	O
smooth	O
muscle	O
cells	O
and	O
inhibited	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
-	O
induced	O
DNA	O
synthesis	O
.	O

Similar	O
but	O
more	O
highly	O
charged	O
compounds	O
failed	O
in	O
this	O
respect	O
,	O
probably	O
because	O
of	O
an	O
impaired	O
uptake	O
in	O
the	O
cells	O
.	O
<EOS>	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
Less	B-X
charged	B-X
derivatives	B-X
were	B-X
designed	B-X
to	B-X
circumvent	B-X
this	B-X
problem	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

Less	O
charged	O
derivatives	O
were	O
designed	O
to	O
circumvent	O
this	O
problem	O
.	O
<EOS>	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
Less	B-X
charged	B-X
derivatives	B-X
were	B-X
designed	B-X
to	B-X
circumvent	B-X
this	B-X
problem	B-X
.	B-X
To	B-X
circumvent	B-X
this	B-X
problem	B-X
,	B-X
a	B-X
glycoengineering	B-X
strategy	B-X
was	B-X
carried	B-X
out	B-X
using	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X

The	O
effect	O
on	O
the	O
GF	O
-	O
induced	O
activation	O
of	O
intermediates	O
in	O
signal	O
transduction	O
pathways	O
was	O
investigated	O
in	O
order	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
action	O
within	O
the	O
cells	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Although	B-X
other	B-X
analogues	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
,	B-X
they	B-X
affected	B-X
neither	B-X
ERK1	B-X
activation	B-X
nor	B-X
p38/stress-activated	B-X
protein	B-X
kinase	B-X
2	B-X
or	B-X
Jun	B-X
N-terminal	B-X
kinase	B-X
1	B-X
activation	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

TR006	O
decreased	O
the	O
bFGF	B-Protein
activation	O
of	O
extracellular	B-Protein
signal	I-Protein
-	I-Protein
regulated	I-Protein
kinase	I-Protein
1	I-Protein
(	O
ERK1	B-Protein
)	O
,	O
suggesting	O
its	O
involvement	O
in	O
inhibiting	O
Ras	O
activity	O
.	O
<EOS>	B-X
For	B-X
example	B-X
,	B-X
the	B-X
farnesylation	B-X
of	B-X
Ras	B-X
by	B-X
the	B-X
action	B-X
of	B-X
the	B-X
enzyme	B-X
protein	B-X
:	B-X
farnesyl	B-X
transferase	B-X
(	B-X
PFT	B-X
)	B-X
is	B-X
pivotal	B-X
for	B-X
its	B-X
signalling	B-X
function	B-X
in	B-X
cell	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
The	B-X
FPP	B-X
analogue	B-X
TR006	B-X
,	B-X
a	B-X
strong	B-X
inhibitor	B-X
of	B-X
PFT	B-X
(	B-X
IC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
67	B-X
nM	B-X
)	B-X
,	B-X
blocked	B-X
the	B-X
proliferation	B-X
of	B-X
cultured	B-X
human	B-X
smooth	B-X
muscle	B-X
cells	B-X
and	B-X
inhibited	B-X
platelet-derived	B-X
growth	B-X
factor-	B-X
and	B-X
basic	B-X
fibroblast	B-X
growth	B-X
factor-induced	B-X
DNA	B-X
synthesis	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Although	B-X
other	B-X
analogues	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
,	B-X
they	B-X
affected	B-X
neither	B-X
ERK1	B-X
activation	B-X
nor	B-X
p38/stress-activated	B-X
protein	B-X
kinase	B-X
2	B-X
or	B-X
Jun	B-X
N-terminal	B-X
kinase	B-X
1	B-X
activation	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X

Although	O
other	O
analogues	O
inhibited	O
DNA	O
synthesis	O
,	O
they	O
affected	O
neither	O
ERK1	B-Protein
activation	O
nor	O
p38	B-Protein
/	O
stress	B-Protein
-	I-Protein
activated	I-Protein
protein	I-Protein
kinase	I-Protein
2	I-Protein
or	O
Jun	B-Protein
N	I-Protein
-	I-Protein
terminal	I-Protein
kinase	I-Protein
1	I-Protein
activation	O
.	O
<EOS>	B-X
c-Jun	B-X
N-terminal	B-X
kinase	B-X
(	B-X
JNK	B-X
)	B-X
signalling	B-X
regulates	B-X
both	B-X
cancer	B-X
cell	B-X
apoptosis	B-X
and	B-X
survival	B-X
.	B-X
Emerging	B-X
evidence	B-X
show	B-X
that	B-X
JNK	B-X
promoted	B-X
tumour	B-X
progression	B-X
is	B-X
involved	B-X
in	B-X
various	B-X
cancers	B-X
,	B-X
that	B-X
include	B-X
human	B-X
pancreatic-	B-X
,	B-X
lung-	B-X
,	B-X
and	B-X
breast	B-X
cancer	B-X
.	B-X
The	B-X
pro-survival	B-X
JNK	B-X
oncoprotein	B-X
functions	B-X
in	B-X
a	B-X
cell	B-X
context-	B-X
and	B-X
cell	B-X
type-specific	B-X
manner	B-X
to	B-X
affect	B-X
signal	B-X
pathways	B-X
that	B-X
modulate	B-X
tumour	B-X
initiation	B-X
,	B-X
proliferation	B-X
,	B-X
and	B-X
migration	B-X
.	B-X
JNK	B-X
is	B-X
therefore	B-X
considered	B-X
a	B-X
potential	B-X
oncogenic	B-X
target	B-X
for	B-X
cancer	B-X
therapy	B-X
.	B-X
Currently	B-X
,	B-X
designing	B-X
effective	B-X
and	B-X
specific	B-X
JNK	B-X
inhibitors	B-X
is	B-X
an	B-X
active	B-X
area	B-X
in	B-X
the	B-X
cancer	B-X
treatment	B-X
.	B-X
Some	B-X
ATP-competitive	B-X
inhibitors	B-X
of	B-X
JNK	B-X
,	B-X
such	B-X
as	B-X
SP600125	B-X
and	B-X
AS601245	B-X
,	B-X
are	B-X
widely	B-X
used	B-X

Since	O
some	O
of	O
these	O
compounds	O
were	O
also	O
shown	O
to	O
be	O
inhibitors	O
of	O
in	O
vitro	O
PGGT	O
-	O
1	O
activity	O
,	O
the	O
geranylgeranylation	O
of	O
other	O
G	O
-	O
proteins	O
may	O
be	O
decreased	O
by	O
these	O
compounds	O
.	O
<EOS>	B-X
Anchoring	B-X
of	B-X
small	B-X
G-proteins	B-X
to	B-X
cellular	B-X
membranes	B-X
via	B-X
a	B-X
covalently	B-X
bound	B-X
lipophylic	B-X
prenyl	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
functioning	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
Similar	B-X
but	B-X
more	B-X
highly	B-X
charged	B-X
compounds	B-X
failed	B-X
in	B-X
this	B-X
respect	B-X
,	B-X
probably	B-X
because	B-X
of	B-X
an	B-X
impaired	B-X
uptake	B-X
in	B-X
the	B-X
cells	B-X
.	B-X
The	B-X
effect	B-X
on	B-X
the	B-X
GF-induced	B-X
activation	B-X
of	B-X
intermediates	B-X
in	B-X
signal	B-X
transduction	B-X
pathways	B-X
was	B-X
investigated	B-X
in	B-X
order	B-X
to	B-X
gain	B-X
insight	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
the	B-X
cells	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Although	B-X
other	B-X
analogues	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
,	B-X
they	B-X
affected	B-X
neither	B-X
ERK1	B-X
activation	B-X
nor	B-X
p38/stress-activated	B-X
protein	B-X
kinase	B-X
2	B-X
or	B-X
Jun	B-X
N-terminal	B-X
kinase	B-X
1	B-X
activation	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

Rho	O
seems	O
to	O
be	O
a	O
good	O
candidate	O
as	O
a	O
target	O
for	O
inhibitors	O
of	O
PGGT	O
-	O
1	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
Besides	B-X
the	B-X
screening	B-X
of	B-X
existing	B-X
compounds	B-X
for	B-X
PFT	B-X
inhibition	B-X
,	B-X
rational	B-X
drug	B-X
design	B-X
has	B-X
also	B-X
led	B-X
to	B-X
new	B-X
inhibitors	B-X
.	B-X
Our	B-X
research	B-X
is	B-X
in	B-X
the	B-X
field	B-X
of	B-X
atherosclerosis	B-X
and	B-X
concerns	B-X
the	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
the	B-X
growth	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
cells	B-X
.	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
and	B-X
the	B-X
so-called	B-X
CAAX	B-X
peptide	B-X
consensus	B-X
sequence	B-X
,	B-X
which	B-X
were	B-X
tested	B-X
in	B-X
vitro	B-X
for	B-X
the	B-X
inhibition	B-X
of	B-X
PFT	B-X
and	B-X
of	B-X
other	B-X
enzymes	B-X
involved	B-X
in	B-X
protein	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
protein	B-X
:	B-X
geranylgeranyl	B-X
transferase-1	B-X
(	B-X
PGGT-1	B-X
)	B-X
.	B-X
TR006	B-X
decreased	B-X
the	B-X
bFGF	B-X
activation	B-X
of	B-X
extracellular	B-X
signal-regulated	B-X
kinase	B-X
1	B-X
(	B-X
ERK1	B-X
)	B-X
,	B-X
suggesting	B-X
its	B-X
involvement	B-X
in	B-X
inhibiting	B-X
Ras	B-X
activity	B-X
.	B-X
Although	B-X
other	B-X
analogues	B-X
inhibited	B-X
DNA	B-X
synthesis	B-X
,	B-X
they	B-X
affected	B-X
neither	B-X
ERK1	B-X
activation	B-X
nor	B-X
p38/stress-activated	B-X
protein	B-X
kinase	B-X
2	B-X
or	B-X
Jun	B-X
N-terminal	B-X
kinase	B-X
1	B-X
activation	B-X
.	B-X
Since	B-X
some	B-X
of	B-X
these	B-X
compounds	B-X
were	B-X
also	B-X
shown	B-X
to	B-X
be	B-X
inhibitors	B-X
of	B-X
in	B-X
vitro	B-X
PGGT-1	B-X
activity	B-X
,	B-X
the	B-X
geranylgeranylation	B-X
of	B-X
other	B-X
G-proteins	B-X
may	B-X
be	B-X
decreased	B-X
by	B-X
these	B-X
compounds	B-X
.	B-X
Rho	B-X
seems	B-X
to	B-X
be	B-X
a	B-X
good	B-X
candidate	B-X
as	B-X
a	B-X
target	B-X
for	B-X
inhibitors	B-X
of	B-X
PGGT-1	B-X
.	B-X
This	B-X
uncertainty	B-X
as	B-X
to	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
within	B-X
non-transformed	B-X
as	B-X
well	B-X
as	B-X
transformed	B-X
cells	B-X
applies	B-X
to	B-X
all	B-X
prenylation	B-X
inhibitors	B-X
,	B-X
but	B-X
is	B-X
not	B-X
holding	B-X
back	B-X
their	B-X
further	B-X
development	B-X
as	B-X
drugs	B-X
.	B-X

This	O
uncertainty	O
as	O
to	O
the	O
mechanism	O
of	O
action	O
within	O
non	O
-	O
transformed	O
as	O
well	O
as	O
transformed	O
cells	O
applies	O
to	O
all	O
prenylation	O
inhibitors	O
,	O
but	O
is	O
not	O
holding	O
back	O
their	O
further	O
development	O
as	O
drugs	O
.	O

Their	O
current	O
and	O
possible	O
future	O
application	O
as	O
therapeutics	O
in	O
cancer	O
,	O
restenosis	O
,	O
angiogenesis	O
,	O
and	O
osteoporosis	O
is	O
briefly	O
discussed	O
.	O
<EOS>	B-X
The	B-X
development	B-X
of	B-X
inhibitors	B-X
of	B-X
PFT	B-X
was	B-X
triggered	B-X
by	B-X
the	B-X
role	B-X
of	B-X
mutated	B-X
Ras	B-X
in	B-X
certain	B-X
types	B-X
of	B-X
cancer	B-X
and	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
non-farnesylated	B-X
Ras	B-X
is	B-X
inactive	B-X
.	B-X
The	B-X
latter	B-X
process	B-X
gives	B-X
rise	B-X
to	B-X
reocclusion	B-X
of	B-X
the	B-X
coronary	B-X
artery	B-X
(	B-X
restenosis	B-X
)	B-X
after	B-X
balloon	B-X
angioplasty	B-X
.	B-X
Their	B-X
current	B-X
and	B-X
possible	B-X
future	B-X
application	B-X
as	B-X
therapeutics	B-X
in	B-X
cancer	B-X
,	B-X
restenosis	B-X
,	B-X
angiogenesis	B-X
,	B-X
and	B-X
osteoporosis	B-X
is	B-X
briefly	B-X
discussed	B-X
.	B-X

Role	O
of	O
metals	O
in	O
the	O
reaction	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
.	O
<EOS>	B-X
Protein	B-X
farnesyltransferase	B-X
catalyzes	B-X
the	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
including	B-X
Ras	B-X
,	B-X
and	B-X
is	B-X
a	B-X
target	B-X
enzyme	B-X
for	B-X
antitumor	B-X
therapies	B-X
.	B-X
Efficient	B-X
product	B-X
formation	B-X
catalyzed	B-X
by	B-X
protein	B-X
farnesyltransferase	B-X
requires	B-X
an	B-X
enzyme-bound	B-X
zinc	B-X
cation	B-X
and	B-X
high	B-X
concentrations	B-X
of	B-X
magnesium	B-X
ions	B-X
.	B-X
Studies	B-X
aimed	B-X
at	B-X
elucidating	B-X
the	B-X
unknown	B-X
Mg2+	B-X
binding	B-X
site	B-X
in	B-X
protein	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
are	B-X
reported	B-X
.	B-X
FTase	B-X
catalyzes	B-X
the	B-X
transfer	B-X
of	B-X
a	B-X
farnesyl	B-X
group	B-X
to	B-X
a	B-X
conserved	B-X
cysteine	B-X
residue	B-X
(	B-X
Cys1p	B-X
)	B-X
on	B-X
a	B-X
target	B-X
protein	B-X
,	B-X
an	B-X
important	B-X
step	B-X
for	B-X
proteins	B-X
in	B-X
the	B-X
signal	B-X
transduction	B-X
pathways	B-X
(	B-X
e.g.	B-X
,	B-X
Ras	B-X
)	B-X
.	B-X
Mg2+	B-X
ions	B-X
accelerate	B-X
the	B-X
protein	B-X
farnesylation	B-X
reaction	B-X
by	B-X
up	B-X
to	B-X
700-fold	B-X
.	B-X

Protein	O
farnesyltransferase	O
catalyzes	O
the	O
posttranslational	O
farnesylation	O
of	O
several	O
proteins	O
involved	O
in	O
signal	O
transduction	O
,	O
including	O
Ras	O
,	O
and	O
is	O
a	O
target	O
enzyme	O
for	O
antitumor	O
therapies	O
.	O
<EOS>	B-X
Protein	B-X
farnesyltransferase	B-X
catalyzes	B-X
the	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
including	B-X
Ras	B-X
,	B-X
and	B-X
is	B-X
a	B-X
target	B-X
enzyme	B-X
for	B-X
antitumor	B-X
therapies	B-X
.	B-X
Efficient	B-X
product	B-X
formation	B-X
catalyzed	B-X
by	B-X
protein	B-X
farnesyltransferase	B-X
requires	B-X
an	B-X
enzyme-bound	B-X
zinc	B-X
cation	B-X
and	B-X
high	B-X
concentrations	B-X
of	B-X
magnesium	B-X
ions	B-X
.	B-X

Efficient	O
product	O
formation	O
catalyzed	O
by	O
protein	O
farnesyltransferase	O
requires	O
an	O
enzyme	O
-	O
bound	O
zinc	O
cation	O
and	O
high	O
concentrations	O
of	O
magnesium	O
ions	O
.	O
<EOS>	B-X
Protein	B-X
farnesyltransferase	B-X
catalyzes	B-X
the	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
including	B-X
Ras	B-X
,	B-X
and	B-X
is	B-X
a	B-X
target	B-X
enzyme	B-X
for	B-X
antitumor	B-X
therapies	B-X
.	B-X
Efficient	B-X
product	B-X
formation	B-X
catalyzed	B-X
by	B-X
protein	B-X
farnesyltransferase	B-X
requires	B-X
an	B-X
enzyme-bound	B-X
zinc	B-X
cation	B-X
and	B-X
high	B-X
concentrations	B-X
of	B-X
magnesium	B-X
ions	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
have	B-X
measured	B-X
the	B-X
pH	B-X
dependence	B-X
of	B-X
the	B-X
chemical	B-X
step	B-X
of	B-X
product	B-X
formation	B-X
,	B-X
determined	B-X
under	B-X
single-turnover	B-X
conditions	B-X
,	B-X
and	B-X
have	B-X
demonstrated	B-X
that	B-X
the	B-X
prenylation	B-X
rate	B-X
constant	B-X
is	B-X
enhanced	B-X
by	B-X
two	B-X
deprotonations	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
active	B-X
site	B-X
zinc	B-X
by	B-X
cadmium	B-X
demonstrated	B-X
that	B-X
one	B-X
of	B-X
the	B-X
ionizations	B-X
reflects	B-X
deprotonation	B-X
of	B-X
the	B-X
metal-coordinated	B-X
thiol	B-X
of	B-X
the	B-X
peptide	B-X
``	B-X
CaaX	B-X
''	B-X
motif	B-X
,	B-X
pK	B-X
(	B-X
a1	B-X
)	B-X
=	B-X
6.0	B-X
.	B-X
Deprotonation	B-X
of	B-X
this	B-X
group	B-X
is	B-X
important	B-X
for	B-X
binding	B-X
of	B-X
magnesium	B-X
.	B-X
This	B-X
second	B-X
ionization	B-X
is	B-X
not	B-X
observed	B-X
for	B-X
catalysis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
magnesium	B-X
or	B-X
when	B-X
the	B-X
substrate	B-X
is	B-X
farnesyl	B-X
monophosphate	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
maximal	B-X
rate	B-X
constant	B-X
for	B-X
prenylation	B-X
requires	B-X
formation	B-X
of	B-X
a	B-X
zinc-coordinated	B-X
thiolate	B-X
nucleophile	B-X
and	B-X
enhancement	B-X
of	B-X
the	B-X
electrophilic	B-X
character	B-X
at	B-X
C1	B-X
of	B-X
the	B-X
farnesyl	B-X
chain	B-X
by	B-X
magnesium	B-X
ion	B-X
coordination	B-X
of	B-X
the	B-X
pyrophosphate	B-X
leaving	B-X
group	B-X
.	B-X

In	O
this	O
work	O
,	O
we	O
have	O
measured	O
the	O
pH	O
dependence	O
of	O
the	O
chemical	O
step	O
of	O
product	O
formation	O
,	O
determined	O
under	O
single	O
-	O
turnover	O
conditions	O
,	O
and	O
have	O
demonstrated	O
that	O
the	O
prenylation	O
rate	O
constant	O
is	O
enhanced	O
by	O
two	O
deprotonations	O
.	O

Substitution	O
of	O
the	O
active	O
site	O
zinc	O
by	O
cadmium	O
demonstrated	O
that	O
one	O
of	O
the	O
ionizations	O
reflects	O
deprotonation	O
of	O
the	O
metal	O
-	O
coordinated	O
thiol	O
of	O
the	O
peptide	O
"	O
CaaX	O
"	O
motif	O
,	O
pK	O
(	O
a1	O
)	O
=	O
6	O
.	O
0	O
.	O

These	O
data	O
provide	O
additional	O
evidence	O
for	O
the	O
direct	O
involvement	O
of	O
a	O
metal	O
-	O
coordinated	O
sulfur	O
nucleophile	O
in	O
catalysis	O
.	O
<EOS>	B-X
Substitution	B-X
of	B-X
the	B-X
active	B-X
site	B-X
zinc	B-X
by	B-X
cadmium	B-X
demonstrated	B-X
that	B-X
one	B-X
of	B-X
the	B-X
ionizations	B-X
reflects	B-X
deprotonation	B-X
of	B-X
the	B-X
metal-coordinated	B-X
thiol	B-X
of	B-X
the	B-X
peptide	B-X
``	B-X
CaaX	B-X
''	B-X
motif	B-X
,	B-X
pK	B-X
(	B-X
a1	B-X
)	B-X
=	B-X
6.0	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
additional	B-X
evidence	B-X
for	B-X
the	B-X
direct	B-X
involvement	B-X
of	B-X
a	B-X
metal-coordinated	B-X
sulfur	B-X
nucleophile	B-X
in	B-X
catalysis	B-X
.	B-X
This	B-X
second	B-X
ionization	B-X
is	B-X
not	B-X
observed	B-X
for	B-X
catalysis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
magnesium	B-X
or	B-X
when	B-X
the	B-X
substrate	B-X
is	B-X
farnesyl	B-X
monophosphate	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
maximal	B-X
rate	B-X
constant	B-X
for	B-X
prenylation	B-X
requires	B-X
formation	B-X
of	B-X
a	B-X
zinc-coordinated	B-X
thiolate	B-X
nucleophile	B-X
and	B-X
enhancement	B-X
of	B-X
the	B-X
electrophilic	B-X
character	B-X
at	B-X
C1	B-X
of	B-X
the	B-X
farnesyl	B-X
chain	B-X
by	B-X
magnesium	B-X
ion	B-X
coordination	B-X
of	B-X
the	B-X
pyrophosphate	B-X
leaving	B-X
group	B-X
.	B-X

The	O
second	O
ionization	O
was	O
assigned	O
to	O
a	O
hydroxyl	O
on	O
the	O
pyrophosphate	O
moiety	O
of	O
farnesyl	O
pyrophosphate	O
,	O
pK	O
(	O
a2	O
)	O
=	O
7	O
.	O
4	O
.	O
<EOS>	B-X
Protein	B-X
farnesyltransferase	B-X
catalyzes	B-X
the	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
including	B-X
Ras	B-X
,	B-X
and	B-X
is	B-X
a	B-X
target	B-X
enzyme	B-X
for	B-X
antitumor	B-X
therapies	B-X
.	B-X
Efficient	B-X
product	B-X
formation	B-X
catalyzed	B-X
by	B-X
protein	B-X
farnesyltransferase	B-X
requires	B-X
an	B-X
enzyme-bound	B-X
zinc	B-X
cation	B-X
and	B-X
high	B-X
concentrations	B-X
of	B-X
magnesium	B-X
ions	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
active	B-X
site	B-X
zinc	B-X
by	B-X
cadmium	B-X
demonstrated	B-X
that	B-X
one	B-X
of	B-X
the	B-X
ionizations	B-X
reflects	B-X
deprotonation	B-X
of	B-X
the	B-X
metal-coordinated	B-X
thiol	B-X
of	B-X
the	B-X
peptide	B-X
``	B-X
CaaX	B-X
''	B-X
motif	B-X
,	B-X
pK	B-X
(	B-X
a1	B-X
)	B-X
=	B-X
6.0	B-X
.	B-X
The	B-X
second	B-X
ionization	B-X
was	B-X
assigned	B-X
to	B-X
a	B-X
hydroxyl	B-X
on	B-X
the	B-X
pyrophosphate	B-X
moiety	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
pK	B-X
(	B-X
a2	B-X
)	B-X
=	B-X
7.4	B-X
.	B-X
This	B-X
second	B-X
ionization	B-X
is	B-X
not	B-X
observed	B-X
for	B-X
catalysis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
magnesium	B-X
or	B-X
when	B-X
the	B-X
substrate	B-X
is	B-X
farnesyl	B-X
monophosphate	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
maximal	B-X
rate	B-X
constant	B-X
for	B-X
prenylation	B-X
requires	B-X
formation	B-X
of	B-X
a	B-X
zinc-coordinated	B-X
thiolate	B-X
nucleophile	B-X
and	B-X
enhancement	B-X
of	B-X
the	B-X
electrophilic	B-X
character	B-X
at	B-X
C1	B-X
of	B-X
the	B-X
farnesyl	B-X
chain	B-X
by	B-X
magnesium	B-X
ion	B-X
coordination	B-X
of	B-X
the	B-X
pyrophosphate	B-X
leaving	B-X
group	B-X
.	B-X

Deprotonation	O
of	O
this	O
group	O
is	O
important	O
for	O
binding	O
of	O
magnesium	O
.	O

This	O
second	O
ionization	O
is	O
not	O
observed	O
for	O
catalysis	O
in	O
the	O
absence	O
of	O
magnesium	O
or	O
when	O
the	O
substrate	O
is	O
farnesyl	O
monophosphate	O
.	O
<EOS>	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
on	B-X
the	B-X
nonlinear	B-X
ionization	B-X
of	B-X
argon	B-X
atoms	B-X
in	B-X
the	B-X
short	B-X
wavelength	B-X
regime	B-X
using	B-X
ultraintense	B-X
x	B-X
rays	B-X
from	B-X
the	B-X
European	B-X
XFEL	B-X
.	B-X
After	B-X
sequential	B-X
multiphoton	B-X
ionization	B-X
,	B-X
high	B-X
charge	B-X
states	B-X
are	B-X
obtained	B-X
.	B-X
For	B-X
photon	B-X
energies	B-X
that	B-X
are	B-X
insufficient	B-X
to	B-X
directly	B-X
ionize	B-X
a	B-X
1s	B-X
electron	B-X
,	B-X
a	B-X
different	B-X
mechanism	B-X
is	B-X
required	B-X
to	B-X
obtain	B-X
ionization	B-X
to	B-X
Ar^	B-X
{	B-X
17+	B-X
}	B-X
.	B-X
We	B-X
propose	B-X
this	B-X
occurs	B-X
through	B-X
a	B-X
two-color	B-X
process	B-X
where	B-X
the	B-X
second	B-X
harmonic	B-X
of	B-X
the	B-X
FEL	B-X
pulse	B-X
resonantly	B-X
excites	B-X
the	B-X
system	B-X
via	B-X
a	B-X
1s→2p	B-X
transition	B-X
followed	B-X
by	B-X
ionization	B-X
by	B-X
the	B-X
fundamental	B-X
FEL	B-X
pulse	B-X
,	B-X
which	B-X
is	B-X
a	B-X
type	B-X
of	B-X
x-ray	B-X
resonance-enhanced	B-X
multiphoton	B-X
ionization	B-X
(	B-X
REMPI	B-X
)	B-X
.	B-X
This	B-X
resonant	B-X
phenomenon	B-X
occurs	B-X
not	B-X
only	B-X
for	B-X
Ar^	B-X
{	B-X
16+	B-X
}	B-X
,	B-X
but	B-X
also	B-X
through	B-X
lower	B-X
charge	B-X
states	B-X
,	B-X
where	B-X
multiple	B-X
ionization	B-X
competes	B-X
with	B-X
decay	B-X
lifetimes	B-X
,	B-X
making	B-X
x-ray	B-X
REMPI	B-X
distinctive	B-X
from	B-X
conventional	B-X
REMPI	B-X
.	B-X

These	O
data	O
indicate	O
that	O
the	O
maximal	O
rate	O
constant	O
for	O
prenylation	O
requires	O
formation	O
of	O
a	O
zinc	O
-	O
coordinated	O
thiolate	O
nucleophile	O
and	O
enhancement	O
of	O
the	O
electrophilic	O
character	O
at	O
C1	O
of	O
the	O
farnesyl	O
chain	O
by	O
magnesium	O
ion	O
coordination	O
of	O
the	O
pyrophosphate	O
leaving	O
group	O
.	O
<EOS>	B-X
Protein	B-X
farnesyltransferase	B-X
catalyzes	B-X
the	B-X
posttranslational	B-X
farnesylation	B-X
of	B-X
several	B-X
proteins	B-X
involved	B-X
in	B-X
signal	B-X
transduction	B-X
,	B-X
including	B-X
Ras	B-X
,	B-X
and	B-X
is	B-X
a	B-X
target	B-X
enzyme	B-X
for	B-X
antitumor	B-X
therapies	B-X
.	B-X
Efficient	B-X
product	B-X
formation	B-X
catalyzed	B-X
by	B-X
protein	B-X
farnesyltransferase	B-X
requires	B-X
an	B-X
enzyme-bound	B-X
zinc	B-X
cation	B-X
and	B-X
high	B-X
concentrations	B-X
of	B-X
magnesium	B-X
ions	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
have	B-X
measured	B-X
the	B-X
pH	B-X
dependence	B-X
of	B-X
the	B-X
chemical	B-X
step	B-X
of	B-X
product	B-X
formation	B-X
,	B-X
determined	B-X
under	B-X
single-turnover	B-X
conditions	B-X
,	B-X
and	B-X
have	B-X
demonstrated	B-X
that	B-X
the	B-X
prenylation	B-X
rate	B-X
constant	B-X
is	B-X
enhanced	B-X
by	B-X
two	B-X
deprotonations	B-X
.	B-X
Substitution	B-X
of	B-X
the	B-X
active	B-X
site	B-X
zinc	B-X
by	B-X
cadmium	B-X
demonstrated	B-X
that	B-X
one	B-X
of	B-X
the	B-X
ionizations	B-X
reflects	B-X
deprotonation	B-X
of	B-X
the	B-X
metal-coordinated	B-X
thiol	B-X
of	B-X
the	B-X
peptide	B-X
``	B-X
CaaX	B-X
''	B-X
motif	B-X
,	B-X
pK	B-X
(	B-X
a1	B-X
)	B-X
=	B-X
6.0	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
additional	B-X
evidence	B-X
for	B-X
the	B-X
direct	B-X
involvement	B-X
of	B-X
a	B-X
metal-coordinated	B-X
sulfur	B-X
nucleophile	B-X
in	B-X
catalysis	B-X
.	B-X
The	B-X
second	B-X
ionization	B-X
was	B-X
assigned	B-X
to	B-X
a	B-X
hydroxyl	B-X
on	B-X
the	B-X
pyrophosphate	B-X
moiety	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
pK	B-X
(	B-X
a2	B-X
)	B-X
=	B-X
7.4	B-X
.	B-X
Deprotonation	B-X
of	B-X
this	B-X
group	B-X
is	B-X
important	B-X
for	B-X
binding	B-X
of	B-X
magnesium	B-X
.	B-X
This	B-X
second	B-X
ionization	B-X
is	B-X
not	B-X
observed	B-X
for	B-X
catalysis	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
magnesium	B-X
or	B-X
when	B-X
the	B-X
substrate	B-X
is	B-X
farnesyl	B-X
monophosphate	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
the	B-X
maximal	B-X
rate	B-X
constant	B-X
for	B-X
prenylation	B-X
requires	B-X
formation	B-X
of	B-X
a	B-X
zinc-coordinated	B-X
thiolate	B-X
nucleophile	B-X
and	B-X
enhancement	B-X
of	B-X
the	B-X
electrophilic	B-X
character	B-X
at	B-X
C1	B-X
of	B-X
the	B-X
farnesyl	B-X
chain	B-X
by	B-X
magnesium	B-X
ion	B-X
coordination	B-X
of	B-X
the	B-X
pyrophosphate	B-X
leaving	B-X
group	B-X
.	B-X

Prenylated	B-Protein
Rab	I-Protein
acceptor	I-Protein
protein	I-Protein
is	O
a	O
receptor	O
for	O
prenylated	O
small	O
GTPases	O
.	O
<EOS>	B-X
Localization	B-X
of	B-X
Ras	B-X
and	B-X
Ras-like	B-X
proteins	B-X
to	B-X
the	B-X
correct	B-X
subcellular	B-X
compartment	B-X
is	B-X
essential	B-X
for	B-X
these	B-X
proteins	B-X
to	B-X
mediate	B-X
their	B-X
biological	B-X
effects	B-X
.	B-X
Many	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
(	B-X
Ha-Ras	B-X
,	B-X
N-Ras	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
RhoA	B-X
)	B-X
are	B-X
prenylated	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
then	B-X
transit	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
on	B-X
their	B-X
way	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
proteins	B-X
that	B-X
aid	B-X
in	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
have	B-X
not	B-X
been	B-X
well	B-X
characterized	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
prenylated	B-X
Rab	B-X
acceptor	B-X
protein	B-X
(	B-X
PRA1	B-X
)	B-X
,	B-X
which	B-X
others	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
prenylation-dependent	B-X
receptor	B-X
for	B-X
Rab	B-X
proteins	B-X
,	B-X
also	B-X
interacts	B-X
with	B-X
Ha-Ras	B-X
,	B-X
RhoA	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
Rap1a	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
with	B-X
PRA1	B-X
requires	B-X
their	B-X
post-translational	B-X
modification	B-X
by	B-X
prenylation	B-X
.	B-X
The	B-X
prenylation-dependent	B-X
association	B-X
of	B-X
PRA1	B-X
with	B-X
multiple	B-X
GTPases	B-X
is	B-X
conserved	B-X
in	B-X
evolution	B-X
;	B-X
the	B-X
yeast	B-X
PRA1	B-X
protein	B-X
associates	B-X
with	B-X
both	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
PRA1	B-X
acts	B-X
as	B-X
an	B-X
escort	B-X
protein	B-X
for	B-X
small	B-X
GTPases	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
hydrophobic	B-X
isoprenoid	B-X
moieties	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
and	B-X
facilitates	B-X
their	B-X
trafficking	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
.	B-X

Localization	O
of	O
Ras	O
and	O
Ras	O
-	O
like	O
proteins	O
to	O
the	O
correct	O
subcellular	O
compartment	O
is	O
essential	O
for	O
these	O
proteins	O
to	O
mediate	O
their	O
biological	O
effects	O
.	O

Many	O
members	O
of	O
the	O
Ras	O
superfamily	O
(	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
,	O
N	B-Protein
-	I-Protein
Ras	I-Protein
,	O
TC21	B-Protein
,	O
and	O
RhoA	B-Protein
)	O
are	O
prenylated	O
in	O
the	O
cytoplasm	O
and	O
then	O
transit	O
through	O
the	O
endomembrane	O
system	O
on	O
their	O
way	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
proteins	O
that	O
aid	O
in	O
the	O
trafficking	O
of	O
the	O
small	O
GTPases	O
have	O
not	O
been	O
well	O
characterized	O
.	O
<EOS>	B-X
It	B-X
is	B-X
emerging	B-X
that	B-X
small	B-X
guanosine	B-X
triphosphatases	B-X
(	B-X
small	B-X
GTPases	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
assist	B-X
plants	B-X
in	B-X
managing	B-X
environmental	B-X
stress	B-X
.	B-X
Small	B-X
GTPases	B-X
function	B-X
as	B-X
tightly	B-X
regulated	B-X
molecular	B-X
switches	B-X
that	B-X
get	B-X
activated	B-X
with	B-X
the	B-X
aid	B-X
of	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
and	B-X
deactivated	B-X
by	B-X
the	B-X
subsequent	B-X
hydrolysis	B-X
of	B-X
GTP	B-X
to	B-X
guanosine	B-X
diphosphate	B-X
(	B-X
GDP	B-X
)	B-X
.	B-X
All	B-X
small	B-X
GTPases	B-X
except	B-X
Rat	B-X
sarcoma	B-X
(	B-X
Ras	B-X
)	B-X
are	B-X
found	B-X
in	B-X
plants	B-X
,	B-X
including	B-X
Ras-like	B-X
in	B-X
brain	B-X
(	B-X
Rab	B-X
)	B-X
,	B-X
Rho	B-X
of	B-X
plant	B-X
(	B-X
Rop	B-X
)	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
Arf	B-X
)	B-X
and	B-X
Ras-like	B-X
nuclear	B-X
(	B-X
Ran	B-X
)	B-X
.	B-X
The	B-X
members	B-X
of	B-X
small	B-X
GTPases	B-X
in	B-X
plants	B-X
interact	B-X
with	B-X
several	B-X
downstream	B-X
effectors	B-X
to	B-X
counteract	B-X
the	B-X
negative	B-X
effects	B-X
of	B-X
environmental	B-X
stress	B-X
and	B-X
disease-causing	B-X
pathogens	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
describe	B-X
processes	B-X
of	B-X
stress	B-X
alleviation	B-X
by	B-X
developing	B-X
pathways	B-X
involving	B-X
several	B-X
small	B-X
GTPases	B-X
and	B-X
their	B-X
associated	B-X
proteins	B-X
which	B-X
are	B-X
important	B-X
for	B-X
neutralizing	B-X
fungal	B-X
infections	B-X
,	B-X
stomatal	B-X
regulation	B-X
,	B-X
and	B-X
activation	B-X
of	B-X
abiotic	B-X
stress-tolerant	B-X
genes	B-X
in	B-X
plants	B-X
.	B-X
Previous	B-X
reviews	B-X
on	B-X
small	B-X
GTPases	B-X
in	B-X
plants	B-X
were	B-X
primarily	B-X
focused	B-X
on	B-X
Rab	B-X
GTPases	B-X
,	B-X
abiotic	B-X
stress	B-X
,	B-X
and	B-X
membrane	B-X
trafficking	B-X
,	B-X
whereas	B-X
this	B-X
review	B-X
seeks	B-X
to	B-X
improve	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
role	B-X
of	B-X
all	B-X
small	B-X
GTPases	B-X
in	B-X
plants	B-X
as	B-X
well	B-X
as	B-X
their	B-X
interactome	B-X
in	B-X
regulating	B-X
mechanisms	B-X
to	B-X
combat	B-X
abiotic	B-X
and	B-X
biotic	B-X
stress	B-X
.	B-X
This	B-X
review	B-X
brings	B-X
to	B-X
the	B-X
attention	B-X
of	B-X
scientists	B-X
recent	B-X
research	B-X
on	B-X
small	B-X
GTPases	B-X
so	B-X
that	B-X
they	B-X
can	B-X
employ	B-X
genome	B-X
editing	B-X
tools	B-X
to	B-X
precisely	B-X
engineer	B-X
economically	B-X
important	B-X
plants	B-X
through	B-X
the	B-X
overexpression/knock-out/knock-in	B-X
of	B-X
stress-related	B-X
small	B-X
GTPase	B-X
genes	B-X
.	B-X

We	O
report	O
here	O
that	O
prenylated	B-Protein
Rab	I-Protein
acceptor	I-Protein
protein	I-Protein
(	O
PRA1	B-Protein
)	O
,	O
which	O
others	O
previously	O
identified	O
as	O
a	O
prenylation	O
-	O
dependent	O
receptor	O
for	O
Rab	O
proteins	O
,	O
also	O
interacts	O
with	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
,	O
RhoA	B-Protein
,	O
TC21	B-Protein
,	O
and	O
Rap1a	B-Protein
.	O
<EOS>	B-X
Localization	B-X
of	B-X
Ras	B-X
and	B-X
Ras-like	B-X
proteins	B-X
to	B-X
the	B-X
correct	B-X
subcellular	B-X
compartment	B-X
is	B-X
essential	B-X
for	B-X
these	B-X
proteins	B-X
to	B-X
mediate	B-X
their	B-X
biological	B-X
effects	B-X
.	B-X
Many	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
(	B-X
Ha-Ras	B-X
,	B-X
N-Ras	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
RhoA	B-X
)	B-X
are	B-X
prenylated	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
then	B-X
transit	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
on	B-X
their	B-X
way	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
proteins	B-X
that	B-X
aid	B-X
in	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
have	B-X
not	B-X
been	B-X
well	B-X
characterized	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
prenylated	B-X
Rab	B-X
acceptor	B-X
protein	B-X
(	B-X
PRA1	B-X
)	B-X
,	B-X
which	B-X
others	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
prenylation-dependent	B-X
receptor	B-X
for	B-X
Rab	B-X
proteins	B-X
,	B-X
also	B-X
interacts	B-X
with	B-X
Ha-Ras	B-X
,	B-X
RhoA	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
Rap1a	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
with	B-X
PRA1	B-X
requires	B-X
their	B-X
post-translational	B-X
modification	B-X
by	B-X
prenylation	B-X
.	B-X
The	B-X
prenylation-dependent	B-X
association	B-X
of	B-X
PRA1	B-X
with	B-X
multiple	B-X
GTPases	B-X
is	B-X
conserved	B-X
in	B-X
evolution	B-X
;	B-X
the	B-X
yeast	B-X
PRA1	B-X
protein	B-X
associates	B-X
with	B-X
both	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
.	B-X
Earlier	B-X
studies	B-X
reported	B-X
the	B-X
presence	B-X
of	B-X
PRA1	B-X
in	B-X
the	B-X
Golgi	B-X
,	B-X
and	B-X
we	B-X
show	B-X
here	B-X
that	B-X
PRA1	B-X
co-localizes	B-X
with	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
in	B-X
the	B-X
Golgi	B-X
compartment	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
PRA1	B-X
acts	B-X
as	B-X
an	B-X
escort	B-X
protein	B-X
for	B-X
small	B-X
GTPases	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
hydrophobic	B-X
isoprenoid	B-X
moieties	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
and	B-X
facilitates	B-X
their	B-X
trafficking	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
.	B-X

The	O
interaction	O
of	O
these	O
small	O
GTPases	O
with	O
PRA1	B-Protein
requires	O
their	O
post	O
-	O
translational	O
modification	O
by	O
prenylation	O
.	O
<EOS>	B-X
Rab	B-X
GTPases	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
intracellular	B-X
vesicle	B-X
trafficking	B-X
.	B-X
This	B-X
protein	B-X
binds	B-X
to	B-X
prenylated	B-X
Rab	B-X
GTPases	B-X
but	B-X
not	B-X
to	B-X
other	B-X
small	B-X
Ras-like	B-X
GTPases	B-X
such	B-X
as	B-X
the	B-X
Rho/Rac	B-X
family	B-X
.	B-X
This	B-X
prenylated	B-X
Rab	B-X
acceptor	B-X
(	B-X
PRA1	B-X
)	B-X
also	B-X
binds	B-X
specifically	B-X
to	B-X
the	B-X
synaptic	B-X
vesicle	B-X
protein	B-X
VAMP2	B-X
(	B-X
or	B-X
synaptobrevin	B-X
II	B-X
)	B-X
but	B-X
shows	B-X
no	B-X
affinity	B-X
for	B-X
VAMP1	B-X
or	B-X
cellubrevin	B-X
in	B-X
both	B-X
the	B-X
yeast	B-X
two-hybrid	B-X
system	B-X
and	B-X
in	B-X
vitro	B-X
binding	B-X
assays	B-X
.	B-X
This	B-X
specificity	B-X
resides	B-X
,	B-X
in	B-X
part	B-X
,	B-X
in	B-X
the	B-X
proline-rich	B-X
domain	B-X
of	B-X
VAMP2	B-X
as	B-X
a	B-X
chimera	B-X
containing	B-X
this	B-X
domain	B-X
of	B-X
VAMP2	B-X
fused	B-X
to	B-X
VAMP1	B-X
is	B-X
able	B-X
to	B-X
bind	B-X
to	B-X
PRA1	B-X
.	B-X
The	B-X
transmembrane	B-X
domain	B-X
of	B-X
VAMP2	B-X
is	B-X
also	B-X
essential	B-X
as	B-X
its	B-X
deletion	B-X
abolished	B-X
binding	B-X
to	B-X
PRA1	B-X
.	B-X
Replacement	B-X
of	B-X
the	B-X
deleted	B-X
VAMP2	B-X
transmembrane	B-X
domain	B-X
by	B-X
a	B-X
CAAX	B-X
prenylation	B-X
signal	B-X
can	B-X
not	B-X
restore	B-X
binding	B-X
to	B-X
PRA1	B-X
.	B-X
This	B-X
interaction	B-X
is	B-X
therefore	B-X
distinct	B-X
from	B-X
that	B-X
required	B-X
for	B-X
VAMP2	B-X
binding	B-X
to	B-X
either	B-X
syntaxin	B-X
or	B-X
both	B-X
syntaxin	B-X
and	B-X
SNAP-25	B-X
.	B-X
Deletion	B-X
analysis	B-X
on	B-X
PRA1	B-X
indicates	B-X
that	B-X
the	B-X
critical	B-X
Rab-	B-X
and	B-X
VAMP2-interacting	B-X
residues	B-X
reside	B-X
in	B-X
two	B-X
regions	B-X
:	B-X
the	B-X
amino-terminal	B-X
residues	B-X
30-54	B-X
and	B-X
the	B-X
extreme	B-X
carboxyl-terminal	B-X
domain	B-X
.	B-X
This	B-X
dual	B-X
Rab	B-X
and	B-X
VAMP2	B-X
binding	B-X
characteristic	B-X
suggests	B-X
that	B-X
PRA1	B-X
may	B-X
serve	B-X
to	B-X
link	B-X
these	B-X
two	B-X
protein	B-X
families	B-X
in	B-X
the	B-X
control	B-X
of	B-X
vesicle	B-X
docking	B-X
and	B-X
fusion	B-X
.	B-X

The	O
prenylation	O
-	O
dependent	O
association	O
of	O
PRA1	B-Protein
with	O
multiple	O
GTPases	O
is	O
conserved	O
in	O
evolution	O
;	O
the	O
yeast	O
PRA1	B-Protein
protein	O
associates	O
with	O
both	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
and	O
RhoA	B-Protein
.	O
<EOS>	B-X
Localization	B-X
of	B-X
Ras	B-X
and	B-X
Ras-like	B-X
proteins	B-X
to	B-X
the	B-X
correct	B-X
subcellular	B-X
compartment	B-X
is	B-X
essential	B-X
for	B-X
these	B-X
proteins	B-X
to	B-X
mediate	B-X
their	B-X
biological	B-X
effects	B-X
.	B-X
Many	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
(	B-X
Ha-Ras	B-X
,	B-X
N-Ras	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
RhoA	B-X
)	B-X
are	B-X
prenylated	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
then	B-X
transit	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
on	B-X
their	B-X
way	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
proteins	B-X
that	B-X
aid	B-X
in	B-X
the	B-X
trafficking	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
have	B-X
not	B-X
been	B-X
well	B-X
characterized	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
prenylated	B-X
Rab	B-X
acceptor	B-X
protein	B-X
(	B-X
PRA1	B-X
)	B-X
,	B-X
which	B-X
others	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
prenylation-dependent	B-X
receptor	B-X
for	B-X
Rab	B-X
proteins	B-X
,	B-X
also	B-X
interacts	B-X
with	B-X
Ha-Ras	B-X
,	B-X
RhoA	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
Rap1a	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
with	B-X
PRA1	B-X
requires	B-X
their	B-X
post-translational	B-X
modification	B-X
by	B-X
prenylation	B-X
.	B-X
The	B-X
prenylation-dependent	B-X
association	B-X
of	B-X
PRA1	B-X
with	B-X
multiple	B-X
GTPases	B-X
is	B-X
conserved	B-X
in	B-X
evolution	B-X
;	B-X
the	B-X
yeast	B-X
PRA1	B-X
protein	B-X
associates	B-X
with	B-X
both	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
.	B-X
Earlier	B-X
studies	B-X
reported	B-X
the	B-X
presence	B-X
of	B-X
PRA1	B-X
in	B-X
the	B-X
Golgi	B-X
,	B-X
and	B-X
we	B-X
show	B-X
here	B-X
that	B-X
PRA1	B-X
co-localizes	B-X
with	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
in	B-X
the	B-X
Golgi	B-X
compartment	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
PRA1	B-X
acts	B-X
as	B-X
an	B-X
escort	B-X
protein	B-X
for	B-X
small	B-X
GTPases	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
hydrophobic	B-X
isoprenoid	B-X
moieties	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
and	B-X
facilitates	B-X
their	B-X
trafficking	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
.	B-X

Earlier	O
studies	O
reported	O
the	O
presence	O
of	O
PRA1	B-Protein
in	O
the	O
Golgi	O
,	O
and	O
we	O
show	O
here	O
that	O
PRA1	B-Protein
co	O
-	O
localizes	O
with	O
Ha	B-Protein
-	I-Protein
Ras	I-Protein
and	O
RhoA	B-Protein
in	O
the	O
Golgi	O
compartment	O
.	O
<EOS>	B-X
Localization	B-X
of	B-X
Ras	B-X
and	B-X
Ras-like	B-X
proteins	B-X
to	B-X
the	B-X
correct	B-X
subcellular	B-X
compartment	B-X
is	B-X
essential	B-X
for	B-X
these	B-X
proteins	B-X
to	B-X
mediate	B-X
their	B-X
biological	B-X
effects	B-X
.	B-X
Many	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
(	B-X
Ha-Ras	B-X
,	B-X
N-Ras	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
RhoA	B-X
)	B-X
are	B-X
prenylated	B-X
in	B-X
the	B-X
cytoplasm	B-X
and	B-X
then	B-X
transit	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
on	B-X
their	B-X
way	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
We	B-X
report	B-X
here	B-X
that	B-X
prenylated	B-X
Rab	B-X
acceptor	B-X
protein	B-X
(	B-X
PRA1	B-X
)	B-X
,	B-X
which	B-X
others	B-X
previously	B-X
identified	B-X
as	B-X
a	B-X
prenylation-dependent	B-X
receptor	B-X
for	B-X
Rab	B-X
proteins	B-X
,	B-X
also	B-X
interacts	B-X
with	B-X
Ha-Ras	B-X
,	B-X
RhoA	B-X
,	B-X
TC21	B-X
,	B-X
and	B-X
Rap1a	B-X
.	B-X
The	B-X
interaction	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
with	B-X
PRA1	B-X
requires	B-X
their	B-X
post-translational	B-X
modification	B-X
by	B-X
prenylation	B-X
.	B-X
The	B-X
prenylation-dependent	B-X
association	B-X
of	B-X
PRA1	B-X
with	B-X
multiple	B-X
GTPases	B-X
is	B-X
conserved	B-X
in	B-X
evolution	B-X
;	B-X
the	B-X
yeast	B-X
PRA1	B-X
protein	B-X
associates	B-X
with	B-X
both	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
.	B-X
Earlier	B-X
studies	B-X
reported	B-X
the	B-X
presence	B-X
of	B-X
PRA1	B-X
in	B-X
the	B-X
Golgi	B-X
,	B-X
and	B-X
we	B-X
show	B-X
here	B-X
that	B-X
PRA1	B-X
co-localizes	B-X
with	B-X
Ha-Ras	B-X
and	B-X
RhoA	B-X
in	B-X
the	B-X
Golgi	B-X
compartment	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
PRA1	B-X
acts	B-X
as	B-X
an	B-X
escort	B-X
protein	B-X
for	B-X
small	B-X
GTPases	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
hydrophobic	B-X
isoprenoid	B-X
moieties	B-X
of	B-X
the	B-X
small	B-X
GTPases	B-X
and	B-X
facilitates	B-X
their	B-X
trafficking	B-X
through	B-X
the	B-X
endomembrane	B-X
system	B-X
.	B-X

We	O
suggest	O
that	O
PRA1	B-Protein
acts	O
as	O
an	O
escort	O
protein	O
for	O
small	O
GTPases	O
by	O
binding	O
to	O
the	O
hydrophobic	O
isoprenoid	O
moieties	O
of	O
the	O
small	O
GTPases	O
and	O
facilitates	O
their	O
trafficking	O
through	O
the	O
endomembrane	O
system	O
.	O

Cloning	O
and	O
identification	O
of	O
MYPT3	B-Protein
:	O
a	O
prenylatable	O
myosin	O
targetting	O
subunit	O
of	O
protein	O
phosphatase	O
1	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

To	O
identify	O
novel	O
protein	O
phosphatase	O
1	O
(	O
PP1	O
)	O
-	O
interacting	O
proteins	O
,	O
a	O
yeast	O
two	O
-	O
hybrid	O
3T3	O
-	O
L1	O
adipocyte	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
catalytic	O
subunit	O
of	O
PP1	O
as	O
bait	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

In	O
the	O
present	O
work	O
,	O
the	O
isolation	O
,	O
identification	O
and	O
initial	O
biochemical	O
characterization	O
of	O
a	O
novel	O
PP1	O
-	O
interacting	O
protein	O
,	O
MYPT3	B-Protein
,	O
which	O
is	O
homologous	O
with	O
the	O
myosin	O
phosphatase	O
targetting	O
subunit	O
(	O
MYPT	O
)	O
family	O
,	O
is	O
described	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

MYPT3	B-Protein
aligns	O
>	O
99	O
%	O
with	O
a	O
region	O
of	O
mouse	O
genomic	O
DNA	O
clone	O
RP23	O
-	O
156P23	O
and	O
localizes	O
to	O
chromosome	O
15	O
,	O
between	O
markers	O
at	O
44	O
.	O
1	O
-	O
46	O
.	O
5	O
cM	O
,	O
as	O
demonstrated	O
by	O
radiation	O
hybrid	O
mapping	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
gene	B-X
consists	B-X
of	B-X
ten	B-X
exons	B-X
that	B-X
encode	B-X
for	B-X
a	B-X
524-amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
predicted	B-X
molecular	B-X
mass	B-X
of	B-X
57529	B-X
Da	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

The	O
gene	O
consists	O
of	O
ten	O
exons	O
that	O
encode	O
for	O
a	O
524	O
-	O
amino	O
acid	O
sequence	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
57529	O
Da	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
consists	B-X
of	B-X
ten	B-X
exons	B-X
that	B-X
encode	B-X
for	B-X
a	B-X
524-amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
predicted	B-X
molecular	B-X
mass	B-X
of	B-X
57529	B-X
Da	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X

The	O
N	O
-	O
terminal	O
region	O
of	O
MYPT3	B-Protein
consists	O
of	O
a	O
consensus	O
PP1	O
-	O
binding	O
site	O
and	O
multiple	O
ankyrin	O
repeats	O
.	O

MYPT3	B-Protein
is	O
distinguished	O
from	O
related	O
approximately	O
110	O
-	O
130	O
kDa	O
MYPT	O
subunits	O
by	O
its	O
molecular	O
mass	O
of	O
58	O
kDa	O
,	O
and	O
a	O
unique	O
C	O
-	O
terminal	O
region	O
that	O
contains	O
several	O
potential	O
signalling	O
motifs	O
and	O
a	O
CaaX	O
prenylation	O
site	O
.	O

We	O
have	O
shown	O
that	O
affinity	O
-	O
purified	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
(	O
GST	B-Protein
)	O
-	O
MYPT3	B-Protein
is	O
prenylated	O
by	O
purified	O
recombinant	O
farnesyltransferase	O
in	O
vitro	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X

Endogenous	O
PP1	O
from	O
3T3	O
-	O
L1	O
lysates	O
specifically	O
interacts	O
with	O
MYPT3	B-Protein
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

Additionally	O
,	O
purified	O
PP1	O
activity	O
was	O
inhibited	O
by	O
GST	B-Protein
-	O
MYPT3	B-Protein
toward	O
phosphorylase	O
a	O
,	O
myosin	O
light	O
chain	O
and	O
myosin	O
substrate	O
in	O
vitro	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

Overall	O
,	O
our	O
findings	O
identify	O
a	O
novel	O
prenylatable	O
subunit	O
of	O
PP1	O
that	O
defines	O
a	O
new	O
subfamily	O
of	O
MYPT	O
.	O
<EOS>	B-X
To	B-X
identify	B-X
novel	B-X
protein	B-X
phosphatase	B-X
1	B-X
(	B-X
PP1	B-X
)	B-X
-interacting	B-X
proteins	B-X
,	B-X
a	B-X
yeast	B-X
two-hybrid	B-X
3T3-L1	B-X
adipocyte	B-X
cDNA	B-X
library	B-X
was	B-X
screened	B-X
with	B-X
the	B-X
catalytic	B-X
subunit	B-X
of	B-X
PP1	B-X
as	B-X
bait	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
the	B-X
isolation	B-X
,	B-X
identification	B-X
and	B-X
initial	B-X
biochemical	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
PP1-interacting	B-X
protein	B-X
,	B-X
MYPT3	B-X
,	B-X
which	B-X
is	B-X
homologous	B-X
with	B-X
the	B-X
myosin	B-X
phosphatase	B-X
targetting	B-X
subunit	B-X
(	B-X
MYPT	B-X
)	B-X
family	B-X
,	B-X
is	B-X
described	B-X
.	B-X
MYPT3	B-X
aligns	B-X
>	B-X
99	B-X
%	B-X
with	B-X
a	B-X
region	B-X
of	B-X
mouse	B-X
genomic	B-X
DNA	B-X
clone	B-X
RP23-156P23	B-X
and	B-X
localizes	B-X
to	B-X
chromosome	B-X
15	B-X
,	B-X
between	B-X
markers	B-X
at	B-X
44.1-46.5	B-X
cM	B-X
,	B-X
as	B-X
demonstrated	B-X
by	B-X
radiation	B-X
hybrid	B-X
mapping	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
of	B-X
MYPT3	B-X
consists	B-X
of	B-X
a	B-X
consensus	B-X
PP1-binding	B-X
site	B-X
and	B-X
multiple	B-X
ankyrin	B-X
repeats	B-X
.	B-X
MYPT3	B-X
is	B-X
distinguished	B-X
from	B-X
related	B-X
approximately	B-X
110-130	B-X
kDa	B-X
MYPT	B-X
subunits	B-X
by	B-X
its	B-X
molecular	B-X
mass	B-X
of	B-X
58	B-X
kDa	B-X
,	B-X
and	B-X
a	B-X
unique	B-X
C-terminal	B-X
region	B-X
that	B-X
contains	B-X
several	B-X
potential	B-X
signalling	B-X
motifs	B-X
and	B-X
a	B-X
CaaX	B-X
prenylation	B-X
site	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
affinity-purified	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-MYPT3	B-X
is	B-X
prenylated	B-X
by	B-X
purified	B-X
recombinant	B-X
farnesyltransferase	B-X
in	B-X
vitro	B-X
.	B-X
Endogenous	B-X
PP1	B-X
from	B-X
3T3-L1	B-X
lysates	B-X
specifically	B-X
interacts	B-X
with	B-X
MYPT3	B-X
.	B-X
Additionally	B-X
,	B-X
purified	B-X
PP1	B-X
activity	B-X
was	B-X
inhibited	B-X
by	B-X
GST-MYPT3	B-X
toward	B-X
phosphorylase	B-X
a	B-X
,	B-X
myosin	B-X
light	B-X
chain	B-X
and	B-X
myosin	B-X
substrate	B-X
in	B-X
vitro	B-X
.	B-X
Overall	B-X
,	B-X
our	B-X
findings	B-X
identify	B-X
a	B-X
novel	B-X
prenylatable	B-X
subunit	B-X
of	B-X
PP1	B-X
that	B-X
defines	B-X
a	B-X
new	B-X
subfamily	B-X
of	B-X
MYPT	B-X
.	B-X

Physiological	O
substrates	O
for	O
human	O
lysosomal	O
beta	O
-	O
hexosaminidase	O
S	O
.	O
<EOS>	B-X
Human	B-X
lysosomal	B-X
beta-hexosaminidases	B-X
remove	B-X
terminal	B-X
beta-glycosidically	B-X
bound	B-X
N-acetylhexosamine	B-X
residues	B-X
from	B-X
a	B-X
number	B-X
of	B-X
glycoconjugates	B-X
.	B-X
Three	B-X
different	B-X
isozymes	B-X
composed	B-X
of	B-X
two	B-X
noncovalently	B-X
linked	B-X
subunits	B-X
alpha	B-X
and	B-X
beta	B-X
exist	B-X
:	B-X
Hex	B-X
A	B-X
(	B-X
alphabeta	B-X
)	B-X
,	B-X
Hex	B-X
B	B-X
(	B-X
betabeta	B-X
)	B-X
,	B-X
and	B-X
Hex	B-X
S	B-X
(	B-X
alphaalpha	B-X
)	B-X
.	B-X
However	B-X
,	B-X
the	B-X
striking	B-X
accumulation	B-X
of	B-X
anionic	B-X
oligosaccharides	B-X
in	B-X
double	B-X
knockout	B-X
mice	B-X
totally	B-X
deficient	B-X
in	B-X
hexosaminidase	B-X
activity	B-X
but	B-X
not	B-X
in	B-X
mice	B-X
expressing	B-X
Hex	B-X
S	B-X
(	B-X
Sango	B-X
,	B-X
K.	B-X
,	B-X
McDonald	B-X
,	B-X
M.	B-X
P.	B-X
,	B-X
Crawley	B-X
,	B-X
J.	B-X
N.	B-X
,	B-X
Mack	B-X
,	B-X
M.	B-X
L.	B-X
,	B-X
Tifft	B-X
,	B-X
C.J.	B-X
,	B-X
Skop	B-X
,	B-X
E.	B-X
,	B-X
Starr	B-X
,	B-X
C.	B-X
M.	B-X
,	B-X
Hoffmann	B-X
,	B-X
A.	B-X
,	B-X
Sandhoff	B-X
,	B-X
K.	B-X
,	B-X
Suzuki	B-X
,	B-X
K.	B-X
,	B-X
and	B-X
Proia	B-X
,	B-X
R.	B-X
L.	B-X
,	B-X
(	B-X
1996	B-X
)	B-X
Nat	B-X
.	B-X
14	B-X
,	B-X
348-352	B-X
)	B-X
prompted	B-X
us	B-X
to	B-X
reinvestigate	B-X
the	B-X
substrate	B-X
specificity	B-X
of	B-X
Hex	B-X
S.	B-X
To	B-X
identify	B-X
physiological	B-X
substrates	B-X
of	B-X
Hex	B-X
S	B-X
,	B-X
anionic	B-X
and	B-X
neutral	B-X
oligosaccharides	B-X
excreted	B-X
in	B-X
the	B-X
urine	B-X
of	B-X
the	B-X
double	B-X
knockout	B-X
mice	B-X
were	B-X
isolated	B-X
and	B-X
analyzed	B-X
.	B-X
In	B-X
vitro	B-X
,	B-X
recombinant	B-X
Hex	B-X
S	B-X
was	B-X
highly	B-X
active	B-X
on	B-X
water-soluble	B-X
and	B-X
amphiphilic	B-X
glycoconjugates	B-X
including	B-X
artificial	B-X
substrates	B-X
,	B-X
sulfated	B-X
GAG	B-X
fragments	B-X
,	B-X
and	B-X
the	B-X
sulfated	B-X
glycosphingolipid	B-X
SM2	B-X
.	B-X
Hydrolysis	B-X
of	B-X
membrane-bound	B-X
SM2	B-X
by	B-X
the	B-X
recombinant	B-X
Hex	B-X
S	B-X
was	B-X
synergistically	B-X
stimulated	B-X
by	B-X
the	B-X
GM2	B-X
activator	B-X
protein	B-X
and	B-X
the	B-X
lysosomal	B-X
anionic	B-X
phospholipid	B-X
bis	B-X
(	B-X
monoacylglycero	B-X
)	B-X
phosphate	B-X
.	B-X

Human	O
lysosomal	O
beta	O
-	O
hexosaminidases	O
remove	O
terminal	O
beta	O
-	O
glycosidically	O
bound	O
N	O
-	O
acetylhexosamine	O
residues	O
from	O
a	O
number	O
of	O
glycoconjugates	O
.	O

Three	O
different	O
isozymes	O
composed	O
of	O
two	O
noncovalently	O
linked	O
subunits	O
alpha	O
and	O
beta	O
exist	O
:	O
Hex	O
A	O
(	O
alphabeta	O
)	O
,	O
Hex	O
B	O
(	O
betabeta	O
)	O
,	O
and	O
Hex	O
S	O
(	O
alphaalpha	O
)	O
.	O

While	O
the	O
role	O
of	O
Hex	O
A	O
and	O
B	O
for	O
the	O
degradation	O
of	O
several	O
anionic	O
and	O
neutral	O
glycoconjugates	O
has	O
been	O
well	O
established	O
,	O
the	O
physiological	O
significance	O
of	O
labile	O
Hex	O
S	O
has	O
remained	O
unclear	O
.	O

However	O
,	O
the	O
striking	O
accumulation	O
of	O
anionic	O
oligosaccharides	O
in	O
double	O
knockout	O
mice	O
totally	O
deficient	O
in	O
hexosaminidase	O
activity	O
but	O
not	O
in	O
mice	O
expressing	O
Hex	O
S	O
(	O
Sango	O
,	O
K	O
.	O
,	O
McDonald	O
,	O
M	O
.	O
P	O
.	O
,	O
Crawley	O
,	O
J	O
.	O
N	O
.	O
,	O
Mack	O
,	O
M	O
.	O
L	O
.	O
,	O
Tifft	O
,	O
C	O
.	O
J	O
.	O
,	O
Skop	O
,	O
E	O
.	O
,	O
Starr	O
,	O
C	O
.	O
M	O
.	O
,	O
Hoffmann	O
,	O
A	O
.	O
,	O
Sandhoff	O
,	O
K	O
.	O
,	O
Suzuki	O
,	O
K	O
.	O
,	O
and	O
Proia	O
,	O
R	O
.	O
L	O
.	O
,	O
(	O
1996	O
)	O
Nat	O
.	O
Genet	O
.	O
14	O
,	O
348	O
-	O
352	O
)	O
prompted	O
us	O
to	O
reinvestigate	O
the	O
substrate	O
specificity	O
of	O
Hex	O
S	O
.	O

To	O
identify	O
physiological	O
substrates	O
of	O
Hex	O
S	O
,	O
anionic	O
and	O
neutral	O
oligosaccharides	O
excreted	O
in	O
the	O
urine	O
of	O
the	O
double	O
knockout	O
mice	O
were	O
isolated	O
and	O
analyzed	O
.	O

Using	O
ESI	O
-	O
MS	O
/	O
MS	O
and	O
glycosidase	O
digestion	O
the	O
anionic	O
glycans	O
were	O
identified	O
as	O
products	O
of	O
incomplete	O
dermatan	O
sulfate	O
degradation	O
whereas	O
the	O
neutral	O
storage	O
oligosaccharides	O
were	O
found	O
to	O
be	O
fragments	O
of	O
N	O
-	O
glycan	O
degradation	O
.	O

In	O
vitro	O
,	O
recombinant	O
Hex	O
S	O
was	O
highly	O
active	O
on	O
water	O
-	O
soluble	O
and	O
amphiphilic	O
glycoconjugates	O
including	O
artificial	O
substrates	O
,	O
sulfated	O
GAG	O
fragments	O
,	O
and	O
the	O
sulfated	O
glycosphingolipid	O
SM2	O
.	O

Hydrolysis	O
of	O
membrane	O
-	O
bound	O
SM2	O
by	O
the	O
recombinant	O
Hex	O
S	O
was	O
synergistically	O
stimulated	O
by	O
the	O
GM2	B-Protein
activator	I-Protein
protein	I-Protein
and	O
the	O
lysosomal	O
anionic	O
phospholipid	O
bis	O
(	O
monoacylglycero	O
)	O
phosphate	O
.	O

An	O
intact	O
NEDD8	B-Protein
pathway	O
is	O
required	O
for	O
Cullin	O
-	O
dependent	O
ubiquitylation	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Cdc53	B-X
and	B-X
the	B-X
Cullins	B-X
can	B-X
become	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
ubiquitin-like	B-X
molecule	B-X
Rub1/NEDD8	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
neddylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
two	B-X
specific	B-X
subclasses	B-X
of	B-X
mammalian	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Skp1	B-Protein
-	O
Cdc53	B-Protein
/	O
Cul1	B-Protein
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
complexes	O
constitute	O
a	O
class	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O
<EOS>	B-X
Skp1-Cdc53/Cul1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
complexes	B-X
constitute	B-X
a	B-X
class	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Recently	B-X
,	B-X
a	B-X
multiprotein	B-X
complex	B-X
containing	B-X
pVHL	B-X
,	B-X
elongin	B-X
C	B-X
and	B-X
Cul2	B-X
(	B-X
VEC	B-X
)	B-X
was	B-X
shown	B-X
to	B-X
structurally	B-X
and	B-X
functionally	B-X
resemble	B-X
SCF	B-X
complexes	B-X
.	B-X
Cdc53	B-X
and	B-X
the	B-X
Cullins	B-X
can	B-X
become	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
ubiquitin-like	B-X
molecule	B-X
Rub1/NEDD8	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
inhibits	B-X
SCF	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
yeast	B-X
and	B-X
plants	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
neddylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
two	B-X
specific	B-X
subclasses	B-X
of	B-X
mammalian	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Recently	O
,	O
a	O
multiprotein	O
complex	O
containing	O
pVHL	B-Protein
,	O
elongin	B-Protein
C	I-Protein
and	O
Cul2	B-Protein
(	O
VEC	O
)	O
was	O
shown	O
to	O
structurally	O
and	O
functionally	O
resemble	O
SCF	O
complexes	O
.	O
<EOS>	B-X
Skp1-Cdc53/Cul1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
complexes	B-X
constitute	B-X
a	B-X
class	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Recently	B-X
,	B-X
a	B-X
multiprotein	B-X
complex	B-X
containing	B-X
pVHL	B-X
,	B-X
elongin	B-X
C	B-X
and	B-X
Cul2	B-X
(	B-X
VEC	B-X
)	B-X
was	B-X
shown	B-X
to	B-X
structurally	B-X
and	B-X
functionally	B-X
resemble	B-X
SCF	B-X
complexes	B-X
.	B-X
Cdc53	B-X
and	B-X
the	B-X
Cullins	B-X
can	B-X
become	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
ubiquitin-like	B-X
molecule	B-X
Rub1/NEDD8	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
inhibits	B-X
SCF	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
yeast	B-X
and	B-X
plants	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X

Cdc53	B-Protein
and	O
the	O
Cullins	O
can	O
become	O
covalently	O
linked	O
to	O
the	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
Rub1	B-Protein
/	O
NEDD8	B-Protein
.	O

Inhibition	O
of	O
neddylation	O
inhibits	O
SCF	O
function	O
in	O
vitro	O
and	O
in	O
yeast	O
and	O
plants	O
.	O
<EOS>	B-X
Skp1-Cdc53/Cul1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
complexes	B-X
constitute	B-X
a	B-X
class	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Recently	B-X
,	B-X
a	B-X
multiprotein	B-X
complex	B-X
containing	B-X
pVHL	B-X
,	B-X
elongin	B-X
C	B-X
and	B-X
Cul2	B-X
(	B-X
VEC	B-X
)	B-X
was	B-X
shown	B-X
to	B-X
structurally	B-X
and	B-X
functionally	B-X
resemble	B-X
SCF	B-X
complexes	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
inhibits	B-X
SCF	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
yeast	B-X
and	B-X
plants	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
neddylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
two	B-X
specific	B-X
subclasses	B-X
of	B-X
mammalian	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Here	O
we	O
show	O
that	O
ongoing	O
neddylation	O
is	O
likewise	O
required	O
for	O
VEC	O
function	O
in	O
vitro	O
and	O
for	O
the	O
degradation	O
of	O
SCF	O
and	O
VEC	O
targets	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Skp1-Cdc53/Cul1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
complexes	B-X
constitute	B-X
a	B-X
class	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Recently	B-X
,	B-X
a	B-X
multiprotein	B-X
complex	B-X
containing	B-X
pVHL	B-X
,	B-X
elongin	B-X
C	B-X
and	B-X
Cul2	B-X
(	B-X
VEC	B-X
)	B-X
was	B-X
shown	B-X
to	B-X
structurally	B-X
and	B-X
functionally	B-X
resemble	B-X
SCF	B-X
complexes	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
inhibits	B-X
SCF	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
yeast	B-X
and	B-X
plants	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
neddylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
two	B-X
specific	B-X
subclasses	B-X
of	B-X
mammalian	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Thus	O
,	O
neddylation	O
regulates	O
the	O
activity	O
of	O
two	O
specific	O
subclasses	O
of	O
mammalian	O
ubiquitin	B-Protein
ligases	O
.	O
<EOS>	B-X
Skp1-Cdc53/Cul1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
complexes	B-X
constitute	B-X
a	B-X
class	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
Cdc53	B-X
and	B-X
the	B-X
Cullins	B-X
can	B-X
become	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
ubiquitin-like	B-X
molecule	B-X
Rub1/NEDD8	B-X
.	B-X
Inhibition	B-X
of	B-X
neddylation	B-X
inhibits	B-X
SCF	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
yeast	B-X
and	B-X
plants	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
ongoing	B-X
neddylation	B-X
is	B-X
likewise	B-X
required	B-X
for	B-X
VEC	B-X
function	B-X
in	B-X
vitro	B-X
and	B-X
for	B-X
the	B-X
degradation	B-X
of	B-X
SCF	B-X
and	B-X
VEC	B-X
targets	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
Thus	B-X
,	B-X
neddylation	B-X
regulates	B-X
the	B-X
activity	B-X
of	B-X
two	B-X
specific	B-X
subclasses	B-X
of	B-X
mammalian	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Effect	O
of	O
modification	O
on	O
physicochemical	O
and	O
biological	O
properties	O
of	O
haptoglobin	B-Protein
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

VI	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
we	B-X
aimed	B-X
to	B-X
prospectively	B-X
validate	B-X
the	B-X
performance	B-X
of	B-X
spleen	B-X
stiffness	B-X
measurement	B-X
(	B-X
cut-off	B-X
46	B-X
kPa	B-X
)	B-X
combined	B-X
with	B-X
Baveno	B-X
VI	B-X
criteria	B-X
in	B-X
ruling	B-X
out	B-X
high-risk	B-X
varices	B-X
in	B-X
these	B-X
patients	B-X
.	B-X
Coronavirus	B-X
disease-19	B-X
(	B-X
COVID-19	B-X
)	B-X
is	B-X
an	B-X
ongoing	B-X
global	B-X
pandemic	B-X
caused	B-X
by	B-X
the	B-X
``	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
2	B-X
''	B-X
(	B-X
SARS-CoV-2	B-X
)	B-X
,	B-X
which	B-X
was	B-X
isolated	B-X
for	B-X
the	B-X
first	B-X
time	B-X
in	B-X
Wuhan	B-X
(	B-X
China	B-X
)	B-X
in	B-X
December	B-X
2019	B-X
.	B-X
Among	B-X
extrapulmonary	B-X
signs	B-X
associated	B-X
with	B-X
COVID-19	B-X
,	B-X
dermatological	B-X
manifestations	B-X
have	B-X
been	B-X
increasingly	B-X
reported	B-X
in	B-X
the	B-X
last	B-X
few	B-X
months	B-X
.	B-X
Vaccine	B-X
Technology	B-X
VI	B-X
:	B-X
Innovative	B-X
and	B-X
integrated	B-X
approaches	B-X
in	B-X
vaccine	B-X
development	B-X
.	B-X

Reaction	O
with	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

The	O
azlactone	O
of	O
p	O
-	O
nitrobenzoyl	O
-	O
valine	O
(	O
Nbz	O
-	O
Val	O
)	O
has	O
been	O
used	O
for	O
modification	O
of	O
xi	O
-	O
amino	O
groups	O
of	O
lysine	O
in	O
haptoglobin	B-Protein
type	I-Protein
1	I-Protein
-	I-Protein
1	I-Protein
,	O
in	O
hemoglobin	O
,	O
and	O
in	O
the	O
haptoglobin	B-Protein
-	O
hemoglobin	O
complex	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

By	O
the	O
use	O
of	O
this	O
reagent	O
95	O
%	O
of	O
amino	O
groups	O
in	O
haptoglobin	B-Protein
and	O
90	O
%	O
in	O
hemoglobin	O
have	O
been	O
blocked	O
without	O
any	O
changes	O
in	O
peroxidase	O
activity	O
of	O
the	O
formed	O
complexes	O
:	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
with	O
hemoglobin	O
,	O
Nbz	O
-	O
Val	O
.	O
hemoglobin	O
with	O
haptoglobin	B-Protein
,	O
and	O
Nbz	O
-	O
Val	O
.	O
(	O
haptoglonin	B-Protein
-	O
hemoglobin	O
)	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

After	O
reduction	O
and	O
reoxidation	O
,	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
was	O
found	O
to	O
retain	O
90	O
%	O
of	O
peroxidase	O
activity	O
when	O
complexed	O
with	O
hemoglobin	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

Beta	O
chains	O
separated	O
either	O
from	O
haptoglobin	B-Protein
or	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
showed	O
15	O
%	O
of	O
peroxidase	O
activity	O
in	O
the	O
complex	O
with	O
hemoglobin	O
,	O
alpha	O
chains	O
of	O
the	O
same	O
origin	O
were	O
completely	O
inactive	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
whole	B-X
saliva	B-X
proteins	B-X
of	B-X
patients	B-X
with	B-X
OSCC	B-X
(	B-X
n	B-X
=	B-X
12	B-X
)	B-X
and	B-X
healthy	B-X
subjects	B-X
(	B-X
n	B-X
=	B-X
12	B-X
)	B-X
were	B-X
separated	B-X
by	B-X
2DE	B-X
to	B-X
identify	B-X
potential	B-X
candidate	B-X
biomarkers	B-X
that	B-X
are	B-X
much	B-X
needed	B-X
to	B-X
improve	B-X
detection	B-X
of	B-X
the	B-X
cancer	B-X
.	B-X
The	B-X
patients	B-X
'	B-X
saliva	B-X
α1-antitrypsin	B-X
(	B-X
AAT	B-X
)	B-X
and	B-X
haptoglobin	B-X
(	B-X
HAP	B-X
)	B-X
β	B-X
chains	B-X
were	B-X
resolved	B-X
into	B-X
polypeptide	B-X
spots	B-X
with	B-X
increased	B-X
microheterogeneity	B-X
,	B-X
although	B-X
these	B-X
were	B-X
not	B-X
apparent	B-X
in	B-X
their	B-X
sera	B-X
.	B-X
Their	B-X
2DE	B-X
protein	B-X
profiles	B-X
also	B-X
showed	B-X
presence	B-X
of	B-X
hemopexin	B-X
and	B-X
α-1B	B-X
glycoprotein	B-X
,	B-X
which	B-X
were	B-X
not	B-X
detected	B-X
in	B-X
the	B-X
profiles	B-X
of	B-X
the	B-X
control	B-X
saliva	B-X
.	B-X
When	B-X
subjected	B-X
to	B-X
densitometry	B-X
analysis	B-X
,	B-X
significant	B-X
altered	B-X
levels	B-X
of	B-X
AAT	B-X
,	B-X
complement	B-X
C3	B-X
,	B-X
transferrin	B-X
,	B-X
transthyretin	B-X
,	B-X
and	B-X
β	B-X
chains	B-X
of	B-X
fibrinogen	B-X
and	B-X
HAP	B-X
were	B-X
detected	B-X
.	B-X

Whereas	O
recombination	O
of	O
haptoglobin	B-Protein
from	O
alpha	O
and	O
beta	O
chains	O
resulted	O
in	O
42	O
%	O
hemoglobin	O
-	O
binding	O
capacity	O
,	O
renaturation	O
of	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
from	O
separated	O
subunits	O
was	O
found	O
to	O
proceed	O
with	O
almost	O
100	O
%	O
yield	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

In	O
immunodiffusion	O
with	O
rabbit	O
anti	O
-	O
haptoglobin	B-Protein
or	O
anti	O
-	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
sera	O
,	O
preparations	O
of	O
haptoglobin	B-Protein
and	O
Nbz	O
-	O
Val	O
.	O
haptoglobin	B-Protein
after	O
reduction	O
and	O
reoxidation	O
or	O
after	O
recombination	O
from	O
separated	O
subunits	O
gave	O
similar	O
precipitation	O
arcs	O
showing	O
the	O
reaction	O
of	O
immunological	O
identity	O
.	O
<EOS>	B-X
The	B-X
azlactone	B-X
of	B-X
p-nitrobenzoyl-valine	B-X
(	B-X
Nbz-Val	B-X
)	B-X
has	B-X
been	B-X
used	B-X
for	B-X
modification	B-X
of	B-X
xi-amino	B-X
groups	B-X
of	B-X
lysine	B-X
in	B-X
haptoglobin	B-X
type	B-X
1-1	B-X
,	B-X
in	B-X
hemoglobin	B-X
,	B-X
and	B-X
in	B-X
the	B-X
haptoglobin-hemoglobin	B-X
complex	B-X
.	B-X
By	B-X
the	B-X
use	B-X
of	B-X
this	B-X
reagent	B-X
95	B-X
%	B-X
of	B-X
amino	B-X
groups	B-X
in	B-X
haptoglobin	B-X
and	B-X
90	B-X
%	B-X
in	B-X
hemoglobin	B-X
have	B-X
been	B-X
blocked	B-X
without	B-X
any	B-X
changes	B-X
in	B-X
peroxidase	B-X
activity	B-X
of	B-X
the	B-X
formed	B-X
complexes	B-X
:	B-X
Nbz-Val.haptoglobin	B-X
with	B-X
hemoglobin	B-X
,	B-X
Nbz-Val	B-X
.	B-X
hemoglobin	B-X
with	B-X
haptoglobin	B-X
,	B-X
and	B-X
Nbz-Val.	B-X
(	B-X
haptoglonin-hemoglobin	B-X
)	B-X
.	B-X
After	B-X
reduction	B-X
and	B-X
reoxidation	B-X
,	B-X
Nbz-Val.haptoglobin	B-X
was	B-X
found	B-X
to	B-X
retain	B-X
90	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
when	B-X
complexed	B-X
with	B-X
hemoglobin	B-X
.	B-X
Beta	B-X
chains	B-X
separated	B-X
either	B-X
from	B-X
haptoglobin	B-X
or	B-X
Nbz-Val.haptoglobin	B-X
showed	B-X
15	B-X
%	B-X
of	B-X
peroxidase	B-X
activity	B-X
in	B-X
the	B-X
complex	B-X
with	B-X
hemoglobin	B-X
,	B-X
alpha	B-X
chains	B-X
of	B-X
the	B-X
same	B-X
origin	B-X
were	B-X
completely	B-X
inactive	B-X
.	B-X
Whereas	B-X
recombination	B-X
of	B-X
haptoglobin	B-X
from	B-X
alpha	B-X
and	B-X
beta	B-X
chains	B-X
resulted	B-X
in	B-X
42	B-X
%	B-X
hemoglobin-binding	B-X
capacity	B-X
,	B-X
renaturation	B-X
of	B-X
Nbz-Val.haptoglobin	B-X
from	B-X
separated	B-X
subunits	B-X
was	B-X
found	B-X
to	B-X
proceed	B-X
with	B-X
almost	B-X
100	B-X
%	B-X
yield	B-X
.	B-X
In	B-X
immunodiffusion	B-X
with	B-X
rabbit	B-X
anti-haptoglobin	B-X
or	B-X
anti-Nbz-Val.haptoglobin	B-X
sera	B-X
,	B-X
preparations	B-X
of	B-X
haptoglobin	B-X
and	B-X
Nbz-Val.haptoglobin	B-X
after	B-X
reduction	B-X
and	B-X
reoxidation	B-X
or	B-X
after	B-X
recombination	B-X
from	B-X
separated	B-X
subunits	B-X
gave	B-X
similar	B-X
precipitation	B-X
arcs	B-X
showing	B-X
the	B-X
reaction	B-X
of	B-X
immunological	B-X
identity	B-X
.	B-X

Site	O
-	O
directed	O
mutagenesis	O
of	O
platelet	B-Protein
glycoprotein	I-Protein
Ib	I-Protein
alpha	I-Protein
demonstrating	O
residues	O
involved	O
in	O
the	O
sulfation	O
of	O
tyrosines	O
276	O
,	O
278	O
,	O
and	O
279	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

The	O
interaction	O
between	O
platelet	B-Protein
glycoprotein	I-Protein
(	I-Protein
GP	I-Protein
)	I-Protein
Ib	I-Protein
alpha	I-Protein
and	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
(	O
VWF	B-Protein
)	O
is	O
essential	O
for	O
initiation	O
of	O
hemostasis	O
.	O
<EOS>	B-X
The	B-X
binding	B-X
of	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
vWF	B-X
)	B-X
to	B-X
the	B-X
platelet	B-X
receptor	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib-IX	B-X
complex	B-X
is	B-X
a	B-X
key	B-X
event	B-X
in	B-X
hemostasis	B-X
and	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
development	B-X
of	B-X
thrombotic	B-X
vascular	B-X
occlusion	B-X
.	B-X
We	B-X
present	B-X
here	B-X
evidence	B-X
that	B-X
residues	B-X
Ser251-Tyr279	B-X
in	B-X
the	B-X
GP	B-X
Ib	B-X
alpha-chain	B-X
participate	B-X
in	B-X
this	B-X
function	B-X
.	B-X
Initial	B-X
studies	B-X
suggested	B-X
that	B-X
the	B-X
modality	B-X
of	B-X
vWF	B-X
interaction	B-X
with	B-X
GP	B-X
Ib	B-X
depended	B-X
on	B-X
the	B-X
conditions	B-X
used	B-X
for	B-X
induction	B-X
of	B-X
binding	B-X
,	B-X
either	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ristocetin	B-X
,	B-X
or	B-X
botrocetin	B-X
,	B-X
or	B-X
with	B-X
asialo-vWF	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
only	B-X
the	B-X
45-kDa	B-X
amino-terminal	B-X
fragment	B-X
of	B-X
GP	B-X
Ib	B-X
alpha	B-X
inhibited	B-X
the	B-X
vWF-GP	B-X
Ib	B-X
interaction	B-X
under	B-X
all	B-X
conditions	B-X
tested	B-X
,	B-X
while	B-X
the	B-X
84-kDa	B-X
macroglycopeptide	B-X
was	B-X
significantly	B-X
effective	B-X
only	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ristocetin	B-X
.	B-X
This	B-X
led	B-X
to	B-X
the	B-X
identification	B-X
of	B-X
a	B-X
linear	B-X
GP	B-X
Ib	B-X
alpha	B-X
sequence	B-X
(	B-X
residues	B-X
Ser251-Tyr279	B-X
)	B-X
that	B-X
effectively	B-X
inhibited	B-X
platelet	B-X
interaction	B-X
with	B-X
vWF	B-X
mediated	B-X
by	B-X
ristocetin	B-X
and	B-X
,	B-X
at	B-X
higher	B-X
concentration	B-X
,	B-X
also	B-X
by	B-X
botrocetin	B-X
.	B-X
Thus	B-X
,	B-X
while	B-X
native	B-X
conformation	B-X
of	B-X
GP	B-X
Ib	B-X
alpha	B-X
appears	B-X
to	B-X
be	B-X
important	B-X
for	B-X
optimal	B-X
interaction	B-X
with	B-X
vWF	B-X
,	B-X
the	B-X
results	B-X
obtained	B-X
with	B-X
short	B-X
synthetic	B-X
peptides	B-X
may	B-X
help	B-X
in	B-X
defining	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
participating	B-X
in	B-X
this	B-X
essential	B-X
function	B-X
.	B-X

The	O
sulfation	O
of	O
the	O
3	O
tyrosine	O
residues	O
276	O
,	O
278	O
,	O
and	O
279	O
in	O
GPIb	B-Protein
alpha	I-Protein
is	O
an	O
important	O
posttranslational	O
modification	O
that	O
seems	O
to	O
promote	O
the	O
interaction	O
with	O
VWF	B-Protein
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

The	O
environment	O
where	O
sulfation	O
of	O
tyrosines	O
occurs	O
has	O
been	O
proposed	O
to	O
contain	O
highly	O
acidic	O
residues	O
.	O
<EOS>	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

This	O
investigation	O
has	O
examined	O
the	O
highly	O
acidic	O
region	O
from	O
Asp249	O
to	O
Asp287	O
in	O
the	O
mature	O
GPIb	B-Protein
alpha	I-Protein
protein	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X

Changes	O
to	O
most	O
of	O
the	O
carboxylic	O
acids	O
in	O
this	O
region	O
resulted	O
in	O
decreased	O
reactivity	O
to	O
VWF	B-Protein
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

Only	O
3	O
mutants	O
(	O
Glu270Gln	O
,	O
Asp283Asn	O
,	O
Asp283Asn	O
/	O
Glu285Gln	O
/	O
Asp287Asn	O
)	O
resulted	O
in	O
the	O
abolition	O
of	O
sulfation	O
.	O
<EOS>	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

Two	O
novel	O
mutations	O
were	O
also	O
created	O
.	O
<EOS>	B-X
Rodent	B-X
models	B-X
bearing	B-X
deletions	B-X
or	B-X
mutations	B-X
of	B-X
the	B-X
corresponding	B-X
genes	B-X
,	B-X
Scn9a	B-X
and	B-X
Scn10a	B-X
,	B-X
were	B-X
created	B-X
in	B-X
order	B-X
to	B-X
understand	B-X
the	B-X
role	B-X
of	B-X
these	B-X
channels	B-X
in	B-X
the	B-X
pathophysiological	B-X
mechanism	B-X
underlying	B-X
pain	B-X
symptoms	B-X
.	B-X
Several	B-X
gain-of-function	B-X
mutations	B-X
were	B-X
identified	B-X
in	B-X
patients	B-X
with	B-X
painful	B-X
small	B-X
fiber	B-X
neuropathy	B-X
.	B-X
Future	B-X
knowledge	B-X
obtained	B-X
from	B-X
preclinical	B-X
models	B-X
bearing	B-X
these	B-X
mutations	B-X
will	B-X
allow	B-X
understanding	B-X
how	B-X
these	B-X
mutations	B-X
affect	B-X
pain	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
review	B-X
gives	B-X
perspectives	B-X
for	B-X
creating	B-X
models	B-X
that	B-X
better	B-X
mimic	B-X
patients	B-X
'	B-X
pain	B-X
symptoms	B-X
in	B-X
view	B-X
to	B-X
developing	B-X
novel	B-X
analgesic	B-X
strategies	B-X
.	B-X

First	O
,	O
a	O
deletion	O
of	O
the	O
7	O
amino	O
acids	O
from	O
Tyr276	O
to	O
Glu282	O
led	O
to	O
a	O
loss	O
of	O
sulfation	O
and	O
totally	O
abolished	O
VWF	B-Protein
binding	O
in	O
the	O
presence	O
of	O
botrocetin	O
.	O

This	O
confirms	O
that	O
it	O
is	O
these	O
3	O
tyrosines	O
that	O
undergo	O
sulfation	O
and	O
that	O
this	O
region	O
is	O
crucial	O
for	O
botrocetin	O
-	O
mediated	O
VWF	B-Protein
binding	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
This	B-X
investigation	B-X
has	B-X
examined	B-X
the	B-X
highly	B-X
acidic	B-X
region	B-X
from	B-X
Asp249	B-X
to	B-X
Asp287	B-X
in	B-X
the	B-X
mature	B-X
GPIb	B-X
alpha	B-X
protein	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

The	O
second	O
mutation	O
involves	O
changing	O
the	O
lysine	O
residues	O
at	O
253	O
,	O
258	O
,	O
and	O
262	O
to	O
alanine	O
.	O
<EOS>	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
Two	B-X
novel	B-X
mutations	B-X
were	B-X
also	B-X
created	B-X
.	B-X
The	B-X
second	B-X
mutation	B-X
involves	B-X
changing	B-X
the	B-X
lysine	B-X
residues	B-X
at	B-X
253	B-X
,	B-X
258	B-X
,	B-X
and	B-X
262	B-X
to	B-X
alanine	B-X
.	B-X

This	O
also	O
led	O
to	O
distinct	O
changes	O
in	O
VWF	B-Protein
binding	O
and	O
abolition	O
of	O
sulfation	O
.	O
<EOS>	B-X
The	B-X
interaction	B-X
between	B-X
platelet	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
alpha	B-X
and	B-X
von	B-X
Willebrand	B-X
factor	B-X
(	B-X
VWF	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
initiation	B-X
of	B-X
hemostasis	B-X
.	B-X
The	B-X
sulfation	B-X
of	B-X
the	B-X
3	B-X
tyrosine	B-X
residues	B-X
276	B-X
,	B-X
278	B-X
,	B-X
and	B-X
279	B-X
in	B-X
GPIb	B-X
alpha	B-X
is	B-X
an	B-X
important	B-X
posttranslational	B-X
modification	B-X
that	B-X
seems	B-X
to	B-X
promote	B-X
the	B-X
interaction	B-X
with	B-X
VWF	B-X
.	B-X
The	B-X
environment	B-X
where	B-X
sulfation	B-X
of	B-X
tyrosines	B-X
occurs	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
contain	B-X
highly	B-X
acidic	B-X
residues	B-X
.	B-X
Changes	B-X
to	B-X
most	B-X
of	B-X
the	B-X
carboxylic	B-X
acids	B-X
in	B-X
this	B-X
region	B-X
resulted	B-X
in	B-X
decreased	B-X
reactivity	B-X
to	B-X
VWF	B-X
.	B-X
Only	B-X
3	B-X
mutants	B-X
(	B-X
Glu270Gln	B-X
,	B-X
Asp283Asn	B-X
,	B-X
Asp283Asn/Glu285Gln/Asp287Asn	B-X
)	B-X
resulted	B-X
in	B-X
the	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X
Two	B-X
novel	B-X
mutations	B-X
were	B-X
also	B-X
created	B-X
.	B-X
First	B-X
,	B-X
a	B-X
deletion	B-X
of	B-X
the	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
Tyr276	B-X
to	B-X
Glu282	B-X
led	B-X
to	B-X
a	B-X
loss	B-X
of	B-X
sulfation	B-X
and	B-X
totally	B-X
abolished	B-X
VWF	B-X
binding	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
botrocetin	B-X
.	B-X
This	B-X
confirms	B-X
that	B-X
it	B-X
is	B-X
these	B-X
3	B-X
tyrosines	B-X
that	B-X
undergo	B-X
sulfation	B-X
and	B-X
that	B-X
this	B-X
region	B-X
is	B-X
crucial	B-X
for	B-X
botrocetin-mediated	B-X
VWF	B-X
binding	B-X
.	B-X
This	B-X
also	B-X
led	B-X
to	B-X
distinct	B-X
changes	B-X
in	B-X
VWF	B-X
binding	B-X
and	B-X
abolition	B-X
of	B-X
sulfation	B-X
.	B-X

Farnesylation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
is	O
required	O
for	O
G2	O
/	O
M	O
progression	O
and	O
degradation	O
after	O
mitosis	O
.	O
<EOS>	B-X
Farnesyl	B-X
transferase	B-X
inhibitors	B-X
induce	B-X
G2/M	B-X
cell	B-X
cycle	B-X
delays	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
Ras	B-X
GTPase	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
kinetochore	B-X
protein	B-X
Cenp-F	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
farnesylated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
kinetochore	B-X
targeting	B-X
domain	B-X
of	B-X
Cenp-F	B-X
delays	B-X
progression	B-X
through	B-X
G2/M	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
localisation	B-X
of	B-X
Cenp-F	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
at	B-X
G2/M	B-X
and	B-X
kinetochores	B-X
in	B-X
prometaphase	B-X
is	B-X
dependent	B-X
both	B-X
on	B-X
its	B-X
CAAX	B-X
motif	B-X
and	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
.	B-X
Strikingly	B-X
,	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
is	B-X
also	B-X
required	B-X
for	B-X
Cenp-F	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
Thus	B-X
,	B-X
these	B-X
observations	B-X
suggest	B-X
that	B-X
farnesylation	B-X
of	B-X
Cenp-F	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
its	B-X
localisation	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
kinetochores	B-X
but	B-X
also	B-X
for	B-X
timely	B-X
progression	B-X
through	B-X
G2/M	B-X
and	B-X
its	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
observations	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
anti-proliferative	B-X
effects	B-X
induced	B-X
by	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
may	B-X
be	B-X
due	B-X
to	B-X
inhibition	B-X
of	B-X
Cenp-F	B-X
function	B-X
and/or	B-X
turnover	B-X
.	B-X

Farnesyl	O
transferase	O
inhibitors	O
induce	O
G2	O
/	O
M	O
cell	O
cycle	O
delays	O
that	O
cannot	O
be	O
explained	O
by	O
inhibition	O
of	O
the	O
Ras	O
GTPase	O
.	O
<EOS>	B-X
Farnesyl	B-X
transferase	B-X
inhibitors	B-X
induce	B-X
G2/M	B-X
cell	B-X
cycle	B-X
delays	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
Ras	B-X
GTPase	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
kinetochore	B-X
targeting	B-X
domain	B-X
of	B-X
Cenp-F	B-X
delays	B-X
progression	B-X
through	B-X
G2/M	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
localisation	B-X
of	B-X
Cenp-F	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
at	B-X
G2/M	B-X
and	B-X
kinetochores	B-X
in	B-X
prometaphase	B-X
is	B-X
dependent	B-X
both	B-X
on	B-X
its	B-X
CAAX	B-X
motif	B-X
and	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
.	B-X
Strikingly	B-X
,	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
is	B-X
also	B-X
required	B-X
for	B-X
Cenp-F	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
Thus	B-X
,	B-X
these	B-X
observations	B-X
suggest	B-X
that	B-X
farnesylation	B-X
of	B-X
Cenp-F	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
its	B-X
localisation	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
kinetochores	B-X
but	B-X
also	B-X
for	B-X
timely	B-X
progression	B-X
through	B-X
G2/M	B-X
and	B-X
its	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
observations	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
anti-proliferative	B-X
effects	B-X
induced	B-X
by	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
may	B-X
be	B-X
due	B-X
to	B-X
inhibition	B-X
of	B-X
Cenp-F	B-X
function	B-X
and/or	B-X
turnover	B-X
.	B-X

Recently	O
,	O
the	O
kinetochore	O
protein	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
has	O
been	O
shown	O
to	O
be	O
farnesylated	O
.	O
<EOS>	B-X
Cenp-F	B-X
(	B-X
mitosin	B-X
)	B-X
is	B-X
a	B-X
large	B-X
coiled-coil	B-X
protein	B-X
whose	B-X
function	B-X
has	B-X
remained	B-X
obscure	B-X
since	B-X
its	B-X
identification	B-X
a	B-X
decade	B-X
ago	B-X
.	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
the	B-X
protein	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
the	B-X
kinetochore-mediated	B-X
mitotic	B-X
functions	B-X
but	B-X
until	B-X
recently	B-X
there	B-X
was	B-X
little	B-X
evidence	B-X
to	B-X
support	B-X
this	B-X
postulation	B-X
.	B-X
Recent	B-X
results	B-X
from	B-X
five	B-X
laboratories	B-X
have	B-X
given	B-X
insights	B-X
on	B-X
how	B-X
Cenp-F	B-X
may	B-X
participate	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cell	B-X
division	B-X
.	B-X
In	B-X
this	B-X
mini-review	B-X
,	B-X
we	B-X
will	B-X
summarize	B-X
the	B-X
current	B-X
data	B-X
regarding	B-X
the	B-X
mitotic	B-X
tasks	B-X
of	B-X
Cenp-F	B-X
as	B-X
well	B-X
as	B-X
discuss	B-X
how	B-X
it	B-X
is	B-X
used	B-X
as	B-X
a	B-X
proliferation	B-X
marker	B-X
of	B-X
malignant	B-X
cell	B-X
growth	B-X
in	B-X
the	B-X
clinic	B-X
.	B-X
Also	B-X
,	B-X
the	B-X
protein	B-X
's	B-X
post-translational	B-X
modification	B-X
by	B-X
farnesylation	B-X
and	B-X
potential	B-X
contribution	B-X
to	B-X
cell	B-X
cycle	B-X
effects	B-X
of	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
will	B-X
be	B-X
addressed	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
kinetochore	O
targeting	O
domain	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
delays	O
progression	O
through	O
G2	O
/	O
M	O
.	O
<EOS>	B-X
Farnesyl	B-X
transferase	B-X
inhibitors	B-X
induce	B-X
G2/M	B-X
cell	B-X
cycle	B-X
delays	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
Ras	B-X
GTPase	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
kinetochore	B-X
protein	B-X
Cenp-F	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
farnesylated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
kinetochore	B-X
targeting	B-X
domain	B-X
of	B-X
Cenp-F	B-X
delays	B-X
progression	B-X
through	B-X
G2/M	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
localisation	B-X
of	B-X
Cenp-F	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
at	B-X
G2/M	B-X
and	B-X
kinetochores	B-X
in	B-X
prometaphase	B-X
is	B-X
dependent	B-X
both	B-X
on	B-X
its	B-X
CAAX	B-X
motif	B-X
and	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
.	B-X
Strikingly	B-X
,	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
is	B-X
also	B-X
required	B-X
for	B-X
Cenp-F	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
Thus	B-X
,	B-X
these	B-X
observations	B-X
suggest	B-X
that	B-X
farnesylation	B-X
of	B-X
Cenp-F	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
its	B-X
localisation	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
kinetochores	B-X
but	B-X
also	B-X
for	B-X
timely	B-X
progression	B-X
through	B-X
G2/M	B-X
and	B-X
its	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
observations	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
anti-proliferative	B-X
effects	B-X
induced	B-X
by	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
may	B-X
be	B-X
due	B-X
to	B-X
inhibition	B-X
of	B-X
Cenp-F	B-X
function	B-X
and/or	B-X
turnover	B-X
.	B-X

Significantly	O
,	O
this	O
is	O
dependent	O
on	O
the	O
CAAX	O
farnesylation	O
motif	O
.	O
<EOS>	B-X
The	B-X
mammalian	B-X
nuclear	B-X
lamina	B-X
protein	B-X
lamin	B-X
B1	B-X
is	B-X
posttranslationally	B-X
modified	B-X
by	B-X
farnesylation	B-X
,	B-X
endoproteolysis	B-X
,	B-X
and	B-X
carboxymethylation	B-X
at	B-X
a	B-X
carboxyl-terminal	B-X
CAAX	B-X
motif	B-X
.	B-X
In	B-X
this	B-X
work	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
CAAX	B-X
endoprotease	B-X
Rce1	B-X
is	B-X
required	B-X
for	B-X
lamin	B-X
B1	B-X
endoproteolysis	B-X
,	B-X
demonstrate	B-X
an	B-X
independent	B-X
pool	B-X
of	B-X
proteolyzed	B-X
but	B-X
nonmethylated	B-X
lamin	B-X
B1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
fully	B-X
processed	B-X
lamin	B-X
B1	B-X
,	B-X
in	B-X
interphase	B-X
nuclei	B-X
,	B-X
and	B-X
show	B-X
a	B-X
role	B-X
for	B-X
methylation	B-X
in	B-X
the	B-X
organization	B-X
of	B-X
lamin	B-X
B1	B-X
into	B-X
domains	B-X
of	B-X
the	B-X
nuclear	B-X
lamina	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
the	B-X
organization	B-X
of	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
lamina	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
mechanism	B-X
involving	B-X
the	B-X
methylation	B-X
of	B-X
lamin	B-X
B1	B-X
,	B-X
and	B-X
they	B-X
identify	B-X
a	B-X
potential	B-X
mechanism	B-X
of	B-X
laminopathy	B-X
involving	B-X
a	B-X
B-type	B-X
lamin	B-X
.	B-X
The	B-X
N-terminal	B-X
part	B-X
of	B-X
TIMAP	B-X
has	B-X
a	B-X
typical	B-X
MYPT	B-X
family	B-X
structure	B-X
with	B-X
a	B-X
sequence	B-X
element	B-X
called	B-X
MyPhone	B-X
(	B-X
myosin	B-X
phosphatase	B-X
N-terminal	B-X
element	B-X
)	B-X
,	B-X
a	B-X
putative	B-X
bipartite	B-X
nuclear	B-X
localization	B-X
signal	B-X
,	B-X
a	B-X
PP1	B-X
catalytic	B-X
subunit	B-X
binding	B-X
motif	B-X
,	B-X
and	B-X
five	B-X
ankyrin	B-X
repeats	B-X
.	B-X
The	B-X
C-terminal	B-X
half	B-X
of	B-X
TIMAP	B-X
is	B-X
intrinsically	B-X
disordered	B-X
,	B-X
but	B-X
ends	B-X
with	B-X
a	B-X
functional	B-X
CAAX	B-X
box	B-X
for	B-X
lipid	B-X
modification	B-X
which	B-X
allows	B-X
localization	B-X
of	B-X
TIMAP	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

We	O
also	O
show	O
that	O
localisation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
to	O
the	O
nuclear	O
envelope	O
at	O
G2	O
/	O
M	O
and	O
kinetochores	O
in	O
prometaphase	O
is	O
dependent	O
both	O
on	O
its	O
CAAX	O
motif	O
and	O
farnesyl	O
transferase	O
activity	O
.	O

Strikingly	O
,	O
farnesyl	O
transferase	O
activity	O
is	O
also	O
required	O
for	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
degradation	O
after	O
mitosis	O
.	O
<EOS>	B-X
Farnesyl	B-X
transferase	B-X
inhibitors	B-X
induce	B-X
G2/M	B-X
cell	B-X
cycle	B-X
delays	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
Ras	B-X
GTPase	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
kinetochore	B-X
protein	B-X
Cenp-F	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
farnesylated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
kinetochore	B-X
targeting	B-X
domain	B-X
of	B-X
Cenp-F	B-X
delays	B-X
progression	B-X
through	B-X
G2/M	B-X
.	B-X
Significantly	B-X
,	B-X
this	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
CAAX	B-X
farnesylation	B-X
motif	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
localisation	B-X
of	B-X
Cenp-F	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
at	B-X
G2/M	B-X
and	B-X
kinetochores	B-X
in	B-X
prometaphase	B-X
is	B-X
dependent	B-X
both	B-X
on	B-X
its	B-X
CAAX	B-X
motif	B-X
and	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
.	B-X
Strikingly	B-X
,	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
is	B-X
also	B-X
required	B-X
for	B-X
Cenp-F	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
Thus	B-X
,	B-X
these	B-X
observations	B-X
suggest	B-X
that	B-X
farnesylation	B-X
of	B-X
Cenp-F	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
its	B-X
localisation	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
kinetochores	B-X
but	B-X
also	B-X
for	B-X
timely	B-X
progression	B-X
through	B-X
G2/M	B-X
and	B-X
its	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
observations	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
anti-proliferative	B-X
effects	B-X
induced	B-X
by	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
may	B-X
be	B-X
due	B-X
to	B-X
inhibition	B-X
of	B-X
Cenp-F	B-X
function	B-X
and/or	B-X
turnover	B-X
.	B-X

Thus	O
,	O
these	O
observations	O
suggest	O
that	O
farnesylation	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
is	O
required	O
not	O
only	O
for	O
its	O
localisation	O
to	O
the	O
nuclear	O
envelope	O
and	O
kinetochores	O
but	O
also	O
for	O
timely	O
progression	O
through	O
G2	O
/	O
M	O
and	O
its	O
degradation	O
after	O
mitosis	O
.	O
<EOS>	B-X
Farnesyl	B-X
transferase	B-X
inhibitors	B-X
induce	B-X
G2/M	B-X
cell	B-X
cycle	B-X
delays	B-X
that	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
inhibition	B-X
of	B-X
the	B-X
Ras	B-X
GTPase	B-X
.	B-X
Recently	B-X
,	B-X
the	B-X
kinetochore	B-X
protein	B-X
Cenp-F	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
farnesylated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
ectopic	B-X
expression	B-X
of	B-X
the	B-X
kinetochore	B-X
targeting	B-X
domain	B-X
of	B-X
Cenp-F	B-X
delays	B-X
progression	B-X
through	B-X
G2/M	B-X
.	B-X
Significantly	B-X
,	B-X
this	B-X
is	B-X
dependent	B-X
on	B-X
the	B-X
CAAX	B-X
farnesylation	B-X
motif	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
localisation	B-X
of	B-X
Cenp-F	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
at	B-X
G2/M	B-X
and	B-X
kinetochores	B-X
in	B-X
prometaphase	B-X
is	B-X
dependent	B-X
both	B-X
on	B-X
its	B-X
CAAX	B-X
motif	B-X
and	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
.	B-X
Strikingly	B-X
,	B-X
farnesyl	B-X
transferase	B-X
activity	B-X
is	B-X
also	B-X
required	B-X
for	B-X
Cenp-F	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
Thus	B-X
,	B-X
these	B-X
observations	B-X
suggest	B-X
that	B-X
farnesylation	B-X
of	B-X
Cenp-F	B-X
is	B-X
required	B-X
not	B-X
only	B-X
for	B-X
its	B-X
localisation	B-X
to	B-X
the	B-X
nuclear	B-X
envelope	B-X
and	B-X
kinetochores	B-X
but	B-X
also	B-X
for	B-X
timely	B-X
progression	B-X
through	B-X
G2/M	B-X
and	B-X
its	B-X
degradation	B-X
after	B-X
mitosis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
observations	B-X
raise	B-X
the	B-X
possibility	B-X
that	B-X
the	B-X
anti-proliferative	B-X
effects	B-X
induced	B-X
by	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
may	B-X
be	B-X
due	B-X
to	B-X
inhibition	B-X
of	B-X
Cenp-F	B-X
function	B-X
and/or	B-X
turnover	B-X
.	B-X

In	O
addition	O
,	O
these	O
observations	O
raise	O
the	O
possibility	O
that	O
the	O
anti	O
-	O
proliferative	O
effects	O
induced	O
by	O
farnesyl	O
transferase	O
inhibitors	O
may	O
be	O
due	O
to	O
inhibition	O
of	O
Cenp	B-Protein
-	I-Protein
F	I-Protein
function	O
and	O
/	O
or	O
turnover	O
.	O
<EOS>	B-X
Registered	B-X
nurse	B-X
turnover	B-X
is	B-X
an	B-X
important	B-X
indicator	B-X
of	B-X
the	B-X
nurse	B-X
job	B-X
market	B-X
.	B-X
Despite	B-X
its	B-X
wide	B-X
use	B-X
as	B-X
a	B-X
measure	B-X
for	B-X
health-care	B-X
system	B-X
analysis	B-X
,	B-X
there	B-X
is	B-X
a	B-X
lack	B-X
of	B-X
consistency	B-X
in	B-X
the	B-X
definition	B-X
of	B-X
turnover	B-X
.	B-X
Some	B-X
definitions	B-X
include	B-X
any	B-X
nurse	B-X
leaving	B-X
an	B-X
organization	B-X
;	B-X
others	B-X
may	B-X
include	B-X
involuntary	B-X
and	B-X
voluntary	B-X
leaving	B-X
.	B-X
These	B-X
inconsistent	B-X
definitions	B-X
also	B-X
result	B-X
in	B-X
various	B-X
turnover	B-X
rates	B-X
.	B-X
Consistent	B-X
and	B-X
accurate	B-X
measurement	B-X
of	B-X
turnover	B-X
is	B-X
an	B-X
important	B-X
step	B-X
in	B-X
addressing	B-X
organizational	B-X
work	B-X
environments	B-X
and	B-X
policies	B-X
about	B-X
the	B-X
nursing	B-X
workforce	B-X
.	B-X

Structural	O
basis	O
for	O
the	O
beta	O
lactam	O
resistance	O
of	O
PBP2a	B-Protein
from	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O
<EOS>	B-X
The	B-X
multiple	B-X
antibiotic	B-X
resistance	B-X
of	B-X
methicillin-resistant	B-X
strains	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
(	B-X
MRSA	B-X
)	B-X
has	B-X
become	B-X
a	B-X
major	B-X
clinical	B-X
problem	B-X
worldwide	B-X
.	B-X
The	B-X
key	B-X
determinant	B-X
of	B-X
the	B-X
broad-spectrum	B-X
beta-lactam	B-X
resistance	B-X
in	B-X
MRSA	B-X
strains	B-X
is	B-X
the	B-X
penicillin-binding	B-X
protein	B-X
2a	B-X
(	B-X
PBP2a	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
low	B-X
affinity	B-X
for	B-X
beta-lactams	B-X
,	B-X
PBP2a	B-X
provides	B-X
transpeptidase	B-X
activity	B-X
to	B-X
allow	B-X
cell	B-X
wall	B-X
synthesis	B-X
at	B-X
beta-lactam	B-X
concentrations	B-X
that	B-X
inhibit	B-X
the	B-X
beta-lactam-sensitive	B-X
PBPs	B-X
normally	B-X
produced	B-X
by	B-X
S.	B-X
aureus	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
a	B-X
soluble	B-X
derivative	B-X
of	B-X
PBP2a	B-X
has	B-X
been	B-X
determined	B-X
to	B-X
1.8	B-X
A	B-X
resolution	B-X
and	B-X
provides	B-X
the	B-X
highest	B-X
resolution	B-X
structure	B-X
for	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
PBP	B-X
.	B-X
Additionally	B-X
,	B-X
structures	B-X
of	B-X
the	B-X
acyl-PBP	B-X
complexes	B-X
of	B-X
PBP2a	B-X
with	B-X
nitrocefin	B-X
,	B-X
penicillin	B-X
G	B-X
and	B-X
methicillin	B-X
allow	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
a	B-X
comparison	B-X
of	B-X
an	B-X
apo	B-X
and	B-X
acylated	B-X
resistant	B-X
PBP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
PBP2a	B-X
active	B-X
site	B-X
in	B-X
these	B-X
forms	B-X
reveals	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
its	B-X
resistance	B-X
and	B-X
identifies	B-X
features	B-X
in	B-X
newly	B-X
developed	B-X
beta-lactams	B-X
that	B-X
are	B-X
likely	B-X
important	B-X
for	B-X
high	B-X
affinity	B-X
binding	B-X
.	B-X

The	O
multiple	O
antibiotic	O
resistance	O
of	O
methicillin	O
-	O
resistant	O
strains	O
of	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
has	O
become	O
a	O
major	O
clinical	O
problem	O
worldwide	O
.	O

The	O
key	O
determinant	O
of	O
the	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactam	O
resistance	O
in	O
MRSA	O
strains	O
is	O
the	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
2a	I-Protein
(	O
PBP2a	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
multiple	B-X
antibiotic	B-X
resistance	B-X
of	B-X
methicillin-resistant	B-X
strains	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
(	B-X
MRSA	B-X
)	B-X
has	B-X
become	B-X
a	B-X
major	B-X
clinical	B-X
problem	B-X
worldwide	B-X
.	B-X
The	B-X
key	B-X
determinant	B-X
of	B-X
the	B-X
broad-spectrum	B-X
beta-lactam	B-X
resistance	B-X
in	B-X
MRSA	B-X
strains	B-X
is	B-X
the	B-X
penicillin-binding	B-X
protein	B-X
2a	B-X
(	B-X
PBP2a	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
low	B-X
affinity	B-X
for	B-X
beta-lactams	B-X
,	B-X
PBP2a	B-X
provides	B-X
transpeptidase	B-X
activity	B-X
to	B-X
allow	B-X
cell	B-X
wall	B-X
synthesis	B-X
at	B-X
beta-lactam	B-X
concentrations	B-X
that	B-X
inhibit	B-X
the	B-X
beta-lactam-sensitive	B-X
PBPs	B-X
normally	B-X
produced	B-X
by	B-X
S.	B-X
aureus	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
a	B-X
soluble	B-X
derivative	B-X
of	B-X
PBP2a	B-X
has	B-X
been	B-X
determined	B-X
to	B-X
1.8	B-X
A	B-X
resolution	B-X
and	B-X
provides	B-X
the	B-X
highest	B-X
resolution	B-X
structure	B-X
for	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
PBP	B-X
.	B-X
Additionally	B-X
,	B-X
structures	B-X
of	B-X
the	B-X
acyl-PBP	B-X
complexes	B-X
of	B-X
PBP2a	B-X
with	B-X
nitrocefin	B-X
,	B-X
penicillin	B-X
G	B-X
and	B-X
methicillin	B-X
allow	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
a	B-X
comparison	B-X
of	B-X
an	B-X
apo	B-X
and	B-X
acylated	B-X
resistant	B-X
PBP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
PBP2a	B-X
active	B-X
site	B-X
in	B-X
these	B-X
forms	B-X
reveals	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
its	B-X
resistance	B-X
and	B-X
identifies	B-X
features	B-X
in	B-X
newly	B-X
developed	B-X
beta-lactams	B-X
that	B-X
are	B-X
likely	B-X
important	B-X
for	B-X
high	B-X
affinity	B-X
binding	B-X
.	B-X

Because	O
of	O
its	O
low	O
affinity	O
for	O
beta	O
-	O
lactams	O
,	O
PBP2a	B-Protein
provides	O
transpeptidase	O
activity	O
to	O
allow	O
cell	O
wall	O
synthesis	O
at	O
beta	O
-	O
lactam	O
concentrations	O
that	O
inhibit	O
the	O
beta	O
-	O
lactam	O
-	O
sensitive	O
PBPs	O
normally	O
produced	O
by	O
S	O
.	O
aureus	O
.	O

The	O
crystal	O
structure	O
of	O
a	O
soluble	O
derivative	O
of	O
PBP2a	B-Protein
has	O
been	O
determined	O
to	O
1	O
.	O
8	O
A	O
resolution	O
and	O
provides	O
the	O
highest	O
resolution	O
structure	O
for	O
a	O
high	O
molecular	O
mass	O
PBP	O
.	O
<EOS>	B-X
The	B-X
key	B-X
determinant	B-X
of	B-X
the	B-X
broad-spectrum	B-X
beta-lactam	B-X
resistance	B-X
in	B-X
MRSA	B-X
strains	B-X
is	B-X
the	B-X
penicillin-binding	B-X
protein	B-X
2a	B-X
(	B-X
PBP2a	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
low	B-X
affinity	B-X
for	B-X
beta-lactams	B-X
,	B-X
PBP2a	B-X
provides	B-X
transpeptidase	B-X
activity	B-X
to	B-X
allow	B-X
cell	B-X
wall	B-X
synthesis	B-X
at	B-X
beta-lactam	B-X
concentrations	B-X
that	B-X
inhibit	B-X
the	B-X
beta-lactam-sensitive	B-X
PBPs	B-X
normally	B-X
produced	B-X
by	B-X
S.	B-X
aureus	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
a	B-X
soluble	B-X
derivative	B-X
of	B-X
PBP2a	B-X
has	B-X
been	B-X
determined	B-X
to	B-X
1.8	B-X
A	B-X
resolution	B-X
and	B-X
provides	B-X
the	B-X
highest	B-X
resolution	B-X
structure	B-X
for	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
PBP	B-X
.	B-X
Additionally	B-X
,	B-X
structures	B-X
of	B-X
the	B-X
acyl-PBP	B-X
complexes	B-X
of	B-X
PBP2a	B-X
with	B-X
nitrocefin	B-X
,	B-X
penicillin	B-X
G	B-X
and	B-X
methicillin	B-X
allow	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
a	B-X
comparison	B-X
of	B-X
an	B-X
apo	B-X
and	B-X
acylated	B-X
resistant	B-X
PBP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
PBP2a	B-X
active	B-X
site	B-X
in	B-X
these	B-X
forms	B-X
reveals	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
its	B-X
resistance	B-X
and	B-X
identifies	B-X
features	B-X
in	B-X
newly	B-X
developed	B-X
beta-lactams	B-X
that	B-X
are	B-X
likely	B-X
important	B-X
for	B-X
high	B-X
affinity	B-X
binding	B-X
.	B-X

Additionally	O
,	O
structures	O
of	O
the	O
acyl	O
-	O
PBP	O
complexes	O
of	O
PBP2a	B-Protein
with	O
nitrocefin	O
,	O
penicillin	O
G	O
and	O
methicillin	O
allow	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
comparison	O
of	O
an	O
apo	O
and	O
acylated	O
resistant	O
PBP	O
.	O

An	O
analysis	O
of	O
the	O
PBP2a	B-Protein
active	O
site	O
in	O
these	O
forms	O
reveals	O
the	O
structural	O
basis	O
of	O
its	O
resistance	O
and	O
identifies	O
features	O
in	O
newly	O
developed	O
beta	O
-	O
lactams	O
that	O
are	O
likely	O
important	O
for	O
high	O
affinity	O
binding	O
.	O
<EOS>	B-X
The	B-X
multiple	B-X
antibiotic	B-X
resistance	B-X
of	B-X
methicillin-resistant	B-X
strains	B-X
of	B-X
Staphylococcus	B-X
aureus	B-X
(	B-X
MRSA	B-X
)	B-X
has	B-X
become	B-X
a	B-X
major	B-X
clinical	B-X
problem	B-X
worldwide	B-X
.	B-X
The	B-X
key	B-X
determinant	B-X
of	B-X
the	B-X
broad-spectrum	B-X
beta-lactam	B-X
resistance	B-X
in	B-X
MRSA	B-X
strains	B-X
is	B-X
the	B-X
penicillin-binding	B-X
protein	B-X
2a	B-X
(	B-X
PBP2a	B-X
)	B-X
.	B-X
Because	B-X
of	B-X
its	B-X
low	B-X
affinity	B-X
for	B-X
beta-lactams	B-X
,	B-X
PBP2a	B-X
provides	B-X
transpeptidase	B-X
activity	B-X
to	B-X
allow	B-X
cell	B-X
wall	B-X
synthesis	B-X
at	B-X
beta-lactam	B-X
concentrations	B-X
that	B-X
inhibit	B-X
the	B-X
beta-lactam-sensitive	B-X
PBPs	B-X
normally	B-X
produced	B-X
by	B-X
S.	B-X
aureus	B-X
.	B-X
The	B-X
crystal	B-X
structure	B-X
of	B-X
a	B-X
soluble	B-X
derivative	B-X
of	B-X
PBP2a	B-X
has	B-X
been	B-X
determined	B-X
to	B-X
1.8	B-X
A	B-X
resolution	B-X
and	B-X
provides	B-X
the	B-X
highest	B-X
resolution	B-X
structure	B-X
for	B-X
a	B-X
high	B-X
molecular	B-X
mass	B-X
PBP	B-X
.	B-X
Additionally	B-X
,	B-X
structures	B-X
of	B-X
the	B-X
acyl-PBP	B-X
complexes	B-X
of	B-X
PBP2a	B-X
with	B-X
nitrocefin	B-X
,	B-X
penicillin	B-X
G	B-X
and	B-X
methicillin	B-X
allow	B-X
,	B-X
for	B-X
the	B-X
first	B-X
time	B-X
,	B-X
a	B-X
comparison	B-X
of	B-X
an	B-X
apo	B-X
and	B-X
acylated	B-X
resistant	B-X
PBP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
PBP2a	B-X
active	B-X
site	B-X
in	B-X
these	B-X
forms	B-X
reveals	B-X
the	B-X
structural	B-X
basis	B-X
of	B-X
its	B-X
resistance	B-X
and	B-X
identifies	B-X
features	B-X
in	B-X
newly	B-X
developed	B-X
beta-lactams	B-X
that	B-X
are	B-X
likely	B-X
important	B-X
for	B-X
high	B-X
affinity	B-X
binding	B-X
.	B-X

Shift	O
of	O
serum	O
osteocalcin	B-Protein
components	O
between	O
cord	O
blood	O
and	O
blood	O
at	O
day	O
5	O
of	O
life	O
.	O
<EOS>	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X

Vitamin	O
K	O
deficiency	O
is	O
a	O
relatively	O
common	O
condition	O
in	O
neonates	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
Eighteen	B-X
full-term	B-X
healthy	B-X
neonates	B-X
were	B-X
enrolled	B-X
in	B-X
this	B-X
study	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X

However	O
,	O
the	O
role	O
of	O
vitamin	O
K	O
in	O
neonatal	O
bone	O
metabolism	O
remains	O
to	O
be	O
determined	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

Osteocalcin	B-Protein
(	O
OC	B-Protein
)	O
is	O
the	O
most	O
abundant	O
noncollagenous	O
protein	O
in	O
bone	O
,	O
and	O
is	O
regulated	O
to	O
be	O
gamma	O
-	O
carboxylated	O
by	O
vitamin	O
K	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
measured	O
gamma	O
-	O
carboxylated	O
osteocalcin	B-Protein
(	O
Gla	O
-	O
OC	B-Protein
)	O
and	O
non	O
-	O
or	O
undercarboxylated	O
osteocalcin	B-Protein
(	O
Glu	O
-	O
OC	B-Protein
)	O
separately	O
,	O
and	O
examined	O
the	O
effects	O
of	O
vitamin	O
K	O
on	O
osteocalcin	B-Protein
metabolism	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
Eighteen	B-X
full-term	B-X
healthy	B-X
neonates	B-X
were	B-X
enrolled	B-X
in	B-X
this	B-X
study	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

Eighteen	O
full	O
-	O
term	O
healthy	O
neonates	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
was	B-X
performed	B-X
to	B-X
investigate	B-X
the	B-X
effect	B-X
of	B-X
neonatal	B-X
hypoxic-ischemic	B-X
encephalopathy	B-X
(	B-X
HIE	B-X
)	B-X
on	B-X
the	B-X
neurotransmitter	B-X
neurokinin	B-X
A	B-X
(	B-X
NKA	B-X
)	B-X
and	B-X
determine	B-X
its	B-X
relation	B-X
to	B-X
the	B-X
severity	B-X
of	B-X
neonatal	B-X
hypoxia	B-X
.	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
Eighteen	B-X
full-term	B-X
healthy	B-X
neonates	B-X
were	B-X
enrolled	B-X
in	B-X
this	B-X
study	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X

In	O
the	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
the	O
OC	B-Protein
levels	O
were	O
determined	O
by	O
three	O
different	O
methods	O
to	O
examine	O
the	O
intact	O
OC	B-Protein
by	O
immunoradiometric	O
assay	O
(	O
IRMA	O
)	O
,	O
Gla	O
-	O
OC	B-Protein
,	O
and	O
Glu	O
-	O
OC	B-Protein
.	O

Serum	O
vitamin	O
K	O
fractions	O
,	O
hepaplastin	O
test	O
,	O
and	O
type	O
1	O
procollagen	O
carboxyl	O
extension	O
peptide	O
were	O
also	O
determined	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X

Urine	O
samples	O
were	O
also	O
collected	O
from	O
the	O
first	O
voiding	O
and	O
on	O
d	O
5	O
to	O
determine	O
urinary	O
pyridinoline	O
,	O
deoxypyridinoline	O
,	O
and	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
.	O

Serum	O
levels	O
of	O
phylloquinone	O
(	O
PK	O
)	O
and	O
menaquinone	O
(	O
MK	O
)	O
-	O
4	O
increased	O
on	O
d	O
5	O
following	O
vitamin	O
K	O
administration	O
and	O
increased	O
intake	O
in	O
breast	O
milk	O
and	O
/	O
or	O
formula	O
.	O
<EOS>	B-X
Enteral	B-X
nutrition	B-X
(	B-X
EN	B-X
)	B-X
provides	B-X
critical	B-X
macro	B-X
and	B-X
micronutrients	B-X
to	B-X
individuals	B-X
who	B-X
can	B-X
not	B-X
maintain	B-X
sufficient	B-X
oral	B-X
intake	B-X
to	B-X
meet	B-X
their	B-X
nutritional	B-X
needs	B-X
.	B-X
Many	B-X
commercial	B-X
EN	B-X
formulas	B-X
are	B-X
available	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
standard	B-X
formulations	B-X
,	B-X
disease	B-X
specific	B-X
,	B-X
peptide-based	B-X
,	B-X
and	B-X
blenderized	B-X
formulas	B-X
are	B-X
also	B-X
available	B-X
.	B-X
Infant	B-X
formulas	B-X
are	B-X
designed	B-X
to	B-X
be	B-X
a	B-X
substitute	B-X
for	B-X
breast	B-X
milk	B-X
.	B-X
All	B-X
ingredients	B-X
in	B-X
infant	B-X
formulas	B-X
must	B-X
be	B-X
considered	B-X
``	B-X
generally	B-X
recognized	B-X
as	B-X
safe	B-X
.	B-X
''	B-X
Manufacturers	B-X
are	B-X
continually	B-X
modifying	B-X
their	B-X
products	B-X
to	B-X
make	B-X
them	B-X
more	B-X
like	B-X
breast	B-X
milk	B-X
.	B-X
Functional	B-X
ingredients	B-X
added	B-X
to	B-X
infant	B-X
formula	B-X
include	B-X
long-chain	B-X
polyunsaturated	B-X
fatty	B-X
acids	B-X
,	B-X
nucleotides	B-X
,	B-X
prebiotics	B-X
,	B-X
and	B-X
probiotics	B-X
.	B-X
The	B-X
most	B-X
common	B-X
breast	B-X
milk	B-X
substitutes	B-X
are	B-X
standard	B-X
cow	B-X
's	B-X
milk-based	B-X
term	B-X
infant	B-X
formulas	B-X
,	B-X
which	B-X
include	B-X
subcategories	B-X
of	B-X
organic	B-X
and	B-X
breast	B-X
milk	B-X
supplementation	B-X
,	B-X
and	B-X
come	B-X
in	B-X
standard	B-X
dilutions	B-X
of	B-X
19	B-X
or	B-X
20	B-X
calories	B-X
per	B-X
ounce	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
standard	B-X
cow	B-X
's	B-X
milk-based	B-X
term	B-X
infant	B-X
formulas	B-X
,	B-X
there	B-X
is	B-X
a	B-X
line	B-X
of	B-X
term	B-X
infant	B-X
formulas	B-X
marketed	B-X
for	B-X
signs	B-X
and	B-X
symptoms	B-X
of	B-X
intolerance	B-X
.	B-X
There	B-X
are	B-X
also	B-X
specialized	B-X
formulas	B-X
for	B-X
medical	B-X
conditions	B-X
such	B-X
as	B-X
prematurity	B-X
,	B-X
gastrointestinal	B-X
disorders	B-X
,	B-X
allergy	B-X
,	B-X
disorders	B-X
of	B-X
fat	B-X
metabolism	B-X
,	B-X
and	B-X
renal	B-X
insufficiency	B-X
.	B-X
Infants	B-X
on	B-X
specialty	B-X
formulas	B-X
should	B-X
be	B-X
monitored	B-X
closely	B-X
by	B-X
medical	B-X
professionals	B-X
.	B-X
Each	B-X
step	B-X
in	B-X
the	B-X
formula	B-X
mixing	B-X
process	B-X
or	B-X
each	B-X
manipulation	B-X
required	B-X
for	B-X
the	B-X
feeding	B-X
is	B-X
another	B-X
opportunity	B-X
to	B-X
introduce	B-X
bacteria	B-X
to	B-X
the	B-X
formula	B-X
.	B-X
There	B-X
are	B-X
guidelines	B-X
for	B-X
preparing	B-X
formula	B-X
in	B-X
institutions	B-X
.	B-X
Standard	B-X
dilution	B-X
and	B-X
mixing	B-X
instructions	B-X
are	B-X
different	B-X
for	B-X
each	B-X
formula	B-X
,	B-X
so	B-X
individual	B-X
recipes	B-X
are	B-X
needed	B-X
.	B-X
Caregivers	B-X
should	B-X
also	B-X
be	B-X
educated	B-X
on	B-X
proper	B-X
hygiene	B-X
when	B-X
preparing	B-X
formula	B-X
at	B-X
home	B-X
.	B-X

The	O
OC	B-Protein
levels	O
determined	O
by	O
IRMA	O
did	O
not	O
change	O
between	O
cord	O
and	O
d	O
-	O
5	O
blood	O
samples	O
,	O
but	O
the	O
Gla	O
-	O
OC	B-Protein
level	O
increased	O
remarkably	O
and	O
Glu	O
-	O
OC	B-Protein
reduced	O
to	O
a	O
negligible	O
level	O
.	O
<EOS>	B-X
Matrix	B-X
Gla	B-X
protein	B-X
(	B-X
MGP	B-X
)	B-X
is	B-X
an	B-X
extrahepatic	B-X
protein	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
glutamate	B-X
carboxylation	B-X
,	B-X
a	B-X
vitamin	B-X
K-dependent	B-X
process	B-X
.	B-X
Its	B-X
dysfunctional	B-X
form	B-X
,	B-X
desphospho-uncarboxylated-MGP	B-X
,	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
increased	B-X
arterial	B-X
calcification	B-X
and	B-X
stiffness	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
measure	B-X
the	B-X
degree	B-X
of	B-X
postoperative	B-X
carboxylation	B-X
of	B-X
MGP	B-X
and	B-X
two	B-X
other	B-X
Gla	B-X
proteins	B-X
in	B-X
patients	B-X
scheduled	B-X
for	B-X
abdominal	B-X
or	B-X
orthopaedic	B-X
surgery	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

OC	B-Protein
in	O
cord	O
blood	O
is	O
mainly	O
Glu	O
-	O
OC	B-Protein
,	O
and	O
Glu	O
-	O
OC	B-Protein
is	O
replaced	O
with	O
Gla	O
-	O
OC	B-Protein
within	O
5	O
d	O
of	O
life	O
after	O
vitamin	O
K	O
supplement	O
.	O
<EOS>	B-X
Vitamin	B-X
K	B-X
deficiency	B-X
is	B-X
a	B-X
relatively	B-X
common	B-X
condition	B-X
in	B-X
neonates	B-X
.	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
Serum	B-X
vitamin	B-X
K	B-X
fractions	B-X
,	B-X
hepaplastin	B-X
test	B-X
,	B-X
and	B-X
type	B-X
1	B-X
procollagen	B-X
carboxyl	B-X
extension	B-X
peptide	B-X
were	B-X
also	B-X
determined	B-X
.	B-X
Urine	B-X
samples	B-X
were	B-X
also	B-X
collected	B-X
from	B-X
the	B-X
first	B-X
voiding	B-X
and	B-X
on	B-X
d	B-X
5	B-X
to	B-X
determine	B-X
urinary	B-X
pyridinoline	B-X
,	B-X
deoxypyridinoline	B-X
,	B-X
and	B-X
gamma-carboxylated	B-X
glutamic	B-X
acid	B-X
.	B-X
Serum	B-X
levels	B-X
of	B-X
phylloquinone	B-X
(	B-X
PK	B-X
)	B-X
and	B-X
menaquinone	B-X
(	B-X
MK	B-X
)	B-X
-4	B-X
increased	B-X
on	B-X
d	B-X
5	B-X
following	B-X
vitamin	B-X
K	B-X
administration	B-X
and	B-X
increased	B-X
intake	B-X
in	B-X
breast	B-X
milk	B-X
and/or	B-X
formula	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

The	O
IRMA	O
assay	O
fails	O
to	O
distinguish	O
Gla	O
-	O
OC	B-Protein
from	O
Glu	O
-	O
OC	B-Protein
and	O
caution	O
is	O
needed	O
to	O
estimate	O
bone	O
turnover	O
with	O
this	O
method	O
in	O
the	O
perinatal	O
period	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
role	B-X
of	B-X
vitamin	B-X
K	B-X
in	B-X
neonatal	B-X
bone	B-X
metabolism	B-X
remains	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Osteocalcin	B-X
(	B-X
OC	B-X
)	B-X
is	B-X
the	B-X
most	B-X
abundant	B-X
noncollagenous	B-X
protein	B-X
in	B-X
bone	B-X
,	B-X
and	B-X
is	B-X
regulated	B-X
to	B-X
be	B-X
gamma-carboxylated	B-X
by	B-X
vitamin	B-X
K.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
measured	B-X
gamma-carboxylated	B-X
osteocalcin	B-X
(	B-X
Gla-OC	B-X
)	B-X
and	B-X
non-	B-X
or	B-X
undercarboxylated	B-X
osteocalcin	B-X
(	B-X
Glu-OC	B-X
)	B-X
separately	B-X
,	B-X
and	B-X
examined	B-X
the	B-X
effects	B-X
of	B-X
vitamin	B-X
K	B-X
on	B-X
osteocalcin	B-X
metabolism	B-X
.	B-X
In	B-X
the	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
the	B-X
OC	B-X
levels	B-X
were	B-X
determined	B-X
by	B-X
three	B-X
different	B-X
methods	B-X
to	B-X
examine	B-X
the	B-X
intact	B-X
OC	B-X
by	B-X
immunoradiometric	B-X
assay	B-X
(	B-X
IRMA	B-X
)	B-X
,	B-X
Gla-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
.	B-X
The	B-X
OC	B-X
levels	B-X
determined	B-X
by	B-X
IRMA	B-X
did	B-X
not	B-X
change	B-X
between	B-X
cord	B-X
and	B-X
d-5	B-X
blood	B-X
samples	B-X
,	B-X
but	B-X
the	B-X
Gla-OC	B-X
level	B-X
increased	B-X
remarkably	B-X
and	B-X
Glu-OC	B-X
reduced	B-X
to	B-X
a	B-X
negligible	B-X
level	B-X
.	B-X
OC	B-X
in	B-X
cord	B-X
blood	B-X
is	B-X
mainly	B-X
Glu-OC	B-X
,	B-X
and	B-X
Glu-OC	B-X
is	B-X
replaced	B-X
with	B-X
Gla-OC	B-X
within	B-X
5	B-X
d	B-X
of	B-X
life	B-X
after	B-X
vitamin	B-X
K	B-X
supplement	B-X
.	B-X
The	B-X
IRMA	B-X
assay	B-X
fails	B-X
to	B-X
distinguish	B-X
Gla-OC	B-X
from	B-X
Glu-OC	B-X
and	B-X
caution	B-X
is	B-X
needed	B-X
to	B-X
estimate	B-X
bone	B-X
turnover	B-X
with	B-X
this	B-X
method	B-X
in	B-X
the	B-X
perinatal	B-X
period	B-X
.	B-X

Ubc9	B-Protein
is	O
essential	O
for	O
viability	O
of	O
higher	O
eukaryotic	O
cells	O
.	O
<EOS>	B-X
Ubc9	B-X
is	B-X
an	B-X
enzyme	B-X
involved	B-X
in	B-X
the	B-X
conjugation	B-X
of	B-X
SUMO-1	B-X
(	B-X
small	B-X
ubiquitin	B-X
related	B-X
modifier	B-X
1	B-X
)	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
The	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
is	B-X
well	B-X
conserved	B-X
from	B-X
yeasts	B-X
to	B-X
higher	B-X
eukaryotes	B-X
,	B-X
but	B-X
many	B-X
SUMO-1	B-X
target	B-X
proteins	B-X
reported	B-X
recently	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
,	B-X
MDM2	B-X
,	B-X
p53	B-X
,	B-X
and	B-X
PML	B-X
,	B-X
are	B-X
not	B-X
present	B-X
in	B-X
yeasts	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
physiological	B-X
roles	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
conditional	B-X
UBC9	B-X
mutant	B-X
of	B-X
chicken	B-X
DT40	B-X
cells	B-X
containing	B-X
the	B-X
UBC9	B-X
transgene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
tetracycline-repressible	B-X
promoter	B-X
and	B-X
characterized	B-X
their	B-X
loss	B-X
of	B-X
function	B-X
phenotypes	B-X
.	B-X
Ubc9	B-X
disappeared	B-X
3	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
tetracycline	B-X
and	B-X
the	B-X
increase	B-X
in	B-X
viable	B-X
cell	B-X
number	B-X
stopped	B-X
4	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
drug	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
cases	B-X
of	B-X
ubc9	B-X
mutants	B-X
of	B-X
budding	B-X
and	B-X
fission	B-X
yeasts	B-X
,	B-X
which	B-X
show	B-X
defects	B-X
in	B-X
progression	B-X
of	B-X
G2	B-X
or	B-X
early	B-X
M	B-X
phase	B-X
and	B-X
in	B-X
chromosome	B-X
segregation	B-X
,	B-X
respectively	B-X
,	B-X
we	B-X
did	B-X
not	B-X
observe	B-X
accumulation	B-X
of	B-X
cells	B-X
in	B-X
G2/M	B-X
phase	B-X
or	B-X
a	B-X
considerable	B-X
increase	B-X
in	B-X
the	B-X
frequency	B-X
of	B-X
chromosome	B-X
missegregation	B-X
upon	B-X
depletion	B-X
of	B-X
Ubc9	B-X
but	B-X
we	B-X
did	B-X
observe	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
containing	B-X
multiple	B-X
nuclei	B-X
,	B-X
indicating	B-X
defects	B-X
in	B-X
cytokinesis	B-X
.	B-X
A	B-X
considerable	B-X
portion	B-X
of	B-X
the	B-X
Ubc9-depleted	B-X
cell	B-X
population	B-X
was	B-X
committed	B-X
to	B-X
apoptosis	B-X
without	B-X
accumulating	B-X
in	B-X
a	B-X
specific	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
chromosome	B-X
damages	B-X
are	B-X
accumulated	B-X
in	B-X
Ubc9-depleted	B-X
cells	B-X
,	B-X
and	B-X
apoptosis	B-X
is	B-X
triggered	B-X
without	B-X
activating	B-X
checkpoint	B-X
mechanisms	B-X
under	B-X
conditions	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
impairment	B-X
.	B-X

Ubc9	B-Protein
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conjugation	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
(	O
small	B-Protein
ubiquitin	I-Protein
related	I-Protein
modifier	I-Protein
1	I-Protein
)	O
to	O
target	O
proteins	O
.	O
<EOS>	B-X
Small	B-X
ubiquitin	B-X
related	B-X
modifier	B-X
SUMO-1	B-X
and	B-X
its	B-X
homologs	B-X
can	B-X
be	B-X
conjugated	B-X
to	B-X
a	B-X
large	B-X
number	B-X
of	B-X
cellular	B-X
proteins	B-X
.	B-X
This	B-X
involves	B-X
an	B-X
enzymatic	B-X
cascade	B-X
that	B-X
resembles	B-X
ubiquitination	B-X
,	B-X
and	B-X
the	B-X
modification	B-X
can	B-X
be	B-X
reverted	B-X
by	B-X
isopeptidases	B-X
.	B-X
SUMOylation	B-X
does	B-X
not	B-X
lead	B-X
to	B-X
degradation	B-X
but	B-X
instead	B-X
appears	B-X
to	B-X
regulate	B-X
protein/protein	B-X
interactions	B-X
,	B-X
intracellular	B-X
localization	B-X
and	B-X
protects	B-X
some	B-X
modified	B-X
targets	B-X
from	B-X
ubiquitin-dependent	B-X
degradation	B-X
.	B-X
Data	B-X
collected	B-X
for	B-X
more	B-X
than	B-X
30	B-X
different	B-X
target	B-X
proteins	B-X
point	B-X
to	B-X
two	B-X
cellular	B-X
processes	B-X
,	B-X
nucleocytoplasmic	B-X
transport	B-X
and	B-X
intranuclear	B-X
targeting	B-X
,	B-X
in	B-X
which	B-X
SUMO	B-X
plays	B-X
an	B-X
active	B-X
role	B-X
.	B-X
Here	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
links	B-X
between	B-X
SUMO	B-X
and	B-X
nuclear	B-X
transport	B-X
.	B-X

The	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
system	O
is	O
well	O
conserved	O
from	O
yeasts	O
to	O
higher	O
eukaryotes	O
,	O
but	O
many	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
target	O
proteins	O
reported	O
recently	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
including	O
IkappaBalpha	B-Protein
,	O
MDM2	B-Protein
,	O
p53	B-Protein
,	O
and	O
PML	B-Protein
,	O
are	O
not	O
present	O
in	O
yeasts	O
.	O

To	O
determine	O
the	O
physiological	O
roles	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
we	O
constructed	O
a	O
conditional	O
UBC9	B-Protein
mutant	O
of	O
chicken	O
DT40	O
cells	O
containing	O
the	O
UBC9	B-Protein
transgene	O
under	O
control	O
of	O
a	O
tetracycline	O
-	O
repressible	O
promoter	O
and	O
characterized	O
their	O
loss	O
of	O
function	O
phenotypes	O
.	O
<EOS>	B-X
Ubc9	B-X
is	B-X
an	B-X
enzyme	B-X
involved	B-X
in	B-X
the	B-X
conjugation	B-X
of	B-X
SUMO-1	B-X
(	B-X
small	B-X
ubiquitin	B-X
related	B-X
modifier	B-X
1	B-X
)	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
The	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
is	B-X
well	B-X
conserved	B-X
from	B-X
yeasts	B-X
to	B-X
higher	B-X
eukaryotes	B-X
,	B-X
but	B-X
many	B-X
SUMO-1	B-X
target	B-X
proteins	B-X
reported	B-X
recently	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
,	B-X
MDM2	B-X
,	B-X
p53	B-X
,	B-X
and	B-X
PML	B-X
,	B-X
are	B-X
not	B-X
present	B-X
in	B-X
yeasts	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
physiological	B-X
roles	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
conditional	B-X
UBC9	B-X
mutant	B-X
of	B-X
chicken	B-X
DT40	B-X
cells	B-X
containing	B-X
the	B-X
UBC9	B-X
transgene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
tetracycline-repressible	B-X
promoter	B-X
and	B-X
characterized	B-X
their	B-X
loss	B-X
of	B-X
function	B-X
phenotypes	B-X
.	B-X
Ubc9	B-X
disappeared	B-X
3	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
tetracycline	B-X
and	B-X
the	B-X
increase	B-X
in	B-X
viable	B-X
cell	B-X
number	B-X
stopped	B-X
4	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
drug	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
cases	B-X
of	B-X
ubc9	B-X
mutants	B-X
of	B-X
budding	B-X
and	B-X
fission	B-X
yeasts	B-X
,	B-X
which	B-X
show	B-X
defects	B-X
in	B-X
progression	B-X
of	B-X
G2	B-X
or	B-X
early	B-X
M	B-X
phase	B-X
and	B-X
in	B-X
chromosome	B-X
segregation	B-X
,	B-X
respectively	B-X
,	B-X
we	B-X
did	B-X
not	B-X
observe	B-X
accumulation	B-X
of	B-X
cells	B-X
in	B-X
G2/M	B-X
phase	B-X
or	B-X
a	B-X
considerable	B-X
increase	B-X
in	B-X
the	B-X
frequency	B-X
of	B-X
chromosome	B-X
missegregation	B-X
upon	B-X
depletion	B-X
of	B-X
Ubc9	B-X
but	B-X
we	B-X
did	B-X
observe	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
containing	B-X
multiple	B-X
nuclei	B-X
,	B-X
indicating	B-X
defects	B-X
in	B-X
cytokinesis	B-X
.	B-X
A	B-X
considerable	B-X
portion	B-X
of	B-X
the	B-X
Ubc9-depleted	B-X
cell	B-X
population	B-X
was	B-X
committed	B-X
to	B-X
apoptosis	B-X
without	B-X
accumulating	B-X
in	B-X
a	B-X
specific	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
chromosome	B-X
damages	B-X
are	B-X
accumulated	B-X
in	B-X
Ubc9-depleted	B-X
cells	B-X
,	B-X
and	B-X
apoptosis	B-X
is	B-X
triggered	B-X
without	B-X
activating	B-X
checkpoint	B-X
mechanisms	B-X
under	B-X
conditions	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
impairment	B-X
.	B-X

Ubc9	B-Protein
disappeared	O
3	O
days	O
after	O
the	O
addition	O
of	O
tetracycline	O
and	O
the	O
increase	O
in	O
viable	O
cell	O
number	O
stopped	O
4	O
days	O
after	O
the	O
addition	O
of	O
drug	O
.	O
<EOS>	B-X
Ubc9	B-X
is	B-X
an	B-X
enzyme	B-X
involved	B-X
in	B-X
the	B-X
conjugation	B-X
of	B-X
SUMO-1	B-X
(	B-X
small	B-X
ubiquitin	B-X
related	B-X
modifier	B-X
1	B-X
)	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
The	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
is	B-X
well	B-X
conserved	B-X
from	B-X
yeasts	B-X
to	B-X
higher	B-X
eukaryotes	B-X
,	B-X
but	B-X
many	B-X
SUMO-1	B-X
target	B-X
proteins	B-X
reported	B-X
recently	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
,	B-X
MDM2	B-X
,	B-X
p53	B-X
,	B-X
and	B-X
PML	B-X
,	B-X
are	B-X
not	B-X
present	B-X
in	B-X
yeasts	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
physiological	B-X
roles	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
conditional	B-X
UBC9	B-X
mutant	B-X
of	B-X
chicken	B-X
DT40	B-X
cells	B-X
containing	B-X
the	B-X
UBC9	B-X
transgene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
tetracycline-repressible	B-X
promoter	B-X
and	B-X
characterized	B-X
their	B-X
loss	B-X
of	B-X
function	B-X
phenotypes	B-X
.	B-X
Ubc9	B-X
disappeared	B-X
3	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
tetracycline	B-X
and	B-X
the	B-X
increase	B-X
in	B-X
viable	B-X
cell	B-X
number	B-X
stopped	B-X
4	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
drug	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
cases	B-X
of	B-X
ubc9	B-X
mutants	B-X
of	B-X
budding	B-X
and	B-X
fission	B-X
yeasts	B-X
,	B-X
which	B-X
show	B-X
defects	B-X
in	B-X
progression	B-X
of	B-X
G2	B-X
or	B-X
early	B-X
M	B-X
phase	B-X
and	B-X
in	B-X
chromosome	B-X
segregation	B-X
,	B-X
respectively	B-X
,	B-X
we	B-X
did	B-X
not	B-X
observe	B-X
accumulation	B-X
of	B-X
cells	B-X
in	B-X
G2/M	B-X
phase	B-X
or	B-X
a	B-X
considerable	B-X
increase	B-X
in	B-X
the	B-X
frequency	B-X
of	B-X
chromosome	B-X
missegregation	B-X
upon	B-X
depletion	B-X
of	B-X
Ubc9	B-X
but	B-X
we	B-X
did	B-X
observe	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
containing	B-X
multiple	B-X
nuclei	B-X
,	B-X
indicating	B-X
defects	B-X
in	B-X
cytokinesis	B-X
.	B-X
A	B-X
considerable	B-X
portion	B-X
of	B-X
the	B-X
Ubc9-depleted	B-X
cell	B-X
population	B-X
was	B-X
committed	B-X
to	B-X
apoptosis	B-X
without	B-X
accumulating	B-X
in	B-X
a	B-X
specific	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
chromosome	B-X
damages	B-X
are	B-X
accumulated	B-X
in	B-X
Ubc9-depleted	B-X
cells	B-X
,	B-X
and	B-X
apoptosis	B-X
is	B-X
triggered	B-X
without	B-X
activating	B-X
checkpoint	B-X
mechanisms	B-X
under	B-X
conditions	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
impairment	B-X
.	B-X

In	O
contrast	O
to	O
the	O
cases	O
of	O
ubc9	B-Protein
mutants	O
of	O
budding	O
and	O
fission	O
yeasts	O
,	O
which	O
show	O
defects	O
in	O
progression	O
of	O
G2	O
or	O
early	O
M	O
phase	O
and	O
in	O
chromosome	O
segregation	O
,	O
respectively	O
,	O
we	O
did	O
not	O
observe	O
accumulation	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
or	O
a	O
considerable	O
increase	O
in	O
the	O
frequency	O
of	O
chromosome	O
missegregation	O
upon	O
depletion	O
of	O
Ubc9	B-Protein
but	O
we	O
did	O
observe	O
an	O
increase	O
in	O
the	O
number	O
of	O
cells	O
containing	O
multiple	O
nuclei	O
,	O
indicating	O
defects	O
in	O
cytokinesis	O
.	O
<EOS>	B-X
Ubc9	B-X
is	B-X
an	B-X
enzyme	B-X
involved	B-X
in	B-X
the	B-X
conjugation	B-X
of	B-X
SUMO-1	B-X
(	B-X
small	B-X
ubiquitin	B-X
related	B-X
modifier	B-X
1	B-X
)	B-X
to	B-X
target	B-X
proteins	B-X
.	B-X
The	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
is	B-X
well	B-X
conserved	B-X
from	B-X
yeasts	B-X
to	B-X
higher	B-X
eukaryotes	B-X
,	B-X
but	B-X
many	B-X
SUMO-1	B-X
target	B-X
proteins	B-X
reported	B-X
recently	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
including	B-X
IkappaBalpha	B-X
,	B-X
MDM2	B-X
,	B-X
p53	B-X
,	B-X
and	B-X
PML	B-X
,	B-X
are	B-X
not	B-X
present	B-X
in	B-X
yeasts	B-X
.	B-X
To	B-X
determine	B-X
the	B-X
physiological	B-X
roles	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
in	B-X
higher	B-X
eukaryotic	B-X
cells	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
conditional	B-X
UBC9	B-X
mutant	B-X
of	B-X
chicken	B-X
DT40	B-X
cells	B-X
containing	B-X
the	B-X
UBC9	B-X
transgene	B-X
under	B-X
control	B-X
of	B-X
a	B-X
tetracycline-repressible	B-X
promoter	B-X
and	B-X
characterized	B-X
their	B-X
loss	B-X
of	B-X
function	B-X
phenotypes	B-X
.	B-X
Ubc9	B-X
disappeared	B-X
3	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
tetracycline	B-X
and	B-X
the	B-X
increase	B-X
in	B-X
viable	B-X
cell	B-X
number	B-X
stopped	B-X
4	B-X
days	B-X
after	B-X
the	B-X
addition	B-X
of	B-X
drug	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
cases	B-X
of	B-X
ubc9	B-X
mutants	B-X
of	B-X
budding	B-X
and	B-X
fission	B-X
yeasts	B-X
,	B-X
which	B-X
show	B-X
defects	B-X
in	B-X
progression	B-X
of	B-X
G2	B-X
or	B-X
early	B-X
M	B-X
phase	B-X
and	B-X
in	B-X
chromosome	B-X
segregation	B-X
,	B-X
respectively	B-X
,	B-X
we	B-X
did	B-X
not	B-X
observe	B-X
accumulation	B-X
of	B-X
cells	B-X
in	B-X
G2/M	B-X
phase	B-X
or	B-X
a	B-X
considerable	B-X
increase	B-X
in	B-X
the	B-X
frequency	B-X
of	B-X
chromosome	B-X
missegregation	B-X
upon	B-X
depletion	B-X
of	B-X
Ubc9	B-X
but	B-X
we	B-X
did	B-X
observe	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
number	B-X
of	B-X
cells	B-X
containing	B-X
multiple	B-X
nuclei	B-X
,	B-X
indicating	B-X
defects	B-X
in	B-X
cytokinesis	B-X
.	B-X
A	B-X
considerable	B-X
portion	B-X
of	B-X
the	B-X
Ubc9-depleted	B-X
cell	B-X
population	B-X
was	B-X
committed	B-X
to	B-X
apoptosis	B-X
without	B-X
accumulating	B-X
in	B-X
a	B-X
specific	B-X
phase	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
,	B-X
suggesting	B-X
that	B-X
chromosome	B-X
damages	B-X
are	B-X
accumulated	B-X
in	B-X
Ubc9-depleted	B-X
cells	B-X
,	B-X
and	B-X
apoptosis	B-X
is	B-X
triggered	B-X
without	B-X
activating	B-X
checkpoint	B-X
mechanisms	B-X
under	B-X
conditions	B-X
of	B-X
SUMO-1	B-X
conjugation	B-X
system	B-X
impairment	B-X
.	B-X

A	O
considerable	O
portion	O
of	O
the	O
Ubc9	B-Protein
-	O
depleted	O
cell	O
population	O
was	O
committed	O
to	O
apoptosis	O
without	O
accumulating	O
in	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
chromosome	O
damages	O
are	O
accumulated	O
in	O
Ubc9	B-Protein
-	O
depleted	O
cells	O
,	O
and	O
apoptosis	O
is	O
triggered	O
without	O
activating	O
checkpoint	O
mechanisms	O
under	O
conditions	O
of	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
conjugation	O
system	O
impairment	O
.	O

Involvement	O
of	O
Src	O
family	O
protein	O
tyrosine	O
kinases	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
coronary	O
artery	O
contraction	O
mediated	O
by	O
a	O
sphingosylphosphorylcholine	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
We	B-X
used	B-X
porcine	B-X
coronary	B-X
VSM	B-X
and	B-X
rat	B-X
aortic	B-X
VSM	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
primary	B-X
culture	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

We	O
recently	O
reported	O
that	O
sphingosylphosphorylcholine	O
(	O
SPC	O
)	O
is	O
a	O
novel	O
messenger	O
for	O
Rho	O
-	O
kinase	O
-	O
mediated	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
vascular	O
smooth	O
muscle	O
(	O
VSM	O
)	O
contraction	O
.	O

Subcellular	O
localization	O
and	O
kinase	O
activity	O
of	O
Src	O
family	O
protein	O
kinases	O
(	O
SrcPTKs	O
)	O
,	O
except	O
for	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
is	O
controlled	O
by	O
a	O
reversible	O
S	O
-	O
palmitoylation	O
,	O
an	O
event	O
inhibited	O
by	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
We	B-X
used	B-X
porcine	B-X
coronary	B-X
VSM	B-X
and	B-X
rat	B-X
aortic	B-X
VSM	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
primary	B-X
culture	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

We	O
examined	O
the	O
possible	O
involvement	O
of	O
SrcPTKs	O
in	O
SPC	O
-	O
induced	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
and	O
effects	O
of	O
EPA	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

We	O
used	O
porcine	O
coronary	O
VSM	O
and	O
rat	O
aortic	O
VSM	O
cells	O
(	O
VSMCs	O
)	O
in	O
primary	O
culture	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
nitrite	B-X
,	B-X
a	B-X
nitric	B-X
oxide	B-X
derivative	B-X
possessing	B-X
potent	B-X
vasodilation	B-X
properties	B-X
,	B-X
stimulates	B-X
K-Cl	B-X
cotransport	B-X
in	B-X
low-K	B-X
sheep	B-X
red	B-X
blood	B-X
cells	B-X
(	B-X
LK	B-X
SRBCs	B-X
)	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
activation	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
K-Cl	B-X
cotransport	B-X
by	B-X
vasodilators	B-X
decreases	B-X
VSM	B-X
tension	B-X
.	B-X
Here	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
comparing	B-X
the	B-X
effects	B-X
of	B-X
commonly	B-X
used	B-X
vasodilators	B-X
,	B-X
hydralazine	B-X
(	B-X
HYZ	B-X
)	B-X
,	B-X
sodium	B-X
nitroprusside	B-X
,	B-X
isosorbide	B-X
mononitrate	B-X
,	B-X
and	B-X
pentaerythritol	B-X
,	B-X
on	B-X
K-Cl	B-X
cotransport	B-X
in	B-X
LK	B-X
SRBCs	B-X
and	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
VSM	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
and	B-X
of	B-X
HYZ-induced	B-X
K-Cl	B-X
cotransport	B-X
activation	B-X
on	B-X
relaxation	B-X
of	B-X
isolated	B-X
porcine	B-X
coronary	B-X
rings	B-X
.	B-X
All	B-X
vasodilators	B-X
activated	B-X
K-Cl	B-X
cotransport	B-X
in	B-X
LK	B-X
SRBCs	B-X
and	B-X
HYZ	B-X
in	B-X
VSMCs	B-X
,	B-X
and	B-X
this	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
calyculin	B-X
and	B-X
genistein	B-X
,	B-X
two	B-X
inhibitors	B-X
of	B-X
K-Cl	B-X
cotransport	B-X
.	B-X
Hydralazine	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
and	B-X
sodium	B-X
nitroprusside	B-X
relaxed	B-X
(	B-X
independently	B-X
of	B-X
the	B-X
endothelium	B-X
)	B-X
precontracted	B-X
arteries	B-X
when	B-X
only	B-X
K-Cl	B-X
cotransport	B-X
was	B-X
operating	B-X
and	B-X
other	B-X
pathways	B-X
for	B-X
K/Rb	B-X
transport	B-X
,	B-X
including	B-X
the	B-X
Ca-activated	B-X
K	B-X
channel	B-X
,	B-X
were	B-X
inhibited	B-X
.	B-X

An	O
SrcPTKs	O
inhibitor	O
,	O
PP1	O
,	O
and	O
EPA	O
inhibited	O
SPC	O
-	O
induced	O
contraction	O
,	O
concentration	O
-	O
dependently	O
,	O
without	O
affecting	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
levels	O
and	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
contraction	O
induced	O
by	O
high	O
K	O
(	O
+	O
)	O
depolarization	O
.	O

A	O
digitized	O
immunocytochemical	O
analysis	O
in	O
VSMCs	O
revealed	O
that	O
SPC	O
induced	O
translocation	O
of	O
Fyn	B-Protein
,	O
but	O
not	O
of	O
c	B-Protein
-	I-Protein
Src	I-Protein
,	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
,	O
an	O
event	O
abolished	O
by	O
EPA	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
We	B-X
used	B-X
porcine	B-X
coronary	B-X
VSM	B-X
and	B-X
rat	B-X
aortic	B-X
VSM	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
primary	B-X
culture	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

Translocation	O
of	O
Rho	O
-	O
kinase	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
by	O
SPC	O
was	O
also	O
inhibited	O
by	O
EPA	O
and	O
PP1	O
.	O

The	O
SPC	O
-	O
induced	O
activation	O
of	O
SrcPTKs	O
was	O
blocked	O
by	O
EPA	O
and	O
PP1	O
,	O
but	O
not	O
by	O
Y27632	O
,	O
an	O
Rho	O
-	O
kinase	O
inhibitor	O
.	O

Rho	O
-	O
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
myosin	O
phosphatase	O
induced	O
by	O
SPC	O
was	O
inhibited	O
by	O
EPA	O
,	O
PP1	O
,	O
and	O
Y27632	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

Translocation	O
and	O
activation	O
of	O
SrcPTKs	O
,	O
including	O
Fyn	B-Protein
,	O
play	O
an	O
important	O
role	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
VSM	O
contractions	O
mediated	O
by	O
a	O
SPC	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O
<EOS>	B-X
We	B-X
recently	B-X
reported	B-X
that	B-X
sphingosylphosphorylcholine	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
a	B-X
novel	B-X
messenger	B-X
for	B-X
Rho-kinase-mediated	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
vascular	B-X
smooth	B-X
muscle	B-X
(	B-X
VSM	B-X
)	B-X
contraction	B-X
.	B-X
Subcellular	B-X
localization	B-X
and	B-X
kinase	B-X
activity	B-X
of	B-X
Src	B-X
family	B-X
protein	B-X
kinases	B-X
(	B-X
SrcPTKs	B-X
)	B-X
,	B-X
except	B-X
for	B-X
c-Src	B-X
,	B-X
is	B-X
controlled	B-X
by	B-X
a	B-X
reversible	B-X
S-palmitoylation	B-X
,	B-X
an	B-X
event	B-X
inhibited	B-X
by	B-X
eicosapentaenoic	B-X
acid	B-X
(	B-X
EPA	B-X
)	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
SrcPTKs	B-X
in	B-X
SPC-induced	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
and	B-X
effects	B-X
of	B-X
EPA	B-X
.	B-X
We	B-X
used	B-X
porcine	B-X
coronary	B-X
VSM	B-X
and	B-X
rat	B-X
aortic	B-X
VSM	B-X
cells	B-X
(	B-X
VSMCs	B-X
)	B-X
in	B-X
primary	B-X
culture	B-X
.	B-X
An	B-X
SrcPTKs	B-X
inhibitor	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
EPA	B-X
inhibited	B-X
SPC-induced	B-X
contraction	B-X
,	B-X
concentration-dependently	B-X
,	B-X
without	B-X
affecting	B-X
[	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
]	B-X
(	B-X
i	B-X
)	B-X
levels	B-X
and	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-dependent	B-X
contraction	B-X
induced	B-X
by	B-X
high	B-X
K	B-X
(	B-X
+	B-X
)	B-X
depolarization	B-X
.	B-X
A	B-X
digitized	B-X
immunocytochemical	B-X
analysis	B-X
in	B-X
VSMCs	B-X
revealed	B-X
that	B-X
SPC	B-X
induced	B-X
translocation	B-X
of	B-X
Fyn	B-X
,	B-X
but	B-X
not	B-X
of	B-X
c-Src	B-X
,	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
an	B-X
event	B-X
abolished	B-X
by	B-X
EPA	B-X
.	B-X
Translocation	B-X
of	B-X
Rho-kinase	B-X
from	B-X
the	B-X
cytosol	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
by	B-X
SPC	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
.	B-X
The	B-X
SPC-induced	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
was	B-X
blocked	B-X
by	B-X
EPA	B-X
and	B-X
PP1	B-X
,	B-X
but	B-X
not	B-X
by	B-X
Y27632	B-X
,	B-X
an	B-X
Rho-kinase	B-X
inhibitor	B-X
.	B-X
Rho-kinase-dependent	B-X
phosphorylation	B-X
of	B-X
myosin	B-X
phosphatase	B-X
induced	B-X
by	B-X
SPC	B-X
was	B-X
inhibited	B-X
by	B-X
EPA	B-X
,	B-X
PP1	B-X
,	B-X
and	B-X
Y27632	B-X
.	B-X
Translocation	B-X
and	B-X
activation	B-X
of	B-X
SrcPTKs	B-X
,	B-X
including	B-X
Fyn	B-X
,	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
sensitization	B-X
of	B-X
VSM	B-X
contractions	B-X
mediated	B-X
by	B-X
a	B-X
SPC-Rho-kinase	B-X
pathway	B-X
.	B-X

The	O
central	O
role	O
of	O
the	O
trans	O
-	O
Golgi	O
network	O
as	O
a	O
gateway	O
of	O
the	O
early	O
secretory	O
pathway	O
:	O
physiologic	O
vs	O
nonphysiologic	O
protein	O
transit	O
.	O
<EOS>	B-X
The	B-X
current	B-X
review	B-X
focuses	B-X
upon	B-X
recent	B-X
advances	B-X
concerning	B-X
the	B-X
interrelationship	B-X
between	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
trans-Golgi	B-X
network	B-X
(	B-X
ER-TGN	B-X
)	B-X
,	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
nucleus	B-X
(	B-X
ER-nucleus	B-X
)	B-X
,	B-X
and	B-X
the	B-X
ER-ubiquitin-proteasomal	B-X
pathways	B-X
at	B-X
the	B-X
level	B-X
of	B-X
basic	B-X
cell	B-X
biology	B-X
.	B-X
The	B-X
overall	B-X
emphasis	B-X
of	B-X
this	B-X
paper	B-X
centers	B-X
upon	B-X
the	B-X
high	B-X
likelihood	B-X
that	B-X
measurements	B-X
of	B-X
ER-associated	B-X
protein	B-X
or	B-X
gene	B-X
expression	B-X
levels	B-X
are	B-X
not	B-X
representative	B-X
of	B-X
a	B-X
strict	B-X
ER	B-X
alone	B-X
phenotype	B-X
.	B-X
The	B-X
ER-TGN	B-X
,	B-X
ER-nuclear	B-X
,	B-X
and	B-X
ER-ubiquitin-proteasomal	B-X
transit	B-X
paths	B-X
share	B-X
the	B-X
ability	B-X
to	B-X
feed	B-X
into	B-X
the	B-X
decision	B-X
of	B-X
whether	B-X
TGN	B-X
vesicles	B-X
can	B-X
interact	B-X
with	B-X
specific	B-X
phosphorylated	B-X
residues	B-X
in	B-X
order	B-X
to	B-X
drive	B-X
physiologic	B-X
,	B-X
constitutive	B-X
,	B-X
anterograde	B-X
traffic	B-X
,	B-X
retrograde	B-X
traffic	B-X
,	B-X
and	B-X
degradation	B-X
.	B-X
TGN	B-X
vesicles	B-X
can	B-X
:	B-X
(	B-X
a	B-X
)	B-X
traffic	B-X
to	B-X
endosomes	B-X
versus	B-X
plasma	B-X
membrane	B-X
phosphodomains	B-X
depending	B-X
upon	B-X
the	B-X
presence	B-X
or	B-X
the	B-X
absence	B-X
of	B-X
select	B-X
Golgi-localized	B-X
gamma-ear	B-X
containing	B-X
ADP	B-X
ribosylation	B-X
factor-binding	B-X
proteins	B-X
and/or	B-X
protein	B-X
kinase	B-X
D	B-X
;	B-X
(	B-X
b	B-X
)	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
TGN	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
phosphosorting	B-X
acidic	B-X
cluster	B-X
motif	B-X
adaptor	B-X
;	B-X
(	B-X
c	B-X
)	B-X
transit	B-X
back	B-X
to	B-X
the	B-X
ER	B-X
via	B-X
specialized	B-X
TGN/ER	B-X
glycosyltransferases	B-X
(	B-X
which	B-X
modulate	B-X
phosphorylated	B-X
proteins	B-X
)	B-X
;	B-X
(	B-X
d	B-X
)	B-X
transit	B-X
to	B-X
the	B-X
nucleus	B-X
via	B-X
phosphatidylinositol-4-kinase-associated	B-X
phosphodomains	B-X
;	B-X
and/or	B-X
(	B-X
e	B-X
)	B-X
retrotranslocate	B-X
to	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
equipped	B-X
with	B-X
E3	B-X
ligase	B-X
potential	B-X
,	B-X
in	B-X
order	B-X
to	B-X
further	B-X
regulate	B-X
endosomal	B-X
versus	B-X
plasma	B-X
membrane	B-X
traffic	B-X
.	B-X
The	B-X
TGN	B-X
is	B-X
also	B-X
a	B-X
critical	B-X
gateway	B-X
for	B-X
protein	B-X
transit	B-X
in	B-X
the	B-X
sense	B-X
that	B-X
,	B-X
as	B-X
a	B-X
function	B-X
of	B-X
sorting	B-X
within	B-X
this	B-X
compartment	B-X
,	B-X
proteins	B-X
are	B-X
sent	B-X
to	B-X
the	B-X
axon	B-X
,	B-X
cell	B-X
body	B-X
,	B-X
or	B-X
dendrites	B-X
.	B-X
As	B-X
the	B-X
decision	B-X
to	B-X
sort	B-X
to	B-X
the	B-X
axon	B-X
versus	B-X
the	B-X
somatodendritic	B-X
compartment	B-X
is	B-X
intimately	B-X
tied	B-X
to	B-X
TGN	B-X
function	B-X
,	B-X
future	B-X
understanding	B-X
of	B-X
TGN	B-X
biology	B-X
at	B-X
the	B-X
levels	B-X
of	B-X
neurogenesis	B-X
and	B-X
protein	B-X
sorting	B-X
is	B-X
predicted	B-X
to	B-X
also	B-X
effectively	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
synaptic	B-X
sorting/regulation	B-X
.	B-X

The	O
current	O
review	O
focuses	O
upon	O
recent	O
advances	O
concerning	O
the	O
interrelationship	O
between	O
the	O
ER	O
and	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
ER	O
-	O
TGN	O
)	O
,	O
the	O
ER	O
and	O
the	O
nucleus	O
(	O
ER	O
-	O
nucleus	O
)	O
,	O
and	O
the	O
ER	O
-	O
ubiquitin	B-Protein
-	O
proteasomal	O
pathways	O
at	O
the	O
level	O
of	O
basic	O
cell	O
biology	O
.	O
<EOS>	B-X
The	B-X
current	B-X
review	B-X
focuses	B-X
upon	B-X
recent	B-X
advances	B-X
concerning	B-X
the	B-X
interrelationship	B-X
between	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
trans-Golgi	B-X
network	B-X
(	B-X
ER-TGN	B-X
)	B-X
,	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
nucleus	B-X
(	B-X
ER-nucleus	B-X
)	B-X
,	B-X
and	B-X
the	B-X
ER-ubiquitin-proteasomal	B-X
pathways	B-X
at	B-X
the	B-X
level	B-X
of	B-X
basic	B-X
cell	B-X
biology	B-X
.	B-X
The	B-X
overall	B-X
emphasis	B-X
of	B-X
this	B-X
paper	B-X
centers	B-X
upon	B-X
the	B-X
high	B-X
likelihood	B-X
that	B-X
measurements	B-X
of	B-X
ER-associated	B-X
protein	B-X
or	B-X
gene	B-X
expression	B-X
levels	B-X
are	B-X
not	B-X
representative	B-X
of	B-X
a	B-X
strict	B-X
ER	B-X
alone	B-X
phenotype	B-X
.	B-X
Rather	B-X
,	B-X
that	B-X
ER	B-X
phenotype	B-X
reflects	B-X
a	B-X
synthesis	B-X
of	B-X
phenotypes	B-X
derived	B-X
from	B-X
intracellular	B-X
compartments	B-X
and	B-X
phosphorylated	B-X
messengers	B-X
in	B-X
rapport	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
ER-TGN	B-X
,	B-X
ER-nuclear	B-X
,	B-X
and	B-X
ER-ubiquitin-proteasomal	B-X
transit	B-X
paths	B-X
share	B-X
the	B-X
ability	B-X
to	B-X
feed	B-X
into	B-X
the	B-X
decision	B-X
of	B-X
whether	B-X
TGN	B-X
vesicles	B-X
can	B-X
interact	B-X
with	B-X
specific	B-X
phosphorylated	B-X
residues	B-X
in	B-X
order	B-X
to	B-X
drive	B-X
physiologic	B-X
,	B-X
constitutive	B-X
,	B-X
anterograde	B-X
traffic	B-X
,	B-X
retrograde	B-X
traffic	B-X
,	B-X
and	B-X
degradation	B-X
.	B-X
TGN	B-X
vesicles	B-X
can	B-X
:	B-X
(	B-X
a	B-X
)	B-X
traffic	B-X
to	B-X
endosomes	B-X
versus	B-X
plasma	B-X
membrane	B-X
phosphodomains	B-X
depending	B-X
upon	B-X
the	B-X
presence	B-X
or	B-X
the	B-X
absence	B-X
of	B-X
select	B-X
Golgi-localized	B-X
gamma-ear	B-X
containing	B-X
ADP	B-X
ribosylation	B-X
factor-binding	B-X
proteins	B-X
and/or	B-X
protein	B-X
kinase	B-X
D	B-X
;	B-X
(	B-X
b	B-X
)	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
TGN	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
phosphosorting	B-X
acidic	B-X
cluster	B-X
motif	B-X
adaptor	B-X
;	B-X
(	B-X
c	B-X
)	B-X
transit	B-X
back	B-X
to	B-X
the	B-X
ER	B-X
via	B-X
specialized	B-X
TGN/ER	B-X
glycosyltransferases	B-X
(	B-X
which	B-X
modulate	B-X
phosphorylated	B-X
proteins	B-X
)	B-X
;	B-X
(	B-X
d	B-X
)	B-X
transit	B-X
to	B-X
the	B-X
nucleus	B-X
via	B-X
phosphatidylinositol-4-kinase-associated	B-X
phosphodomains	B-X
;	B-X
and/or	B-X
(	B-X
e	B-X
)	B-X
retrotranslocate	B-X
to	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
equipped	B-X
with	B-X
E3	B-X
ligase	B-X
potential	B-X
,	B-X
in	B-X
order	B-X
to	B-X
further	B-X
regulate	B-X
endosomal	B-X
versus	B-X
plasma	B-X
membrane	B-X
traffic	B-X
.	B-X
The	B-X
TGN	B-X
is	B-X
also	B-X
a	B-X
critical	B-X
gateway	B-X
for	B-X
protein	B-X
transit	B-X
in	B-X
the	B-X
sense	B-X
that	B-X
,	B-X
as	B-X
a	B-X
function	B-X
of	B-X
sorting	B-X
within	B-X
this	B-X
compartment	B-X
,	B-X
proteins	B-X
are	B-X
sent	B-X
to	B-X
the	B-X
axon	B-X
,	B-X
cell	B-X
body	B-X
,	B-X
or	B-X
dendrites	B-X
.	B-X
As	B-X
the	B-X
decision	B-X
to	B-X
sort	B-X
to	B-X
the	B-X
axon	B-X
versus	B-X
the	B-X
somatodendritic	B-X
compartment	B-X
is	B-X
intimately	B-X
tied	B-X
to	B-X
TGN	B-X
function	B-X
,	B-X
future	B-X
understanding	B-X
of	B-X
TGN	B-X
biology	B-X
at	B-X
the	B-X
levels	B-X
of	B-X
neurogenesis	B-X
and	B-X
protein	B-X
sorting	B-X
is	B-X
predicted	B-X
to	B-X
also	B-X
effectively	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
synaptic	B-X
sorting/regulation	B-X
.	B-X

The	O
overall	O
emphasis	O
of	O
this	O
paper	O
centers	O
upon	O
the	O
high	O
likelihood	O
that	O
measurements	O
of	O
ER	O
-	O
associated	O
protein	O
or	O
gene	O
expression	O
levels	O
are	O
not	O
representative	O
of	O
a	O
strict	O
ER	O
alone	O
phenotype	O
.	O
<EOS>	B-X
There	B-X
is	B-X
abundant	B-X
variation	B-X
in	B-X
gene	B-X
expression	B-X
between	B-X
individuals	B-X
,	B-X
populations	B-X
,	B-X
and	B-X
species	B-X
.	B-X
The	B-X
evolution	B-X
of	B-X
gene	B-X
regulation	B-X
and	B-X
expression	B-X
within	B-X
and	B-X
between	B-X
species	B-X
is	B-X
thought	B-X
to	B-X
frequently	B-X
contribute	B-X
to	B-X
adaptation	B-X
.	B-X
Yet	B-X
considerable	B-X
evidence	B-X
suggests	B-X
that	B-X
the	B-X
primary	B-X
evolutionary	B-X
force	B-X
acting	B-X
on	B-X
variation	B-X
in	B-X
gene	B-X
expression	B-X
is	B-X
stabilizing	B-X
selection	B-X
.	B-X
We	B-X
review	B-X
here	B-X
the	B-X
results	B-X
of	B-X
recent	B-X
studies	B-X
characterizing	B-X
the	B-X
evolution	B-X
of	B-X
gene	B-X
expression	B-X
occurring	B-X
in	B-X
cis	B-X
(	B-X
via	B-X
linked	B-X
polymorphisms	B-X
)	B-X
or	B-X
in	B-X
trans	B-X
(	B-X
through	B-X
diffusible	B-X
products	B-X
of	B-X
other	B-X
genes	B-X
)	B-X
and	B-X
their	B-X
contribution	B-X
to	B-X
adaptation	B-X
and	B-X
response	B-X
to	B-X
the	B-X
environment	B-X
.	B-X
We	B-X
review	B-X
the	B-X
evidence	B-X
for	B-X
buffering	B-X
of	B-X
variation	B-X
in	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
level	B-X
of	B-X
both	B-X
transcription	B-X
and	B-X
translation	B-X
,	B-X
and	B-X
the	B-X
possible	B-X
mechanisms	B-X
for	B-X
this	B-X
buffering	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
summarize	B-X
unresolved	B-X
questions	B-X
about	B-X
the	B-X
evolution	B-X
of	B-X
gene	B-X
regulation	B-X
.	B-X

Rather	O
,	O
that	O
ER	O
phenotype	O
reflects	O
a	O
synthesis	O
of	O
phenotypes	O
derived	O
from	O
intracellular	O
compartments	O
and	O
phosphorylated	O
messengers	O
in	O
rapport	O
with	O
the	O
ER	O
.	O
<EOS>	B-X
The	B-X
current	B-X
review	B-X
focuses	B-X
upon	B-X
recent	B-X
advances	B-X
concerning	B-X
the	B-X
interrelationship	B-X
between	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
trans-Golgi	B-X
network	B-X
(	B-X
ER-TGN	B-X
)	B-X
,	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
nucleus	B-X
(	B-X
ER-nucleus	B-X
)	B-X
,	B-X
and	B-X
the	B-X
ER-ubiquitin-proteasomal	B-X
pathways	B-X
at	B-X
the	B-X
level	B-X
of	B-X
basic	B-X
cell	B-X
biology	B-X
.	B-X
The	B-X
overall	B-X
emphasis	B-X
of	B-X
this	B-X
paper	B-X
centers	B-X
upon	B-X
the	B-X
high	B-X
likelihood	B-X
that	B-X
measurements	B-X
of	B-X
ER-associated	B-X
protein	B-X
or	B-X
gene	B-X
expression	B-X
levels	B-X
are	B-X
not	B-X
representative	B-X
of	B-X
a	B-X
strict	B-X
ER	B-X
alone	B-X
phenotype	B-X
.	B-X
Rather	B-X
,	B-X
that	B-X
ER	B-X
phenotype	B-X
reflects	B-X
a	B-X
synthesis	B-X
of	B-X
phenotypes	B-X
derived	B-X
from	B-X
intracellular	B-X
compartments	B-X
and	B-X
phosphorylated	B-X
messengers	B-X
in	B-X
rapport	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
ER-TGN	B-X
,	B-X
ER-nuclear	B-X
,	B-X
and	B-X
ER-ubiquitin-proteasomal	B-X
transit	B-X
paths	B-X
share	B-X
the	B-X
ability	B-X
to	B-X
feed	B-X
into	B-X
the	B-X
decision	B-X
of	B-X
whether	B-X
TGN	B-X
vesicles	B-X
can	B-X
interact	B-X
with	B-X
specific	B-X
phosphorylated	B-X
residues	B-X
in	B-X
order	B-X
to	B-X
drive	B-X
physiologic	B-X
,	B-X
constitutive	B-X
,	B-X
anterograde	B-X
traffic	B-X
,	B-X
retrograde	B-X
traffic	B-X
,	B-X
and	B-X
degradation	B-X
.	B-X
TGN	B-X
vesicles	B-X
can	B-X
:	B-X
(	B-X
a	B-X
)	B-X
traffic	B-X
to	B-X
endosomes	B-X
versus	B-X
plasma	B-X
membrane	B-X
phosphodomains	B-X
depending	B-X
upon	B-X
the	B-X
presence	B-X
or	B-X
the	B-X
absence	B-X
of	B-X
select	B-X
Golgi-localized	B-X
gamma-ear	B-X
containing	B-X
ADP	B-X
ribosylation	B-X
factor-binding	B-X
proteins	B-X
and/or	B-X
protein	B-X
kinase	B-X
D	B-X
;	B-X
(	B-X
b	B-X
)	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
TGN	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
phosphosorting	B-X
acidic	B-X
cluster	B-X
motif	B-X
adaptor	B-X
;	B-X
(	B-X
c	B-X
)	B-X
transit	B-X
back	B-X
to	B-X
the	B-X
ER	B-X
via	B-X
specialized	B-X
TGN/ER	B-X
glycosyltransferases	B-X
(	B-X
which	B-X
modulate	B-X
phosphorylated	B-X
proteins	B-X
)	B-X
;	B-X
(	B-X
d	B-X
)	B-X
transit	B-X
to	B-X
the	B-X
nucleus	B-X
via	B-X
phosphatidylinositol-4-kinase-associated	B-X
phosphodomains	B-X
;	B-X
and/or	B-X
(	B-X
e	B-X
)	B-X
retrotranslocate	B-X
to	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
equipped	B-X
with	B-X
E3	B-X
ligase	B-X
potential	B-X
,	B-X
in	B-X
order	B-X
to	B-X
further	B-X
regulate	B-X
endosomal	B-X
versus	B-X
plasma	B-X
membrane	B-X
traffic	B-X
.	B-X

The	O
ER	O
-	O
TGN	O
,	O
ER	O
-	O
nuclear	O
,	O
and	O
ER	O
-	O
ubiquitin	B-Protein
-	O
proteasomal	O
transit	O
paths	O
share	O
the	O
ability	O
to	O
feed	O
into	O
the	O
decision	O
of	O
whether	O
TGN	O
vesicles	O
can	O
interact	O
with	O
specific	O
phosphorylated	O
residues	O
in	O
order	O
to	O
drive	O
physiologic	O
,	O
constitutive	O
,	O
anterograde	O
traffic	O
,	O
retrograde	O
traffic	O
,	O
and	O
degradation	O
.	O
<EOS>	B-X
The	B-X
current	B-X
review	B-X
focuses	B-X
upon	B-X
recent	B-X
advances	B-X
concerning	B-X
the	B-X
interrelationship	B-X
between	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
trans-Golgi	B-X
network	B-X
(	B-X
ER-TGN	B-X
)	B-X
,	B-X
the	B-X
ER	B-X
and	B-X
the	B-X
nucleus	B-X
(	B-X
ER-nucleus	B-X
)	B-X
,	B-X
and	B-X
the	B-X
ER-ubiquitin-proteasomal	B-X
pathways	B-X
at	B-X
the	B-X
level	B-X
of	B-X
basic	B-X
cell	B-X
biology	B-X
.	B-X
The	B-X
overall	B-X
emphasis	B-X
of	B-X
this	B-X
paper	B-X
centers	B-X
upon	B-X
the	B-X
high	B-X
likelihood	B-X
that	B-X
measurements	B-X
of	B-X
ER-associated	B-X
protein	B-X
or	B-X
gene	B-X
expression	B-X
levels	B-X
are	B-X
not	B-X
representative	B-X
of	B-X
a	B-X
strict	B-X
ER	B-X
alone	B-X
phenotype	B-X
.	B-X
Rather	B-X
,	B-X
that	B-X
ER	B-X
phenotype	B-X
reflects	B-X
a	B-X
synthesis	B-X
of	B-X
phenotypes	B-X
derived	B-X
from	B-X
intracellular	B-X
compartments	B-X
and	B-X
phosphorylated	B-X
messengers	B-X
in	B-X
rapport	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
The	B-X
ER-TGN	B-X
,	B-X
ER-nuclear	B-X
,	B-X
and	B-X
ER-ubiquitin-proteasomal	B-X
transit	B-X
paths	B-X
share	B-X
the	B-X
ability	B-X
to	B-X
feed	B-X
into	B-X
the	B-X
decision	B-X
of	B-X
whether	B-X
TGN	B-X
vesicles	B-X
can	B-X
interact	B-X
with	B-X
specific	B-X
phosphorylated	B-X
residues	B-X
in	B-X
order	B-X
to	B-X
drive	B-X
physiologic	B-X
,	B-X
constitutive	B-X
,	B-X
anterograde	B-X
traffic	B-X
,	B-X
retrograde	B-X
traffic	B-X
,	B-X
and	B-X
degradation	B-X
.	B-X
TGN	B-X
vesicles	B-X
can	B-X
:	B-X
(	B-X
a	B-X
)	B-X
traffic	B-X
to	B-X
endosomes	B-X
versus	B-X
plasma	B-X
membrane	B-X
phosphodomains	B-X
depending	B-X
upon	B-X
the	B-X
presence	B-X
or	B-X
the	B-X
absence	B-X
of	B-X
select	B-X
Golgi-localized	B-X
gamma-ear	B-X
containing	B-X
ADP	B-X
ribosylation	B-X
factor-binding	B-X
proteins	B-X
and/or	B-X
protein	B-X
kinase	B-X
D	B-X
;	B-X
(	B-X
b	B-X
)	B-X
be	B-X
maintained	B-X
within	B-X
the	B-X
TGN	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
phosphosorting	B-X
acidic	B-X
cluster	B-X
motif	B-X
adaptor	B-X
;	B-X
(	B-X
c	B-X
)	B-X
transit	B-X
back	B-X
to	B-X
the	B-X
ER	B-X
via	B-X
specialized	B-X
TGN/ER	B-X
glycosyltransferases	B-X
(	B-X
which	B-X
modulate	B-X
phosphorylated	B-X
proteins	B-X
)	B-X
;	B-X
(	B-X
d	B-X
)	B-X
transit	B-X
to	B-X
the	B-X
nucleus	B-X
via	B-X
phosphatidylinositol-4-kinase-associated	B-X
phosphodomains	B-X
;	B-X
and/or	B-X
(	B-X
e	B-X
)	B-X
retrotranslocate	B-X
to	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
which	B-X
is	B-X
equipped	B-X
with	B-X
E3	B-X
ligase	B-X
potential	B-X
,	B-X
in	B-X
order	B-X
to	B-X
further	B-X
regulate	B-X
endosomal	B-X
versus	B-X
plasma	B-X
membrane	B-X
traffic	B-X
.	B-X
The	B-X
TGN	B-X
is	B-X
also	B-X
a	B-X
critical	B-X
gateway	B-X
for	B-X
protein	B-X
transit	B-X
in	B-X
the	B-X
sense	B-X
that	B-X
,	B-X
as	B-X
a	B-X
function	B-X
of	B-X
sorting	B-X
within	B-X
this	B-X
compartment	B-X
,	B-X
proteins	B-X
are	B-X
sent	B-X
to	B-X
the	B-X
axon	B-X
,	B-X
cell	B-X
body	B-X
,	B-X
or	B-X
dendrites	B-X
.	B-X
As	B-X
the	B-X
decision	B-X
to	B-X
sort	B-X
to	B-X
the	B-X
axon	B-X
versus	B-X
the	B-X
somatodendritic	B-X
compartment	B-X
is	B-X
intimately	B-X
tied	B-X
to	B-X
TGN	B-X
function	B-X
,	B-X
future	B-X
understanding	B-X
of	B-X
TGN	B-X
biology	B-X
at	B-X
the	B-X
levels	B-X
of	B-X
neurogenesis	B-X
and	B-X
protein	B-X
sorting	B-X
is	B-X
predicted	B-X
to	B-X
also	B-X
effectively	B-X
increase	B-X
our	B-X
understanding	B-X
of	B-X
synaptic	B-X
sorting/regulation	B-X
.	B-X

TGN	O
vesicles	O
can	O
:	O
(	O
a	O
)	O
traffic	O
to	O
endosomes	O
versus	O
plasma	O
membrane	O
phosphodomains	O
depending	O
upon	O
the	O
presence	O
or	O
the	O
absence	O
of	O
select	O
Golgi	O
-	O
localized	O
gamma	O
-	O
ear	O
containing	O
ADP	O
ribosylation	O
factor	O
-	O
binding	O
proteins	O
and	O
/	O
or	O
protein	O
kinase	O
D	O
;	O
(	O
b	O
)	O
be	O
maintained	O
within	O
the	O
TGN	O
in	O
the	O
presence	O
of	O
a	O
phosphosorting	O
acidic	O
cluster	O
motif	O
adaptor	O
;	O
(	O
c	O
)	O
transit	O
back	O
to	O
the	O
ER	O
via	O
specialized	O
TGN	O
/	O
ER	O
glycosyltransferases	O
(	O
which	O
modulate	O
phosphorylated	O
proteins	O
)	O
;	O
(	O
d	O
)	O
transit	O
to	O
the	O
nucleus	O
via	O
phosphatidylinositol	O
-	O
4	O
-	O
kinase	O
-	O
associated	O
phosphodomains	O
;	O
and	O
/	O
or	O
(	O
e	O
)	O
retrotranslocate	O
to	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
,	O
which	O
is	O
equipped	O
with	O
E3	O
ligase	O
potential	O
,	O
in	O
order	O
to	O
further	O
regulate	O
endosomal	O
versus	O
plasma	O
membrane	O
traffic	O
.	O
<EOS>	B-X
Membrane	B-X
trafficking	B-X
is	B-X
essential	B-X
for	B-X
processing	B-X
and	B-X
transport	B-X
of	B-X
proteins	B-X
and	B-X
lipids	B-X
and	B-X
to	B-X
establish	B-X
cell	B-X
compartmentation	B-X
and	B-X
tissue	B-X
organization	B-X
.	B-X
Cells	B-X
respond	B-X
to	B-X
their	B-X
needs	B-X
and	B-X
control	B-X
the	B-X
quantity	B-X
and	B-X
quality	B-X
of	B-X
protein	B-X
secretion	B-X
accordingly	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
focus	B-X
on	B-X
a	B-X
particular	B-X
membrane	B-X
trafficking	B-X
route	B-X
from	B-X
the	B-X
Pancreatic	B-X
ductal	B-X
adenocarcinoma	B-X
(	B-X
PDA	B-X
)	B-X
is	B-X
characterized	B-X
by	B-X
advanced	B-X
stage	B-X
desmoplastic	B-X
tumors	B-X
with	B-X
a	B-X
high	B-X
prevalence	B-X
of	B-X
genetic	B-X
abnormalities	B-X
.	B-X
Occurrence	B-X
of	B-X
PDA	B-X
is	B-X
linked	B-X
to	B-X
activating	B-X
Kras	B-X
mutations	B-X
and	B-X
aberrant	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptor	B-X
signaling	B-X
,	B-X
leading	B-X
to	B-X
additional	B-X
activation	B-X
of	B-X
wild-type	B-X
Kras	B-X
.	B-X
As	B-X
Kras	B-X
is	B-X
difficult	B-X
to	B-X
target	B-X
,	B-X
there	B-X
is	B-X
a	B-X
constant	B-X
need	B-X
to	B-X
identify	B-X
novel	B-X
targets	B-X
acting	B-X
downstream	B-X
of	B-X
this	B-X
molecule	B-X
in	B-X
driving	B-X
the	B-X
formation	B-X
or	B-X
progression	B-X
of	B-X
PDA	B-X
.	B-X
Recently	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
protein	B-X
kinase	B-X
D	B-X
enzymes	B-X
not	B-X
only	B-X
are	B-X
increasingly	B-X
expressed	B-X
in	B-X
PDA	B-X
but	B-X
also	B-X
causatively	B-X
linked	B-X
to	B-X
the	B-X
development	B-X
and	B-X
progression	B-X
of	B-X
this	B-X
cancer	B-X
.	B-X
They	B-X
act	B-X
downstream	B-X
of	B-X
both	B-X
mutant	B-X
Kras	B-X
and	B-X
growth	B-X
factors	B-X
and	B-X
therefore	B-X
may	B-X
represent	B-X
ideal	B-X
novel	B-X
targets	B-X
.	B-X

The	O
TGN	O
is	O
also	O
a	O
critical	O
gateway	O
for	O
protein	O
transit	O
in	O
the	O
sense	O
that	O
,	O
as	O
a	O
function	O
of	O
sorting	O
within	O
this	O
compartment	O
,	O
proteins	O
are	O
sent	O
to	O
the	O
axon	O
,	O
cell	O
body	O
,	O
or	O
dendrites	O
.	O
<EOS>	B-X
Intellectual	B-X
disability	B-X
(	B-X
ID	B-X
)	B-X
corresponds	B-X
to	B-X
several	B-X
neurodevelopmental	B-X
disorders	B-X
of	B-X
heterogeneous	B-X
origin	B-X
in	B-X
which	B-X
cognitive	B-X
deficits	B-X
are	B-X
commonly	B-X
associated	B-X
with	B-X
abnormalities	B-X
of	B-X
dendrites	B-X
and	B-X
dendritic	B-X
spines	B-X
.	B-X
Greater	B-X
understanding	B-X
of	B-X
the	B-X
roles	B-X
of	B-X
these	B-X
putative	B-X
ID	B-X
genes	B-X
and	B-X
their	B-X
functional	B-X
interactions	B-X
might	B-X
boost	B-X
investigations	B-X
into	B-X
determining	B-X
the	B-X
plausible	B-X
link	B-X
between	B-X
cellular	B-X
and	B-X
behavioral	B-X
alterations	B-X
as	B-X
well	B-X
as	B-X
the	B-X
mechanisms	B-X
contributing	B-X
to	B-X
the	B-X
cognitive	B-X
impairment	B-X
observed	B-X
in	B-X
ID	B-X
.	B-X
Genetic	B-X
data	B-X
combined	B-X
with	B-X
histological	B-X
abnormalities	B-X
,	B-X
clinical	B-X
presentation	B-X
,	B-X
and	B-X
transgenic	B-X
animal	B-X
models	B-X
provide	B-X
support	B-X
for	B-X
the	B-X
primacy	B-X
of	B-X
dysregulation	B-X
in	B-X
dendrite	B-X
structure	B-X
and	B-X
function	B-X
as	B-X
the	B-X
basis	B-X
for	B-X
the	B-X
cognitive	B-X
deficits	B-X
observed	B-X
in	B-X
ID	B-X
.	B-X
Clinical	B-X
characteristics	B-X
of	B-X
ID	B-X
have	B-X
also	B-X
been	B-X
reported	B-X
in	B-X
individuals	B-X
with	B-X
deletions	B-X
in	B-X
the	B-X
long	B-X
arm	B-X
of	B-X
chromosome	B-X
10	B-X
(	B-X
the	B-X
q26.2/q26.3	B-X
)	B-X
,	B-X
a	B-X
region	B-X
containing	B-X
the	B-X
gene	B-X
for	B-X
the	B-X
collapsin	B-X
response	B-X
mediator	B-X
protein	B-X
3	B-X
(	B-X
CRMP3	B-X
)	B-X
,	B-X
also	B-X
known	B-X
as	B-X
dihydropyrimidinase-related	B-X
protein-4	B-X
(	B-X
DRP-4	B-X
,	B-X
DPYSL4	B-X
)	B-X
,	B-X
which	B-X
is	B-X
involved	B-X
in	B-X
dendritogenesis	B-X
.	B-X

As	O
the	O
decision	O
to	O
sort	O
to	O
the	O
axon	O
versus	O
the	O
somatodendritic	O
compartment	O
is	O
intimately	O
tied	O
to	O
TGN	O
function	O
,	O
future	O
understanding	O
of	O
TGN	O
biology	O
at	O
the	O
levels	O
of	O
neurogenesis	O
and	O
protein	O
sorting	O
is	O
predicted	O
to	O
also	O
effectively	O
increase	O
our	O
understanding	O
of	O
synaptic	O
sorting	O
/	O
regulation	O
.	O

CAND1	B-Protein
binds	O
to	O
unneddylated	O
CUL1	B-Protein
and	O
regulates	O
the	O
formation	O
of	O
SCF	O
ubiquitin	B-Protein
E3	O
ligase	O
complex	O
.	O
<EOS>	B-X
The	B-X
SCF	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
regulates	B-X
ubiquitin-dependent	B-X
proteolysis	B-X
of	B-X
many	B-X
regulatory	B-X
proteins	B-X
such	B-X
as	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
IkappaB	B-X
,	B-X
and	B-X
beta-catenin	B-X
.	B-X
We	B-X
report	B-X
the	B-X
isolation	B-X
of	B-X
a	B-X
CUL1	B-X
binding	B-X
protein	B-X
,	B-X
p120	B-X
(	B-X
CAND1	B-X
)	B-X
.	B-X
We	B-X
found	B-X
the	B-X
majority	B-X
of	B-X
CUL1	B-X
is	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
CAND1	B-X
and	B-X
ROC1	B-X
independent	B-X
of	B-X
SKP1	B-X
and	B-X
F	B-X
box	B-X
protein	B-X
SKP2	B-X
.	B-X
Both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
CAND1	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
SKP1	B-X
and	B-X
SKP2	B-X
to	B-X
CUL1	B-X
while	B-X
dissociation	B-X
of	B-X
CAND1	B-X
from	B-X
CUL1	B-X
promotes	B-X
the	B-X
reverse	B-X
reaction	B-X
.	B-X
Neddylation	B-X
of	B-X
CUL1	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
SKP1	B-X
and	B-X
ATP	B-X
causes	B-X
CAND1	B-X
dissociation	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CAND1	B-X
regulates	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
and	B-X
its	B-X
dissociation	B-X
from	B-X
CUL1	B-X
is	B-X
coupled	B-X
with	B-X
the	B-X
incorporation	B-X
of	B-X
F	B-X
box	B-X
proteins	B-X
into	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
causing	B-X
their	B-X
destabilization	B-X
.	B-X

The	O
SCF	O
ubiquitin	B-Protein
E3	O
ligase	O
regulates	O
ubiquitin	B-Protein
-	O
dependent	O
proteolysis	O
of	O
many	O
regulatory	O
proteins	O
such	O
as	O
p27	B-Protein
(	O
Kip1	B-Protein
)	O
,	O
IkappaB	O
,	O
and	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
.	O
<EOS>	B-X
The	B-X
SCF	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
regulates	B-X
ubiquitin-dependent	B-X
proteolysis	B-X
of	B-X
many	B-X
regulatory	B-X
proteins	B-X
such	B-X
as	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
IkappaB	B-X
,	B-X
and	B-X
beta-catenin	B-X
.	B-X
We	B-X
found	B-X
the	B-X
majority	B-X
of	B-X
CUL1	B-X
is	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
CAND1	B-X
and	B-X
ROC1	B-X
independent	B-X
of	B-X
SKP1	B-X
and	B-X
F	B-X
box	B-X
protein	B-X
SKP2	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CAND1	B-X
regulates	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
and	B-X
its	B-X
dissociation	B-X
from	B-X
CUL1	B-X
is	B-X
coupled	B-X
with	B-X
the	B-X
incorporation	B-X
of	B-X
F	B-X
box	B-X
proteins	B-X
into	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
causing	B-X
their	B-X
destabilization	B-X
.	B-X

We	O
report	O
the	O
isolation	O
of	O
a	O
CUL1	B-Protein
binding	O
protein	O
,	O
p120	B-Protein
(	O
CAND1	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
SCF	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
regulates	B-X
ubiquitin-dependent	B-X
proteolysis	B-X
of	B-X
many	B-X
regulatory	B-X
proteins	B-X
such	B-X
as	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
IkappaB	B-X
,	B-X
and	B-X
beta-catenin	B-X
.	B-X
We	B-X
report	B-X
the	B-X
isolation	B-X
of	B-X
a	B-X
CUL1	B-X
binding	B-X
protein	B-X
,	B-X
p120	B-X
(	B-X
CAND1	B-X
)	B-X
.	B-X
We	B-X
found	B-X
the	B-X
majority	B-X
of	B-X
CUL1	B-X
is	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
CAND1	B-X
and	B-X
ROC1	B-X
independent	B-X
of	B-X
SKP1	B-X
and	B-X
F	B-X
box	B-X
protein	B-X
SKP2	B-X
.	B-X
Both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
CAND1	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
SKP1	B-X
and	B-X
SKP2	B-X
to	B-X
CUL1	B-X
while	B-X
dissociation	B-X
of	B-X
CAND1	B-X
from	B-X
CUL1	B-X
promotes	B-X
the	B-X
reverse	B-X
reaction	B-X
.	B-X
Neddylation	B-X
of	B-X
CUL1	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
SKP1	B-X
and	B-X
ATP	B-X
causes	B-X
CAND1	B-X
dissociation	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CAND1	B-X
regulates	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
and	B-X
its	B-X
dissociation	B-X
from	B-X
CUL1	B-X
is	B-X
coupled	B-X
with	B-X
the	B-X
incorporation	B-X
of	B-X
F	B-X
box	B-X
proteins	B-X
into	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
causing	B-X
their	B-X
destabilization	B-X
.	B-X

We	O
found	O
the	O
majority	O
of	O
CUL1	B-Protein
is	O
in	O
a	O
complex	O
with	O
CAND1	B-Protein
and	O
ROC1	B-Protein
independent	O
of	O
SKP1	B-Protein
and	O
F	O
box	O
protein	O
SKP2	B-Protein
.	O

Both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
CAND1	B-Protein
prevents	O
the	O
binding	O
of	O
SKP1	B-Protein
and	O
SKP2	B-Protein
to	O
CUL1	B-Protein
while	O
dissociation	O
of	O
CAND1	B-Protein
from	O
CUL1	B-Protein
promotes	O
the	O
reverse	O
reaction	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
isolation	B-X
of	B-X
a	B-X
CUL1	B-X
binding	B-X
protein	B-X
,	B-X
p120	B-X
(	B-X
CAND1	B-X
)	B-X
.	B-X
We	B-X
found	B-X
the	B-X
majority	B-X
of	B-X
CUL1	B-X
is	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
CAND1	B-X
and	B-X
ROC1	B-X
independent	B-X
of	B-X
SKP1	B-X
and	B-X
F	B-X
box	B-X
protein	B-X
SKP2	B-X
.	B-X
Both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
CAND1	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
SKP1	B-X
and	B-X
SKP2	B-X
to	B-X
CUL1	B-X
while	B-X
dissociation	B-X
of	B-X
CAND1	B-X
from	B-X
CUL1	B-X
promotes	B-X
the	B-X
reverse	B-X
reaction	B-X
.	B-X
Neddylation	B-X
of	B-X
CUL1	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
SKP1	B-X
and	B-X
ATP	B-X
causes	B-X
CAND1	B-X
dissociation	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CAND1	B-X
regulates	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
and	B-X
its	B-X
dissociation	B-X
from	B-X
CUL1	B-X
is	B-X
coupled	B-X
with	B-X
the	B-X
incorporation	B-X
of	B-X
F	B-X
box	B-X
proteins	B-X
into	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
causing	B-X
their	B-X
destabilization	B-X
.	B-X

Neddylation	O
of	O
CUL1	B-Protein
or	O
the	O
presence	O
of	O
SKP1	B-Protein
and	O
ATP	O
causes	O
CAND1	B-Protein
dissociation	O
.	O
<EOS>	B-X
Cullin-associated	B-X
and	B-X
Neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
coordinator	B-X
to	B-X
modulate	B-X
substrate	B-X
protein	B-X
degradation	B-X
by	B-X
promoting	B-X
the	B-X
formation	B-X
of	B-X
specific	B-X
cullin-based	B-X
ubiquitin	B-X
ligase	B-X
3	B-X
complex	B-X
in	B-X
response	B-X
to	B-X
substrate	B-X
accumulation	B-X
,	B-X
which	B-X
thereby	B-X
facilitate	B-X
the	B-X
maintaining	B-X
of	B-X
normal	B-X
protein	B-X
homeostasis	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
CAND1	B-X
titrates	B-X
the	B-X
degradation	B-X
of	B-X
hypertrophy	B-X
related	B-X
protein	B-X
eg	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
CAND1	B-X
in	B-X
cardiac	B-X
hypertrophy	B-X
and	B-X
heart	B-X
failure	B-X
and	B-X
the	B-X
underlying	B-X
molecular	B-X
mechanism	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
protein	B-X
level	B-X
of	B-X
CAND1	B-X
was	B-X
increased	B-X
in	B-X
cardiac	B-X
tissues	B-X
from	B-X
heart	B-X
failure	B-X
(	B-X
HF	B-X
)	B-X
patients	B-X
and	B-X
TAC	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
mRNA	B-X
level	B-X
did	B-X
not	B-X
change	B-X
.	B-X
CAND1-KO+	B-X
/-	B-X
aggravated	B-X
TAC-induced	B-X
cardiac	B-X
hypertrophic	B-X
phenotypes	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
CAND1-Tg	B-X
attenuated	B-X
the	B-X
maladaptive	B-X
cardiac	B-X
remodeling	B-X
.	B-X
At	B-X
the	B-X
molecular	B-X
level	B-X
,	B-X
CAND1	B-X
overexpression	B-X
downregulated	B-X
,	B-X
whereas	B-X
CAND1-KO+	B-X
/-	B-X
or	B-X
knockdown	B-X
upregulated	B-X
calcineurin	B-X
expression	B-X
at	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
conditions	B-X
.	B-X
Mechanistically	B-X
,	B-X
CAND1	B-X
overexpression	B-X
favored	B-X
the	B-X
assembly	B-X
of	B-X
Cul1/atrogin1/calcineurin	B-X
complex	B-X
and	B-X
rendered	B-X
the	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
calcineurin	B-X
.	B-X
Notably	B-X
,	B-X
CAND1	B-X
deficiency-induced	B-X
hypertrophic	B-X
phenotypes	B-X
were	B-X
partially	B-X
rescued	B-X
by	B-X
knockdown	B-X
of	B-X
calcineurin	B-X
,	B-X
and	B-X
application	B-X
of	B-X
exogenous	B-X
CAND1	B-X
prevented	B-X
TAC-induced	B-X
cardiac	B-X
hypertrophy	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
our	B-X
findings	B-X
demonstrate	B-X
that	B-X
CAND1	B-X
exerts	B-X
a	B-X
protective	B-X
effect	B-X
against	B-X
cardiac	B-X
hypertrophy	B-X
and	B-X
heart	B-X
failure	B-X
partially	B-X
by	B-X
inducing	B-X
the	B-X
degradation	B-X
of	B-X
calcineurin	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
CAND1	B-Protein
regulates	O
the	O
formation	O
of	O
the	O
SCF	O
complex	O
,	O
and	O
its	O
dissociation	O
from	O
CUL1	B-Protein
is	O
coupled	O
with	O
the	O
incorporation	O
of	O
F	O
box	O
proteins	O
into	O
the	O
SCF	O
complex	O
,	O
causing	O
their	O
destabilization	O
.	O
<EOS>	B-X
The	B-X
SCF	B-X
ubiquitin	B-X
E3	B-X
ligase	B-X
regulates	B-X
ubiquitin-dependent	B-X
proteolysis	B-X
of	B-X
many	B-X
regulatory	B-X
proteins	B-X
such	B-X
as	B-X
p27	B-X
(	B-X
Kip1	B-X
)	B-X
,	B-X
IkappaB	B-X
,	B-X
and	B-X
beta-catenin	B-X
.	B-X
We	B-X
report	B-X
the	B-X
isolation	B-X
of	B-X
a	B-X
CUL1	B-X
binding	B-X
protein	B-X
,	B-X
p120	B-X
(	B-X
CAND1	B-X
)	B-X
.	B-X
We	B-X
found	B-X
the	B-X
majority	B-X
of	B-X
CUL1	B-X
is	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
CAND1	B-X
and	B-X
ROC1	B-X
independent	B-X
of	B-X
SKP1	B-X
and	B-X
F	B-X
box	B-X
protein	B-X
SKP2	B-X
.	B-X
Both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
CAND1	B-X
prevents	B-X
the	B-X
binding	B-X
of	B-X
SKP1	B-X
and	B-X
SKP2	B-X
to	B-X
CUL1	B-X
while	B-X
dissociation	B-X
of	B-X
CAND1	B-X
from	B-X
CUL1	B-X
promotes	B-X
the	B-X
reverse	B-X
reaction	B-X
.	B-X
Neddylation	B-X
of	B-X
CUL1	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
SKP1	B-X
and	B-X
ATP	B-X
causes	B-X
CAND1	B-X
dissociation	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
CAND1	B-X
regulates	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
and	B-X
its	B-X
dissociation	B-X
from	B-X
CUL1	B-X
is	B-X
coupled	B-X
with	B-X
the	B-X
incorporation	B-X
of	B-X
F	B-X
box	B-X
proteins	B-X
into	B-X
the	B-X
SCF	B-X
complex	B-X
,	B-X
causing	B-X
their	B-X
destabilization	B-X
.	B-X

Rheb	B-Protein
binds	O
tuberous	B-Protein
sclerosis	I-Protein
complex	I-Protein
2	I-Protein
(	O
TSC2	B-Protein
)	O
and	O
promotes	O
S6	B-Protein
kinase	O
activation	O
in	O
a	O
rapamycin	O
-	O
and	O
farnesylation	O
-	O
dependent	O
manner	O
.	O

Recently	O
the	O
tuberous	B-Protein
sclerosis	I-Protein
complex	I-Protein
2	I-Protein
(	O
TSC2	B-Protein
)	O
tumor	O
suppressor	O
gene	O
product	O
has	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
protein	O
synthesis	O
upstream	O
of	O
the	O
mTOR	B-Protein
and	O
ribosomal	O
S6	B-Protein
kinases	O
.	O
<EOS>	B-X
Recently	B-X
the	B-X
tuberous	B-X
sclerosis	B-X
complex	B-X
2	B-X
(	B-X
TSC2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
product	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
protein	B-X
synthesis	B-X
upstream	B-X
of	B-X
the	B-X
mTOR	B-X
and	B-X
ribosomal	B-X
S6	B-X
kinases	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
homology	B-X
of	B-X
TSC2	B-X
with	B-X
GTPase-activating	B-X
proteins	B-X
for	B-X
Rap1	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
a	B-X
Ras/Rap-related	B-X
GTPase	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
TSC2	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
Rheb-GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
reduce	B-X
Rheb	B-X
GTP	B-X
levels	B-X
in	B-X
vivo	B-X
.	B-X
Over-expression	B-X
of	B-X
Rheb	B-X
but	B-X
not	B-X
Rap1	B-X
promoted	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
in	B-X
a	B-X
rapamycin-dependent	B-X
manner	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
acts	B-X
upstream	B-X
of	B-X
mTOR	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Rheb	B-X
to	B-X
induce	B-X
S6	B-X
phosphorylation	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
a	B-X
farnesyl	B-X
transferase	B-X
inhibitor	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
Ras-independent	B-X
anti-neoplastic	B-X
properties	B-X
of	B-X
this	B-X
drug	B-X
.	B-X

Because	O
of	O
the	O
homology	O
of	O
TSC2	B-Protein
with	O
GTPase	O
-	O
activating	O
proteins	O
for	O
Rap1	B-Protein
,	O
we	O
examined	O
whether	O
a	O
Ras	O
/	O
Rap	O
-	O
related	O
GTPase	O
might	O
be	O
involved	O
in	O
this	O
process	O
.	O
<EOS>	B-X
Recently	B-X
the	B-X
tuberous	B-X
sclerosis	B-X
complex	B-X
2	B-X
(	B-X
TSC2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
product	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
protein	B-X
synthesis	B-X
upstream	B-X
of	B-X
the	B-X
mTOR	B-X
and	B-X
ribosomal	B-X
S6	B-X
kinases	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
homology	B-X
of	B-X
TSC2	B-X
with	B-X
GTPase-activating	B-X
proteins	B-X
for	B-X
Rap1	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
a	B-X
Ras/Rap-related	B-X
GTPase	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
TSC2	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
Rheb-GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
reduce	B-X
Rheb	B-X
GTP	B-X
levels	B-X
in	B-X
vivo	B-X
.	B-X
Over-expression	B-X
of	B-X
Rheb	B-X
but	B-X
not	B-X
Rap1	B-X
promoted	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
in	B-X
a	B-X
rapamycin-dependent	B-X
manner	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
acts	B-X
upstream	B-X
of	B-X
mTOR	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Rheb	B-X
to	B-X
induce	B-X
S6	B-X
phosphorylation	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
a	B-X
farnesyl	B-X
transferase	B-X
inhibitor	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
Ras-independent	B-X
anti-neoplastic	B-X
properties	B-X
of	B-X
this	B-X
drug	B-X
.	B-X

TSC2	B-Protein
was	O
found	O
to	O
bind	O
to	O
Rheb	B-Protein
-	O
GTP	O
in	O
vitro	O
and	O
to	O
reduce	O
Rheb	B-Protein
GTP	O
levels	O
in	O
vivo	O
.	O
<EOS>	B-X
Recently	B-X
the	B-X
tuberous	B-X
sclerosis	B-X
complex	B-X
2	B-X
(	B-X
TSC2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
product	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
protein	B-X
synthesis	B-X
upstream	B-X
of	B-X
the	B-X
mTOR	B-X
and	B-X
ribosomal	B-X
S6	B-X
kinases	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
homology	B-X
of	B-X
TSC2	B-X
with	B-X
GTPase-activating	B-X
proteins	B-X
for	B-X
Rap1	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
a	B-X
Ras/Rap-related	B-X
GTPase	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
TSC2	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
Rheb-GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
reduce	B-X
Rheb	B-X
GTP	B-X
levels	B-X
in	B-X
vivo	B-X
.	B-X
Over-expression	B-X
of	B-X
Rheb	B-X
but	B-X
not	B-X
Rap1	B-X
promoted	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
in	B-X
a	B-X
rapamycin-dependent	B-X
manner	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
acts	B-X
upstream	B-X
of	B-X
mTOR	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Rheb	B-X
to	B-X
induce	B-X
S6	B-X
phosphorylation	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
a	B-X
farnesyl	B-X
transferase	B-X
inhibitor	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
Ras-independent	B-X
anti-neoplastic	B-X
properties	B-X
of	B-X
this	B-X
drug	B-X
.	B-X

Over	O
-	O
expression	O
of	O
Rheb	B-Protein
but	O
not	O
Rap1	B-Protein
promoted	O
the	O
activation	O
of	O
S6	B-Protein
kinase	O
in	O
a	O
rapamycin	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
Rheb	B-Protein
acts	O
upstream	O
of	O
mTOR	B-Protein
.	O
<EOS>	B-X
Cib2	B-X
mutant	B-X
mice	B-X
exhibit	B-X
reduced	B-X
lysosomal	B-X
capacity	B-X
and	B-X
autophagic	B-X
clearance	B-X
,	B-X
and	B-X
increased	B-X
mTORC1	B-X
signaling-a	B-X
negative	B-X
regulator	B-X
of	B-X
autophagy	B-X
.	B-X
Mechanistically	B-X
,	B-X
CIB2	B-X
negatively	B-X
regulates	B-X
mTORC1	B-X
by	B-X
preferentially	B-X
binding	B-X
to	B-X
'nucleotide	B-X
empty	B-X
'	B-X
or	B-X
inactive	B-X
GDP-loaded	B-X
Rheb	B-X
.	B-X
Upregulated	B-X
mTORC1	B-X
signaling	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
lymphangioleiomyomatosis	B-X
(	B-X
LAM	B-X
)	B-X
cancer	B-X
.	B-X
Over-expressing	B-X
CIB2	B-X
in	B-X
LAM	B-X
patient-derived	B-X
fibroblasts	B-X
downregulates	B-X
hyperactive	B-X
mTORC1	B-X
signaling	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
findings	B-X
have	B-X
significant	B-X
implications	B-X
for	B-X
treatment	B-X
of	B-X
AMD	B-X
and	B-X
other	B-X
mTORC1	B-X
hyperactivity-associated	B-X
disorders	B-X
.	B-X

The	O
ability	O
of	O
Rheb	B-Protein
to	O
induce	O
S6	B-Protein
phosphorylation	O
was	O
also	O
inhibited	O
by	O
a	O
farnesyl	O
transferase	O
inhibitor	O
,	O
suggesting	O
that	O
Rheb	B-Protein
may	O
be	O
responsible	O
for	O
the	O
Ras	O
-	O
independent	O
anti	O
-	O
neoplastic	O
properties	O
of	O
this	O
drug	O
.	O
<EOS>	B-X
Recently	B-X
the	B-X
tuberous	B-X
sclerosis	B-X
complex	B-X
2	B-X
(	B-X
TSC2	B-X
)	B-X
tumor	B-X
suppressor	B-X
gene	B-X
product	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
protein	B-X
synthesis	B-X
upstream	B-X
of	B-X
the	B-X
mTOR	B-X
and	B-X
ribosomal	B-X
S6	B-X
kinases	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
homology	B-X
of	B-X
TSC2	B-X
with	B-X
GTPase-activating	B-X
proteins	B-X
for	B-X
Rap1	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
a	B-X
Ras/Rap-related	B-X
GTPase	B-X
might	B-X
be	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
.	B-X
TSC2	B-X
was	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
Rheb-GTP	B-X
in	B-X
vitro	B-X
and	B-X
to	B-X
reduce	B-X
Rheb	B-X
GTP	B-X
levels	B-X
in	B-X
vivo	B-X
.	B-X
Over-expression	B-X
of	B-X
Rheb	B-X
but	B-X
not	B-X
Rap1	B-X
promoted	B-X
the	B-X
activation	B-X
of	B-X
S6	B-X
kinase	B-X
in	B-X
a	B-X
rapamycin-dependent	B-X
manner	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
acts	B-X
upstream	B-X
of	B-X
mTOR	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
Rheb	B-X
to	B-X
induce	B-X
S6	B-X
phosphorylation	B-X
was	B-X
also	B-X
inhibited	B-X
by	B-X
a	B-X
farnesyl	B-X
transferase	B-X
inhibitor	B-X
,	B-X
suggesting	B-X
that	B-X
Rheb	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
Ras-independent	B-X
anti-neoplastic	B-X
properties	B-X
of	B-X
this	B-X
drug	B-X
.	B-X

Rab	O
and	O
ARF	O
GTPase	O
regulation	O
of	O
exocytosis	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
governing	B-X
of	B-X
Rab	B-X
and	B-X
Arf	B-X
protein	B-X
function	B-X
has	B-X
exploded	B-X
in	B-X
recent	B-X
years	B-X
with	B-X
a	B-X
convergence	B-X
of	B-X
information	B-X
from	B-X
model	B-X
genetic	B-X
organisms	B-X
,	B-X
biochemical	B-X
studies	B-X
,	B-X
cell	B-X
biological	B-X
observations	B-X
and	B-X
protein	B-X
structural	B-X
information	B-X
.	B-X
However	B-X
,	B-X
the	B-X
list	B-X
of	B-X
known	B-X
Rab	B-X
and	B-X
Arf	B-X
interacting	B-X
factors	B-X
still	B-X
remains	B-X
small	B-X
relative	B-X
to	B-X
the	B-X
number	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
through	B-X
complete	B-X
genomic	B-X
sequencing	B-X
.	B-X
It	B-X
can	B-X
be	B-X
anticipated	B-X
that	B-X
the	B-X
factors	B-X
listed	B-X
and	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
probably	B-X
represent	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
accessory	B-X
molecules	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
regulators	B-X
and	B-X
accessory	B-X
molecules	B-X
for	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
families	B-X
has	B-X
allowed	B-X
investigators	B-X
to	B-X
elaborate	B-X
themes	B-X
and	B-X
develop	B-X
a	B-X
framework	B-X
for	B-X
a	B-X
mechanistic	B-X
understanding	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
themes	B-X
are	B-X
highlighted	B-X
in	B-X
this	B-X
review	B-X
,	B-X
which	B-X
aims	B-X
to	B-X
concentrate	B-X
on	B-X
Rab	B-X
and	B-X
Arf	B-X
function	B-X
in	B-X
exocytosis	B-X
.	B-X

Our	O
understanding	O
of	O
the	O
mechanisms	O
governing	O
of	O
Rab	O
and	O
Arf	O
protein	O
function	O
has	O
exploded	O
in	O
recent	O
years	O
with	O
a	O
convergence	O
of	O
information	O
from	O
model	O
genetic	O
organisms	O
,	O
biochemical	O
studies	O
,	O
cell	O
biological	O
observations	O
and	O
protein	O
structural	O
information	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
governing	B-X
of	B-X
Rab	B-X
and	B-X
Arf	B-X
protein	B-X
function	B-X
has	B-X
exploded	B-X
in	B-X
recent	B-X
years	B-X
with	B-X
a	B-X
convergence	B-X
of	B-X
information	B-X
from	B-X
model	B-X
genetic	B-X
organisms	B-X
,	B-X
biochemical	B-X
studies	B-X
,	B-X
cell	B-X
biological	B-X
observations	B-X
and	B-X
protein	B-X
structural	B-X
information	B-X
.	B-X
However	B-X
,	B-X
the	B-X
list	B-X
of	B-X
known	B-X
Rab	B-X
and	B-X
Arf	B-X
interacting	B-X
factors	B-X
still	B-X
remains	B-X
small	B-X
relative	B-X
to	B-X
the	B-X
number	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
through	B-X
complete	B-X
genomic	B-X
sequencing	B-X
.	B-X
It	B-X
can	B-X
be	B-X
anticipated	B-X
that	B-X
the	B-X
factors	B-X
listed	B-X
and	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
probably	B-X
represent	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
accessory	B-X
molecules	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
regulators	B-X
and	B-X
accessory	B-X
molecules	B-X
for	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
families	B-X
has	B-X
allowed	B-X
investigators	B-X
to	B-X
elaborate	B-X
themes	B-X
and	B-X
develop	B-X
a	B-X
framework	B-X
for	B-X
a	B-X
mechanistic	B-X
understanding	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
themes	B-X
are	B-X
highlighted	B-X
in	B-X
this	B-X
review	B-X
,	B-X
which	B-X
aims	B-X
to	B-X
concentrate	B-X
on	B-X
Rab	B-X
and	B-X
Arf	B-X
function	B-X
in	B-X
exocytosis	B-X
.	B-X

However	O
,	O
the	O
list	O
of	O
known	O
Rab	O
and	O
Arf	O
interacting	O
factors	O
still	O
remains	O
small	O
relative	O
to	O
the	O
number	O
of	O
these	O
small	O
GTPases	O
that	O
have	O
been	O
identified	O
through	O
complete	O
genomic	O
sequencing	O
.	O

It	O
can	O
be	O
anticipated	O
that	O
the	O
factors	O
listed	O
and	O
discussed	O
in	O
this	O
review	O
probably	O
represent	O
a	O
small	O
fraction	O
of	O
the	O
Rab	O
and	O
Arf	O
accessory	O
molecules	O
that	O
remain	O
to	O
be	O
discovered	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
governing	B-X
of	B-X
Rab	B-X
and	B-X
Arf	B-X
protein	B-X
function	B-X
has	B-X
exploded	B-X
in	B-X
recent	B-X
years	B-X
with	B-X
a	B-X
convergence	B-X
of	B-X
information	B-X
from	B-X
model	B-X
genetic	B-X
organisms	B-X
,	B-X
biochemical	B-X
studies	B-X
,	B-X
cell	B-X
biological	B-X
observations	B-X
and	B-X
protein	B-X
structural	B-X
information	B-X
.	B-X
However	B-X
,	B-X
the	B-X
list	B-X
of	B-X
known	B-X
Rab	B-X
and	B-X
Arf	B-X
interacting	B-X
factors	B-X
still	B-X
remains	B-X
small	B-X
relative	B-X
to	B-X
the	B-X
number	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
through	B-X
complete	B-X
genomic	B-X
sequencing	B-X
.	B-X
It	B-X
can	B-X
be	B-X
anticipated	B-X
that	B-X
the	B-X
factors	B-X
listed	B-X
and	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
probably	B-X
represent	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
accessory	B-X
molecules	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
regulators	B-X
and	B-X
accessory	B-X
molecules	B-X
for	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
families	B-X
has	B-X
allowed	B-X
investigators	B-X
to	B-X
elaborate	B-X
themes	B-X
and	B-X
develop	B-X
a	B-X
framework	B-X
for	B-X
a	B-X
mechanistic	B-X
understanding	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
themes	B-X
are	B-X
highlighted	B-X
in	B-X
this	B-X
review	B-X
,	B-X
which	B-X
aims	B-X
to	B-X
concentrate	B-X
on	B-X
Rab	B-X
and	B-X
Arf	B-X
function	B-X
in	B-X
exocytosis	B-X
.	B-X

The	O
identification	O
of	O
regulators	O
and	O
accessory	O
molecules	O
for	O
the	O
Rab	O
and	O
Arf	O
families	O
has	O
allowed	O
investigators	O
to	O
elaborate	O
themes	O
and	O
develop	O
a	O
framework	O
for	O
a	O
mechanistic	O
understanding	O
of	O
these	O
proteins	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
governing	B-X
of	B-X
Rab	B-X
and	B-X
Arf	B-X
protein	B-X
function	B-X
has	B-X
exploded	B-X
in	B-X
recent	B-X
years	B-X
with	B-X
a	B-X
convergence	B-X
of	B-X
information	B-X
from	B-X
model	B-X
genetic	B-X
organisms	B-X
,	B-X
biochemical	B-X
studies	B-X
,	B-X
cell	B-X
biological	B-X
observations	B-X
and	B-X
protein	B-X
structural	B-X
information	B-X
.	B-X
However	B-X
,	B-X
the	B-X
list	B-X
of	B-X
known	B-X
Rab	B-X
and	B-X
Arf	B-X
interacting	B-X
factors	B-X
still	B-X
remains	B-X
small	B-X
relative	B-X
to	B-X
the	B-X
number	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
through	B-X
complete	B-X
genomic	B-X
sequencing	B-X
.	B-X
It	B-X
can	B-X
be	B-X
anticipated	B-X
that	B-X
the	B-X
factors	B-X
listed	B-X
and	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
probably	B-X
represent	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
accessory	B-X
molecules	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
regulators	B-X
and	B-X
accessory	B-X
molecules	B-X
for	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
families	B-X
has	B-X
allowed	B-X
investigators	B-X
to	B-X
elaborate	B-X
themes	B-X
and	B-X
develop	B-X
a	B-X
framework	B-X
for	B-X
a	B-X
mechanistic	B-X
understanding	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
themes	B-X
are	B-X
highlighted	B-X
in	B-X
this	B-X
review	B-X
,	B-X
which	B-X
aims	B-X
to	B-X
concentrate	B-X
on	B-X
Rab	B-X
and	B-X
Arf	B-X
function	B-X
in	B-X
exocytosis	B-X
.	B-X

The	O
themes	O
are	O
highlighted	O
in	O
this	O
review	O
,	O
which	O
aims	O
to	O
concentrate	O
on	O
Rab	O
and	O
Arf	O
function	O
in	O
exocytosis	O
.	O
<EOS>	B-X
Our	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
governing	B-X
of	B-X
Rab	B-X
and	B-X
Arf	B-X
protein	B-X
function	B-X
has	B-X
exploded	B-X
in	B-X
recent	B-X
years	B-X
with	B-X
a	B-X
convergence	B-X
of	B-X
information	B-X
from	B-X
model	B-X
genetic	B-X
organisms	B-X
,	B-X
biochemical	B-X
studies	B-X
,	B-X
cell	B-X
biological	B-X
observations	B-X
and	B-X
protein	B-X
structural	B-X
information	B-X
.	B-X
However	B-X
,	B-X
the	B-X
list	B-X
of	B-X
known	B-X
Rab	B-X
and	B-X
Arf	B-X
interacting	B-X
factors	B-X
still	B-X
remains	B-X
small	B-X
relative	B-X
to	B-X
the	B-X
number	B-X
of	B-X
these	B-X
small	B-X
GTPases	B-X
that	B-X
have	B-X
been	B-X
identified	B-X
through	B-X
complete	B-X
genomic	B-X
sequencing	B-X
.	B-X
It	B-X
can	B-X
be	B-X
anticipated	B-X
that	B-X
the	B-X
factors	B-X
listed	B-X
and	B-X
discussed	B-X
in	B-X
this	B-X
review	B-X
probably	B-X
represent	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
accessory	B-X
molecules	B-X
that	B-X
remain	B-X
to	B-X
be	B-X
discovered	B-X
.	B-X
The	B-X
identification	B-X
of	B-X
regulators	B-X
and	B-X
accessory	B-X
molecules	B-X
for	B-X
the	B-X
Rab	B-X
and	B-X
Arf	B-X
families	B-X
has	B-X
allowed	B-X
investigators	B-X
to	B-X
elaborate	B-X
themes	B-X
and	B-X
develop	B-X
a	B-X
framework	B-X
for	B-X
a	B-X
mechanistic	B-X
understanding	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
The	B-X
themes	B-X
are	B-X
highlighted	B-X
in	B-X
this	B-X
review	B-X
,	B-X
which	B-X
aims	B-X
to	B-X
concentrate	B-X
on	B-X
Rab	B-X
and	B-X
Arf	B-X
function	B-X
in	B-X
exocytosis	B-X
.	B-X

Studies	O
on	O
G	O
-	O
protein	O
alpha	O
.	O
betagamma	O
heterotrimer	O
formation	O
reveal	O
a	O
putative	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
the	O
alpha	O
subunit	O
.	O

The	O
alpha	O
and	O
betagamma	O
subunits	O
of	O
heterotrimeric	O
G	O
-	O
proteins	O
contain	O
specific	O
lipid	O
modifications	O
,	O
which	O
are	O
required	O
for	O
their	O
biological	O
function	O
.	O
<EOS>	B-X
The	B-X
alpha	B-X
and	B-X
betagamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
contain	B-X
specific	B-X
lipid	B-X
modifications	B-X
,	B-X
which	B-X
are	B-X
required	B-X
for	B-X
their	B-X
biological	B-X
function	B-X
.	B-X
However	B-X
,	B-X
the	B-X
relevance	B-X
of	B-X
these	B-X
modifications	B-X
to	B-X
the	B-X
interactions	B-X
within	B-X
the	B-X
heterotrimeric	B-X
G-protein	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
the	B-X
S-prenyl	B-X
moiety	B-X
of	B-X
the	B-X
isoprenylated	B-X
betagamma	B-X
dimer	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
,	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
heterotrimeric	B-X
complex	B-X
with	B-X
the	B-X
corresponding	B-X
N-acylated	B-X
alpha	B-X
subunit	B-X
,	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
we	B-X
employed	B-X
purified	B-X
fully	B-X
processed	B-X
subunits	B-X
,	B-X
which	B-X
are	B-X
soluble	B-X
in	B-X
aqueous	B-X
solutions	B-X
without	B-X
detergents	B-X
.	B-X
Pertussis-toxin-mediated	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
is	B-X
strongly	B-X
stimulated	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
and	B-X
can	B-X
thus	B-X
serve	B-X
as	B-X
a	B-X
measure	B-X
for	B-X
heterotrimer	B-X
formation	B-X
.	B-X
Using	B-X
this	B-X
assay	B-X
,	B-X
preincubation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
with	B-X
S-prenyl	B-X
analogues	B-X
containing	B-X
farnesyl	B-X
or	B-X
geranylgeranyl	B-X
moieties	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
heterotrimer	B-X
formation	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
The	B-X
inhibition	B-X
was	B-X
competitive	B-X
and	B-X
reversible	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
its	B-X
reversal	B-X
upon	B-X
increase	B-X
of	B-X
the	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
dimer	B-X
concentration	B-X
or	B-X
by	B-X
removal	B-X
of	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
using	B-X
gel	B-X
filtration	B-X
.	B-X
The	B-X
competitive	B-X
nature	B-X
of	B-X
the	B-X
inhibition	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
marked	B-X
attenuation	B-X
of	B-X
the	B-X
inhibition	B-X
when	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
was	B-X
added	B-X
to	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
together	B-X
with	B-X
or	B-X
after	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X
The	B-X
inhibition	B-X
does	B-X
not	B-X
involve	B-X
interaction	B-X
with	B-X
the	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
acyl	B-X
group	B-X
,	B-X
since	B-X
an	B-X
S-prenyl	B-X
analogue	B-X
inhibited	B-X
the	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
an	B-X
unlipidated	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
S-prenyl-binding	B-X
site	B-X
in	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
which	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
prenylated	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X

However	O
,	O
the	O
relevance	O
of	O
these	O
modifications	O
to	O
the	O
interactions	O
within	O
the	O
heterotrimeric	O
G	O
-	O
protein	O
is	O
not	O
fully	O
understood	O
.	O

In	O
order	O
to	O
explore	O
the	O
role	O
of	O
the	O
S	O
-	O
prenyl	O
moiety	O
of	O
the	O
isoprenylated	O
betagamma	O
dimer	O
of	O
retinal	O
transducin	O
,	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
,	O
in	O
the	O
formation	O
of	O
the	O
heterotrimeric	O
complex	O
with	O
the	O
corresponding	O
N	O
-	O
acylated	O
alpha	O
subunit	O
,	O
alpha	O
(	O
t	O
)	O
,	O
we	O
employed	O
purified	O
fully	O
processed	O
subunits	O
,	O
which	O
are	O
soluble	O
in	O
aqueous	O
solutions	O
without	O
detergents	O
.	O

Pertussis	O
-	O
toxin	O
-	O
mediated	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
alpha	O
(	O
t	O
)	O
is	O
strongly	O
stimulated	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
in	O
the	O
presence	O
of	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
and	O
can	O
thus	O
serve	O
as	O
a	O
measure	O
for	O
heterotrimer	O
formation	O
.	O

Using	O
this	O
assay	O
,	O
preincubation	O
of	O
alpha	O
(	O
t	O
)	O
with	O
S	O
-	O
prenyl	O
analogues	O
containing	O
farnesyl	O
or	O
geranylgeranyl	O
moieties	O
was	O
found	O
to	O
inhibit	O
heterotrimer	O
formation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
was	O
competitive	O
and	O
reversible	O
,	O
as	O
indicated	O
by	O
its	O
reversal	O
upon	O
increase	O
of	O
the	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
dimer	O
concentration	O
or	O
by	O
removal	O
of	O
the	O
S	O
-	O
prenyl	O
analogue	O
using	O
gel	O
filtration	O
.	O
<EOS>	B-X
The	B-X
alpha	B-X
and	B-X
betagamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
contain	B-X
specific	B-X
lipid	B-X
modifications	B-X
,	B-X
which	B-X
are	B-X
required	B-X
for	B-X
their	B-X
biological	B-X
function	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
the	B-X
S-prenyl	B-X
moiety	B-X
of	B-X
the	B-X
isoprenylated	B-X
betagamma	B-X
dimer	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
,	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
heterotrimeric	B-X
complex	B-X
with	B-X
the	B-X
corresponding	B-X
N-acylated	B-X
alpha	B-X
subunit	B-X
,	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
we	B-X
employed	B-X
purified	B-X
fully	B-X
processed	B-X
subunits	B-X
,	B-X
which	B-X
are	B-X
soluble	B-X
in	B-X
aqueous	B-X
solutions	B-X
without	B-X
detergents	B-X
.	B-X
Pertussis-toxin-mediated	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
is	B-X
strongly	B-X
stimulated	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
and	B-X
can	B-X
thus	B-X
serve	B-X
as	B-X
a	B-X
measure	B-X
for	B-X
heterotrimer	B-X
formation	B-X
.	B-X
Using	B-X
this	B-X
assay	B-X
,	B-X
preincubation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
with	B-X
S-prenyl	B-X
analogues	B-X
containing	B-X
farnesyl	B-X
or	B-X
geranylgeranyl	B-X
moieties	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
heterotrimer	B-X
formation	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
The	B-X
inhibition	B-X
was	B-X
competitive	B-X
and	B-X
reversible	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
its	B-X
reversal	B-X
upon	B-X
increase	B-X
of	B-X
the	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
dimer	B-X
concentration	B-X
or	B-X
by	B-X
removal	B-X
of	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
using	B-X
gel	B-X
filtration	B-X
.	B-X
The	B-X
competitive	B-X
nature	B-X
of	B-X
the	B-X
inhibition	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
marked	B-X
attenuation	B-X
of	B-X
the	B-X
inhibition	B-X
when	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
was	B-X
added	B-X
to	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
together	B-X
with	B-X
or	B-X
after	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X
The	B-X
inhibition	B-X
does	B-X
not	B-X
involve	B-X
interaction	B-X
with	B-X
the	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
acyl	B-X
group	B-X
,	B-X
since	B-X
an	B-X
S-prenyl	B-X
analogue	B-X
inhibited	B-X
the	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
an	B-X
unlipidated	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
S-prenyl-binding	B-X
site	B-X
in	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
which	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
prenylated	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X

The	O
competitive	O
nature	O
of	O
the	O
inhibition	O
is	O
supported	O
by	O
the	O
marked	O
attenuation	O
of	O
the	O
inhibition	O
when	O
the	O
S	O
-	O
prenyl	O
analogue	O
was	O
added	O
to	O
alpha	O
(	O
t	O
)	O
together	O
with	O
or	O
after	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
a	B-X
natural	B-X
soluble	B-X
form	B-X
of	B-X
IL-15R	B-X
alpha	B-X
chain	B-X
corresponding	B-X
to	B-X
the	B-X
entire	B-X
extracellular	B-X
domain	B-X
of	B-X
IL-15R	B-X
alpha	B-X
behaves	B-X
as	B-X
a	B-X
high	B-X
affinity	B-X
IL-15	B-X
antagonist	B-X
.	B-X
In	B-X
sharp	B-X
contrast	B-X
with	B-X
this	B-X
finding	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
this	B-X
report	B-X
that	B-X
a	B-X
recombinant	B-X
,	B-X
soluble	B-X
sushi	B-X
domain	B-X
of	B-X
IL-15R	B-X
alpha	B-X
,	B-X
which	B-X
bears	B-X
most	B-X
of	B-X
the	B-X
binding	B-X
affinity	B-X
for	B-X
IL-15	B-X
,	B-X
behaves	B-X
as	B-X
a	B-X
potent	B-X
IL-15	B-X
agonist	B-X
by	B-X
enhancing	B-X
its	B-X
binding	B-X
and	B-X
biological	B-X
effects	B-X
(	B-X
proliferation	B-X
and	B-X
protection	B-X
from	B-X
apoptosis	B-X
)	B-X
through	B-X
the	B-X
IL-15R	B-X
beta/gamma	B-X
heterodimer	B-X
,	B-X
whereas	B-X
it	B-X
does	B-X
not	B-X
affect	B-X
IL-15	B-X
binding	B-X
and	B-X
function	B-X
of	B-X
the	B-X
tripartite	B-X
IL-15R	B-X
alpha/beta/gamma	B-X
membrane	B-X
receptor	B-X
.	B-X
Fusion	B-X
proteins	B-X
(	B-X
RLI	B-X
and	B-X
ILR	B-X
)	B-X
,	B-X
in	B-X
which	B-X
IL-15	B-X
and	B-X
IL-15R	B-X
alpha-sushi	B-X
are	B-X
attached	B-X
by	B-X
a	B-X
flexible	B-X
linker	B-X
,	B-X
are	B-X
even	B-X
more	B-X
potent	B-X
than	B-X
the	B-X
combination	B-X
of	B-X
IL-15	B-X
plus	B-X
sIL-15R	B-X
alpha-sushi	B-X
.	B-X
IL-15	B-X
is	B-X
normally	B-X
presented	B-X
in	B-X
vivo	B-X
as	B-X
a	B-X
cell-associated	B-X
cytokine	B-X
bound	B-X
to	B-X
IL-15Ralpha	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
biological	B-X
activity	B-X
of	B-X
soluble	B-X
IL-15	B-X
is	B-X
much	B-X
improved	B-X
after	B-X
interaction	B-X
with	B-X
recombinant	B-X
soluble	B-X
IL-15Ralpha	B-X
;	B-X
after	B-X
injection	B-X
,	B-X
soluble	B-X
IL-15/IL-15Ralpha	B-X
complexes	B-X
rapidly	B-X
induce	B-X
strong	B-X
and	B-X
selective	B-X
expansion	B-X
of	B-X
memory-phenotype	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
cells	B-X
and	B-X
natural	B-X
killer	B-X
cells	B-X
.	B-X
These	B-X
findings	B-X
imply	B-X
that	B-X
binding	B-X
of	B-X
IL-15Ralpha	B-X
to	B-X
IL-15	B-X
may	B-X
create	B-X
a	B-X
conformational	B-X
change	B-X
that	B-X
potentiates	B-X
IL-15	B-X
recognition	B-X
by	B-X
the	B-X
betagamma	B-X
(	B-X
c	B-X
)	B-X
receptor	B-X
on	B-X
T	B-X
cells	B-X
.	B-X
The	B-X
enhancing	B-X
effect	B-X
of	B-X
IL-15Ralpha	B-X
binding	B-X
may	B-X
explain	B-X
why	B-X
IL-15	B-X
normally	B-X
functions	B-X
as	B-X
a	B-X
cell-associated	B-X
cytokine	B-X
.	B-X
Significantly	B-X
,	B-X
the	B-X
results	B-X
with	B-X
IL-2	B-X
,	B-X
a	B-X
soluble	B-X
cytokine	B-X
,	B-X
are	B-X
quite	B-X
different	B-X
;	B-X
thus	B-X
,	B-X
IL-2	B-X
function	B-X
is	B-X
markedly	B-X
inhibited	B-X
by	B-X
binding	B-X
to	B-X
soluble	B-X
IL-2Ralpha	B-X
.	B-X

The	O
inhibition	O
does	O
not	O
involve	O
interaction	O
with	O
the	O
alpha	O
(	O
t	O
)	O
acyl	O
group	O
,	O
since	O
an	O
S	O
-	O
prenyl	O
analogue	O
inhibited	O
the	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
an	O
unlipidated	O
alpha	O
(	O
t	O
)	O
mutant	O
.	O

These	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
hitherto	O
unrecognized	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
alpha	O
(	O
t	O
)	O
,	O
which	O
is	O
critical	O
for	O
its	O
interaction	O
with	O
prenylated	O
betagamma	B-Protein
(	I-Protein
t	I-Protein
)	I-Protein
.	O
<EOS>	B-X
The	B-X
alpha	B-X
and	B-X
betagamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G-proteins	B-X
contain	B-X
specific	B-X
lipid	B-X
modifications	B-X
,	B-X
which	B-X
are	B-X
required	B-X
for	B-X
their	B-X
biological	B-X
function	B-X
.	B-X
However	B-X
,	B-X
the	B-X
relevance	B-X
of	B-X
these	B-X
modifications	B-X
to	B-X
the	B-X
interactions	B-X
within	B-X
the	B-X
heterotrimeric	B-X
G-protein	B-X
is	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
In	B-X
order	B-X
to	B-X
explore	B-X
the	B-X
role	B-X
of	B-X
the	B-X
S-prenyl	B-X
moiety	B-X
of	B-X
the	B-X
isoprenylated	B-X
betagamma	B-X
dimer	B-X
of	B-X
retinal	B-X
transducin	B-X
,	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
,	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
heterotrimeric	B-X
complex	B-X
with	B-X
the	B-X
corresponding	B-X
N-acylated	B-X
alpha	B-X
subunit	B-X
,	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
we	B-X
employed	B-X
purified	B-X
fully	B-X
processed	B-X
subunits	B-X
,	B-X
which	B-X
are	B-X
soluble	B-X
in	B-X
aqueous	B-X
solutions	B-X
without	B-X
detergents	B-X
.	B-X
Pertussis-toxin-mediated	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
is	B-X
strongly	B-X
stimulated	B-X
(	B-X
approximately	B-X
10-fold	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
and	B-X
can	B-X
thus	B-X
serve	B-X
as	B-X
a	B-X
measure	B-X
for	B-X
heterotrimer	B-X
formation	B-X
.	B-X
Using	B-X
this	B-X
assay	B-X
,	B-X
preincubation	B-X
of	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
with	B-X
S-prenyl	B-X
analogues	B-X
containing	B-X
farnesyl	B-X
or	B-X
geranylgeranyl	B-X
moieties	B-X
was	B-X
found	B-X
to	B-X
inhibit	B-X
heterotrimer	B-X
formation	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
The	B-X
inhibition	B-X
was	B-X
competitive	B-X
and	B-X
reversible	B-X
,	B-X
as	B-X
indicated	B-X
by	B-X
its	B-X
reversal	B-X
upon	B-X
increase	B-X
of	B-X
the	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
dimer	B-X
concentration	B-X
or	B-X
by	B-X
removal	B-X
of	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
using	B-X
gel	B-X
filtration	B-X
.	B-X
The	B-X
competitive	B-X
nature	B-X
of	B-X
the	B-X
inhibition	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
marked	B-X
attenuation	B-X
of	B-X
the	B-X
inhibition	B-X
when	B-X
the	B-X
S-prenyl	B-X
analogue	B-X
was	B-X
added	B-X
to	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
together	B-X
with	B-X
or	B-X
after	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X
The	B-X
inhibition	B-X
does	B-X
not	B-X
involve	B-X
interaction	B-X
with	B-X
the	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
acyl	B-X
group	B-X
,	B-X
since	B-X
an	B-X
S-prenyl	B-X
analogue	B-X
inhibited	B-X
the	B-X
[	B-X
(	B-X
32	B-X
)	B-X
P	B-X
]	B-X
ADP-ribosylation	B-X
of	B-X
an	B-X
unlipidated	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
mutant	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
hitherto	B-X
unrecognized	B-X
S-prenyl-binding	B-X
site	B-X
in	B-X
alpha	B-X
(	B-X
t	B-X
)	B-X
,	B-X
which	B-X
is	B-X
critical	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
prenylated	B-X
betagamma	B-X
(	B-X
t	B-X
)	B-X
.	B-X

Retroviral	O
insertional	O
mutagenesis	O
identifies	O
a	O
small	O
protein	O
required	O
for	O
synthesis	O
of	O
diphthamide	O
,	O
the	O
target	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O
<EOS>	B-X
Retroviral	B-X
insertional	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
mutant	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cell	B-X
line	B-X
that	B-X
is	B-X
completely	B-X
resistant	B-X
to	B-X
several	B-X
different	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X
The	B-X
gene	B-X
responsible	B-X
for	B-X
toxin	B-X
resistance	B-X
,	B-X
termed	B-X
diphtheria	B-X
toxin	B-X
(	B-X
DT	B-X
)	B-X
and	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
(	B-X
ETA	B-X
)	B-X
sensitivity	B-X
required	B-X
gene	B-X
1	B-X
(	B-X
DESR1	B-X
)	B-X
,	B-X
encodes	B-X
two	B-X
small	B-X
protein	B-X
isoforms	B-X
of	B-X
82	B-X
and	B-X
57	B-X
residues	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X
KTI11	B-X
,	B-X
the	B-X
analog	B-X
of	B-X
DESR1	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
regulating	B-X
the	B-X
sensitivity	B-X
of	B-X
yeast	B-X
to	B-X
zymocin	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
diphthamide	B-X
biosynthesis	B-X
,	B-X
implicating	B-X
DESR1/KTI11	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
.	B-X

Retroviral	O
insertional	O
mutagenesis	O
was	O
used	O
to	O
produce	O
a	O
mutant	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
that	O
is	O
completely	O
resistant	O
to	O
several	O
different	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O
<EOS>	B-X
Retroviral	B-X
insertional	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
mutant	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cell	B-X
line	B-X
that	B-X
is	B-X
completely	B-X
resistant	B-X
to	B-X
several	B-X
different	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X
Only	B-X
the	B-X
longer	B-X
isoform	B-X
is	B-X
functional	B-X
because	B-X
the	B-X
mutant	B-X
cell	B-X
line	B-X
can	B-X
be	B-X
complemented	B-X
by	B-X
transfection	B-X
with	B-X
the	B-X
long	B-X
but	B-X
not	B-X
the	B-X
short	B-X
isoform	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X

The	O
gene	O
responsible	O
for	O
toxin	O
resistance	O
,	O
termed	O
diphtheria	B-Protein
toxin	I-Protein
(	I-Protein
DT	I-Protein
)	I-Protein
and	I-Protein
Pseudomonas	I-Protein
exotoxin	I-Protein
A	I-Protein
(	I-Protein
ETA	I-Protein
)	I-Protein
sensitivity	I-Protein
required	I-Protein
gene	I-Protein
1	I-Protein
(	O
DESR1	B-Protein
)	O
,	O
encodes	O
two	O
small	O
protein	O
isoforms	O
of	O
82	O
and	O
57	O
residues	O
.	O
<EOS>	B-X
Retroviral	B-X
insertional	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
mutant	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cell	B-X
line	B-X
that	B-X
is	B-X
completely	B-X
resistant	B-X
to	B-X
several	B-X
different	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X
The	B-X
gene	B-X
responsible	B-X
for	B-X
toxin	B-X
resistance	B-X
,	B-X
termed	B-X
diphtheria	B-X
toxin	B-X
(	B-X
DT	B-X
)	B-X
and	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
(	B-X
ETA	B-X
)	B-X
sensitivity	B-X
required	B-X
gene	B-X
1	B-X
(	B-X
DESR1	B-X
)	B-X
,	B-X
encodes	B-X
two	B-X
small	B-X
protein	B-X
isoforms	B-X
of	B-X
82	B-X
and	B-X
57	B-X
residues	B-X
.	B-X
DESR1	B-X
is	B-X
evolutionally	B-X
conserved	B-X
and	B-X
ubiquitously	B-X
expressed	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X
KTI11	B-X
,	B-X
the	B-X
analog	B-X
of	B-X
DESR1	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
regulating	B-X
the	B-X
sensitivity	B-X
of	B-X
yeast	B-X
to	B-X
zymocin	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
diphthamide	B-X
biosynthesis	B-X
,	B-X
implicating	B-X
DESR1/KTI11	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
.	B-X

DESR1	B-Protein
is	O
evolutionally	O
conserved	O
and	O
ubiquitously	O
expressed	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
responsible	B-X
for	B-X
toxin	B-X
resistance	B-X
,	B-X
termed	B-X
diphtheria	B-X
toxin	B-X
(	B-X
DT	B-X
)	B-X
and	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
(	B-X
ETA	B-X
)	B-X
sensitivity	B-X
required	B-X
gene	B-X
1	B-X
(	B-X
DESR1	B-X
)	B-X
,	B-X
encodes	B-X
two	B-X
small	B-X
protein	B-X
isoforms	B-X
of	B-X
82	B-X
and	B-X
57	B-X
residues	B-X
.	B-X
DESR1	B-X
is	B-X
evolutionally	B-X
conserved	B-X
and	B-X
ubiquitously	B-X
expressed	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X
KTI11	B-X
,	B-X
the	B-X
analog	B-X
of	B-X
DESR1	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
regulating	B-X
the	B-X
sensitivity	B-X
of	B-X
yeast	B-X
to	B-X
zymocin	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
diphthamide	B-X
biosynthesis	B-X
,	B-X
implicating	B-X
DESR1/KTI11	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
.	B-X

Only	O
the	O
longer	O
isoform	O
is	O
functional	O
because	O
the	O
mutant	O
cell	O
line	O
can	O
be	O
complemented	O
by	O
transfection	O
with	O
the	O
long	O
but	O
not	O
the	O
short	O
isoform	O
.	O

We	O
demonstrate	O
that	O
DESR1	B-Protein
is	O
required	O
for	O
the	O
first	O
step	O
in	O
the	O
posttranslational	O
modification	O
of	O
elongation	B-Protein
factor	I-Protein
-	I-Protein
2	I-Protein
at	O
His	O
(	O
715	O
)	O
that	O
yields	O
diphthamide	O
,	O
the	O
target	O
site	O
for	O
ADP	O
ribosylation	O
by	O
DT	B-Protein
and	O
ETA	B-Protein
.	O
<EOS>	B-X
Retroviral	B-X
insertional	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
mutant	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cell	B-X
line	B-X
that	B-X
is	B-X
completely	B-X
resistant	B-X
to	B-X
several	B-X
different	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X
The	B-X
gene	B-X
responsible	B-X
for	B-X
toxin	B-X
resistance	B-X
,	B-X
termed	B-X
diphtheria	B-X
toxin	B-X
(	B-X
DT	B-X
)	B-X
and	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
(	B-X
ETA	B-X
)	B-X
sensitivity	B-X
required	B-X
gene	B-X
1	B-X
(	B-X
DESR1	B-X
)	B-X
,	B-X
encodes	B-X
two	B-X
small	B-X
protein	B-X
isoforms	B-X
of	B-X
82	B-X
and	B-X
57	B-X
residues	B-X
.	B-X
DESR1	B-X
is	B-X
evolutionally	B-X
conserved	B-X
and	B-X
ubiquitously	B-X
expressed	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X
KTI11	B-X
,	B-X
the	B-X
analog	B-X
of	B-X
DESR1	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
regulating	B-X
the	B-X
sensitivity	B-X
of	B-X
yeast	B-X
to	B-X
zymocin	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
diphthamide	B-X
biosynthesis	B-X
,	B-X
implicating	B-X
DESR1/KTI11	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
.	B-X

KTI11	B-Protein
,	O
the	O
analog	O
of	O
DESR1	B-Protein
in	O
yeast	O
,	O
which	O
was	O
originally	O
identified	O
as	O
a	O
gene	O
regulating	O
the	O
sensitivity	O
of	O
yeast	O
to	O
zymocin	O
,	O
is	O
also	O
required	O
for	O
diphthamide	O
biosynthesis	O
,	O
implicating	O
DESR1	B-Protein
/	O
KTI11	B-Protein
in	O
multiple	O
biological	O
processes	O
.	O
<EOS>	B-X
Retroviral	B-X
insertional	B-X
mutagenesis	B-X
was	B-X
used	B-X
to	B-X
produce	B-X
a	B-X
mutant	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cell	B-X
line	B-X
that	B-X
is	B-X
completely	B-X
resistant	B-X
to	B-X
several	B-X
different	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X
The	B-X
gene	B-X
responsible	B-X
for	B-X
toxin	B-X
resistance	B-X
,	B-X
termed	B-X
diphtheria	B-X
toxin	B-X
(	B-X
DT	B-X
)	B-X
and	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
(	B-X
ETA	B-X
)	B-X
sensitivity	B-X
required	B-X
gene	B-X
1	B-X
(	B-X
DESR1	B-X
)	B-X
,	B-X
encodes	B-X
two	B-X
small	B-X
protein	B-X
isoforms	B-X
of	B-X
82	B-X
and	B-X
57	B-X
residues	B-X
.	B-X
DESR1	B-X
is	B-X
evolutionally	B-X
conserved	B-X
and	B-X
ubiquitously	B-X
expressed	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
DESR1	B-X
is	B-X
required	B-X
for	B-X
the	B-X
first	B-X
step	B-X
in	B-X
the	B-X
posttranslational	B-X
modification	B-X
of	B-X
elongation	B-X
factor-2	B-X
at	B-X
His	B-X
(	B-X
715	B-X
)	B-X
that	B-X
yields	B-X
diphthamide	B-X
,	B-X
the	B-X
target	B-X
site	B-X
for	B-X
ADP	B-X
ribosylation	B-X
by	B-X
DT	B-X
and	B-X
ETA	B-X
.	B-X
KTI11	B-X
,	B-X
the	B-X
analog	B-X
of	B-X
DESR1	B-X
in	B-X
yeast	B-X
,	B-X
which	B-X
was	B-X
originally	B-X
identified	B-X
as	B-X
a	B-X
gene	B-X
regulating	B-X
the	B-X
sensitivity	B-X
of	B-X
yeast	B-X
to	B-X
zymocin	B-X
,	B-X
is	B-X
also	B-X
required	B-X
for	B-X
diphthamide	B-X
biosynthesis	B-X
,	B-X
implicating	B-X
DESR1/KTI11	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
.	B-X

The	O
redox	O
domain	O
of	O
the	O
Yap1p	B-Protein
transcription	O
factor	O
contains	O
two	O
disulfide	O
bonds	O
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
These	B-X
peptides	B-X
are	B-X
separated	B-X
by	B-X
250	B-X
amino	B-X
acids	B-X
and	B-X
are	B-X
joined	B-X
by	B-X
the	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
disulfide	B-X
bonds	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

The	O
subcellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
transcription	O
factor	O
Yap1p	B-Protein
is	O
regulated	O
by	O
oxidation	O
and	O
reduction	O
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

We	O
purified	O
Yap1p	B-Protein
from	O
yeast	O
and	O
characterized	O
its	O
properties	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
purified	B-X
protein	B-X
can	B-X
specifically	B-X
bind	B-X
the	B-X
TRX2	B-X
target	B-X
promoter	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
purified	O
protein	O
can	O
specifically	O
bind	O
the	O
TRX2	B-Protein
target	O
promoter	O
.	O
<EOS>	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
purified	B-X
protein	B-X
can	B-X
specifically	B-X
bind	B-X
the	B-X
TRX2	B-X
target	B-X
promoter	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X

Yap1p	B-Protein
was	O
purified	O
under	O
reducing	O
conditions	O
,	O
but	O
removal	O
of	O
reducing	O
agents	O
resulted	O
in	O
the	O
formation	O
of	O
an	O
oxidized	O
Yap1p	B-Protein
species	O
with	O
properties	O
similar	O
to	O
in	O
vivo	O
oxidized	O
Yap1p	B-Protein
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
purified	B-X
protein	B-X
can	B-X
specifically	B-X
bind	B-X
the	B-X
TRX2	B-X
target	B-X
promoter	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
revealed	O
that	O
the	O
oxidized	O
form	O
of	O
Yap1p	B-Protein
contains	O
two	O
disulfide	O
bonds	O
between	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
These	B-X
peptides	B-X
are	B-X
separated	B-X
by	B-X
250	B-X
amino	B-X
acids	B-X
and	B-X
are	B-X
joined	B-X
by	B-X
the	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
disulfide	B-X
bonds	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

A	O
stable	O
domain	O
of	O
approximately	O
15	O
kDa	O
was	O
detected	O
upon	O
limited	O
proteolysis	O
of	O
oxidized	O
but	O
not	O
reduced	O
Yap1p	B-Protein
.	O

This	O
Yap1p	B-Protein
protease	O
resistant	O
domain	O
was	O
purified	O
,	O
and	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
analysis	O
showed	O
that	O
it	O
was	O
comprised	O
of	O
two	O
separate	O
cysteine	O
-	O
containing	O
peptides	O
of	O
Yap1p	B-Protein
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Electrophoretic	B-X
mobility	B-X
shift	B-X
assays	B-X
showed	B-X
that	B-X
the	B-X
purified	B-X
protein	B-X
can	B-X
specifically	B-X
bind	B-X
the	B-X
TRX2	B-X
target	B-X
promoter	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
These	B-X
peptides	B-X
are	B-X
separated	B-X
by	B-X
250	B-X
amino	B-X
acids	B-X
and	B-X
are	B-X
joined	B-X
by	B-X
the	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
disulfide	B-X
bonds	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

These	O
peptides	O
are	O
separated	O
by	O
250	O
amino	O
acids	O
and	O
are	O
joined	O
by	O
the	O
C303	O
-	O
C598	O
and	O
C310	O
-	O
C629	O
disulfide	O
bonds	O
.	O
<EOS>	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
These	B-X
peptides	B-X
are	B-X
separated	B-X
by	B-X
250	B-X
amino	B-X
acids	B-X
and	B-X
are	B-X
joined	B-X
by	B-X
the	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
disulfide	B-X
bonds	B-X
.	B-X

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
domain	O
that	O
controls	O
Yap1p	B-Protein
subcellular	O
localization	O
is	O
modular	O
and	O
contains	O
a	O
redox	O
center	O
comprised	O
of	O
four	O
cysteine	O
residues	O
.	O
<EOS>	B-X
The	B-X
subcellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
transcription	B-X
factor	B-X
Yap1p	B-X
is	B-X
regulated	B-X
by	B-X
oxidation	B-X
and	B-X
reduction	B-X
.	B-X
We	B-X
purified	B-X
Yap1p	B-X
from	B-X
yeast	B-X
and	B-X
characterized	B-X
its	B-X
properties	B-X
in	B-X
vitro	B-X
.	B-X
Yap1p	B-X
was	B-X
purified	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
but	B-X
removal	B-X
of	B-X
reducing	B-X
agents	B-X
resulted	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
an	B-X
oxidized	B-X
Yap1p	B-X
species	B-X
with	B-X
properties	B-X
similar	B-X
to	B-X
in	B-X
vivo	B-X
oxidized	B-X
Yap1p	B-X
.	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
revealed	B-X
that	B-X
the	B-X
oxidized	B-X
form	B-X
of	B-X
Yap1p	B-X
contains	B-X
two	B-X
disulfide	B-X
bonds	B-X
between	B-X
C303-C598	B-X
and	B-X
C310-C629	B-X
.	B-X
A	B-X
stable	B-X
domain	B-X
of	B-X
approximately	B-X
15	B-X
kDa	B-X
was	B-X
detected	B-X
upon	B-X
limited	B-X
proteolysis	B-X
of	B-X
oxidized	B-X
but	B-X
not	B-X
reduced	B-X
Yap1p	B-X
.	B-X
This	B-X
Yap1p	B-X
protease	B-X
resistant	B-X
domain	B-X
was	B-X
purified	B-X
,	B-X
and	B-X
MALDI-TOF	B-X
mass	B-X
spectrometry	B-X
analysis	B-X
showed	B-X
that	B-X
it	B-X
was	B-X
comprised	B-X
of	B-X
two	B-X
separate	B-X
cysteine-containing	B-X
peptides	B-X
of	B-X
Yap1p	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
domain	B-X
that	B-X
controls	B-X
Yap1p	B-X
subcellular	B-X
localization	B-X
is	B-X
modular	B-X
and	B-X
contains	B-X
a	B-X
redox	B-X
center	B-X
comprised	B-X
of	B-X
four	B-X
cysteine	B-X
residues	B-X
.	B-X

Rho	B-Protein
A	I-Protein
negatively	O
regulates	O
cytokine	O
-	O
mediated	O
inducible	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
expression	O
in	O
brain	O
-	O
derived	O
transformed	O
cell	O
lines	O
:	O
negative	O
regulation	O
of	O
IKKalpha	B-Protein
.	O

The	O
present	O
study	O
describes	O
the	O
role	O
of	O
RhoA	B-Protein
as	O
a	O
negative	O
regulator	O
of	O
iNOS	B-Protein
expression	O
via	O
the	O
inactivation	O
of	O
NF	O
-	O
kappaB	O
in	O
transformed	O
brain	O
cell	O
lines	O
[	O
C	O
(	O
6	O
)	O
glioma	O
,	O
human	O
astrocytoma	O
(	O
T98G	O
,	O
A172	O
)	O
,	O
neuroblastoma	O
(	O
NEB	O
)	O
,	O
and	O
immortal	O
rat	O
astrocytes	O
]	O
.	O

Treatment	O
with	O
lovastatin	O
resulted	O
in	O
the	O
induction	O
of	O
LPS	O
/	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
iNOS	B-Protein
mRNA	O
and	O
increased	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
inactivation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
transformed	B-X
brain	B-X
cell	B-X
lines	B-X
[	B-X
C	B-X
(	B-X
6	B-X
)	B-X
glioma	B-X
,	B-X
human	B-X
astrocytoma	B-X
(	B-X
T98G	B-X
,	B-X
A172	B-X
)	B-X
,	B-X
neuroblastoma	B-X
(	B-X
NEB	B-X
)	B-X
,	B-X
and	B-X
immortal	B-X
rat	B-X
astrocytes	B-X
]	B-X
.	B-X
Treatment	B-X
with	B-X
lovastatin	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
mRNA	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
mevalonate	B-X
and	B-X
geranylgeranylpyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
reversed	B-X
the	B-X
lovastatin-mediated	B-X
effect	B-X
,	B-X
whereas	B-X
FPP	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
geranylgeranyltransferase	B-X
inhibitor	B-X
(	B-X
GGTI	B-X
298	B-X
)	B-X
further	B-X
induced	B-X
the	B-X
cytokine	B-X
and	B-X
lovastatin-mediated	B-X
iNOS	B-X
expression	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
iNOS	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Inhibition	B-X
of	B-X
RhoA	B-X
resulted	B-X
in	B-X
increased	B-X
activation	B-X
of	B-X
IKKalpha	B-X
.	B-X
Cotransfection	B-X
studies	B-X
with	B-X
dominant-negative	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
iNOS-luciferase	B-X
or	B-X
NF-kappaB-luciferase	B-X
reporter	B-X
constructs	B-X
further	B-X
support	B-X
these	B-X
observations	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

The	O
addition	O
of	O
mevalonate	O
and	O
geranylgeranylpyrophosphate	O
(	O
GGPP	O
)	O
reversed	O
the	O
lovastatin	O
-	O
mediated	O
effect	O
,	O
whereas	O
FPP	O
had	O
no	O
effect	O
.	O
<EOS>	B-X
Treatment	B-X
with	B-X
lovastatin	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
mRNA	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
mevalonate	B-X
and	B-X
geranylgeranylpyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
reversed	B-X
the	B-X
lovastatin-mediated	B-X
effect	B-X
,	B-X
whereas	B-X
FPP	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
geranylgeranyltransferase	B-X
inhibitor	B-X
(	B-X
GGTI	B-X
298	B-X
)	B-X
further	B-X
induced	B-X
the	B-X
cytokine	B-X
and	B-X
lovastatin-mediated	B-X
iNOS	B-X
expression	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
iNOS	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

An	O
inhibitor	O
of	O
geranylgeranyltransferase	O
inhibitor	O
(	O
GGTI	O
298	O
)	O
further	O
induced	O
the	O
cytokine	O
and	O
lovastatin	O
-	O
mediated	O
iNOS	B-Protein
expression	O
,	O
suggesting	O
the	O
involvement	O
of	O
geranylgeranylated	O
proteins	O
in	O
the	O
regulation	O
of	O
iNOS	B-Protein
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
inactivation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
transformed	B-X
brain	B-X
cell	B-X
lines	B-X
[	B-X
C	B-X
(	B-X
6	B-X
)	B-X
glioma	B-X
,	B-X
human	B-X
astrocytoma	B-X
(	B-X
T98G	B-X
,	B-X
A172	B-X
)	B-X
,	B-X
neuroblastoma	B-X
(	B-X
NEB	B-X
)	B-X
,	B-X
and	B-X
immortal	B-X
rat	B-X
astrocytes	B-X
]	B-X
.	B-X
Treatment	B-X
with	B-X
lovastatin	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
mRNA	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
mevalonate	B-X
and	B-X
geranylgeranylpyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
reversed	B-X
the	B-X
lovastatin-mediated	B-X
effect	B-X
,	B-X
whereas	B-X
FPP	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
geranylgeranyltransferase	B-X
inhibitor	B-X
(	B-X
GGTI	B-X
298	B-X
)	B-X
further	B-X
induced	B-X
the	B-X
cytokine	B-X
and	B-X
lovastatin-mediated	B-X
iNOS	B-X
expression	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
iNOS	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Lovastatin	B-X
treatment	B-X
induced	B-X
NO	B-X
by	B-X
increasing	B-X
NF-kappaB	B-X
translocation	B-X
and	B-X
its	B-X
association	B-X
with	B-X
the	B-X
CREB-binding	B-X
protein	B-X
(	B-X
CBP/p300	B-X
)	B-X
via	B-X
the	B-X
downregulation	B-X
of	B-X
RhoA	B-X
.	B-X
Cotransfection	B-X
studies	B-X
with	B-X
dominant-negative	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
iNOS-luciferase	B-X
or	B-X
NF-kappaB-luciferase	B-X
reporter	B-X
constructs	B-X
further	B-X
support	B-X
these	B-X
observations	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

Bacterial	O
toxin	B-Protein
B	I-Protein
(	O
inactivates	O
RhoA	B-Protein
,	O
B	B-Protein
,	O
and	O
C	B-Protein
;	O
CDC42	B-Protein
;	O
Rac	O
proteins	O
)	O
,	O
C3	B-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
C3	B-Protein
)	O
toxin	O
from	O
C	O
.	O
botulinum	O
(	O
inactivates	O
RhoA	B-Protein
,	O
B	B-Protein
,	O
and	O
C	B-Protein
proteins	O
)	O
,	O
and	O
Y	O
-	O
27632	O
(	O
selective	O
inhibitor	O
of	O
Rho	O
-	O
associated	O
kinases	O
)	O
increased	O
the	O
LPS	O
/	O
IFN	B-Protein
-	I-Protein
gamma	I-Protein
-	O
mediated	O
iNOS	B-Protein
expression	O
.	O

Lovastatin	O
treatment	O
induced	O
NO	O
by	O
increasing	O
NF	O
-	O
kappaB	O
translocation	O
and	O
its	O
association	O
with	O
the	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	B-Protein
/	O
p300	B-Protein
)	O
via	O
the	O
downregulation	O
of	O
RhoA	B-Protein
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
inactivation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
transformed	B-X
brain	B-X
cell	B-X
lines	B-X
[	B-X
C	B-X
(	B-X
6	B-X
)	B-X
glioma	B-X
,	B-X
human	B-X
astrocytoma	B-X
(	B-X
T98G	B-X
,	B-X
A172	B-X
)	B-X
,	B-X
neuroblastoma	B-X
(	B-X
NEB	B-X
)	B-X
,	B-X
and	B-X
immortal	B-X
rat	B-X
astrocytes	B-X
]	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
geranylgeranyltransferase	B-X
inhibitor	B-X
(	B-X
GGTI	B-X
298	B-X
)	B-X
further	B-X
induced	B-X
the	B-X
cytokine	B-X
and	B-X
lovastatin-mediated	B-X
iNOS	B-X
expression	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
iNOS	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Lovastatin	B-X
treatment	B-X
induced	B-X
NO	B-X
by	B-X
increasing	B-X
NF-kappaB	B-X
translocation	B-X
and	B-X
its	B-X
association	B-X
with	B-X
the	B-X
CREB-binding	B-X
protein	B-X
(	B-X
CBP/p300	B-X
)	B-X
via	B-X
the	B-X
downregulation	B-X
of	B-X
RhoA	B-X
.	B-X
Inhibition	B-X
of	B-X
RhoA	B-X
resulted	B-X
in	B-X
increased	B-X
activation	B-X
of	B-X
IKKalpha	B-X
.	B-X
Cotransfection	B-X
studies	B-X
with	B-X
dominant-negative	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
iNOS-luciferase	B-X
or	B-X
NF-kappaB-luciferase	B-X
reporter	B-X
constructs	B-X
further	B-X
support	B-X
these	B-X
observations	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

Inhibition	O
of	O
RhoA	B-Protein
resulted	O
in	O
increased	O
activation	O
of	O
IKKalpha	B-Protein
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
inactivation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
transformed	B-X
brain	B-X
cell	B-X
lines	B-X
[	B-X
C	B-X
(	B-X
6	B-X
)	B-X
glioma	B-X
,	B-X
human	B-X
astrocytoma	B-X
(	B-X
T98G	B-X
,	B-X
A172	B-X
)	B-X
,	B-X
neuroblastoma	B-X
(	B-X
NEB	B-X
)	B-X
,	B-X
and	B-X
immortal	B-X
rat	B-X
astrocytes	B-X
]	B-X
.	B-X
Treatment	B-X
with	B-X
lovastatin	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
mRNA	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Lovastatin	B-X
treatment	B-X
induced	B-X
NO	B-X
by	B-X
increasing	B-X
NF-kappaB	B-X
translocation	B-X
and	B-X
its	B-X
association	B-X
with	B-X
the	B-X
CREB-binding	B-X
protein	B-X
(	B-X
CBP/p300	B-X
)	B-X
via	B-X
the	B-X
downregulation	B-X
of	B-X
RhoA	B-X
.	B-X
Inhibition	B-X
of	B-X
RhoA	B-X
resulted	B-X
in	B-X
increased	B-X
activation	B-X
of	B-X
IKKalpha	B-X
.	B-X
Cotransfection	B-X
studies	B-X
with	B-X
dominant-negative	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
iNOS-luciferase	B-X
or	B-X
NF-kappaB-luciferase	B-X
reporter	B-X
constructs	B-X
further	B-X
support	B-X
these	B-X
observations	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

Cotransfection	O
studies	O
with	O
dominant	O
-	O
negative	O
form	O
of	O
RhoA	B-Protein
and	O
iNOS	B-Protein
-	O
luciferase	B-Protein
or	O
NF	O
-	O
kappaB	O
-	O
luciferase	B-Protein
reporter	O
constructs	O
further	O
support	O
these	O
observations	O
.	O
<EOS>	B-X
Luciferase	B-X
reporter	B-X
assays	B-X
(	B-X
LRAs	B-X
)	B-X
are	B-X
widely	B-X
used	B-X
to	B-X
assess	B-X
the	B-X
activity	B-X
of	B-X
specific	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
Here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
previously	B-X
reported	B-X
inhibitory	B-X
effect	B-X
of	B-X
the	B-X
Nod-like	B-X
receptor	B-X
(	B-X
NLR	B-X
)	B-X
protein	B-X
NLRX1	B-X
on	B-X
NF-κB-	B-X
and	B-X
type	B-X
I	B-X
interferon-dependent	B-X
pathways	B-X
in	B-X
LRAs	B-X
was	B-X
a	B-X
nonspecific	B-X
consequence	B-X
of	B-X
the	B-X
overexpression	B-X
of	B-X
the	B-X
NLRX1	B-X
leucine-rich	B-X
repeat	B-X
(	B-X
LRR	B-X
)	B-X
domain	B-X
.	B-X
By	B-X
comparing	B-X
luciferase	B-X
activity	B-X
and	B-X
luciferase	B-X
gene	B-X
expression	B-X
using	B-X
quantitative	B-X
PCR	B-X
from	B-X
the	B-X
same	B-X
samples	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
NLRX1	B-X
inhibited	B-X
LRAs	B-X
in	B-X
a	B-X
post-transcriptional	B-X
manner	B-X
.	B-X
In	B-X
agreement	B-X
,	B-X
NLRX1	B-X
also	B-X
repressed	B-X
LRAs	B-X
if	B-X
luciferase	B-X
was	B-X
expressed	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
constitutive	B-X
promoter	B-X
,	B-X
although	B-X
the	B-X
degree	B-X
of	B-X
inhibition	B-X
by	B-X
NLRX1	B-X
seemed	B-X
to	B-X
correlate	B-X
with	B-X
the	B-X
dynamic	B-X
inducibility	B-X
of	B-X
luciferase	B-X
reporter	B-X
constructs	B-X
.	B-X

Taken	O
together	O
,	O
these	O
studies	O
show	O
that	O
downregulation	O
of	O
RhoA	B-Protein
by	O
lovastatin	O
resulted	O
in	O
increased	O
iNOS	B-Protein
expression	O
via	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
-	O
CBP	B-Protein
/	O
p300	B-Protein
pathway	O
in	O
transformed	O
brain	O
cells	O
.	O
<EOS>	B-X
The	B-X
present	B-X
study	B-X
describes	B-X
the	B-X
role	B-X
of	B-X
RhoA	B-X
as	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
inactivation	B-X
of	B-X
NF-kappaB	B-X
in	B-X
transformed	B-X
brain	B-X
cell	B-X
lines	B-X
[	B-X
C	B-X
(	B-X
6	B-X
)	B-X
glioma	B-X
,	B-X
human	B-X
astrocytoma	B-X
(	B-X
T98G	B-X
,	B-X
A172	B-X
)	B-X
,	B-X
neuroblastoma	B-X
(	B-X
NEB	B-X
)	B-X
,	B-X
and	B-X
immortal	B-X
rat	B-X
astrocytes	B-X
]	B-X
.	B-X
Treatment	B-X
with	B-X
lovastatin	B-X
resulted	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
mRNA	B-X
and	B-X
increased	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
mevalonate	B-X
and	B-X
geranylgeranylpyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
reversed	B-X
the	B-X
lovastatin-mediated	B-X
effect	B-X
,	B-X
whereas	B-X
FPP	B-X
had	B-X
no	B-X
effect	B-X
.	B-X
An	B-X
inhibitor	B-X
of	B-X
geranylgeranyltransferase	B-X
inhibitor	B-X
(	B-X
GGTI	B-X
298	B-X
)	B-X
further	B-X
induced	B-X
the	B-X
cytokine	B-X
and	B-X
lovastatin-mediated	B-X
iNOS	B-X
expression	B-X
,	B-X
suggesting	B-X
the	B-X
involvement	B-X
of	B-X
geranylgeranylated	B-X
proteins	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
iNOS	B-X
.	B-X
Bacterial	B-X
toxin	B-X
B	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
;	B-X
CDC42	B-X
;	B-X
Rac	B-X
proteins	B-X
)	B-X
,	B-X
C3	B-X
ADP-ribosyltransferase	B-X
(	B-X
C3	B-X
)	B-X
toxin	B-X
from	B-X
C.	B-X
botulinum	B-X
(	B-X
inactivates	B-X
RhoA	B-X
,	B-X
B	B-X
,	B-X
and	B-X
C	B-X
proteins	B-X
)	B-X
,	B-X
and	B-X
Y-27632	B-X
(	B-X
selective	B-X
inhibitor	B-X
of	B-X
Rho-associated	B-X
kinases	B-X
)	B-X
increased	B-X
the	B-X
LPS/IFN-gamma-mediated	B-X
iNOS	B-X
expression	B-X
.	B-X
Lovastatin	B-X
treatment	B-X
induced	B-X
NO	B-X
by	B-X
increasing	B-X
NF-kappaB	B-X
translocation	B-X
and	B-X
its	B-X
association	B-X
with	B-X
the	B-X
CREB-binding	B-X
protein	B-X
(	B-X
CBP/p300	B-X
)	B-X
via	B-X
the	B-X
downregulation	B-X
of	B-X
RhoA	B-X
.	B-X
Inhibition	B-X
of	B-X
RhoA	B-X
resulted	B-X
in	B-X
increased	B-X
activation	B-X
of	B-X
IKKalpha	B-X
.	B-X
Cotransfection	B-X
studies	B-X
with	B-X
dominant-negative	B-X
form	B-X
of	B-X
RhoA	B-X
and	B-X
iNOS-luciferase	B-X
or	B-X
NF-kappaB-luciferase	B-X
reporter	B-X
constructs	B-X
further	B-X
support	B-X
these	B-X
observations	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
studies	B-X
show	B-X
that	B-X
downregulation	B-X
of	B-X
RhoA	B-X
by	B-X
lovastatin	B-X
resulted	B-X
in	B-X
increased	B-X
iNOS	B-X
expression	B-X
via	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB-CBP/p300	B-X
pathway	B-X
in	B-X
transformed	B-X
brain	B-X
cells	B-X
.	B-X

Caspase	B-Protein
-	I-Protein
2	I-Protein
/	O
NEDD	B-Protein
-	I-Protein
2	I-Protein
protease	O
mediates	O
execution	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
tumor	O
cells	O
.	O
<EOS>	B-X
AK-5	B-X
tumour	B-X
cells	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
efficient	B-X
killing	B-X
of	B-X
tumour	B-X
cells	B-X
by	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
leads	B-X
to	B-X
spontaneous	B-X
regression	B-X
of	B-X
the	B-X
tumour	B-X
.	B-X
To	B-X
investigate	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
caspase-2/Nedd-2	B-X
protease	B-X
in	B-X
AK-5	B-X
apoptosis	B-X
,	B-X
we	B-X
introduced	B-X
Nedd-2	B-X
gene	B-X
in	B-X
antisense	B-X
orientation	B-X
and	B-X
showed	B-X
inhibition	B-X
of	B-X
tumour	B-X
cell	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
introduction	B-X
of	B-X
the	B-X
bcl-2	B-X
gene	B-X
in	B-X
tumour	B-X
cells	B-X
also	B-X
inhibited	B-X
the	B-X
apoptotic	B-X
programme	B-X
.	B-X
NK	B-X
cells	B-X
which	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
effector	B-X
cells	B-X
also	B-X
fail	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
Nedd-2	B-X
antisense	B-X
and	B-X
bcl-2	B-X
transfected	B-X
clones	B-X
whereas	B-X
NK	B-X
mediated	B-X
cytotoxic	B-X
activity	B-X
is	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
transfectants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
participation	B-X
of	B-X
Nedd-2	B-X
protease	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
cells	B-X
leading	B-X
to	B-X
tumour	B-X
regression	B-X
.	B-X

AK	O
-	O
5	O
tumour	O
cells	O
have	O
been	O
shown	O
to	O
undergo	O
apoptosis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
AK-5	B-X
tumor	B-X
cell	B-X
death	B-X
is	B-X
mediated	B-X
through	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
.	B-X
The	B-X
apoptotic	B-X
activity	B-X
in	B-X
AK-5	B-X
cells	B-X
has	B-X
been	B-X
studied	B-X
after	B-X
introduction	B-X
of	B-X
wild-type	B-X
p53	B-X
gene	B-X
.	B-X
Apoptotic	B-X
activity	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
is	B-X
significantly	B-X
increased	B-X
in	B-X
p53	B-X
transfected	B-X
cells	B-X
.	B-X
Similarly	B-X
there	B-X
is	B-X
fragmentation	B-X
of	B-X
tumor	B-X
cell	B-X
DNA	B-X
after	B-X
undergoing	B-X
apoptosis	B-X
.	B-X
These	B-X
observations	B-X
suggest	B-X
an	B-X
active	B-X
participation	B-X
of	B-X
p53	B-X
in	B-X
inducing	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
tumor	B-X
cells	B-X
.	B-X

The	O
efficient	O
killing	O
of	O
tumour	O
cells	O
by	O
necrosis	O
and	O
apoptosis	O
leads	O
to	O
spontaneous	O
regression	O
of	O
the	O
tumour	O
.	O
<EOS>	B-X
AK-5	B-X
tumour	B-X
cells	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
efficient	B-X
killing	B-X
of	B-X
tumour	B-X
cells	B-X
by	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
leads	B-X
to	B-X
spontaneous	B-X
regression	B-X
of	B-X
the	B-X
tumour	B-X
.	B-X
To	B-X
investigate	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
caspase-2/Nedd-2	B-X
protease	B-X
in	B-X
AK-5	B-X
apoptosis	B-X
,	B-X
we	B-X
introduced	B-X
Nedd-2	B-X
gene	B-X
in	B-X
antisense	B-X
orientation	B-X
and	B-X
showed	B-X
inhibition	B-X
of	B-X
tumour	B-X
cell	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
introduction	B-X
of	B-X
the	B-X
bcl-2	B-X
gene	B-X
in	B-X
tumour	B-X
cells	B-X
also	B-X
inhibited	B-X
the	B-X
apoptotic	B-X
programme	B-X
.	B-X
NK	B-X
cells	B-X
which	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
effector	B-X
cells	B-X
also	B-X
fail	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
Nedd-2	B-X
antisense	B-X
and	B-X
bcl-2	B-X
transfected	B-X
clones	B-X
whereas	B-X
NK	B-X
mediated	B-X
cytotoxic	B-X
activity	B-X
is	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
transfectants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
participation	B-X
of	B-X
Nedd-2	B-X
protease	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
cells	B-X
leading	B-X
to	B-X
tumour	B-X
regression	B-X
.	B-X

To	O
investigate	O
a	O
possible	O
involvement	O
of	O
caspase	B-Protein
-	I-Protein
2	I-Protein
/	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
protease	O
in	O
AK	O
-	O
5	O
apoptosis	O
,	O
we	O
introduced	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
gene	O
in	O
antisense	O
orientation	O
and	O
showed	O
inhibition	O
of	O
tumour	O
cell	O
apoptosis	O
.	O
<EOS>	B-X
AK-5	B-X
tumour	B-X
cells	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
efficient	B-X
killing	B-X
of	B-X
tumour	B-X
cells	B-X
by	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
leads	B-X
to	B-X
spontaneous	B-X
regression	B-X
of	B-X
the	B-X
tumour	B-X
.	B-X
To	B-X
investigate	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
caspase-2/Nedd-2	B-X
protease	B-X
in	B-X
AK-5	B-X
apoptosis	B-X
,	B-X
we	B-X
introduced	B-X
Nedd-2	B-X
gene	B-X
in	B-X
antisense	B-X
orientation	B-X
and	B-X
showed	B-X
inhibition	B-X
of	B-X
tumour	B-X
cell	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
introduction	B-X
of	B-X
the	B-X
bcl-2	B-X
gene	B-X
in	B-X
tumour	B-X
cells	B-X
also	B-X
inhibited	B-X
the	B-X
apoptotic	B-X
programme	B-X
.	B-X
NK	B-X
cells	B-X
which	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
effector	B-X
cells	B-X
also	B-X
fail	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
Nedd-2	B-X
antisense	B-X
and	B-X
bcl-2	B-X
transfected	B-X
clones	B-X
whereas	B-X
NK	B-X
mediated	B-X
cytotoxic	B-X
activity	B-X
is	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
transfectants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
participation	B-X
of	B-X
Nedd-2	B-X
protease	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
cells	B-X
leading	B-X
to	B-X
tumour	B-X
regression	B-X
.	B-X

Similarly	O
introduction	O
of	O
the	O
bcl	B-Protein
-	I-Protein
2	I-Protein
gene	O
in	O
tumour	O
cells	O
also	O
inhibited	O
the	O
apoptotic	O
programme	O
.	O
<EOS>	B-X
AK-5	B-X
tumour	B-X
cells	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
efficient	B-X
killing	B-X
of	B-X
tumour	B-X
cells	B-X
by	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
leads	B-X
to	B-X
spontaneous	B-X
regression	B-X
of	B-X
the	B-X
tumour	B-X
.	B-X
To	B-X
investigate	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
caspase-2/Nedd-2	B-X
protease	B-X
in	B-X
AK-5	B-X
apoptosis	B-X
,	B-X
we	B-X
introduced	B-X
Nedd-2	B-X
gene	B-X
in	B-X
antisense	B-X
orientation	B-X
and	B-X
showed	B-X
inhibition	B-X
of	B-X
tumour	B-X
cell	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
introduction	B-X
of	B-X
the	B-X
bcl-2	B-X
gene	B-X
in	B-X
tumour	B-X
cells	B-X
also	B-X
inhibited	B-X
the	B-X
apoptotic	B-X
programme	B-X
.	B-X
NK	B-X
cells	B-X
which	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
effector	B-X
cells	B-X
also	B-X
fail	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
Nedd-2	B-X
antisense	B-X
and	B-X
bcl-2	B-X
transfected	B-X
clones	B-X
whereas	B-X
NK	B-X
mediated	B-X
cytotoxic	B-X
activity	B-X
is	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
transfectants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
participation	B-X
of	B-X
Nedd-2	B-X
protease	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
cells	B-X
leading	B-X
to	B-X
tumour	B-X
regression	B-X
.	B-X

NK	O
cells	O
which	O
have	O
previously	O
been	O
shown	O
to	O
be	O
the	O
effector	O
cells	O
also	O
fail	O
to	O
induce	O
apoptosis	O
in	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
antisense	O
and	O
bcl	B-Protein
-	I-Protein
2	I-Protein
transfected	O
clones	O
whereas	O
NK	O
mediated	O
cytotoxic	O
activity	O
is	O
not	O
altered	O
in	O
the	O
transfectants	O
.	O

These	O
results	O
suggest	O
participation	O
of	O
Nedd	B-Protein
-	I-Protein
2	I-Protein
protease	O
in	O
the	O
induction	O
of	O
apoptosis	O
in	O
AK	O
-	O
5	O
cells	O
leading	O
to	O
tumour	O
regression	O
.	O
<EOS>	B-X
AK-5	B-X
tumour	B-X
cells	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
apoptosis	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
efficient	B-X
killing	B-X
of	B-X
tumour	B-X
cells	B-X
by	B-X
necrosis	B-X
and	B-X
apoptosis	B-X
leads	B-X
to	B-X
spontaneous	B-X
regression	B-X
of	B-X
the	B-X
tumour	B-X
.	B-X
To	B-X
investigate	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
caspase-2/Nedd-2	B-X
protease	B-X
in	B-X
AK-5	B-X
apoptosis	B-X
,	B-X
we	B-X
introduced	B-X
Nedd-2	B-X
gene	B-X
in	B-X
antisense	B-X
orientation	B-X
and	B-X
showed	B-X
inhibition	B-X
of	B-X
tumour	B-X
cell	B-X
apoptosis	B-X
.	B-X
Similarly	B-X
introduction	B-X
of	B-X
the	B-X
bcl-2	B-X
gene	B-X
in	B-X
tumour	B-X
cells	B-X
also	B-X
inhibited	B-X
the	B-X
apoptotic	B-X
programme	B-X
.	B-X
NK	B-X
cells	B-X
which	B-X
have	B-X
previously	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
effector	B-X
cells	B-X
also	B-X
fail	B-X
to	B-X
induce	B-X
apoptosis	B-X
in	B-X
Nedd-2	B-X
antisense	B-X
and	B-X
bcl-2	B-X
transfected	B-X
clones	B-X
whereas	B-X
NK	B-X
mediated	B-X
cytotoxic	B-X
activity	B-X
is	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
transfectants	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
participation	B-X
of	B-X
Nedd-2	B-X
protease	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
apoptosis	B-X
in	B-X
AK-5	B-X
cells	B-X
leading	B-X
to	B-X
tumour	B-X
regression	B-X
.	B-X

Antifungal	O
activity	O
of	O
fluconazole	O
in	O
combination	O
with	O
lovastatin	O
and	O
their	O
effects	O
on	O
gene	O
expression	O
in	O
the	O
ergosterol	O
and	O
prenylation	O
pathways	O
in	O
Candida	O
albicans	O
.	O
<EOS>	B-X
The	B-X
sterol	B-X
pathway	B-X
in	B-X
Candida	B-X
albicans	B-X
is	B-X
the	B-X
target	B-X
for	B-X
several	B-X
classes	B-X
of	B-X
antifungal	B-X
drugs	B-X
.	B-X
Intermediates	B-X
in	B-X
the	B-X
sterol	B-X
pathway	B-X
are	B-X
involved	B-X
in	B-X
ergosterol	B-X
synthesis	B-X
,	B-X
prenylation	B-X
and	B-X
dolichol	B-X
synthesis	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
gene	B-X
expression	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
(	B-X
Hmg1p	B-X
)	B-X
,	B-X
and	B-X
fluconazole	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
14	B-X
alpha-lanosterol	B-X
demethylase	B-X
(	B-X
Erg11p	B-X
)	B-X
.	B-X
Minimum	B-X
inhibitory	B-X
concentration	B-X
(	B-X
MIC	B-X
)	B-X
studies	B-X
indicated	B-X
that	B-X
lovastatin	B-X
acts	B-X
synergistically	B-X
with	B-X
fluconazole	B-X
in	B-X
vitro	B-X
.	B-X
Semi-quantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
results	B-X
indicated	B-X
that	B-X
genes	B-X
in	B-X
the	B-X
early	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
HMG1	B-X
and	B-X
ERG20	B-X
,	B-X
did	B-X
not	B-X
alter	B-X
expression	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
lovastatin	B-X
and	B-X
fluconazole	B-X
,	B-X
whereas	B-X
genes	B-X
in	B-X
the	B-X
later	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
ERG9	B-X
and	B-X
ERG11	B-X
,	B-X
had	B-X
increased	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
.	B-X
Genes	B-X
involved	B-X
in	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
RAM1	B-X
and	B-X
RAM2	B-X
,	B-X
also	B-X
respond	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
,	B-X
although	B-X
another	B-X
prenylation	B-X
gene	B-X
,	B-X
CDC43	B-X
,	B-X
was	B-X
not	B-X
affected	B-X
.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
growth	B-X
,	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
ERG20	B-X
,	B-X
ERG9	B-X
,	B-X
and	B-X
ERG11	B-X
remained	B-X
unchanged	B-X
or	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
drugs	B-X
,	B-X
while	B-X
all	B-X
other	B-X
genes	B-X
decreased	B-X
in	B-X
expression	B-X
under	B-X
all	B-X
drug	B-X
treatments	B-X
.	B-X

The	O
sterol	O
pathway	O
in	O
Candida	O
albicans	O
is	O
the	O
target	O
for	O
several	O
classes	O
of	O
antifungal	O
drugs	O
.	O
<EOS>	B-X
Candida	B-X
albicans	B-X
is	B-X
an	B-X
opportunistic	B-X
yeast	B-X
and	B-X
the	B-X
major	B-X
human	B-X
fungal	B-X
pathogen	B-X
in	B-X
the	B-X
USA	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
many	B-X
other	B-X
regions	B-X
of	B-X
the	B-X
world	B-X
.	B-X
Infections	B-X
with	B-X
C.	B-X
albicans	B-X
can	B-X
range	B-X
from	B-X
superficial	B-X
mucosal	B-X
and	B-X
dermatological	B-X
infections	B-X
to	B-X
life-threatening	B-X
infections	B-X
of	B-X
the	B-X
bloodstream	B-X
and	B-X
vital	B-X
organs	B-X
.	B-X
The	B-X
azole	B-X
antifungals	B-X
remain	B-X
an	B-X
important	B-X
mainstay	B-X
treatment	B-X
of	B-X
candidiasis	B-X
and	B-X
therefore	B-X
the	B-X
investigation	B-X
and	B-X
understanding	B-X
of	B-X
the	B-X
evolution	B-X
,	B-X
frequency	B-X
and	B-X
mechanisms	B-X
of	B-X
azole	B-X
resistance	B-X
are	B-X
vital	B-X
to	B-X
improving	B-X
treatment	B-X
strategies	B-X
against	B-X
this	B-X
organism	B-X
.	B-X
Here	B-X
the	B-X
organism	B-X
C.	B-X
albicans	B-X
and	B-X
the	B-X
genetic	B-X
changes	B-X
and	B-X
molecular	B-X
bases	B-X
underlying	B-X
the	B-X
currently	B-X
known	B-X
resistance	B-X
mechanisms	B-X
to	B-X
the	B-X
azole	B-X
antifungal	B-X
class	B-X
are	B-X
reviewed	B-X
,	B-X
including	B-X
up-regulated	B-X
expression	B-X
of	B-X
efflux	B-X
pumps	B-X
,	B-X
changes	B-X
in	B-X
the	B-X
expression	B-X
and	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
the	B-X
azole	B-X
target	B-X
Erg11	B-X
and	B-X
alterations	B-X
to	B-X
the	B-X
organism	B-X
's	B-X
typical	B-X
sterol	B-X
biosynthesis	B-X
pathways	B-X
.	B-X
Lastly	B-X
,	B-X
investigations	B-X
of	B-X
azole	B-X
tolerance	B-X
in	B-X
C.	B-X
albicans	B-X
and	B-X
its	B-X
implicated	B-X
clinical	B-X
significance	B-X
are	B-X
reviewed	B-X
.	B-X

Intermediates	O
in	O
the	O
sterol	O
pathway	O
are	O
involved	O
in	O
ergosterol	O
synthesis	O
,	O
prenylation	O
and	O
dolichol	O
synthesis	O
.	O
<EOS>	B-X
The	B-X
sterol	B-X
pathway	B-X
in	B-X
Candida	B-X
albicans	B-X
is	B-X
the	B-X
target	B-X
for	B-X
several	B-X
classes	B-X
of	B-X
antifungal	B-X
drugs	B-X
.	B-X
Intermediates	B-X
in	B-X
the	B-X
sterol	B-X
pathway	B-X
are	B-X
involved	B-X
in	B-X
ergosterol	B-X
synthesis	B-X
,	B-X
prenylation	B-X
and	B-X
dolichol	B-X
synthesis	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
gene	B-X
expression	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
(	B-X
Hmg1p	B-X
)	B-X
,	B-X
and	B-X
fluconazole	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
14	B-X
alpha-lanosterol	B-X
demethylase	B-X
(	B-X
Erg11p	B-X
)	B-X
.	B-X
Semi-quantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
results	B-X
indicated	B-X
that	B-X
genes	B-X
in	B-X
the	B-X
early	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
HMG1	B-X
and	B-X
ERG20	B-X
,	B-X
did	B-X
not	B-X
alter	B-X
expression	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
lovastatin	B-X
and	B-X
fluconazole	B-X
,	B-X
whereas	B-X
genes	B-X
in	B-X
the	B-X
later	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
ERG9	B-X
and	B-X
ERG11	B-X
,	B-X
had	B-X
increased	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
.	B-X
Genes	B-X
involved	B-X
in	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
RAM1	B-X
and	B-X
RAM2	B-X
,	B-X
also	B-X
respond	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
,	B-X
although	B-X
another	B-X
prenylation	B-X
gene	B-X
,	B-X
CDC43	B-X
,	B-X
was	B-X
not	B-X
affected	B-X
.	B-X

This	O
study	O
examines	O
gene	O
expression	O
of	O
the	O
sterol	O
pathway	O
in	O
response	O
to	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
(	O
Hmg1p	B-Protein
)	O
,	O
and	O
fluconazole	O
,	O
an	O
inhibitor	O
of	O
14	B-Protein
alpha	I-Protein
-	I-Protein
lanosterol	I-Protein
demethylase	I-Protein
(	O
Erg11p	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
sterol	B-X
pathway	B-X
in	B-X
Candida	B-X
albicans	B-X
is	B-X
the	B-X
target	B-X
for	B-X
several	B-X
classes	B-X
of	B-X
antifungal	B-X
drugs	B-X
.	B-X
Intermediates	B-X
in	B-X
the	B-X
sterol	B-X
pathway	B-X
are	B-X
involved	B-X
in	B-X
ergosterol	B-X
synthesis	B-X
,	B-X
prenylation	B-X
and	B-X
dolichol	B-X
synthesis	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
gene	B-X
expression	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
(	B-X
Hmg1p	B-X
)	B-X
,	B-X
and	B-X
fluconazole	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
14	B-X
alpha-lanosterol	B-X
demethylase	B-X
(	B-X
Erg11p	B-X
)	B-X
.	B-X
Minimum	B-X
inhibitory	B-X
concentration	B-X
(	B-X
MIC	B-X
)	B-X
studies	B-X
indicated	B-X
that	B-X
lovastatin	B-X
acts	B-X
synergistically	B-X
with	B-X
fluconazole	B-X
in	B-X
vitro	B-X
.	B-X
Semi-quantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
results	B-X
indicated	B-X
that	B-X
genes	B-X
in	B-X
the	B-X
early	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
HMG1	B-X
and	B-X
ERG20	B-X
,	B-X
did	B-X
not	B-X
alter	B-X
expression	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
lovastatin	B-X
and	B-X
fluconazole	B-X
,	B-X
whereas	B-X
genes	B-X
in	B-X
the	B-X
later	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
ERG9	B-X
and	B-X
ERG11	B-X
,	B-X
had	B-X
increased	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
.	B-X
Genes	B-X
involved	B-X
in	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
RAM1	B-X
and	B-X
RAM2	B-X
,	B-X
also	B-X
respond	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
,	B-X
although	B-X
another	B-X
prenylation	B-X
gene	B-X
,	B-X
CDC43	B-X
,	B-X
was	B-X
not	B-X
affected	B-X
.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
growth	B-X
,	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
ERG20	B-X
,	B-X
ERG9	B-X
,	B-X
and	B-X
ERG11	B-X
remained	B-X
unchanged	B-X
or	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
drugs	B-X
,	B-X
while	B-X
all	B-X
other	B-X
genes	B-X
decreased	B-X
in	B-X
expression	B-X
under	B-X
all	B-X
drug	B-X
treatments	B-X
.	B-X

Minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
studies	O
indicated	O
that	O
lovastatin	O
acts	O
synergistically	O
with	O
fluconazole	O
in	O
vitro	O
.	O
<EOS>	B-X
This	B-X
study	B-X
examines	B-X
gene	B-X
expression	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
(	B-X
Hmg1p	B-X
)	B-X
,	B-X
and	B-X
fluconazole	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
14	B-X
alpha-lanosterol	B-X
demethylase	B-X
(	B-X
Erg11p	B-X
)	B-X
.	B-X
Minimum	B-X
inhibitory	B-X
concentration	B-X
(	B-X
MIC	B-X
)	B-X
studies	B-X
indicated	B-X
that	B-X
lovastatin	B-X
acts	B-X
synergistically	B-X
with	B-X
fluconazole	B-X
in	B-X
vitro	B-X
.	B-X
Semi-quantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
results	B-X
indicated	B-X
that	B-X
genes	B-X
in	B-X
the	B-X
early	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
HMG1	B-X
and	B-X
ERG20	B-X
,	B-X
did	B-X
not	B-X
alter	B-X
expression	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
lovastatin	B-X
and	B-X
fluconazole	B-X
,	B-X
whereas	B-X
genes	B-X
in	B-X
the	B-X
later	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
ERG9	B-X
and	B-X
ERG11	B-X
,	B-X
had	B-X
increased	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
.	B-X

Semi	O
-	O
quantitative	O
reverse	B-Protein
transcriptase	I-Protein
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
results	O
indicated	O
that	O
genes	O
in	O
the	O
early	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
HMG1	B-Protein
and	O
ERG20	B-Protein
,	O
did	O
not	O
alter	O
expression	O
in	O
the	O
presence	O
of	O
both	O
lovastatin	O
and	O
fluconazole	O
,	O
whereas	O
genes	O
in	O
the	O
later	O
part	O
of	O
the	O
sterol	O
pathway	O
,	O
such	O
as	O
ERG9	B-Protein
and	O
ERG11	B-Protein
,	O
had	O
increased	O
expression	O
in	O
response	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
.	O

Genes	O
involved	O
in	O
prenylation	O
,	O
such	O
as	O
RAM1	B-Protein
and	O
RAM2	B-Protein
,	O
also	O
respond	O
to	O
these	O
drugs	O
in	O
mid	O
-	O
logarithmic	O
growth	O
,	O
although	O
another	O
prenylation	O
gene	O
,	O
CDC43	B-Protein
,	O
was	O
not	O
affected	O
.	O

After	O
24	O
h	O
of	O
growth	O
,	O
the	O
relative	O
expression	O
of	O
ERG20	B-Protein
,	O
ERG9	B-Protein
,	O
and	O
ERG11	B-Protein
remained	O
unchanged	O
or	O
increased	O
in	O
the	O
presence	O
of	O
both	O
drugs	O
,	O
while	O
all	O
other	O
genes	O
decreased	O
in	O
expression	O
under	O
all	O
drug	O
treatments	O
.	O
<EOS>	B-X
The	B-X
sterol	B-X
pathway	B-X
in	B-X
Candida	B-X
albicans	B-X
is	B-X
the	B-X
target	B-X
for	B-X
several	B-X
classes	B-X
of	B-X
antifungal	B-X
drugs	B-X
.	B-X
Intermediates	B-X
in	B-X
the	B-X
sterol	B-X
pathway	B-X
are	B-X
involved	B-X
in	B-X
ergosterol	B-X
synthesis	B-X
,	B-X
prenylation	B-X
and	B-X
dolichol	B-X
synthesis	B-X
.	B-X
This	B-X
study	B-X
examines	B-X
gene	B-X
expression	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
in	B-X
response	B-X
to	B-X
lovastatin	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
(	B-X
Hmg1p	B-X
)	B-X
,	B-X
and	B-X
fluconazole	B-X
,	B-X
an	B-X
inhibitor	B-X
of	B-X
14	B-X
alpha-lanosterol	B-X
demethylase	B-X
(	B-X
Erg11p	B-X
)	B-X
.	B-X
Minimum	B-X
inhibitory	B-X
concentration	B-X
(	B-X
MIC	B-X
)	B-X
studies	B-X
indicated	B-X
that	B-X
lovastatin	B-X
acts	B-X
synergistically	B-X
with	B-X
fluconazole	B-X
in	B-X
vitro	B-X
.	B-X
Semi-quantitative	B-X
reverse	B-X
transcriptase-polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
RT-PCR	B-X
)	B-X
results	B-X
indicated	B-X
that	B-X
genes	B-X
in	B-X
the	B-X
early	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
HMG1	B-X
and	B-X
ERG20	B-X
,	B-X
did	B-X
not	B-X
alter	B-X
expression	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
lovastatin	B-X
and	B-X
fluconazole	B-X
,	B-X
whereas	B-X
genes	B-X
in	B-X
the	B-X
later	B-X
part	B-X
of	B-X
the	B-X
sterol	B-X
pathway	B-X
,	B-X
such	B-X
as	B-X
ERG9	B-X
and	B-X
ERG11	B-X
,	B-X
had	B-X
increased	B-X
expression	B-X
in	B-X
response	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
.	B-X
Genes	B-X
involved	B-X
in	B-X
prenylation	B-X
,	B-X
such	B-X
as	B-X
RAM1	B-X
and	B-X
RAM2	B-X
,	B-X
also	B-X
respond	B-X
to	B-X
these	B-X
drugs	B-X
in	B-X
mid-logarithmic	B-X
growth	B-X
,	B-X
although	B-X
another	B-X
prenylation	B-X
gene	B-X
,	B-X
CDC43	B-X
,	B-X
was	B-X
not	B-X
affected	B-X
.	B-X
After	B-X
24	B-X
h	B-X
of	B-X
growth	B-X
,	B-X
the	B-X
relative	B-X
expression	B-X
of	B-X
ERG20	B-X
,	B-X
ERG9	B-X
,	B-X
and	B-X
ERG11	B-X
remained	B-X
unchanged	B-X
or	B-X
increased	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
both	B-X
drugs	B-X
,	B-X
while	B-X
all	B-X
other	B-X
genes	B-X
decreased	B-X
in	B-X
expression	B-X
under	B-X
all	B-X
drug	B-X
treatments	B-X
.	B-X

Neisseria	O
gonorrhoeae	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
3	I-Protein
exhibits	O
exceptionally	O
high	O
carboxypeptidase	O
and	O
beta	O
-	O
lactam	O
binding	O
activities	O
.	O
<EOS>	B-X
A	B-X
soluble	B-X
form	B-X
of	B-X
penicillin-binding	B-X
protein	B-X
3	B-X
(	B-X
PBP	B-X
3	B-X
)	B-X
from	B-X
Neisseria	B-X
gonorrhoeae	B-X
was	B-X
expressed	B-X
and	B-X
purified	B-X
from	B-X
Escherichia	B-X
coli	B-X
and	B-X
characterized	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
beta-lactam	B-X
antibiotics	B-X
,	B-X
its	B-X
catalytic	B-X
properties	B-X
with	B-X
peptide	B-X
and	B-X
peptidoglycan	B-X
substrates	B-X
,	B-X
and	B-X
its	B-X
role	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
morphology	B-X
.	B-X
PBP	B-X
3	B-X
had	B-X
an	B-X
unusually	B-X
high	B-X
k	B-X
(	B-X
2	B-X
)	B-X
/K	B-X
'	B-X
value	B-X
relative	B-X
to	B-X
other	B-X
PBPs	B-X
for	B-X
acylation	B-X
with	B-X
penicillin	B-X
(	B-X
7.7	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
)	B-X
at	B-X
pH	B-X
8.5	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
and	B-X
hydrolyzed	B-X
bound	B-X
antibiotic	B-X
very	B-X
slowly	B-X
(	B-X
k	B-X
(	B-X
3	B-X
)	B-X
<	B-X
4.6	B-X
x	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
t	B-X
(	B-X
1/2	B-X
)	B-X
>	B-X
230	B-X
min	B-X
)	B-X
.	B-X
PBP	B-X
3	B-X
also	B-X
demonstrated	B-X
exceptionally	B-X
high	B-X
carboxypeptidase	B-X
activity	B-X
with	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
of	B-X
580	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
and	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
m	B-X
)	B-X
of	B-X
1.8	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
with	B-X
the	B-X
substrate	B-X
N	B-X
(	B-X
alpha	B-X
)	B-X
-Boc-N	B-X
(	B-X
epsilon	B-X
)	B-X
-Cbz-L-Lys-D-Ala-D-Ala	B-X
.	B-X
This	B-X
is	B-X
the	B-X
highest	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
value	B-X
yet	B-X
reported	B-X
for	B-X
a	B-X
PBP	B-X
or	B-X
other	B-X
serine	B-X
peptidases	B-X
.	B-X
The	B-X
pH	B-X
dependence	B-X
profiles	B-X
of	B-X
both	B-X
carboxypeptidase	B-X
activity	B-X
and	B-X
beta-lactam	B-X
acylation	B-X
were	B-X
bell-shaped	B-X
with	B-X
maximal	B-X
activity	B-X
at	B-X
pH	B-X
8.0-8.5	B-X
.	B-X
PBP	B-X
3	B-X
displayed	B-X
weak	B-X
transpeptidase	B-X
activity	B-X
in	B-X
a	B-X
model	B-X
transpeptidase	B-X
reaction	B-X
but	B-X
was	B-X
active	B-X
as	B-X
an	B-X
endopeptidase	B-X
,	B-X
cleaving	B-X
dimeric	B-X
peptide	B-X
cross-links	B-X
.	B-X
Deletion	B-X
of	B-X
PBP	B-X
3	B-X
alone	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
viability	B-X
,	B-X
growth	B-X
rate	B-X
,	B-X
and	B-X
morphology	B-X
of	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
although	B-X
deletion	B-X
of	B-X
both	B-X
PBP	B-X
3	B-X
and	B-X
PBP	B-X
4	B-X
,	B-X
the	B-X
other	B-X
low-molecular-mass	B-X
PBP	B-X
in	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
growth	B-X
rate	B-X
and	B-X
marked	B-X
morphological	B-X
abnormalities	B-X
.	B-X

A	O
soluble	O
form	O
of	O
penicillin	B-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
3	I-Protein
(	O
PBP	B-Protein
3	I-Protein
)	O
from	O
Neisseria	O
gonorrhoeae	O
was	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
and	O
characterized	O
for	O
its	O
interaction	O
with	O
beta	O
-	O
lactam	O
antibiotics	O
,	O
its	O
catalytic	O
properties	O
with	O
peptide	O
and	O
peptidoglycan	O
substrates	O
,	O
and	O
its	O
role	O
in	O
cell	O
viability	O
and	O
morphology	O
.	O
<EOS>	B-X
A	B-X
soluble	B-X
form	B-X
of	B-X
penicillin-binding	B-X
protein	B-X
3	B-X
(	B-X
PBP	B-X
3	B-X
)	B-X
from	B-X
Neisseria	B-X
gonorrhoeae	B-X
was	B-X
expressed	B-X
and	B-X
purified	B-X
from	B-X
Escherichia	B-X
coli	B-X
and	B-X
characterized	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
beta-lactam	B-X
antibiotics	B-X
,	B-X
its	B-X
catalytic	B-X
properties	B-X
with	B-X
peptide	B-X
and	B-X
peptidoglycan	B-X
substrates	B-X
,	B-X
and	B-X
its	B-X
role	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
morphology	B-X
.	B-X
PBP	B-X
3	B-X
had	B-X
an	B-X
unusually	B-X
high	B-X
k	B-X
(	B-X
2	B-X
)	B-X
/K	B-X
'	B-X
value	B-X
relative	B-X
to	B-X
other	B-X
PBPs	B-X
for	B-X
acylation	B-X
with	B-X
penicillin	B-X
(	B-X
7.7	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
)	B-X
at	B-X
pH	B-X
8.5	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
and	B-X
hydrolyzed	B-X
bound	B-X
antibiotic	B-X
very	B-X
slowly	B-X
(	B-X
k	B-X
(	B-X
3	B-X
)	B-X
<	B-X
4.6	B-X
x	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
t	B-X
(	B-X
1/2	B-X
)	B-X
>	B-X
230	B-X
min	B-X
)	B-X
.	B-X
PBP	B-X
3	B-X
also	B-X
demonstrated	B-X
exceptionally	B-X
high	B-X
carboxypeptidase	B-X
activity	B-X
with	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
of	B-X
580	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
and	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
m	B-X
)	B-X
of	B-X
1.8	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
with	B-X
the	B-X
substrate	B-X
N	B-X
(	B-X
alpha	B-X
)	B-X
-Boc-N	B-X
(	B-X
epsilon	B-X
)	B-X
-Cbz-L-Lys-D-Ala-D-Ala	B-X
.	B-X
This	B-X
is	B-X
the	B-X
highest	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
value	B-X
yet	B-X
reported	B-X
for	B-X
a	B-X
PBP	B-X
or	B-X
other	B-X
serine	B-X
peptidases	B-X
.	B-X
Activity	B-X
against	B-X
a	B-X
approximately	B-X
D-Ala-D-Lac	B-X
peptide	B-X
substrate	B-X
was	B-X
approximately	B-X
2-fold	B-X
lower	B-X
than	B-X
against	B-X
the	B-X
analogous	B-X
approximately	B-X
D-Ala-D-Ala	B-X
peptide	B-X
substrate	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
is	B-X
rate	B-X
determining	B-X
for	B-X
both	B-X
amide	B-X
and	B-X
ester	B-X
hydrolysis	B-X
.	B-X
The	B-X
pH	B-X
dependence	B-X
profiles	B-X
of	B-X
both	B-X
carboxypeptidase	B-X
activity	B-X
and	B-X
beta-lactam	B-X
acylation	B-X
were	B-X
bell-shaped	B-X
with	B-X
maximal	B-X
activity	B-X
at	B-X
pH	B-X
8.0-8.5	B-X
.	B-X
PBP	B-X
3	B-X
displayed	B-X
weak	B-X
transpeptidase	B-X
activity	B-X
in	B-X
a	B-X
model	B-X
transpeptidase	B-X
reaction	B-X
but	B-X
was	B-X
active	B-X
as	B-X
an	B-X
endopeptidase	B-X
,	B-X
cleaving	B-X
dimeric	B-X
peptide	B-X
cross-links	B-X
.	B-X
Deletion	B-X
of	B-X
PBP	B-X
3	B-X
alone	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
viability	B-X
,	B-X
growth	B-X
rate	B-X
,	B-X
and	B-X
morphology	B-X
of	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
although	B-X
deletion	B-X
of	B-X
both	B-X
PBP	B-X
3	B-X
and	B-X
PBP	B-X
4	B-X
,	B-X
the	B-X
other	B-X
low-molecular-mass	B-X
PBP	B-X
in	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
growth	B-X
rate	B-X
and	B-X
marked	B-X
morphological	B-X
abnormalities	B-X
.	B-X

PBP	B-Protein
3	I-Protein
had	O
an	O
unusually	O
high	O
k	O
(	O
2	O
)	O
/	O
K	O
'	O
value	O
relative	O
to	O
other	O
PBPs	O
for	O
acylation	O
with	O
penicillin	O
(	O
7	O
.	O
7	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
)	O
at	O
pH	O
8	O
.	O
5	O
at	O
25	O
degrees	O
C	O
and	O
hydrolyzed	O
bound	O
antibiotic	O
very	O
slowly	O
(	O
k	O
(	O
3	O
)	O
<	O
4	O
.	O
6	O
x	O
10	O
(	O
-	O
5	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
t	O
(	O
1	O
/	O
2	O
)	O
>	O
230	O
min	O
)	O
.	O

PBP	B-Protein
3	I-Protein
also	O
demonstrated	O
exceptionally	O
high	O
carboxypeptidase	O
activity	O
with	O
a	O
k	O
(	O
cat	O
)	O
of	O
580	O
s	O
(	O
-	O
1	O
)	O
and	O
a	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
m	O
)	O
of	O
1	O
.	O
8	O
x	O
10	O
(	O
5	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
with	O
the	O
substrate	O
N	O
(	O
alpha	O
)	O
-	O
Boc	O
-	O
N	O
(	O
epsilon	O
)	O
-	O
Cbz	O
-	O
L	O
-	O
Lys	O
-	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
.	O

This	O
is	O
the	O
highest	O
k	O
(	O
cat	O
)	O
value	O
yet	O
reported	O
for	O
a	O
PBP	O
or	O
other	O
serine	O
peptidases	O
.	O
<EOS>	B-X
Lysosomal	B-X
hydrolases	B-X
,	B-X
known	B-X
as	B-X
cathepsins	B-X
,	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
several	B-X
groups	B-X
based	B-X
on	B-X
the	B-X
catalitic	B-X
residue	B-X
in	B-X
the	B-X
active	B-X
site	B-X
,	B-X
namely	B-X
,	B-X
cysteine	B-X
,	B-X
serine	B-X
and	B-X
aspartic	B-X
cathepsins	B-X
,	B-X
which	B-X
catalyse	B-X
the	B-X
cleavage	B-X
of	B-X
peptide	B-X
bonds	B-X
of	B-X
autophagy	B-X
substrates	B-X
and	B-X
,	B-X
together	B-X
with	B-X
other	B-X
factors	B-X
,	B-X
dispose	B-X
of	B-X
the	B-X
autophagic	B-X
flux	B-X
.	B-X
Whilst	B-X
most	B-X
cathepsins	B-X
degrade	B-X
autophagosomal	B-X
content	B-X
,	B-X
some	B-X
,	B-X
such	B-X
as	B-X
cathepsin	B-X
L	B-X
,	B-X
also	B-X
degrade	B-X
lysosomal	B-X
membrane	B-X
components	B-X
,	B-X
GABARAP-II	B-X
and	B-X
LC3-II	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
cathepsin	B-X
A	B-X
,	B-X
a	B-X
serine	B-X
protease	B-X
,	B-X
is	B-X
involved	B-X
in	B-X
inhibition	B-X
of	B-X
chaperon-mediated	B-X
autophagy	B-X
through	B-X
proteolytic	B-X
processing	B-X
of	B-X
LAMP-2A	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
the	B-X
current	B-X
state	B-X
of	B-X
knowledge	B-X
concerning	B-X
protein	B-X
degradation	B-X
by	B-X
autophagy	B-X
and	B-X
outline	B-X
the	B-X
role	B-X
of	B-X
proteases	B-X
in	B-X
autophagic	B-X
processes	B-X
.	B-X

Activity	O
against	O
a	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Lac	O
peptide	O
substrate	O
was	O
approximately	O
2	O
-	O
fold	O
lower	O
than	O
against	O
the	O
analogous	O
approximately	O
D	O
-	O
Ala	O
-	O
D	O
-	O
Ala	O
peptide	O
substrate	O
,	O
indicating	O
that	O
deacylation	O
is	O
rate	O
determining	O
for	O
both	O
amide	O
and	O
ester	O
hydrolysis	O
.	O
<EOS>	B-X
A	B-X
soluble	B-X
form	B-X
of	B-X
penicillin-binding	B-X
protein	B-X
3	B-X
(	B-X
PBP	B-X
3	B-X
)	B-X
from	B-X
Neisseria	B-X
gonorrhoeae	B-X
was	B-X
expressed	B-X
and	B-X
purified	B-X
from	B-X
Escherichia	B-X
coli	B-X
and	B-X
characterized	B-X
for	B-X
its	B-X
interaction	B-X
with	B-X
beta-lactam	B-X
antibiotics	B-X
,	B-X
its	B-X
catalytic	B-X
properties	B-X
with	B-X
peptide	B-X
and	B-X
peptidoglycan	B-X
substrates	B-X
,	B-X
and	B-X
its	B-X
role	B-X
in	B-X
cell	B-X
viability	B-X
and	B-X
morphology	B-X
.	B-X
PBP	B-X
3	B-X
had	B-X
an	B-X
unusually	B-X
high	B-X
k	B-X
(	B-X
2	B-X
)	B-X
/K	B-X
'	B-X
value	B-X
relative	B-X
to	B-X
other	B-X
PBPs	B-X
for	B-X
acylation	B-X
with	B-X
penicillin	B-X
(	B-X
7.7	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
)	B-X
at	B-X
pH	B-X
8.5	B-X
at	B-X
25	B-X
degrees	B-X
C	B-X
and	B-X
hydrolyzed	B-X
bound	B-X
antibiotic	B-X
very	B-X
slowly	B-X
(	B-X
k	B-X
(	B-X
3	B-X
)	B-X
<	B-X
4.6	B-X
x	B-X
10	B-X
(	B-X
-5	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
t	B-X
(	B-X
1/2	B-X
)	B-X
>	B-X
230	B-X
min	B-X
)	B-X
.	B-X
PBP	B-X
3	B-X
also	B-X
demonstrated	B-X
exceptionally	B-X
high	B-X
carboxypeptidase	B-X
activity	B-X
with	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
of	B-X
580	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
and	B-X
a	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
m	B-X
)	B-X
of	B-X
1.8	B-X
x	B-X
10	B-X
(	B-X
5	B-X
)	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
with	B-X
the	B-X
substrate	B-X
N	B-X
(	B-X
alpha	B-X
)	B-X
-Boc-N	B-X
(	B-X
epsilon	B-X
)	B-X
-Cbz-L-Lys-D-Ala-D-Ala.	B-X
Activity	B-X
against	B-X
a	B-X
approximately	B-X
D-Ala-D-Lac	B-X
peptide	B-X
substrate	B-X
was	B-X
approximately	B-X
2-fold	B-X
lower	B-X
than	B-X
against	B-X
the	B-X
analogous	B-X
approximately	B-X
D-Ala-D-Ala	B-X
peptide	B-X
substrate	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
is	B-X
rate	B-X
determining	B-X
for	B-X
both	B-X
amide	B-X
and	B-X
ester	B-X
hydrolysis	B-X
.	B-X
PBP	B-X
3	B-X
displayed	B-X
weak	B-X
transpeptidase	B-X
activity	B-X
in	B-X
a	B-X
model	B-X
transpeptidase	B-X
reaction	B-X
but	B-X
was	B-X
active	B-X
as	B-X
an	B-X
endopeptidase	B-X
,	B-X
cleaving	B-X
dimeric	B-X
peptide	B-X
cross-links	B-X
.	B-X
Deletion	B-X
of	B-X
PBP	B-X
3	B-X
alone	B-X
had	B-X
little	B-X
effect	B-X
on	B-X
viability	B-X
,	B-X
growth	B-X
rate	B-X
,	B-X
and	B-X
morphology	B-X
of	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
although	B-X
deletion	B-X
of	B-X
both	B-X
PBP	B-X
3	B-X
and	B-X
PBP	B-X
4	B-X
,	B-X
the	B-X
other	B-X
low-molecular-mass	B-X
PBP	B-X
in	B-X
N.	B-X
gonorrhoeae	B-X
,	B-X
resulted	B-X
in	B-X
a	B-X
decreased	B-X
growth	B-X
rate	B-X
and	B-X
marked	B-X
morphological	B-X
abnormalities	B-X
.	B-X

The	O
pH	O
dependence	O
profiles	O
of	O
both	O
carboxypeptidase	O
activity	O
and	O
beta	O
-	O
lactam	O
acylation	O
were	O
bell	O
-	O
shaped	O
with	O
maximal	O
activity	O
at	O
pH	O
8	O
.	O
0	O
-	O
8	O
.	O
5	O
.	O

PBP	B-Protein
3	I-Protein
displayed	O
weak	O
transpeptidase	O
activity	O
in	O
a	O
model	O
transpeptidase	O
reaction	O
but	O
was	O
active	O
as	O
an	O
endopeptidase	O
,	O
cleaving	O
dimeric	O
peptide	O
cross	O
-	O
links	O
.	O

Deletion	O
of	O
PBP	B-Protein
3	I-Protein
alone	O
had	O
little	O
effect	O
on	O
viability	O
,	O
growth	O
rate	O
,	O
and	O
morphology	O
of	O
N	O
.	O
gonorrhoeae	O
,	O
although	O
deletion	O
of	O
both	O
PBP	B-Protein
3	I-Protein
and	O
PBP	B-Protein
4	I-Protein
,	O
the	O
other	O
low	O
-	O
molecular	O
-	O
mass	O
PBP	O
in	O
N	O
.	O
gonorrhoeae	O
,	O
resulted	O
in	O
a	O
decreased	O
growth	O
rate	O
and	O
marked	O
morphological	O
abnormalities	O
.	O

A	O
recombinant	O
form	O
of	O
Pseudomonas	O
exotoxin	O
directed	O
at	O
the	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptor	I-Protein
that	O
is	O
cytotoxic	O
without	O
requiring	O
proteolytic	O
processing	O
.	O
<EOS>	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
is	B-X
composed	B-X
of	B-X
three	B-X
structural	B-X
domains	B-X
that	B-X
mediate	B-X
cell	B-X
recognition	B-X
(	B-X
I	B-X
)	B-X
,	B-X
membrane	B-X
translocation	B-X
(	B-X
II	B-X
)	B-X
,	B-X
and	B-X
ADP-ribosylation	B-X
(	B-X
III	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
mutant	B-X
protein	B-X
(	B-X
PE37	B-X
)	B-X
,	B-X
composed	B-X
of	B-X
amino	B-X
acids	B-X
280-613	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
,	B-X
which	B-X
does	B-X
not	B-X
require	B-X
proteolysis	B-X
to	B-X
translocate	B-X
.	B-X
PE37	B-X
was	B-X
targeted	B-X
specifically	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
by	B-X
inserting	B-X
transforming	B-X
growth	B-X
factor-alpha	B-X
(	B-X
TGF-alpha	B-X
)	B-X
after	B-X
amino	B-X
acid	B-X
607	B-X
near	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A.	B-X
PE37/TGF-alpha	B-X
was	B-X
very	B-X
cytotoxic	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
It	B-X
was	B-X
severalfold	B-X
more	B-X
cytotoxic	B-X
than	B-X
a	B-X
derivative	B-X
of	B-X
full-length	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
containing	B-X
TGF-alpha	B-X
in	B-X
the	B-X
same	B-X
position	B-X
,	B-X
probably	B-X
because	B-X
the	B-X
latter	B-X
requires	B-X
intracellular	B-X
proteolytic	B-X
processing	B-X
to	B-X
exhibit	B-X
its	B-X
cytotoxicity	B-X
,	B-X
and	B-X
proteolytic	B-X
processing	B-X
is	B-X
not	B-X
100	B-X
%	B-X
efficient	B-X
.	B-X
Deletion	B-X
of	B-X
2	B-X
,	B-X
4	B-X
,	B-X
or	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
PE37/TGF-alpha	B-X
greatly	B-X
diminished	B-X
cytotoxic	B-X
activity	B-X
,	B-X
indicating	B-X
the	B-X
need	B-X
for	B-X
a	B-X
proper	B-X
amino-terminal	B-X
sequence	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
mutant	B-X
containing	B-X
an	B-X
internal	B-X
deletion	B-X
of	B-X
amino	B-X
acids	B-X
314-380	B-X
was	B-X
minimally	B-X
active	B-X
,	B-X
indicating	B-X
that	B-X
other	B-X
regions	B-X
of	B-X
domain	B-X
II	B-X
are	B-X
also	B-X
required	B-X
for	B-X
the	B-X
cytotoxic	B-X
activity	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
.	B-X

Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
is	O
composed	O
of	O
three	O
structural	O
domains	O
that	O
mediate	O
cell	O
recognition	O
(	O
I	O
)	O
,	O
membrane	O
translocation	O
(	O
II	O
)	O
,	O
and	O
ADP	O
-	O
ribosylation	O
(	O
III	O
)	O
.	O

Within	O
the	O
cell	O
,	O
the	O
toxin	O
is	O
cleaved	O
within	O
domain	O
II	O
to	O
produce	O
a	O
37	O
-	O
kDa	O
carboxyl	O
-	O
terminal	O
fragment	O
,	O
containing	O
amino	O
acids	O
280	O
-	O
613	O
,	O
which	O
is	O
translocated	O
to	O
the	O
cytosol	O
and	O
causes	O
cell	O
death	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
mutant	O
protein	O
(	O
PE37	O
)	O
,	O
composed	O
of	O
amino	O
acids	O
280	O
-	O
613	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
,	O
which	O
does	O
not	O
require	O
proteolysis	O
to	O
translocate	O
.	O

PE37	O
was	O
targeted	O
specifically	O
to	O
cells	O
with	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
receptors	I-Protein
by	O
inserting	O
transforming	B-Protein
growth	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
(	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
)	O
after	O
amino	O
acid	O
607	O
near	O
the	O
carboxyl	O
terminus	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
.	O
<EOS>	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
is	B-X
composed	B-X
of	B-X
three	B-X
structural	B-X
domains	B-X
that	B-X
mediate	B-X
cell	B-X
recognition	B-X
(	B-X
I	B-X
)	B-X
,	B-X
membrane	B-X
translocation	B-X
(	B-X
II	B-X
)	B-X
,	B-X
and	B-X
ADP-ribosylation	B-X
(	B-X
III	B-X
)	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
the	B-X
toxin	B-X
is	B-X
cleaved	B-X
within	B-X
domain	B-X
II	B-X
to	B-X
produce	B-X
a	B-X
37-kDa	B-X
carboxyl-terminal	B-X
fragment	B-X
,	B-X
containing	B-X
amino	B-X
acids	B-X
280-613	B-X
,	B-X
which	B-X
is	B-X
translocated	B-X
to	B-X
the	B-X
cytosol	B-X
and	B-X
causes	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
mutant	B-X
protein	B-X
(	B-X
PE37	B-X
)	B-X
,	B-X
composed	B-X
of	B-X
amino	B-X
acids	B-X
280-613	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
,	B-X
which	B-X
does	B-X
not	B-X
require	B-X
proteolysis	B-X
to	B-X
translocate	B-X
.	B-X
PE37	B-X
was	B-X
targeted	B-X
specifically	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
by	B-X
inserting	B-X
transforming	B-X
growth	B-X
factor-alpha	B-X
(	B-X
TGF-alpha	B-X
)	B-X
after	B-X
amino	B-X
acid	B-X
607	B-X
near	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A.	B-X
PE37/TGF-alpha	B-X
was	B-X
very	B-X
cytotoxic	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
It	B-X
was	B-X
severalfold	B-X
more	B-X
cytotoxic	B-X
than	B-X
a	B-X
derivative	B-X
of	B-X
full-length	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
containing	B-X
TGF-alpha	B-X
in	B-X
the	B-X
same	B-X
position	B-X
,	B-X
probably	B-X
because	B-X
the	B-X
latter	B-X
requires	B-X
intracellular	B-X
proteolytic	B-X
processing	B-X
to	B-X
exhibit	B-X
its	B-X
cytotoxicity	B-X
,	B-X
and	B-X
proteolytic	B-X
processing	B-X
is	B-X
not	B-X
100	B-X
%	B-X
efficient	B-X
.	B-X
Deletion	B-X
of	B-X
2	B-X
,	B-X
4	B-X
,	B-X
or	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
PE37/TGF-alpha	B-X
greatly	B-X
diminished	B-X
cytotoxic	B-X
activity	B-X
,	B-X
indicating	B-X
the	B-X
need	B-X
for	B-X
a	B-X
proper	B-X
amino-terminal	B-X
sequence	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
mutant	B-X
containing	B-X
an	B-X
internal	B-X
deletion	B-X
of	B-X
amino	B-X
acids	B-X
314-380	B-X
was	B-X
minimally	B-X
active	B-X
,	B-X
indicating	B-X
that	B-X
other	B-X
regions	B-X
of	B-X
domain	B-X
II	B-X
are	B-X
also	B-X
required	B-X
for	B-X
the	B-X
cytotoxic	B-X
activity	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
.	B-X

PE37	O
/	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
was	O
very	O
cytotoxic	O
to	O
cells	O
with	O
epidermal	O
growth	O
factor	O
receptors	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
mutant	B-X
protein	B-X
(	B-X
PE37	B-X
)	B-X
,	B-X
composed	B-X
of	B-X
amino	B-X
acids	B-X
280-613	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
,	B-X
which	B-X
does	B-X
not	B-X
require	B-X
proteolysis	B-X
to	B-X
translocate	B-X
.	B-X
PE37	B-X
was	B-X
targeted	B-X
specifically	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
by	B-X
inserting	B-X
transforming	B-X
growth	B-X
factor-alpha	B-X
(	B-X
TGF-alpha	B-X
)	B-X
after	B-X
amino	B-X
acid	B-X
607	B-X
near	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A.	B-X
PE37/TGF-alpha	B-X
was	B-X
very	B-X
cytotoxic	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
It	B-X
was	B-X
severalfold	B-X
more	B-X
cytotoxic	B-X
than	B-X
a	B-X
derivative	B-X
of	B-X
full-length	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
containing	B-X
TGF-alpha	B-X
in	B-X
the	B-X
same	B-X
position	B-X
,	B-X
probably	B-X
because	B-X
the	B-X
latter	B-X
requires	B-X
intracellular	B-X
proteolytic	B-X
processing	B-X
to	B-X
exhibit	B-X
its	B-X
cytotoxicity	B-X
,	B-X
and	B-X
proteolytic	B-X
processing	B-X
is	B-X
not	B-X
100	B-X
%	B-X
efficient	B-X
.	B-X
Deletion	B-X
of	B-X
2	B-X
,	B-X
4	B-X
,	B-X
or	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
PE37/TGF-alpha	B-X
greatly	B-X
diminished	B-X
cytotoxic	B-X
activity	B-X
,	B-X
indicating	B-X
the	B-X
need	B-X
for	B-X
a	B-X
proper	B-X
amino-terminal	B-X
sequence	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
mutant	B-X
containing	B-X
an	B-X
internal	B-X
deletion	B-X
of	B-X
amino	B-X
acids	B-X
314-380	B-X
was	B-X
minimally	B-X
active	B-X
,	B-X
indicating	B-X
that	B-X
other	B-X
regions	B-X
of	B-X
domain	B-X
II	B-X
are	B-X
also	B-X
required	B-X
for	B-X
the	B-X
cytotoxic	B-X
activity	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
.	B-X

It	O
was	O
severalfold	O
more	O
cytotoxic	O
than	O
a	O
derivative	O
of	O
full	O
-	O
length	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
containing	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
in	O
the	O
same	O
position	O
,	O
probably	O
because	O
the	O
latter	O
requires	O
intracellular	O
proteolytic	O
processing	O
to	O
exhibit	O
its	O
cytotoxicity	O
,	O
and	O
proteolytic	O
processing	O
is	O
not	O
100	O
%	O
efficient	O
.	O

Deletion	O
of	O
2	O
,	O
4	O
,	O
or	O
7	O
amino	O
acids	O
from	O
the	O
amino	O
terminus	O
of	O
PE37	O
/	O
TGF	B-Protein
-	I-Protein
alpha	I-Protein
greatly	O
diminished	O
cytotoxic	O
activity	O
,	O
indicating	O
the	O
need	O
for	O
a	O
proper	O
amino	O
-	O
terminal	O
sequence	O
.	O
<EOS>	B-X
Depending	B-X
on	B-X
the	B-X
level	B-X
of	B-X
stringency	B-X
of	B-X
the	B-X
map	B-X
,	B-X
we	B-X
estimated	B-X
that	B-X
4.8-9.5	B-X
%	B-X
of	B-X
the	B-X
genome	B-X
contributes	B-X
to	B-X
CNV	B-X
and	B-X
found	B-X
approximately	B-X
100	B-X
genes	B-X
that	B-X
can	B-X
be	B-X
completely	B-X
deleted	B-X
without	B-X
producing	B-X
apparent	B-X
phenotypic	B-X
consequences	B-X
.	B-X
These	B-X
protocols	B-X
are	B-X
adapted	B-X
to	B-X
the	B-X
96-well	B-X
format	B-X
of	B-X
the	B-X
3004	B-X
strains	B-X
of	B-X
the	B-X
Version	B-X
2.0	B-X
Bioneer	B-X
set	B-X
but	B-X
can	B-X
also	B-X
be	B-X
used	B-X
for	B-X
later	B-X
releases	B-X
of	B-X
the	B-X
collection	B-X
.	B-X
22q11.2	B-X
deletion	B-X
syndrome	B-X
(	B-X
22q11DS	B-X
)	B-X
,	B-X
a	B-X
copy	B-X
number	B-X
variation	B-X
(	B-X
CNV	B-X
)	B-X
disorder	B-X
,	B-X
occurs	B-X
in	B-X
approximately	B-X
1:4000	B-X
live	B-X
births	B-X
due	B-X
to	B-X
a	B-X
heterozygous	B-X
microdeletion	B-X
at	B-X
position	B-X
11.2	B-X
(	B-X
proximal	B-X
)	B-X
on	B-X
the	B-X
q	B-X
arm	B-X
of	B-X
human	B-X
chromosome	B-X
22	B-X
(	B-X
hChr22	B-X
)	B-X
(	B-X
McDonald-McGinn	B-X
and	B-X
Sullivan	B-X
,	B-X
Medicine	B-X
90:1-18	B-X
,	B-X
2011	B-X
)	B-X
.	B-X
This	B-X
disorder	B-X
was	B-X
known	B-X
as	B-X
DiGeorge	B-X
syndrome	B-X
,	B-X
Velo-cardio-facial	B-X
syndrome	B-X
(	B-X
VCFS	B-X
)	B-X
or	B-X
conotruncal	B-X
anomaly	B-X
face	B-X
syndrome	B-X
(	B-X
CTAF	B-X
)	B-X
based	B-X
upon	B-X
diagnostic	B-X
cardiovascular	B-X
,	B-X
pharyngeal	B-X
,	B-X
and	B-X
craniofacial	B-X
anomalies	B-X
(	B-X
McDonald-McGinn	B-X
and	B-X
Sullivan	B-X
,	B-X
Medicine	B-X
90:1-18	B-X
,	B-X
2011	B-X
;	B-X
Burn	B-X
et	B-X
al.	B-X
,	B-X
J	B-X
Med	B-X
Genet	B-X
30:822-4	B-X
,	B-X
1993	B-X
)	B-X
before	B-X
this	B-X
phenotypic	B-X
spectrum	B-X
was	B-X
associated	B-X
with	B-X
22q11.2	B-X
CNVs	B-X
.	B-X
Subsequently	B-X
,	B-X
22q11.2	B-X
deletion	B-X
emerged	B-X
as	B-X
a	B-X
major	B-X
genomic	B-X
lesion	B-X
associated	B-X
with	B-X
vulnerability	B-X
for	B-X
several	B-X
clinically	B-X
defined	B-X
behavioral	B-X
deficits	B-X
common	B-X
to	B-X
a	B-X
number	B-X
of	B-X
neurodevelopmental	B-X
disorders	B-X
(	B-X
Fernandez	B-X
et	B-X
al.	B-X
,	B-X
Principles	B-X
of	B-X
Developmental	B-X
Genetics	B-X
,	B-X
2015	B-X
;	B-X
Robin	B-X
and	B-X
Shprintzen	B-X
,	B-X
J	B-X
Pediatr	B-X
147:90-6	B-X
,	B-X
2005	B-X
;	B-X
Schneider	B-X
et	B-X
al.	B-X
,	B-X
Am	B-X
J	B-X
Psychiatry	B-X
171:627-39	B-X
,	B-X
2014	B-X
)	B-X
.	B-X

In	O
addition	O
,	O
a	O
mutant	O
containing	O
an	O
internal	O
deletion	O
of	O
amino	O
acids	O
314	O
-	O
380	O
was	O
minimally	O
active	O
,	O
indicating	O
that	O
other	O
regions	O
of	O
domain	O
II	O
are	O
also	O
required	O
for	O
the	O
cytotoxic	O
activity	O
of	O
Pseudomonas	O
exotoxin	B-Protein
A	I-Protein
.	O
<EOS>	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
is	B-X
composed	B-X
of	B-X
three	B-X
structural	B-X
domains	B-X
that	B-X
mediate	B-X
cell	B-X
recognition	B-X
(	B-X
I	B-X
)	B-X
,	B-X
membrane	B-X
translocation	B-X
(	B-X
II	B-X
)	B-X
,	B-X
and	B-X
ADP-ribosylation	B-X
(	B-X
III	B-X
)	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
the	B-X
toxin	B-X
is	B-X
cleaved	B-X
within	B-X
domain	B-X
II	B-X
to	B-X
produce	B-X
a	B-X
37-kDa	B-X
carboxyl-terminal	B-X
fragment	B-X
,	B-X
containing	B-X
amino	B-X
acids	B-X
280-613	B-X
,	B-X
which	B-X
is	B-X
translocated	B-X
to	B-X
the	B-X
cytosol	B-X
and	B-X
causes	B-X
cell	B-X
death	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
constructed	B-X
a	B-X
mutant	B-X
protein	B-X
(	B-X
PE37	B-X
)	B-X
,	B-X
composed	B-X
of	B-X
amino	B-X
acids	B-X
280-613	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
,	B-X
which	B-X
does	B-X
not	B-X
require	B-X
proteolysis	B-X
to	B-X
translocate	B-X
.	B-X
PE37	B-X
was	B-X
targeted	B-X
specifically	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
by	B-X
inserting	B-X
transforming	B-X
growth	B-X
factor-alpha	B-X
(	B-X
TGF-alpha	B-X
)	B-X
after	B-X
amino	B-X
acid	B-X
607	B-X
near	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A.	B-X
PE37/TGF-alpha	B-X
was	B-X
very	B-X
cytotoxic	B-X
to	B-X
cells	B-X
with	B-X
epidermal	B-X
growth	B-X
factor	B-X
receptors	B-X
.	B-X
It	B-X
was	B-X
severalfold	B-X
more	B-X
cytotoxic	B-X
than	B-X
a	B-X
derivative	B-X
of	B-X
full-length	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
containing	B-X
TGF-alpha	B-X
in	B-X
the	B-X
same	B-X
position	B-X
,	B-X
probably	B-X
because	B-X
the	B-X
latter	B-X
requires	B-X
intracellular	B-X
proteolytic	B-X
processing	B-X
to	B-X
exhibit	B-X
its	B-X
cytotoxicity	B-X
,	B-X
and	B-X
proteolytic	B-X
processing	B-X
is	B-X
not	B-X
100	B-X
%	B-X
efficient	B-X
.	B-X
Deletion	B-X
of	B-X
2	B-X
,	B-X
4	B-X
,	B-X
or	B-X
7	B-X
amino	B-X
acids	B-X
from	B-X
the	B-X
amino	B-X
terminus	B-X
of	B-X
PE37/TGF-alpha	B-X
greatly	B-X
diminished	B-X
cytotoxic	B-X
activity	B-X
,	B-X
indicating	B-X
the	B-X
need	B-X
for	B-X
a	B-X
proper	B-X
amino-terminal	B-X
sequence	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
mutant	B-X
containing	B-X
an	B-X
internal	B-X
deletion	B-X
of	B-X
amino	B-X
acids	B-X
314-380	B-X
was	B-X
minimally	B-X
active	B-X
,	B-X
indicating	B-X
that	B-X
other	B-X
regions	B-X
of	B-X
domain	B-X
II	B-X
are	B-X
also	B-X
required	B-X
for	B-X
the	B-X
cytotoxic	B-X
activity	B-X
of	B-X
Pseudomonas	B-X
exotoxin	B-X
A	B-X
.	B-X

The	O
RAM1	B-Protein
gene	O
encoding	O
a	O
protein	B-Protein
-	I-Protein
farnesyltransferase	I-Protein
beta	I-Protein
-	I-Protein
subunit	I-Protein
homologue	I-Protein
is	O
essential	O
in	O
Cryptococcus	O
neoformans	O
.	O
<EOS>	B-X
Many	B-X
small	B-X
G	B-X
proteins	B-X
require	B-X
post-translational	B-X
modification	B-X
to	B-X
allow	B-X
functional	B-X
association	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X
This	B-X
process	B-X
often	B-X
involves	B-X
the	B-X
enzymic	B-X
addition	B-X
of	B-X
hydrophobic	B-X
prenyl	B-X
groups	B-X
to	B-X
a	B-X
conserved	B-X
cysteine	B-X
residue	B-X
near	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
enzymes	B-X
that	B-X
catalyse	B-X
these	B-X
reactions	B-X
include	B-X
protein	B-X
farnesyltransferase	B-X
and	B-X
protein	B-X
geranylgeranyltransferases	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
We	B-X
cloned	B-X
the	B-X
RAM1	B-X
gene	B-X
encoding	B-X
the	B-X
single	B-X
protein-farnesyltransferase	B-X
beta-chain	B-X
homologue	B-X
in	B-X
C.	B-X
neoformans	B-X
.	B-X
Using	B-X
a	B-X
gene-disruption	B-X
strategy	B-X
in	B-X
a	B-X
diploid	B-X
C.	B-X
neoformans	B-X
strain	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
this	B-X
gene	B-X
encodes	B-X
an	B-X
essential	B-X
function	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
case	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
in	B-X
which	B-X
the	B-X
homologous	B-X
RAM1	B-X
gene	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
growth	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X
Protein	B-X
farnesylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
differentiation	B-X
of	B-X
C.	B-X
neoformans	B-X
and	B-X
may	B-X
provide	B-X
novel	B-X
targets	B-X
for	B-X
antifungal	B-X
therapy	B-X
.	B-X

Many	O
small	O
G	O
proteins	O
require	O
post	O
-	O
translational	O
modification	O
to	O
allow	O
functional	O
association	O
to	O
the	O
cell	O
membrane	O
.	O

This	O
process	O
often	O
involves	O
the	O
enzymic	O
addition	O
of	O
hydrophobic	O
prenyl	O
groups	O
to	O
a	O
conserved	O
cysteine	O
residue	O
near	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
enzymes	O
that	O
catalyse	O
these	O
reactions	O
include	O
protein	O
farnesyltransferase	O
and	O
protein	O
geranylgeranyltransferases	O
.	O
<EOS>	B-X
Many	B-X
small	B-X
G	B-X
proteins	B-X
require	B-X
post-translational	B-X
modification	B-X
to	B-X
allow	B-X
functional	B-X
association	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X
This	B-X
process	B-X
often	B-X
involves	B-X
the	B-X
enzymic	B-X
addition	B-X
of	B-X
hydrophobic	B-X
prenyl	B-X
groups	B-X
to	B-X
a	B-X
conserved	B-X
cysteine	B-X
residue	B-X
near	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
enzymes	B-X
that	B-X
catalyse	B-X
these	B-X
reactions	B-X
include	B-X
protein	B-X
farnesyltransferase	B-X
and	B-X
protein	B-X
geranylgeranyltransferases	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
We	B-X
cloned	B-X
the	B-X
RAM1	B-X
gene	B-X
encoding	B-X
the	B-X
single	B-X
protein-farnesyltransferase	B-X
beta-chain	B-X
homologue	B-X
in	B-X
C.	B-X
neoformans	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X

The	O
human	O
fungal	O
pathogen	O
Cryptococcus	O
neoformans	O
requires	O
functional	O
Ras	B-Protein
and	O
Rho	B-Protein
proteins	O
in	O
order	O
to	O
undergo	O
normal	O
growth	O
and	O
differentiation	O
.	O
<EOS>	B-X
Many	B-X
small	B-X
G	B-X
proteins	B-X
require	B-X
post-translational	B-X
modification	B-X
to	B-X
allow	B-X
functional	B-X
association	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
We	B-X
cloned	B-X
the	B-X
RAM1	B-X
gene	B-X
encoding	B-X
the	B-X
single	B-X
protein-farnesyltransferase	B-X
beta-chain	B-X
homologue	B-X
in	B-X
C.	B-X
neoformans	B-X
.	B-X
Using	B-X
a	B-X
gene-disruption	B-X
strategy	B-X
in	B-X
a	B-X
diploid	B-X
C.	B-X
neoformans	B-X
strain	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
this	B-X
gene	B-X
encodes	B-X
an	B-X
essential	B-X
function	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
case	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
in	B-X
which	B-X
the	B-X
homologous	B-X
RAM1	B-X
gene	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
growth	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X
Simultaneous	B-X
inhibition	B-X
of	B-X
farnesylation	B-X
and	B-X
calcineurin	B-X
signalling	B-X
results	B-X
in	B-X
a	B-X
synthetic	B-X
effect	B-X
on	B-X
growth	B-X
.	B-X
Protein	B-X
farnesylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
differentiation	B-X
of	B-X
C.	B-X
neoformans	B-X
and	B-X
may	B-X
provide	B-X
novel	B-X
targets	B-X
for	B-X
antifungal	B-X
therapy	B-X
.	B-X

Since	O
farnesylation	O
and	O
geranylgeranylation	O
are	O
likely	O
required	O
for	O
the	O
proper	O
function	O
of	O
these	O
small	O
G	O
proteins	O
,	O
we	O
hypothesized	O
that	O
inhibition	O
of	O
these	O
prenylation	O
events	O
would	O
alter	O
the	O
growth	O
and	O
cellular	O
morphogenesis	O
of	O
this	O
fungus	O
.	O
<EOS>	B-X
Many	B-X
small	B-X
G	B-X
proteins	B-X
require	B-X
post-translational	B-X
modification	B-X
to	B-X
allow	B-X
functional	B-X
association	B-X
to	B-X
the	B-X
cell	B-X
membrane	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
Using	B-X
a	B-X
gene-disruption	B-X
strategy	B-X
in	B-X
a	B-X
diploid	B-X
C.	B-X
neoformans	B-X
strain	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
this	B-X
gene	B-X
encodes	B-X
an	B-X
essential	B-X
function	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
case	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
in	B-X
which	B-X
the	B-X
homologous	B-X
RAM1	B-X
gene	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
growth	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X
Simultaneous	B-X
inhibition	B-X
of	B-X
farnesylation	B-X
and	B-X
calcineurin	B-X
signalling	B-X
results	B-X
in	B-X
a	B-X
synthetic	B-X
effect	B-X
on	B-X
growth	B-X
.	B-X
Protein	B-X
farnesylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
differentiation	B-X
of	B-X
C.	B-X
neoformans	B-X
and	B-X
may	B-X
provide	B-X
novel	B-X
targets	B-X
for	B-X
antifungal	B-X
therapy	B-X
.	B-X

We	O
cloned	O
the	O
RAM1	B-Protein
gene	O
encoding	O
the	O
single	O
protein	B-Protein
-	I-Protein
farnesyltransferase	I-Protein
beta	I-Protein
-	I-Protein
chain	I-Protein
homologue	I-Protein
in	O
C	O
.	O
neoformans	O
.	O

Using	O
a	O
gene	O
-	O
disruption	O
strategy	O
in	O
a	O
diploid	O
C	O
.	O
neoformans	O
strain	O
,	O
we	O
demonstrated	O
that	O
this	O
gene	O
encodes	O
an	O
essential	O
function	O
,	O
in	O
contrast	O
to	O
the	O
case	O
in	O
Saccharomyces	O
cerevisiae	O
,	O
in	O
which	O
the	O
homologous	O
RAM1	B-Protein
gene	O
is	O
not	O
essential	O
for	O
growth	O
.	O

Pharmacological	O
inhibition	O
of	O
farnesyltransferase	O
activity	O
resulted	O
in	O
dose	O
-	O
dependent	O
cytostasis	O
of	O
C	O
.	O
neoformans	O
,	O
as	O
well	O
as	O
prevention	O
of	O
hyphal	O
differentiation	O
.	O
<EOS>	B-X
This	B-X
process	B-X
often	B-X
involves	B-X
the	B-X
enzymic	B-X
addition	B-X
of	B-X
hydrophobic	B-X
prenyl	B-X
groups	B-X
to	B-X
a	B-X
conserved	B-X
cysteine	B-X
residue	B-X
near	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
enzymes	B-X
that	B-X
catalyse	B-X
these	B-X
reactions	B-X
include	B-X
protein	B-X
farnesyltransferase	B-X
and	B-X
protein	B-X
geranylgeranyltransferases	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
We	B-X
cloned	B-X
the	B-X
RAM1	B-X
gene	B-X
encoding	B-X
the	B-X
single	B-X
protein-farnesyltransferase	B-X
beta-chain	B-X
homologue	B-X
in	B-X
C.	B-X
neoformans	B-X
.	B-X
Using	B-X
a	B-X
gene-disruption	B-X
strategy	B-X
in	B-X
a	B-X
diploid	B-X
C.	B-X
neoformans	B-X
strain	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
this	B-X
gene	B-X
encodes	B-X
an	B-X
essential	B-X
function	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
case	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
in	B-X
which	B-X
the	B-X
homologous	B-X
RAM1	B-X
gene	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
growth	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X
Simultaneous	B-X
inhibition	B-X
of	B-X
farnesylation	B-X
and	B-X
calcineurin	B-X
signalling	B-X
results	B-X
in	B-X
a	B-X
synthetic	B-X
effect	B-X
on	B-X
growth	B-X
.	B-X
Protein	B-X
farnesylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
differentiation	B-X
of	B-X
C.	B-X
neoformans	B-X
and	B-X
may	B-X
provide	B-X
novel	B-X
targets	B-X
for	B-X
antifungal	B-X
therapy	B-X
.	B-X

Simultaneous	O
inhibition	O
of	O
farnesylation	O
and	O
calcineurin	O
signalling	O
results	O
in	O
a	O
synthetic	O
effect	O
on	O
growth	O
.	O

Protein	O
farnesylation	O
is	O
required	O
for	O
the	O
growth	O
and	O
cellular	O
differentiation	O
of	O
C	O
.	O
neoformans	O
and	O
may	O
provide	O
novel	O
targets	O
for	O
antifungal	O
therapy	O
.	O
<EOS>	B-X
This	B-X
process	B-X
often	B-X
involves	B-X
the	B-X
enzymic	B-X
addition	B-X
of	B-X
hydrophobic	B-X
prenyl	B-X
groups	B-X
to	B-X
a	B-X
conserved	B-X
cysteine	B-X
residue	B-X
near	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
human	B-X
fungal	B-X
pathogen	B-X
Cryptococcus	B-X
neoformans	B-X
requires	B-X
functional	B-X
Ras	B-X
and	B-X
Rho	B-X
proteins	B-X
in	B-X
order	B-X
to	B-X
undergo	B-X
normal	B-X
growth	B-X
and	B-X
differentiation	B-X
.	B-X
Since	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
are	B-X
likely	B-X
required	B-X
for	B-X
the	B-X
proper	B-X
function	B-X
of	B-X
these	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
inhibition	B-X
of	B-X
these	B-X
prenylation	B-X
events	B-X
would	B-X
alter	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
morphogenesis	B-X
of	B-X
this	B-X
fungus	B-X
.	B-X
We	B-X
cloned	B-X
the	B-X
RAM1	B-X
gene	B-X
encoding	B-X
the	B-X
single	B-X
protein-farnesyltransferase	B-X
beta-chain	B-X
homologue	B-X
in	B-X
C.	B-X
neoformans	B-X
.	B-X
Using	B-X
a	B-X
gene-disruption	B-X
strategy	B-X
in	B-X
a	B-X
diploid	B-X
C.	B-X
neoformans	B-X
strain	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
this	B-X
gene	B-X
encodes	B-X
an	B-X
essential	B-X
function	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
the	B-X
case	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
in	B-X
which	B-X
the	B-X
homologous	B-X
RAM1	B-X
gene	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
growth	B-X
.	B-X
Pharmacological	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
activity	B-X
resulted	B-X
in	B-X
dose-dependent	B-X
cytostasis	B-X
of	B-X
C.	B-X
neoformans	B-X
,	B-X
as	B-X
well	B-X
as	B-X
prevention	B-X
of	B-X
hyphal	B-X
differentiation	B-X
.	B-X
Simultaneous	B-X
inhibition	B-X
of	B-X
farnesylation	B-X
and	B-X
calcineurin	B-X
signalling	B-X
results	B-X
in	B-X
a	B-X
synthetic	B-X
effect	B-X
on	B-X
growth	B-X
.	B-X
Protein	B-X
farnesylation	B-X
is	B-X
required	B-X
for	B-X
the	B-X
growth	B-X
and	B-X
cellular	B-X
differentiation	B-X
of	B-X
C.	B-X
neoformans	B-X
and	B-X
may	B-X
provide	B-X
novel	B-X
targets	B-X
for	B-X
antifungal	B-X
therapy	B-X
.	B-X

Lipoprotein	O
processing	O
is	O
required	O
for	O
virulence	O
of	O
Mycobacterium	O
tuberculosis	O
.	O
<EOS>	B-X
Lipoproteins	B-X
are	B-X
a	B-X
subgroup	B-X
of	B-X
secreted	B-X
bacterial	B-X
proteins	B-X
characterized	B-X
by	B-X
a	B-X
lipidated	B-X
N-terminus	B-X
,	B-X
processing	B-X
of	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
consecutive	B-X
activity	B-X
of	B-X
prolipoprotein	B-X
diacylglyceryl	B-X
transferase	B-X
(	B-X
Lgt	B-X
)	B-X
and	B-X
lipoprotein	B-X
signal	B-X
peptidase	B-X
(	B-X
LspA	B-X
)	B-X
.	B-X
To	B-X
study	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
LspA	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
infections	B-X
,	B-X
we	B-X
have	B-X
disrupted	B-X
lspA	B-X
by	B-X
allelic	B-X
replacement	B-X
in	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
one	B-X
of	B-X
the	B-X
world	B-X
's	B-X
most	B-X
devastating	B-X
pathogens	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
mutant	B-X
was	B-X
markedly	B-X
attenuated	B-X
in	B-X
virulence	B-X
models	B-X
of	B-X
tuberculosis	B-X
.	B-X
Our	B-X
findings	B-X
establish	B-X
lipoprotein	B-X
metabolism	B-X
as	B-X
a	B-X
major	B-X
virulence	B-X
determinant	B-X
of	B-X
tuberculosis	B-X
and	B-X
define	B-X
a	B-X
role	B-X
for	B-X
lipoprotein	B-X
processing	B-X
in	B-X
bacterial	B-X
pathogenesis	B-X
.	B-X

Lipoproteins	O
are	O
a	O
subgroup	O
of	O
secreted	O
bacterial	O
proteins	O
characterized	O
by	O
a	O
lipidated	O
N	O
-	O
terminus	O
,	O
processing	O
of	O
which	O
is	O
mediated	O
by	O
the	O
consecutive	O
activity	O
of	O
prolipoprotein	B-Protein
diacylglyceryl	I-Protein
transferase	I-Protein
(	O
Lgt	B-Protein
)	O
and	O
lipoprotein	B-Protein
signal	I-Protein
peptidase	I-Protein
(	O
LspA	B-Protein
)	O
.	O
<EOS>	B-X
Lipoproteins	B-X
are	B-X
a	B-X
subgroup	B-X
of	B-X
secreted	B-X
bacterial	B-X
proteins	B-X
characterized	B-X
by	B-X
a	B-X
lipidated	B-X
N-terminus	B-X
,	B-X
processing	B-X
of	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
consecutive	B-X
activity	B-X
of	B-X
prolipoprotein	B-X
diacylglyceryl	B-X
transferase	B-X
(	B-X
Lgt	B-X
)	B-X
and	B-X
lipoprotein	B-X
signal	B-X
peptidase	B-X
(	B-X
LspA	B-X
)	B-X
.	B-X
The	B-X
study	B-X
of	B-X
LspA	B-X
function	B-X
has	B-X
been	B-X
limited	B-X
mainly	B-X
to	B-X
non-pathogenic	B-X
microorganisms	B-X
.	B-X
To	B-X
study	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
LspA	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
infections	B-X
,	B-X
we	B-X
have	B-X
disrupted	B-X
lspA	B-X
by	B-X
allelic	B-X
replacement	B-X
in	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
one	B-X
of	B-X
the	B-X
world	B-X
's	B-X
most	B-X
devastating	B-X
pathogens	B-X
.	B-X
Despite	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
impermeable	B-X
lipid	B-X
outer	B-X
layer	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
LspA	B-X
was	B-X
dispensable	B-X
for	B-X
growth	B-X
under	B-X
in	B-X
vitro	B-X
culture	B-X
conditions	B-X
.	B-X
Our	B-X
findings	B-X
establish	B-X
lipoprotein	B-X
metabolism	B-X
as	B-X
a	B-X
major	B-X
virulence	B-X
determinant	B-X
of	B-X
tuberculosis	B-X
and	B-X
define	B-X
a	B-X
role	B-X
for	B-X
lipoprotein	B-X
processing	B-X
in	B-X
bacterial	B-X
pathogenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
results	B-X
hint	B-X
at	B-X
a	B-X
promising	B-X
new	B-X
target	B-X
for	B-X
therapeutic	B-X
intervention	B-X
,	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
inhibitor	B-X
of	B-X
bacterial	B-X
lipoprotein	B-X
signal	B-X
peptidases	B-X
is	B-X
available	B-X
.	B-X

The	O
study	O
of	O
LspA	B-Protein
function	O
has	O
been	O
limited	O
mainly	O
to	O
non	O
-	O
pathogenic	O
microorganisms	O
.	O

To	O
study	O
a	O
potential	O
role	O
for	O
LspA	B-Protein
in	O
the	O
pathogenesis	O
of	O
bacterial	O
infections	O
,	O
we	O
have	O
disrupted	O
lspA	B-Protein
by	O
allelic	O
replacement	O
in	O
Mycobacterium	O
tuberculosis	O
,	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
pathogens	O
.	O
<EOS>	B-X
Lipoproteins	B-X
are	B-X
a	B-X
subgroup	B-X
of	B-X
secreted	B-X
bacterial	B-X
proteins	B-X
characterized	B-X
by	B-X
a	B-X
lipidated	B-X
N-terminus	B-X
,	B-X
processing	B-X
of	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
consecutive	B-X
activity	B-X
of	B-X
prolipoprotein	B-X
diacylglyceryl	B-X
transferase	B-X
(	B-X
Lgt	B-X
)	B-X
and	B-X
lipoprotein	B-X
signal	B-X
peptidase	B-X
(	B-X
LspA	B-X
)	B-X
.	B-X
The	B-X
study	B-X
of	B-X
LspA	B-X
function	B-X
has	B-X
been	B-X
limited	B-X
mainly	B-X
to	B-X
non-pathogenic	B-X
microorganisms	B-X
.	B-X
To	B-X
study	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
LspA	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
infections	B-X
,	B-X
we	B-X
have	B-X
disrupted	B-X
lspA	B-X
by	B-X
allelic	B-X
replacement	B-X
in	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
one	B-X
of	B-X
the	B-X
world	B-X
's	B-X
most	B-X
devastating	B-X
pathogens	B-X
.	B-X
Despite	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
impermeable	B-X
lipid	B-X
outer	B-X
layer	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
LspA	B-X
was	B-X
dispensable	B-X
for	B-X
growth	B-X
under	B-X
in	B-X
vitro	B-X
culture	B-X
conditions	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
mutant	B-X
was	B-X
markedly	B-X
attenuated	B-X
in	B-X
virulence	B-X
models	B-X
of	B-X
tuberculosis	B-X
.	B-X
Our	B-X
findings	B-X
establish	B-X
lipoprotein	B-X
metabolism	B-X
as	B-X
a	B-X
major	B-X
virulence	B-X
determinant	B-X
of	B-X
tuberculosis	B-X
and	B-X
define	B-X
a	B-X
role	B-X
for	B-X
lipoprotein	B-X
processing	B-X
in	B-X
bacterial	B-X
pathogenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
results	B-X
hint	B-X
at	B-X
a	B-X
promising	B-X
new	B-X
target	B-X
for	B-X
therapeutic	B-X
intervention	B-X
,	B-X
as	B-X
a	B-X
highly	B-X
specific	B-X
inhibitor	B-X
of	B-X
bacterial	B-X
lipoprotein	B-X
signal	B-X
peptidases	B-X
is	B-X
available	B-X
.	B-X

Despite	O
the	O
presence	O
of	O
an	O
impermeable	O
lipid	O
outer	O
layer	O
,	O
it	O
was	O
found	O
that	O
LspA	B-Protein
was	O
dispensable	O
for	O
growth	O
under	O
in	O
vitro	O
culture	O
conditions	O
.	O
<EOS>	B-X
Lipoproteins	B-X
are	B-X
a	B-X
subgroup	B-X
of	B-X
secreted	B-X
bacterial	B-X
proteins	B-X
characterized	B-X
by	B-X
a	B-X
lipidated	B-X
N-terminus	B-X
,	B-X
processing	B-X
of	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
consecutive	B-X
activity	B-X
of	B-X
prolipoprotein	B-X
diacylglyceryl	B-X
transferase	B-X
(	B-X
Lgt	B-X
)	B-X
and	B-X
lipoprotein	B-X
signal	B-X
peptidase	B-X
(	B-X
LspA	B-X
)	B-X
.	B-X
The	B-X
study	B-X
of	B-X
LspA	B-X
function	B-X
has	B-X
been	B-X
limited	B-X
mainly	B-X
to	B-X
non-pathogenic	B-X
microorganisms	B-X
.	B-X
To	B-X
study	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
LspA	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
infections	B-X
,	B-X
we	B-X
have	B-X
disrupted	B-X
lspA	B-X
by	B-X
allelic	B-X
replacement	B-X
in	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
one	B-X
of	B-X
the	B-X
world	B-X
's	B-X
most	B-X
devastating	B-X
pathogens	B-X
.	B-X
Despite	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
impermeable	B-X
lipid	B-X
outer	B-X
layer	B-X
,	B-X
it	B-X
was	B-X
found	B-X
that	B-X
LspA	B-X
was	B-X
dispensable	B-X
for	B-X
growth	B-X
under	B-X
in	B-X
vitro	B-X
culture	B-X
conditions	B-X
.	B-X

In	O
contrast	O
,	O
the	O
mutant	O
was	O
markedly	O
attenuated	O
in	O
virulence	O
models	O
of	O
tuberculosis	O
.	O
<EOS>	B-X
To	B-X
study	B-X
a	B-X
potential	B-X
role	B-X
for	B-X
LspA	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
bacterial	B-X
infections	B-X
,	B-X
we	B-X
have	B-X
disrupted	B-X
lspA	B-X
by	B-X
allelic	B-X
replacement	B-X
in	B-X
Mycobacterium	B-X
tuberculosis	B-X
,	B-X
one	B-X
of	B-X
the	B-X
world	B-X
's	B-X
most	B-X
devastating	B-X
pathogens	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
mutant	B-X
was	B-X
markedly	B-X
attenuated	B-X
in	B-X
virulence	B-X
models	B-X
of	B-X
tuberculosis	B-X
.	B-X
Our	B-X
findings	B-X
establish	B-X
lipoprotein	B-X
metabolism	B-X
as	B-X
a	B-X
major	B-X
virulence	B-X
determinant	B-X
of	B-X
tuberculosis	B-X
and	B-X
define	B-X
a	B-X
role	B-X
for	B-X
lipoprotein	B-X
processing	B-X
in	B-X
bacterial	B-X
pathogenesis	B-X
.	B-X
Reactive	B-X
nitrogen	B-X
species	B-X
(	B-X
RNS	B-X
)	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
host	B-X
defence	B-X
against	B-X
Mycobacterium	B-X
tuberculosis	B-X
(	B-X
MTB	B-X
)	B-X
in	B-X
the	B-X
mouse	B-X
model	B-X
of	B-X
tuberculosis	B-X
(	B-X
TB	B-X
)	B-X
,	B-X
as	B-X
evidenced	B-X
by	B-X
the	B-X
increased	B-X
susceptibility	B-X
of	B-X
mice	B-X
deficient	B-X
in	B-X
the	B-X
inducible	B-X
isoform	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
NOS2	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
role	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
in	B-X
protection	B-X
against	B-X
MTB	B-X
is	B-X
less	B-X
clear	B-X
,	B-X
and	B-X
mice	B-X
defective	B-X
in	B-X
the	B-X
ROS-generating	B-X
phagocyte	B-X
NADPH	B-X
oxidase	B-X
(	B-X
Phox	B-X
)	B-X
are	B-X
relatively	B-X
resistant	B-X
.	B-X
In	B-X
order	B-X
to	B-X
assess	B-X
the	B-X
role	B-X
of	B-X
ROS	B-X
detoxification	B-X
pathways	B-X
in	B-X
MTB	B-X
virulence	B-X
,	B-X
we	B-X
generated	B-X
a	B-X
katG	B-X
null	B-X
mutant	B-X
of	B-X
MTB	B-X
,	B-X
deficient	B-X
in	B-X
the	B-X
KatG	B-X
catalase-peroxidase-peroxynitritase	B-X
,	B-X
and	B-X
evaluated	B-X
the	B-X
mutant	B-X
's	B-X
ability	B-X
to	B-X
replicate	B-X
and	B-X
persist	B-X
in	B-X
macrophages	B-X
and	B-X
mice	B-X
.	B-X
Although	B-X
markedly	B-X
attenuated	B-X
in	B-X
wild-type	B-X
C57Bl/6	B-X
mice	B-X
and	B-X
NOS2	B-X
(	B-X
-/-	B-X
)	B-X
mice	B-X
,	B-X
the	B-X
DeltakatG	B-X
MTB	B-X
strain	B-X
was	B-X
indistinguishable	B-X
from	B-X
wild-type	B-X
MTB	B-X
in	B-X
its	B-X
ability	B-X
to	B-X
replicate	B-X
and	B-X
persist	B-X
in	B-X
gp91	B-X
(	B-X
Phox-/-	B-X
)	B-X
mice	B-X
lacking	B-X
the	B-X
gp91	B-X
subunit	B-X
of	B-X
NADPH	B-X
oxidase	B-X
.	B-X

Our	O
findings	O
establish	O
lipoprotein	O
metabolism	O
as	O
a	O
major	O
virulence	O
determinant	O
of	O
tuberculosis	O
and	O
define	O
a	O
role	O
for	O
lipoprotein	O
processing	O
in	O
bacterial	O
pathogenesis	O
.	O

In	O
addition	O
,	O
these	O
results	O
hint	O
at	O
a	O
promising	O
new	O
target	O
for	O
therapeutic	O
intervention	O
,	O
as	O
a	O
highly	O
specific	O
inhibitor	O
of	O
bacterial	O
lipoprotein	O
signal	O
peptidases	O
is	O
available	O
.	O

Two	O
closely	O
related	O
ubiquitin	B-Protein
C	O
-	O
terminal	O
hydrolase	O
isozymes	O
function	O
as	O
reciprocal	O
modulators	O
of	O
germ	O
cell	O
apoptosis	O
in	O
cryptorchid	O
testis	O
.	O
<EOS>	B-X
The	B-X
two	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
These	B-X
two	B-X
UCH	B-X
isozymes	B-X
have	B-X
52	B-X
%	B-X
amino	B-X
acid	B-X
identity	B-X
and	B-X
share	B-X
significant	B-X
structural	B-X
similarity	B-X
.	B-X
A	B-X
new	B-X
function	B-X
of	B-X
these	B-X
two	B-X
closely	B-X
related	B-X
UCH	B-X
enzymes	B-X
during	B-X
spermatogenesis	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
germ	B-X
cell	B-X
apoptosis	B-X
has	B-X
been	B-X
analyzed	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
During	B-X
spermatogenesis	B-X
,	B-X
apoptosis	B-X
controls	B-X
germ	B-X
cell	B-X
numbers	B-X
and	B-X
eliminates	B-X
defective	B-X
germ	B-X
cells	B-X
to	B-X
facilitate	B-X
testicular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
I	B-X
review	B-X
the	B-X
distinct	B-X
function	B-X
of	B-X
the	B-X
two	B-X
UCH	B-X
isozymes	B-X
in	B-X
the	B-X
testis	B-X
of	B-X
gad	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
which	B-X
are	B-X
strongly	B-X
but	B-X
reciprocally	B-X
expressed	B-X
during	B-X
spermatogenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
importance	B-X
of	B-X
UCHL1-dependent	B-X
apoptosis	B-X
for	B-X
normal	B-X
spermatogenesis	B-X
and	B-X
sperm	B-X
quality	B-X
control	B-X
is	B-X
discussed	B-X
.	B-X

The	O
experimentally	O
induced	O
cryptorchid	O
mouse	O
model	O
is	O
useful	O
for	O
elucidating	O
the	O
in	O
vivo	O
molecular	O
mechanism	O
of	O
germ	O
cell	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

Apoptosis	O
,	O
in	O
general	O
,	O
is	O
thought	O
to	O
be	O
partly	O
regulated	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
.	O
<EOS>	B-X
The	B-X
two	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X

Here	O
,	O
we	O
analyzed	O
the	O
function	O
of	O
two	O
closely	O
related	O
members	O
of	O
the	O
ubiquitin	B-Protein
C	O
-	O
terminal	O
hydrolase	O
(	O
UCH	O
)	O
family	O
in	O
testicular	O
germ	O
cell	O
apoptosis	O
experimentally	O
induced	O
by	O
cryptorchidism	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

The	O
two	O
enzymes	O
,	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
and	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
,	O
deubiquitinate	O
ubiquitin	B-Protein
-	O
protein	O
conjugates	O
and	O
control	O
the	O
cellular	O
balance	O
of	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
The	B-X
two	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
These	B-X
two	B-X
UCH	B-X
isozymes	B-X
have	B-X
52	B-X
%	B-X
amino	B-X
acid	B-X
identity	B-X
and	B-X
share	B-X
significant	B-X
structural	B-X
similarity	B-X
.	B-X
A	B-X
new	B-X
function	B-X
of	B-X
these	B-X
two	B-X
closely	B-X
related	B-X
UCH	B-X
enzymes	B-X
during	B-X
spermatogenesis	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
germ	B-X
cell	B-X
apoptosis	B-X
has	B-X
been	B-X
analyzed	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
During	B-X
spermatogenesis	B-X
,	B-X
apoptosis	B-X
controls	B-X
germ	B-X
cell	B-X
numbers	B-X
and	B-X
eliminates	B-X
defective	B-X
germ	B-X
cells	B-X
to	B-X
facilitate	B-X
testicular	B-X
homeostasis	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
I	B-X
review	B-X
the	B-X
distinct	B-X
function	B-X
of	B-X
the	B-X
two	B-X
UCH	B-X
isozymes	B-X
in	B-X
the	B-X
testis	B-X
of	B-X
gad	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
which	B-X
are	B-X
strongly	B-X
but	B-X
reciprocally	B-X
expressed	B-X
during	B-X
spermatogenesis	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
importance	B-X
of	B-X
UCHL1-dependent	B-X
apoptosis	B-X
for	B-X
normal	B-X
spermatogenesis	B-X
and	B-X
sperm	B-X
quality	B-X
control	B-X
is	B-X
discussed	B-X
.	B-X

The	O
testes	O
of	O
gracile	O
axonal	O
dystrophy	O
(	O
gad	O
)	O
mice	O
,	O
which	O
lack	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
,	O
were	O
resistant	O
to	O
cryptorchid	O
stress	O
-	O
related	O
injury	O
and	O
had	O
reduced	O
ubiquitin	B-Protein
levels	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
Ubiquitin	B-X
level	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
wild-type	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
levels	B-X
of	B-X
Nedd8	B-X
and	B-X
the	B-X
apoptotic	B-X
proteins	B-X
p53	B-X
,	B-X
Bax	B-X
,	B-X
and	B-X
caspase3	B-X
were	B-X
elevated	B-X
in	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

The	O
level	O
of	O
both	O
anti	O
-	O
apoptotic	O
(	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
family	O
and	O
XIAP	B-Protein
)	O
and	O
prosurvival	O
(	O
pCREB	O
and	O
BDNF	B-Protein
)	O
proteins	O
was	O
significantly	O
higher	O
in	O
gad	O
mice	O
after	O
cryptorchid	O
stress	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
Ubiquitin	B-X
level	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
wild-type	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
levels	B-X
of	B-X
Nedd8	B-X
and	B-X
the	B-X
apoptotic	B-X
proteins	B-X
p53	B-X
,	B-X
Bax	B-X
,	B-X
and	B-X
caspase3	B-X
were	B-X
elevated	B-X
in	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

In	O
contrast	O
,	O
Uchl3	B-Protein
knockout	O
mice	O
showed	O
profound	O
testicular	O
atrophy	O
and	O
apoptotic	O
germ	O
cell	O
loss	O
after	O
cryptorchid	O
injury	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
Ubiquitin	B-X
level	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
wild-type	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
levels	B-X
of	B-X
Nedd8	B-X
and	B-X
the	B-X
apoptotic	B-X
proteins	B-X
p53	B-X
,	B-X
Bax	B-X
,	B-X
and	B-X
caspase3	B-X
were	B-X
elevated	B-X
in	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

Ubiquitin	B-Protein
level	O
was	O
not	O
significantly	O
different	O
between	O
wild	O
-	O
type	O
and	O
Uchl3	B-Protein
knockout	O
mice	O
,	O
whereas	O
the	O
levels	O
of	O
Nedd8	B-Protein
and	O
the	O
apoptotic	O
proteins	O
p53	B-Protein
,	O
Bax	B-Protein
,	O
and	O
caspase3	B-Protein
were	O
elevated	O
in	O
Uchl3	B-Protein
knockout	O
mice	O
.	O
<EOS>	B-X
Ubiquitination	B-X
is	B-X
tightly	B-X
regulated	B-X
at	B-X
different	B-X
levels	B-X
by	B-X
a	B-X
range	B-X
of	B-X
enzymes	B-X
including	B-X
E1s	B-X
,	B-X
E2s	B-X
,	B-X
and	B-X
E3s	B-X
,	B-X
and	B-X
an	B-X
array	B-X
of	B-X
DUBs	B-X
.	B-X
The	B-X
UPS	B-X
directs	B-X
protein	B-X
degradation	B-X
through	B-X
the	B-X
proteasome	B-X
,	B-X
and	B-X
regulates	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
cellular	B-X
processes	B-X
including	B-X
transcription	B-X
and	B-X
epigenetic	B-X
factors	B-X
as	B-X
well	B-X
as	B-X
key	B-X
oncoproteins	B-X
.	B-X
Ubiquitination	B-X
is	B-X
key	B-X
to	B-X
the	B-X
dynamic	B-X
regulation	B-X
of	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
Protein	B-X
ubiquitination	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
powerful	B-X
posttranslational	B-X
modifications	B-X
of	B-X
proteins	B-X
,	B-X
as	B-X
it	B-X
regulates	B-X
a	B-X
plethora	B-X
of	B-X
cellular	B-X
processes	B-X
in	B-X
distinct	B-X
manners	B-X
.	B-X
Simple	B-X
monoubiquitination	B-X
events	B-X
coexist	B-X
with	B-X
more	B-X
complex	B-X
forms	B-X
of	B-X
polyubiquitination	B-X
,	B-X
the	B-X
latter	B-X
featuring	B-X
many	B-X
different	B-X
chain	B-X
architectures	B-X
.	B-X
Ubiquitin	B-X
can	B-X
be	B-X
subjected	B-X
to	B-X
further	B-X
posttranslational	B-X
modifications	B-X
(	B-X
e.g.	B-X
,	B-X
phosphorylation	B-X
and	B-X
acetylation	B-X
)	B-X
and	B-X
can	B-X
also	B-X
be	B-X
part	B-X
of	B-X
mixed	B-X
polymers	B-X
with	B-X
ubiquitin-like	B-X
modifiers	B-X
such	B-X
as	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
or	B-X
NEDD8	B-X
(	B-X
neural	B-X
precursor	B-X
cell	B-X
expressed	B-X
,	B-X
developmentally	B-X
downregulated	B-X
8	B-X
)	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
conceptualize	B-X
the	B-X
many	B-X
layers	B-X
of	B-X
specificity	B-X
that	B-X
DUBs	B-X
encompass	B-X
to	B-X
control	B-X
the	B-X
ubiquitin	B-X
code	B-X
and	B-X
discuss	B-X
examples	B-X
in	B-X
which	B-X
DUB	B-X
specificity	B-X
has	B-X
been	B-X
understood	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
UCH	B-Protein
-	I-Protein
L1	I-Protein
and	O
UCH	B-Protein
-	I-Protein
L3	I-Protein
function	O
differentially	O
to	O
regulate	O
the	O
cellular	O
levels	O
of	O
anti	O
-	O
apoptotic	O
,	O
prosurvival	O
,	O
and	O
apoptotic	O
proteins	O
during	O
testicular	O
germ	O
cell	O
apoptosis	O
.	O
<EOS>	B-X
The	B-X
experimentally	B-X
induced	B-X
cryptorchid	B-X
mouse	B-X
model	B-X
is	B-X
useful	B-X
for	B-X
elucidating	B-X
the	B-X
in	B-X
vivo	B-X
molecular	B-X
mechanism	B-X
of	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X
Apoptosis	B-X
,	B-X
in	B-X
general	B-X
,	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
partly	B-X
regulated	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
analyzed	B-X
the	B-X
function	B-X
of	B-X
two	B-X
closely	B-X
related	B-X
members	B-X
of	B-X
the	B-X
ubiquitin	B-X
C-terminal	B-X
hydrolase	B-X
(	B-X
UCH	B-X
)	B-X
family	B-X
in	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
experimentally	B-X
induced	B-X
by	B-X
cryptorchidism	B-X
.	B-X
The	B-X
two	B-X
enzymes	B-X
,	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
,	B-X
deubiquitinate	B-X
ubiquitin-protein	B-X
conjugates	B-X
and	B-X
control	B-X
the	B-X
cellular	B-X
balance	B-X
of	B-X
ubiquitin	B-X
.	B-X
The	B-X
testes	B-X
of	B-X
gracile	B-X
axonal	B-X
dystrophy	B-X
(	B-X
gad	B-X
)	B-X
mice	B-X
,	B-X
which	B-X
lack	B-X
UCH-L1	B-X
,	B-X
were	B-X
resistant	B-X
to	B-X
cryptorchid	B-X
stress-related	B-X
injury	B-X
and	B-X
had	B-X
reduced	B-X
ubiquitin	B-X
levels	B-X
.	B-X
The	B-X
level	B-X
of	B-X
both	B-X
anti-apoptotic	B-X
(	B-X
Bcl-2	B-X
family	B-X
and	B-X
XIAP	B-X
)	B-X
and	B-X
prosurvival	B-X
(	B-X
pCREB	B-X
and	B-X
BDNF	B-X
)	B-X
proteins	B-X
was	B-X
significantly	B-X
higher	B-X
in	B-X
gad	B-X
mice	B-X
after	B-X
cryptorchid	B-X
stress	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
showed	B-X
profound	B-X
testicular	B-X
atrophy	B-X
and	B-X
apoptotic	B-X
germ	B-X
cell	B-X
loss	B-X
after	B-X
cryptorchid	B-X
injury	B-X
.	B-X
Ubiquitin	B-X
level	B-X
was	B-X
not	B-X
significantly	B-X
different	B-X
between	B-X
wild-type	B-X
and	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
,	B-X
whereas	B-X
the	B-X
levels	B-X
of	B-X
Nedd8	B-X
and	B-X
the	B-X
apoptotic	B-X
proteins	B-X
p53	B-X
,	B-X
Bax	B-X
,	B-X
and	B-X
caspase3	B-X
were	B-X
elevated	B-X
in	B-X
Uchl3	B-X
knockout	B-X
mice	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
UCH-L1	B-X
and	B-X
UCH-L3	B-X
function	B-X
differentially	B-X
to	B-X
regulate	B-X
the	B-X
cellular	B-X
levels	B-X
of	B-X
anti-apoptotic	B-X
,	B-X
prosurvival	B-X
,	B-X
and	B-X
apoptotic	B-X
proteins	B-X
during	B-X
testicular	B-X
germ	B-X
cell	B-X
apoptosis	B-X
.	B-X

Structure	O
of	O
a	O
complex	O
between	O
Nedd8	B-Protein
and	O
the	O
Ulp	O
/	O
Senp	O
protease	O
family	O
member	O
Den1	B-Protein
.	O
<EOS>	B-X
The	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
is	B-X
conserved	B-X
from	B-X
yeast	B-X
to	B-X
humans	B-X
and	B-X
is	B-X
essential	B-X
in	B-X
many	B-X
organisms	B-X
.	B-X
Nedd8	B-X
is	B-X
conjugated	B-X
to	B-X
cullin	B-X
proteins	B-X
in	B-X
a	B-X
process	B-X
that	B-X
alters	B-X
SCF	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
,	B-X
and	B-X
it	B-X
is	B-X
presumed	B-X
that	B-X
Nedd8	B-X
deconjugation	B-X
would	B-X
reverse	B-X
these	B-X
effects	B-X
.	B-X
We	B-X
now	B-X
report	B-X
the	B-X
X-ray	B-X
structures	B-X
of	B-X
the	B-X
human	B-X
Nedd8-specific	B-X
protease	B-X
,	B-X
Den1	B-X
,	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
inhibitor	B-X
Nedd8	B-X
aldehyde	B-X
,	B-X
thus	B-X
revealing	B-X
a	B-X
model	B-X
for	B-X
the	B-X
tetrahedral	B-X
transition	B-X
state	B-X
intermediate	B-X
generated	B-X
during	B-X
proteolysis	B-X
.	B-X
Although	B-X
Den1	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
SUMO-specific	B-X
protease	B-X
family	B-X
(	B-X
Ulp/Senp	B-X
family	B-X
)	B-X
,	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
interface	B-X
suggests	B-X
determinants	B-X
involved	B-X
in	B-X
Nedd8	B-X
selectivity	B-X
by	B-X
Den1	B-X
over	B-X
other	B-X
ubiquitin-like	B-X
family	B-X
members	B-X
and	B-X
suggests	B-X
how	B-X
the	B-X
Ulp/Senp	B-X
architecture	B-X
has	B-X
been	B-X
modified	B-X
to	B-X
interact	B-X
with	B-X
different	B-X
ubiquitin-like	B-X
modifiers	B-X
.	B-X

The	O
Nedd8	B-Protein
conjugation	O
pathway	O
is	O
conserved	O
from	O
yeast	O
to	O
humans	O
and	O
is	O
essential	O
in	O
many	O
organisms	O
.	O
<EOS>	B-X
The	B-X
Nedd8	B-X
conjugation	B-X
pathway	B-X
is	B-X
conserved	B-X
from	B-X
yeast	B-X
to	B-X
humans	B-X
and	B-X
is	B-X
essential	B-X
in	B-X
many	B-X
organisms	B-X
.	B-X
Nedd8	B-X
is	B-X
conjugated	B-X
to	B-X
cullin	B-X
proteins	B-X
in	B-X
a	B-X
process	B-X
that	B-X
alters	B-X
SCF	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
activity	B-X
,	B-X
and	B-X
it	B-X
is	B-X
presumed	B-X
that	B-X
Nedd8	B-X
deconjugation	B-X
would	B-X
reverse	B-X
these	B-X
effects	B-X
.	B-X
We	B-X
now	B-X
report	B-X
the	B-X
X-ray	B-X
structures	B-X
of	B-X
the	B-X
human	B-X
Nedd8-specific	B-X
protease	B-X
,	B-X
Den1	B-X
,	B-X
in	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
inhibitor	B-X
Nedd8	B-X
aldehyde	B-X
,	B-X
thus	B-X
revealing	B-X
a	B-X
model	B-X
for	B-X
the	B-X
tetrahedral	B-X
transition	B-X
state	B-X
intermediate	B-X
generated	B-X
during	B-X
proteolysis	B-X
.	B-X
Although	B-X
Den1	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
the	B-X
SUMO-specific	B-X
protease	B-X
family	B-X
(	B-X
Ulp/Senp	B-X
family	B-X
)	B-X
,	B-X
structural	B-X
analysis	B-X
of	B-X
the	B-X
interface	B-X
suggests	B-X
determinants	B-X
involved	B-X
in	B-X
Nedd8	B-X
selectivity	B-X
by	B-X
Den1	B-X
over	B-X
other	B-X
ubiquitin-like	B-X
family	B-X
members	B-X
and	B-X
suggests	B-X
how	B-X
the	B-X
Ulp/Senp	B-X
architecture	B-X
has	B-X
been	B-X
modified	B-X
to	B-X
interact	B-X
with	B-X
different	B-X
ubiquitin-like	B-X
modifiers	B-X
.	B-X

Nedd8	B-Protein
is	O
conjugated	O
to	O
cullin	O
proteins	O
in	O
a	O
process	O
that	O
alters	O
SCF	O
E3	O
ubiquitin	B-Protein
ligase	O
activity	O
,	O
and	O
it	O
is	O
presumed	O
that	O
Nedd8	B-Protein
deconjugation	O
would	O
reverse	O
these	O
effects	O
.	O

We	O
now	O
report	O
the	O
X	O
-	O
ray	O
structures	O
of	O
the	O
human	O
Nedd8	B-Protein
-	O
specific	O
protease	O
,	O
Den1	B-Protein
,	O
in	O
a	O
complex	O
with	O
the	O
inhibitor	O
Nedd8	B-Protein
aldehyde	O
,	O
thus	O
revealing	O
a	O
model	O
for	O
the	O
tetrahedral	O
transition	O
state	O
intermediate	O
generated	O
during	O
proteolysis	O
.	O

Although	O
Den1	B-Protein
is	O
closely	O
related	O
to	O
the	O
SUMO	O
-	O
specific	O
protease	O
family	O
(	O
Ulp	O
/	O
Senp	O
family	O
)	O
,	O
structural	O
analysis	O
of	O
the	O
interface	O
suggests	O
determinants	O
involved	O
in	O
Nedd8	B-Protein
selectivity	O
by	O
Den1	B-Protein
over	O
other	O
ubiquitin	B-Protein
-	O
like	O
family	O
members	O
and	O
suggests	O
how	O
the	O
Ulp	O
/	O
Senp	O
architecture	O
has	O
been	O
modified	O
to	O
interact	O
with	O
different	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
.	O

Functional	O
analysis	O
of	O
TbARL1	B-Protein
,	O
an	O
N	O
-	O
myristoylated	O
Golgi	O
protein	O
essential	O
for	O
viability	O
in	O
bloodstream	O
trypanosomes	O
.	O

Myristoyl	B-Protein
-	I-Protein
CoA	I-Protein
:	I-Protein
protein	I-Protein
N	I-Protein
-	I-Protein
myristoyltransferase	I-Protein
(	O
NMT	B-Protein
)	O
,	O
an	O
essential	O
protein	O
in	O
Trypanosoma	O
brucei	O
and	O
Leishmania	O
major	O
,	O
catalyses	O
the	O
covalent	O
attachment	O
of	O
the	O
fatty	O
acid	O
myristate	O
to	O
the	O
N	O
-	O
terminus	O
of	O
a	O
range	O
of	O
target	O
proteins	O
.	O

In	O
order	O
to	O
define	O
the	O
essential	O
targets	O
contributing	O
to	O
lethality	O
in	O
the	O
absence	O
of	O
NMT	B-Protein
activity	O
,	O
we	O
have	O
focused	O
on	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
Arf	O
)	O
family	O
of	O
GTP	O
-	O
binding	O
proteins	O
,	O
as	O
growth	O
arrest	O
in	O
Saccharomyces	O
cerevisiae	O
mutants	O
with	O
reduced	O
NMT	B-Protein
activity	O
correlates	O
with	O
a	O
decrease	O
in	O
N	O
-	O
myristoylated	O
Arf	O
proteins	O
.	O

We	O
have	O
identified	O
nine	O
Arf	O
/	O
Arls	O
in	O
the	O
T	O
.	O
brucei	O
and	O
T	O
.	O
cruzi	O
genomes	O
and	O
ten	O
in	O
L	O
.	O
major	O
.	O

Characterization	O
of	O
the	O
T	O
.	O
brucei	O
ARL1	B-Protein
homologue	O
has	O
revealed	O
that	O
the	O
protein	O
is	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
and	O
is	O
expressed	O
only	O
in	O
the	O
mammalian	O
bloodstream	O
form	O
of	O
the	O
parasite	O
and	O
not	O
in	O
the	O
insect	O
procyclic	O
stage	O
.	O

This	O
is	O
the	O
only	O
reported	O
example	O
to	O
date	O
of	O
a	O
differentially	O
expressed	O
ARL1	B-Protein
homologue	O
in	O
any	O
species	O
.	O
<EOS>	B-X
Characterization	B-X
of	B-X
the	B-X
T.	B-X
brucei	B-X
ARL1	B-X
homologue	B-X
has	B-X
revealed	B-X
that	B-X
the	B-X
protein	B-X
is	B-X
localized	B-X
in	B-X
the	B-X
Golgi	B-X
apparatus	B-X
and	B-X
is	B-X
expressed	B-X
only	B-X
in	B-X
the	B-X
mammalian	B-X
bloodstream	B-X
form	B-X
of	B-X
the	B-X
parasite	B-X
and	B-X
not	B-X
in	B-X
the	B-X
insect	B-X
procyclic	B-X
stage	B-X
.	B-X
This	B-X
is	B-X
the	B-X
only	B-X
reported	B-X
example	B-X
to	B-X
date	B-X
of	B-X
a	B-X
differentially	B-X
expressed	B-X
ARL1	B-X
homologue	B-X
in	B-X
any	B-X
species	B-X
.	B-X
We	B-X
have	B-X
used	B-X
RNA	B-X
interference	B-X
to	B-X
demonstrate	B-X
that	B-X
ARL1	B-X
is	B-X
essential	B-X
for	B-X
viability	B-X
in	B-X
T.	B-X
brucei	B-X
bloodstream	B-X
parasites	B-X
.	B-X
Prior	B-X
to	B-X
cell	B-X
death	B-X
,	B-X
depletion	B-X
of	B-X
ARL1	B-X
protein	B-X
in	B-X
bloodstream	B-X
parasites	B-X
results	B-X
in	B-X
abnormal	B-X
morphology	B-X
,	B-X
including	B-X
disintegration	B-X
of	B-X
the	B-X
Golgi	B-X
structure	B-X
,	B-X
multiple	B-X
flagella	B-X
and	B-X
nuclei	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
vesicles	B-X
.	B-X
RNA	B-X
interference	B-X
of	B-X
ARL1	B-X
in	B-X
procyclic	B-X
cells	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
parasite	B-X
growth	B-X
or	B-X
morphology	B-X
.	B-X

We	O
have	O
used	O
RNA	O
interference	O
to	O
demonstrate	O
that	O
ARL1	B-Protein
is	O
essential	O
for	O
viability	O
in	O
T	O
.	O
brucei	O
bloodstream	O
parasites	O
.	O

Prior	O
to	O
cell	O
death	O
,	O
depletion	O
of	O
ARL1	B-Protein
protein	O
in	O
bloodstream	O
parasites	O
results	O
in	O
abnormal	O
morphology	O
,	O
including	O
disintegration	O
of	O
the	O
Golgi	O
structure	O
,	O
multiple	O
flagella	O
and	O
nuclei	O
,	O
and	O
the	O
presence	O
of	O
large	O
numbers	O
of	O
vesicles	O
.	O
<EOS>	B-X
Myristoyl-CoA	B-X
:	B-X
protein	B-X
N-myristoyltransferase	B-X
(	B-X
NMT	B-X
)	B-X
,	B-X
an	B-X
essential	B-X
protein	B-X
in	B-X
Trypanosoma	B-X
brucei	B-X
and	B-X
Leishmania	B-X
major	B-X
,	B-X
catalyses	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
myristate	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
a	B-X
range	B-X
of	B-X
target	B-X
proteins	B-X
.	B-X
In	B-X
order	B-X
to	B-X
define	B-X
the	B-X
essential	B-X
targets	B-X
contributing	B-X
to	B-X
lethality	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
NMT	B-X
activity	B-X
,	B-X
we	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
Arf	B-X
)	B-X
family	B-X
of	B-X
GTP-binding	B-X
proteins	B-X
,	B-X
as	B-X
growth	B-X
arrest	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
mutants	B-X
with	B-X
reduced	B-X
NMT	B-X
activity	B-X
correlates	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
N-myristoylated	B-X
Arf	B-X
proteins	B-X
.	B-X
Characterization	B-X
of	B-X
the	B-X
T.	B-X
brucei	B-X
ARL1	B-X
homologue	B-X
has	B-X
revealed	B-X
that	B-X
the	B-X
protein	B-X
is	B-X
localized	B-X
in	B-X
the	B-X
Golgi	B-X
apparatus	B-X
and	B-X
is	B-X
expressed	B-X
only	B-X
in	B-X
the	B-X
mammalian	B-X
bloodstream	B-X
form	B-X
of	B-X
the	B-X
parasite	B-X
and	B-X
not	B-X
in	B-X
the	B-X
insect	B-X
procyclic	B-X
stage	B-X
.	B-X
This	B-X
is	B-X
the	B-X
only	B-X
reported	B-X
example	B-X
to	B-X
date	B-X
of	B-X
a	B-X
differentially	B-X
expressed	B-X
ARL1	B-X
homologue	B-X
in	B-X
any	B-X
species	B-X
.	B-X
We	B-X
have	B-X
used	B-X
RNA	B-X
interference	B-X
to	B-X
demonstrate	B-X
that	B-X
ARL1	B-X
is	B-X
essential	B-X
for	B-X
viability	B-X
in	B-X
T.	B-X
brucei	B-X
bloodstream	B-X
parasites	B-X
.	B-X
Prior	B-X
to	B-X
cell	B-X
death	B-X
,	B-X
depletion	B-X
of	B-X
ARL1	B-X
protein	B-X
in	B-X
bloodstream	B-X
parasites	B-X
results	B-X
in	B-X
abnormal	B-X
morphology	B-X
,	B-X
including	B-X
disintegration	B-X
of	B-X
the	B-X
Golgi	B-X
structure	B-X
,	B-X
multiple	B-X
flagella	B-X
and	B-X
nuclei	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
vesicles	B-X
.	B-X
The	B-X
cells	B-X
have	B-X
only	B-X
a	B-X
minor	B-X
apparent	B-X
defect	B-X
in	B-X
endocytosis	B-X
but	B-X
exocytosis	B-X
of	B-X
variant	B-X
surface	B-X
glycoprotein	B-X
to	B-X
the	B-X
parasite	B-X
surface	B-X
is	B-X
significantly	B-X
delayed	B-X
.	B-X
RNA	B-X
interference	B-X
of	B-X
ARL1	B-X
in	B-X
procyclic	B-X
cells	B-X
has	B-X
no	B-X
effect	B-X
on	B-X
parasite	B-X
growth	B-X
or	B-X
morphology	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
may	B-X
be	B-X
different	B-X
pathways	B-X
regulating	B-X
Golgi	B-X
structure	B-X
and	B-X
function	B-X
in	B-X
the	B-X
two	B-X
major	B-X
life	B-X
cycle	B-X
stages	B-X
of	B-X
T.	B-X
brucei	B-X
.	B-X

The	O
cells	O
have	O
only	O
a	O
minor	O
apparent	O
defect	O
in	O
endocytosis	O
but	O
exocytosis	O
of	O
variant	O
surface	O
glycoprotein	O
to	O
the	O
parasite	O
surface	O
is	O
significantly	O
delayed	O
.	O

RNA	O
interference	O
of	O
ARL1	B-Protein
in	O
procyclic	O
cells	O
has	O
no	O
effect	O
on	O
parasite	O
growth	O
or	O
morphology	O
.	O
<EOS>	B-X
The	B-X
morphology	B-X
of	B-X
the	B-X
scleral	B-X
cartilage	B-X
and	B-X
ossicles	B-X
varies	B-X
within	B-X
different	B-X
extant	B-X
reptiles	B-X
(	B-X
including	B-X
birds	B-X
)	B-X
and	B-X
also	B-X
varies	B-X
dramatically	B-X
from	B-X
the	B-X
morphology	B-X
in	B-X
extant	B-X
teleosts	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
observed	B-X
variation	B-X
in	B-X
morphology	B-X
and	B-X
development	B-X
of	B-X
the	B-X
ocular	B-X
skeleton	B-X
in	B-X
the	B-X
context	B-X
of	B-X
evolution	B-X
and	B-X
highlights	B-X
our	B-X
knowledge	B-X
gaps	B-X
in	B-X
these	B-X
areas	B-X
.	B-X
Female	B-X
steroid	B-X
hormones	B-X
,	B-X
estrogen	B-X
and	B-X
progesterone	B-X
,	B-X
are	B-X
known	B-X
to	B-X
modulate	B-X
the	B-X
morphology	B-X
and	B-X
function	B-X
of	B-X
cells	B-X
in	B-X
the	B-X
oviduct	B-X
.	B-X
We	B-X
review	B-X
some	B-X
aspects	B-X
of	B-X
oviductal	B-X
anatomy	B-X
and	B-X
histology	B-X
and	B-X
discuss	B-X
current	B-X
assisted	B-X
reproductive	B-X
technologies	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
bypass	B-X
the	B-X
oviduct	B-X
and	B-X
their	B-X
effects	B-X
on	B-X
embryo	B-X
quality	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
there	O
may	O
be	O
different	O
pathways	O
regulating	O
Golgi	O
structure	O
and	O
function	O
in	O
the	O
two	O
major	O
life	O
cycle	O
stages	O
of	O
T	O
.	O
brucei	O
.	O
<EOS>	B-X
Myristoyl-CoA	B-X
:	B-X
protein	B-X
N-myristoyltransferase	B-X
(	B-X
NMT	B-X
)	B-X
,	B-X
an	B-X
essential	B-X
protein	B-X
in	B-X
Trypanosoma	B-X
brucei	B-X
and	B-X
Leishmania	B-X
major	B-X
,	B-X
catalyses	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
myristate	B-X
to	B-X
the	B-X
N-terminus	B-X
of	B-X
a	B-X
range	B-X
of	B-X
target	B-X
proteins	B-X
.	B-X
We	B-X
have	B-X
identified	B-X
nine	B-X
Arf/Arls	B-X
in	B-X
the	B-X
T.	B-X
brucei	B-X
and	B-X
T.	B-X
cruzi	B-X
genomes	B-X
and	B-X
ten	B-X
in	B-X
L.	B-X
major	B-X
.	B-X
Characterization	B-X
of	B-X
the	B-X
T.	B-X
brucei	B-X
ARL1	B-X
homologue	B-X
has	B-X
revealed	B-X
that	B-X
the	B-X
protein	B-X
is	B-X
localized	B-X
in	B-X
the	B-X
Golgi	B-X
apparatus	B-X
and	B-X
is	B-X
expressed	B-X
only	B-X
in	B-X
the	B-X
mammalian	B-X
bloodstream	B-X
form	B-X
of	B-X
the	B-X
parasite	B-X
and	B-X
not	B-X
in	B-X
the	B-X
insect	B-X
procyclic	B-X
stage	B-X
.	B-X
This	B-X
is	B-X
the	B-X
only	B-X
reported	B-X
example	B-X
to	B-X
date	B-X
of	B-X
a	B-X
differentially	B-X
expressed	B-X
ARL1	B-X
homologue	B-X
in	B-X
any	B-X
species	B-X
.	B-X
We	B-X
have	B-X
used	B-X
RNA	B-X
interference	B-X
to	B-X
demonstrate	B-X
that	B-X
ARL1	B-X
is	B-X
essential	B-X
for	B-X
viability	B-X
in	B-X
T.	B-X
brucei	B-X
bloodstream	B-X
parasites	B-X
.	B-X
Prior	B-X
to	B-X
cell	B-X
death	B-X
,	B-X
depletion	B-X
of	B-X
ARL1	B-X
protein	B-X
in	B-X
bloodstream	B-X
parasites	B-X
results	B-X
in	B-X
abnormal	B-X
morphology	B-X
,	B-X
including	B-X
disintegration	B-X
of	B-X
the	B-X
Golgi	B-X
structure	B-X
,	B-X
multiple	B-X
flagella	B-X
and	B-X
nuclei	B-X
,	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
large	B-X
numbers	B-X
of	B-X
vesicles	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
may	B-X
be	B-X
different	B-X
pathways	B-X
regulating	B-X
Golgi	B-X
structure	B-X
and	B-X
function	B-X
in	B-X
the	B-X
two	B-X
major	B-X
life	B-X
cycle	B-X
stages	B-X
of	B-X
T.	B-X
brucei	B-X
.	B-X

Effects	O
of	O
over	O
-	O
expression	O
of	O
the	O
regulatory	O
enzymes	O
DraT	B-Protein
and	O
DraG	B-Protein
on	O
the	O
ammonium	O
-	O
dependent	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	O
reductase	O
in	O
Azospirillum	O
brasilense	O
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

Nitrogen	O
fixation	O
in	O
Azospirillum	O
brasilense	O
is	O
regulated	O
at	O
transcriptional	O
and	O
post	O
-	O
translational	O
levels	O
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X

Post	O
-	O
translational	O
control	O
occurs	O
through	O
the	O
reversible	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
(	O
Fe	B-Protein
Protein	I-Protein
)	O
,	O
mediated	O
by	O
the	O
dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DraT	B-Protein
)	O
and	O
dinitrogenase	B-Protein
reductase	I-Protein
glycohydrolase	I-Protein
(	O
DraG	B-Protein
)	O
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

Although	O
the	O
DraT	B-Protein
and	O
DraG	B-Protein
activities	O
are	O
regulated	O
in	O
vivo	O
,	O
the	O
molecules	O
responsible	O
for	O
such	O
regulation	O
remain	O
unknown	O
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

We	O
have	O
constructed	O
broad	O
-	O
host	O
-	O
range	O
plasmids	O
capable	O
of	O
over	O
-	O
expressing	O
,	O
upon	O
IPTG	O
induction	O
,	O
the	O
regulatory	O
enzymes	O
DraT	B-Protein
and	O
DraG	B-Protein
as	O
six	O
-	O
histidine	O
-	O
N	O
-	O
terminal	O
fused	O
proteins	O
(	O
His	O
)	O
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

Both	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
are	O
functional	O
in	O
vivo	O
.	O
<EOS>	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

We	O
have	O
analyzed	O
the	O
effects	O
of	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
over	O
-	O
expression	O
on	O
the	O
post	O
-	O
translational	O
modification	O
of	O
Fe	B-Protein
Protein	I-Protein
.	O
<EOS>	B-X
Nitrogen	B-X
fixation	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
is	B-X
regulated	B-X
at	B-X
transcriptional	B-X
and	B-X
post-translational	B-X
levels	B-X
.	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

The	O
DraT	B-Protein
-	O
His	O
over	O
-	O
expression	O
led	O
to	O
Fe	B-Protein
Protein	I-Protein
modification	O
in	O
the	O
absence	O
of	O
ammonium	O
addition	O
,	O
while	O
cells	O
over	O
-	O
expressing	O
DraG	B-Protein
-	O
His	O
showed	O
only	O
partial	O
ADP	O
-	O
ribosylation	O
of	O
Fe	B-Protein
Protein	I-Protein
by	O
adding	O
ammonium	O
.	O
<EOS>	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

These	O
results	O
suggest	O
that	O
both	O
DraT	B-Protein
-	O
His	O
and	O
DraG	B-Protein
-	O
His	O
lose	O
their	O
regulation	O
upon	O
over	O
-	O
expression	O
,	O
possible	O
by	O
titrating	O
out	O
negative	O
regulators	O
.	O
<EOS>	B-X
Post-translational	B-X
control	B-X
occurs	B-X
through	B-X
the	B-X
reversible	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
(	B-X
Fe	B-X
Protein	B-X
)	B-X
,	B-X
mediated	B-X
by	B-X
the	B-X
dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DraT	B-X
)	B-X
and	B-X
dinitrogenase	B-X
reductase	B-X
glycohydrolase	B-X
(	B-X
DraG	B-X
)	B-X
.	B-X
Although	B-X
the	B-X
DraT	B-X
and	B-X
DraG	B-X
activities	B-X
are	B-X
regulated	B-X
in	B-X
vivo	B-X
,	B-X
the	B-X
molecules	B-X
responsible	B-X
for	B-X
such	B-X
regulation	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
have	B-X
constructed	B-X
broad-host-range	B-X
plasmids	B-X
capable	B-X
of	B-X
over-expressing	B-X
,	B-X
upon	B-X
IPTG	B-X
induction	B-X
,	B-X
the	B-X
regulatory	B-X
enzymes	B-X
DraT	B-X
and	B-X
DraG	B-X
as	B-X
six-histidine-N-terminal	B-X
fused	B-X
proteins	B-X
(	B-X
His	B-X
)	B-X
.	B-X
Both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
are	B-X
functional	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
have	B-X
analyzed	B-X
the	B-X
effects	B-X
of	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
over-expression	B-X
on	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
Fe	B-X
Protein	B-X
.	B-X
The	B-X
DraT-His	B-X
over-expression	B-X
led	B-X
to	B-X
Fe	B-X
Protein	B-X
modification	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
ammonium	B-X
addition	B-X
,	B-X
while	B-X
cells	B-X
over-expressing	B-X
DraG-His	B-X
showed	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
Fe	B-X
Protein	B-X
by	B-X
adding	B-X
ammonium	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
DraT-His	B-X
and	B-X
DraG-His	B-X
lose	B-X
their	B-X
regulation	B-X
upon	B-X
over-expression	B-X
,	B-X
possible	B-X
by	B-X
titrating	B-X
out	B-X
negative	B-X
regulators	B-X
.	B-X

Nep1	B-Protein
,	O
a	O
Schizosaccharomyces	O
pombe	O
deneddylating	O
enzyme	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
on	B-X
the	B-X
characterization	B-X
of	B-X
Nep1	B-X
,	B-X
a	B-X
deneddylating	B-X
enzyme	B-X
in	B-X
fission	B-X
yeast	B-X
(	B-X
Schizosaccharomyces	B-X
pombe	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
the	B-X
Pcu1	B-X
,	B-X
Pcu3	B-X
and	B-X
Pcu4	B-X
cullins	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
its	B-X
activity	B-X
is	B-X
sensitive	B-X
to	B-X
N-ethylmaleimide	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
idea	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
cysteine	B-X
protease	B-X
family	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Nep1	B-X
can	B-X
be	B-X
co-precipitated	B-X
with	B-X
the	B-X
signalosome	B-X
subunit	B-X
Csn5	B-X
.	B-X
Nep1	B-X
itself	B-X
is	B-X
present	B-X
in	B-X
a	B-X
high-molecular-mass	B-X
complex	B-X
,	B-X
but	B-X
the	B-X
presence	B-X
of	B-X
this	B-X
complex	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
production	B-X
of	B-X
intact	B-X
signalosomes	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
Nep1	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
deneddylating	B-X
proteins	B-X
other	B-X
than	B-X
cullins	B-X
.	B-X

Nedd8	B-Protein
is	O
a	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
that	O
is	O
attached	O
to	O
the	O
cullin	O
components	O
of	O
E3	O
ubiquitin	B-Protein
ligases	O
.	O

More	O
recently	O
,	O
p53	B-Protein
has	O
also	O
been	O
shown	O
to	O
be	O
Nedd8	B-Protein
-	O
modified	O
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
modifier	B-X
that	B-X
is	B-X
attached	B-X
to	B-X
the	B-X
cullin	B-X
components	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
More	B-X
recently	B-X
,	B-X
p53	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
Nedd8-modified	B-X
.	B-X
Nedd8	B-X
attachment	B-X
occurs	B-X
in	B-X
a	B-X
manner	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
for	B-X
other	B-X
ubiquitin-like	B-X
modifiers	B-X
.	B-X
Deletion	B-X
of	B-X
a	B-X
related	B-X
gene	B-X
(	B-X
nep2	B-X
)	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
nep1.d	B-X
,	B-X
also	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
cell	B-X
viability	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X

Nedd8	B-Protein
attachment	O
occurs	O
in	O
a	O
manner	O
similar	O
to	O
that	O
observed	O
for	O
other	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
on	O
the	O
characterization	O
of	O
Nep1	B-Protein
,	O
a	O
deneddylating	O
enzyme	O
in	O
fission	O
yeast	O
(	O
Schizosaccharomyces	O
pombe	O
)	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
on	B-X
the	B-X
characterization	B-X
of	B-X
Nep1	B-X
,	B-X
a	B-X
deneddylating	B-X
enzyme	B-X
in	B-X
fission	B-X
yeast	B-X
(	B-X
Schizosaccharomyces	B-X
pombe	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
the	B-X
Pcu1	B-X
,	B-X
Pcu3	B-X
and	B-X
Pcu4	B-X
cullins	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
its	B-X
activity	B-X
is	B-X
sensitive	B-X
to	B-X
N-ethylmaleimide	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
idea	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
cysteine	B-X
protease	B-X
family	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Nep1	B-X
can	B-X
be	B-X
co-precipitated	B-X
with	B-X
the	B-X
signalosome	B-X
subunit	B-X
Csn5	B-X
.	B-X
Nep1	B-X
itself	B-X
is	B-X
present	B-X
in	B-X
a	B-X
high-molecular-mass	B-X
complex	B-X
,	B-X
but	B-X
the	B-X
presence	B-X
of	B-X
this	B-X
complex	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
production	B-X
of	B-X
intact	B-X
signalosomes	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
Nep1	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
deneddylating	B-X
proteins	B-X
other	B-X
than	B-X
cullins	B-X
.	B-X

Unlike	O
loss	O
of	O
ned8	B-Protein
,	O
deletion	O
of	O
the	O
nep1	B-Protein
gene	O
is	O
not	O
lethal	O
,	O
although	O
nep1	B-Protein
.	O
d	O
cells	O
are	O
heterogeneous	O
in	O
length	O
,	O
suggesting	O
a	O
defect	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

Viability	O
of	O
nep1	B-Protein
.	O
d	O
cells	O
is	O
dependent	O
on	O
a	O
functional	O
spindle	O
checkpoint	O
but	O
not	O
on	O
the	O
DNA	O
integrity	O
checkpoint	O
.	O

Deletion	O
of	O
a	O
related	O
gene	O
(	O
nep2	B-Protein
)	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
nep1	B-Protein
.	O
d	O
,	O
also	O
has	O
little	O
effect	O
on	O
cell	O
viability	O
.	O
<EOS>	B-X
More	B-X
recently	B-X
,	B-X
p53	B-X
has	B-X
also	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
Nedd8-modified	B-X
.	B-X
Unlike	B-X
loss	B-X
of	B-X
ned8	B-X
,	B-X
deletion	B-X
of	B-X
the	B-X
nep1	B-X
gene	B-X
is	B-X
not	B-X
lethal	B-X
,	B-X
although	B-X
nep1.d	B-X
cells	B-X
are	B-X
heterogeneous	B-X
in	B-X
length	B-X
,	B-X
suggesting	B-X
a	B-X
defect	B-X
in	B-X
cell-cycle	B-X
progression	B-X
.	B-X
Viability	B-X
of	B-X
nep1.d	B-X
cells	B-X
is	B-X
dependent	B-X
on	B-X
a	B-X
functional	B-X
spindle	B-X
checkpoint	B-X
but	B-X
not	B-X
on	B-X
the	B-X
DNA	B-X
integrity	B-X
checkpoint	B-X
.	B-X
Deletion	B-X
of	B-X
a	B-X
related	B-X
gene	B-X
(	B-X
nep2	B-X
)	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
nep1.d	B-X
,	B-X
also	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
cell	B-X
viability	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X

We	O
show	O
that	O
Nep1	B-Protein
can	O
deneddylate	O
the	O
Pcu1	B-Protein
,	O
Pcu3	B-Protein
and	O
Pcu4	B-Protein
cullins	O
in	O
vitro	O
and	O
that	O
its	O
activity	O
is	O
sensitive	O
to	O
N	O
-	O
ethylmaleimide	O
,	O
consistent	O
with	O
the	O
idea	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
cysteine	O
protease	O
family	O
.	O

nep1	B-Protein
.	O
d	O
cells	O
accumulate	O
Nedd8	B-Protein
-	O
modified	O
proteins	O
,	O
although	O
these	O
do	O
not	O
correspond	O
to	O
modified	O
forms	O
of	O
the	O
cullins	O
,	O
suggesting	O
that	O
,	O
although	O
Nep1	B-Protein
can	O
deneddylate	O
cullins	O
in	O
vitro	O
,	O
this	O
is	O
not	O
its	O
main	O
function	O
in	O
vivo	O
.	O

Nep1	B-Protein
can	O
be	O
co	O
-	O
precipitated	O
with	O
the	O
signalosome	O
subunit	O
Csn5	B-Protein
.	O
<EOS>	B-X
Nedd8	B-X
is	B-X
a	B-X
ubiquitin-like	B-X
modifier	B-X
that	B-X
is	B-X
attached	B-X
to	B-X
the	B-X
cullin	B-X
components	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
on	B-X
the	B-X
characterization	B-X
of	B-X
Nep1	B-X
,	B-X
a	B-X
deneddylating	B-X
enzyme	B-X
in	B-X
fission	B-X
yeast	B-X
(	B-X
Schizosaccharomyces	B-X
pombe	B-X
)	B-X
.	B-X
Deletion	B-X
of	B-X
a	B-X
related	B-X
gene	B-X
(	B-X
nep2	B-X
)	B-X
,	B-X
either	B-X
alone	B-X
or	B-X
in	B-X
combination	B-X
with	B-X
nep1.d	B-X
,	B-X
also	B-X
has	B-X
little	B-X
effect	B-X
on	B-X
cell	B-X
viability	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
the	B-X
Pcu1	B-X
,	B-X
Pcu3	B-X
and	B-X
Pcu4	B-X
cullins	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
its	B-X
activity	B-X
is	B-X
sensitive	B-X
to	B-X
N-ethylmaleimide	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
idea	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
cysteine	B-X
protease	B-X
family	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Nep1	B-X
can	B-X
be	B-X
co-precipitated	B-X
with	B-X
the	B-X
signalosome	B-X
subunit	B-X
Csn5	B-X
.	B-X
Nep1	B-X
itself	B-X
is	B-X
present	B-X
in	B-X
a	B-X
high-molecular-mass	B-X
complex	B-X
,	B-X
but	B-X
the	B-X
presence	B-X
of	B-X
this	B-X
complex	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
production	B-X
of	B-X
intact	B-X
signalosomes	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
Nep1	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
deneddylating	B-X
proteins	B-X
other	B-X
than	B-X
cullins	B-X
.	B-X

Nep1	B-Protein
itself	O
is	O
present	O
in	O
a	O
high	O
-	O
molecular	O
-	O
mass	O
complex	O
,	O
but	O
the	O
presence	O
of	O
this	O
complex	O
is	O
not	O
dependent	O
on	O
the	O
production	O
of	O
intact	O
signalosomes	O
.	O

Our	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
Nep1	B-Protein
may	O
be	O
responsible	O
for	O
deneddylating	O
proteins	O
other	O
than	O
cullins	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
on	B-X
the	B-X
characterization	B-X
of	B-X
Nep1	B-X
,	B-X
a	B-X
deneddylating	B-X
enzyme	B-X
in	B-X
fission	B-X
yeast	B-X
(	B-X
Schizosaccharomyces	B-X
pombe	B-X
)	B-X
.	B-X
Unlike	B-X
loss	B-X
of	B-X
ned8	B-X
,	B-X
deletion	B-X
of	B-X
the	B-X
nep1	B-X
gene	B-X
is	B-X
not	B-X
lethal	B-X
,	B-X
although	B-X
nep1.d	B-X
cells	B-X
are	B-X
heterogeneous	B-X
in	B-X
length	B-X
,	B-X
suggesting	B-X
a	B-X
defect	B-X
in	B-X
cell-cycle	B-X
progression	B-X
.	B-X
We	B-X
show	B-X
that	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
the	B-X
Pcu1	B-X
,	B-X
Pcu3	B-X
and	B-X
Pcu4	B-X
cullins	B-X
in	B-X
vitro	B-X
and	B-X
that	B-X
its	B-X
activity	B-X
is	B-X
sensitive	B-X
to	B-X
N-ethylmaleimide	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
idea	B-X
that	B-X
it	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
cysteine	B-X
protease	B-X
family	B-X
.	B-X
nep1.d	B-X
cells	B-X
accumulate	B-X
Nedd8-modified	B-X
proteins	B-X
,	B-X
although	B-X
these	B-X
do	B-X
not	B-X
correspond	B-X
to	B-X
modified	B-X
forms	B-X
of	B-X
the	B-X
cullins	B-X
,	B-X
suggesting	B-X
that	B-X
,	B-X
although	B-X
Nep1	B-X
can	B-X
deneddylate	B-X
cullins	B-X
in	B-X
vitro	B-X
,	B-X
this	B-X
is	B-X
not	B-X
its	B-X
main	B-X
function	B-X
in	B-X
vivo	B-X
.	B-X
Nep1	B-X
can	B-X
be	B-X
co-precipitated	B-X
with	B-X
the	B-X
signalosome	B-X
subunit	B-X
Csn5	B-X
.	B-X
Nep1	B-X
itself	B-X
is	B-X
present	B-X
in	B-X
a	B-X
high-molecular-mass	B-X
complex	B-X
,	B-X
but	B-X
the	B-X
presence	B-X
of	B-X
this	B-X
complex	B-X
is	B-X
not	B-X
dependent	B-X
on	B-X
the	B-X
production	B-X
of	B-X
intact	B-X
signalosomes	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
,	B-X
in	B-X
vivo	B-X
,	B-X
Nep1	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
deneddylating	B-X
proteins	B-X
other	B-X
than	B-X
cullins	B-X
.	B-X

Requirement	O
of	O
Cul3	B-Protein
for	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
in	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

Cul3	B-Protein
belongs	O
to	O
the	O
family	O
of	O
cullin	O
proteins	O
,	O
which	O
function	O
as	O
scaffold	O
proteins	O
of	O
E3	O
ubiquitin	B-Protein
ligase	O
complexes	O
.	O

Here	O
we	O
show	O
cell	O
-	O
autonomous	O
involvement	O
of	O
Cul3	B-Protein
in	O
axonal	O
arborization	O
and	O
dendritic	O
elaboration	O
of	O
Drosophila	O
mushroom	O
body	O
neurons	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Function	B-X
of	B-X
cullin-type	B-X
proteins	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
require	B-X
covalent	B-X
attachment	B-X
of	B-X
Nedd8	B-X
(	B-X
neural	B-X
precursor	B-X
cell-expressed	B-X
developmentally	B-X
downregulated	B-X
)	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

Cul3	B-Protein
mutant	O
neurons	O
are	O
defective	O
in	O
terminal	O
morphogenesis	O
of	O
neurites	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
Interestingly	B-X
,	B-X
mutant	B-X
axons	B-X
often	B-X
terminate	B-X
around	B-X
branching	B-X
points	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

Interestingly	O
,	O
mutant	O
axons	O
often	O
terminate	O
around	O
branching	O
points	O
.	O
<EOS>	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
Interestingly	B-X
,	B-X
mutant	B-X
axons	B-X
often	B-X
terminate	B-X
around	B-X
branching	B-X
points	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X

In	O
addition	O
,	O
dendritic	O
elaboration	O
is	O
severely	O
affected	O
in	O
Cul3	B-Protein
mutant	O
neurons	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
Interestingly	B-X
,	B-X
mutant	B-X
axons	B-X
often	B-X
terminate	B-X
around	B-X
branching	B-X
points	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

However	O
,	O
loss	O
of	O
Cul3	B-Protein
function	O
does	O
not	O
affect	O
extension	O
of	O
the	O
axons	O
that	O
rarely	O
arborize	O
.	O
<EOS>	B-X
The	B-X
simplicity	B-X
of	B-X
programming	B-X
the	B-X
CRISPR	B-X
(	B-X
clustered	B-X
regularly	B-X
interspaced	B-X
short	B-X
palindromic	B-X
repeats	B-X
)	B-X
-associated	B-X
nuclease	B-X
Cas9	B-X
to	B-X
modify	B-X
specific	B-X
genomic	B-X
loci	B-X
suggests	B-X
a	B-X
new	B-X
way	B-X
to	B-X
interrogate	B-X
gene	B-X
function	B-X
on	B-X
a	B-X
genome-wide	B-X
scale	B-X
.	B-X
Next	B-X
,	B-X
in	B-X
a	B-X
melanoma	B-X
model	B-X
,	B-X
we	B-X
screened	B-X
for	B-X
genes	B-X
whose	B-X
loss	B-X
is	B-X
involved	B-X
in	B-X
resistance	B-X
to	B-X
vemurafenib	B-X
,	B-X
a	B-X
therapeutic	B-X
RAF	B-X
inhibitor	B-X
.	B-X
The	B-X
precise	B-X
cellular	B-X
function	B-X
of	B-X
SPT5	B-X
is	B-X
not	B-X
clear	B-X
,	B-X
because	B-X
conventional	B-X
gene	B-X
depletion	B-X
strategies	B-X
for	B-X
SPT5	B-X
result	B-X
in	B-X
loss	B-X
of	B-X
cellular	B-X
viability	B-X
.	B-X
Using	B-X
an	B-X
acute	B-X
inducible	B-X
protein	B-X
depletion	B-X
strategy	B-X
to	B-X
circumvent	B-X
this	B-X
issue	B-X
,	B-X
we	B-X
report	B-X
that	B-X
SPT5	B-X
loss	B-X
triggers	B-X
the	B-X
ubiquitination	B-X
and	B-X
proteasomal	B-X
degradation	B-X
of	B-X
the	B-X
core	B-X
RNA	B-X
Pol	B-X
II	B-X
subunit	B-X
RPB1	B-X
,	B-X
a	B-X
process	B-X
that	B-X
we	B-X
show	B-X
to	B-X
be	B-X
evolutionarily	B-X
conserved	B-X
from	B-X
yeast	B-X
to	B-X
human	B-X
cells	B-X
.	B-X
Our	B-X
study	B-X
demonstrates	B-X
that	B-X
SPT5	B-X
stabilizes	B-X
RNA	B-X
Pol	B-X
II	B-X
specifically	B-X
at	B-X
promoter-proximal	B-X
regions	B-X
,	B-X
permitting	B-X
RNA	B-X
Pol	B-X
II	B-X
release	B-X
from	B-X
promoters	B-X
into	B-X
gene	B-X
bodies	B-X
and	B-X
providing	B-X
mechanistic	B-X
insight	B-X
into	B-X
the	B-X
cellular	B-X
function	B-X
of	B-X
SPT5	B-X
in	B-X
safeguarding	B-X
accurate	B-X
gene	B-X
expression	B-X
.	B-X

Function	O
of	O
cullin	O
-	O
type	O
proteins	O
has	O
been	O
shown	O
to	O
require	O
covalent	O
attachment	O
of	O
Nedd8	B-Protein
(	O
neural	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
downregulated	O
)	O
,	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
.	O
<EOS>	B-X
Ubiquitin	B-X
and	B-X
UBL	B-X
(	B-X
ubiquitin-like	B-X
)	B-X
modifiers	B-X
are	B-X
small	B-X
proteins	B-X
that	B-X
covalently	B-X
modify	B-X
other	B-X
proteins	B-X
to	B-X
alter	B-X
their	B-X
properties	B-X
or	B-X
behaviours	B-X
.	B-X
NEDD8	B-X
(	B-X
neural-precursor-cell-expressed	B-X
developmentally	B-X
down-regulated	B-X
8	B-X
)	B-X
is	B-X
the	B-X
UBL	B-X
most	B-X
closely	B-X
related	B-X
to	B-X
ubiquitin	B-X
,	B-X
and	B-X
its	B-X
best-studied	B-X
role	B-X
is	B-X
the	B-X
activation	B-X
of	B-X
CRLs	B-X
(	B-X
cullin-RING	B-X
ubiquitin	B-X
ligases	B-X
)	B-X
by	B-X
its	B-X
conjugation	B-X
to	B-X
a	B-X
conserved	B-X
C-terminal	B-X
lysine	B-X
residue	B-X
on	B-X
cullin	B-X
proteins	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
UBLs	B-X
requires	B-X
three	B-X
UBL-specific	B-X
enzymes	B-X
,	B-X
termed	B-X
E1	B-X
,	B-X
E2	B-X
and	B-X
E3	B-X
,	B-X
which	B-X
are	B-X
usually	B-X
well	B-X
insulated	B-X
from	B-X
parallel	B-X
UBL	B-X
pathways	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
a	B-X
new	B-X
mode	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
(	B-X
NEDDylation	B-X
)	B-X
whereby	B-X
the	B-X
UBL	B-X
NEDD8	B-X
is	B-X
linked	B-X
to	B-X
proteins	B-X
by	B-X
ubiquitin	B-X
enzymes	B-X
in	B-X
vivo	B-X
.	B-X
We	B-X
found	B-X
that	B-X
this	B-X
atypical	B-X
NEDDylation	B-X
is	B-X
independent	B-X
of	B-X
classical	B-X
NEDD8	B-X
enzymes	B-X
,	B-X
conserved	B-X
from	B-X
yeast	B-X
to	B-X
mammals	B-X
,	B-X
and	B-X
triggered	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
the	B-X
NEDD8	B-X
to	B-X
ubiquitin	B-X
ratio	B-X
.	B-X
In	B-X
cells	B-X
,	B-X
NEDD8	B-X
overexpression	B-X
leads	B-X
to	B-X
this	B-X
type	B-X
of	B-X
NEDDylation	B-X
by	B-X
increasing	B-X
the	B-X
concentration	B-X
of	B-X
NEDD8	B-X
,	B-X
whereas	B-X
proteasome	B-X
inhibition	B-X
has	B-X
the	B-X
same	B-X
effect	B-X
by	B-X
depleting	B-X
free	B-X
ubiquitin	B-X
.	B-X

Consistent	O
with	O
this	O
notion	O
,	O
Cul3	B-Protein
is	O
inactivated	O
by	O
a	O
mutation	O
in	O
its	O
conserved	O
neddylation	O
site	O
,	O
and	O
Nedd8	B-Protein
mutant	O
neurons	O
exhibit	O
similar	O
neuronal	O
morphogenetic	O
defects	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
Interestingly	B-X
,	B-X
mutant	B-X
axons	B-X
often	B-X
terminate	B-X
around	B-X
branching	B-X
points	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Function	B-X
of	B-X
cullin-type	B-X
proteins	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
require	B-X
covalent	B-X
attachment	B-X
of	B-X
Nedd8	B-X
(	B-X
neural	B-X
precursor	B-X
cell-expressed	B-X
developmentally	B-X
downregulated	B-X
)	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

Together	O
,	O
Cul3	B-Protein
plays	O
an	O
essential	O
role	O
in	O
both	O
axonal	O
arborization	O
and	O
proper	O
elaboration	O
of	O
dendrites	O
and	O
may	O
require	O
neddylation	O
for	O
its	O
proper	O
function	O
.	O
<EOS>	B-X
Cul3	B-X
belongs	B-X
to	B-X
the	B-X
family	B-X
of	B-X
cullin	B-X
proteins	B-X
,	B-X
which	B-X
function	B-X
as	B-X
scaffold	B-X
proteins	B-X
of	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
complexes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
cell-autonomous	B-X
involvement	B-X
of	B-X
Cul3	B-X
in	B-X
axonal	B-X
arborization	B-X
and	B-X
dendritic	B-X
elaboration	B-X
of	B-X
Drosophila	B-X
mushroom	B-X
body	B-X
neurons	B-X
.	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
are	B-X
defective	B-X
in	B-X
terminal	B-X
morphogenesis	B-X
of	B-X
neurites	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
dendritic	B-X
elaboration	B-X
is	B-X
severely	B-X
affected	B-X
in	B-X
Cul3	B-X
mutant	B-X
neurons	B-X
.	B-X
However	B-X
,	B-X
loss	B-X
of	B-X
Cul3	B-X
function	B-X
does	B-X
not	B-X
affect	B-X
extension	B-X
of	B-X
the	B-X
axons	B-X
that	B-X
rarely	B-X
arborize	B-X
.	B-X
Function	B-X
of	B-X
cullin-type	B-X
proteins	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
require	B-X
covalent	B-X
attachment	B-X
of	B-X
Nedd8	B-X
(	B-X
neural	B-X
precursor	B-X
cell-expressed	B-X
developmentally	B-X
downregulated	B-X
)	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
notion	B-X
,	B-X
Cul3	B-X
is	B-X
inactivated	B-X
by	B-X
a	B-X
mutation	B-X
in	B-X
its	B-X
conserved	B-X
neddylation	B-X
site	B-X
,	B-X
and	B-X
Nedd8	B-X
mutant	B-X
neurons	B-X
exhibit	B-X
similar	B-X
neuronal	B-X
morphogenetic	B-X
defects	B-X
.	B-X
Together	B-X
,	B-X
Cul3	B-X
plays	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
both	B-X
axonal	B-X
arborization	B-X
and	B-X
proper	B-X
elaboration	B-X
of	B-X
dendrites	B-X
and	B-X
may	B-X
require	B-X
neddylation	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X

Phosphonocarboxylate	O
inhibitors	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
disrupt	O
the	O
prenylation	O
and	O
membrane	O
localization	O
of	O
Rab	O
proteins	O
in	O
osteoclasts	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

Nitrogen	O
-	O
containing	O
bisphosphonate	O
drugs	O
such	O
as	O
risedronate	O
act	O
by	O
inhibiting	O
farnesyl	B-Protein
diphosphate	I-Protein
synthase	I-Protein
,	O
thereby	O
disrupting	O
protein	O
prenylation	O
in	O
osteoclasts	O
.	O
<EOS>	B-X
N-BPs	B-X
,	B-X
which	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
preventing	B-X
prenylation	B-X
of	B-X
small	B-X
GTPases	B-X
,	B-X
unexpectedly	B-X
cause	B-X
the	B-X
accumulation	B-X
of	B-X
GTP-bound	B-X
,	B-X
unprenylated	B-X
Rho	B-X
family	B-X
GTPases	B-X
in	B-X
macrophages	B-X
and	B-X
osteoclasts	B-X
.	B-X
In	B-X
macrophages	B-X
,	B-X
this	B-X
also	B-X
leads	B-X
to	B-X
sustained	B-X
,	B-X
Rac-mediated	B-X
activation	B-X
of	B-X
p38	B-X
.	B-X
The	B-X
antiresorptive	B-X
activity	B-X
of	B-X
N-BPs	B-X
may	B-X
therefore	B-X
be	B-X
caused	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
by	B-X
the	B-X
accumulation	B-X
of	B-X
unprenylated	B-X
small	B-X
GTPases	B-X
,	B-X
causing	B-X
inappropriate	B-X
activation	B-X
of	B-X
downstream	B-X
signaling	B-X
pathways	B-X
.	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

We	O
recently	O
found	O
that	O
an	O
anti	O
-	O
resorptive	O
phosphonocarboxylate	O
analogue	O
of	O
risedronate	O
,	O
3	O
-	O
PEHPC	O
(	O
previously	O
referred	O
to	O
as	O
NE10790	O
)	O
,	O
selectively	O
prevents	O
prenylation	O
of	O
Rab	O
GTPases	O
in	O
vitro	O
by	O
specifically	O
inhibiting	O
Rab	O
geranylgeranyl	O
transferase	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
unprenylated	O
Rab6	B-Protein
could	O
be	O
detected	O
in	O
J774	O
cells	O
after	O
treatment	O
with	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
for	O
as	O
little	O
as	O
4	O
h	O
,	O
and	O
reached	O
50	O
%	O
after	O
24	O
h	O
.	O
<EOS>	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

Furthermore	O
,	O
treatment	O
of	O
J774	O
cells	O
or	O
osteoclasts	O
with	O
either	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
disrupted	O
membrane	O
association	O
of	O
several	O
Rab	O
family	O
proteins	O
.	O
<EOS>	B-X
High-dose	B-X
propofol	B-X
treatment	B-X
with	B-X
a	B-X
prolonged	B-X
duration	B-X
can	B-X
damage	B-X
the	B-X
immune	B-X
system	B-X
.	B-X
Using	B-X
primary	B-X
cultured	B-X
bone	B-X
marrow-derived	B-X
macrophages	B-X
,	B-X
murine	B-X
macrophage	B-X
cell	B-X
lines	B-X
(	B-X
RAW264.7	B-X
,	B-X
RAW-asc	B-X
and	B-X
J774	B-X
)	B-X
and	B-X
a	B-X
mouse	B-X
model	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
NLRP3	B-X
inflammasome	B-X
activation	B-X
and	B-X
secondary	B-X
pyroptosis	B-X
in	B-X
propofol-induced	B-X
cell	B-X
death	B-X
.	B-X
Moreover	B-X
,	B-X
NLRP3	B-X
deletion	B-X
moderately	B-X
suppressed	B-X
cleaved	B-X
caspase-1	B-X
as	B-X
well	B-X
as	B-X
the	B-X
proportion	B-X
of	B-X
pyroptosis	B-X
,	B-X
while	B-X
levels	B-X
of	B-X
AIM2	B-X
were	B-X
increased	B-X
,	B-X
triggering	B-X
a	B-X
compensatory	B-X
pathway	B-X
to	B-X
pyroptosis	B-X
in	B-X
NLRP3	B-X
Research	B-X
over	B-X
the	B-X
last	B-X
decade	B-X
has	B-X
revealed	B-X
that	B-X
CYP11A1	B-X
can	B-X
hydroxylate	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
vitamin	B-X
D3	B-X
at	B-X
carbons	B-X
17	B-X
,	B-X
20	B-X
,	B-X
22	B-X
and	B-X
23	B-X
to	B-X
produce	B-X
at	B-X
least	B-X
10	B-X
metabolites	B-X
,	B-X
with	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
,	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
20,22	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
17,20	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
and	B-X
17,20,23	B-X
(	B-X
OH	B-X
)	B-X
3D3	B-X
being	B-X
the	B-X
main	B-X
products	B-X
.	B-X
However	B-X
,	B-X
CYP11A1	B-X
does	B-X
not	B-X
act	B-X
on	B-X
25	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
.	B-X
The	B-X
placenta	B-X
,	B-X
adrenal	B-X
glands	B-X
and	B-X
epidermal	B-X
keratinocytes	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
metabolize	B-X
vitamin	B-X
D3	B-X
via	B-X
this	B-X
CYP11A1-mediated	B-X
pathway	B-X
that	B-X
is	B-X
modified	B-X
by	B-X
the	B-X
activity	B-X
of	B-X
CYP27B1	B-X
,	B-X
with	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
(	B-X
the	B-X
major	B-X
metabolite	B-X
)	B-X
,	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
1,20	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
1,20,23	B-X
(	B-X
OH	B-X
)	B-X
3D3	B-X
and	B-X
17,20,23	B-X
(	B-X
OH	B-X
)	B-X
3D3	B-X
being	B-X
detected	B-X
,	B-X
defining	B-X
these	B-X
secosteroids	B-X
as	B-X
endogenous	B-X
regulators/natural	B-X
products	B-X
.	B-X
This	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
detection	B-X
of	B-X
a	B-X
mono-hydroxyvitamin	B-X
D3	B-X
with	B-X
the	B-X
retention	B-X
time	B-X
of	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
in	B-X
human	B-X
serum	B-X
.	B-X
In	B-X
new	B-X
work	B-X
presented	B-X
here	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
CYP11A1-initiated	B-X
pathways	B-X
also	B-X
occurs	B-X
in	B-X
Caco-2	B-X
colon	B-X
cells	B-X
.	B-X
Our	B-X
previous	B-X
studies	B-X
show	B-X
that	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
and	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
are	B-X
non-calcemic	B-X
at	B-X
pharmacological	B-X
doses	B-X
,	B-X
dependent	B-X
in	B-X
part	B-X
on	B-X
their	B-X
lack	B-X
of	B-X
a	B-X
C1α	B-X
hydroxyl	B-X
group	B-X
.	B-X
In	B-X
epidermal	B-X
keratinocytes	B-X
,	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
,	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D2	B-X
and	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
inhibited	B-X
cell	B-X
proliferation	B-X
,	B-X
stimulated	B-X
differentiation	B-X
and	B-X
inhibited	B-X
NF-κB	B-X
activity	B-X
with	B-X
potencies	B-X
comparable	B-X
to	B-X
1,25	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
acting	B-X
as	B-X
partial	B-X
agonists	B-X
on	B-X
the	B-X
VDR	B-X
.	B-X
22	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
and	B-X
20,22	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
,	B-X
as	B-X
well	B-X
as	B-X
secosteroids	B-X
with	B-X
a	B-X
short	B-X
or	B-X
no	B-X
side	B-X
chain	B-X
,	B-X
showed	B-X
antiproliferative	B-X
and	B-X
prodifferentiation	B-X
effects	B-X
,	B-X
however	B-X
,	B-X
with	B-X
lower	B-X
potency	B-X
than	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
and	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
.	B-X
Furthermore	B-X
,	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
and	B-X
20,23	B-X
(	B-X
OH	B-X
)	B-X
2D3	B-X
showed	B-X
anti-fibrosing	B-X
effects	B-X
in	B-X
vitro	B-X
,	B-X
and	B-X
also	B-X
in	B-X
vivo	B-X
for	B-X
the	B-X
former	B-X
.	B-X
New	B-X
data	B-X
presented	B-X
here	B-X
shows	B-X
that	B-X
20	B-X
(	B-X
OH	B-X
)	B-X
D3	B-X
inhibits	B-X
LPS-induced	B-X
production	B-X
of	B-X
TNFα	B-X
in	B-X
the	B-X
J774	B-X
line	B-X
,	B-X
TNFα	B-X
and	B-X
IL-6	B-X
in	B-X
peritoneal	B-X
macrophages	B-X
and	B-X
suppresses	B-X
the	B-X
production	B-X
of	B-X
proinflammatory	B-X
Th1/Th17-related	B-X
cytokines	B-X
,	B-X
while	B-X
promoting	B-X
the	B-X
production	B-X
of	B-X
the	B-X
anti-inflammatory	B-X
cytokine	B-X
IL-10	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
the	B-X
skin	B-X
,	B-X
CYP11A1-derived	B-X
secosteroids	B-X
could	B-X
serve	B-X
both	B-X
as	B-X
endogenous	B-X
regulators	B-X
of	B-X
skin	B-X
functions	B-X
and	B-X
as	B-X
excellent	B-X
candidates	B-X
for	B-X
treatment	B-X
of	B-X
hyperproliferative	B-X
and	B-X
inflammatory	B-X
skin	B-X
disorders	B-X
,	B-X
and	B-X
skin	B-X
cancer	B-X
.	B-X

Like	O
risedronate	O
,	O
the	O
effects	O
of	O
3	O
-	O
PEHPC	O
are	O
likely	O
to	O
be	O
restricted	O
to	O
osteoclasts	O
in	O
vivo	O
,	O
since	O
both	O
risedronate	O
and	O
3	O
-	O
PEHPC	O
inhibited	O
Rab	O
prenylation	O
in	O
osteoclasts	O
,	O
but	O
not	O
in	O
general	O
bone	O
marrow	O
cells	O
,	O
when	O
administered	O
to	O
rabbits	O
in	O
vivo	O
.	O

Analysis	O
of	O
two	O
new	O
phosphonocarboxylate	O
analogues	O
of	O
3	O
-	O
PEHPC	O
(	O
3	O
-	O
PEPC	O
and	O
2	O
-	O
PEPC	O
)	O
revealed	O
that	O
,	O
first	O
,	O
the	O
geminal	O
hydroxyl	O
group	O
is	O
not	O
essential	O
for	O
inhibition	O
of	O
Rab	O
prenylation	O
by	O
phosphonocarboxylates	O
,	O
but	O
does	O
contribute	O
to	O
their	O
anti	O
-	O
resorptive	O
potency	O
,	O
most	O
likely	O
by	O
enhancing	O
their	O
affinity	O
for	O
bone	O
mineral	O
.	O

Second	O
,	O
the	O
position	O
of	O
the	O
nitrogen	O
in	O
the	O
side	O
chain	O
of	O
phosphonocarboxylates	O
is	O
crucial	O
for	O
their	O
ability	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
hence	O
to	O
inhibit	O
bone	O
resorption	O
.	O
<EOS>	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

In	O
addition	O
,	O
there	O
is	O
a	O
good	O
correlation	O
between	O
the	O
ability	O
of	O
the	O
phosphonocarboxylates	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
to	O
inhibit	O
bone	O
resorption	O
in	O
vitro	O
,	O
indicating	O
that	O
these	O
compounds	O
are	O
a	O
new	O
class	O
of	O
pharmacological	O
agents	O
that	O
inhibit	O
bone	O
resorption	O
by	O
specifically	O
preventing	O
prenylation	O
of	O
Rab	O
proteins	O
.	O
<EOS>	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

Furthermore	O
,	O
although	O
phosphonocarboxylates	O
are	O
analogues	O
of	O
bisphosphonates	O
,	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
phosphonocarboxylates	O
for	O
inhibiting	O
Rab	O
geranylgeranyltransferase	O
appear	O
to	O
differ	O
from	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
bisphosphonates	O
for	O
inhibiting	O
farnesyl	B-Protein
diphosphate	I-Protein
synthase	I-Protein
.	O
<EOS>	B-X
Nitrogen-containing	B-X
bisphosphonate	B-X
drugs	B-X
such	B-X
as	B-X
risedronate	B-X
act	B-X
by	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
,	B-X
thereby	B-X
disrupting	B-X
protein	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
.	B-X
We	B-X
recently	B-X
found	B-X
that	B-X
an	B-X
anti-resorptive	B-X
phosphonocarboxylate	B-X
analogue	B-X
of	B-X
risedronate	B-X
,	B-X
3-PEHPC	B-X
(	B-X
previously	B-X
referred	B-X
to	B-X
as	B-X
NE10790	B-X
)	B-X
,	B-X
selectively	B-X
prevents	B-X
prenylation	B-X
of	B-X
Rab	B-X
GTPases	B-X
in	B-X
vitro	B-X
by	B-X
specifically	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
unprenylated	B-X
Rab6	B-X
could	B-X
be	B-X
detected	B-X
in	B-X
J774	B-X
cells	B-X
after	B-X
treatment	B-X
with	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
for	B-X
as	B-X
little	B-X
as	B-X
4	B-X
h	B-X
,	B-X
and	B-X
reached	B-X
50	B-X
%	B-X
after	B-X
24	B-X
h.	B-X
Furthermore	B-X
,	B-X
treatment	B-X
of	B-X
J774	B-X
cells	B-X
or	B-X
osteoclasts	B-X
with	B-X
either	B-X
3-PEHPC	B-X
or	B-X
risedronate	B-X
disrupted	B-X
membrane	B-X
association	B-X
of	B-X
several	B-X
Rab	B-X
family	B-X
proteins	B-X
.	B-X
Like	B-X
risedronate	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
3-PEHPC	B-X
are	B-X
likely	B-X
to	B-X
be	B-X
restricted	B-X
to	B-X
osteoclasts	B-X
in	B-X
vivo	B-X
,	B-X
since	B-X
both	B-X
risedronate	B-X
and	B-X
3-PEHPC	B-X
inhibited	B-X
Rab	B-X
prenylation	B-X
in	B-X
osteoclasts	B-X
,	B-X
but	B-X
not	B-X
in	B-X
general	B-X
bone	B-X
marrow	B-X
cells	B-X
,	B-X
when	B-X
administered	B-X
to	B-X
rabbits	B-X
in	B-X
vivo	B-X
.	B-X
Analysis	B-X
of	B-X
two	B-X
new	B-X
phosphonocarboxylate	B-X
analogues	B-X
of	B-X
3-PEHPC	B-X
(	B-X
3-PEPC	B-X
and	B-X
2-PEPC	B-X
)	B-X
revealed	B-X
that	B-X
,	B-X
first	B-X
,	B-X
the	B-X
geminal	B-X
hydroxyl	B-X
group	B-X
is	B-X
not	B-X
essential	B-X
for	B-X
inhibition	B-X
of	B-X
Rab	B-X
prenylation	B-X
by	B-X
phosphonocarboxylates	B-X
,	B-X
but	B-X
does	B-X
contribute	B-X
to	B-X
their	B-X
anti-resorptive	B-X
potency	B-X
,	B-X
most	B-X
likely	B-X
by	B-X
enhancing	B-X
their	B-X
affinity	B-X
for	B-X
bone	B-X
mineral	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
position	B-X
of	B-X
the	B-X
nitrogen	B-X
in	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
phosphonocarboxylates	B-X
is	B-X
crucial	B-X
for	B-X
their	B-X
ability	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
hence	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
there	B-X
is	B-X
a	B-X
good	B-X
correlation	B-X
between	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
phosphonocarboxylates	B-X
to	B-X
inhibit	B-X
Rab	B-X
prenylation	B-X
and	B-X
to	B-X
inhibit	B-X
bone	B-X
resorption	B-X
in	B-X
vitro	B-X
,	B-X
indicating	B-X
that	B-X
these	B-X
compounds	B-X
are	B-X
a	B-X
new	B-X
class	B-X
of	B-X
pharmacological	B-X
agents	B-X
that	B-X
inhibit	B-X
bone	B-X
resorption	B-X
by	B-X
specifically	B-X
preventing	B-X
prenylation	B-X
of	B-X
Rab	B-X
proteins	B-X
.	B-X
Furthermore	B-X
,	B-X
although	B-X
phosphonocarboxylates	B-X
are	B-X
analogues	B-X
of	B-X
bisphosphonates	B-X
,	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
phosphonocarboxylates	B-X
for	B-X
inhibiting	B-X
Rab	B-X
geranylgeranyltransferase	B-X
appear	B-X
to	B-X
differ	B-X
from	B-X
the	B-X
structure-activity	B-X
relationships	B-X
of	B-X
bisphosphonates	B-X
for	B-X
inhibiting	B-X
farnesyl	B-X
diphosphate	B-X
synthase	B-X
.	B-X

CAND1	B-Protein
enhances	O
deneddylation	O
of	O
CUL1	B-Protein
by	O
COP9	O
signalosome	O
.	O
<EOS>	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
CAND1	B-X
expression	B-X
by	B-X
small	B-X
inhibitory	B-X
RNA	B-X
enhanced	B-X
the	B-X
interaction	B-X
between	B-X
CUL1	B-X
and	B-X
CSN	B-X
,	B-X
suggesting	B-X
that	B-X
CAND1	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
required	B-X
the	B-X
four	B-X
helix	B-X
bundle	B-X
in	B-X
CUL1	B-X
C-terminal	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
wrapped	B-X
around	B-X
by	B-X
CAND1	B-X
in	B-X
the	B-X
CAND1-CUL1-Rbx1	B-X
complex	B-X
.	B-X
CAND1	B-X
greatly	B-X
facilitated	B-X
CSN-mediated	B-X
deneddylation	B-X
of	B-X
CUL1	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
was	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
CUL1	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhancement	B-X
of	B-X
CSN-mediated	B-X
deneddylation	B-X
by	B-X
CAND1	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
SCFs	B-X
in	B-X
vivo	B-X
.	B-X

Cullin	O
-	O
RING	O
ligases	O
(	O
CRLs	O
)	O
regulate	O
diverse	O
cellular	O
functions	O
such	O
as	O
cell	O
cycle	O
progression	O
and	O
cytokine	O
signaling	O
by	O
ubiquitinating	O
key	O
regulatory	O
proteins	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
regulate	B-X
diverse	B-X
cellular	B-X
functions	B-X
such	B-X
as	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
cytokine	B-X
signaling	B-X
by	B-X
ubiquitinating	B-X
key	B-X
regulatory	B-X
proteins	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
CRLs	B-X
is	B-X
controlled	B-X
by	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
cullin	B-X
subunits	B-X
.	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X

The	O
activity	O
of	O
CRLs	O
is	O
controlled	O
by	O
Nedd8	B-Protein
modification	O
of	O
the	O
cullin	O
subunits	O
.	O
<EOS>	B-X
CSN	B-X
recognizes	B-X
Skp1/cullin-1/Fbx	B-X
E3	B-X
cullin-RING	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
without	B-X
substrate	B-X
and	B-X
removes	B-X
their	B-X
posttranslational	B-X
Nedd8	B-X
modification	B-X
from	B-X
the	B-X
cullin	B-X
scaffold	B-X
.	B-X
Cullin-RING	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
regulate	B-X
diverse	B-X
cellular	B-X
functions	B-X
such	B-X
as	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
cytokine	B-X
signaling	B-X
by	B-X
ubiquitinating	B-X
key	B-X
regulatory	B-X
proteins	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
CRLs	B-X
is	B-X
controlled	B-X
by	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
cullin	B-X
subunits	B-X
.	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X

Recent	O
reports	O
have	O
suggested	O
that	O
CAND1	B-Protein
,	O
which	O
specifically	O
binds	O
to	O
unmodified	O
CUL1	B-Protein
but	O
not	O
to	O
neddylated	O
one	O
,	O
is	O
required	O
for	O
the	O
in	O
vivo	O
function	O
of	O
SCFs	O
,	O
the	O
CUL1	B-Protein
-	O
containing	O
CRLs	O
.	O
<EOS>	B-X
In	B-X
response	B-X
to	B-X
the	B-X
hormone	B-X
,	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
targets	B-X
members	B-X
of	B-X
the	B-X
auxin/indoleacetic	B-X
acid	B-X
(	B-X
Aux/IAA	B-X
)	B-X
family	B-X
of	B-X
transcriptional	B-X
regulators	B-X
for	B-X
ubiquitin-mediated	B-X
proteolysis	B-X
.	B-X
ETA2	B-X
encodes	B-X
the	B-X
Arabidopsis	B-X
ortholog	B-X
of	B-X
human	B-X
Cullin	B-X
Associated	B-X
and	B-X
Neddylation-Dissociated	B-X
(	B-X
CAND1	B-X
)	B-X
/TIP120A	B-X
,	B-X
a	B-X
protein	B-X
recently	B-X
identified	B-X
as	B-X
a	B-X
cullin-interacting	B-X
factor	B-X
.	B-X
Previous	B-X
biochemical	B-X
studies	B-X
of	B-X
CAND1	B-X
have	B-X
suggested	B-X
that	B-X
it	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
to	B-X
negatively	B-X
regulate	B-X
SCF	B-X
assembly	B-X
.	B-X
Modification	B-X
of	B-X
CUL1	B-X
by	B-X
the	B-X
RUB1/NEDD8	B-X
ubiquitin-like	B-X
protein	B-X
has	B-X
been	B-X
proposed	B-X
to	B-X
free	B-X
CUL1	B-X
from	B-X
CAND1	B-X
and	B-X
promote	B-X
SCF	B-X
assembly	B-X
.	B-X
We	B-X
present	B-X
double	B-X
mutant	B-X
analyses	B-X
of	B-X
eta2	B-X
axr1	B-X
plants	B-X
indicating	B-X
that	B-X
liberating	B-X
CUL1	B-X
from	B-X
ETA2/CAND1	B-X
is	B-X
not	B-X
the	B-X
primary	B-X
role	B-X
of	B-X
the	B-X
RUB	B-X
modification	B-X
pathway	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
SCF	B-X
activity	B-X
.	B-X
Our	B-X
genetic	B-X
and	B-X
molecular	B-X
analysis	B-X
of	B-X
SCF	B-X
(	B-X
TIR1	B-X
)	B-X
function	B-X
in	B-X
eta2	B-X
mutants	B-X
provides	B-X
novel	B-X
insight	B-X
into	B-X
the	B-X
role	B-X
of	B-X
CAND1	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
SCF	B-X
ubiquitin-ligase	B-X
activity	B-X
.	B-X

We	O
show	O
here	O
that	O
CAND1	B-Protein
and	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
,	O
the	O
major	O
deneddylase	O
of	O
cullins	O
,	O
bind	O
to	O
unneddylated	O
CUL1	B-Protein
in	O
a	O
mutually	O
exclusive	O
way	O
.	O

The	O
suppression	O
of	O
CAND1	B-Protein
expression	O
by	O
small	O
inhibitory	O
RNA	O
enhanced	O
the	O
interaction	O
between	O
CUL1	B-Protein
and	O
CSN	O
,	O
suggesting	O
that	O
CAND1	B-Protein
inhibited	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-Protein
.	O
<EOS>	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
CAND1	B-X
expression	B-X
by	B-X
small	B-X
inhibitory	B-X
RNA	B-X
enhanced	B-X
the	B-X
interaction	B-X
between	B-X
CUL1	B-X
and	B-X
CSN	B-X
,	B-X
suggesting	B-X
that	B-X
CAND1	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
required	B-X
the	B-X
four	B-X
helix	B-X
bundle	B-X
in	B-X
CUL1	B-X
C-terminal	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
wrapped	B-X
around	B-X
by	B-X
CAND1	B-X
in	B-X
the	B-X
CAND1-CUL1-Rbx1	B-X
complex	B-X
.	B-X
CAND1	B-X
greatly	B-X
facilitated	B-X
CSN-mediated	B-X
deneddylation	B-X
of	B-X
CUL1	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
was	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
CUL1	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhancement	B-X
of	B-X
CSN-mediated	B-X
deneddylation	B-X
by	B-X
CAND1	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
SCFs	B-X
in	B-X
vivo	B-X
.	B-X

We	O
found	O
that	O
the	O
binding	O
of	O
CSN	O
to	O
CUL1	B-Protein
required	O
the	O
four	O
helix	O
bundle	O
in	O
CUL1	B-Protein
C	O
-	O
terminal	O
domain	O
,	O
which	O
was	O
wrapped	O
around	O
by	O
CAND1	B-Protein
in	O
the	O
CAND1	B-Protein
-	O
CUL1	B-Protein
-	O
Rbx1	B-Protein
complex	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
regulate	B-X
diverse	B-X
cellular	B-X
functions	B-X
such	B-X
as	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
cytokine	B-X
signaling	B-X
by	B-X
ubiquitinating	B-X
key	B-X
regulatory	B-X
proteins	B-X
.	B-X
The	B-X
activity	B-X
of	B-X
CRLs	B-X
is	B-X
controlled	B-X
by	B-X
Nedd8	B-X
modification	B-X
of	B-X
the	B-X
cullin	B-X
subunits	B-X
.	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
CAND1	B-X
expression	B-X
by	B-X
small	B-X
inhibitory	B-X
RNA	B-X
enhanced	B-X
the	B-X
interaction	B-X
between	B-X
CUL1	B-X
and	B-X
CSN	B-X
,	B-X
suggesting	B-X
that	B-X
CAND1	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
required	B-X
the	B-X
four	B-X
helix	B-X
bundle	B-X
in	B-X
CUL1	B-X
C-terminal	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
wrapped	B-X
around	B-X
by	B-X
CAND1	B-X
in	B-X
the	B-X
CAND1-CUL1-Rbx1	B-X
complex	B-X
.	B-X
CAND1	B-X
greatly	B-X
facilitated	B-X
CSN-mediated	B-X
deneddylation	B-X
of	B-X
CUL1	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
was	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
CUL1	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhancement	B-X
of	B-X
CSN-mediated	B-X
deneddylation	B-X
by	B-X
CAND1	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
SCFs	B-X
in	B-X
vivo	B-X
.	B-X

CAND1	B-Protein
greatly	O
facilitated	O
CSN	O
-	O
mediated	O
deneddylation	O
of	O
CUL1	B-Protein
in	O
vitro	O
,	O
which	O
was	O
dependent	O
on	O
its	O
binding	O
to	O
CUL1	B-Protein
.	O
<EOS>	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
CAND1	B-X
expression	B-X
by	B-X
small	B-X
inhibitory	B-X
RNA	B-X
enhanced	B-X
the	B-X
interaction	B-X
between	B-X
CUL1	B-X
and	B-X
CSN	B-X
,	B-X
suggesting	B-X
that	B-X
CAND1	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
required	B-X
the	B-X
four	B-X
helix	B-X
bundle	B-X
in	B-X
CUL1	B-X
C-terminal	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
wrapped	B-X
around	B-X
by	B-X
CAND1	B-X
in	B-X
the	B-X
CAND1-CUL1-Rbx1	B-X
complex	B-X
.	B-X
CAND1	B-X
greatly	B-X
facilitated	B-X
CSN-mediated	B-X
deneddylation	B-X
of	B-X
CUL1	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
was	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
CUL1	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhancement	B-X
of	B-X
CSN-mediated	B-X
deneddylation	B-X
by	B-X
CAND1	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
SCFs	B-X
in	B-X
vivo	B-X
.	B-X

Our	O
data	O
suggest	O
that	O
enhancement	O
of	O
CSN	O
-	O
mediated	O
deneddylation	O
by	O
CAND1	B-Protein
may	O
contribute	O
to	O
its	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
SCFs	O
in	O
vivo	O
.	O
<EOS>	B-X
Cullin-RING	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
regulate	B-X
diverse	B-X
cellular	B-X
functions	B-X
such	B-X
as	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
cytokine	B-X
signaling	B-X
by	B-X
ubiquitinating	B-X
key	B-X
regulatory	B-X
proteins	B-X
.	B-X
Recent	B-X
reports	B-X
have	B-X
suggested	B-X
that	B-X
CAND1	B-X
,	B-X
which	B-X
specifically	B-X
binds	B-X
to	B-X
unmodified	B-X
CUL1	B-X
but	B-X
not	B-X
to	B-X
neddylated	B-X
one	B-X
,	B-X
is	B-X
required	B-X
for	B-X
the	B-X
in	B-X
vivo	B-X
function	B-X
of	B-X
SCFs	B-X
,	B-X
the	B-X
CUL1-containing	B-X
CRLs	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
CAND1	B-X
and	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
,	B-X
the	B-X
major	B-X
deneddylase	B-X
of	B-X
cullins	B-X
,	B-X
bind	B-X
to	B-X
unneddylated	B-X
CUL1	B-X
in	B-X
a	B-X
mutually	B-X
exclusive	B-X
way	B-X
.	B-X
The	B-X
suppression	B-X
of	B-X
CAND1	B-X
expression	B-X
by	B-X
small	B-X
inhibitory	B-X
RNA	B-X
enhanced	B-X
the	B-X
interaction	B-X
between	B-X
CUL1	B-X
and	B-X
CSN	B-X
,	B-X
suggesting	B-X
that	B-X
CAND1	B-X
inhibited	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
binding	B-X
of	B-X
CSN	B-X
to	B-X
CUL1	B-X
required	B-X
the	B-X
four	B-X
helix	B-X
bundle	B-X
in	B-X
CUL1	B-X
C-terminal	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
wrapped	B-X
around	B-X
by	B-X
CAND1	B-X
in	B-X
the	B-X
CAND1-CUL1-Rbx1	B-X
complex	B-X
.	B-X
CAND1	B-X
greatly	B-X
facilitated	B-X
CSN-mediated	B-X
deneddylation	B-X
of	B-X
CUL1	B-X
in	B-X
vitro	B-X
,	B-X
which	B-X
was	B-X
dependent	B-X
on	B-X
its	B-X
binding	B-X
to	B-X
CUL1	B-X
.	B-X
Our	B-X
data	B-X
suggest	B-X
that	B-X
enhancement	B-X
of	B-X
CSN-mediated	B-X
deneddylation	B-X
by	B-X
CAND1	B-X
may	B-X
contribute	B-X
to	B-X
its	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
SCFs	B-X
in	B-X
vivo	B-X
.	B-X

Interaction	O
of	O
NUB1	B-Protein
with	O
the	O
proteasome	O
subunit	O
S5a	B-Protein
.	O
<EOS>	B-X
NUB1	B-X
interacts	B-X
with	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
NEDD8	B-X
to	B-X
target	B-X
the	B-X
NEDD8	B-X
monomer	B-X
and	B-X
neddylated	B-X
proteins	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Therefore	B-X
,	B-X
NUB1	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
downregulator	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
system	B-X
.	B-X
Since	B-X
NUB1	B-X
possesses	B-X
a	B-X
UBL	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
RAD23/HHR23	B-X
,	B-X
we	B-X
initially	B-X
hypothesized	B-X
that	B-X
NUB1	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
of	B-X
the	B-X
proteasome	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Unexpectedly	B-X
,	B-X
our	B-X
studies	B-X
revealed	B-X
that	B-X
NUB1	B-X
directly	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
through	B-X
its	B-X
C-terminal	B-X
region	B-X
between	B-X
amino	B-X
acid	B-X
residues	B-X
536	B-X
and	B-X
584	B-X
,	B-X
not	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Although	B-X
the	B-X
UBL	B-X
domain	B-X
was	B-X
not	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
NUB1	B-X
,	B-X
our	B-X
further	B-X
studies	B-X
revealed	B-X
that	B-X
the	B-X
UBL	B-X
domain	B-X
is	B-X
required	B-X
for	B-X
the	B-X
function	B-X
of	B-X
NUB1	B-X
.	B-X

NUB1	B-Protein
interacts	O
with	O
a	O
ubiquitin	B-Protein
-	O
like	O
protein	O
NEDD8	B-Protein
to	O
target	O
the	O
NEDD8	B-Protein
monomer	O
and	O
neddylated	O
proteins	O
to	O
the	O
proteasome	O
for	O
degradation	O
.	O

Therefore	O
,	O
NUB1	B-Protein
is	O
thought	O
to	O
be	O
a	O
potent	O
downregulator	O
of	O
NEDD8	B-Protein
conjugation	O
system	O
.	O
<EOS>	B-X
NUB1	B-X
interacts	B-X
with	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
NEDD8	B-X
to	B-X
target	B-X
the	B-X
NEDD8	B-X
monomer	B-X
and	B-X
neddylated	B-X
proteins	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Therefore	B-X
,	B-X
NUB1	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
downregulator	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
system	B-X
.	B-X
Since	B-X
NUB1	B-X
possesses	B-X
a	B-X
UBL	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
RAD23/HHR23	B-X
,	B-X
we	B-X
initially	B-X
hypothesized	B-X
that	B-X
NUB1	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
of	B-X
the	B-X
proteasome	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Unexpectedly	B-X
,	B-X
our	B-X
studies	B-X
revealed	B-X
that	B-X
NUB1	B-X
directly	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
through	B-X
its	B-X
C-terminal	B-X
region	B-X
between	B-X
amino	B-X
acid	B-X
residues	B-X
536	B-X
and	B-X
584	B-X
,	B-X
not	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Although	B-X
the	B-X
UBL	B-X
domain	B-X
was	B-X
not	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
NUB1	B-X
,	B-X
our	B-X
further	B-X
studies	B-X
revealed	B-X
that	B-X
the	B-X
UBL	B-X
domain	B-X
is	B-X
required	B-X
for	B-X
the	B-X
function	B-X
of	B-X
NUB1	B-X
.	B-X

Since	O
NUB1	B-Protein
possesses	O
a	O
UBL	O
domain	O
,	O
which	O
was	O
previously	O
shown	O
to	O
be	O
an	O
S5a	B-Protein
-	O
interacting	O
motif	O
in	O
RAD23	B-Protein
/	O
HHR23	B-Protein
,	O
we	O
initially	O
hypothesized	O
that	O
NUB1	B-Protein
interacts	O
with	O
the	O
S5a	B-Protein
subunit	O
of	O
the	O
proteasome	O
through	O
its	O
UBL	O
domain	O
.	O
<EOS>	B-X
NUB1	B-X
interacts	B-X
with	B-X
a	B-X
ubiquitin-like	B-X
protein	B-X
NEDD8	B-X
to	B-X
target	B-X
the	B-X
NEDD8	B-X
monomer	B-X
and	B-X
neddylated	B-X
proteins	B-X
to	B-X
the	B-X
proteasome	B-X
for	B-X
degradation	B-X
.	B-X
Therefore	B-X
,	B-X
NUB1	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
a	B-X
potent	B-X
downregulator	B-X
of	B-X
NEDD8	B-X
conjugation	B-X
system	B-X
.	B-X
Since	B-X
NUB1	B-X
possesses	B-X
a	B-X
UBL	B-X
domain	B-X
,	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
RAD23/HHR23	B-X
,	B-X
we	B-X
initially	B-X
hypothesized	B-X
that	B-X
NUB1	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
of	B-X
the	B-X
proteasome	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Unexpectedly	B-X
,	B-X
our	B-X
studies	B-X
revealed	B-X
that	B-X
NUB1	B-X
directly	B-X
interacts	B-X
with	B-X
the	B-X
S5a	B-X
subunit	B-X
through	B-X
its	B-X
C-terminal	B-X
region	B-X
between	B-X
amino	B-X
acid	B-X
residues	B-X
536	B-X
and	B-X
584	B-X
,	B-X
not	B-X
through	B-X
its	B-X
UBL	B-X
domain	B-X
.	B-X
Although	B-X
the	B-X
UBL	B-X
domain	B-X
was	B-X
not	B-X
an	B-X
S5a-interacting	B-X
motif	B-X
in	B-X
NUB1	B-X
,	B-X
our	B-X
further	B-X
studies	B-X
revealed	B-X
that	B-X
the	B-X
UBL	B-X
domain	B-X
is	B-X
required	B-X
for	B-X
the	B-X
function	B-X
of	B-X
NUB1	B-X
.	B-X

To	O
examine	O
this	O
,	O
we	O
performed	O
an	O
in	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
and	O
a	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

Unexpectedly	O
,	O
our	O
studies	O
revealed	O
that	O
NUB1	B-Protein
directly	O
interacts	O
with	O
the	O
S5a	B-Protein
subunit	O
through	O
its	O
C	O
-	O
terminal	O
region	O
between	O
amino	O
acid	O
residues	O
536	O
and	O
584	O
,	O
not	O
through	O
its	O
UBL	O
domain	O
.	O

Although	O
the	O
UBL	O
domain	O
was	O
not	O
an	O
S5a	B-Protein
-	O
interacting	O
motif	O
in	O
NUB1	B-Protein
,	O
our	O
further	O
studies	O
revealed	O
that	O
the	O
UBL	O
domain	O
is	O
required	O
for	O
the	O
function	O
of	O
NUB1	B-Protein
.	O
<EOS>	B-X
Mitochondrial	B-X
dysfunction	B-X
is	B-X
involved	B-X
in	B-X
aging	B-X
and	B-X
multiple	B-X
degenerative	B-X
diseases	B-X
,	B-X
including	B-X
intervertebral	B-X
disc	B-X
degeneration	B-X
(	B-X
IVDD	B-X
)	B-X
and	B-X
osteoarthritis	B-X
(	B-X
OA	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
maintenance	B-X
of	B-X
mitochondria	B-X
homeostasis	B-X
and	B-X
function	B-X
is	B-X
important	B-X
.	B-X
Mitophagy	B-X
,	B-X
a	B-X
process	B-X
that	B-X
selectively	B-X
clears	B-X
damaged	B-X
or	B-X
dysfunctional	B-X
mitochondria	B-X
through	B-X
autophagic	B-X
machinery	B-X
,	B-X
functions	B-X
to	B-X
maintain	B-X
mitochondrial	B-X
quality	B-X
control	B-X
and	B-X
homeostasis	B-X
.	B-X
Ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
,	B-X
a	B-X
small	B-X
protein	B-X
modifier	B-X
,	B-X
is	B-X
conjugated	B-X
to	B-X
diverse	B-X
protein	B-X
substrates	B-X
to	B-X
regulate	B-X
many	B-X
functions	B-X
.	B-X
Structurally	B-X
diverse	B-X
linkages	B-X
of	B-X
poly-Ub	B-X
to	B-X
target	B-X
proteins	B-X
allow	B-X
enormous	B-X
functional	B-X
diversity	B-X
with	B-X
specificity	B-X
being	B-X
governed	B-X
by	B-X
evolutionarily	B-X
conserved	B-X
enzymes	B-X
(	B-X
E3-Ub	B-X
ligases	B-X
)	B-X
.	B-X
The	B-X
Ub-binding	B-X
domain	B-X
(	B-X
UBD	B-X
)	B-X
and	B-X
LC3-interacting	B-X
region	B-X
(	B-X
LIR	B-X
)	B-X
are	B-X
critical	B-X
features	B-X
of	B-X
macroautophagy/autophagy	B-X
receptors	B-X
that	B-X
recognize	B-X
Ub-conjugated	B-X
on	B-X
protein	B-X
substrates	B-X
.	B-X

S	O
-	O
palmitoylation	O
modulates	O
estrogen	B-Protein
receptor	I-Protein
alpha	I-Protein
localization	O
and	O
functions	O
.	O
<EOS>	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Several	B-X
laboratories	B-X
,	B-X
including	B-X
our	B-X
own	B-X
,	B-X
have	B-X
recently	B-X
elucidated	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
plasma	B-X
membrane	B-X
ERalpha	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

17beta	O
-	O
Estradiol	O
(	O
E2	O
)	O
acts	O
as	O
a	O
chemical	O
messenger	O
in	O
target	O
tissues	O
inducing	O
both	O
slow	O
nuclear	O
and	O
rapid	O
extra	O
-	O
nuclear	O
responses	O
.	O
<EOS>	B-X
17beta-Estradiol	B-X
(	B-X
E2	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
chemical	B-X
messenger	B-X
in	B-X
target	B-X
tissues	B-X
inducing	B-X
both	B-X
slow	B-X
nuclear	B-X
and	B-X
rapid	B-X
extra-nuclear	B-X
responses	B-X
.	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

E2	O
binds	O
to	O
its	O
cognate	O
nuclear	O
receptors	O
(	O
ER	O
)	O
resulting	O
in	O
the	O
activation	O
of	O
target	O
gene	O
transcription	O
in	O
the	O
nucleus	O
.	O
<EOS>	B-X
17beta-Estradiol	B-X
(	B-X
E2	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
chemical	B-X
messenger	B-X
in	B-X
target	B-X
tissues	B-X
inducing	B-X
both	B-X
slow	B-X
nuclear	B-X
and	B-X
rapid	B-X
extra-nuclear	B-X
responses	B-X
.	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
Several	B-X
laboratories	B-X
,	B-X
including	B-X
our	B-X
own	B-X
,	B-X
have	B-X
recently	B-X
elucidated	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
plasma	B-X
membrane	B-X
ERalpha	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

In	O
addition	O
to	O
these	O
genomic	O
effects	O
,	O
E2	O
modulates	O
cell	O
functions	O
through	O
rapid	O
non	O
-	O
genomic	O
actions	O
.	O
<EOS>	B-X
17beta-Estradiol	B-X
(	B-X
E2	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
chemical	B-X
messenger	B-X
in	B-X
target	B-X
tissues	B-X
inducing	B-X
both	B-X
slow	B-X
nuclear	B-X
and	B-X
rapid	B-X
extra-nuclear	B-X
responses	B-X
.	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

Stimulation	O
of	O
G	O
-	O
proteins	O
,	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
,	O
inositol	O
phosphate	O
generation	O
as	O
well	O
as	O
phospholipase	O
C	O
,	O
ERK	O
/	O
MAPK	O
,	O
and	O
PI3K	O
/	O
AKT	O
activation	O
all	O
occur	O
within	O
seconds	O
to	O
minutes	O
after	O
E2	O
binding	O
to	O
a	O
small	O
population	O
of	O
ERalpha	B-Protein
located	O
at	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
17beta-Estradiol	B-X
(	B-X
E2	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
chemical	B-X
messenger	B-X
in	B-X
target	B-X
tissues	B-X
inducing	B-X
both	B-X
slow	B-X
nuclear	B-X
and	B-X
rapid	B-X
extra-nuclear	B-X
responses	B-X
.	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
Several	B-X
laboratories	B-X
,	B-X
including	B-X
our	B-X
own	B-X
,	B-X
have	B-X
recently	B-X
elucidated	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
plasma	B-X
membrane	B-X
ERalpha	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

The	O
great	O
impact	O
of	O
these	O
rapid	O
signals	O
on	O
cell	O
physiology	O
renders	O
central	O
the	O
knowledge	O
of	O
the	O
structural	O
bases	O
and	O
mechanisms	O
that	O
mediate	O
extra	O
-	O
nuclear	O
signaling	O
by	O
E2	O
.	O
<EOS>	B-X
17beta-Estradiol	B-X
(	B-X
E2	B-X
)	B-X
acts	B-X
as	B-X
a	B-X
chemical	B-X
messenger	B-X
in	B-X
target	B-X
tissues	B-X
inducing	B-X
both	B-X
slow	B-X
nuclear	B-X
and	B-X
rapid	B-X
extra-nuclear	B-X
responses	B-X
.	B-X
E2	B-X
binds	B-X
to	B-X
its	B-X
cognate	B-X
nuclear	B-X
receptors	B-X
(	B-X
ER	B-X
)	B-X
resulting	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
target	B-X
gene	B-X
transcription	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
Several	B-X
laboratories	B-X
,	B-X
including	B-X
our	B-X
own	B-X
,	B-X
have	B-X
recently	B-X
elucidated	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
plasma	B-X
membrane	B-X
ERalpha	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

Several	O
laboratories	O
,	O
including	O
our	O
own	O
,	O
have	O
recently	O
elucidated	O
the	O
structural	O
requirements	O
for	O
localization	O
and	O
function	O
of	O
plasma	O
membrane	O
ERalpha	B-Protein
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
genomic	B-X
effects	B-X
,	B-X
E2	B-X
modulates	B-X
cell	B-X
functions	B-X
through	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
.	B-X
Stimulation	B-X
of	B-X
G-proteins	B-X
,	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
influx	B-X
,	B-X
inositol	B-X
phosphate	B-X
generation	B-X
as	B-X
well	B-X
as	B-X
phospholipase	B-X
C	B-X
,	B-X
ERK/MAPK	B-X
,	B-X
and	B-X
PI3K/AKT	B-X
activation	B-X
all	B-X
occur	B-X
within	B-X
seconds	B-X
to	B-X
minutes	B-X
after	B-X
E2	B-X
binding	B-X
to	B-X
a	B-X
small	B-X
population	B-X
of	B-X
ERalpha	B-X
located	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
great	B-X
impact	B-X
of	B-X
these	B-X
rapid	B-X
signals	B-X
on	B-X
cell	B-X
physiology	B-X
renders	B-X
central	B-X
the	B-X
knowledge	B-X
of	B-X
the	B-X
structural	B-X
bases	B-X
and	B-X
mechanisms	B-X
that	B-X
mediate	B-X
extra-nuclear	B-X
signaling	B-X
by	B-X
E2	B-X
.	B-X
Several	B-X
laboratories	B-X
,	B-X
including	B-X
our	B-X
own	B-X
,	B-X
have	B-X
recently	B-X
elucidated	B-X
the	B-X
structural	B-X
requirements	B-X
for	B-X
localization	B-X
and	B-X
function	B-X
of	B-X
plasma	B-X
membrane	B-X
ERalpha	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
the	B-X
molecular	B-X
mechanisms	B-X
of	B-X
E2-induced	B-X
rapid	B-X
non-genomic	B-X
actions	B-X
relevant	B-X
for	B-X
cell	B-X
functions	B-X
,	B-X
highlighting	B-X
the	B-X
role	B-X
of	B-X
lipid	B-X
modification	B-X
(	B-X
i.e.	B-X
,	B-X
palmitoylation	B-X
)	B-X
in	B-X
the	B-X
ERalpha	B-X
localization	B-X
to	B-X
and	B-X
residence	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X

This	O
review	O
summarizes	O
the	O
molecular	O
mechanisms	O
of	O
E2	O
-	O
induced	O
rapid	O
non	O
-	O
genomic	O
actions	O
relevant	O
for	O
cell	O
functions	O
,	O
highlighting	O
the	O
role	O
of	O
lipid	O
modification	O
(	O
i	O
.	O
e	O
.	O
,	O
palmitoylation	O
)	O
in	O
the	O
ERalpha	B-Protein
localization	O
to	O
and	O
residence	O
at	O
the	O
plasma	O
membrane	O
.	O

Functional	O
interactions	O
of	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
and	O
their	O
common	O
substrate	O
small	O
GTP	O
-	O
binding	O
protein	O
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X

smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
are	O
stimulatory	O
and	O
inhibitory	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
,	O
respectively	O
,	O
for	O
a	O
group	O
of	O
ras	B-Protein
p21	I-Protein
-	O
related	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O
rho	B-Protein
p21	I-Protein
is	O
a	O
common	O
substrate	O
small	O
G	O
protein	O
for	O
both	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

We	O
examined	O
here	O
the	O
functional	O
interactions	O
of	O
these	O
GDP	O
/	O
GTP	O
exchange	O
proteins	O
with	O
rho	B-Protein
p21	I-Protein
as	O
a	O
substrate	O
.	O
smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
interacted	O
with	O
the	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-Protein
p21	I-Protein
and	O
thereby	O
stimulated	O
and	O
inhibited	O
,	O
respectively	O
,	O
the	O
dissociation	O
of	O
GDP	O
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

The	O
inhibitory	O
effect	O
of	O
rho	O
GDI	O
was	O
much	O
stronger	O
than	O
the	O
stimulatory	O
effect	O
of	O
smg	B-Protein
GDS	I-Protein
.	O

The	O
GDP	O
-	O
bound	O
form	O
of	O
rho	B-Protein
p21	I-Protein
formed	O
a	O
complex	O
with	O
rho	O
GDI	O
but	O
not	O
with	O
smg	B-Protein
GDS	I-Protein
in	O
their	O
simultaneous	O
presence	O
.	O
<EOS>	B-X
rho	B-X
GDI	B-X
is	B-X
an	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
protein	B-X
for	B-X
the	B-X
rho	B-X
family	B-X
.	B-X
Recently	B-X
,	B-X
rho	B-X
GDI	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
interact	B-X
with	B-X
the	B-X
GTP-bound	B-X
form	B-X
of	B-X
G25K	B-X
and	B-X
rac1	B-X
p21	B-X
and	B-X
to	B-X
inhibit	B-X
their	B-X
basal	B-X
and	B-X
GTPase-activating	B-X
protein	B-X
(	B-X
GAP	B-X
)	B-X
-stimulated	B-X
GTPase	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
rho	B-X
GDI	B-X
interacts	B-X
with	B-X
the	B-X
GTP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
rac	B-X
p21	B-X
and	B-X
inhibits	B-X
their	B-X
basal	B-X
and	B-X
rho	B-X
GAP-stimulated	B-X
GTPase	B-X
activity	B-X
,	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
both	B-X
the	B-X
GDP-	B-X
and	B-X
GTP-bound	B-X
forms	B-X
of	B-X
rhoA	B-X
p21	B-X
and	B-X
rac1	B-X
p21	B-X
as	B-X
estimated	B-X
by	B-X
measuring	B-X
its	B-X
ability	B-X
to	B-X
form	B-X
a	B-X
complex	B-X
with	B-X
both	B-X
forms	B-X
and	B-X
to	B-X
inhibit	B-X
the	B-X
membrane-binding	B-X
activity	B-X
of	B-X
both	B-X
forms	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
rho	B-X
GDI	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
GTP-bound	B-X
form	B-X
was	B-X
,	B-X
however	B-X
,	B-X
about	B-X
10	B-X
%	B-X
that	B-X
for	B-X
interaction	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
.	B-X
Moreover	B-X
,	B-X
rho	B-X
GDI	B-X
inhibited	B-X
both	B-X
the	B-X
basal	B-X
and	B-X
rho	B-X
GAP-stimulated	B-X
GTPase	B-X
activity	B-X
of	B-X
rhoA	B-X
p21	B-X
and	B-X
rac1	B-X
p21	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
The	B-X
doses	B-X
of	B-X
rho	B-X
GDI	B-X
necessary	B-X
for	B-X
this	B-X
action	B-X
were	B-X
,	B-X
however	B-X
,	B-X
about	B-X
10-fold	B-X
higher	B-X
than	B-X
those	B-X
necessary	B-X
for	B-X
the	B-X
action	B-X
to	B-X
inhibit	B-X
their	B-X
GDP/GTP	B-X
exchange	B-X
reaction	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
rho	B-X
GDI	B-X
interacts	B-X
with	B-X
the	B-X
GTP-bound	B-X
form	B-X
of	B-X
its	B-X
substrate	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
as	B-X
well	B-X
as	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
,	B-X
but	B-X
much	B-X
less	B-X
efficiently	B-X
than	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
.	B-X

Since	O
the	O
content	O
of	O
smg	B-Protein
GDS	I-Protein
was	O
generally	O
less	O
than	O
that	O
of	O
rho	O
GDI	O
in	O
cells	O
,	O
these	O
results	O
suggest	O
that	O
there	O
is	O
some	O
mechanism	O
to	O
release	O
the	O
inhibitory	O
action	O
of	O
rho	O
GDI	O
and	O
to	O
make	O
rho	B-Protein
p21	I-Protein
sensitive	O
to	O
the	O
smg	B-Protein
GDS	I-Protein
action	O
during	O
the	O
conversion	O
of	O
rhoA	B-Protein
p21	B-Protein
from	O
the	O
GDP	O
-	O
bound	O
inactive	O
form	O
to	O
the	O
GTP	O
-	O
bound	O
active	O
form	O
in	O
intact	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
rho	B-Protein
p21	I-Protein
was	O
previously	O
shown	O
to	O
be	O
ADP	O
-	O
ribosylated	O
by	O
bacterial	O
ADP	O
-	O
ribosyltransferases	O
,	O
named	O
C3	B-Protein
and	O
EDIN	B-Protein
,	O
at	O
Asn41	O
in	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-Protein
p21	I-Protein
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

This	O
ADP	O
-	O
ribosylation	O
was	O
inhibited	O
by	O
rho	O
GDI	O
much	O
more	O
efficiently	O
than	O
by	O
smg	B-Protein
GDS	I-Protein
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

These	O
results	O
suggest	O
that	O
rho	O
GDI	O
may	O
mask	O
the	O
putative	O
effector	O
region	O
of	O
rho	B-Protein
p21	I-Protein
and	O
thereby	O
inhibit	O
its	O
interaction	O
with	O
the	O
target	O
protein	O
even	O
in	O
the	O
presence	O
of	O
smg	B-Protein
GDS	I-Protein
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

Thus	O
,	O
both	O
smg	B-Protein
GDS	I-Protein
and	O
rho	O
GDI	O
are	O
important	O
to	O
regulate	O
the	O
rho	B-Protein
p21	I-Protein
activity	O
and	O
action	O
in	O
cooperation	O
with	O
each	O
other	O
.	O
<EOS>	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
stimulatory	B-X
and	B-X
inhibitory	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
,	B-X
respectively	B-X
,	B-X
for	B-X
a	B-X
group	B-X
of	B-X
ras	B-X
p21-related	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
.	B-X
rho	B-X
p21	B-X
is	B-X
a	B-X
common	B-X
substrate	B-X
small	B-X
G	B-X
protein	B-X
for	B-X
both	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
.	B-X
We	B-X
examined	B-X
here	B-X
the	B-X
functional	B-X
interactions	B-X
of	B-X
these	B-X
GDP/GTP	B-X
exchange	B-X
proteins	B-X
with	B-X
rho	B-X
p21	B-X
as	B-X
a	B-X
substrate	B-X
.	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
interacted	B-X
with	B-X
the	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
stimulated	B-X
and	B-X
inhibited	B-X
,	B-X
respectively	B-X
,	B-X
the	B-X
dissociation	B-X
of	B-X
GDP	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
rho	B-X
GDI	B-X
was	B-X
much	B-X
stronger	B-X
than	B-X
the	B-X
stimulatory	B-X
effect	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
The	B-X
GDP-bound	B-X
form	B-X
of	B-X
rho	B-X
p21	B-X
formed	B-X
a	B-X
complex	B-X
with	B-X
rho	B-X
GDI	B-X
but	B-X
not	B-X
with	B-X
smg	B-X
GDS	B-X
in	B-X
their	B-X
simultaneous	B-X
presence	B-X
.	B-X
Since	B-X
the	B-X
content	B-X
of	B-X
smg	B-X
GDS	B-X
was	B-X
generally	B-X
less	B-X
than	B-X
that	B-X
of	B-X
rho	B-X
GDI	B-X
in	B-X
cells	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
there	B-X
is	B-X
some	B-X
mechanism	B-X
to	B-X
release	B-X
the	B-X
inhibitory	B-X
action	B-X
of	B-X
rho	B-X
GDI	B-X
and	B-X
to	B-X
make	B-X
rho	B-X
p21	B-X
sensitive	B-X
to	B-X
the	B-X
smg	B-X
GDS	B-X
action	B-X
during	B-X
the	B-X
conversion	B-X
of	B-X
rhoA	B-X
p21	B-X
from	B-X
the	B-X
GDP-bound	B-X
inactive	B-X
form	B-X
to	B-X
the	B-X
GTP-bound	B-X
active	B-X
form	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X
On	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
rho	B-X
p21	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
ADP-ribosylated	B-X
by	B-X
bacterial	B-X
ADP-ribosyltransferases	B-X
,	B-X
named	B-X
C3	B-X
and	B-X
EDIN	B-X
,	B-X
at	B-X
Asn41	B-X
in	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
.	B-X
This	B-X
ADP-ribosylation	B-X
was	B-X
inhibited	B-X
by	B-X
rho	B-X
GDI	B-X
much	B-X
more	B-X
efficiently	B-X
than	B-X
by	B-X
smg	B-X
GDS	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rho	B-X
GDI	B-X
may	B-X
mask	B-X
the	B-X
putative	B-X
effector	B-X
region	B-X
of	B-X
rho	B-X
p21	B-X
and	B-X
thereby	B-X
inhibit	B-X
its	B-X
interaction	B-X
with	B-X
the	B-X
target	B-X
protein	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
smg	B-X
GDS	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
smg	B-X
GDS	B-X
and	B-X
rho	B-X
GDI	B-X
are	B-X
important	B-X
to	B-X
regulate	B-X
the	B-X
rho	B-X
p21	B-X
activity	B-X
and	B-X
action	B-X
in	B-X
cooperation	B-X
with	B-X
each	B-X
other	B-X
.	B-X

Structure	O
of	O
a	O
putative	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
from	O
Thermoplasma	O
acidophilum	O
and	O
the	O
mechanism	O
of	O
target	O
selection	O
for	O
post	O
-	O
translational	O
modification	O
.	O
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
putative	B-X
lipoate	B-X
protein	B-X
ligase	B-X
(	B-X
LplA	B-X
)	B-X
of	B-X
Thermoplasma	B-X
acidophilum	B-X
was	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
recombinant	B-X
protein	B-X
,	B-X
a	B-X
monomer	B-X
of	B-X
molecular	B-X
mass	B-X
29	B-X
kDa	B-X
,	B-X
was	B-X
catalytically	B-X
inactive	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
fall	B-X
into	B-X
the	B-X
alpha/beta	B-X
class	B-X
and	B-X
to	B-X
be	B-X
structurally	B-X
homologous	B-X
to	B-X
the	B-X
catalytic	B-X
domains	B-X
of	B-X
class	B-X
II	B-X
aminoacyl-tRNA	B-X
synthases	B-X
and	B-X
biotin	B-X
protein	B-X
ligase	B-X
,	B-X
BirA	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
T.acidophilum	B-X
LplA	B-X
and	B-X
limited	B-X
proteolysis	B-X
of	B-X
E.coli	B-X
LplA	B-X
together	B-X
highlighted	B-X
some	B-X
key	B-X
features	B-X
of	B-X
the	B-X
post-translational	B-X
modification	B-X
.	B-X
A	B-X
loop	B-X
comprising	B-X
residues	B-X
71-79	B-X
in	B-X
the	B-X
T.acidophilum	B-X
ligase	B-X
is	B-X
proposed	B-X
as	B-X
interacting	B-X
with	B-X
the	B-X
dithiolane	B-X
ring	B-X
of	B-X
lipoic	B-X
acid	B-X
and	B-X
discriminating	B-X
against	B-X
the	B-X
entry	B-X
of	B-X
biotin	B-X
.	B-X
A	B-X
second	B-X
loop	B-X
comprising	B-X
residues	B-X
179-193	B-X
was	B-X
disordered	B-X
in	B-X
the	B-X
T.acidophilum	B-X
structure	B-X
;	B-X
tryptic	B-X
cleavage	B-X
of	B-X
the	B-X
corresponding	B-X
loop	B-X
in	B-X
the	B-X
E.coli	B-X
LplA	B-X
under	B-X
non-denaturing	B-X
conditions	B-X
rendered	B-X
the	B-X
enzyme	B-X
catalytically	B-X
inactive	B-X
,	B-X
emphasizing	B-X
its	B-X
importance	B-X
.	B-X
The	B-X
putative	B-X
LplA	B-X
of	B-X
T.acidophilum	B-X
lacks	B-X
a	B-X
C-terminal	B-X
domain	B-X
found	B-X
in	B-X
its	B-X
counterparts	B-X
in	B-X
E.coli	B-X
(	B-X
Gram-negative	B-X
)	B-X
or	B-X
Streptococcus	B-X
pneumoniae	B-X
(	B-X
Gram-positive	B-X
)	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
additional	B-X
domain	B-X
in	B-X
the	B-X
E.coli	B-X
and	B-X
S.pneumoniae	B-X
enzymes	B-X
was	B-X
detected	B-X
alongside	B-X
the	B-X
structural	B-X
gene	B-X
encoding	B-X
the	B-X
putative	B-X
LplA	B-X
in	B-X
the	B-X
T.acidophilum	B-X
genome	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
required	B-X
to	B-X
confer	B-X
activity	B-X
on	B-X
the	B-X
LplA	B-X
as	B-X
currently	B-X
purified	B-X
,	B-X
one	B-X
protein	B-X
perhaps	B-X
catalysing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
obligatory	B-X
lipoyl-AMP	B-X
intermediate	B-X
,	B-X
and	B-X
the	B-X
other	B-X
transferring	B-X
the	B-X
lipoyl	B-X
group	B-X
from	B-X
it	B-X
to	B-X
the	B-X
specific	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
target	B-X
protein	B-X
.	B-X

Lipoyl	O
-	O
lysine	O
swinging	O
arms	O
are	O
crucial	O
to	O
the	O
reactions	O
catalysed	O
by	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
multienzyme	O
complexes	O
.	O

A	O
gene	O
encoding	O
a	O
putative	O
lipoate	B-Protein
protein	I-Protein
ligase	I-Protein
(	O
LplA	B-Protein
)	O
of	O
Thermoplasma	O
acidophilum	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
putative	B-X
lipoate	B-X
protein	B-X
ligase	B-X
(	B-X
LplA	B-X
)	B-X
of	B-X
Thermoplasma	B-X
acidophilum	B-X
was	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
recombinant	B-X
protein	B-X
,	B-X
a	B-X
monomer	B-X
of	B-X
molecular	B-X
mass	B-X
29	B-X
kDa	B-X
,	B-X
was	B-X
catalytically	B-X
inactive	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
fall	B-X
into	B-X
the	B-X
alpha/beta	B-X
class	B-X
and	B-X
to	B-X
be	B-X
structurally	B-X
homologous	B-X
to	B-X
the	B-X
catalytic	B-X
domains	B-X
of	B-X
class	B-X
II	B-X
aminoacyl-tRNA	B-X
synthases	B-X
and	B-X
biotin	B-X
protein	B-X
ligase	B-X
,	B-X
BirA	B-X
.	B-X
Lipoic	B-X
acid	B-X
in	B-X
LplA	B-X
was	B-X
bound	B-X
in	B-X
the	B-X
same	B-X
position	B-X
as	B-X
biotin	B-X
in	B-X
BirA	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
T.acidophilum	B-X
LplA	B-X
and	B-X
limited	B-X
proteolysis	B-X
of	B-X
E.coli	B-X
LplA	B-X
together	B-X
highlighted	B-X
some	B-X
key	B-X
features	B-X
of	B-X
the	B-X
post-translational	B-X
modification	B-X
.	B-X
A	B-X
loop	B-X
comprising	B-X
residues	B-X
71-79	B-X
in	B-X
the	B-X
T.acidophilum	B-X
ligase	B-X
is	B-X
proposed	B-X
as	B-X
interacting	B-X
with	B-X
the	B-X
dithiolane	B-X
ring	B-X
of	B-X
lipoic	B-X
acid	B-X
and	B-X
discriminating	B-X
against	B-X
the	B-X
entry	B-X
of	B-X
biotin	B-X
.	B-X
A	B-X
second	B-X
loop	B-X
comprising	B-X
residues	B-X
179-193	B-X
was	B-X
disordered	B-X
in	B-X
the	B-X
T.acidophilum	B-X
structure	B-X
;	B-X
tryptic	B-X
cleavage	B-X
of	B-X
the	B-X
corresponding	B-X
loop	B-X
in	B-X
the	B-X
E.coli	B-X
LplA	B-X
under	B-X
non-denaturing	B-X
conditions	B-X
rendered	B-X
the	B-X
enzyme	B-X
catalytically	B-X
inactive	B-X
,	B-X
emphasizing	B-X
its	B-X
importance	B-X
.	B-X
The	B-X
putative	B-X
LplA	B-X
of	B-X
T.acidophilum	B-X
lacks	B-X
a	B-X
C-terminal	B-X
domain	B-X
found	B-X
in	B-X
its	B-X
counterparts	B-X
in	B-X
E.coli	B-X
(	B-X
Gram-negative	B-X
)	B-X
or	B-X
Streptococcus	B-X
pneumoniae	B-X
(	B-X
Gram-positive	B-X
)	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
additional	B-X
domain	B-X
in	B-X
the	B-X
E.coli	B-X
and	B-X
S.pneumoniae	B-X
enzymes	B-X
was	B-X
detected	B-X
alongside	B-X
the	B-X
structural	B-X
gene	B-X
encoding	B-X
the	B-X
putative	B-X
LplA	B-X
in	B-X
the	B-X
T.acidophilum	B-X
genome	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
required	B-X
to	B-X
confer	B-X
activity	B-X
on	B-X
the	B-X
LplA	B-X
as	B-X
currently	B-X
purified	B-X
,	B-X
one	B-X
protein	B-X
perhaps	B-X
catalysing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
obligatory	B-X
lipoyl-AMP	B-X
intermediate	B-X
,	B-X
and	B-X
the	B-X
other	B-X
transferring	B-X
the	B-X
lipoyl	B-X
group	B-X
from	B-X
it	B-X
to	B-X
the	B-X
specific	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
target	B-X
protein	B-X
.	B-X

The	O
recombinant	O
protein	O
,	O
a	O
monomer	O
of	O
molecular	O
mass	O
29	O
kDa	O
,	O
was	O
catalytically	O
inactive	O
.	O
<EOS>	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
putative	B-X
lipoate	B-X
protein	B-X
ligase	B-X
(	B-X
LplA	B-X
)	B-X
of	B-X
Thermoplasma	B-X
acidophilum	B-X
was	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
recombinant	B-X
protein	B-X
,	B-X
a	B-X
monomer	B-X
of	B-X
molecular	B-X
mass	B-X
29	B-X
kDa	B-X
,	B-X
was	B-X
catalytically	B-X
inactive	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
fall	B-X
into	B-X
the	B-X
alpha/beta	B-X
class	B-X
and	B-X
to	B-X
be	B-X
structurally	B-X
homologous	B-X
to	B-X
the	B-X
catalytic	B-X
domains	B-X
of	B-X
class	B-X
II	B-X
aminoacyl-tRNA	B-X
synthases	B-X
and	B-X
biotin	B-X
protein	B-X
ligase	B-X
,	B-X
BirA	B-X
.	B-X
A	B-X
second	B-X
loop	B-X
comprising	B-X
residues	B-X
179-193	B-X
was	B-X
disordered	B-X
in	B-X
the	B-X
T.acidophilum	B-X
structure	B-X
;	B-X
tryptic	B-X
cleavage	B-X
of	B-X
the	B-X
corresponding	B-X
loop	B-X
in	B-X
the	B-X
E.coli	B-X
LplA	B-X
under	B-X
non-denaturing	B-X
conditions	B-X
rendered	B-X
the	B-X
enzyme	B-X
catalytically	B-X
inactive	B-X
,	B-X
emphasizing	B-X
its	B-X
importance	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
additional	B-X
domain	B-X
in	B-X
the	B-X
E.coli	B-X
and	B-X
S.pneumoniae	B-X
enzymes	B-X
was	B-X
detected	B-X
alongside	B-X
the	B-X
structural	B-X
gene	B-X
encoding	B-X
the	B-X
putative	B-X
LplA	B-X
in	B-X
the	B-X
T.acidophilum	B-X
genome	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
required	B-X
to	B-X
confer	B-X
activity	B-X
on	B-X
the	B-X
LplA	B-X
as	B-X
currently	B-X
purified	B-X
,	B-X
one	B-X
protein	B-X
perhaps	B-X
catalysing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
obligatory	B-X
lipoyl-AMP	B-X
intermediate	B-X
,	B-X
and	B-X
the	B-X
other	B-X
transferring	B-X
the	B-X
lipoyl	B-X
group	B-X
from	B-X
it	B-X
to	B-X
the	B-X
specific	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
target	B-X
protein	B-X
.	B-X

Crystal	O
structures	O
in	O
the	O
absence	O
and	O
presence	O
of	O
bound	O
lipoic	O
acid	O
were	O
solved	O
at	O
2	O
.	O
1	O
A	O
resolution	O
.	O
<EOS>	B-X
Lipoyl-lysine	B-X
swinging	B-X
arms	B-X
are	B-X
crucial	B-X
to	B-X
the	B-X
reactions	B-X
catalysed	B-X
by	B-X
the	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
putative	B-X
lipoate	B-X
protein	B-X
ligase	B-X
(	B-X
LplA	B-X
)	B-X
of	B-X
Thermoplasma	B-X
acidophilum	B-X
was	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
recombinant	B-X
protein	B-X
,	B-X
a	B-X
monomer	B-X
of	B-X
molecular	B-X
mass	B-X
29	B-X
kDa	B-X
,	B-X
was	B-X
catalytically	B-X
inactive	B-X
.	B-X
Crystal	B-X
structures	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
bound	B-X
lipoic	B-X
acid	B-X
were	B-X
solved	B-X
at	B-X
2.1	B-X
A	B-X
resolution	B-X
.	B-X
Lipoic	B-X
acid	B-X
in	B-X
LplA	B-X
was	B-X
bound	B-X
in	B-X
the	B-X
same	B-X
position	B-X
as	B-X
biotin	B-X
in	B-X
BirA	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
T.acidophilum	B-X
LplA	B-X
and	B-X
limited	B-X
proteolysis	B-X
of	B-X
E.coli	B-X
LplA	B-X
together	B-X
highlighted	B-X
some	B-X
key	B-X
features	B-X
of	B-X
the	B-X
post-translational	B-X
modification	B-X
.	B-X
A	B-X
loop	B-X
comprising	B-X
residues	B-X
71-79	B-X
in	B-X
the	B-X
T.acidophilum	B-X
ligase	B-X
is	B-X
proposed	B-X
as	B-X
interacting	B-X
with	B-X
the	B-X
dithiolane	B-X
ring	B-X
of	B-X
lipoic	B-X
acid	B-X
and	B-X
discriminating	B-X
against	B-X
the	B-X
entry	B-X
of	B-X
biotin	B-X
.	B-X
A	B-X
second	B-X
loop	B-X
comprising	B-X
residues	B-X
179-193	B-X
was	B-X
disordered	B-X
in	B-X
the	B-X
T.acidophilum	B-X
structure	B-X
;	B-X
tryptic	B-X
cleavage	B-X
of	B-X
the	B-X
corresponding	B-X
loop	B-X
in	B-X
the	B-X
E.coli	B-X
LplA	B-X
under	B-X
non-denaturing	B-X
conditions	B-X
rendered	B-X
the	B-X
enzyme	B-X
catalytically	B-X
inactive	B-X
,	B-X
emphasizing	B-X
its	B-X
importance	B-X
.	B-X
The	B-X
putative	B-X
LplA	B-X
of	B-X
T.acidophilum	B-X
lacks	B-X
a	B-X
C-terminal	B-X
domain	B-X
found	B-X
in	B-X
its	B-X
counterparts	B-X
in	B-X
E.coli	B-X
(	B-X
Gram-negative	B-X
)	B-X
or	B-X
Streptococcus	B-X
pneumoniae	B-X
(	B-X
Gram-positive	B-X
)	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
additional	B-X
domain	B-X
in	B-X
the	B-X
E.coli	B-X
and	B-X
S.pneumoniae	B-X
enzymes	B-X
was	B-X
detected	B-X
alongside	B-X
the	B-X
structural	B-X
gene	B-X
encoding	B-X
the	B-X
putative	B-X
LplA	B-X
in	B-X
the	B-X
T.acidophilum	B-X
genome	B-X
.	B-X

The	O
protein	O
was	O
found	O
to	O
fall	O
into	O
the	O
alpha	O
/	O
beta	O
class	O
and	O
to	O
be	O
structurally	O
homologous	O
to	O
the	O
catalytic	O
domains	O
of	O
class	O
II	O
aminoacyl	O
-	O
tRNA	O
synthases	O
and	O
biotin	B-Protein
protein	I-Protein
ligase	I-Protein
,	O
BirA	B-Protein
.	O

Lipoic	O
acid	O
in	O
LplA	B-Protein
was	O
bound	O
in	O
the	O
same	O
position	O
as	O
biotin	O
in	O
BirA	B-Protein
.	O
<EOS>	B-X
Lipoyl-lysine	B-X
swinging	B-X
arms	B-X
are	B-X
crucial	B-X
to	B-X
the	B-X
reactions	B-X
catalysed	B-X
by	B-X
the	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
putative	B-X
lipoate	B-X
protein	B-X
ligase	B-X
(	B-X
LplA	B-X
)	B-X
of	B-X
Thermoplasma	B-X
acidophilum	B-X
was	B-X
cloned	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Crystal	B-X
structures	B-X
in	B-X
the	B-X
absence	B-X
and	B-X
presence	B-X
of	B-X
bound	B-X
lipoic	B-X
acid	B-X
were	B-X
solved	B-X
at	B-X
2.1	B-X
A	B-X
resolution	B-X
.	B-X
The	B-X
protein	B-X
was	B-X
found	B-X
to	B-X
fall	B-X
into	B-X
the	B-X
alpha/beta	B-X
class	B-X
and	B-X
to	B-X
be	B-X
structurally	B-X
homologous	B-X
to	B-X
the	B-X
catalytic	B-X
domains	B-X
of	B-X
class	B-X
II	B-X
aminoacyl-tRNA	B-X
synthases	B-X
and	B-X
biotin	B-X
protein	B-X
ligase	B-X
,	B-X
BirA	B-X
.	B-X
Lipoic	B-X
acid	B-X
in	B-X
LplA	B-X
was	B-X
bound	B-X
in	B-X
the	B-X
same	B-X
position	B-X
as	B-X
biotin	B-X
in	B-X
BirA	B-X
.	B-X
The	B-X
structure	B-X
of	B-X
the	B-X
T.acidophilum	B-X
LplA	B-X
and	B-X
limited	B-X
proteolysis	B-X
of	B-X
E.coli	B-X
LplA	B-X
together	B-X
highlighted	B-X
some	B-X
key	B-X
features	B-X
of	B-X
the	B-X
post-translational	B-X
modification	B-X
.	B-X
A	B-X
loop	B-X
comprising	B-X
residues	B-X
71-79	B-X
in	B-X
the	B-X
T.acidophilum	B-X
ligase	B-X
is	B-X
proposed	B-X
as	B-X
interacting	B-X
with	B-X
the	B-X
dithiolane	B-X
ring	B-X
of	B-X
lipoic	B-X
acid	B-X
and	B-X
discriminating	B-X
against	B-X
the	B-X
entry	B-X
of	B-X
biotin	B-X
.	B-X
A	B-X
second	B-X
loop	B-X
comprising	B-X
residues	B-X
179-193	B-X
was	B-X
disordered	B-X
in	B-X
the	B-X
T.acidophilum	B-X
structure	B-X
;	B-X
tryptic	B-X
cleavage	B-X
of	B-X
the	B-X
corresponding	B-X
loop	B-X
in	B-X
the	B-X
E.coli	B-X
LplA	B-X
under	B-X
non-denaturing	B-X
conditions	B-X
rendered	B-X
the	B-X
enzyme	B-X
catalytically	B-X
inactive	B-X
,	B-X
emphasizing	B-X
its	B-X
importance	B-X
.	B-X
The	B-X
putative	B-X
LplA	B-X
of	B-X
T.acidophilum	B-X
lacks	B-X
a	B-X
C-terminal	B-X
domain	B-X
found	B-X
in	B-X
its	B-X
counterparts	B-X
in	B-X
E.coli	B-X
(	B-X
Gram-negative	B-X
)	B-X
or	B-X
Streptococcus	B-X
pneumoniae	B-X
(	B-X
Gram-positive	B-X
)	B-X
.	B-X
A	B-X
gene	B-X
encoding	B-X
a	B-X
protein	B-X
that	B-X
appears	B-X
to	B-X
have	B-X
structural	B-X
homology	B-X
to	B-X
the	B-X
additional	B-X
domain	B-X
in	B-X
the	B-X
E.coli	B-X
and	B-X
S.pneumoniae	B-X
enzymes	B-X
was	B-X
detected	B-X
alongside	B-X
the	B-X
structural	B-X
gene	B-X
encoding	B-X
the	B-X
putative	B-X
LplA	B-X
in	B-X
the	B-X
T.acidophilum	B-X
genome	B-X
.	B-X
It	B-X
is	B-X
likely	B-X
that	B-X
this	B-X
protein	B-X
is	B-X
required	B-X
to	B-X
confer	B-X
activity	B-X
on	B-X
the	B-X
LplA	B-X
as	B-X
currently	B-X
purified	B-X
,	B-X
one	B-X
protein	B-X
perhaps	B-X
catalysing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
obligatory	B-X
lipoyl-AMP	B-X
intermediate	B-X
,	B-X
and	B-X
the	B-X
other	B-X
transferring	B-X
the	B-X
lipoyl	B-X
group	B-X
from	B-X
it	B-X
to	B-X
the	B-X
specific	B-X
lysine	B-X
residue	B-X
in	B-X
the	B-X
target	B-X
protein	B-X
.	B-X

The	O
structure	O
of	O
the	O
T	O
.	O
acidophilum	O
LplA	B-Protein
and	O
limited	O
proteolysis	O
of	O
E	O
.	O
coli	O
LplA	B-Protein
together	O
highlighted	O
some	O
key	O
features	O
of	O
the	O
post	O
-	O
translational	O
modification	O
.	O

A	O
loop	O
comprising	O
residues	O
71	O
-	O
79	O
in	O
the	O
T	O
.	O
acidophilum	O
ligase	O
is	O
proposed	O
as	O
interacting	O
with	O
the	O
dithiolane	O
ring	O
of	O
lipoic	O
acid	O
and	O
discriminating	O
against	O
the	O
entry	O
of	O
biotin	O
.	O

A	O
second	O
loop	O
comprising	O
residues	O
179	O
-	O
193	O
was	O
disordered	O
in	O
the	O
T	O
.	O
acidophilum	O
structure	O
;	O
tryptic	O
cleavage	O
of	O
the	O
corresponding	O
loop	O
in	O
the	O
E	O
.	O
coli	O
LplA	B-Protein
under	O
non	O
-	O
denaturing	O
conditions	O
rendered	O
the	O
enzyme	O
catalytically	O
inactive	O
,	O
emphasizing	O
its	O
importance	O
.	O

The	O
putative	O
LplA	B-Protein
of	O
T	O
.	O
acidophilum	O
lacks	O
a	O
C	O
-	O
terminal	O
domain	O
found	O
in	O
its	O
counterparts	O
in	O
E	O
.	O
coli	O
(	O
Gram	O
-	O
negative	O
)	O
or	O
Streptococcus	O
pneumoniae	O
(	O
Gram	O
-	O
positive	O
)	O
.	O
<EOS>	B-X
Pneumococcal	B-X
Vaccines	B-X
.	B-X
Streptococcus	B-X
pneumoniae	B-X
is	B-X
a	B-X
Gram-positive	B-X
bacterial	B-X
pathogen	B-X
that	B-X
colonizes	B-X
the	B-X
mucosal	B-X
surfaces	B-X
of	B-X
the	B-X
host	B-X
nasopharynx	B-X
and	B-X
upper	B-X
airway	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
describe	B-X
how	B-X
S.	B-X
pneumoniae	B-X
uses	B-X
its	B-X
armamentarium	B-X
of	B-X
virulence	B-X
factors	B-X
to	B-X
colonize	B-X
the	B-X
upper	B-X
and	B-X
lower	B-X
respiratory	B-X
tracts	B-X
of	B-X
the	B-X
host	B-X
and	B-X
cause	B-X
disease	B-X
.	B-X
Antimicrobial	B-X
resistance	B-X
among	B-X
Gram-positive	B-X
bacteria	B-X
,	B-X
especially	B-X
in	B-X
Staphylococcus	B-X
aureus	B-X
,	B-X
Enterococcus	B-X
faecium	B-X
,	B-X
Enterococcus	B-X
faecalis	B-X
,	B-X
and	B-X
Streptococcus	B-X
pneumoniae	B-X
,	B-X
is	B-X
a	B-X
serious	B-X
threat	B-X
to	B-X
public	B-X
health	B-X
.	B-X

A	O
gene	O
encoding	O
a	O
protein	O
that	O
appears	O
to	O
have	O
structural	O
homology	O
to	O
the	O
additional	O
domain	O
in	O
the	O
E	O
.	O
coli	O
and	O
S	O
.	O
pneumoniae	O
enzymes	O
was	O
detected	O
alongside	O
the	O
structural	O
gene	O
encoding	O
the	O
putative	O
LplA	B-Protein
in	O
the	O
T	O
.	O
acidophilum	O
genome	O
.	O

It	O
is	O
likely	O
that	O
this	O
protein	O
is	O
required	O
to	O
confer	O
activity	O
on	O
the	O
LplA	B-Protein
as	O
currently	O
purified	O
,	O
one	O
protein	O
perhaps	O
catalysing	O
the	O
formation	O
of	O
the	O
obligatory	O
lipoyl	O
-	O
AMP	O
intermediate	O
,	O
and	O
the	O
other	O
transferring	O
the	O
lipoyl	O
group	O
from	O
it	O
to	O
the	O
specific	O
lysine	O
residue	O
in	O
the	O
target	O
protein	O
.	O

Tax	B-Protein
ubiquitylation	O
and	O
sumoylation	O
control	O
critical	O
cytoplasmic	O
and	O
nuclear	O
steps	O
of	O
NF	O
-	O
kappaB	O
activation	O
.	O
<EOS>	B-X
The	B-X
Tax	B-X
oncoprotein	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
proliferation	B-X
and	B-X
transformation	B-X
of	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
-infected	B-X
T	B-X
lymphocytes	B-X
through	B-X
various	B-X
mechanisms	B-X
,	B-X
including	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
cytoplasmic	B-X
ubiquitylation	B-X
of	B-X
Tax	B-X
C-terminal	B-X
lysines	B-X
is	B-X
critical	B-X
for	B-X
Tax	B-X
binding	B-X
to	B-X
the	B-X
IkappaB	B-X
kinase	B-X
complex	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
of	B-X
RelA	B-X
.	B-X
Conversely	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
same	B-X
lysines	B-X
are	B-X
sumoylated	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
an	B-X
event	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
RelA/p300-enriched	B-X
Tax	B-X
nuclear	B-X
bodies	B-X
and	B-X
full	B-X
NF-kappaB	B-X
transcriptional	B-X
activation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Tax	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
are	B-X
dispensable	B-X
for	B-X
its	B-X
activation	B-X
of	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
-dependent	B-X
genes	B-X
.	B-X
Thus	B-X
,	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
of	B-X
the	B-X
same	B-X
residues	B-X
of	B-X
Tax	B-X
regulate	B-X
2	B-X
essential	B-X
steps	B-X
controlling	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
demonstrating	B-X
how	B-X
these	B-X
posttranslational	B-X
modifications	B-X
can	B-X
cooperate	B-X
to	B-X
promote	B-X
Tax-induced	B-X
transformation	B-X
.	B-X

The	O
Tax	B-Protein
oncoprotein	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
lymphocytes	O
through	O
various	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
nuclear	O
factor	O
(	O
NF	O
)	O
-	O
kappaB	O
pathway	O
.	O

We	O
found	O
that	O
cytoplasmic	O
ubiquitylation	O
of	O
Tax	B-Protein
C	O
-	O
terminal	O
lysines	O
is	O
critical	O
for	O
Tax	B-Protein
binding	O
to	O
the	O
IkappaB	O
kinase	O
complex	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
RelA	B-Protein
.	O

Conversely	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
lysines	O
are	O
sumoylated	O
in	O
the	O
nucleus	O
,	O
an	O
event	O
required	O
for	O
the	O
formation	O
of	O
RelA	B-Protein
/	O
p300	B-Protein
-	O
enriched	O
Tax	B-Protein
nuclear	O
bodies	O
and	O
full	O
NF	O
-	O
kappaB	O
transcriptional	O
activation	O
.	O
<EOS>	B-X
The	B-X
Tax	B-X
oncoprotein	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
proliferation	B-X
and	B-X
transformation	B-X
of	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
-infected	B-X
T	B-X
lymphocytes	B-X
through	B-X
various	B-X
mechanisms	B-X
,	B-X
including	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
cytoplasmic	B-X
ubiquitylation	B-X
of	B-X
Tax	B-X
C-terminal	B-X
lysines	B-X
is	B-X
critical	B-X
for	B-X
Tax	B-X
binding	B-X
to	B-X
the	B-X
IkappaB	B-X
kinase	B-X
complex	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
of	B-X
RelA	B-X
.	B-X
Conversely	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
same	B-X
lysines	B-X
are	B-X
sumoylated	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
an	B-X
event	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
RelA/p300-enriched	B-X
Tax	B-X
nuclear	B-X
bodies	B-X
and	B-X
full	B-X
NF-kappaB	B-X
transcriptional	B-X
activation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Tax	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
are	B-X
dispensable	B-X
for	B-X
its	B-X
activation	B-X
of	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
-dependent	B-X
genes	B-X
.	B-X
Thus	B-X
,	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
of	B-X
the	B-X
same	B-X
residues	B-X
of	B-X
Tax	B-X
regulate	B-X
2	B-X
essential	B-X
steps	B-X
controlling	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
demonstrating	B-X
how	B-X
these	B-X
posttranslational	B-X
modifications	B-X
can	B-X
cooperate	B-X
to	B-X
promote	B-X
Tax-induced	B-X
transformation	B-X
.	B-X

In	O
contrast	O
,	O
Tax	B-Protein
ubiquitylation	O
and	O
sumoylation	O
are	O
dispensable	O
for	O
its	O
activation	O
of	O
cyclic	B-Protein
adenosine	I-Protein
monophosphate	I-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
(	O
CREB	B-Protein
)	O
-	O
dependent	O
genes	O
.	O
<EOS>	B-X
The	B-X
Tax	B-X
oncoprotein	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
proliferation	B-X
and	B-X
transformation	B-X
of	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
-infected	B-X
T	B-X
lymphocytes	B-X
through	B-X
various	B-X
mechanisms	B-X
,	B-X
including	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
cytoplasmic	B-X
ubiquitylation	B-X
of	B-X
Tax	B-X
C-terminal	B-X
lysines	B-X
is	B-X
critical	B-X
for	B-X
Tax	B-X
binding	B-X
to	B-X
the	B-X
IkappaB	B-X
kinase	B-X
complex	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
of	B-X
RelA	B-X
.	B-X
Conversely	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
same	B-X
lysines	B-X
are	B-X
sumoylated	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
an	B-X
event	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
RelA/p300-enriched	B-X
Tax	B-X
nuclear	B-X
bodies	B-X
and	B-X
full	B-X
NF-kappaB	B-X
transcriptional	B-X
activation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Tax	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
are	B-X
dispensable	B-X
for	B-X
its	B-X
activation	B-X
of	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
-dependent	B-X
genes	B-X
.	B-X
Thus	B-X
,	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
of	B-X
the	B-X
same	B-X
residues	B-X
of	B-X
Tax	B-X
regulate	B-X
2	B-X
essential	B-X
steps	B-X
controlling	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
demonstrating	B-X
how	B-X
these	B-X
posttranslational	B-X
modifications	B-X
can	B-X
cooperate	B-X
to	B-X
promote	B-X
Tax-induced	B-X
transformation	B-X
.	B-X

Thus	O
,	O
ubiquitylation	O
and	O
sumoylation	O
of	O
the	O
same	O
residues	O
of	O
Tax	B-Protein
regulate	O
2	O
essential	O
steps	O
controlling	O
NF	O
-	O
kappaB	O
activation	O
,	O
demonstrating	O
how	O
these	O
posttranslational	O
modifications	O
can	O
cooperate	O
to	O
promote	O
Tax	B-Protein
-	O
induced	O
transformation	O
.	O
<EOS>	B-X
The	B-X
Tax	B-X
oncoprotein	B-X
plays	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
the	B-X
proliferation	B-X
and	B-X
transformation	B-X
of	B-X
human	B-X
T-cell	B-X
leukemia	B-X
virus	B-X
type	B-X
I	B-X
(	B-X
HTLV-I	B-X
)	B-X
-infected	B-X
T	B-X
lymphocytes	B-X
through	B-X
various	B-X
mechanisms	B-X
,	B-X
including	B-X
activation	B-X
of	B-X
the	B-X
nuclear	B-X
factor	B-X
(	B-X
NF	B-X
)	B-X
-kappaB	B-X
pathway	B-X
.	B-X
We	B-X
found	B-X
that	B-X
cytoplasmic	B-X
ubiquitylation	B-X
of	B-X
Tax	B-X
C-terminal	B-X
lysines	B-X
is	B-X
critical	B-X
for	B-X
Tax	B-X
binding	B-X
to	B-X
the	B-X
IkappaB	B-X
kinase	B-X
complex	B-X
and	B-X
subsequent	B-X
nuclear	B-X
translocation	B-X
of	B-X
RelA	B-X
.	B-X
Conversely	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
the	B-X
same	B-X
lysines	B-X
are	B-X
sumoylated	B-X
in	B-X
the	B-X
nucleus	B-X
,	B-X
an	B-X
event	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
of	B-X
RelA/p300-enriched	B-X
Tax	B-X
nuclear	B-X
bodies	B-X
and	B-X
full	B-X
NF-kappaB	B-X
transcriptional	B-X
activation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
Tax	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
are	B-X
dispensable	B-X
for	B-X
its	B-X
activation	B-X
of	B-X
cyclic	B-X
adenosine	B-X
monophosphate	B-X
response	B-X
element	B-X
binding	B-X
protein	B-X
(	B-X
CREB	B-X
)	B-X
-dependent	B-X
genes	B-X
.	B-X
Thus	B-X
,	B-X
ubiquitylation	B-X
and	B-X
sumoylation	B-X
of	B-X
the	B-X
same	B-X
residues	B-X
of	B-X
Tax	B-X
regulate	B-X
2	B-X
essential	B-X
steps	B-X
controlling	B-X
NF-kappaB	B-X
activation	B-X
,	B-X
demonstrating	B-X
how	B-X
these	B-X
posttranslational	B-X
modifications	B-X
can	B-X
cooperate	B-X
to	B-X
promote	B-X
Tax-induced	B-X
transformation	B-X
.	B-X

Understanding	O
GFP	B-Protein
posttranslational	O
chemistry	O
:	O
structures	O
of	O
designed	O
variants	O
that	O
achieve	O
backbone	O
fragmentation	O
,	O
hydrolysis	O
,	O
and	O
decarboxylation	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

The	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	B-Protein
)	O
creates	O
a	O
fluorophore	O
out	O
of	O
three	O
sequential	O
amino	O
acids	O
by	O
promoting	O
spontaneous	O
posttranslational	O
modifications	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

Here	O
,	O
we	O
use	O
high	O
-	O
resolution	O
crystallography	O
to	O
characterize	O
GFP	B-Protein
variants	O
that	O
not	O
only	O
undergo	O
peptide	O
backbone	O
cyclization	O
but	O
additional	O
denaturation	O
-	O
induced	O
peptide	O
backbone	O
fragmentation	O
,	O
native	O
peptide	O
hydrolysis	O
,	O
and	O
decarboxylation	O
reactions	O
.	O
<EOS>	B-X
The	B-X
Aequorea	B-X
victoria	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
from	B-X
its	B-X
component	B-X
amino	B-X
acids	B-X
Ser65	B-X
,	B-X
Tyr66	B-X
,	B-X
and	B-X
Gly67	B-X
through	B-X
a	B-X
remarkable	B-X
post-translational	B-X
modification	B-X
,	B-X
involving	B-X
spontaneous	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
,	B-X
dehydration	B-X
,	B-X
and	B-X
oxidation	B-X
reactions	B-X
.	B-X
Two	B-X
high-resolution	B-X
structures	B-X
of	B-X
dithionite-treated	B-X
GFP	B-X
variants	B-X
reveal	B-X
a	B-X
previously	B-X
uncharacterized	B-X
enolate	B-X
intermediate	B-X
form	B-X
of	B-X
the	B-X
chromophore	B-X
that	B-X
is	B-X
viable	B-X
in	B-X
generating	B-X
a	B-X
fluorophore	B-X
(	B-X
t1/2	B-X
=	B-X
39	B-X
min-1	B-X
)	B-X
upon	B-X
exposure	B-X
to	B-X
air	B-X
.	B-X
Isolation	B-X
of	B-X
this	B-X
enolate	B-X
intermediate	B-X
will	B-X
now	B-X
allow	B-X
specific	B-X
probing	B-X
of	B-X
the	B-X
rate-limiting	B-X
oxidation	B-X
step	B-X
for	B-X
fluorophore	B-X
biosynthesis	B-X
in	B-X
GFP	B-X
and	B-X
its	B-X
red	B-X
fluorescent	B-X
protein	B-X
homologues	B-X
.	B-X
Moreover	B-X
,	B-X
our	B-X
results	B-X
reveal	B-X
how	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
mimics	B-X
enzyme	B-X
systems	B-X
,	B-X
by	B-X
stabilizing	B-X
an	B-X
otherwise	B-X
high	B-X
energy	B-X
enolate	B-X
intermediate	B-X
to	B-X
achieve	B-X
its	B-X
post-translational	B-X
modification	B-X
.	B-X

Our	O
analyses	O
indicate	O
that	O
architectural	O
features	O
that	O
favor	O
GFP	B-Protein
peptide	O
cyclization	O
also	O
drive	O
peptide	O
hydrolysis	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

These	O
results	O
are	O
relevant	O
for	O
the	O
maturation	O
pathways	O
of	O
GFP	B-Protein
homologues	O
,	O
such	O
as	O
the	O
kindling	O
fluorescent	O
protein	O
and	O
the	O
Kaede	O
protein	O
,	O
which	O
use	O
backbone	O
cleavage	O
to	O
red	O
-	O
shift	O
the	O
spectral	O
properties	O
of	O
their	O
chromophores	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

We	O
further	O
propose	O
a	O
photochemical	O
mechanism	O
for	O
the	O
decarboxylation	O
reaction	O
,	O
supporting	O
a	O
role	O
for	O
the	O
GFP	B-Protein
protein	O
environment	O
in	O
facilitating	O
radical	O
formation	O
and	O
one	O
-	O
electron	O
chemistry	O
,	O
which	O
may	O
be	O
important	O
in	O
activating	O
oxygen	O
for	O
the	O
oxidation	O
step	O
of	O
chromophore	O
biosynthesis	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

Together	O
,	O
our	O
results	O
characterize	O
GFP	B-Protein
posttranslational	O
modification	O
chemistry	O
with	O
implications	O
for	O
the	O
energetic	O
landscape	O
of	O
backbone	O
cyclization	O
and	O
subsequent	O
reactions	O
,	O
and	O
for	O
the	O
rational	O
design	O
of	O
predetermined	O
spontaneous	O
backbone	O
cyclization	O
and	O
cleavage	O
reactions	O
.	O
<EOS>	B-X
The	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
creates	B-X
a	B-X
fluorophore	B-X
out	B-X
of	B-X
three	B-X
sequential	B-X
amino	B-X
acids	B-X
by	B-X
promoting	B-X
spontaneous	B-X
posttranslational	B-X
modifications	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
use	B-X
high-resolution	B-X
crystallography	B-X
to	B-X
characterize	B-X
GFP	B-X
variants	B-X
that	B-X
not	B-X
only	B-X
undergo	B-X
peptide	B-X
backbone	B-X
cyclization	B-X
but	B-X
additional	B-X
denaturation-induced	B-X
peptide	B-X
backbone	B-X
fragmentation	B-X
,	B-X
native	B-X
peptide	B-X
hydrolysis	B-X
,	B-X
and	B-X
decarboxylation	B-X
reactions	B-X
.	B-X
Our	B-X
analyses	B-X
indicate	B-X
that	B-X
architectural	B-X
features	B-X
that	B-X
favor	B-X
GFP	B-X
peptide	B-X
cyclization	B-X
also	B-X
drive	B-X
peptide	B-X
hydrolysis	B-X
.	B-X
These	B-X
results	B-X
are	B-X
relevant	B-X
for	B-X
the	B-X
maturation	B-X
pathways	B-X
of	B-X
GFP	B-X
homologues	B-X
,	B-X
such	B-X
as	B-X
the	B-X
kindling	B-X
fluorescent	B-X
protein	B-X
and	B-X
the	B-X
Kaede	B-X
protein	B-X
,	B-X
which	B-X
use	B-X
backbone	B-X
cleavage	B-X
to	B-X
red-shift	B-X
the	B-X
spectral	B-X
properties	B-X
of	B-X
their	B-X
chromophores	B-X
.	B-X
We	B-X
further	B-X
propose	B-X
a	B-X
photochemical	B-X
mechanism	B-X
for	B-X
the	B-X
decarboxylation	B-X
reaction	B-X
,	B-X
supporting	B-X
a	B-X
role	B-X
for	B-X
the	B-X
GFP	B-X
protein	B-X
environment	B-X
in	B-X
facilitating	B-X
radical	B-X
formation	B-X
and	B-X
one-electron	B-X
chemistry	B-X
,	B-X
which	B-X
may	B-X
be	B-X
important	B-X
in	B-X
activating	B-X
oxygen	B-X
for	B-X
the	B-X
oxidation	B-X
step	B-X
of	B-X
chromophore	B-X
biosynthesis	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
results	B-X
characterize	B-X
GFP	B-X
posttranslational	B-X
modification	B-X
chemistry	B-X
with	B-X
implications	B-X
for	B-X
the	B-X
energetic	B-X
landscape	B-X
of	B-X
backbone	B-X
cyclization	B-X
and	B-X
subsequent	B-X
reactions	B-X
,	B-X
and	B-X
for	B-X
the	B-X
rational	B-X
design	B-X
of	B-X
predetermined	B-X
spontaneous	B-X
backbone	B-X
cyclization	B-X
and	B-X
cleavage	B-X
reactions	B-X
.	B-X

Gs	B-Protein
alpha	I-Protein
availability	O
to	O
cholera	O
toxin	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
is	O
decreased	O
in	O
membranes	O
of	O
retinoic	O
acid	O
-	O
treated	O
leukemic	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

A	O
posttranslational	O
effect	O
.	O
<EOS>	B-X
Rheumatoid	B-X
arthritis	B-X
(	B-X
RA	B-X
)	B-X
is	B-X
a	B-X
systemic	B-X
auto-immune	B-X
disease	B-X
principally	B-X
effecting	B-X
synovial	B-X
joints	B-X
.	B-X
Research	B-X
on	B-X
the	B-X
characteristics	B-X
and	B-X
effector	B-X
function	B-X
of	B-X
these	B-X
autoantibodies	B-X
is	B-X
ongoing	B-X
and	B-X
will	B-X
give	B-X
more	B-X
knowledge	B-X
in	B-X
the	B-X
inflammatory	B-X
responses	B-X
underlying	B-X
RA	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
investigating	B-X
the	B-X
potential	B-X
pathogenic	B-X
effector	B-X
functions	B-X
of	B-X
autoantibody	B-X
isotypes	B-X
and	B-X
their	B-X
molecular-	B-X
and	B-X
physicochemical-compositions	B-X
might	B-X
improve	B-X
understanding	B-X
of	B-X
the	B-X
disease	B-X
origin	B-X
and	B-X
its	B-X
underlying	B-X
immunological	B-X
processes	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
cancers	B-X
can	B-X
not	B-X
be	B-X
effectively	B-X
diagnosed	B-X
at	B-X
the	B-X
early	B-X
stage	B-X
.	B-X
Although	B-X
there	B-X
are	B-X
multiple	B-X
therapeutic	B-X
treatments	B-X
,	B-X
including	B-X
surgery	B-X
,	B-X
radiotherapy	B-X
,	B-X
chemotherapy	B-X
,	B-X
and	B-X
targeted	B-X
drugs	B-X
,	B-X
their	B-X
effectiveness	B-X
is	B-X
still	B-X
limited	B-X
.	B-X
It	B-X
is	B-X
necessary	B-X
to	B-X
further	B-X
study	B-X
the	B-X
mechanisms	B-X
for	B-X
malignant	B-X
cancers	B-X
,	B-X
and	B-X
explore	B-X
new	B-X
biomarkers	B-X
and	B-X
targets	B-X
that	B-X
are	B-X
more	B-X
sensitive	B-X
and	B-X
effective	B-X
for	B-X
early	B-X
diagnosis	B-X
,	B-X
treatment	B-X
,	B-X
and	B-X
prognosis	B-X
of	B-X
cancers	B-X
than	B-X
traditional	B-X
biomarkers	B-X
and	B-X
methods	B-X
.	B-X

Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
leukemic	O
cell	O
lines	O
to	O
differentiate	O
into	O
granulocyte	O
-	O
like	O
and	O
monocyte	O
-	O
like	O
cells	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

Limited	O
data	O
are	O
available	O
concerning	O
the	O
effects	O
of	O
RA	O
on	O
components	O
of	O
the	O
cyclic	O
AMP	O
pathway	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

We	O
showed	O
previously	O
a	O
decrease	O
in	O
adenylate	O
cyclase	O
activity	O
in	O
the	O
presence	O
of	O
histamine	O
,	O
prostaglandin	O
E1	O
and	O
forskolin	O
in	O
RA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
as	O
compared	O
to	O
untreated	O
cells	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

We	O
examined	O
the	O
elements	O
of	O
the	O
signal	O
transduction	O
pathway	O
utilized	O
by	O
RA	O
in	O
the	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
60	O
and	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
therefore	O
studied	O
the	O
effect	O
of	O
RA	O
on	O
the	O
activity	O
of	O
the	O
stimulatory	O
G	O
-	O
protein	O
(	O
Gs	O
)	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

We	O
demonstrate	O
that	O
addition	O
of	O
RA	O
to	O
two	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
,	O
does	O
not	O
induce	O
a	O
reduction	O
of	O
the	O
2	O
subunit	O
of	O
Gs	O
(	O
Gs	B-Protein
alpha	I-Protein
)	O
RNA	O
or	O
Gs	B-Protein
alpha	I-Protein
protein	O
in	O
the	O
plasma	O
membrane	O
but	O
leads	O
to	O
a	O
rapid	O
decrease	O
in	O
the	O
cholera	O
toxin	O
(	O
CTX	O
)	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
of	O
Gs	B-Protein
alpha	I-Protein
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

In	O
addition	O
,	O
this	O
effect	O
seems	O
to	O
be	O
specific	O
to	O
RA	O
,	O
since	O
there	O
was	O
no	O
modification	O
in	O
Gs	B-Protein
alpha	I-Protein
ADP	O
-	O
ribosylation	O
in	O
the	O
membranes	O
of	O
cells	O
treated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
another	O
inducer	O
of	O
differentiation	O
in	O
HL	O
-	O
60	O
cells	O
.	O
<EOS>	B-X
Retinoic	B-X
acid	B-X
(	B-X
RA	B-X
)	B-X
induces	B-X
HL-60	B-X
and	B-X
THP-1	B-X
leukemic	B-X
cell	B-X
lines	B-X
to	B-X
differentiate	B-X
into	B-X
granulocyte-like	B-X
and	B-X
monocyte-like	B-X
cells	B-X
.	B-X
Limited	B-X
data	B-X
are	B-X
available	B-X
concerning	B-X
the	B-X
effects	B-X
of	B-X
RA	B-X
on	B-X
components	B-X
of	B-X
the	B-X
cyclic	B-X
AMP	B-X
pathway	B-X
in	B-X
human	B-X
myeloid	B-X
leukemic	B-X
cells	B-X
.	B-X
We	B-X
showed	B-X
previously	B-X
a	B-X
decrease	B-X
in	B-X
adenylate	B-X
cyclase	B-X
activity	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
histamine	B-X
,	B-X
prostaglandin	B-X
E1	B-X
and	B-X
forskolin	B-X
in	B-X
RA-treated	B-X
HL-60	B-X
cells	B-X
as	B-X
compared	B-X
to	B-X
untreated	B-X
cells	B-X
.	B-X
We	B-X
examined	B-X
the	B-X
elements	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
pathway	B-X
utilized	B-X
by	B-X
RA	B-X
in	B-X
the	B-X
human	B-X
myeloid	B-X
cell	B-X
line	B-X
HL-60	B-X
and	B-X
the	B-X
human	B-X
monocytic	B-X
cell	B-X
line	B-X
THP-1	B-X
.	B-X
We	B-X
therefore	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
RA	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
stimulatory	B-X
G-protein	B-X
(	B-X
Gs	B-X
)	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
addition	B-X
of	B-X
RA	B-X
to	B-X
two	B-X
human	B-X
myeloid	B-X
leukemia	B-X
cell	B-X
lines	B-X
,	B-X
HL-60	B-X
and	B-X
THP-1	B-X
,	B-X
does	B-X
not	B-X
induce	B-X
a	B-X
reduction	B-X
of	B-X
the	B-X
2	B-X
subunit	B-X
of	B-X
Gs	B-X
(	B-X
Gs	B-X
alpha	B-X
)	B-X
RNA	B-X
or	B-X
Gs	B-X
alpha	B-X
protein	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
but	B-X
leads	B-X
to	B-X
a	B-X
rapid	B-X
decrease	B-X
in	B-X
the	B-X
cholera	B-X
toxin	B-X
(	B-X
CTX	B-X
)	B-X
-catalysed	B-X
ADP-ribosylation	B-X
of	B-X
Gs	B-X
alpha	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
this	B-X
effect	B-X
seems	B-X
to	B-X
be	B-X
specific	B-X
to	B-X
RA	B-X
,	B-X
since	B-X
there	B-X
was	B-X
no	B-X
modification	B-X
in	B-X
Gs	B-X
alpha	B-X
ADP-ribosylation	B-X
in	B-X
the	B-X
membranes	B-X
of	B-X
cells	B-X
treated	B-X
with	B-X
dimethyl	B-X
sulfoxide	B-X
(	B-X
DMSO	B-X
)	B-X
,	B-X
another	B-X
inducer	B-X
of	B-X
differentiation	B-X
in	B-X
HL-60	B-X
cells	B-X
.	B-X

ADP	O
-	O
ribosylation	O
of	O
membrane	O
proteins	O
:	O
unveiling	O
the	O
secrets	O
of	O
a	O
crucial	O
regulatory	O
mechanism	O
in	O
mammalian	O
cells	O
.	O
<EOS>	B-X
Many	B-X
bacterial	B-X
toxins	B-X
kill	B-X
animal	B-X
cells	B-X
by	B-X
adenosine	B-X
diphosphate	B-X
(	B-X
ADP	B-X
)	B-X
-ribosylating	B-X
intracellular	B-X
target	B-X
proteins	B-X
.	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

Many	O
bacterial	O
toxins	O
kill	O
animal	O
cells	O
by	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
-	O
ribosylating	O
intracellular	O
target	O
proteins	O
.	O
<EOS>	B-X
Many	B-X
bacterial	B-X
toxins	B-X
kill	B-X
animal	B-X
cells	B-X
by	B-X
adenosine	B-X
diphosphate	B-X
(	B-X
ADP	B-X
)	B-X
-ribosylating	B-X
intracellular	B-X
target	B-X
proteins	B-X
.	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

Mammalian	O
cells	O
express	O
toxin	O
-	O
related	O
cell	O
surface	O
ADP	O
-	O
ribosyltransferases	O
(	O
ARTs	O
)	O
that	O
transfer	O
ADP	O
-	O
ribose	O
from	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NAD	O
)	O
onto	O
arginine	O
residues	O
of	O
other	O
membrane	O
proteins	O
.	O
<EOS>	B-X
Many	B-X
bacterial	B-X
toxins	B-X
kill	B-X
animal	B-X
cells	B-X
by	B-X
adenosine	B-X
diphosphate	B-X
(	B-X
ADP	B-X
)	B-X
-ribosylating	B-X
intracellular	B-X
target	B-X
proteins	B-X
.	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
-anchored	B-X
ectoenzymes	B-X
with	B-X
glycolipid	B-X
rafts	B-X
focuses	B-X
them	B-X
onto	B-X
components	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
machinery	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
In	B-X
the	B-X
extracellular	B-X
environment	B-X
,	B-X
the	B-X
signaling	B-X
function	B-X
of	B-X
NAD	B-X
is	B-X
terminated	B-X
by	B-X
NAD-degrading	B-X
ectoenzymes	B-X
such	B-X
as	B-X
CD38	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

The	O
association	O
of	O
these	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
ectoenzymes	O
with	O
glycolipid	O
rafts	O
focuses	O
them	O
onto	O
components	O
of	O
the	O
signal	O
transduction	O
machinery	O
.	O
<EOS>	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
-anchored	B-X
ectoenzymes	B-X
with	B-X
glycolipid	B-X
rafts	B-X
focuses	B-X
them	B-X
onto	B-X
components	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
machinery	B-X
.	B-X
In	B-X
the	B-X
extracellular	B-X
environment	B-X
,	B-X
the	B-X
signaling	B-X
function	B-X
of	B-X
NAD	B-X
is	B-X
terminated	B-X
by	B-X
NAD-degrading	B-X
ectoenzymes	B-X
such	B-X
as	B-X
CD38	B-X
.	B-X

Exposing	O
murine	O
T	O
cells	O
to	O
NAD	O
,	O
the	O
ART	O
substrate	O
,	O
induces	O
a	O
cascade	O
of	O
reactions	O
that	O
culminates	O
in	O
cell	O
death	O
by	O
apoptosis	O
.	O
<EOS>	B-X
Many	B-X
bacterial	B-X
toxins	B-X
kill	B-X
animal	B-X
cells	B-X
by	B-X
adenosine	B-X
diphosphate	B-X
(	B-X
ADP	B-X
)	B-X
-ribosylating	B-X
intracellular	B-X
target	B-X
proteins	B-X
.	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
In	B-X
the	B-X
extracellular	B-X
environment	B-X
,	B-X
the	B-X
signaling	B-X
function	B-X
of	B-X
NAD	B-X
is	B-X
terminated	B-X
by	B-X
NAD-degrading	B-X
ectoenzymes	B-X
such	B-X
as	B-X
CD38	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

This	O
mechanism	O
,	O
dubbed	O
'	O
NAD	O
-	O
induced	O
cell	O
death	O
'	O
or	O
NICD	O
,	O
is	O
initiated	O
when	O
ART2	B-Protein
ADP	O
-	O
ribosylates	O
the	O
cytolytic	O
P2X7	B-Protein
purinergic	O
receptor	O
,	O
inducing	O
formation	O
of	O
a	O
cation	O
channel	O
,	O
opening	O
of	O
a	O
nonselective	O
pore	O
,	O
shedding	O
of	O
CD62L	B-Protein
from	O
the	O
cell	O
surface	O
,	O
exposure	O
of	O
phosphatidylserine	O
on	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
,	O
breakdown	O
of	O
the	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
DNA	O
-	O
fragmentation	O
.	O
<EOS>	B-X
Many	B-X
bacterial	B-X
toxins	B-X
kill	B-X
animal	B-X
cells	B-X
by	B-X
adenosine	B-X
diphosphate	B-X
(	B-X
ADP	B-X
)	B-X
-ribosylating	B-X
intracellular	B-X
target	B-X
proteins	B-X
.	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
In	B-X
the	B-X
extracellular	B-X
environment	B-X
,	B-X
the	B-X
signaling	B-X
function	B-X
of	B-X
NAD	B-X
is	B-X
terminated	B-X
by	B-X
NAD-degrading	B-X
ectoenzymes	B-X
such	B-X
as	B-X
CD38	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

The	O
ART	O
substrate	O
NAD	O
is	O
produced	O
in	O
large	O
amounts	O
inside	O
the	O
cell	O
and	O
can	O
be	O
released	O
from	O
damaged	O
cells	O
during	O
inflammation	O
and	O
tissue	O
injury	O
.	O

In	O
the	O
extracellular	O
environment	O
,	O
the	O
signaling	O
function	O
of	O
NAD	O
is	O
terminated	O
by	O
NAD	O
-	O
degrading	O
ectoenzymes	O
such	O
as	O
CD38	B-Protein
.	O
<EOS>	B-X
Mammalian	B-X
cells	B-X
express	B-X
toxin-related	B-X
cell	B-X
surface	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
that	B-X
transfer	B-X
ADP-ribose	B-X
from	B-X
nicotinamide	B-X
adenine	B-X
dinucleotide	B-X
(	B-X
NAD	B-X
)	B-X
onto	B-X
arginine	B-X
residues	B-X
of	B-X
other	B-X
membrane	B-X
proteins	B-X
.	B-X
The	B-X
association	B-X
of	B-X
these	B-X
glycosylphosphatidylinositol	B-X
(	B-X
GPI	B-X
)	B-X
-anchored	B-X
ectoenzymes	B-X
with	B-X
glycolipid	B-X
rafts	B-X
focuses	B-X
them	B-X
onto	B-X
components	B-X
of	B-X
the	B-X
signal	B-X
transduction	B-X
machinery	B-X
.	B-X
Exposing	B-X
murine	B-X
T	B-X
cells	B-X
to	B-X
NAD	B-X
,	B-X
the	B-X
ART	B-X
substrate	B-X
,	B-X
induces	B-X
a	B-X
cascade	B-X
of	B-X
reactions	B-X
that	B-X
culminates	B-X
in	B-X
cell	B-X
death	B-X
by	B-X
apoptosis	B-X
.	B-X
This	B-X
mechanism	B-X
,	B-X
dubbed	B-X
'NAD-induced	B-X
cell	B-X
death	B-X
'	B-X
or	B-X
NICD	B-X
,	B-X
is	B-X
initiated	B-X
when	B-X
ART2	B-X
ADP-ribosylates	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
purinergic	B-X
receptor	B-X
,	B-X
inducing	B-X
formation	B-X
of	B-X
a	B-X
cation	B-X
channel	B-X
,	B-X
opening	B-X
of	B-X
a	B-X
nonselective	B-X
pore	B-X
,	B-X
shedding	B-X
of	B-X
CD62L	B-X
from	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
exposure	B-X
of	B-X
phosphatidylserine	B-X
on	B-X
the	B-X
outer	B-X
leaflet	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
breakdown	B-X
of	B-X
the	B-X
mitochondrial	B-X
membrane	B-X
potential	B-X
,	B-X
and	B-X
DNA-fragmentation	B-X
.	B-X
The	B-X
ART	B-X
substrate	B-X
NAD	B-X
is	B-X
produced	B-X
in	B-X
large	B-X
amounts	B-X
inside	B-X
the	B-X
cell	B-X
and	B-X
can	B-X
be	B-X
released	B-X
from	B-X
damaged	B-X
cells	B-X
during	B-X
inflammation	B-X
and	B-X
tissue	B-X
injury	B-X
.	B-X
In	B-X
the	B-X
extracellular	B-X
environment	B-X
,	B-X
the	B-X
signaling	B-X
function	B-X
of	B-X
NAD	B-X
is	B-X
terminated	B-X
by	B-X
NAD-degrading	B-X
ectoenzymes	B-X
such	B-X
as	B-X
CD38	B-X
.	B-X
We	B-X
propose	B-X
that	B-X
ART2-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
P2X7	B-X
represents	B-X
the	B-X
paradigm	B-X
of	B-X
a	B-X
regulatory	B-X
mechanism	B-X
by	B-X
which	B-X
ART-expressing	B-X
cells	B-X
can	B-X
sense	B-X
and	B-X
respond	B-X
to	B-X
the	B-X
release	B-X
of	B-X
NAD	B-X
from	B-X
damaged	B-X
cells	B-X
.	B-X

We	O
propose	O
that	O
ART2	B-Protein
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
P2X7	B-Protein
represents	O
the	O
paradigm	O
of	O
a	O
regulatory	O
mechanism	O
by	O
which	O
ART	O
-	O
expressing	O
cells	O
can	O
sense	O
and	O
respond	O
to	O
the	O
release	O
of	O
NAD	O
from	O
damaged	O
cells	O
.	O

SUMO	O
modification	O
enhances	O
p66	O
-	O
mediated	O
transcriptional	O
repression	O
of	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

Human	B-Protein
p66alpha	I-Protein
and	O
p66beta	B-Protein
are	O
two	O
potent	O
transcriptional	O
repressors	O
that	O
interact	O
with	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
domain	O
proteins	O
MBD2	B-Protein
and	O
MBD3	B-Protein
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

An	O
analysis	O
of	O
the	O
molecular	O
mechanisms	O
mediating	O
repression	O
resulted	O
in	O
the	O
identification	O
of	O
two	O
major	O
repression	O
domains	O
in	O
p66alpha	B-Protein
and	O
one	O
in	O
p66beta	B-Protein
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

Both	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
are	O
SUMO	O
-	O
modified	O
in	O
vivo	O
:	O
p66alpha	B-Protein
at	O
two	O
sites	O
(	O
Lys	O
-	O
30	O
and	O
Lys	O
-	O
487	O
)	O
and	O
p66beta	B-Protein
at	O
one	O
site	O
(	O
Lys	O
-	O
33	O
)	O
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

Expression	O
of	O
SUMO1	B-Protein
enhanced	O
the	O
transcriptional	O
repression	O
activity	O
of	O
Gal	B-Protein
-	O
p66alpha	B-Protein
and	O
Gal	B-Protein
-	O
p66beta	B-Protein
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

Mutation	O
of	O
the	O
SUMO	O
modification	O
sites	O
or	O
using	O
a	O
SUMO1	B-Protein
mutant	O
or	O
a	O
dominant	O
negative	O
Ubc9	B-Protein
ligase	O
resulted	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
transcriptional	O
repression	O
of	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
.	O
<EOS>	B-X
The	B-X
methyltransferase	B-X
like	B-X
3	B-X
(	B-X
METTL3	B-X
)	B-X
is	B-X
a	B-X
key	B-X
component	B-X
of	B-X
the	B-X
large	B-X
N6-adenosine-methyltransferase	B-X
complex	B-X
in	B-X
mammalian	B-X
responsible	B-X
for	B-X
N6-methyladenosine	B-X
(	B-X
m6A	B-X
)	B-X
modification	B-X
in	B-X
diverse	B-X
RNAs	B-X
including	B-X
mRNA	B-X
,	B-X
tRNA	B-X
,	B-X
rRNA	B-X
,	B-X
small	B-X
nuclear	B-X
RNA	B-X
,	B-X
microRNA	B-X
precursor	B-X
and	B-X
long	B-X
non-coding	B-X
RNA	B-X
.	B-X
However	B-X
,	B-X
the	B-X
characteristics	B-X
of	B-X
METTL3	B-X
in	B-X
activation	B-X
and	B-X
post-translational	B-X
modification	B-X
(	B-X
PTM	B-X
)	B-X
is	B-X
seldom	B-X
understood	B-X
.	B-X
Here	B-X
we	B-X
find	B-X
that	B-X
METTL3	B-X
is	B-X
modified	B-X
by	B-X
SUMO1	B-X
mainly	B-X
at	B-X
lysine	B-X
residues	B-X
K177	B-X
,	B-X
K211	B-X
,	B-X
K212	B-X
and	B-X
K215	B-X
,	B-X
which	B-X
can	B-X
be	B-X
reduced	B-X
by	B-X
an	B-X
SUMO1-specific	B-X
protease	B-X
SENP1	B-X
.	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
does	B-X
not	B-X
alter	B-X
its	B-X
stability	B-X
,	B-X
localization	B-X
and	B-X
interaction	B-X
with	B-X
METTL14	B-X
and	B-X
WTAP	B-X
,	B-X
but	B-X
significantly	B-X
represses	B-X
its	B-X
m6A	B-X
methytransferase	B-X
activity	B-X
resulting	B-X
in	B-X
the	B-X
decrease	B-X
of	B-X
m6A	B-X
levels	B-X
in	B-X
mRNAs	B-X
.	B-X
Consistently	B-X
with	B-X
this	B-X
,	B-X
the	B-X
abundance	B-X
of	B-X
m6A	B-X
in	B-X
mRNAs	B-X
is	B-X
increased	B-X
with	B-X
re-expression	B-X
of	B-X
the	B-X
mutant	B-X
METTL3-4KR	B-X
compared	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
METTL3	B-X
in	B-X
human	B-X
non-small	B-X
cell	B-X
lung	B-X
carcinoma	B-X
(	B-X
NSCLC	B-X
)	B-X
cell	B-X
line	B-X
H1299-shMETTL3	B-X
,	B-X
in	B-X
which	B-X
endogenous	B-X
METTL3	B-X
was	B-X
knockdown	B-X
.	B-X
The	B-X
alternation	B-X
of	B-X
m6A	B-X
in	B-X
mRNAs	B-X
and	B-X
subsequently	B-X
change	B-X
of	B-X
gene	B-X
expression	B-X
profiles	B-X
,	B-X
which	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
,	B-X
may	B-X
directly	B-X
influence	B-X
the	B-X
soft-agar	B-X
colony	B-X
formation	B-X
and	B-X
xenografted	B-X
tumor	B-X
growth	B-X
of	B-X
H1299	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
uncover	B-X
an	B-X
important	B-X
mechanism	B-X
for	B-X
SUMOylation	B-X
of	B-X
METTL3	B-X
regulating	B-X
its	B-X
m6A	B-X
RNA	B-X
methyltransferase	B-X
activity	B-X
.	B-X

The	O
Mi	O
-	O
2	O
/	O
NuRD	O
components	O
MBD3	B-Protein
,	O
RbAp46	B-Protein
,	O
RbAp48	B-Protein
,	O
and	O
HDAC1	B-Protein
were	O
found	O
to	O
bind	O
to	O
both	O
p66alpha	B-Protein
and	O
p66beta	B-Protein
in	O
vivo	O
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

Most	O
of	O
the	O
interactions	O
were	O
not	O
affected	O
by	O
the	O
SUMO	O
site	O
mutations	O
in	O
p66alpha	B-Protein
or	O
p66beta	B-Protein
,	O
with	O
two	O
exceptions	O
.	O
<EOS>	B-X
Biochemical	B-X
characteristics	B-X
and	B-X
biological	B-X
functions	B-X
both	B-X
appear	B-X
to	B-X
be	B-X
affected	B-X
by	B-X
interacting	B-X
protein	B-X
partners	B-X
.	B-X
We	B-X
also	B-X
briefly	B-X
describe	B-X
prion	B-X
disease-related	B-X
mutations	B-X
at	B-X
the	B-X
end	B-X
of	B-X
this	B-X
review	B-X
.	B-X
This	B-X
is	B-X
a	B-X
mini	B-X
review	B-X
that	B-X
summarizes	B-X
what	B-X
is	B-X
known	B-X
from	B-X
quantitative	B-X
observational	B-X
studies	B-X
of	B-X
social	B-X
interactions	B-X
between	B-X
domestic	B-X
cats	B-X
and	B-X
humans	B-X
in	B-X
both	B-X
laboratory	B-X
colonies	B-X
and	B-X
the	B-X
home	B-X
setting	B-X
.	B-X
All	B-X
social	B-X
interactions	B-X
between	B-X
cats	B-X
and	B-X
humans	B-X
that	B-X
are	B-X
discussed	B-X
below	B-X
assume	B-X
that	B-X
the	B-X
animals	B-X
were	B-X
socialized	B-X
to	B-X
people	B-X
as	B-X
kittens	B-X
,	B-X
the	B-X
first	B-X
topic	B-X
of	B-X
this	B-X
review	B-X
.	B-X
The	B-X
initiation	B-X
,	B-X
and	B-X
the	B-X
initiator	B-X
of	B-X
social	B-X
interactions	B-X
between	B-X
cats	B-X
and	B-X
humans	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
influence	B-X
both	B-X
the	B-X
duration	B-X
of	B-X
the	B-X
interaction	B-X
bout	B-X
and	B-X
total	B-X
interaction	B-X
time	B-X
in	B-X
the	B-X
relationship	B-X
.	B-X
Finally	B-X
,	B-X
differences	B-X
have	B-X
been	B-X
found	B-X
between	B-X
interactions	B-X
with	B-X
purebred	B-X
and	B-X
non-purebred	B-X
cats	B-X
and	B-X
between	B-X
younger	B-X
and	B-X
older	B-X
cats	B-X
.	B-X

HDAC1	B-Protein
binding	O
to	O
p66alpha	B-Protein
was	O
lost	O
in	O
the	O
case	O
of	O
a	O
p66alphaK30R	B-Protein
mutant	O
,	O
and	O
RbAp46	B-Protein
binding	O
was	O
reduced	O
in	O
the	O
case	O
of	O
a	O
p66betaK33R	B-Protein
mutant	O
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
SUMO-modified	B-X
in	B-X
vivo	B-X
:	B-X
p66alpha	B-X
at	B-X
two	B-X
sites	B-X
(	B-X
Lys-30	B-X
and	B-X
Lys-487	B-X
)	B-X
and	B-X
p66beta	B-X
at	B-X
one	B-X
site	B-X
(	B-X
Lys-33	B-X
)	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
HDAC1	B-X
binding	B-X
to	B-X
p66alpha	B-X
was	B-X
lost	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66alphaK30R	B-X
mutant	B-X
,	B-X
and	B-X
RbAp46	B-X
binding	B-X
was	B-X
reduced	B-X
in	B-X
the	B-X
case	B-X
of	B-X
a	B-X
p66betaK33R	B-X
mutant	B-X
.	B-X

These	O
results	O
suggest	O
that	O
interactions	O
within	O
the	O
Mi	O
-	O
2	O
/	O
NuRD	O
complex	O
as	O
well	O
as	O
optimal	O
repression	O
are	O
mediated	O
by	O
SUMOylation	O
.	O
<EOS>	B-X
Human	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
are	B-X
two	B-X
potent	B-X
transcriptional	B-X
repressors	B-X
that	B-X
interact	B-X
with	B-X
the	B-X
methyl-CpG-binding	B-X
domain	B-X
proteins	B-X
MBD2	B-X
and	B-X
MBD3	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
mediating	B-X
repression	B-X
resulted	B-X
in	B-X
the	B-X
identification	B-X
of	B-X
two	B-X
major	B-X
repression	B-X
domains	B-X
in	B-X
p66alpha	B-X
and	B-X
one	B-X
in	B-X
p66beta	B-X
.	B-X
Expression	B-X
of	B-X
SUMO1	B-X
enhanced	B-X
the	B-X
transcriptional	B-X
repression	B-X
activity	B-X
of	B-X
Gal-p66alpha	B-X
and	B-X
Gal-p66beta	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
SUMO	B-X
modification	B-X
sites	B-X
or	B-X
using	B-X
a	B-X
SUMO1	B-X
mutant	B-X
or	B-X
a	B-X
dominant	B-X
negative	B-X
Ubc9	B-X
ligase	B-X
resulted	B-X
in	B-X
a	B-X
significant	B-X
decrease	B-X
of	B-X
the	B-X
transcriptional	B-X
repression	B-X
of	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
.	B-X
The	B-X
Mi-2/NuRD	B-X
components	B-X
MBD3	B-X
,	B-X
RbAp46	B-X
,	B-X
RbAp48	B-X
,	B-X
and	B-X
HDAC1	B-X
were	B-X
found	B-X
to	B-X
bind	B-X
to	B-X
both	B-X
p66alpha	B-X
and	B-X
p66beta	B-X
in	B-X
vivo	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
interactions	B-X
were	B-X
not	B-X
affected	B-X
by	B-X
the	B-X
SUMO	B-X
site	B-X
mutations	B-X
in	B-X
p66alpha	B-X
or	B-X
p66beta	B-X
,	B-X
with	B-X
two	B-X
exceptions	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
interactions	B-X
within	B-X
the	B-X
Mi-2/NuRD	B-X
complex	B-X
as	B-X
well	B-X
as	B-X
optimal	B-X
repression	B-X
are	B-X
mediated	B-X
by	B-X
SUMOylation	B-X
.	B-X

[	O
Ubiquitins	B-Protein
,	O
proteasomes	O
,	O
sumoylation	O
and	O
therapeutic	O
application	O
today	O
and	O
in	O
future	O
for	O
cancer	O
and	O
other	O
diseases	O
.	O
I	O
.	O
Ubiquitin	B-Protein
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
]	O
.	O
<EOS>	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

Proteasome	O
is	O
protein	O
complex	O
with	O
proteolytic	O
activity	O
.	O
<EOS>	B-X
Targeted	B-X
protein	B-X
degradation	B-X
(	B-X
TPD	B-X
)	B-X
is	B-X
an	B-X
emerging	B-X
therapeutic	B-X
modality	B-X
with	B-X
the	B-X
potential	B-X
to	B-X
tackle	B-X
disease-causing	B-X
proteins	B-X
that	B-X
have	B-X
historically	B-X
been	B-X
highly	B-X
challenging	B-X
to	B-X
target	B-X
with	B-X
conventional	B-X
small	B-X
molecules	B-X
.	B-X
In	B-X
the	B-X
20	B-X
years	B-X
since	B-X
the	B-X
concept	B-X
of	B-X
a	B-X
proteolysis-targeting	B-X
chimera	B-X
(	B-X
PROTAC	B-X
)	B-X
molecule	B-X
harnessing	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
to	B-X
degrade	B-X
a	B-X
target	B-X
protein	B-X
was	B-X
reported	B-X
,	B-X
TPD	B-X
has	B-X
moved	B-X
from	B-X
academia	B-X
to	B-X
industry	B-X
,	B-X
where	B-X
numerous	B-X
companies	B-X
have	B-X
disclosed	B-X
programmes	B-X
in	B-X
preclinical	B-X
and	B-X
early	B-X
clinical	B-X
development	B-X
.	B-X
In	B-X
this	B-X
Review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
first	B-X
two	B-X
decades	B-X
of	B-X
PROTAC	B-X
discovery	B-X
and	B-X
assess	B-X
the	B-X
current	B-X
landscape	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
industry	B-X
activity	B-X
.	B-X
The	B-X
ubiquitin	B-X
proteasome	B-X
pathway	B-X
is	B-X
responsible	B-X
for	B-X
most	B-X
of	B-X
the	B-X
protein	B-X
degradation	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
However	B-X
,	B-X
recent	B-X
studies	B-X
indicate	B-X
that	B-X
proteasome	B-X
function	B-X
is	B-X
also	B-X
tightly	B-X
regulated	B-X
and	B-X
determines	B-X
whether	B-X
a	B-X
ubiquitylated	B-X
protein	B-X
is	B-X
destroyed	B-X
or	B-X
deubiquitylated	B-X
and	B-X
survives	B-X
longer	B-X
.	B-X
This	B-X
article	B-X
reviews	B-X
recent	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
proteasome	B-X
's	B-X
multistep	B-X
ATP-dependent	B-X
mechanism	B-X
,	B-X
its	B-X
biochemical	B-X
and	B-X
structural	B-X
features	B-X
that	B-X
ensure	B-X
efficient	B-X
proteolysis	B-X
and	B-X
ubiquitin	B-X
recycling	B-X
while	B-X
preventing	B-X
nonselective	B-X
proteolysis	B-X
,	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
proteasome	B-X
activity	B-X
by	B-X
interacting	B-X
proteins	B-X
and	B-X
subunit	B-X
modifications	B-X
,	B-X
especially	B-X
phosphorylation	B-X
.	B-X

Proteasomes	O
are	O
in	O
addition	O
to	O
lysosomes	O
the	O
main	O
proteolytic	O
machinery	O
of	O
the	O
eukaryotic	O
cell	O
.	O
<EOS>	B-X
Proteasome	B-X
is	B-X
protein	B-X
complex	B-X
with	B-X
proteolytic	B-X
activity	B-X
.	B-X
Proteasomes	B-X
are	B-X
in	B-X
addition	B-X
to	B-X
lysosomes	B-X
the	B-X
main	B-X
proteolytic	B-X
machinery	B-X
of	B-X
the	B-X
eukaryotic	B-X
cell	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X

Proteins	O
destined	O
for	O
degradation	O
in	O
proteasomes	O
are	O
marked	O
by	O
ubiquitinylation	O
,	O
which	O
consists	O
in	O
attachment	O
of	O
polyubiquitin	B-Protein
to	O
relevant	O
protein	O
.	O
<EOS>	B-X
Proteasome	B-X
is	B-X
protein	B-X
complex	B-X
with	B-X
proteolytic	B-X
activity	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X

The	O
transport	O
of	O
polyubiquitinylated	O
protein	O
follows	O
to	O
proteasome	O
,	O
where	O
protein	O
is	O
cleaved	O
into	O
small	O
peptides	O
.	O
<EOS>	B-X
Proteasome	B-X
is	B-X
protein	B-X
complex	B-X
with	B-X
proteolytic	B-X
activity	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

Besides	O
polyubiquitin	B-Protein
attachment	O
to	O
protein	O
,	O
monoubiquitinylation	O
of	O
proteins	O
exists	O
and	O
has	O
an	O
important	O
role	O
in	O
DNA	O
repair	O
,	O
transcription	O
of	O
genes	O
,	O
endocytosis	O
and	O
signal	O
transduction	O
.	O
<EOS>	B-X
Proteasome	B-X
is	B-X
protein	B-X
complex	B-X
with	B-X
proteolytic	B-X
activity	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X

The	O
function	O
of	O
an	O
important	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
is	O
connected	O
with	O
proteasome	O
.	O
<EOS>	B-X
Ubiquitin-conjugating	B-X
enzymes	B-X
(	B-X
E2s	B-X
)	B-X
are	B-X
one	B-X
of	B-X
the	B-X
three	B-X
enzymes	B-X
required	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
to	B-X
connect	B-X
activated	B-X
ubiquitin	B-X
to	B-X
target	B-X
proteins	B-X
via	B-X
ubiquitin	B-X
ligases	B-X
.	B-X
We	B-X
reviewed	B-X
this	B-X
issue	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
the	B-X
special	B-X
position	B-X
and	B-X
role	B-X
of	B-X
E2s	B-X
in	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
E2s	B-X
and	B-X
biological	B-X
processes	B-X
they	B-X
are	B-X
involved	B-X
in	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

NF	O
-	O
kappaB	O
is	O
activated	O
after	O
the	O
proteolysis	O
of	O
its	O
inhibitor	O
IkappaB	O
in	O
proteasome	O
.	O
<EOS>	B-X
The	B-X
effect	B-X
was	B-X
attenuated	B-X
by	B-X
the	B-X
specific	B-X
proteasome	B-X
inhibitor	B-X
lactacystin	B-X
and	B-X
there	B-X
was	B-X
an	B-X
elevation	B-X
of	B-X
proteasome	B-X
'chymotrypsin-like	B-X
'	B-X
enzyme	B-X
activity	B-X
and	B-X
expression	B-X
of	B-X
20S	B-X
proteasome	B-X
alpha-subunits	B-X
at	B-X
concentrations	B-X
of	B-X
PIF	B-X
between	B-X
2	B-X
and	B-X
16	B-X
nM	B-X
.	B-X
At	B-X
a	B-X
concentration	B-X
of	B-X
4	B-X
nM	B-X
,	B-X
PIF	B-X
induced	B-X
a	B-X
transient	B-X
decrease	B-X
in	B-X
IkappaBalpha	B-X
levels	B-X
after	B-X
30	B-X
min	B-X
incubation	B-X
,	B-X
while	B-X
no	B-X
effect	B-X
was	B-X
seen	B-X
at	B-X
20	B-X
nM	B-X
PIF	B-X
.	B-X
The	B-X
level	B-X
of	B-X
IkappaBalpha	B-X
,	B-X
an	B-X
NF-kappaB	B-X
inhibitory	B-X
protein	B-X
,	B-X
returned	B-X
to	B-X
normal	B-X
after	B-X
60	B-X
min	B-X
.	B-X
Depletion	B-X
of	B-X
IkappaBalpha	B-X
from	B-X
the	B-X
cytosol	B-X
was	B-X
not	B-X
seen	B-X
in	B-X
myotubes	B-X
pretreated	B-X
with	B-X
EPA	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
NF-kappaB/IkappaB	B-X
complex	B-X
was	B-X
stabilised	B-X
.	B-X
At	B-X
concentrations	B-X
between	B-X
2	B-X
and	B-X
8	B-X
nM	B-X
,	B-X
PIF	B-X
stimulated	B-X
an	B-X
increased	B-X
nuclear	B-X
migration	B-X
of	B-X
NF-kappaB	B-X
,	B-X
which	B-X
was	B-X
not	B-X
seen	B-X
in	B-X
myotubes	B-X
pretreated	B-X
with	B-X
EPA	B-X
.	B-X
The	B-X
PIF-induced	B-X
increase	B-X
in	B-X
chymotrypsin-like	B-X
enzyme	B-X
activity	B-X
was	B-X
also	B-X
attenuated	B-X
by	B-X
the	B-X
NF-kappaB	B-X
inhibitor	B-X
peptide	B-X
SN50	B-X
,	B-X
suggesting	B-X
that	B-X
NF-kappaB	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
PIF-induced	B-X
increase	B-X
in	B-X
proteasome	B-X
expression	B-X
.	B-X
The	B-X
results	B-X
further	B-X
suggest	B-X
that	B-X
EPA	B-X
may	B-X
attenuate	B-X
protein	B-X
degradation	B-X
induced	B-X
by	B-X
PIF	B-X
,	B-X
at	B-X
least	B-X
partly	B-X
,	B-X
by	B-X
preventing	B-X
NF-kappaB	B-X
accumulation	B-X
in	B-X
the	B-X
nucleus	B-X
.	B-X

Ubiqutinylation	O
and	O
degradation	O
of	O
protein	O
in	O
proteasome	O
and	O
the	O
activation	O
of	O
NF	O
-	O
kappaB	O
play	O
significant	O
roles	O
in	O
taking	O
proteins	O
away	O
and	O
in	O
expression	O
of	O
great	O
numbers	O
of	O
genes	O
important	O
for	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
and	O
apoptosis	O
of	O
cells	O
.	O
<EOS>	B-X
Proteasome	B-X
is	B-X
protein	B-X
complex	B-X
with	B-X
proteolytic	B-X
activity	B-X
.	B-X
Proteasomes	B-X
are	B-X
in	B-X
addition	B-X
to	B-X
lysosomes	B-X
the	B-X
main	B-X
proteolytic	B-X
machinery	B-X
of	B-X
the	B-X
eukaryotic	B-X
cell	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

The	O
inhibition	O
of	O
proteasomes	O
has	O
antiproliferative	O
and	O
antiinflammatory	O
effects	O
and	O
opens	O
new	O
therapeutic	O
approaches	O
to	O
a	O
treatment	O
of	O
cancer	O
and	O
some	O
inflammatory	O
diseases	O
.	O
<EOS>	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

We	O
divided	O
the	O
review	O
into	O
three	O
parts	O
:	O
I	O
.	O
<EOS>	B-X
This	B-X
review	B-X
is	B-X
divided	B-X
into	B-X
three	B-X
parts	B-X
.	B-X
This	B-X
is	B-X
followed	B-X
by	B-X
reviewing	B-X
previously	B-X
reported	B-X
management	B-X
strategies	B-X
of	B-X
the	B-X
disease	B-X
based	B-X
on	B-X
its	B-X
pathophysiological	B-X
derangements	B-X
.	B-X
The	B-X
review	B-X
concludes	B-X
that	B-X
multi-center	B-X
trials	B-X
are	B-X
required	B-X
to	B-X
include	B-X
multiple	B-X
drugs	B-X
in	B-X
the	B-X
same	B-X
management	B-X
protocol	B-X
.	B-X
PREG	B-X
has	B-X
three	B-X
main	B-X
sources	B-X
of	B-X
synthesis	B-X
,	B-X
the	B-X
gonads	B-X
,	B-X
adrenal	B-X
glands	B-X
and	B-X
brain	B-X
and	B-X
is	B-X
submitted	B-X
to	B-X
various	B-X
metabolizing	B-X
pathways	B-X
which	B-X
are	B-X
modulated	B-X
depending	B-X
on	B-X
various	B-X
factors	B-X
including	B-X
species	B-X
,	B-X
steroidogenic	B-X
tissues	B-X
and	B-X
steroidogenic	B-X
enzymes	B-X
.	B-X
On	B-X
this	B-X
basis	B-X
,	B-X
this	B-X
review	B-X
will	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
parts	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
review	B-X
will	B-X
highlight	B-X
the	B-X
possible	B-X
therapeutic	B-X
uses	B-X
of	B-X
PREG	B-X
that	B-X
point	B-X
towards	B-X
the	B-X
development	B-X
of	B-X
pregnenolone-like	B-X
molecules	B-X
.	B-X

Ubiquitin	B-Protein
-	O
proteasome	O
system	O
and	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
,	O
II	O
.	O
<EOS>	B-X
Increasing	B-X
evidence	B-X
suggests	B-X
systemic	B-X
inflammation-caused	B-X
skeletal	B-X
muscle	B-X
atrophy	B-X
as	B-X
a	B-X
major	B-X
clinical	B-X
feature	B-X
of	B-X
cachexia	B-X
.	B-X
The	B-X
pathogenesis	B-X
of	B-X
sarcopenia	B-X
is	B-X
multifaceted	B-X
and	B-X
encompasses	B-X
lifestyle	B-X
habits	B-X
,	B-X
systemic	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
chronic	B-X
inflammation	B-X
and	B-X
hormonal	B-X
alterations	B-X
)	B-X
,	B-X
local	B-X
environment	B-X
perturbations	B-X
(	B-X
e.g.	B-X
,	B-X
vascular	B-X
dysfunction	B-X
)	B-X
,	B-X
and	B-X
intramuscular	B-X
specific	B-X
processes	B-X
.	B-X
In	B-X
this	B-X
scenario	B-X
,	B-X
derangements	B-X
in	B-X
skeletal	B-X
myocyte	B-X
mitochondrial	B-X
function	B-X
are	B-X
recognized	B-X
as	B-X
major	B-X
factors	B-X
contributing	B-X
to	B-X
the	B-X
age-dependent	B-X
muscle	B-X
degeneration	B-X
.	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

Sumoylation	O
and	O
neddylation	O
as	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
similar	O
to	O
ubiquitinylation	O
and	O
their	O
significance	O
and	O
lastly	O
III	O
.	O
<EOS>	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X

Using	O
of	O
the	O
knowledge	O
of	O
ubiquitin	B-Protein
-	O
proteasome	O
system	O
in	O
cancer	O
and	O
other	O
diseases	O
therapy	O
.	O
<EOS>	B-X
Proteins	B-X
destined	B-X
for	B-X
degradation	B-X
in	B-X
proteasomes	B-X
are	B-X
marked	B-X
by	B-X
ubiquitinylation	B-X
,	B-X
which	B-X
consists	B-X
in	B-X
attachment	B-X
of	B-X
polyubiquitin	B-X
to	B-X
relevant	B-X
protein	B-X
.	B-X
The	B-X
transport	B-X
of	B-X
polyubiquitinylated	B-X
protein	B-X
follows	B-X
to	B-X
proteasome	B-X
,	B-X
where	B-X
protein	B-X
is	B-X
cleaved	B-X
into	B-X
small	B-X
peptides	B-X
.	B-X
Besides	B-X
polyubiquitin	B-X
attachment	B-X
to	B-X
protein	B-X
,	B-X
monoubiquitinylation	B-X
of	B-X
proteins	B-X
exists	B-X
and	B-X
has	B-X
an	B-X
important	B-X
role	B-X
in	B-X
DNA	B-X
repair	B-X
,	B-X
transcription	B-X
of	B-X
genes	B-X
,	B-X
endocytosis	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
The	B-X
function	B-X
of	B-X
an	B-X
important	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
is	B-X
connected	B-X
with	B-X
proteasome	B-X
.	B-X
NF-kappaB	B-X
is	B-X
activated	B-X
after	B-X
the	B-X
proteolysis	B-X
of	B-X
its	B-X
inhibitor	B-X
IkappaB	B-X
in	B-X
proteasome	B-X
.	B-X
Ubiqutinylation	B-X
and	B-X
degradation	B-X
of	B-X
protein	B-X
in	B-X
proteasome	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
play	B-X
significant	B-X
roles	B-X
in	B-X
taking	B-X
proteins	B-X
away	B-X
and	B-X
in	B-X
expression	B-X
of	B-X
great	B-X
numbers	B-X
of	B-X
genes	B-X
important	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
the	B-X
cell	B-X
cycle	B-X
and	B-X
apoptosis	B-X
of	B-X
cells	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
proteasomes	B-X
has	B-X
antiproliferative	B-X
and	B-X
antiinflammatory	B-X
effects	B-X
and	B-X
opens	B-X
new	B-X
therapeutic	B-X
approaches	B-X
to	B-X
a	B-X
treatment	B-X
of	B-X
cancer	B-X
and	B-X
some	B-X
inflammatory	B-X
diseases	B-X
.	B-X
We	B-X
divided	B-X
the	B-X
review	B-X
into	B-X
three	B-X
parts	B-X
:	B-X
I.	B-X
Ubiquitin-proteasome	B-X
system	B-X
and	B-X
the	B-X
transcription	B-X
factor	B-X
NF-kappaB	B-X
,	B-X
II	B-X
.	B-X
Sumoylation	B-X
and	B-X
neddylation	B-X
as	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
similar	B-X
to	B-X
ubiquitinylation	B-X
and	B-X
their	B-X
significance	B-X
and	B-X
lastly	B-X
III	B-X
.	B-X
Using	B-X
of	B-X
the	B-X
knowledge	B-X
of	B-X
ubiquitin-proteasome	B-X
system	B-X
in	B-X
cancer	B-X
and	B-X
other	B-X
diseases	B-X
therapy	B-X
.	B-X

A	O
theoretical	O
study	O
on	O
the	O
substrate	O
deacylation	O
mechanism	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
.	O

The	O
whole	O
reaction	O
of	O
the	O
deacylation	O
of	O
class	O
C	O
beta	O
-	O
lactamase	O
was	O
investigated	O
by	O
performing	O
quantum	O
chemical	O
calculations	O
under	O
physiological	O
conditions	O
.	O

In	O
this	O
study	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
of	O
the	O
inhibitor	O
moxalactam	O
-	O
bound	O
class	O
C	O
beta	O
-	O
lactamase	O
(	O
Patera	O
et	O
al	O
.	O
J	O
.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
2000	O
,	O
122	O
,	O
10504	O
-	O
10512	O
.	O
)	O
was	O
utilized	O
and	O
moxalactam	O
was	O
changed	O
into	O
the	O
substrate	O
cefaclor	O
.	O

A	O
model	O
for	O
quantum	O
chemical	O
calculations	O
was	O
constructed	O
using	O
an	O
energy	O
-	O
minimized	O
structure	O
of	O
the	O
substrate	O
-	O
bound	O
enzyme	O
obtained	O
by	O
molecular	O
mechanics	O
calculation	O
,	O
in	O
which	O
the	O
enzyme	O
was	O
soaked	O
in	O
thousands	O
of	O
TIP3P	O
water	O
molecules	O
.	O

It	O
was	O
found	O
that	O
the	O
deacylation	O
reaction	O
consisted	O
of	O
two	O
elementary	O
processes	O
.	O
<EOS>	B-X
The	B-X
substrate	B-X
deacylation	B-X
mechanisms	B-X
of	B-X
serine-beta-lactamases	B-X
(	B-X
classes	B-X
A	B-X
,	B-X
C	B-X
and	B-X
D	B-X
)	B-X
were	B-X
investigated	B-X
by	B-X
theoretical	B-X
calculations	B-X
.	B-X
The	B-X
deacylation	B-X
of	B-X
class	B-X
A	B-X
proceeds	B-X
via	B-X
four	B-X
elementary	B-X
reactions	B-X
.	B-X
The	B-X
deacylation	B-X
does	B-X
not	B-X
proceed	B-X
only	B-X
by	B-X
Glu166	B-X
,	B-X
which	B-X
acts	B-X
as	B-X
a	B-X
general	B-X
base	B-X
,	B-X
but	B-X
Lys73	B-X
also	B-X
participates	B-X
in	B-X
the	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
case	B-X
of	B-X
class	B-X
C	B-X
,	B-X
the	B-X
deacylation	B-X
consists	B-X
of	B-X
two	B-X
elementary	B-X
processes	B-X
.	B-X
This	B-X
situation	B-X
can	B-X
exist	B-X
due	B-X
to	B-X
the	B-X
interaction	B-X
with	B-X
two	B-X
positively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
lysine	B-X
(	B-X
Lys67	B-X
and	B-X
Lys315	B-X
)	B-X
.	B-X
The	B-X
deacylation	B-X
of	B-X
class	B-X
D	B-X
also	B-X
consists	B-X
of	B-X
two	B-X
elementary	B-X
reaction	B-X
processes	B-X
.	B-X
This	B-X
suggests	B-X
that	B-X
the	B-X
high	B-X
hydrolysis	B-X
activity	B-X
of	B-X
class	B-X
D	B-X
with	B-X
carbamylated	B-X
Lys70	B-X
is	B-X
due	B-X
to	B-X
the	B-X
reduction	B-X
of	B-X
activation	B-X
energy	B-X
for	B-X
deacylation	B-X
.	B-X
From	B-X
these	B-X
results	B-X
,	B-X
it	B-X
is	B-X
concluded	B-X
that	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
lysine	B-X
residue	B-X
adjacent	B-X
to	B-X
the	B-X
serine	B-X
residue	B-X
is	B-X
indispensable	B-X
for	B-X
the	B-X
enzymatic	B-X
reactions	B-X
by	B-X
serine-beta-lactamases	B-X
.	B-X

The	O
first	O
process	O
was	O
formation	O
of	O
a	O
tetrahedral	O
intermediate	O
,	O
which	O
was	O
initiated	O
by	O
the	O
activation	O
of	O
catalytic	O
water	O
by	O
Tyr150	O
,	O
and	O
the	O
second	O
process	O
was	O
detachment	O
of	O
the	O
hydroxylated	O
substrate	O
from	O
the	O
enzyme	O
,	O
which	O
associated	O
with	O
proton	O
transfer	O
from	O
the	O
side	O
chain	O
of	O
Lys67	O
to	O
Ser64O	O
(	O
gamma	O
)	O
.	O
<EOS>	B-X
was	B-X
utilized	B-X
and	B-X
moxalactam	B-X
was	B-X
changed	B-X
into	B-X
the	B-X
substrate	B-X
cefaclor	B-X
.	B-X
A	B-X
model	B-X
for	B-X
quantum	B-X
chemical	B-X
calculations	B-X
was	B-X
constructed	B-X
using	B-X
an	B-X
energy-minimized	B-X
structure	B-X
of	B-X
the	B-X
substrate-bound	B-X
enzyme	B-X
obtained	B-X
by	B-X
molecular	B-X
mechanics	B-X
calculation	B-X
,	B-X
in	B-X
which	B-X
the	B-X
enzyme	B-X
was	B-X
soaked	B-X
in	B-X
thousands	B-X
of	B-X
TIP3P	B-X
water	B-X
molecules	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
deacylation	B-X
reaction	B-X
consisted	B-X
of	B-X
two	B-X
elementary	B-X
processes	B-X
.	B-X
The	B-X
first	B-X
process	B-X
was	B-X
formation	B-X
of	B-X
a	B-X
tetrahedral	B-X
intermediate	B-X
,	B-X
which	B-X
was	B-X
initiated	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
catalytic	B-X
water	B-X
by	B-X
Tyr150	B-X
,	B-X
and	B-X
the	B-X
second	B-X
process	B-X
was	B-X
detachment	B-X
of	B-X
the	B-X
hydroxylated	B-X
substrate	B-X
from	B-X
the	B-X
enzyme	B-X
,	B-X
which	B-X
associated	B-X
with	B-X
proton	B-X
transfer	B-X
from	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
Lys67	B-X
to	B-X
Ser64O	B-X
(	B-X
gamma	B-X
)	B-X
.	B-X
The	B-X
first	B-X
process	B-X
is	B-X
a	B-X
rate-determining	B-X
process	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
energy	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
30.47	B-X
kcal/mol	B-X
from	B-X
density	B-X
functional	B-X
theory	B-X
calculations	B-X
considering	B-X
electron	B-X
correlation	B-X
(	B-X
B3LYP/6-31G	B-X
*	B-X
*	B-X
)	B-X
.	B-X
The	B-X
side	B-X
chain	B-X
of	B-X
Tyr150	B-X
was	B-X
initially	B-X
in	B-X
a	B-X
deprotonated	B-X
state	B-X
and	B-X
was	B-X
stably	B-X
present	B-X
in	B-X
the	B-X
active	B-X
site	B-X
of	B-X
the	B-X
acyl-enzyme	B-X
complex	B-X
,	B-X
being	B-X
held	B-X
by	B-X
Lys67	B-X
and	B-X
Lys315	B-X
cooperatively	B-X
.	B-X

The	O
first	O
process	O
is	O
a	O
rate	O
-	O
determining	O
process	O
,	O
and	O
the	O
activation	O
energy	O
was	O
estimated	O
to	O
be	O
30	O
.	O
47	O
kcal	O
/	O
mol	O
from	O
density	O
functional	O
theory	O
calculations	O
considering	O
electron	O
correlation	O
(	O
B3LYP	O
/	O
6	O
-	O
31G	O
*	O
*	O
)	O
.	O
<EOS>	B-X
The	B-X
whole	B-X
reaction	B-X
of	B-X
the	B-X
deacylation	B-X
of	B-X
class	B-X
C	B-X
beta-lactamase	B-X
was	B-X
investigated	B-X
by	B-X
performing	B-X
quantum	B-X
chemical	B-X
calculations	B-X
under	B-X
physiological	B-X
conditions	B-X
.	B-X
was	B-X
utilized	B-X
and	B-X
moxalactam	B-X
was	B-X
changed	B-X
into	B-X
the	B-X
substrate	B-X
cefaclor	B-X
.	B-X
A	B-X
model	B-X
for	B-X
quantum	B-X
chemical	B-X
calculations	B-X
was	B-X
constructed	B-X
using	B-X
an	B-X
energy-minimized	B-X
structure	B-X
of	B-X
the	B-X
substrate-bound	B-X
enzyme	B-X
obtained	B-X
by	B-X
molecular	B-X
mechanics	B-X
calculation	B-X
,	B-X
in	B-X
which	B-X
the	B-X
enzyme	B-X
was	B-X
soaked	B-X
in	B-X
thousands	B-X
of	B-X
TIP3P	B-X
water	B-X
molecules	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
deacylation	B-X
reaction	B-X
consisted	B-X
of	B-X
two	B-X
elementary	B-X
processes	B-X
.	B-X
The	B-X
first	B-X
process	B-X
was	B-X
formation	B-X
of	B-X
a	B-X
tetrahedral	B-X
intermediate	B-X
,	B-X
which	B-X
was	B-X
initiated	B-X
by	B-X
the	B-X
activation	B-X
of	B-X
catalytic	B-X
water	B-X
by	B-X
Tyr150	B-X
,	B-X
and	B-X
the	B-X
second	B-X
process	B-X
was	B-X
detachment	B-X
of	B-X
the	B-X
hydroxylated	B-X
substrate	B-X
from	B-X
the	B-X
enzyme	B-X
,	B-X
which	B-X
associated	B-X
with	B-X
proton	B-X
transfer	B-X
from	B-X
the	B-X
side	B-X
chain	B-X
of	B-X
Lys67	B-X
to	B-X
Ser64O	B-X
(	B-X
gamma	B-X
)	B-X
.	B-X
The	B-X
first	B-X
process	B-X
is	B-X
a	B-X
rate-determining	B-X
process	B-X
,	B-X
and	B-X
the	B-X
activation	B-X
energy	B-X
was	B-X
estimated	B-X
to	B-X
be	B-X
30.47	B-X
kcal/mol	B-X
from	B-X
density	B-X
functional	B-X
theory	B-X
calculations	B-X
considering	B-X
electron	B-X
correlation	B-X
(	B-X
B3LYP/6-31G	B-X
*	B-X
*	B-X
)	B-X
.	B-X
The	B-X
side	B-X
chain	B-X
of	B-X
Tyr150	B-X
was	B-X
initially	B-X
in	B-X
a	B-X
deprotonated	B-X
state	B-X
and	B-X
was	B-X
stably	B-X
present	B-X
in	B-X
the	B-X
active	B-X
site	B-X
of	B-X
the	B-X
acyl-enzyme	B-X
complex	B-X
,	B-X
being	B-X
held	B-X
by	B-X
Lys67	B-X
and	B-X
Lys315	B-X
cooperatively	B-X
.	B-X

The	O
side	O
chain	O
of	O
Tyr150	O
was	O
initially	O
in	O
a	O
deprotonated	O
state	O
and	O
was	O
stably	O
present	O
in	O
the	O
active	O
site	O
of	O
the	O
acyl	O
-	O
enzyme	O
complex	O
,	O
being	O
held	O
by	O
Lys67	O
and	O
Lys315	O
cooperatively	O
.	O

Chemical	O
characterization	O
of	O
the	O
parasitophorous	O
vacuole	O
membrane	O
antigen	O
QF	B-Protein
116	I-Protein
from	O
Plasmodium	O
falciparum	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
immunological	B-X
cross-reactivity	B-X
,	B-X
the	B-X
Plasmodium	B-X
falciparum	B-X
parasitophorous	B-X
vacuole	B-X
antigens	B-X
QF116	B-X
and	B-X
exp-1/CRA	B-X
are	B-X
apparently	B-X
identical	B-X
.	B-X
The	B-X
epitope	B-X
recognized	B-X
by	B-X
an	B-X
inhibitory	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
against	B-X
QF116	B-X
is	B-X
located	B-X
proximal	B-X
to	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
QF116	B-X
protein	B-X
is	B-X
processed	B-X
during	B-X
maturation	B-X
by	B-X
the	B-X
cleavage	B-X
of	B-X
a	B-X
22-amino-acid	B-X
signal	B-X
peptide	B-X
and	B-X
acylated	B-X
as	B-X
measured	B-X
by	B-X
labeling	B-X
with	B-X
myristic	B-X
acid	B-X
.	B-X
A	B-X
double	B-X
and	B-X
triple	B-X
immunogold	B-X
labeling	B-X
technique	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
demonstrate	B-X
that	B-X
several	B-X
malarial	B-X
antigens	B-X
of	B-X
the	B-X
erythrocytic	B-X
stages	B-X
of	B-X
Plasmodium	B-X
falciparum	B-X
are	B-X
exported	B-X
from	B-X
the	B-X
parasite	B-X
into	B-X
distinct	B-X
compartments	B-X
within	B-X
the	B-X
host	B-X
cell	B-X
cytoplasm	B-X
.	B-X
Multiple	B-X
species	B-X
of	B-X
vesicles	B-X
,	B-X
each	B-X
with	B-X
specifically	B-X
packaged	B-X
contents	B-X
,	B-X
are	B-X
consistent	B-X
with	B-X
a	B-X
sorting	B-X
function	B-X
of	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
Plasmodium	B-X
infected	B-X
erythrocyte	B-X
.	B-X
During	B-X
schizogony	B-X
,	B-X
two	B-X
parasite	B-X
antigens	B-X
,	B-X
an	B-X
S-antigen	B-X
and	B-X
a	B-X
parasitophorous	B-X
vacuole	B-X
membrane	B-X
antigen	B-X
,	B-X
QF	B-X
116	B-X
,	B-X
become	B-X
packaged	B-X
into	B-X
such	B-X
vesicles	B-X
and	B-X
are	B-X
transported	B-X
into	B-X
the	B-X
erythrocyte	B-X
cytoplasm	B-X
.	B-X
At	B-X
this	B-X
stage	B-X
of	B-X
parasite	B-X
development	B-X
,	B-X
host	B-X
cell	B-X
material	B-X
is	B-X
taken	B-X
in	B-X
through	B-X
the	B-X
parasitophorous	B-X
vacuole	B-X
membrane	B-X
into	B-X
the	B-X
vacuolar	B-X
space	B-X
surrounding	B-X
the	B-X
parasite	B-X
.	B-X

On	O
the	O
basis	O
of	O
amino	O
acid	O
sequencing	O
and	O
immunological	O
cross	O
-	O
reactivity	O
,	O
the	O
Plasmodium	O
falciparum	O
parasitophorous	O
vacuole	O
antigens	O
QF116	B-Protein
and	O
exp	B-Protein
-	I-Protein
1	I-Protein
/	O
CRA	B-Protein
are	O
apparently	O
identical	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
immunological	B-X
cross-reactivity	B-X
,	B-X
the	B-X
Plasmodium	B-X
falciparum	B-X
parasitophorous	B-X
vacuole	B-X
antigens	B-X
QF116	B-X
and	B-X
exp-1/CRA	B-X
are	B-X
apparently	B-X
identical	B-X
.	B-X
The	B-X
epitope	B-X
recognized	B-X
by	B-X
an	B-X
inhibitory	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
against	B-X
QF116	B-X
is	B-X
located	B-X
proximal	B-X
to	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
QF116	B-X
protein	B-X
is	B-X
processed	B-X
during	B-X
maturation	B-X
by	B-X
the	B-X
cleavage	B-X
of	B-X
a	B-X
22-amino-acid	B-X
signal	B-X
peptide	B-X
and	B-X
acylated	B-X
as	B-X
measured	B-X
by	B-X
labeling	B-X
with	B-X
myristic	B-X
acid	B-X
.	B-X

The	O
epitope	O
recognized	O
by	O
an	O
inhibitory	O
monoclonal	O
antibody	O
directed	O
against	O
QF116	B-Protein
is	O
located	O
proximal	O
to	O
the	O
C	O
-	O
terminus	O
of	O
the	O
protein	O
.	O

The	O
QF116	B-Protein
protein	O
is	O
processed	O
during	O
maturation	O
by	O
the	O
cleavage	O
of	O
a	O
22	O
-	O
amino	O
-	O
acid	O
signal	O
peptide	O
and	O
acylated	O
as	O
measured	O
by	O
labeling	O
with	O
myristic	O
acid	O
.	O
<EOS>	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
amino	B-X
acid	B-X
sequencing	B-X
and	B-X
immunological	B-X
cross-reactivity	B-X
,	B-X
the	B-X
Plasmodium	B-X
falciparum	B-X
parasitophorous	B-X
vacuole	B-X
antigens	B-X
QF116	B-X
and	B-X
exp-1/CRA	B-X
are	B-X
apparently	B-X
identical	B-X
.	B-X
The	B-X
epitope	B-X
recognized	B-X
by	B-X
an	B-X
inhibitory	B-X
monoclonal	B-X
antibody	B-X
directed	B-X
against	B-X
QF116	B-X
is	B-X
located	B-X
proximal	B-X
to	B-X
the	B-X
C-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
The	B-X
QF116	B-X
protein	B-X
is	B-X
processed	B-X
during	B-X
maturation	B-X
by	B-X
the	B-X
cleavage	B-X
of	B-X
a	B-X
22-amino-acid	B-X
signal	B-X
peptide	B-X
and	B-X
acylated	B-X
as	B-X
measured	B-X
by	B-X
labeling	B-X
with	B-X
myristic	B-X
acid	B-X
.	B-X

Insulin	B-Protein
secretion	O
:	O
SIRT4	B-Protein
gets	O
in	O
on	O
the	O
act	O
.	O

Despite	O
their	O
initial	O
characterization	O
as	O
histone	B-Protein
deacetylases	O
controlling	O
transcription	O
,	O
sirtuins	O
also	O
turn	O
out	O
to	O
be	O
critical	O
regulators	O
of	O
metabolism	O
.	O
<EOS>	B-X
Despite	B-X
their	B-X
initial	B-X
characterization	B-X
as	B-X
histone	B-X
deacetylases	B-X
controlling	B-X
transcription	B-X
,	B-X
sirtuins	B-X
also	B-X
turn	B-X
out	B-X
to	B-X
be	B-X
critical	B-X
regulators	B-X
of	B-X
metabolism	B-X
.	B-X

In	O
this	O
issue	O
of	O
Cell	O
,	O
Haigis	O
et	O
al	O
.	O
<EOS>	B-X
In	B-X
this	B-X
issue	B-X
of	B-X
Cancer	B-X
Cell	B-X
,	B-X
Kumagai	B-X
et	B-X
al	B-X
.	B-X
reveal	B-X
lactic	B-X
acid	B-X
as	B-X
a	B-X
mediator	B-X
of	B-X
checkpoint	B-X
blockade	B-X
resistance	B-X
.	B-X
In	B-X
a	B-X
recent	B-X
issue	B-X
of	B-X
Nature	B-X
,	B-X
Zhang	B-X
et	B-X
al	B-X
.	B-X
(	B-X
2019	B-X
)	B-X
describe	B-X
an	B-X
additional	B-X
histone	B-X
post-translational	B-X
modification	B-X
,	B-X
named	B-X
histone	B-X
lactylation	B-X
.	B-X
Following	B-X
increased	B-X
lactate	B-X
production	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
M1	B-X
polarization	B-X
,	B-X
histone	B-X
lactylation	B-X
regulates	B-X
the	B-X
induction	B-X
of	B-X
an	B-X
M2-like	B-X
phenotype	B-X
in	B-X
late	B-X
stages	B-X
of	B-X
M1	B-X
macrophage	B-X
activation	B-X
to	B-X
promote	B-X
wound	B-X
healing	B-X
.	B-X

(	O
2006	O
)	O
demonstrate	O
that	O
the	O
mammalian	O
Sir2	B-Protein
homolog	O
SIRT4	B-Protein
acts	O
in	O
the	O
mitochondria	O
of	O
pancreatic	O
beta	O
cells	O
to	O
repress	O
the	O
activity	O
of	O
glutamate	B-Protein
dehydrogenase	I-Protein
through	O
ADP	O
-	O
ribosylation	O
.	O
<EOS>	B-X
(	B-X
2006	B-X
)	B-X
demonstrate	B-X
that	B-X
the	B-X
mammalian	B-X
Sir2	B-X
homolog	B-X
SIRT4	B-X
acts	B-X
in	B-X
the	B-X
mitochondria	B-X
of	B-X
pancreatic	B-X
beta	B-X
cells	B-X
to	B-X
repress	B-X
the	B-X
activity	B-X
of	B-X
glutamate	B-X
dehydrogenase	B-X
through	B-X
ADP-ribosylation	B-X
.	B-X
In	B-X
this	B-X
way	B-X
,	B-X
SIRT4	B-X
downregulates	B-X
insulin	B-X
secretion	B-X
by	B-X
beta	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
amino	B-X
acids	B-X
.	B-X

In	O
this	O
way	O
,	O
SIRT4	B-Protein
downregulates	O
insulin	B-Protein
secretion	O
by	O
beta	O
cells	O
in	O
response	O
to	O
amino	O
acids	O
.	O
<EOS>	B-X
(	B-X
2006	B-X
)	B-X
demonstrate	B-X
that	B-X
the	B-X
mammalian	B-X
Sir2	B-X
homolog	B-X
SIRT4	B-X
acts	B-X
in	B-X
the	B-X
mitochondria	B-X
of	B-X
pancreatic	B-X
beta	B-X
cells	B-X
to	B-X
repress	B-X
the	B-X
activity	B-X
of	B-X
glutamate	B-X
dehydrogenase	B-X
through	B-X
ADP-ribosylation	B-X
.	B-X
In	B-X
this	B-X
way	B-X
,	B-X
SIRT4	B-X
downregulates	B-X
insulin	B-X
secretion	B-X
by	B-X
beta	B-X
cells	B-X
in	B-X
response	B-X
to	B-X
amino	B-X
acids	B-X
.	B-X

Triterpenoid	O
CDDO	O
-	O
Me	O
blocks	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
direct	O
inhibition	O
of	O
IKKbeta	B-Protein
on	O
Cys	O
-	O
179	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
oleanane	B-X
triterpenoid	B-X
2-cyano-3,12-dioxooleana-1,9	B-X
,	B-X
-dien-28-oic	B-X
acid	B-X
(	B-X
CDDO	B-X
)	B-X
and	B-X
the	B-X
C-28	B-X
methyl	B-X
ester	B-X
(	B-X
CDDO-Me	B-X
)	B-X
induce	B-X
apoptosis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
by	B-X
disruption	B-X
of	B-X
redox	B-X
balance	B-X
and	B-X
are	B-X
currently	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
block	B-X
tumor	B-X
necrosis	B-X
factoralpha-induced	B-X
targeting	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
CDDO-Me	B-X
also	B-X
blocked	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
concert	B-X
with	B-X
these	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CDDO-Me	B-X
inhibits	B-X
IkappaBalpha	B-X
kinasebeta	B-X
(	B-X
IKKbeta	B-X
)	B-X
activity	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
support	B-X
of	B-X
a	B-X
direct	B-X
mechanism	B-X
,	B-X
CDDO-Me	B-X
inhibited	B-X
recombinant	B-X
IKKbeta	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
results	B-X
also	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
form	B-X
adducts	B-X
with	B-X
IKKbeta	B-X
,	B-X
but	B-X
not	B-X
IKKbeta	B-X
with	B-X
mutation	B-X
of	B-X
Cys-179	B-X
to	B-X
Ala	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
CDDO-Me	B-X
inhibits	B-X
IKKbeta	B-X
by	B-X
a	B-X
mechanism	B-X
dependent	B-X
on	B-X
oxidation	B-X
of	B-X
Cys-179	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
directly	B-X
block	B-X
IKKbeta	B-X
activity	B-X
and	B-X
thereby	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
interacting	B-X
with	B-X
Cys-179	B-X
in	B-X
the	B-X
IKKbeta	B-X
activation	B-X
loop	B-X
.	B-X

The	O
novel	O
oleanane	O
triterpenoid	O
2	O
-	O
cyano	O
-	O
3	O
,	O
12	O
-	O
dioxooleana	O
-	O
1	O
,	O
9	O
,	O
-	O
dien	O
-	O
28	O
-	O
oic	O
acid	O
(	O
CDDO	O
)	O
and	O
the	O
C	O
-	O
28	O
methyl	O
ester	O
(	O
CDDO	O
-	O
Me	O
)	O
induce	O
apoptosis	O
of	O
human	O
tumor	O
cells	O
by	O
disruption	O
of	O
redox	O
balance	O
and	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

The	O
present	O
studies	O
show	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
block	O
tumor	O
necrosis	O
factoralpha	O
-	O
induced	O
targeting	O
of	O
NF	O
-	O
kappaB	O
p65	B-Protein
to	O
the	O
nucleus	O
.	O

CDDO	O
-	O
Me	O
also	O
blocked	O
tumor	B-Protein
necrosis	I-Protein
factor	I-Protein
alpha	I-Protein
-	O
induced	O
phosphorylation	O
of	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
The	B-X
novel	B-X
oleanane	B-X
triterpenoid	B-X
2-cyano-3,12-dioxooleana-1,9	B-X
,	B-X
-dien-28-oic	B-X
acid	B-X
(	B-X
CDDO	B-X
)	B-X
and	B-X
the	B-X
C-28	B-X
methyl	B-X
ester	B-X
(	B-X
CDDO-Me	B-X
)	B-X
induce	B-X
apoptosis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
by	B-X
disruption	B-X
of	B-X
redox	B-X
balance	B-X
and	B-X
are	B-X
currently	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
block	B-X
tumor	B-X
necrosis	B-X
factoralpha-induced	B-X
targeting	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
CDDO-Me	B-X
also	B-X
blocked	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
concert	B-X
with	B-X
these	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CDDO-Me	B-X
inhibits	B-X
IkappaBalpha	B-X
kinasebeta	B-X
(	B-X
IKKbeta	B-X
)	B-X
activity	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
support	B-X
of	B-X
a	B-X
direct	B-X
mechanism	B-X
,	B-X
CDDO-Me	B-X
inhibited	B-X
recombinant	B-X
IKKbeta	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
results	B-X
also	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
form	B-X
adducts	B-X
with	B-X
IKKbeta	B-X
,	B-X
but	B-X
not	B-X
IKKbeta	B-X
with	B-X
mutation	B-X
of	B-X
Cys-179	B-X
to	B-X
Ala	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
CDDO-Me	B-X
inhibits	B-X
IKKbeta	B-X
by	B-X
a	B-X
mechanism	B-X
dependent	B-X
on	B-X
oxidation	B-X
of	B-X
Cys-179	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
directly	B-X
block	B-X
IKKbeta	B-X
activity	B-X
and	B-X
thereby	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
interacting	B-X
with	B-X
Cys-179	B-X
in	B-X
the	B-X
IKKbeta	B-X
activation	B-X
loop	B-X
.	B-X

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
found	O
that	O
CDDO	O
-	O
Me	O
inhibits	O
IkappaBalpha	B-Protein
kinasebeta	I-Protein
(	O
IKKbeta	B-Protein
)	O
activity	O
in	O
cells	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
oleanane	B-X
triterpenoid	B-X
2-cyano-3,12-dioxooleana-1,9	B-X
,	B-X
-dien-28-oic	B-X
acid	B-X
(	B-X
CDDO	B-X
)	B-X
and	B-X
the	B-X
C-28	B-X
methyl	B-X
ester	B-X
(	B-X
CDDO-Me	B-X
)	B-X
induce	B-X
apoptosis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
by	B-X
disruption	B-X
of	B-X
redox	B-X
balance	B-X
and	B-X
are	B-X
currently	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
block	B-X
tumor	B-X
necrosis	B-X
factoralpha-induced	B-X
targeting	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
CDDO-Me	B-X
also	B-X
blocked	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
concert	B-X
with	B-X
these	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CDDO-Me	B-X
inhibits	B-X
IkappaBalpha	B-X
kinasebeta	B-X
(	B-X
IKKbeta	B-X
)	B-X
activity	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
support	B-X
of	B-X
a	B-X
direct	B-X
mechanism	B-X
,	B-X
CDDO-Me	B-X
inhibited	B-X
recombinant	B-X
IKKbeta	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
results	B-X
also	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
form	B-X
adducts	B-X
with	B-X
IKKbeta	B-X
,	B-X
but	B-X
not	B-X
IKKbeta	B-X
with	B-X
mutation	B-X
of	B-X
Cys-179	B-X
to	B-X
Ala	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
CDDO-Me	B-X
inhibits	B-X
IKKbeta	B-X
by	B-X
a	B-X
mechanism	B-X
dependent	B-X
on	B-X
oxidation	B-X
of	B-X
Cys-179	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
directly	B-X
block	B-X
IKKbeta	B-X
activity	B-X
and	B-X
thereby	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
interacting	B-X
with	B-X
Cys-179	B-X
in	B-X
the	B-X
IKKbeta	B-X
activation	B-X
loop	B-X
.	B-X

In	O
support	O
of	O
a	O
direct	O
mechanism	O
,	O
CDDO	O
-	O
Me	O
inhibited	O
recombinant	O
IKKbeta	B-Protein
activity	O
in	O
vitro	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
oleanane	B-X
triterpenoid	B-X
2-cyano-3,12-dioxooleana-1,9	B-X
,	B-X
-dien-28-oic	B-X
acid	B-X
(	B-X
CDDO	B-X
)	B-X
and	B-X
the	B-X
C-28	B-X
methyl	B-X
ester	B-X
(	B-X
CDDO-Me	B-X
)	B-X
induce	B-X
apoptosis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
by	B-X
disruption	B-X
of	B-X
redox	B-X
balance	B-X
and	B-X
are	B-X
currently	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
block	B-X
tumor	B-X
necrosis	B-X
factoralpha-induced	B-X
targeting	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
CDDO-Me	B-X
also	B-X
blocked	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
concert	B-X
with	B-X
these	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CDDO-Me	B-X
inhibits	B-X
IkappaBalpha	B-X
kinasebeta	B-X
(	B-X
IKKbeta	B-X
)	B-X
activity	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
support	B-X
of	B-X
a	B-X
direct	B-X
mechanism	B-X
,	B-X
CDDO-Me	B-X
inhibited	B-X
recombinant	B-X
IKKbeta	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
results	B-X
also	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
form	B-X
adducts	B-X
with	B-X
IKKbeta	B-X
,	B-X
but	B-X
not	B-X
IKKbeta	B-X
with	B-X
mutation	B-X
of	B-X
Cys-179	B-X
to	B-X
Ala	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
CDDO-Me	B-X
inhibits	B-X
IKKbeta	B-X
by	B-X
a	B-X
mechanism	B-X
dependent	B-X
on	B-X
oxidation	B-X
of	B-X
Cys-179	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
directly	B-X
block	B-X
IKKbeta	B-X
activity	B-X
and	B-X
thereby	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
interacting	B-X
with	B-X
Cys-179	B-X
in	B-X
the	B-X
IKKbeta	B-X
activation	B-X
loop	B-X
.	B-X

The	O
results	O
also	O
demonstrate	O
that	O
(	O
i	O
)	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
form	O
adducts	O
with	O
IKKbeta	B-Protein
,	O
but	O
not	O
IKKbeta	B-Protein
with	O
mutation	O
of	O
Cys	O
-	O
179	O
to	O
Ala	O
,	O
and	O
(	O
ii	O
)	O
CDDO	O
-	O
Me	O
inhibits	O
IKKbeta	B-Protein
by	O
a	O
mechanism	O
dependent	O
on	O
oxidation	O
of	O
Cys	O
-	O
179	O
.	O

These	O
findings	O
indicate	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
directly	O
block	O
IKKbeta	B-Protein
activity	O
and	O
thereby	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
interacting	O
with	O
Cys	O
-	O
179	O
in	O
the	O
IKKbeta	B-Protein
activation	O
loop	O
.	O
<EOS>	B-X
The	B-X
novel	B-X
oleanane	B-X
triterpenoid	B-X
2-cyano-3,12-dioxooleana-1,9	B-X
,	B-X
-dien-28-oic	B-X
acid	B-X
(	B-X
CDDO	B-X
)	B-X
and	B-X
the	B-X
C-28	B-X
methyl	B-X
ester	B-X
(	B-X
CDDO-Me	B-X
)	B-X
induce	B-X
apoptosis	B-X
of	B-X
human	B-X
tumor	B-X
cells	B-X
by	B-X
disruption	B-X
of	B-X
redox	B-X
balance	B-X
and	B-X
are	B-X
currently	B-X
in	B-X
clinical	B-X
trials	B-X
.	B-X
The	B-X
present	B-X
studies	B-X
show	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
block	B-X
tumor	B-X
necrosis	B-X
factoralpha-induced	B-X
targeting	B-X
of	B-X
NF-kappaB	B-X
p65	B-X
to	B-X
the	B-X
nucleus	B-X
.	B-X
CDDO-Me	B-X
also	B-X
blocked	B-X
tumor	B-X
necrosis	B-X
factor	B-X
alpha-induced	B-X
phosphorylation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
In	B-X
concert	B-X
with	B-X
these	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
CDDO-Me	B-X
inhibits	B-X
IkappaBalpha	B-X
kinasebeta	B-X
(	B-X
IKKbeta	B-X
)	B-X
activity	B-X
in	B-X
cells	B-X
.	B-X
In	B-X
support	B-X
of	B-X
a	B-X
direct	B-X
mechanism	B-X
,	B-X
CDDO-Me	B-X
inhibited	B-X
recombinant	B-X
IKKbeta	B-X
activity	B-X
in	B-X
vitro	B-X
.	B-X
The	B-X
results	B-X
also	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
form	B-X
adducts	B-X
with	B-X
IKKbeta	B-X
,	B-X
but	B-X
not	B-X
IKKbeta	B-X
with	B-X
mutation	B-X
of	B-X
Cys-179	B-X
to	B-X
Ala	B-X
,	B-X
and	B-X
(	B-X
ii	B-X
)	B-X
CDDO-Me	B-X
inhibits	B-X
IKKbeta	B-X
by	B-X
a	B-X
mechanism	B-X
dependent	B-X
on	B-X
oxidation	B-X
of	B-X
Cys-179	B-X
.	B-X
These	B-X
findings	B-X
indicate	B-X
that	B-X
CDDO	B-X
and	B-X
CDDO-Me	B-X
directly	B-X
block	B-X
IKKbeta	B-X
activity	B-X
and	B-X
thereby	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
interacting	B-X
with	B-X
Cys-179	B-X
in	B-X
the	B-X
IKKbeta	B-X
activation	B-X
loop	B-X
.	B-X

Processing	O
of	O
the	O
gastrin	B-Protein
precursor	O
.	O
<EOS>	B-X
The	B-X
gastrointestinal	B-X
hormone	B-X
gastrin	B-X
is	B-X
measured	B-X
in	B-X
plasma	B-X
in	B-X
physiological	B-X
,	B-X
pathophysiological	B-X
and	B-X
diagnostic	B-X
investigations	B-X
.	B-X
In	B-X
the	B-X
diagnosis	B-X
of	B-X
hypergastrinaemic	B-X
diseases	B-X
such	B-X
as	B-X
gastrinomas	B-X
and	B-X
gastric	B-X
achlorhydria	B-X
,	B-X
measurement	B-X
of	B-X
gastrin	B-X
concentrations	B-X
in	B-X
circulation	B-X
is	B-X
crucial	B-X
.	B-X
Moreover	B-X
,	B-X
in	B-X
hypergastrinaemia	B-X
the	B-X
peptide	B-X
pattern	B-X
changes	B-X
.	B-X
Consequently	B-X
,	B-X
diagnostic	B-X
gastrin	B-X
measurements	B-X
require	B-X
immunoassays	B-X
that	B-X
recognize	B-X
the	B-X
pathological	B-X
plasma	B-X
patterns	B-X
,	B-X
which	B-X
are	B-X
characterized	B-X
by	B-X
a	B-X
predominance	B-X
of	B-X
the	B-X
large	B-X
peptides	B-X
(	B-X
gastrin-34	B-X
and	B-X
gastrin-71	B-X
)	B-X
and	B-X
less	B-X
,	B-X
if	B-X
any	B-X
,	B-X
of	B-X
the	B-X
shorter	B-X
main	B-X
form	B-X
of	B-X
gastrin	B-X
in	B-X
normal	B-X
tissue	B-X
,	B-X
gastrin-17	B-X
.	B-X
Alternatively	B-X
,	B-X
and	B-X
in	B-X
specific	B-X
cases	B-X
,	B-X
``	B-X
processing-independent	B-X
assays	B-X
''	B-X
(	B-X
PIA	B-X
)	B-X
for	B-X
progastrin	B-X
may	B-X
be	B-X
considered	B-X
,	B-X
since	B-X
hypersecreting	B-X
gastrin	B-X
cells	B-X
also	B-X
release	B-X
substantial	B-X
amounts	B-X
of	B-X
biosynthetic	B-X
precursors	B-X
and	B-X
processing	B-X
intermediates	B-X
.	B-X
Recently	B-X
,	B-X
gastrin	B-X
kits	B-X
that	B-X
do	B-X
not	B-X
take	B-X
the	B-X
pathological	B-X
plasma	B-X
patterns	B-X
into	B-X
account	B-X
have	B-X
been	B-X
marketed	B-X
and	B-X
may	B-X
miss	B-X
the	B-X
diagnosis	B-X
.	B-X
Therefore	B-X
,	B-X
proper	B-X
diagnosis	B-X
of	B-X
gastrinomas	B-X
and	B-X
other	B-X
hypergastrinaemic	B-X
diseases	B-X
requires	B-X
insight	B-X
into	B-X
cellular	B-X
gastrin	B-X
synthesis	B-X
and	B-X
peripheral	B-X
metabolism	B-X
,	B-X
and	B-X
also	B-X
into	B-X
the	B-X
design	B-X
of	B-X
useful	B-X
immunoassays	B-X
.	B-X
This	B-X
review	B-X
discusses	B-X
the	B-X
art	B-X
of	B-X
measuring	B-X
gastrin	B-X
in	B-X
plasma	B-X
with	B-X
adequate	B-X
diagnostic	B-X
specificity	B-X
.	B-X

Modulation	O
of	O
phosphorylated	O
,	O
sulfated	O
,	O
and	O
amidated	O
products	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

Post	O
-	O
translational	O
processing	O
of	O
the	O
precursor	O
for	O
rat	O
gastrin	B-Protein
yields	O
products	O
that	O
include	O
peptides	O
phosphorylated	O
at	O
Ser96	O
,	O
amidated	O
at	O
Phe92	O
,	O
and	O
sulfated	O
at	O
Tyr87	O
or	O
Tyr103	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
post-translational	B-X
processing	B-X
which	B-X
occur	B-X
in	B-X
gastrin	B-X
cells	B-X
from	B-X
rats	B-X
that	B-X
are	B-X
physiologically	B-X
stimulated	B-X
(	B-X
by	B-X
feeding	B-X
)	B-X
or	B-X
unstimulated	B-X
(	B-X
by	B-X
fasting	B-X
)	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
The	B-X
endopeptidase	B-X
cleavage	B-X
of	B-X
progastrin	B-X
was	B-X
not	B-X
influenced	B-X
significantly	B-X
by	B-X
fasting	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

The	O
phosphorylation	O
site	O
is	O
immediately	O
adjacent	O
to	O
the	O
processing	O
point	O
that	O
gives	O
rise	O
to	O
the	O
biologically	O
active	O
amidated	O
gastrins	B-Protein
.	O

We	O
have	O
examined	O
changes	O
in	O
post	O
-	O
translational	O
processing	O
which	O
occur	O
in	O
gastrin	B-Protein
cells	O
from	O
rats	O
that	O
are	O
physiologically	O
stimulated	O
(	O
by	O
feeding	O
)	O
or	O
unstimulated	O
(	O
by	O
fasting	O
)	O
.	O
<EOS>	B-X
Hyperglycemia	B-X
in	B-X
diabetes	B-X
is	B-X
consequence	B-X
of	B-X
chronic	B-X
resistance	B-X
to	B-X
insulin	B-X
and	B-X
relative	B-X
insulin	B-X
deficiency	B-X
on	B-X
target	B-X
cells	B-X
.	B-X
This	B-X
fragment	B-X
causes	B-X
GLUT4	B-X
translocation	B-X
in	B-X
unstimulated	B-X
3T3-L1	B-X
adipocytes	B-X
.	B-X
We	B-X
predicted	B-X
that	B-X
transgenic	B-X
mice	B-X
would	B-X
have	B-X
GLUT4	B-X
translocation	B-X
in	B-X
muscle	B-X
during	B-X
fasting	B-X
.	B-X
Whereas	B-X
insulin	B-X
stimulated	B-X
TUG	B-X
proteolysis	B-X
in	B-X
control	B-X
muscles	B-X
,	B-X
proteolysis	B-X
was	B-X
constitutive	B-X
in	B-X
transgenic	B-X
muscles	B-X
.	B-X
Whole-body	B-X
glucose	B-X
turnover	B-X
was	B-X
increased	B-X
during	B-X
fasting	B-X
but	B-X
not	B-X
during	B-X
hyperinsulinemic	B-X
clamp	B-X
studies	B-X
.	B-X
In	B-X
muscles	B-X
with	B-X
the	B-X
greatest	B-X
UBX-Cter	B-X
expression	B-X
,	B-X
2-deoxyglucose	B-X
uptake	B-X
during	B-X
fasting	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
in	B-X
control	B-X
muscles	B-X
during	B-X
hyperinsulinemic	B-X
clamp	B-X
studies	B-X
.	B-X
After	B-X
3	B-X
weeks	B-X
on	B-X
a	B-X
high	B-X
fat	B-X
diet	B-X
,	B-X
the	B-X
decreased	B-X
fasting	B-X
plasma	B-X
glucose	B-X
in	B-X
transgenic	B-X
mice	B-X
compared	B-X
with	B-X
controls	B-X
was	B-X
more	B-X
marked	B-X
,	B-X
and	B-X
increased	B-X
glucose	B-X
turnover	B-X
was	B-X
not	B-X
observed	B-X
;	B-X
the	B-X
transgenic	B-X
mice	B-X
continued	B-X
to	B-X
have	B-X
an	B-X
increased	B-X
metabolic	B-X
rate	B-X
.	B-X

Peptides	O
were	O
identified	O
using	O
site	O
-	O
directed	O
radioimmunoassays	O
and	O
chromatographic	O
systems	O
that	O
resolve	O
phosphorylated	O
,	O
amidated	O
,	O
and	O
sulfated	O
progastrin	B-Protein
products	O
,	O
including	O
intermediates	O
generated	O
prior	O
to	O
amidation	O
(	O
i	O
.	O
e	O
.	O
C	O
-	O
terminal	O
glycine	O
-	O
extended	O
variants	O
)	O
.	O

Assays	O
for	O
Phe92	O
-	O
amidated	O
peptides	O
and	O
for	O
the	O
C	O
-	O
terminal	O
tryptic	O
fragment	O
of	O
progastrin	B-Protein
indicated	O
decreases	O
in	O
the	O
total	O
tissue	O
concentrations	O
of	O
immunoreactive	O
peptide	O
with	O
fasting	O
;	O
in	O
contrast	O
,	O
the	O
tissue	O
concentrations	O
of	O
glycine	O
-	O
extended	O
biosynthetic	O
intermediates	O
were	O
similar	O
in	O
fasted	O
and	O
fed	O
rats	O
.	O

Taken	O
together	O
the	O
data	O
suggest	O
a	O
relative	O
failure	O
in	O
amidation	O
mechanisms	O
in	O
unstimulated	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
post-translational	B-X
processing	B-X
which	B-X
occur	B-X
in	B-X
gastrin	B-X
cells	B-X
from	B-X
rats	B-X
that	B-X
are	B-X
physiologically	B-X
stimulated	B-X
(	B-X
by	B-X
feeding	B-X
)	B-X
or	B-X
unstimulated	B-X
(	B-X
by	B-X
fasting	B-X
)	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Taken	B-X
together	B-X
the	B-X
data	B-X
suggest	B-X
a	B-X
relative	B-X
failure	B-X
in	B-X
amidation	B-X
mechanisms	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

The	O
endopeptidase	O
cleavage	O
of	O
progastrin	B-Protein
was	O
not	O
influenced	O
significantly	O
by	O
fasting	O
.	O
<EOS>	B-X
The	B-X
tryptic	B-X
peptide	B-X
generation	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
protein	B-X
dependent	B-X
and	B-X
influenced	B-X
by	B-X
protein	B-X
folding	B-X
and	B-X
accessibility	B-X
towards	B-X
trypsin	B-X
both	B-X
on-beads	B-X
and	B-X
in	B-X
the	B-X
eluate	B-X
.	B-X
A	B-X
combination	B-X
of	B-X
on-beads	B-X
digestion	B-X
and	B-X
elution	B-X
may	B-X
be	B-X
applied	B-X
to	B-X
improve	B-X
both	B-X
the	B-X
quantitative	B-X
(	B-X
peak	B-X
area	B-X
of	B-X
the	B-X
signature	B-X
peptides	B-X
)	B-X
and	B-X
qualitative	B-X
yield	B-X
(	B-X
number	B-X
of	B-X
missed	B-X
cleavages	B-X
,	B-X
total	B-X
number	B-X
of	B-X
identified	B-X
peptides	B-X
,	B-X
coverage	B-X
,	B-X
signal	B-X
intensity	B-X
and	B-X
number	B-X
of	B-X
zero	B-X
missed	B-X
cleavage	B-X
peptides	B-X
)	B-X
of	B-X
the	B-X
target	B-X
proteins	B-X
.	B-X
The	B-X
precursor	B-X
for	B-X
the	B-X
acid-stimulating	B-X
hormone	B-X
gastrin	B-X
provides	B-X
a	B-X
useful	B-X
model	B-X
for	B-X
studies	B-X
of	B-X
post-translational	B-X
processing	B-X
because	B-X
defined	B-X
sites	B-X
of	B-X
cleavage	B-X
,	B-X
amidation	B-X
,	B-X
sulphation	B-X
and	B-X
phosphorylation	B-X
occur	B-X
within	B-X
a	B-X
dodecapeptide	B-X
sequence	B-X
.	B-X
We	B-X
have	B-X
used	B-X
brefeldin	B-X
A	B-X
,	B-X
which	B-X
disrupts	B-X
transport	B-X
from	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
,	B-X
to	B-X
examine	B-X
the	B-X
mechanisms	B-X
of	B-X
cleavage	B-X
,	B-X
phosphorylation	B-X
and	B-X
sulphation	B-X
of	B-X
rat	B-X
progastrin-derived	B-X
peptides	B-X
.	B-X
Biosynthetic	B-X
products	B-X
were	B-X
detected	B-X
after	B-X
immunoprecipitation	B-X
using	B-X
antibodies	B-X
specific	B-X
for	B-X
the	B-X
extreme	B-X
C-terminus	B-X
of	B-X
progastrin	B-X
,	B-X
followed	B-X
by	B-X
reversed-phase	B-X
and	B-X
ion-exchange	B-X
h.p.l.c	B-X
.	B-X
Gastrin	B-X
cells	B-X
incorporated	B-X
[	B-X
3H	B-X
]	B-X
tyrosine	B-X
,	B-X
[	B-X
32P	B-X
]	B-X
phosphate	B-X
and	B-X
[	B-X
35S	B-X
]	B-X
sulphate	B-X
into	B-X
both	B-X
progastrin	B-X
and	B-X
its	B-X
extreme	B-X
C-terminal	B-X
tryptic	B-X
(	B-X
nona-	B-X
)	B-X
peptide	B-X
.	B-X
Ion-exchange	B-X
chromatography	B-X
resolved	B-X
four	B-X
forms	B-X
of	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
which	B-X
differed	B-X
in	B-X
whether	B-X
they	B-X
were	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
sulphated	B-X
at	B-X
Tyr103	B-X
,	B-X
both	B-X
or	B-X
neither	B-X
.	B-X
Brefeldin	B-X
A	B-X
inhibited	B-X
the	B-X
appearance	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
tyrosine-labelled	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
but	B-X
there	B-X
was	B-X
an	B-X
accumulation	B-X
of	B-X
labelled	B-X
progastrin	B-X
and	B-X
a	B-X
peptide	B-X
corresponding	B-X
to	B-X
the	B-X
C-terminal	B-X
46	B-X
residues	B-X
of	B-X
progastrin	B-X
.	B-X
Brefeldin	B-X
A	B-X
also	B-X
inhibited	B-X
incorporation	B-X
of	B-X
32P	B-X
and	B-X
35S	B-X
into	B-X
both	B-X
progastrin	B-X
and	B-X
its	B-X
C-terminal	B-X
fragment	B-X
.	B-X
Thus	B-X
phosphorylation	B-X
of	B-X
Ser96	B-X
,	B-X
sulphation	B-X
of	B-X
Tyr103	B-X
and	B-X
cleavage	B-X
at	B-X
Arg94-Arg95	B-X
depend	B-X
on	B-X
passage	B-X
of	B-X
newly	B-X
synthesized	B-X
progastrin	B-X
along	B-X
the	B-X
secretory	B-X
pathway	B-X
;	B-X
as	B-X
brefeldin	B-X
A	B-X
is	B-X
thought	B-X
to	B-X
act	B-X
proximal	B-X
to	B-X
the	B-X
trans-Golgi	B-X
,	B-X
these	B-X
processing	B-X
steps	B-X
would	B-X
appear	B-X
to	B-X
occur	B-X
distal	B-X
to	B-X
this	B-X
point	B-X
.	B-X
The	B-X
data	B-X
also	B-X
indicate	B-X
that	B-X
the	B-X
stores	B-X
of	B-X
unphosphorylated	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
are	B-X
not	B-X
available	B-X
for	B-X
phosphorylation	B-X
,	B-X
implying	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
proximal	B-X
to	B-X
the	B-X
secretory	B-X
granule	B-X
;	B-X
cleavage	B-X
is	B-X
known	B-X
to	B-X
occur	B-X
in	B-X
the	B-X
secretory	B-X
granule	B-X
which	B-X
suggests	B-X
that	B-X
it	B-X
occurs	B-X
after	B-X
phosphorylation	B-X
.	B-X

However	O
,	O
the	O
phosphorylation	O
of	O
peptide	O
products	O
containing	O
Ser96	O
was	O
depressed	O
significantly	O
in	O
fasted	O
rats	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
post-translational	B-X
processing	B-X
which	B-X
occur	B-X
in	B-X
gastrin	B-X
cells	B-X
from	B-X
rats	B-X
that	B-X
are	B-X
physiologically	B-X
stimulated	B-X
(	B-X
by	B-X
feeding	B-X
)	B-X
or	B-X
unstimulated	B-X
(	B-X
by	B-X
fasting	B-X
)	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
The	B-X
endopeptidase	B-X
cleavage	B-X
of	B-X
progastrin	B-X
was	B-X
not	B-X
influenced	B-X
significantly	B-X
by	B-X
fasting	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

The	O
proportions	O
of	O
amidated	O
peptides	O
sulfated	O
at	O
Tyr87	O
were	O
generally	O
lower	O
than	O
their	O
corresponding	O
glycine	O
-	O
extended	O
biosynthetic	O
precursors	O
,	O
but	O
in	O
both	O
cases	O
the	O
proportion	O
of	O
peptide	O
in	O
the	O
sulfated	O
form	O
was	O
lower	O
than	O
for	O
peptides	O
sulfated	O
at	O
Tyr103	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
C-terminal	B-X
glycine-extended	B-X
variants	B-X
)	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

Feeding	O
did	O
not	O
change	O
the	O
sulfation	O
of	O
amidated	O
heptadecapeptide	O
gastrin	B-Protein
or	O
its	O
glycine	O
-	O
extended	O
variant	O
.	O
<EOS>	B-X
The	B-X
recent	B-X
Chandos	B-X
House	B-X
meeting	B-X
of	B-X
the	B-X
Alport	B-X
Variant	B-X
Collaborative	B-X
extended	B-X
the	B-X
indications	B-X
for	B-X
screening	B-X
for	B-X
pathogenic	B-X
variants	B-X
in	B-X
the	B-X
COL4A5	B-X
,	B-X
COL4A3	B-X
and	B-X
COL4A4	B-X
genes	B-X
beyond	B-X
the	B-X
classical	B-X
Alport	B-X
phenotype	B-X
(	B-X
haematuria	B-X
,	B-X
renal	B-X
failure	B-X
;	B-X
family	B-X
history	B-X
of	B-X
haematuria	B-X
or	B-X
renal	B-X
failure	B-X
)	B-X
to	B-X
include	B-X
persistent	B-X
proteinuria	B-X
,	B-X
steroid-resistant	B-X
nephrotic	B-X
syndrome	B-X
,	B-X
focal	B-X
and	B-X
segmental	B-X
glomerulosclerosis	B-X
(	B-X
FSGS	B-X
)	B-X
,	B-X
familial	B-X
IgA	B-X
glomerulonephritis	B-X
and	B-X
end-stage	B-X
kidney	B-X
failure	B-X
without	B-X
an	B-X
obvious	B-X
cause	B-X
.	B-X
The	B-X
meeting	B-X
refined	B-X
the	B-X
ACMG	B-X
criteria	B-X
for	B-X
variant	B-X
assessment	B-X
for	B-X
the	B-X
Alport	B-X
genes	B-X
(	B-X
COL4A3-5	B-X
)	B-X
.	B-X
It	B-X
considered	B-X
that	B-X
'well-established	B-X
'	B-X
functional	B-X
assays	B-X
(	B-X
PS3	B-X
,	B-X
BS3	B-X
)	B-X
were	B-X
still	B-X
mainly	B-X
research	B-X
tools	B-X
but	B-X
sequencing	B-X
and	B-X
minigene	B-X
assays	B-X
were	B-X
commonly	B-X
used	B-X
to	B-X
confirm	B-X
splicing	B-X
variants	B-X
.	B-X
It	B-X
was	B-X
not	B-X
possible	B-X
to	B-X
define	B-X
the	B-X
Minor	B-X
Allele	B-X
Frequency	B-X
(	B-X
MAF	B-X
)	B-X
threshold	B-X
above	B-X
which	B-X
variants	B-X
were	B-X
considered	B-X
Benign	B-X
(	B-X
BA1	B-X
,	B-X
BS1	B-X
)	B-X
,	B-X
because	B-X
of	B-X
the	B-X
different	B-X
modes	B-X
of	B-X
inheritances	B-X
of	B-X
Alport	B-X
syndrome	B-X
,	B-X
and	B-X
the	B-X
occurrence	B-X
of	B-X
hypomorphic	B-X
variants	B-X
(	B-X
often	B-X
Glycine	B-X
adjacent	B-X
to	B-X
a	B-X
non-collagenous	B-X
interruption	B-X
)	B-X
and	B-X
local	B-X
founder	B-X
effects	B-X
.	B-X
Heterozygous	B-X
COL4A3	B-X
and	B-X
COL4A4	B-X
variants	B-X
were	B-X
common	B-X
'incidental	B-X
'	B-X
findings	B-X
also	B-X
present	B-X
in	B-X
normal	B-X
reference	B-X
databases	B-X
.	B-X
The	B-X
recognition	B-X
and	B-X
interpretation	B-X
of	B-X
hypomorphic	B-X
variants	B-X
in	B-X
the	B-X
COL4A3-COL4A5	B-X
genes	B-X
remains	B-X
a	B-X
challenge	B-X
.	B-X

The	O
results	O
suggest	O
that	O
the	O
mechanisms	O
determining	O
phosphorylation	O
and	O
amidation	O
of	O
progastrin	B-Protein
-	O
related	O
peptides	O
depend	O
on	O
the	O
patterns	O
of	O
stimulation	O
of	O
gastrin	B-Protein
cells	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
post-translational	B-X
processing	B-X
which	B-X
occur	B-X
in	B-X
gastrin	B-X
cells	B-X
from	B-X
rats	B-X
that	B-X
are	B-X
physiologically	B-X
stimulated	B-X
(	B-X
by	B-X
feeding	B-X
)	B-X
or	B-X
unstimulated	B-X
(	B-X
by	B-X
fasting	B-X
)	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
Taken	B-X
together	B-X
the	B-X
data	B-X
suggest	B-X
a	B-X
relative	B-X
failure	B-X
in	B-X
amidation	B-X
mechanisms	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
The	B-X
endopeptidase	B-X
cleavage	B-X
of	B-X
progastrin	B-X
was	B-X
not	B-X
influenced	B-X
significantly	B-X
by	B-X
fasting	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

The	O
observation	O
that	O
decreased	O
phosphorylation	O
is	O
associated	O
with	O
a	O
failure	O
to	O
produce	O
active	O
amidated	O
products	O
is	O
consistent	O
with	O
a	O
regulatory	O
function	O
for	O
phosphorylation	O
in	O
gastrin	B-Protein
production	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
the	B-X
precursor	B-X
for	B-X
rat	B-X
gastrin	B-X
yields	B-X
products	B-X
that	B-X
include	B-X
peptides	B-X
phosphorylated	B-X
at	B-X
Ser96	B-X
,	B-X
amidated	B-X
at	B-X
Phe92	B-X
,	B-X
and	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
or	B-X
Tyr103	B-X
.	B-X
The	B-X
phosphorylation	B-X
site	B-X
is	B-X
immediately	B-X
adjacent	B-X
to	B-X
the	B-X
processing	B-X
point	B-X
that	B-X
gives	B-X
rise	B-X
to	B-X
the	B-X
biologically	B-X
active	B-X
amidated	B-X
gastrins	B-X
.	B-X
We	B-X
have	B-X
examined	B-X
changes	B-X
in	B-X
post-translational	B-X
processing	B-X
which	B-X
occur	B-X
in	B-X
gastrin	B-X
cells	B-X
from	B-X
rats	B-X
that	B-X
are	B-X
physiologically	B-X
stimulated	B-X
(	B-X
by	B-X
feeding	B-X
)	B-X
or	B-X
unstimulated	B-X
(	B-X
by	B-X
fasting	B-X
)	B-X
.	B-X
Peptides	B-X
were	B-X
identified	B-X
using	B-X
site-directed	B-X
radioimmunoassays	B-X
and	B-X
chromatographic	B-X
systems	B-X
that	B-X
resolve	B-X
phosphorylated	B-X
,	B-X
amidated	B-X
,	B-X
and	B-X
sulfated	B-X
progastrin	B-X
products	B-X
,	B-X
including	B-X
intermediates	B-X
generated	B-X
prior	B-X
to	B-X
amidation	B-X
(	B-X
i.e	B-X
.	B-X
Assays	B-X
for	B-X
Phe92-amidated	B-X
peptides	B-X
and	B-X
for	B-X
the	B-X
C-terminal	B-X
tryptic	B-X
fragment	B-X
of	B-X
progastrin	B-X
indicated	B-X
decreases	B-X
in	B-X
the	B-X
total	B-X
tissue	B-X
concentrations	B-X
of	B-X
immunoreactive	B-X
peptide	B-X
with	B-X
fasting	B-X
;	B-X
in	B-X
contrast	B-X
,	B-X
the	B-X
tissue	B-X
concentrations	B-X
of	B-X
glycine-extended	B-X
biosynthetic	B-X
intermediates	B-X
were	B-X
similar	B-X
in	B-X
fasted	B-X
and	B-X
fed	B-X
rats	B-X
.	B-X
Taken	B-X
together	B-X
the	B-X
data	B-X
suggest	B-X
a	B-X
relative	B-X
failure	B-X
in	B-X
amidation	B-X
mechanisms	B-X
in	B-X
unstimulated	B-X
cells	B-X
.	B-X
The	B-X
endopeptidase	B-X
cleavage	B-X
of	B-X
progastrin	B-X
was	B-X
not	B-X
influenced	B-X
significantly	B-X
by	B-X
fasting	B-X
.	B-X
However	B-X
,	B-X
the	B-X
phosphorylation	B-X
of	B-X
peptide	B-X
products	B-X
containing	B-X
Ser96	B-X
was	B-X
depressed	B-X
significantly	B-X
in	B-X
fasted	B-X
rats	B-X
.	B-X
The	B-X
proportions	B-X
of	B-X
amidated	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr87	B-X
were	B-X
generally	B-X
lower	B-X
than	B-X
their	B-X
corresponding	B-X
glycine-extended	B-X
biosynthetic	B-X
precursors	B-X
,	B-X
but	B-X
in	B-X
both	B-X
cases	B-X
the	B-X
proportion	B-X
of	B-X
peptide	B-X
in	B-X
the	B-X
sulfated	B-X
form	B-X
was	B-X
lower	B-X
than	B-X
for	B-X
peptides	B-X
sulfated	B-X
at	B-X
Tyr103	B-X
.	B-X
Feeding	B-X
did	B-X
not	B-X
change	B-X
the	B-X
sulfation	B-X
of	B-X
amidated	B-X
heptadecapeptide	B-X
gastrin	B-X
or	B-X
its	B-X
glycine-extended	B-X
variant	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
mechanisms	B-X
determining	B-X
phosphorylation	B-X
and	B-X
amidation	B-X
of	B-X
progastrin-related	B-X
peptides	B-X
depend	B-X
on	B-X
the	B-X
patterns	B-X
of	B-X
stimulation	B-X
of	B-X
gastrin	B-X
cells	B-X
.	B-X
The	B-X
observation	B-X
that	B-X
decreased	B-X
phosphorylation	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
failure	B-X
to	B-X
produce	B-X
active	B-X
amidated	B-X
products	B-X
is	B-X
consistent	B-X
with	B-X
a	B-X
regulatory	B-X
function	B-X
for	B-X
phosphorylation	B-X
in	B-X
gastrin	B-X
production	B-X
.	B-X

Involvement	O
of	O
the	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
-	O
related	O
kinases	O
tank	B-Protein
-	I-Protein
binding	I-Protein
kinase	I-Protein
1	I-Protein
/	O
IKKi	B-Protein
and	O
cullin	O
-	O
based	O
ubiquitin	B-Protein
ligases	O
in	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
-	I-Protein
3	I-Protein
degradation	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
innate	B-X
arm	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
following	B-X
pathogen	B-X
infection	B-X
relies	B-X
on	B-X
the	B-X
recruitment	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
viral	B-X
clearance	B-X
.	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

Activation	O
of	O
the	O
innate	O
arm	O
of	O
the	O
immune	O
system	O
following	O
pathogen	O
infection	O
relies	O
on	O
the	O
recruitment	O
of	O
latent	O
transcription	O
factors	O
involved	O
in	O
the	O
induction	O
of	O
a	O
subset	O
of	O
genes	O
responsible	O
for	O
viral	O
clearance	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
innate	B-X
arm	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
following	B-X
pathogen	B-X
infection	B-X
relies	B-X
on	B-X
the	B-X
recruitment	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
viral	B-X
clearance	B-X
.	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanisms	B-X
involved	B-X
in	B-X
this	B-X
process	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

One	O
of	O
these	O
transcription	O
factors	O
,	O
IFN	B-Protein
regulatory	I-Protein
factor	I-Protein
3	I-Protein
(	O
IRF	B-Protein
-	I-Protein
3	I-Protein
)	O
,	O
is	O
targeted	O
for	O
proteosomal	O
degradation	O
following	O
virus	O
infection	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
innate	B-X
arm	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
following	B-X
pathogen	B-X
infection	B-X
relies	B-X
on	B-X
the	B-X
recruitment	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
viral	B-X
clearance	B-X
.	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
process	O
are	O
still	O
unknown	O
.	O
<EOS>	B-X
The	B-X
relationship	B-X
between	B-X
pancreatic	B-X
cancer	B-X
(	B-X
PC	B-X
)	B-X
and	B-X
type	B-X
2	B-X
diabetes	B-X
mellitus	B-X
(	B-X
T2DM	B-X
)	B-X
has	B-X
long	B-X
been	B-X
widely	B-X
recognized	B-X
,	B-X
but	B-X
the	B-X
interaction	B-X
mechanisms	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
This	B-X
study	B-X
was	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
shared	B-X
gene	B-X
signatures	B-X
and	B-X
molecular	B-X
processes	B-X
between	B-X
PC	B-X
and	B-X
T2DM	B-X
.	B-X
The	B-X
molecular	B-X
mechanisms	B-X
causing	B-X
the	B-X
loss	B-X
of	B-X
dopaminergic	B-X
neurons	B-X
containing	B-X
neuromelanin	B-X
in	B-X
the	B-X
substantia	B-X
nigra	B-X
and	B-X
responsible	B-X
for	B-X
motor	B-X
symptoms	B-X
of	B-X
Parkinson	B-X
's	B-X
disease	B-X
are	B-X
still	B-X
unknown	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
generally	B-X
accepted	B-X
by	B-X
the	B-X
scientific	B-X
community	B-X
that	B-X
mitochondria	B-X
dysfunction	B-X
,	B-X
alpha	B-X
synuclein	B-X
aggregation	B-X
,	B-X
dysfunction	B-X
of	B-X
protein	B-X
degradation	B-X
,	B-X
oxidative	B-X
stress	B-X
and	B-X
neuroinflammation	B-X
are	B-X
involved	B-X
in	B-X
neurodegeneration	B-X
.	B-X
However	B-X
,	B-X
both	B-X
dopamine	B-X
o-quinone	B-X
and	B-X
5,6-indolequinone	B-X
are	B-X
so	B-X
unstable	B-X
that	B-X
is	B-X
difficult	B-X
to	B-X
study	B-X
and	B-X
separate	B-X
their	B-X
roles	B-X
in	B-X
the	B-X
degenerative	B-X
process	B-X
occurring	B-X
in	B-X
Parkinson	B-X
's	B-X
disease	B-X
.	B-X
Dopamine	B-X
oxidation	B-X
to	B-X
dopamine	B-X
o-quinone	B-X
,	B-X
aminochrome	B-X
and	B-X
5,6-indolequinone	B-X
seems	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
neurodegenerative	B-X
processes	B-X
of	B-X
Parkinson	B-X
's	B-X
disease	B-X
as	B-X
aminochrome	B-X
induces	B-X
:	B-X
(	B-X
i	B-X
)	B-X
mitochondria	B-X
dysfunction	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
formation	B-X
and	B-X
stabilization	B-X
of	B-X
neurotoxic	B-X
protofibrils	B-X
of	B-X
alpha	B-X
synuclein	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
protein	B-X
degradation	B-X
dysfunction	B-X
of	B-X
both	B-X
proteasomal	B-X
and	B-X
lysosomal	B-X
systems	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
oxidative	B-X
stress	B-X
.	B-X
However	B-X
,	B-X
the	B-X
cells	B-X
have	B-X
a	B-X
protective	B-X
system	B-X
against	B-X
dopamine	B-X
oxidation	B-X
composed	B-X
by	B-X
dopamine	B-X
uptake	B-X
mediated	B-X
by	B-X
Vesicular	B-X
monoaminergic	B-X
transporter-2	B-X
(	B-X
VMAT-2	B-X
)	B-X
,	B-X
neuromelanin	B-X
formation	B-X
,	B-X
two-electron	B-X
reduction	B-X
and	B-X
GSH-conjugation	B-X
mediated	B-X
by	B-X
Glutathione	B-X
S-transferase	B-X
M2-2	B-X
(	B-X
GSTM2	B-X
)	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
show	O
that	O
polyubiquitination	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
increases	O
in	O
response	O
to	O
Sendai	O
virus	O
infection	O
.	O
<EOS>	B-X
Upon	B-X
viral	B-X
infection	B-X
,	B-X
activated	B-X
RLRs	B-X
interact	B-X
with	B-X
VISA	B-X
on	B-X
mitochondria	B-X
,	B-X
forming	B-X
a	B-X
RLR‑VISA	B-X
platform	B-X
,	B-X
leading	B-X
to	B-X
the	B-X
recruitment	B-X
of	B-X
different	B-X
TRAF	B-X
family	B-X
members	B-X
,	B-X
including	B-X
TRAF3	B-X
,	B-X
TRAF2	B-X
and	B-X
TRAF6	B-X
.	B-X
This	B-X
results	B-X
in	B-X
the	B-X
phosphorylation	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
interferon	B-X
regulatory	B-X
factors	B-X
3	B-X
and	B-X
7	B-X
(	B-X
IRF3/IRF7	B-X
)	B-X
by	B-X
TANK	B-X
binding	B-X
kinase	B-X
1	B-X
(	B-X
TBK1	B-X
)	B-X
and/or	B-X
IKKε	B-X
,	B-X
as	B-X
well	B-X
as	B-X
activation	B-X
of	B-X
NF‑κB	B-X
,	B-X
to	B-X
induce	B-X
type	B-X
I	B-X
interferons	B-X
(	B-X
IFNs	B-X
)	B-X
and	B-X
pro‑inflammatory	B-X
cytokines	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
HAUS	B-X
augmin	B-X
like	B-X
complex	B-X
subunit	B-X
8	B-X
(	B-X
HAUS8	B-X
)	B-X
augments	B-X
the	B-X
RLR‑VISA‑dependent	B-X
antiviral	B-X
signaling	B-X
pathway	B-X
by	B-X
targeting	B-X
the	B-X
VISA	B-X
complex	B-X
.	B-X
The	B-X
data	B-X
demonstrated	B-X
that	B-X
overexpression	B-X
of	B-X
HAUS8	B-X
significantly	B-X
promoted	B-X
the	B-X
activity	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
NF‑κB	B-X
,	B-X
IRF3	B-X
and	B-X
the	B-X
IFN‑β	B-X
promoter	B-X
induced	B-X
by	B-X
Sendai	B-X
virus‑mediated	B-X
RLR‑VISA	B-X
signaling	B-X
.	B-X
HAUS8	B-X
increased	B-X
the	B-X
polyubiquitination	B-X
of	B-X
VISA	B-X
,	B-X
RIG‑I	B-X
and	B-X
TBK1	B-X
.	B-X
Knockdown	B-X
of	B-X
HAUS8	B-X
inhibited	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
IRF‑3	B-X
,	B-X
NF‑κB	B-X
and	B-X
the	B-X
IFN‑β	B-X
promoter	B-X
triggered	B-X
by	B-X
Sendai	B-X
virus	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
demonstrated	B-X
that	B-X
HAUS8	B-X
may	B-X
function	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
RLR‑VISA	B-X
dependent	B-X
antiviral	B-X
signaling	B-X
by	B-X
targeting	B-X
the	B-X
VISA	B-X
complex	B-X
,	B-X
providing	B-X
a	B-X
novel	B-X
regulatory	B-X
mechanism	B-X
of	B-X
antiviral	B-X
responses	B-X
.	B-X

Using	O
an	O
E1	O
temperature	O
-	O
sensitive	O
cell	O
line	O
,	O
we	O
demonstrate	O
that	O
polyubiquitination	O
is	O
required	O
for	O
the	O
observed	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
.	O
<EOS>	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

Inactivation	O
of	O
NEDD8	B-Protein
-	O
activating	O
E1	O
enzyme	O
also	O
results	O
in	O
stabilization	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
suggesting	O
the	O
NEDDylation	O
also	O
plays	O
a	O
role	O
in	O
IRF	B-Protein
-	I-Protein
3	I-Protein
degradation	O
following	O
Sendai	O
virus	O
infection	O
.	O

In	O
agreement	O
with	O
this	O
observation	O
,	O
IRF	B-Protein
-	I-Protein
3	I-Protein
is	O
recruited	O
to	O
Cullin1	B-Protein
following	O
virus	O
infection	O
and	O
overexpression	O
of	O
a	O
dominant	O
-	O
negative	O
mutant	O
of	O
Cullin1	B-Protein
significantly	O
inhibits	O
the	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
observed	O
in	O
infected	O
cells	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
innate	B-X
arm	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
following	B-X
pathogen	B-X
infection	B-X
relies	B-X
on	B-X
the	B-X
recruitment	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
viral	B-X
clearance	B-X
.	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

We	O
also	O
asked	O
whether	O
the	O
C	O
-	O
terminal	O
cluster	O
of	O
phosphoacceptor	O
sites	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
could	O
serve	O
as	O
a	O
destabilization	O
signal	O
and	O
we	O
therefore	O
measured	O
the	O
half	O
-	O
life	O
of	O
C	O
-	O
terminal	O
phosphomimetic	O
IRF	B-Protein
-	I-Protein
3	I-Protein
mutants	O
.	O

Interestingly	O
,	O
we	O
found	O
them	O
to	O
be	O
short	O
-	O
lived	O
in	O
contrast	O
to	O
wild	O
-	O
type	O
IRF	B-Protein
-	I-Protein
3	I-Protein
.	O
<EOS>	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

In	O
addition	O
,	O
no	O
degradation	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
was	O
observed	O
in	O
TBK1	B-Protein
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
.	O
<EOS>	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

All	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
virus	O
infection	O
stimulates	O
a	O
host	O
cell	O
signaling	O
pathway	O
that	O
modulates	O
the	O
expression	O
level	O
of	O
IRF	B-Protein
-	I-Protein
3	I-Protein
through	O
its	O
C	O
-	O
terminal	O
phosphorylation	O
by	O
the	O
IkappaB	O
kinase	O
-	O
related	O
kinases	O
followed	O
by	O
its	O
polyubiquitination	O
,	O
which	O
is	O
mediated	O
in	O
part	O
by	O
a	O
Cullin	O
-	O
based	O
ubiquitin	B-Protein
ligase	O
.	O
<EOS>	B-X
Activation	B-X
of	B-X
the	B-X
innate	B-X
arm	B-X
of	B-X
the	B-X
immune	B-X
system	B-X
following	B-X
pathogen	B-X
infection	B-X
relies	B-X
on	B-X
the	B-X
recruitment	B-X
of	B-X
latent	B-X
transcription	B-X
factors	B-X
involved	B-X
in	B-X
the	B-X
induction	B-X
of	B-X
a	B-X
subset	B-X
of	B-X
genes	B-X
responsible	B-X
for	B-X
viral	B-X
clearance	B-X
.	B-X
One	B-X
of	B-X
these	B-X
transcription	B-X
factors	B-X
,	B-X
IFN	B-X
regulatory	B-X
factor	B-X
3	B-X
(	B-X
IRF-3	B-X
)	B-X
,	B-X
is	B-X
targeted	B-X
for	B-X
proteosomal	B-X
degradation	B-X
following	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
polyubiquitination	B-X
of	B-X
IRF-3	B-X
increases	B-X
in	B-X
response	B-X
to	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
Using	B-X
an	B-X
E1	B-X
temperature-sensitive	B-X
cell	B-X
line	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
polyubiquitination	B-X
is	B-X
required	B-X
for	B-X
the	B-X
observed	B-X
degradation	B-X
of	B-X
IRF-3	B-X
.	B-X
Inactivation	B-X
of	B-X
NEDD8-activating	B-X
E1	B-X
enzyme	B-X
also	B-X
results	B-X
in	B-X
stabilization	B-X
of	B-X
IRF-3	B-X
suggesting	B-X
the	B-X
NEDDylation	B-X
also	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
IRF-3	B-X
degradation	B-X
following	B-X
Sendai	B-X
virus	B-X
infection	B-X
.	B-X
In	B-X
agreement	B-X
with	B-X
this	B-X
observation	B-X
,	B-X
IRF-3	B-X
is	B-X
recruited	B-X
to	B-X
Cullin1	B-X
following	B-X
virus	B-X
infection	B-X
and	B-X
overexpression	B-X
of	B-X
a	B-X
dominant-negative	B-X
mutant	B-X
of	B-X
Cullin1	B-X
significantly	B-X
inhibits	B-X
the	B-X
degradation	B-X
of	B-X
IRF-3	B-X
observed	B-X
in	B-X
infected	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
asked	B-X
whether	B-X
the	B-X
C-terminal	B-X
cluster	B-X
of	B-X
phosphoacceptor	B-X
sites	B-X
of	B-X
IRF-3	B-X
could	B-X
serve	B-X
as	B-X
a	B-X
destabilization	B-X
signal	B-X
and	B-X
we	B-X
therefore	B-X
measured	B-X
the	B-X
half-life	B-X
of	B-X
C-terminal	B-X
phosphomimetic	B-X
IRF-3	B-X
mutants	B-X
.	B-X
Interestingly	B-X
,	B-X
we	B-X
found	B-X
them	B-X
to	B-X
be	B-X
short-lived	B-X
in	B-X
contrast	B-X
to	B-X
wild-type	B-X
IRF-3	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
no	B-X
degradation	B-X
of	B-X
IRF-3	B-X
was	B-X
observed	B-X
in	B-X
TBK1	B-X
(	B-X
-/-	B-X
)	B-X
mouse	B-X
embryonic	B-X
fibroblasts	B-X
.	B-X
All	B-X
together	B-X
,	B-X
these	B-X
data	B-X
demonstrate	B-X
that	B-X
virus	B-X
infection	B-X
stimulates	B-X
a	B-X
host	B-X
cell	B-X
signaling	B-X
pathway	B-X
that	B-X
modulates	B-X
the	B-X
expression	B-X
level	B-X
of	B-X
IRF-3	B-X
through	B-X
its	B-X
C-terminal	B-X
phosphorylation	B-X
by	B-X
the	B-X
IkappaB	B-X
kinase-related	B-X
kinases	B-X
followed	B-X
by	B-X
its	B-X
polyubiquitination	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
in	B-X
part	B-X
by	B-X
a	B-X
Cullin-based	B-X
ubiquitin	B-X
ligase	B-X
.	B-X

Structural	O
basis	O
for	O
SENP2	B-Protein
protease	O
interactions	O
with	O
SUMO	O
precursors	O
and	O
conjugated	O
substrates	O
.	O
<EOS>	B-X
SUMO	B-X
processing	B-X
and	B-X
deconjugation	B-X
are	B-X
essential	B-X
proteolytic	B-X
activities	B-X
for	B-X
nuclear	B-X
metabolism	B-X
and	B-X
cell-cycle	B-X
progression	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
eukaryotes	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
used	B-X
during	B-X
substrate	B-X
lysine	B-X
deconjugation	B-X
,	B-X
SUMO	B-X
isoform	B-X
processing	B-X
and	B-X
SUMO	B-X
isoform	B-X
interactions	B-X
,	B-X
X-ray	B-X
structures	B-X
were	B-X
determined	B-X
for	B-X
a	B-X
catalytically	B-X
inert	B-X
SENP2	B-X
protease	B-X
domain	B-X
in	B-X
complex	B-X
with	B-X
conjugated	B-X
RanGAP1-SUMO-1	B-X
or	B-X
RanGAP1-SUMO-2	B-X
,	B-X
or	B-X
in	B-X
complex	B-X
with	B-X
SUMO-2	B-X
or	B-X
SUMO-3	B-X
precursors	B-X
.	B-X
Common	B-X
features	B-X
within	B-X
the	B-X
active	B-X
site	B-X
include	B-X
a	B-X
90	B-X
degrees	B-X
kink	B-X
proximal	B-X
to	B-X
the	B-X
scissile	B-X
bond	B-X
that	B-X
forces	B-X
C-terminal	B-X
amino	B-X
acid	B-X
residues	B-X
or	B-X
the	B-X
lysine	B-X
side	B-X
chain	B-X
toward	B-X
a	B-X
protease	B-X
surface	B-X
that	B-X
appears	B-X
optimized	B-X
for	B-X
lysine	B-X
deconjugation	B-X
.	B-X
Analysis	B-X
of	B-X
this	B-X
surface	B-X
reveals	B-X
SENP2	B-X
residues	B-X
,	B-X
particularly	B-X
Met497	B-X
,	B-X
that	B-X
mediate	B-X
,	B-X
and	B-X
in	B-X
some	B-X
instances	B-X
reverse	B-X
,	B-X
in	B-X
vitro	B-X
substrate	B-X
specificity	B-X
.	B-X
Mutational	B-X
analysis	B-X
and	B-X
biochemistry	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
SENP2	B-X
substrate	B-X
preferences	B-X
that	B-X
explains	B-X
why	B-X
SENP2	B-X
catalyzes	B-X
SUMO	B-X
deconjugation	B-X
more	B-X
efficiently	B-X
than	B-X
processing	B-X
.	B-X

SUMO	O
processing	O
and	O
deconjugation	O
are	O
essential	O
proteolytic	O
activities	O
for	O
nuclear	O
metabolism	O
and	O
cell	O
-	O
cycle	O
progression	O
in	O
yeast	O
and	O
higher	O
eukaryotes	O
.	O
<EOS>	B-X
SUMO	B-X
processing	B-X
and	B-X
deconjugation	B-X
are	B-X
essential	B-X
proteolytic	B-X
activities	B-X
for	B-X
nuclear	B-X
metabolism	B-X
and	B-X
cell-cycle	B-X
progression	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
eukaryotes	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
used	B-X
during	B-X
substrate	B-X
lysine	B-X
deconjugation	B-X
,	B-X
SUMO	B-X
isoform	B-X
processing	B-X
and	B-X
SUMO	B-X
isoform	B-X
interactions	B-X
,	B-X
X-ray	B-X
structures	B-X
were	B-X
determined	B-X
for	B-X
a	B-X
catalytically	B-X
inert	B-X
SENP2	B-X
protease	B-X
domain	B-X
in	B-X
complex	B-X
with	B-X
conjugated	B-X
RanGAP1-SUMO-1	B-X
or	B-X
RanGAP1-SUMO-2	B-X
,	B-X
or	B-X
in	B-X
complex	B-X
with	B-X
SUMO-2	B-X
or	B-X
SUMO-3	B-X
precursors	B-X
.	B-X
Common	B-X
features	B-X
within	B-X
the	B-X
active	B-X
site	B-X
include	B-X
a	B-X
90	B-X
degrees	B-X
kink	B-X
proximal	B-X
to	B-X
the	B-X
scissile	B-X
bond	B-X
that	B-X
forces	B-X
C-terminal	B-X
amino	B-X
acid	B-X
residues	B-X
or	B-X
the	B-X
lysine	B-X
side	B-X
chain	B-X
toward	B-X
a	B-X
protease	B-X
surface	B-X
that	B-X
appears	B-X
optimized	B-X
for	B-X
lysine	B-X
deconjugation	B-X
.	B-X
Mutational	B-X
analysis	B-X
and	B-X
biochemistry	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
SENP2	B-X
substrate	B-X
preferences	B-X
that	B-X
explains	B-X
why	B-X
SENP2	B-X
catalyzes	B-X
SUMO	B-X
deconjugation	B-X
more	B-X
efficiently	B-X
than	B-X
processing	B-X
.	B-X

To	O
elucidate	O
the	O
mechanisms	O
used	O
during	O
substrate	O
lysine	O
deconjugation	O
,	O
SUMO	O
isoform	O
processing	O
and	O
SUMO	O
isoform	O
interactions	O
,	O
X	O
-	O
ray	O
structures	O
were	O
determined	O
for	O
a	O
catalytically	O
inert	O
SENP2	B-Protein
protease	O
domain	O
in	O
complex	O
with	O
conjugated	O
RanGAP1	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
or	O
RanGAP1	B-Protein
-	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
,	O
or	O
in	O
complex	O
with	O
SUMO	B-Protein
-	I-Protein
2	I-Protein
or	O
SUMO	B-Protein
-	I-Protein
3	I-Protein
precursors	O
.	O
<EOS>	B-X
Sentrin/small	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
is	B-X
protein	B-X
modification	B-X
pathway	B-X
that	B-X
regulates	B-X
multiple	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
division	B-X
,	B-X
DNA	B-X
replication/repair	B-X
,	B-X
signal	B-X
transduction	B-X
,	B-X
and	B-X
cellular	B-X
metabolism	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
focus	B-X
on	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
disease	B-X
pathogenesis	B-X
,	B-X
such	B-X
as	B-X
cancer	B-X
,	B-X
diabetes	B-X
,	B-X
seizure	B-X
,	B-X
and	B-X
heart	B-X
failure	B-X
,	B-X
which	B-X
have	B-X
been	B-X
linked	B-X
to	B-X
the	B-X
SUMO	B-X
pathway	B-X
.	B-X
SUMO	B-X
is	B-X
conjugated	B-X
to	B-X
lysine	B-X
residues	B-X
in	B-X
target	B-X
proteins	B-X
through	B-X
an	B-X
isopeptide	B-X
linkage	B-X
catalyzed	B-X
by	B-X
SUMO-specific	B-X
activating	B-X
(	B-X
E1	B-X
)	B-X
,	B-X
conjugating	B-X
(	B-X
E2	B-X
)	B-X
,	B-X
and	B-X
ligating	B-X
(	B-X
E3	B-X
)	B-X
enzymes	B-X
.	B-X
In	B-X
steady	B-X
state	B-X
,	B-X
the	B-X
quantity	B-X
of	B-X
SUMO-modified	B-X
substrates	B-X
is	B-X
usually	B-X
a	B-X
small	B-X
fraction	B-X
of	B-X
unmodified	B-X
substrates	B-X
due	B-X
to	B-X
the	B-X
deconjugation	B-X
activity	B-X
of	B-X
the	B-X
family	B-X
Sentrin/SUMO-specific	B-X
proteases	B-X
(	B-X
SENPs	B-X
)	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
the	B-X
complexity	B-X
of	B-X
the	B-X
ubiquitination/deubiquitination	B-X
machinery	B-X
,	B-X
the	B-X
biochemistry	B-X
of	B-X
SUMOylation	B-X
and	B-X
de-SUMOylation	B-X
is	B-X
relatively	B-X
modest	B-X
.	B-X
Specificity	B-X
of	B-X
the	B-X
SUMO	B-X
pathway	B-X
is	B-X
achieved	B-X
through	B-X
redox	B-X
regulation	B-X
,	B-X
acetylation	B-X
,	B-X
phosphorylation	B-X
,	B-X
or	B-X
other	B-X
posttranslational	B-X
protein	B-X
modification	B-X
of	B-X
the	B-X
SUMOylation	B-X
and	B-X
de-SUMOylation	B-X
enzymes	B-X
.	B-X
There	B-X
are	B-X
three	B-X
major	B-X
SUMOs	B-X
.	B-X
SUMO-1	B-X
usually	B-X
modifies	B-X
a	B-X
substrate	B-X
as	B-X
a	B-X
monomer	B-X
;	B-X
however	B-X
,	B-X
SUMO-2/3	B-X
can	B-X
form	B-X
poly-SUMO	B-X
chains	B-X
.	B-X
The	B-X
monomeric	B-X
SUMO-1	B-X
or	B-X
poly-SUMO	B-X
chains	B-X
can	B-X
interact	B-X
with	B-X
other	B-X
proteins	B-X
through	B-X
SUMO-interactive	B-X
motif	B-X
(	B-X
SIM	B-X
)	B-X
.	B-X
Thus	B-X
SUMO	B-X
modification	B-X
provides	B-X
a	B-X
platform	B-X
to	B-X
enhance	B-X
protein-protein	B-X
interaction	B-X
.	B-X
The	B-X
consequence	B-X
of	B-X
SUMOylation	B-X
includes	B-X
changes	B-X
in	B-X
cellular	B-X
localization	B-X
,	B-X
protein	B-X
activity	B-X
,	B-X
or	B-X
protein	B-X
stability	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO	B-X
may	B-X
join	B-X
force	B-X
with	B-X
ubiquitin	B-X
to	B-X
degrade	B-X
proteins	B-X
through	B-X
SUMO-targeted	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
STUbL	B-X
)	B-X
.	B-X
After	B-X
20	B-X
yr	B-X
of	B-X
research	B-X
,	B-X
SUMO	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
play	B-X
critical	B-X
roles	B-X
in	B-X
most	B-X
,	B-X
if	B-X
not	B-X
all	B-X
,	B-X
biological	B-X
pathways	B-X
.	B-X
Thus	B-X
the	B-X
SUMO	B-X
enzymes	B-X
could	B-X
be	B-X
targets	B-X
for	B-X
drug	B-X
development	B-X
to	B-X
treat	B-X
human	B-X
diseases	B-X
.	B-X

Common	O
features	O
within	O
the	O
active	O
site	O
include	O
a	O
90	O
degrees	O
kink	O
proximal	O
to	O
the	O
scissile	O
bond	O
that	O
forces	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
or	O
the	O
lysine	O
side	O
chain	O
toward	O
a	O
protease	O
surface	O
that	O
appears	O
optimized	O
for	O
lysine	O
deconjugation	O
.	O

Analysis	O
of	O
this	O
surface	O
reveals	O
SENP2	B-Protein
residues	O
,	O
particularly	O
Met497	O
,	O
that	O
mediate	O
,	O
and	O
in	O
some	O
instances	O
reverse	O
,	O
in	O
vitro	O
substrate	O
specificity	O
.	O
<EOS>	B-X
To	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
used	B-X
during	B-X
substrate	B-X
lysine	B-X
deconjugation	B-X
,	B-X
SUMO	B-X
isoform	B-X
processing	B-X
and	B-X
SUMO	B-X
isoform	B-X
interactions	B-X
,	B-X
X-ray	B-X
structures	B-X
were	B-X
determined	B-X
for	B-X
a	B-X
catalytically	B-X
inert	B-X
SENP2	B-X
protease	B-X
domain	B-X
in	B-X
complex	B-X
with	B-X
conjugated	B-X
RanGAP1-SUMO-1	B-X
or	B-X
RanGAP1-SUMO-2	B-X
,	B-X
or	B-X
in	B-X
complex	B-X
with	B-X
SUMO-2	B-X
or	B-X
SUMO-3	B-X
precursors	B-X
.	B-X
Common	B-X
features	B-X
within	B-X
the	B-X
active	B-X
site	B-X
include	B-X
a	B-X
90	B-X
degrees	B-X
kink	B-X
proximal	B-X
to	B-X
the	B-X
scissile	B-X
bond	B-X
that	B-X
forces	B-X
C-terminal	B-X
amino	B-X
acid	B-X
residues	B-X
or	B-X
the	B-X
lysine	B-X
side	B-X
chain	B-X
toward	B-X
a	B-X
protease	B-X
surface	B-X
that	B-X
appears	B-X
optimized	B-X
for	B-X
lysine	B-X
deconjugation	B-X
.	B-X
Analysis	B-X
of	B-X
this	B-X
surface	B-X
reveals	B-X
SENP2	B-X
residues	B-X
,	B-X
particularly	B-X
Met497	B-X
,	B-X
that	B-X
mediate	B-X
,	B-X
and	B-X
in	B-X
some	B-X
instances	B-X
reverse	B-X
,	B-X
in	B-X
vitro	B-X
substrate	B-X
specificity	B-X
.	B-X
Mutational	B-X
analysis	B-X
and	B-X
biochemistry	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
SENP2	B-X
substrate	B-X
preferences	B-X
that	B-X
explains	B-X
why	B-X
SENP2	B-X
catalyzes	B-X
SUMO	B-X
deconjugation	B-X
more	B-X
efficiently	B-X
than	B-X
processing	B-X
.	B-X

Mutational	O
analysis	O
and	O
biochemistry	O
provide	O
a	O
mechanism	O
for	O
SENP2	B-Protein
substrate	O
preferences	O
that	O
explains	O
why	O
SENP2	B-Protein
catalyzes	O
SUMO	O
deconjugation	O
more	O
efficiently	O
than	O
processing	O
.	O
<EOS>	B-X
SUMO	B-X
processing	B-X
and	B-X
deconjugation	B-X
are	B-X
essential	B-X
proteolytic	B-X
activities	B-X
for	B-X
nuclear	B-X
metabolism	B-X
and	B-X
cell-cycle	B-X
progression	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
eukaryotes	B-X
.	B-X
To	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
used	B-X
during	B-X
substrate	B-X
lysine	B-X
deconjugation	B-X
,	B-X
SUMO	B-X
isoform	B-X
processing	B-X
and	B-X
SUMO	B-X
isoform	B-X
interactions	B-X
,	B-X
X-ray	B-X
structures	B-X
were	B-X
determined	B-X
for	B-X
a	B-X
catalytically	B-X
inert	B-X
SENP2	B-X
protease	B-X
domain	B-X
in	B-X
complex	B-X
with	B-X
conjugated	B-X
RanGAP1-SUMO-1	B-X
or	B-X
RanGAP1-SUMO-2	B-X
,	B-X
or	B-X
in	B-X
complex	B-X
with	B-X
SUMO-2	B-X
or	B-X
SUMO-3	B-X
precursors	B-X
.	B-X
Common	B-X
features	B-X
within	B-X
the	B-X
active	B-X
site	B-X
include	B-X
a	B-X
90	B-X
degrees	B-X
kink	B-X
proximal	B-X
to	B-X
the	B-X
scissile	B-X
bond	B-X
that	B-X
forces	B-X
C-terminal	B-X
amino	B-X
acid	B-X
residues	B-X
or	B-X
the	B-X
lysine	B-X
side	B-X
chain	B-X
toward	B-X
a	B-X
protease	B-X
surface	B-X
that	B-X
appears	B-X
optimized	B-X
for	B-X
lysine	B-X
deconjugation	B-X
.	B-X
Analysis	B-X
of	B-X
this	B-X
surface	B-X
reveals	B-X
SENP2	B-X
residues	B-X
,	B-X
particularly	B-X
Met497	B-X
,	B-X
that	B-X
mediate	B-X
,	B-X
and	B-X
in	B-X
some	B-X
instances	B-X
reverse	B-X
,	B-X
in	B-X
vitro	B-X
substrate	B-X
specificity	B-X
.	B-X
Mutational	B-X
analysis	B-X
and	B-X
biochemistry	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
SENP2	B-X
substrate	B-X
preferences	B-X
that	B-X
explains	B-X
why	B-X
SENP2	B-X
catalyzes	B-X
SUMO	B-X
deconjugation	B-X
more	B-X
efficiently	B-X
than	B-X
processing	B-X
.	B-X

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
-	O
encoded	O
protein	O
kinase	O
and	O
its	O
interaction	O
with	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
.	O

The	O
oncogenic	O
herpesvirus	O
,	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
,	O
also	O
identified	O
as	O
human	O
herpesvirus	O
8	O
,	O
contains	O
genes	O
producing	O
proteins	O
that	O
control	O
transcription	O
and	O
influence	O
cell	O
signaling	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

Open	B-Protein
reading	I-Protein
frame	I-Protein
36	I-Protein
(	O
ORF36	B-Protein
)	O
of	O
this	O
virus	O
encodes	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
,	O
which	O
is	O
designated	O
the	O
viral	O
protein	B-Protein
kinase	I-Protein
(	O
vPK	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

Our	O
recent	O
efforts	O
to	O
elucidate	O
the	O
role	O
of	O
vPK	B-Protein
in	O
the	O
viral	O
life	O
cycle	O
have	O
focused	O
on	O
identifying	O
viral	O
protein	O
substrates	O
and	O
determining	O
the	O
effects	O
of	O
vPK	B-Protein
-	O
mediated	O
phosphorylation	O
on	O
specific	O
steps	O
in	O
viral	O
replication	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

The	O
vPK	B-Protein
gene	O
was	O
transcribed	O
into	O
4	O
.	O
2	O
-	O
kb	O
and	O
3	O
.	O
6	O
-	O
kb	O
mRNAs	O
during	O
the	O
early	O
and	O
late	O
phases	O
of	O
viral	O
reactivation	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

vPK	B-Protein
is	O
colocalized	O
with	O
viral	O
DNA	O
replication	O
/	O
transcription	O
compartments	O
as	O
marked	O
by	O
a	O
polymerase	O
processivity	O
factor	O
,	O
and	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
,	O
a	O
protein	O
known	O
to	O
bind	O
the	O
viral	O
DNA	O
replication	O
origin	O
(	O
Ori	O
-	O
Lyt	O
)	O
and	O
to	O
regulate	O
viral	O
transcription	O
.	O

The	O
vPK	B-Protein
physically	O
associated	O
with	O
and	O
strongly	O
phosphorylated	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
at	O
threonine	O
111	O
,	O
a	O
site	O
also	O
recognized	O
by	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
Cdk2	B-Protein
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

Both	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
and	O
vPK	B-Protein
were	O
corecruited	O
to	O
viral	O
promoters	O
targeted	O
by	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
as	O
well	O
as	O
to	O
the	O
Ori	O
-	O
Lyt	O
region	O
.	O

Phosphorylation	O
of	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
by	O
vPK	B-Protein
had	O
a	O
negative	O
impact	O
on	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
transcription	O
repression	O
activity	O
.	O

The	O
extent	O
of	O
posttranslational	O
modification	O
of	O
K	B-Protein
-	I-Protein
bZIP	I-Protein
by	O
sumoylation	O
,	O
a	O
process	O
that	O
influences	O
its	O
repression	O
function	O
,	O
was	O
decreased	O
by	O
vPK	B-Protein
phosphorylation	O
at	O
threonine	O
111	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

Our	O
data	O
thus	O
identify	O
a	O
new	O
role	O
of	O
vPK	B-Protein
as	O
a	O
modulator	O
of	O
viral	O
transcription	O
.	O
<EOS>	B-X
The	B-X
oncogenic	B-X
herpesvirus	B-X
,	B-X
Kaposi	B-X
's	B-X
sarcoma-associated	B-X
herpesvirus	B-X
,	B-X
also	B-X
identified	B-X
as	B-X
human	B-X
herpesvirus	B-X
8	B-X
,	B-X
contains	B-X
genes	B-X
producing	B-X
proteins	B-X
that	B-X
control	B-X
transcription	B-X
and	B-X
influence	B-X
cell	B-X
signaling	B-X
.	B-X
Open	B-X
reading	B-X
frame	B-X
36	B-X
(	B-X
ORF36	B-X
)	B-X
of	B-X
this	B-X
virus	B-X
encodes	B-X
a	B-X
serine/threonine	B-X
protein	B-X
kinase	B-X
,	B-X
which	B-X
is	B-X
designated	B-X
the	B-X
viral	B-X
protein	B-X
kinase	B-X
(	B-X
vPK	B-X
)	B-X
.	B-X
Our	B-X
recent	B-X
efforts	B-X
to	B-X
elucidate	B-X
the	B-X
role	B-X
of	B-X
vPK	B-X
in	B-X
the	B-X
viral	B-X
life	B-X
cycle	B-X
have	B-X
focused	B-X
on	B-X
identifying	B-X
viral	B-X
protein	B-X
substrates	B-X
and	B-X
determining	B-X
the	B-X
effects	B-X
of	B-X
vPK-mediated	B-X
phosphorylation	B-X
on	B-X
specific	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
.	B-X
The	B-X
vPK	B-X
gene	B-X
was	B-X
transcribed	B-X
into	B-X
4.2-kb	B-X
and	B-X
3.6-kb	B-X
mRNAs	B-X
during	B-X
the	B-X
early	B-X
and	B-X
late	B-X
phases	B-X
of	B-X
viral	B-X
reactivation	B-X
.	B-X
vPK	B-X
is	B-X
colocalized	B-X
with	B-X
viral	B-X
DNA	B-X
replication/transcription	B-X
compartments	B-X
as	B-X
marked	B-X
by	B-X
a	B-X
polymerase	B-X
processivity	B-X
factor	B-X
,	B-X
and	B-X
K-bZIP	B-X
,	B-X
a	B-X
protein	B-X
known	B-X
to	B-X
bind	B-X
the	B-X
viral	B-X
DNA	B-X
replication	B-X
origin	B-X
(	B-X
Ori-Lyt	B-X
)	B-X
and	B-X
to	B-X
regulate	B-X
viral	B-X
transcription	B-X
.	B-X
The	B-X
vPK	B-X
physically	B-X
associated	B-X
with	B-X
and	B-X
strongly	B-X
phosphorylated	B-X
K-bZIP	B-X
at	B-X
threonine	B-X
111	B-X
,	B-X
a	B-X
site	B-X
also	B-X
recognized	B-X
by	B-X
the	B-X
cyclin-dependent	B-X
kinase	B-X
Cdk2	B-X
.	B-X
Both	B-X
K-bZIP	B-X
and	B-X
vPK	B-X
were	B-X
corecruited	B-X
to	B-X
viral	B-X
promoters	B-X
targeted	B-X
by	B-X
K-bZIP	B-X
as	B-X
well	B-X
as	B-X
to	B-X
the	B-X
Ori-Lyt	B-X
region	B-X
.	B-X
Phosphorylation	B-X
of	B-X
K-bZIP	B-X
by	B-X
vPK	B-X
had	B-X
a	B-X
negative	B-X
impact	B-X
on	B-X
K-bZIP	B-X
transcription	B-X
repression	B-X
activity	B-X
.	B-X
The	B-X
extent	B-X
of	B-X
posttranslational	B-X
modification	B-X
of	B-X
K-bZIP	B-X
by	B-X
sumoylation	B-X
,	B-X
a	B-X
process	B-X
that	B-X
influences	B-X
its	B-X
repression	B-X
function	B-X
,	B-X
was	B-X
decreased	B-X
by	B-X
vPK	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
111	B-X
.	B-X
Our	B-X
data	B-X
thus	B-X
identify	B-X
a	B-X
new	B-X
role	B-X
of	B-X
vPK	B-X
as	B-X
a	B-X
modulator	B-X
of	B-X
viral	B-X
transcription	B-X
.	B-X

Preventing	O
apoptotic	O
cell	O
death	O
by	O
a	O
novel	O
small	O
heat	O
shock	O
protein	O
.	O
<EOS>	B-X
BIRC5/Survivin	B-X
is	B-X
known	B-X
as	B-X
a	B-X
dual	B-X
cellular	B-X
functions	B-X
protein	B-X
that	B-X
directly	B-X
regulates	B-X
both	B-X
apoptosis	B-X
and	B-X
mitosis	B-X
in	B-X
embryonic	B-X
cells	B-X
during	B-X
embryogenesis	B-X
and	B-X
in	B-X
cancer	B-X
cells	B-X
during	B-X
tumorigenesis	B-X
and	B-X
tumor	B-X
metastasis	B-X
.	B-X
However	B-X
,	B-X
BIRC5	B-X
has	B-X
seldom	B-X
been	B-X
demonstrated	B-X
as	B-X
a	B-X
direct	B-X
macroautophagy/autophagy	B-X
regulator	B-X
in	B-X
cells	B-X
.	B-X
ATG7	B-X
expression	B-X
and	B-X
ATG12-ATG5-ATG16L1	B-X
complex	B-X
formation	B-X
are	B-X
crucial	B-X
for	B-X
the	B-X
phagophore	B-X
elongation	B-X
during	B-X
autophagy	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
observed	B-X
that	B-X
the	B-X
protein	B-X
expression	B-X
levels	B-X
of	B-X
BIRC5	B-X
and	B-X
ATG7	B-X
were	B-X
inversely	B-X
correlated	B-X
,	B-X
whereas	B-X
the	B-X
expression	B-X
levels	B-X
of	B-X
BIRC5	B-X
and	B-X
SQSTM1/p62	B-X
were	B-X
positively	B-X
correlated	B-X
in	B-X
normal	B-X
breast	B-X
tissues	B-X
and	B-X
tumor	B-X
tissues	B-X
.	B-X
Mechanistically	B-X
,	B-X
we	B-X
found	B-X
that	B-X
BIRC5	B-X
negatively	B-X
modulates	B-X
the	B-X
protein	B-X
stability	B-X
of	B-X
ATG7	B-X
and	B-X
physically	B-X
binds	B-X
to	B-X
the	B-X
ATG12-ATG5	B-X
conjugate	B-X
,	B-X
preventing	B-X
the	B-X
formation	B-X
of	B-X
the	B-X
ATG12-ATG5-ATG16L1	B-X
protein	B-X
complex	B-X
in	B-X
human	B-X
cancer	B-X
(	B-X
MDA-MB-231	B-X
,	B-X
MCF7	B-X
,	B-X
and	B-X
A549	B-X
)	B-X
and	B-X
mouse	B-X
embryonic	B-X
fibroblast	B-X
(	B-X
MEF	B-X
)	B-X
cells	B-X
.	B-X
We	B-X
also	B-X
observed	B-X
a	B-X
concurrent	B-X
physical	B-X
dissociation	B-X
between	B-X
BIRC5	B-X
and	B-X
ATG12-ATG5	B-X
(	B-X
but	B-X
not	B-X
CASP3/caspase-3	B-X
)	B-X
and	B-X
upregulation	B-X
of	B-X
autophagy	B-X
in	B-X
MDA-MB-231	B-X
and	B-X
A549	B-X
cells	B-X
under	B-X
serum-deprived	B-X
conditions	B-X
.	B-X
Importantly	B-X
,	B-X
despite	B-X
the	B-X
fact	B-X
that	B-X
upregulation	B-X
of	B-X
autophagy	B-X
is	B-X
widely	B-X
thought	B-X
to	B-X
promote	B-X
DNA	B-X
repair	B-X
in	B-X
cells	B-X
under	B-X
genotoxic	B-X
stress	B-X
,	B-X
we	B-X
found	B-X
that	B-X
BIRC5	B-X
maintains	B-X
DNA	B-X
integrity	B-X
through	B-X
autophagy	B-X
negative-modulations	B-X
in	B-X
both	B-X
human	B-X
cancer	B-X
and	B-X
MEF	B-X
cells	B-X
under	B-X
non-stressed	B-X
conditions	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
study	B-X
reveals	B-X
a	B-X
novel	B-X
role	B-X
of	B-X
BIRC5	B-X
in	B-X
cancer	B-X
cells	B-X
as	B-X
a	B-X
direct	B-X
regulator	B-X
of	B-X
autophagy	B-X
.	B-X
BIRC5	B-X
may	B-X
act	B-X
as	B-X
a	B-X
``	B-X
bridging	B-X
molecule	B-X
''	B-X
,	B-X
which	B-X
regulates	B-X
the	B-X
interplay	B-X
between	B-X
mitosis	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
autophagy	B-X
in	B-X
embryonic	B-X
and	B-X
cancer	B-X
cells	B-X
.	B-X

NCBI	O
database	O
analysis	O
indicated	O
that	O
the	O
human	O
C1orf41	B-Protein
protein	O
(	O
small	O
heat	O
shock	O
-	O
like	O
protein	O
-	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
)	O
has	O
sequence	O
similarity	O
with	O
small	O
heat	O
shock	O
proteins	O
(	O
sHsps	O
)	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Since	O
sHsps	O
have	O
chaperone	O
function	O
,	O
and	O
so	O
prevent	O
aggregation	O
of	O
denatured	O
proteins	O
,	O
we	O
determined	O
whether	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
could	O
prevent	O
the	O
heat	O
-	O
induced	O
aggregation	O
of	O
denatured	O
proteins	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Under	O
our	O
experimental	O
conditions	O
,	O
recombinant	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
prevented	O
aggregation	O
of	O
aldolase	O
and	O
glyceraldehyde	B-Protein
-	I-Protein
3	I-Protein
-	I-Protein
phosphate	I-Protein
dehydrogenase	I-Protein
,	O
and	O
protected	O
Escherichia	O
coli	O
cells	O
from	O
heat	O
stress	O
indicating	O
its	O
chaperone	O
function	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Hsp16	B-Protein
.	I-Protein
2	I-Protein
also	O
formed	O
oligomeric	O
complexes	O
in	O
aqueous	O
solution	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Hsp16	B-Protein
.	I-Protein
2	I-Protein
was	O
found	O
to	O
be	O
expressed	O
at	O
different	O
levels	O
in	O
cell	O
lines	O
and	O
tissues	O
,	O
and	O
was	O
mainly	O
localized	O
to	O
the	O
nucleus	O
and	O
the	O
cytosol	O
,	O
but	O
to	O
a	O
smaller	O
extent	O
,	O
it	O
could	O
be	O
also	O
found	O
in	O
mitochondria	O
.	O

Hsp16	B-Protein
.	I-Protein
2	I-Protein
could	O
be	O
modified	O
covalently	O
by	O
poly	O
(	O
ADP	O
ribosylation	O
)	O
and	O
acetylation	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Hsp16	B-Protein
.	I-Protein
2	I-Protein
over	O
-	O
expression	O
prevented	O
etoposide	O
-	O
induced	O
cell	O
death	O
as	O
well	O
as	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	B-Protein
c	I-Protein
and	O
caspase	O
activation	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

These	O
data	O
suggest	O
that	O
Hsp16	B-Protein
.	I-Protein
2	I-Protein
can	O
prevent	O
the	O
destabilization	O
of	O
mitochondrial	O
membrane	O
systems	O
and	O
could	O
represent	O
a	O
suitable	O
target	O
for	O
modulating	O
cell	O
death	O
pathways	O
.	O
<EOS>	B-X
NCBI	B-X
database	B-X
analysis	B-X
indicated	B-X
that	B-X
the	B-X
human	B-X
C1orf41	B-X
protein	B-X
(	B-X
small	B-X
heat	B-X
shock-like	B-X
protein-Hsp16.2	B-X
)	B-X
has	B-X
sequence	B-X
similarity	B-X
with	B-X
small	B-X
heat	B-X
shock	B-X
proteins	B-X
(	B-X
sHsps	B-X
)	B-X
.	B-X
Since	B-X
sHsps	B-X
have	B-X
chaperone	B-X
function	B-X
,	B-X
and	B-X
so	B-X
prevent	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
,	B-X
we	B-X
determined	B-X
whether	B-X
Hsp16.2	B-X
could	B-X
prevent	B-X
the	B-X
heat-induced	B-X
aggregation	B-X
of	B-X
denatured	B-X
proteins	B-X
.	B-X
Under	B-X
our	B-X
experimental	B-X
conditions	B-X
,	B-X
recombinant	B-X
Hsp16.2	B-X
prevented	B-X
aggregation	B-X
of	B-X
aldolase	B-X
and	B-X
glyceraldehyde-3-phosphate	B-X
dehydrogenase	B-X
,	B-X
and	B-X
protected	B-X
Escherichia	B-X
coli	B-X
cells	B-X
from	B-X
heat	B-X
stress	B-X
indicating	B-X
its	B-X
chaperone	B-X
function	B-X
.	B-X
Hsp16.2	B-X
also	B-X
formed	B-X
oligomeric	B-X
complexes	B-X
in	B-X
aqueous	B-X
solution	B-X
.	B-X
Hsp16.2	B-X
was	B-X
found	B-X
to	B-X
be	B-X
expressed	B-X
at	B-X
different	B-X
levels	B-X
in	B-X
cell	B-X
lines	B-X
and	B-X
tissues	B-X
,	B-X
and	B-X
was	B-X
mainly	B-X
localized	B-X
to	B-X
the	B-X
nucleus	B-X
and	B-X
the	B-X
cytosol	B-X
,	B-X
but	B-X
to	B-X
a	B-X
smaller	B-X
extent	B-X
,	B-X
it	B-X
could	B-X
be	B-X
also	B-X
found	B-X
in	B-X
mitochondria	B-X
.	B-X
Hsp16.2	B-X
could	B-X
be	B-X
modified	B-X
covalently	B-X
by	B-X
poly	B-X
(	B-X
ADP	B-X
ribosylation	B-X
)	B-X
and	B-X
acetylation	B-X
.	B-X
Hsp16.2	B-X
over-expression	B-X
prevented	B-X
etoposide-induced	B-X
cell	B-X
death	B-X
as	B-X
well	B-X
as	B-X
the	B-X
release	B-X
of	B-X
mitochondrial	B-X
cytochrome	B-X
c	B-X
and	B-X
caspase	B-X
activation	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
Hsp16.2	B-X
can	B-X
prevent	B-X
the	B-X
destabilization	B-X
of	B-X
mitochondrial	B-X
membrane	B-X
systems	B-X
and	B-X
could	B-X
represent	B-X
a	B-X
suitable	B-X
target	B-X
for	B-X
modulating	B-X
cell	B-X
death	B-X
pathways	B-X
.	B-X

Coupling	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthesis	O
and	O
lipoylation	O
pathways	O
in	O
mammalian	O
mitochondria	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
products	O
and	O
possible	O
role	O
of	O
a	O
putative	O
pathway	O
for	O
de	O
novo	O
fatty	O
acid	O
synthesis	O
in	O
mammalian	O
mitochondria	O
.	O

Bovine	O
heart	O
mitochondrial	O
matrix	O
preparations	O
were	O
prepared	O
free	O
from	O
contamination	O
by	O
proteins	O
from	O
other	O
subcellular	O
components	O
and	O
,	O
using	O
a	O
combination	O
of	O
radioisotopic	O
labeling	O
and	O
mass	O
spectrometry	O
,	O
were	O
shown	O
to	O
contain	O
all	O
of	O
the	O
enzymes	O
required	O
for	O
the	O
extension	O
of	O
a	O
2	O
-	O
carbon	O
precursor	O
by	O
malonyl	O
moieties	O
to	O
saturated	O
acyl	O
-	O
ACP	B-Protein
thioesters	O
containing	O
up	O
to	O
14	O
carbon	O
atoms	O
.	O
<EOS>	B-X
Bovine	B-X
heart	B-X
mitochondrial	B-X
matrix	B-X
preparations	B-X
were	B-X
prepared	B-X
free	B-X
from	B-X
contamination	B-X
by	B-X
proteins	B-X
from	B-X
other	B-X
subcellular	B-X
components	B-X
and	B-X
,	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
radioisotopic	B-X
labeling	B-X
and	B-X
mass	B-X
spectrometry	B-X
,	B-X
were	B-X
shown	B-X
to	B-X
contain	B-X
all	B-X
of	B-X
the	B-X
enzymes	B-X
required	B-X
for	B-X
the	B-X
extension	B-X
of	B-X
a	B-X
2-carbon	B-X
precursor	B-X
by	B-X
malonyl	B-X
moieties	B-X
to	B-X
saturated	B-X
acyl-ACP	B-X
thioesters	B-X
containing	B-X
up	B-X
to	B-X
14	B-X
carbon	B-X
atoms	B-X
.	B-X
A	B-X
major	B-X
product	B-X
was	B-X
octanoyl-ACP	B-X
and	B-X
,	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
apo-H-protein	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
complex	B-X
,	B-X
the	B-X
newly	B-X
synthesized	B-X
octanoyl	B-X
moieties	B-X
were	B-X
translocated	B-X
to	B-X
the	B-X
lipoylation	B-X
site	B-X
on	B-X
the	B-X
acceptor	B-X
protein	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
one	B-X
of	B-X
the	B-X
functions	B-X
of	B-X
the	B-X
de	B-X
novo	B-X
fatty	B-X
acid	B-X
biosynthetic	B-X
pathway	B-X
in	B-X
mammalian	B-X
mitochondria	B-X
is	B-X
to	B-X
provide	B-X
the	B-X
octanoyl	B-X
precursor	B-X
required	B-X
for	B-X
the	B-X
essential	B-X
protein	B-X
lipoylation	B-X
pathway	B-X
.	B-X

A	O
major	O
product	O
was	O
octanoyl	O
-	O
ACP	B-Protein
and	O
,	O
in	O
the	O
presence	O
of	O
the	O
apo	O
-	O
H	B-Protein
-	I-Protein
protein	I-Protein
of	O
the	O
glycine	O
cleavage	O
complex	O
,	O
the	O
newly	O
synthesized	O
octanoyl	O
moieties	O
were	O
translocated	O
to	O
the	O
lipoylation	O
site	O
on	O
the	O
acceptor	O
protein	O
.	O

These	O
studies	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
the	O
de	O
novo	O
fatty	O
acid	O
biosynthetic	O
pathway	O
in	O
mammalian	O
mitochondria	O
is	O
to	O
provide	O
the	O
octanoyl	O
precursor	O
required	O
for	O
the	O
essential	O
protein	O
lipoylation	O
pathway	O
.	O

Depletion	O
of	O
GGA3	B-Protein
stabilizes	O
BACE	B-Protein
and	O
enhances	O
beta	O
-	O
secretase	O
activity	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

Beta	B-Protein
-	I-Protein
site	I-Protein
APP	I-Protein
-	I-Protein
cleaving	I-Protein
enzyme	I-Protein
(	O
BACE	B-Protein
)	O
is	O
required	O
for	O
production	O
of	O
the	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
-	O
associated	O
Abeta	B-Protein
protein	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

BACE	B-Protein
levels	O
are	O
elevated	O
in	O
AD	O
brain	O
,	O
and	O
increasing	O
evidence	O
reveals	O
BACE	B-Protein
as	O
a	O
stress	O
-	O
related	O
protease	O
that	O
is	O
upregulated	O
following	O
cerebral	O
ischemia	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

However	O
,	O
the	O
molecular	O
mechanism	O
responsible	O
is	O
unknown	O
.	O
<EOS>	B-X
However	B-X
,	B-X
epithelial	B-X
cells	B-X
are	B-X
also	B-X
responsible	B-X
for	B-X
the	B-X
absorption	B-X
of	B-X
nutrients	B-X
and	B-X
electrolytes	B-X
,	B-X
hence	B-X
a	B-X
semipermeable	B-X
barrier	B-X
is	B-X
required	B-X
that	B-X
selectively	B-X
allows	B-X
a	B-X
number	B-X
of	B-X
substances	B-X
in	B-X
while	B-X
keeping	B-X
others	B-X
out	B-X
.	B-X
Disturbances	B-X
in	B-X
the	B-X
mechanisms	B-X
of	B-X
the	B-X
barrier	B-X
function	B-X
favor	B-X
the	B-X
development	B-X
of	B-X
exaggerated	B-X
immune	B-X
responses	B-X
;	B-X
while	B-X
exact	B-X
implications	B-X
remain	B-X
unknown	B-X
,	B-X
changes	B-X
in	B-X
intestinal	B-X
barrier	B-X
function	B-X
have	B-X
been	B-X
associated	B-X
with	B-X
the	B-X
development	B-X
of	B-X
inflammatory	B-X
conditions	B-X
in	B-X
the	B-X
gastrointestinal	B-X
tract	B-X
.	B-X
This	B-X
review	B-X
details	B-X
de	B-X
various	B-X
elements	B-X
of	B-X
the	B-X
intestinal	B-X
barrier	B-X
function	B-X
,	B-X
and	B-X
the	B-X
key	B-X
molecular	B-X
and	B-X
cellular	B-X
changes	B-X
described	B-X
for	B-X
gastrointestinal	B-X
diseases	B-X
associated	B-X
with	B-X
dysfunction	B-X
in	B-X
this	B-X
defensive	B-X
mechanism	B-X
.	B-X
Though	B-X
diffusion	B-X
in	B-X
protonated	B-X
form	B-X
is	B-X
a	B-X
significant	B-X
route	B-X
,	B-X
carrier-mediated	B-X
mechanisms	B-X
constitute	B-X
the	B-X
major	B-X
route	B-X
for	B-X
the	B-X
entry	B-X
of	B-X
SCFA	B-X
in	B-X
their	B-X
anionic	B-X
form	B-X
into	B-X
colonic	B-X
epithelium	B-X
.	B-X
An	B-X
anion-exchange	B-X
mechanism	B-X
also	B-X
operates	B-X
in	B-X
the	B-X
apical	B-X
membrane	B-X
in	B-X
which	B-X
SCFA	B-X
entry	B-X
in	B-X
anionic	B-X
form	B-X
is	B-X
coupled	B-X
to	B-X
bicarbonate	B-X
efflux	B-X
;	B-X
the	B-X
molecular	B-X
identity	B-X
of	B-X
this	B-X
exchanger	B-X
however	B-X
remains	B-X
unknown	B-X
.	B-X
As	B-X
SCFA	B-X
are	B-X
obligatory	B-X
for	B-X
optimal	B-X
colonic	B-X
health	B-X
,	B-X
the	B-X
transporters	B-X
responsible	B-X
for	B-X
the	B-X
entry	B-X
and	B-X
transcellular	B-X
transfer	B-X
of	B-X
these	B-X
bacterial	B-X
products	B-X
in	B-X
colonic	B-X
epithelium	B-X
are	B-X
critical	B-X
determinants	B-X
of	B-X
colonic	B-X
function	B-X
under	B-X
physiological	B-X
conditions	B-X
and	B-X
in	B-X
disease	B-X
states	B-X
.	B-X

We	O
show	O
that	O
increases	O
in	O
BACE	B-Protein
and	O
beta	O
-	O
secretase	O
activity	O
are	O
due	O
to	O
posttranslational	O
stabilization	O
following	O
caspase	O
activation	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

We	O
also	O
found	O
that	O
during	O
cerebral	O
ischemia	O
,	O
levels	O
of	O
GGA3	B-Protein
,	O
an	O
adaptor	O
protein	O
involved	O
in	O
BACE	B-Protein
trafficking	O
,	O
are	O
reduced	O
,	O
while	O
BACE	B-Protein
levels	O
are	O
increased	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

RNAi	O
silencing	O
of	O
GGA3	B-Protein
also	O
elevated	O
levels	O
of	O
BACE	B-Protein
and	O
Abeta	B-Protein
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

Finally	O
,	O
in	O
AD	O
brain	O
samples	O
,	O
GGA3	B-Protein
protein	O
levels	O
were	O
significantly	O
decreased	O
and	O
inversely	O
correlated	O
with	O
increased	O
levels	O
of	O
BACE	B-Protein
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

In	O
summary	O
,	O
we	O
have	O
elucidated	O
a	O
GGA3	B-Protein
-	O
dependent	O
mechanism	O
regulating	O
BACE	B-Protein
levels	O
and	O
beta	O
-	O
secretase	O
activity	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
responsible	B-X
is	B-X
unknown	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

This	O
mechanism	O
may	O
explain	O
increased	O
cerebral	O
levels	O
of	O
BACE	B-Protein
and	O
Abeta	B-Protein
following	O
cerebral	O
ischemia	O
and	O
existing	O
in	O
AD	O
.	O
<EOS>	B-X
Beta-site	B-X
APP-cleaving	B-X
enzyme	B-X
(	B-X
BACE	B-X
)	B-X
is	B-X
required	B-X
for	B-X
production	B-X
of	B-X
the	B-X
Alzheimer	B-X
's	B-X
disease	B-X
(	B-X
AD	B-X
)	B-X
-associated	B-X
Abeta	B-X
protein	B-X
.	B-X
BACE	B-X
levels	B-X
are	B-X
elevated	B-X
in	B-X
AD	B-X
brain	B-X
,	B-X
and	B-X
increasing	B-X
evidence	B-X
reveals	B-X
BACE	B-X
as	B-X
a	B-X
stress-related	B-X
protease	B-X
that	B-X
is	B-X
upregulated	B-X
following	B-X
cerebral	B-X
ischemia	B-X
.	B-X
However	B-X
,	B-X
the	B-X
molecular	B-X
mechanism	B-X
responsible	B-X
is	B-X
unknown	B-X
.	B-X
We	B-X
show	B-X
that	B-X
increases	B-X
in	B-X
BACE	B-X
and	B-X
beta-secretase	B-X
activity	B-X
are	B-X
due	B-X
to	B-X
posttranslational	B-X
stabilization	B-X
following	B-X
caspase	B-X
activation	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
during	B-X
cerebral	B-X
ischemia	B-X
,	B-X
levels	B-X
of	B-X
GGA3	B-X
,	B-X
an	B-X
adaptor	B-X
protein	B-X
involved	B-X
in	B-X
BACE	B-X
trafficking	B-X
,	B-X
are	B-X
reduced	B-X
,	B-X
while	B-X
BACE	B-X
levels	B-X
are	B-X
increased	B-X
.	B-X
RNAi	B-X
silencing	B-X
of	B-X
GGA3	B-X
also	B-X
elevated	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
.	B-X
Finally	B-X
,	B-X
in	B-X
AD	B-X
brain	B-X
samples	B-X
,	B-X
GGA3	B-X
protein	B-X
levels	B-X
were	B-X
significantly	B-X
decreased	B-X
and	B-X
inversely	B-X
correlated	B-X
with	B-X
increased	B-X
levels	B-X
of	B-X
BACE	B-X
.	B-X
In	B-X
summary	B-X
,	B-X
we	B-X
have	B-X
elucidated	B-X
a	B-X
GGA3-dependent	B-X
mechanism	B-X
regulating	B-X
BACE	B-X
levels	B-X
and	B-X
beta-secretase	B-X
activity	B-X
.	B-X
This	B-X
mechanism	B-X
may	B-X
explain	B-X
increased	B-X
cerebral	B-X
levels	B-X
of	B-X
BACE	B-X
and	B-X
Abeta	B-X
following	B-X
cerebral	B-X
ischemia	B-X
and	B-X
existing	B-X
in	B-X
AD	B-X
.	B-X

Increased	O
acylated	O
plasma	O
ghrelin	B-Protein
,	O
but	O
improved	O
lipid	O
profiles	O
24	O
-	O
h	O
after	O
consumption	O
of	O
carob	O
pulp	O
preparation	O
rich	O
in	O
dietary	O
fibre	O
and	O
polyphenols	O
.	O

We	O
have	O
recently	O
shown	O
that	O
a	O
polyphenol	O
-	O
rich	O
insoluble	O
dietary	O
fibre	O
preparation	O
from	O
carob	O
pulp	O
(	O
Ceratonia	O
siliqua	O
L	O
;	O
carob	O
fibre	O
)	O
decreased	O
postprandial	O
acylated	O
ghrelin	B-Protein
,	O
TAG	O
and	O
NEFA	O
during	O
an	O
acute	O
liquid	O
meal	O
challenge	O
test	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
However	B-X
,	B-X
delayed	B-X
effects	B-X
of	B-X
carob	B-X
fibre	B-X
consumption	B-X
are	B-X
unknown	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
On	B-X
the	B-X
subsequent	B-X
day	B-X
(	B-X
day	B-X
2	B-X
)	B-X
,	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
as	B-X
well	B-X
as	B-X
insulin	B-X
,	B-X
NEFA	B-X
and	B-X
leptin	B-X
were	B-X
assessed	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
timed	B-X
intervals	B-X
for	B-X
300	B-X
min	B-X
after	B-X
ingestion	B-X
of	B-X
standardized	B-X
bread	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

However	O
,	O
delayed	O
effects	O
of	O
carob	O
fibre	O
consumption	O
are	O
unknown	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
However	B-X
,	B-X
delayed	B-X
effects	B-X
of	B-X
carob	B-X
fibre	B-X
consumption	B-X
are	B-X
unknown	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

Therefore	O
,	O
a	O
randomized	O
controlled	O
crossover	O
study	O
in	O
nineteen	O
healthy	O
volunteers	O
consuming	O
foods	O
with	O
or	O
without	O
50	O
g	O
carob	O
fibre	O
was	O
conducted	O
.	O
<EOS>	B-X
Inositol-stabilized	B-X
arginine	B-X
silicate	B-X
(	B-X
ASI	B-X
)	B-X
is	B-X
an	B-X
ergogenic	B-X
aid	B-X
that	B-X
upregulates	B-X
nitric	B-X
oxide	B-X
.	B-X
Acute	B-X
ASI	B-X
supplementation	B-X
improves	B-X
working	B-X
memory	B-X
and	B-X
processing	B-X
speed	B-X
in	B-X
young	B-X
adults	B-X
but	B-X
there	B-X
is	B-X
a	B-X
lack	B-X
of	B-X
data	B-X
examining	B-X
other	B-X
cognitive	B-X
tasks	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
purpose	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
acute	B-X
ASI	B-X
effects	B-X
on	B-X
young	B-X
healthy	B-X
adults	B-X
by	B-X
assessing	B-X
multiple	B-X
cognitive	B-X
domains	B-X
.	B-X
Nineteen	B-X
young	B-X
adults	B-X
(	B-X
20.9	B-X
±	B-X
3.2	B-X
years	B-X
)	B-X
completed	B-X
this	B-X
randomized	B-X
,	B-X
double-blind	B-X
,	B-X
crossover	B-X
study	B-X
consuming	B-X
ASI	B-X
(	B-X
1.5	B-X
g	B-X
ASI	B-X
+	B-X
12	B-X
g	B-X
dextrose	B-X
)	B-X
and	B-X
placebo	B-X
(	B-X
12	B-X
g	B-X
dextrose	B-X
)	B-X
.	B-X
The	B-X
participants	B-X
completed	B-X
the	B-X
Repeatable	B-X
Battery	B-X
for	B-X
the	B-X
Assessment	B-X
of	B-X
Neuropsychological	B-X
Status	B-X
(	B-X
RBANS	B-X
)	B-X
and	B-X
two	B-X
digital	B-X
cognitive	B-X
assessments	B-X
before	B-X
consuming	B-X
the	B-X
supplement	B-X
and	B-X
then	B-X
completed	B-X
the	B-X
same	B-X
battery	B-X
of	B-X
tests	B-X
60	B-X
min	B-X
post-supplementation	B-X
.	B-X
Repeated	B-X
measures	B-X
ANOVA	B-X
demonstrated	B-X
that	B-X
ASI	B-X
consumption	B-X
significantly	B-X
improved	B-X
total	B-X
RBANS	B-X
and	B-X
immediate	B-X
memory	B-X
scores	B-X
compared	B-X
to	B-X
the	B-X
placebo	B-X
(	B-X

On	O
the	O
subsequent	O
day	O
(	O
day	O
2	O
)	O
,	O
glucose	O
,	O
TAG	O
,	O
total	O
and	O
acylated	O
ghrelin	B-Protein
as	O
well	O
as	O
insulin	B-Protein
,	O
NEFA	O
and	O
leptin	B-Protein
were	O
assessed	O
at	O
baseline	O
and	O
at	O
timed	O
intervals	O
for	O
300	O
min	O
after	O
ingestion	O
of	O
standardized	O
bread	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
On	B-X
the	B-X
subsequent	B-X
day	B-X
(	B-X
day	B-X
2	B-X
)	B-X
,	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
as	B-X
well	B-X
as	B-X
insulin	B-X
,	B-X
NEFA	B-X
and	B-X
leptin	B-X
were	B-X
assessed	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
timed	B-X
intervals	B-X
for	B-X
300	B-X
min	B-X
after	B-X
ingestion	B-X
of	B-X
standardized	B-X
bread	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

Consumption	O
of	O
carob	O
fibre	O
-	O
enriched	O
foods	O
did	O
not	O
affect	O
fasting	O
concentrations	O
of	O
glucose	O
,	O
TAG	O
,	O
total	O
ghrelin	B-Protein
,	O
NEFA	O
,	O
insulin	B-Protein
and	O
leptin	B-Protein
.	O
<EOS>	B-X
Recently	B-X
,	B-X
insoluble	B-X
fibre	B-X
from	B-X
carob	B-X
pulp	B-X
has	B-X
been	B-X
found	B-X
to	B-X
affect	B-X
blood	B-X
lipids	B-X
in	B-X
animals	B-X
in	B-X
a	B-X
similar	B-X
manner	B-X
as	B-X
soluble	B-X
dietary	B-X
fibre	B-X
.	B-X
The	B-X
design	B-X
of	B-X
functional	B-X
foods	B-X
enriched	B-X
in	B-X
nutrients	B-X
that	B-X
favorably	B-X
alter	B-X
the	B-X
lipid	B-X
profile	B-X
to	B-X
prevent	B-X
cardiovascular	B-X
diseases	B-X
and	B-X
stimulate	B-X
bowel	B-X
function	B-X
is	B-X
of	B-X
great	B-X
interest	B-X
.	B-X
We	B-X
have	B-X
assayed	B-X
a	B-X
non-extractable-tannates-rich	B-X
carob-fiber	B-X
(	B-X
PF-1®	B-X
)	B-X
in	B-X
a	B-X
milk	B-X
matrix	B-X
developed	B-X
by	B-X
Biosearch	B-X
S.A.	B-X
to	B-X
discover	B-X
its	B-X
effects	B-X
on	B-X
the	B-X
lipid	B-X
profile	B-X
and	B-X
bowel	B-X
function	B-X
of	B-X
human	B-X
volunteers	B-X
.	B-X
A	B-X
4-week	B-X
interventional	B-X
study	B-X
(	B-X
400	B-X
mL	B-X
daily	B-X
consumption	B-X
of	B-X
this	B-X
functional	B-X
food	B-X
,	B-X
containing	B-X
20	B-X
g	B-X
of	B-X
PF-1®/L	B-X
)	B-X
,	B-X
was	B-X
conducted	B-X
:	B-X
blood	B-X
samples	B-X
were	B-X
analyzed	B-X
for	B-X
lipid	B-X
profile	B-X
,	B-X
glucose	B-X
,	B-X
transaminases	B-X
,	B-X
creatinine	B-X
and	B-X
fat-soluble	B-X
vitamins	B-X
.	B-X
Another	B-X
tendency	B-X
to	B-X
total	B-X
cholesterol	B-X
levels	B-X
fell	B-X
in	B-X
the	B-X
hypercholesterolemic	B-X
group	B-X
(	B-X
P	B-X
=	B-X
0.061	B-X
)	B-X
was	B-X
also	B-X
found	B-X
.	B-X
In	B-X
the	B-X
normal-cholesterol	B-X
group	B-X
,	B-X
total	B-X
cholesterol	B-X
(	B-X
CT	B-X
)	B-X
,	B-X
HDL-cholesterol	B-X
and	B-X
LDL-cholesterol	B-X
levels	B-X
significantly	B-X
increased	B-X
with	B-X
the	B-X
consumption	B-X
of	B-X
the	B-X
functional	B-X
food	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X

Fasting	O
acylated	O
ghrelin	B-Protein
was	O
increased	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
compared	O
with	O
control	O
(	O
P	O
=	O
0	O
.	O
046	O
)	O
.	O

After	O
consumption	O
of	O
the	O
standard	O
bread	O
on	O
day	O
2	O
,	O
glucose	O
response	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
was	O
increased	O
,	O
and	O
TAG	O
(	O
P	O
=	O
0	O
.	O
033	O
)	O
and	O
NEFA	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
responses	O
were	O
decreased	O
compared	O
with	O
control	O
.	O

Postprandial	O
responses	O
of	O
total	O
and	O
acylated	O
ghrelin	B-Protein
,	O
insulin	B-Protein
and	O
leptin	B-Protein
on	O
day	O
2	O
were	O
unaffected	O
by	O
carob	O
fibre	O
consumption	O
the	O
previous	O
day	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
However	B-X
,	B-X
delayed	B-X
effects	B-X
of	B-X
carob	B-X
fibre	B-X
consumption	B-X
are	B-X
unknown	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
On	B-X
the	B-X
subsequent	B-X
day	B-X
(	B-X
day	B-X
2	B-X
)	B-X
,	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
as	B-X
well	B-X
as	B-X
insulin	B-X
,	B-X
NEFA	B-X
and	B-X
leptin	B-X
were	B-X
assessed	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
timed	B-X
intervals	B-X
for	B-X
300	B-X
min	B-X
after	B-X
ingestion	B-X
of	B-X
standardized	B-X
bread	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

In	O
conclusion	O
,	O
an	O
increase	O
in	O
total	O
and	O
acylated	O
plasma	O
ghrelin	B-Protein
accompanied	O
by	O
enhanced	O
lipid	O
metabolism	O
after	O
carob	O
fibre	O
consumption	O
suggests	O
higher	O
lipid	O
utilization	O
and	O
suppressed	O
lipolysis	O
on	O
the	O
day	O
subsequent	O
to	O
carob	O
fibre	O
consumption	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
However	B-X
,	B-X
delayed	B-X
effects	B-X
of	B-X
carob	B-X
fibre	B-X
consumption	B-X
are	B-X
unknown	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
On	B-X
the	B-X
subsequent	B-X
day	B-X
(	B-X
day	B-X
2	B-X
)	B-X
,	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
as	B-X
well	B-X
as	B-X
insulin	B-X
,	B-X
NEFA	B-X
and	B-X
leptin	B-X
were	B-X
assessed	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
timed	B-X
intervals	B-X
for	B-X
300	B-X
min	B-X
after	B-X
ingestion	B-X
of	B-X
standardized	B-X
bread	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

However	O
,	O
elevated	O
glucose	O
levels	O
after	O
carob	O
fibre	O
consumption	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O
<EOS>	B-X
We	B-X
have	B-X
recently	B-X
shown	B-X
that	B-X
a	B-X
polyphenol-rich	B-X
insoluble	B-X
dietary	B-X
fibre	B-X
preparation	B-X
from	B-X
carob	B-X
pulp	B-X
(	B-X
Ceratonia	B-X
siliqua	B-X
L	B-X
;	B-X
carob	B-X
fibre	B-X
)	B-X
decreased	B-X
postprandial	B-X
acylated	B-X
ghrelin	B-X
,	B-X
TAG	B-X
and	B-X
NEFA	B-X
during	B-X
an	B-X
acute	B-X
liquid	B-X
meal	B-X
challenge	B-X
test	B-X
.	B-X
However	B-X
,	B-X
delayed	B-X
effects	B-X
of	B-X
carob	B-X
fibre	B-X
consumption	B-X
are	B-X
unknown	B-X
.	B-X
Therefore	B-X
,	B-X
a	B-X
randomized	B-X
controlled	B-X
crossover	B-X
study	B-X
in	B-X
nineteen	B-X
healthy	B-X
volunteers	B-X
consuming	B-X
foods	B-X
with	B-X
or	B-X
without	B-X
50	B-X
g	B-X
carob	B-X
fibre	B-X
was	B-X
conducted	B-X
.	B-X
On	B-X
the	B-X
subsequent	B-X
day	B-X
(	B-X
day	B-X
2	B-X
)	B-X
,	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
as	B-X
well	B-X
as	B-X
insulin	B-X
,	B-X
NEFA	B-X
and	B-X
leptin	B-X
were	B-X
assessed	B-X
at	B-X
baseline	B-X
and	B-X
at	B-X
timed	B-X
intervals	B-X
for	B-X
300	B-X
min	B-X
after	B-X
ingestion	B-X
of	B-X
standardized	B-X
bread	B-X
.	B-X
Consumption	B-X
of	B-X
carob	B-X
fibre-enriched	B-X
foods	B-X
did	B-X
not	B-X
affect	B-X
fasting	B-X
concentrations	B-X
of	B-X
glucose	B-X
,	B-X
TAG	B-X
,	B-X
total	B-X
ghrelin	B-X
,	B-X
NEFA	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
.	B-X
Fasting	B-X
acylated	B-X
ghrelin	B-X
was	B-X
increased	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
compared	B-X
with	B-X
control	B-X
(	B-X
P	B-X
=	B-X
0.046	B-X
)	B-X
.	B-X
After	B-X
consumption	B-X
of	B-X
the	B-X
standard	B-X
bread	B-X
on	B-X
day	B-X
2	B-X
,	B-X
glucose	B-X
response	B-X
(	B-X
P	B-X
=	B-X
0.029	B-X
)	B-X
was	B-X
increased	B-X
,	B-X
and	B-X
TAG	B-X
(	B-X
P	B-X
=	B-X
0.033	B-X
)	B-X
and	B-X
NEFA	B-X
(	B-X
P	B-X
<	B-X
0.001	B-X
)	B-X
responses	B-X
were	B-X
decreased	B-X
compared	B-X
with	B-X
control	B-X
.	B-X
Postprandial	B-X
responses	B-X
of	B-X
total	B-X
and	B-X
acylated	B-X
ghrelin	B-X
,	B-X
insulin	B-X
and	B-X
leptin	B-X
on	B-X
day	B-X
2	B-X
were	B-X
unaffected	B-X
by	B-X
carob	B-X
fibre	B-X
consumption	B-X
the	B-X
previous	B-X
day	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
an	B-X
increase	B-X
in	B-X
total	B-X
and	B-X
acylated	B-X
plasma	B-X
ghrelin	B-X
accompanied	B-X
by	B-X
enhanced	B-X
lipid	B-X
metabolism	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
suggests	B-X
higher	B-X
lipid	B-X
utilization	B-X
and	B-X
suppressed	B-X
lipolysis	B-X
on	B-X
the	B-X
day	B-X
subsequent	B-X
to	B-X
carob	B-X
fibre	B-X
consumption	B-X
.	B-X
However	B-X
,	B-X
elevated	B-X
glucose	B-X
levels	B-X
after	B-X
carob	B-X
fibre	B-X
consumption	B-X
need	B-X
to	B-X
be	B-X
addressed	B-X
in	B-X
future	B-X
studies	B-X
.	B-X

Evidence	O
for	O
two	O
protein	O
-	O
lipoylation	O
activities	O
in	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
Two	B-X
distinct	B-X
lipoate-protein	B-X
ligase	B-X
activities	B-X
,	B-X
LPL-A	B-X
and	B-X
LPL-B	B-X
,	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
E.	B-X
coli	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
modify	B-X
purified	B-X
lipoyl	B-X
apo-domains	B-X
of	B-X
the	B-X
bacterial	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
.	B-X
Post-translational	B-X
lipoylation	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
component	B-X
of	B-X
these	B-X
complexes	B-X
is	B-X
essential	B-X
for	B-X
their	B-X
activity	B-X
,	B-X
the	B-X
lipoyllysine	B-X
moiety	B-X
performing	B-X
the	B-X
transfer	B-X
of	B-X
substrates	B-X
and	B-X
intermediates	B-X
between	B-X
the	B-X
different	B-X
active	B-X
sites	B-X
within	B-X
these	B-X
multienzyme	B-X
systems	B-X
.	B-X
We	B-X
have	B-X
previously	B-X
shown	B-X
that	B-X
the	B-X
thermophilic	B-X
archaeon	B-X
,	B-X
Thermoplasma	B-X
acidophilum	B-X
,	B-X
has	B-X
a	B-X
four-gene	B-X
cluster	B-X
encoding	B-X
the	B-X
components	B-X
of	B-X
such	B-X
a	B-X
complex	B-X
,	B-X
which	B-X
,	B-X
when	B-X
recombinantly	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
,	B-X
can	B-X
be	B-X
assembled	B-X
into	B-X
an	B-X
active	B-X
multienzyme	B-X
in	B-X
vitro	B-X
.	B-X
Crucially	B-X
,	B-X
the	B-X
E.	B-X
coli	B-X
host	B-X
carries	B-X
out	B-X
the	B-X
required	B-X
lipoylation	B-X
of	B-X
the	B-X
archaeal	B-X
dihydrolipoyl	B-X
acyltransferase	B-X
component	B-X
.	B-X
Because	B-X
active	B-X
2-oxoacid	B-X
dehydrogenase	B-X
multienzyme	B-X
complexes	B-X
have	B-X
never	B-X
been	B-X
detected	B-X
in	B-X
any	B-X
archaeon	B-X
,	B-X
the	B-X
question	B-X
arises	B-X
as	B-X
to	B-X
whether	B-X
Archaea	B-X
possess	B-X
a	B-X
functional	B-X
lipoylation	B-X
system	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
heterologous	B-X
expression	B-X
of	B-X
two	B-X
genes	B-X
from	B-X
Tp	B-X
.	B-X
acidophilum	B-X
whose	B-X
protein	B-X
products	B-X
together	B-X
show	B-X
significant	B-X
sequence	B-X
identity	B-X
with	B-X
the	B-X
single	B-X
lipoate	B-X
protein	B-X
ligase	B-X
enzyme	B-X
of	B-X
bacteria	B-X
.	B-X
acidophilum	B-X
proteins	B-X
are	B-X
required	B-X
for	B-X
lipoylation	B-X
of	B-X
the	B-X
acyltransferase	B-X
,	B-X
and	B-X
that	B-X
the	B-X
two	B-X
proteins	B-X
associate	B-X
together	B-X
to	B-X
carry	B-X
out	B-X
this	B-X
post-translational	B-X
modification	B-X
.	B-X
From	B-X
the	B-X
published	B-X
DNA	B-X
sequences	B-X
,	B-X
we	B-X
suggest	B-X
the	B-X
presence	B-X
of	B-X
functional	B-X
transcriptional	B-X
and	B-X
translational	B-X
regulatory	B-X
elements	B-X
,	B-X
and	B-X
furthermore	B-X
we	B-X
present	B-X
preliminary	B-X
evidence	B-X
that	B-X
lipoylation	B-X
occurs	B-X
in	B-X
vivo	B-X
in	B-X
Tp	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
the	B-X
lipoylation	B-X
machinery	B-X
in	B-X
the	B-X
Archaea	B-X
,	B-X
which	B-X
is	B-X
unique	B-X
in	B-X
that	B-X
the	B-X
catalytic	B-X
activity	B-X
is	B-X
dependent	B-X
on	B-X
two	B-X
separate	B-X
gene	B-X
products	B-X
.	B-X

The	O
lipoate	O
acyltransferase	O
subunits	O
of	O
the	O
2	O
-	O
oxo	O
acid	O
dehydrogenase	O
complexes	O
are	O
post	O
-	O
translationally	O
modified	O
with	O
one	O
or	O
more	O
covalently	O
-	O
bound	O
lipoyl	O
cofactors	O
.	O
<EOS>	B-X
Although	B-X
the	B-X
structure	B-X
of	B-X
lipoic	B-X
acid	B-X
and	B-X
its	B-X
role	B-X
in	B-X
bacterial	B-X
metabolism	B-X
were	B-X
clear	B-X
over	B-X
50	B-X
years	B-X
ago	B-X
,	B-X
it	B-X
is	B-X
only	B-X
in	B-X
the	B-X
past	B-X
decade	B-X
that	B-X
the	B-X
pathways	B-X
of	B-X
biosynthesis	B-X
of	B-X
this	B-X
universally	B-X
conserved	B-X
cofactor	B-X
have	B-X
become	B-X
understood	B-X
.	B-X
Unlike	B-X
most	B-X
cofactors	B-X
,	B-X
lipoic	B-X
acid	B-X
must	B-X
be	B-X
covalently	B-X
bound	B-X
to	B-X
its	B-X
cognate	B-X
enzyme	B-X
proteins	B-X
(	B-X
the	B-X
2-oxoacid	B-X
dehydrogenases	B-X
and	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
)	B-X
in	B-X
order	B-X
to	B-X
function	B-X
in	B-X
central	B-X
metabolism	B-X
.	B-X
The	B-X
first	B-X
lipoate	B-X
biosynthetic	B-X
pathway	B-X
determined	B-X
was	B-X
that	B-X
of	B-X
Escherichia	B-X
coli	B-X
,	B-X
which	B-X
utilizes	B-X
two	B-X
enzymes	B-X
to	B-X
form	B-X
the	B-X
active	B-X
lipoylated	B-X
protein	B-X
from	B-X
a	B-X
fatty	B-X
acid	B-X
biosynthetic	B-X
intermediate	B-X
.	B-X
This	B-X
pathway	B-X
requires	B-X
the	B-X
H	B-X
protein	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
of	B-X
single-carbon	B-X
metabolism	B-X
to	B-X
form	B-X
active	B-X
(	B-X
lipoyl	B-X
)	B-X
2-oxoacid	B-X
dehydrogenases	B-X
.	B-X
The	B-X
bacterial	B-X
pathways	B-X
inform	B-X
the	B-X
lipoate	B-X
pathways	B-X
of	B-X
eukaryotic	B-X
organisms	B-X
.	B-X
The	B-X
lipoate	B-X
metabolism	B-X
enzymes	B-X
(	B-X
except	B-X
those	B-X
of	B-X
sulfur	B-X
insertion	B-X
)	B-X
are	B-X
members	B-X
of	B-X
PFAM	B-X
family	B-X
PF03099	B-X
(	B-X
the	B-X
cofactor	B-X
transferase	B-X
family	B-X
)	B-X
.	B-X
Although	B-X
these	B-X
enzymes	B-X
share	B-X
some	B-X
sequence	B-X
similarity	B-X
,	B-X
they	B-X
catalyze	B-X
three	B-X
markedly	B-X
distinct	B-X
enzyme	B-X
reactions	B-X
,	B-X
making	B-X
the	B-X
usual	B-X
assignment	B-X
of	B-X
function	B-X
based	B-X
on	B-X
alignments	B-X
prone	B-X
to	B-X
frequent	B-X
mistaken	B-X
annotations	B-X
.	B-X
This	B-X
state	B-X
of	B-X
affairs	B-X
has	B-X
possibly	B-X
clouded	B-X
the	B-X
interpretation	B-X
of	B-X
one	B-X
of	B-X
the	B-X
disorders	B-X
of	B-X
human	B-X
lipoate	B-X
metabolism	B-X
.	B-X

Two	O
distinct	O
lipoate	O
-	O
protein	O
ligase	O
activities	O
,	O
LPL	B-Protein
-	I-Protein
A	I-Protein
and	O
LPL	B-Protein
-	I-Protein
B	I-Protein
,	O
have	O
been	O
detected	O
in	O
E	O
.	O
coli	O
by	O
their	O
ability	O
to	O
modify	O
purified	O
lipoyl	O
apo	O
-	O
domains	O
of	O
the	O
bacterial	O
pyruvate	O
dehydrogenase	O
complex	O
.	O

Both	O
enzymes	O
require	O
ATP	O
and	O
Mg2	O
+	O
,	O
use	O
L	O
-	O
lipoate	O
,	O
8	O
-	O
methyllipoate	O
,	O
lipoyl	O
adenylate	O
and	O
octanoyl	O
adenylate	O
as	O
substrates	O
,	O
and	O
both	O
activate	O
lipoyl	O
-	O
deficient	O
pyruvate	O
dehydrogenase	O
complexes	O
.	O
<EOS>	B-X
The	B-X
lipoate	B-X
acyltransferase	B-X
subunits	B-X
of	B-X
the	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
complexes	B-X
are	B-X
post-translationally	B-X
modified	B-X
with	B-X
one	B-X
or	B-X
more	B-X
covalently-bound	B-X
lipoyl	B-X
cofactors	B-X
.	B-X
Two	B-X
distinct	B-X
lipoate-protein	B-X
ligase	B-X
activities	B-X
,	B-X
LPL-A	B-X
and	B-X
LPL-B	B-X
,	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
E.	B-X
coli	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
modify	B-X
purified	B-X
lipoyl	B-X
apo-domains	B-X
of	B-X
the	B-X
bacterial	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
.	B-X
Both	B-X
enzymes	B-X
require	B-X
ATP	B-X
and	B-X
Mg2+	B-X
,	B-X
use	B-X
L-lipoate	B-X
,	B-X
8-methyllipoate	B-X
,	B-X
lipoyl	B-X
adenylate	B-X
and	B-X
octanoyl	B-X
adenylate	B-X
as	B-X
substrates	B-X
,	B-X
and	B-X
both	B-X
activate	B-X
lipoyl-deficient	B-X
pyruvate	B-X
dehydrogenase	B-X
complexes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
only	B-X
LPL-B	B-X
uses	B-X
D-lipoate	B-X
and	B-X
octanoate	B-X
and	B-X
there	B-X
are	B-X
differences	B-X
in	B-X
the	B-X
metal-ion	B-X
and	B-X
phosphate	B-X
requirements	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
LPL-B	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
octanoylation	B-X
of	B-X
lipoyl	B-X
domains	B-X
observed	B-X
previously	B-X
under	B-X
lipoate-deficient	B-X
conditions	B-X
.	B-X

In	O
contrast	O
,	O
only	O
LPL	B-Protein
-	I-Protein
B	I-Protein
uses	O
D	O
-	O
lipoate	O
and	O
octanoate	O
and	O
there	O
are	O
differences	O
in	O
the	O
metal	O
-	O
ion	O
and	O
phosphate	O
requirements	O
.	O
<EOS>	B-X
The	B-X
lipoate	B-X
acyltransferase	B-X
subunits	B-X
of	B-X
the	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
complexes	B-X
are	B-X
post-translationally	B-X
modified	B-X
with	B-X
one	B-X
or	B-X
more	B-X
covalently-bound	B-X
lipoyl	B-X
cofactors	B-X
.	B-X
Two	B-X
distinct	B-X
lipoate-protein	B-X
ligase	B-X
activities	B-X
,	B-X
LPL-A	B-X
and	B-X
LPL-B	B-X
,	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
E.	B-X
coli	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
modify	B-X
purified	B-X
lipoyl	B-X
apo-domains	B-X
of	B-X
the	B-X
bacterial	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
.	B-X
Both	B-X
enzymes	B-X
require	B-X
ATP	B-X
and	B-X
Mg2+	B-X
,	B-X
use	B-X
L-lipoate	B-X
,	B-X
8-methyllipoate	B-X
,	B-X
lipoyl	B-X
adenylate	B-X
and	B-X
octanoyl	B-X
adenylate	B-X
as	B-X
substrates	B-X
,	B-X
and	B-X
both	B-X
activate	B-X
lipoyl-deficient	B-X
pyruvate	B-X
dehydrogenase	B-X
complexes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
only	B-X
LPL-B	B-X
uses	B-X
D-lipoate	B-X
and	B-X
octanoate	B-X
and	B-X
there	B-X
are	B-X
differences	B-X
in	B-X
the	B-X
metal-ion	B-X
and	B-X
phosphate	B-X
requirements	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
LPL-B	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
octanoylation	B-X
of	B-X
lipoyl	B-X
domains	B-X
observed	B-X
previously	B-X
under	B-X
lipoate-deficient	B-X
conditions	B-X
.	B-X

It	O
is	O
suggested	O
that	O
LPL	B-Protein
-	I-Protein
B	I-Protein
may	O
be	O
responsible	O
for	O
the	O
octanoylation	O
of	O
lipoyl	O
domains	O
observed	O
previously	O
under	O
lipoate	O
-	O
deficient	O
conditions	O
.	O
<EOS>	B-X
The	B-X
lipoate	B-X
acyltransferase	B-X
subunits	B-X
of	B-X
the	B-X
2-oxo	B-X
acid	B-X
dehydrogenase	B-X
complexes	B-X
are	B-X
post-translationally	B-X
modified	B-X
with	B-X
one	B-X
or	B-X
more	B-X
covalently-bound	B-X
lipoyl	B-X
cofactors	B-X
.	B-X
Two	B-X
distinct	B-X
lipoate-protein	B-X
ligase	B-X
activities	B-X
,	B-X
LPL-A	B-X
and	B-X
LPL-B	B-X
,	B-X
have	B-X
been	B-X
detected	B-X
in	B-X
E.	B-X
coli	B-X
by	B-X
their	B-X
ability	B-X
to	B-X
modify	B-X
purified	B-X
lipoyl	B-X
apo-domains	B-X
of	B-X
the	B-X
bacterial	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
.	B-X
Both	B-X
enzymes	B-X
require	B-X
ATP	B-X
and	B-X
Mg2+	B-X
,	B-X
use	B-X
L-lipoate	B-X
,	B-X
8-methyllipoate	B-X
,	B-X
lipoyl	B-X
adenylate	B-X
and	B-X
octanoyl	B-X
adenylate	B-X
as	B-X
substrates	B-X
,	B-X
and	B-X
both	B-X
activate	B-X
lipoyl-deficient	B-X
pyruvate	B-X
dehydrogenase	B-X
complexes	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
only	B-X
LPL-B	B-X
uses	B-X
D-lipoate	B-X
and	B-X
octanoate	B-X
and	B-X
there	B-X
are	B-X
differences	B-X
in	B-X
the	B-X
metal-ion	B-X
and	B-X
phosphate	B-X
requirements	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
LPL-B	B-X
may	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
octanoylation	B-X
of	B-X
lipoyl	B-X
domains	B-X
observed	B-X
previously	B-X
under	B-X
lipoate-deficient	B-X
conditions	B-X
.	B-X

Selectivity	O
in	O
ISG15	B-Protein
and	O
ubiquitin	B-Protein
recognition	O
by	O
the	O
SARS	O
coronavirus	O
papain	B-Protein
-	I-Protein
like	I-Protein
protease	I-Protein
.	O
<EOS>	B-X
The	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
papain-like	B-X
protease	B-X
(	B-X
SARS-CoV	B-X
PLpro	B-X
)	B-X
carries	B-X
out	B-X
N-terminal	B-X
processing	B-X
of	B-X
the	B-X
viral	B-X
replicase	B-X
polyprotein	B-X
,	B-X
and	B-X
also	B-X
exhibits	B-X
Lys48-linked	B-X
polyubiquitin	B-X
chain	B-X
debranching	B-X
and	B-X
ISG15	B-X
precursor	B-X
processing	B-X
activities	B-X
in	B-X
vitro	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
used	B-X
SDS-PAGE	B-X
and	B-X
fluorescence-based	B-X
assays	B-X
to	B-X
demonstrate	B-X
that	B-X
ISG15	B-X
derivatives	B-X
are	B-X
the	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
deubiquitinating	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
.	B-X
With	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
M	B-X
)	B-X
of	B-X
602,000	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
PLpro	B-X
hydrolyzes	B-X
ISG15-AMC	B-X
30-	B-X
and	B-X
60-fold	B-X
more	B-X
efficiently	B-X
than	B-X
Ub-AMC	B-X
and	B-X
Nedd8-AMC	B-X
,	B-X
respectively	B-X
.	B-X
Data	B-X
obtained	B-X
with	B-X
truncated	B-X
ISG15	B-X
and	B-X
hybrid	B-X
Ub/ISG15	B-X
substrates	B-X
indicate	B-X
that	B-X
both	B-X
the	B-X
N-	B-X
and	B-X
C-terminal	B-X
Ub-like	B-X
domains	B-X
of	B-X
ISG15	B-X
contribute	B-X
to	B-X
this	B-X
preference	B-X
.	B-X
The	B-X
enzyme	B-X
also	B-X
displays	B-X
a	B-X
preference	B-X
for	B-X
debranching	B-X
Lys48-	B-X
over	B-X
Lys63-linked	B-X
polyubiquitin	B-X
chains	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
SARS-CoV	B-X
PLpro	B-X
can	B-X
differentiate	B-X
between	B-X
ubiquitin-like	B-X
modifiers	B-X
sharing	B-X
a	B-X
common	B-X
C-terminal	B-X
sequence	B-X
,	B-X
and	B-X
that	B-X
the	B-X
debranching	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
is	B-X
linkage	B-X
type	B-X
selective	B-X
.	B-X
The	B-X
potential	B-X
structural	B-X
basis	B-X
for	B-X
the	B-X
demonstrated	B-X
specificity	B-X
of	B-X
SARS-CoV	B-X
PLpro	B-X
is	B-X
discussed	B-X
.	B-X

The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-Protein
-	I-Protein
like	I-Protein
protease	I-Protein
(	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
)	O
carries	O
out	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
viral	O
replicase	B-Protein
polyprotein	I-Protein
,	O
and	O
also	O
exhibits	O
Lys48	O
-	O
linked	O
polyubiquitin	B-Protein
chain	O
debranching	O
and	O
ISG15	B-Protein
precursor	O
processing	O
activities	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
used	O
SDS	O
-	O
PAGE	O
and	O
fluorescence	O
-	O
based	O
assays	O
to	O
demonstrate	O
that	O
ISG15	B-Protein
derivatives	O
are	O
the	O
preferred	O
substrates	O
for	O
the	O
deubiquitinating	O
activity	O
of	O
the	O
PLpro	B-Protein
.	O
<EOS>	B-X
The	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
papain-like	B-X
protease	B-X
(	B-X
SARS-CoV	B-X
PLpro	B-X
)	B-X
carries	B-X
out	B-X
N-terminal	B-X
processing	B-X
of	B-X
the	B-X
viral	B-X
replicase	B-X
polyprotein	B-X
,	B-X
and	B-X
also	B-X
exhibits	B-X
Lys48-linked	B-X
polyubiquitin	B-X
chain	B-X
debranching	B-X
and	B-X
ISG15	B-X
precursor	B-X
processing	B-X
activities	B-X
in	B-X
vitro	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
used	B-X
SDS-PAGE	B-X
and	B-X
fluorescence-based	B-X
assays	B-X
to	B-X
demonstrate	B-X
that	B-X
ISG15	B-X
derivatives	B-X
are	B-X
the	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
deubiquitinating	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
.	B-X
With	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
M	B-X
)	B-X
of	B-X
602,000	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
PLpro	B-X
hydrolyzes	B-X
ISG15-AMC	B-X
30-	B-X
and	B-X
60-fold	B-X
more	B-X
efficiently	B-X
than	B-X
Ub-AMC	B-X
and	B-X
Nedd8-AMC	B-X
,	B-X
respectively	B-X
.	B-X
Data	B-X
obtained	B-X
with	B-X
truncated	B-X
ISG15	B-X
and	B-X
hybrid	B-X
Ub/ISG15	B-X
substrates	B-X
indicate	B-X
that	B-X
both	B-X
the	B-X
N-	B-X
and	B-X
C-terminal	B-X
Ub-like	B-X
domains	B-X
of	B-X
ISG15	B-X
contribute	B-X
to	B-X
this	B-X
preference	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
SARS-CoV	B-X
PLpro	B-X
can	B-X
differentiate	B-X
between	B-X
ubiquitin-like	B-X
modifiers	B-X
sharing	B-X
a	B-X
common	B-X
C-terminal	B-X
sequence	B-X
,	B-X
and	B-X
that	B-X
the	B-X
debranching	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
is	B-X
linkage	B-X
type	B-X
selective	B-X
.	B-X
The	B-X
potential	B-X
structural	B-X
basis	B-X
for	B-X
the	B-X
demonstrated	B-X
specificity	B-X
of	B-X
SARS-CoV	B-X
PLpro	B-X
is	B-X
discussed	B-X
.	B-X

With	O
k	O
(	O
cat	O
)	O
/	O
K	O
(	O
M	O
)	O
of	O
602	O
,	O
000	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
,	O
PLpro	B-Protein
hydrolyzes	O
ISG15	B-Protein
-	O
AMC	O
30	O
-	O
and	O
60	O
-	O
fold	O
more	O
efficiently	O
than	O
Ub	B-Protein
-	O
AMC	O
and	O
Nedd8	B-Protein
-	O
AMC	O
,	O
respectively	O
.	O

Data	O
obtained	O
with	O
truncated	O
ISG15	B-Protein
and	O
hybrid	O
Ub	B-Protein
/	O
ISG15	B-Protein
substrates	O
indicate	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
Ub	B-Protein
-	O
like	O
domains	O
of	O
ISG15	B-Protein
contribute	O
to	O
this	O
preference	O
.	O

The	O
enzyme	O
also	O
displays	O
a	O
preference	O
for	O
debranching	O
Lys48	O
-	O
over	O
Lys63	O
-	O
linked	O
polyubiquitin	B-Protein
chains	O
.	O
<EOS>	B-X
The	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
papain-like	B-X
protease	B-X
(	B-X
SARS-CoV	B-X
PLpro	B-X
)	B-X
carries	B-X
out	B-X
N-terminal	B-X
processing	B-X
of	B-X
the	B-X
viral	B-X
replicase	B-X
polyprotein	B-X
,	B-X
and	B-X
also	B-X
exhibits	B-X
Lys48-linked	B-X
polyubiquitin	B-X
chain	B-X
debranching	B-X
and	B-X
ISG15	B-X
precursor	B-X
processing	B-X
activities	B-X
in	B-X
vitro	B-X
.	B-X
Data	B-X
obtained	B-X
with	B-X
truncated	B-X
ISG15	B-X
and	B-X
hybrid	B-X
Ub/ISG15	B-X
substrates	B-X
indicate	B-X
that	B-X
both	B-X
the	B-X
N-	B-X
and	B-X
C-terminal	B-X
Ub-like	B-X
domains	B-X
of	B-X
ISG15	B-X
contribute	B-X
to	B-X
this	B-X
preference	B-X
.	B-X
The	B-X
enzyme	B-X
also	B-X
displays	B-X
a	B-X
preference	B-X
for	B-X
debranching	B-X
Lys48-	B-X
over	B-X
Lys63-linked	B-X
polyubiquitin	B-X
chains	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
SARS-CoV	B-X
PLpro	B-X
can	B-X
differentiate	B-X
between	B-X
ubiquitin-like	B-X
modifiers	B-X
sharing	B-X
a	B-X
common	B-X
C-terminal	B-X
sequence	B-X
,	B-X
and	B-X
that	B-X
the	B-X
debranching	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
is	B-X
linkage	B-X
type	B-X
selective	B-X
.	B-X

Our	O
results	O
demonstrate	O
that	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
can	O
differentiate	O
between	O
ubiquitin	B-Protein
-	O
like	O
modifiers	O
sharing	O
a	O
common	O
C	O
-	O
terminal	O
sequence	O
,	O
and	O
that	O
the	O
debranching	O
activity	O
of	O
the	O
PLpro	B-Protein
is	O
linkage	O
type	O
selective	O
.	O

The	O
potential	O
structural	O
basis	O
for	O
the	O
demonstrated	O
specificity	O
of	O
SARS	O
-	O
CoV	O
PLpro	B-Protein
is	O
discussed	O
.	O
<EOS>	B-X
The	B-X
severe	B-X
acute	B-X
respiratory	B-X
syndrome	B-X
coronavirus	B-X
papain-like	B-X
protease	B-X
(	B-X
SARS-CoV	B-X
PLpro	B-X
)	B-X
carries	B-X
out	B-X
N-terminal	B-X
processing	B-X
of	B-X
the	B-X
viral	B-X
replicase	B-X
polyprotein	B-X
,	B-X
and	B-X
also	B-X
exhibits	B-X
Lys48-linked	B-X
polyubiquitin	B-X
chain	B-X
debranching	B-X
and	B-X
ISG15	B-X
precursor	B-X
processing	B-X
activities	B-X
in	B-X
vitro	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
used	B-X
SDS-PAGE	B-X
and	B-X
fluorescence-based	B-X
assays	B-X
to	B-X
demonstrate	B-X
that	B-X
ISG15	B-X
derivatives	B-X
are	B-X
the	B-X
preferred	B-X
substrates	B-X
for	B-X
the	B-X
deubiquitinating	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
.	B-X
With	B-X
k	B-X
(	B-X
cat	B-X
)	B-X
/K	B-X
(	B-X
M	B-X
)	B-X
of	B-X
602,000	B-X
M	B-X
(	B-X
-1	B-X
)	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
,	B-X
PLpro	B-X
hydrolyzes	B-X
ISG15-AMC	B-X
30-	B-X
and	B-X
60-fold	B-X
more	B-X
efficiently	B-X
than	B-X
Ub-AMC	B-X
and	B-X
Nedd8-AMC	B-X
,	B-X
respectively	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
that	B-X
SARS-CoV	B-X
PLpro	B-X
can	B-X
differentiate	B-X
between	B-X
ubiquitin-like	B-X
modifiers	B-X
sharing	B-X
a	B-X
common	B-X
C-terminal	B-X
sequence	B-X
,	B-X
and	B-X
that	B-X
the	B-X
debranching	B-X
activity	B-X
of	B-X
the	B-X
PLpro	B-X
is	B-X
linkage	B-X
type	B-X
selective	B-X
.	B-X
The	B-X
potential	B-X
structural	B-X
basis	B-X
for	B-X
the	B-X
demonstrated	B-X
specificity	B-X
of	B-X
SARS-CoV	B-X
PLpro	B-X
is	B-X
discussed	B-X
.	B-X

Modification	O
of	O
cellular	O
autophagy	O
protein	O
LC3	O
by	O
poliovirus	O
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Autophagy	B-X
results	B-X
in	B-X
the	B-X
covalent	B-X
lipidation	B-X
of	B-X
LC3	B-X
,	B-X
conferring	B-X
the	B-X
property	B-X
of	B-X
membrane	B-X
association	B-X
to	B-X
this	B-X
previously	B-X
microtubule-associated	B-X
protein	B-X
and	B-X
providing	B-X
a	B-X
biochemical	B-X
marker	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Poliovirus	O
infection	O
remodels	O
intracellular	O
membranes	O
,	O
creating	O
a	O
large	O
number	O
of	O
membranous	O
vesicles	O
on	O
which	O
viral	O
RNA	O
replication	O
occurs	O
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Poliovirus	O
-	O
induced	O
vesicles	O
display	O
hallmarks	O
of	O
cellular	O
autophagosomes	O
,	O
including	O
delimiting	O
double	O
membranes	O
surrounding	O
the	O
cytosolic	O
lumen	O
,	O
acquisition	O
of	O
the	O
endosomal	O
marker	O
LAMP	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
recruitment	O
of	O
the	O
18	O
-	O
kDa	O
host	O
protein	O
LC3	O
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Autophagy	B-X
results	B-X
in	B-X
the	B-X
covalent	B-X
lipidation	B-X
of	B-X
LC3	B-X
,	B-X
conferring	B-X
the	B-X
property	B-X
of	B-X
membrane	B-X
association	B-X
to	B-X
this	B-X
previously	B-X
microtubule-associated	B-X
protein	B-X
and	B-X
providing	B-X
a	B-X
biochemical	B-X
marker	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Autophagy	O
results	O
in	O
the	O
covalent	O
lipidation	O
of	O
LC3	O
,	O
conferring	O
the	O
property	O
of	O
membrane	O
association	O
to	O
this	O
previously	O
microtubule	O
-	O
associated	O
protein	O
and	O
providing	O
a	O
biochemical	O
marker	O
for	O
the	O
induction	O
of	O
autophagy	O
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Autophagy	B-X
results	B-X
in	B-X
the	B-X
covalent	B-X
lipidation	B-X
of	B-X
LC3	B-X
,	B-X
conferring	B-X
the	B-X
property	B-X
of	B-X
membrane	B-X
association	B-X
to	B-X
this	B-X
previously	B-X
microtubule-associated	B-X
protein	B-X
and	B-X
providing	B-X
a	B-X
biochemical	B-X
marker	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Here	O
,	O
we	O
report	O
that	O
a	O
similar	O
modification	O
of	O
LC3	O
occurs	O
both	O
during	O
poliovirus	O
infection	O
and	O
following	O
expression	O
of	O
a	O
single	O
viral	O
protein	O
,	O
a	O
stable	O
precursor	O
termed	O
2BC	B-Protein
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Autophagy	B-X
results	B-X
in	B-X
the	B-X
covalent	B-X
lipidation	B-X
of	B-X
LC3	B-X
,	B-X
conferring	B-X
the	B-X
property	B-X
of	B-X
membrane	B-X
association	B-X
to	B-X
this	B-X
previously	B-X
microtubule-associated	B-X
protein	B-X
and	B-X
providing	B-X
a	B-X
biochemical	B-X
marker	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Therefore	O
,	O
one	O
of	O
the	O
early	O
steps	O
in	O
cellular	O
autophagy	O
,	O
LC3	O
modification	O
,	O
can	O
be	O
genetically	O
separated	O
from	O
the	O
induction	O
of	O
double	O
-	O
membraned	O
vesicles	O
that	O
contain	O
the	O
modified	O
LC3	O
,	O
which	O
requires	O
both	O
viral	O
proteins	O
2BC	B-Protein
and	O
3A	B-Protein
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Autophagy	B-X
results	B-X
in	B-X
the	B-X
covalent	B-X
lipidation	B-X
of	B-X
LC3	B-X
,	B-X
conferring	B-X
the	B-X
property	B-X
of	B-X
membrane	B-X
association	B-X
to	B-X
this	B-X
previously	B-X
microtubule-associated	B-X
protein	B-X
and	B-X
providing	B-X
a	B-X
biochemical	B-X
marker	B-X
for	B-X
the	B-X
induction	B-X
of	B-X
autophagy	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

The	O
existence	O
of	O
viral	O
inducers	O
that	O
promote	O
a	O
distinct	O
aspect	O
of	O
the	O
formation	O
of	O
autophagosome	O
-	O
like	O
membranes	O
both	O
facilitates	O
the	O
dissection	O
of	O
this	O
cellular	O
process	O
and	O
supports	O
the	O
hypothesis	O
that	O
this	O
branch	O
of	O
the	O
innate	O
immune	O
response	O
is	O
directly	O
subverted	O
by	O
poliovirus	O
.	O
<EOS>	B-X
Poliovirus	B-X
infection	B-X
remodels	B-X
intracellular	B-X
membranes	B-X
,	B-X
creating	B-X
a	B-X
large	B-X
number	B-X
of	B-X
membranous	B-X
vesicles	B-X
on	B-X
which	B-X
viral	B-X
RNA	B-X
replication	B-X
occurs	B-X
.	B-X
Poliovirus-induced	B-X
vesicles	B-X
display	B-X
hallmarks	B-X
of	B-X
cellular	B-X
autophagosomes	B-X
,	B-X
including	B-X
delimiting	B-X
double	B-X
membranes	B-X
surrounding	B-X
the	B-X
cytosolic	B-X
lumen	B-X
,	B-X
acquisition	B-X
of	B-X
the	B-X
endosomal	B-X
marker	B-X
LAMP-1	B-X
,	B-X
and	B-X
recruitment	B-X
of	B-X
the	B-X
18-kDa	B-X
host	B-X
protein	B-X
LC3	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
similar	B-X
modification	B-X
of	B-X
LC3	B-X
occurs	B-X
both	B-X
during	B-X
poliovirus	B-X
infection	B-X
and	B-X
following	B-X
expression	B-X
of	B-X
a	B-X
single	B-X
viral	B-X
protein	B-X
,	B-X
a	B-X
stable	B-X
precursor	B-X
termed	B-X
2BC	B-X
.	B-X
Therefore	B-X
,	B-X
one	B-X
of	B-X
the	B-X
early	B-X
steps	B-X
in	B-X
cellular	B-X
autophagy	B-X
,	B-X
LC3	B-X
modification	B-X
,	B-X
can	B-X
be	B-X
genetically	B-X
separated	B-X
from	B-X
the	B-X
induction	B-X
of	B-X
double-membraned	B-X
vesicles	B-X
that	B-X
contain	B-X
the	B-X
modified	B-X
LC3	B-X
,	B-X
which	B-X
requires	B-X
both	B-X
viral	B-X
proteins	B-X
2BC	B-X
and	B-X
3A	B-X
.	B-X
The	B-X
existence	B-X
of	B-X
viral	B-X
inducers	B-X
that	B-X
promote	B-X
a	B-X
distinct	B-X
aspect	B-X
of	B-X
the	B-X
formation	B-X
of	B-X
autophagosome-like	B-X
membranes	B-X
both	B-X
facilitates	B-X
the	B-X
dissection	B-X
of	B-X
this	B-X
cellular	B-X
process	B-X
and	B-X
supports	B-X
the	B-X
hypothesis	B-X
that	B-X
this	B-X
branch	B-X
of	B-X
the	B-X
innate	B-X
immune	B-X
response	B-X
is	B-X
directly	B-X
subverted	B-X
by	B-X
poliovirus	B-X
.	B-X

Refined	O
crystal	O
structures	O
of	O
red	B-Protein
and	O
green	B-Protein
fluorescent	I-Protein
proteins	I-Protein
from	O
the	O
button	O
polyp	O
Zoanthus	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

The	O
three	O
-	O
dimensional	O
structures	O
of	O
the	O
wild	O
-	O
type	O
red	O
(	O
zRFP574	B-Protein
)	O
and	O
green	O
(	O
zGFP506	B-Protein
)	O
fluorescent	O
proteins	O
(	O
FP	O
)	O
from	O
the	O
button	O
polyp	O
Zoanthus	O
have	O
been	O
determined	O
at	O
1	O
.	O
51	O
and	O
2	O
.	O
2	O
A	O
resolution	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

In	O
addition	O
,	O
the	O
crystal	O
structures	O
of	O
a	O
zGFP506	B-Protein
variant	O
(	O
zGFP506	B-Protein
_	O
N66D	O
)	O
with	O
replacement	O
of	O
the	O
first	O
chromophore	O
-	O
forming	O
residue	O
(	O
Asn66	O
to	O
Asp	O
)	O
have	O
been	O
determined	O
in	O
the	O
transitional	O
'	O
green	O
'	O
and	O
mature	O
'	O
red	O
'	O
states	O
at	O
2	O
.	O
4	O
and	O
2	O
.	O
2	O
A	O
,	O
respectively	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

The	O
monomers	O
of	O
these	O
proteins	O
adopt	O
the	O
typical	O
fold	O
of	O
the	O
green	B-Protein
fluorescent	I-Protein
protein	I-Protein
(	O
GFP	O
)	O
family	O
,	O
consisting	O
of	O
an	O
11	O
-	O
stranded	O
beta	O
-	O
barrel	O
with	O
a	O
chromophore	O
embedded	O
in	O
the	O
middle	O
of	O
an	O
internal	O
alpha	O
-	O
helix	O
directed	O
along	O
the	O
beta	O
-	O
barrel	O
axis	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

Post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asn66	O
-	O
Tyr67	O
-	O
Gly68	O
within	O
zGFP506	B-Protein
results	O
in	O
a	O
typical	O
GFP	O
-	O
like	O
coplanar	O
two	O
-	O
ring	O
structure	O
consisting	O
of	O
a	O
five	O
-	O
membered	O
imidazolinone	O
heterocycle	O
with	O
the	O
phenolic	O
ring	O
of	O
Tyr67	O
in	O
a	O
cis	O
orientation	O
to	O
the	O
C	O
(	O
alpha	O
)	O
-	O
N	O
(	O
67	O
)	O
bond	O
.	O

A	O
novel	O
post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asp66	O
-	O
Tyr67	O
-	O
Gly68	O
in	O
zRFP574	B-Protein
expands	O
the	O
protein	O
maturation	O
beyond	O
the	O
green	O
-	O
emitting	O
form	O
and	O
results	O
in	O
decarboxylation	O
of	O
the	O
Asp66	O
side	O
chain	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

It	O
is	O
suggested	O
that	O
electrostatic	O
conflict	O
between	O
the	O
closely	O
spaced	O
negatively	O
charged	O
side	O
chains	O
of	O
the	O
chromophore	O
Asp66	O
and	O
the	O
proximal	O
catalytic	O
Glu221	O
is	O
most	O
likely	O
to	O
be	O
the	O
trigger	O
for	O
the	O
chain	O
of	O
reactions	O
resulting	O
in	O
the	O
observed	O
decarboxylation	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X

The	O
chromophore	O
structures	O
of	O
wild	O
-	O
type	O
zGFP506	B-Protein
and	O
of	O
its	O
mutant	O
zGFP506	B-Protein
_	O
N66D	O
in	O
the	O
'	O
green	O
'	O
and	O
'	O
red	O
'	O
states	O
support	O
this	O
suggestion	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
electrostatic	B-X
conflict	B-X
between	B-X
the	B-X
closely	B-X
spaced	B-X
negatively	B-X
charged	B-X
side	B-X
chains	B-X
of	B-X
the	B-X
chromophore	B-X
Asp66	B-X
and	B-X
the	B-X
proximal	B-X
catalytic	B-X
Glu221	B-X
is	B-X
most	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
trigger	B-X
for	B-X
the	B-X
chain	B-X
of	B-X
reactions	B-X
resulting	B-X
in	B-X
the	B-X
observed	B-X
decarboxylation	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X

The	O
beta	O
-	O
barrel	O
frames	O
of	O
zRFP574	B-Protein
and	O
zGFP506	B-Protein
reveal	O
the	O
presence	O
of	O
a	O
water	O
-	O
filled	O
pore	O
leading	O
to	O
the	O
chromophore	O
Tyr67	O
,	O
similar	O
to	O
that	O
observed	O
previously	O
in	O
TurboGFP	B-Protein
.	O

An	O
analysis	O
of	O
the	O
residue	O
composition	O
at	O
two	O
inter	O
-	O
monomer	O
interfaces	O
in	O
the	O
tetrameric	O
biological	O
unit	O
of	O
zRFP574	B-Protein
and	O
zGFP506	B-Protein
,	O
as	O
well	O
as	O
of	O
zYFP538	B-Protein
from	O
the	O
same	O
species	O
,	O
has	O
revealed	O
a	O
group	O
of	O
highly	O
conserved	O
residues	O
that	O
are	O
apparently	O
responsible	O
for	O
oligomerization	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
a	B-X
zGFP506	B-X
variant	B-X
(	B-X
zGFP506_N66D	B-X
)	B-X
with	B-X
replacement	B-X
of	B-X
the	B-X
first	B-X
chromophore-forming	B-X
residue	B-X
(	B-X
Asn66	B-X
to	B-X
Asp	B-X
)	B-X
have	B-X
been	B-X
determined	B-X
in	B-X
the	B-X
transitional	B-X
'green	B-X
'	B-X
and	B-X
mature	B-X
'red	B-X
'	B-X
states	B-X
at	B-X
2.4	B-X
and	B-X
2.2	B-X
A	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
Post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asn66-Tyr67-Gly68	B-X
within	B-X
zGFP506	B-X
results	B-X
in	B-X
a	B-X
typical	B-X
GFP-like	B-X
coplanar	B-X
two-ring	B-X
structure	B-X
consisting	B-X
of	B-X
a	B-X
five-membered	B-X
imidazolinone	B-X
heterocycle	B-X
with	B-X
the	B-X
phenolic	B-X
ring	B-X
of	B-X
Tyr67	B-X
in	B-X
a	B-X
cis	B-X
orientation	B-X
to	B-X
the	B-X
C	B-X
(	B-X
alpha	B-X
)	B-X
-N	B-X
(	B-X
67	B-X
)	B-X
bond	B-X
.	B-X
A	B-X
novel	B-X
post-translational	B-X
modification	B-X
of	B-X
the	B-X
chromophore-forming	B-X
sequence	B-X
Asp66-Tyr67-Gly68	B-X
in	B-X
zRFP574	B-X
expands	B-X
the	B-X
protein	B-X
maturation	B-X
beyond	B-X
the	B-X
green-emitting	B-X
form	B-X
and	B-X
results	B-X
in	B-X
decarboxylation	B-X
of	B-X
the	B-X
Asp66	B-X
side	B-X
chain	B-X
.	B-X
The	B-X
chromophore	B-X
structures	B-X
of	B-X
wild-type	B-X
zGFP506	B-X
and	B-X
of	B-X
its	B-X
mutant	B-X
zGFP506_N66D	B-X
in	B-X
the	B-X
'green	B-X
'	B-X
and	B-X
'red	B-X
'	B-X
states	B-X
support	B-X
this	B-X
suggestion	B-X
.	B-X
The	B-X
beta-barrel	B-X
frames	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
reveal	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
water-filled	B-X
pore	B-X
leading	B-X
to	B-X
the	B-X
chromophore	B-X
Tyr67	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
observed	B-X
previously	B-X
in	B-X
TurboGFP	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

These	O
residues	O
present	O
initial	O
useful	O
targets	O
for	O
rational	O
mutagenesis	O
aimed	O
at	O
designing	O
monomeric	O
forms	O
of	O
the	O
fluorescent	O
proteins	O
,	O
which	O
are	O
more	O
suitable	O
for	O
practical	O
applications	O
.	O
<EOS>	B-X
The	B-X
three-dimensional	B-X
structures	B-X
of	B-X
the	B-X
wild-type	B-X
red	B-X
(	B-X
zRFP574	B-X
)	B-X
and	B-X
green	B-X
(	B-X
zGFP506	B-X
)	B-X
fluorescent	B-X
proteins	B-X
(	B-X
FP	B-X
)	B-X
from	B-X
the	B-X
button	B-X
polyp	B-X
Zoanthus	B-X
have	B-X
been	B-X
determined	B-X
at	B-X
1.51	B-X
and	B-X
2.2	B-X
A	B-X
resolution	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
monomers	B-X
of	B-X
these	B-X
proteins	B-X
adopt	B-X
the	B-X
typical	B-X
fold	B-X
of	B-X
the	B-X
green	B-X
fluorescent	B-X
protein	B-X
(	B-X
GFP	B-X
)	B-X
family	B-X
,	B-X
consisting	B-X
of	B-X
an	B-X
11-stranded	B-X
beta-barrel	B-X
with	B-X
a	B-X
chromophore	B-X
embedded	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
an	B-X
internal	B-X
alpha-helix	B-X
directed	B-X
along	B-X
the	B-X
beta-barrel	B-X
axis	B-X
.	B-X
An	B-X
analysis	B-X
of	B-X
the	B-X
residue	B-X
composition	B-X
at	B-X
two	B-X
inter-monomer	B-X
interfaces	B-X
in	B-X
the	B-X
tetrameric	B-X
biological	B-X
unit	B-X
of	B-X
zRFP574	B-X
and	B-X
zGFP506	B-X
,	B-X
as	B-X
well	B-X
as	B-X
of	B-X
zYFP538	B-X
from	B-X
the	B-X
same	B-X
species	B-X
,	B-X
has	B-X
revealed	B-X
a	B-X
group	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
that	B-X
are	B-X
apparently	B-X
responsible	B-X
for	B-X
oligomerization	B-X
.	B-X
These	B-X
residues	B-X
present	B-X
initial	B-X
useful	B-X
targets	B-X
for	B-X
rational	B-X
mutagenesis	B-X
aimed	B-X
at	B-X
designing	B-X
monomeric	B-X
forms	B-X
of	B-X
the	B-X
fluorescent	B-X
proteins	B-X
,	B-X
which	B-X
are	B-X
more	B-X
suitable	B-X
for	B-X
practical	B-X
applications	B-X
.	B-X

Genetic	O
characterization	O
of	O
mutants	O
resistant	O
to	O
the	O
antiauxin	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
reveals	O
that	O
AAR3	B-Protein
,	O
a	O
gene	O
encoding	O
a	O
DCN1	B-Protein
-	O
like	O
protein	O
,	O
regulates	O
responses	O
to	O
the	O
synthetic	O
auxin	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
in	O
Arabidopsis	O
roots	O
.	O

To	O
isolate	O
novel	O
auxin	O
-	O
responsive	O
mutants	O
in	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
,	O
we	O
screened	O
mutants	O
for	O
root	O
growth	O
resistance	O
to	O
a	O
putative	O
antiauxin	O
,	O
p	O
-	O
chlorophenoxyisobutyric	O
acid	O
(	O
PCIB	O
)	O
,	O
which	O
inhibits	O
auxin	O
action	O
by	O
interfering	O
the	O
upstream	O
auxin	O
-	O
signaling	O
events	O
.	O
<EOS>	B-X
To	B-X
isolate	B-X
novel	B-X
auxin-responsive	B-X
mutants	B-X
in	B-X
Arabidopsis	B-X
(	B-X
Arabidopsis	B-X
thaliana	B-X
)	B-X
,	B-X
we	B-X
screened	B-X
mutants	B-X
for	B-X
root	B-X
growth	B-X
resistance	B-X
to	B-X
a	B-X
putative	B-X
antiauxin	B-X
,	B-X
p-chlorophenoxyisobutyric	B-X
acid	B-X
(	B-X
PCIB	B-X
)	B-X
,	B-X
which	B-X
inhibits	B-X
auxin	B-X
action	B-X
by	B-X
interfering	B-X
the	B-X
upstream	B-X
auxin-signaling	B-X
events	B-X
.	B-X
Eleven	B-X
PCIB-resistant	B-X
mutants	B-X
were	B-X
obtained	B-X
.	B-X
Genetic	B-X
mapping	B-X
indicates	B-X
that	B-X
the	B-X
mutations	B-X
are	B-X
located	B-X
in	B-X
at	B-X
least	B-X
five	B-X
independent	B-X
loci	B-X
,	B-X
including	B-X
two	B-X
known	B-X
auxin-related	B-X
loci	B-X
,	B-X
TRANSPORT	B-X
INHIBITOR	B-X
RESPONSE1	B-X
and	B-X
Arabidopsis	B-X
CULLIN1	B-X
.	B-X
antiauxin-resistant	B-X
mutants	B-X
(	B-X
aars	B-X
)	B-X
aar3-1	B-X
,	B-X
aar4	B-X
,	B-X
and	B-X
aar5	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
2,4-dichlorophenoxyacetic	B-X
acid	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
root	B-X
growth	B-X
assay	B-X
.	B-X
Positional	B-X
cloning	B-X
of	B-X
aar3-1	B-X
revealed	B-X
that	B-X
the	B-X
AAR3	B-X
gene	B-X
encodes	B-X
a	B-X
protein	B-X
with	B-X
a	B-X
domain	B-X
of	B-X
unknown	B-X
function	B-X
(	B-X
DUF298	B-X
)	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
implicated	B-X
in	B-X
auxin	B-X
signaling	B-X
.	B-X
The	B-X
protein	B-X
has	B-X
a	B-X
putative	B-X
nuclear	B-X
localization	B-X
signal	B-X
and	B-X
shares	B-X
homology	B-X
with	B-X
the	B-X
DEFECTIVE	B-X
IN	B-X
CULLIN	B-X
NEDDYLATION-1	B-X
protein	B-X
through	B-X
the	B-X
DUF298	B-X
domain	B-X
.	B-X
The	B-X
results	B-X
also	B-X
indicate	B-X
that	B-X
PCIB	B-X
can	B-X
facilitate	B-X
the	B-X
identification	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
auxin	B-X
or	B-X
auxin-related	B-X
signaling	B-X
.	B-X

Eleven	O
PCIB	O
-	O
resistant	O
mutants	O
were	O
obtained	O
.	O
<EOS>	B-X
To	B-X
isolate	B-X
novel	B-X
auxin-responsive	B-X
mutants	B-X
in	B-X
Arabidopsis	B-X
(	B-X
Arabidopsis	B-X
thaliana	B-X
)	B-X
,	B-X
we	B-X
screened	B-X
mutants	B-X
for	B-X
root	B-X
growth	B-X
resistance	B-X
to	B-X
a	B-X
putative	B-X
antiauxin	B-X
,	B-X
p-chlorophenoxyisobutyric	B-X
acid	B-X
(	B-X
PCIB	B-X
)	B-X
,	B-X
which	B-X
inhibits	B-X
auxin	B-X
action	B-X
by	B-X
interfering	B-X
the	B-X
upstream	B-X
auxin-signaling	B-X
events	B-X
.	B-X
Eleven	B-X
PCIB-resistant	B-X
mutants	B-X
were	B-X
obtained	B-X
.	B-X
antiauxin-resistant	B-X
mutants	B-X
(	B-X
aars	B-X
)	B-X
aar3-1	B-X
,	B-X
aar4	B-X
,	B-X
and	B-X
aar5	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
2,4-dichlorophenoxyacetic	B-X
acid	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
root	B-X
growth	B-X
assay	B-X
.	B-X
The	B-X
results	B-X
also	B-X
indicate	B-X
that	B-X
PCIB	B-X
can	B-X
facilitate	B-X
the	B-X
identification	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
auxin	B-X
or	B-X
auxin-related	B-X
signaling	B-X
.	B-X

Genetic	O
mapping	O
indicates	O
that	O
the	O
mutations	O
are	O
located	O
in	O
at	O
least	O
five	O
independent	O
loci	O
,	O
including	O
two	O
known	O
auxin	O
-	O
related	O
loci	O
,	O
TRANSPORT	B-Protein
INHIBITOR	I-Protein
RESPONSE1	I-Protein
and	O
Arabidopsis	O
CULLIN1	B-Protein
.	O
antiauxin	O
-	O
resistant	O
mutants	O
(	O
aars	O
)	O
aar3	O
-	O
1	O
,	O
aar4	O
,	O
and	O
aar5	O
were	O
also	O
resistant	O
to	O
2	O
,	O
4	O
-	O
dichlorophenoxyacetic	O
acid	O
as	O
shown	O
by	O
a	O
root	O
growth	O
assay	O
.	O
<EOS>	B-X
To	B-X
isolate	B-X
novel	B-X
auxin-responsive	B-X
mutants	B-X
in	B-X
Arabidopsis	B-X
(	B-X
Arabidopsis	B-X
thaliana	B-X
)	B-X
,	B-X
we	B-X
screened	B-X
mutants	B-X
for	B-X
root	B-X
growth	B-X
resistance	B-X
to	B-X
a	B-X
putative	B-X
antiauxin	B-X
,	B-X
p-chlorophenoxyisobutyric	B-X
acid	B-X
(	B-X
PCIB	B-X
)	B-X
,	B-X
which	B-X
inhibits	B-X
auxin	B-X
action	B-X
by	B-X
interfering	B-X
the	B-X
upstream	B-X
auxin-signaling	B-X
events	B-X
.	B-X
Eleven	B-X
PCIB-resistant	B-X
mutants	B-X
were	B-X
obtained	B-X
.	B-X
Genetic	B-X
mapping	B-X
indicates	B-X
that	B-X
the	B-X
mutations	B-X
are	B-X
located	B-X
in	B-X
at	B-X
least	B-X
five	B-X
independent	B-X
loci	B-X
,	B-X
including	B-X
two	B-X
known	B-X
auxin-related	B-X
loci	B-X
,	B-X
TRANSPORT	B-X
INHIBITOR	B-X
RESPONSE1	B-X
and	B-X
Arabidopsis	B-X
CULLIN1	B-X
.	B-X
antiauxin-resistant	B-X
mutants	B-X
(	B-X
aars	B-X
)	B-X
aar3-1	B-X
,	B-X
aar4	B-X
,	B-X
and	B-X
aar5	B-X
were	B-X
also	B-X
resistant	B-X
to	B-X
2,4-dichlorophenoxyacetic	B-X
acid	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
root	B-X
growth	B-X
assay	B-X
.	B-X
Positional	B-X
cloning	B-X
of	B-X
aar3-1	B-X
revealed	B-X
that	B-X
the	B-X
AAR3	B-X
gene	B-X
encodes	B-X
a	B-X
protein	B-X
with	B-X
a	B-X
domain	B-X
of	B-X
unknown	B-X
function	B-X
(	B-X
DUF298	B-X
)	B-X
,	B-X
which	B-X
has	B-X
not	B-X
previously	B-X
been	B-X
implicated	B-X
in	B-X
auxin	B-X
signaling	B-X
.	B-X
The	B-X
protein	B-X
has	B-X
a	B-X
putative	B-X
nuclear	B-X
localization	B-X
signal	B-X
and	B-X
shares	B-X
homology	B-X
with	B-X
the	B-X
DEFECTIVE	B-X
IN	B-X
CULLIN	B-X
NEDDYLATION-1	B-X
protein	B-X
through	B-X
the	B-X
DUF298	B-X
domain	B-X
.	B-X
The	B-X
results	B-X
also	B-X
indicate	B-X
that	B-X
PCIB	B-X
can	B-X
facilitate	B-X
the	B-X
identification	B-X
of	B-X
factors	B-X
involved	B-X
in	B-X
auxin	B-X
or	B-X
auxin-related	B-X
signaling	B-X
.	B-X

Positional	O
cloning	O
of	O
aar3	O
-	O
1	O
revealed	O
that	O
the	O
AAR3	B-Protein
gene	O
encodes	O
a	O
protein	O
with	O
a	O
domain	O
of	O
unknown	O
function	O
(	O
DUF298	O
)	O
,	O
which	O
has	O
not	O
previously	O
been	O
implicated	O
in	O
auxin	O
signaling	O
.	O

The	O
protein	O
has	O
a	O
putative	O
nuclear	O
localization	O
signal	O
and	O
shares	O
homology	O
with	O
the	O
DEFECTIVE	B-Protein
IN	I-Protein
CULLIN	I-Protein
NEDDYLATION	I-Protein
-	I-Protein
1	I-Protein
protein	O
through	O
the	O
DUF298	O
domain	O
.	O

The	O
results	O
also	O
indicate	O
that	O
PCIB	O
can	O
facilitate	O
the	O
identification	O
of	O
factors	O
involved	O
in	O
auxin	O
or	O
auxin	O
-	O
related	O
signaling	O
.	O
<EOS>	B-X
The	B-X
auxin	B-X
signaling	B-X
pathway	B-X
relies	B-X
on	B-X
the	B-X
auxin	B-X
gradient	B-X
within	B-X
tissues	B-X
and	B-X
cells	B-X
,	B-X
which	B-X
is	B-X
facilitated	B-X
by	B-X
both	B-X
local	B-X
auxin	B-X
biosynthesis	B-X
and	B-X
polar	B-X
auxin	B-X
transport	B-X
(	B-X
PAT	B-X
)	B-X
.	B-X
The	B-X
TRYPTOPHAN	B-X
AMINOTRANSFERASE	B-X
OF	B-X
ARABIDOPSIS	B-X
(	B-X
TAA	B-X
)	B-X
/YUCCA	B-X
(	B-X
YUC	B-X
)	B-X
pathway	B-X
is	B-X
the	B-X
most	B-X
important	B-X
and	B-X
well-characterized	B-X
pathway	B-X
that	B-X
plants	B-X
deploy	B-X
to	B-X
produce	B-X
auxin	B-X
.	B-X
The	B-X
spatiotemporal	B-X
dynamic	B-X
expression	B-X
of	B-X
different	B-X
YUC	B-X
gene	B-X
members	B-X
finely	B-X
tunes	B-X
the	B-X
local	B-X
auxin	B-X
biosynthesis	B-X
in	B-X
plants	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
plant	B-X
development	B-X
as	B-X
well	B-X
as	B-X
environmental	B-X
responses	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
recent	B-X
advances	B-X
in	B-X
the	B-X
identification	B-X
,	B-X
evolution	B-X
,	B-X
molecular	B-X
structures	B-X
,	B-X
and	B-X
functions	B-X
in	B-X
plant	B-X
development	B-X
and	B-X
stress	B-X
response	B-X
regarding	B-X
the	B-X
YUC	B-X
gene	B-X
family	B-X
are	B-X
addressed	B-X
.	B-X

Not	O
insulin	B-Protein
but	O
insulin	B-Protein
sensitivity	O
,	O
leptin	B-Protein
,	O
and	O
cortisol	O
are	O
major	O
factors	O
regulating	O
serum	O
acylated	O
ghrelin	B-Protein
level	O
in	O
healthy	O
women	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
performed	B-X
using	B-X
total	B-X
ghrelin	B-X
assays	B-X
,	B-X
detecting	B-X
two	B-X
forms	B-X
of	B-X
ghrelin	B-X
(	B-X
acylated	B-X
and	B-X
desacyl	B-X
)	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
same	B-X
peptide	B-X
precursor	B-X
but	B-X
having	B-X
different	B-X
biological	B-X
effects	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
Insulin	B-X
sensitivity	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
insulin	B-X
sensitivity	B-X
check	B-X
index	B-X
(	B-X
QUICKI	B-X
)	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

It	O
has	O
been	O
suggested	O
that	O
insulin	B-Protein
and	O
glucose	O
are	O
the	O
most	O
important	O
factors	O
for	O
ghrelin	B-Protein
secretion	O
.	O
<EOS>	B-X
The	B-X
octanoyl	B-X
modification	B-X
at	B-X
Ser³	B-X
,	B-X
mediated	B-X
by	B-X
ghrelin	B-X
O-acyltransferase	B-X
(	B-X
GOAT	B-X
)	B-X
,	B-X
is	B-X
essential	B-X
for	B-X
ghrelin	B-X
's	B-X
biological	B-X
activity	B-X
.	B-X
Accordingly	B-X
,	B-X
several	B-X
recent	B-X
studies	B-X
now	B-X
point	B-X
towards	B-X
an	B-X
important	B-X
role	B-X
for	B-X
ghrelin	B-X
and	B-X
its	B-X
receptor	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
blood	B-X
glucose	B-X
homeostasis	B-X
,	B-X
which	B-X
is	B-X
the	B-X
main	B-X
focus	B-X
of	B-X
this	B-X
review	B-X
.	B-X
Several	B-X
mechanisms	B-X
of	B-X
this	B-X
regulation	B-X
by	B-X
ghrelin	B-X
have	B-X
been	B-X
proposed	B-X
,	B-X
and	B-X
one	B-X
possibility	B-X
is	B-X
through	B-X
the	B-X
regulation	B-X
of	B-X
insulin	B-X
secretion	B-X
.	B-X
Despite	B-X
some	B-X
controversy	B-X
,	B-X
most	B-X
studies	B-X
suggest	B-X
that	B-X
ghrelin	B-X
exerts	B-X
an	B-X
inhibitory	B-X
effect	B-X
on	B-X
insulin	B-X
secretion	B-X
,	B-X
resulting	B-X
in	B-X
increased	B-X
circulating	B-X
glucose	B-X
levels	B-X
.	B-X
Obesity-related	B-X
type	B-X
2	B-X
diabetes	B-X
has	B-X
become	B-X
an	B-X
increasingly	B-X
important	B-X
health	B-X
problem	B-X
,	B-X
almost	B-X
reaching	B-X
epidemic	B-X
proportions	B-X
in	B-X
the	B-X
world	B-X
;	B-X
therefore	B-X
,	B-X
antagonists	B-X
of	B-X
the	B-X
ghrelin-GOAT	B-X
signaling	B-X
pathway	B-X
,	B-X
which	B-X
will	B-X
tackle	B-X
both	B-X
energy-	B-X
and	B-X
glucose	B-X
homeostasis	B-X
,	B-X
may	B-X
be	B-X
considered	B-X
as	B-X
promising	B-X
new	B-X
therapies	B-X
for	B-X
this	B-X
disease	B-X
.	B-X

Most	O
of	O
these	O
studies	O
were	O
performed	O
using	O
total	O
ghrelin	B-Protein
assays	O
,	O
detecting	O
two	O
forms	O
of	O
ghrelin	B-Protein
(	O
acylated	O
and	O
desacyl	O
)	O
,	O
derived	O
from	O
the	O
same	O
peptide	O
precursor	O
but	O
having	O
different	O
biological	O
effects	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
performed	B-X
using	B-X
total	B-X
ghrelin	B-X
assays	B-X
,	B-X
detecting	B-X
two	B-X
forms	B-X
of	B-X
ghrelin	B-X
(	B-X
acylated	B-X
and	B-X
desacyl	B-X
)	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
same	B-X
peptide	B-X
precursor	B-X
but	B-X
having	B-X
different	B-X
biological	B-X
effects	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
Insulin	B-X
sensitivity	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
insulin	B-X
sensitivity	B-X
check	B-X
index	B-X
(	B-X
QUICKI	B-X
)	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

This	O
study	O
was	O
therefore	O
designed	O
to	O
characterize	O
associations	O
between	O
serum	O
acylated	O
ghrelin	B-Protein
levels	O
(	O
Ghr	B-Protein
)	O
,	O
selected	O
adipocytokines	O
,	O
hormones	O
,	O
and	O
carbohydrate	O
metabolism	O
parameters	O
in	O
healthy	O
women	O
in	O
stable	O
energy	O
metabolism	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
performed	B-X
using	B-X
total	B-X
ghrelin	B-X
assays	B-X
,	B-X
detecting	B-X
two	B-X
forms	B-X
of	B-X
ghrelin	B-X
(	B-X
acylated	B-X
and	B-X
desacyl	B-X
)	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
same	B-X
peptide	B-X
precursor	B-X
but	B-X
having	B-X
different	B-X
biological	B-X
effects	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
adiponectin	B-X
,	B-X
and	B-X
body	B-X
composition	B-X
parameters	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
Ghr	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

The	O
study	O
was	O
performed	O
on	O
32	O
healthy	O
,	O
normal	O
-	O
weight	O
,	O
non	O
-	O
pregnant	O
women	O
with	O
normal	O
[	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
18	O
.	O
9	O
-	O
24	O
.	O
2	O
kg	O
/	O
m2	O
]	O
and	O
stable	O
(	O
the	O
difference	O
between	O
two	O
measurements	O
performed	O
within	O
1	O
month	O
being	O
less	O
than	O
0	O
.	O
5	O
kg	O
)	O
body	O
weight	O
,	O
aged	O
22	O
-	O
47	O
yr	O
.	O

Leptin	B-Protein
,	O
Ghr	B-Protein
,	O
GH	B-Protein
,	O
IGF	B-Protein
-	I-Protein
I	I-Protein
,	O
cortisol	O
,	O
insulin	B-Protein
,	O
and	O
glucose	O
were	O
measured	O
in	O
the	O
early	O
follicular	O
phase	O
of	O
the	O
menstruation	O
cycle	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
Insulin	B-X
sensitivity	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
insulin	B-X
sensitivity	B-X
check	B-X
index	B-X
(	B-X
QUICKI	B-X
)	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
adiponectin	B-X
,	B-X
and	B-X
body	B-X
composition	B-X
parameters	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
Ghr	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

Insulin	B-Protein
sensitivity	O
was	O
measured	O
using	O
quantitative	O
insulin	B-Protein
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
.	O
<EOS>	B-X
Excess	B-X
adipose	B-X
tissue	B-X
impairs	B-X
the	B-X
action	B-X
of	B-X
insulin	B-X
,	B-X
leading	B-X
to	B-X
insulin	B-X
resistance	B-X
(	B-X
IR	B-X
)	B-X
.	B-X
IR	B-X
is	B-X
assessed	B-X
using	B-X
indicators	B-X
of	B-X
epidemiological	B-X
significance	B-X
,	B-X
most	B-X
often	B-X
calculated	B-X
from	B-X
fasting	B-X
and	B-X
postprandial	B-X
glucose	B-X
and	B-X
insulin	B-X
values	B-X
,	B-X
so-called	B-X
indirect	B-X
indicators	B-X
of	B-X
insulin	B-X
resistance	B-X
.	B-X
Although	B-X
the	B-X
Quantitative	B-X
Insulin	B-X
Sensitivity	B-X
Check	B-X
Index	B-X
(	B-X
QUICKI	B-X
)	B-X
,	B-X
Matsuda	B-X
Index	B-X
and	B-X
the	B-X
Insulin	B-X
Secretion-Sensitivity	B-X
Index-2	B-X
(	B-X
ISSI-2	B-X
)	B-X
are	B-X
also	B-X
used	B-X
,	B-X
the	B-X
values	B-X
of	B-X
these	B-X
indices	B-X
established	B-X
for	B-X
IR	B-X
vary	B-X
for	B-X
different	B-X
age	B-X
,	B-X
sex	B-X
,	B-X
populations	B-X
and	B-X
ethnic	B-X
groups	B-X
.	B-X
Some	B-X
foods	B-X
and	B-X
drinks	B-X
contain	B-X
special	B-X
ingredients	B-X
,	B-X
causing	B-X
impressive	B-X
effects	B-X
on	B-X
human	B-X
health	B-X
.	B-X

Body	O
composition	O
was	O
assessed	O
by	O
bioimpedance	O
.	O
<EOS>	B-X
Body	B-X
composition	B-X
is	B-X
acknowledged	B-X
as	B-X
a	B-X
determinant	B-X
of	B-X
athletic	B-X
health	B-X
and	B-X
performance	B-X
.	B-X
Despite	B-X
the	B-X
methods	B-X
traditionally	B-X
used	B-X
to	B-X
assess	B-X
body	B-X
composition	B-X
,	B-X
bioelectric	B-X
impedance	B-X
analysis	B-X
(	B-X
BIA	B-X
)	B-X
and	B-X
bioelectric	B-X
impedance	B-X
vector	B-X
analysis	B-X
(	B-X
BIVA	B-X
)	B-X
have	B-X
recently	B-X
gained	B-X
attention	B-X
in	B-X
sports	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
a	B-X
research	B-X
context	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
present	B-X
narrative	B-X
review	B-X
summarizes	B-X
the	B-X
current	B-X
literature	B-X
regarding	B-X
body	B-X
composition	B-X
analysis	B-X
,	B-X
with	B-X
a	B-X
special	B-X
focus	B-X
on	B-X
BIA	B-X
and	B-X
BIVA	B-X
.	B-X
The	B-X
use	B-X
of	B-X
specific	B-X
technologies	B-X
and	B-X
sampling	B-X
frequencies	B-X
is	B-X
described	B-X
,	B-X
and	B-X
recommendations	B-X
for	B-X
the	B-X
assessment	B-X
of	B-X
body	B-X
composition	B-X
in	B-X
athletes	B-X
are	B-X
provided	B-X
.	B-X
Additionally	B-X
,	B-X
the	B-X
estimation	B-X
of	B-X
body	B-X
composition	B-X
parameters	B-X
(	B-X
i.e.	B-X
,	B-X
quantitative	B-X
analysis	B-X
)	B-X
and	B-X
the	B-X
interpretation	B-X
of	B-X
the	B-X
raw	B-X
bioelectrical	B-X
data	B-X
(	B-X
i.e.	B-X
,	B-X
qualitative	B-X
analysis	B-X
)	B-X
are	B-X
examined	B-X
,	B-X
highlighting	B-X
the	B-X
innovations	B-X
now	B-X
available	B-X
in	B-X
athletes	B-X
.	B-X
In	B-X
light	B-X
of	B-X
this	B-X
,	B-X
BIA	B-X
and	B-X
especially	B-X
BIVA	B-X
can	B-X
be	B-X
utilized	B-X
to	B-X
monitor	B-X
the	B-X
nutritional	B-X
status	B-X
and	B-X
the	B-X
seasonal	B-X
changes	B-X
in	B-X
body	B-X
composition	B-X
in	B-X
athletes	B-X
,	B-X
as	B-X
well	B-X
as	B-X
provide	B-X
accurate	B-X
within-	B-X
and	B-X
between-athlete	B-X
comparisons	B-X
.	B-X

We	O
found	O
a	O
positive	O
linear	O
correlation	O
between	O
leptin	B-Protein
and	O
Ghr	B-Protein
(	O
r	O
=	O
0	O
.	O
375	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
negative	O
correlation	O
between	O
insulin	B-Protein
and	O
Ghr	B-Protein
(	O
r	O
=	O
-	O
0	O
.	O
374	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
.	O

GH	B-Protein
,	O
IGF	B-Protein
-	I-Protein
I	I-Protein
,	O
adiponectin	B-Protein
,	O
and	O
body	O
composition	O
parameters	O
did	O
not	O
correlate	O
with	O
Ghr	B-Protein
.	O
<EOS>	B-X
Obesity	B-X
and	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
deficiency	B-X
are	B-X
common	B-X
in	B-X
Prader-Willi	B-X
syndrome	B-X
(	B-X
PWS	B-X
)	B-X
and	B-X
these	B-X
patients	B-X
are	B-X
at	B-X
risk	B-X
of	B-X
metabolic	B-X
diseases	B-X
in	B-X
adult	B-X
life	B-X
and	B-X
of	B-X
reduced	B-X
life	B-X
span	B-X
.	B-X
Low	B-X
adiponectin	B-X
values	B-X
are	B-X
associated	B-X
with	B-X
obesity	B-X
and	B-X
the	B-X
metabolic	B-X
syndrome	B-X
.	B-X
We	B-X
therefore	B-X
found	B-X
it	B-X
of	B-X
interest	B-X
to	B-X
measure	B-X
adiponectin	B-X
levels	B-X
in	B-X
PWS	B-X
.	B-X
Body	B-X
composition	B-X
(	B-X
BC	B-X
)	B-X
and	B-X
adipokines	B-X
share	B-X
bone	B-X
active	B-X
properties	B-X
and	B-X
display	B-X
an	B-X
altered	B-X
profile	B-X
in	B-X
acromegaly	B-X
.	B-X
The	B-X
fibroblast	B-X
growth	B-X
factor	B-X
23	B-X
(	B-X
FGF23	B-X
)	B-X
/α-Klotho	B-X
system	B-X
,	B-X
also	B-X
involved	B-X
in	B-X
bone	B-X
metabolism	B-X
,	B-X
is	B-X
upregulated	B-X
in	B-X
growth	B-X
hormone	B-X
(	B-X
GH	B-X
)	B-X
excess	B-X
states	B-X
.	B-X

In	O
multiple	O
regression	O
analysis	O
only	O
QUICKI	O
,	O
leptin	B-Protein
,	O
glucose	O
,	O
and	O
cortisol	O
(	O
positively	O
)	O
and	O
age	O
(	O
negatively	O
)	O
accounted	O
for	O
50	O
%	O
variation	O
of	O
Ghr	B-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
Insulin	B-X
sensitivity	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
insulin	B-X
sensitivity	B-X
check	B-X
index	B-X
(	B-X
QUICKI	B-X
)	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
adiponectin	B-X
,	B-X
and	B-X
body	B-X
composition	B-X
parameters	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
Ghr	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

Insulin	B-Protein
and	O
BMI	O
did	O
not	O
contribute	O
significantly	O
to	O
the	O
model	O
.	O
<EOS>	B-X
Statistical	B-X
models	B-X
included	B-X
adjustment	B-X
for	B-X
age	B-X
,	B-X
sex	B-X
,	B-X
ethnicity	B-X
,	B-X
BMI	B-X
,	B-X
and	B-X
liver	B-X
fat	B-X
.	B-X
Intrapancreatic	B-X
fat	B-X
deposition	B-X
in	B-X
the	B-X
head	B-X
,	B-X
body	B-X
,	B-X
and	B-X
tail	B-X
of	B-X
the	B-X
pancreas	B-X
did	B-X
not	B-X
differ	B-X
significantly	B-X
in	B-X
adjusted	B-X
models	B-X
in	B-X
either	B-X
the	B-X
overall	B-X
cohort	B-X
or	B-X
the	B-X
three	B-X
subgroups	B-X
based	B-X
on	B-X
diabetes	B-X
status	B-X
.	B-X
HOMA	B-X
of	B-X
insulin	B-X
resistance	B-X
and	B-X
fasting	B-X
insulin	B-X
were	B-X
significantly	B-X
positively	B-X
associated	B-X
with	B-X
fat	B-X
in	B-X
the	B-X
tail	B-X
and	B-X
body	B-X
of	B-X
the	B-X
pancreas	B-X
.	B-X
We	B-X
examined	B-X
associations	B-X
among	B-X
36	B-X
butyrate-producing	B-X
taxa	B-X
(	B-X
n	B-X
=	B-X
7	B-X
genera	B-X
and	B-X
29	B-X
species	B-X
)	B-X
and	B-X
insulin	B-X
sensitivity	B-X
,	B-X
insulin	B-X
secretion	B-X
,	B-X
disposition	B-X
index	B-X
,	B-X
insulin	B-X
clearance	B-X
,	B-X
and	B-X
prevalence	B-X
of	B-X
dysglycemia	B-X
(	B-X
prediabetes	B-X
plus	B-X
diabetes	B-X
,	B-X
46	B-X
%	B-X
of	B-X
cohort	B-X
)	B-X
,	B-X
adjusting	B-X
for	B-X
age	B-X
,	B-X
sex	B-X
,	B-X
BMI	B-X
,	B-X
and	B-X
race	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
in	O
healthy	O
women	O
basal	O
Ghr	B-Protein
level	O
is	O
regulated	O
by	O
multiple	O
factors	O
,	O
mainly	O
by	O
insulin	B-Protein
sensitivity	O
,	O
leptin	B-Protein
,	O
and	O
adrenal	O
glands	O
activity	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
Insulin	B-X
sensitivity	B-X
was	B-X
measured	B-X
using	B-X
quantitative	B-X
insulin	B-X
sensitivity	B-X
check	B-X
index	B-X
(	B-X
QUICKI	B-X
)	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
adiponectin	B-X
,	B-X
and	B-X
body	B-X
composition	B-X
parameters	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
Ghr	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

However	O
,	O
further	O
studies	O
are	O
needed	O
to	O
elucidate	O
the	O
physiological	O
mechanisms	O
involved	O
in	O
acylated	O
Ghr	B-Protein
secretion	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
suggested	B-X
that	B-X
insulin	B-X
and	B-X
glucose	B-X
are	B-X
the	B-X
most	B-X
important	B-X
factors	B-X
for	B-X
ghrelin	B-X
secretion	B-X
.	B-X
Most	B-X
of	B-X
these	B-X
studies	B-X
were	B-X
performed	B-X
using	B-X
total	B-X
ghrelin	B-X
assays	B-X
,	B-X
detecting	B-X
two	B-X
forms	B-X
of	B-X
ghrelin	B-X
(	B-X
acylated	B-X
and	B-X
desacyl	B-X
)	B-X
,	B-X
derived	B-X
from	B-X
the	B-X
same	B-X
peptide	B-X
precursor	B-X
but	B-X
having	B-X
different	B-X
biological	B-X
effects	B-X
.	B-X
This	B-X
study	B-X
was	B-X
therefore	B-X
designed	B-X
to	B-X
characterize	B-X
associations	B-X
between	B-X
serum	B-X
acylated	B-X
ghrelin	B-X
levels	B-X
(	B-X
Ghr	B-X
)	B-X
,	B-X
selected	B-X
adipocytokines	B-X
,	B-X
hormones	B-X
,	B-X
and	B-X
carbohydrate	B-X
metabolism	B-X
parameters	B-X
in	B-X
healthy	B-X
women	B-X
in	B-X
stable	B-X
energy	B-X
metabolism	B-X
.	B-X
The	B-X
study	B-X
was	B-X
performed	B-X
on	B-X
32	B-X
healthy	B-X
,	B-X
normal-weight	B-X
,	B-X
non-pregnant	B-X
women	B-X
with	B-X
normal	B-X
[	B-X
body	B-X
mass	B-X
index	B-X
(	B-X
BMI	B-X
)	B-X
18.9-24.2	B-X
kg/m2	B-X
]	B-X
and	B-X
stable	B-X
(	B-X
the	B-X
difference	B-X
between	B-X
two	B-X
measurements	B-X
performed	B-X
within	B-X
1	B-X
month	B-X
being	B-X
less	B-X
than	B-X
0.5	B-X
kg	B-X
)	B-X
body	B-X
weight	B-X
,	B-X
aged	B-X
22-47	B-X
yr.	B-X
Leptin	B-X
,	B-X
Ghr	B-X
,	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
cortisol	B-X
,	B-X
insulin	B-X
,	B-X
and	B-X
glucose	B-X
were	B-X
measured	B-X
in	B-X
the	B-X
early	B-X
follicular	B-X
phase	B-X
of	B-X
the	B-X
menstruation	B-X
cycle	B-X
.	B-X
We	B-X
found	B-X
a	B-X
positive	B-X
linear	B-X
correlation	B-X
between	B-X
leptin	B-X
and	B-X
Ghr	B-X
(	B-X
r=0.375	B-X
;	B-X
p=0.034	B-X
)	B-X
and	B-X
negative	B-X
correlation	B-X
between	B-X
insulin	B-X
and	B-X
Ghr	B-X
(	B-X
r=-0.374	B-X
;	B-X
p=0.034	B-X
)	B-X
.	B-X
GH	B-X
,	B-X
IGF-I	B-X
,	B-X
adiponectin	B-X
,	B-X
and	B-X
body	B-X
composition	B-X
parameters	B-X
did	B-X
not	B-X
correlate	B-X
with	B-X
Ghr	B-X
.	B-X
In	B-X
multiple	B-X
regression	B-X
analysis	B-X
only	B-X
QUICKI	B-X
,	B-X
leptin	B-X
,	B-X
glucose	B-X
,	B-X
and	B-X
cortisol	B-X
(	B-X
positively	B-X
)	B-X
and	B-X
age	B-X
(	B-X
negatively	B-X
)	B-X
accounted	B-X
for	B-X
50	B-X
%	B-X
variation	B-X
of	B-X
Ghr	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
healthy	B-X
women	B-X
basal	B-X
Ghr	B-X
level	B-X
is	B-X
regulated	B-X
by	B-X
multiple	B-X
factors	B-X
,	B-X
mainly	B-X
by	B-X
insulin	B-X
sensitivity	B-X
,	B-X
leptin	B-X
,	B-X
and	B-X
adrenal	B-X
glands	B-X
activity	B-X
.	B-X
However	B-X
,	B-X
further	B-X
studies	B-X
are	B-X
needed	B-X
to	B-X
elucidate	B-X
the	B-X
physiological	B-X
mechanisms	B-X
involved	B-X
in	B-X
acylated	B-X
Ghr	B-X
secretion	B-X
.	B-X

The	O
role	O
of	O
loop	O
and	O
beta	O
-	O
turn	O
residues	O
as	O
structural	O
and	O
functional	O
determinants	O
for	O
the	O
lipoyl	O
domain	O
from	O
the	O
Escherichia	O
coli	O
2	O
-	O
oxoglutarate	O
dehydrogenase	O
complex	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domain	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
succinyltransferase	B-X
(	B-X
E2o	B-X
)	B-X
component	B-X
of	B-X
the	B-X
2OGDH	B-X
(	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
)	B-X
multienzyme	B-X
complex	B-X
houses	B-X
the	B-X
lipoic	B-X
acid	B-X
cofactor	B-X
through	B-X
covalent	B-X
attachment	B-X
to	B-X
a	B-X
specific	B-X
lysine	B-X
side	B-X
chain	B-X
residing	B-X
at	B-X
the	B-X
tip	B-X
of	B-X
a	B-X
beta-turn	B-X
.	B-X
Residues	B-X
within	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
and	B-X
a	B-X
nearby	B-X
prominent	B-X
loop	B-X
have	B-X
been	B-X
implicated	B-X
as	B-X
determinants	B-X
of	B-X
lipoyl	B-X
domain	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
Protein	B-X
engineering	B-X
of	B-X
the	B-X
Escherichia	B-X
coli	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2olip	B-X
)	B-X
revealed	B-X
that	B-X
removal	B-X
of	B-X
residues	B-X
from	B-X
the	B-X
loop	B-X
caused	B-X
a	B-X
major	B-X
structural	B-X
change	B-X
in	B-X
the	B-X
protein	B-X
,	B-X
which	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
succinylation	B-X
by	B-X
2-oxoglutarate	B-X
decarboxylase	B-X
(	B-X
E1o	B-X
)	B-X
and	B-X
reduced	B-X
the	B-X
lipoylation	B-X
efficiency	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
corresponding	B-X
to	B-X
that	B-X
of	B-X
the	B-X
E.	B-X
coli	B-X
pyruvate	B-X
dehydrogenase	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2plip	B-X
)	B-X
restored	B-X
lipoylation	B-X
efficiency	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
returned	B-X
,	B-X
albeit	B-X
at	B-X
a	B-X
lower	B-X
rate	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
E2olip	B-X
loop	B-X
sequence	B-X
significantly	B-X
improved	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
pyruvate	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
)	B-X
,	B-X
retaining	B-X
approx	B-X
.	B-X
10-fold	B-X
more	B-X
acetyl	B-X
groups	B-X
after	B-X
25	B-X
min	B-X
than	B-X
wild-type	B-X
E2olip	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
beta-turn	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
E2o	B-X
lipoyl-lysine	B-X
DK	B-X
(	B-X
A	B-X
)	B-X
/	B-X
(	B-X
V	B-X
)	B-X
motif	B-X
to	B-X
the	B-X
equivalent	B-X
residue	B-X
in	B-X
E2plip	B-X
(	B-X
T42G	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
reduced	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
succinylated	B-X
,	B-X
but	B-X
led	B-X
to	B-X
an	B-X
increased	B-X
capacity	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
the	B-X
non-cognate	B-X
E1p	B-X
.	B-X
The	B-X
T42G	B-X
mutation	B-X
also	B-X
slightly	B-X
enhanced	B-X
the	B-X
lipoylation	B-X
rate	B-X
of	B-X
the	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
and	B-X
together	B-X
with	B-X
Thr42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
specifying	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
with	B-X
its	B-X
partner	B-X
E1o	B-X
in	B-X
the	B-X
E.	B-X
coli	B-X
2OGDH	B-X
complex	B-X
.	B-X

The	O
lipoyl	O
domain	O
of	O
the	O
dihydrolipoyl	B-Protein
succinyltransferase	I-Protein
(	I-Protein
E2o	I-Protein
)	I-Protein
component	I-Protein
of	I-Protein
the	I-Protein
2OGDH	I-Protein
(	I-Protein
2	I-Protein
-	I-Protein
oxoglutarate	I-Protein
dehydrogenase	I-Protein
)	I-Protein
multienzyme	I-Protein
complex	I-Protein
houses	O
the	O
lipoic	O
acid	O
cofactor	O
through	O
covalent	O
attachment	O
to	O
a	O
specific	O
lysine	O
side	O
chain	O
residing	O
at	O
the	O
tip	O
of	O
a	O
beta	O
-	O
turn	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domain	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
succinyltransferase	B-X
(	B-X
E2o	B-X
)	B-X
component	B-X
of	B-X
the	B-X
2OGDH	B-X
(	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
)	B-X
multienzyme	B-X
complex	B-X
houses	B-X
the	B-X
lipoic	B-X
acid	B-X
cofactor	B-X
through	B-X
covalent	B-X
attachment	B-X
to	B-X
a	B-X
specific	B-X
lysine	B-X
side	B-X
chain	B-X
residing	B-X
at	B-X
the	B-X
tip	B-X
of	B-X
a	B-X
beta-turn	B-X
.	B-X
Residues	B-X
within	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
and	B-X
a	B-X
nearby	B-X
prominent	B-X
loop	B-X
have	B-X
been	B-X
implicated	B-X
as	B-X
determinants	B-X
of	B-X
lipoyl	B-X
domain	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
Protein	B-X
engineering	B-X
of	B-X
the	B-X
Escherichia	B-X
coli	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2olip	B-X
)	B-X
revealed	B-X
that	B-X
removal	B-X
of	B-X
residues	B-X
from	B-X
the	B-X
loop	B-X
caused	B-X
a	B-X
major	B-X
structural	B-X
change	B-X
in	B-X
the	B-X
protein	B-X
,	B-X
which	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
succinylation	B-X
by	B-X
2-oxoglutarate	B-X
decarboxylase	B-X
(	B-X
E1o	B-X
)	B-X
and	B-X
reduced	B-X
the	B-X
lipoylation	B-X
efficiency	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
corresponding	B-X
to	B-X
that	B-X
of	B-X
the	B-X
E.	B-X
coli	B-X
pyruvate	B-X
dehydrogenase	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2plip	B-X
)	B-X
restored	B-X
lipoylation	B-X
efficiency	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
returned	B-X
,	B-X
albeit	B-X
at	B-X
a	B-X
lower	B-X
rate	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
E2olip	B-X
loop	B-X
sequence	B-X
significantly	B-X
improved	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
pyruvate	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
)	B-X
,	B-X
retaining	B-X
approx	B-X
.	B-X
10-fold	B-X
more	B-X
acetyl	B-X
groups	B-X
after	B-X
25	B-X
min	B-X
than	B-X
wild-type	B-X
E2olip	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
beta-turn	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
E2o	B-X
lipoyl-lysine	B-X
DK	B-X
(	B-X
A	B-X
)	B-X
/	B-X
(	B-X
V	B-X
)	B-X
motif	B-X
to	B-X
the	B-X
equivalent	B-X
residue	B-X
in	B-X
E2plip	B-X
(	B-X
T42G	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
reduced	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
succinylated	B-X
,	B-X
but	B-X
led	B-X
to	B-X
an	B-X
increased	B-X
capacity	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
the	B-X
non-cognate	B-X
E1p	B-X
.	B-X
The	B-X
T42G	B-X
mutation	B-X
also	B-X
slightly	B-X
enhanced	B-X
the	B-X
lipoylation	B-X
rate	B-X
of	B-X
the	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
and	B-X
together	B-X
with	B-X
Thr42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
specifying	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
with	B-X
its	B-X
partner	B-X
E1o	B-X
in	B-X
the	B-X
E.	B-X
coli	B-X
2OGDH	B-X
complex	B-X
.	B-X

Residues	O
within	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
and	O
a	O
nearby	O
prominent	O
loop	O
have	O
been	O
implicated	O
as	O
determinants	O
of	O
lipoyl	O
domain	O
structure	O
and	O
function	O
.	O

Protein	O
engineering	O
of	O
the	O
Escherichia	O
coli	O
E2o	B-Protein
lipoyl	O
domain	O
(	O
E2olip	B-Protein
)	O
revealed	O
that	O
removal	O
of	O
residues	O
from	O
the	O
loop	O
caused	O
a	O
major	O
structural	O
change	O
in	O
the	O
protein	O
,	O
which	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
succinylation	O
by	O
2	B-Protein
-	I-Protein
oxoglutarate	I-Protein
decarboxylase	I-Protein
(	O
E1o	B-Protein
)	O
and	O
reduced	O
the	O
lipoylation	O
efficiency	O
.	O

Insertion	O
of	O
a	O
new	O
loop	O
corresponding	O
to	O
that	O
of	O
the	O
E	O
.	O
coli	O
pyruvate	O
dehydrogenase	O
lipoyl	O
domain	O
(	O
E2plip	B-Protein
)	O
restored	O
lipoylation	O
efficiency	O
and	O
the	O
capacity	O
to	O
undergo	O
reductive	O
succinylation	O
returned	O
,	O
albeit	O
at	O
a	O
lower	O
rate	O
.	O

Exchange	O
of	O
the	O
E2olip	B-Protein
loop	O
sequence	O
significantly	O
improved	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
acetylated	O
by	O
pyruvate	B-Protein
decarboxylase	I-Protein
(	O
E1p	B-Protein
)	O
,	O
retaining	O
approx	O
.	O
10	O
-	O
fold	O
more	O
acetyl	O
groups	O
after	O
25	O
min	O
than	O
wild	O
-	O
type	O
E2olip	B-Protein
.	O

Exchange	O
of	O
the	O
beta	O
-	O
turn	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
E2o	B-Protein
lipoyl	O
-	O
lysine	O
DK	O
(	O
A	O
)	O
/	O
(	O
V	O
)	O
motif	O
to	O
the	O
equivalent	O
residue	O
in	O
E2plip	B-Protein
(	O
T42G	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
reduced	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
succinylated	O
,	O
but	O
led	O
to	O
an	O
increased	O
capacity	O
to	O
be	O
reductively	O
acetylated	O
by	O
the	O
non	O
-	O
cognate	O
E1p	B-Protein
.	O

The	O
T42G	O
mutation	O
also	O
slightly	O
enhanced	O
the	O
lipoylation	O
rate	O
of	O
the	O
domain	O
.	O
<EOS>	B-X
The	B-X
lipoyl	B-X
domain	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
succinyltransferase	B-X
(	B-X
E2o	B-X
)	B-X
component	B-X
of	B-X
the	B-X
2OGDH	B-X
(	B-X
2-oxoglutarate	B-X
dehydrogenase	B-X
)	B-X
multienzyme	B-X
complex	B-X
houses	B-X
the	B-X
lipoic	B-X
acid	B-X
cofactor	B-X
through	B-X
covalent	B-X
attachment	B-X
to	B-X
a	B-X
specific	B-X
lysine	B-X
side	B-X
chain	B-X
residing	B-X
at	B-X
the	B-X
tip	B-X
of	B-X
a	B-X
beta-turn	B-X
.	B-X
Residues	B-X
within	B-X
the	B-X
lipoyl-lysine	B-X
beta-turn	B-X
and	B-X
a	B-X
nearby	B-X
prominent	B-X
loop	B-X
have	B-X
been	B-X
implicated	B-X
as	B-X
determinants	B-X
of	B-X
lipoyl	B-X
domain	B-X
structure	B-X
and	B-X
function	B-X
.	B-X
Protein	B-X
engineering	B-X
of	B-X
the	B-X
Escherichia	B-X
coli	B-X
E2o	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2olip	B-X
)	B-X
revealed	B-X
that	B-X
removal	B-X
of	B-X
residues	B-X
from	B-X
the	B-X
loop	B-X
caused	B-X
a	B-X
major	B-X
structural	B-X
change	B-X
in	B-X
the	B-X
protein	B-X
,	B-X
which	B-X
rendered	B-X
the	B-X
domain	B-X
incapable	B-X
of	B-X
reductive	B-X
succinylation	B-X
by	B-X
2-oxoglutarate	B-X
decarboxylase	B-X
(	B-X
E1o	B-X
)	B-X
and	B-X
reduced	B-X
the	B-X
lipoylation	B-X
efficiency	B-X
.	B-X
Insertion	B-X
of	B-X
a	B-X
new	B-X
loop	B-X
corresponding	B-X
to	B-X
that	B-X
of	B-X
the	B-X
E.	B-X
coli	B-X
pyruvate	B-X
dehydrogenase	B-X
lipoyl	B-X
domain	B-X
(	B-X
E2plip	B-X
)	B-X
restored	B-X
lipoylation	B-X
efficiency	B-X
and	B-X
the	B-X
capacity	B-X
to	B-X
undergo	B-X
reductive	B-X
succinylation	B-X
returned	B-X
,	B-X
albeit	B-X
at	B-X
a	B-X
lower	B-X
rate	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
E2olip	B-X
loop	B-X
sequence	B-X
significantly	B-X
improved	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
pyruvate	B-X
decarboxylase	B-X
(	B-X
E1p	B-X
)	B-X
,	B-X
retaining	B-X
approx	B-X
.	B-X
Exchange	B-X
of	B-X
the	B-X
beta-turn	B-X
residue	B-X
on	B-X
the	B-X
N-terminal	B-X
side	B-X
of	B-X
the	B-X
E2o	B-X
lipoyl-lysine	B-X
DK	B-X
(	B-X
A	B-X
)	B-X
/	B-X
(	B-X
V	B-X
)	B-X
motif	B-X
to	B-X
the	B-X
equivalent	B-X
residue	B-X
in	B-X
E2plip	B-X
(	B-X
T42G	B-X
)	B-X
,	B-X
both	B-X
singly	B-X
and	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
loop	B-X
exchange	B-X
,	B-X
reduced	B-X
the	B-X
ability	B-X
of	B-X
the	B-X
domain	B-X
to	B-X
be	B-X
reductively	B-X
succinylated	B-X
,	B-X
but	B-X
led	B-X
to	B-X
an	B-X
increased	B-X
capacity	B-X
to	B-X
be	B-X
reductively	B-X
acetylated	B-X
by	B-X
the	B-X
non-cognate	B-X
E1p	B-X
.	B-X
The	B-X
T42G	B-X
mutation	B-X
also	B-X
slightly	B-X
enhanced	B-X
the	B-X
lipoylation	B-X
rate	B-X
of	B-X
the	B-X
domain	B-X
.	B-X
The	B-X
surface	B-X
loop	B-X
is	B-X
important	B-X
to	B-X
the	B-X
structural	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
and	B-X
together	B-X
with	B-X
Thr42	B-X
plays	B-X
an	B-X
important	B-X
role	B-X
in	B-X
specifying	B-X
the	B-X
interaction	B-X
of	B-X
the	B-X
lipoyl	B-X
domain	B-X
with	B-X
its	B-X
partner	B-X
E1o	B-X
in	B-X
the	B-X
E.	B-X
coli	B-X
2OGDH	B-X
complex	B-X
.	B-X

The	O
surface	O
loop	O
is	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
protein	O
and	O
together	O
with	O
Thr42	O
plays	O
an	O
important	O
role	O
in	O
specifying	O
the	O
interaction	O
of	O
the	O
lipoyl	O
domain	O
with	O
its	O
partner	O
E1o	O
in	O
the	O
E	O
.	O
coli	O
2OGDH	O
complex	O
.	O

Daxx	B-Protein
mediates	O
SUMO	O
-	O
dependent	O
transcriptional	O
control	O
and	O
subnuclear	O
compartmentalization	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

SUMO	O
(	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
)	O
modification	O
is	O
emerging	O
as	O
an	O
important	O
post	O
-	O
translational	O
control	O
in	O
transcription	O
.	O
<EOS>	B-X
Sumoylation	B-X
is	B-X
a	B-X
reversible	B-X
post-translational	B-X
modification	B-X
that	B-X
targets	B-X
a	B-X
variety	B-X
of	B-X
proteins	B-X
mainly	B-X
within	B-X
the	B-X
nucleus	B-X
,	B-X
but	B-X
also	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
cytoplasm	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
It	B-X
controls	B-X
diverse	B-X
cellular	B-X
mechanisms	B-X
such	B-X
as	B-X
subcellular	B-X
localization	B-X
,	B-X
protein-protein	B-X
interactions	B-X
,	B-X
or	B-X
transcription	B-X
factor	B-X
activity	B-X
.	B-X
In	B-X
particular	B-X
,	B-X
detailed	B-X
analyses	B-X
of	B-X
mutant	B-X
organisms	B-X
in	B-X
both	B-X
the	B-X
components	B-X
of	B-X
the	B-X
SUMO	B-X
pathway	B-X
and	B-X
their	B-X
targets	B-X
have	B-X
established	B-X
the	B-X
importance	B-X
of	B-X
the	B-X
SUMO	B-X
system	B-X
in	B-X
early	B-X
developmental	B-X
processes	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
division	B-X
,	B-X
cell	B-X
lineage	B-X
commitment	B-X
,	B-X
specification	B-X
,	B-X
and/or	B-X
differentiation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
an	B-X
increasing	B-X
number	B-X
of	B-X
developmental	B-X
proteins	B-X
,	B-X
including	B-X
transcription	B-X
factors	B-X
and	B-X
epigenetic	B-X
regulators	B-X
,	B-X
have	B-X
been	B-X
identified	B-X
as	B-X
sumoylation	B-X
substrates	B-X
.	B-X
For	B-X
example	B-X
,	B-X
this	B-X
modification	B-X
has	B-X
been	B-X
involved	B-X
in	B-X
converting	B-X
a	B-X
transcription	B-X
factor	B-X
from	B-X
an	B-X
activator	B-X
to	B-X
a	B-X
repressor	B-X
or	B-X
in	B-X
regulating	B-X
the	B-X
localization	B-X
and/or	B-X
stability	B-X
of	B-X
numerous	B-X
transcription	B-X
factors	B-X
.	B-X

In	O
general	O
,	O
SUMO	O
modification	O
is	O
associated	O
with	O
transcriptional	O
repression	O
.	O
<EOS>	B-X
Many	B-X
of	B-X
the	B-X
known	B-X
SUMO	B-X
substrates	B-X
are	B-X
nuclear	B-X
proteins	B-X
,	B-X
which	B-X
regulate	B-X
gene	B-X
expression	B-X
and	B-X
chromatin	B-X
dynamics	B-X
.	B-X
Sumoylation	B-X
,	B-X
in	B-X
general	B-X
,	B-X
appears	B-X
to	B-X
correlate	B-X
with	B-X
decreased	B-X
transcriptional	B-X
activity	B-X
,	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
modulation	B-X
of	B-X
the	B-X
chromatin	B-X
template	B-X
is	B-X
implicated	B-X
.	B-X
Sumoylation	B-X
of	B-X
the	B-X
core	B-X
histones	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
silencing	B-X
,	B-X
and	B-X
transcription	B-X
factor	B-X
sumoylation	B-X
can	B-X
decrease	B-X
gene	B-X
expression	B-X
by	B-X
promoting	B-X
recruitment	B-X
of	B-X
chromatin	B-X
modifying	B-X
enzymes	B-X
.	B-X
Additionally	B-X
,	B-X
sumoylation	B-X
of	B-X
transcriptional	B-X
corepressors	B-X
and	B-X
chromatin	B-X
remodeling	B-X
enzymes	B-X
can	B-X
influence	B-X
interactions	B-X
with	B-X
other	B-X
transcriptional	B-X
regulators	B-X
,	B-X
and	B-X
alter	B-X
their	B-X
enzymatic	B-X
activity	B-X
.	B-X
In	B-X
some	B-X
cases	B-X
,	B-X
proteins	B-X
that	B-X
are	B-X
components	B-X
of	B-X
transcriptional	B-X
corepressor	B-X
complexes	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMO	B-X
E3	B-X
ligases	B-X
,	B-X
further	B-X
emphasizing	B-X
the	B-X
integration	B-X
of	B-X
sumoylation	B-X
with	B-X
the	B-X
regulation	B-X
of	B-X
chromatin	B-X
remodeling	B-X
.	B-X
Elucidating	B-X
the	B-X
dynamic	B-X
interplay	B-X
of	B-X
sumoylation	B-X
with	B-X
other	B-X
post-translational	B-X
modifications	B-X
of	B-X
histones	B-X
and	B-X
chromatin	B-X
associated	B-X
proteins	B-X
will	B-X
be	B-X
key	B-X
to	B-X
fully	B-X
understanding	B-X
the	B-X
regulation	B-X
of	B-X
access	B-X
to	B-X
the	B-X
chromatin	B-X
template	B-X
.	B-X

Although	O
many	O
SUMO	O
-	O
modified	O
transcription	O
factors	O
and	O
co	O
-	O
activators	O
have	O
been	O
identified	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
underlying	O
SUMOylation	O
-	O
elicited	O
transcriptional	O
repression	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

Here	O
,	O
we	O
summarize	O
that	O
SUMO	O
modification	O
of	O
transcription	O
factors	O
such	O
as	O
androgen	B-Protein
receptor	I-Protein
,	O
glucocorticoid	B-Protein
receptor	I-Protein
,	O
Smad4	B-Protein
and	O
CBP	B-Protein
[	O
CREB	B-Protein
(	I-Protein
cAMP	I-Protein
-	I-Protein
response	I-Protein
-	I-Protein
element	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
)	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
]	O
co	O
-	O
activator	O
results	O
in	O
the	O
recruitment	O
of	O
a	O
transcriptional	O
co	O
-	O
repressor	O
Daxx	B-Protein
,	O
thereby	O
causing	O
transcriptional	O
repression	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

Such	O
a	O
SUMO	O
-	O
dependent	O
recruitment	O
of	O
Daxx	B-Protein
is	O
mediated	O
by	O
the	O
interaction	O
between	O
the	O
SUMO	O
moiety	O
of	O
SUMOylated	O
factors	O
and	O
Daxx	B-Protein
SUMO	O
-	O
interacting	O
motif	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

Interestingly	O
,	O
the	O
transrepression	O
effect	O
of	O
Daxx	B-Protein
on	O
these	O
SUMOylated	O
transcription	O
factors	O
can	O
be	O
relieved	O
by	O
SUMOylated	O
PML	B-Protein
(	O
promyelocytic	B-Protein
leukaemia	I-Protein
)	O
via	O
altering	O
Daxx	B-Protein
partition	O
from	O
the	O
targeted	O
gene	O
promoter	O
to	O
PML	B-Protein
nuclear	O
bodies	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

Because	O
Daxx	B-Protein
SUMO	O
-	O
interacting	O
motif	O
is	O
a	O
common	O
binding	O
site	O
for	O
SUMOylated	O
factors	O
,	O
a	O
model	O
of	O
competition	O
for	O
Daxx	B-Protein
recruitment	O
between	O
SUMOylated	O
PML	B-Protein
and	O
SUMOylated	O
transcription	O
factors	O
was	O
proposed	O
.	O

Together	O
,	O
our	O
findings	O
strongly	O
suggest	O
that	O
Daxx	B-Protein
functions	O
as	O
a	O
SUMO	O
reader	O
in	O
the	O
SUMO	O
-	O
dependent	O
regulation	O
of	O
transcription	O
and	O
subnuclear	O
compartmentalization	O
.	O
<EOS>	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
)	B-X
modification	B-X
is	B-X
emerging	B-X
as	B-X
an	B-X
important	B-X
post-translational	B-X
control	B-X
in	B-X
transcription	B-X
.	B-X
In	B-X
general	B-X
,	B-X
SUMO	B-X
modification	B-X
is	B-X
associated	B-X
with	B-X
transcriptional	B-X
repression	B-X
.	B-X
Although	B-X
many	B-X
SUMO-modified	B-X
transcription	B-X
factors	B-X
and	B-X
co-activators	B-X
have	B-X
been	B-X
identified	B-X
,	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
mechanism	B-X
underlying	B-X
SUMOylation-elicited	B-X
transcriptional	B-X
repression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
summarize	B-X
that	B-X
SUMO	B-X
modification	B-X
of	B-X
transcription	B-X
factors	B-X
such	B-X
as	B-X
androgen	B-X
receptor	B-X
,	B-X
glucocorticoid	B-X
receptor	B-X
,	B-X
Smad4	B-X
and	B-X
CBP	B-X
[	B-X
CREB	B-X
(	B-X
cAMP-response-element-binding	B-X
protein	B-X
)	B-X
-binding	B-X
protein	B-X
]	B-X
co-activator	B-X
results	B-X
in	B-X
the	B-X
recruitment	B-X
of	B-X
a	B-X
transcriptional	B-X
co-repressor	B-X
Daxx	B-X
,	B-X
thereby	B-X
causing	B-X
transcriptional	B-X
repression	B-X
.	B-X
Such	B-X
a	B-X
SUMO-dependent	B-X
recruitment	B-X
of	B-X
Daxx	B-X
is	B-X
mediated	B-X
by	B-X
the	B-X
interaction	B-X
between	B-X
the	B-X
SUMO	B-X
moiety	B-X
of	B-X
SUMOylated	B-X
factors	B-X
and	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
transrepression	B-X
effect	B-X
of	B-X
Daxx	B-X
on	B-X
these	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
can	B-X
be	B-X
relieved	B-X
by	B-X
SUMOylated	B-X
PML	B-X
(	B-X
promyelocytic	B-X
leukaemia	B-X
)	B-X
via	B-X
altering	B-X
Daxx	B-X
partition	B-X
from	B-X
the	B-X
targeted	B-X
gene	B-X
promoter	B-X
to	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Because	B-X
Daxx	B-X
SUMO-interacting	B-X
motif	B-X
is	B-X
a	B-X
common	B-X
binding	B-X
site	B-X
for	B-X
SUMOylated	B-X
factors	B-X
,	B-X
a	B-X
model	B-X
of	B-X
competition	B-X
for	B-X
Daxx	B-X
recruitment	B-X
between	B-X
SUMOylated	B-X
PML	B-X
and	B-X
SUMOylated	B-X
transcription	B-X
factors	B-X
was	B-X
proposed	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
strongly	B-X
suggest	B-X
that	B-X
Daxx	B-X
functions	B-X
as	B-X
a	B-X
SUMO	B-X
reader	B-X
in	B-X
the	B-X
SUMO-dependent	B-X
regulation	B-X
of	B-X
transcription	B-X
and	B-X
subnuclear	B-X
compartmentalization	B-X
.	B-X

Drugs	O
affecting	O
prelamin	B-Protein
A	I-Protein
processing	O
:	O
effects	O
on	O
heterochromatin	O
organization	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

Increasing	O
interest	O
in	O
drugs	O
acting	O
on	O
prelamin	B-Protein
A	I-Protein
has	O
derived	O
from	O
the	O
finding	O
of	O
prelamin	B-Protein
A	I-Protein
involvement	O
in	O
severe	O
laminopathies	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

Amelioration	O
of	O
the	O
nuclear	O
morphology	O
by	O
inhibitors	O
of	O
prelamin	B-Protein
A	I-Protein
farnesylation	O
has	O
been	O
widely	O
reported	O
in	O
progeroid	O
laminopathies	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

We	O
investigated	O
the	O
effects	O
on	O
chromatin	O
organization	O
of	O
two	O
drugs	O
inhibiting	O
prelamin	B-Protein
A	I-Protein
processing	O
by	O
an	O
ultrastructural	O
and	O
biochemical	O
approach	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

The	O
farnesyltransferase	O
inhibitor	O
FTI	O
-	O
277	O
and	O
the	O
non	O
-	O
peptidomimetic	O
drug	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
farnesyl	O
-	O
l	O
-	O
cysteine	O
methylester	O
(	O
AFCMe	O
)	O
were	O
administered	O
to	O
cultured	O
control	O
human	O
fibroblasts	O
for	O
6	O
or	O
18	O
h	O
.	O
<EOS>	B-X
The	B-X
reaction	B-X
of	B-X
Li	B-X
(	B-X
2	B-X
)	B-X
(	B-X
C	B-X
(	B-X
14	B-X
)	B-X
H	B-X
(	B-X
18	B-X
)	B-X
)	B-X
(	B-X
TMEDA	B-X
)	B-X
(	B-X
x	B-X
)	B-X
with	B-X
UCl	B-X
(	B-X
4	B-X
)	B-X
yields	B-X
U	B-X
(	B-X
eta	B-X
(	B-X
8	B-X
)	B-X
-C	B-X
(	B-X
14	B-X
)	B-X
H	B-X
(	B-X
18	B-X
)	B-X
)	B-X
(	B-X
2	B-X
)	B-X
,	B-X
(	B-X
UPn	B-X
*	B-X
(	B-X
2	B-X
)	B-X
;	B-X
Pn	B-X
*	B-X
=	B-X
C	B-X
(	B-X
14	B-X
)	B-X
H	B-X
(	B-X
18	B-X
)	B-X
)	B-X
an	B-X
analogue	B-X
of	B-X
CePn	B-X
*	B-X
(	B-X
2	B-X
)	B-X
and	B-X
U	B-X
{	B-X
eta	B-X
(	B-X
8	B-X
)	B-X
-C	B-X
(	B-X
8	B-X
)	B-X
H	B-X
(	B-X
4	B-X
)	B-X
(	B-X
1,4-Si	B-X
(	B-X
i	B-X
)	B-X
Pr	B-X
(	B-X
3	B-X
)	B-X
)	B-X
(	B-X
2	B-X
)	B-X
}	B-X
(	B-X
2	B-X
)	B-X
.	B-X
The	B-X
UPn	B-X
*	B-X
(	B-X
2	B-X
)	B-X
molecule	B-X
is	B-X
structurally	B-X
characterised	B-X
via	B-X
a	B-X
variety	B-X
of	B-X
techniques	B-X
,	B-X
its	B-X
magnetism	B-X
is	B-X
probed	B-X
in	B-X
the	B-X
solution	B-X
and	B-X
solid	B-X
phase	B-X
and	B-X
the	B-X
redox	B-X
properties	B-X
are	B-X
investigated	B-X
using	B-X
cyclic	B-X
voltammetry	B-X
.	B-X
During	B-X
this	B-X
study	B-X
it	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
reducible	B-X
and	B-X
the	B-X
reduced	B-X
species	B-X
reacted	B-X
with	B-X
N	B-X
(	B-X
2	B-X
)	B-X
to	B-X
form	B-X
a	B-X
stable	B-X
complex	B-X
.	B-X
An	B-X
analogous	B-X
complex	B-X
was	B-X
not	B-X
found	B-X
under	B-X
Ar	B-X
.	B-X

FTI	O
-	O
277	O
interferes	O
with	O
protein	O
farnesylation	O
causing	O
accumulation	O
of	O
non	O
-	O
farnesylated	O
prelamin	B-Protein
A	I-Protein
,	O
while	O
AFCMe	O
impairs	O
the	O
last	O
cleavage	O
of	O
the	O
lamin	B-Protein
A	I-Protein
precursor	O
and	O
is	O
expected	O
to	O
accumulate	O
farnesylated	O
prelamin	B-Protein
A	I-Protein
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

FTI	O
-	O
277	O
caused	O
redistribution	O
of	O
heterochromatin	O
domains	O
at	O
the	O
nuclear	O
interior	O
,	O
while	O
AFCMe	O
caused	O
loss	O
of	O
heterochromatin	O
domains	O
,	O
increase	O
of	O
nuclear	O
size	O
and	O
nuclear	O
lamina	O
thickening	O
.	O
<EOS>	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

At	O
the	O
biochemical	O
level	O
,	O
heterochromatin	O
-	O
associated	O
proteins	O
and	O
LAP2	B-Protein
alpha	I-Protein
were	O
clustered	O
at	O
the	O
nuclear	O
interior	O
following	O
FTI	O
-	O
277	O
treatment	O
,	O
while	O
they	O
were	O
unevenly	O
distributed	O
or	O
absent	O
in	O
AFCMe	O
-	O
treated	O
nuclei	O
.	O
<EOS>	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

The	O
reported	O
effects	O
show	O
that	O
chromatin	O
is	O
an	O
immediate	O
target	O
of	O
FTI	O
-	O
277	O
and	O
AFCMe	O
and	O
that	O
dramatic	O
remodeling	O
of	O
chromatin	O
domains	O
occurs	O
following	O
treatment	O
with	O
the	O
drugs	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

These	O
effects	O
appear	O
to	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
accumulation	O
of	O
prelamin	B-Protein
A	I-Protein
forms	O
,	O
since	O
impairment	O
of	O
prelamin	B-Protein
A	I-Protein
accumulation	O
,	O
here	O
obtained	O
by	O
5	O
-	O
azadeoxycytidine	O
treatment	O
,	O
abolishes	O
the	O
chromatin	O
effects	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
At	B-X
the	B-X
biochemical	B-X
level	B-X
,	B-X
heterochromatin-associated	B-X
proteins	B-X
and	B-X
LAP2	B-X
alpha	B-X
were	B-X
clustered	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
following	B-X
FTI-277	B-X
treatment	B-X
,	B-X
while	B-X
they	B-X
were	B-X
unevenly	B-X
distributed	B-X
or	B-X
absent	B-X
in	B-X
AFCMe-treated	B-X
nuclei	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

These	O
results	O
may	O
be	O
used	O
to	O
evaluate	O
downstream	O
effects	O
of	O
FTIs	O
or	O
other	O
prelamin	B-Protein
A	I-Protein
inhibitors	O
potentially	O
useful	O
for	O
the	O
therapy	O
of	O
laminopathies	O
.	O
<EOS>	B-X
Increasing	B-X
interest	B-X
in	B-X
drugs	B-X
acting	B-X
on	B-X
prelamin	B-X
A	B-X
has	B-X
derived	B-X
from	B-X
the	B-X
finding	B-X
of	B-X
prelamin	B-X
A	B-X
involvement	B-X
in	B-X
severe	B-X
laminopathies	B-X
.	B-X
Amelioration	B-X
of	B-X
the	B-X
nuclear	B-X
morphology	B-X
by	B-X
inhibitors	B-X
of	B-X
prelamin	B-X
A	B-X
farnesylation	B-X
has	B-X
been	B-X
widely	B-X
reported	B-X
in	B-X
progeroid	B-X
laminopathies	B-X
.	B-X
We	B-X
investigated	B-X
the	B-X
effects	B-X
on	B-X
chromatin	B-X
organization	B-X
of	B-X
two	B-X
drugs	B-X
inhibiting	B-X
prelamin	B-X
A	B-X
processing	B-X
by	B-X
an	B-X
ultrastructural	B-X
and	B-X
biochemical	B-X
approach	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
inhibitor	B-X
FTI-277	B-X
and	B-X
the	B-X
non-peptidomimetic	B-X
drug	B-X
N-acetyl-S-farnesyl-l-cysteine	B-X
methylester	B-X
(	B-X
AFCMe	B-X
)	B-X
were	B-X
administered	B-X
to	B-X
cultured	B-X
control	B-X
human	B-X
fibroblasts	B-X
for	B-X
6	B-X
or	B-X
18	B-X
h.	B-X
FTI-277	B-X
interferes	B-X
with	B-X
protein	B-X
farnesylation	B-X
causing	B-X
accumulation	B-X
of	B-X
non-farnesylated	B-X
prelamin	B-X
A	B-X
,	B-X
while	B-X
AFCMe	B-X
impairs	B-X
the	B-X
last	B-X
cleavage	B-X
of	B-X
the	B-X
lamin	B-X
A	B-X
precursor	B-X
and	B-X
is	B-X
expected	B-X
to	B-X
accumulate	B-X
farnesylated	B-X
prelamin	B-X
A.	B-X
FTI-277	B-X
caused	B-X
redistribution	B-X
of	B-X
heterochromatin	B-X
domains	B-X
at	B-X
the	B-X
nuclear	B-X
interior	B-X
,	B-X
while	B-X
AFCMe	B-X
caused	B-X
loss	B-X
of	B-X
heterochromatin	B-X
domains	B-X
,	B-X
increase	B-X
of	B-X
nuclear	B-X
size	B-X
and	B-X
nuclear	B-X
lamina	B-X
thickening	B-X
.	B-X
The	B-X
reported	B-X
effects	B-X
show	B-X
that	B-X
chromatin	B-X
is	B-X
an	B-X
immediate	B-X
target	B-X
of	B-X
FTI-277	B-X
and	B-X
AFCMe	B-X
and	B-X
that	B-X
dramatic	B-X
remodeling	B-X
of	B-X
chromatin	B-X
domains	B-X
occurs	B-X
following	B-X
treatment	B-X
with	B-X
the	B-X
drugs	B-X
.	B-X
These	B-X
effects	B-X
appear	B-X
to	B-X
depend	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
on	B-X
the	B-X
accumulation	B-X
of	B-X
prelamin	B-X
A	B-X
forms	B-X
,	B-X
since	B-X
impairment	B-X
of	B-X
prelamin	B-X
A	B-X
accumulation	B-X
,	B-X
here	B-X
obtained	B-X
by	B-X
5-azadeoxycytidine	B-X
treatment	B-X
,	B-X
abolishes	B-X
the	B-X
chromatin	B-X
effects	B-X
.	B-X
These	B-X
results	B-X
may	B-X
be	B-X
used	B-X
to	B-X
evaluate	B-X
downstream	B-X
effects	B-X
of	B-X
FTIs	B-X
or	B-X
other	B-X
prelamin	B-X
A	B-X
inhibitors	B-X
potentially	B-X
useful	B-X
for	B-X
the	B-X
therapy	B-X
of	B-X
laminopathies	B-X
.	B-X

H2O2	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
determined	O
by	O
mass	O
spectrometry	O
:	O
redox	O
regulation	O
of	O
tyrosine	O
nitration	O
and	O
3	O
-	O
nitrotyrosine	O
reduction	O
by	O
antioxidants	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
of	B-X
proteins	B-X
by	B-X
endogenous	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
lead	B-X
to	B-X
cytotoxic	B-X
effects	B-X
that	B-X
are	B-X
implicated	B-X
in	B-X
diseases	B-X
associated	B-X
with	B-X
chronic	B-X
infections	B-X
and	B-X
inflammation	B-X
.	B-X
Tyrosine	B-X
nitration	B-X
is	B-X
a	B-X
major	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
by	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
nitrotyrosine	B-X
is	B-X
not	B-X
a	B-X
permanent	B-X
protein	B-X
modification	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
lipoyl	B-X
dehydrogenase	B-X
is	B-X
capable	B-X
of	B-X
converting	B-X
3-nitrotyrosine	B-X
into	B-X
3-aminotyrosine	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
certain	B-X
reducing	B-X
agents	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
The	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-induced	B-X
post-translational	B-X
modifications	B-X
of	B-X
human	B-X
hemoglobin	B-X
identified	B-X
by	B-X
nanoLC/nanospray	B-X
ionization	B-X
tandem	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
digest	B-X
include	B-X
nitration	B-X
of	B-X
tyrosine	B-X
and	B-X
tryptophan	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
.	B-X
Nitration	B-X
of	B-X
human	B-X
hemoglobin	B-X
by	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite	B-X
was	B-X
detected	B-X
on	B-X
Tyr24	B-X
and	B-X
Tyr42	B-X
(	B-X
alpha-chain	B-X
)	B-X
and	B-X
on	B-X
Tyr130	B-X
and	B-X
Trp15	B-X
(	B-X
beta-chain	B-X
)	B-X
in	B-X
the	B-X
alphabeta-dimer	B-X
.	B-X
Furthermore	B-X
,	B-X
hemoglobin	B-X
also	B-X
catalyzed	B-X
nitro	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
form	B-X
3-aminotyrosine	B-X
,	B-X
at	B-X
Tyr24	B-X
in	B-X
the	B-X
alpha-chain	B-X
peptide	B-X
of	B-X
human	B-X
Hb	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ascorbate	B-X
.	B-X
The	B-X
enhanced	B-X
peroxidase	B-X
activity	B-X
of	B-X
nitrated	B-X
hemoglobin	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
antioxidant	B-X
ascorbate	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
in	B-X
vivo	B-X
pathway	B-X
for	B-X
hemoglobin	B-X
contributing	B-X
to	B-X
denitration	B-X
of	B-X
nitrated	B-X
proteins	B-X
through	B-X
redox	B-X
regulation	B-X
.	B-X

Covalent	O
modifications	O
of	O
proteins	O
by	O
endogenous	O
reactive	O
nitrogen	O
oxide	O
species	O
lead	O
to	O
cytotoxic	O
effects	O
that	O
are	O
implicated	O
in	O
diseases	O
associated	O
with	O
chronic	O
infections	O
and	O
inflammation	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
of	B-X
proteins	B-X
by	B-X
endogenous	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
lead	B-X
to	B-X
cytotoxic	B-X
effects	B-X
that	B-X
are	B-X
implicated	B-X
in	B-X
diseases	B-X
associated	B-X
with	B-X
chronic	B-X
infections	B-X
and	B-X
inflammation	B-X
.	B-X
Tyrosine	B-X
nitration	B-X
is	B-X
a	B-X
major	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
by	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
The	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-induced	B-X
post-translational	B-X
modifications	B-X
of	B-X
human	B-X
hemoglobin	B-X
identified	B-X
by	B-X
nanoLC/nanospray	B-X
ionization	B-X
tandem	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
digest	B-X
include	B-X
nitration	B-X
of	B-X
tyrosine	B-X
and	B-X
tryptophan	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
in	B-X
vivo	B-X
pathway	B-X
for	B-X
hemoglobin	B-X
contributing	B-X
to	B-X
denitration	B-X
of	B-X
nitrated	B-X
proteins	B-X
through	B-X
redox	B-X
regulation	B-X
.	B-X

Tyrosine	O
nitration	O
is	O
a	O
major	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
by	O
reactive	O
nitrogen	O
oxide	O
species	O
.	O

Recent	O
studies	O
suggest	O
that	O
nitrotyrosine	O
is	O
not	O
a	O
permanent	O
protein	O
modification	O
.	O
<EOS>	B-X
These	B-X
findings	B-X
indicated	B-X
that	B-X
acetaminophen	B-X
was	B-X
metabolically	B-X
activated	B-X
by	B-X
cytochrome	B-X
P450	B-X
enzymes	B-X
to	B-X
a	B-X
reactive	B-X
metabolite	B-X
that	B-X
depleted	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
and	B-X
covalently	B-X
bound	B-X
to	B-X
protein	B-X
.	B-X
Recent	B-X
data	B-X
have	B-X
shown	B-X
that	B-X
nitrated	B-X
tyrosine	B-X
residues	B-X
as	B-X
well	B-X
as	B-X
acetaminophen	B-X
adducts	B-X
occur	B-X
in	B-X
the	B-X
necrotic	B-X
cells	B-X
following	B-X
toxic	B-X
doses	B-X
of	B-X
acetaminophen	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
NO	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
controlling	B-X
lipid	B-X
peroxidation	B-X
and	B-X
that	B-X
reactive	B-X
nitrogen/oxygen	B-X
species	B-X
may	B-X
be	B-X
important	B-X
in	B-X
toxicity	B-X
.	B-X
The	B-X
source	B-X
of	B-X
the	B-X
superoxide	B-X
has	B-X
not	B-X
been	B-X
identified	B-X
,	B-X
but	B-X
our	B-X
recent	B-X
finding	B-X
that	B-X
NADPH	B-X
oxidase	B-X
knockout	B-X
mice	B-X
were	B-X
equally	B-X
sensitive	B-X
to	B-X
acetaminophen	B-X
and	B-X
had	B-X
equal	B-X
nitration	B-X
of	B-X
tyrosine	B-X
suggests	B-X
that	B-X
the	B-X
superoxide	B-X
is	B-X
not	B-X
from	B-X
the	B-X
activation	B-X
of	B-X
Kupffer	B-X
cells	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
significance	B-X
of	B-X
cytokines	B-X
and	B-X
chemokines	B-X
in	B-X
the	B-X
development	B-X
of	B-X
toxicity	B-X
and	B-X
repair	B-X
processes	B-X
has	B-X
been	B-X
demonstrated	B-X
by	B-X
several	B-X
recent	B-X
studies	B-X
.	B-X
Other	B-X
cytokines	B-X
,	B-X
such	B-X
as	B-X
IL-10	B-X
,	B-X
macrophage	B-X
inhibitory	B-X
protein-2	B-X
(	B-X
MIP-2	B-X
)	B-X
,	B-X
and	B-X
monocyte	B-X
chemoattractant	B-X
protein-1	B-X
(	B-X
MCP-1	B-X
)	B-X
,	B-X
appear	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
hepatocyte	B-X
repair	B-X
and	B-X
the	B-X
regulation	B-X
of	B-X
proinflammatory	B-X
cytokines	B-X
.	B-X

We	O
previously	O
demonstrated	O
that	O
lipoyl	O
dehydrogenase	O
is	O
capable	O
of	O
converting	O
3	O
-	O
nitrotyrosine	O
into	O
3	O
-	O
aminotyrosine	O
in	O
the	O
presence	O
of	O
certain	O
reducing	O
agents	O
.	O
<EOS>	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
nitrotyrosine	B-X
is	B-X
not	B-X
a	B-X
permanent	B-X
protein	B-X
modification	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
lipoyl	B-X
dehydrogenase	B-X
is	B-X
capable	B-X
of	B-X
converting	B-X
3-nitrotyrosine	B-X
into	B-X
3-aminotyrosine	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
certain	B-X
reducing	B-X
agents	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
Nitration	B-X
of	B-X
human	B-X
hemoglobin	B-X
by	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite	B-X
was	B-X
detected	B-X
on	B-X
Tyr24	B-X
and	B-X
Tyr42	B-X
(	B-X
alpha-chain	B-X
)	B-X
and	B-X
on	B-X
Tyr130	B-X
and	B-X
Trp15	B-X
(	B-X
beta-chain	B-X
)	B-X
in	B-X
the	B-X
alphabeta-dimer	B-X
.	B-X
Furthermore	B-X
,	B-X
hemoglobin	B-X
also	B-X
catalyzed	B-X
nitro	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
form	B-X
3-aminotyrosine	B-X
,	B-X
at	B-X
Tyr24	B-X
in	B-X
the	B-X
alpha-chain	B-X
peptide	B-X
of	B-X
human	B-X
Hb	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ascorbate	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
compared	O
the	O
abilities	O
of	O
various	O
hemoproteins	O
,	O
hemin	O
,	O
and	O
the	O
cobalt	O
-	O
containing	O
cofactor	O
cyanocobalamin	O
to	O
mediate	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
dependent	O
tyrosine	O
nitration	O
and	O
found	O
that	O
these	O
hemoproteins	O
and	O
metal	O
-	O
containing	O
cofactors	O
also	O
catalyzed	O
the	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
various	O
extents	O
in	O
the	O
presence	O
of	O
thiol	O
reducing	O
agents	O
or	O
ascorbate	O
.	O
<EOS>	B-X
Ascorbate	B-X
acts	B-X
as	B-X
an	B-X
electron-donor	B-X
keeping	B-X
iron	B-X
in	B-X
the	B-X
ferrous	B-X
state	B-X
thereby	B-X
maintaining	B-X
the	B-X
full	B-X
activity	B-X
of	B-X
collagen	B-X
hydroxylases	B-X
;	B-X
parallel	B-X
reactions	B-X
with	B-X
a	B-X
variety	B-X
of	B-X
dioxygenases	B-X
affect	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
wide	B-X
array	B-X
of	B-X
genes	B-X
,	B-X
for	B-X
example	B-X
via	B-X
the	B-X
HIF	B-X
system	B-X
,	B-X
as	B-X
well	B-X
as	B-X
via	B-X
the	B-X
epigenetic	B-X
landscape	B-X
of	B-X
cells	B-X
and	B-X
tissues	B-X
.	B-X
In	B-X
fact	B-X
,	B-X
all	B-X
known	B-X
physiological	B-X
and	B-X
biochemical	B-X
functions	B-X
of	B-X
ascorbate	B-X
are	B-X
due	B-X
to	B-X
its	B-X
action	B-X
as	B-X
an	B-X
electron	B-X
donor	B-X
.	B-X
The	B-X
ability	B-X
to	B-X
donate	B-X
one	B-X
or	B-X
two	B-X
electrons	B-X
makes	B-X
AscH	B-X
(	B-X
-	B-X
)	B-X
an	B-X
excellent	B-X
reducing	B-X
agent	B-X
and	B-X
antioxidant	B-X
.	B-X
Ascorbate	B-X
readily	B-X
undergoes	B-X
pH-dependent	B-X
autoxidation	B-X
producing	B-X
hydrogen	B-X
peroxide	B-X
(	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
)	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
catalytic	B-X
metals	B-X
this	B-X
oxidation	B-X
is	B-X
accelerated	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
chemical	B-X
and	B-X
biochemical	B-X
nature	B-X
of	B-X
ascorbate	B-X
contribute	B-X
to	B-X
its	B-X
antioxidant	B-X
as	B-X
well	B-X
as	B-X
its	B-X
prooxidant	B-X
properties	B-X
.	B-X
administration	B-X
of	B-X
ascorbate	B-X
bypasses	B-X
the	B-X
tight	B-X
control	B-X
of	B-X
the	B-X
gut	B-X
producing	B-X
highly	B-X
elevated	B-X
plasma	B-X
levels	B-X
;	B-X
ascorbate	B-X
at	B-X
very	B-X
high	B-X
levels	B-X
can	B-X
act	B-X
as	B-X
prodrug	B-X
to	B-X
deliver	B-X
a	B-X
significant	B-X
flux	B-X
of	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
to	B-X
tumors	B-X
.	B-X
This	B-X
new	B-X
knowledge	B-X
has	B-X
rekindled	B-X
interest	B-X
and	B-X
spurred	B-X
new	B-X
research	B-X
into	B-X
the	B-X
clinical	B-X
potential	B-X
of	B-X
pharmacological	B-X
ascorbate	B-X
.	B-X
Knowledge	B-X
and	B-X
understanding	B-X
of	B-X
the	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
pharmacological	B-X
ascorbate	B-X
bring	B-X
a	B-X
rationale	B-X
to	B-X
its	B-X
use	B-X
to	B-X
treat	B-X
disease	B-X
especially	B-X
the	B-X
use	B-X
of	B-X
i.v	B-X
.	B-X
delivery	B-X
of	B-X
pharmacological	B-X
ascorbate	B-X
as	B-X
an	B-X
adjuvant	B-X
in	B-X
the	B-X
treatment	B-X
of	B-X
cancer	B-X
.	B-X

The	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
-	O
induced	O
post	O
-	O
translational	O
modifications	O
of	O
human	O
hemoglobin	O
identified	O
by	O
nanoLC	O
/	O
nanospray	O
ionization	O
tandem	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
digest	O
include	O
nitration	O
of	O
tyrosine	O
and	O
tryptophan	O
,	O
as	O
well	O
as	O
oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
.	O

Nitration	O
of	O
human	O
hemoglobin	O
by	O
H	O
(	O
2	O
)	O
O	O
(	O
2	O
)	O
/	O
nitrite	O
was	O
detected	O
on	O
Tyr24	O
and	O
Tyr42	O
(	O
alpha	B-Protein
-	I-Protein
chain	I-Protein
)	O
and	O
on	O
Tyr130	O
and	O
Trp15	O
(	O
beta	B-Protein
-	I-Protein
chain	I-Protein
)	O
in	O
the	O
alphabeta	O
-	O
dimer	O
.	O

Oxidation	O
of	O
methionine	O
and	O
cysteine	O
residues	O
was	O
also	O
observed	O
.	O
<EOS>	B-X
The	B-X
nuclear	B-X
isoform	B-X
of	B-X
dUTPase	B-X
is	B-X
a	B-X
164-amino-acids-long	B-X
protein	B-X
containing	B-X
three	B-X
cysteine	B-X
residues	B-X
.	B-X
nDut	B-X
's	B-X
starting	B-X
methionine	B-X
is	B-X
post-translationally	B-X
cleaved	B-X
,	B-X
leaving	B-X
four	B-X
unique	B-X
amino	B-X
acids	B-X
on	B-X
its	B-X
amino-terminus	B-X
including	B-X
one	B-X
cysteine	B-X
residue	B-X
(	B-X
C3	B-X
)	B-X
.	B-X
Using	B-X
mass	B-X
spectrometry	B-X
analyses	B-X
of	B-X
recombinant	B-X
dUTPase	B-X
constructs	B-X
,	B-X
we	B-X
have	B-X
discovered	B-X
an	B-X
intermolecular	B-X
disulfide	B-X
bridge	B-X
between	B-X
cysteine-3	B-X
of	B-X
each	B-X
nDut	B-X
monomer	B-X
.	B-X
We	B-X
have	B-X
found	B-X
that	B-X
these	B-X
two	B-X
residues	B-X
stabilize	B-X
a	B-X
dimer	B-X
configuration	B-X
that	B-X
is	B-X
unique	B-X
to	B-X
the	B-X
nDut	B-X
isoform	B-X
.	B-X
We	B-X
have	B-X
also	B-X
uncovered	B-X
an	B-X
intramolecular	B-X
disulfide	B-X
linkage	B-X
between	B-X
cysteine	B-X
residues	B-X
C78	B-X
and	B-X
C134	B-X
,	B-X
stabilizing	B-X
the	B-X
monomeric	B-X
state	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
We	B-X
observed	B-X
that	B-X
mDut	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
mixture	B-X
of	B-X
monomer	B-X
,	B-X
dimer	B-X
,	B-X
and	B-X
trimer	B-X
conformations	B-X
,	B-X
as	B-X
well	B-X
as	B-X
higher-order	B-X
subunit	B-X
interactions	B-X
.	B-X
In	B-X
light	B-X
of	B-X
this	B-X
and	B-X
our	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
nDut	B-X
possesses	B-X
a	B-X
redox	B-X
switch	B-X
whereby	B-X
cysteine	B-X
interactions	B-X
regulate	B-X
nDut	B-X
's	B-X
dUTP-hydrolyzing	B-X
activity	B-X
.	B-X

Furthermore	O
,	O
hemoglobin	O
also	O
catalyzed	O
nitro	O
reduction	O
of	O
3	O
-	O
nitrotyrosine	O
to	O
form	O
3	O
-	O
aminotyrosine	O
,	O
at	O
Tyr24	O
in	O
the	O
alpha	B-Protein
-	I-Protein
chain	I-Protein
peptide	O
of	O
human	O
Hb	O
in	O
the	O
presence	O
of	O
ascorbate	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
of	B-X
proteins	B-X
by	B-X
endogenous	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
lead	B-X
to	B-X
cytotoxic	B-X
effects	B-X
that	B-X
are	B-X
implicated	B-X
in	B-X
diseases	B-X
associated	B-X
with	B-X
chronic	B-X
infections	B-X
and	B-X
inflammation	B-X
.	B-X
Tyrosine	B-X
nitration	B-X
is	B-X
a	B-X
major	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
by	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
nitrotyrosine	B-X
is	B-X
not	B-X
a	B-X
permanent	B-X
protein	B-X
modification	B-X
.	B-X
We	B-X
previously	B-X
demonstrated	B-X
that	B-X
lipoyl	B-X
dehydrogenase	B-X
is	B-X
capable	B-X
of	B-X
converting	B-X
3-nitrotyrosine	B-X
into	B-X
3-aminotyrosine	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
certain	B-X
reducing	B-X
agents	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
The	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-induced	B-X
post-translational	B-X
modifications	B-X
of	B-X
human	B-X
hemoglobin	B-X
identified	B-X
by	B-X
nanoLC/nanospray	B-X
ionization	B-X
tandem	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
digest	B-X
include	B-X
nitration	B-X
of	B-X
tyrosine	B-X
and	B-X
tryptophan	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
.	B-X
Nitration	B-X
of	B-X
human	B-X
hemoglobin	B-X
by	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite	B-X
was	B-X
detected	B-X
on	B-X
Tyr24	B-X
and	B-X
Tyr42	B-X
(	B-X
alpha-chain	B-X
)	B-X
and	B-X
on	B-X
Tyr130	B-X
and	B-X
Trp15	B-X
(	B-X
beta-chain	B-X
)	B-X
in	B-X
the	B-X
alphabeta-dimer	B-X
.	B-X
Oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
was	B-X
also	B-X
observed	B-X
.	B-X
Furthermore	B-X
,	B-X
hemoglobin	B-X
also	B-X
catalyzed	B-X
nitro	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
form	B-X
3-aminotyrosine	B-X
,	B-X
at	B-X
Tyr24	B-X
in	B-X
the	B-X
alpha-chain	B-X
peptide	B-X
of	B-X
human	B-X
Hb	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ascorbate	B-X
.	B-X
The	B-X
enhanced	B-X
peroxidase	B-X
activity	B-X
of	B-X
nitrated	B-X
hemoglobin	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
antioxidant	B-X
ascorbate	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
in	B-X
vivo	B-X
pathway	B-X
for	B-X
hemoglobin	B-X
contributing	B-X
to	B-X
denitration	B-X
of	B-X
nitrated	B-X
proteins	B-X
through	B-X
redox	B-X
regulation	B-X
.	B-X

The	O
enhanced	O
peroxidase	O
activity	O
of	O
nitrated	O
hemoglobin	O
can	O
be	O
reversed	O
by	O
the	O
antioxidant	O
ascorbate	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
The	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-induced	B-X
post-translational	B-X
modifications	B-X
of	B-X
human	B-X
hemoglobin	B-X
identified	B-X
by	B-X
nanoLC/nanospray	B-X
ionization	B-X
tandem	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
digest	B-X
include	B-X
nitration	B-X
of	B-X
tyrosine	B-X
and	B-X
tryptophan	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
.	B-X
Nitration	B-X
of	B-X
human	B-X
hemoglobin	B-X
by	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite	B-X
was	B-X
detected	B-X
on	B-X
Tyr24	B-X
and	B-X
Tyr42	B-X
(	B-X
alpha-chain	B-X
)	B-X
and	B-X
on	B-X
Tyr130	B-X
and	B-X
Trp15	B-X
(	B-X
beta-chain	B-X
)	B-X
in	B-X
the	B-X
alphabeta-dimer	B-X
.	B-X
Furthermore	B-X
,	B-X
hemoglobin	B-X
also	B-X
catalyzed	B-X
nitro	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
form	B-X
3-aminotyrosine	B-X
,	B-X
at	B-X
Tyr24	B-X
in	B-X
the	B-X
alpha-chain	B-X
peptide	B-X
of	B-X
human	B-X
Hb	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ascorbate	B-X
.	B-X
The	B-X
enhanced	B-X
peroxidase	B-X
activity	B-X
of	B-X
nitrated	B-X
hemoglobin	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
antioxidant	B-X
ascorbate	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
in	B-X
vivo	B-X
pathway	B-X
for	B-X
hemoglobin	B-X
contributing	B-X
to	B-X
denitration	B-X
of	B-X
nitrated	B-X
proteins	B-X
through	B-X
redox	B-X
regulation	B-X
.	B-X

These	O
results	O
suggest	O
a	O
possible	O
in	O
vivo	O
pathway	O
for	O
hemoglobin	O
contributing	O
to	O
denitration	O
of	O
nitrated	O
proteins	O
through	O
redox	O
regulation	O
.	O
<EOS>	B-X
Covalent	B-X
modifications	B-X
of	B-X
proteins	B-X
by	B-X
endogenous	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
lead	B-X
to	B-X
cytotoxic	B-X
effects	B-X
that	B-X
are	B-X
implicated	B-X
in	B-X
diseases	B-X
associated	B-X
with	B-X
chronic	B-X
infections	B-X
and	B-X
inflammation	B-X
.	B-X
Tyrosine	B-X
nitration	B-X
is	B-X
a	B-X
major	B-X
post-translational	B-X
modification	B-X
of	B-X
proteins	B-X
by	B-X
reactive	B-X
nitrogen	B-X
oxide	B-X
species	B-X
.	B-X
Recent	B-X
studies	B-X
suggest	B-X
that	B-X
nitrotyrosine	B-X
is	B-X
not	B-X
a	B-X
permanent	B-X
protein	B-X
modification	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
compared	B-X
the	B-X
abilities	B-X
of	B-X
various	B-X
hemoproteins	B-X
,	B-X
hemin	B-X
,	B-X
and	B-X
the	B-X
cobalt-containing	B-X
cofactor	B-X
cyanocobalamin	B-X
to	B-X
mediate	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-dependent	B-X
tyrosine	B-X
nitration	B-X
and	B-X
found	B-X
that	B-X
these	B-X
hemoproteins	B-X
and	B-X
metal-containing	B-X
cofactors	B-X
also	B-X
catalyzed	B-X
the	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
various	B-X
extents	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
thiol	B-X
reducing	B-X
agents	B-X
or	B-X
ascorbate	B-X
.	B-X
The	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite-induced	B-X
post-translational	B-X
modifications	B-X
of	B-X
human	B-X
hemoglobin	B-X
identified	B-X
by	B-X
nanoLC/nanospray	B-X
ionization	B-X
tandem	B-X
mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
digest	B-X
include	B-X
nitration	B-X
of	B-X
tyrosine	B-X
and	B-X
tryptophan	B-X
,	B-X
as	B-X
well	B-X
as	B-X
oxidation	B-X
of	B-X
methionine	B-X
and	B-X
cysteine	B-X
residues	B-X
.	B-X
Nitration	B-X
of	B-X
human	B-X
hemoglobin	B-X
by	B-X
H	B-X
(	B-X
2	B-X
)	B-X
O	B-X
(	B-X
2	B-X
)	B-X
/nitrite	B-X
was	B-X
detected	B-X
on	B-X
Tyr24	B-X
and	B-X
Tyr42	B-X
(	B-X
alpha-chain	B-X
)	B-X
and	B-X
on	B-X
Tyr130	B-X
and	B-X
Trp15	B-X
(	B-X
beta-chain	B-X
)	B-X
in	B-X
the	B-X
alphabeta-dimer	B-X
.	B-X
Furthermore	B-X
,	B-X
hemoglobin	B-X
also	B-X
catalyzed	B-X
nitro	B-X
reduction	B-X
of	B-X
3-nitrotyrosine	B-X
to	B-X
form	B-X
3-aminotyrosine	B-X
,	B-X
at	B-X
Tyr24	B-X
in	B-X
the	B-X
alpha-chain	B-X
peptide	B-X
of	B-X
human	B-X
Hb	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
ascorbate	B-X
.	B-X
The	B-X
enhanced	B-X
peroxidase	B-X
activity	B-X
of	B-X
nitrated	B-X
hemoglobin	B-X
can	B-X
be	B-X
reversed	B-X
by	B-X
the	B-X
antioxidant	B-X
ascorbate	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
a	B-X
possible	B-X
in	B-X
vivo	B-X
pathway	B-X
for	B-X
hemoglobin	B-X
contributing	B-X
to	B-X
denitration	B-X
of	B-X
nitrated	B-X
proteins	B-X
through	B-X
redox	B-X
regulation	B-X
.	B-X

Specific	O
ion	O
influences	O
on	O
self	O
-	O
association	O
of	O
pyruvate	B-Protein
dehydrogenase	I-Protein
kinase	I-Protein
isoform	I-Protein
2	I-Protein
(	O
PDHK2	B-Protein
)	O
,	O
binding	O
of	O
PDHK2	B-Protein
to	O
the	O
L2	O
lipoyl	O
domain	O
,	O
and	O
effects	O
of	O
the	O
lipoyl	O
group	O
-	O
binding	O
site	O
inhibitor	O
,	O
Nov3r	O
.	O

Association	O
of	O
the	O
PDHK2	B-Protein
and	O
GST	B-Protein
-	O
L2	O
(	O
glutathione	B-Protein
-	I-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
fused	O
to	O
the	O
inner	O
lipoyl	O
domain	O
(	O
L2	O
)	O
of	O
dihydrolipoyl	B-Protein
acetyltransferase	I-Protein
(	O
E2	B-Protein
)	O
)	O
dimers	O
was	O
enhanced	O
by	O
K	O
+	O
with	O
higher	O
affinity	O
K	O
+	O
binding	O
than	O
occurs	O
at	O
the	O
PDHK2	B-Protein
active	O
site	O
.	O

Supporting	O
a	O
distinct	O
K	O
+	O
binding	O
site	O
,	O
the	O
NH4	O
+	O
ion	O
did	O
not	O
effectively	O
replace	O
K	O
+	O
in	O
aiding	O
GST	B-Protein
-	O
L2	O
binding	O
.	O
<EOS>	B-X
Thrombin-binding	B-X
aptamers	B-X
are	B-X
promising	B-X
anticoagulants	B-X
.	B-X
Aptamer-thrombin	B-X
interactions	B-X
are	B-X
mediated	B-X
with	B-X
two	B-X
TT-loops	B-X
that	B-X
bind	B-X
thrombin	B-X
exosite	B-X
I	B-X
.	B-X
Several	B-X
cations	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
coordinated	B-X
inside	B-X
the	B-X
G-quadruplex	B-X
,	B-X
including	B-X
K	B-X
An	B-X
alpha	B-X
2-adrenoceptor	B-X
antagonist	B-X
,	B-X
idazoxan	B-X
,	B-X
that	B-X
binds	B-X
to	B-X
both	B-X
alpha	B-X
2-adrenoceptors	B-X
and	B-X
to	B-X
imidazoline	B-X
sites	B-X
(	B-X
IR	B-X
)	B-X
,	B-X
has	B-X
been	B-X
used	B-X
to	B-X
characterize	B-X
human	B-X
placental	B-X
IR	B-X
.	B-X
Human	B-X
placenta	B-X
is	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
richest	B-X
source	B-X
of	B-X
IR	B-X
(	B-X
1800	B-X
+/-	B-X
100	B-X
fmol	B-X
mg-1	B-X
protein	B-X
;	B-X
Kd	B-X
38.9	B-X
+/-	B-X
3.4	B-X
nM	B-X
)	B-X
.	B-X
[	B-X
3H	B-X
]	B-X
-idazoxan	B-X
did	B-X
not	B-X
show	B-X
binding	B-X
characteristics	B-X
of	B-X
alpha	B-X
2-adrenoceptors	B-X
in	B-X
human	B-X
placental	B-X
membranes	B-X
or	B-X
human	B-X
trophoblastic	B-X
cells	B-X
,	B-X
thus	B-X
making	B-X
it	B-X
a	B-X
ligand	B-X
of	B-X
choice	B-X
to	B-X
study	B-X
the	B-X
imidazoline	B-X
site	B-X
.	B-X
IRs	B-X
are	B-X
localized	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
the	B-X
release	B-X
of	B-X
bound	B-X
[	B-X
3H	B-X
]	B-X
-idazoxan	B-X
from	B-X
cells	B-X
,	B-X
when	B-X
washed	B-X
with	B-X
high	B-X
ionic/acidic	B-X
medium	B-X
.	B-X
The	B-X
high	B-X
affinity	B-X
was	B-X
used	B-X
as	B-X
a	B-X
criterion	B-X
to	B-X
classify	B-X
IR	B-X
to	B-X
IRa	B-X
subtype	B-X
(	B-X
placenta	B-X
,	B-X
rabbit	B-X
kidney	B-X
,	B-X
rabbit	B-X
liver	B-X
and	B-X
rabbit	B-X
adipose	B-X
cells	B-X
)	B-X
as	B-X
opposed	B-X
to	B-X
the	B-X
IRb	B-X
subtype	B-X
which	B-X
display	B-X
low	B-X
affinity	B-X
for	B-X
amiloride	B-X
(	B-X
greater	B-X
than	B-X
2	B-X
microM	B-X
,	B-X
in	B-X
all	B-X
the	B-X
other	B-X
tissues	B-X
)	B-X
.6	B-X
.	B-X
Several	B-X
novel	B-X
ligands	B-X
comprising	B-X
a	B-X
guanido	B-X
functional	B-X
group	B-X
attached	B-X
to	B-X
an	B-X
aromatic	B-X
residue	B-X
(	B-X
e.g	B-X
.	B-X
benziliden-amino-guanidine	B-X
(	B-X
BAG	B-X
)	B-X
,	B-X
guanido	B-X
pyrole	B-X
)	B-X
display	B-X
pronounced	B-X
selectivity	B-X
for	B-X
IR	B-X
over	B-X
the	B-X
M2-adrenoceptors	B-X
as	B-X
the	B-X
affinity	B-X
of	B-X
BAG	B-X
is	B-X
about	B-X
40	B-X
fold	B-X
higher	B-X
(	B-X
Kd=	B-X
18.9	B-X
+/-	B-X
13.8	B-X
nM	B-X
in	B-X
human	B-X
placenta	B-X
)	B-X
,	B-X
than	B-X
the	B-X
affinity	B-X
for	B-X
M2-adrenoceptors	B-X
(	B-X
Kd	B-X
=	B-X
768	B-X
+/-	B-X
299	B-X
nM	B-X
in	B-X
human	B-X
platelets	B-X
)	B-X
.	B-X
Imidazoline	B-X
sites	B-X
bind	B-X
selectively	B-X
BAG	B-X
and	B-X
other	B-X
guanido	B-X
ligands	B-X
thus	B-X
indicating	B-X
a	B-X
distinct	B-X
structural	B-X
requirement	B-X
at	B-X
its	B-X
site	B-X
of	B-X
binding.7	B-X
.	B-X
K+	B-X
channel	B-X
blockers	B-X
and	B-X
monovalent	B-X
ions	B-X
(	B-X
e.g	B-X
.	B-X
Cs	B-X
'	B-X
and	B-X
NH4+	B-X
)	B-X
interfere	B-X
with	B-X
idazoxan	B-X
binding	B-X
to	B-X
IR	B-X
,	B-X
indicating	B-X
a	B-X
possible	B-X
involvement	B-X
of	B-X
IR	B-X
in	B-X
K+	B-X
transport	B-X
.	B-X

With	O
50	O
mM	O
K	O
+	O
,	O
Pi	O
enhanced	O
interference	O
by	O
ADP	O
,	O
ATP	O
,	O
or	O
pyruvate	O
of	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
.	O
<EOS>	B-X
Tryptophan	B-X
fluorescence	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
binding	B-X
of	B-X
ligands	B-X
to	B-X
human	B-X
pyruvate	B-X
dehydrogenase	B-X
isoform	B-X
2	B-X
(	B-X
PDHK2	B-X
)	B-X
and	B-X
to	B-X
demonstrate	B-X
effects	B-X
of	B-X
ligand	B-X
binding	B-X
on	B-X
distal	B-X
structure	B-X
of	B-X
PDHK2	B-X
that	B-X
is	B-X
required	B-X
for	B-X
binding	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
the	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
.	B-X
Ligand-altered	B-X
binding	B-X
of	B-X
PDHK2	B-X
to	B-X
L2	B-X
and	B-X
effects	B-X
of	B-X
specific	B-X
ligands	B-X
on	B-X
PDHK2	B-X
oligomeric	B-X
state	B-X
were	B-X
characterized	B-X
by	B-X
analytical	B-X
ultracentrifugation	B-X
.	B-X
ATP	B-X
,	B-X
ADP	B-X
,	B-X
and	B-X
pyruvate	B-X
markedly	B-X
quenched	B-X
the	B-X
tryptophan	B-X
fluorescence	B-X
of	B-X
PDHK2	B-X
and	B-X
gave	B-X
maximum	B-X
quenching/L0.5	B-X
estimates	B-X
:	B-X
approximately	B-X
53	B-X
%	B-X
/3	B-X
microM	B-X
for	B-X
ATP	B-X
;	B-X
approximately	B-X
49	B-X
%	B-X
/15	B-X
microM	B-X
for	B-X
ADP	B-X
;	B-X
and	B-X
approximately	B-X
71	B-X
%	B-X
/approximately	B-X
590	B-X
microM	B-X
for	B-X
pyruvate	B-X
.	B-X
The	B-X
conversion	B-X
of	B-X
Trp-383	B-X
to	B-X
phenylalanine	B-X
completely	B-X
removed	B-X
ATP-	B-X
and	B-X
ADP-induced	B-X
quenching	B-X
and	B-X
>	B-X
or	B-X
=	B-X
80	B-X
%	B-X
of	B-X
the	B-X
absolute	B-X
decrease	B-X
in	B-X
fluorescence	B-X
due	B-X
to	B-X
pyruvate	B-X
.	B-X
The	B-X
W383F-PDHK2	B-X
mutant	B-X
retained	B-X
high	B-X
catalytic	B-X
activity	B-X
.	B-X
Pyruvate	B-X
,	B-X
added	B-X
after	B-X
ADP	B-X
,	B-X
quenched	B-X
Trp	B-X
fluorescence	B-X
with	B-X
an	B-X
L0.5	B-X
of	B-X
3.4	B-X
microM	B-X
pyruvate	B-X
,	B-X
>	B-X
or	B-X
=	B-X
150-fold	B-X
lower	B-X
concentration	B-X
than	B-X
needed	B-X
with	B-X
pyruvate	B-X
alone	B-X
.	B-X
ADP-enhanced	B-X
binding	B-X
of	B-X
pyruvate	B-X
was	B-X
maintained	B-X
with	B-X
W383F-PDHK2	B-X
.	B-X
Binding	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
L2	B-X
is	B-X
enhanced	B-X
when	B-X
L2	B-X
are	B-X
housed	B-X
in	B-X
oligomeric	B-X
structures	B-X
,	B-X
including	B-X
the	B-X
glutathione	B-X
S-transferase	B-X
(	B-X
GST	B-X
)	B-X
-L2	B-X
dimer	B-X
,	B-X
and	B-X
further	B-X
strengthened	B-X
by	B-X
reduction	B-X
of	B-X
the	B-X
lipoyl	B-X
groups	B-X
(	B-X
GST-L2	B-X
(	B-X
red	B-X
)	B-X
)	B-X
(	B-X
Hiromasa	B-X
and	B-X
Roche	B-X
(	B-X
2003	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
Binding	B-X
of	B-X
PDHK2	B-X
to	B-X
GST-L2	B-X
(	B-X
red	B-X
)	B-X
was	B-X
modestly	B-X
hindered	B-X
by	B-X
200	B-X
microM	B-X
level	B-X
of	B-X
ATP	B-X
or	B-X
ADP	B-X
or	B-X
5.0	B-X
mM	B-X
pyruvate	B-X
;	B-X
a	B-X
marked	B-X
change	B-X
to	B-X
nearly	B-X
complete	B-X
prevention	B-X
of	B-X
binding	B-X
was	B-X
observed	B-X
with	B-X
ATP	B-X
or	B-X
ADP	B-X
plus	B-X
pyruvate	B-X
at	B-X
only	B-X
100	B-X
microM	B-X
levels	B-X
,	B-X
and	B-X
these	B-X
conditions	B-X
caused	B-X
PDHK2	B-X
dimer	B-X
to	B-X
associate	B-X
to	B-X
a	B-X
tetramer	B-X
.	B-X
These	B-X
changes	B-X
should	B-X
make	B-X
major	B-X
contributions	B-X
to	B-X
synergistic	B-X
inhibition	B-X
of	B-X
PDHK2	B-X
activity	B-X
by	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Ligand-induced	B-X
changes	B-X
that	B-X
interfere	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
(	B-X
red	B-X
)	B-X
may	B-X
involve	B-X
release	B-X
of	B-X
an	B-X
interdomain	B-X
cross	B-X
arm	B-X
between	B-X
PDHK2	B-X
subunits	B-X
in	B-X
which	B-X
Trp-383	B-X
plays	B-X
a	B-X
critical	B-X
anchoring	B-X
role	B-X
.	B-X

The	O
inclusion	O
of	O
Pi	O
with	O
ADP	O
or	O
ATP	O
plus	O
pyruvate	O
greatly	O
hindered	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
and	O
promoted	O
PDHK2	O
forming	O
a	O
tetramer	O
.	O
<EOS>	B-X
It	B-X
is	B-X
also	B-X
a	B-X
very	B-X
sensitive	B-X
technique	B-X
for	B-X
localizing	B-X
nonhomogeneous	B-X
inflammation	B-X
in	B-X
inflammatory	B-X
myopathies	B-X
such	B-X
as	B-X
dermatomyositis	B-X
,	B-X
juvenile	B-X
dermatomyositis	B-X
,	B-X
amyopathic	B-X
dermatomyositis	B-X
,	B-X
polymyositis	B-X
,	B-X
and	B-X
inclusion	B-X
body	B-X
myositis	B-X
.	B-X
With	B-X
P-31	B-X
MRS	B-X
,	B-X
biochemical	B-X
defects	B-X
are	B-X
quantitated	B-X
,	B-X
including	B-X
low	B-X
levels	B-X
of	B-X
ATP	B-X
and	B-X
phosphocreatine	B-X
(	B-X
PCr	B-X
)	B-X
and	B-X
elevated	B-X
concentrations	B-X
of	B-X
ADP	B-X
and	B-X
inorganic	B-X
phosphate	B-X
(	B-X
Pi	B-X
)	B-X
,	B-X
which	B-X
may	B-X
all	B-X
be	B-X
related	B-X
to	B-X
weakness	B-X
and	B-X
fatigue	B-X
.	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
Supporting	B-X
a	B-X
distinct	B-X
K+	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
NH4+	B-X
ion	B-X
did	B-X
not	B-X
effectively	B-X
replace	B-X
K+	B-X
in	B-X
aiding	B-X
GST-L2	B-X
binding	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Reciprocally	B-X
,	B-X
GST-L2	B-X
interference	B-X
with	B-X
ATP/ADP	B-X
binding	B-X
also	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
was	B-X
increased	B-X
by	B-X
Pi	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Reciprocally	O
,	O
GST	B-Protein
-	O
L2	O
interference	O
with	O
ATP	O
/	O
ADP	O
binding	O
also	O
required	O
elevated	O
K	O
+	O
and	O
was	O
increased	O
by	O
Pi	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
Supporting	B-X
a	B-X
distinct	B-X
K+	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
NH4+	B-X
ion	B-X
did	B-X
not	B-X
effectively	B-X
replace	B-X
K+	B-X
in	B-X
aiding	B-X
GST-L2	B-X
binding	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Reciprocally	B-X
,	B-X
GST-L2	B-X
interference	B-X
with	B-X
ATP/ADP	B-X
binding	B-X
also	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
was	B-X
increased	B-X
by	B-X
Pi	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Potent	O
inhibition	O
by	O
Nov3r	O
of	O
E2	B-Protein
-	O
activated	O
PDHK2	B-Protein
activity	O
(	O
IC50	O
of	O
approximately	O
7	O
.	O
8	O
nM	O
)	O
required	O
elevated	O
K	O
+	O
and	O
Pi	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
Supporting	B-X
a	B-X
distinct	B-X
K+	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
NH4+	B-X
ion	B-X
did	B-X
not	B-X
effectively	B-X
replace	B-X
K+	B-X
in	B-X
aiding	B-X
GST-L2	B-X
binding	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Reciprocally	B-X
,	B-X
GST-L2	B-X
interference	B-X
with	B-X
ATP/ADP	B-X
binding	B-X
also	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
was	B-X
increased	B-X
by	B-X
Pi	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Nov3r	O
only	O
modestly	O
inhibited	O
the	O
low	O
activity	O
of	O
PDHK2	B-Protein
without	O
E2	B-Protein
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

By	O
binding	O
at	O
the	O
lipoyl	O
group	O
binding	O
site	O
,	O
Nov3r	O
prevented	O
PDHK2	O
binding	O
to	O
E2	B-Protein
and	O
GST	B-Protein
-	O
L2	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
Supporting	B-X
a	B-X
distinct	B-X
K+	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
NH4+	B-X
ion	B-X
did	B-X
not	B-X
effectively	B-X
replace	B-X
K+	B-X
in	B-X
aiding	B-X
GST-L2	B-X
binding	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Reciprocally	B-X
,	B-X
GST-L2	B-X
interference	B-X
with	B-X
ATP/ADP	B-X
binding	B-X
also	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
was	B-X
increased	B-X
by	B-X
Pi	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Nov3r	O
interfered	O
with	O
high	O
-	O
affinity	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
via	O
a	O
Pi	O
-	O
dependent	O
mechanism	O
.	O

Thus	O
,	O
GST	B-Protein
-	O
L2	O
binding	O
to	O
PDHK2	B-Protein
is	O
supported	O
by	O
K	O
+	O
binding	O
at	O
a	O
site	O
distinct	O
from	O
the	O
active	O
site	O
.	O

Pi	O
makes	O
major	O
contributions	O
to	O
ligands	O
interfering	O
with	O
PDHK2	B-Protein
binding	O
to	O
GST	B-Protein
-	O
L2	O
,	O
the	O
conversion	O
of	O
PDHK2	B-Protein
dimer	O
to	O
a	O
tetramer	O
,	O
and	O
Nov3r	O
(	O
an	O
acetyl	O
-	O
lipoate	O
analog	O
)	O
interfering	O
with	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
.	O
<EOS>	B-X
Association	B-X
of	B-X
the	B-X
PDHK2	B-X
and	B-X
GST-L2	B-X
(	B-X
glutathione-S-transferase	B-X
fused	B-X
to	B-X
the	B-X
inner	B-X
lipoyl	B-X
domain	B-X
(	B-X
L2	B-X
)	B-X
of	B-X
dihydrolipoyl	B-X
acetyltransferase	B-X
(	B-X
E2	B-X
)	B-X
)	B-X
dimers	B-X
was	B-X
enhanced	B-X
by	B-X
K+	B-X
with	B-X
higher	B-X
affinity	B-X
K+	B-X
binding	B-X
than	B-X
occurs	B-X
at	B-X
the	B-X
PDHK2	B-X
active	B-X
site	B-X
.	B-X
Supporting	B-X
a	B-X
distinct	B-X
K+	B-X
binding	B-X
site	B-X
,	B-X
the	B-X
NH4+	B-X
ion	B-X
did	B-X
not	B-X
effectively	B-X
replace	B-X
K+	B-X
in	B-X
aiding	B-X
GST-L2	B-X
binding	B-X
.	B-X
With	B-X
50	B-X
mM	B-X
K+	B-X
,	B-X
Pi	B-X
enhanced	B-X
interference	B-X
by	B-X
ADP	B-X
,	B-X
ATP	B-X
,	B-X
or	B-X
pyruvate	B-X
of	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
.	B-X
The	B-X
inclusion	B-X
of	B-X
Pi	B-X
with	B-X
ADP	B-X
or	B-X
ATP	B-X
plus	B-X
pyruvate	B-X
greatly	B-X
hindered	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
and	B-X
promoted	B-X
PDHK2	B-X
forming	B-X
a	B-X
tetramer	B-X
.	B-X
Reciprocally	B-X
,	B-X
GST-L2	B-X
interference	B-X
with	B-X
ATP/ADP	B-X
binding	B-X
also	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
was	B-X
increased	B-X
by	B-X
Pi	B-X
.	B-X
Potent	B-X
inhibition	B-X
by	B-X
Nov3r	B-X
of	B-X
E2-activated	B-X
PDHK2	B-X
activity	B-X
(	B-X
IC50	B-X
of	B-X
approximately	B-X
7.8	B-X
nM	B-X
)	B-X
required	B-X
elevated	B-X
K+	B-X
and	B-X
Pi	B-X
.	B-X
Nov3r	B-X
only	B-X
modestly	B-X
inhibited	B-X
the	B-X
low	B-X
activity	B-X
of	B-X
PDHK2	B-X
without	B-X
E2	B-X
.	B-X
By	B-X
binding	B-X
at	B-X
the	B-X
lipoyl	B-X
group	B-X
binding	B-X
site	B-X
,	B-X
Nov3r	B-X
prevented	B-X
PDHK2	B-X
binding	B-X
to	B-X
E2	B-X
and	B-X
GST-L2	B-X
.	B-X
Nov3r	B-X
interfered	B-X
with	B-X
high-affinity	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
via	B-X
a	B-X
Pi-dependent	B-X
mechanism	B-X
.	B-X
Thus	B-X
,	B-X
GST-L2	B-X
binding	B-X
to	B-X
PDHK2	B-X
is	B-X
supported	B-X
by	B-X
K+	B-X
binding	B-X
at	B-X
a	B-X
site	B-X
distinct	B-X
from	B-X
the	B-X
active	B-X
site	B-X
.	B-X
Pi	B-X
makes	B-X
major	B-X
contributions	B-X
to	B-X
ligands	B-X
interfering	B-X
with	B-X
PDHK2	B-X
binding	B-X
to	B-X
GST-L2	B-X
,	B-X
the	B-X
conversion	B-X
of	B-X
PDHK2	B-X
dimer	B-X
to	B-X
a	B-X
tetramer	B-X
,	B-X
and	B-X
Nov3r	B-X
(	B-X
an	B-X
acetyl-lipoate	B-X
analog	B-X
)	B-X
interfering	B-X
with	B-X
binding	B-X
of	B-X
ADP	B-X
and	B-X
pyruvate	B-X
.	B-X
Pi	B-X
is	B-X
suggested	B-X
to	B-X
facilitate	B-X
transmission	B-X
within	B-X
PDHK2	B-X
of	B-X
the	B-X
stimulatory	B-X
signal	B-X
of	B-X
acetylation	B-X
from	B-X
the	B-X
distal	B-X
lipoyl-group	B-X
binding	B-X
site	B-X
to	B-X
the	B-X
active	B-X
site	B-X
.	B-X

Pi	O
is	O
suggested	O
to	O
facilitate	O
transmission	O
within	O
PDHK2	B-Protein
of	O
the	O
stimulatory	O
signal	O
of	O
acetylation	O
from	O
the	O
distal	O
lipoyl	O
-	O
group	O
binding	O
site	O
to	O
the	O
active	O
site	O
.	O

Studies	O
of	O
the	O
ubiquitin	B-Protein
proteasome	O
system	O
.	O
<EOS>	B-X
As	B-X
the	B-X
endpoint	B-X
for	B-X
the	B-X
ubiquitin-proteasome	B-X
system	B-X
,	B-X
the	B-X
26S	B-X
proteasome	B-X
is	B-X
the	B-X
principal	B-X
proteolytic	B-X
machine	B-X
responsible	B-X
for	B-X
regulated	B-X
protein	B-X
degradation	B-X
in	B-X
eukaryotic	B-X
cells	B-X
.	B-X
The	B-X
proteasome	B-X
's	B-X
cellular	B-X
functions	B-X
range	B-X
from	B-X
general	B-X
protein	B-X
homeostasis	B-X
and	B-X
stress	B-X
response	B-X
to	B-X
the	B-X
control	B-X
of	B-X
vital	B-X
processes	B-X
such	B-X
as	B-X
cell	B-X
division	B-X
and	B-X
signal	B-X
transduction	B-X
.	B-X
To	B-X
reliably	B-X
process	B-X
all	B-X
the	B-X
proteins	B-X
presented	B-X
to	B-X
it	B-X
in	B-X
the	B-X
complex	B-X
cellular	B-X
environment	B-X
,	B-X
the	B-X
proteasome	B-X
must	B-X
combine	B-X
high	B-X
promiscuity	B-X
with	B-X
exceptional	B-X
substrate	B-X
selectivity	B-X
.	B-X
Recent	B-X
structural	B-X
and	B-X
biochemical	B-X
studies	B-X
have	B-X
shed	B-X
new	B-X
light	B-X
on	B-X
the	B-X
many	B-X
steps	B-X
involved	B-X
in	B-X
proteasomal	B-X
substrate	B-X
processing	B-X
,	B-X
including	B-X
recognition	B-X
,	B-X
deubiquitination	B-X
,	B-X
and	B-X
ATP-driven	B-X
translocation	B-X
and	B-X
unfolding	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
these	B-X
studies	B-X
revealed	B-X
a	B-X
complex	B-X
conformational	B-X
landscape	B-X
that	B-X
ensures	B-X
proper	B-X
substrate	B-X
selection	B-X
before	B-X
the	B-X
proteasome	B-X
commits	B-X
to	B-X
processive	B-X
degradation	B-X
.	B-X
These	B-X
advances	B-X
in	B-X
our	B-X
understanding	B-X
of	B-X
the	B-X
proteasome	B-X
's	B-X
intricate	B-X
machinery	B-X
set	B-X
the	B-X
stage	B-X
for	B-X
future	B-X
studies	B-X
on	B-X
how	B-X
the	B-X
proteasome	B-X
functions	B-X
as	B-X
a	B-X
major	B-X
regulator	B-X
of	B-X
the	B-X
eukaryotic	B-X
proteome	B-X
.	B-X

A	O
concept	O
that	O
has	O
arisen	O
over	O
the	O
last	O
decade	O
is	O
that	O
proteins	O
can	O
,	O
in	O
general	O
,	O
be	O
covalently	O
modified	O
by	O
polypeptides	O
,	O
resulting	O
in	O
alterations	O
in	O
their	O
fate	O
and	O
function	O
.	O

The	O
first	O
-	O
identified	O
and	O
most	O
well	O
studied	O
of	O
these	O
modifying	O
polypeptides	O
is	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
A	B-X
concept	B-X
that	B-X
has	B-X
arisen	B-X
over	B-X
the	B-X
last	B-X
decade	B-X
is	B-X
that	B-X
proteins	B-X
can	B-X
,	B-X
in	B-X
general	B-X
,	B-X
be	B-X
covalently	B-X
modified	B-X
by	B-X
polypeptides	B-X
,	B-X
resulting	B-X
in	B-X
alterations	B-X
in	B-X
their	B-X
fate	B-X
and	B-X
function	B-X
.	B-X
The	B-X
first-identified	B-X
and	B-X
most	B-X
well	B-X
studied	B-X
of	B-X
these	B-X
modifying	B-X
polypeptides	B-X
is	B-X
ubiquitin	B-X
.	B-X
Although	B-X
targeting	B-X
for	B-X
proteasomal	B-X
degradation	B-X
is	B-X
the	B-X
best	B-X
studied	B-X
outcome	B-X
of	B-X
ubiquitylation	B-X
,	B-X
we	B-X
now	B-X
understand	B-X
that	B-X
modification	B-X
of	B-X
proteins	B-X
with	B-X
ubiquitin	B-X
has	B-X
numerous	B-X
other	B-X
cellular	B-X
roles	B-X
that	B-X
alter	B-X
protein	B-X
function	B-X
and	B-X
that	B-X
are	B-X
unrelated	B-X
to	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Ubiquitylation	B-X
is	B-X
a	B-X
complex	B-X
process	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
both	B-X
addition	B-X
and	B-X
removal	B-X
of	B-X
ubiquitin	B-X
from	B-X
target	B-X
proteins	B-X
.	B-X
This	B-X
unit	B-X
includes	B-X
a	B-X
number	B-X
of	B-X
different	B-X
basic	B-X
protocols	B-X
that	B-X
will	B-X
facilitate	B-X
the	B-X
study	B-X
of	B-X
components	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
and	B-X
substrate	B-X
ubiquitylation	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Because	B-X
another	B-X
protein	B-X
modifier	B-X
,	B-X
NEDD8	B-X
,	B-X
itself	B-X
regulates	B-X
aspects	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
,	B-X
basic	B-X
protocols	B-X
on	B-X
neddylation	B-X
are	B-X
also	B-X
included	B-X
in	B-X
this	B-X
unit	B-X
.	B-X

Although	O
targeting	O
for	O
proteasomal	O
degradation	O
is	O
the	O
best	O
studied	O
outcome	O
of	O
ubiquitylation	O
,	O
we	O
now	O
understand	O
that	O
modification	O
of	O
proteins	O
with	O
ubiquitin	B-Protein
has	O
numerous	O
other	O
cellular	O
roles	O
that	O
alter	O
protein	O
function	O
and	O
that	O
are	O
unrelated	O
to	O
proteasomal	O
degradation	O
.	O
<EOS>	B-X
A	B-X
concept	B-X
that	B-X
has	B-X
arisen	B-X
over	B-X
the	B-X
last	B-X
decade	B-X
is	B-X
that	B-X
proteins	B-X
can	B-X
,	B-X
in	B-X
general	B-X
,	B-X
be	B-X
covalently	B-X
modified	B-X
by	B-X
polypeptides	B-X
,	B-X
resulting	B-X
in	B-X
alterations	B-X
in	B-X
their	B-X
fate	B-X
and	B-X
function	B-X
.	B-X
The	B-X
first-identified	B-X
and	B-X
most	B-X
well	B-X
studied	B-X
of	B-X
these	B-X
modifying	B-X
polypeptides	B-X
is	B-X
ubiquitin	B-X
.	B-X
Although	B-X
targeting	B-X
for	B-X
proteasomal	B-X
degradation	B-X
is	B-X
the	B-X
best	B-X
studied	B-X
outcome	B-X
of	B-X
ubiquitylation	B-X
,	B-X
we	B-X
now	B-X
understand	B-X
that	B-X
modification	B-X
of	B-X
proteins	B-X
with	B-X
ubiquitin	B-X
has	B-X
numerous	B-X
other	B-X
cellular	B-X
roles	B-X
that	B-X
alter	B-X
protein	B-X
function	B-X
and	B-X
that	B-X
are	B-X
unrelated	B-X
to	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Ubiquitylation	B-X
is	B-X
a	B-X
complex	B-X
process	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
both	B-X
addition	B-X
and	B-X
removal	B-X
of	B-X
ubiquitin	B-X
from	B-X
target	B-X
proteins	B-X
.	B-X
This	B-X
unit	B-X
includes	B-X
a	B-X
number	B-X
of	B-X
different	B-X
basic	B-X
protocols	B-X
that	B-X
will	B-X
facilitate	B-X
the	B-X
study	B-X
of	B-X
components	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
and	B-X
substrate	B-X
ubiquitylation	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Because	B-X
another	B-X
protein	B-X
modifier	B-X
,	B-X
NEDD8	B-X
,	B-X
itself	B-X
regulates	B-X
aspects	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
,	B-X
basic	B-X
protocols	B-X
on	B-X
neddylation	B-X
are	B-X
also	B-X
included	B-X
in	B-X
this	B-X
unit	B-X
.	B-X

Ubiquitylation	O
is	O
a	O
complex	O
process	O
that	O
is	O
regulated	O
at	O
the	O
level	O
of	O
both	O
addition	O
and	O
removal	O
of	O
ubiquitin	B-Protein
from	O
target	O
proteins	O
.	O
<EOS>	B-X
Death	B-X
receptors	B-X
are	B-X
a	B-X
subset	B-X
of	B-X
the	B-X
tumor	B-X
necrosis	B-X
factor	B-X
receptor	B-X
(	B-X
TNFR	B-X
)	B-X
family	B-X
of	B-X
proteins	B-X
and	B-X
share	B-X
a	B-X
characteristic	B-X
cytoplasmic	B-X
motif	B-X
called	B-X
the	B-X
``	B-X
death	B-X
domain	B-X
''	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
mediating	B-X
cell	B-X
death	B-X
,	B-X
these	B-X
receptors	B-X
regulate	B-X
cell	B-X
proliferation	B-X
,	B-X
inflammatory	B-X
responses	B-X
,	B-X
and	B-X
tumor	B-X
progression	B-X
.	B-X
Receptor	B-X
occupancy	B-X
triggers	B-X
the	B-X
assembly	B-X
of	B-X
several	B-X
cytoplasmic	B-X
molecules	B-X
into	B-X
distinct	B-X
complexes	B-X
,	B-X
each	B-X
initiating	B-X
separate	B-X
signaling	B-X
events	B-X
leading	B-X
to	B-X
different	B-X
biological	B-X
responses	B-X
.	B-X
Post-translational	B-X
modifications	B-X
involving	B-X
ubiquitin	B-X
,	B-X
a	B-X
peptide	B-X
of	B-X
76	B-X
amino	B-X
acids	B-X
,	B-X
regulate	B-X
events	B-X
at	B-X
nearly	B-X
all	B-X
stages	B-X
of	B-X
signaling	B-X
.	B-X
All	B-X
ubiquitin	B-X
chains	B-X
function	B-X
as	B-X
docking	B-X
platforms	B-X
for	B-X
molecules	B-X
with	B-X
specific	B-X
recognition	B-X
motifs	B-X
that	B-X
either	B-X
propagate	B-X
the	B-X
signal	B-X
or	B-X
target	B-X
the	B-X
protein	B-X
for	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Moreover	B-X
,	B-X
enzymes	B-X
with	B-X
ubiquitin	B-X
thioesterase	B-X
activity	B-X
(	B-X
deubiquitinating	B-X
enzymes	B-X
,	B-X
or	B-X
DUBs	B-X
)	B-X
reverse	B-X
modifications	B-X
by	B-X
removing	B-X
the	B-X
ubiquitin	B-X
chains	B-X
,	B-X
allowing	B-X
ubiquitin	B-X
editing	B-X
at	B-X
the	B-X
molecular	B-X
level	B-X
.	B-X
Ubiquitin	B-X
protein	B-X
ligases	B-X
(	B-X
E3s	B-X
)	B-X
,	B-X
DUBs	B-X
,	B-X
and	B-X
signaling	B-X
molecules	B-X
with	B-X
ubiquitin	B-X
recognition	B-X
motifs	B-X
control	B-X
TNFR1	B-X
mediated	B-X
cell	B-X
death	B-X
and	B-X
activation	B-X
of	B-X
NF-kappaB	B-X
and	B-X
JNK	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
current	B-X
understanding	B-X
of	B-X
how	B-X
these	B-X
proteins	B-X
regulate	B-X
TNFR1	B-X
signaling	B-X
.	B-X

This	O
unit	O
includes	O
a	O
number	O
of	O
different	O
basic	O
protocols	O
that	O
will	O
facilitate	O
the	O
study	O
of	O
components	O
of	O
the	O
ubiquitin	B-Protein
system	O
and	O
substrate	O
ubiquitylation	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Because	O
another	O
protein	O
modifier	O
,	O
NEDD8	B-Protein
,	O
itself	O
regulates	O
aspects	O
of	O
the	O
ubiquitin	B-Protein
system	O
,	O
basic	O
protocols	O
on	O
neddylation	O
are	O
also	O
included	O
in	O
this	O
unit	O
.	O
<EOS>	B-X
A	B-X
concept	B-X
that	B-X
has	B-X
arisen	B-X
over	B-X
the	B-X
last	B-X
decade	B-X
is	B-X
that	B-X
proteins	B-X
can	B-X
,	B-X
in	B-X
general	B-X
,	B-X
be	B-X
covalently	B-X
modified	B-X
by	B-X
polypeptides	B-X
,	B-X
resulting	B-X
in	B-X
alterations	B-X
in	B-X
their	B-X
fate	B-X
and	B-X
function	B-X
.	B-X
The	B-X
first-identified	B-X
and	B-X
most	B-X
well	B-X
studied	B-X
of	B-X
these	B-X
modifying	B-X
polypeptides	B-X
is	B-X
ubiquitin	B-X
.	B-X
Although	B-X
targeting	B-X
for	B-X
proteasomal	B-X
degradation	B-X
is	B-X
the	B-X
best	B-X
studied	B-X
outcome	B-X
of	B-X
ubiquitylation	B-X
,	B-X
we	B-X
now	B-X
understand	B-X
that	B-X
modification	B-X
of	B-X
proteins	B-X
with	B-X
ubiquitin	B-X
has	B-X
numerous	B-X
other	B-X
cellular	B-X
roles	B-X
that	B-X
alter	B-X
protein	B-X
function	B-X
and	B-X
that	B-X
are	B-X
unrelated	B-X
to	B-X
proteasomal	B-X
degradation	B-X
.	B-X
Ubiquitylation	B-X
is	B-X
a	B-X
complex	B-X
process	B-X
that	B-X
is	B-X
regulated	B-X
at	B-X
the	B-X
level	B-X
of	B-X
both	B-X
addition	B-X
and	B-X
removal	B-X
of	B-X
ubiquitin	B-X
from	B-X
target	B-X
proteins	B-X
.	B-X
This	B-X
unit	B-X
includes	B-X
a	B-X
number	B-X
of	B-X
different	B-X
basic	B-X
protocols	B-X
that	B-X
will	B-X
facilitate	B-X
the	B-X
study	B-X
of	B-X
components	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
and	B-X
substrate	B-X
ubiquitylation	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
cells	B-X
.	B-X
Because	B-X
another	B-X
protein	B-X
modifier	B-X
,	B-X
NEDD8	B-X
,	B-X
itself	B-X
regulates	B-X
aspects	B-X
of	B-X
the	B-X
ubiquitin	B-X
system	B-X
,	B-X
basic	B-X
protocols	B-X
on	B-X
neddylation	B-X
are	B-X
also	B-X
included	B-X
in	B-X
this	B-X
unit	B-X
.	B-X

Fine	O
mapping	O
of	O
posttranslational	O
modifications	O
of	O
the	O
linker	O
histone	B-Protein
H1	I-Protein
from	O
Drosophila	O
melanogaster	O
.	O
<EOS>	B-X
The	B-X
linker	B-X
histone	B-X
H1	B-X
binds	B-X
to	B-X
the	B-X
DNA	B-X
in	B-X
between	B-X
adjacent	B-X
nucleosomes	B-X
and	B-X
contributes	B-X
to	B-X
chromatin	B-X
organization	B-X
and	B-X
transcriptional	B-X
control	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
H1	B-X
carries	B-X
diverse	B-X
posttranslational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
,	B-X
including	B-X
phosphorylation	B-X
,	B-X
lysine	B-X
methylation	B-X
and	B-X
ADP-ribosylation	B-X
.	B-X
This	B-X
is	B-X
in	B-X
part	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
most	B-X
of	B-X
the	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
in	B-X
organisms	B-X
that	B-X
have	B-X
several	B-X
H1	B-X
variants	B-X
,	B-X
which	B-X
complicates	B-X
the	B-X
analyses	B-X
.	B-X
We	B-X
have	B-X
chosen	B-X
Drosophila	B-X
melanogaster	B-X
,	B-X
a	B-X
model	B-X
organism	B-X
,	B-X
which	B-X
has	B-X
a	B-X
single	B-X
H1	B-X
variant	B-X
,	B-X
to	B-X
approach	B-X
the	B-X
study	B-X
of	B-X
the	B-X
role	B-X
of	B-X
H1	B-X
PTMs	B-X
during	B-X
embryonic	B-X
development	B-X
.	B-X
Mass	B-X
spectrometry	B-X
mapping	B-X
of	B-X
the	B-X
entire	B-X
sequence	B-X
of	B-X
the	B-X
protein	B-X
showed	B-X
phosphorylation	B-X
only	B-X
in	B-X
the	B-X
ten	B-X
N-terminal	B-X
amino	B-X
acids	B-X
,	B-X
mostly	B-X
at	B-X
S10	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
,	B-X
changes	B-X
in	B-X
the	B-X
PTMs	B-X
of	B-X
a	B-X
linker	B-X
H1	B-X
during	B-X
the	B-X
development	B-X
of	B-X
a	B-X
multicellular	B-X
organism	B-X
are	B-X
reported	B-X
.	B-X
The	B-X
abundance	B-X
of	B-X
H1	B-X
monophosphorylated	B-X
at	B-X
S10	B-X
decreases	B-X
as	B-X
the	B-X
embryos	B-X
age	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
this	B-X
PTM	B-X
is	B-X
related	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
and/or	B-X
cell	B-X
differentiation	B-X
.	B-X

The	O
linker	O
histone	B-Protein
H1	I-Protein
binds	O
to	O
the	O
DNA	O
in	O
between	O
adjacent	O
nucleosomes	O
and	O
contributes	O
to	O
chromatin	O
organization	O
and	O
transcriptional	O
control	O
.	O

It	O
is	O
known	O
that	O
H1	B-Protein
carries	O
diverse	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
,	O
including	O
phosphorylation	O
,	O
lysine	O
methylation	O
and	O
ADP	O
-	O
ribosylation	O
.	O
<EOS>	B-X
The	B-X
linker	B-X
histone	B-X
H1	B-X
binds	B-X
to	B-X
the	B-X
DNA	B-X
in	B-X
between	B-X
adjacent	B-X
nucleosomes	B-X
and	B-X
contributes	B-X
to	B-X
chromatin	B-X
organization	B-X
and	B-X
transcriptional	B-X
control	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
H1	B-X
carries	B-X
diverse	B-X
posttranslational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
,	B-X
including	B-X
phosphorylation	B-X
,	B-X
lysine	B-X
methylation	B-X
and	B-X
ADP-ribosylation	B-X
.	B-X
This	B-X
is	B-X
in	B-X
part	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
most	B-X
of	B-X
the	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
in	B-X
organisms	B-X
that	B-X
have	B-X
several	B-X
H1	B-X
variants	B-X
,	B-X
which	B-X
complicates	B-X
the	B-X
analyses	B-X
.	B-X
We	B-X
have	B-X
chosen	B-X
Drosophila	B-X
melanogaster	B-X
,	B-X
a	B-X
model	B-X
organism	B-X
,	B-X
which	B-X
has	B-X
a	B-X
single	B-X
H1	B-X
variant	B-X
,	B-X
to	B-X
approach	B-X
the	B-X
study	B-X
of	B-X
the	B-X
role	B-X
of	B-X
H1	B-X
PTMs	B-X
during	B-X
embryonic	B-X
development	B-X
.	B-X
Mass	B-X
spectrometry	B-X
mapping	B-X
of	B-X
the	B-X
entire	B-X
sequence	B-X
of	B-X
the	B-X
protein	B-X
showed	B-X
phosphorylation	B-X
only	B-X
in	B-X
the	B-X
ten	B-X
N-terminal	B-X
amino	B-X
acids	B-X
,	B-X
mostly	B-X
at	B-X
S10	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
,	B-X
changes	B-X
in	B-X
the	B-X
PTMs	B-X
of	B-X
a	B-X
linker	B-X
H1	B-X
during	B-X
the	B-X
development	B-X
of	B-X
a	B-X
multicellular	B-X
organism	B-X
are	B-X
reported	B-X
.	B-X
The	B-X
abundance	B-X
of	B-X
H1	B-X
monophosphorylated	B-X
at	B-X
S10	B-X
decreases	B-X
as	B-X
the	B-X
embryos	B-X
age	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
this	B-X
PTM	B-X
is	B-X
related	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
and/or	B-X
cell	B-X
differentiation	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
have	B-X
found	B-X
a	B-X
polymorphism	B-X
in	B-X
the	B-X
protein	B-X
sequence	B-X
that	B-X
can	B-X
be	B-X
mistaken	B-X
with	B-X
lysine	B-X
methylation	B-X
if	B-X
the	B-X
analysis	B-X
is	B-X
not	B-X
rigorous	B-X
.	B-X

Their	O
biological	O
functions	O
,	O
however	O
,	O
remain	O
largely	O
unclear	O
.	O
<EOS>	B-X
However	B-X
,	B-X
the	B-X
roles	B-X
played	B-X
by	B-X
endogenous	B-X
growth	B-X
factors	B-X
have	B-X
remained	B-X
largely	B-X
unclear	B-X
.	B-X
Most	B-X
importantly	B-X
,	B-X
we	B-X
also	B-X
report	B-X
on	B-X
genetic	B-X
studies	B-X
addressing	B-X
the	B-X
functions	B-X
of	B-X
endogenous	B-X
growth	B-X
factors	B-X
in	B-X
the	B-X
wound	B-X
repair	B-X
process	B-X
.	B-X
Muscle	B-X
phenotypes	B-X
and	B-X
sarcopenia	B-X
risk	B-X
are	B-X
heritable	B-X
;	B-X
however	B-X
,	B-X
the	B-X
genetic	B-X
architecture	B-X
and	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
sarcopenia	B-X
remain	B-X
largely	B-X
unclear	B-X
.	B-X
However	B-X
,	B-X
each	B-X
individual	B-X
technology	B-X
can	B-X
not	B-X
capture	B-X
the	B-X
entire	B-X
view	B-X
of	B-X
the	B-X
biological	B-X
complexity	B-X
of	B-X
this	B-X
disorder	B-X
,	B-X
while	B-X
integrative	B-X
multi-omics	B-X
analyses	B-X
may	B-X
be	B-X
able	B-X
to	B-X
reveal	B-X
new	B-X
insights	B-X
.	B-X

This	O
is	O
in	O
part	O
due	O
to	O
the	O
fact	O
that	O
most	O
of	O
the	O
studies	O
have	O
been	O
performed	O
in	O
organisms	O
that	O
have	O
several	O
H1	B-Protein
variants	O
,	O
which	O
complicates	O
the	O
analyses	O
.	O

We	O
have	O
chosen	O
Drosophila	O
melanogaster	O
,	O
a	O
model	O
organism	O
,	O
which	O
has	O
a	O
single	O
H1	B-Protein
variant	O
,	O
to	O
approach	O
the	O
study	O
of	O
the	O
role	O
of	O
H1	B-Protein
PTMs	O
during	O
embryonic	O
development	O
.	O

Mass	O
spectrometry	O
mapping	O
of	O
the	O
entire	O
sequence	O
of	O
the	O
protein	O
showed	O
phosphorylation	O
only	O
in	O
the	O
ten	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
mostly	O
at	O
S10	O
.	O

For	O
the	O
first	O
time	O
,	O
changes	O
in	O
the	O
PTMs	O
of	O
a	O
linker	O
H1	B-Protein
during	O
the	O
development	O
of	O
a	O
multicellular	O
organism	O
are	O
reported	O
.	O
<EOS>	B-X
The	B-X
linker	B-X
histone	B-X
H1	B-X
binds	B-X
to	B-X
the	B-X
DNA	B-X
in	B-X
between	B-X
adjacent	B-X
nucleosomes	B-X
and	B-X
contributes	B-X
to	B-X
chromatin	B-X
organization	B-X
and	B-X
transcriptional	B-X
control	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
H1	B-X
carries	B-X
diverse	B-X
posttranslational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
,	B-X
including	B-X
phosphorylation	B-X
,	B-X
lysine	B-X
methylation	B-X
and	B-X
ADP-ribosylation	B-X
.	B-X
This	B-X
is	B-X
in	B-X
part	B-X
due	B-X
to	B-X
the	B-X
fact	B-X
that	B-X
most	B-X
of	B-X
the	B-X
studies	B-X
have	B-X
been	B-X
performed	B-X
in	B-X
organisms	B-X
that	B-X
have	B-X
several	B-X
H1	B-X
variants	B-X
,	B-X
which	B-X
complicates	B-X
the	B-X
analyses	B-X
.	B-X
We	B-X
have	B-X
chosen	B-X
Drosophila	B-X
melanogaster	B-X
,	B-X
a	B-X
model	B-X
organism	B-X
,	B-X
which	B-X
has	B-X
a	B-X
single	B-X
H1	B-X
variant	B-X
,	B-X
to	B-X
approach	B-X
the	B-X
study	B-X
of	B-X
the	B-X
role	B-X
of	B-X
H1	B-X
PTMs	B-X
during	B-X
embryonic	B-X
development	B-X
.	B-X
For	B-X
the	B-X
first	B-X
time	B-X
,	B-X
changes	B-X
in	B-X
the	B-X
PTMs	B-X
of	B-X
a	B-X
linker	B-X
H1	B-X
during	B-X
the	B-X
development	B-X
of	B-X
a	B-X
multicellular	B-X
organism	B-X
are	B-X
reported	B-X
.	B-X
The	B-X
abundance	B-X
of	B-X
H1	B-X
monophosphorylated	B-X
at	B-X
S10	B-X
decreases	B-X
as	B-X
the	B-X
embryos	B-X
age	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
this	B-X
PTM	B-X
is	B-X
related	B-X
to	B-X
cell	B-X
cycle	B-X
progression	B-X
and/or	B-X
cell	B-X
differentiation	B-X
.	B-X

The	O
abundance	O
of	O
H1	B-Protein
monophosphorylated	O
at	O
S10	O
decreases	O
as	O
the	O
embryos	O
age	O
,	O
which	O
suggests	O
that	O
this	O
PTM	O
is	O
related	O
to	O
cell	O
cycle	O
progression	O
and	O
/	O
or	O
cell	O
differentiation	O
.	O
<EOS>	B-X
The	B-X
reprogramming	B-X
of	B-X
somatic	B-X
cells	B-X
with	B-X
defined	B-X
factors	B-X
,	B-X
which	B-X
converts	B-X
cells	B-X
from	B-X
one	B-X
lineage	B-X
into	B-X
cells	B-X
of	B-X
another	B-X
,	B-X
has	B-X
greatly	B-X
reshaped	B-X
our	B-X
traditional	B-X
views	B-X
on	B-X
cell	B-X
identity	B-X
and	B-X
cell	B-X
fate	B-X
determination	B-X
.	B-X
Direct	B-X
reprogramming	B-X
(	B-X
also	B-X
known	B-X
as	B-X
transdifferentiation	B-X
)	B-X
refers	B-X
to	B-X
cell	B-X
fate	B-X
conversion	B-X
without	B-X
transitioning	B-X
through	B-X
an	B-X
intermediary	B-X
pluripotent	B-X
state	B-X
.	B-X
Given	B-X
that	B-X
the	B-X
number	B-X
of	B-X
cell	B-X
types	B-X
that	B-X
can	B-X
be	B-X
generated	B-X
by	B-X
direct	B-X
reprogramming	B-X
is	B-X
rapidly	B-X
increasing	B-X
,	B-X
it	B-X
has	B-X
become	B-X
a	B-X
promising	B-X
strategy	B-X
to	B-X
produce	B-X
functional	B-X
cells	B-X
for	B-X
therapeutic	B-X
purposes	B-X
.	B-X
This	B-X
Review	B-X
discusses	B-X
the	B-X
evolution	B-X
of	B-X
direct	B-X
reprogramming	B-X
from	B-X
a	B-X
transcription	B-X
factor-based	B-X
method	B-X
to	B-X
a	B-X
small-molecule-driven	B-X
approach	B-X
,	B-X
the	B-X
recent	B-X
progress	B-X
in	B-X
enhancing	B-X
reprogrammed	B-X
cell	B-X
maturation	B-X
,	B-X
and	B-X
the	B-X
challenges	B-X
associated	B-X
with	B-X
in	B-X
vivo	B-X
direct	B-X
reprogramming	B-X
for	B-X
translational	B-X
applications	B-X
.	B-X
It	B-X
also	B-X
describes	B-X
our	B-X
current	B-X
understanding	B-X
of	B-X
the	B-X
molecular	B-X
mechanisms	B-X
underlying	B-X
direct	B-X
reprogramming	B-X
,	B-X
including	B-X
the	B-X
role	B-X
of	B-X
transcription	B-X
factors	B-X
,	B-X
epigenetic	B-X
modifications	B-X
,	B-X
non-coding	B-X
RNAs	B-X
,	B-X
and	B-X
the	B-X
function	B-X
of	B-X
metabolic	B-X
reprogramming	B-X
,	B-X
and	B-X
highlights	B-X
novel	B-X
insights	B-X
gained	B-X
from	B-X
single-cell	B-X
omics	B-X
studies	B-X
.	B-X

Additionally	O
,	O
we	O
have	O
found	O
a	O
polymorphism	O
in	O
the	O
protein	O
sequence	O
that	O
can	O
be	O
mistaken	O
with	O
lysine	O
methylation	O
if	O
the	O
analysis	O
is	O
not	O
rigorous	O
.	O

NEDD8	B-Protein
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-Protein
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
important	B-X
in	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
ECV	B-X
(	B-X
Elongin	B-X
B/C-CUL2-VHL	B-X
)	B-X
-mediated	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
and	B-X
the	B-X
promotion	B-X
of	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
extracellular	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
controlling	B-X
the	B-X
selectivity	B-X
of	B-X
VHL	B-X
function	B-X
remains	B-X
unknown	B-X
,	B-X
a	B-X
failure	B-X
in	B-X
either	B-X
process	B-X
is	B-X
associated	B-X
with	B-X
oncogenic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
VHL	B-X
performs	B-X
its	B-X
FN-associated	B-X
function	B-X
independently	B-X
of	B-X
the	B-X
ECV	B-X
complex	B-X
,	B-X
highlighting	B-X
the	B-X
autonomy	B-X
of	B-X
these	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
'molecular	B-X
switch	B-X
'	B-X
in	B-X
which	B-X
its	B-X
covalent	B-X
conjugation	B-X
to	B-X
VHL	B-X
prohibits	B-X
the	B-X
engagement	B-X
of	B-X
the	B-X
scaffold	B-X
component	B-X
CUL2	B-X
and	B-X
,	B-X
concomitantly	B-X
,	B-X
activates	B-X
the	B-X
association	B-X
with	B-X
FN	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
mechanistic	B-X
step	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
selectivity	B-X
of	B-X
VHL	B-X
and	B-X
explain	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
NEDD8	B-X
.	B-X

The	O
von	B-Protein
Hippel	I-Protein
-	I-Protein
Lindau	I-Protein
(	I-Protein
VHL	I-Protein
)	I-Protein
tumour	I-Protein
suppressor	I-Protein
protein	O
is	O
important	O
in	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
ECV	O
(	O
Elongin	B-Protein
B	I-Protein
/	O
C	B-Protein
-	O
CUL2	B-Protein
-	O
VHL	B-Protein
)	O
-	O
mediated	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
and	O
the	O
promotion	O
of	O
fibronectin	B-Protein
(	O
FN	B-Protein
)	O
extracellular	O
matrix	O
assembly	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanism	O
controlling	O
the	O
selectivity	O
of	O
VHL	B-Protein
function	O
remains	O
unknown	O
,	O
a	O
failure	O
in	O
either	O
process	O
is	O
associated	O
with	O
oncogenic	O
progression	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
important	B-X
in	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
ECV	B-X
(	B-X
Elongin	B-X
B/C-CUL2-VHL	B-X
)	B-X
-mediated	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
and	B-X
the	B-X
promotion	B-X
of	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
extracellular	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
controlling	B-X
the	B-X
selectivity	B-X
of	B-X
VHL	B-X
function	B-X
remains	B-X
unknown	B-X
,	B-X
a	B-X
failure	B-X
in	B-X
either	B-X
process	B-X
is	B-X
associated	B-X
with	B-X
oncogenic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
VHL	B-X
performs	B-X
its	B-X
FN-associated	B-X
function	B-X
independently	B-X
of	B-X
the	B-X
ECV	B-X
complex	B-X
,	B-X
highlighting	B-X
the	B-X
autonomy	B-X
of	B-X
these	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
'molecular	B-X
switch	B-X
'	B-X
in	B-X
which	B-X
its	B-X
covalent	B-X
conjugation	B-X
to	B-X
VHL	B-X
prohibits	B-X
the	B-X
engagement	B-X
of	B-X
the	B-X
scaffold	B-X
component	B-X
CUL2	B-X
and	B-X
,	B-X
concomitantly	B-X
,	B-X
activates	B-X
the	B-X
association	B-X
with	B-X
FN	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
mechanistic	B-X
step	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
selectivity	B-X
of	B-X
VHL	B-X
and	B-X
explain	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
NEDD8	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
VHL	B-Protein
performs	O
its	O
FN	B-Protein
-	O
associated	O
function	O
independently	O
of	O
the	O
ECV	O
complex	O
,	O
highlighting	O
the	O
autonomy	O
of	O
these	O
pathways	O
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
important	B-X
in	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
ECV	B-X
(	B-X
Elongin	B-X
B/C-CUL2-VHL	B-X
)	B-X
-mediated	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
and	B-X
the	B-X
promotion	B-X
of	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
extracellular	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
controlling	B-X
the	B-X
selectivity	B-X
of	B-X
VHL	B-X
function	B-X
remains	B-X
unknown	B-X
,	B-X
a	B-X
failure	B-X
in	B-X
either	B-X
process	B-X
is	B-X
associated	B-X
with	B-X
oncogenic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
VHL	B-X
performs	B-X
its	B-X
FN-associated	B-X
function	B-X
independently	B-X
of	B-X
the	B-X
ECV	B-X
complex	B-X
,	B-X
highlighting	B-X
the	B-X
autonomy	B-X
of	B-X
these	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
'molecular	B-X
switch	B-X
'	B-X
in	B-X
which	B-X
its	B-X
covalent	B-X
conjugation	B-X
to	B-X
VHL	B-X
prohibits	B-X
the	B-X
engagement	B-X
of	B-X
the	B-X
scaffold	B-X
component	B-X
CUL2	B-X
and	B-X
,	B-X
concomitantly	B-X
,	B-X
activates	B-X
the	B-X
association	B-X
with	B-X
FN	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
mechanistic	B-X
step	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
selectivity	B-X
of	B-X
VHL	B-X
and	B-X
explain	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
NEDD8	B-X
.	B-X

Furthermore	O
,	O
we	O
show	O
that	O
NEDD8	B-Protein
,	O
a	O
ubiquitin	B-Protein
-	O
like	O
molecule	O
,	O
acts	O
as	O
a	O
'	O
molecular	O
switch	O
'	O
in	O
which	O
its	O
covalent	O
conjugation	O
to	O
VHL	B-Protein
prohibits	O
the	O
engagement	O
of	O
the	O
scaffold	O
component	O
CUL2	B-Protein
and	O
,	O
concomitantly	O
,	O
activates	O
the	O
association	O
with	O
FN	B-Protein
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
important	B-X
in	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
ECV	B-X
(	B-X
Elongin	B-X
B/C-CUL2-VHL	B-X
)	B-X
-mediated	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
and	B-X
the	B-X
promotion	B-X
of	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
extracellular	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
controlling	B-X
the	B-X
selectivity	B-X
of	B-X
VHL	B-X
function	B-X
remains	B-X
unknown	B-X
,	B-X
a	B-X
failure	B-X
in	B-X
either	B-X
process	B-X
is	B-X
associated	B-X
with	B-X
oncogenic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
VHL	B-X
performs	B-X
its	B-X
FN-associated	B-X
function	B-X
independently	B-X
of	B-X
the	B-X
ECV	B-X
complex	B-X
,	B-X
highlighting	B-X
the	B-X
autonomy	B-X
of	B-X
these	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
'molecular	B-X
switch	B-X
'	B-X
in	B-X
which	B-X
its	B-X
covalent	B-X
conjugation	B-X
to	B-X
VHL	B-X
prohibits	B-X
the	B-X
engagement	B-X
of	B-X
the	B-X
scaffold	B-X
component	B-X
CUL2	B-X
and	B-X
,	B-X
concomitantly	B-X
,	B-X
activates	B-X
the	B-X
association	B-X
with	B-X
FN	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
mechanistic	B-X
step	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
selectivity	B-X
of	B-X
VHL	B-X
and	B-X
explain	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
NEDD8	B-X
.	B-X

These	O
findings	O
provide	O
the	O
first	O
mechanistic	O
step	O
in	O
defining	O
the	O
functional	O
selectivity	O
of	O
VHL	B-Protein
and	O
explain	O
a	O
previously	O
unrecognized	O
function	O
of	O
NEDD8	B-Protein
.	O
<EOS>	B-X
The	B-X
von	B-X
Hippel-Lindau	B-X
(	B-X
VHL	B-X
)	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
important	B-X
in	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
ECV	B-X
(	B-X
Elongin	B-X
B/C-CUL2-VHL	B-X
)	B-X
-mediated	B-X
destruction	B-X
of	B-X
hypoxia-inducible	B-X
factor	B-X
and	B-X
the	B-X
promotion	B-X
of	B-X
fibronectin	B-X
(	B-X
FN	B-X
)	B-X
extracellular	B-X
matrix	B-X
assembly	B-X
.	B-X
Although	B-X
the	B-X
precise	B-X
molecular	B-X
mechanism	B-X
controlling	B-X
the	B-X
selectivity	B-X
of	B-X
VHL	B-X
function	B-X
remains	B-X
unknown	B-X
,	B-X
a	B-X
failure	B-X
in	B-X
either	B-X
process	B-X
is	B-X
associated	B-X
with	B-X
oncogenic	B-X
progression	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
VHL	B-X
performs	B-X
its	B-X
FN-associated	B-X
function	B-X
independently	B-X
of	B-X
the	B-X
ECV	B-X
complex	B-X
,	B-X
highlighting	B-X
the	B-X
autonomy	B-X
of	B-X
these	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
show	B-X
that	B-X
NEDD8	B-X
,	B-X
a	B-X
ubiquitin-like	B-X
molecule	B-X
,	B-X
acts	B-X
as	B-X
a	B-X
'molecular	B-X
switch	B-X
'	B-X
in	B-X
which	B-X
its	B-X
covalent	B-X
conjugation	B-X
to	B-X
VHL	B-X
prohibits	B-X
the	B-X
engagement	B-X
of	B-X
the	B-X
scaffold	B-X
component	B-X
CUL2	B-X
and	B-X
,	B-X
concomitantly	B-X
,	B-X
activates	B-X
the	B-X
association	B-X
with	B-X
FN	B-X
.	B-X
These	B-X
findings	B-X
provide	B-X
the	B-X
first	B-X
mechanistic	B-X
step	B-X
in	B-X
defining	B-X
the	B-X
functional	B-X
selectivity	B-X
of	B-X
VHL	B-X
and	B-X
explain	B-X
a	B-X
previously	B-X
unrecognized	B-X
function	B-X
of	B-X
NEDD8	B-X
.	B-X

Redox	O
-	O
mediated	O
modification	O
of	O
PLZF	B-Protein
by	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
ubiquitination	B-X
was	B-X
increased	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

Earlier	O
,	O
we	O
reported	O
that	O
the	O
transcriptional	O
repressor	O
promyelocytic	B-Protein
leukemia	I-Protein
zinc	I-Protein
-	I-Protein
finger	I-Protein
protein	I-Protein
(	O
PLZF	B-Protein
)	O
is	O
sumoylated	O
at	O
position	O
K242	O
,	O
and	O
the	O
sumoylation	O
regulated	O
its	O
biological	O
function	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
the	O
sumoylation	O
site	O
can	O
be	O
modified	O
by	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
Herein	B-X
,	B-X
we	B-X
summarize	B-X
and	B-X
discuss	B-X
the	B-X
signal	B-X
crosstalk	B-X
between	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
of	B-X
proteins	B-X
,	B-X
protein	B-X
SUMOylation	B-X
relations	B-X
with	B-X
several	B-X
diseases	B-X
,	B-X
and	B-X
the	B-X
identification	B-X
approaches	B-X
for	B-X
SUMOylation	B-X
site	B-X
.	B-X
With	B-X
the	B-X
continuous	B-X
development	B-X
of	B-X
bioinformatics	B-X
and	B-X
mass	B-X
spectrometry	B-X
,	B-X
several	B-X
accurate	B-X
and	B-X
high-throughput	B-X
methods	B-X
have	B-X
been	B-X
implemented	B-X
to	B-X
explore	B-X
small	B-X
ubiquitin-like	B-X
modifier-modified	B-X
substrates	B-X
and	B-X
sites	B-X
,	B-X
which	B-X
is	B-X
helpful	B-X
for	B-X
deciphering	B-X
protein	B-X
SUMOylation-mediated	B-X
molecular	B-X
mechanisms	B-X
of	B-X
disease	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
YTHDF2	B-X
is	B-X
SUMOylated	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
at	B-X
the	B-X
major	B-X
site	B-X
of	B-X
K571	B-X
,	B-X
which	B-X
can	B-X
be	B-X
induced	B-X
by	B-X
hypoxia	B-X
while	B-X
reduced	B-X
by	B-X
oxidative	B-X
stress	B-X
and	B-X
SUMOylation	B-X
inhibitors	B-X
.	B-X
SUMOylation	B-X
of	B-X
YTHDF2	B-X
has	B-X
little	B-X
impact	B-X
on	B-X
its	B-X
ubiquitination	B-X
and	B-X
localization	B-X
,	B-X
but	B-X
significantly	B-X
increases	B-X
its	B-X
binding	B-X
affinity	B-X
of	B-X
m6A-modified	B-X
mRNAs	B-X
and	B-X
subsequently	B-X
results	B-X
in	B-X
deregulated	B-X
gene	B-X
expressions	B-X
which	B-X
accounts	B-X
for	B-X
cancer	B-X
progression	B-X
.	B-X

The	O
stability	O
and	O
nuclear	O
localization	O
of	O
PLZF	B-Protein
were	O
regulated	O
by	O
the	O
antagonistic	O
relationship	O
between	O
sumoylation	O
and	O
ubiquitination	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
ubiquitination	B-X
was	B-X
increased	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

We	O
observed	O
the	O
antagonistic	O
effects	O
of	O
ubiquitin	B-Protein
and	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
on	O
PLZF	B-Protein
under	O
oxidative	O
stress	O
induced	O
by	O
serum	O
deprivation	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
ubiquitination	B-X
was	B-X
increased	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

Thus	O
,	O
the	O
choice	O
between	O
modification	O
of	O
PLZF	B-Protein
by	O
SUMO	O
or	O
ubiquitin	B-Protein
was	O
determined	O
by	O
the	O
intracellular	O
level	O
of	O
ROS	O
,	O
which	O
was	O
generated	O
by	O
serum	O
deprivation	O
that	O
inactivated	O
the	O
SUMO	O
-	O
conjugating	O
enzymes	O
Uba2	B-Protein
and	O
Ubc9	B-Protein
,	O
and	O
resulted	O
in	O
decrease	O
of	O
sumoylation	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
ubiquitination	B-X
was	B-X
increased	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

The	O
ubiquitination	O
was	O
increased	O
under	O
these	O
conditions	O
.	O
<EOS>	B-X
Ubiquitylation	B-X
and	B-X
deubiquitylation	B-X
are	B-X
reversible	B-X
protein	B-X
post-translational	B-X
modification	B-X
(	B-X
PTM	B-X
)	B-X
processes	B-X
involving	B-X
the	B-X
regulation	B-X
of	B-X
protein	B-X
degradation	B-X
under	B-X
physiological	B-X
conditions	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
under	B-X
nutrient-deficient	B-X
conditions	B-X
,	B-X
cellular	B-X
p62	B-X
specifically	B-X
undergoes	B-X
acetylation	B-X
,	B-X
which	B-X
is	B-X
required	B-X
for	B-X
the	B-X
formation	B-X
and	B-X
subsequent	B-X
autophagic	B-X
clearance	B-X
of	B-X
p62	B-X
bodies	B-X
.	B-X
Phosphorylation	B-X
of	B-X
UVRAG	B-X
by	B-X
MTORC1	B-X
negatively	B-X
regulates	B-X
autophagosome	B-X
maturation	B-X
under	B-X
nutrient-enriched	B-X
conditions	B-X
.	B-X
However	B-X
,	B-X
how	B-X
UVRAG	B-X
ubiquitination	B-X
is	B-X
regulated	B-X
is	B-X
still	B-X
unknown	B-X
.	B-X
We	B-X
also	B-X
demonstrate	B-X
that	B-X
CSNK1A1-mediated	B-X
UVRAG	B-X
phosphorylation	B-X
at	B-X
Ser522	B-X
disrupts	B-X
the	B-X
binding	B-X
of	B-X
SMURF1	B-X
to	B-X
UVRAG	B-X
through	B-X
PPxY	B-X
motif	B-X
and	B-X
blocks	B-X
UVRAG	B-X
ubiquitination-mediated	B-X
autophagosome	B-X
maturation	B-X
.	B-X

The	O
expression	O
of	O
BID	B-Protein
,	O
a	O
known	O
transcriptional	O
target	O
protein	O
of	O
PLZF	B-Protein
,	O
was	O
decreased	O
,	O
and	O
the	O
consequent	O
apoptosis	O
was	O
induced	O
by	O
the	O
ROS	O
generated	O
during	O
serum	O
starvation	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
propose	O
that	O
PLZF	B-Protein
post	O
-	O
translational	O
modification	O
is	O
controlled	O
by	O
intracellular	O
ROS	O
,	O
and	O
the	O
biological	O
function	O
of	O
PLZF	B-Protein
is	O
regulated	O
by	O
sumoylation	O
and	O
ubiquitination	O
.	O
<EOS>	B-X
Earlier	B-X
,	B-X
we	B-X
reported	B-X
that	B-X
the	B-X
transcriptional	B-X
repressor	B-X
promyelocytic	B-X
leukemia	B-X
zinc-finger	B-X
protein	B-X
(	B-X
PLZF	B-X
)	B-X
is	B-X
sumoylated	B-X
at	B-X
position	B-X
K242	B-X
,	B-X
and	B-X
the	B-X
sumoylation	B-X
regulated	B-X
its	B-X
biological	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
sumoylation	B-X
site	B-X
can	B-X
be	B-X
modified	B-X
by	B-X
ubiquitin	B-X
.	B-X
The	B-X
stability	B-X
and	B-X
nuclear	B-X
localization	B-X
of	B-X
PLZF	B-X
were	B-X
regulated	B-X
by	B-X
the	B-X
antagonistic	B-X
relationship	B-X
between	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
We	B-X
observed	B-X
the	B-X
antagonistic	B-X
effects	B-X
of	B-X
ubiquitin	B-X
and	B-X
SUMO-1	B-X
on	B-X
PLZF	B-X
under	B-X
oxidative	B-X
stress	B-X
induced	B-X
by	B-X
serum	B-X
deprivation	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
choice	B-X
between	B-X
modification	B-X
of	B-X
PLZF	B-X
by	B-X
SUMO	B-X
or	B-X
ubiquitin	B-X
was	B-X
determined	B-X
by	B-X
the	B-X
intracellular	B-X
level	B-X
of	B-X
ROS	B-X
,	B-X
which	B-X
was	B-X
generated	B-X
by	B-X
serum	B-X
deprivation	B-X
that	B-X
inactivated	B-X
the	B-X
SUMO-conjugating	B-X
enzymes	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
,	B-X
and	B-X
resulted	B-X
in	B-X
decrease	B-X
of	B-X
sumoylation	B-X
.	B-X
The	B-X
ubiquitination	B-X
was	B-X
increased	B-X
under	B-X
these	B-X
conditions	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
BID	B-X
,	B-X
a	B-X
known	B-X
transcriptional	B-X
target	B-X
protein	B-X
of	B-X
PLZF	B-X
,	B-X
was	B-X
decreased	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
apoptosis	B-X
was	B-X
induced	B-X
by	B-X
the	B-X
ROS	B-X
generated	B-X
during	B-X
serum	B-X
starvation	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
these	B-X
results	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
PLZF	B-X
post-translational	B-X
modification	B-X
is	B-X
controlled	B-X
by	B-X
intracellular	B-X
ROS	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
function	B-X
of	B-X
PLZF	B-X
is	B-X
regulated	B-X
by	B-X
sumoylation	B-X
and	B-X
ubiquitination	B-X
.	B-X

Sumoylation	O
and	O
the	O
function	O
of	O
CCAAT	B-Protein
enhancer	I-Protein
binding	I-Protein
protein	I-Protein
alpha	I-Protein
(	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
)	O
.	O
<EOS>	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
alpha	B-X
(	B-X
C/EBP	B-X
alpha	B-X
)	B-X
is	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
basic	B-X
region/leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
transcription	B-X
factors	B-X
and	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
granulopoiesis	B-X
.	B-X
Profound	B-X
hematopoietic	B-X
abnormalities	B-X
occur	B-X
in	B-X
mice	B-X
nullizygous	B-X
for	B-X
C/EBP	B-X
alpha	B-X
including	B-X
a	B-X
selective	B-X
early	B-X
block	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
granulocytes	B-X
.	B-X
Mutations	B-X
in	B-X
C/EBP	B-X
alpha	B-X
are	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
patients	B-X
with	B-X
AML	B-X
presenting	B-X
with	B-X
a	B-X
normal	B-X
karyotype	B-X
.	B-X
These	B-X
mutations	B-X
can	B-X
result	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
30	B-X
kDa	B-X
dominant	B-X
negative	B-X
C/EBP	B-X
alpha	B-X
isoform	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
loss	B-X
of	B-X
C/EBP	B-X
alpha	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
phosphorylation	B-X
,	B-X
C/EBP	B-X
alpha	B-X
is	B-X
modified	B-X
,	B-X
post-translationally	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
at	B-X
a	B-X
lysine	B-X
residue	B-X
(	B-X
K159	B-X
)	B-X
,	B-X
which	B-X
lies	B-X
within	B-X
the	B-X
growth	B-X
inhibitory	B-X
region	B-X
of	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
.	B-X
Sumoylation	B-X
at	B-X
K159	B-X
in	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
prevents	B-X
association	B-X
of	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
with	B-X
C/EBP	B-X
alpha	B-X
,	B-X
thereby	B-X
hampering	B-X
transactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
functional	B-X
implications	B-X
of	B-X
post-translational	B-X
modification	B-X
,	B-X
particularly	B-X
sumoylation	B-X
,	B-X
of	B-X
C/EBP	B-X
alpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
and	B-X
leukemia	B-X
are	B-X
considered	B-X
.	B-X

CCAAT	B-Protein
enhancer	I-Protein
binding	I-Protein
protein	I-Protein
alpha	I-Protein
(	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
)	O
is	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
basic	O
region	O
/	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
transcription	O
factors	O
and	O
is	O
a	O
master	O
regulator	O
of	O
granulopoiesis	O
.	O
<EOS>	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
alpha	B-X
(	B-X
C/EBP	B-X
alpha	B-X
)	B-X
is	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
basic	B-X
region/leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
transcription	B-X
factors	B-X
and	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
granulopoiesis	B-X
.	B-X
Profound	B-X
hematopoietic	B-X
abnormalities	B-X
occur	B-X
in	B-X
mice	B-X
nullizygous	B-X
for	B-X
C/EBP	B-X
alpha	B-X
including	B-X
a	B-X
selective	B-X
early	B-X
block	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
granulocytes	B-X
.	B-X
Mutations	B-X
in	B-X
C/EBP	B-X
alpha	B-X
are	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
patients	B-X
with	B-X
AML	B-X
presenting	B-X
with	B-X
a	B-X
normal	B-X
karyotype	B-X
.	B-X
These	B-X
mutations	B-X
can	B-X
result	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
30	B-X
kDa	B-X
dominant	B-X
negative	B-X
C/EBP	B-X
alpha	B-X
isoform	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
loss	B-X
of	B-X
C/EBP	B-X
alpha	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
phosphorylation	B-X
,	B-X
C/EBP	B-X
alpha	B-X
is	B-X
modified	B-X
,	B-X
post-translationally	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
at	B-X
a	B-X
lysine	B-X
residue	B-X
(	B-X
K159	B-X
)	B-X
,	B-X
which	B-X
lies	B-X
within	B-X
the	B-X
growth	B-X
inhibitory	B-X
region	B-X
of	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
.	B-X
Sumoylation	B-X
at	B-X
K159	B-X
in	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
prevents	B-X
association	B-X
of	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
with	B-X
C/EBP	B-X
alpha	B-X
,	B-X
thereby	B-X
hampering	B-X
transactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
functional	B-X
implications	B-X
of	B-X
post-translational	B-X
modification	B-X
,	B-X
particularly	B-X
sumoylation	B-X
,	B-X
of	B-X
C/EBP	B-X
alpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
and	B-X
leukemia	B-X
are	B-X
considered	B-X
.	B-X

It	O
is	O
expressed	O
at	O
high	O
levels	O
throughout	O
myeloid	O
differentiation	O
and	O
binds	O
to	O
the	O
promoters	O
of	O
multiple	O
myeloid	O
-	O
specific	O
genes	O
at	O
different	O
stages	O
of	O
myeloid	O
maturation	O
.	O

Profound	O
hematopoietic	O
abnormalities	O
occur	O
in	O
mice	O
nullizygous	O
for	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
including	O
a	O
selective	O
early	O
block	O
in	O
the	O
differentiation	O
of	O
granulocytes	O
.	O
<EOS>	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
alpha	B-X
(	B-X
C/EBP	B-X
alpha	B-X
)	B-X
is	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
basic	B-X
region/leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
transcription	B-X
factors	B-X
and	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
granulopoiesis	B-X
.	B-X
It	B-X
is	B-X
expressed	B-X
at	B-X
high	B-X
levels	B-X
throughout	B-X
myeloid	B-X
differentiation	B-X
and	B-X
binds	B-X
to	B-X
the	B-X
promoters	B-X
of	B-X
multiple	B-X
myeloid-specific	B-X
genes	B-X
at	B-X
different	B-X
stages	B-X
of	B-X
myeloid	B-X
maturation	B-X
.	B-X
Profound	B-X
hematopoietic	B-X
abnormalities	B-X
occur	B-X
in	B-X
mice	B-X
nullizygous	B-X
for	B-X
C/EBP	B-X
alpha	B-X
including	B-X
a	B-X
selective	B-X
early	B-X
block	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
granulocytes	B-X
.	B-X
Mutations	B-X
in	B-X
C/EBP	B-X
alpha	B-X
are	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
patients	B-X
with	B-X
AML	B-X
presenting	B-X
with	B-X
a	B-X
normal	B-X
karyotype	B-X
.	B-X
These	B-X
mutations	B-X
can	B-X
result	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
30	B-X
kDa	B-X
dominant	B-X
negative	B-X
C/EBP	B-X
alpha	B-X
isoform	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
loss	B-X
of	B-X
C/EBP	B-X
alpha	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
phosphorylation	B-X
,	B-X
C/EBP	B-X
alpha	B-X
is	B-X
modified	B-X
,	B-X
post-translationally	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
at	B-X
a	B-X
lysine	B-X
residue	B-X
(	B-X
K159	B-X
)	B-X
,	B-X
which	B-X
lies	B-X
within	B-X
the	B-X
growth	B-X
inhibitory	B-X
region	B-X
of	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
.	B-X
Sumoylation	B-X
at	B-X
K159	B-X
in	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
prevents	B-X
association	B-X
of	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
with	B-X
C/EBP	B-X
alpha	B-X
,	B-X
thereby	B-X
hampering	B-X
transactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
functional	B-X
implications	B-X
of	B-X
post-translational	B-X
modification	B-X
,	B-X
particularly	B-X
sumoylation	B-X
,	B-X
of	B-X
C/EBP	B-X
alpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
and	B-X
leukemia	B-X
are	B-X
considered	B-X
.	B-X

Mutations	O
in	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
are	O
present	O
in	O
a	O
subset	O
of	O
patients	O
with	O
AML	O
presenting	O
with	O
a	O
normal	O
karyotype	O
.	O

These	O
mutations	O
can	O
result	O
in	O
the	O
expression	O
of	O
a	O
30	O
kDa	O
dominant	O
negative	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
isoform	O
,	O
which	O
contributes	O
to	O
loss	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
function	O
.	O
<EOS>	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
alpha	B-X
(	B-X
C/EBP	B-X
alpha	B-X
)	B-X
is	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
basic	B-X
region/leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
transcription	B-X
factors	B-X
and	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
granulopoiesis	B-X
.	B-X
Profound	B-X
hematopoietic	B-X
abnormalities	B-X
occur	B-X
in	B-X
mice	B-X
nullizygous	B-X
for	B-X
C/EBP	B-X
alpha	B-X
including	B-X
a	B-X
selective	B-X
early	B-X
block	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
granulocytes	B-X
.	B-X
Mutations	B-X
in	B-X
C/EBP	B-X
alpha	B-X
are	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
patients	B-X
with	B-X
AML	B-X
presenting	B-X
with	B-X
a	B-X
normal	B-X
karyotype	B-X
.	B-X
These	B-X
mutations	B-X
can	B-X
result	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
30	B-X
kDa	B-X
dominant	B-X
negative	B-X
C/EBP	B-X
alpha	B-X
isoform	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
loss	B-X
of	B-X
C/EBP	B-X
alpha	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
phosphorylation	B-X
,	B-X
C/EBP	B-X
alpha	B-X
is	B-X
modified	B-X
,	B-X
post-translationally	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
at	B-X
a	B-X
lysine	B-X
residue	B-X
(	B-X
K159	B-X
)	B-X
,	B-X
which	B-X
lies	B-X
within	B-X
the	B-X
growth	B-X
inhibitory	B-X
region	B-X
of	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
.	B-X
Sumoylation	B-X
at	B-X
K159	B-X
in	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
prevents	B-X
association	B-X
of	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
with	B-X
C/EBP	B-X
alpha	B-X
,	B-X
thereby	B-X
hampering	B-X
transactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
functional	B-X
implications	B-X
of	B-X
post-translational	B-X
modification	B-X
,	B-X
particularly	B-X
sumoylation	B-X
,	B-X
of	B-X
C/EBP	B-X
alpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
and	B-X
leukemia	B-X
are	B-X
considered	B-X
.	B-X

The	O
molecular	O
basis	O
for	O
this	O
observation	O
remains	O
unknown	O
.	O
<EOS>	B-X
The	B-X
biological	B-X
basis	B-X
of	B-X
male-female	B-X
brain	B-X
differences	B-X
has	B-X
been	B-X
difficult	B-X
to	B-X
elucidate	B-X
in	B-X
humans	B-X
.	B-X
A	B-X
molecular	B-X
diagnosis	B-X
can	B-X
be	B-X
performed	B-X
by	B-X
gene	B-X
sequencing	B-X
and	B-X
allele	B-X
quantification	B-X
for	B-X
the	B-X
four	B-X
main	B-X
genes	B-X
SHH	B-X
,	B-X
ZIC2	B-X
,	B-X
SIX3	B-X
and	B-X
TGIF	B-X
.	B-X
Nevertheless	B-X
,	B-X
in	B-X
about	B-X
70	B-X
%	B-X
of	B-X
cases	B-X
,	B-X
the	B-X
molecular	B-X
basis	B-X
of	B-X
the	B-X
disease	B-X
remains	B-X
unknown	B-X
,	B-X
suggesting	B-X
the	B-X
existence	B-X
of	B-X
several	B-X
other	B-X
candidate	B-X
genes	B-X
or	B-X
environmental	B-X
factors	B-X
.	B-X
In	B-X
a	B-X
practical	B-X
approach	B-X
,	B-X
prenatal	B-X
diagnosis	B-X
is	B-X
based	B-X
on	B-X
ultrasound	B-X
and	B-X
magnetic	B-X
resonance	B-X
imaging	B-X
(	B-X
MRI	B-X
)	B-X
rather	B-X
than	B-X
on	B-X
molecular	B-X
diagnosis	B-X
.	B-X

In	O
addition	O
to	O
phosphorylation	O
,	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
is	O
modified	O
,	O
post	O
-	O
translationally	O
by	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
at	O
a	O
lysine	O
residue	O
(	O
K159	O
)	O
,	O
which	O
lies	O
within	O
the	O
growth	O
inhibitory	O
region	O
of	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
protein	O
.	O

Sumoylation	O
at	O
K159	O
in	O
the	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
protein	O
prevents	O
association	O
of	O
the	O
SWI	O
/	O
SNF	O
chromatin	O
remodeling	O
complex	O
with	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
,	O
thereby	O
hampering	O
transactivation	O
.	O

In	O
this	O
review	O
,	O
the	O
functional	O
implications	O
of	O
post	O
-	O
translational	O
modification	O
,	O
particularly	O
sumoylation	O
,	O
of	O
C	B-Protein
/	I-Protein
EBP	I-Protein
alpha	I-Protein
in	O
normal	O
granulopoiesis	O
and	O
leukemia	O
are	O
considered	O
.	O
<EOS>	B-X
CCAAT	B-X
enhancer	B-X
binding	B-X
protein	B-X
alpha	B-X
(	B-X
C/EBP	B-X
alpha	B-X
)	B-X
is	B-X
the	B-X
founding	B-X
member	B-X
of	B-X
a	B-X
family	B-X
of	B-X
basic	B-X
region/leucine	B-X
zipper	B-X
(	B-X
bZIP	B-X
)	B-X
transcription	B-X
factors	B-X
and	B-X
is	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
granulopoiesis	B-X
.	B-X
Profound	B-X
hematopoietic	B-X
abnormalities	B-X
occur	B-X
in	B-X
mice	B-X
nullizygous	B-X
for	B-X
C/EBP	B-X
alpha	B-X
including	B-X
a	B-X
selective	B-X
early	B-X
block	B-X
in	B-X
the	B-X
differentiation	B-X
of	B-X
granulocytes	B-X
.	B-X
Mutations	B-X
in	B-X
C/EBP	B-X
alpha	B-X
are	B-X
present	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
patients	B-X
with	B-X
AML	B-X
presenting	B-X
with	B-X
a	B-X
normal	B-X
karyotype	B-X
.	B-X
These	B-X
mutations	B-X
can	B-X
result	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
a	B-X
30	B-X
kDa	B-X
dominant	B-X
negative	B-X
C/EBP	B-X
alpha	B-X
isoform	B-X
,	B-X
which	B-X
contributes	B-X
to	B-X
loss	B-X
of	B-X
C/EBP	B-X
alpha	B-X
function	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
phosphorylation	B-X
,	B-X
C/EBP	B-X
alpha	B-X
is	B-X
modified	B-X
,	B-X
post-translationally	B-X
by	B-X
a	B-X
small	B-X
ubiquitin-related	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
at	B-X
a	B-X
lysine	B-X
residue	B-X
(	B-X
K159	B-X
)	B-X
,	B-X
which	B-X
lies	B-X
within	B-X
the	B-X
growth	B-X
inhibitory	B-X
region	B-X
of	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
.	B-X
Sumoylation	B-X
at	B-X
K159	B-X
in	B-X
the	B-X
C/EBP	B-X
alpha	B-X
protein	B-X
prevents	B-X
association	B-X
of	B-X
the	B-X
SWI/SNF	B-X
chromatin	B-X
remodeling	B-X
complex	B-X
with	B-X
C/EBP	B-X
alpha	B-X
,	B-X
thereby	B-X
hampering	B-X
transactivation	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
the	B-X
functional	B-X
implications	B-X
of	B-X
post-translational	B-X
modification	B-X
,	B-X
particularly	B-X
sumoylation	B-X
,	B-X
of	B-X
C/EBP	B-X
alpha	B-X
in	B-X
normal	B-X
granulopoiesis	B-X
and	B-X
leukemia	B-X
are	B-X
considered	B-X
.	B-X

Interaction	O
of	O
a	O
peptide	O
derived	O
from	O
glycoprotein	O
gp36	B-Protein
of	O
feline	O
immunodeficiency	O
virus	O
and	O
its	O
lipoylated	O
analogue	O
with	O
phospholipid	O
membranes	O
.	O
<EOS>	B-X
P59	B-X
,	B-X
a	B-X
20-mer	B-X
peptide	B-X
modeled	B-X
on	B-X
the	B-X
membrane-proximal	B-X
external	B-X
region	B-X
(	B-X
MPER	B-X
)	B-X
of	B-X
the	B-X
feline	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
FIV	B-X
)	B-X
gp36	B-X
ectodomain	B-X
,	B-X
has	B-X
potent	B-X
antiviral	B-X
activity	B-X
.	B-X
The	B-X
lipoylated	B-X
analogue	B-X
,	B-X
lipo-P59	B-X
,	B-X
displays	B-X
a	B-X
similar	B-X
activity	B-X
,	B-X
which	B-X
is	B-X
preferentially	B-X
retained	B-X
by	B-X
cellular	B-X
substrates	B-X
.	B-X
A	B-X
mechanism	B-X
has	B-X
been	B-X
proposed	B-X
recently	B-X
in	B-X
which	B-X
the	B-X
peptide	B-X
,	B-X
being	B-X
positioned	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
inhibits	B-X
its	B-X
fusion	B-X
with	B-X
the	B-X
virus	B-X
;	B-X
the	B-X
lipophilic	B-X
chain	B-X
of	B-X
lipo-P59	B-X
is	B-X
thought	B-X
to	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
interior	B-X
,	B-X
thus	B-X
anchoring	B-X
the	B-X
peptide	B-X
at	B-X
the	B-X
surface	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
lipid-peptide	B-X
interactions	B-X
of	B-X
P59	B-X
and	B-X
lipo-P59	B-X
with	B-X
phospholipid	B-X
liposomes	B-X
are	B-X
investigated	B-X
using	B-X
spin-label	B-X
electron	B-X
spin	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Two	B-X
phospholipids	B-X
have	B-X
been	B-X
examined	B-X
,	B-X
the	B-X
zwitterionic	B-X
dimyristoyl	B-X
phosphatidylcholine	B-X
and	B-X
the	B-X
anionic	B-X
dimyristoyl	B-X
phosphatidylglycerol	B-X
,	B-X
and	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
lipid	B-X
spin	B-X
labels	B-X
,	B-X
including	B-X
positional	B-X
isomers	B-X
.	B-X
Independent	B-X
of	B-X
the	B-X
membrane	B-X
charge	B-X
,	B-X
both	B-X
peptides	B-X
bind	B-X
to	B-X
lipid	B-X
bilayers	B-X
;	B-X
however	B-X
,	B-X
whereas	B-X
P59	B-X
insertion	B-X
between	B-X
the	B-X
lipid	B-X
headgroups	B-X
leads	B-X
to	B-X
significant	B-X
liposome	B-X
destabilization	B-X
,	B-X
eventually	B-X
resulting	B-X
in	B-X
vesicle	B-X
fragmentation	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
smaller	B-X
aggregates	B-X
,	B-X
lipo-P59	B-X
inserts	B-X
with	B-X
the	B-X
lipophilic	B-X
tail	B-X
among	B-X
the	B-X
lipid	B-X
chains	B-X
,	B-X
while	B-X
the	B-X
peptidic	B-X
portion	B-X
remains	B-X
adsorbed	B-X
onto	B-X
the	B-X
membrane	B-X
,	B-X
where	B-X
it	B-X
can	B-X
effectively	B-X
exert	B-X
its	B-X
antiviral	B-X
activity	B-X
.	B-X

P59	O
,	O
a	O
20	O
-	O
mer	O
peptide	O
modeled	O
on	O
the	O
membrane	O
-	O
proximal	O
external	O
region	O
(	O
MPER	O
)	O
of	O
the	O
feline	O
immunodeficiency	O
virus	O
(	O
FIV	O
)	O
gp36	B-Protein
ectodomain	O
,	O
has	O
potent	O
antiviral	O
activity	O
.	O
<EOS>	B-X
P59	B-X
,	B-X
a	B-X
20-mer	B-X
peptide	B-X
modeled	B-X
on	B-X
the	B-X
membrane-proximal	B-X
external	B-X
region	B-X
(	B-X
MPER	B-X
)	B-X
of	B-X
the	B-X
feline	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
FIV	B-X
)	B-X
gp36	B-X
ectodomain	B-X
,	B-X
has	B-X
potent	B-X
antiviral	B-X
activity	B-X
.	B-X
The	B-X
lipoylated	B-X
analogue	B-X
,	B-X
lipo-P59	B-X
,	B-X
displays	B-X
a	B-X
similar	B-X
activity	B-X
,	B-X
which	B-X
is	B-X
preferentially	B-X
retained	B-X
by	B-X
cellular	B-X
substrates	B-X
.	B-X
A	B-X
mechanism	B-X
has	B-X
been	B-X
proposed	B-X
recently	B-X
in	B-X
which	B-X
the	B-X
peptide	B-X
,	B-X
being	B-X
positioned	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
inhibits	B-X
its	B-X
fusion	B-X
with	B-X
the	B-X
virus	B-X
;	B-X
the	B-X
lipophilic	B-X
chain	B-X
of	B-X
lipo-P59	B-X
is	B-X
thought	B-X
to	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
interior	B-X
,	B-X
thus	B-X
anchoring	B-X
the	B-X
peptide	B-X
at	B-X
the	B-X
surface	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
lipid-peptide	B-X
interactions	B-X
of	B-X
P59	B-X
and	B-X
lipo-P59	B-X
with	B-X
phospholipid	B-X
liposomes	B-X
are	B-X
investigated	B-X
using	B-X
spin-label	B-X
electron	B-X
spin	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Two	B-X
phospholipids	B-X
have	B-X
been	B-X
examined	B-X
,	B-X
the	B-X
zwitterionic	B-X
dimyristoyl	B-X
phosphatidylcholine	B-X
and	B-X
the	B-X
anionic	B-X
dimyristoyl	B-X
phosphatidylglycerol	B-X
,	B-X
and	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
lipid	B-X
spin	B-X
labels	B-X
,	B-X
including	B-X
positional	B-X
isomers	B-X
.	B-X
Independent	B-X
of	B-X
the	B-X
membrane	B-X
charge	B-X
,	B-X
both	B-X
peptides	B-X
bind	B-X
to	B-X
lipid	B-X
bilayers	B-X
;	B-X
however	B-X
,	B-X
whereas	B-X
P59	B-X
insertion	B-X
between	B-X
the	B-X
lipid	B-X
headgroups	B-X
leads	B-X
to	B-X
significant	B-X
liposome	B-X
destabilization	B-X
,	B-X
eventually	B-X
resulting	B-X
in	B-X
vesicle	B-X
fragmentation	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
smaller	B-X
aggregates	B-X
,	B-X
lipo-P59	B-X
inserts	B-X
with	B-X
the	B-X
lipophilic	B-X
tail	B-X
among	B-X
the	B-X
lipid	B-X
chains	B-X
,	B-X
while	B-X
the	B-X
peptidic	B-X
portion	B-X
remains	B-X
adsorbed	B-X
onto	B-X
the	B-X
membrane	B-X
,	B-X
where	B-X
it	B-X
can	B-X
effectively	B-X
exert	B-X
its	B-X
antiviral	B-X
activity	B-X
.	B-X

The	O
lipoylated	O
analogue	O
,	O
lipo	O
-	O
P59	O
,	O
displays	O
a	O
similar	O
activity	O
,	O
which	O
is	O
preferentially	O
retained	O
by	O
cellular	O
substrates	O
.	O
<EOS>	B-X
P59	B-X
,	B-X
a	B-X
20-mer	B-X
peptide	B-X
modeled	B-X
on	B-X
the	B-X
membrane-proximal	B-X
external	B-X
region	B-X
(	B-X
MPER	B-X
)	B-X
of	B-X
the	B-X
feline	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
FIV	B-X
)	B-X
gp36	B-X
ectodomain	B-X
,	B-X
has	B-X
potent	B-X
antiviral	B-X
activity	B-X
.	B-X
The	B-X
lipoylated	B-X
analogue	B-X
,	B-X
lipo-P59	B-X
,	B-X
displays	B-X
a	B-X
similar	B-X
activity	B-X
,	B-X
which	B-X
is	B-X
preferentially	B-X
retained	B-X
by	B-X
cellular	B-X
substrates	B-X
.	B-X
A	B-X
mechanism	B-X
has	B-X
been	B-X
proposed	B-X
recently	B-X
in	B-X
which	B-X
the	B-X
peptide	B-X
,	B-X
being	B-X
positioned	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
inhibits	B-X
its	B-X
fusion	B-X
with	B-X
the	B-X
virus	B-X
;	B-X
the	B-X
lipophilic	B-X
chain	B-X
of	B-X
lipo-P59	B-X
is	B-X
thought	B-X
to	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
interior	B-X
,	B-X
thus	B-X
anchoring	B-X
the	B-X
peptide	B-X
at	B-X
the	B-X
surface	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
lipid-peptide	B-X
interactions	B-X
of	B-X
P59	B-X
and	B-X
lipo-P59	B-X
with	B-X
phospholipid	B-X
liposomes	B-X
are	B-X
investigated	B-X
using	B-X
spin-label	B-X
electron	B-X
spin	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Independent	B-X
of	B-X
the	B-X
membrane	B-X
charge	B-X
,	B-X
both	B-X
peptides	B-X
bind	B-X
to	B-X
lipid	B-X
bilayers	B-X
;	B-X
however	B-X
,	B-X
whereas	B-X
P59	B-X
insertion	B-X
between	B-X
the	B-X
lipid	B-X
headgroups	B-X
leads	B-X
to	B-X
significant	B-X
liposome	B-X
destabilization	B-X
,	B-X
eventually	B-X
resulting	B-X
in	B-X
vesicle	B-X
fragmentation	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
smaller	B-X
aggregates	B-X
,	B-X
lipo-P59	B-X
inserts	B-X
with	B-X
the	B-X
lipophilic	B-X
tail	B-X
among	B-X
the	B-X
lipid	B-X
chains	B-X
,	B-X
while	B-X
the	B-X
peptidic	B-X
portion	B-X
remains	B-X
adsorbed	B-X
onto	B-X
the	B-X
membrane	B-X
,	B-X
where	B-X
it	B-X
can	B-X
effectively	B-X
exert	B-X
its	B-X
antiviral	B-X
activity	B-X
.	B-X

A	O
mechanism	O
has	O
been	O
proposed	O
recently	O
in	O
which	O
the	O
peptide	O
,	O
being	O
positioned	O
on	O
the	O
surface	O
of	O
the	O
cell	O
membrane	O
,	O
inhibits	O
its	O
fusion	O
with	O
the	O
virus	O
;	O
the	O
lipophilic	O
chain	O
of	O
lipo	O
-	O
P59	O
is	O
thought	O
to	O
insert	O
into	O
the	O
membrane	O
interior	O
,	O
thus	O
anchoring	O
the	O
peptide	O
at	O
the	O
surface	O
.	O
<EOS>	B-X
P59	B-X
,	B-X
a	B-X
20-mer	B-X
peptide	B-X
modeled	B-X
on	B-X
the	B-X
membrane-proximal	B-X
external	B-X
region	B-X
(	B-X
MPER	B-X
)	B-X
of	B-X
the	B-X
feline	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
FIV	B-X
)	B-X
gp36	B-X
ectodomain	B-X
,	B-X
has	B-X
potent	B-X
antiviral	B-X
activity	B-X
.	B-X
The	B-X
lipoylated	B-X
analogue	B-X
,	B-X
lipo-P59	B-X
,	B-X
displays	B-X
a	B-X
similar	B-X
activity	B-X
,	B-X
which	B-X
is	B-X
preferentially	B-X
retained	B-X
by	B-X
cellular	B-X
substrates	B-X
.	B-X
A	B-X
mechanism	B-X
has	B-X
been	B-X
proposed	B-X
recently	B-X
in	B-X
which	B-X
the	B-X
peptide	B-X
,	B-X
being	B-X
positioned	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
inhibits	B-X
its	B-X
fusion	B-X
with	B-X
the	B-X
virus	B-X
;	B-X
the	B-X
lipophilic	B-X
chain	B-X
of	B-X
lipo-P59	B-X
is	B-X
thought	B-X
to	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
interior	B-X
,	B-X
thus	B-X
anchoring	B-X
the	B-X
peptide	B-X
at	B-X
the	B-X
surface	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
lipid-peptide	B-X
interactions	B-X
of	B-X
P59	B-X
and	B-X
lipo-P59	B-X
with	B-X
phospholipid	B-X
liposomes	B-X
are	B-X
investigated	B-X
using	B-X
spin-label	B-X
electron	B-X
spin	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Independent	B-X
of	B-X
the	B-X
membrane	B-X
charge	B-X
,	B-X
both	B-X
peptides	B-X
bind	B-X
to	B-X
lipid	B-X
bilayers	B-X
;	B-X
however	B-X
,	B-X
whereas	B-X
P59	B-X
insertion	B-X
between	B-X
the	B-X
lipid	B-X
headgroups	B-X
leads	B-X
to	B-X
significant	B-X
liposome	B-X
destabilization	B-X
,	B-X
eventually	B-X
resulting	B-X
in	B-X
vesicle	B-X
fragmentation	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
smaller	B-X
aggregates	B-X
,	B-X
lipo-P59	B-X
inserts	B-X
with	B-X
the	B-X
lipophilic	B-X
tail	B-X
among	B-X
the	B-X
lipid	B-X
chains	B-X
,	B-X
while	B-X
the	B-X
peptidic	B-X
portion	B-X
remains	B-X
adsorbed	B-X
onto	B-X
the	B-X
membrane	B-X
,	B-X
where	B-X
it	B-X
can	B-X
effectively	B-X
exert	B-X
its	B-X
antiviral	B-X
activity	B-X
.	B-X

In	O
the	O
present	O
work	O
,	O
lipid	O
-	O
peptide	O
interactions	O
of	O
P59	O
and	O
lipo	O
-	O
P59	O
with	O
phospholipid	O
liposomes	O
are	O
investigated	O
using	O
spin	O
-	O
label	O
electron	O
spin	O
resonance	O
spectroscopy	O
.	O
<EOS>	B-X
P59	B-X
,	B-X
a	B-X
20-mer	B-X
peptide	B-X
modeled	B-X
on	B-X
the	B-X
membrane-proximal	B-X
external	B-X
region	B-X
(	B-X
MPER	B-X
)	B-X
of	B-X
the	B-X
feline	B-X
immunodeficiency	B-X
virus	B-X
(	B-X
FIV	B-X
)	B-X
gp36	B-X
ectodomain	B-X
,	B-X
has	B-X
potent	B-X
antiviral	B-X
activity	B-X
.	B-X
The	B-X
lipoylated	B-X
analogue	B-X
,	B-X
lipo-P59	B-X
,	B-X
displays	B-X
a	B-X
similar	B-X
activity	B-X
,	B-X
which	B-X
is	B-X
preferentially	B-X
retained	B-X
by	B-X
cellular	B-X
substrates	B-X
.	B-X
A	B-X
mechanism	B-X
has	B-X
been	B-X
proposed	B-X
recently	B-X
in	B-X
which	B-X
the	B-X
peptide	B-X
,	B-X
being	B-X
positioned	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
the	B-X
cell	B-X
membrane	B-X
,	B-X
inhibits	B-X
its	B-X
fusion	B-X
with	B-X
the	B-X
virus	B-X
;	B-X
the	B-X
lipophilic	B-X
chain	B-X
of	B-X
lipo-P59	B-X
is	B-X
thought	B-X
to	B-X
insert	B-X
into	B-X
the	B-X
membrane	B-X
interior	B-X
,	B-X
thus	B-X
anchoring	B-X
the	B-X
peptide	B-X
at	B-X
the	B-X
surface	B-X
.	B-X
In	B-X
the	B-X
present	B-X
work	B-X
,	B-X
lipid-peptide	B-X
interactions	B-X
of	B-X
P59	B-X
and	B-X
lipo-P59	B-X
with	B-X
phospholipid	B-X
liposomes	B-X
are	B-X
investigated	B-X
using	B-X
spin-label	B-X
electron	B-X
spin	B-X
resonance	B-X
spectroscopy	B-X
.	B-X
Two	B-X
phospholipids	B-X
have	B-X
been	B-X
examined	B-X
,	B-X
the	B-X
zwitterionic	B-X
dimyristoyl	B-X
phosphatidylcholine	B-X
and	B-X
the	B-X
anionic	B-X
dimyristoyl	B-X
phosphatidylglycerol	B-X
,	B-X
and	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
lipid	B-X
spin	B-X
labels	B-X
,	B-X
including	B-X
positional	B-X
isomers	B-X
.	B-X
Independent	B-X
of	B-X
the	B-X
membrane	B-X
charge	B-X
,	B-X
both	B-X
peptides	B-X
bind	B-X
to	B-X
lipid	B-X
bilayers	B-X
;	B-X
however	B-X
,	B-X
whereas	B-X
P59	B-X
insertion	B-X
between	B-X
the	B-X
lipid	B-X
headgroups	B-X
leads	B-X
to	B-X
significant	B-X
liposome	B-X
destabilization	B-X
,	B-X
eventually	B-X
resulting	B-X
in	B-X
vesicle	B-X
fragmentation	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
smaller	B-X
aggregates	B-X
,	B-X
lipo-P59	B-X
inserts	B-X
with	B-X
the	B-X
lipophilic	B-X
tail	B-X
among	B-X
the	B-X
lipid	B-X
chains	B-X
,	B-X
while	B-X
the	B-X
peptidic	B-X
portion	B-X
remains	B-X
adsorbed	B-X
onto	B-X
the	B-X
membrane	B-X
,	B-X
where	B-X
it	B-X
can	B-X
effectively	B-X
exert	B-X
its	B-X
antiviral	B-X
activity	B-X
.	B-X

Two	O
phospholipids	O
have	O
been	O
examined	O
,	O
the	O
zwitterionic	O
dimyristoyl	O
phosphatidylcholine	O
and	O
the	O
anionic	O
dimyristoyl	O
phosphatidylglycerol	O
,	O
and	O
a	O
wide	O
range	O
of	O
lipid	O
spin	O
labels	O
,	O
including	O
positional	O
isomers	O
.	O

Independent	O
of	O
the	O
membrane	O
charge	O
,	O
both	O
peptides	O
bind	O
to	O
lipid	O
bilayers	O
;	O
however	O
,	O
whereas	O
P59	O
insertion	O
between	O
the	O
lipid	O
headgroups	O
leads	O
to	O
significant	O
liposome	O
destabilization	O
,	O
eventually	O
resulting	O
in	O
vesicle	O
fragmentation	O
with	O
the	O
formation	O
of	O
smaller	O
aggregates	O
,	O
lipo	O
-	O
P59	O
inserts	O
with	O
the	O
lipophilic	O
tail	O
among	O
the	O
lipid	O
chains	O
,	O
while	O
the	O
peptidic	O
portion	O
remains	O
adsorbed	O
onto	O
the	O
membrane	O
,	O
where	O
it	O
can	O
effectively	O
exert	O
its	O
antiviral	O
activity	O
.	O
<EOS>	B-X
An	B-X
amphipathic	B-X
model	B-X
peptide	B-X
,	B-X
KLALKLALKALKAAKLA-NH2	B-X
,	B-X
and	B-X
its	B-X
complete	B-X
double	B-X
D-amino	B-X
acid	B-X
replacement	B-X
set	B-X
was	B-X
used	B-X
to	B-X
analyze	B-X
the	B-X
process	B-X
of	B-X
peptide	B-X
binding	B-X
at	B-X
lipid	B-X
vesicles	B-X
of	B-X
different	B-X
surface	B-X
charge	B-X
and	B-X
to	B-X
determine	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
lipid-bound	B-X
peptides	B-X
using	B-X
CD	B-X
spectroscopy	B-X
.	B-X
The	B-X
relationship	B-X
between	B-X
peptide	B-X
helicity	B-X
,	B-X
model	B-X
membrane	B-X
permeability	B-X
,	B-X
and	B-X
biological	B-X
activity	B-X
has	B-X
been	B-X
studied	B-X
by	B-X
dye	B-X
release	B-X
from	B-X
liposomes	B-X
and	B-X
investigation	B-X
of	B-X
antibacterial	B-X
and	B-X
hemolytic	B-X
activity	B-X
.	B-X
The	B-X
accumulation	B-X
of	B-X
cationic	B-X
KLAL	B-X
peptides	B-X
at	B-X
and	B-X
the	B-X
membrane-disturbing	B-X
effect	B-X
on	B-X
bilayers	B-X
of	B-X
high	B-X
negative	B-X
surface	B-X
charge	B-X
were	B-X
found	B-X
to	B-X
be	B-X
dominated	B-X
by	B-X
charge	B-X
interactions	B-X
.	B-X
Independent	B-X
of	B-X
any	B-X
structural	B-X
propensity	B-X
,	B-X
the	B-X
cationic	B-X
peptide	B-X
side	B-X
chains	B-X
bind	B-X
to	B-X
the	B-X
anionic	B-X
phosphatidylglycerol	B-X
moieties	B-X
.	B-X
The	B-X
charge	B-X
interactions	B-X
hold	B-X
the	B-X
peptides	B-X
at	B-X
the	B-X
bilayer	B-X
surface	B-X
,	B-X
where	B-X
they	B-X
may	B-X
disturb	B-X
preferentially	B-X
lipid	B-X
headgroup	B-X
organization	B-X
by	B-X
formation	B-X
of	B-X
peptide-lipid	B-X
clusters	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
KLAL	B-X
peptide	B-X
interaction	B-X
with	B-X
bilayers	B-X
of	B-X
low	B-X
negative	B-X
surface	B-X
charge	B-X
is	B-X
highly	B-X
dependent	B-X
on	B-X
peptide	B-X
helicity	B-X
.	B-X
With	B-X
decreasing	B-X
amounts	B-X
of	B-X
anionic	B-X
phosphatidylglycerol	B-X
in	B-X
the	B-X
bilayer	B-X
the	B-X
membrane-disturbing	B-X
effect	B-X
of	B-X
KLAL	B-X
and	B-X
other	B-X
helical	B-X
analogs	B-X
substantially	B-X
increases	B-X
despite	B-X
drastically	B-X
reduced	B-X
binding	B-X
affinity	B-X
.	B-X
Less	B-X
helical	B-X
peptides	B-X
exhibit	B-X
reduced	B-X
bilayer-disturbing	B-X
activity	B-X
,	B-X
showing	B-X
that	B-X
the	B-X
hydrophobic	B-X
helix	B-X
domain	B-X
is	B-X
decisive	B-X
for	B-X
binding	B-X
at	B-X
and	B-X
inducing	B-X
permeability	B-X
in	B-X
membranes	B-X
of	B-X
low	B-X
negative	B-X
surface	B-X
charge	B-X
.	B-X
It	B-X
is	B-X
suggested	B-X
that	B-X
hydrophobic	B-X
interactions	B-X
drive	B-X
the	B-X
penetration	B-X
of	B-X
the	B-X
amphipathic	B-X
peptide	B-X
structure	B-X
into	B-X
the	B-X
inner	B-X
membrane	B-X
region	B-X
,	B-X
thus	B-X
disturbing	B-X
the	B-X
arrangement	B-X
of	B-X
the	B-X
lipid	B-X
acyl	B-X
chains	B-X
and	B-X
causing	B-X
local	B-X
disruption	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
proposed	B-X
model	B-X
for	B-X
membrane	B-X
disturbance	B-X
,	B-X
interactions	B-X
modulating	B-X
antibacterial	B-X
and	B-X
hemolytic	B-X
activity	B-X
are	B-X
discussed	B-X
.	B-X

MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
in	O
the	O
Caenorhabditis	O
elegans	O
sensory	O
mechanotransduction	O
complex	O
:	O
auxiliary	O
subunits	O
that	O
enable	O
channel	O
activity	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
use	B-X
two-electrode	B-X
voltage	B-X
clamp	B-X
and	B-X
outside-out	B-X
macropatch	B-X
recording	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
divalent	B-X
cations	B-X
and	B-X
proteases	B-X
,	B-X
known	B-X
regulators	B-X
of	B-X
channel	B-X
family	B-X
members	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

The	O
ion	O
channel	O
formed	O
by	O
the	O
homologous	O
proteins	O
MEC	B-Protein
-	I-Protein
4	I-Protein
and	O
MEC	B-Protein
-	I-Protein
10	I-Protein
forms	O
the	O
core	O
of	O
a	O
sensory	O
mechanotransduction	O
channel	O
in	O
Caenorhabditis	O
elegans	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
use	B-X
two-electrode	B-X
voltage	B-X
clamp	B-X
and	B-X
outside-out	B-X
macropatch	B-X
recording	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
divalent	B-X
cations	B-X
and	B-X
proteases	B-X
,	B-X
known	B-X
regulators	B-X
of	B-X
channel	B-X
family	B-X
members	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

Although	O
the	O
products	O
of	O
other	O
mec	O
genes	O
are	O
key	O
players	O
in	O
the	O
biophysics	O
of	O
transduction	O
,	O
the	O
mechanism	O
by	O
which	O
they	O
contribute	O
to	O
the	O
properties	O
of	O
the	O
channel	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
two	O
auxiliary	O
channel	O
subunits	O
,	O
MEC	B-Protein
-	I-Protein
2	I-Protein
(	O
stomatin	O
-	O
like	O
)	O
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
(	O
paraoxonase	O
-	O
like	O
)	O
,	O
by	O
coexpressing	O
them	O
with	O
constitutively	O
active	O
MEC	B-Protein
-	I-Protein
4	I-Protein
/	O
MEC	B-Protein
-	I-Protein
10	I-Protein
heteromeric	O
channels	O
in	O
Xenopus	O
oocytes	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
use	B-X
two-electrode	B-X
voltage	B-X
clamp	B-X
and	B-X
outside-out	B-X
macropatch	B-X
recording	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
divalent	B-X
cations	B-X
and	B-X
proteases	B-X
,	B-X
known	B-X
regulators	B-X
of	B-X
channel	B-X
family	B-X
members	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

This	O
work	O
extends	O
prior	O
work	O
demonstrating	O
that	O
MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
synergistically	O
increase	O
macroscopic	O
current	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

We	O
use	O
single	O
-	O
channel	O
recordings	O
and	O
biochemistry	O
to	O
show	O
that	O
these	O
auxiliary	O
subunits	O
alter	O
function	O
by	O
increasing	O
the	O
number	O
of	O
channels	O
in	O
an	O
active	O
state	O
rather	O
than	O
by	O
dramatically	O
affecting	O
either	O
single	O
-	O
channel	O
properties	O
or	O
surface	O
expression	O
.	O
<EOS>	B-X
Despite	B-X
this	B-X
clear	B-X
functional	B-X
definition	B-X
,	B-X
highly	B-X
enriched	B-X
isolation	B-X
of	B-X
human	B-X
HSCs	B-X
can	B-X
currently	B-X
only	B-X
be	B-X
achieved	B-X
through	B-X
combinatorial	B-X
assessment	B-X
of	B-X
multiple	B-X
surface	B-X
antigens	B-X
.	B-X
Although	B-X
several	B-X
transgenic	B-X
HSC	B-X
reporter	B-X
mouse	B-X
strains	B-X
have	B-X
been	B-X
described	B-X
,	B-X
no	B-X
analogous	B-X
approach	B-X
to	B-X
prospectively	B-X
isolate	B-X
human	B-X
HSCs	B-X
has	B-X
been	B-X
reported	B-X
.	B-X
To	B-X
identify	B-X
genes	B-X
with	B-X
the	B-X
most	B-X
selective	B-X
expression	B-X
in	B-X
human	B-X
HSCs	B-X
,	B-X
we	B-X
profiled	B-X
population	B-X
and	B-X
single-cell	B-X
transcriptomes	B-X
of	B-X
unexpanded	B-X
and	B-X
ex	B-X
vivo	B-X
cultured	B-X
cord	B-X
blood-derived	B-X
hematopoietic	B-X
stem	B-X
and	B-X
progenitor	B-X
cells	B-X
as	B-X
well	B-X
as	B-X
peripheral	B-X
blood	B-X
,	B-X
adult	B-X
bone	B-X
marrow	B-X
,	B-X
and	B-X
fetal	B-X
liver	B-X
.	B-X
To	B-X
directly	B-X
track	B-X
its	B-X
expression	B-X
in	B-X
human	B-X
hematopoietic	B-X
cells	B-X
,	B-X
we	B-X
developed	B-X
a	B-X
genomic	B-X
HLF	B-X
reporter	B-X
strategy	B-X
,	B-X
capable	B-X
of	B-X
selectively	B-X
labeling	B-X
the	B-X
most	B-X
immature	B-X
blood	B-X
cells	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
a	B-X
single	B-X
engineered	B-X
parameter	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
results	B-X
experimentally	B-X
establish	B-X
HLF	B-X
as	B-X
a	B-X
defining	B-X
gene	B-X
of	B-X
the	B-X
human	B-X
HSC	B-X
state	B-X
and	B-X
outline	B-X
a	B-X
new	B-X
approach	B-X
to	B-X
continuously	B-X
mark	B-X
these	B-X
cells	B-X
with	B-X
high	B-X
fidelity	B-X
.	B-X

We	O
also	O
use	O
two	O
-	O
electrode	O
voltage	O
clamp	O
and	O
outside	O
-	O
out	O
macropatch	O
recording	O
to	O
examine	O
the	O
effects	O
of	O
divalent	O
cations	O
and	O
proteases	O
,	O
known	O
regulators	O
of	O
channel	O
family	O
members	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
use	B-X
two-electrode	B-X
voltage	B-X
clamp	B-X
and	B-X
outside-out	B-X
macropatch	B-X
recording	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
divalent	B-X
cations	B-X
and	B-X
proteases	B-X
,	B-X
known	B-X
regulators	B-X
of	B-X
channel	B-X
family	B-X
members	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

Finally	O
,	O
we	O
examine	O
the	O
role	O
of	O
cholesterol	O
binding	O
in	O
the	O
mechanism	O
of	O
MEC	B-Protein
-	I-Protein
2	I-Protein
action	O
by	O
measuring	O
whole	O
-	O
cell	O
and	O
single	O
-	O
channel	O
currents	O
in	O
MEC	B-Protein
-	I-Protein
2	I-Protein
mutants	O
deficient	O
in	O
cholesterol	O
binding	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
We	B-X
also	B-X
use	B-X
two-electrode	B-X
voltage	B-X
clamp	B-X
and	B-X
outside-out	B-X
macropatch	B-X
recording	B-X
to	B-X
examine	B-X
the	B-X
effects	B-X
of	B-X
divalent	B-X
cations	B-X
and	B-X
proteases	B-X
,	B-X
known	B-X
regulators	B-X
of	B-X
channel	B-X
family	B-X
members	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

We	O
suggest	O
that	O
MEC	B-Protein
-	I-Protein
2	I-Protein
and	O
MEC	B-Protein
-	I-Protein
6	I-Protein
play	O
essential	O
roles	O
in	O
modulating	O
both	O
the	O
local	O
membrane	O
environment	O
of	O
MEC	B-Protein
-	I-Protein
4	I-Protein
/	O
MEC	B-Protein
-	I-Protein
10	I-Protein
channels	O
and	O
the	O
availability	O
of	O
such	O
channels	O
to	O
be	O
gated	O
by	O
force	O
in	O
vivo	O
.	O
<EOS>	B-X
The	B-X
ion	B-X
channel	B-X
formed	B-X
by	B-X
the	B-X
homologous	B-X
proteins	B-X
MEC-4	B-X
and	B-X
MEC-10	B-X
forms	B-X
the	B-X
core	B-X
of	B-X
a	B-X
sensory	B-X
mechanotransduction	B-X
channel	B-X
in	B-X
Caenorhabditis	B-X
elegans	B-X
.	B-X
Although	B-X
the	B-X
products	B-X
of	B-X
other	B-X
mec	B-X
genes	B-X
are	B-X
key	B-X
players	B-X
in	B-X
the	B-X
biophysics	B-X
of	B-X
transduction	B-X
,	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
they	B-X
contribute	B-X
to	B-X
the	B-X
properties	B-X
of	B-X
the	B-X
channel	B-X
is	B-X
unknown	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
investigate	B-X
the	B-X
role	B-X
of	B-X
two	B-X
auxiliary	B-X
channel	B-X
subunits	B-X
,	B-X
MEC-2	B-X
(	B-X
stomatin-like	B-X
)	B-X
and	B-X
MEC-6	B-X
(	B-X
paraoxonase-like	B-X
)	B-X
,	B-X
by	B-X
coexpressing	B-X
them	B-X
with	B-X
constitutively	B-X
active	B-X
MEC-4/MEC-10	B-X
heteromeric	B-X
channels	B-X
in	B-X
Xenopus	B-X
oocytes	B-X
.	B-X
This	B-X
work	B-X
extends	B-X
prior	B-X
work	B-X
demonstrating	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
synergistically	B-X
increase	B-X
macroscopic	B-X
current	B-X
.	B-X
We	B-X
use	B-X
single-channel	B-X
recordings	B-X
and	B-X
biochemistry	B-X
to	B-X
show	B-X
that	B-X
these	B-X
auxiliary	B-X
subunits	B-X
alter	B-X
function	B-X
by	B-X
increasing	B-X
the	B-X
number	B-X
of	B-X
channels	B-X
in	B-X
an	B-X
active	B-X
state	B-X
rather	B-X
than	B-X
by	B-X
dramatically	B-X
affecting	B-X
either	B-X
single-channel	B-X
properties	B-X
or	B-X
surface	B-X
expression	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
cholesterol	B-X
binding	B-X
in	B-X
the	B-X
mechanism	B-X
of	B-X
MEC-2	B-X
action	B-X
by	B-X
measuring	B-X
whole-cell	B-X
and	B-X
single-channel	B-X
currents	B-X
in	B-X
MEC-2	B-X
mutants	B-X
deficient	B-X
in	B-X
cholesterol	B-X
binding	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
MEC-2	B-X
and	B-X
MEC-6	B-X
play	B-X
essential	B-X
roles	B-X
in	B-X
modulating	B-X
both	B-X
the	B-X
local	B-X
membrane	B-X
environment	B-X
of	B-X
MEC-4/MEC-10	B-X
channels	B-X
and	B-X
the	B-X
availability	B-X
of	B-X
such	B-X
channels	B-X
to	B-X
be	B-X
gated	B-X
by	B-X
force	B-X
in	B-X
vivo	B-X
.	B-X

Constitutively	O
active	O
Rheb	B-Protein
induces	O
oncogenic	O
transformation	O
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Constitutively	B-X
active	B-X
mutants	B-X
of	B-X
Rheb	B-X
induce	B-X
oncogenic	B-X
transformation	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
Immunofluorescence	B-X
localizes	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rheb	B-X
to	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
overlapping	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X

Rheb	B-Protein
(	O
Ras	B-Protein
-	I-Protein
homolog	I-Protein
enriched	I-Protein
in	I-Protein
brain	I-Protein
)	O
is	O
a	O
component	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
target	B-Protein
of	I-Protein
rapamycin	I-Protein
(	O
TOR	B-Protein
)	O
signaling	O
pathway	O
,	O
functioning	O
as	O
a	O
positive	O
regulator	O
of	O
TOR	B-Protein
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Constitutively	B-X
active	B-X
mutants	B-X
of	B-X
Rheb	B-X
induce	B-X
oncogenic	B-X
transformation	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
They	B-X
show	B-X
constitutive	B-X
phosphorylation	B-X
of	B-X
the	B-X
ribosomal	B-X
protein	B-X
S6	B-X
kinase	B-X
and	B-X
the	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
4E-binding	B-X
protein	B-X
1	B-X
,	B-X
two	B-X
downstream	B-X
targets	B-X
of	B-X
TOR	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
Immunofluorescence	B-X
localizes	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rheb	B-X
to	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
overlapping	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X

Constitutively	O
active	O
mutants	O
of	O
Rheb	B-Protein
induce	O
oncogenic	O
transformation	O
in	O
cell	O
culture	O
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Constitutively	B-X
active	B-X
mutants	B-X
of	B-X
Rheb	B-X
induce	B-X
oncogenic	B-X
transformation	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
transformed	B-X
cells	B-X
are	B-X
larger	B-X
and	B-X
contain	B-X
more	B-X
protein	B-X
than	B-X
their	B-X
normal	B-X
counterparts	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
Immunofluorescence	B-X
localizes	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rheb	B-X
to	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
overlapping	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X

The	O
transformed	O
cells	O
are	O
larger	O
and	O
contain	O
more	O
protein	O
than	O
their	O
normal	O
counterparts	O
.	O
<EOS>	B-X
Despite	B-X
significant	B-X
advances	B-X
in	B-X
cancer	B-X
therapy	B-X
,	B-X
there	B-X
is	B-X
an	B-X
urgent	B-X
need	B-X
for	B-X
drugs	B-X
with	B-X
a	B-X
new	B-X
mode	B-X
of	B-X
action	B-X
that	B-X
will	B-X
preferentially	B-X
kill	B-X
cancer	B-X
cells	B-X
.	B-X
Several	B-X
cationic	B-X
antimicrobial	B-X
peptides	B-X
,	B-X
which	B-X
bind	B-X
strongly	B-X
to	B-X
negatively	B-X
charged	B-X
membranes	B-X
,	B-X
were	B-X
shown	B-X
to	B-X
kill	B-X
cancer	B-X
cells	B-X
slightly	B-X
better	B-X
than	B-X
normal	B-X
cells	B-X
.	B-X
This	B-X
was	B-X
explained	B-X
by	B-X
a	B-X
slight	B-X
increase	B-X
(	B-X
3-9	B-X
%	B-X
)	B-X
in	B-X
the	B-X
level	B-X
of	B-X
the	B-X
negatively	B-X
charged	B-X
membrane	B-X
phosphatidylserine	B-X
(	B-X
PS	B-X
)	B-X
in	B-X
many	B-X
cancer	B-X
cells	B-X
compared	B-X
to	B-X
their	B-X
normal	B-X
counterparts	B-X
.	B-X
Here	B-X
we	B-X
synthesized	B-X
and	B-X
investigated	B-X
the	B-X
anticancer	B-X
activity	B-X
and	B-X
the	B-X
role	B-X
of	B-X
peptide	B-X
charge	B-X
,	B-X
peptide	B-X
structure	B-X
,	B-X
and	B-X
phospholipid	B-X
headgroup	B-X
charge	B-X
on	B-X
the	B-X
activity	B-X
of	B-X
a	B-X
new	B-X
group	B-X
of	B-X
diastereomeric	B-X
lytic	B-X
peptides	B-X
(	B-X
containing	B-X
D-	B-X
and	B-X
L-forms	B-X
of	B-X
leucine	B-X
and	B-X
lysine	B-X
;	B-X
15-17	B-X
amino	B-X
acids	B-X
long	B-X
)	B-X
.	B-X
The	B-X
peptides	B-X
are	B-X
highly	B-X
toxic	B-X
to	B-X
cancer	B-X
cells	B-X
,	B-X
to	B-X
a	B-X
degree	B-X
similar	B-X
to	B-X
or	B-X
larger	B-X
than	B-X
that	B-X
of	B-X
mitomycin	B-X
C.	B-X
However	B-X
,	B-X
compared	B-X
with	B-X
mitomycin	B-X
C	B-X
and	B-X
many	B-X
native	B-X
antimicrobial	B-X
peptides	B-X
,	B-X
they	B-X
are	B-X
more	B-X
selective	B-X
for	B-X
cancer	B-X
cells	B-X
.	B-X
The	B-X
peptides	B-X
were	B-X
investigated	B-X
for	B-X
(	B-X
i	B-X
)	B-X
their	B-X
binding	B-X
to	B-X
mono-	B-X
and	B-X
bilayer	B-X
membranes	B-X
by	B-X
using	B-X
the	B-X
surface	B-X
plasmon	B-X
resonance	B-X
(	B-X
SPR	B-X
)	B-X
technique	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
their	B-X
ability	B-X
to	B-X
permeate	B-X
membranes	B-X
by	B-X
using	B-X
fluorescence	B-X
spectroscopy	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
their	B-X
structure	B-X
and	B-X
their	B-X
effect	B-X
on	B-X
the	B-X
lipid	B-X
order	B-X
by	B-X
using	B-X
ATR-FTIR	B-X
spectroscopy	B-X
,	B-X
and	B-X
(	B-X
iv	B-X
)	B-X
their	B-X
ability	B-X
to	B-X
bind	B-X
to	B-X
cancer	B-X
versus	B-X
normal	B-X
cells	B-X
by	B-X
using	B-X
confocal	B-X
microscopy	B-X
.	B-X
However	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
native	B-X
antimicrobial	B-X
peptides	B-X
,	B-X
the	B-X
diastereomers	B-X
bind	B-X
and	B-X
permeate	B-X
similarly	B-X
zwitterionic	B-X
and	B-X
PS-containing	B-X
model	B-X
membranes	B-X
.	B-X
Therefore	B-X
,	B-X
cell	B-X
selectivity	B-X
is	B-X
probably	B-X
determined	B-X
mainly	B-X
by	B-X
improved	B-X
electrostatic	B-X
attraction	B-X
of	B-X
the	B-X
peptides	B-X
to	B-X
acidic	B-X
components	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
cancer	B-X
cells	B-X
(	B-X
e.g.	B-X
,	B-X
O-glycosylation	B-X
of	B-X
mucines	B-X
)	B-X
.	B-X

They	O
show	O
constitutive	O
phosphorylation	O
of	O
the	O
ribosomal	O
protein	O
S6	O
kinase	O
and	O
the	O
eukaryotic	B-Protein
initiation	I-Protein
factor	I-Protein
4E	I-Protein
-	I-Protein
binding	I-Protein
protein	I-Protein
1	I-Protein
,	O
two	O
downstream	O
targets	O
of	O
TOR	B-Protein
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
The	B-X
transformed	B-X
cells	B-X
are	B-X
larger	B-X
and	B-X
contain	B-X
more	B-X
protein	B-X
than	B-X
their	B-X
normal	B-X
counterparts	B-X
.	B-X
They	B-X
show	B-X
constitutive	B-X
phosphorylation	B-X
of	B-X
the	B-X
ribosomal	B-X
protein	B-X
S6	B-X
kinase	B-X
and	B-X
the	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
4E-binding	B-X
protein	B-X
1	B-X
,	B-X
two	B-X
downstream	B-X
targets	B-X
of	B-X
TOR	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X

The	O
TOR	B-Protein
-	O
specific	O
inhibitor	O
rapamycin	O
strongly	O
interferes	O
with	O
transformation	O
induced	O
by	O
constitutively	O
active	O
Rheb	B-Protein
,	O
suggesting	O
that	O
TOR	B-Protein
activity	O
is	O
essential	O
for	O
the	O
oncogenic	O
effects	O
of	O
mutant	O
Rheb	B-Protein
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Constitutively	B-X
active	B-X
mutants	B-X
of	B-X
Rheb	B-X
induce	B-X
oncogenic	B-X
transformation	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
They	B-X
show	B-X
constitutive	B-X
phosphorylation	B-X
of	B-X
the	B-X
ribosomal	B-X
protein	B-X
S6	B-X
kinase	B-X
and	B-X
the	B-X
eukaryotic	B-X
initiation	B-X
factor	B-X
4E-binding	B-X
protein	B-X
1	B-X
,	B-X
two	B-X
downstream	B-X
targets	B-X
of	B-X
TOR	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
Immunofluorescence	B-X
localizes	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rheb	B-X
to	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
overlapping	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X

Rheb	B-Protein
-	O
induced	O
transformation	O
is	O
also	O
dependent	O
on	O
a	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
that	O
mediates	O
localization	O
to	O
a	O
cellular	O
membrane	O
.	O

An	O
engineered	O
N	O
-	O
terminal	O
myristylation	O
signal	O
can	O
substitute	O
for	O
the	O
farnesylation	O
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
An	B-X
engineered	B-X
N-terminal	B-X
myristylation	B-X
signal	B-X
can	B-X
substitute	B-X
for	B-X
the	B-X
farnesylation	B-X
.	B-X

Immunofluorescence	O
localizes	O
wild	O
-	O
type	O
and	O
mutant	O
Rheb	B-Protein
to	O
vesicular	O
structures	O
in	O
the	O
cytoplasm	O
,	O
overlapping	O
with	O
the	O
endoplasmic	O
reticulum	O
.	O
<EOS>	B-X
Rheb	B-X
(	B-X
Ras-homolog	B-X
enriched	B-X
in	B-X
brain	B-X
)	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
phosphatidylinositol	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
target	B-X
of	B-X
rapamycin	B-X
(	B-X
TOR	B-X
)	B-X
signaling	B-X
pathway	B-X
,	B-X
functioning	B-X
as	B-X
a	B-X
positive	B-X
regulator	B-X
of	B-X
TOR	B-X
.	B-X
Constitutively	B-X
active	B-X
mutants	B-X
of	B-X
Rheb	B-X
induce	B-X
oncogenic	B-X
transformation	B-X
in	B-X
cell	B-X
culture	B-X
.	B-X
The	B-X
TOR-specific	B-X
inhibitor	B-X
rapamycin	B-X
strongly	B-X
interferes	B-X
with	B-X
transformation	B-X
induced	B-X
by	B-X
constitutively	B-X
active	B-X
Rheb	B-X
,	B-X
suggesting	B-X
that	B-X
TOR	B-X
activity	B-X
is	B-X
essential	B-X
for	B-X
the	B-X
oncogenic	B-X
effects	B-X
of	B-X
mutant	B-X
Rheb	B-X
.	B-X
Rheb-induced	B-X
transformation	B-X
is	B-X
also	B-X
dependent	B-X
on	B-X
a	B-X
C-terminal	B-X
farnesylation	B-X
signal	B-X
that	B-X
mediates	B-X
localization	B-X
to	B-X
a	B-X
cellular	B-X
membrane	B-X
.	B-X
Immunofluorescence	B-X
localizes	B-X
wild-type	B-X
and	B-X
mutant	B-X
Rheb	B-X
to	B-X
vesicular	B-X
structures	B-X
in	B-X
the	B-X
cytoplasm	B-X
,	B-X
overlapping	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
.	B-X

Hhat	B-Protein
is	O
a	O
palmitoylacyltransferase	O
with	O
specificity	O
for	O
N	O
-	O
palmitoylation	O
of	O
Sonic	B-Protein
Hedgehog	I-Protein
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
Sonic	B-X
Hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
effective	B-X
long-	B-X
and	B-X
short-range	B-X
signaling	B-X
.	B-X
Genetic	B-X
screens	B-X
uncovered	B-X
a	B-X
potential	B-X
palmitoylacyltransferase	B-X
(	B-X
PAT	B-X
)	B-X
for	B-X
Shh	B-X
,	B-X
Hhat	B-X
,	B-X
but	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
Shh	B-X
palmitoylation	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
and	B-X
exploited	B-X
an	B-X
in	B-X
vitro	B-X
Shh	B-X
palmitoylation	B-X
assay	B-X
to	B-X
purify	B-X
Hhat	B-X
to	B-X
homogeneity	B-X
.	B-X
We	B-X
provide	B-X
direct	B-X
biochemical	B-X
evidence	B-X
that	B-X
Hhat	B-X
is	B-X
a	B-X
PAT	B-X
with	B-X
specificity	B-X
for	B-X
attaching	B-X
palmitate	B-X
via	B-X
amide	B-X
linkage	B-X
to	B-X
the	B-X
N-terminal	B-X
cysteine	B-X
of	B-X
Shh	B-X
.	B-X
PSD95	B-X
and	B-X
Wnt	B-X
)	B-X
are	B-X
not	B-X
substrates	B-X
for	B-X
Hhat	B-X
,	B-X
and	B-X
Porcupine	B-X
,	B-X
a	B-X
putative	B-X
Wnt	B-X
PAT	B-X
,	B-X
does	B-X
not	B-X
palmitoylate	B-X
Shh	B-X
.	B-X
Neither	B-X
autocleavage	B-X
nor	B-X
cholesterol	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
Shh	B-X
palmitoylation	B-X
.	B-X
Both	B-X
the	B-X
Shh	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
are	B-X
N-palmitoylated	B-X
by	B-X
Hhat	B-X
,	B-X
and	B-X
the	B-X
reaction	B-X
occurs	B-X
during	B-X
passage	B-X
through	B-X
the	B-X
secretory	B-X
pathway	B-X
.	B-X
This	B-X
study	B-X
establishes	B-X
Hhat	B-X
as	B-X
a	B-X
bona	B-X
fide	B-X
Shh	B-X
PAT	B-X
and	B-X
serves	B-X
as	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
how	B-X
secreted	B-X
morphogens	B-X
are	B-X
modified	B-X
by	B-X
distinct	B-X
PATs	B-X
.	B-X

Palmitoylation	O
of	O
Sonic	B-Protein
Hedgehog	I-Protein
(	O
Shh	B-Protein
)	O
is	O
critical	O
for	O
effective	O
long	O
-	O
and	O
short	O
-	O
range	O
signaling	O
.	O
<EOS>	B-X
Sonic	B-X
hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
is	B-X
a	B-X
palmitoylated	B-X
protein	B-X
that	B-X
plays	B-X
key	B-X
roles	B-X
in	B-X
mammalian	B-X
development	B-X
and	B-X
human	B-X
cancers	B-X
.	B-X
Palmitoylation	B-X
of	B-X
Shh	B-X
is	B-X
required	B-X
for	B-X
effective	B-X
long	B-X
and	B-X
short	B-X
range	B-X
Shh-mediated	B-X
signaling	B-X
.	B-X
Attachment	B-X
of	B-X
palmitate	B-X
to	B-X
Shh	B-X
is	B-X
catalyzed	B-X
by	B-X
Hedgehog	B-X
acyltransferase	B-X
(	B-X
Hhat	B-X
)	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
membrane	B-X
bound	B-X
O-acyl	B-X
transferase	B-X
(	B-X
MBOAT	B-X
)	B-X
family	B-X
of	B-X
multipass	B-X
membrane	B-X
proteins	B-X
.	B-X
Except	B-X
for	B-X
mutagenesis	B-X
of	B-X
two	B-X
conserved	B-X
residues	B-X
,	B-X
there	B-X
has	B-X
been	B-X
no	B-X
structure-function	B-X
analysis	B-X
of	B-X
Hhat	B-X
,	B-X
and	B-X
the	B-X
regions	B-X
of	B-X
the	B-X
protein	B-X
required	B-X
for	B-X
Shh	B-X
palmitoylation	B-X
are	B-X
unknown	B-X
.	B-X

Genetic	O
screens	O
uncovered	O
a	O
potential	O
palmitoylacyltransferase	O
(	O
PAT	O
)	O
for	O
Shh	B-Protein
,	O
Hhat	B-Protein
,	O
but	O
the	O
molecular	O
mechanism	O
of	O
Shh	B-Protein
palmitoylation	O
remains	O
unclear	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
Sonic	B-X
Hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
effective	B-X
long-	B-X
and	B-X
short-range	B-X
signaling	B-X
.	B-X
Genetic	B-X
screens	B-X
uncovered	B-X
a	B-X
potential	B-X
palmitoylacyltransferase	B-X
(	B-X
PAT	B-X
)	B-X
for	B-X
Shh	B-X
,	B-X
Hhat	B-X
,	B-X
but	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
Shh	B-X
palmitoylation	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
and	B-X
exploited	B-X
an	B-X
in	B-X
vitro	B-X
Shh	B-X
palmitoylation	B-X
assay	B-X
to	B-X
purify	B-X
Hhat	B-X
to	B-X
homogeneity	B-X
.	B-X
We	B-X
provide	B-X
direct	B-X
biochemical	B-X
evidence	B-X
that	B-X
Hhat	B-X
is	B-X
a	B-X
PAT	B-X
with	B-X
specificity	B-X
for	B-X
attaching	B-X
palmitate	B-X
via	B-X
amide	B-X
linkage	B-X
to	B-X
the	B-X
N-terminal	B-X
cysteine	B-X
of	B-X
Shh	B-X
.	B-X
PSD95	B-X
and	B-X
Wnt	B-X
)	B-X
are	B-X
not	B-X
substrates	B-X
for	B-X
Hhat	B-X
,	B-X
and	B-X
Porcupine	B-X
,	B-X
a	B-X
putative	B-X
Wnt	B-X
PAT	B-X
,	B-X
does	B-X
not	B-X
palmitoylate	B-X
Shh	B-X
.	B-X
Neither	B-X
autocleavage	B-X
nor	B-X
cholesterol	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
Shh	B-X
palmitoylation	B-X
.	B-X
Both	B-X
the	B-X
Shh	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
are	B-X
N-palmitoylated	B-X
by	B-X
Hhat	B-X
,	B-X
and	B-X
the	B-X
reaction	B-X
occurs	B-X
during	B-X
passage	B-X
through	B-X
the	B-X
secretory	B-X
pathway	B-X
.	B-X
This	B-X
study	B-X
establishes	B-X
Hhat	B-X
as	B-X
a	B-X
bona	B-X
fide	B-X
Shh	B-X
PAT	B-X
and	B-X
serves	B-X
as	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
how	B-X
secreted	B-X
morphogens	B-X
are	B-X
modified	B-X
by	B-X
distinct	B-X
PATs	B-X
.	B-X

Here	O
,	O
we	O
have	O
developed	O
and	O
exploited	O
an	O
in	O
vitro	O
Shh	B-Protein
palmitoylation	O
assay	O
to	O
purify	O
Hhat	B-Protein
to	O
homogeneity	O
.	O

We	O
provide	O
direct	O
biochemical	O
evidence	O
that	O
Hhat	B-Protein
is	O
a	O
PAT	O
with	O
specificity	O
for	O
attaching	O
palmitate	O
via	O
amide	O
linkage	O
to	O
the	O
N	O
-	O
terminal	O
cysteine	O
of	O
Shh	B-Protein
.	O

Other	O
palmitoylated	O
proteins	O
(	O
e	O
.	O
g	O
.	O
PSD95	B-Protein
and	O
Wnt	O
)	O
are	O
not	O
substrates	O
for	O
Hhat	B-Protein
,	O
and	O
Porcupine	O
,	O
a	O
putative	O
Wnt	O
PAT	O
,	O
does	O
not	O
palmitoylate	O
Shh	B-Protein
.	O

Neither	O
autocleavage	O
nor	O
cholesterol	O
modification	O
is	O
required	O
for	O
Shh	B-Protein
palmitoylation	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
Sonic	B-X
Hedgehog	B-X
(	B-X
Shh	B-X
)	B-X
is	B-X
critical	B-X
for	B-X
effective	B-X
long-	B-X
and	B-X
short-range	B-X
signaling	B-X
.	B-X
Genetic	B-X
screens	B-X
uncovered	B-X
a	B-X
potential	B-X
palmitoylacyltransferase	B-X
(	B-X
PAT	B-X
)	B-X
for	B-X
Shh	B-X
,	B-X
Hhat	B-X
,	B-X
but	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
Shh	B-X
palmitoylation	B-X
remains	B-X
unclear	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
and	B-X
exploited	B-X
an	B-X
in	B-X
vitro	B-X
Shh	B-X
palmitoylation	B-X
assay	B-X
to	B-X
purify	B-X
Hhat	B-X
to	B-X
homogeneity	B-X
.	B-X
We	B-X
provide	B-X
direct	B-X
biochemical	B-X
evidence	B-X
that	B-X
Hhat	B-X
is	B-X
a	B-X
PAT	B-X
with	B-X
specificity	B-X
for	B-X
attaching	B-X
palmitate	B-X
via	B-X
amide	B-X
linkage	B-X
to	B-X
the	B-X
N-terminal	B-X
cysteine	B-X
of	B-X
Shh	B-X
.	B-X
PSD95	B-X
and	B-X
Wnt	B-X
)	B-X
are	B-X
not	B-X
substrates	B-X
for	B-X
Hhat	B-X
,	B-X
and	B-X
Porcupine	B-X
,	B-X
a	B-X
putative	B-X
Wnt	B-X
PAT	B-X
,	B-X
does	B-X
not	B-X
palmitoylate	B-X
Shh	B-X
.	B-X
Neither	B-X
autocleavage	B-X
nor	B-X
cholesterol	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
Shh	B-X
palmitoylation	B-X
.	B-X
Both	B-X
the	B-X
Shh	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
are	B-X
N-palmitoylated	B-X
by	B-X
Hhat	B-X
,	B-X
and	B-X
the	B-X
reaction	B-X
occurs	B-X
during	B-X
passage	B-X
through	B-X
the	B-X
secretory	B-X
pathway	B-X
.	B-X
This	B-X
study	B-X
establishes	B-X
Hhat	B-X
as	B-X
a	B-X
bona	B-X
fide	B-X
Shh	B-X
PAT	B-X
and	B-X
serves	B-X
as	B-X
a	B-X
model	B-X
for	B-X
understanding	B-X
how	B-X
secreted	B-X
morphogens	B-X
are	B-X
modified	B-X
by	B-X
distinct	B-X
PATs	B-X
.	B-X

Both	O
the	O
Shh	B-Protein
precursor	O
and	O
mature	O
protein	O
are	O
N	O
-	O
palmitoylated	O
by	O
Hhat	B-Protein
,	O
and	O
the	O
reaction	O
occurs	O
during	O
passage	O
through	O
the	O
secretory	O
pathway	O
.	O

This	O
study	O
establishes	O
Hhat	B-Protein
as	O
a	O
bona	O
fide	O
Shh	B-Protein
PAT	O
and	O
serves	O
as	O
a	O
model	O
for	O
understanding	O
how	O
secreted	O
morphogens	O
are	O
modified	O
by	O
distinct	O
PATs	O
.	O

Effect	O
of	O
metal	O
binding	O
and	O
posttranslational	O
lysine	O
carboxylation	O
on	O
the	O
activity	O
of	O
recombinant	O
hydantoinase	B-Protein
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

Bacterial	O
hydantoinase	B-Protein
possesses	O
a	O
binuclear	O
metal	O
center	O
in	O
which	O
two	O
metal	O
ions	O
are	O
bridged	O
by	O
a	O
posttranslationally	O
carboxylated	O
lysine	O
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

How	O
the	O
carboxylated	O
lysine	O
and	O
metal	O
binding	O
affect	O
the	O
activity	O
of	O
hydantoinase	B-Protein
was	O
investigated	O
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

A	O
significant	O
amount	O
of	O
iron	O
was	O
always	O
found	O
in	O
Agrobacterium	O
radiobacter	O
hydantoinase	B-Protein
purified	O
from	O
unsupplemented	O
cobalt	O
-	O
,	O
manganese	O
-	O
,	O
or	O
zinc	O
-	O
amended	O
Escherichia	O
coli	O
cell	O
cultures	O
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

A	O
titration	O
curve	O
for	O
the	O
reactivation	O
of	O
apohydantoinase	B-Protein
with	O
cobalt	O
indicates	O
that	O
the	O
first	O
metal	O
was	O
preferentially	O
bound	O
but	O
did	O
not	O
give	O
any	O
enzyme	O
activity	O
until	O
the	O
second	O
metal	O
was	O
also	O
attached	O
to	O
the	O
hydantoinase	B-Protein
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

The	O
pH	O
profiles	O
of	O
the	O
metal	O
-	O
reconstituted	O
hydantoinase	O
were	O
dependent	O
on	O
the	O
specific	O
metal	O
ion	O
bound	O
to	O
the	O
active	O
site	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
metal	O
in	O
catalysis	O
.	O

Mutation	O
of	O
the	O
metal	O
binding	O
site	O
residues	O
,	O
H57A	O
,	O
H59A	O
,	O
K148A	O
,	O
H181A	O
,	O
H237A	O
,	O
and	O
D313A	O
,	O
completely	O
abolished	O
hydantoinase	B-Protein
activity	O
but	O
preserved	O
about	O
half	O
of	O
the	O
metal	O
content	O
,	O
except	O
for	O
K148A	O
,	O
which	O
lost	O
both	O
metals	O
in	O
its	O
active	O
site	O
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

However	O
,	O
the	O
activity	O
of	O
K148A	O
could	O
be	O
chemically	O
rescued	O
by	O
short	O
-	O
chain	O
carboxylic	O
acids	O
in	O
the	O
presence	O
of	O
cobalt	O
,	O
indicating	O
that	O
the	O
carboxylated	O
lysine	O
was	O
needed	O
to	O
coordinate	O
the	O
binuclear	O
ion	O
within	O
the	O
active	O
site	O
of	O
hydantoinase	B-Protein
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

The	O
mutant	O
D313E	O
enzyme	O
was	O
also	O
active	O
but	O
resulted	O
in	O
a	O
pH	O
profile	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
hydantoinase	B-Protein
.	O

A	O
mechanism	O
for	O
hydantoinase	B-Protein
involving	O
metal	O
,	O
carboxylated	O
K148	O
,	O
and	O
D313	O
was	O
proposed	O
.	O
<EOS>	B-X
Bacterial	B-X
hydantoinase	B-X
possesses	B-X
a	B-X
binuclear	B-X
metal	B-X
center	B-X
in	B-X
which	B-X
two	B-X
metal	B-X
ions	B-X
are	B-X
bridged	B-X
by	B-X
a	B-X
posttranslationally	B-X
carboxylated	B-X
lysine	B-X
.	B-X
How	B-X
the	B-X
carboxylated	B-X
lysine	B-X
and	B-X
metal	B-X
binding	B-X
affect	B-X
the	B-X
activity	B-X
of	B-X
hydantoinase	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
significant	B-X
amount	B-X
of	B-X
iron	B-X
was	B-X
always	B-X
found	B-X
in	B-X
Agrobacterium	B-X
radiobacter	B-X
hydantoinase	B-X
purified	B-X
from	B-X
unsupplemented	B-X
cobalt-	B-X
,	B-X
manganese-	B-X
,	B-X
or	B-X
zinc-amended	B-X
Escherichia	B-X
coli	B-X
cell	B-X
cultures	B-X
.	B-X
A	B-X
titration	B-X
curve	B-X
for	B-X
the	B-X
reactivation	B-X
of	B-X
apohydantoinase	B-X
with	B-X
cobalt	B-X
indicates	B-X
that	B-X
the	B-X
first	B-X
metal	B-X
was	B-X
preferentially	B-X
bound	B-X
but	B-X
did	B-X
not	B-X
give	B-X
any	B-X
enzyme	B-X
activity	B-X
until	B-X
the	B-X
second	B-X
metal	B-X
was	B-X
also	B-X
attached	B-X
to	B-X
the	B-X
hydantoinase	B-X
.	B-X
The	B-X
pH	B-X
profiles	B-X
of	B-X
the	B-X
metal-reconstituted	B-X
hydantoinase	B-X
were	B-X
dependent	B-X
on	B-X
the	B-X
specific	B-X
metal	B-X
ion	B-X
bound	B-X
to	B-X
the	B-X
active	B-X
site	B-X
,	B-X
indicating	B-X
a	B-X
direct	B-X
involvement	B-X
of	B-X
metal	B-X
in	B-X
catalysis	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
metal	B-X
binding	B-X
site	B-X
residues	B-X
,	B-X
H57A	B-X
,	B-X
H59A	B-X
,	B-X
K148A	B-X
,	B-X
H181A	B-X
,	B-X
H237A	B-X
,	B-X
and	B-X
D313A	B-X
,	B-X
completely	B-X
abolished	B-X
hydantoinase	B-X
activity	B-X
but	B-X
preserved	B-X
about	B-X
half	B-X
of	B-X
the	B-X
metal	B-X
content	B-X
,	B-X
except	B-X
for	B-X
K148A	B-X
,	B-X
which	B-X
lost	B-X
both	B-X
metals	B-X
in	B-X
its	B-X
active	B-X
site	B-X
.	B-X
However	B-X
,	B-X
the	B-X
activity	B-X
of	B-X
K148A	B-X
could	B-X
be	B-X
chemically	B-X
rescued	B-X
by	B-X
short-chain	B-X
carboxylic	B-X
acids	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
cobalt	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
carboxylated	B-X
lysine	B-X
was	B-X
needed	B-X
to	B-X
coordinate	B-X
the	B-X
binuclear	B-X
ion	B-X
within	B-X
the	B-X
active	B-X
site	B-X
of	B-X
hydantoinase	B-X
.	B-X
The	B-X
mutant	B-X
D313E	B-X
enzyme	B-X
was	B-X
also	B-X
active	B-X
but	B-X
resulted	B-X
in	B-X
a	B-X
pH	B-X
profile	B-X
different	B-X
from	B-X
that	B-X
of	B-X
wild-type	B-X
hydantoinase	B-X
.	B-X
A	B-X
mechanism	B-X
for	B-X
hydantoinase	B-X
involving	B-X
metal	B-X
,	B-X
carboxylated	B-X
K148	B-X
,	B-X
and	B-X
D313	B-X
was	B-X
proposed	B-X
.	B-X

Versatile	O
role	O
of	O
the	O
yeast	O
ubiquitin	B-Protein
ligase	O
Rsp5p	B-Protein
in	O
intracellular	O
trafficking	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

The	O
ubiquitin	B-Protein
ligase	O
(	O
E3	O
)	O
Rsp5p	B-Protein
is	O
the	O
only	O
member	O
of	O
the	O
Nedd	B-Protein
(	I-Protein
neural	I-Protein
-	I-Protein
precursor	I-Protein
-	I-Protein
cell	I-Protein
-	I-Protein
expressed	I-Protein
,	I-Protein
developmentally	I-Protein
down	I-Protein
-	I-Protein
regulated	I-Protein
)	I-Protein
4	I-Protein
family	O
of	O
E3s	O
present	O
in	O
yeast	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

Rsp5p	B-Protein
has	O
several	O
proteasome	O
-	O
independent	O
functions	O
in	O
membrane	O
protein	O
trafficking	O
,	O
including	O
a	O
role	O
in	O
the	O
ubiquitination	O
of	O
most	O
plasma	O
membrane	O
proteins	O
,	O
leading	O
to	O
their	O
endocytosis	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

Rsp5p	B-Protein
is	O
also	O
required	O
for	O
the	O
ubiquitination	O
of	O
endosomal	O
proteins	O
,	O
leading	O
to	O
their	O
sorting	O
to	O
the	O
internal	O
vesicles	O
of	O
MVBs	O
(	O
multivesicular	O
bodies	O
)	O
.	O

Rsp5p	B-Protein
catalyses	O
the	O
attachment	O
of	O
non	O
-	O
conventional	O
ubiquitin	B-Protein
chains	O
,	O
linked	O
through	O
ubiquitin	B-Protein
Lys	O
-	O
63	O
,	O
to	O
some	O
endocytic	O
and	O
MVB	O
cargoes	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

This	O
modification	O
appears	O
to	O
be	O
required	O
for	O
efficient	O
sorting	O
,	O
possibly	O
because	O
these	O
chains	O
have	O
a	O
greater	O
affinity	O
for	O
the	O
ubiquitin	B-Protein
-	O
binding	O
domains	O
present	O
within	O
endocytic	O
or	O
MVB	O
sorting	O
complexes	O
.	O
<EOS>	B-X
Multivesicular	B-X
bodies	B-X
(	B-X
MVBs	B-X
)	B-X
deliver	B-X
cargo	B-X
destined	B-X
for	B-X
degradation	B-X
to	B-X
the	B-X
vacuole	B-X
or	B-X
lysosome	B-X
.	B-X
The	B-X
ESCRT	B-X
(	B-X
endosomal	B-X
sorting	B-X
complex	B-X
required	B-X
for	B-X
transport	B-X
)	B-X
pathway	B-X
is	B-X
a	B-X
key	B-X
mediator	B-X
of	B-X
MVB	B-X
biogenesis	B-X
,	B-X
but	B-X
it	B-X
also	B-X
plays	B-X
critical	B-X
roles	B-X
in	B-X
retroviral	B-X
budding	B-X
and	B-X
cytokinetic	B-X
abscission	B-X
.	B-X
Exosomes	B-X
are	B-X
vesicles	B-X
secreted	B-X
to	B-X
the	B-X
extracellular	B-X
environment	B-X
through	B-X
fusion	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
of	B-X
specific	B-X
endosomes	B-X
called	B-X
multivesicular	B-X
bodies	B-X
(	B-X
MVB	B-X
)	B-X
and	B-X
mediate	B-X
cell-to-cell	B-X
communication	B-X
in	B-X
many	B-X
biological	B-X
processes	B-X
.	B-X
Posttranslational	B-X
modifications	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
sorting	B-X
of	B-X
specific	B-X
proteins	B-X
into	B-X
exosomes	B-X
.	B-X
Here	B-X
we	B-X
identify	B-X
ISGylation	B-X
as	B-X
a	B-X
ubiquitin-like	B-X
modification	B-X
that	B-X
controls	B-X
exosome	B-X
release	B-X
.	B-X
ISGylation	B-X
induction	B-X
decreases	B-X
MVB	B-X
numbers	B-X
and	B-X
impairs	B-X
exosome	B-X
secretion	B-X
.	B-X
ISG15	B-X
conjugation	B-X
triggers	B-X
MVB	B-X
co-localization	B-X
with	B-X
lysosomes	B-X
and	B-X
promotes	B-X
the	B-X
aggregation	B-X
and	B-X
degradation	B-X
of	B-X
MVB	B-X
proteins	B-X
.	B-X
Specifically	B-X
,	B-X
ISGylation	B-X
of	B-X
the	B-X
MVB	B-X
protein	B-X
TSG101	B-X
induces	B-X
its	B-X
aggregation	B-X
and	B-X
degradation	B-X
,	B-X
being	B-X
sufficient	B-X
to	B-X
impair	B-X
exosome	B-X
secretion	B-X
.	B-X
These	B-X
results	B-X
identify	B-X
ISGylation	B-X
as	B-X
a	B-X
novel	B-X
ubiquitin-like	B-X
modifier	B-X
in	B-X
the	B-X
control	B-X
of	B-X
exosome	B-X
production	B-X
.	B-X

The	O
mechanisms	O
involved	O
in	O
the	O
recognition	O
of	O
plasma	O
membrane	O
and	O
MVB	O
substrates	O
by	O
Rsp5p	B-Protein
remain	O
unclear	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

A	O
subset	O
of	O
Rsp5	B-Protein
/	O
Nedd4	B-Protein
substrates	O
have	O
a	O
'	O
PY	O
motif	O
'	O
and	O
are	O
recognized	O
directly	O
by	O
the	O
WW	O
(	O
Trp	O
-	O
Trp	O
)	O
domains	O
of	O
Rsp5p	B-Protein
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

Most	O
Rsp5p	B-Protein
substrates	O
do	O
not	O
carry	O
PY	O
motifs	O
,	O
but	O
some	O
may	O
depend	O
on	O
PY	O
-	O
containing	O
proteins	O
for	O
their	O
ubiquitination	O
by	O
Rsp5p	B-Protein
,	O
consistent	O
with	O
the	O
latter	O
'	O
s	O
acting	O
as	O
specificity	O
factors	O
or	O
adaptors	O
.	O
<EOS>	B-X
Recent	B-X
accumulating	B-X
evidence	B-X
has	B-X
demonstrated	B-X
that	B-X
TIR	B-X
domain-containing	B-X
adaptors	B-X
,	B-X
such	B-X
as	B-X
MyD88	B-X
,	B-X
TIRAP	B-X
,	B-X
and	B-X
TRIF	B-X
,	B-X
modulate	B-X
TLR	B-X
signaling	B-X
pathways	B-X
.	B-X
TIRAP	B-X
is	B-X
specifically	B-X
involved	B-X
in	B-X
the	B-X
MyD88-dependent	B-X
pathway	B-X
via	B-X
TLR2	B-X
and	B-X
TLR4	B-X
,	B-X
whereas	B-X
TRIF	B-X
is	B-X
implicated	B-X
in	B-X
the	B-X
TLR3-	B-X
and	B-X
TLR4-mediated	B-X
MyD88-independent	B-X
pathway	B-X
.	B-X
Thus	B-X
,	B-X
TIR	B-X
domain-containing	B-X
adaptors	B-X
provide	B-X
specificity	B-X
of	B-X
TLR	B-X
signaling	B-X
.	B-X
TLRs	B-X
signal	B-X
through	B-X
the	B-X
recruitment	B-X
of	B-X
specific	B-X
adaptor	B-X
molecules	B-X
,	B-X
leading	B-X
to	B-X
activation	B-X
of	B-X
the	B-X
transcription	B-X
factors	B-X
NF-κB	B-X
and	B-X
IRFs	B-X
,	B-X
which	B-X
dictate	B-X
the	B-X
outcome	B-X
of	B-X
innate	B-X
immune	B-X
responses	B-X
.	B-X

As	O
in	O
other	O
ubiquitin	B-Protein
-	O
conjugating	O
systems	O
,	O
these	O
adaptors	O
are	O
also	O
Rsp5p	B-Protein
substrates	O
and	O
undergo	O
ubiquitin	B-Protein
-	O
dependent	O
trafficking	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

In	O
the	O
present	O
review	O
,	O
we	O
discuss	O
recent	O
examples	O
illustrating	O
the	O
role	O
of	O
Rsp5p	B-Protein
in	O
membrane	O
protein	O
trafficking	O
and	O
providing	O
new	O
insights	O
into	O
the	O
regulation	O
of	O
this	O
E3	O
by	O
adaptor	O
proteins	O
.	O
<EOS>	B-X
The	B-X
ubiquitin	B-X
ligase	B-X
(	B-X
E3	B-X
)	B-X
Rsp5p	B-X
is	B-X
the	B-X
only	B-X
member	B-X
of	B-X
the	B-X
Nedd	B-X
(	B-X
neural-precursor-cell-expressed	B-X
,	B-X
developmentally	B-X
down-regulated	B-X
)	B-X
4	B-X
family	B-X
of	B-X
E3s	B-X
present	B-X
in	B-X
yeast	B-X
.	B-X
Rsp5p	B-X
has	B-X
several	B-X
proteasome-independent	B-X
functions	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
,	B-X
including	B-X
a	B-X
role	B-X
in	B-X
the	B-X
ubiquitination	B-X
of	B-X
most	B-X
plasma	B-X
membrane	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
endocytosis	B-X
.	B-X
Rsp5p	B-X
is	B-X
also	B-X
required	B-X
for	B-X
the	B-X
ubiquitination	B-X
of	B-X
endosomal	B-X
proteins	B-X
,	B-X
leading	B-X
to	B-X
their	B-X
sorting	B-X
to	B-X
the	B-X
internal	B-X
vesicles	B-X
of	B-X
MVBs	B-X
(	B-X
multivesicular	B-X
bodies	B-X
)	B-X
.	B-X
Rsp5p	B-X
catalyses	B-X
the	B-X
attachment	B-X
of	B-X
non-conventional	B-X
ubiquitin	B-X
chains	B-X
,	B-X
linked	B-X
through	B-X
ubiquitin	B-X
Lys-63	B-X
,	B-X
to	B-X
some	B-X
endocytic	B-X
and	B-X
MVB	B-X
cargoes	B-X
.	B-X
This	B-X
modification	B-X
appears	B-X
to	B-X
be	B-X
required	B-X
for	B-X
efficient	B-X
sorting	B-X
,	B-X
possibly	B-X
because	B-X
these	B-X
chains	B-X
have	B-X
a	B-X
greater	B-X
affinity	B-X
for	B-X
the	B-X
ubiquitin-binding	B-X
domains	B-X
present	B-X
within	B-X
endocytic	B-X
or	B-X
MVB	B-X
sorting	B-X
complexes	B-X
.	B-X
The	B-X
mechanisms	B-X
involved	B-X
in	B-X
the	B-X
recognition	B-X
of	B-X
plasma	B-X
membrane	B-X
and	B-X
MVB	B-X
substrates	B-X
by	B-X
Rsp5p	B-X
remain	B-X
unclear	B-X
.	B-X
A	B-X
subset	B-X
of	B-X
Rsp5/Nedd4	B-X
substrates	B-X
have	B-X
a	B-X
'PY	B-X
motif	B-X
'	B-X
and	B-X
are	B-X
recognized	B-X
directly	B-X
by	B-X
the	B-X
WW	B-X
(	B-X
Trp-Trp	B-X
)	B-X
domains	B-X
of	B-X
Rsp5p	B-X
.	B-X
Most	B-X
Rsp5p	B-X
substrates	B-X
do	B-X
not	B-X
carry	B-X
PY	B-X
motifs	B-X
,	B-X
but	B-X
some	B-X
may	B-X
depend	B-X
on	B-X
PY-containing	B-X
proteins	B-X
for	B-X
their	B-X
ubiquitination	B-X
by	B-X
Rsp5p	B-X
,	B-X
consistent	B-X
with	B-X
the	B-X
latter	B-X
's	B-X
acting	B-X
as	B-X
specificity	B-X
factors	B-X
or	B-X
adaptors	B-X
.	B-X
As	B-X
in	B-X
other	B-X
ubiquitin-conjugating	B-X
systems	B-X
,	B-X
these	B-X
adaptors	B-X
are	B-X
also	B-X
Rsp5p	B-X
substrates	B-X
and	B-X
undergo	B-X
ubiquitin-dependent	B-X
trafficking	B-X
.	B-X
In	B-X
the	B-X
present	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
recent	B-X
examples	B-X
illustrating	B-X
the	B-X
role	B-X
of	B-X
Rsp5p	B-X
in	B-X
membrane	B-X
protein	B-X
trafficking	B-X
and	B-X
providing	B-X
new	B-X
insights	B-X
into	B-X
the	B-X
regulation	B-X
of	B-X
this	B-X
E3	B-X
by	B-X
adaptor	B-X
proteins	B-X
.	B-X

Characterization	O
of	O
the	O
35	O
-	O
kilodalton	O
Treponema	O
pallidum	O
subsp	O
.	O
pallidum	O
recombinant	O
lipoprotein	O
TmpC	B-Protein
and	O
antibody	O
response	O
to	O
lipidated	O
and	O
nonlipidated	O
T	O
.	O
pallidum	O
antigens	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
35-kDa	B-X
immunogenic	B-X
Treponema	B-X
pallidium	B-X
subsp	B-X
.	B-X
pallidum	B-X
(	B-X
T.	B-X
pallidum	B-X
)	B-X
membrane	B-X
protein	B-X
C	B-X
,	B-X
TmpC	B-X
,	B-X
was	B-X
cloned	B-X
,	B-X
sequenced	B-X
,	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
carries	B-X
on	B-X
N-terminal	B-X
signal	B-X
sequence	B-X
with	B-X
a	B-X
four-amino-acid	B-X
motif	B-X
,	B-X
which	B-X
is	B-X
characteristic	B-X
for	B-X
bacterial	B-X
lipoproteins	B-X
.	B-X
Metabolic	B-X
labeling	B-X
with	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
of	B-X
E.	B-X
coli	B-X
expressing	B-X
TmpC	B-X
revealed	B-X
incorporation	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
into	B-X
the	B-X
antigen	B-X
.	B-X
Although	B-X
all	B-X
sera	B-X
from	B-X
untreated	B-X
secondary	B-X
syphilis	B-X
patients	B-X
were	B-X
reactive	B-X
in	B-X
this	B-X
TmpC	B-X
ELISA	B-X
,	B-X
only	B-X
a	B-X
minority	B-X
of	B-X
the	B-X
serum	B-X
samples	B-X
from	B-X
untreated	B-X
patients	B-X
in	B-X
the	B-X
primary	B-X
or	B-X
early	B-X
latent	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
contained	B-X
significant	B-X
anti-TmpC	B-X
antibodies	B-X
.	B-X
To	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
antigenic	B-X
properties	B-X
of	B-X
the	B-X
TmpC	B-X
,	B-X
TmpA	B-X
,	B-X
and	B-X
TpD	B-X
lipoproteins	B-X
,	B-X
plasmids	B-X
encoding	B-X
nonlipidated	B-X
forms	B-X
of	B-X
these	B-X
antigens	B-X
were	B-X
constructed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
plasmid	B-X
expressing	B-X
a	B-X
lipidated	B-X
form	B-X
of	B-X
the	B-X
otherwise	B-X
non-lipid-modified	B-X
antigen	B-X
TmpB	B-X
was	B-X
constructed	B-X
.	B-X
Immunization	B-X
and	B-X
absorption	B-X
experiments	B-X
with	B-X
these	B-X
lipidated	B-X
and	B-X
nonlipidated	B-X
antigens	B-X
showed	B-X
that	B-X
antibodies	B-X
against	B-X
the	B-X
lipid	B-X
moiety	B-X
of	B-X
lipoproteins	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
immunoblots	B-X
,	B-X
neither	B-X
in	B-X
sera	B-X
from	B-X
infected	B-X
rabbits	B-X
nor	B-X
in	B-X
sera	B-X
from	B-X
animals	B-X
immunized	B-X
with	B-X
the	B-X
lipoproteins	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
cross-reactivity	B-X
between	B-X
antibodies	B-X
against	B-X
the	B-X
T.	B-X
pallidum	B-X
lipoproteins	B-X
and	B-X
those	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
,	B-X
suggesting	B-X
that	B-X
antibodies	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
are	B-X
unrelated	B-X
to	B-X
antilipoprotein	B-X
antibodies	B-X
.	B-X

The	O
gene	O
encoding	O
the	O
35	O
-	O
kDa	O
immunogenic	O
Treponema	O
pallidium	O
subsp	O
.	O
pallidum	O
(	O
T	O
.	O
pallidum	O
)	O
membrane	O
protein	O
C	O
,	O
TmpC	B-Protein
,	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
The	B-X
gene	B-X
encoding	B-X
the	B-X
35-kDa	B-X
immunogenic	B-X
Treponema	B-X
pallidium	B-X
subsp	B-X
.	B-X
pallidum	B-X
(	B-X
T.	B-X
pallidum	B-X
)	B-X
membrane	B-X
protein	B-X
C	B-X
,	B-X
TmpC	B-X
,	B-X
was	B-X
cloned	B-X
,	B-X
sequenced	B-X
,	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
carries	B-X
on	B-X
N-terminal	B-X
signal	B-X
sequence	B-X
with	B-X
a	B-X
four-amino-acid	B-X
motif	B-X
,	B-X
which	B-X
is	B-X
characteristic	B-X
for	B-X
bacterial	B-X
lipoproteins	B-X
.	B-X
Metabolic	B-X
labeling	B-X
with	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
of	B-X
E.	B-X
coli	B-X
expressing	B-X
TmpC	B-X
revealed	B-X
incorporation	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
into	B-X
the	B-X
antigen	B-X
.	B-X
The	B-X
antigen	B-X
was	B-X
overproduced	B-X
,	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
used	B-X
in	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
to	B-X
evaluate	B-X
its	B-X
potential	B-X
for	B-X
the	B-X
serodiagnosis	B-X
of	B-X
syphilis	B-X
.	B-X
Although	B-X
all	B-X
sera	B-X
from	B-X
untreated	B-X
secondary	B-X
syphilis	B-X
patients	B-X
were	B-X
reactive	B-X
in	B-X
this	B-X
TmpC	B-X
ELISA	B-X
,	B-X
only	B-X
a	B-X
minority	B-X
of	B-X
the	B-X
serum	B-X
samples	B-X
from	B-X
untreated	B-X
patients	B-X
in	B-X
the	B-X
primary	B-X
or	B-X
early	B-X
latent	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
contained	B-X
significant	B-X
anti-TmpC	B-X
antibodies	B-X
.	B-X
To	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
antigenic	B-X
properties	B-X
of	B-X
the	B-X
TmpC	B-X
,	B-X
TmpA	B-X
,	B-X
and	B-X
TpD	B-X
lipoproteins	B-X
,	B-X
plasmids	B-X
encoding	B-X
nonlipidated	B-X
forms	B-X
of	B-X
these	B-X
antigens	B-X
were	B-X
constructed	B-X
.	B-X
Immunization	B-X
and	B-X
absorption	B-X
experiments	B-X
with	B-X
these	B-X
lipidated	B-X
and	B-X
nonlipidated	B-X
antigens	B-X
showed	B-X
that	B-X
antibodies	B-X
against	B-X
the	B-X
lipid	B-X
moiety	B-X
of	B-X
lipoproteins	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
immunoblots	B-X
,	B-X
neither	B-X
in	B-X
sera	B-X
from	B-X
infected	B-X
rabbits	B-X
nor	B-X
in	B-X
sera	B-X
from	B-X
animals	B-X
immunized	B-X
with	B-X
the	B-X
lipoproteins	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
cross-reactivity	B-X
between	B-X
antibodies	B-X
against	B-X
the	B-X
T.	B-X
pallidum	B-X
lipoproteins	B-X
and	B-X
those	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
,	B-X
suggesting	B-X
that	B-X
antibodies	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
are	B-X
unrelated	B-X
to	B-X
antilipoprotein	B-X
antibodies	B-X
.	B-X

The	O
deduced	O
amino	O
acid	O
sequence	O
carries	O
on	O
N	O
-	O
terminal	O
signal	O
sequence	O
with	O
a	O
four	O
-	O
amino	O
-	O
acid	O
motif	O
,	O
which	O
is	O
characteristic	O
for	O
bacterial	O
lipoproteins	O
.	O

Metabolic	O
labeling	O
with	O
radioactive	O
palmitic	O
acid	O
of	O
E	O
.	O
coli	O
expressing	O
TmpC	B-Protein
revealed	O
incorporation	O
of	O
the	O
fatty	O
acid	O
into	O
the	O
antigen	O
.	O
<EOS>	B-X
pallidum	B-X
(	B-X
T.	B-X
pallidum	B-X
)	B-X
membrane	B-X
protein	B-X
C	B-X
,	B-X
TmpC	B-X
,	B-X
was	B-X
cloned	B-X
,	B-X
sequenced	B-X
,	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
carries	B-X
on	B-X
N-terminal	B-X
signal	B-X
sequence	B-X
with	B-X
a	B-X
four-amino-acid	B-X
motif	B-X
,	B-X
which	B-X
is	B-X
characteristic	B-X
for	B-X
bacterial	B-X
lipoproteins	B-X
.	B-X
Metabolic	B-X
labeling	B-X
with	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
of	B-X
E.	B-X
coli	B-X
expressing	B-X
TmpC	B-X
revealed	B-X
incorporation	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
into	B-X
the	B-X
antigen	B-X
.	B-X
The	B-X
antigen	B-X
was	B-X
overproduced	B-X
,	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
used	B-X
in	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
to	B-X
evaluate	B-X
its	B-X
potential	B-X
for	B-X
the	B-X
serodiagnosis	B-X
of	B-X
syphilis	B-X
.	B-X
Although	B-X
all	B-X
sera	B-X
from	B-X
untreated	B-X
secondary	B-X
syphilis	B-X
patients	B-X
were	B-X
reactive	B-X
in	B-X
this	B-X
TmpC	B-X
ELISA	B-X
,	B-X
only	B-X
a	B-X
minority	B-X
of	B-X
the	B-X
serum	B-X
samples	B-X
from	B-X
untreated	B-X
patients	B-X
in	B-X
the	B-X
primary	B-X
or	B-X
early	B-X
latent	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
contained	B-X
significant	B-X
anti-TmpC	B-X
antibodies	B-X
.	B-X
To	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
antigenic	B-X
properties	B-X
of	B-X
the	B-X
TmpC	B-X
,	B-X
TmpA	B-X
,	B-X
and	B-X
TpD	B-X
lipoproteins	B-X
,	B-X
plasmids	B-X
encoding	B-X
nonlipidated	B-X
forms	B-X
of	B-X
these	B-X
antigens	B-X
were	B-X
constructed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
plasmid	B-X
expressing	B-X
a	B-X
lipidated	B-X
form	B-X
of	B-X
the	B-X
otherwise	B-X
non-lipid-modified	B-X
antigen	B-X
TmpB	B-X
was	B-X
constructed	B-X
.	B-X
Immunization	B-X
and	B-X
absorption	B-X
experiments	B-X
with	B-X
these	B-X
lipidated	B-X
and	B-X
nonlipidated	B-X
antigens	B-X
showed	B-X
that	B-X
antibodies	B-X
against	B-X
the	B-X
lipid	B-X
moiety	B-X
of	B-X
lipoproteins	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
immunoblots	B-X
,	B-X
neither	B-X
in	B-X
sera	B-X
from	B-X
infected	B-X
rabbits	B-X
nor	B-X
in	B-X
sera	B-X
from	B-X
animals	B-X
immunized	B-X
with	B-X
the	B-X
lipoproteins	B-X
.	B-X

The	O
antigen	O
was	O
overproduced	O
,	O
purified	O
to	O
near	O
homogeneity	O
and	O
used	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
evaluate	O
its	O
potential	O
for	O
the	O
serodiagnosis	O
of	O
syphilis	O
.	O

Although	O
all	O
sera	O
from	O
untreated	O
secondary	O
syphilis	O
patients	O
were	O
reactive	O
in	O
this	O
TmpC	B-Protein
ELISA	O
,	O
only	O
a	O
minority	O
of	O
the	O
serum	O
samples	O
from	O
untreated	O
patients	O
in	O
the	O
primary	O
or	O
early	O
latent	O
stage	O
of	O
the	O
disease	O
contained	O
significant	O
anti	O
-	O
TmpC	B-Protein
antibodies	O
.	O
<EOS>	B-X
pallidum	B-X
(	B-X
T.	B-X
pallidum	B-X
)	B-X
membrane	B-X
protein	B-X
C	B-X
,	B-X
TmpC	B-X
,	B-X
was	B-X
cloned	B-X
,	B-X
sequenced	B-X
,	B-X
and	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
Metabolic	B-X
labeling	B-X
with	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
of	B-X
E.	B-X
coli	B-X
expressing	B-X
TmpC	B-X
revealed	B-X
incorporation	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
into	B-X
the	B-X
antigen	B-X
.	B-X
The	B-X
antigen	B-X
was	B-X
overproduced	B-X
,	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
used	B-X
in	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
to	B-X
evaluate	B-X
its	B-X
potential	B-X
for	B-X
the	B-X
serodiagnosis	B-X
of	B-X
syphilis	B-X
.	B-X
Although	B-X
all	B-X
sera	B-X
from	B-X
untreated	B-X
secondary	B-X
syphilis	B-X
patients	B-X
were	B-X
reactive	B-X
in	B-X
this	B-X
TmpC	B-X
ELISA	B-X
,	B-X
only	B-X
a	B-X
minority	B-X
of	B-X
the	B-X
serum	B-X
samples	B-X
from	B-X
untreated	B-X
patients	B-X
in	B-X
the	B-X
primary	B-X
or	B-X
early	B-X
latent	B-X
stage	B-X
of	B-X
the	B-X
disease	B-X
contained	B-X
significant	B-X
anti-TmpC	B-X
antibodies	B-X
.	B-X
To	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
antigenic	B-X
properties	B-X
of	B-X
the	B-X
TmpC	B-X
,	B-X
TmpA	B-X
,	B-X
and	B-X
TpD	B-X
lipoproteins	B-X
,	B-X
plasmids	B-X
encoding	B-X
nonlipidated	B-X
forms	B-X
of	B-X
these	B-X
antigens	B-X
were	B-X
constructed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
plasmid	B-X
expressing	B-X
a	B-X
lipidated	B-X
form	B-X
of	B-X
the	B-X
otherwise	B-X
non-lipid-modified	B-X
antigen	B-X
TmpB	B-X
was	B-X
constructed	B-X
.	B-X
Immunization	B-X
and	B-X
absorption	B-X
experiments	B-X
with	B-X
these	B-X
lipidated	B-X
and	B-X
nonlipidated	B-X
antigens	B-X
showed	B-X
that	B-X
antibodies	B-X
against	B-X
the	B-X
lipid	B-X
moiety	B-X
of	B-X
lipoproteins	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
immunoblots	B-X
,	B-X
neither	B-X
in	B-X
sera	B-X
from	B-X
infected	B-X
rabbits	B-X
nor	B-X
in	B-X
sera	B-X
from	B-X
animals	B-X
immunized	B-X
with	B-X
the	B-X
lipoproteins	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
cross-reactivity	B-X
between	B-X
antibodies	B-X
against	B-X
the	B-X
T.	B-X
pallidum	B-X
lipoproteins	B-X
and	B-X
those	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
,	B-X
suggesting	B-X
that	B-X
antibodies	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
are	B-X
unrelated	B-X
to	B-X
antilipoprotein	B-X
antibodies	B-X
.	B-X

To	O
study	O
the	O
influence	O
of	O
the	O
lipid	O
moiety	O
on	O
the	O
antigenic	O
properties	O
of	O
the	O
TmpC	B-Protein
,	O
TmpA	B-Protein
,	O
and	O
TpD	B-Protein
lipoproteins	O
,	O
plasmids	O
encoding	O
nonlipidated	O
forms	O
of	O
these	O
antigens	O
were	O
constructed	O
.	O

In	O
addition	O
,	O
a	O
plasmid	O
expressing	O
a	O
lipidated	O
form	O
of	O
the	O
otherwise	O
non	O
-	O
lipid	O
-	O
modified	O
antigen	O
TmpB	B-Protein
was	O
constructed	O
.	O
<EOS>	B-X
Metabolic	B-X
labeling	B-X
with	B-X
radioactive	B-X
palmitic	B-X
acid	B-X
of	B-X
E.	B-X
coli	B-X
expressing	B-X
TmpC	B-X
revealed	B-X
incorporation	B-X
of	B-X
the	B-X
fatty	B-X
acid	B-X
into	B-X
the	B-X
antigen	B-X
.	B-X
The	B-X
antigen	B-X
was	B-X
overproduced	B-X
,	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
used	B-X
in	B-X
an	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
(	B-X
ELISA	B-X
)	B-X
to	B-X
evaluate	B-X
its	B-X
potential	B-X
for	B-X
the	B-X
serodiagnosis	B-X
of	B-X
syphilis	B-X
.	B-X
To	B-X
study	B-X
the	B-X
influence	B-X
of	B-X
the	B-X
lipid	B-X
moiety	B-X
on	B-X
the	B-X
antigenic	B-X
properties	B-X
of	B-X
the	B-X
TmpC	B-X
,	B-X
TmpA	B-X
,	B-X
and	B-X
TpD	B-X
lipoproteins	B-X
,	B-X
plasmids	B-X
encoding	B-X
nonlipidated	B-X
forms	B-X
of	B-X
these	B-X
antigens	B-X
were	B-X
constructed	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
a	B-X
plasmid	B-X
expressing	B-X
a	B-X
lipidated	B-X
form	B-X
of	B-X
the	B-X
otherwise	B-X
non-lipid-modified	B-X
antigen	B-X
TmpB	B-X
was	B-X
constructed	B-X
.	B-X
Immunization	B-X
and	B-X
absorption	B-X
experiments	B-X
with	B-X
these	B-X
lipidated	B-X
and	B-X
nonlipidated	B-X
antigens	B-X
showed	B-X
that	B-X
antibodies	B-X
against	B-X
the	B-X
lipid	B-X
moiety	B-X
of	B-X
lipoproteins	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
immunoblots	B-X
,	B-X
neither	B-X
in	B-X
sera	B-X
from	B-X
infected	B-X
rabbits	B-X
nor	B-X
in	B-X
sera	B-X
from	B-X
animals	B-X
immunized	B-X
with	B-X
the	B-X
lipoproteins	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
were	B-X
unable	B-X
to	B-X
demonstrate	B-X
cross-reactivity	B-X
between	B-X
antibodies	B-X
against	B-X
the	B-X
T.	B-X
pallidum	B-X
lipoproteins	B-X
and	B-X
those	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
,	B-X
suggesting	B-X
that	B-X
antibodies	B-X
reactive	B-X
to	B-X
the	B-X
Venereal	B-X
Diseases	B-X
Research	B-X
Laboratories	B-X
test	B-X
are	B-X
unrelated	B-X
to	B-X
antilipoprotein	B-X
antibodies	B-X
.	B-X

Immunization	O
and	O
absorption	O
experiments	O
with	O
these	O
lipidated	O
and	O
nonlipidated	O
antigens	O
showed	O
that	O
antibodies	O
against	O
the	O
lipid	O
moiety	O
of	O
lipoproteins	O
could	O
not	O
be	O
detected	O
on	O
immunoblots	O
,	O
neither	O
in	O
sera	O
from	O
infected	O
rabbits	O
nor	O
in	O
sera	O
from	O
animals	O
immunized	O
with	O
the	O
lipoproteins	O
.	O

In	O
addition	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
cross	O
-	O
reactivity	O
between	O
antibodies	O
against	O
the	O
T	O
.	O
pallidum	O
lipoproteins	O
and	O
those	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
,	O
suggesting	O
that	O
antibodies	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
are	O
unrelated	O
to	O
antilipoprotein	O
antibodies	O
.	O

Xenobiotic	O
incorporation	O
into	O
pyruvate	O
dehydrogenase	O
complex	O
can	O
occur	O
via	O
the	O
exogenous	O
lipoylation	O
pathway	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

Lipoylated	O
enzymes	O
such	O
as	O
the	O
E2	O
component	O
of	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
)	O
are	O
targets	O
for	O
autoreactive	O
immune	O
responses	O
in	O
primary	O
biliary	O
cirrhosis	O
,	O
with	O
lipoic	O
acid	O
itself	O
forming	O
a	O
component	O
of	O
the	O
dominant	O
auto	O
-	O
epitopes	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

A	O
candidate	O
mechanism	O
for	O
the	O
initiation	O
of	O
tolerance	O
breakdown	O
in	O
this	O
disease	O
is	O
immune	O
recognition	O
of	O
neo	O
-	O
antigens	O
formed	O
by	O
xenobiotic	O
substitution	O
of	O
normal	O
proteins	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X

Importantly	O
,	O
sensitization	O
with	O
proteins	O
artificially	O
substituted	O
with	O
the	O
lipoic	O
acid	O
analogue	O
xenobiotic	O
6	O
-	O
bromohexanoic	O
acid	O
(	O
6BH	O
)	O
can	O
induce	O
an	O
immune	O
response	O
that	O
cross	O
-	O
reacts	O
with	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

This	O
study	O
investigated	O
the	O
potential	O
of	O
recombinant	O
lipoylation	O
enzymes	O
lipoate	O
activating	O
enzyme	O
and	O
lipoyl	O
-	O
AMP	O
(	O
GMP	O
)	O
:	O
N	O
-	O
lysine	O
lipoyl	O
transferase	O
to	O
aberrantly	O
incorporate	O
xenobiotics	O
into	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

It	O
was	O
found	O
that	O
these	O
enzymes	O
could	O
incorporate	O
lipoic	O
acid	O
analogues	O
including	O
octanoic	O
and	O
hexanoic	O
acids	O
and	O
the	O
xenobiotic	O
6BH	O
into	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

The	O
efficiency	O
of	O
incorporation	O
of	O
these	O
analogues	O
showed	O
a	O
variable	O
dependence	O
on	O
activation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
or	O
guanosine	O
triphosphate	O
(	O
GTP	O
)	O
,	O
with	O
ATP	O
favoring	O
the	O
incorporation	O
of	O
hexanoic	O
acid	O
and	O
6BH	O
whereas	O
GTP	O
enhanced	O
substitution	O
by	O
octanoic	O
acid	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

Importantly	O
,	O
competition	O
studies	O
showed	O
that	O
the	O
relative	O
incorporation	O
of	O
both	O
6BH	O
and	O
lipoic	O
acid	O
could	O
be	O
regulated	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
,	O
with	O
the	O
formation	O
of	O
6BH	O
-	O
substituted	O
PDC	B-Protein
-	I-Protein
E2	I-Protein
predominating	O
in	O
an	O
ATP	O
-	O
rich	O
environment	O
.	O

Conclusion	O
:	O
Using	O
a	O
well	O
-	O
defined	O
system	O
in	O
vitro	O
we	O
have	O
shown	O
that	O
an	O
important	O
xenobiotic	O
can	O
be	O
incorporated	O
into	O
PDC	O
in	O
place	O
of	O
lipoic	O
acid	O
by	O
the	O
exogenous	O
lipoylation	O
system	O
;	O
the	O
relative	O
levels	O
of	O
lipoic	O
acid	O
and	O
xenobiotic	O
incorporation	O
may	O
be	O
determined	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X
Importantly	B-X
,	B-X
sensitization	B-X
with	B-X
proteins	B-X
artificially	B-X
substituted	B-X
with	B-X
the	B-X
lipoic	B-X
acid	B-X
analogue	B-X
xenobiotic	B-X
6-bromohexanoic	B-X
acid	B-X
(	B-X
6BH	B-X
)	B-X
can	B-X
induce	B-X
an	B-X
immune	B-X
response	B-X
that	B-X
cross-reacts	B-X
with	B-X
PDC-E2	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
potential	B-X
of	B-X
recombinant	B-X
lipoylation	B-X
enzymes	B-X
lipoate	B-X
activating	B-X
enzyme	B-X
and	B-X
lipoyl-AMP	B-X
(	B-X
GMP	B-X
)	B-X
:	B-X
N-lysine	B-X
lipoyl	B-X
transferase	B-X
to	B-X
aberrantly	B-X
incorporate	B-X
xenobiotics	B-X
into	B-X
PDC-E2	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
these	B-X
enzymes	B-X
could	B-X
incorporate	B-X
lipoic	B-X
acid	B-X
analogues	B-X
including	B-X
octanoic	B-X
and	B-X
hexanoic	B-X
acids	B-X
and	B-X
the	B-X
xenobiotic	B-X
6BH	B-X
into	B-X
PDC-E2	B-X
.	B-X
The	B-X
efficiency	B-X
of	B-X
incorporation	B-X
of	B-X
these	B-X
analogues	B-X
showed	B-X
a	B-X
variable	B-X
dependence	B-X
on	B-X
activation	B-X
by	B-X
adenosine	B-X
triphosphate	B-X
(	B-X
ATP	B-X
)	B-X
or	B-X
guanosine	B-X
triphosphate	B-X
(	B-X
GTP	B-X
)	B-X
,	B-X
with	B-X
ATP	B-X
favoring	B-X
the	B-X
incorporation	B-X
of	B-X
hexanoic	B-X
acid	B-X
and	B-X
6BH	B-X
whereas	B-X
GTP	B-X
enhanced	B-X
substitution	B-X
by	B-X
octanoic	B-X
acid	B-X
.	B-X
Importantly	B-X
,	B-X
competition	B-X
studies	B-X
showed	B-X
that	B-X
the	B-X
relative	B-X
incorporation	B-X
of	B-X
both	B-X
6BH	B-X
and	B-X
lipoic	B-X
acid	B-X
could	B-X
be	B-X
regulated	B-X
by	B-X
the	B-X
balance	B-X
between	B-X
ATP	B-X
and	B-X
GTP	B-X
,	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
6BH-substituted	B-X
PDC-E2	B-X
predominating	B-X
in	B-X
an	B-X
ATP-rich	B-X
environment	B-X
.	B-X

These	O
observations	O
suggest	O
a	O
clear	O
mechanism	O
for	O
the	O
generation	O
of	O
an	O
auto	O
-	O
immunogenic	O
neo	O
-	O
antigen	O
of	O
relevance	O
for	O
the	O
pathogenesis	O
of	O
primary	O
biliary	O
cirrhosis	O
.	O
<EOS>	B-X
Lipoylated	B-X
enzymes	B-X
such	B-X
as	B-X
the	B-X
E2	B-X
component	B-X
of	B-X
pyruvate	B-X
dehydrogenase	B-X
complex	B-X
(	B-X
PDC-E2	B-X
)	B-X
are	B-X
targets	B-X
for	B-X
autoreactive	B-X
immune	B-X
responses	B-X
in	B-X
primary	B-X
biliary	B-X
cirrhosis	B-X
,	B-X
with	B-X
lipoic	B-X
acid	B-X
itself	B-X
forming	B-X
a	B-X
component	B-X
of	B-X
the	B-X
dominant	B-X
auto-epitopes	B-X
.	B-X
A	B-X
candidate	B-X
mechanism	B-X
for	B-X
the	B-X
initiation	B-X
of	B-X
tolerance	B-X
breakdown	B-X
in	B-X
this	B-X
disease	B-X
is	B-X
immune	B-X
recognition	B-X
of	B-X
neo-antigens	B-X
formed	B-X
by	B-X
xenobiotic	B-X
substitution	B-X
of	B-X
normal	B-X
proteins	B-X
.	B-X

SUMOylation	O
inhibits	O
SF	B-Protein
-	I-Protein
1	I-Protein
activity	O
by	O
reducing	O
CDK7	B-Protein
-	O
mediated	O
serine	O
203	O
phosphorylation	O
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

Steroidogenic	B-Protein
factor	I-Protein
1	I-Protein
(	O
SF	B-Protein
-	I-Protein
1	I-Protein
)	O
is	O
an	O
orphan	O
nuclear	O
receptor	O
selectively	O
expressed	O
in	O
the	O
adrenal	O
cortex	O
and	O
gonads	O
,	O
where	O
it	O
mediates	O
the	O
hormonal	O
stimulation	O
of	O
multiple	O
genes	O
involved	O
in	O
steroid	O
hormone	O
biosynthesis	O
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

SF	B-Protein
-	I-Protein
1	I-Protein
is	O
the	O
target	O
of	O
both	O
phosphorylation	O
and	O
SUMOylation	O
,	O
but	O
how	O
these	O
modifications	O
interact	O
or	O
contribute	O
to	O
SF	B-Protein
-	I-Protein
1	I-Protein
regulation	O
of	O
endogenous	O
genes	O
remains	O
poorly	O
defined	O
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

We	O
found	O
that	O
SF	B-Protein
-	I-Protein
1	I-Protein
is	O
selectively	O
SUMOylated	O
at	O
K194	O
in	O
Y1	O
adrenocarcinoma	O
cells	O
and	O
that	O
although	O
SUMOylation	O
does	O
not	O
alter	O
the	O
subcellular	O
localization	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
,	O
the	O
modification	O
inhibits	O
the	O
ability	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
to	O
activate	O
target	O
genes	O
.	O

Notably	O
,	O
whereas	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
is	O
independent	O
of	O
S203	O
phosphorylation	O
and	O
is	O
unaffected	O
by	O
adrenocorticotropin	B-Protein
(	O
ACTH	B-Protein
)	O
treatment	O
,	O
loss	O
of	O
SUMOylation	O
leads	O
to	O
enhanced	O
SF	B-Protein
-	I-Protein
1	I-Protein
phosphorylation	O
at	O
serine	O
203	O
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

Furthermore	O
,	O
preventing	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
multiple	O
steroidogenic	O
enzyme	O
genes	O
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

Analysis	O
of	O
the	O
StAR	B-Protein
promoter	O
indicates	O
that	O
blockade	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
SUMOylation	O
leads	O
to	O
an	O
increase	O
in	O
overall	O
promoter	O
occupancy	O
but	O
does	O
not	O
alter	O
the	O
oscillatory	O
recruitment	O
dynamics	O
in	O
response	O
to	O
ACTH	B-Protein
.	O

Notably	O
,	O
we	O
find	O
that	O
CDK7	B-Protein
binds	O
preferentially	O
to	O
the	O
SUMOylation	O
-	O
deficient	O
form	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
and	O
that	O
CDK7	B-Protein
inhibition	O
reduces	O
phosphorylation	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
propose	O
a	O
coordinated	O
modification	O
model	O
in	O
which	O
inhibition	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
-	O
mediated	O
transcription	O
by	O
SUMOylation	O
in	O
adrenocortical	O
cancer	O
cells	O
is	O
mediated	O
through	O
reduced	O
CDK7	B-Protein
-	O
induced	O
phosphorylation	O
of	O
SF	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Steroidogenic	B-X
factor	B-X
1	B-X
(	B-X
SF-1	B-X
)	B-X
is	B-X
an	B-X
orphan	B-X
nuclear	B-X
receptor	B-X
selectively	B-X
expressed	B-X
in	B-X
the	B-X
adrenal	B-X
cortex	B-X
and	B-X
gonads	B-X
,	B-X
where	B-X
it	B-X
mediates	B-X
the	B-X
hormonal	B-X
stimulation	B-X
of	B-X
multiple	B-X
genes	B-X
involved	B-X
in	B-X
steroid	B-X
hormone	B-X
biosynthesis	B-X
.	B-X
SF-1	B-X
is	B-X
the	B-X
target	B-X
of	B-X
both	B-X
phosphorylation	B-X
and	B-X
SUMOylation	B-X
,	B-X
but	B-X
how	B-X
these	B-X
modifications	B-X
interact	B-X
or	B-X
contribute	B-X
to	B-X
SF-1	B-X
regulation	B-X
of	B-X
endogenous	B-X
genes	B-X
remains	B-X
poorly	B-X
defined	B-X
.	B-X
We	B-X
found	B-X
that	B-X
SF-1	B-X
is	B-X
selectively	B-X
SUMOylated	B-X
at	B-X
K194	B-X
in	B-X
Y1	B-X
adrenocarcinoma	B-X
cells	B-X
and	B-X
that	B-X
although	B-X
SUMOylation	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
SF-1	B-X
,	B-X
the	B-X
modification	B-X
inhibits	B-X
the	B-X
ability	B-X
of	B-X
SF-1	B-X
to	B-X
activate	B-X
target	B-X
genes	B-X
.	B-X
Notably	B-X
,	B-X
whereas	B-X
SF-1	B-X
SUMOylation	B-X
is	B-X
independent	B-X
of	B-X
S203	B-X
phosphorylation	B-X
and	B-X
is	B-X
unaffected	B-X
by	B-X
adrenocorticotropin	B-X
(	B-X
ACTH	B-X
)	B-X
treatment	B-X
,	B-X
loss	B-X
of	B-X
SUMOylation	B-X
leads	B-X
to	B-X
enhanced	B-X
SF-1	B-X
phosphorylation	B-X
at	B-X
serine	B-X
203	B-X
.	B-X
Furthermore	B-X
,	B-X
preventing	B-X
SF-1	B-X
SUMOylation	B-X
increases	B-X
the	B-X
mRNA	B-X
and	B-X
protein	B-X
levels	B-X
of	B-X
multiple	B-X
steroidogenic	B-X
enzyme	B-X
genes	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
StAR	B-X
promoter	B-X
indicates	B-X
that	B-X
blockade	B-X
of	B-X
SF-1	B-X
SUMOylation	B-X
leads	B-X
to	B-X
an	B-X
increase	B-X
in	B-X
overall	B-X
promoter	B-X
occupancy	B-X
but	B-X
does	B-X
not	B-X
alter	B-X
the	B-X
oscillatory	B-X
recruitment	B-X
dynamics	B-X
in	B-X
response	B-X
to	B-X
ACTH	B-X
.	B-X
Notably	B-X
,	B-X
we	B-X
find	B-X
that	B-X
CDK7	B-X
binds	B-X
preferentially	B-X
to	B-X
the	B-X
SUMOylation-deficient	B-X
form	B-X
of	B-X
SF-1	B-X
and	B-X
that	B-X
CDK7	B-X
inhibition	B-X
reduces	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
observations	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
coordinated	B-X
modification	B-X
model	B-X
in	B-X
which	B-X
inhibition	B-X
of	B-X
SF-1-mediated	B-X
transcription	B-X
by	B-X
SUMOylation	B-X
in	B-X
adrenocortical	B-X
cancer	B-X
cells	B-X
is	B-X
mediated	B-X
through	B-X
reduced	B-X
CDK7-induced	B-X
phosphorylation	B-X
of	B-X
SF-1	B-X
.	B-X

Dynamic	O
compartmentalization	O
of	O
base	O
excision	O
repair	O
proteins	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
To	B-X
execute	B-X
an	B-X
appropriate	B-X
repair	B-X
response	B-X
,	B-X
BER	B-X
components	B-X
must	B-X
be	B-X
distributed	B-X
to	B-X
accommodate	B-X
levels	B-X
of	B-X
genotoxic	B-X
stress	B-X
that	B-X
may	B-X
vary	B-X
considerably	B-X
between	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
growth	B-X
state	B-X
and	B-X
stress	B-X
environment	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Numerous	B-X
examples	B-X
exist	B-X
where	B-X
cells	B-X
respond	B-X
to	B-X
signals	B-X
,	B-X
resulting	B-X
in	B-X
relocalization	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
key	B-X
biological	B-X
transactions	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
such	B-X
dynamic	B-X
localization	B-X
contributes	B-X
to	B-X
efficient	B-X
organelle-specific	B-X
DNA	B-X
repair	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
intracellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
N-glycosylase/AP	B-X
lyases	B-X
,	B-X
Ntg1	B-X
and	B-X
Ntg2	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nuclear	B-X
and	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
.	B-X
Fluorescence	B-X
microscopy	B-X
revealed	B-X
that	B-X
Ntg1	B-X
is	B-X
differentially	B-X
localized	B-X
to	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
likely	B-X
in	B-X
response	B-X
to	B-X
the	B-X
oxidative	B-X
DNA	B-X
damage	B-X
status	B-X
of	B-X
the	B-X
organelle	B-X
.	B-X
Sumoylation	B-X
is	B-X
associated	B-X
with	B-X
targeting	B-X
of	B-X
Ntg1	B-X
to	B-X
nuclei	B-X
containing	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

DNAs	O
harbored	O
in	O
both	O
nuclei	O
and	O
mitochondria	O
of	O
eukaryotic	O
cells	O
are	O
subject	O
to	O
continuous	O
oxidative	O
damage	O
resulting	O
from	O
normal	O
metabolic	O
activities	O
or	O
environmental	O
insults	O
.	O
<EOS>	B-X
Human	B-X
skin	B-X
forms	B-X
a	B-X
protective	B-X
barrier	B-X
against	B-X
the	B-X
external	B-X
environment	B-X
and	B-X
is	B-X
our	B-X
first	B-X
line	B-X
of	B-X
defense	B-X
against	B-X
toxic	B-X
,	B-X
solar	B-X
,	B-X
and	B-X
pathogenic	B-X
insults	B-X
.	B-X
The	B-X
skin	B-X
is	B-X
a	B-X
complex	B-X
organ	B-X
that	B-X
has	B-X
devised	B-X
numerous	B-X
strategies	B-X
,	B-X
such	B-X
as	B-X
physical	B-X
,	B-X
chemical	B-X
,	B-X
and	B-X
microbiological	B-X
barriers	B-X
,	B-X
to	B-X
protect	B-X
the	B-X
host	B-X
from	B-X
external	B-X
insults	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
skin	B-X
contains	B-X
an	B-X
intricate	B-X
network	B-X
of	B-X
immune	B-X
cells	B-X
resident	B-X
to	B-X
the	B-X
tissue	B-X
,	B-X
crucial	B-X
for	B-X
host	B-X
defense	B-X
as	B-X
well	B-X
as	B-X
tissue	B-X
homeostasis	B-X
.	B-X
In	B-X
the	B-X
event	B-X
of	B-X
an	B-X
insult	B-X
,	B-X
the	B-X
skin-resident	B-X
immune	B-X
cells	B-X
are	B-X
crucial	B-X
not	B-X
only	B-X
for	B-X
prevention	B-X
of	B-X
infection	B-X
but	B-X
also	B-X
for	B-X
tissue	B-X
reconstruction	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
will	B-X
discuss	B-X
the	B-X
defensive	B-X
components	B-X
of	B-X
the	B-X
skin	B-X
and	B-X
focus	B-X
on	B-X
the	B-X
function	B-X
of	B-X
skin-resident	B-X
immune	B-X
cells	B-X
in	B-X
homeostasis	B-X
and	B-X
their	B-X
role	B-X
in	B-X
wound	B-X
healing	B-X
.	B-X

Oxidative	O
DNA	O
damage	O
is	O
primarily	O
reversed	O
by	O
the	O
base	O
excision	O
repair	O
(	O
BER	O
)	O
pathway	O
,	O
initiated	O
by	O
N	O
-	O
glycosylase	O
apurinic	O
/	O
apyrimidinic	O
(	O
AP	O
)	O
lyase	O
proteins	O
.	O

To	O
execute	O
an	O
appropriate	O
repair	O
response	O
,	O
BER	O
components	O
must	O
be	O
distributed	O
to	O
accommodate	O
levels	O
of	O
genotoxic	O
stress	O
that	O
may	O
vary	O
considerably	O
between	O
nuclei	O
and	O
mitochondria	O
,	O
depending	O
on	O
the	O
growth	O
state	O
and	O
stress	O
environment	O
of	O
the	O
cell	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
To	B-X
execute	B-X
an	B-X
appropriate	B-X
repair	B-X
response	B-X
,	B-X
BER	B-X
components	B-X
must	B-X
be	B-X
distributed	B-X
to	B-X
accommodate	B-X
levels	B-X
of	B-X
genotoxic	B-X
stress	B-X
that	B-X
may	B-X
vary	B-X
considerably	B-X
between	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
growth	B-X
state	B-X
and	B-X
stress	B-X
environment	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Numerous	B-X
examples	B-X
exist	B-X
where	B-X
cells	B-X
respond	B-X
to	B-X
signals	B-X
,	B-X
resulting	B-X
in	B-X
relocalization	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
key	B-X
biological	B-X
transactions	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
such	B-X
dynamic	B-X
localization	B-X
contributes	B-X
to	B-X
efficient	B-X
organelle-specific	B-X
DNA	B-X
repair	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
intracellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
N-glycosylase/AP	B-X
lyases	B-X
,	B-X
Ntg1	B-X
and	B-X
Ntg2	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nuclear	B-X
and	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
.	B-X
Fluorescence	B-X
microscopy	B-X
revealed	B-X
that	B-X
Ntg1	B-X
is	B-X
differentially	B-X
localized	B-X
to	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
likely	B-X
in	B-X
response	B-X
to	B-X
the	B-X
oxidative	B-X
DNA	B-X
damage	B-X
status	B-X
of	B-X
the	B-X
organelle	B-X
.	B-X
Sumoylation	B-X
is	B-X
associated	B-X
with	B-X
targeting	B-X
of	B-X
Ntg1	B-X
to	B-X
nuclei	B-X
containing	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

Numerous	O
examples	O
exist	O
where	O
cells	O
respond	O
to	O
signals	O
,	O
resulting	O
in	O
relocalization	O
of	O
proteins	O
involved	O
in	O
key	O
biological	O
transactions	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
Numerous	B-X
examples	B-X
exist	B-X
where	B-X
cells	B-X
respond	B-X
to	B-X
signals	B-X
,	B-X
resulting	B-X
in	B-X
relocalization	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
key	B-X
biological	B-X
transactions	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

To	O
address	O
whether	O
such	O
dynamic	O
localization	O
contributes	O
to	O
efficient	O
organelle	O
-	O
specific	O
DNA	O
repair	O
,	O
we	O
determined	O
the	O
intracellular	O
localization	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
N	O
-	O
glycosylase	O
/	O
AP	O
lyases	O
,	O
Ntg1	B-Protein
and	O
Ntg2	B-Protein
,	O
in	O
response	O
to	O
nuclear	O
and	O
mitochondrial	O
oxidative	O
stress	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
To	B-X
execute	B-X
an	B-X
appropriate	B-X
repair	B-X
response	B-X
,	B-X
BER	B-X
components	B-X
must	B-X
be	B-X
distributed	B-X
to	B-X
accommodate	B-X
levels	B-X
of	B-X
genotoxic	B-X
stress	B-X
that	B-X
may	B-X
vary	B-X
considerably	B-X
between	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
growth	B-X
state	B-X
and	B-X
stress	B-X
environment	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Numerous	B-X
examples	B-X
exist	B-X
where	B-X
cells	B-X
respond	B-X
to	B-X
signals	B-X
,	B-X
resulting	B-X
in	B-X
relocalization	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
key	B-X
biological	B-X
transactions	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
such	B-X
dynamic	B-X
localization	B-X
contributes	B-X
to	B-X
efficient	B-X
organelle-specific	B-X
DNA	B-X
repair	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
intracellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
N-glycosylase/AP	B-X
lyases	B-X
,	B-X
Ntg1	B-X
and	B-X
Ntg2	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nuclear	B-X
and	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
.	B-X
Fluorescence	B-X
microscopy	B-X
revealed	B-X
that	B-X
Ntg1	B-X
is	B-X
differentially	B-X
localized	B-X
to	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
likely	B-X
in	B-X
response	B-X
to	B-X
the	B-X
oxidative	B-X
DNA	B-X
damage	B-X
status	B-X
of	B-X
the	B-X
organelle	B-X
.	B-X
Sumoylation	B-X
is	B-X
associated	B-X
with	B-X
targeting	B-X
of	B-X
Ntg1	B-X
to	B-X
nuclei	B-X
containing	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

Fluorescence	O
microscopy	O
revealed	O
that	O
Ntg1	B-Protein
is	O
differentially	O
localized	O
to	O
nuclei	O
and	O
mitochondria	O
,	O
likely	O
in	O
response	O
to	O
the	O
oxidative	O
DNA	O
damage	O
status	O
of	O
the	O
organelle	O
.	O

Sumoylation	O
is	O
associated	O
with	O
targeting	O
of	O
Ntg1	B-Protein
to	O
nuclei	O
containing	O
oxidative	O
DNA	O
damage	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
To	B-X
execute	B-X
an	B-X
appropriate	B-X
repair	B-X
response	B-X
,	B-X
BER	B-X
components	B-X
must	B-X
be	B-X
distributed	B-X
to	B-X
accommodate	B-X
levels	B-X
of	B-X
genotoxic	B-X
stress	B-X
that	B-X
may	B-X
vary	B-X
considerably	B-X
between	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
growth	B-X
state	B-X
and	B-X
stress	B-X
environment	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
such	B-X
dynamic	B-X
localization	B-X
contributes	B-X
to	B-X
efficient	B-X
organelle-specific	B-X
DNA	B-X
repair	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
intracellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
N-glycosylase/AP	B-X
lyases	B-X
,	B-X
Ntg1	B-X
and	B-X
Ntg2	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nuclear	B-X
and	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
.	B-X
Fluorescence	B-X
microscopy	B-X
revealed	B-X
that	B-X
Ntg1	B-X
is	B-X
differentially	B-X
localized	B-X
to	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
likely	B-X
in	B-X
response	B-X
to	B-X
the	B-X
oxidative	B-X
DNA	B-X
damage	B-X
status	B-X
of	B-X
the	B-X
organelle	B-X
.	B-X
Sumoylation	B-X
is	B-X
associated	B-X
with	B-X
targeting	B-X
of	B-X
Ntg1	B-X
to	B-X
nuclei	B-X
containing	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

These	O
studies	O
demonstrate	O
that	O
trafficking	O
of	O
DNA	O
repair	O
proteins	O
to	O
organelles	O
containing	O
high	O
levels	O
of	O
oxidative	O
DNA	O
damage	O
may	O
be	O
a	O
central	O
point	O
for	O
regulating	O
BER	O
in	O
response	O
to	O
oxidative	O
stress	O
.	O
<EOS>	B-X
DNAs	B-X
harbored	B-X
in	B-X
both	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
of	B-X
eukaryotic	B-X
cells	B-X
are	B-X
subject	B-X
to	B-X
continuous	B-X
oxidative	B-X
damage	B-X
resulting	B-X
from	B-X
normal	B-X
metabolic	B-X
activities	B-X
or	B-X
environmental	B-X
insults	B-X
.	B-X
Oxidative	B-X
DNA	B-X
damage	B-X
is	B-X
primarily	B-X
reversed	B-X
by	B-X
the	B-X
base	B-X
excision	B-X
repair	B-X
(	B-X
BER	B-X
)	B-X
pathway	B-X
,	B-X
initiated	B-X
by	B-X
N-glycosylase	B-X
apurinic/apyrimidinic	B-X
(	B-X
AP	B-X
)	B-X
lyase	B-X
proteins	B-X
.	B-X
To	B-X
execute	B-X
an	B-X
appropriate	B-X
repair	B-X
response	B-X
,	B-X
BER	B-X
components	B-X
must	B-X
be	B-X
distributed	B-X
to	B-X
accommodate	B-X
levels	B-X
of	B-X
genotoxic	B-X
stress	B-X
that	B-X
may	B-X
vary	B-X
considerably	B-X
between	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
depending	B-X
on	B-X
the	B-X
growth	B-X
state	B-X
and	B-X
stress	B-X
environment	B-X
of	B-X
the	B-X
cell	B-X
.	B-X
Numerous	B-X
examples	B-X
exist	B-X
where	B-X
cells	B-X
respond	B-X
to	B-X
signals	B-X
,	B-X
resulting	B-X
in	B-X
relocalization	B-X
of	B-X
proteins	B-X
involved	B-X
in	B-X
key	B-X
biological	B-X
transactions	B-X
.	B-X
To	B-X
address	B-X
whether	B-X
such	B-X
dynamic	B-X
localization	B-X
contributes	B-X
to	B-X
efficient	B-X
organelle-specific	B-X
DNA	B-X
repair	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
intracellular	B-X
localization	B-X
of	B-X
the	B-X
Saccharomyces	B-X
cerevisiae	B-X
N-glycosylase/AP	B-X
lyases	B-X
,	B-X
Ntg1	B-X
and	B-X
Ntg2	B-X
,	B-X
in	B-X
response	B-X
to	B-X
nuclear	B-X
and	B-X
mitochondrial	B-X
oxidative	B-X
stress	B-X
.	B-X
Fluorescence	B-X
microscopy	B-X
revealed	B-X
that	B-X
Ntg1	B-X
is	B-X
differentially	B-X
localized	B-X
to	B-X
nuclei	B-X
and	B-X
mitochondria	B-X
,	B-X
likely	B-X
in	B-X
response	B-X
to	B-X
the	B-X
oxidative	B-X
DNA	B-X
damage	B-X
status	B-X
of	B-X
the	B-X
organelle	B-X
.	B-X
Sumoylation	B-X
is	B-X
associated	B-X
with	B-X
targeting	B-X
of	B-X
Ntg1	B-X
to	B-X
nuclei	B-X
containing	B-X
oxidative	B-X
DNA	B-X
damage	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
trafficking	B-X
of	B-X
DNA	B-X
repair	B-X
proteins	B-X
to	B-X
organelles	B-X
containing	B-X
high	B-X
levels	B-X
of	B-X
oxidative	B-X
DNA	B-X
damage	B-X
may	B-X
be	B-X
a	B-X
central	B-X
point	B-X
for	B-X
regulating	B-X
BER	B-X
in	B-X
response	B-X
to	B-X
oxidative	B-X
stress	B-X
.	B-X

Lipid	O
-	O
mediated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
guides	O
thymocytes	O
to	O
the	O
CD4	B-Protein
lineage	O
.	O

Previous	O
studies	O
on	O
the	O
MHC	O
class	O
-	O
specific	O
differentiation	O
of	O
CD4	B-Protein
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
thymocytes	O
into	O
CD4	B-Protein
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
have	O
focused	O
on	O
the	O
role	O
of	O
coreceptor	O
molecules	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
on	B-X
the	B-X
MHC	B-X
class-specific	B-X
differentiation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
into	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
coreceptor	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
develop	B-X
according	B-X
to	B-X
their	B-X
MHC	B-X
class	B-X
specificities	B-X
even	B-X
in	B-X
these	B-X
mice	B-X
lacking	B-X
coreceptors	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
possibility	B-X
that	B-X
lineage	B-X
is	B-X
determined	B-X
not	B-X
only	B-X
by	B-X
coreceptors	B-X
,	B-X
but	B-X
is	B-X
also	B-X
guided	B-X
by	B-X
the	B-X
way	B-X
how	B-X
MHC	B-X
molecules	B-X
are	B-X
presented	B-X
.	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
possess	B-X
a	B-X
highly	B-X
conserved	B-X
Cys	B-X
in	B-X
their	B-X
transmembrane	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
palmitoylated	B-X
and	B-X
thereby	B-X
associates	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
whereas	B-X
neither	B-X
palmitoylation	B-X
nor	B-X
raft	B-X
association	B-X
was	B-X
observed	B-X
with	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
impaired	B-X
and	B-X
that	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
was	B-X
augmented	B-X
when	B-X
the	B-X
rafts	B-X
on	B-X
the	B-X
thymic	B-X
epithelial	B-X
cells	B-X
were	B-X
disrupted	B-X
.	B-X
This	B-X
was	B-X
due	B-X
to	B-X
the	B-X
conversion	B-X
of	B-X
MHC	B-X
class	B-X
II-specific	B-X
thymocytes	B-X
from	B-X
the	B-X
CD4	B-X
lineage	B-X
to	B-X
CD8	B-X
.	B-X
The	B-X
development	B-X
of	B-X
DO11.10	B-X
thymocytes	B-X
recognizing	B-X
this	B-X
mutant	B-X
I-A	B-X
(	B-X
dm	B-X
)	B-X
was	B-X
converted	B-X
from	B-X
CD4	B-X
to	B-X
CD8	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
CD4	B-X
lineage	B-X
commitment	B-X
is	B-X
directed	B-X
by	B-X
the	B-X
raft-associated	B-X
presentation	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
.	B-X

However	O
,	O
CD4	B-Protein
and	O
CD8	O
T	O
cells	O
develop	O
according	O
to	O
their	O
MHC	O
class	O
specificities	O
even	O
in	O
these	O
mice	O
lacking	O
coreceptors	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
on	B-X
the	B-X
MHC	B-X
class-specific	B-X
differentiation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
into	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
coreceptor	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
develop	B-X
according	B-X
to	B-X
their	B-X
MHC	B-X
class	B-X
specificities	B-X
even	B-X
in	B-X
these	B-X
mice	B-X
lacking	B-X
coreceptors	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
possibility	B-X
that	B-X
lineage	B-X
is	B-X
determined	B-X
not	B-X
only	B-X
by	B-X
coreceptors	B-X
,	B-X
but	B-X
is	B-X
also	B-X
guided	B-X
by	B-X
the	B-X
way	B-X
how	B-X
MHC	B-X
molecules	B-X
are	B-X
presented	B-X
.	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
possess	B-X
a	B-X
highly	B-X
conserved	B-X
Cys	B-X
in	B-X
their	B-X
transmembrane	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
palmitoylated	B-X
and	B-X
thereby	B-X
associates	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
whereas	B-X
neither	B-X
palmitoylation	B-X
nor	B-X
raft	B-X
association	B-X
was	B-X
observed	B-X
with	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
impaired	B-X
and	B-X
that	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
was	B-X
augmented	B-X
when	B-X
the	B-X
rafts	B-X
on	B-X
the	B-X
thymic	B-X
epithelial	B-X
cells	B-X
were	B-X
disrupted	B-X
.	B-X
This	B-X
was	B-X
due	B-X
to	B-X
the	B-X
conversion	B-X
of	B-X
MHC	B-X
class	B-X
II-specific	B-X
thymocytes	B-X
from	B-X
the	B-X
CD4	B-X
lineage	B-X
to	B-X
CD8	B-X
.	B-X
The	B-X
development	B-X
of	B-X
DO11.10	B-X
thymocytes	B-X
recognizing	B-X
this	B-X
mutant	B-X
I-A	B-X
(	B-X
dm	B-X
)	B-X
was	B-X
converted	B-X
from	B-X
CD4	B-X
to	B-X
CD8	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
CD4	B-X
lineage	B-X
commitment	B-X
is	B-X
directed	B-X
by	B-X
the	B-X
raft-associated	B-X
presentation	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
.	B-X

This	O
study	O
investigated	O
the	O
possibility	O
that	O
lineage	O
is	O
determined	O
not	O
only	O
by	O
coreceptors	O
,	O
but	O
is	O
also	O
guided	O
by	O
the	O
way	O
how	O
MHC	O
molecules	O
are	O
presented	O
.	O
<EOS>	B-X
MicroRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
small	B-X
noncoding	B-X
RNA	B-X
molecules	B-X
that	B-X
modulate	B-X
gene	B-X
expression	B-X
at	B-X
the	B-X
posttranscriptional	B-X
level	B-X
.	B-X
Very	B-X
recent	B-X
studies	B-X
reveal	B-X
that	B-X
several	B-X
miRNAs	B-X
are	B-X
highly	B-X
enriched	B-X
in	B-X
mature	B-X
EECs	B-X
and/or	B-X
in	B-X
intestinal	B-X
stem	B-X
cells	B-X
that	B-X
are	B-X
primed	B-X
to	B-X
the	B-X
EEC	B-X
lineage	B-X
.	B-X
Another	B-X
report	B-X
has	B-X
raised	B-X
the	B-X
possibility	B-X
that	B-X
EECs	B-X
secrete	B-X
miRNAs	B-X
into	B-X
circulation	B-X
.	B-X
When	B-X
using	B-X
genomic	B-X
data	B-X
to	B-X
study	B-X
the	B-X
Tree	B-X
of	B-X
Life	B-X
,	B-X
one	B-X
can	B-X
use	B-X
any	B-X
of	B-X
the	B-X
four	B-X
broad	B-X
approaches	B-X
:	B-X
(	B-X
i	B-X
)	B-X
build	B-X
lots	B-X
of	B-X
individual	B-X
gene	B-X
trees	B-X
(	B-X
``	B-X
phylogenomics	B-X
''	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
concatenate	B-X
genes	B-X
together	B-X
for	B-X
an	B-X
analysis	B-X
yielding	B-X
one	B-X
``	B-X
supergene	B-X
''	B-X
tree	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
form	B-X
a	B-X
single	B-X
tree	B-X
based	B-X
on	B-X
the	B-X
``	B-X
gene	B-X
content	B-X
''	B-X
within	B-X
genomes	B-X
using	B-X
either	B-X
orthologs	B-X
or	B-X
homologs	B-X
,	B-X
or	B-X
(	B-X
iv	B-X
)	B-X
investigate	B-X
the	B-X
order	B-X
of	B-X
genes	B-X
within	B-X
genomes	B-X
to	B-X
discern	B-X
some	B-X
aspects	B-X
of	B-X
microbial	B-X
evolution	B-X
.	B-X
The	B-X
application	B-X
of	B-X
whole	B-X
genome	B-X
tree	B-X
building	B-X
has	B-X
suggested	B-X
that	B-X
there	B-X
is	B-X
a	B-X
core	B-X
tree	B-X
,	B-X
that	B-X
such	B-X
a	B-X
core	B-X
tree	B-X
can	B-X
be	B-X
investigated	B-X
using	B-X
these	B-X
varied	B-X
methods	B-X
,	B-X
and	B-X
that	B-X
the	B-X
results	B-X
are	B-X
largely	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
rRNA	B-X
universal	B-X
Tree	B-X
of	B-X
Life	B-X
.	B-X
Some	B-X
of	B-X
the	B-X
most	B-X
interesting	B-X
features	B-X
of	B-X
the	B-X
rRNA	B-X
tree	B-X
,	B-X
such	B-X
as	B-X
early	B-X
diverging	B-X
hyperthermophilic	B-X
lineages	B-X
are	B-X
still	B-X
uncertain	B-X
,	B-X
but	B-X
remain	B-X
a	B-X
possibility	B-X
.	B-X
Genomic	B-X
trees	B-X
and	B-X
geologic	B-X
evidence	B-X
together	B-X
suggest	B-X
that	B-X
the	B-X
vertical	B-X
descent	B-X
of	B-X
genes	B-X
and	B-X
the	B-X
horizontal	B-X
transfer	B-X
of	B-X
genes	B-X
between	B-X
genetically	B-X
similar	B-X
lineages	B-X
ultimately	B-X
results	B-X
in	B-X
a	B-X
core	B-X
Tree	B-X
of	B-X
Life	B-X
with	B-X
at	B-X
least	B-X
some	B-X
lineages	B-X
that	B-X
have	B-X
phenotypic	B-X
characteristics	B-X
recognizable	B-X
for	B-X
billions	B-X
of	B-X
years	B-X
.	B-X

MHC	O
class	O
II	O
molecules	O
possess	O
a	O
highly	O
conserved	O
Cys	O
in	O
their	O
transmembrane	O
domain	O
,	O
which	O
is	O
palmitoylated	O
and	O
thereby	O
associates	O
with	O
lipid	O
rafts	O
,	O
whereas	O
neither	O
palmitoylation	O
nor	O
raft	O
association	O
was	O
observed	O
with	O
MHC	O
class	O
I	O
molecules	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
on	B-X
the	B-X
MHC	B-X
class-specific	B-X
differentiation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
into	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
coreceptor	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
develop	B-X
according	B-X
to	B-X
their	B-X
MHC	B-X
class	B-X
specificities	B-X
even	B-X
in	B-X
these	B-X
mice	B-X
lacking	B-X
coreceptors	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
possibility	B-X
that	B-X
lineage	B-X
is	B-X
determined	B-X
not	B-X
only	B-X
by	B-X
coreceptors	B-X
,	B-X
but	B-X
is	B-X
also	B-X
guided	B-X
by	B-X
the	B-X
way	B-X
how	B-X
MHC	B-X
molecules	B-X
are	B-X
presented	B-X
.	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
possess	B-X
a	B-X
highly	B-X
conserved	B-X
Cys	B-X
in	B-X
their	B-X
transmembrane	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
palmitoylated	B-X
and	B-X
thereby	B-X
associates	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
whereas	B-X
neither	B-X
palmitoylation	B-X
nor	B-X
raft	B-X
association	B-X
was	B-X
observed	B-X
with	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
impaired	B-X
and	B-X
that	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
was	B-X
augmented	B-X
when	B-X
the	B-X
rafts	B-X
on	B-X
the	B-X
thymic	B-X
epithelial	B-X
cells	B-X
were	B-X
disrupted	B-X
.	B-X
This	B-X
was	B-X
due	B-X
to	B-X
the	B-X
conversion	B-X
of	B-X
MHC	B-X
class	B-X
II-specific	B-X
thymocytes	B-X
from	B-X
the	B-X
CD4	B-X
lineage	B-X
to	B-X
CD8	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
I-A	B-X
(	B-X
d	B-X
)	B-X
molecule	B-X
to	B-X
associate	B-X
with	B-X
rafts	B-X
was	B-X
lost	B-X
when	B-X
its	B-X
transmembrane	B-X
Cys	B-X
was	B-X
replaced	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
CD4	B-X
lineage	B-X
commitment	B-X
is	B-X
directed	B-X
by	B-X
the	B-X
raft-associated	B-X
presentation	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
.	B-X

The	O
generation	O
of	O
CD4	B-Protein
T	O
cells	O
was	O
impaired	O
and	O
that	O
of	O
CD8	O
T	O
cells	O
was	O
augmented	O
when	O
the	O
rafts	O
on	O
the	O
thymic	O
epithelial	O
cells	O
were	O
disrupted	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
on	B-X
the	B-X
MHC	B-X
class-specific	B-X
differentiation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
into	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
coreceptor	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
develop	B-X
according	B-X
to	B-X
their	B-X
MHC	B-X
class	B-X
specificities	B-X
even	B-X
in	B-X
these	B-X
mice	B-X
lacking	B-X
coreceptors	B-X
.	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
possess	B-X
a	B-X
highly	B-X
conserved	B-X
Cys	B-X
in	B-X
their	B-X
transmembrane	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
palmitoylated	B-X
and	B-X
thereby	B-X
associates	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
whereas	B-X
neither	B-X
palmitoylation	B-X
nor	B-X
raft	B-X
association	B-X
was	B-X
observed	B-X
with	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
impaired	B-X
and	B-X
that	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
was	B-X
augmented	B-X
when	B-X
the	B-X
rafts	B-X
on	B-X
the	B-X
thymic	B-X
epithelial	B-X
cells	B-X
were	B-X
disrupted	B-X
.	B-X
This	B-X
was	B-X
due	B-X
to	B-X
the	B-X
conversion	B-X
of	B-X
MHC	B-X
class	B-X
II-specific	B-X
thymocytes	B-X
from	B-X
the	B-X
CD4	B-X
lineage	B-X
to	B-X
CD8	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
I-A	B-X
(	B-X
d	B-X
)	B-X
molecule	B-X
to	B-X
associate	B-X
with	B-X
rafts	B-X
was	B-X
lost	B-X
when	B-X
its	B-X
transmembrane	B-X
Cys	B-X
was	B-X
replaced	B-X
.	B-X
The	B-X
development	B-X
of	B-X
DO11.10	B-X
thymocytes	B-X
recognizing	B-X
this	B-X
mutant	B-X
I-A	B-X
(	B-X
dm	B-X
)	B-X
was	B-X
converted	B-X
from	B-X
CD4	B-X
to	B-X
CD8	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
CD4	B-X
lineage	B-X
commitment	B-X
is	B-X
directed	B-X
by	B-X
the	B-X
raft-associated	B-X
presentation	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
.	B-X

This	O
was	O
due	O
to	O
the	O
conversion	O
of	O
MHC	O
class	O
II	O
-	O
specific	O
thymocytes	O
from	O
the	O
CD4	B-Protein
lineage	O
to	O
CD8	O
.	O

The	O
ability	O
of	O
I	B-Protein
-	I-Protein
A	I-Protein
(	O
d	O
)	O
molecule	O
to	O
associate	O
with	O
rafts	O
was	O
lost	O
when	O
its	O
transmembrane	O
Cys	O
was	O
replaced	O
.	O

The	O
development	O
of	O
DO11	O
.	O
10	O
thymocytes	O
recognizing	O
this	O
mutant	O
I	B-Protein
-	I-Protein
A	I-Protein
(	O
dm	O
)	O
was	O
converted	O
from	O
CD4	B-Protein
to	O
CD8	O
.	O

These	O
results	O
suggest	O
that	O
the	O
CD4	B-Protein
lineage	O
commitment	O
is	O
directed	O
by	O
the	O
raft	O
-	O
associated	O
presentation	O
of	O
MHC	O
class	O
II	O
molecules	O
.	O
<EOS>	B-X
Previous	B-X
studies	B-X
on	B-X
the	B-X
MHC	B-X
class-specific	B-X
differentiation	B-X
of	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
thymocytes	B-X
into	B-X
CD4	B-X
(	B-X
+	B-X
)	B-X
and	B-X
CD8	B-X
(	B-X
+	B-X
)	B-X
T	B-X
cells	B-X
have	B-X
focused	B-X
on	B-X
the	B-X
role	B-X
of	B-X
coreceptor	B-X
molecules	B-X
.	B-X
However	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
develop	B-X
according	B-X
to	B-X
their	B-X
MHC	B-X
class	B-X
specificities	B-X
even	B-X
in	B-X
these	B-X
mice	B-X
lacking	B-X
coreceptors	B-X
.	B-X
This	B-X
study	B-X
investigated	B-X
the	B-X
possibility	B-X
that	B-X
lineage	B-X
is	B-X
determined	B-X
not	B-X
only	B-X
by	B-X
coreceptors	B-X
,	B-X
but	B-X
is	B-X
also	B-X
guided	B-X
by	B-X
the	B-X
way	B-X
how	B-X
MHC	B-X
molecules	B-X
are	B-X
presented	B-X
.	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
possess	B-X
a	B-X
highly	B-X
conserved	B-X
Cys	B-X
in	B-X
their	B-X
transmembrane	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
palmitoylated	B-X
and	B-X
thereby	B-X
associates	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
whereas	B-X
neither	B-X
palmitoylation	B-X
nor	B-X
raft	B-X
association	B-X
was	B-X
observed	B-X
with	B-X
MHC	B-X
class	B-X
I	B-X
molecules	B-X
.	B-X
The	B-X
generation	B-X
of	B-X
CD4	B-X
T	B-X
cells	B-X
was	B-X
impaired	B-X
and	B-X
that	B-X
of	B-X
CD8	B-X
T	B-X
cells	B-X
was	B-X
augmented	B-X
when	B-X
the	B-X
rafts	B-X
on	B-X
the	B-X
thymic	B-X
epithelial	B-X
cells	B-X
were	B-X
disrupted	B-X
.	B-X
This	B-X
was	B-X
due	B-X
to	B-X
the	B-X
conversion	B-X
of	B-X
MHC	B-X
class	B-X
II-specific	B-X
thymocytes	B-X
from	B-X
the	B-X
CD4	B-X
lineage	B-X
to	B-X
CD8	B-X
.	B-X
The	B-X
ability	B-X
of	B-X
I-A	B-X
(	B-X
d	B-X
)	B-X
molecule	B-X
to	B-X
associate	B-X
with	B-X
rafts	B-X
was	B-X
lost	B-X
when	B-X
its	B-X
transmembrane	B-X
Cys	B-X
was	B-X
replaced	B-X
.	B-X
The	B-X
development	B-X
of	B-X
DO11.10	B-X
thymocytes	B-X
recognizing	B-X
this	B-X
mutant	B-X
I-A	B-X
(	B-X
dm	B-X
)	B-X
was	B-X
converted	B-X
from	B-X
CD4	B-X
to	B-X
CD8	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
CD4	B-X
lineage	B-X
commitment	B-X
is	B-X
directed	B-X
by	B-X
the	B-X
raft-associated	B-X
presentation	B-X
of	B-X
MHC	B-X
class	B-X
II	B-X
molecules	B-X
.	B-X

Protein	O
acylation	O
and	O
localization	O
in	O
T	O
cell	O
signaling	O
(	O
Review	O
)	O
.	O

Many	O
proteins	O
with	O
pivotal	O
roles	O
in	O
T	O
cell	O
activation	O
are	O
modified	O
by	O
fatty	O
acylation	O
.	O

Examples	O
of	O
these	O
include	O
transmembrane	O
proteins	O
such	O
as	O
the	O
co	O
-	O
receptors	O
CD4	B-Protein
and	O
CD8	O
,	O
the	O
adaptors	O
LAT	B-Protein
and	O
Cbp	B-Protein
/	O
PAG	B-Protein
,	O
the	O
pre	O
-	O
TCR	O
as	O
well	O
as	O
proteins	O
synthesized	O
on	O
free	O
cytosolic	O
ribosomes	O
,	O
such	O
as	O
the	O
Src	O
-	O
related	O
tyrosine	O
kinases	O
Lck	B-Protein
and	O
Fyn	B-Protein
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
The	B-X
two	B-X
main	B-X
types	B-X
of	B-X
fatty	B-X
acylations	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
N-myristoylation	B-X
and	B-X
S-acylation	B-X
,	B-X
the	B-X
latter	B-X
being	B-X
more	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
palmitoylation	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

The	O
two	O
main	O
types	O
of	O
fatty	O
acylations	O
in	O
eukaryotic	O
cells	O
are	O
N	O
-	O
myristoylation	O
and	O
S	O
-	O
acylation	O
,	O
the	O
latter	O
being	O
more	O
commonly	O
referred	O
to	O
as	O
palmitoylation	O
.	O

N	O
-	O
Myristoylation	O
occurs	O
exclusively	O
on	O
proteins	O
synthesized	O
on	O
soluble	O
ribosomes	O
and	O
provides	O
substrates	O
with	O
an	O
affinity	O
for	O
membranes	O
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
The	B-X
two	B-X
main	B-X
types	B-X
of	B-X
fatty	B-X
acylations	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
N-myristoylation	B-X
and	B-X
S-acylation	B-X
,	B-X
the	B-X
latter	B-X
being	B-X
more	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
palmitoylation	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

Palmitoylation	O
modifies	O
a	O
wide	O
range	O
of	O
substrates	O
that	O
includes	O
both	O
cytosolic	O
and	O
transmembrane	O
proteins	O
,	O
its	O
functions	O
are	O
diverse	O
and	O
in	O
many	O
cases	O
not	O
yet	O
understood	O
.	O

Like	O
myristoylation	O
,	O
palmitoylation	O
promotes	O
membrane	O
-	O
binding	O
of	O
cytosolic	O
proteins	O
,	O
but	O
it	O
has	O
also	O
been	O
implicated	O
in	O
protein	O
targeting	O
,	O
trafficking	O
,	O
stability	O
and	O
activity	O
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
The	B-X
two	B-X
main	B-X
types	B-X
of	B-X
fatty	B-X
acylations	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
N-myristoylation	B-X
and	B-X
S-acylation	B-X
,	B-X
the	B-X
latter	B-X
being	B-X
more	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
palmitoylation	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

In	O
addition	O
,	O
many	O
palmitoylated	O
proteins	O
are	O
insoluble	O
in	O
cold	O
non	O
-	O
ionic	O
detergent	O
,	O
and	O
have	O
therefore	O
been	O
proposed	O
to	O
localize	O
to	O
lipid	O
rafts	O
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

The	O
organization	O
of	O
receptors	O
and	O
signaling	O
proteins	O
into	O
microdomains	O
such	O
as	O
lipid	O
rafts	O
provides	O
an	O
attractive	O
model	O
for	O
the	O
initiation	O
and	O
propagation	O
of	O
T	O
cell	O
signaling	O
,	O
although	O
many	O
aspects	O
of	O
this	O
are	O
still	O
poorly	O
understood	O
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
The	B-X
two	B-X
main	B-X
types	B-X
of	B-X
fatty	B-X
acylations	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
N-myristoylation	B-X
and	B-X
S-acylation	B-X
,	B-X
the	B-X
latter	B-X
being	B-X
more	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
palmitoylation	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

This	O
review	O
will	O
discuss	O
the	O
current	O
evidence	O
for	O
the	O
involvement	O
of	O
acylations	O
in	O
the	O
localizations	O
and	O
functions	O
of	O
T	O
cell	O
signaling	O
proteins	O
.	O
<EOS>	B-X
Many	B-X
proteins	B-X
with	B-X
pivotal	B-X
roles	B-X
in	B-X
T	B-X
cell	B-X
activation	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
.	B-X
Examples	B-X
of	B-X
these	B-X
include	B-X
transmembrane	B-X
proteins	B-X
such	B-X
as	B-X
the	B-X
co-receptors	B-X
CD4	B-X
and	B-X
CD8	B-X
,	B-X
the	B-X
adaptors	B-X
LAT	B-X
and	B-X
Cbp/PAG	B-X
,	B-X
the	B-X
pre-TCR	B-X
as	B-X
well	B-X
as	B-X
proteins	B-X
synthesized	B-X
on	B-X
free	B-X
cytosolic	B-X
ribosomes	B-X
,	B-X
such	B-X
as	B-X
the	B-X
Src-related	B-X
tyrosine	B-X
kinases	B-X
Lck	B-X
and	B-X
Fyn	B-X
.	B-X
The	B-X
two	B-X
main	B-X
types	B-X
of	B-X
fatty	B-X
acylations	B-X
in	B-X
eukaryotic	B-X
cells	B-X
are	B-X
N-myristoylation	B-X
and	B-X
S-acylation	B-X
,	B-X
the	B-X
latter	B-X
being	B-X
more	B-X
commonly	B-X
referred	B-X
to	B-X
as	B-X
palmitoylation	B-X
.	B-X
N-Myristoylation	B-X
occurs	B-X
exclusively	B-X
on	B-X
proteins	B-X
synthesized	B-X
on	B-X
soluble	B-X
ribosomes	B-X
and	B-X
provides	B-X
substrates	B-X
with	B-X
an	B-X
affinity	B-X
for	B-X
membranes	B-X
.	B-X
Palmitoylation	B-X
modifies	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
substrates	B-X
that	B-X
includes	B-X
both	B-X
cytosolic	B-X
and	B-X
transmembrane	B-X
proteins	B-X
,	B-X
its	B-X
functions	B-X
are	B-X
diverse	B-X
and	B-X
in	B-X
many	B-X
cases	B-X
not	B-X
yet	B-X
understood	B-X
.	B-X
Like	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
promotes	B-X
membrane-binding	B-X
of	B-X
cytosolic	B-X
proteins	B-X
,	B-X
but	B-X
it	B-X
has	B-X
also	B-X
been	B-X
implicated	B-X
in	B-X
protein	B-X
targeting	B-X
,	B-X
trafficking	B-X
,	B-X
stability	B-X
and	B-X
activity	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
many	B-X
palmitoylated	B-X
proteins	B-X
are	B-X
insoluble	B-X
in	B-X
cold	B-X
non-ionic	B-X
detergent	B-X
,	B-X
and	B-X
have	B-X
therefore	B-X
been	B-X
proposed	B-X
to	B-X
localize	B-X
to	B-X
lipid	B-X
rafts	B-X
.	B-X
The	B-X
organization	B-X
of	B-X
receptors	B-X
and	B-X
signaling	B-X
proteins	B-X
into	B-X
microdomains	B-X
such	B-X
as	B-X
lipid	B-X
rafts	B-X
provides	B-X
an	B-X
attractive	B-X
model	B-X
for	B-X
the	B-X
initiation	B-X
and	B-X
propagation	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
,	B-X
although	B-X
many	B-X
aspects	B-X
of	B-X
this	B-X
are	B-X
still	B-X
poorly	B-X
understood	B-X
.	B-X
This	B-X
review	B-X
will	B-X
discuss	B-X
the	B-X
current	B-X
evidence	B-X
for	B-X
the	B-X
involvement	B-X
of	B-X
acylations	B-X
in	B-X
the	B-X
localizations	B-X
and	B-X
functions	B-X
of	B-X
T	B-X
cell	B-X
signaling	B-X
proteins	B-X
.	B-X

Palmitoylation	O
modification	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
depresses	O
its	O
susceptibility	O
to	O
GAP	B-Protein
-	I-Protein
43	I-Protein
activation	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
GAP-43	B-X
(	B-X
growth	B-X
associated	B-X
protein-43	B-X
)	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
(	B-X
alpha	B-X
subunit	B-X
of	B-X
Go	B-X
protein	B-X
)	B-X
influences	B-X
the	B-X
signal	B-X
transduction	B-X
pathways	B-X
leading	B-X
to	B-X
differentiation	B-X
of	B-X
neural	B-X
cells	B-X
.	B-X
GAP-43	B-X
is	B-X
known	B-X
to	B-X
increase	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
by	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
major	B-X
component	B-X
of	B-X
neuronal	B-X
growth	B-X
cone	B-X
membranes	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
GAP-43	B-X
stimulation	B-X
is	B-X
related	B-X
to	B-X
the	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
palmitoylation	B-X
or	B-X
the	B-X
conversion	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligmers	B-X
to	B-X
monomers	B-X
,	B-X
which	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
necessary	B-X
regulatory	B-X
factor	B-X
in	B-X
GDP/GTP	B-X
exchange	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
expressed	B-X
and	B-X
purified	B-X
GAP-43	B-X
,	B-X
GST-GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
proteins	B-X
,	B-X
detected	B-X
their	B-X
stimulatory	B-X
effect	B-X
on	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
-GTPgammaS	B-X
binding	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
EC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
both	B-X
GAP-43	B-X
and	B-X
GST-GAP-43	B-X
activation	B-X
were	B-X
tenfold	B-X
lower	B-X
in	B-X
case	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
than	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Non-denaturing	B-X
gel	B-X
electrophoresis	B-X
and	B-X
p-PDM	B-X
cross-linking	B-X
analysis	B-X
revealed	B-X
that	B-X
addition	B-X
of	B-X
GST-GAP-43	B-X
induced	B-X
disassociation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
but	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
oligomeric	B-X
state	B-X
of	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
palmitoylation	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
factor	B-X
in	B-X
GAP-43	B-X
stimulation	B-X
on	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
the	B-X
interaction	B-X
of	B-X
GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
could	B-X
accelerate	B-X
conversion	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
but	B-X
not	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
so	B-X
as	B-X
to	B-X
increase	B-X
the	B-X
GTPgammaS	B-X
binding	B-X
activity	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Results	B-X
here	B-X
provide	B-X
new	B-X
evidence	B-X
about	B-X
how	B-X
signaling	B-X
protein	B-X
palmitoylation	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
G-protein-coupled	B-X
signal	B-X
transduction	B-X
cascade	B-X
,	B-X
and	B-X
give	B-X
a	B-X
useful	B-X
clue	B-X
on	B-X
the	B-X
participation	B-X
of	B-X
GAP-43	B-X
in	B-X
G-protein	B-X
cycle	B-X
by	B-X
its	B-X
preferential	B-X
activation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X

Interaction	O
between	O
GAP	B-Protein
-	I-Protein
43	I-Protein
(	O
growth	B-Protein
associated	I-Protein
protein	I-Protein
-	I-Protein
43	I-Protein
)	O
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
(	O
alpha	O
subunit	O
of	O
Go	O
protein	O
)	O
influences	O
the	O
signal	O
transduction	O
pathways	O
leading	O
to	O
differentiation	O
of	O
neural	O
cells	O
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
GAP-43	B-X
(	B-X
growth	B-X
associated	B-X
protein-43	B-X
)	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
(	B-X
alpha	B-X
subunit	B-X
of	B-X
Go	B-X
protein	B-X
)	B-X
influences	B-X
the	B-X
signal	B-X
transduction	B-X
pathways	B-X
leading	B-X
to	B-X
differentiation	B-X
of	B-X
neural	B-X
cells	B-X
.	B-X
GAP-43	B-X
is	B-X
known	B-X
to	B-X
increase	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
by	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
major	B-X
component	B-X
of	B-X
neuronal	B-X
growth	B-X
cone	B-X
membranes	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
GAP-43	B-X
stimulation	B-X
is	B-X
related	B-X
to	B-X
the	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
palmitoylation	B-X
or	B-X
the	B-X
conversion	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligmers	B-X
to	B-X
monomers	B-X
,	B-X
which	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
necessary	B-X
regulatory	B-X
factor	B-X
in	B-X
GDP/GTP	B-X
exchange	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
expressed	B-X
and	B-X
purified	B-X
GAP-43	B-X
,	B-X
GST-GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
proteins	B-X
,	B-X
detected	B-X
their	B-X
stimulatory	B-X
effect	B-X
on	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
-GTPgammaS	B-X
binding	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
EC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
both	B-X
GAP-43	B-X
and	B-X
GST-GAP-43	B-X
activation	B-X
were	B-X
tenfold	B-X
lower	B-X
in	B-X
case	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
than	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Non-denaturing	B-X
gel	B-X
electrophoresis	B-X
and	B-X
p-PDM	B-X
cross-linking	B-X
analysis	B-X
revealed	B-X
that	B-X
addition	B-X
of	B-X
GST-GAP-43	B-X
induced	B-X
disassociation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
but	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
oligomeric	B-X
state	B-X
of	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
palmitoylation	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
factor	B-X
in	B-X
GAP-43	B-X
stimulation	B-X
on	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
the	B-X
interaction	B-X
of	B-X
GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
could	B-X
accelerate	B-X
conversion	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
but	B-X
not	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
so	B-X
as	B-X
to	B-X
increase	B-X
the	B-X
GTPgammaS	B-X
binding	B-X
activity	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Results	B-X
here	B-X
provide	B-X
new	B-X
evidence	B-X
about	B-X
how	B-X
signaling	B-X
protein	B-X
palmitoylation	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
G-protein-coupled	B-X
signal	B-X
transduction	B-X
cascade	B-X
,	B-X
and	B-X
give	B-X
a	B-X
useful	B-X
clue	B-X
on	B-X
the	B-X
participation	B-X
of	B-X
GAP-43	B-X
in	B-X
G-protein	B-X
cycle	B-X
by	B-X
its	B-X
preferential	B-X
activation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X

GAP	B-Protein
-	I-Protein
43	I-Protein
is	O
known	O
to	O
increase	O
guanine	O
nucleotide	O
exchange	O
by	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
,	O
which	O
is	O
a	O
major	O
component	O
of	O
neuronal	O
growth	O
cone	O
membranes	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
GAP	B-Protein
-	I-Protein
43	I-Protein
stimulation	O
is	O
related	O
to	O
the	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
palmitoylation	O
or	O
the	O
conversion	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligmers	O
to	O
monomers	O
,	O
which	O
was	O
shown	O
to	O
be	O
a	O
necessary	O
regulatory	O
factor	O
in	O
GDP	O
/	O
GTP	O
exchange	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O
<EOS>	B-X
Interaction	B-X
between	B-X
GAP-43	B-X
(	B-X
growth	B-X
associated	B-X
protein-43	B-X
)	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
(	B-X
alpha	B-X
subunit	B-X
of	B-X
Go	B-X
protein	B-X
)	B-X
influences	B-X
the	B-X
signal	B-X
transduction	B-X
pathways	B-X
leading	B-X
to	B-X
differentiation	B-X
of	B-X
neural	B-X
cells	B-X
.	B-X
GAP-43	B-X
is	B-X
known	B-X
to	B-X
increase	B-X
guanine	B-X
nucleotide	B-X
exchange	B-X
by	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
is	B-X
a	B-X
major	B-X
component	B-X
of	B-X
neuronal	B-X
growth	B-X
cone	B-X
membranes	B-X
.	B-X
However	B-X
,	B-X
it	B-X
is	B-X
not	B-X
clear	B-X
whether	B-X
GAP-43	B-X
stimulation	B-X
is	B-X
related	B-X
to	B-X
the	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
palmitoylation	B-X
or	B-X
the	B-X
conversion	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligmers	B-X
to	B-X
monomers	B-X
,	B-X
which	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
a	B-X
necessary	B-X
regulatory	B-X
factor	B-X
in	B-X
GDP/GTP	B-X
exchange	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Here	B-X
we	B-X
expressed	B-X
and	B-X
purified	B-X
GAP-43	B-X
,	B-X
GST-GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
proteins	B-X
,	B-X
detected	B-X
their	B-X
stimulatory	B-X
effect	B-X
on	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
-GTPgammaS	B-X
binding	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
the	B-X
EC	B-X
(	B-X
50	B-X
)	B-X
of	B-X
both	B-X
GAP-43	B-X
and	B-X
GST-GAP-43	B-X
activation	B-X
were	B-X
tenfold	B-X
lower	B-X
in	B-X
case	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
than	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Non-denaturing	B-X
gel	B-X
electrophoresis	B-X
and	B-X
p-PDM	B-X
cross-linking	B-X
analysis	B-X
revealed	B-X
that	B-X
addition	B-X
of	B-X
GST-GAP-43	B-X
induced	B-X
disassociation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
but	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
oligomeric	B-X
state	B-X
of	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
,	B-X
which	B-X
suggests	B-X
that	B-X
palmitoylation	B-X
is	B-X
a	B-X
key	B-X
regulatory	B-X
factor	B-X
in	B-X
GAP-43	B-X
stimulation	B-X
on	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
These	B-X
results	B-X
indicated	B-X
the	B-X
interaction	B-X
of	B-X
GAP-43	B-X
and	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
could	B-X
accelerate	B-X
conversion	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
but	B-X
not	B-X
palmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
from	B-X
oligomers	B-X
to	B-X
monomers	B-X
,	B-X
so	B-X
as	B-X
to	B-X
increase	B-X
the	B-X
GTPgammaS	B-X
binding	B-X
activity	B-X
of	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X
Results	B-X
here	B-X
provide	B-X
new	B-X
evidence	B-X
about	B-X
how	B-X
signaling	B-X
protein	B-X
palmitoylation	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
G-protein-coupled	B-X
signal	B-X
transduction	B-X
cascade	B-X
,	B-X
and	B-X
give	B-X
a	B-X
useful	B-X
clue	B-X
on	B-X
the	B-X
participation	B-X
of	B-X
GAP-43	B-X
in	B-X
G-protein	B-X
cycle	B-X
by	B-X
its	B-X
preferential	B-X
activation	B-X
of	B-X
depalmitoylated	B-X
Galpha	B-X
(	B-X
o	B-X
)	B-X
.	B-X

Here	O
we	O
expressed	O
and	O
purified	O
GAP	B-Protein
-	I-Protein
43	I-Protein
,	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
proteins	O
,	O
detected	O
their	O
stimulatory	O
effect	O
on	O
[	O
(	O
35	O
)	O
S	O
]	O
-	O
GTPgammaS	O
binding	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

It	O
was	O
found	O
that	O
the	O
EC	O
(	O
50	O
)	O
of	O
both	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
activation	O
were	O
tenfold	O
lower	O
in	O
case	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
than	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Non	O
-	O
denaturing	O
gel	O
electrophoresis	O
and	O
p	O
-	O
PDM	O
cross	O
-	O
linking	O
analysis	O
revealed	O
that	O
addition	O
of	O
GST	B-Protein
-	O
GAP	B-Protein
-	I-Protein
43	I-Protein
induced	O
disassociation	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligomers	O
to	O
monomers	O
,	O
but	O
did	O
not	O
influence	O
the	O
oligomeric	O
state	O
of	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
,	O
which	O
suggests	O
that	O
palmitoylation	O
is	O
a	O
key	O
regulatory	O
factor	O
in	O
GAP	B-Protein
-	I-Protein
43	I-Protein
stimulation	O
on	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

These	O
results	O
indicated	O
the	O
interaction	O
of	O
GAP	B-Protein
-	I-Protein
43	I-Protein
and	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
could	O
accelerate	O
conversion	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
but	O
not	O
palmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
from	O
oligomers	O
to	O
monomers	O
,	O
so	O
as	O
to	O
increase	O
the	O
GTPgammaS	O
binding	O
activity	O
of	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Results	O
here	O
provide	O
new	O
evidence	O
about	O
how	O
signaling	O
protein	O
palmitoylation	O
is	O
involved	O
in	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
signal	O
transduction	O
cascade	O
,	O
and	O
give	O
a	O
useful	O
clue	O
on	O
the	O
participation	O
of	O
GAP	B-Protein
-	I-Protein
43	I-Protein
in	O
G	O
-	O
protein	O
cycle	O
by	O
its	O
preferential	O
activation	O
of	O
depalmitoylated	O
Galpha	B-Protein
(	I-Protein
o	I-Protein
)	I-Protein
.	O

Identification	O
of	O
a	O
palmitoyl	O
acyltransferase	O
required	O
for	O
protein	O
sorting	O
to	O
the	O
flagellar	O
membrane	O
.	O

Protein	O
palmitoylation	O
has	O
diverse	O
effects	O
in	O
regulating	O
protein	O
membrane	O
affinity	O
,	O
localization	O
,	O
binding	O
partner	O
interactions	O
,	O
turnover	O
and	O
function	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
regulating	B-X
protein	B-X
membrane	B-X
affinity	B-X
,	B-X
localization	B-X
,	B-X
binding	B-X
partner	B-X
interactions	B-X
,	B-X
turnover	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
sorting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
eukaryotic	B-X
flagellum	B-X
.	B-X
African	B-X
trypanosomes	B-X
are	B-X
protozoan	B-X
pathogens	B-X
that	B-X
express	B-X
a	B-X
family	B-X
of	B-X
unique	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
the	B-X
calflagins	B-X
,	B-X
which	B-X
undergo	B-X
N-terminal	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
calflagins	B-X
depends	B-X
on	B-X
their	B-X
acylation	B-X
status	B-X
.	B-X
Myristoylation	B-X
alone	B-X
is	B-X
sufficient	B-X
for	B-X
membrane	B-X
association	B-X
,	B-X
but	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
palmitoylation	B-X
,	B-X
the	B-X
calflagins	B-X
localize	B-X
to	B-X
the	B-X
pellicular	B-X
(	B-X
cell	B-X
body	B-X
)	B-X
membrane	B-X
.	B-X
Palmitoylation	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
specific	B-X
palmitoyl	B-X
acyltransferase	B-X
,	B-X
is	B-X
then	B-X
required	B-X
for	B-X
subsequent	B-X
trafficking	B-X
of	B-X
calflagin	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Coincident	B-X
with	B-X
the	B-X
redistribution	B-X
of	B-X
calflagin	B-X
from	B-X
the	B-X
pellicular	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
is	B-X
their	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
which	B-X
are	B-X
highly	B-X
enriched	B-X
in	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Screening	B-X
of	B-X
candidate	B-X
palmitoyl	B-X
acyltranferases	B-X
identified	B-X
a	B-X
single	B-X
enzyme	B-X
,	B-X
TbPAT7	B-X
,	B-X
that	B-X
is	B-X
necessary	B-X
for	B-X
calflagin	B-X
palmitoylation	B-X
and	B-X
flagellar	B-X
membrane	B-X
targeting	B-X
.	B-X
Our	B-X
results	B-X
implicate	B-X
protein	B-X
palmitoylation	B-X
in	B-X
flagellar	B-X
trafficking	B-X
,	B-X
and	B-X
demonstrate	B-X
the	B-X
conservation	B-X
and	B-X
specificity	B-X
of	B-X
palmitoyl	B-X
acyltransferase	B-X
activity	B-X
by	B-X
DHHC-CRD	B-X
proteins	B-X
across	B-X
kingdoms	B-X
.	B-X

Here	O
,	O
we	O
show	O
that	O
palmitoylation	O
also	O
contributes	O
to	O
the	O
sorting	O
of	O
proteins	O
to	O
the	O
eukaryotic	O
flagellum	O
.	O

African	O
trypanosomes	O
are	O
protozoan	O
pathogens	O
that	O
express	O
a	O
family	O
of	O
unique	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
proteins	O
,	O
the	O
calflagins	O
,	O
which	O
undergo	O
N	O
-	O
terminal	O
myristoylation	O
and	O
palmitoylation	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
regulating	B-X
protein	B-X
membrane	B-X
affinity	B-X
,	B-X
localization	B-X
,	B-X
binding	B-X
partner	B-X
interactions	B-X
,	B-X
turnover	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
sorting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
eukaryotic	B-X
flagellum	B-X
.	B-X
African	B-X
trypanosomes	B-X
are	B-X
protozoan	B-X
pathogens	B-X
that	B-X
express	B-X
a	B-X
family	B-X
of	B-X
unique	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
the	B-X
calflagins	B-X
,	B-X
which	B-X
undergo	B-X
N-terminal	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
calflagins	B-X
depends	B-X
on	B-X
their	B-X
acylation	B-X
status	B-X
.	B-X
Myristoylation	B-X
alone	B-X
is	B-X
sufficient	B-X
for	B-X
membrane	B-X
association	B-X
,	B-X
but	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
palmitoylation	B-X
,	B-X
the	B-X
calflagins	B-X
localize	B-X
to	B-X
the	B-X
pellicular	B-X
(	B-X
cell	B-X
body	B-X
)	B-X
membrane	B-X
.	B-X
Screening	B-X
of	B-X
candidate	B-X
palmitoyl	B-X
acyltranferases	B-X
identified	B-X
a	B-X
single	B-X
enzyme	B-X
,	B-X
TbPAT7	B-X
,	B-X
that	B-X
is	B-X
necessary	B-X
for	B-X
calflagin	B-X
palmitoylation	B-X
and	B-X
flagellar	B-X
membrane	B-X
targeting	B-X
.	B-X
Our	B-X
results	B-X
implicate	B-X
protein	B-X
palmitoylation	B-X
in	B-X
flagellar	B-X
trafficking	B-X
,	B-X
and	B-X
demonstrate	B-X
the	B-X
conservation	B-X
and	B-X
specificity	B-X
of	B-X
palmitoyl	B-X
acyltransferase	B-X
activity	B-X
by	B-X
DHHC-CRD	B-X
proteins	B-X
across	B-X
kingdoms	B-X
.	B-X

The	O
localization	O
of	O
calflagins	O
depends	O
on	O
their	O
acylation	O
status	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
regulating	B-X
protein	B-X
membrane	B-X
affinity	B-X
,	B-X
localization	B-X
,	B-X
binding	B-X
partner	B-X
interactions	B-X
,	B-X
turnover	B-X
and	B-X
function	B-X
.	B-X
African	B-X
trypanosomes	B-X
are	B-X
protozoan	B-X
pathogens	B-X
that	B-X
express	B-X
a	B-X
family	B-X
of	B-X
unique	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
the	B-X
calflagins	B-X
,	B-X
which	B-X
undergo	B-X
N-terminal	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
calflagins	B-X
depends	B-X
on	B-X
their	B-X
acylation	B-X
status	B-X
.	B-X
Myristoylation	B-X
alone	B-X
is	B-X
sufficient	B-X
for	B-X
membrane	B-X
association	B-X
,	B-X
but	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
palmitoylation	B-X
,	B-X
the	B-X
calflagins	B-X
localize	B-X
to	B-X
the	B-X
pellicular	B-X
(	B-X
cell	B-X
body	B-X
)	B-X
membrane	B-X
.	B-X

Myristoylation	O
alone	O
is	O
sufficient	O
for	O
membrane	O
association	O
,	O
but	O
,	O
in	O
the	O
absence	O
of	O
palmitoylation	O
,	O
the	O
calflagins	O
localize	O
to	O
the	O
pellicular	O
(	O
cell	O
body	O
)	O
membrane	O
.	O

Palmitoylation	O
,	O
which	O
is	O
mediated	O
by	O
a	O
specific	O
palmitoyl	O
acyltransferase	O
,	O
is	O
then	O
required	O
for	O
subsequent	O
trafficking	O
of	O
calflagin	O
to	O
the	O
flagellar	O
membrane	O
.	O

Coincident	O
with	O
the	O
redistribution	O
of	O
calflagin	O
from	O
the	O
pellicular	O
to	O
the	O
flagellar	O
membrane	O
is	O
their	O
association	O
with	O
lipid	O
rafts	O
,	O
which	O
are	O
highly	O
enriched	O
in	O
the	O
flagellar	O
membrane	O
.	O

Screening	O
of	O
candidate	O
palmitoyl	O
acyltranferases	O
identified	O
a	O
single	O
enzyme	O
,	O
TbPAT7	B-Protein
,	O
that	O
is	O
necessary	O
for	O
calflagin	O
palmitoylation	O
and	O
flagellar	O
membrane	O
targeting	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
regulating	B-X
protein	B-X
membrane	B-X
affinity	B-X
,	B-X
localization	B-X
,	B-X
binding	B-X
partner	B-X
interactions	B-X
,	B-X
turnover	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
sorting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
eukaryotic	B-X
flagellum	B-X
.	B-X
African	B-X
trypanosomes	B-X
are	B-X
protozoan	B-X
pathogens	B-X
that	B-X
express	B-X
a	B-X
family	B-X
of	B-X
unique	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
the	B-X
calflagins	B-X
,	B-X
which	B-X
undergo	B-X
N-terminal	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
The	B-X
localization	B-X
of	B-X
calflagins	B-X
depends	B-X
on	B-X
their	B-X
acylation	B-X
status	B-X
.	B-X
Myristoylation	B-X
alone	B-X
is	B-X
sufficient	B-X
for	B-X
membrane	B-X
association	B-X
,	B-X
but	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
palmitoylation	B-X
,	B-X
the	B-X
calflagins	B-X
localize	B-X
to	B-X
the	B-X
pellicular	B-X
(	B-X
cell	B-X
body	B-X
)	B-X
membrane	B-X
.	B-X
Palmitoylation	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
specific	B-X
palmitoyl	B-X
acyltransferase	B-X
,	B-X
is	B-X
then	B-X
required	B-X
for	B-X
subsequent	B-X
trafficking	B-X
of	B-X
calflagin	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Coincident	B-X
with	B-X
the	B-X
redistribution	B-X
of	B-X
calflagin	B-X
from	B-X
the	B-X
pellicular	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
is	B-X
their	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
which	B-X
are	B-X
highly	B-X
enriched	B-X
in	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Screening	B-X
of	B-X
candidate	B-X
palmitoyl	B-X
acyltranferases	B-X
identified	B-X
a	B-X
single	B-X
enzyme	B-X
,	B-X
TbPAT7	B-X
,	B-X
that	B-X
is	B-X
necessary	B-X
for	B-X
calflagin	B-X
palmitoylation	B-X
and	B-X
flagellar	B-X
membrane	B-X
targeting	B-X
.	B-X
Our	B-X
results	B-X
implicate	B-X
protein	B-X
palmitoylation	B-X
in	B-X
flagellar	B-X
trafficking	B-X
,	B-X
and	B-X
demonstrate	B-X
the	B-X
conservation	B-X
and	B-X
specificity	B-X
of	B-X
palmitoyl	B-X
acyltransferase	B-X
activity	B-X
by	B-X
DHHC-CRD	B-X
proteins	B-X
across	B-X
kingdoms	B-X
.	B-X

Our	O
results	O
implicate	O
protein	O
palmitoylation	O
in	O
flagellar	O
trafficking	O
,	O
and	O
demonstrate	O
the	O
conservation	O
and	O
specificity	O
of	O
palmitoyl	O
acyltransferase	O
activity	O
by	O
DHHC	O
-	O
CRD	O
proteins	O
across	O
kingdoms	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
has	B-X
diverse	B-X
effects	B-X
in	B-X
regulating	B-X
protein	B-X
membrane	B-X
affinity	B-X
,	B-X
localization	B-X
,	B-X
binding	B-X
partner	B-X
interactions	B-X
,	B-X
turnover	B-X
and	B-X
function	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
palmitoylation	B-X
also	B-X
contributes	B-X
to	B-X
the	B-X
sorting	B-X
of	B-X
proteins	B-X
to	B-X
the	B-X
eukaryotic	B-X
flagellum	B-X
.	B-X
African	B-X
trypanosomes	B-X
are	B-X
protozoan	B-X
pathogens	B-X
that	B-X
express	B-X
a	B-X
family	B-X
of	B-X
unique	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-binding	B-X
proteins	B-X
,	B-X
the	B-X
calflagins	B-X
,	B-X
which	B-X
undergo	B-X
N-terminal	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Myristoylation	B-X
alone	B-X
is	B-X
sufficient	B-X
for	B-X
membrane	B-X
association	B-X
,	B-X
but	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
palmitoylation	B-X
,	B-X
the	B-X
calflagins	B-X
localize	B-X
to	B-X
the	B-X
pellicular	B-X
(	B-X
cell	B-X
body	B-X
)	B-X
membrane	B-X
.	B-X
Palmitoylation	B-X
,	B-X
which	B-X
is	B-X
mediated	B-X
by	B-X
a	B-X
specific	B-X
palmitoyl	B-X
acyltransferase	B-X
,	B-X
is	B-X
then	B-X
required	B-X
for	B-X
subsequent	B-X
trafficking	B-X
of	B-X
calflagin	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Coincident	B-X
with	B-X
the	B-X
redistribution	B-X
of	B-X
calflagin	B-X
from	B-X
the	B-X
pellicular	B-X
to	B-X
the	B-X
flagellar	B-X
membrane	B-X
is	B-X
their	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
,	B-X
which	B-X
are	B-X
highly	B-X
enriched	B-X
in	B-X
the	B-X
flagellar	B-X
membrane	B-X
.	B-X
Screening	B-X
of	B-X
candidate	B-X
palmitoyl	B-X
acyltranferases	B-X
identified	B-X
a	B-X
single	B-X
enzyme	B-X
,	B-X
TbPAT7	B-X
,	B-X
that	B-X
is	B-X
necessary	B-X
for	B-X
calflagin	B-X
palmitoylation	B-X
and	B-X
flagellar	B-X
membrane	B-X
targeting	B-X
.	B-X
Our	B-X
results	B-X
implicate	B-X
protein	B-X
palmitoylation	B-X
in	B-X
flagellar	B-X
trafficking	B-X
,	B-X
and	B-X
demonstrate	B-X
the	B-X
conservation	B-X
and	B-X
specificity	B-X
of	B-X
palmitoyl	B-X
acyltransferase	B-X
activity	B-X
by	B-X
DHHC-CRD	B-X
proteins	B-X
across	B-X
kingdoms	B-X
.	B-X

Mutation	O
of	O
juxtamembrane	O
cysteines	O
in	O
the	O
tetraspanin	O
CD81	B-Protein
affects	O
palmitoylation	O
and	O
alters	O
interaction	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
tetraspanins	B-X
affects	B-X
protein-protein	B-X
interactions	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
tetraspanin	B-X
web	B-X
.	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Palmitoylation	O
of	O
tetraspanins	O
affects	O
protein	O
-	O
protein	O
interactions	O
,	O
suggesting	O
a	O
key	O
role	O
in	O
the	O
assembly	O
of	O
the	O
tetraspanin	O
web	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
tetraspanins	B-X
affects	B-X
protein-protein	B-X
interactions	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
tetraspanin	B-X
web	B-X
.	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Since	O
palmitoylation	O
occurs	O
on	O
intracellular	O
cysteine	O
residues	O
,	O
we	O
examined	O
whether	O
mutating	O
these	O
residues	O
in	O
the	O
human	O
tetraspanin	O
CD81	B-Protein
would	O
affect	O
the	O
association	O
of	O
CD81	B-Protein
with	O
other	O
surface	O
membrane	O
proteins	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
tetraspanins	B-X
affects	B-X
protein-protein	B-X
interactions	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
tetraspanin	B-X
web	B-X
.	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Mutation	O
of	O
at	O
least	O
six	O
of	O
the	O
eight	O
juxtamembrane	O
cysteines	O
was	O
required	O
to	O
completely	O
eliminate	O
detectable	O
CD81	B-Protein
palmitoylation	O
,	O
indicating	O
that	O
several	O
sites	O
can	O
be	O
palmitoylated	O
.	O
<EOS>	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Interestingly	O
,	O
these	O
mutated	O
proteins	O
exhibited	O
reduced	O
cell	O
surface	O
detection	O
by	O
antibody	O
compared	O
to	O
wild	O
-	O
type	O
CD81	B-Protein
,	O
but	O
this	O
was	O
not	O
due	O
to	O
differences	O
in	O
the	O
level	O
of	O
protein	O
expression	O
,	O
trafficking	O
to	O
the	O
cell	O
surface	O
,	O
protein	O
stability	O
,	O
or	O
anti	O
-	O
CD81	B-Protein
antibody	O
binding	O
affinity	O
.	O
<EOS>	B-X
Rather	B-X
than	B-X
target	B-X
the	B-X
rapidly	B-X
shifting	B-X
viruses	B-X
and	B-X
their	B-X
numerous	B-X
serotypes	B-X
,	B-X
four	B-X
independent	B-X
antibodies	B-X
were	B-X
made	B-X
to	B-X
target	B-X
the	B-X
host	B-X
antigen	B-X
CD81	B-X
and	B-X
were	B-X
shown	B-X
to	B-X
block	B-X
hepatitis	B-X
C	B-X
viral	B-X
entry	B-X
.	B-X
The	B-X
single-chain	B-X
variable	B-X
fragment	B-X
of	B-X
each	B-X
antibody	B-X
was	B-X
crystallized	B-X
in	B-X
complex	B-X
with	B-X
the	B-X
CD81	B-X
large	B-X
extracellular	B-X
loop	B-X
in	B-X
order	B-X
to	B-X
guide	B-X
affinity	B-X
maturation	B-X
of	B-X
two	B-X
distinct	B-X
antibodies	B-X
by	B-X
phage	B-X
display	B-X
.	B-X
Affinity	B-X
maturation	B-X
of	B-X
antibodies	B-X
using	B-X
phage	B-X
display	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
critical	B-X
to	B-X
therapeutic	B-X
antibody	B-X
development	B-X
and	B-X
typically	B-X
involves	B-X
modification	B-X
of	B-X
the	B-X
paratope	B-X
for	B-X
increased	B-X
affinity	B-X
,	B-X
improved	B-X
specificity	B-X
,	B-X
enhanced	B-X
stability	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
these	B-X
traits	B-X
.	B-X
One	B-X
antibody	B-X
was	B-X
engineered	B-X
for	B-X
increased	B-X
affinity	B-X
for	B-X
human	B-X
CD81	B-X
large	B-X
extracellular	B-X
loop	B-X
that	B-X
equated	B-X
to	B-X
increased	B-X
efficacy	B-X
,	B-X
while	B-X
the	B-X
second	B-X
antibody	B-X
was	B-X
engineered	B-X
for	B-X
cross-reactivity	B-X
with	B-X
cynomolgus	B-X
CD81	B-X
to	B-X
facilitate	B-X
animal	B-X
model	B-X
testing	B-X
.	B-X
The	B-X
use	B-X
of	B-X
structures	B-X
to	B-X
guide	B-X
affinity	B-X
maturation	B-X
library	B-X
design	B-X
demonstrates	B-X
the	B-X
utility	B-X
of	B-X
combining	B-X
structural	B-X
analysis	B-X
with	B-X
phage	B-X
display	B-X
technologies	B-X
.	B-X

Instead	O
,	O
the	O
mutant	O
CD81	B-Protein
proteins	O
appeared	O
to	O
be	O
partially	O
hidden	O
from	O
detection	O
by	O
anti	O
-	O
CD81	B-Protein
antibody	O
,	O
presumably	O
due	O
to	O
altered	O
interactions	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
tetraspanins	B-X
affects	B-X
protein-protein	B-X
interactions	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
tetraspanin	B-X
web	B-X
.	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Associations	O
with	O
the	O
known	O
CD81	B-Protein
-	O
interacting	O
proteins	O
CD9	B-Protein
and	O
EWI	B-Protein
-	I-Protein
2	I-Protein
were	O
also	O
impaired	O
with	O
the	O
mutant	O
CD81	B-Protein
proteins	O
.	O
<EOS>	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
mutation	O
of	O
juxtamembrane	O
cysteines	O
alters	O
the	O
interaction	O
of	O
CD81	B-Protein
with	O
other	O
proteins	O
,	O
either	O
because	O
of	O
reduced	O
palmitoylation	O
,	O
structural	O
alterations	O
in	O
the	O
mutant	O
proteins	O
,	O
or	O
a	O
combination	O
of	O
both	O
factors	O
,	O
and	O
this	O
affects	O
the	O
CD81	B-Protein
microenvironment	O
on	O
the	O
cell	O
surface	O
.	O
<EOS>	B-X
Palmitoylation	B-X
of	B-X
tetraspanins	B-X
affects	B-X
protein-protein	B-X
interactions	B-X
,	B-X
suggesting	B-X
a	B-X
key	B-X
role	B-X
in	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
tetraspanin	B-X
web	B-X
.	B-X
Since	B-X
palmitoylation	B-X
occurs	B-X
on	B-X
intracellular	B-X
cysteine	B-X
residues	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
mutating	B-X
these	B-X
residues	B-X
in	B-X
the	B-X
human	B-X
tetraspanin	B-X
CD81	B-X
would	B-X
affect	B-X
the	B-X
association	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
surface	B-X
membrane	B-X
proteins	B-X
.	B-X
Mutation	B-X
of	B-X
at	B-X
least	B-X
six	B-X
of	B-X
the	B-X
eight	B-X
juxtamembrane	B-X
cysteines	B-X
was	B-X
required	B-X
to	B-X
completely	B-X
eliminate	B-X
detectable	B-X
CD81	B-X
palmitoylation	B-X
,	B-X
indicating	B-X
that	B-X
several	B-X
sites	B-X
can	B-X
be	B-X
palmitoylated	B-X
.	B-X
Interestingly	B-X
,	B-X
these	B-X
mutated	B-X
proteins	B-X
exhibited	B-X
reduced	B-X
cell	B-X
surface	B-X
detection	B-X
by	B-X
antibody	B-X
compared	B-X
to	B-X
wild-type	B-X
CD81	B-X
,	B-X
but	B-X
this	B-X
was	B-X
not	B-X
due	B-X
to	B-X
differences	B-X
in	B-X
the	B-X
level	B-X
of	B-X
protein	B-X
expression	B-X
,	B-X
trafficking	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
or	B-X
anti-CD81	B-X
antibody	B-X
binding	B-X
affinity	B-X
.	B-X
Instead	B-X
,	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
appeared	B-X
to	B-X
be	B-X
partially	B-X
hidden	B-X
from	B-X
detection	B-X
by	B-X
anti-CD81	B-X
antibody	B-X
,	B-X
presumably	B-X
due	B-X
to	B-X
altered	B-X
interactions	B-X
with	B-X
other	B-X
proteins	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
Associations	B-X
with	B-X
the	B-X
known	B-X
CD81-interacting	B-X
proteins	B-X
CD9	B-X
and	B-X
EWI-2	B-X
were	B-X
also	B-X
impaired	B-X
with	B-X
the	B-X
mutant	B-X
CD81	B-X
proteins	B-X
.	B-X
Taken	B-X
together	B-X
,	B-X
these	B-X
findings	B-X
indicate	B-X
that	B-X
mutation	B-X
of	B-X
juxtamembrane	B-X
cysteines	B-X
alters	B-X
the	B-X
interaction	B-X
of	B-X
CD81	B-X
with	B-X
other	B-X
proteins	B-X
,	B-X
either	B-X
because	B-X
of	B-X
reduced	B-X
palmitoylation	B-X
,	B-X
structural	B-X
alterations	B-X
in	B-X
the	B-X
mutant	B-X
proteins	B-X
,	B-X
or	B-X
a	B-X
combination	B-X
of	B-X
both	B-X
factors	B-X
,	B-X
and	B-X
this	B-X
affects	B-X
the	B-X
CD81	B-X
microenvironment	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X

INF2	B-Protein
is	O
an	O
endoplasmic	O
reticulum	O
-	O
associated	O
formin	O
protein	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
accelerate	B-X
filament	B-X
assembly	B-X
,	B-X
which	B-X
is	B-X
common	B-X
to	B-X
formins	B-X
,	B-X
INF2	B-X
is	B-X
a	B-X
formin	B-X
protein	B-X
with	B-X
the	B-X
unique	B-X
biochemical	B-X
ability	B-X
to	B-X
accelerate	B-X
actin	B-X
filament	B-X
depolymerization	B-X
.	B-X
The	B-X
depolymerization	B-X
activity	B-X
of	B-X
INF2	B-X
requires	B-X
its	B-X
actin	B-X
monomer-binding	B-X
WASP	B-X
homology	B-X
2	B-X
(	B-X
WH2	B-X
)	B-X
motif	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
INF2	B-X
is	B-X
peripherally	B-X
bound	B-X
to	B-X
the	B-X
cytoplasmic	B-X
face	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
Swiss	B-X
3T3	B-X
cells	B-X
.	B-X
Both	B-X
endogenous	B-X
INF2	B-X
and	B-X
GFP-fusion	B-X
constructs	B-X
display	B-X
ER	B-X
localization	B-X
.	B-X
INF2	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
C-terminal	B-X
farnesyl	B-X
group	B-X
,	B-X
and	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
ER	B-X
interaction	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
does	B-X
not	B-X
inhibit	B-X
the	B-X
actin	B-X
nucleation	B-X
activity	B-X
of	B-X
INF2	B-X
;	B-X
however	B-X
,	B-X
it	B-X
does	B-X
inhibit	B-X
the	B-X
depolymerization	B-X
activity	B-X
.	B-X
Expression	B-X
of	B-X
GFP-INF2	B-X
containing	B-X
these	B-X
DAD/WH2	B-X
mutations	B-X
causes	B-X
the	B-X
ER	B-X
to	B-X
collapse	B-X
around	B-X
the	B-X
nucleus	B-X
,	B-X
with	B-X
accumulation	B-X
of	B-X
actin	B-X
filaments	B-X
around	B-X
the	B-X
collapsed	B-X
ER	B-X
.	B-X

In	O
addition	O
to	O
its	O
ability	O
to	O
accelerate	O
filament	O
assembly	O
,	O
which	O
is	O
common	O
to	O
formins	O
,	O
INF2	B-Protein
is	O
a	O
formin	O
protein	O
with	O
the	O
unique	O
biochemical	O
ability	O
to	O
accelerate	O
actin	O
filament	O
depolymerization	O
.	O
<EOS>	B-X
INF2	B-X
(	B-X
inverted	B-X
formin	B-X
2	B-X
)	B-X
is	B-X
a	B-X
formin	B-X
protein	B-X
with	B-X
unique	B-X
biochemical	B-X
effects	B-X
on	B-X
actin	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
the	B-X
common	B-X
formin	B-X
ability	B-X
to	B-X
accelerate	B-X
actin	B-X
nucleation	B-X
and	B-X
elongation	B-X
,	B-X
INF2	B-X
can	B-X
also	B-X
sever	B-X
filaments	B-X
and	B-X
accelerate	B-X
their	B-X
depolymerization	B-X
.	B-X
Although	B-X
we	B-X
understand	B-X
key	B-X
attributes	B-X
of	B-X
INF2-mediated	B-X
severing	B-X
,	B-X
we	B-X
do	B-X
not	B-X
understand	B-X
the	B-X
mechanism	B-X
by	B-X
which	B-X
INF2	B-X
accelerates	B-X
depolymerization	B-X
subsequent	B-X
to	B-X
severing	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
INF2	B-X
can	B-X
create	B-X
short	B-X
filaments	B-X
(	B-X
<	B-X
60	B-X
nm	B-X
)	B-X
that	B-X
continuously	B-X
turn	B-X
over	B-X
actin	B-X
subunits	B-X
through	B-X
a	B-X
combination	B-X
of	B-X
barbed	B-X
end	B-X
elongation	B-X
,	B-X
severing	B-X
,	B-X
and	B-X
WH2	B-X
motif-mediated	B-X
depolymerization	B-X
.	B-X
This	B-X
pseudo-steady	B-X
state	B-X
condition	B-X
occurs	B-X
whether	B-X
starting	B-X
from	B-X
actin	B-X
filaments	B-X
or	B-X
monomers	B-X
.	B-X
The	B-X
rate-limiting	B-X
step	B-X
of	B-X
the	B-X
cycle	B-X
is	B-X
nucleotide	B-X
exchange	B-X
of	B-X
ADP	B-X
for	B-X
ATP	B-X
on	B-X
actin	B-X
monomers	B-X
after	B-X
release	B-X
from	B-X
the	B-X
INF2/actin	B-X
complex	B-X
.	B-X
Profilin	B-X
addition	B-X
has	B-X
two	B-X
effects	B-X
:	B-X
1	B-X
)	B-X
to	B-X
accelerate	B-X
filament	B-X
turnover	B-X
6-fold	B-X
by	B-X
accelerating	B-X
nucleotide	B-X
exchange	B-X
and	B-X
2	B-X
)	B-X
to	B-X
shift	B-X
the	B-X
equilibrium	B-X
toward	B-X
polymerization	B-X
,	B-X
resulting	B-X
in	B-X
longer	B-X
filaments	B-X
.	B-X
In	B-X
sum	B-X
,	B-X
our	B-X
findings	B-X
show	B-X
that	B-X
the	B-X
combination	B-X
of	B-X
multiple	B-X
interactions	B-X
of	B-X
INF2	B-X
with	B-X
actin	B-X
can	B-X
work	B-X
in	B-X
concert	B-X
to	B-X
increase	B-X
the	B-X
ATP	B-X
turnover	B-X
rate	B-X
of	B-X
actin	B-X
.	B-X
Depending	B-X
on	B-X
the	B-X
ratio	B-X
of	B-X
INF2	B-X
:	B-X
actin	B-X
,	B-X
this	B-X
increased	B-X
flux	B-X
can	B-X
result	B-X
in	B-X
rapid	B-X
filament	B-X
depolymerization	B-X
or	B-X
maintenance	B-X
of	B-X
short	B-X
filaments	B-X
.	B-X
We	B-X
also	B-X
show	B-X
that	B-X
high	B-X
concentrations	B-X
of	B-X
cytochalasin	B-X
D	B-X
accelerate	B-X
ATP	B-X
turnover	B-X
by	B-X
actin	B-X
but	B-X
through	B-X
a	B-X
different	B-X
mechanism	B-X
from	B-X
that	B-X
of	B-X
INF2	B-X
.	B-X

The	O
depolymerization	O
activity	O
of	O
INF2	B-Protein
requires	O
its	O
actin	O
monomer	O
-	O
binding	O
WASP	O
homology	O
2	O
(	O
WH2	O
)	O
motif	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
accelerate	B-X
filament	B-X
assembly	B-X
,	B-X
which	B-X
is	B-X
common	B-X
to	B-X
formins	B-X
,	B-X
INF2	B-X
is	B-X
a	B-X
formin	B-X
protein	B-X
with	B-X
the	B-X
unique	B-X
biochemical	B-X
ability	B-X
to	B-X
accelerate	B-X
actin	B-X
filament	B-X
depolymerization	B-X
.	B-X
The	B-X
depolymerization	B-X
activity	B-X
of	B-X
INF2	B-X
requires	B-X
its	B-X
actin	B-X
monomer-binding	B-X
WASP	B-X
homology	B-X
2	B-X
(	B-X
WH2	B-X
)	B-X
motif	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
INF2	B-X
is	B-X
peripherally	B-X
bound	B-X
to	B-X
the	B-X
cytoplasmic	B-X
face	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
Swiss	B-X
3T3	B-X
cells	B-X
.	B-X
Both	B-X
endogenous	B-X
INF2	B-X
and	B-X
GFP-fusion	B-X
constructs	B-X
display	B-X
ER	B-X
localization	B-X
.	B-X
INF2	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
C-terminal	B-X
farnesyl	B-X
group	B-X
,	B-X
and	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
ER	B-X
interaction	B-X
.	B-X
The	B-X
WH2	B-X
motif	B-X
also	B-X
serves	B-X
as	B-X
a	B-X
diaphanous	B-X
autoregulatory	B-X
domain	B-X
(	B-X
DAD	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
N-terminal	B-X
diaphanous	B-X
inhibitory	B-X
domain	B-X
(	B-X
DID	B-X
)	B-X
,	B-X
with	B-X
an	B-X
apparent	B-X
dissociation	B-X
constant	B-X
of	B-X
1.1	B-X
muM	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
does	B-X
not	B-X
inhibit	B-X
the	B-X
actin	B-X
nucleation	B-X
activity	B-X
of	B-X
INF2	B-X
;	B-X
however	B-X
,	B-X
it	B-X
does	B-X
inhibit	B-X
the	B-X
depolymerization	B-X
activity	B-X
.	B-X
Point	B-X
mutations	B-X
to	B-X
the	B-X
DAD/WH2	B-X
inhibit	B-X
both	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
and	B-X
depolymerization	B-X
activity	B-X
.	B-X
Expression	B-X
of	B-X
GFP-INF2	B-X
containing	B-X
these	B-X
DAD/WH2	B-X
mutations	B-X
causes	B-X
the	B-X
ER	B-X
to	B-X
collapse	B-X
around	B-X
the	B-X
nucleus	B-X
,	B-X
with	B-X
accumulation	B-X
of	B-X
actin	B-X
filaments	B-X
around	B-X
the	B-X
collapsed	B-X
ER	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
show	B-X
the	B-X
association	B-X
of	B-X
an	B-X
actin-assembly	B-X
factor	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
show	O
that	O
INF2	B-Protein
is	O
peripherally	O
bound	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
in	O
Swiss	O
3T3	O
cells	O
.	O

Both	O
endogenous	O
INF2	B-Protein
and	O
GFP	B-Protein
-	O
fusion	O
constructs	O
display	O
ER	O
localization	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
accelerate	B-X
filament	B-X
assembly	B-X
,	B-X
which	B-X
is	B-X
common	B-X
to	B-X
formins	B-X
,	B-X
INF2	B-X
is	B-X
a	B-X
formin	B-X
protein	B-X
with	B-X
the	B-X
unique	B-X
biochemical	B-X
ability	B-X
to	B-X
accelerate	B-X
actin	B-X
filament	B-X
depolymerization	B-X
.	B-X
The	B-X
depolymerization	B-X
activity	B-X
of	B-X
INF2	B-X
requires	B-X
its	B-X
actin	B-X
monomer-binding	B-X
WASP	B-X
homology	B-X
2	B-X
(	B-X
WH2	B-X
)	B-X
motif	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
INF2	B-X
is	B-X
peripherally	B-X
bound	B-X
to	B-X
the	B-X
cytoplasmic	B-X
face	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
Swiss	B-X
3T3	B-X
cells	B-X
.	B-X
Both	B-X
endogenous	B-X
INF2	B-X
and	B-X
GFP-fusion	B-X
constructs	B-X
display	B-X
ER	B-X
localization	B-X
.	B-X
INF2	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
C-terminal	B-X
farnesyl	B-X
group	B-X
,	B-X
and	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
ER	B-X
interaction	B-X
.	B-X
However	B-X
,	B-X
farnesylation	B-X
is	B-X
not	B-X
sufficient	B-X
for	B-X
ER	B-X
association	B-X
,	B-X
and	B-X
membrane	B-X
extraction	B-X
experiments	B-X
suggest	B-X
that	B-X
ionic	B-X
interactions	B-X
are	B-X
also	B-X
important	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
does	B-X
not	B-X
inhibit	B-X
the	B-X
actin	B-X
nucleation	B-X
activity	B-X
of	B-X
INF2	B-X
;	B-X
however	B-X
,	B-X
it	B-X
does	B-X
inhibit	B-X
the	B-X
depolymerization	B-X
activity	B-X
.	B-X
Expression	B-X
of	B-X
GFP-INF2	B-X
containing	B-X
these	B-X
DAD/WH2	B-X
mutations	B-X
causes	B-X
the	B-X
ER	B-X
to	B-X
collapse	B-X
around	B-X
the	B-X
nucleus	B-X
,	B-X
with	B-X
accumulation	B-X
of	B-X
actin	B-X
filaments	B-X
around	B-X
the	B-X
collapsed	B-X
ER	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
show	B-X
the	B-X
association	B-X
of	B-X
an	B-X
actin-assembly	B-X
factor	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

INF2	B-Protein
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
C	O
-	O
terminal	O
farnesyl	O
group	O
,	O
and	O
this	O
modification	O
is	O
required	O
for	O
ER	O
interaction	O
.	O

However	O
,	O
farnesylation	O
is	O
not	O
sufficient	O
for	O
ER	O
association	O
,	O
and	O
membrane	O
extraction	O
experiments	O
suggest	O
that	O
ionic	O
interactions	O
are	O
also	O
important	O
.	O
<EOS>	B-X
This	B-X
enzymatic	B-X
posttranslational	B-X
modification	B-X
is	B-X
important	B-X
for	B-X
the	B-X
maturation	B-X
and	B-X
processing	B-X
of	B-X
proteins	B-X
.	B-X
Both	B-X
processes	B-X
are	B-X
necessary	B-X
to	B-X
mediate	B-X
protein-protein	B-X
and	B-X
membrane-protein	B-X
associations	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
regulating	B-X
the	B-X
localisation	B-X
and	B-X
function	B-X
of	B-X
proteins	B-X
.	B-X
Aromatic	B-X
prenyltransferases	B-X
(	B-X
PTases	B-X
)	B-X
,	B-X
including	B-X
ABBA-type	B-X
and	B-X
dimethylallyl	B-X
tryptophan	B-X
synthase	B-X
(	B-X
DMATS	B-X
)	B-X
-type	B-X
enzymes	B-X
from	B-X
bacteria	B-X
and	B-X
fungi	B-X
,	B-X
play	B-X
important	B-X
role	B-X
for	B-X
diversification	B-X
of	B-X
the	B-X
natural	B-X
products	B-X
and	B-X
improvement	B-X
of	B-X
the	B-X
biological	B-X
activities	B-X
.	B-X
We	B-X
also	B-X
illustrate	B-X
how	B-X
complex	B-X
these	B-X
reactions	B-X
are	B-X
and	B-X
highlight	B-X
the	B-X
challenges	B-X
faced	B-X
when	B-X
attempting	B-X
to	B-X
design	B-X
de	B-X
novo	B-X
catalysts	B-X
.	B-X
However	B-X
,	B-X
the	B-X
challenge	B-X
with	B-X
these	B-X
methods	B-X
is	B-X
to	B-X
reach	B-X
the	B-X
level	B-X
of	B-X
sampling	B-X
needed	B-X
to	B-X
study	B-X
systems	B-X
where	B-X
large	B-X
conformational	B-X
changes	B-X
happen	B-X
in	B-X
the	B-X
many	B-X
nanoseconds	B-X
to	B-X
microsecond	B-X
time	B-X
regimes	B-X
.	B-X
Hence	B-X
,	B-X
how	B-X
to	B-X
couple	B-X
expensive	B-X
and	B-X
accurate	B-X
QM	B-X
methods	B-X
with	B-X
sophisticated	B-X
sampling	B-X
algorithms	B-X
is	B-X
an	B-X
important	B-X
future	B-X
challenge	B-X
especially	B-X
when	B-X
large-scale	B-X
studies	B-X
of	B-X
catalyst	B-X
design	B-X
become	B-X
of	B-X
interest	B-X
.	B-X
While	B-X
this	B-X
Account	B-X
summarizes	B-X
where	B-X
we	B-X
have	B-X
been	B-X
,	B-X
we	B-X
also	B-X
discuss	B-X
briefly	B-X
future	B-X
directions	B-X
that	B-X
improve	B-X
our	B-X
fundamental	B-X
ability	B-X
to	B-X
understand	B-X
enzyme	B-X
catalysis	B-X
.	B-X

The	O
WH2	O
motif	O
also	O
serves	O
as	O
a	O
diaphanous	O
autoregulatory	O
domain	O
(	O
DAD	O
)	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
diaphanous	O
inhibitory	O
domain	O
(	O
DID	O
)	O
,	O
with	O
an	O
apparent	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
muM	O
.	O

Surprisingly	O
,	O
the	O
DID	O
-	O
DAD	O
interaction	O
does	O
not	O
inhibit	O
the	O
actin	O
nucleation	O
activity	O
of	O
INF2	B-Protein
;	O
however	O
,	O
it	O
does	O
inhibit	O
the	O
depolymerization	O
activity	O
.	O
<EOS>	B-X
Inspired	B-X
by	B-X
the	B-X
study	B-X
of	B-X
species	B-X
abundance	B-X
distributions	B-X
(	B-X
SADs	B-X
)	B-X
,	B-X
we	B-X
tested	B-X
for	B-X
generalities	B-X
in	B-X
the	B-X
structure	B-X
of	B-X
vertebrate	B-X
diets	B-X
by	B-X
characterising	B-X
them	B-X
as	B-X
dietary	B-X
abundance	B-X
distributions	B-X
(	B-X
DADs	B-X
)	B-X
.	B-X
DADs	B-X
near-universally	B-X
(	B-X
92.5	B-X
%	B-X
)	B-X
followed	B-X
a	B-X
hollow-curve	B-X
shape	B-X
,	B-X
with	B-X
scant	B-X
support	B-X
for	B-X
other	B-X
plausible	B-X
rank-abundance-distribution	B-X
shapes	B-X
.	B-X
Future	B-X
challenges	B-X
include	B-X
identifying	B-X
the	B-X
mechanisms	B-X
underpinning	B-X
the	B-X
hollow-curve	B-X
DAD	B-X
,	B-X
its	B-X
generality	B-X
beyond	B-X
vertebrates	B-X
,	B-X
and	B-X
the	B-X
biological	B-X
determinants	B-X
of	B-X
dietary	B-X
generalisation	B-X
.	B-X
Quorum	B-X
sensing	B-X
(	B-X
QS	B-X
)	B-X
regulates	B-X
bacterial	B-X
gene	B-X
expression	B-X
and	B-X
studies	B-X
suggest	B-X
quercetin	B-X
,	B-X
a	B-X
flavonol	B-X
found	B-X
in	B-X
onion	B-X
,	B-X
as	B-X
a	B-X
QS	B-X
inhibitor	B-X
.	B-X
There	B-X
are	B-X
no	B-X
studies	B-X
showing	B-X
the	B-X
anti-QS	B-X
activity	B-X
of	B-X
plants	B-X
containing	B-X
quercetin	B-X
in	B-X
its	B-X
native	B-X
glycosylated	B-X
forms	B-X
.	B-X

Point	O
mutations	O
to	O
the	O
DAD	O
/	O
WH2	O
inhibit	O
both	O
the	O
DID	O
-	O
DAD	O
interaction	O
and	O
depolymerization	O
activity	O
.	O

Expression	O
of	O
GFP	B-Protein
-	O
INF2	B-Protein
containing	O
these	O
DAD	O
/	O
WH2	O
mutations	O
causes	O
the	O
ER	O
to	O
collapse	O
around	O
the	O
nucleus	O
,	O
with	O
accumulation	O
of	O
actin	O
filaments	O
around	O
the	O
collapsed	O
ER	O
.	O
<EOS>	B-X
In	B-X
addition	B-X
to	B-X
its	B-X
ability	B-X
to	B-X
accelerate	B-X
filament	B-X
assembly	B-X
,	B-X
which	B-X
is	B-X
common	B-X
to	B-X
formins	B-X
,	B-X
INF2	B-X
is	B-X
a	B-X
formin	B-X
protein	B-X
with	B-X
the	B-X
unique	B-X
biochemical	B-X
ability	B-X
to	B-X
accelerate	B-X
actin	B-X
filament	B-X
depolymerization	B-X
.	B-X
The	B-X
depolymerization	B-X
activity	B-X
of	B-X
INF2	B-X
requires	B-X
its	B-X
actin	B-X
monomer-binding	B-X
WASP	B-X
homology	B-X
2	B-X
(	B-X
WH2	B-X
)	B-X
motif	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
show	B-X
that	B-X
INF2	B-X
is	B-X
peripherally	B-X
bound	B-X
to	B-X
the	B-X
cytoplasmic	B-X
face	B-X
of	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
in	B-X
Swiss	B-X
3T3	B-X
cells	B-X
.	B-X
Both	B-X
endogenous	B-X
INF2	B-X
and	B-X
GFP-fusion	B-X
constructs	B-X
display	B-X
ER	B-X
localization	B-X
.	B-X
INF2	B-X
is	B-X
post-translationally	B-X
modified	B-X
by	B-X
a	B-X
C-terminal	B-X
farnesyl	B-X
group	B-X
,	B-X
and	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
ER	B-X
interaction	B-X
.	B-X
However	B-X
,	B-X
farnesylation	B-X
is	B-X
not	B-X
sufficient	B-X
for	B-X
ER	B-X
association	B-X
,	B-X
and	B-X
membrane	B-X
extraction	B-X
experiments	B-X
suggest	B-X
that	B-X
ionic	B-X
interactions	B-X
are	B-X
also	B-X
important	B-X
.	B-X
The	B-X
WH2	B-X
motif	B-X
also	B-X
serves	B-X
as	B-X
a	B-X
diaphanous	B-X
autoregulatory	B-X
domain	B-X
(	B-X
DAD	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
to	B-X
the	B-X
N-terminal	B-X
diaphanous	B-X
inhibitory	B-X
domain	B-X
(	B-X
DID	B-X
)	B-X
,	B-X
with	B-X
an	B-X
apparent	B-X
dissociation	B-X
constant	B-X
of	B-X
1.1	B-X
muM	B-X
.	B-X
Surprisingly	B-X
,	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
does	B-X
not	B-X
inhibit	B-X
the	B-X
actin	B-X
nucleation	B-X
activity	B-X
of	B-X
INF2	B-X
;	B-X
however	B-X
,	B-X
it	B-X
does	B-X
inhibit	B-X
the	B-X
depolymerization	B-X
activity	B-X
.	B-X
Point	B-X
mutations	B-X
to	B-X
the	B-X
DAD/WH2	B-X
inhibit	B-X
both	B-X
the	B-X
DID-DAD	B-X
interaction	B-X
and	B-X
depolymerization	B-X
activity	B-X
.	B-X
Expression	B-X
of	B-X
GFP-INF2	B-X
containing	B-X
these	B-X
DAD/WH2	B-X
mutations	B-X
causes	B-X
the	B-X
ER	B-X
to	B-X
collapse	B-X
around	B-X
the	B-X
nucleus	B-X
,	B-X
with	B-X
accumulation	B-X
of	B-X
actin	B-X
filaments	B-X
around	B-X
the	B-X
collapsed	B-X
ER	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
show	B-X
the	B-X
association	B-X
of	B-X
an	B-X
actin-assembly	B-X
factor	B-X
with	B-X
the	B-X
ER	B-X
.	B-X

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
association	O
of	O
an	O
actin	O
-	O
assembly	O
factor	O
with	O
the	O
ER	O
.	O

Mouse	O
recombinant	O
phenylalanine	B-Protein
monooxygenase	I-Protein
and	O
the	O
S	O
-	O
oxygenation	O
of	O
thioether	O
substrates	O
.	O

The	O
substrate	O
specificity	O
of	O
mouse	O
recombinant	O
phenylalanine	B-Protein
monooxygenase	I-Protein
(	O
mPAH	B-Protein
)	O
has	O
been	O
investigated	O
with	O
respect	O
to	O
the	O
mucoactive	O
drug	O
,	O
S	O
-	O
carboxymethyl	O
-	O
L	O
-	O
cysteine	O
(	O
SCMC	O
)	O
and	O
its	O
thioether	O
metabolites	O
.	O

Phenylalanine	B-Protein
monooxygenase	I-Protein
was	O
shown	O
to	O
be	O
able	O
to	O
catalyze	O
the	O
S	O
-	O
oxygenation	O
of	O
SCMC	O
,	O
its	O
decarboxylated	O
metabolite	O
,	O
S	O
-	O
methyl	O
-	O
L	O
-	O
cysteine	O
and	O
both	O
their	O
corresponding	O
N	O
-	O
acetylated	O
forms	O
.	O

However	O
,	O
thiodiglycolic	O
acid	O
was	O
found	O
not	O
to	O
be	O
a	O
substrate	O
.	O
<EOS>	B-X
However	B-X
,	B-X
several	B-X
recent	B-X
studies	B-X
could	B-X
not	B-X
confirm	B-X
the	B-X
formation	B-X
of	B-X
significant	B-X
amounts	B-X
of	B-X
urinary	B-X
sulfoxides	B-X
of	B-X
CMC	B-X
or	B-X
its	B-X
decarboxylation	B-X
product	B-X
S-methyl-L-cysteine	B-X
.	B-X
Three	B-X
nitrogen-free	B-X
metabolites	B-X
that	B-X
were	B-X
identified	B-X
as	B-X
thiodiglycolic	B-X
acid	B-X
(	B-X
TDGA	B-X
,	B-X
mean	B-X
:	B-X
19.8	B-X
%	B-X
of	B-X
the	B-X
dose/24	B-X
hr	B-X
)	B-X
,	B-X
thiodiglycolic	B-X
acid	B-X
sulfoxide	B-X
(	B-X
TDGA-SO	B-X
,	B-X
mean	B-X
:	B-X
13.3	B-X
%	B-X
of	B-X
the	B-X
dose/24	B-X
hr	B-X
)	B-X
,	B-X
and	B-X
(	B-X
3-carboxymethylthio	B-X
)	B-X
lactic	B-X
acid	B-X
(	B-X
TLA	B-X
,	B-X
mean	B-X
:	B-X
2.1	B-X
%	B-X
of	B-X
the	B-X
dose/8	B-X
hr	B-X
)	B-X
,	B-X
cumulatively	B-X
account	B-X
for	B-X
about	B-X
one-third	B-X
of	B-X
the	B-X
dose	B-X
during	B-X
a	B-X
urinary	B-X
collection	B-X
period	B-X
of	B-X
24	B-X
hr	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
assess	B-X
the	B-X
association	B-X
among	B-X
urinary	B-X
thiodiglycolic	B-X
acid	B-X
(	B-X
TDGA	B-X
)	B-X
level	B-X
,	B-X
abnormal	B-X
liver	B-X
function	B-X
,	B-X
and	B-X
hepatic	B-X
fibrosis	B-X
in	B-X
school-aged	B-X
children	B-X
living	B-X
near	B-X
a	B-X
petrochemical	B-X
complex	B-X
.	B-X
After	B-X
adjustment	B-X
for	B-X
potential	B-X
confounding	B-X
factors	B-X
,	B-X
children	B-X
in	B-X
the	B-X
highest	B-X
quartiles	B-X
(	B-X
Q	B-X

The	O
enzyme	O
profiles	O
for	O
both	O
phenylalanine	O
and	O
SCMC	O
showed	O
Michaelis	O
-	O
Menten	O
with	O
noncompetitive	O
substrate	O
inhibition	O
for	O
both	O
the	O
substrate	O
-	O
activated	O
and	O
the	O
lysophosphatidylcholine	O
-	O
activated	O
mPAH	B-Protein
assays	O
.	O
<EOS>	B-X
The	B-X
substrate	B-X
specificity	B-X
of	B-X
mouse	B-X
recombinant	B-X
phenylalanine	B-X
monooxygenase	B-X
(	B-X
mPAH	B-X
)	B-X
has	B-X
been	B-X
investigated	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
mucoactive	B-X
drug	B-X
,	B-X
S-carboxymethyl-L-cysteine	B-X
(	B-X
SCMC	B-X
)	B-X
and	B-X
its	B-X
thioether	B-X
metabolites	B-X
.	B-X
Phenylalanine	B-X
monooxygenase	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
catalyze	B-X
the	B-X
S-oxygenation	B-X
of	B-X
SCMC	B-X
,	B-X
its	B-X
decarboxylated	B-X
metabolite	B-X
,	B-X
S-methyl-L-cysteine	B-X
and	B-X
both	B-X
their	B-X
corresponding	B-X
N-acetylated	B-X
forms	B-X
.	B-X
However	B-X
,	B-X
thiodiglycolic	B-X
acid	B-X
was	B-X
found	B-X
not	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
.	B-X
The	B-X
enzyme	B-X
profiles	B-X
for	B-X
both	B-X
phenylalanine	B-X
and	B-X
SCMC	B-X
showed	B-X
Michaelis-Menten	B-X
with	B-X
noncompetitive	B-X
substrate	B-X
inhibition	B-X
for	B-X
both	B-X
the	B-X
substrate-activated	B-X
and	B-X
the	B-X
lysophosphatidylcholine-activated	B-X
mPAH	B-X
assays	B-X
.	B-X
The	B-X
tetrameric	B-X
enzyme	B-X
was	B-X
shown	B-X
to	B-X
undergo	B-X
posttranslational	B-X
activation	B-X
by	B-X
preincubation	B-X
with	B-X
substrate	B-X
,	B-X
lysophosphatidylcholine	B-X
,	B-X
N-ethylmaleimide	B-X
(	B-X
a	B-X
thiol	B-X
alkylating	B-X
agent	B-X
)	B-X
,	B-X
and	B-X
the	B-X
proteolytic	B-X
enzymes	B-X
alpha-chymotrypsin	B-X
and	B-X
trypsin	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
the	B-X
mouse	B-X
,	B-X
PAH	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
S-oxidation	B-X
of	B-X
SCMC	B-X
and	B-X
that	B-X
the	B-X
mouse	B-X
models	B-X
of	B-X
the	B-X
hyperphenylalaninemias	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
tool	B-X
in	B-X
the	B-X
investigation	B-X
of	B-X
the	B-X
S-oxidation	B-X
polymorphism	B-X
in	B-X
man	B-X
.	B-X

The	O
tetrameric	O
enzyme	O
was	O
shown	O
to	O
undergo	O
posttranslational	O
activation	O
by	O
preincubation	O
with	O
substrate	O
,	O
lysophosphatidylcholine	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
a	O
thiol	O
alkylating	O
agent	O
)	O
,	O
and	O
the	O
proteolytic	O
enzymes	O
alpha	B-Protein
-	I-Protein
chymotrypsin	I-Protein
and	O
trypsin	O
.	O
<EOS>	B-X
The	B-X
substrate	B-X
specificity	B-X
of	B-X
mouse	B-X
recombinant	B-X
phenylalanine	B-X
monooxygenase	B-X
(	B-X
mPAH	B-X
)	B-X
has	B-X
been	B-X
investigated	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
mucoactive	B-X
drug	B-X
,	B-X
S-carboxymethyl-L-cysteine	B-X
(	B-X
SCMC	B-X
)	B-X
and	B-X
its	B-X
thioether	B-X
metabolites	B-X
.	B-X
Phenylalanine	B-X
monooxygenase	B-X
was	B-X
shown	B-X
to	B-X
be	B-X
able	B-X
to	B-X
catalyze	B-X
the	B-X
S-oxygenation	B-X
of	B-X
SCMC	B-X
,	B-X
its	B-X
decarboxylated	B-X
metabolite	B-X
,	B-X
S-methyl-L-cysteine	B-X
and	B-X
both	B-X
their	B-X
corresponding	B-X
N-acetylated	B-X
forms	B-X
.	B-X
However	B-X
,	B-X
thiodiglycolic	B-X
acid	B-X
was	B-X
found	B-X
not	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
.	B-X
The	B-X
enzyme	B-X
profiles	B-X
for	B-X
both	B-X
phenylalanine	B-X
and	B-X
SCMC	B-X
showed	B-X
Michaelis-Menten	B-X
with	B-X
noncompetitive	B-X
substrate	B-X
inhibition	B-X
for	B-X
both	B-X
the	B-X
substrate-activated	B-X
and	B-X
the	B-X
lysophosphatidylcholine-activated	B-X
mPAH	B-X
assays	B-X
.	B-X
The	B-X
tetrameric	B-X
enzyme	B-X
was	B-X
shown	B-X
to	B-X
undergo	B-X
posttranslational	B-X
activation	B-X
by	B-X
preincubation	B-X
with	B-X
substrate	B-X
,	B-X
lysophosphatidylcholine	B-X
,	B-X
N-ethylmaleimide	B-X
(	B-X
a	B-X
thiol	B-X
alkylating	B-X
agent	B-X
)	B-X
,	B-X
and	B-X
the	B-X
proteolytic	B-X
enzymes	B-X
alpha-chymotrypsin	B-X
and	B-X
trypsin	B-X
.	B-X
Similar	B-X
posttranslational	B-X
activation	B-X
of	B-X
PAH	B-X
activity	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
human	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
.	B-X

Similar	O
posttranslational	O
activation	O
of	O
PAH	B-Protein
activity	O
in	O
the	O
rat	O
and	O
human	O
has	O
also	O
been	O
reported	O
.	O
<EOS>	B-X
The	B-X
substrate	B-X
specificity	B-X
of	B-X
mouse	B-X
recombinant	B-X
phenylalanine	B-X
monooxygenase	B-X
(	B-X
mPAH	B-X
)	B-X
has	B-X
been	B-X
investigated	B-X
with	B-X
respect	B-X
to	B-X
the	B-X
mucoactive	B-X
drug	B-X
,	B-X
S-carboxymethyl-L-cysteine	B-X
(	B-X
SCMC	B-X
)	B-X
and	B-X
its	B-X
thioether	B-X
metabolites	B-X
.	B-X
However	B-X
,	B-X
thiodiglycolic	B-X
acid	B-X
was	B-X
found	B-X
not	B-X
to	B-X
be	B-X
a	B-X
substrate	B-X
.	B-X
The	B-X
enzyme	B-X
profiles	B-X
for	B-X
both	B-X
phenylalanine	B-X
and	B-X
SCMC	B-X
showed	B-X
Michaelis-Menten	B-X
with	B-X
noncompetitive	B-X
substrate	B-X
inhibition	B-X
for	B-X
both	B-X
the	B-X
substrate-activated	B-X
and	B-X
the	B-X
lysophosphatidylcholine-activated	B-X
mPAH	B-X
assays	B-X
.	B-X
The	B-X
tetrameric	B-X
enzyme	B-X
was	B-X
shown	B-X
to	B-X
undergo	B-X
posttranslational	B-X
activation	B-X
by	B-X
preincubation	B-X
with	B-X
substrate	B-X
,	B-X
lysophosphatidylcholine	B-X
,	B-X
N-ethylmaleimide	B-X
(	B-X
a	B-X
thiol	B-X
alkylating	B-X
agent	B-X
)	B-X
,	B-X
and	B-X
the	B-X
proteolytic	B-X
enzymes	B-X
alpha-chymotrypsin	B-X
and	B-X
trypsin	B-X
.	B-X
Similar	B-X
posttranslational	B-X
activation	B-X
of	B-X
PAH	B-X
activity	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
human	B-X
has	B-X
also	B-X
been	B-X
reported	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
in	B-X
the	B-X
mouse	B-X
,	B-X
PAH	B-X
was	B-X
responsible	B-X
for	B-X
the	B-X
S-oxidation	B-X
of	B-X
SCMC	B-X
and	B-X
that	B-X
the	B-X
mouse	B-X
models	B-X
of	B-X
the	B-X
hyperphenylalaninemias	B-X
may	B-X
be	B-X
a	B-X
potential	B-X
tool	B-X
in	B-X
the	B-X
investigation	B-X
of	B-X
the	B-X
S-oxidation	B-X
polymorphism	B-X
in	B-X
man	B-X
.	B-X

These	O
results	O
suggest	O
that	O
in	O
the	O
mouse	O
,	O
PAH	B-Protein
was	O
responsible	O
for	O
the	O
S	O
-	O
oxidation	O
of	O
SCMC	O
and	O
that	O
the	O
mouse	O
models	O
of	O
the	O
hyperphenylalaninemias	O
may	O
be	O
a	O
potential	O
tool	O
in	O
the	O
investigation	O
of	O
the	O
S	O
-	O
oxidation	O
polymorphism	O
in	O
man	O
.	O

The	O
cataract	O
-	O
associated	O
R14C	O
mutant	O
of	O
human	O
gamma	B-Protein
D	I-Protein
-	I-Protein
crystallin	I-Protein
shows	O
a	O
variety	O
of	O
intermolecular	O
disulfide	O
cross	O
-	O
links	O
:	O
a	O
Raman	O
spectroscopic	O
study	O
.	O

The	O
Arg14	O
to	O
Cys	O
(	O
R14C	O
)	O
mutation	O
in	O
the	O
human	O
gammaD	B-Protein
-	I-Protein
crystallin	I-Protein
(	O
HGD	B-Protein
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
juvenile	O
-	O
onset	O
hereditary	O
cataract	O
.	O
<EOS>	B-X
The	B-X
Arg14	B-X
to	B-X
Cys	B-X
(	B-X
R14C	B-X
)	B-X
mutation	B-X
in	B-X
the	B-X
human	B-X
gammaD-crystallin	B-X
(	B-X
HGD	B-X
)	B-X
gene	B-X
has	B-X
been	B-X
associated	B-X
with	B-X
a	B-X
juvenile-onset	B-X
hereditary	B-X
cataract	B-X
.	B-X
U.S.A.	B-X
97	B-X
,	B-X
1993-1998	B-X
]	B-X
that	B-X
rapid	B-X
oxidation	B-X
of	B-X
Cys14	B-X
in	B-X
the	B-X
mutant	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
intermolecular	B-X
,	B-X
disulfide-cross-linked	B-X
aggregates	B-X
at	B-X
physiological	B-X
pH	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
a	B-X
Raman	B-X
spectroscopic	B-X
analysis	B-X
of	B-X
R14C	B-X
and	B-X
HGD	B-X
and	B-X
show	B-X
that	B-X
R14C	B-X
forms	B-X
such	B-X
aggregates	B-X
even	B-X
at	B-X
pH	B-X
4.5	B-X
.	B-X
From	B-X
the	B-X
pattern	B-X
of	B-X
the	B-X
S-S	B-X
and	B-X
Trp	B-X
Raman	B-X
bands	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
Cys32	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
cross-linking	B-X
.	B-X
Thus	B-X
,	B-X
our	B-X
Raman	B-X
data	B-X
not	B-X
only	B-X
enhance	B-X
the	B-X
understanding	B-X
of	B-X
the	B-X
reactivity	B-X
of	B-X
Cys14	B-X
in	B-X
the	B-X
R14C	B-X
mutant	B-X
and	B-X
the	B-X
mechanism	B-X
of	B-X
opacity	B-X
,	B-X
but	B-X
also	B-X
shed	B-X
light	B-X
on	B-X
the	B-X
mechanism	B-X
of	B-X
oxidative	B-X
degradation	B-X
during	B-X
long-term	B-X
storage	B-X
of	B-X
thiol-containing	B-X
pharmaceuticals	B-X
.	B-X

We	O
showed	O
previously	O
[	O
Pande	O
,	O
A	O
.	O
,	O
et	O
al	O
.	O
(	O
2000	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
97	O
,	O
1993	O
-	O
1998	O
]	O
that	O
rapid	O
oxidation	O
of	O
Cys14	O
in	O
the	O
mutant	O
leads	O
to	O
the	O
formation	O
of	O
intermolecular	O
,	O
disulfide	O
-	O
cross	O
-	O
linked	O
aggregates	O
at	O
physiological	O
pH	O
.	O

Here	O
we	O
present	O
a	O
Raman	O
spectroscopic	O
analysis	O
of	O
R14C	O
and	O
HGD	B-Protein
and	O
show	O
that	O
R14C	O
forms	O
such	O
aggregates	O
even	O
at	O
pH	O
4	O
.	O
5	O
.	O

The	O
lower	O
pH	O
enabled	O
us	O
to	O
monitor	O
the	O
evolution	O
of	O
a	O
variety	O
of	O
disulfide	O
cross	O
-	O
links	O
with	O
distinct	O
conformations	O
around	O
the	O
CC	O
-	O
SS	O
-	O
CC	O
dihedral	O
angles	O
.	O

At	O
least	O
three	O
cysteine	O
residues	O
are	O
involved	O
,	O
forming	O
protein	O
-	O
protein	O
cross	O
-	O
links	O
through	O
disulfide	O
-	O
exchange	O
reactions	O
.	O
<EOS>	B-X
U.S.A.	B-X
97	B-X
,	B-X
1993-1998	B-X
]	B-X
that	B-X
rapid	B-X
oxidation	B-X
of	B-X
Cys14	B-X
in	B-X
the	B-X
mutant	B-X
leads	B-X
to	B-X
the	B-X
formation	B-X
of	B-X
intermolecular	B-X
,	B-X
disulfide-cross-linked	B-X
aggregates	B-X
at	B-X
physiological	B-X
pH	B-X
.	B-X
The	B-X
lower	B-X
pH	B-X
enabled	B-X
us	B-X
to	B-X
monitor	B-X
the	B-X
evolution	B-X
of	B-X
a	B-X
variety	B-X
of	B-X
disulfide	B-X
cross-links	B-X
with	B-X
distinct	B-X
conformations	B-X
around	B-X
the	B-X
CC-SS-CC	B-X
dihedral	B-X
angles	B-X
.	B-X
At	B-X
least	B-X
three	B-X
cysteine	B-X
residues	B-X
are	B-X
involved	B-X
,	B-X
forming	B-X
protein-protein	B-X
cross-links	B-X
through	B-X
disulfide-exchange	B-X
reactions	B-X
.	B-X
From	B-X
the	B-X
pattern	B-X
of	B-X
the	B-X
S-S	B-X
and	B-X
Trp	B-X
Raman	B-X
bands	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
Cys32	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
cross-linking	B-X
.	B-X
The	B-X
data	B-X
suggest	B-X
that	B-X
protein	B-X
precipitation	B-X
in	B-X
the	B-X
mutant	B-X
may	B-X
not	B-X
be	B-X
the	B-X
direct	B-X
result	B-X
of	B-X
disulfide	B-X
cross-linking	B-X
,	B-X
although	B-X
such	B-X
cross-linking	B-X
is	B-X
the	B-X
initiating	B-X
event	B-X
.	B-X

From	O
the	O
pattern	O
of	O
the	O
S	O
-	O
S	O
and	O
Trp	O
Raman	O
bands	O
,	O
we	O
infer	O
that	O
Cys32	O
is	O
likely	O
to	O
be	O
involved	O
in	O
the	O
cross	O
-	O
linking	O
.	O

The	O
data	O
suggest	O
that	O
protein	O
precipitation	O
in	O
the	O
mutant	O
may	O
not	O
be	O
the	O
direct	O
result	O
of	O
disulfide	O
cross	O
-	O
linking	O
,	O
although	O
such	O
cross	O
-	O
linking	O
is	O
the	O
initiating	O
event	O
.	O
<EOS>	B-X
After	B-X
the	B-X
successful	B-X
cloning	B-X
of	B-X
the	B-X
first	B-X
gene	B-X
for	B-X
a	B-X
polyglutamine	B-X
disease	B-X
in	B-X
1991	B-X
,	B-X
the	B-X
expanded	B-X
polyglutamine	B-X
tract	B-X
in	B-X
the	B-X
nine	B-X
polyglutamine	B-X
disease	B-X
proteins	B-X
became	B-X
an	B-X
obvious	B-X
therapeutic	B-X
target	B-X
.	B-X
Early	B-X
hypotheses	B-X
were	B-X
that	B-X
misfolded	B-X
,	B-X
precipitated	B-X
protein	B-X
could	B-X
be	B-X
a	B-X
universal	B-X
pathogenic	B-X
mechanism	B-X
.	B-X
However	B-X
,	B-X
new	B-X
data	B-X
are	B-X
accumulating	B-X
on	B-X
Huntington	B-X
's	B-X
disease	B-X
and	B-X
other	B-X
polyglutamine	B-X
diseases	B-X
that	B-X
appear	B-X
to	B-X
contradict	B-X
the	B-X
toxic	B-X
aggregate	B-X
hypothesis	B-X
.	B-X
Recent	B-X
data	B-X
suggest	B-X
that	B-X
the	B-X
toxic	B-X
species	B-X
of	B-X
protein	B-X
in	B-X
these	B-X
diseases	B-X
may	B-X
be	B-X
soluble	B-X
mutant	B-X
conformers	B-X
,	B-X
and	B-X
that	B-X
the	B-X
protein	B-X
context	B-X
of	B-X
expanded	B-X
polyglutamine	B-X
is	B-X
critical	B-X
to	B-X
understanding	B-X
disease	B-X
specificity	B-X
.	B-X
Here	B-X
we	B-X
discuss	B-X
recent	B-X
publications	B-X
that	B-X
define	B-X
other	B-X
important	B-X
therapeutic	B-X
targets	B-X
for	B-X
polyglutamine-mediated	B-X
neurodegeneration	B-X
related	B-X
to	B-X
the	B-X
context	B-X
of	B-X
the	B-X
expanded	B-X
polyglutamine	B-X
tract	B-X
in	B-X
the	B-X
disease	B-X
protein	B-X
.	B-X

Thus	O
,	O
our	O
Raman	O
data	O
not	O
only	O
enhance	O
the	O
understanding	O
of	O
the	O
reactivity	O
of	O
Cys14	O
in	O
the	O
R14C	O
mutant	O
and	O
the	O
mechanism	O
of	O
opacity	O
,	O
but	O
also	O
shed	O
light	O
on	O
the	O
mechanism	O
of	O
oxidative	O
degradation	O
during	O
long	O
-	O
term	O
storage	O
of	O
thiol	O
-	O
containing	O
pharmaceuticals	O
.	O
<EOS>	B-X
Raman	B-X
spectroscopy	B-X
can	B-X
be	B-X
used	B-X
to	B-X
measure	B-X
the	B-X
chemical	B-X
composition	B-X
of	B-X
a	B-X
sample	B-X
,	B-X
which	B-X
can	B-X
in	B-X
turn	B-X
be	B-X
used	B-X
to	B-X
extract	B-X
biological	B-X
information	B-X
.	B-X
Many	B-X
materials	B-X
have	B-X
characteristic	B-X
Raman	B-X
spectra	B-X
,	B-X
which	B-X
means	B-X
that	B-X
Raman	B-X
spectroscopy	B-X
has	B-X
proven	B-X
to	B-X
be	B-X
an	B-X
effective	B-X
analytical	B-X
approach	B-X
in	B-X
geology	B-X
,	B-X
semiconductor	B-X
,	B-X
materials	B-X
and	B-X
polymer	B-X
science	B-X
fields	B-X
.	B-X
The	B-X
application	B-X
of	B-X
Raman	B-X
spectroscopy	B-X
and	B-X
microscopy	B-X
within	B-X
biology	B-X
is	B-X
rapidly	B-X
increasing	B-X
because	B-X
it	B-X
can	B-X
provide	B-X
chemical	B-X
and	B-X
compositional	B-X
information	B-X
,	B-X
but	B-X
it	B-X
does	B-X
not	B-X
typically	B-X
suffer	B-X
from	B-X
interference	B-X
from	B-X
water	B-X
molecules	B-X
.	B-X
In	B-X
this	B-X
protocol	B-X
,	B-X
we	B-X
aim	B-X
to	B-X
standardize	B-X
and	B-X
bring	B-X
together	B-X
multiple	B-X
experimental	B-X
approaches	B-X
from	B-X
key	B-X
leaders	B-X
in	B-X
the	B-X
field	B-X
for	B-X
obtaining	B-X
Raman	B-X
spectra	B-X
using	B-X
a	B-X
microspectrometer	B-X
.	B-X
As	B-X
examples	B-X
of	B-X
the	B-X
range	B-X
of	B-X
biological	B-X
samples	B-X
that	B-X
can	B-X
be	B-X
analyzed	B-X
,	B-X
we	B-X
provide	B-X
instructions	B-X
for	B-X
acquiring	B-X
Raman	B-X
spectra	B-X
,	B-X
maps	B-X
and	B-X
images	B-X
for	B-X
fresh	B-X
plant	B-X
tissue	B-X
,	B-X
formalin-fixed	B-X
and	B-X
fresh	B-X
frozen	B-X
mammalian	B-X
tissue	B-X
,	B-X
fixed	B-X
cells	B-X
and	B-X
biofluids	B-X
.	B-X
We	B-X
explore	B-X
a	B-X
robust	B-X
approach	B-X
for	B-X
sample	B-X
preparation	B-X
,	B-X
instrumentation	B-X
,	B-X
acquisition	B-X
parameters	B-X
and	B-X
data	B-X
processing	B-X
.	B-X
By	B-X
using	B-X
this	B-X
approach	B-X
,	B-X
we	B-X
expect	B-X
that	B-X
a	B-X
typical	B-X
Raman	B-X
experiment	B-X
can	B-X
be	B-X
performed	B-X
by	B-X
a	B-X
nonspecialist	B-X
user	B-X
to	B-X
generate	B-X
high-quality	B-X
data	B-X
for	B-X
biological	B-X
materials	B-X
analysis	B-X
.	B-X

Bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
:	O
molecular	O
structures	O
and	O
signal	O
transducing	O
functions	O
.	O
<EOS>	B-X
Mono-ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
modification	B-X
of	B-X
proteins	B-X
employed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
to	B-X
modify	B-X
the	B-X
metabolism	B-X
of	B-X
target	B-X
cells	B-X
.	B-X
The	B-X
ADP-ribosyltransferases	B-X
of	B-X
bacterial	B-X
toxins	B-X
,	B-X
in	B-X
general	B-X
,	B-X
use	B-X
NAD	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
covalent	B-X
modification	B-X
by	B-X
ADP-ribose	B-X
to	B-X
certain	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
as	B-X
signal	B-X
transducers	B-X
resulting	B-X
in	B-X
altered	B-X
enzymatic	B-X
activity	B-X
of	B-X
the	B-X
membrane	B-X
enzymes	B-X
as	B-X
effectors	B-X
.	B-X
These	B-X
ADP-ribosylating	B-X
toxins	B-X
are	B-X
characterized	B-X
in	B-X
Table	B-X
1	B-X
.	B-X
G	B-X
proteins	B-X
that	B-X
serve	B-X
to	B-X
transduce	B-X
external	B-X
signals	B-X
in	B-X
membranes	B-X
share	B-X
with	B-X
protein	B-X
synthesis	B-X
factors	B-X
and	B-X
tubulin	B-X
structural	B-X
and	B-X
functional	B-X
features	B-X
that	B-X
are	B-X
common	B-X
to	B-X
proteins	B-X
that	B-X
participate	B-X
in	B-X
reversible	B-X
GTP-mediated	B-X
macromolecular	B-X
interactions	B-X
.	B-X
These	B-X
proteins	B-X
can	B-X
bind	B-X
GTP	B-X
and	B-X
GDP	B-X
with	B-X
high	B-X
affinity	B-X
,	B-X
adopting	B-X
different	B-X
structures	B-X
depending	B-X
on	B-X
whether	B-X
they	B-X
are	B-X
complexed	B-X
with	B-X
the	B-X
nucleotide	B-X
diphosphate	B-X
or	B-X
triphosphate	B-X
.	B-X
A	B-X
detailed	B-X
comparison	B-X
of	B-X
the	B-X
features	B-X
of	B-X
the	B-X
different	B-X
systems	B-X
is	B-X
made	B-X
with	B-X
respect	B-X
to	B-X
structural	B-X
similarities	B-X
,	B-X
regulation	B-X
by	B-X
protein	B-X
phosphorylation	B-X
,	B-X
ADP	B-X
ribosylation	B-X
by	B-X
bacterial	B-X
toxins	B-X
,	B-X
and	B-X
requirements	B-X
for	B-X
exchange	B-X
factors	B-X
.	B-X
It	B-X
is	B-X
also	B-X
proposed	B-X
that	B-X
there	B-X
is	B-X
a	B-X
similar	B-X
mechanism	B-X
that	B-X
involves	B-X
ATP/ADP-binding	B-X
proteins	B-X
.	B-X

Mono	O
-	O
ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
modification	O
of	O
proteins	O
employed	O
by	O
a	O
variety	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
to	O
modify	O
the	O
metabolism	O
of	O
target	O
cells	O
.	O

The	O
ADP	O
-	O
ribosyltransferases	O
of	O
bacterial	O
toxins	O
,	O
in	O
general	O
,	O
use	O
NAD	O
as	O
a	O
substrate	O
for	O
covalent	O
modification	O
by	O
ADP	O
-	O
ribose	O
to	O
certain	O
GTP	O
-	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
as	O
signal	O
transducers	O
resulting	O
in	O
altered	O
enzymatic	O
activity	O
of	O
the	O
membrane	O
enzymes	O
as	O
effectors	O
.	O
<EOS>	B-X
Mono-ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
modification	B-X
of	B-X
proteins	B-X
employed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
to	B-X
modify	B-X
the	B-X
metabolism	B-X
of	B-X
target	B-X
cells	B-X
.	B-X
The	B-X
ADP-ribosyltransferases	B-X
of	B-X
bacterial	B-X
toxins	B-X
,	B-X
in	B-X
general	B-X
,	B-X
use	B-X
NAD	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
covalent	B-X
modification	B-X
by	B-X
ADP-ribose	B-X
to	B-X
certain	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
as	B-X
signal	B-X
transducers	B-X
resulting	B-X
in	B-X
altered	B-X
enzymatic	B-X
activity	B-X
of	B-X
the	B-X
membrane	B-X
enzymes	B-X
as	B-X
effectors	B-X
.	B-X
These	B-X
ADP-ribosylating	B-X
toxins	B-X
are	B-X
characterized	B-X
in	B-X
Table	B-X
1	B-X
.	B-X

Such	O
a	O
mechanism	O
has	O
the	O
potential	O
of	O
being	O
of	O
importance	O
in	O
the	O
physiological	O
regulation	O
of	O
cellular	O
metabolism	O
,	O
particularly	O
if	O
the	O
process	O
is	O
reversible	O
.	O
<EOS>	B-X
Autism	B-X
and	B-X
autism	B-X
spectrum	B-X
disorders	B-X
(	B-X
ASDs	B-X
)	B-X
are	B-X
behaviorally	B-X
defined	B-X
,	B-X
but	B-X
the	B-X
biochemical	B-X
pathogenesis	B-X
of	B-X
the	B-X
underlying	B-X
disease	B-X
process	B-X
remains	B-X
uncharacterized	B-X
.	B-X
Studies	B-X
indicate	B-X
that	B-X
antioxidant	B-X
status	B-X
is	B-X
diminished	B-X
in	B-X
autistic	B-X
subjects	B-X
,	B-X
suggesting	B-X
its	B-X
pathology	B-X
is	B-X
associated	B-X
with	B-X
augmented	B-X
production	B-X
of	B-X
oxidative	B-X
species	B-X
and/or	B-X
compromised	B-X
antioxidant	B-X
metabolism	B-X
.	B-X
This	B-X
suggests	B-X
ASD	B-X
may	B-X
result	B-X
from	B-X
defects	B-X
in	B-X
the	B-X
metabolism	B-X
of	B-X
cellular	B-X
antioxidants	B-X
which	B-X
maintain	B-X
intracellular	B-X
redox	B-X
status	B-X
by	B-X
quenching	B-X
reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
.	B-X
Selenium-dependent	B-X
enzymes	B-X
(	B-X
selenoenzymes	B-X
)	B-X
are	B-X
important	B-X
in	B-X
maintaining	B-X
intercellular	B-X
reducing	B-X
conditions	B-X
,	B-X
particularly	B-X
in	B-X
the	B-X
brain	B-X
.	B-X
Since	B-X
the	B-X
brain	B-X
's	B-X
high	B-X
rate	B-X
of	B-X
oxygen	B-X
consumption	B-X
is	B-X
accompanied	B-X
by	B-X
high	B-X
ROS	B-X
production	B-X
,	B-X
selenoenzyme	B-X
activities	B-X
are	B-X
particularly	B-X
important	B-X
in	B-X
this	B-X
tissue	B-X
.	B-X
This	B-X
can	B-X
impair	B-X
brain	B-X
development	B-X
,	B-X
particularly	B-X
via	B-X
the	B-X
adverse	B-X
influence	B-X
of	B-X
oxidative	B-X
stress	B-X
on	B-X
epigenetic	B-X
regulation	B-X
.	B-X
Here	B-X
we	B-X
review	B-X
the	B-X
physiological	B-X
roles	B-X
of	B-X
selenoproteins	B-X
in	B-X
relation	B-X
to	B-X
potential	B-X
biochemical	B-X
mechanisms	B-X
of	B-X
ASD	B-X
etiology	B-X
and	B-X
pathology	B-X
.	B-X

These	O
ADP	O
-	O
ribosylating	O
toxins	O
are	O
characterized	O
in	O
Table	O
1	O
.	O
<EOS>	B-X
Mono-ADP-ribosylation	B-X
is	B-X
a	B-X
posttranslational	B-X
modification	B-X
of	B-X
proteins	B-X
employed	B-X
by	B-X
a	B-X
variety	B-X
of	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
to	B-X
modify	B-X
the	B-X
metabolism	B-X
of	B-X
target	B-X
cells	B-X
.	B-X
The	B-X
ADP-ribosyltransferases	B-X
of	B-X
bacterial	B-X
toxins	B-X
,	B-X
in	B-X
general	B-X
,	B-X
use	B-X
NAD	B-X
as	B-X
a	B-X
substrate	B-X
for	B-X
covalent	B-X
modification	B-X
by	B-X
ADP-ribose	B-X
to	B-X
certain	B-X
GTP-binding	B-X
proteins	B-X
(	B-X
G	B-X
proteins	B-X
)	B-X
as	B-X
signal	B-X
transducers	B-X
resulting	B-X
in	B-X
altered	B-X
enzymatic	B-X
activity	B-X
of	B-X
the	B-X
membrane	B-X
enzymes	B-X
as	B-X
effectors	B-X
.	B-X
These	B-X
ADP-ribosylating	B-X
toxins	B-X
are	B-X
characterized	B-X
in	B-X
Table	B-X
1	B-X
.	B-X

Concerted	O
action	O
of	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-Protein
,	O
and	O
catechol	B-Protein
-	I-Protein
O	I-Protein
-	I-Protein
methyltransferase	I-Protein
in	O
the	O
metabolism	O
of	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
human	O
neuroblastoma	O
cells	O
.	O

Conjugation	O
reactions	O
catalyzed	O
by	O
the	O
cytosolic	O
sulfotransferase	O
,	O
SULT1A3	B-Protein
,	O
or	O
catechol	B-Protein
-	I-Protein
O	I-Protein
-	I-Protein
methyltransferase	I-Protein
(	O
COMT	B-Protein
)	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
and	O
homeostasis	O
of	O
dopamine	O
and	O
other	O
monoamine	O
neurotransmitters	O
.	O
<EOS>	B-X
Conjugation	B-X
reactions	B-X
catalyzed	B-X
by	B-X
the	B-X
cytosolic	B-X
sulfotransferase	B-X
,	B-X
SULT1A3	B-X
,	B-X
or	B-X
catechol-O-methyltransferase	B-X
(	B-X
COMT	B-X
)	B-X
are	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
and	B-X
homeostasis	B-X
of	B-X
dopamine	B-X
and	B-X
other	B-X
monoamine	B-X
neurotransmitters	B-X
.	B-X
Whether	B-X
different	B-X
conjugation	B-X
reactions	B-X
may	B-X
act	B-X
in	B-X
a	B-X
concerted	B-X
manner	B-X
,	B-X
however	B-X
,	B-X
remains	B-X
unclear	B-X
.	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
SULT1A3	B-X
and	B-X
COMT	B-X
in	B-X
dopamine	B-X
metabolism	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
medium	B-X
of	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
metabolically	B-X
labeled	B-X
with	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dopamine	B-X
,	B-X
revealed	B-X
the	B-X
generation	B-X
and	B-X
release	B-X
of	B-X
predominantly	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
.	B-X
Addition	B-X
to	B-X
the	B-X
labeling	B-X
medium	B-X
of	B-X
tropolone	B-X
,	B-X
a	B-X
COMT	B-X
inhibitor	B-X
,	B-X
enhanced	B-X
the	B-X
production	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
,	B-X
with	B-X
a	B-X
concomitant	B-X
decrease	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
.	B-X
Enzymatic	B-X
assays	B-X
using	B-X
the	B-X
eleven	B-X
known	B-X
human	B-X
cytosolic	B-X
SULTs	B-X
revealed	B-X
SULT1A3	B-X
as	B-X
the	B-X
major	B-X
enzyme	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
both	B-X
dopamine	B-X
and	B-X
3-methyldopamine	B-X
.	B-X
Kinetic	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
catalytic	B-X
efficiency	B-X
of	B-X
SULT1A3	B-X
with	B-X
3-methyldopamine	B-X
was	B-X
1.6	B-X
times	B-X
than	B-X
that	B-X
with	B-X
dopamine	B-X
.	B-X
Using	B-X
subcellular	B-X
fractions	B-X
prepared	B-X
from	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
COMT	B-X
dopamine-methylating	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
imply	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
sulfation	B-X
and	B-X
methylation	B-X
in	B-X
the	B-X
irreversible	B-X
inactivation	B-X
and	B-X
disposal	B-X
of	B-X
excess	B-X
dopamine	B-X
in	B-X
SK-N-MC	B-X
cells	B-X
.	B-X

Whether	O
different	O
conjugation	O
reactions	O
may	O
act	O
in	O
a	O
concerted	O
manner	O
,	O
however	O
,	O
remains	O
unclear	O
.	O

The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
concerted	O
action	O
of	O
SULT1A3	B-Protein
and	O
COMT	B-Protein
in	O
dopamine	O
metabolism	O
.	O
<EOS>	B-X
Conjugation	B-X
reactions	B-X
catalyzed	B-X
by	B-X
the	B-X
cytosolic	B-X
sulfotransferase	B-X
,	B-X
SULT1A3	B-X
,	B-X
or	B-X
catechol-O-methyltransferase	B-X
(	B-X
COMT	B-X
)	B-X
are	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
and	B-X
homeostasis	B-X
of	B-X
dopamine	B-X
and	B-X
other	B-X
monoamine	B-X
neurotransmitters	B-X
.	B-X
Whether	B-X
different	B-X
conjugation	B-X
reactions	B-X
may	B-X
act	B-X
in	B-X
a	B-X
concerted	B-X
manner	B-X
,	B-X
however	B-X
,	B-X
remains	B-X
unclear	B-X
.	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
SULT1A3	B-X
and	B-X
COMT	B-X
in	B-X
dopamine	B-X
metabolism	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
medium	B-X
of	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
metabolically	B-X
labeled	B-X
with	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dopamine	B-X
,	B-X
revealed	B-X
the	B-X
generation	B-X
and	B-X
release	B-X
of	B-X
predominantly	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
.	B-X
Addition	B-X
to	B-X
the	B-X
labeling	B-X
medium	B-X
of	B-X
tropolone	B-X
,	B-X
a	B-X
COMT	B-X
inhibitor	B-X
,	B-X
enhanced	B-X
the	B-X
production	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
,	B-X
with	B-X
a	B-X
concomitant	B-X
decrease	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
.	B-X
Enzymatic	B-X
assays	B-X
using	B-X
the	B-X
eleven	B-X
known	B-X
human	B-X
cytosolic	B-X
SULTs	B-X
revealed	B-X
SULT1A3	B-X
as	B-X
the	B-X
major	B-X
enzyme	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
both	B-X
dopamine	B-X
and	B-X
3-methyldopamine	B-X
.	B-X
Kinetic	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
catalytic	B-X
efficiency	B-X
of	B-X
SULT1A3	B-X
with	B-X
3-methyldopamine	B-X
was	B-X
1.6	B-X
times	B-X
than	B-X
that	B-X
with	B-X
dopamine	B-X
.	B-X
Using	B-X
subcellular	B-X
fractions	B-X
prepared	B-X
from	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
COMT	B-X
dopamine-methylating	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
imply	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
sulfation	B-X
and	B-X
methylation	B-X
in	B-X
the	B-X
irreversible	B-X
inactivation	B-X
and	B-X
disposal	B-X
of	B-X
excess	B-X
dopamine	B-X
in	B-X
SK-N-MC	B-X
cells	B-X
.	B-X

Analysis	O
of	O
the	O
medium	O
of	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
metabolically	O
labeled	O
with	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfate	O
in	O
the	O
presence	O
of	O
dopamine	O
,	O
revealed	O
the	O
generation	O
and	O
release	O
of	O
predominantly	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
.	O

Addition	O
to	O
the	O
labeling	O
medium	O
of	O
tropolone	O
,	O
a	O
COMT	B-Protein
inhibitor	O
,	O
enhanced	O
the	O
production	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
dopamine	O
,	O
with	O
a	O
concomitant	O
decrease	O
of	O
[	O
(	O
35	O
)	O
S	O
]	O
sulfated	O
3	O
-	O
methyldopamine	O
.	O

Enzymatic	O
assays	O
using	O
the	O
eleven	O
known	O
human	O
cytosolic	O
SULTs	O
revealed	O
SULT1A3	B-Protein
as	O
the	O
major	O
enzyme	O
responsible	O
for	O
the	O
sulfation	O
of	O
both	O
dopamine	O
and	O
3	O
-	O
methyldopamine	O
.	O
<EOS>	B-X
Conjugation	B-X
reactions	B-X
catalyzed	B-X
by	B-X
the	B-X
cytosolic	B-X
sulfotransferase	B-X
,	B-X
SULT1A3	B-X
,	B-X
or	B-X
catechol-O-methyltransferase	B-X
(	B-X
COMT	B-X
)	B-X
are	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
and	B-X
homeostasis	B-X
of	B-X
dopamine	B-X
and	B-X
other	B-X
monoamine	B-X
neurotransmitters	B-X
.	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
SULT1A3	B-X
and	B-X
COMT	B-X
in	B-X
dopamine	B-X
metabolism	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
medium	B-X
of	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
metabolically	B-X
labeled	B-X
with	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dopamine	B-X
,	B-X
revealed	B-X
the	B-X
generation	B-X
and	B-X
release	B-X
of	B-X
predominantly	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
.	B-X
Addition	B-X
to	B-X
the	B-X
labeling	B-X
medium	B-X
of	B-X
tropolone	B-X
,	B-X
a	B-X
COMT	B-X
inhibitor	B-X
,	B-X
enhanced	B-X
the	B-X
production	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
,	B-X
with	B-X
a	B-X
concomitant	B-X
decrease	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
.	B-X
Enzymatic	B-X
assays	B-X
using	B-X
the	B-X
eleven	B-X
known	B-X
human	B-X
cytosolic	B-X
SULTs	B-X
revealed	B-X
SULT1A3	B-X
as	B-X
the	B-X
major	B-X
enzyme	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
both	B-X
dopamine	B-X
and	B-X
3-methyldopamine	B-X
.	B-X
Kinetic	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
catalytic	B-X
efficiency	B-X
of	B-X
SULT1A3	B-X
with	B-X
3-methyldopamine	B-X
was	B-X
1.6	B-X
times	B-X
than	B-X
that	B-X
with	B-X
dopamine	B-X
.	B-X
Using	B-X
subcellular	B-X
fractions	B-X
prepared	B-X
from	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
COMT	B-X
dopamine-methylating	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
imply	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
sulfation	B-X
and	B-X
methylation	B-X
in	B-X
the	B-X
irreversible	B-X
inactivation	B-X
and	B-X
disposal	B-X
of	B-X
excess	B-X
dopamine	B-X
in	B-X
SK-N-MC	B-X
cells	B-X
.	B-X

Kinetic	O
analysis	O
showed	O
that	O
the	O
catalytic	O
efficiency	O
of	O
SULT1A3	B-Protein
with	O
3	O
-	O
methyldopamine	O
was	O
1	O
.	O
6	O
times	O
than	O
that	O
with	O
dopamine	O
.	O
<EOS>	B-X
Conjugation	B-X
reactions	B-X
catalyzed	B-X
by	B-X
the	B-X
cytosolic	B-X
sulfotransferase	B-X
,	B-X
SULT1A3	B-X
,	B-X
or	B-X
catechol-O-methyltransferase	B-X
(	B-X
COMT	B-X
)	B-X
are	B-X
known	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
and	B-X
homeostasis	B-X
of	B-X
dopamine	B-X
and	B-X
other	B-X
monoamine	B-X
neurotransmitters	B-X
.	B-X
The	B-X
current	B-X
study	B-X
aimed	B-X
to	B-X
investigate	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
SULT1A3	B-X
and	B-X
COMT	B-X
in	B-X
dopamine	B-X
metabolism	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
medium	B-X
of	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
metabolically	B-X
labeled	B-X
with	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfate	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dopamine	B-X
,	B-X
revealed	B-X
the	B-X
generation	B-X
and	B-X
release	B-X
of	B-X
predominantly	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
and	B-X
,	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
.	B-X
Addition	B-X
to	B-X
the	B-X
labeling	B-X
medium	B-X
of	B-X
tropolone	B-X
,	B-X
a	B-X
COMT	B-X
inhibitor	B-X
,	B-X
enhanced	B-X
the	B-X
production	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
dopamine	B-X
,	B-X
with	B-X
a	B-X
concomitant	B-X
decrease	B-X
of	B-X
[	B-X
(	B-X
35	B-X
)	B-X
S	B-X
]	B-X
sulfated	B-X
3-methyldopamine	B-X
.	B-X
Enzymatic	B-X
assays	B-X
using	B-X
the	B-X
eleven	B-X
known	B-X
human	B-X
cytosolic	B-X
SULTs	B-X
revealed	B-X
SULT1A3	B-X
as	B-X
the	B-X
major	B-X
enzyme	B-X
responsible	B-X
for	B-X
the	B-X
sulfation	B-X
of	B-X
both	B-X
dopamine	B-X
and	B-X
3-methyldopamine	B-X
.	B-X
Kinetic	B-X
analysis	B-X
showed	B-X
that	B-X
the	B-X
catalytic	B-X
efficiency	B-X
of	B-X
SULT1A3	B-X
with	B-X
3-methyldopamine	B-X
was	B-X
1.6	B-X
times	B-X
than	B-X
that	B-X
with	B-X
dopamine	B-X
.	B-X
Using	B-X
subcellular	B-X
fractions	B-X
prepared	B-X
from	B-X
SK-N-MC	B-X
cells	B-X
,	B-X
the	B-X
majority	B-X
of	B-X
COMT	B-X
dopamine-methylating	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
present	B-X
in	B-X
the	B-X
cytosol	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
imply	B-X
a	B-X
concerted	B-X
action	B-X
of	B-X
sulfation	B-X
and	B-X
methylation	B-X
in	B-X
the	B-X
irreversible	B-X
inactivation	B-X
and	B-X
disposal	B-X
of	B-X
excess	B-X
dopamine	B-X
in	B-X
SK-N-MC	B-X
cells	B-X
.	B-X

Using	O
subcellular	O
fractions	O
prepared	O
from	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
,	O
the	O
majority	O
of	O
COMT	B-Protein
dopamine	O
-	O
methylating	O
activity	O
was	O
found	O
to	O
be	O
present	O
in	O
the	O
cytosol	O
.	O

Collectively	O
,	O
these	O
results	O
imply	O
a	O
concerted	O
action	O
of	O
sulfation	O
and	O
methylation	O
in	O
the	O
irreversible	O
inactivation	O
and	O
disposal	O
of	O
excess	O
dopamine	O
in	O
SK	O
-	O
N	O
-	O
MC	O
cells	O
.	O

Palmitoylation	O
of	O
the	O
synaptic	O
vesicle	O
fusion	O
machinery	O
.	O
<EOS>	B-X
The	B-X
fusion	B-X
of	B-X
synaptic	B-X
vesicles	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
mediates	B-X
the	B-X
secretion	B-X
of	B-X
neurotransmitters	B-X
at	B-X
nerve	B-X
terminals	B-X
.	B-X
Of	B-X
central	B-X
importance	B-X
are	B-X
the	B-X
soluble	B-X
NSF	B-X
(	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
)	B-X
attachment	B-X
protein	B-X
receptor	B-X
(	B-X
SNARE	B-X
)	B-X
proteins	B-X
syntaxin	B-X
1	B-X
and	B-X
SNAP25	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
and	B-X
vesicle-associated	B-X
membrane	B-X
protein	B-X
(	B-X
VAMP2	B-X
)	B-X
,	B-X
a	B-X
synaptic	B-X
vesicle	B-X
SNARE	B-X
.	B-X
Syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
and	B-X
VAMP2	B-X
interact	B-X
to	B-X
form	B-X
a	B-X
tight	B-X
complex	B-X
bridging	B-X
the	B-X
vesicle	B-X
and	B-X
plasma	B-X
membranes	B-X
,	B-X
which	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
represent	B-X
the	B-X
minimal	B-X
membrane	B-X
fusion	B-X
machinery	B-X
.	B-X
Synaptic	B-X
vesicle	B-X
fusion	B-X
is	B-X
stimulated	B-X
by	B-X
a	B-X
rise	B-X
in	B-X
intraterminal	B-X
Ca2+	B-X
levels	B-X
,	B-X
and	B-X
a	B-X
major	B-X
Ca2+	B-X
sensor	B-X
for	B-X
vesicle	B-X
fusion	B-X
is	B-X
synaptotagmin	B-X
I.	B-X
Synaptotagmin	B-X
is	B-X
likely	B-X
to	B-X
couple	B-X
Ca2+	B-X
entry	B-X
to	B-X
vesicle	B-X
fusion	B-X
via	B-X
Ca2+-dependent	B-X
and	B-X
independent	B-X
interactions	B-X
with	B-X
membrane	B-X
phospholipids	B-X
and	B-X
the	B-X
SNARE	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
and	B-X
dynamics	B-X
of	B-X
palmitoylation	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
speculate	B-X
on	B-X
how	B-X
palmitoylation	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
vesicle	B-X
fusion	B-X
.	B-X

The	O
fusion	O
of	O
synaptic	O
vesicles	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
mediates	O
the	O
secretion	O
of	O
neurotransmitters	O
at	O
nerve	O
terminals	O
.	O
<EOS>	B-X
The	B-X
fusion	B-X
of	B-X
synaptic	B-X
vesicles	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
mediates	B-X
the	B-X
secretion	B-X
of	B-X
neurotransmitters	B-X
at	B-X
nerve	B-X
terminals	B-X
.	B-X
Of	B-X
central	B-X
importance	B-X
are	B-X
the	B-X
soluble	B-X
NSF	B-X
(	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
)	B-X
attachment	B-X
protein	B-X
receptor	B-X
(	B-X
SNARE	B-X
)	B-X
proteins	B-X
syntaxin	B-X
1	B-X
and	B-X
SNAP25	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
and	B-X
vesicle-associated	B-X
membrane	B-X
protein	B-X
(	B-X
VAMP2	B-X
)	B-X
,	B-X
a	B-X
synaptic	B-X
vesicle	B-X
SNARE	B-X
.	B-X
Syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
and	B-X
VAMP2	B-X
interact	B-X
to	B-X
form	B-X
a	B-X
tight	B-X
complex	B-X
bridging	B-X
the	B-X
vesicle	B-X
and	B-X
plasma	B-X
membranes	B-X
,	B-X
which	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
represent	B-X
the	B-X
minimal	B-X
membrane	B-X
fusion	B-X
machinery	B-X
.	B-X
Synaptic	B-X
vesicle	B-X
fusion	B-X
is	B-X
stimulated	B-X
by	B-X
a	B-X
rise	B-X
in	B-X
intraterminal	B-X
Ca2+	B-X
levels	B-X
,	B-X
and	B-X
a	B-X
major	B-X
Ca2+	B-X
sensor	B-X
for	B-X
vesicle	B-X
fusion	B-X
is	B-X
synaptotagmin	B-X
I.	B-X
Synaptotagmin	B-X
is	B-X
likely	B-X
to	B-X
couple	B-X
Ca2+	B-X
entry	B-X
to	B-X
vesicle	B-X
fusion	B-X
via	B-X
Ca2+-dependent	B-X
and	B-X
independent	B-X
interactions	B-X
with	B-X
membrane	B-X
phospholipids	B-X
and	B-X
the	B-X
SNARE	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
and	B-X
dynamics	B-X
of	B-X
palmitoylation	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
speculate	B-X
on	B-X
how	B-X
palmitoylation	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
vesicle	B-X
fusion	B-X
.	B-X

This	O
pathway	O
is	O
regulated	O
by	O
an	O
array	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O
<EOS>	B-X
YAP	B-X
and	B-X
TAZ	B-X
are	B-X
ubiquitously	B-X
expressed	B-X
homologous	B-X
proteins	B-X
originally	B-X
identified	B-X
as	B-X
penultimate	B-X
effectors	B-X
of	B-X
the	B-X
Hippo	B-X
signaling	B-X
pathway	B-X
,	B-X
which	B-X
plays	B-X
a	B-X
key	B-X
role	B-X
in	B-X
maintaining	B-X
mammalian	B-X
tissue/organ	B-X
size	B-X
.	B-X
Presently	B-X
,	B-X
it	B-X
is	B-X
known	B-X
that	B-X
YAP/TAZ	B-X
also	B-X
interact	B-X
with	B-X
various	B-X
non-Hippo	B-X
signaling	B-X
pathways	B-X
,	B-X
and	B-X
have	B-X
diverse	B-X
roles	B-X
in	B-X
multiple	B-X
biological	B-X
processes	B-X
,	B-X
including	B-X
cell	B-X
proliferation	B-X
,	B-X
tissue	B-X
regeneration	B-X
,	B-X
cell	B-X
lineage	B-X
fate	B-X
determination	B-X
,	B-X
tumorigenesis	B-X
,	B-X
and	B-X
mechanosensing	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
first	B-X
examine	B-X
the	B-X
various	B-X
microenvironmental	B-X
cues	B-X
and	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
YAP/TAZ	B-X
activation	B-X
,	B-X
through	B-X
the	B-X
Hippo	B-X
and	B-X
non-Hippo	B-X
signaling	B-X
pathways	B-X
.	B-X
This	B-X
is	B-X
followed	B-X
by	B-X
a	B-X
brief	B-X
summary	B-X
of	B-X
the	B-X
interactions	B-X
of	B-X
YAP/TAZ	B-X
with	B-X
TEAD1-4	B-X
and	B-X
a	B-X
diverse	B-X
array	B-X
of	B-X
other	B-X
non-TEAD	B-X
transcription	B-X
factors	B-X
.	B-X

Of	O
central	O
importance	O
are	O
the	O
soluble	O
NSF	B-Protein
(	O
N	B-Protein
-	I-Protein
ethylmaleimide	I-Protein
-	I-Protein
sensitive	I-Protein
factor	I-Protein
)	O
attachment	O
protein	O
receptor	O
(	O
SNARE	O
)	O
proteins	O
syntaxin	O
1	O
and	O
SNAP25	B-Protein
,	O
which	O
are	O
associated	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
and	O
vesicle	O
-	O
associated	O
membrane	O
protein	O
(	O
VAMP2	B-Protein
)	O
,	O
a	O
synaptic	O
vesicle	O
SNARE	O
.	O
<EOS>	B-X
The	B-X
fusion	B-X
of	B-X
synaptic	B-X
vesicles	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
mediates	B-X
the	B-X
secretion	B-X
of	B-X
neurotransmitters	B-X
at	B-X
nerve	B-X
terminals	B-X
.	B-X
This	B-X
pathway	B-X
is	B-X
regulated	B-X
by	B-X
an	B-X
array	B-X
of	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Of	B-X
central	B-X
importance	B-X
are	B-X
the	B-X
soluble	B-X
NSF	B-X
(	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
)	B-X
attachment	B-X
protein	B-X
receptor	B-X
(	B-X
SNARE	B-X
)	B-X
proteins	B-X
syntaxin	B-X
1	B-X
and	B-X
SNAP25	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
and	B-X
vesicle-associated	B-X
membrane	B-X
protein	B-X
(	B-X
VAMP2	B-X
)	B-X
,	B-X
a	B-X
synaptic	B-X
vesicle	B-X
SNARE	B-X
.	B-X
Syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
and	B-X
VAMP2	B-X
interact	B-X
to	B-X
form	B-X
a	B-X
tight	B-X
complex	B-X
bridging	B-X
the	B-X
vesicle	B-X
and	B-X
plasma	B-X
membranes	B-X
,	B-X
which	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
represent	B-X
the	B-X
minimal	B-X
membrane	B-X
fusion	B-X
machinery	B-X
.	B-X
Synaptic	B-X
vesicle	B-X
fusion	B-X
is	B-X
stimulated	B-X
by	B-X
a	B-X
rise	B-X
in	B-X
intraterminal	B-X
Ca2+	B-X
levels	B-X
,	B-X
and	B-X
a	B-X
major	B-X
Ca2+	B-X
sensor	B-X
for	B-X
vesicle	B-X
fusion	B-X
is	B-X
synaptotagmin	B-X
I.	B-X
Synaptotagmin	B-X
is	B-X
likely	B-X
to	B-X
couple	B-X
Ca2+	B-X
entry	B-X
to	B-X
vesicle	B-X
fusion	B-X
via	B-X
Ca2+-dependent	B-X
and	B-X
independent	B-X
interactions	B-X
with	B-X
membrane	B-X
phospholipids	B-X
and	B-X
the	B-X
SNARE	B-X
proteins	B-X
.	B-X
Intriguingly	B-X
,	B-X
syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
,	B-X
VAMP2	B-X
and	B-X
synaptotagmin	B-X
I	B-X
have	B-X
all	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
palmitoylation	B-X
in	B-X
neurons	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
and	B-X
dynamics	B-X
of	B-X
palmitoylation	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
speculate	B-X
on	B-X
how	B-X
palmitoylation	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
vesicle	B-X
fusion	B-X
.	B-X

Syntaxin	O
1	O
,	O
SNAP25	B-Protein
and	O
VAMP2	B-Protein
interact	O
to	O
form	O
a	O
tight	O
complex	O
bridging	O
the	O
vesicle	O
and	O
plasma	O
membranes	O
,	O
which	O
has	O
been	O
suggested	O
to	O
represent	O
the	O
minimal	O
membrane	O
fusion	O
machinery	O
.	O

Synaptic	O
vesicle	O
fusion	O
is	O
stimulated	O
by	O
a	O
rise	O
in	O
intraterminal	O
Ca2	O
+	O
levels	O
,	O
and	O
a	O
major	O
Ca2	O
+	O
sensor	O
for	O
vesicle	O
fusion	O
is	O
synaptotagmin	B-Protein
I	I-Protein
.	O

Synaptotagmin	O
is	O
likely	O
to	O
couple	O
Ca2	O
+	O
entry	O
to	O
vesicle	O
fusion	O
via	O
Ca2	O
+	O
-	O
dependent	O
and	O
independent	O
interactions	O
with	O
membrane	O
phospholipids	O
and	O
the	O
SNARE	O
proteins	O
.	O
<EOS>	B-X
The	B-X
fusion	B-X
of	B-X
synaptic	B-X
vesicles	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
mediates	B-X
the	B-X
secretion	B-X
of	B-X
neurotransmitters	B-X
at	B-X
nerve	B-X
terminals	B-X
.	B-X
This	B-X
pathway	B-X
is	B-X
regulated	B-X
by	B-X
an	B-X
array	B-X
of	B-X
protein-protein	B-X
interactions	B-X
.	B-X
Of	B-X
central	B-X
importance	B-X
are	B-X
the	B-X
soluble	B-X
NSF	B-X
(	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
)	B-X
attachment	B-X
protein	B-X
receptor	B-X
(	B-X
SNARE	B-X
)	B-X
proteins	B-X
syntaxin	B-X
1	B-X
and	B-X
SNAP25	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
and	B-X
vesicle-associated	B-X
membrane	B-X
protein	B-X
(	B-X
VAMP2	B-X
)	B-X
,	B-X
a	B-X
synaptic	B-X
vesicle	B-X
SNARE	B-X
.	B-X
Syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
and	B-X
VAMP2	B-X
interact	B-X
to	B-X
form	B-X
a	B-X
tight	B-X
complex	B-X
bridging	B-X
the	B-X
vesicle	B-X
and	B-X
plasma	B-X
membranes	B-X
,	B-X
which	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
represent	B-X
the	B-X
minimal	B-X
membrane	B-X
fusion	B-X
machinery	B-X
.	B-X
Synaptic	B-X
vesicle	B-X
fusion	B-X
is	B-X
stimulated	B-X
by	B-X
a	B-X
rise	B-X
in	B-X
intraterminal	B-X
Ca2+	B-X
levels	B-X
,	B-X
and	B-X
a	B-X
major	B-X
Ca2+	B-X
sensor	B-X
for	B-X
vesicle	B-X
fusion	B-X
is	B-X
synaptotagmin	B-X
I.	B-X
Synaptotagmin	B-X
is	B-X
likely	B-X
to	B-X
couple	B-X
Ca2+	B-X
entry	B-X
to	B-X
vesicle	B-X
fusion	B-X
via	B-X
Ca2+-dependent	B-X
and	B-X
independent	B-X
interactions	B-X
with	B-X
membrane	B-X
phospholipids	B-X
and	B-X
the	B-X
SNARE	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
and	B-X
dynamics	B-X
of	B-X
palmitoylation	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
speculate	B-X
on	B-X
how	B-X
palmitoylation	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
vesicle	B-X
fusion	B-X
.	B-X

Intriguingly	O
,	O
syntaxin	O
1	O
,	O
SNAP25	B-Protein
,	O
VAMP2	B-Protein
and	O
synaptotagmin	B-Protein
I	I-Protein
have	O
all	O
been	O
reported	O
to	O
be	O
modified	O
by	O
palmitoylation	O
in	O
neurons	O
.	O
<EOS>	B-X
Of	B-X
central	B-X
importance	B-X
are	B-X
the	B-X
soluble	B-X
NSF	B-X
(	B-X
N-ethylmaleimide-sensitive	B-X
factor	B-X
)	B-X
attachment	B-X
protein	B-X
receptor	B-X
(	B-X
SNARE	B-X
)	B-X
proteins	B-X
syntaxin	B-X
1	B-X
and	B-X
SNAP25	B-X
,	B-X
which	B-X
are	B-X
associated	B-X
with	B-X
the	B-X
pre-synaptic	B-X
plasma	B-X
membrane	B-X
and	B-X
vesicle-associated	B-X
membrane	B-X
protein	B-X
(	B-X
VAMP2	B-X
)	B-X
,	B-X
a	B-X
synaptic	B-X
vesicle	B-X
SNARE	B-X
.	B-X
Syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
and	B-X
VAMP2	B-X
interact	B-X
to	B-X
form	B-X
a	B-X
tight	B-X
complex	B-X
bridging	B-X
the	B-X
vesicle	B-X
and	B-X
plasma	B-X
membranes	B-X
,	B-X
which	B-X
has	B-X
been	B-X
suggested	B-X
to	B-X
represent	B-X
the	B-X
minimal	B-X
membrane	B-X
fusion	B-X
machinery	B-X
.	B-X
Synaptic	B-X
vesicle	B-X
fusion	B-X
is	B-X
stimulated	B-X
by	B-X
a	B-X
rise	B-X
in	B-X
intraterminal	B-X
Ca2+	B-X
levels	B-X
,	B-X
and	B-X
a	B-X
major	B-X
Ca2+	B-X
sensor	B-X
for	B-X
vesicle	B-X
fusion	B-X
is	B-X
synaptotagmin	B-X
I.	B-X
Synaptotagmin	B-X
is	B-X
likely	B-X
to	B-X
couple	B-X
Ca2+	B-X
entry	B-X
to	B-X
vesicle	B-X
fusion	B-X
via	B-X
Ca2+-dependent	B-X
and	B-X
independent	B-X
interactions	B-X
with	B-X
membrane	B-X
phospholipids	B-X
and	B-X
the	B-X
SNARE	B-X
proteins	B-X
.	B-X
Intriguingly	B-X
,	B-X
syntaxin	B-X
1	B-X
,	B-X
SNAP25	B-X
,	B-X
VAMP2	B-X
and	B-X
synaptotagmin	B-X
I	B-X
have	B-X
all	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
palmitoylation	B-X
in	B-X
neurons	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
and	B-X
dynamics	B-X
of	B-X
palmitoylation	B-X
of	B-X
these	B-X
proteins	B-X
and	B-X
speculate	B-X
on	B-X
how	B-X
palmitoylation	B-X
might	B-X
contribute	B-X
to	B-X
the	B-X
regulation	B-X
of	B-X
synaptic	B-X
vesicle	B-X
fusion	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
and	O
dynamics	O
of	O
palmitoylation	O
of	O
these	O
proteins	O
and	O
speculate	O
on	O
how	O
palmitoylation	O
might	O
contribute	O
to	O
the	O
regulation	O
of	O
synaptic	O
vesicle	O
fusion	O
.	O

Palmitoylation	O
-	O
dependent	O
plasma	O
membrane	O
transport	O
but	O
lipid	O
raft	O
-	O
independent	O
signaling	O
by	O
linker	B-Protein
for	I-Protein
activation	I-Protein
of	I-Protein
T	I-Protein
cells	I-Protein
.	O
<EOS>	B-X
Linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
(	B-X
LAT	B-X
)	B-X
is	B-X
a	B-X
dually	B-X
palmitoylated	B-X
transmembrane	B-X
adaptor	B-X
protein	B-X
essential	B-X
for	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
LAT	B-X
palmitoylation	B-X
and/or	B-X
lipid	B-X
raft	B-X
localization	B-X
are	B-X
required	B-X
for	B-X
its	B-X
function	B-X
is	B-X
controversial	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
biochemical	B-X
,	B-X
imaging	B-X
,	B-X
and	B-X
genetic	B-X
approaches	B-X
,	B-X
including	B-X
LAT	B-X
retrovirus-transduced	B-X
mouse	B-X
T	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
nonpalmitoylated	B-X
,	B-X
non-lipid	B-X
raft-residing	B-X
mutant	B-X
of	B-X
transmembrane	B-X
LAT	B-X
could	B-X
not	B-X
reconstitute	B-X
T	B-X
cell	B-X
development	B-X
in	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
This	B-X
mutant	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
and	B-X
was	B-X
restricted	B-X
mainly	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
A	B-X
chimeric	B-X
,	B-X
nonpalmitoylated	B-X
LAT	B-X
protein	B-X
consisting	B-X
of	B-X
the	B-X
PM-targeting	B-X
N-terminal	B-X
sequence	B-X
of	B-X
Src	B-X
kinase	B-X
and	B-X
the	B-X
LAT	B-X
cytoplasmic	B-X
domain	B-X
(	B-X
Src-LAT	B-X
)	B-X
localized	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
in	B-X
the	B-X
PM	B-X
,	B-X
but	B-X
outside	B-X
lipid	B-X
rafts	B-X
.	B-X
Nevertheless	B-X
,	B-X
Src-LAT	B-X
restored	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
Lastly	B-X
,	B-X
monopalmitoylation	B-X
of	B-X
LAT	B-X
on	B-X
Cys	B-X
(	B-X
26	B-X
)	B-X
(	B-X
but	B-X
not	B-X
Cys	B-X
(	B-X
29	B-X
)	B-X
)	B-X
was	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
and	B-X
function	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
function	B-X
of	B-X
LAT	B-X
in	B-X
T	B-X
cells	B-X
requires	B-X
its	B-X
PM	B-X
,	B-X
but	B-X
not	B-X
raft	B-X
,	B-X
localization	B-X
,	B-X
even	B-X
when	B-X
expressed	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
LAT	B-X
palmitoylation	B-X
functions	B-X
primarily	B-X
as	B-X
a	B-X
sorting	B-X
signal	B-X
required	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
.	B-X

Linker	B-Protein
for	I-Protein
activation	I-Protein
of	I-Protein
T	I-Protein
cells	I-Protein
(	O
LAT	B-Protein
)	O
is	O
a	O
dually	O
palmitoylated	O
transmembrane	O
adaptor	O
protein	O
essential	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

However	O
,	O
whether	O
LAT	B-Protein
palmitoylation	O
and	O
/	O
or	O
lipid	O
raft	O
localization	O
are	O
required	O
for	O
its	O
function	O
is	O
controversial	O
.	O
<EOS>	B-X
Linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
(	B-X
LAT	B-X
)	B-X
is	B-X
a	B-X
dually	B-X
palmitoylated	B-X
transmembrane	B-X
adaptor	B-X
protein	B-X
essential	B-X
for	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
LAT	B-X
palmitoylation	B-X
and/or	B-X
lipid	B-X
raft	B-X
localization	B-X
are	B-X
required	B-X
for	B-X
its	B-X
function	B-X
is	B-X
controversial	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
biochemical	B-X
,	B-X
imaging	B-X
,	B-X
and	B-X
genetic	B-X
approaches	B-X
,	B-X
including	B-X
LAT	B-X
retrovirus-transduced	B-X
mouse	B-X
T	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
nonpalmitoylated	B-X
,	B-X
non-lipid	B-X
raft-residing	B-X
mutant	B-X
of	B-X
transmembrane	B-X
LAT	B-X
could	B-X
not	B-X
reconstitute	B-X
T	B-X
cell	B-X
development	B-X
in	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
chimeric	B-X
,	B-X
nonpalmitoylated	B-X
LAT	B-X
protein	B-X
consisting	B-X
of	B-X
the	B-X
PM-targeting	B-X
N-terminal	B-X
sequence	B-X
of	B-X
Src	B-X
kinase	B-X
and	B-X
the	B-X
LAT	B-X
cytoplasmic	B-X
domain	B-X
(	B-X
Src-LAT	B-X
)	B-X
localized	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
in	B-X
the	B-X
PM	B-X
,	B-X
but	B-X
outside	B-X
lipid	B-X
rafts	B-X
.	B-X
Nevertheless	B-X
,	B-X
Src-LAT	B-X
restored	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
Lastly	B-X
,	B-X
monopalmitoylation	B-X
of	B-X
LAT	B-X
on	B-X
Cys	B-X
(	B-X
26	B-X
)	B-X
(	B-X
but	B-X
not	B-X
Cys	B-X
(	B-X
29	B-X
)	B-X
)	B-X
was	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
and	B-X
function	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
function	B-X
of	B-X
LAT	B-X
in	B-X
T	B-X
cells	B-X
requires	B-X
its	B-X
PM	B-X
,	B-X
but	B-X
not	B-X
raft	B-X
,	B-X
localization	B-X
,	B-X
even	B-X
when	B-X
expressed	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
LAT	B-X
palmitoylation	B-X
functions	B-X
primarily	B-X
as	B-X
a	B-X
sorting	B-X
signal	B-X
required	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
.	B-X

To	O
address	O
this	O
question	O
,	O
we	O
used	O
a	O
combination	O
of	O
biochemical	O
,	O
imaging	O
,	O
and	O
genetic	O
approaches	O
,	O
including	O
LAT	B-Protein
retrovirus	O
-	O
transduced	O
mouse	O
T	O
cells	O
and	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

A	O
nonpalmitoylated	O
,	O
non	O
-	O
lipid	O
raft	O
-	O
residing	O
mutant	O
of	O
transmembrane	O
LAT	B-Protein
could	O
not	O
reconstitute	O
T	O
cell	O
development	O
in	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

This	O
mutant	O
was	O
absent	O
from	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
and	O
was	O
restricted	O
mainly	O
to	O
the	O
Golgi	O
apparatus	O
.	O

A	O
chimeric	O
,	O
nonpalmitoylated	O
LAT	B-Protein
protein	O
consisting	O
of	O
the	O
PM	O
-	O
targeting	O
N	O
-	O
terminal	O
sequence	O
of	O
Src	O
kinase	O
and	O
the	O
LAT	B-Protein
cytoplasmic	O
domain	O
(	O
Src	O
-	O
LAT	O
)	O
localized	O
as	O
a	O
peripheral	O
membrane	O
protein	O
in	O
the	O
PM	O
,	O
but	O
outside	O
lipid	O
rafts	O
.	O

Nevertheless	O
,	O
Src	O
-	O
LAT	O
restored	O
T	O
cell	O
development	O
and	O
activation	O
.	O
<EOS>	B-X
Linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
(	B-X
LAT	B-X
)	B-X
is	B-X
a	B-X
dually	B-X
palmitoylated	B-X
transmembrane	B-X
adaptor	B-X
protein	B-X
essential	B-X
for	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
LAT	B-X
palmitoylation	B-X
and/or	B-X
lipid	B-X
raft	B-X
localization	B-X
are	B-X
required	B-X
for	B-X
its	B-X
function	B-X
is	B-X
controversial	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
biochemical	B-X
,	B-X
imaging	B-X
,	B-X
and	B-X
genetic	B-X
approaches	B-X
,	B-X
including	B-X
LAT	B-X
retrovirus-transduced	B-X
mouse	B-X
T	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
nonpalmitoylated	B-X
,	B-X
non-lipid	B-X
raft-residing	B-X
mutant	B-X
of	B-X
transmembrane	B-X
LAT	B-X
could	B-X
not	B-X
reconstitute	B-X
T	B-X
cell	B-X
development	B-X
in	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
chimeric	B-X
,	B-X
nonpalmitoylated	B-X
LAT	B-X
protein	B-X
consisting	B-X
of	B-X
the	B-X
PM-targeting	B-X
N-terminal	B-X
sequence	B-X
of	B-X
Src	B-X
kinase	B-X
and	B-X
the	B-X
LAT	B-X
cytoplasmic	B-X
domain	B-X
(	B-X
Src-LAT	B-X
)	B-X
localized	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
in	B-X
the	B-X
PM	B-X
,	B-X
but	B-X
outside	B-X
lipid	B-X
rafts	B-X
.	B-X
Nevertheless	B-X
,	B-X
Src-LAT	B-X
restored	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
Lastly	B-X
,	B-X
monopalmitoylation	B-X
of	B-X
LAT	B-X
on	B-X
Cys	B-X
(	B-X
26	B-X
)	B-X
(	B-X
but	B-X
not	B-X
Cys	B-X
(	B-X
29	B-X
)	B-X
)	B-X
was	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
and	B-X
function	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
function	B-X
of	B-X
LAT	B-X
in	B-X
T	B-X
cells	B-X
requires	B-X
its	B-X
PM	B-X
,	B-X
but	B-X
not	B-X
raft	B-X
,	B-X
localization	B-X
,	B-X
even	B-X
when	B-X
expressed	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
LAT	B-X
palmitoylation	B-X
functions	B-X
primarily	B-X
as	B-X
a	B-X
sorting	B-X
signal	B-X
required	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
.	B-X

Lastly	O
,	O
monopalmitoylation	O
of	O
LAT	B-Protein
on	O
Cys	O
(	O
26	O
)	O
(	O
but	O
not	O
Cys	O
(	O
29	O
)	O
)	O
was	O
required	O
and	O
sufficient	O
for	O
its	O
PM	O
transport	O
and	O
function	O
.	O

Thus	O
,	O
the	O
function	O
of	O
LAT	B-Protein
in	O
T	O
cells	O
requires	O
its	O
PM	O
,	O
but	O
not	O
raft	O
,	O
localization	O
,	O
even	O
when	O
expressed	O
as	O
a	O
peripheral	O
membrane	O
protein	O
.	O

Furthermore	O
,	O
LAT	B-Protein
palmitoylation	O
functions	O
primarily	O
as	O
a	O
sorting	O
signal	O
required	O
for	O
its	O
PM	O
transport	O
.	O
<EOS>	B-X
Linker	B-X
for	B-X
activation	B-X
of	B-X
T	B-X
cells	B-X
(	B-X
LAT	B-X
)	B-X
is	B-X
a	B-X
dually	B-X
palmitoylated	B-X
transmembrane	B-X
adaptor	B-X
protein	B-X
essential	B-X
for	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
However	B-X
,	B-X
whether	B-X
LAT	B-X
palmitoylation	B-X
and/or	B-X
lipid	B-X
raft	B-X
localization	B-X
are	B-X
required	B-X
for	B-X
its	B-X
function	B-X
is	B-X
controversial	B-X
.	B-X
To	B-X
address	B-X
this	B-X
question	B-X
,	B-X
we	B-X
used	B-X
a	B-X
combination	B-X
of	B-X
biochemical	B-X
,	B-X
imaging	B-X
,	B-X
and	B-X
genetic	B-X
approaches	B-X
,	B-X
including	B-X
LAT	B-X
retrovirus-transduced	B-X
mouse	B-X
T	B-X
cells	B-X
and	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
A	B-X
nonpalmitoylated	B-X
,	B-X
non-lipid	B-X
raft-residing	B-X
mutant	B-X
of	B-X
transmembrane	B-X
LAT	B-X
could	B-X
not	B-X
reconstitute	B-X
T	B-X
cell	B-X
development	B-X
in	B-X
bone	B-X
marrow	B-X
chimeric	B-X
mice	B-X
.	B-X
This	B-X
mutant	B-X
was	B-X
absent	B-X
from	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
and	B-X
was	B-X
restricted	B-X
mainly	B-X
to	B-X
the	B-X
Golgi	B-X
apparatus	B-X
.	B-X
A	B-X
chimeric	B-X
,	B-X
nonpalmitoylated	B-X
LAT	B-X
protein	B-X
consisting	B-X
of	B-X
the	B-X
PM-targeting	B-X
N-terminal	B-X
sequence	B-X
of	B-X
Src	B-X
kinase	B-X
and	B-X
the	B-X
LAT	B-X
cytoplasmic	B-X
domain	B-X
(	B-X
Src-LAT	B-X
)	B-X
localized	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
in	B-X
the	B-X
PM	B-X
,	B-X
but	B-X
outside	B-X
lipid	B-X
rafts	B-X
.	B-X
Nevertheless	B-X
,	B-X
Src-LAT	B-X
restored	B-X
T	B-X
cell	B-X
development	B-X
and	B-X
activation	B-X
.	B-X
Lastly	B-X
,	B-X
monopalmitoylation	B-X
of	B-X
LAT	B-X
on	B-X
Cys	B-X
(	B-X
26	B-X
)	B-X
(	B-X
but	B-X
not	B-X
Cys	B-X
(	B-X
29	B-X
)	B-X
)	B-X
was	B-X
required	B-X
and	B-X
sufficient	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
and	B-X
function	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
function	B-X
of	B-X
LAT	B-X
in	B-X
T	B-X
cells	B-X
requires	B-X
its	B-X
PM	B-X
,	B-X
but	B-X
not	B-X
raft	B-X
,	B-X
localization	B-X
,	B-X
even	B-X
when	B-X
expressed	B-X
as	B-X
a	B-X
peripheral	B-X
membrane	B-X
protein	B-X
.	B-X
Furthermore	B-X
,	B-X
LAT	B-X
palmitoylation	B-X
functions	B-X
primarily	B-X
as	B-X
a	B-X
sorting	B-X
signal	B-X
required	B-X
for	B-X
its	B-X
PM	B-X
transport	B-X
.	B-X

Mobile	O
DHHC	O
palmitoylating	O
enzyme	O
mediates	O
activity	O
-	O
sensitive	O
synaptic	O
targeting	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
posttranslational	B-X
lipid	B-X
modification	B-X
;	B-X
its	B-X
reversibility	B-X
mediates	B-X
protein	B-X
shuttling	B-X
between	B-X
intracellular	B-X
compartments	B-X
.	B-X
A	B-X
large	B-X
family	B-X
of	B-X
DHHC	B-X
(	B-X
Asp-His-His-Cys	B-X
)	B-X
proteins	B-X
has	B-X
emerged	B-X
as	B-X
protein	B-X
palmitoyl	B-X
acyltransferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
efficiently	B-X
monitored	B-X
the	B-X
dynamic	B-X
palmitate	B-X
cycling	B-X
on	B-X
synaptic	B-X
scaffold	B-X
PSD-95	B-X
.	B-X
We	B-X
found	B-X
that	B-X
blocking	B-X
synaptic	B-X
activity	B-X
rapidly	B-X
induces	B-X
PSD-95	B-X
palmitoylation	B-X
and	B-X
mediates	B-X
synaptic	B-X
clustering	B-X
of	B-X
PSD-95	B-X
and	B-X
associated	B-X
AMPA	B-X
(	B-X
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-X
propionic	B-X
acid	B-X
)	B-X
-type	B-X
glutamate	B-X
receptors	B-X
.	B-X
A	B-X
dendritically	B-X
localized	B-X
DHHC2	B-X
but	B-X
not	B-X
the	B-X
Golgi-resident	B-X
DHHC3	B-X
mediates	B-X
this	B-X
activity-sensitive	B-X
palmitoylation	B-X
.	B-X
Upon	B-X
activity	B-X
blockade	B-X
,	B-X
DHHC2	B-X
translocates	B-X
to	B-X
the	B-X
postsynaptic	B-X
density	B-X
to	B-X
transduce	B-X
this	B-X
effect	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
individual	B-X
DHHC	B-X
members	B-X
are	B-X
differentially	B-X
regulated	B-X
and	B-X
that	B-X
dynamic	B-X
recruitment	B-X
of	B-X
protein	B-X
palmitoylation	B-X
machinery	B-X
enables	B-X
compartmentalized	B-X
regulation	B-X
of	B-X
protein	B-X
trafficking	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X

Protein	O
palmitoylation	O
is	O
the	O
most	O
common	O
posttranslational	O
lipid	O
modification	O
;	O
its	O
reversibility	O
mediates	O
protein	O
shuttling	O
between	O
intracellular	O
compartments	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
,	B-X
in	B-X
which	B-X
C16	B-X
fatty	B-X
acid	B-X
chains	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
a	B-X
reversible	B-X
thioester	B-X
linkage	B-X
,	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
common	B-X
lipid	B-X
modifications	B-X
and	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
regulating	B-X
protein	B-X
stability	B-X
,	B-X
subcellular	B-X
localization	B-X
,	B-X
membrane	B-X
trafficking	B-X
,	B-X
interactions	B-X
with	B-X
effector	B-X
proteins	B-X
,	B-X
enzymatic	B-X
activity	B-X
,	B-X
and	B-X
a	B-X
variety	B-X
of	B-X
other	B-X
cellular	B-X
processes	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
unique	B-X
reversibility	B-X
of	B-X
palmitoylation	B-X
allows	B-X
proteins	B-X
to	B-X
be	B-X
rapidly	B-X
shuttled	B-X
between	B-X
biological	B-X
membranes	B-X
and	B-X
cytoplasmic	B-X
substrates	B-X
in	B-X
a	B-X
process	B-X
usually	B-X
controlled	B-X
by	B-X
a	B-X
member	B-X
of	B-X
the	B-X
DHHC	B-X
family	B-X
of	B-X
protein	B-X
palmitoyl	B-X
transferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
PATs	B-X
,	B-X
intracellular	B-X
palmitoylation	B-X
dynamics	B-X
are	B-X
also	B-X
regulated	B-X
by	B-X
the	B-X
interplay	B-X
between	B-X
distinct	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
ubiquitination	B-X
and	B-X
phosphorylation	B-X
.	B-X
Understanding	B-X
the	B-X
specific	B-X
mechanisms	B-X
of	B-X
palmitoylation	B-X
may	B-X
reveal	B-X
novel	B-X
potential	B-X
therapeutic	B-X
targets	B-X
for	B-X
many	B-X
human	B-X
diseases	B-X
.	B-X

A	O
large	O
family	O
of	O
DHHC	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
proteins	O
has	O
emerged	O
as	O
protein	O
palmitoyl	O
acyltransferases	O
(	O
PATs	O
)	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
posttranslational	B-X
lipid	B-X
modification	B-X
;	B-X
its	B-X
reversibility	B-X
mediates	B-X
protein	B-X
shuttling	B-X
between	B-X
intracellular	B-X
compartments	B-X
.	B-X
A	B-X
large	B-X
family	B-X
of	B-X
DHHC	B-X
(	B-X
Asp-His-His-Cys	B-X
)	B-X
proteins	B-X
has	B-X
emerged	B-X
as	B-X
protein	B-X
palmitoyl	B-X
acyltransferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
However	B-X
,	B-X
mechanisms	B-X
that	B-X
regulate	B-X
these	B-X
PATs	B-X
in	B-X
a	B-X
physiological	B-X
context	B-X
remain	B-X
unknown	B-X
.	B-X
We	B-X
found	B-X
that	B-X
blocking	B-X
synaptic	B-X
activity	B-X
rapidly	B-X
induces	B-X
PSD-95	B-X
palmitoylation	B-X
and	B-X
mediates	B-X
synaptic	B-X
clustering	B-X
of	B-X
PSD-95	B-X
and	B-X
associated	B-X
AMPA	B-X
(	B-X
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-X
propionic	B-X
acid	B-X
)	B-X
-type	B-X
glutamate	B-X
receptors	B-X
.	B-X
A	B-X
dendritically	B-X
localized	B-X
DHHC2	B-X
but	B-X
not	B-X
the	B-X
Golgi-resident	B-X
DHHC3	B-X
mediates	B-X
this	B-X
activity-sensitive	B-X
palmitoylation	B-X
.	B-X
Upon	B-X
activity	B-X
blockade	B-X
,	B-X
DHHC2	B-X
translocates	B-X
to	B-X
the	B-X
postsynaptic	B-X
density	B-X
to	B-X
transduce	B-X
this	B-X
effect	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
individual	B-X
DHHC	B-X
members	B-X
are	B-X
differentially	B-X
regulated	B-X
and	B-X
that	B-X
dynamic	B-X
recruitment	B-X
of	B-X
protein	B-X
palmitoylation	B-X
machinery	B-X
enables	B-X
compartmentalized	B-X
regulation	B-X
of	B-X
protein	B-X
trafficking	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X

However	O
,	O
mechanisms	O
that	O
regulate	O
these	O
PATs	O
in	O
a	O
physiological	O
context	O
remain	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
efficiently	O
monitored	O
the	O
dynamic	O
palmitate	O
cycling	O
on	O
synaptic	O
scaffold	O
PSD	B-Protein
-	I-Protein
95	I-Protein
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
efficiently	B-X
monitored	B-X
the	B-X
dynamic	B-X
palmitate	B-X
cycling	B-X
on	B-X
synaptic	B-X
scaffold	B-X
PSD-95	B-X
.	B-X
We	B-X
found	B-X
that	B-X
blocking	B-X
synaptic	B-X
activity	B-X
rapidly	B-X
induces	B-X
PSD-95	B-X
palmitoylation	B-X
and	B-X
mediates	B-X
synaptic	B-X
clustering	B-X
of	B-X
PSD-95	B-X
and	B-X
associated	B-X
AMPA	B-X
(	B-X
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-X
propionic	B-X
acid	B-X
)	B-X
-type	B-X
glutamate	B-X
receptors	B-X
.	B-X
Upon	B-X
activity	B-X
blockade	B-X
,	B-X
DHHC2	B-X
translocates	B-X
to	B-X
the	B-X
postsynaptic	B-X
density	B-X
to	B-X
transduce	B-X
this	B-X
effect	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
individual	B-X
DHHC	B-X
members	B-X
are	B-X
differentially	B-X
regulated	B-X
and	B-X
that	B-X
dynamic	B-X
recruitment	B-X
of	B-X
protein	B-X
palmitoylation	B-X
machinery	B-X
enables	B-X
compartmentalized	B-X
regulation	B-X
of	B-X
protein	B-X
trafficking	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X

We	O
found	O
that	O
blocking	O
synaptic	O
activity	O
rapidly	O
induces	O
PSD	B-Protein
-	I-Protein
95	I-Protein
palmitoylation	O
and	O
mediates	O
synaptic	O
clustering	O
of	O
PSD	B-Protein
-	I-Protein
95	I-Protein
and	O
associated	O
AMPA	O
(	O
alpha	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
isoxazole	O
propionic	O
acid	O
)	O
-	O
type	O
glutamate	O
receptors	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
posttranslational	B-X
lipid	B-X
modification	B-X
;	B-X
its	B-X
reversibility	B-X
mediates	B-X
protein	B-X
shuttling	B-X
between	B-X
intracellular	B-X
compartments	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
efficiently	B-X
monitored	B-X
the	B-X
dynamic	B-X
palmitate	B-X
cycling	B-X
on	B-X
synaptic	B-X
scaffold	B-X
PSD-95	B-X
.	B-X
We	B-X
found	B-X
that	B-X
blocking	B-X
synaptic	B-X
activity	B-X
rapidly	B-X
induces	B-X
PSD-95	B-X
palmitoylation	B-X
and	B-X
mediates	B-X
synaptic	B-X
clustering	B-X
of	B-X
PSD-95	B-X
and	B-X
associated	B-X
AMPA	B-X
(	B-X
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-X
propionic	B-X
acid	B-X
)	B-X
-type	B-X
glutamate	B-X
receptors	B-X
.	B-X
A	B-X
dendritically	B-X
localized	B-X
DHHC2	B-X
but	B-X
not	B-X
the	B-X
Golgi-resident	B-X
DHHC3	B-X
mediates	B-X
this	B-X
activity-sensitive	B-X
palmitoylation	B-X
.	B-X
Upon	B-X
activity	B-X
blockade	B-X
,	B-X
DHHC2	B-X
translocates	B-X
to	B-X
the	B-X
postsynaptic	B-X
density	B-X
to	B-X
transduce	B-X
this	B-X
effect	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
individual	B-X
DHHC	B-X
members	B-X
are	B-X
differentially	B-X
regulated	B-X
and	B-X
that	B-X
dynamic	B-X
recruitment	B-X
of	B-X
protein	B-X
palmitoylation	B-X
machinery	B-X
enables	B-X
compartmentalized	B-X
regulation	B-X
of	B-X
protein	B-X
trafficking	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X

A	O
dendritically	O
localized	O
DHHC2	B-Protein
but	O
not	O
the	O
Golgi	O
-	O
resident	O
DHHC3	B-Protein
mediates	O
this	O
activity	O
-	O
sensitive	O
palmitoylation	O
.	O
<EOS>	B-X
Intracellular	B-X
palmitoylation	B-X
dynamics	B-X
are	B-X
regulated	B-X
by	B-X
a	B-X
large	B-X
family	B-X
of	B-X
DHHC	B-X
(	B-X
Asp-His-His-Cys	B-X
)	B-X
palmitoyl	B-X
transferases	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
DHHC	B-X
proteins	B-X
associate	B-X
with	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
or	B-X
Golgi	B-X
membranes	B-X
,	B-X
but	B-X
an	B-X
interesting	B-X
exception	B-X
is	B-X
DHHC2	B-X
,	B-X
which	B-X
localizes	B-X
to	B-X
dendritic	B-X
vesicles	B-X
of	B-X
unknown	B-X
origin	B-X
in	B-X
neurons	B-X
,	B-X
where	B-X
it	B-X
regulates	B-X
dynamic	B-X
palmitoylation	B-X
of	B-X
PSD95	B-X
.	B-X
Dendritic	B-X
targeting	B-X
of	B-X
newly	B-X
synthesized	B-X
PSD95	B-X
is	B-X
likely	B-X
preceded	B-X
by	B-X
palmitoylation	B-X
on	B-X
Golgi	B-X
membranes	B-X
by	B-X
DHHC3	B-X
and/or	B-X
DHHC15	B-X
.	B-X
The	B-X
precise	B-X
intracellular	B-X
distribution	B-X
of	B-X
DHHC2	B-X
is	B-X
presently	B-X
unclear	B-X
,	B-X
and	B-X
there	B-X
is	B-X
very	B-X
little	B-X
known	B-X
in	B-X
general	B-X
about	B-X
how	B-X
DHHC	B-X
proteins	B-X
achieve	B-X
their	B-X
respective	B-X
localizations	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
membrane	B-X
targeting	B-X
of	B-X
DHHC2	B-X
in	B-X
live	B-X
and	B-X
fixed	B-X
neuroendocrine	B-X
cells	B-X
was	B-X
investigated	B-X
and	B-X
mutational	B-X
analysis	B-X
employed	B-X
to	B-X
define	B-X
regions	B-X
of	B-X
DHHC2	B-X
that	B-X
regulate	B-X
targeting	B-X
.	B-X
We	B-X
report	B-X
that	B-X
DHHC2	B-X
associates	B-X
with	B-X
the	B-X
plasma	B-X
membrane	B-X
,	B-X
Rab11-positive	B-X
recycling	B-X
endosomes	B-X
,	B-X
and	B-X
vesicular	B-X
structures	B-X
.	B-X
Plasma	B-X
membrane	B-X
integration	B-X
of	B-X
DHHC2	B-X
was	B-X
confirmed	B-X
by	B-X
labeling	B-X
of	B-X
an	B-X
extrafacial	B-X
HA	B-X
epitope	B-X
in	B-X
nonpermeabilized	B-X
cells	B-X
.	B-X
Antibody-uptake	B-X
experiments	B-X
suggested	B-X
that	B-X
DHHC2	B-X
traffics	B-X
between	B-X
the	B-X
plasma	B-X
membrane	B-X
and	B-X
intracellular	B-X
membranes	B-X
.	B-X
This	B-X
dynamic	B-X
localization	B-X
was	B-X
confirmed	B-X
using	B-X
fluorescence	B-X
recovery	B-X
after	B-X
photo-bleaching	B-X
analysis	B-X
,	B-X
which	B-X
revealed	B-X
constitutive	B-X
refilling	B-X
of	B-X
the	B-X
recycling	B-X
endosome	B-X
(	B-X
RE	B-X
)	B-X
pool	B-X
of	B-X
DHHC2	B-X
.	B-X
The	B-X
cytoplasmic	B-X
C-terminus	B-X
of	B-X
DHHC2	B-X
regulates	B-X
membrane	B-X
targeting	B-X
and	B-X
a	B-X
mutant	B-X
lacking	B-X
this	B-X
domain	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
ER	B-X
.	B-X
Although	B-X
DHHC2	B-X
is	B-X
closely	B-X
related	B-X
to	B-X
DHHC15	B-X
,	B-X
these	B-X
proteins	B-X
populate	B-X
distinct	B-X
membrane	B-X
compartments	B-X
.	B-X
Construction	B-X
of	B-X
chimeric	B-X
DHHC2/DHHC15	B-X
proteins	B-X
revealed	B-X
that	B-X
this	B-X
difference	B-X
in	B-X
localization	B-X
is	B-X
a	B-X
consequence	B-X
of	B-X
divergent	B-X
sequences	B-X
within	B-X
their	B-X
C-terminal	B-X
tails	B-X
.	B-X

Upon	O
activity	O
blockade	O
,	O
DHHC2	B-Protein
translocates	O
to	O
the	O
postsynaptic	O
density	O
to	O
transduce	O
this	O
effect	O
.	O

These	O
data	O
demonstrate	O
that	O
individual	O
DHHC	O
members	O
are	O
differentially	O
regulated	O
and	O
that	O
dynamic	O
recruitment	O
of	O
protein	O
palmitoylation	O
machinery	O
enables	O
compartmentalized	O
regulation	O
of	O
protein	O
trafficking	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O
<EOS>	B-X
Protein	B-X
palmitoylation	B-X
is	B-X
the	B-X
most	B-X
common	B-X
posttranslational	B-X
lipid	B-X
modification	B-X
;	B-X
its	B-X
reversibility	B-X
mediates	B-X
protein	B-X
shuttling	B-X
between	B-X
intracellular	B-X
compartments	B-X
.	B-X
A	B-X
large	B-X
family	B-X
of	B-X
DHHC	B-X
(	B-X
Asp-His-His-Cys	B-X
)	B-X
proteins	B-X
has	B-X
emerged	B-X
as	B-X
protein	B-X
palmitoyl	B-X
acyltransferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
efficiently	B-X
monitored	B-X
the	B-X
dynamic	B-X
palmitate	B-X
cycling	B-X
on	B-X
synaptic	B-X
scaffold	B-X
PSD-95	B-X
.	B-X
We	B-X
found	B-X
that	B-X
blocking	B-X
synaptic	B-X
activity	B-X
rapidly	B-X
induces	B-X
PSD-95	B-X
palmitoylation	B-X
and	B-X
mediates	B-X
synaptic	B-X
clustering	B-X
of	B-X
PSD-95	B-X
and	B-X
associated	B-X
AMPA	B-X
(	B-X
alpha-amino-3-hydroxy-5-methyl-4-isoxazole	B-X
propionic	B-X
acid	B-X
)	B-X
-type	B-X
glutamate	B-X
receptors	B-X
.	B-X
A	B-X
dendritically	B-X
localized	B-X
DHHC2	B-X
but	B-X
not	B-X
the	B-X
Golgi-resident	B-X
DHHC3	B-X
mediates	B-X
this	B-X
activity-sensitive	B-X
palmitoylation	B-X
.	B-X
Upon	B-X
activity	B-X
blockade	B-X
,	B-X
DHHC2	B-X
translocates	B-X
to	B-X
the	B-X
postsynaptic	B-X
density	B-X
to	B-X
transduce	B-X
this	B-X
effect	B-X
.	B-X
These	B-X
data	B-X
demonstrate	B-X
that	B-X
individual	B-X
DHHC	B-X
members	B-X
are	B-X
differentially	B-X
regulated	B-X
and	B-X
that	B-X
dynamic	B-X
recruitment	B-X
of	B-X
protein	B-X
palmitoylation	B-X
machinery	B-X
enables	B-X
compartmentalized	B-X
regulation	B-X
of	B-X
protein	B-X
trafficking	B-X
in	B-X
response	B-X
to	B-X
extracellular	B-X
signals	B-X
.	B-X

The	O
trafficking	O
/	O
interaction	O
of	O
eNOS	B-Protein
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
induced	O
by	O
insulin	B-Protein
modulates	O
endothelial	O
nitric	O
oxide	O
production	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Endothelial	B-Protein
nitric	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
eNOS	B-Protein
)	O
activity	O
is	O
tightly	O
regulated	O
by	O
posttranscriptional	O
modification	O
and	O
its	O
subcellular	O
localization	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Here	O
we	O
examined	O
whether	O
insulin	B-Protein
modulates	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
by	O
regulating	O
eNOS	B-Protein
subcellular	O
localization	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

We	O
used	O
confocal	O
microscopy	O
and	O
immunoblots	O
to	O
examine	O
the	O
time	O
course	O
for	O
1	O
)	O
subcellular	O
targeting	O
/	O
association	O
of	O
eNOS	B-Protein
and	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
(	O
CAV	B-Protein
-	I-Protein
1	I-Protein
)	O
;	O
2	O
)	O
eNOS	B-Protein
Ser	O
(	O
1179	O
)	O
phosphorylation	O
;	O
and	O
3	O
)	O
NO	O
production	O
in	O
cultured	O
bovine	O
aorta	O
endothelial	O
cells	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Serum	O
starvation	O
increased	O
eNOS	B-Protein
/	O
CAV	B-Protein
-	I-Protein
1	I-Protein
localization	O
to	O
the	O
perinuclear	O
region	O
.	O

Adding	O
insulin	B-Protein
provoked	O
their	O
prompt	O
translocation	O
to	O
and	O
association	O
at	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O
<EOS>	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Specific	O
monoclonal	O
antibodies	O
against	O
either	O
CAV	B-Protein
-	I-Protein
1	I-Protein
or	O
eNOS	B-Protein
coimmunoprecipitated	O
the	O
other	O
from	O
bovine	O
aorta	O
endothelial	O
cell	O
membrane	O
extracts	O
,	O
and	O
insulin	B-Protein
increased	O
this	O
interaction	O
.	O
<EOS>	B-X
To	B-X
date	B-X
,	B-X
there	B-X
are	B-X
no	B-X
monoclonal	B-X
antibodies	B-X
(	B-X
MAb	B-X
)	B-X
for	B-X
immunoassay	B-X
against	B-X
ω-conotoxin	B-X
MVIIA	B-X
.	B-X
The	B-X
conotoxin-coding	B-X
DNA	B-X
sequence	B-X
was	B-X
chemically	B-X
synthesized	B-X
and	B-X
cloned	B-X
into	B-X
expression	B-X
vector	B-X
pGEX-6p-1	B-X
and	B-X
pET32a	B-X
(	B-X
+	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
spleen	B-X
cells	B-X
were	B-X
fused	B-X
with	B-X
SP2/0	B-X
myeloma	B-X
cells	B-X
after	B-X
the	B-X
titer	B-X
of	B-X
antiserum	B-X
was	B-X
detected	B-X
and	B-X
qualified	B-X
.	B-X
After	B-X
being	B-X
screened	B-X
by	B-X
indirect	B-X
ELISA	B-X
and	B-X
cloned	B-X
by	B-X
limiting	B-X
dilution	B-X
,	B-X
a	B-X
hybridoma	B-X
named	B-X
4A12	B-X
,	B-X
which	B-X
produces	B-X
monoclonal	B-X
antibody	B-X
specifically	B-X
against	B-X
ω-CTX	B-X
MVIIA	B-X
,	B-X
was	B-X
successfully	B-X
obtained	B-X
.	B-X
It	B-X
was	B-X
found	B-X
that	B-X
there	B-X
are	B-X
102	B-X
chromosomes	B-X
in	B-X
the	B-X
4A12	B-X
cell	B-X
,	B-X
and	B-X
the	B-X
subclass	B-X
for	B-X
the	B-X
MAb	B-X
is	B-X
IgM	B-X
.	B-X
The	B-X
MAb	B-X
affinity	B-X
against	B-X
ω-CTX	B-X
MVIIA	B-X
was	B-X
7.33×10	B-X
(	B-X
9	B-X
)	B-X
L/mol	B-X
,	B-X
and	B-X
the	B-X
cross-reaction	B-X
test	B-X
showed	B-X
that	B-X
the	B-X
MAb	B-X
specifically	B-X
bound	B-X
ω-CTX	B-X
MVIIA	B-X
.	B-X

Insulin	B-Protein
stimulated	O
NO	O
production	O
transiently	O
despite	O
a	O
persistent	O
eNOS	B-Protein
Ser	O
(	O
1179	O
)	O
phosphorylation	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

The	O
decline	O
of	O
NO	O
production	O
correlated	O
temporally	O
to	O
insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Knockdown	O
of	O
CAV	B-Protein
-	I-Protein
1	I-Protein
expression	O
with	O
a	O
specific	O
small	O
interfering	O
RNA	O
duplex	O
resulted	O
in	O
eNOS	B-Protein
redistributing	O
to	O
the	O
perinuclear	O
region	O
and	O
nearly	O
doubled	O
insulin	B-Protein
-	O
induced	O
NO	O
production	O
.	O

Inhibition	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
activity	O
with	O
wortmannin	O
not	O
only	O
significantly	O
inhibited	O
insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
but	O
also	O
blocked	O
insulin	B-Protein
-	O
induced	O
interaction	O
of	O
CAV	B-Protein
-	I-Protein
1	I-Protein
with	O
eNOS	B-Protein
at	O
PM	O
.	O
<EOS>	B-X
The	B-X
phosphatidylinositol-3-kinase	B-X
(	B-X
PI	B-X
Phosphoinositide	B-X
3-kinase	B-X
(	B-X
PI3K	B-X
)	B-X
is	B-X
an	B-X
enzyme	B-X
that	B-X
mediates	B-X
endocrinological	B-X
responses	B-X
,	B-X
such	B-X
as	B-X
intracellular	B-X
signaling	B-X
of	B-X
insulin	B-X
and	B-X
growth	B-X
factors	B-X
,	B-X
and	B-X
plays	B-X
important	B-X
roles	B-X
in	B-X
muscle	B-X
homeostasis	B-X
and	B-X
growth	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
effect	B-X
of	B-X
antemortem	B-X
PI3K	B-X
activity	B-X
on	B-X
meat	B-X
quality	B-X
traits	B-X
was	B-X
investigated	B-X
using	B-X
broiler	B-X
chickens	B-X
whose	B-X
PI3K	B-X
was	B-X
inhibited	B-X
pharmacologically	B-X
.	B-X
Breast	B-X
and	B-X
thigh	B-X
muscles	B-X
were	B-X
harvested	B-X
from	B-X
broilers	B-X
treated	B-X
with	B-X
the	B-X
PI3K	B-X
inhibitor	B-X
wortmannin	B-X
,	B-X
and	B-X
meat	B-X
quality	B-X
traits	B-X
were	B-X
evaluated	B-X
by	B-X
determination	B-X
of	B-X
color	B-X
,	B-X
water-holding	B-X
capacity	B-X
,	B-X
and	B-X
breaking	B-X
strength	B-X
.	B-X
The	B-X
pH	B-X
and	B-X
concentrations	B-X
of	B-X
glycogen	B-X
and	B-X
free	B-X
amino	B-X
acids	B-X
were	B-X
also	B-X
investigated	B-X
as	B-X
determinants	B-X
of	B-X
the	B-X
chemical	B-X
properties	B-X
of	B-X
meat	B-X
.	B-X
The	B-X
results	B-X
indicated	B-X
that	B-X
antemortem	B-X
PI3K	B-X
inhibition	B-X
by	B-X
wortmannin	B-X
modified	B-X
breast	B-X
muscle	B-X
color	B-X
with	B-X
lower	B-X
L∗	B-X
values	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
b∗	B-X
values	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
higher	B-X
a∗	B-X
values	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Antemortem	B-X
PI3K	B-X
inhibition	B-X
also	B-X
increased	B-X
the	B-X
water-holding	B-X
capacity	B-X
of	B-X
breast	B-X
muscles	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
,	B-X
although	B-X
breaking	B-X
strength	B-X
was	B-X
not	B-X
much	B-X
affected	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
antemortem	B-X
PI3K	B-X
inhibition	B-X
increased	B-X
the	B-X
concentrations	B-X
of	B-X
free	B-X
amino	B-X
acids	B-X
in	B-X
breast	B-X
muscles	B-X
,	B-X
especially	B-X
arginine	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
glutamic	B-X
acid	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
.	B-X
Lower	B-X
glycogen	B-X
levels	B-X
at	B-X
sacrifice	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
and	B-X
the	B-X
resultant	B-X
higher	B-X
pH	B-X
during	B-X
the	B-X
postmortem	B-X
period	B-X
(	B-X
P	B-X
<	B-X
0.05	B-X
)	B-X
were	B-X
associated	B-X
with	B-X
PI3K	B-X
inhibition-induced	B-X
changes	B-X
in	B-X
meat	B-X
quality	B-X
traits	B-X
.	B-X
The	B-X
wortmannin-treated	B-X
muscles	B-X
shared	B-X
certain	B-X
features	B-X
with	B-X
dark	B-X
,	B-X
firm	B-X
,	B-X
and	B-X
dry	B-X
meat	B-X
which	B-X
is	B-X
a	B-X
common	B-X
abnormal	B-X
meat	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
antemortem	B-X
PI3K	B-X
activity	B-X
contributes	B-X
to	B-X
meat	B-X
quality	B-X
traits	B-X
and	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
molecular	B-X
mechanism	B-X
of	B-X
the	B-X
production	B-X
of	B-X
meat	B-X
quality	B-X
abnormalities	B-X
.	B-X

Insulin	B-Protein
increased	O
incorporation	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
palmitic	O
acid	O
into	O
eNOS	B-Protein
immunoprecipitates	O
by	O
approximately	O
140	O
%	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Insulin	B-Protein
-	O
induced	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
was	O
palmitoylation	O
dependent	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Inhibiting	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
palmitoylation	O
enhanced	O
the	O
NO	O
production	O
while	O
blocking	O
the	O
translocation	O
of	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
to	O
PM	O
induced	O
by	O
insulin	B-Protein
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

These	O
data	O
show	O
that	O
insulin	B-Protein
acutely	O
regulates	O
eNOS	B-Protein
and	O
CAV	B-Protein
-	I-Protein
1	I-Protein
trafficking	O
to	O
PM	O
of	O
vascular	O
endothelial	O
cells	O
where	O
their	O
interaction	O
can	O
regulate	O
eNOS	B-Protein
activity	O
.	O
<EOS>	B-X
Endothelial	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
activity	B-X
is	B-X
tightly	B-X
regulated	B-X
by	B-X
posttranscriptional	B-X
modification	B-X
and	B-X
its	B-X
subcellular	B-X
localization	B-X
.	B-X
Here	B-X
we	B-X
examined	B-X
whether	B-X
insulin	B-X
modulates	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
production	B-X
by	B-X
regulating	B-X
eNOS	B-X
subcellular	B-X
localization	B-X
.	B-X
We	B-X
used	B-X
confocal	B-X
microscopy	B-X
and	B-X
immunoblots	B-X
to	B-X
examine	B-X
the	B-X
time	B-X
course	B-X
for	B-X
1	B-X
)	B-X
subcellular	B-X
targeting/association	B-X
of	B-X
eNOS	B-X
and	B-X
caveolin-1	B-X
(	B-X
CAV-1	B-X
)	B-X
;	B-X
2	B-X
)	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
;	B-X
and	B-X
3	B-X
)	B-X
NO	B-X
production	B-X
in	B-X
cultured	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cells	B-X
.	B-X
Serum	B-X
starvation	B-X
increased	B-X
eNOS/CAV-1	B-X
localization	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
.	B-X
Adding	B-X
insulin	B-X
provoked	B-X
their	B-X
prompt	B-X
translocation	B-X
to	B-X
and	B-X
association	B-X
at	B-X
the	B-X
plasma	B-X
membrane	B-X
(	B-X
PM	B-X
)	B-X
.	B-X
Specific	B-X
monoclonal	B-X
antibodies	B-X
against	B-X
either	B-X
CAV-1	B-X
or	B-X
eNOS	B-X
coimmunoprecipitated	B-X
the	B-X
other	B-X
from	B-X
bovine	B-X
aorta	B-X
endothelial	B-X
cell	B-X
membrane	B-X
extracts	B-X
,	B-X
and	B-X
insulin	B-X
increased	B-X
this	B-X
interaction	B-X
.	B-X
Insulin	B-X
stimulated	B-X
NO	B-X
production	B-X
transiently	B-X
despite	B-X
a	B-X
persistent	B-X
eNOS	B-X
Ser	B-X
(	B-X
1179	B-X
)	B-X
phosphorylation	B-X
.	B-X
The	B-X
decline	B-X
of	B-X
NO	B-X
production	B-X
correlated	B-X
temporally	B-X
to	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
.	B-X
Knockdown	B-X
of	B-X
CAV-1	B-X
expression	B-X
with	B-X
a	B-X
specific	B-X
small	B-X
interfering	B-X
RNA	B-X
duplex	B-X
resulted	B-X
in	B-X
eNOS	B-X
redistributing	B-X
to	B-X
the	B-X
perinuclear	B-X
region	B-X
and	B-X
nearly	B-X
doubled	B-X
insulin-induced	B-X
NO	B-X
production	B-X
.	B-X
Inhibition	B-X
of	B-X
phosphatidylinositol	B-X
3-kinase	B-X
activity	B-X
with	B-X
wortmannin	B-X
not	B-X
only	B-X
significantly	B-X
inhibited	B-X
insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
but	B-X
also	B-X
blocked	B-X
insulin-induced	B-X
interaction	B-X
of	B-X
CAV-1	B-X
with	B-X
eNOS	B-X
at	B-X
PM	B-X
.	B-X
Insulin	B-X
increased	B-X
incorporation	B-X
of	B-X
[	B-X
(	B-X
3	B-X
)	B-X
H	B-X
]	B-X
palmitic	B-X
acid	B-X
into	B-X
eNOS	B-X
immunoprecipitates	B-X
by	B-X
approximately	B-X
140	B-X
%	B-X
.	B-X
Insulin-induced	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
was	B-X
palmitoylation	B-X
dependent	B-X
.	B-X
Inhibiting	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
palmitoylation	B-X
enhanced	B-X
the	B-X
NO	B-X
production	B-X
while	B-X
blocking	B-X
the	B-X
translocation	B-X
of	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
to	B-X
PM	B-X
induced	B-X
by	B-X
insulin	B-X
.	B-X
These	B-X
data	B-X
show	B-X
that	B-X
insulin	B-X
acutely	B-X
regulates	B-X
eNOS	B-X
and	B-X
CAV-1	B-X
trafficking	B-X
to	B-X
PM	B-X
of	B-X
vascular	B-X
endothelial	B-X
cells	B-X
where	B-X
their	B-X
interaction	B-X
can	B-X
regulate	B-X
eNOS	B-X
activity	B-X
.	B-X

Crosstalk	O
between	O
the	O
NF	O
-	O
kappaB	O
activating	O
IKK	O
-	O
complex	O
and	O
the	O
CSN	O
signalosome	O
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

A	O
great	O
variety	O
of	O
signalling	O
pathways	O
regulating	O
inflammation	O
,	O
cell	O
development	O
and	O
cell	O
survival	O
require	O
NF	O
-	O
kappaB	O
transcription	O
factors	O
,	O
which	O
are	O
normally	O
inactive	O
due	O
to	O
binding	O
to	O
inhibitors	O
,	O
such	O
as	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
Csn5/JAB1	B-X
requires	B-X
a	B-X
functional	B-X
MPN	B-X
(	B-X
+	B-X
)	B-X
metalloprotease	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
cleaving	B-X
ubiquitin-like	B-X
Nedd8-modifications	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

The	O
canonical	O
activation	O
pathway	O
of	O
NF	O
-	O
kappaB	O
is	O
initiated	O
by	O
phosphorylation	O
of	O
the	O
inhibitor	O
by	O
an	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
complex	O
triggering	O
ubiquitination	O
of	O
IkappaB	O
molecules	O
by	O
SCF	O
-	O
type	O
E3	O
-	O
ligase	O
complexes	O
and	O
rapid	O
degradation	O
by	O
26S	O
-	O
proteasomes	O
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
Csn5/JAB1	B-X
requires	B-X
a	B-X
functional	B-X
MPN	B-X
(	B-X
+	B-X
)	B-X
metalloprotease	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
cleaving	B-X
ubiquitin-like	B-X
Nedd8-modifications	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

The	O
ubiquitination	O
machinery	O
is	O
regulated	O
by	O
the	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
.	O
<EOS>	B-X
The	B-X
Cullin-RING	B-X
E3	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
are	B-X
major	B-X
ubiquitylation	B-X
machineries	B-X
regulated	B-X
by	B-X
reversible	B-X
cycles	B-X
of	B-X
neddylation	B-X
and	B-X
deneddylation	B-X
.	B-X
The	B-X
deneddylase	B-X
COP9	B-X
Signalosome	B-X
(	B-X
CSN	B-X
)	B-X
terminates	B-X
CRL	B-X
catalytic	B-X
cycle	B-X
.	B-X
CSN	B-X
also	B-X
provides	B-X
a	B-X
docking	B-X
platform	B-X
for	B-X
several	B-X
kinases	B-X
and	B-X
deubiquitinases	B-X
that	B-X
might	B-X
play	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
CRL	B-X
.	B-X
The	B-X
cryo-EM	B-X
structures	B-X
of	B-X
CRL-CSN	B-X
complexes	B-X
provide	B-X
the	B-X
biochemical	B-X
basis	B-X
of	B-X
their	B-X
cognate	B-X
interactions	B-X
and	B-X
reveal	B-X
potential	B-X
regulatory	B-X
mechanisms	B-X
during	B-X
complex	B-X
disassembly	B-X
.	B-X
Moreover	B-X
,	B-X
novel	B-X
players	B-X
beyond	B-X
the	B-X
canonical	B-X
eight	B-X
subunits	B-X
of	B-X
CSN	B-X
were	B-X
identified	B-X
.	B-X
This	B-X
includes	B-X
CSNAP	B-X
,	B-X
a	B-X
potential	B-X
9th	B-X
CSN	B-X
subunit	B-X
with	B-X
regulatory	B-X
functions	B-X
,	B-X
and	B-X
the	B-X
metabolite	B-X
inositol	B-X
hexakisphosphate	B-X
(	B-X
IP	B-X

We	O
show	O
that	O
IkappaB	O
kinases	O
interact	O
with	O
the	O
CSN	O
-	O
complex	O
,	O
as	O
well	O
as	O
the	O
SCF	O
-	O
ubiquitination	O
machinery	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
rapid	O
signalling	O
-	O
induced	O
ubiquitination	O
and	O
degradation	O
of	O
IkappaBalpha	B-Protein
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

Furthermore	O
,	O
we	O
reveal	O
that	O
IKK	O
'	O
s	O
phosphorylate	O
not	O
only	O
IkappaBalpha	B-Protein
,	O
but	O
also	O
the	O
CSN	O
-	O
subunit	O
Csn5	B-Protein
/	O
JAB1	B-Protein
(	O
c	B-Protein
-	I-Protein
Jun	I-Protein
activation	I-Protein
domain	I-Protein
binding	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
)	O
and	O
that	O
IKK2	B-Protein
influences	O
ubiquitination	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
.	O
<EOS>	B-X
25-hydroxycholesterol	B-X
(	B-X
25-HC	B-X
)	B-X
is	B-X
one	B-X
of	B-X
the	B-X
oxysterols	B-X
,	B-X
which	B-X
are	B-X
oxidized	B-X
derivatives	B-X
of	B-X
cholesterol	B-X
,	B-X
and	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
atherosclerosis	B-X
and	B-X
Alzheimer	B-X
's	B-X
disease	B-X
.	B-X
In	B-X
lung	B-X
,	B-X
the	B-X
possible	B-X
involvement	B-X
of	B-X
25-HC	B-X
in	B-X
airway	B-X
diseases	B-X
has	B-X
been	B-X
revealed	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
examined	B-X
whether	B-X
25-HC	B-X
affects	B-X
the	B-X
release	B-X
of	B-X
cytokines	B-X
and	B-X
also	B-X
modulates	B-X
the	B-X
responses	B-X
of	B-X
toll-like	B-X
receptor	B-X
3	B-X
(	B-X
TLR3	B-X
)	B-X
in	B-X
airway	B-X
epithelial	B-X
cells	B-X
.	B-X
Herpes	B-X
simplex	B-X
virus	B-X
type	B-X
2	B-X
(	B-X
HSV-2	B-X
)	B-X
is	B-X
a	B-X
prevalent	B-X
human	B-X
pathogen	B-X
and	B-X
the	B-X
main	B-X
cause	B-X
of	B-X
genital	B-X
herpes	B-X
.	B-X
After	B-X
initial	B-X
infection	B-X
,	B-X
HSV-2	B-X
can	B-X
establish	B-X
lifelong	B-X
latency	B-X
within	B-X
dorsal	B-X
root	B-X
ganglia	B-X
by	B-X
evading	B-X
the	B-X
innate	B-X
immunity	B-X
of	B-X
the	B-X
host	B-X
.	B-X
NF-κB	B-X
has	B-X
a	B-X
crucial	B-X
role	B-X
in	B-X
regulating	B-X
cell	B-X
proliferation	B-X
,	B-X
inflammation	B-X
,	B-X
apoptosis	B-X
,	B-X
and	B-X
immune	B-X
responses	B-X
.	B-X
It	B-X
is	B-X
known	B-X
that	B-X
inhibition	B-X
of	B-X
NF-κB	B-X
activation	B-X
by	B-X
a	B-X
virus	B-X
could	B-X
facilitate	B-X
it	B-X
to	B-X
establish	B-X
infection	B-X
in	B-X
the	B-X
host	B-X
.	B-X
In	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
found	B-X
that	B-X
HSV-2	B-X
inhibited	B-X
TNF-α-induced	B-X
activation	B-X
of	B-X
NF-κB-responsive	B-X
promoter	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
,	B-X
while	B-X
UV-inactivated	B-X
HSV-2	B-X
did	B-X
not	B-X
have	B-X
such	B-X
capability	B-X
.	B-X
We	B-X
further	B-X
identified	B-X
the	B-X
immediate	B-X
early	B-X
protein	B-X
ICP22	B-X
of	B-X
HSV-2	B-X
as	B-X
a	B-X
vital	B-X
viral	B-X
element	B-X
in	B-X
inhibiting	B-X
the	B-X
activation	B-X
of	B-X
NF-κB-responsive	B-X
promoter	B-X
.	B-X
The	B-X
role	B-X
of	B-X
ICP22	B-X
was	B-X
confirmed	B-X
in	B-X
human	B-X
cervical	B-X
cell	B-X
line	B-X
HeLa	B-X
and	B-X
primary	B-X
cervical	B-X
fibroblasts	B-X
in	B-X
the	B-X
context	B-X
of	B-X
HSV-2	B-X
infection	B-X
,	B-X
showing	B-X
that	B-X
ICP22	B-X
deficient	B-X
HSV-2	B-X
largely	B-X
lost	B-X
the	B-X
capability	B-X
in	B-X
suppressing	B-X
NF-κB	B-X
activation	B-X
.	B-X
HSV-2	B-X
ICP22	B-X
was	B-X
further	B-X
shown	B-X
to	B-X
suppress	B-X
the	B-X
activity	B-X
of	B-X
TNF	B-X
receptor-associated	B-X
factor	B-X
2	B-X
(	B-X
TRAF2	B-X
)	B-X
-	B-X
,	B-X
IκB	B-X
kinase	B-X
α	B-X
(	B-X
IKK	B-X
α	B-X
)	B-X
-	B-X
,	B-X
IKK	B-X
β-	B-X
,	B-X
IKK	B-X
γ-	B-X
,	B-X
or	B-X
p65-induced	B-X
activation	B-X
of	B-X
NF-κB-responsive	B-X
promoter	B-X
.	B-X
Mechanistically	B-X
,	B-X
HSV-2	B-X
ICP22	B-X
inhibited	B-X
the	B-X
phosphorylation	B-X
and	B-X
nuclear	B-X
translocation	B-X
of	B-X
p65	B-X
by	B-X
directly	B-X
interacting	B-X
with	B-X
p65	B-X
,	B-X
resulting	B-X
in	B-X
the	B-X
blockade	B-X
of	B-X
NF-κB	B-X
activation	B-X
.	B-X
Furthermore	B-X
,	B-X
ICP22	B-X
from	B-X
several	B-X
alpha-herpesviruses	B-X
could	B-X
also	B-X
inhibit	B-X
NF-κB	B-X
activation	B-X
,	B-X
suggesting	B-X
the	B-X
significance	B-X
of	B-X
ICP22	B-X
in	B-X
herpesvirus	B-X
immune	B-X
evasion	B-X
.	B-X
Findings	B-X
in	B-X
this	B-X
study	B-X
highlight	B-X
the	B-X
importance	B-X
of	B-X
ICP22	B-X
in	B-X
inhibiting	B-X
NF-κB	B-X
activation	B-X
,	B-X
revealing	B-X
a	B-X
novel	B-X
mechanism	B-X
by	B-X
which	B-X
HSV-2	B-X
evades	B-X
the	B-X
host	B-X
antiviral	B-X
responses	B-X
.	B-X

Our	O
observations	O
imply	O
that	O
the	O
CSN	O
complex	O
acts	O
as	O
an	O
inhibitor	O
of	O
constitutive	O
NF	O
-	O
kappaB	O
activity	O
in	O
non	O
-	O
activated	O
cells	O
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
Csn5/JAB1	B-X
requires	B-X
a	B-X
functional	B-X
MPN	B-X
(	B-X
+	B-X
)	B-X
metalloprotease	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
cleaving	B-X
ubiquitin-like	B-X
Nedd8-modifications	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

Knock	O
-	O
down	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
clearly	O
enhanced	O
basal	O
NF	O
-	O
kappaB	O
activity	O
and	O
improved	O
cell	O
survival	O
under	O
stress	O
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
Csn5/JAB1	B-X
requires	B-X
a	B-X
functional	B-X
MPN	B-X
(	B-X
+	B-X
)	B-X
metalloprotease	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
cleaving	B-X
ubiquitin-like	B-X
Nedd8-modifications	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

The	O
inhibitory	O
effect	O
of	O
Csn5	B-Protein
/	O
JAB1	B-Protein
requires	O
a	O
functional	O
MPN	O
(	O
+	O
)	O
metalloprotease	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
cleaving	O
ubiquitin	B-Protein
-	O
like	O
Nedd8	B-Protein
-	O
modifications	O
.	O
<EOS>	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
The	B-X
inhibitory	B-X
effect	B-X
of	B-X
Csn5/JAB1	B-X
requires	B-X
a	B-X
functional	B-X
MPN	B-X
(	B-X
+	B-X
)	B-X
metalloprotease	B-X
domain	B-X
,	B-X
which	B-X
is	B-X
responsible	B-X
for	B-X
cleaving	B-X
ubiquitin-like	B-X
Nedd8-modifications	B-X
.	B-X

Upon	O
activation	O
of	O
cells	O
with	O
tumour	B-Protein
necrosis	I-Protein
factor	I-Protein
-	I-Protein
alpha	I-Protein
,	O
the	O
CSN	O
complex	O
dissociates	O
from	O
IKK	O
'	O
s	O
allowing	O
full	O
and	O
rapid	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
pathway	O
by	O
the	O
concerted	O
action	O
of	O
interacting	O
protein	O
complexes	O
.	O
<EOS>	B-X
A	B-X
great	B-X
variety	B-X
of	B-X
signalling	B-X
pathways	B-X
regulating	B-X
inflammation	B-X
,	B-X
cell	B-X
development	B-X
and	B-X
cell	B-X
survival	B-X
require	B-X
NF-kappaB	B-X
transcription	B-X
factors	B-X
,	B-X
which	B-X
are	B-X
normally	B-X
inactive	B-X
due	B-X
to	B-X
binding	B-X
to	B-X
inhibitors	B-X
,	B-X
such	B-X
as	B-X
IkappaBalpha	B-X
.	B-X
The	B-X
canonical	B-X
activation	B-X
pathway	B-X
of	B-X
NF-kappaB	B-X
is	B-X
initiated	B-X
by	B-X
phosphorylation	B-X
of	B-X
the	B-X
inhibitor	B-X
by	B-X
an	B-X
IkappaB	B-X
kinase	B-X
(	B-X
IKK	B-X
)	B-X
complex	B-X
triggering	B-X
ubiquitination	B-X
of	B-X
IkappaB	B-X
molecules	B-X
by	B-X
SCF-type	B-X
E3-ligase	B-X
complexes	B-X
and	B-X
rapid	B-X
degradation	B-X
by	B-X
26S-proteasomes	B-X
.	B-X
The	B-X
ubiquitination	B-X
machinery	B-X
is	B-X
regulated	B-X
by	B-X
the	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
.	B-X
We	B-X
show	B-X
that	B-X
IkappaB	B-X
kinases	B-X
interact	B-X
with	B-X
the	B-X
CSN-complex	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
SCF-ubiquitination	B-X
machinery	B-X
,	B-X
providing	B-X
an	B-X
explanation	B-X
for	B-X
the	B-X
rapid	B-X
signalling-induced	B-X
ubiquitination	B-X
and	B-X
degradation	B-X
of	B-X
IkappaBalpha	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
reveal	B-X
that	B-X
IKK	B-X
's	B-X
phosphorylate	B-X
not	B-X
only	B-X
IkappaBalpha	B-X
,	B-X
but	B-X
also	B-X
the	B-X
CSN-subunit	B-X
Csn5/JAB1	B-X
(	B-X
c-Jun	B-X
activation	B-X
domain	B-X
binding	B-X
protein-1	B-X
)	B-X
and	B-X
that	B-X
IKK2	B-X
influences	B-X
ubiquitination	B-X
of	B-X
Csn5/JAB1	B-X
.	B-X
Our	B-X
observations	B-X
imply	B-X
that	B-X
the	B-X
CSN	B-X
complex	B-X
acts	B-X
as	B-X
an	B-X
inhibitor	B-X
of	B-X
constitutive	B-X
NF-kappaB	B-X
activity	B-X
in	B-X
non-activated	B-X
cells	B-X
.	B-X
Knock-down	B-X
of	B-X
Csn5/JAB1	B-X
clearly	B-X
enhanced	B-X
basal	B-X
NF-kappaB	B-X
activity	B-X
and	B-X
improved	B-X
cell	B-X
survival	B-X
under	B-X
stress	B-X
.	B-X
Upon	B-X
activation	B-X
of	B-X
cells	B-X
with	B-X
tumour	B-X
necrosis	B-X
factor-alpha	B-X
,	B-X
the	B-X
CSN	B-X
complex	B-X
dissociates	B-X
from	B-X
IKK	B-X
's	B-X
allowing	B-X
full	B-X
and	B-X
rapid	B-X
activation	B-X
of	B-X
the	B-X
NF-kappaB	B-X
pathway	B-X
by	B-X
the	B-X
concerted	B-X
action	B-X
of	B-X
interacting	B-X
protein	B-X
complexes	B-X
.	B-X

Prenylation	O
-	O
deficient	O
G	O
protein	O
gamma	O
subunits	O
disrupt	O
GPCR	O
signaling	O
in	O
the	O
zebrafish	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
This	B-X
disruption	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
calcium	B-X
accumulation	B-X
in	B-X
the	B-X
protrusions	B-X
of	B-X
migrating	B-X
PGCs	B-X
and	B-X
a	B-X
failure	B-X
of	B-X
PGCs	B-X
to	B-X
directionally	B-X
migrate	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

Prenylation	O
of	O
G	O
protein	O
gamma	O
(	O
gamma	O
)	O
subunits	O
is	O
necessary	O
for	O
the	O
membrane	O
localization	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
for	O
functional	O
heterotrimeric	O
G	O
protein	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
signaling	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
This	B-X
disruption	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
calcium	B-X
accumulation	B-X
in	B-X
the	B-X
protrusions	B-X
of	B-X
migrating	B-X
PGCs	B-X
and	B-X
a	B-X
failure	B-X
of	B-X
PGCs	B-X
to	B-X
directionally	B-X
migrate	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

To	O
evaluate	O
GPCR	O
signaling	O
pathways	O
during	O
development	O
,	O
we	O
injected	O
zebrafish	O
embryos	O
with	O
mRNAs	O
encoding	O
Ggamma	O
subunits	O
mutated	O
so	O
that	O
they	O
can	O
no	O
longer	O
be	O
prenylated	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

Low	O
-	O
level	O
expression	O
of	O
these	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
driven	O
either	O
ubiquitously	O
or	O
specifically	O
in	O
the	O
primordial	O
germ	O
cells	O
(	O
PGCs	O
)	O
disrupts	O
GPCR	O
signaling	O
and	O
manifests	O
as	O
a	O
PGC	O
migration	O
defect	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
This	B-X
disruption	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
calcium	B-X
accumulation	B-X
in	B-X
the	B-X
protrusions	B-X
of	B-X
migrating	B-X
PGCs	B-X
and	B-X
a	B-X
failure	B-X
of	B-X
PGCs	B-X
to	B-X
directionally	B-X
migrate	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

This	O
disruption	O
results	O
in	O
a	O
reduction	O
of	O
calcium	O
accumulation	O
in	O
the	O
protrusions	O
of	O
migrating	O
PGCs	O
and	O
a	O
failure	O
of	O
PGCs	O
to	O
directionally	O
migrate	O
.	O

When	O
co	O
-	O
expressed	O
with	O
a	O
prenylation	O
-	O
deficient	O
Ggamma	O
,	O
8	O
of	O
the	O
17	O
wildtype	O
Ggamma	O
isoforms	O
individually	O
confer	O
the	O
ability	O
to	O
restore	O
calcium	O
accumulation	O
and	O
directional	O
migration	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
This	B-X
disruption	B-X
results	B-X
in	B-X
a	B-X
reduction	B-X
of	B-X
calcium	B-X
accumulation	B-X
in	B-X
the	B-X
protrusions	B-X
of	B-X
migrating	B-X
PGCs	B-X
and	B-X
a	B-X
failure	B-X
of	B-X
PGCs	B-X
to	B-X
directionally	B-X
migrate	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

These	O
results	O
suggest	O
that	O
while	O
the	O
Ggamma	O
subunits	O
possess	O
the	O
ability	O
to	O
interact	O
with	O
G	O
Beta	O
(	O
beta	O
)	O
proteins	O
,	O
only	O
a	O
subset	O
of	O
wildtype	O
Ggamma	O
proteins	O
are	O
stable	O
within	O
PGCs	O
and	O
can	O
interact	O
with	O
key	O
signaling	O
components	O
necessary	O
for	O
PGC	O
migration	O
.	O

This	O
in	O
vivo	O
study	O
highlights	O
the	O
functional	O
redundancy	O
of	O
these	O
signaling	O
components	O
and	O
demonstrates	O
that	O
prenylation	O
-	O
deficient	O
Ggamma	O
subunits	O
are	O
an	O
effective	O
tool	O
to	O
investigate	O
the	O
roles	O
of	O
GPCR	O
signaling	O
events	O
during	O
vertebrate	O
development	O
.	O
<EOS>	B-X
Prenylation	B-X
of	B-X
G	B-X
protein	B-X
gamma	B-X
(	B-X
gamma	B-X
)	B-X
subunits	B-X
is	B-X
necessary	B-X
for	B-X
the	B-X
membrane	B-X
localization	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
for	B-X
functional	B-X
heterotrimeric	B-X
G	B-X
protein	B-X
coupled	B-X
receptor	B-X
(	B-X
GPCR	B-X
)	B-X
signaling	B-X
.	B-X
To	B-X
evaluate	B-X
GPCR	B-X
signaling	B-X
pathways	B-X
during	B-X
development	B-X
,	B-X
we	B-X
injected	B-X
zebrafish	B-X
embryos	B-X
with	B-X
mRNAs	B-X
encoding	B-X
Ggamma	B-X
subunits	B-X
mutated	B-X
so	B-X
that	B-X
they	B-X
can	B-X
no	B-X
longer	B-X
be	B-X
prenylated	B-X
.	B-X
Low-level	B-X
expression	B-X
of	B-X
these	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
driven	B-X
either	B-X
ubiquitously	B-X
or	B-X
specifically	B-X
in	B-X
the	B-X
primordial	B-X
germ	B-X
cells	B-X
(	B-X
PGCs	B-X
)	B-X
disrupts	B-X
GPCR	B-X
signaling	B-X
and	B-X
manifests	B-X
as	B-X
a	B-X
PGC	B-X
migration	B-X
defect	B-X
.	B-X
When	B-X
co-expressed	B-X
with	B-X
a	B-X
prenylation-deficient	B-X
Ggamma	B-X
,	B-X
8	B-X
of	B-X
the	B-X
17	B-X
wildtype	B-X
Ggamma	B-X
isoforms	B-X
individually	B-X
confer	B-X
the	B-X
ability	B-X
to	B-X
restore	B-X
calcium	B-X
accumulation	B-X
and	B-X
directional	B-X
migration	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
while	B-X
the	B-X
Ggamma	B-X
subunits	B-X
possess	B-X
the	B-X
ability	B-X
to	B-X
interact	B-X
with	B-X
G	B-X
Beta	B-X
(	B-X
beta	B-X
)	B-X
proteins	B-X
,	B-X
only	B-X
a	B-X
subset	B-X
of	B-X
wildtype	B-X
Ggamma	B-X
proteins	B-X
are	B-X
stable	B-X
within	B-X
PGCs	B-X
and	B-X
can	B-X
interact	B-X
with	B-X
key	B-X
signaling	B-X
components	B-X
necessary	B-X
for	B-X
PGC	B-X
migration	B-X
.	B-X
This	B-X
in	B-X
vivo	B-X
study	B-X
highlights	B-X
the	B-X
functional	B-X
redundancy	B-X
of	B-X
these	B-X
signaling	B-X
components	B-X
and	B-X
demonstrates	B-X
that	B-X
prenylation-deficient	B-X
Ggamma	B-X
subunits	B-X
are	B-X
an	B-X
effective	B-X
tool	B-X
to	B-X
investigate	B-X
the	B-X
roles	B-X
of	B-X
GPCR	B-X
signaling	B-X
events	B-X
during	B-X
vertebrate	B-X
development	B-X
.	B-X

Statins	O
inhibit	O
protein	O
lipidation	O
and	O
induce	O
the	O
unfolded	O
protein	O
response	O
in	O
the	O
non	O
-	O
sterol	O
producing	O
nematode	O
Caenorhabditis	O
elegans	O
.	O
<EOS>	B-X
Statins	B-X
are	B-X
compounds	B-X
prescribed	B-X
to	B-X
lower	B-X
blood	B-X
cholesterol	B-X
in	B-X
millions	B-X
of	B-X
patients	B-X
worldwide	B-X
.	B-X
They	B-X
act	B-X
by	B-X
inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
,	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
the	B-X
mevalonate	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
a	B-X
precursor	B-X
for	B-X
cholesterol	B-X
synthesis	B-X
and	B-X
the	B-X
source	B-X
of	B-X
lipid	B-X
moieties	B-X
for	B-X
protein	B-X
prenylation	B-X
.	B-X
The	B-X
nematode	B-X
Caenorhabditis	B-X
elegans	B-X
possesses	B-X
a	B-X
mevalonate	B-X
pathway	B-X
that	B-X
lacks	B-X
the	B-X
branch	B-X
leading	B-X
to	B-X
cholesterol	B-X
synthesis	B-X
,	B-X
and	B-X
thus	B-X
represents	B-X
an	B-X
ideal	B-X
organism	B-X
to	B-X
specifically	B-X
study	B-X
the	B-X
noncholesterol	B-X
roles	B-X
of	B-X
the	B-X
pathway	B-X
.	B-X
Inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
in	B-X
C.	B-X
elegans	B-X
using	B-X
statins	B-X
or	B-X
RNAi	B-X
leads	B-X
to	B-X
developmental	B-X
arrest	B-X
and	B-X
loss	B-X
of	B-X
membrane	B-X
association	B-X
of	B-X
a	B-X
GFP-based	B-X
prenylation	B-X
reporter	B-X
.	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
is	B-X
also	B-X
strongly	B-X
activated	B-X
,	B-X
suggesting	B-X
that	B-X
impaired	B-X
prenylation	B-X
of	B-X
small	B-X
GTPases	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
and	B-X
ER	B-X
stress	B-X
.	B-X
UPR	B-X
induction	B-X
was	B-X
also	B-X
observed	B-X
upon	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
farnesyl	B-X
transferases	B-X
or	B-X
RNAi	B-X
inhibition	B-X
of	B-X
a	B-X
specific	B-X
isoprenoid	B-X
transferase	B-X
(	B-X
M57.2	B-X
)	B-X
and	B-X
found	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
both	B-X
ire-1	B-X
and	B-X
xbp-1	B-X
but	B-X
not	B-X
on	B-X
pek-1	B-X
or	B-X
atf-6	B-X
,	B-X
which	B-X
are	B-X
all	B-X
known	B-X
regulators	B-X
of	B-X
the	B-X
UPR	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
inhibitors	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
or	B-X
of	B-X
farnesyl	B-X
transferases	B-X
induce	B-X
the	B-X
UPR	B-X
by	B-X
inhibiting	B-X
the	B-X
prenylation	B-X
of	B-X
M57.2	B-X
substrates	B-X
,	B-X
resulting	B-X
in	B-X
developmental	B-X
arrest	B-X
in	B-X
C.	B-X
elegans	B-X
.	B-X

Statins	O
are	O
compounds	O
prescribed	O
to	O
lower	O
blood	O
cholesterol	O
in	O
millions	O
of	O
patients	O
worldwide	O
.	O
<EOS>	B-X
Statins	B-X
are	B-X
compounds	B-X
prescribed	B-X
to	B-X
lower	B-X
blood	B-X
cholesterol	B-X
in	B-X
millions	B-X
of	B-X
patients	B-X
worldwide	B-X
.	B-X
They	B-X
act	B-X
by	B-X
inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
,	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
the	B-X
mevalonate	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
a	B-X
precursor	B-X
for	B-X
cholesterol	B-X
synthesis	B-X
and	B-X
the	B-X
source	B-X
of	B-X
lipid	B-X
moieties	B-X
for	B-X
protein	B-X
prenylation	B-X
.	B-X
The	B-X
nematode	B-X
Caenorhabditis	B-X
elegans	B-X
possesses	B-X
a	B-X
mevalonate	B-X
pathway	B-X
that	B-X
lacks	B-X
the	B-X
branch	B-X
leading	B-X
to	B-X
cholesterol	B-X
synthesis	B-X
,	B-X
and	B-X
thus	B-X
represents	B-X
an	B-X
ideal	B-X
organism	B-X
to	B-X
specifically	B-X
study	B-X
the	B-X
noncholesterol	B-X
roles	B-X
of	B-X
the	B-X
pathway	B-X
.	B-X

They	O
act	O
by	O
inhibiting	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
mevalonate	O
pathway	O
that	O
leads	O
to	O
the	O
synthesis	O
of	O
farnesyl	O
pyrophosphate	O
,	O
a	O
precursor	O
for	O
cholesterol	O
synthesis	O
and	O
the	O
source	O
of	O
lipid	O
moieties	O
for	O
protein	O
prenylation	O
.	O

The	O
nematode	O
Caenorhabditis	O
elegans	O
possesses	O
a	O
mevalonate	O
pathway	O
that	O
lacks	O
the	O
branch	O
leading	O
to	O
cholesterol	O
synthesis	O
,	O
and	O
thus	O
represents	O
an	O
ideal	O
organism	O
to	O
specifically	O
study	O
the	O
noncholesterol	O
roles	O
of	O
the	O
pathway	O
.	O

Inhibiting	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
in	O
C	O
.	O
elegans	O
using	O
statins	O
or	O
RNAi	O
leads	O
to	O
developmental	O
arrest	O
and	O
loss	O
of	O
membrane	O
association	O
of	O
a	O
GFP	B-Protein
-	O
based	O
prenylation	O
reporter	O
.	O
<EOS>	B-X
They	B-X
act	B-X
by	B-X
inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
,	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
the	B-X
mevalonate	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
a	B-X
precursor	B-X
for	B-X
cholesterol	B-X
synthesis	B-X
and	B-X
the	B-X
source	B-X
of	B-X
lipid	B-X
moieties	B-X
for	B-X
protein	B-X
prenylation	B-X
.	B-X
The	B-X
nematode	B-X
Caenorhabditis	B-X
elegans	B-X
possesses	B-X
a	B-X
mevalonate	B-X
pathway	B-X
that	B-X
lacks	B-X
the	B-X
branch	B-X
leading	B-X
to	B-X
cholesterol	B-X
synthesis	B-X
,	B-X
and	B-X
thus	B-X
represents	B-X
an	B-X
ideal	B-X
organism	B-X
to	B-X
specifically	B-X
study	B-X
the	B-X
noncholesterol	B-X
roles	B-X
of	B-X
the	B-X
pathway	B-X
.	B-X
Inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
in	B-X
C.	B-X
elegans	B-X
using	B-X
statins	B-X
or	B-X
RNAi	B-X
leads	B-X
to	B-X
developmental	B-X
arrest	B-X
and	B-X
loss	B-X
of	B-X
membrane	B-X
association	B-X
of	B-X
a	B-X
GFP-based	B-X
prenylation	B-X
reporter	B-X
.	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
is	B-X
also	B-X
strongly	B-X
activated	B-X
,	B-X
suggesting	B-X
that	B-X
impaired	B-X
prenylation	B-X
of	B-X
small	B-X
GTPases	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
and	B-X
ER	B-X
stress	B-X
.	B-X
UPR	B-X
induction	B-X
was	B-X
also	B-X
observed	B-X
upon	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
farnesyl	B-X
transferases	B-X
or	B-X
RNAi	B-X
inhibition	B-X
of	B-X
a	B-X
specific	B-X
isoprenoid	B-X
transferase	B-X
(	B-X
M57.2	B-X
)	B-X
and	B-X
found	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
both	B-X
ire-1	B-X
and	B-X
xbp-1	B-X
but	B-X
not	B-X
on	B-X
pek-1	B-X
or	B-X
atf-6	B-X
,	B-X
which	B-X
are	B-X
all	B-X
known	B-X
regulators	B-X
of	B-X
the	B-X
UPR	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
inhibitors	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
or	B-X
of	B-X
farnesyl	B-X
transferases	B-X
induce	B-X
the	B-X
UPR	B-X
by	B-X
inhibiting	B-X
the	B-X
prenylation	B-X
of	B-X
M57.2	B-X
substrates	B-X
,	B-X
resulting	B-X
in	B-X
developmental	B-X
arrest	B-X
in	B-X
C.	B-X
elegans	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
statins	B-X
and	B-X
suggest	B-X
that	B-X
statins	B-X
could	B-X
be	B-X
used	B-X
clinically	B-X
where	B-X
UPR	B-X
activation	B-X
may	B-X
be	B-X
of	B-X
therapeutic	B-X
benefit	B-X
.	B-X

The	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
also	O
strongly	O
activated	O
,	O
suggesting	O
that	O
impaired	O
prenylation	O
of	O
small	O
GTPases	O
leads	O
to	O
the	O
accumulation	O
of	O
unfolded	O
proteins	O
and	O
ER	O
stress	O
.	O

UPR	O
induction	O
was	O
also	O
observed	O
upon	O
pharmacological	O
inhibition	O
of	O
farnesyl	O
transferases	O
or	O
RNAi	O
inhibition	O
of	O
a	O
specific	O
isoprenoid	O
transferase	O
(	O
M57	B-Protein
.	I-Protein
2	I-Protein
)	O
and	O
found	O
to	O
be	O
dependent	O
on	O
both	O
ire	B-Protein
-	I-Protein
1	I-Protein
and	O
xbp	B-Protein
-	I-Protein
1	I-Protein
but	O
not	O
on	O
pek	B-Protein
-	I-Protein
1	I-Protein
or	O
atf	B-Protein
-	I-Protein
6	I-Protein
,	O
which	O
are	O
all	O
known	O
regulators	O
of	O
the	O
UPR	O
.	O
<EOS>	B-X
One	B-X
of	B-X
the	B-X
early	B-X
cellular	B-X
responses	B-X
to	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
stress	B-X
is	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
.	B-X
ER	B-X
stress	B-X
and	B-X
the	B-X
UPR	B-X
are	B-X
both	B-X
implicated	B-X
in	B-X
numerous	B-X
human	B-X
diseases	B-X
and	B-X
pathologies	B-X
.	B-X
The	B-X
UPR	B-X
is	B-X
initiated	B-X
by	B-X
three	B-X
ER	B-X
transmembrane	B-X
receptors	B-X
:	B-X
PKR-like	B-X
ER	B-X
kinase	B-X
(	B-X
PERK	B-X
)	B-X
,	B-X
activating	B-X
transcription	B-X
factor	B-X
(	B-X
ATF	B-X
)	B-X
6	B-X
and	B-X
inositol-requiring	B-X
enzyme	B-X
1	B-X
(	B-X
IRE1	B-X
)	B-X
.	B-X
These	B-X
proteins	B-X
sense	B-X
the	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
and	B-X
their	B-X
activation	B-X
triggers	B-X
specific	B-X
adaptive	B-X
responses	B-X
to	B-X
resolve	B-X
the	B-X
stress	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
describe	B-X
the	B-X
known	B-X
pro-apoptotic	B-X
signalling	B-X
pathways	B-X
emanating	B-X
from	B-X
activated	B-X
PERK	B-X
,	B-X
ATF6	B-X
and	B-X
IRE1	B-X
and	B-X
discuss	B-X
how	B-X
their	B-X
signalling	B-X
switches	B-X
from	B-X
an	B-X
adaptive	B-X
to	B-X
a	B-X
pro-apoptotic	B-X
response	B-X
.	B-X

The	O
lipid	O
stores	O
and	O
fatty	O
acid	O
composition	O
were	O
unaffected	O
in	O
statin	O
-	O
treated	O
worms	O
,	O
even	O
though	O
they	O
showed	O
reduced	O
staining	O
with	O
Nile	O
red	O
.	O
<EOS>	B-X
They	B-X
act	B-X
by	B-X
inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
,	B-X
the	B-X
rate-limiting	B-X
enzyme	B-X
in	B-X
the	B-X
mevalonate	B-X
pathway	B-X
that	B-X
leads	B-X
to	B-X
the	B-X
synthesis	B-X
of	B-X
farnesyl	B-X
pyrophosphate	B-X
,	B-X
a	B-X
precursor	B-X
for	B-X
cholesterol	B-X
synthesis	B-X
and	B-X
the	B-X
source	B-X
of	B-X
lipid	B-X
moieties	B-X
for	B-X
protein	B-X
prenylation	B-X
.	B-X
Inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
in	B-X
C.	B-X
elegans	B-X
using	B-X
statins	B-X
or	B-X
RNAi	B-X
leads	B-X
to	B-X
developmental	B-X
arrest	B-X
and	B-X
loss	B-X
of	B-X
membrane	B-X
association	B-X
of	B-X
a	B-X
GFP-based	B-X
prenylation	B-X
reporter	B-X
.	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
is	B-X
also	B-X
strongly	B-X
activated	B-X
,	B-X
suggesting	B-X
that	B-X
impaired	B-X
prenylation	B-X
of	B-X
small	B-X
GTPases	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
and	B-X
ER	B-X
stress	B-X
.	B-X
The	B-X
lipid	B-X
stores	B-X
and	B-X
fatty	B-X
acid	B-X
composition	B-X
were	B-X
unaffected	B-X
in	B-X
statin-treated	B-X
worms	B-X
,	B-X
even	B-X
though	B-X
they	B-X
showed	B-X
reduced	B-X
staining	B-X
with	B-X
Nile	B-X
red	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
inhibitors	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
or	B-X
of	B-X
farnesyl	B-X
transferases	B-X
induce	B-X
the	B-X
UPR	B-X
by	B-X
inhibiting	B-X
the	B-X
prenylation	B-X
of	B-X
M57.2	B-X
substrates	B-X
,	B-X
resulting	B-X
in	B-X
developmental	B-X
arrest	B-X
in	B-X
C.	B-X
elegans	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
statins	B-X
and	B-X
suggest	B-X
that	B-X
statins	B-X
could	B-X
be	B-X
used	B-X
clinically	B-X
where	B-X
UPR	B-X
activation	B-X
may	B-X
be	B-X
of	B-X
therapeutic	B-X
benefit	B-X
.	B-X

We	O
conclude	O
that	O
inhibitors	O
of	O
HMG	B-Protein
-	I-Protein
CoA	I-Protein
reductase	I-Protein
or	O
of	O
farnesyl	O
transferases	O
induce	O
the	O
UPR	O
by	O
inhibiting	O
the	O
prenylation	O
of	O
M57	B-Protein
.	I-Protein
2	I-Protein
substrates	O
,	O
resulting	O
in	O
developmental	O
arrest	O
in	O
C	O
.	O
elegans	O
.	O
<EOS>	B-X
Endothelial	B-X
Klf2-Foxp1-TGFβ	B-X
signal	B-X
mediates	B-X
the	B-X
inhibitory	B-X
effects	B-X
of	B-X
simvastatin	B-X
on	B-X
maladaptive	B-X
cardiac	B-X
remodeling	B-X
.	B-X
Ceramide	B-X
released	B-X
as	B-X
a	B-X
consequence	B-X
of	B-X
N-SMase	B-X
reaction	B-X
would	B-X
then	B-X
carry	B-X
out	B-X
various	B-X
biological	B-X
phenomena	B-X
,	B-X
such	B-X
as	B-X
cell	B-X
proliferation	B-X
and	B-X
differentiation	B-X
.	B-X
Cholesterol	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
may	B-X
undergo	B-X
oxidation	B-X
and	B-X
inhibit	B-X
HMG-CoA	B-X
reductase	B-X
activity	B-X
;	B-X
it	B-X
may	B-X
also	B-X
be	B-X
utilized	B-X
by	B-X
ACAT	B-X
to	B-X
form	B-X
cholesteryl	B-X
esters	B-X
.	B-X
We	B-X
can	B-X
safely	B-X
conclude	B-X
that	B-X
N-SMase	B-X
action	B-X
may	B-X
be	B-X
required	B-X
to	B-X
carry	B-X
out	B-X
a	B-X
myriad	B-X
of	B-X
important	B-X
cellular	B-X
functions	B-X
either	B-X
directly	B-X
or	B-X
by	B-X
cholesterol	B-X
mobilization	B-X
,	B-X
or	B-X
generation	B-X
of	B-X
ceramide	B-X
,	B-X
ceramide-1-phosphate	B-X
,	B-X
and	B-X
sphingoid	B-X
bases	B-X
.	B-X

These	O
results	O
provide	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
statins	O
and	O
suggest	O
that	O
statins	O
could	O
be	O
used	O
clinically	O
where	O
UPR	O
activation	O
may	O
be	O
of	O
therapeutic	O
benefit	O
.	O
<EOS>	B-X
Inhibiting	B-X
HMG-CoA	B-X
reductase	B-X
in	B-X
C.	B-X
elegans	B-X
using	B-X
statins	B-X
or	B-X
RNAi	B-X
leads	B-X
to	B-X
developmental	B-X
arrest	B-X
and	B-X
loss	B-X
of	B-X
membrane	B-X
association	B-X
of	B-X
a	B-X
GFP-based	B-X
prenylation	B-X
reporter	B-X
.	B-X
The	B-X
unfolded	B-X
protein	B-X
response	B-X
(	B-X
UPR	B-X
)	B-X
is	B-X
also	B-X
strongly	B-X
activated	B-X
,	B-X
suggesting	B-X
that	B-X
impaired	B-X
prenylation	B-X
of	B-X
small	B-X
GTPases	B-X
leads	B-X
to	B-X
the	B-X
accumulation	B-X
of	B-X
unfolded	B-X
proteins	B-X
and	B-X
ER	B-X
stress	B-X
.	B-X
UPR	B-X
induction	B-X
was	B-X
also	B-X
observed	B-X
upon	B-X
pharmacological	B-X
inhibition	B-X
of	B-X
farnesyl	B-X
transferases	B-X
or	B-X
RNAi	B-X
inhibition	B-X
of	B-X
a	B-X
specific	B-X
isoprenoid	B-X
transferase	B-X
(	B-X
M57.2	B-X
)	B-X
and	B-X
found	B-X
to	B-X
be	B-X
dependent	B-X
on	B-X
both	B-X
ire-1	B-X
and	B-X
xbp-1	B-X
but	B-X
not	B-X
on	B-X
pek-1	B-X
or	B-X
atf-6	B-X
,	B-X
which	B-X
are	B-X
all	B-X
known	B-X
regulators	B-X
of	B-X
the	B-X
UPR	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
inhibitors	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
or	B-X
of	B-X
farnesyl	B-X
transferases	B-X
induce	B-X
the	B-X
UPR	B-X
by	B-X
inhibiting	B-X
the	B-X
prenylation	B-X
of	B-X
M57.2	B-X
substrates	B-X
,	B-X
resulting	B-X
in	B-X
developmental	B-X
arrest	B-X
in	B-X
C.	B-X
elegans	B-X
.	B-X
These	B-X
results	B-X
provide	B-X
a	B-X
mechanism	B-X
for	B-X
the	B-X
pleiotropic	B-X
effects	B-X
of	B-X
statins	B-X
and	B-X
suggest	B-X
that	B-X
statins	B-X
could	B-X
be	B-X
used	B-X
clinically	B-X
where	B-X
UPR	B-X
activation	B-X
may	B-X
be	B-X
of	B-X
therapeutic	B-X
benefit	B-X
.	B-X

SUMOylation	O
attenuates	O
the	O
aggregation	O
propensity	O
and	O
cellular	O
toxicity	O
of	O
the	O
polyglutamine	O
expanded	O
ataxin	B-Protein
-	I-Protein
7	I-Protein
.	O
<EOS>	B-X
Spinocerebellar	B-X
ataxia	B-X
type	B-X
7	B-X
(	B-X
SCA7	B-X
)	B-X
is	B-X
a	B-X
neurodegenerative	B-X
disorder	B-X
,	B-X
whose	B-X
pathology	B-X
is	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
protein	B-X
ataxin-7	B-X
(	B-X
ATXN7	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Non-homogenous	B-X
inclusions	B-X
showed	B-X
significantly	B-X
reduced	B-X
colocalization	B-X
with	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
,	B-X
but	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
Hsp70	B-X
,	B-X
19S	B-X
proteasome	B-X
and	B-X
ubiquitin	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

Post	O
-	O
translational	O
modification	O
by	O
SUMO	O
(	O
small	O
ubiquitin	B-Protein
-	O
like	O
modifier	O
)	O
was	O
proposed	O
to	O
modulate	O
the	O
pathogenesis	O
of	O
several	O
neurodegenerative	O
diseases	O
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
)	B-X
was	B-X
proposed	B-X
to	B-X
modulate	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Spinocerebellar	B-X
ataxia	B-X
type	B-X
7	B-X
(	B-X
SCA7	B-X
)	B-X
is	B-X
a	B-X
neurodegenerative	B-X
disorder	B-X
,	B-X
whose	B-X
pathology	B-X
is	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
protein	B-X
ataxin-7	B-X
(	B-X
ATXN7	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
Non-homogenous	B-X
inclusions	B-X
showed	B-X
significantly	B-X
reduced	B-X
colocalization	B-X
with	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
,	B-X
but	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
Hsp70	B-X
,	B-X
19S	B-X
proteasome	B-X
and	B-X
ubiquitin	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

Spinocerebellar	O
ataxia	O
type	O
7	O
(	O
SCA7	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
,	O
whose	O
pathology	O
is	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
polyglutamine	O
stretch	O
in	O
the	O
protein	O
ataxin	B-Protein
-	I-Protein
7	I-Protein
(	O
ATXN7	B-Protein
)	O
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
)	B-X
was	B-X
proposed	B-X
to	B-X
modulate	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Spinocerebellar	B-X
ataxia	B-X
type	B-X
7	B-X
(	B-X
SCA7	B-X
)	B-X
is	B-X
a	B-X
neurodegenerative	B-X
disorder	B-X
,	B-X
whose	B-X
pathology	B-X
is	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
protein	B-X
ataxin-7	B-X
(	B-X
ATXN7	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Non-homogenous	B-X
inclusions	B-X
showed	B-X
significantly	B-X
reduced	B-X
colocalization	B-X
with	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
,	B-X
but	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
Hsp70	B-X
,	B-X
19S	B-X
proteasome	B-X
and	B-X
ubiquitin	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

Here	O
,	O
we	O
identified	O
ATXN7	B-Protein
as	O
new	O
target	O
for	O
SUMOylation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
<EOS>	B-X
Spinocerebellar	B-X
ataxia	B-X
type	B-X
7	B-X
(	B-X
SCA7	B-X
)	B-X
is	B-X
a	B-X
neurodegenerative	B-X
disorder	B-X
,	B-X
whose	B-X
pathology	B-X
is	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
protein	B-X
ataxin-7	B-X
(	B-X
ATXN7	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

The	O
major	O
SUMO	O
acceptor	O
site	O
was	O
mapped	O
to	O
lysine	O
257	O
,	O
which	O
is	O
part	O
of	O
an	O
evolutionarily	O
conserved	O
consensus	O
SUMOylation	O
motif	O
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
)	B-X
was	B-X
proposed	B-X
to	B-X
modulate	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
Non-homogenous	B-X
inclusions	B-X
showed	B-X
significantly	B-X
reduced	B-X
colocalization	B-X
with	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
,	B-X
but	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
Hsp70	B-X
,	B-X
19S	B-X
proteasome	B-X
and	B-X
ubiquitin	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

SUMOylation	O
did	O
not	O
influence	O
the	O
subcellular	O
localization	O
of	O
ATXN7	B-Protein
nor	O
its	O
interaction	O
with	O
components	O
of	O
the	O
TFTC	O
/	O
STAGA	O
complex	O
.	O
<EOS>	B-X
SUMOylation	B-X
is	B-X
a	B-X
reversible	B-X
post-translational	B-X
modification	B-X
which	B-X
has	B-X
emerged	B-X
as	B-X
a	B-X
crucial	B-X
molecular	B-X
regulatory	B-X
mechanism	B-X
,	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
DNA	B-X
damage	B-X
repair	B-X
,	B-X
immune	B-X
responses	B-X
,	B-X
carcinogenesis	B-X
,	B-X
cell	B-X
cycle	B-X
progression	B-X
and	B-X
apoptosis	B-X
.	B-X
SUMOylation	B-X
is	B-X
widely	B-X
involved	B-X
in	B-X
carcinogenesis	B-X
,	B-X
DNA	B-X
damage	B-X
response	B-X
,	B-X
cancer	B-X
cell	B-X
proliferation	B-X
,	B-X
metastasis	B-X
and	B-X
apoptosis	B-X
.	B-X
Various	B-X
posttranslational	B-X
modifications	B-X
(	B-X
PTMs	B-X
)	B-X
,	B-X
including	B-X
phosphorylation	B-X
and	B-X
ubiquitination	B-X
,	B-X
control	B-X
NLRP3	B-X
protein	B-X
degradation	B-X
and	B-X
inflammasome	B-X
activation	B-X
;	B-X
however	B-X
,	B-X
the	B-X
function	B-X
of	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
SUMO	B-X
)	B-X
modification	B-X
(	B-X
called	B-X
SUMOylation	B-X
)	B-X
in	B-X
controlling	B-X
NLRP3	B-X
stability	B-X
and	B-X
subsequent	B-X
inflammasome	B-X
activation	B-X
is	B-X
unclear	B-X
.	B-X
These	B-X
data	B-X
identify	B-X
a	B-X
mechanism	B-X
by	B-X
which	B-X
SUMOylation	B-X
controls	B-X
the	B-X
cellular	B-X
NLRP3	B-X
level	B-X
and	B-X
inflammasome	B-X
activation	B-X
,	B-X
and	B-X
reveal	B-X
correlations	B-X
and	B-X
interactions	B-X
of	B-X
NLRP3	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
during	B-X
inflammasome	B-X
activation	B-X
.	B-X

Expansion	O
of	O
the	O
polyglutamine	O
stretch	O
did	O
not	O
impair	O
the	O
SUMOylation	O
of	O
ATXN7	B-Protein
.	O
<EOS>	B-X
The	B-X
causative	B-X
genetic	B-X
mutation	B-X
is	B-X
an	B-X
expanded	B-X
CAG	B-X
trinucleotide	B-X
repeat	B-X
in	B-X
the	B-X
gene	B-X
encoding	B-X
the	B-X
Huntingtin	B-X
protein	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
a	B-X
prolonged	B-X
polyglutamine	B-X
stretch	B-X
at	B-X
the	B-X
N-terminus	B-X
of	B-X
the	B-X
protein	B-X
.	B-X
Huntington	B-X
disease	B-X
is	B-X
caused	B-X
by	B-X
a	B-X
CAG	B-X
repeat	B-X
expansion	B-X
in	B-X
exon	B-X
1	B-X
of	B-X
the	B-X
huntingtin	B-X
gene	B-X
(	B-X
HTT	B-X
)	B-X
that	B-X
is	B-X
translated	B-X
into	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
huntingtin	B-X
protein	B-X
(	B-X
HTT	B-X
)	B-X
.	B-X
Expanded	B-X
polyglutamine	B-X
(	B-X
polyQ	B-X
)	B-X
stretches	B-X
in	B-X
at	B-X
least	B-X
nine	B-X
unrelated	B-X
proteins	B-X
lead	B-X
to	B-X
inherited	B-X
neuronal	B-X
dysfunction	B-X
and	B-X
degeneration	B-X
.	B-X
The	B-X
expansion	B-X
size	B-X
in	B-X
all	B-X
diseases	B-X
correlates	B-X
with	B-X
age	B-X
at	B-X
onset	B-X
(	B-X
AO	B-X
)	B-X
of	B-X
disease	B-X
and	B-X
with	B-X
polyQ	B-X
protein	B-X
aggregation	B-X
,	B-X
indicating	B-X
that	B-X
the	B-X
expanded	B-X
polyQ	B-X
stretch	B-X
is	B-X
the	B-X
main	B-X
driving	B-X
force	B-X
for	B-X
the	B-X
disease	B-X
onset	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
factors	B-X
differentially	B-X
influencing	B-X
polyQ	B-X
aggregation	B-X
:	B-X
the	B-X
Q-stretch	B-X
itself	B-X
,	B-X
modulatory	B-X
flanking	B-X
sequences	B-X
,	B-X
interaction	B-X
partners	B-X
,	B-X
cleavage	B-X
of	B-X
polyQ-containing	B-X
proteins	B-X
,	B-X
and	B-X
post-translational	B-X
modifications	B-X
,	B-X
with	B-X
a	B-X
special	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
of	B-X
molecular	B-X
chaperones	B-X
.	B-X

Furthermore	O
,	O
SUMO1	B-Protein
and	O
SUMO2	B-Protein
colocalized	O
with	O
ATXN7	B-Protein
in	O
a	O
subset	O
of	O
neuronal	O
intranuclear	O
inclusions	O
in	O
the	O
brain	O
of	O
SCA7	O
patients	O
and	O
SCA7	O
knock	O
-	O
in	O
mice	O
.	O

In	O
a	O
COS	O
-	O
7	O
cellular	O
model	O
of	O
SCA7	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
staining	O
we	O
identified	O
two	O
populations	O
of	O
nuclear	O
inclusions	O
:	O
homogenous	O
or	O
non	O
-	O
homogenous	O
.	O
<EOS>	B-X
Historically	B-X
,	B-X
the	B-X
field	B-X
of	B-X
radiation	B-X
chemistry	B-X
began	B-X
shortly	B-X
after	B-X
the	B-X
discovery	B-X
of	B-X
radioactivity	B-X
,	B-X
and	B-X
its	B-X
development	B-X
has	B-X
been	B-X
closely	B-X
related	B-X
to	B-X
discoveries	B-X
in	B-X
other	B-X
related	B-X
fields	B-X
such	B-X
as	B-X
radiation	B-X
and	B-X
nuclear	B-X
physics	B-X
.	B-X
Track	B-X
structure	B-X
results	B-X
from	B-X
early	B-X
physical	B-X
and	B-X
physicochemical	B-X
events	B-X
that	B-X
lead	B-X
to	B-X
a	B-X
highly	B-X
non-homogenous	B-X
distribution	B-X
of	B-X
radiolytic	B-X
species	B-X
.	B-X
Because	B-X
ionizing	B-X
radiation	B-X
creates	B-X
unstable	B-X
species	B-X
that	B-X
are	B-X
distributed	B-X
non-homogenously	B-X
,	B-X
the	B-X
use	B-X
of	B-X
conventional	B-X
reaction	B-X
kinetics	B-X
methods	B-X
does	B-X
not	B-X
describe	B-X
this	B-X
chemistry	B-X
well	B-X
.	B-X
In	B-X
network	B-X
science	B-X
,	B-X
the	B-X
non-homogeneity	B-X
of	B-X
node	B-X
degrees	B-X
has	B-X
been	B-X
a	B-X
concerning	B-X
issue	B-X
for	B-X
study	B-X
.	B-X
Yet	B-X
,	B-X
with	B-X
today	B-X
's	B-X
modern	B-X
web	B-X
technologies	B-X
,	B-X
the	B-X
traditional	B-X
social	B-X
communication	B-X
topologies	B-X
have	B-X
evolved	B-X
from	B-X
node-central	B-X
structures	B-X
into	B-X
online	B-X
cycle-based	B-X
communities	B-X
,	B-X
urgently	B-X
requiring	B-X
new	B-X
network	B-X
theories	B-X
and	B-X
tools	B-X
.	B-X
Switching	B-X
the	B-X
focus	B-X
from	B-X
node	B-X
degrees	B-X
to	B-X
network	B-X
cycles	B-X
could	B-X
reveal	B-X
many	B-X
interesting	B-X
properties	B-X
from	B-X
the	B-X
perspective	B-X
of	B-X
totally	B-X
homogenous	B-X
networks	B-X
or	B-X
sub-networks	B-X
in	B-X
a	B-X
complex	B-X
network	B-X
,	B-X
especially	B-X
basic	B-X
simplexes	B-X
(	B-X
cliques	B-X
)	B-X
such	B-X
as	B-X
links	B-X
and	B-X
triangles	B-X
.	B-X
Clearly	B-X
,	B-X
compared	B-X
with	B-X
node	B-X
degrees	B-X
,	B-X
it	B-X
is	B-X
much	B-X
more	B-X
challenging	B-X
to	B-X
deal	B-X
with	B-X
network	B-X
cycles	B-X
.	B-X
These	B-X
two	B-X
vector	B-X
spaces	B-X
are	B-X
related	B-X
through	B-X
a	B-X
boundary	B-X
operator	B-X
,	B-X
for	B-X
example	B-X
mapping	B-X
the	B-X
boundary	B-X
of	B-X
a	B-X
triangle	B-X
in	B-X
one	B-X
space	B-X
to	B-X
the	B-X
sum	B-X
of	B-X
three	B-X
links	B-X
in	B-X
the	B-X
other	B-X
space	B-X
.	B-X
Under	B-X
the	B-X
new	B-X
framework	B-X
,	B-X
some	B-X
important	B-X
concepts	B-X
and	B-X
methodologies	B-X
from	B-X
algebraic	B-X
topology	B-X
,	B-X
such	B-X
as	B-X
characteristic	B-X
number	B-X
,	B-X
homology	B-X
group	B-X
and	B-X
Betti	B-X
number	B-X
,	B-X
will	B-X
play	B-X
a	B-X
part	B-X
in	B-X
network	B-X
science	B-X
leading	B-X
to	B-X
foreseeable	B-X
new	B-X
research	B-X
directions	B-X
.	B-X
As	B-X
immediate	B-X
applications	B-X
,	B-X
the	B-X
paper	B-X
illustrates	B-X
some	B-X
important	B-X
characteristics	B-X
affecting	B-X
the	B-X
collective	B-X
behaviors	B-X
of	B-X
complex	B-X
networks	B-X
,	B-X
some	B-X
new	B-X
cycle-dependent	B-X
importance	B-X
indexes	B-X
of	B-X
nodes	B-X
and	B-X
implications	B-X
for	B-X
network	B-X
synchronization	B-X
and	B-X
brain-network	B-X
analysis	B-X
.	B-X

Non	O
-	O
homogenous	O
inclusions	O
showed	O
significantly	O
reduced	O
colocalization	O
with	O
SUMO1	B-Protein
and	O
SUMO2	B-Protein
,	O
but	O
were	O
highly	O
enriched	O
in	O
Hsp70	B-Protein
,	O
19S	O
proteasome	O
and	O
ubiquitin	B-Protein
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
)	B-X
was	B-X
proposed	B-X
to	B-X
modulate	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Non-homogenous	B-X
inclusions	B-X
showed	B-X
significantly	B-X
reduced	B-X
colocalization	B-X
with	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
,	B-X
but	B-X
were	B-X
highly	B-X
enriched	B-X
in	B-X
Hsp70	B-X
,	B-X
19S	B-X
proteasome	B-X
and	B-X
ubiquitin	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X

Interestingly	O
,	O
they	O
were	O
characterized	O
by	O
increased	O
staining	O
with	O
the	O
apoptotic	O
marker	O
caspase	B-Protein
-	I-Protein
3	I-Protein
and	O
by	O
disruption	O
of	O
PML	B-Protein
nuclear	O
bodies	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Interestingly	B-X
,	B-X
they	B-X
were	B-X
characterized	B-X
by	B-X
increased	B-X
staining	B-X
with	B-X
the	B-X
apoptotic	B-X
marker	B-X
caspase-3	B-X
and	B-X
by	B-X
disruption	B-X
of	B-X
PML	B-X
nuclear	B-X
bodies	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X

Importantly	O
,	O
preventing	O
the	O
SUMOylation	O
of	O
expanded	O
ATXN7	B-Protein
by	O
mutating	O
the	O
SUMO	O
site	O
increased	O
both	O
the	O
amount	O
of	O
SDS	O
-	O
insoluble	O
aggregates	O
and	O
of	O
caspase	B-Protein
-	I-Protein
3	I-Protein
positive	O
non	O
-	O
homogenous	O
inclusions	O
,	O
which	O
act	O
toxic	O
to	O
the	O
cells	O
.	O

Our	O
results	O
demonstrate	O
an	O
influence	O
of	O
SUMOylation	O
on	O
the	O
multistep	O
aggregation	O
process	O
of	O
ATXN7	B-Protein
and	O
implicate	O
a	O
role	O
for	O
ATXN7	B-Protein
SUMOylation	O
in	O
SCA7	O
pathogenesis	O
.	O
<EOS>	B-X
Post-translational	B-X
modification	B-X
by	B-X
SUMO	B-X
(	B-X
small	B-X
ubiquitin-like	B-X
modifier	B-X
)	B-X
was	B-X
proposed	B-X
to	B-X
modulate	B-X
the	B-X
pathogenesis	B-X
of	B-X
several	B-X
neurodegenerative	B-X
diseases	B-X
.	B-X
Spinocerebellar	B-X
ataxia	B-X
type	B-X
7	B-X
(	B-X
SCA7	B-X
)	B-X
is	B-X
a	B-X
neurodegenerative	B-X
disorder	B-X
,	B-X
whose	B-X
pathology	B-X
is	B-X
caused	B-X
by	B-X
an	B-X
expansion	B-X
of	B-X
a	B-X
polyglutamine	B-X
stretch	B-X
in	B-X
the	B-X
protein	B-X
ataxin-7	B-X
(	B-X
ATXN7	B-X
)	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
ATXN7	B-X
as	B-X
new	B-X
target	B-X
for	B-X
SUMOylation	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X
The	B-X
major	B-X
SUMO	B-X
acceptor	B-X
site	B-X
was	B-X
mapped	B-X
to	B-X
lysine	B-X
257	B-X
,	B-X
which	B-X
is	B-X
part	B-X
of	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
consensus	B-X
SUMOylation	B-X
motif	B-X
.	B-X
SUMOylation	B-X
did	B-X
not	B-X
influence	B-X
the	B-X
subcellular	B-X
localization	B-X
of	B-X
ATXN7	B-X
nor	B-X
its	B-X
interaction	B-X
with	B-X
components	B-X
of	B-X
the	B-X
TFTC/STAGA	B-X
complex	B-X
.	B-X
Expansion	B-X
of	B-X
the	B-X
polyglutamine	B-X
stretch	B-X
did	B-X
not	B-X
impair	B-X
the	B-X
SUMOylation	B-X
of	B-X
ATXN7	B-X
.	B-X
Furthermore	B-X
,	B-X
SUMO1	B-X
and	B-X
SUMO2	B-X
colocalized	B-X
with	B-X
ATXN7	B-X
in	B-X
a	B-X
subset	B-X
of	B-X
neuronal	B-X
intranuclear	B-X
inclusions	B-X
in	B-X
the	B-X
brain	B-X
of	B-X
SCA7	B-X
patients	B-X
and	B-X
SCA7	B-X
knock-in	B-X
mice	B-X
.	B-X
In	B-X
a	B-X
COS-7	B-X
cellular	B-X
model	B-X
of	B-X
SCA7	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
diffuse	B-X
nucleoplasmic	B-X
staining	B-X
we	B-X
identified	B-X
two	B-X
populations	B-X
of	B-X
nuclear	B-X
inclusions	B-X
:	B-X
homogenous	B-X
or	B-X
non-homogenous	B-X
.	B-X
Importantly	B-X
,	B-X
preventing	B-X
the	B-X
SUMOylation	B-X
of	B-X
expanded	B-X
ATXN7	B-X
by	B-X
mutating	B-X
the	B-X
SUMO	B-X
site	B-X
increased	B-X
both	B-X
the	B-X
amount	B-X
of	B-X
SDS-insoluble	B-X
aggregates	B-X
and	B-X
of	B-X
caspase-3	B-X
positive	B-X
non-homogenous	B-X
inclusions	B-X
,	B-X
which	B-X
act	B-X
toxic	B-X
to	B-X
the	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
demonstrate	B-X
an	B-X
influence	B-X
of	B-X
SUMOylation	B-X
on	B-X
the	B-X
multistep	B-X
aggregation	B-X
process	B-X
of	B-X
ATXN7	B-X
and	B-X
implicate	B-X
a	B-X
role	B-X
for	B-X
ATXN7	B-X
SUMOylation	B-X
in	B-X
SCA7	B-X
pathogenesis	B-X
.	B-X

Orientation	O
of	O
palmitoylated	O
CaVbeta2a	B-Protein
relative	O
to	O
CaV2	O
.	O
2	O
is	O
critical	O
for	O
slow	O
pathway	O
modulation	O
of	O
N	O
-	O
type	O
Ca2	O
+	O
current	O
by	O
tachykinin	O
receptor	O
activation	O
.	O

The	O
G	O
(	O
q	O
)	O
-	O
coupled	O
tachykinin	O
receptor	O
(	O
neurokinin	B-Protein
-	I-Protein
1	I-Protein
receptor	I-Protein
[	O
NK	B-Protein
-	I-Protein
1R	I-Protein
]	O
)	O
modulates	O
N	O
-	O
type	O
Ca	O
(	O
2	O
+	O
)	O
channel	O
(	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
N	O
channel	O
)	O
activity	O
at	O
two	O
distinct	O
sites	O
by	O
a	O
pathway	O
involving	O
a	O
lipid	O
metabolite	O
,	O
most	O
likely	O
arachidonic	O
acid	O
(	O
AA	O
)	O
.	O

In	O
another	O
study	O
published	O
in	O
this	O
issue	O
(	O
Heneghan	O
et	O
al	O
.	O
2009	O
.	O
J	O
.	O
Gen	O
Physiol	O
.	O
doi	O
:	O
10	O
.	O
1085	O
/	O
jgp	O
.	O
200910203	O
)	O
,	O
we	O
found	O
that	O
the	O
form	O
of	O
modulation	O
observed	O
depends	O
on	O
which	O
Ca	O
(	O
V	O
)	O
beta	O
is	O
coexpressed	O
with	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
.	O

When	O
palmitoylated	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
is	O
coexpressed	O
,	O
activation	O
of	O
NK	B-Protein
-	I-Protein
1Rs	I-Protein
by	O
substance	B-Protein
P	I-Protein
(	O
SP	B-Protein
)	O
enhances	O
N	O
current	O
.	O
<EOS>	B-X
The	B-X
G	B-X
(	B-X
q	B-X
)	B-X
-coupled	B-X
tachykinin	B-X
receptor	B-X
(	B-X
neurokinin-1	B-X
receptor	B-X
[	B-X
NK-1R	B-X
]	B-X
)	B-X
modulates	B-X
N-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channel	B-X
(	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
N	B-X
channel	B-X
)	B-X
activity	B-X
at	B-X
two	B-X
distinct	B-X
sites	B-X
by	B-X
a	B-X
pathway	B-X
involving	B-X
a	B-X
lipid	B-X
metabolite	B-X
,	B-X
most	B-X
likely	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
.	B-X
J.	B-X
Gen	B-X
Physiol	B-X
.	B-X
doi:10.1085/jgp.200910203	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
form	B-X
of	B-X
modulation	B-X
observed	B-X
depends	B-X
on	B-X
which	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta	B-X
is	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
.	B-X
When	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
coexpressed	B-X
,	B-X
activation	B-X
of	B-X
NK-1Rs	B-X
by	B-X
substance	B-X
P	B-X
(	B-X
SP	B-X
)	B-X
enhances	B-X
N	B-X
current	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
is	B-X
coexpressed	B-X
,	B-X
SP	B-X
inhibits	B-X
N	B-X
current	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
the	B-X
palmitoyl	B-X
groups	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
may	B-X
occupy	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
prevent	B-X
AA	B-X
from	B-X
interacting	B-X
with	B-X
that	B-X
site	B-X
,	B-X
thereby	B-X
minimizing	B-X
inhibition	B-X
.	B-X
If	B-X
so	B-X
,	B-X
changing	B-X
the	B-X
orientation	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
relative	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
may	B-X
displace	B-X
the	B-X
palmitoyl	B-X
groups	B-X
and	B-X
prevent	B-X
them	B-X
from	B-X
antagonizing	B-X
AA	B-X
's	B-X
actions	B-X
,	B-X
thereby	B-X
allowing	B-X
inhibition	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
deleting	B-X
one	B-X
(	B-X
Bdel1	B-X
)	B-X
or	B-X
two	B-X
(	B-X
Bdel2	B-X
)	B-X
amino	B-X
acids	B-X
proximal	B-X
to	B-X
the	B-X
alpha	B-X
interacting	B-X
domain	B-X
(	B-X
AID	B-X
)	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
's	B-X
I-II	B-X
linker	B-X
.	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
betas	B-X
bind	B-X
tightly	B-X
to	B-X
the	B-X
AID	B-X
,	B-X
whereas	B-X
the	B-X
rigid	B-X
region	B-X
proximal	B-X
to	B-X
the	B-X
AID	B-X
is	B-X
thought	B-X
to	B-X
couple	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta	B-X
's	B-X
movements	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
gating	B-X
.	B-X
Although	B-X
Bdel1/beta2a	B-X
currents	B-X
exhibited	B-X
more	B-X
variable	B-X
enhancement	B-X
by	B-X
SP	B-X
,	B-X
Bdel2/beta2a	B-X
current	B-X
enhancement	B-X
was	B-X
lost	B-X
at	B-X
all	B-X
voltages	B-X
.	B-X
Instead	B-X
,	B-X
inhibition	B-X
was	B-X
observed	B-X
that	B-X
matched	B-X
the	B-X
profile	B-X
of	B-X
N-current	B-X
inhibition	B-X
from	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
.	B-X
Moreover	B-X
,	B-X
adding	B-X
back	B-X
exogenous	B-X
palmitic	B-X
acid	B-X
minimized	B-X
inhibition	B-X
of	B-X
Bdel2/beta2a	B-X
currents	B-X
,	B-X
suggesting	B-X
that	B-X
when	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
sufficiently	B-X
displaced	B-X
,	B-X
endogenously	B-X
released	B-X
AA	B-X
can	B-X
bind	B-X
to	B-X
the	B-X
inhibitory	B-X
site	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
our	B-X
previous	B-X
hypothesis	B-X
that	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
's	B-X
palmitoyl	B-X
groups	B-X
directly	B-X
interact	B-X
with	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
to	B-X
block	B-X
N-current	B-X
inhibition	B-X
by	B-X
SP	B-X
.	B-X

In	O
contrast	O
,	O
when	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta3	I-Protein
is	O
coexpressed	O
,	O
SP	B-Protein
inhibits	O
N	O
current	O
.	O

However	O
,	O
exogenously	O
applied	O
palmitic	O
acid	O
minimizes	O
this	O
inhibition	O
.	O
<EOS>	B-X
The	B-X
G	B-X
(	B-X
q	B-X
)	B-X
-coupled	B-X
tachykinin	B-X
receptor	B-X
(	B-X
neurokinin-1	B-X
receptor	B-X
[	B-X
NK-1R	B-X
]	B-X
)	B-X
modulates	B-X
N-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channel	B-X
(	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
N	B-X
channel	B-X
)	B-X
activity	B-X
at	B-X
two	B-X
distinct	B-X
sites	B-X
by	B-X
a	B-X
pathway	B-X
involving	B-X
a	B-X
lipid	B-X
metabolite	B-X
,	B-X
most	B-X
likely	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
.	B-X
However	B-X
,	B-X
exogenously	B-X
applied	B-X
palmitic	B-X
acid	B-X
minimizes	B-X
this	B-X
inhibition	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
the	B-X
palmitoyl	B-X
groups	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
may	B-X
occupy	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
prevent	B-X
AA	B-X
from	B-X
interacting	B-X
with	B-X
that	B-X
site	B-X
,	B-X
thereby	B-X
minimizing	B-X
inhibition	B-X
.	B-X
If	B-X
so	B-X
,	B-X
changing	B-X
the	B-X
orientation	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
relative	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
may	B-X
displace	B-X
the	B-X
palmitoyl	B-X
groups	B-X
and	B-X
prevent	B-X
them	B-X
from	B-X
antagonizing	B-X
AA	B-X
's	B-X
actions	B-X
,	B-X
thereby	B-X
allowing	B-X
inhibition	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
deleting	B-X
one	B-X
(	B-X
Bdel1	B-X
)	B-X
or	B-X
two	B-X
(	B-X
Bdel2	B-X
)	B-X
amino	B-X
acids	B-X
proximal	B-X
to	B-X
the	B-X
alpha	B-X
interacting	B-X
domain	B-X
(	B-X
AID	B-X
)	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
's	B-X
I-II	B-X
linker	B-X
.	B-X
Instead	B-X
,	B-X
inhibition	B-X
was	B-X
observed	B-X
that	B-X
matched	B-X
the	B-X
profile	B-X
of	B-X
N-current	B-X
inhibition	B-X
from	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
.	B-X
Moreover	B-X
,	B-X
adding	B-X
back	B-X
exogenous	B-X
palmitic	B-X
acid	B-X
minimized	B-X
inhibition	B-X
of	B-X
Bdel2/beta2a	B-X
currents	B-X
,	B-X
suggesting	B-X
that	B-X
when	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
sufficiently	B-X
displaced	B-X
,	B-X
endogenously	B-X
released	B-X
AA	B-X
can	B-X
bind	B-X
to	B-X
the	B-X
inhibitory	B-X
site	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
our	B-X
previous	B-X
hypothesis	B-X
that	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
's	B-X
palmitoyl	B-X
groups	B-X
directly	B-X
interact	B-X
with	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
to	B-X
block	B-X
N-current	B-X
inhibition	B-X
by	B-X
SP	B-X
.	B-X

These	O
findings	O
suggested	O
that	O
the	O
palmitoyl	O
groups	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
may	O
occupy	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
or	O
prevent	O
AA	O
from	O
interacting	O
with	O
that	O
site	O
,	O
thereby	O
minimizing	O
inhibition	O
.	O
<EOS>	B-X
The	B-X
G	B-X
(	B-X
q	B-X
)	B-X
-coupled	B-X
tachykinin	B-X
receptor	B-X
(	B-X
neurokinin-1	B-X
receptor	B-X
[	B-X
NK-1R	B-X
]	B-X
)	B-X
modulates	B-X
N-type	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
channel	B-X
(	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
N	B-X
channel	B-X
)	B-X
activity	B-X
at	B-X
two	B-X
distinct	B-X
sites	B-X
by	B-X
a	B-X
pathway	B-X
involving	B-X
a	B-X
lipid	B-X
metabolite	B-X
,	B-X
most	B-X
likely	B-X
arachidonic	B-X
acid	B-X
(	B-X
AA	B-X
)	B-X
.	B-X
2009.	B-X
doi:10.1085/jgp.200910203	B-X
)	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
form	B-X
of	B-X
modulation	B-X
observed	B-X
depends	B-X
on	B-X
which	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta	B-X
is	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
.	B-X
When	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
coexpressed	B-X
,	B-X
activation	B-X
of	B-X
NK-1Rs	B-X
by	B-X
substance	B-X
P	B-X
(	B-X
SP	B-X
)	B-X
enhances	B-X
N	B-X
current	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
is	B-X
coexpressed	B-X
,	B-X
SP	B-X
inhibits	B-X
N	B-X
current	B-X
.	B-X
However	B-X
,	B-X
exogenously	B-X
applied	B-X
palmitic	B-X
acid	B-X
minimizes	B-X
this	B-X
inhibition	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
the	B-X
palmitoyl	B-X
groups	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
may	B-X
occupy	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
prevent	B-X
AA	B-X
from	B-X
interacting	B-X
with	B-X
that	B-X
site	B-X
,	B-X
thereby	B-X
minimizing	B-X
inhibition	B-X
.	B-X
If	B-X
so	B-X
,	B-X
changing	B-X
the	B-X
orientation	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
relative	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
may	B-X
displace	B-X
the	B-X
palmitoyl	B-X
groups	B-X
and	B-X
prevent	B-X
them	B-X
from	B-X
antagonizing	B-X
AA	B-X
's	B-X
actions	B-X
,	B-X
thereby	B-X
allowing	B-X
inhibition	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
deleting	B-X
one	B-X
(	B-X
Bdel1	B-X
)	B-X
or	B-X
two	B-X
(	B-X
Bdel2	B-X
)	B-X
amino	B-X
acids	B-X
proximal	B-X
to	B-X
the	B-X
alpha	B-X
interacting	B-X
domain	B-X
(	B-X
AID	B-X
)	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
's	B-X
I-II	B-X
linker	B-X
.	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
betas	B-X
bind	B-X
tightly	B-X
to	B-X
the	B-X
AID	B-X
,	B-X
whereas	B-X
the	B-X
rigid	B-X
region	B-X
proximal	B-X
to	B-X
the	B-X
AID	B-X
is	B-X
thought	B-X
to	B-X
couple	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta	B-X
's	B-X
movements	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
gating	B-X
.	B-X
Although	B-X
Bdel1/beta2a	B-X
currents	B-X
exhibited	B-X
more	B-X
variable	B-X
enhancement	B-X
by	B-X
SP	B-X
,	B-X
Bdel2/beta2a	B-X
current	B-X
enhancement	B-X
was	B-X
lost	B-X
at	B-X
all	B-X
voltages	B-X
.	B-X
Instead	B-X
,	B-X
inhibition	B-X
was	B-X
observed	B-X
that	B-X
matched	B-X
the	B-X
profile	B-X
of	B-X
N-current	B-X
inhibition	B-X
from	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
.	B-X
Moreover	B-X
,	B-X
adding	B-X
back	B-X
exogenous	B-X
palmitic	B-X
acid	B-X
minimized	B-X
inhibition	B-X
of	B-X
Bdel2/beta2a	B-X
currents	B-X
,	B-X
suggesting	B-X
that	B-X
when	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
sufficiently	B-X
displaced	B-X
,	B-X
endogenously	B-X
released	B-X
AA	B-X
can	B-X
bind	B-X
to	B-X
the	B-X
inhibitory	B-X
site	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
our	B-X
previous	B-X
hypothesis	B-X
that	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
's	B-X
palmitoyl	B-X
groups	B-X
directly	B-X
interact	B-X
with	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
to	B-X
block	B-X
N-current	B-X
inhibition	B-X
by	B-X
SP	B-X
.	B-X

If	O
so	O
,	O
changing	O
the	O
orientation	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
relative	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
may	O
displace	O
the	O
palmitoyl	O
groups	O
and	O
prevent	O
them	O
from	O
antagonizing	O
AA	O
'	O
s	O
actions	O
,	O
thereby	O
allowing	O
inhibition	O
even	O
in	O
the	O
presence	O
of	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
this	O
hypothesis	O
by	O
deleting	O
one	O
(	O
Bdel1	O
)	O
or	O
two	O
(	O
Bdel2	O
)	O
amino	O
acids	O
proximal	O
to	O
the	O
alpha	O
interacting	O
domain	O
(	O
AID	O
)	O
of	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
'	O
s	O
I	O
-	O
II	O
linker	O
.	O

Ca	O
(	O
V	O
)	O
betas	O
bind	O
tightly	O
to	O
the	O
AID	O
,	O
whereas	O
the	O
rigid	O
region	O
proximal	O
to	O
the	O
AID	O
is	O
thought	O
to	O
couple	O
Ca	O
(	O
V	O
)	O
beta	O
'	O
s	O
movements	O
to	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
gating	O
.	O

Although	O
Bdel1	O
/	O
beta2a	O
currents	O
exhibited	O
more	O
variable	O
enhancement	O
by	O
SP	B-Protein
,	O
Bdel2	O
/	O
beta2a	O
current	O
enhancement	O
was	O
lost	O
at	O
all	O
voltages	O
.	O
<EOS>	B-X
When	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
coexpressed	B-X
,	B-X
activation	B-X
of	B-X
NK-1Rs	B-X
by	B-X
substance	B-X
P	B-X
(	B-X
SP	B-X
)	B-X
enhances	B-X
N	B-X
current	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
is	B-X
coexpressed	B-X
,	B-X
SP	B-X
inhibits	B-X
N	B-X
current	B-X
.	B-X
These	B-X
findings	B-X
suggested	B-X
that	B-X
the	B-X
palmitoyl	B-X
groups	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
may	B-X
occupy	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
or	B-X
prevent	B-X
AA	B-X
from	B-X
interacting	B-X
with	B-X
that	B-X
site	B-X
,	B-X
thereby	B-X
minimizing	B-X
inhibition	B-X
.	B-X
If	B-X
so	B-X
,	B-X
changing	B-X
the	B-X
orientation	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
relative	B-X
to	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
may	B-X
displace	B-X
the	B-X
palmitoyl	B-X
groups	B-X
and	B-X
prevent	B-X
them	B-X
from	B-X
antagonizing	B-X
AA	B-X
's	B-X
actions	B-X
,	B-X
thereby	B-X
allowing	B-X
inhibition	B-X
even	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
tested	B-X
this	B-X
hypothesis	B-X
by	B-X
deleting	B-X
one	B-X
(	B-X
Bdel1	B-X
)	B-X
or	B-X
two	B-X
(	B-X
Bdel2	B-X
)	B-X
amino	B-X
acids	B-X
proximal	B-X
to	B-X
the	B-X
alpha	B-X
interacting	B-X
domain	B-X
(	B-X
AID	B-X
)	B-X
of	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
's	B-X
I-II	B-X
linker	B-X
.	B-X
Although	B-X
Bdel1/beta2a	B-X
currents	B-X
exhibited	B-X
more	B-X
variable	B-X
enhancement	B-X
by	B-X
SP	B-X
,	B-X
Bdel2/beta2a	B-X
current	B-X
enhancement	B-X
was	B-X
lost	B-X
at	B-X
all	B-X
voltages	B-X
.	B-X
Instead	B-X
,	B-X
inhibition	B-X
was	B-X
observed	B-X
that	B-X
matched	B-X
the	B-X
profile	B-X
of	B-X
N-current	B-X
inhibition	B-X
from	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
coexpressed	B-X
with	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta3	B-X
.	B-X
Moreover	B-X
,	B-X
adding	B-X
back	B-X
exogenous	B-X
palmitic	B-X
acid	B-X
minimized	B-X
inhibition	B-X
of	B-X
Bdel2/beta2a	B-X
currents	B-X
,	B-X
suggesting	B-X
that	B-X
when	B-X
palmitoylated	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
is	B-X
sufficiently	B-X
displaced	B-X
,	B-X
endogenously	B-X
released	B-X
AA	B-X
can	B-X
bind	B-X
to	B-X
the	B-X
inhibitory	B-X
site	B-X
.	B-X
These	B-X
findings	B-X
support	B-X
our	B-X
previous	B-X
hypothesis	B-X
that	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
beta2a	B-X
's	B-X
palmitoyl	B-X
groups	B-X
directly	B-X
interact	B-X
with	B-X
an	B-X
inhibitory	B-X
site	B-X
on	B-X
Ca	B-X
(	B-X
V	B-X
)	B-X
2.2	B-X
to	B-X
block	B-X
N-current	B-X
inhibition	B-X
by	B-X
SP	B-X
.	B-X

Instead	O
,	O
inhibition	O
was	O
observed	O
that	O
matched	O
the	O
profile	O
of	O
N	O
-	O
current	O
inhibition	O
from	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
coexpressed	O
with	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta3	I-Protein
.	O

Moreover	O
,	O
adding	O
back	O
exogenous	O
palmitic	O
acid	O
minimized	O
inhibition	O
of	O
Bdel2	O
/	O
beta2a	O
currents	O
,	O
suggesting	O
that	O
when	O
palmitoylated	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
is	O
sufficiently	O
displaced	O
,	O
endogenously	O
released	O
AA	O
can	O
bind	O
to	O
the	O
inhibitory	O
site	O
.	O

These	O
findings	O
support	O
our	O
previous	O
hypothesis	O
that	O
Ca	B-Protein
(	I-Protein
V	I-Protein
)	I-Protein
beta2a	I-Protein
'	O
s	O
palmitoyl	O
groups	O
directly	O
interact	O
with	O
an	O
inhibitory	O
site	O
on	O
Ca	O
(	O
V	O
)	O
2	O
.	O
2	O
to	O
block	O
N	O
-	O
current	O
inhibition	O
by	O
SP	B-Protein
.	O

Validation	O
of	O
a	O
method	O
for	O
the	O
quantitation	O
of	O
ghrelin	B-Protein
and	O
unacylated	O
ghrelin	B-Protein
by	O
HPLC	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
This	B-X
method	B-X
was	B-X
validated	B-X
by	B-X
an	B-X
original	B-X
approach	B-X
using	B-X
accuracy	B-X
profiles	B-X
based	B-X
on	B-X
tolerance	B-X
intervals	B-X
for	B-X
the	B-X
total	B-X
error	B-X
measurement	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

An	O
HPLC	O
/	O
UV	O
method	O
was	O
first	O
optimized	O
for	O
the	O
separation	O
and	O
quantitation	O
of	O
human	O
acylated	O
and	O
unacylated	O
(	O
or	O
des	O
-	O
acyl	O
)	O
ghrelin	B-Protein
from	O
aqueous	O
solutions	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
This	B-X
method	B-X
was	B-X
validated	B-X
by	B-X
an	B-X
original	B-X
approach	B-X
using	B-X
accuracy	B-X
profiles	B-X
based	B-X
on	B-X
tolerance	B-X
intervals	B-X
for	B-X
the	B-X
total	B-X
error	B-X
measurement	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

This	O
method	O
was	O
validated	O
by	O
an	O
original	O
approach	O
using	O
accuracy	O
profiles	O
based	O
on	O
tolerance	O
intervals	O
for	O
the	O
total	O
error	O
measurement	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
This	B-X
method	B-X
was	B-X
validated	B-X
by	B-X
an	B-X
original	B-X
approach	B-X
using	B-X
accuracy	B-X
profiles	B-X
based	B-X
on	B-X
tolerance	B-X
intervals	B-X
for	B-X
the	B-X
total	B-X
error	B-X
measurement	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

The	O
concentration	O
range	O
that	O
achieved	O
adequate	O
accuracy	O
extended	O
from	O
1	O
.	O
85	O
to	O
59	O
.	O
30microM	O
and	O
1	O
.	O
93	O
to	O
61	O
.	O
60microM	O
for	O
acylated	O
and	O
unacylated	O
ghrelin	B-Protein
,	O
respectively	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
This	B-X
method	B-X
was	B-X
validated	B-X
by	B-X
an	B-X
original	B-X
approach	B-X
using	B-X
accuracy	B-X
profiles	B-X
based	B-X
on	B-X
tolerance	B-X
intervals	B-X
for	B-X
the	B-X
total	B-X
error	B-X
measurement	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

Then	O
,	O
optimal	O
temperature	O
,	O
pH	O
and	O
buffer	O
for	O
sample	O
storage	O
were	O
determined	O
.	O
<EOS>	B-X
It	B-X
is	B-X
often	B-X
necessary	B-X
to	B-X
go	B-X
through	B-X
several	B-X
iterations	B-X
of	B-X
trial-and-error	B-X
to	B-X
optimize	B-X
the	B-X
homogeneity	B-X
,	B-X
stability	B-X
and	B-X
solubility	B-X
of	B-X
the	B-X
protein	B-X
sample	B-X
.	B-X
The	B-X
first	B-X
screen	B-X
has	B-X
been	B-X
designed	B-X
in	B-X
such	B-X
a	B-X
way	B-X
,	B-X
that	B-X
it	B-X
is	B-X
possible	B-X
to	B-X
discern	B-X
global	B-X
stability	B-X
trends	B-X
according	B-X
to	B-X
pH	B-X
,	B-X
salt	B-X
concentration	B-X
,	B-X
buffer	B-X
type	B-X
and	B-X
concentration	B-X
.	B-X
The	B-X
screens	B-X
are	B-X
designed	B-X
to	B-X
evaluate	B-X
purification	B-X
and	B-X
storage	B-X
protocols	B-X
,	B-X
and	B-X
aim	B-X
to	B-X
provide	B-X
hints	B-X
to	B-X
optimize	B-X
these	B-X
protocols	B-X
.	B-X
However	B-X
,	B-X
optimal	B-X
and	B-X
practical	B-X
storage	B-X
conditions	B-X
that	B-X
result	B-X
in	B-X
preservation	B-X
of	B-X
urinary	B-X
DNA	B-X
,	B-X
and	B-X
in	B-X
particular	B-X
hypermethylated	B-X
DNA	B-X
(	B-X
hmDNA	B-X
)	B-X
,	B-X
are	B-X
yet	B-X
to	B-X
be	B-X
determined	B-X
.	B-X

Unacylated	O
ghrelin	B-Protein
was	O
found	O
to	O
be	O
stable	O
in	O
all	O
conditions	O
tested	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

At	O
37	O
degrees	O
C	O
acylated	O
ghrelin	B-Protein
was	O
stable	O
at	O
pH	O
4	O
but	O
unstable	O
at	O
pH	O
7	O
.	O
4	O
,	O
the	O
main	O
degradation	O
product	O
was	O
unacylated	O
ghrelin	B-Protein
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Then	B-X
,	B-X
optimal	B-X
temperature	B-X
,	B-X
pH	B-X
and	B-X
buffer	B-X
for	B-X
sample	B-X
storage	B-X
were	B-X
determined	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

Finally	O
,	O
this	O
validated	O
HPLC	O
/	O
UV	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
binding	O
of	O
acylated	O
and	O
unacylated	O
ghrelin	B-Protein
to	O
liposomes	O
.	O
<EOS>	B-X
An	B-X
HPLC/UV	B-X
method	B-X
was	B-X
first	B-X
optimized	B-X
for	B-X
the	B-X
separation	B-X
and	B-X
quantitation	B-X
of	B-X
human	B-X
acylated	B-X
and	B-X
unacylated	B-X
(	B-X
or	B-X
des-acyl	B-X
)	B-X
ghrelin	B-X
from	B-X
aqueous	B-X
solutions	B-X
.	B-X
This	B-X
method	B-X
was	B-X
validated	B-X
by	B-X
an	B-X
original	B-X
approach	B-X
using	B-X
accuracy	B-X
profiles	B-X
based	B-X
on	B-X
tolerance	B-X
intervals	B-X
for	B-X
the	B-X
total	B-X
error	B-X
measurement	B-X
.	B-X
The	B-X
concentration	B-X
range	B-X
that	B-X
achieved	B-X
adequate	B-X
accuracy	B-X
extended	B-X
from	B-X
1.85	B-X
to	B-X
59.30microM	B-X
and	B-X
1.93	B-X
to	B-X
61.60microM	B-X
for	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
,	B-X
respectively	B-X
.	B-X
Unacylated	B-X
ghrelin	B-X
was	B-X
found	B-X
to	B-X
be	B-X
stable	B-X
in	B-X
all	B-X
conditions	B-X
tested	B-X
.	B-X
At	B-X
37	B-X
degrees	B-X
C	B-X
acylated	B-X
ghrelin	B-X
was	B-X
stable	B-X
at	B-X
pH	B-X
4	B-X
but	B-X
unstable	B-X
at	B-X
pH	B-X
7.4	B-X
,	B-X
the	B-X
main	B-X
degradation	B-X
product	B-X
was	B-X
unacylated	B-X
ghrelin	B-X
.	B-X
Finally	B-X
,	B-X
this	B-X
validated	B-X
HPLC/UV	B-X
method	B-X
was	B-X
used	B-X
to	B-X
evaluate	B-X
the	B-X
binding	B-X
of	B-X
acylated	B-X
and	B-X
unacylated	B-X
ghrelin	B-X
to	B-X
liposomes	B-X
.	B-X

Phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
by	O
protein	O
kinase	O
A	O
regulates	O
its	O
neddylation	O
and	O
antiproliferative	O
effect	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Expression	O
of	O
the	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
cul5	B-Protein
gene	O
in	O
endothelial	O
and	O
in	O
cancer	O
cell	O
lines	O
in	O
vitro	O
inhibits	O
cellular	O
proliferation	O
and	O
decreases	O
phosphorylation	O
of	O
MAPK	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Structure	O
-	O
function	O
analysis	O
of	O
the	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
sequence	O
identified	O
consensus	O
sites	O
specific	O
for	O
phosphorylation	O
by	O
protein	O
kinases	O
A	O
and	O
C	O
(	O
PKA	O
and	O
PKC	O
)	O
and	O
a	O
Nedd8	B-Protein
protein	O
modification	O
site	O
.	O

Mutations	O
at	O
the	O
PKA	O
-	O
specific	O
site	O
in	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
(	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
)	O
sequence	O
resulted	O
in	O
increased	O
cellular	O
growth	O
and	O
the	O
appearance	O
of	O
a	O
Nedd8	B-Protein
-	O
modified	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
if	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
controls	O
its	O
neddylation	O
status	O
,	O
phosphorylation	O
by	O
PKC	O
,	O
and	O
ultimately	O
growth	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
in	O
vitro	O
transfection	O
of	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
with	O
anti	O
-	O
VACM	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
small	O
interfering	O
RNA	O
oligonucleotides	O
decreases	O
endogenous	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
concentration	O
and	O
increases	O
cell	O
growth	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
immunoprecipitated	O
with	O
an	O
antibody	O
directed	O
against	O
a	O
PKA	O
-	O
specific	O
phosphorylation	O
site	O
and	O
probed	O
with	O
anti	O
-	O
VACM	B-Protein
-	I-Protein
1	I-Protein
-	O
specific	O
antibody	O
showed	O
that	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
was	O
decreased	O
in	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
cDNA	O
when	O
compared	O
with	O
the	O
cytomegalovirus	O
-	O
transfected	O
cells	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

This	O
change	O
was	O
associated	O
with	O
increased	O
modification	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
by	O
Nedd8	B-Protein
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Induction	O
of	O
PKA	O
activity	O
with	O
forskolin	O
reduced	O
modification	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
protein	O
by	O
Nedd8	B-Protein
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Finally	O
,	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
cul5	B-Protein
cDNA	O
and	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
10	O
and	O
100	O
nm	O
)	O
to	O
induce	O
PKC	O
activity	O
grew	O
significantly	O
faster	O
than	O
the	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
antiproliferative	O
effect	O
of	O
VACM	B-Protein
-	I-Protein
1	I-Protein
/	O
Cul5	B-Protein
is	O
dependent	O
on	O
its	O
posttranslational	O
modifications	O
and	O
will	O
help	O
in	O
the	O
design	O
of	O
new	O
anticancer	O
therapeutics	O
that	O
target	O
the	O
Nedd8	B-Protein
pathway	O
.	O
<EOS>	B-X
Expression	B-X
of	B-X
the	B-X
VACM-1/cul5	B-X
gene	B-X
in	B-X
endothelial	B-X
and	B-X
in	B-X
cancer	B-X
cell	B-X
lines	B-X
in	B-X
vitro	B-X
inhibits	B-X
cellular	B-X
proliferation	B-X
and	B-X
decreases	B-X
phosphorylation	B-X
of	B-X
MAPK	B-X
.	B-X
Structure-function	B-X
analysis	B-X
of	B-X
the	B-X
VACM-1	B-X
protein	B-X
sequence	B-X
identified	B-X
consensus	B-X
sites	B-X
specific	B-X
for	B-X
phosphorylation	B-X
by	B-X
protein	B-X
kinases	B-X
A	B-X
and	B-X
C	B-X
(	B-X
PKA	B-X
and	B-X
PKC	B-X
)	B-X
and	B-X
a	B-X
Nedd8	B-X
protein	B-X
modification	B-X
site	B-X
.	B-X
Mutations	B-X
at	B-X
the	B-X
PKA-specific	B-X
site	B-X
in	B-X
VACM-1/Cul5	B-X
(	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
)	B-X
sequence	B-X
resulted	B-X
in	B-X
increased	B-X
cellular	B-X
growth	B-X
and	B-X
the	B-X
appearance	B-X
of	B-X
a	B-X
Nedd8-modified	B-X
VACM-1/Cul5	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
examine	B-X
if	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1/Cul5	B-X
controls	B-X
its	B-X
neddylation	B-X
status	B-X
,	B-X
phosphorylation	B-X
by	B-X
PKC	B-X
,	B-X
and	B-X
ultimately	B-X
growth	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
in	B-X
vitro	B-X
transfection	B-X
of	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
with	B-X
anti-VACM-1-specific	B-X
small	B-X
interfering	B-X
RNA	B-X
oligonucleotides	B-X
decreases	B-X
endogenous	B-X
VACM-1	B-X
protein	B-X
concentration	B-X
and	B-X
increases	B-X
cell	B-X
growth	B-X
.	B-X
Western	B-X
blot	B-X
analysis	B-X
of	B-X
cell	B-X
lysates	B-X
immunoprecipitated	B-X
with	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
a	B-X
PKA-specific	B-X
phosphorylation	B-X
site	B-X
and	B-X
probed	B-X
with	B-X
anti-VACM-1-specific	B-X
antibody	B-X
showed	B-X
that	B-X
PKA-dependent	B-X
phosphorylation	B-X
of	B-X
VACM-1	B-X
protein	B-X
was	B-X
decreased	B-X
in	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1	B-X
cDNA	B-X
when	B-X
compared	B-X
with	B-X
the	B-X
cytomegalovirus-transfected	B-X
cells	B-X
.	B-X
This	B-X
change	B-X
was	B-X
associated	B-X
with	B-X
increased	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Induction	B-X
of	B-X
PKA	B-X
activity	B-X
with	B-X
forskolin	B-X
reduced	B-X
modification	B-X
of	B-X
VACM-1	B-X
protein	B-X
by	B-X
Nedd8	B-X
.	B-X
Finally	B-X
,	B-X
rat	B-X
adrenal	B-X
medullary	B-X
endothelial	B-X
cells	B-X
transfected	B-X
with	B-X
(	B-X
S730A	B-X
)	B-X
VACM-1/cul5	B-X
cDNA	B-X
and	B-X
treated	B-X
with	B-X
phorbol	B-X
12-myristate	B-X
13-acetate	B-X
(	B-X
10	B-X
and	B-X
100	B-X
nm	B-X
)	B-X
to	B-X
induce	B-X
PKC	B-X
activity	B-X
grew	B-X
significantly	B-X
faster	B-X
than	B-X
the	B-X
control	B-X
cells	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
antiproliferative	B-X
effect	B-X
of	B-X
VACM-1/Cul5	B-X
is	B-X
dependent	B-X
on	B-X
its	B-X
posttranslational	B-X
modifications	B-X
and	B-X
will	B-X
help	B-X
in	B-X
the	B-X
design	B-X
of	B-X
new	B-X
anticancer	B-X
therapeutics	B-X
that	B-X
target	B-X
the	B-X
Nedd8	B-X
pathway	B-X
.	B-X

Recognition	O
of	O
lipopeptide	O
patterns	O
by	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
-	O
Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
6	I-Protein
heterodimer	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
initiates	B-X
potent	B-X
immune	B-X
responses	B-X
by	B-X
recognizing	B-X
diacylated	B-X
and	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Its	B-X
ligand	B-X
specificity	B-X
is	B-X
controlled	B-X
by	B-X
whether	B-X
it	B-X
heterodimerizes	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
First	B-X
,	B-X
the	B-X
lipid	B-X
channel	B-X
of	B-X
TLR6	B-X
is	B-X
blocked	B-X
by	B-X
two	B-X
phenylalanines	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
the	B-X
TLR2-lipoteichoic	B-X
acid	B-X
and	B-X
the	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
demonstrate	B-X
that	B-X
a	B-X
precise	B-X
interaction	B-X
pattern	B-X
of	B-X
the	B-X
head	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
robust	B-X
immune	B-X
response	B-X
by	B-X
TLR2	B-X
heterodimers	B-X
.	B-X

Toll	B-Protein
-	I-Protein
like	I-Protein
receptor	I-Protein
2	I-Protein
(	O
TLR2	B-Protein
)	O
initiates	O
potent	O
immune	O
responses	O
by	O
recognizing	O
diacylated	O
and	O
triacylated	O
lipopeptides	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
initiates	B-X
potent	B-X
immune	B-X
responses	B-X
by	B-X
recognizing	B-X
diacylated	B-X
and	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
the	B-X
TLR2-lipoteichoic	B-X
acid	B-X
and	B-X
the	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
demonstrate	B-X
that	B-X
a	B-X
precise	B-X
interaction	B-X
pattern	B-X
of	B-X
the	B-X
head	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
robust	B-X
immune	B-X
response	B-X
by	B-X
TLR2	B-X
heterodimers	B-X
.	B-X

Its	O
ligand	O
specificity	O
is	O
controlled	O
by	O
whether	O
it	O
heterodimerizes	O
with	O
TLR1	B-Protein
or	O
TLR6	B-Protein
.	O
<EOS>	B-X
They	B-X
can	B-X
be	B-X
classified	B-X
into	B-X
cell	B-X
surface	B-X
(	B-X
TLR1	B-X
,	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
TLR5	B-X
,	B-X
TLR6	B-X
)	B-X
and	B-X
intracellular	B-X
TLRs	B-X
(	B-X
TLR3	B-X
,	B-X
TLR7	B-X
,	B-X
TLR8	B-X
,	B-X
TLR9	B-X
)	B-X
,	B-X
expressed	B-X
on	B-X
endosomal	B-X
membranes	B-X
.	B-X
The	B-X
present	B-X
review	B-X
will	B-X
elaborate	B-X
on	B-X
applications	B-X
of	B-X
TLR	B-X
ligands	B-X
as	B-X
vaccine	B-X
adjuvants	B-X
and	B-X
immunotherapeutic	B-X
agents	B-X
,	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
clinically	B-X
relevant	B-X
adjuvants	B-X
.	B-X
The	B-X
upregulation	B-X
of	B-X
TLR6	B-X
and	B-X
MMP9	B-X
,	B-X
which	B-X
promote	B-X
the	B-X
neutrophils-mediated	B-X
inflammatory	B-X
response	B-X
,	B-X
and	B-X
the	B-X
downregulation	B-X
of	B-X
SKAP1	B-X
and	B-X
LAG3	B-X
,	B-X
which	B-X
regulate	B-X
T	B-X
cells	B-X
function	B-X
,	B-X
were	B-X
associated	B-X
with	B-X
disease	B-X
severity	B-X
.	B-X
I602S	B-X
(	B-X
TLR1	B-X
)	B-X
,	B-X
R677W	B-X
(	B-X
TLR2	B-X
)	B-X
,	B-X
P554S	B-X
(	B-X
TLR3	B-X
)	B-X
,	B-X
D299G	B-X
(	B-X
TLR4	B-X
)	B-X
,	B-X
F616L	B-X
(	B-X
TLR5	B-X
)	B-X
,	B-X
S249P	B-X
(	B-X
TLR6	B-X
)	B-X
,	B-X
Q11L	B-X
(	B-X
TLR7	B-X
)	B-X
,	B-X
M1V	B-X
(	B-X
TLR8	B-X
)	B-X
,	B-X
G1174A	B-X
(	B-X
TLR9	B-X
)	B-X
and	B-X
G1031T	B-X
(	B-X
TLR10	B-X
)	B-X
are	B-X
presented	B-X
as	B-X
the	B-X
major	B-X
influential	B-X
SNPs	B-X
in	B-X
shaping	B-X
immunity	B-X
to	B-X
pathogenic	B-X
infections	B-X
.	B-X

We	O
have	O
determined	O
the	O
crystal	O
structures	O
of	O
TLR2	B-Protein
-	O
TLR6	B-Protein
-	O
diacylated	O
lipopeptide	O
,	O
TLR2	B-Protein
-	O
lipoteichoic	O
acid	O
,	O
and	O
TLR2	B-Protein
-	O
PE	O
-	O
DTPA	O
complexes	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
initiates	B-X
potent	B-X
immune	B-X
responses	B-X
by	B-X
recognizing	B-X
diacylated	B-X
and	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Its	B-X
ligand	B-X
specificity	B-X
is	B-X
controlled	B-X
by	B-X
whether	B-X
it	B-X
heterodimerizes	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
First	B-X
,	B-X
the	B-X
lipid	B-X
channel	B-X
of	B-X
TLR6	B-X
is	B-X
blocked	B-X
by	B-X
two	B-X
phenylalanines	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
the	B-X
TLR2-lipoteichoic	B-X
acid	B-X
and	B-X
the	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
demonstrate	B-X
that	B-X
a	B-X
precise	B-X
interaction	B-X
pattern	B-X
of	B-X
the	B-X
head	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
robust	B-X
immune	B-X
response	B-X
by	B-X
TLR2	B-X
heterodimers	B-X
.	B-X

PE	O
-	O
DTPA	O
,	O
1	O
,	O
2	O
-	O
dimyristoyl	O
-	O
sn	O
-	O
glycero	O
-	O
3	O
-	O
phosphoethanolamine	O
-	O
N	O
-	O
diethylenetriaminepentaacetic	O
acid	O
,	O
is	O
a	O
synthetic	O
phospholipid	O
derivative	O
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
initiates	B-X
potent	B-X
immune	B-X
responses	B-X
by	B-X
recognizing	B-X
diacylated	B-X
and	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Its	B-X
ligand	B-X
specificity	B-X
is	B-X
controlled	B-X
by	B-X
whether	B-X
it	B-X
heterodimerizes	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
the	B-X
TLR2-lipoteichoic	B-X
acid	B-X
and	B-X
the	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
demonstrate	B-X
that	B-X
a	B-X
precise	B-X
interaction	B-X
pattern	B-X
of	B-X
the	B-X
head	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
robust	B-X
immune	B-X
response	B-X
by	B-X
TLR2	B-X
heterodimers	B-X
.	B-X

Two	O
major	O
factors	O
contribute	O
to	O
the	O
ligand	O
specificity	O
of	O
TLR2	B-Protein
-	O
TLR1	B-Protein
or	O
TLR2	B-Protein
-	O
TLR6	B-Protein
heterodimers	O
.	O
<EOS>	B-X
TLR2	B-X
makes	B-X
heterodimer	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
and	B-X
recognizes	B-X
a	B-X
wide	B-X
variety	B-X
of	B-X
microbial	B-X
ligands	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
studies	B-X
of	B-X
polymorphisms	B-X
in	B-X
genes	B-X
encoding	B-X
TLR1	B-X
,	B-X
TLR2	B-X
,	B-X
TLR4	B-X
,	B-X
TLR6	B-X
,	B-X
and	B-X
most	B-X
polymorphic	B-X
adaptor	B-X
protein	B-X
,	B-X
Mal/TIRAP	B-X
,	B-X
revealing	B-X
their	B-X
effect	B-X
on	B-X
susceptibility	B-X
to	B-X
diseases	B-X
.	B-X
The	B-X
TLR2	B-X
receptor	B-X
complex	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
contain	B-X
heterodimers	B-X
of	B-X
TLR2	B-X
with	B-X
either	B-X
TLR1	B-X
or	B-X
TLR6	B-X
enabling	B-X
the	B-X
host	B-X
to	B-X
detect	B-X
different	B-X
microbial	B-X
molecules	B-X
,	B-X
such	B-X
as	B-X
lipopeptides	B-X
of	B-X
different	B-X
chemical	B-X
composition	B-X
.	B-X
In	B-X
this	B-X
issue	B-X
of	B-X
the	B-X
European	B-X
Journal	B-X
of	B-X
Immunology	B-X
,	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
sensing	B-X
of	B-X
microbial	B-X
products	B-X
for	B-X
I602S	B-X
,	B-X
a	B-X
single	B-X
nucleotide	B-X
polymorphism	B-X
(	B-X
SNP	B-X
)	B-X
in	B-X
human	B-X
TLR1	B-X
has	B-X
been	B-X
identified	B-X
.	B-X
This	B-X
result	B-X
,	B-X
in	B-X
combination	B-X
with	B-X
another	B-X
recently	B-X
published	B-X
report	B-X
on	B-X
this	B-X
polymorphism	B-X
elucidating	B-X
a	B-X
functional	B-X
role	B-X
in	B-X
cell	B-X
trafficking	B-X
(	B-X
surface	B-X
expression	B-X
of	B-X
the	B-X
receptor	B-X
complex	B-X
in	B-X
individuals	B-X
carrying	B-X
the	B-X
SNP	B-X
was	B-X
altered	B-X
)	B-X
,	B-X
provide	B-X
genetic	B-X
evidence	B-X
affirming	B-X
the	B-X
important	B-X
function	B-X
of	B-X
TLR1	B-X
as	B-X
an	B-X
essential	B-X
co-receptor	B-X
for	B-X
TLR2	B-X
.	B-X

First	O
,	O
the	O
lipid	O
channel	O
of	O
TLR6	B-Protein
is	O
blocked	O
by	O
two	O
phenylalanines	O
.	O
<EOS>	B-X
Its	B-X
ligand	B-X
specificity	B-X
is	B-X
controlled	B-X
by	B-X
whether	B-X
it	B-X
heterodimerizes	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
First	B-X
,	B-X
the	B-X
lipid	B-X
channel	B-X
of	B-X
TLR6	B-X
is	B-X
blocked	B-X
by	B-X
two	B-X
phenylalanines	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X

Simultaneous	O
mutation	O
of	O
these	O
phenylalanines	O
made	O
TLR2	B-Protein
-	O
TLR6	B-Protein
fully	O
responsive	O
not	O
only	O
to	O
diacylated	O
but	O
also	O
to	O
triacylated	O
lipopeptides	O
.	O

Second	O
,	O
the	O
hydrophobic	O
dimerization	O
interface	O
of	O
TLR2	B-Protein
-	O
TLR6	B-Protein
is	O
increased	O
by	O
80	O
%	O
,	O
which	O
compensates	O
for	O
the	O
lack	O
of	O
amide	O
lipid	O
interaction	O
between	O
the	O
lipopeptide	O
and	O
TLR2	B-Protein
-	O
TLR6	B-Protein
.	O
<EOS>	B-X
Toll-like	B-X
receptor	B-X
2	B-X
(	B-X
TLR2	B-X
)	B-X
initiates	B-X
potent	B-X
immune	B-X
responses	B-X
by	B-X
recognizing	B-X
diacylated	B-X
and	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Its	B-X
ligand	B-X
specificity	B-X
is	B-X
controlled	B-X
by	B-X
whether	B-X
it	B-X
heterodimerizes	B-X
with	B-X
TLR1	B-X
or	B-X
TLR6	B-X
.	B-X
We	B-X
have	B-X
determined	B-X
the	B-X
crystal	B-X
structures	B-X
of	B-X
TLR2-TLR6-diacylated	B-X
lipopeptide	B-X
,	B-X
TLR2-lipoteichoic	B-X
acid	B-X
,	B-X
and	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
.	B-X
PE-DTPA	B-X
,	B-X
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic	B-X
acid	B-X
,	B-X
is	B-X
a	B-X
synthetic	B-X
phospholipid	B-X
derivative	B-X
.	B-X
Two	B-X
major	B-X
factors	B-X
contribute	B-X
to	B-X
the	B-X
ligand	B-X
specificity	B-X
of	B-X
TLR2-TLR1	B-X
or	B-X
TLR2-TLR6	B-X
heterodimers	B-X
.	B-X
First	B-X
,	B-X
the	B-X
lipid	B-X
channel	B-X
of	B-X
TLR6	B-X
is	B-X
blocked	B-X
by	B-X
two	B-X
phenylalanines	B-X
.	B-X
Simultaneous	B-X
mutation	B-X
of	B-X
these	B-X
phenylalanines	B-X
made	B-X
TLR2-TLR6	B-X
fully	B-X
responsive	B-X
not	B-X
only	B-X
to	B-X
diacylated	B-X
but	B-X
also	B-X
to	B-X
triacylated	B-X
lipopeptides	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
hydrophobic	B-X
dimerization	B-X
interface	B-X
of	B-X
TLR2-TLR6	B-X
is	B-X
increased	B-X
by	B-X
80	B-X
%	B-X
,	B-X
which	B-X
compensates	B-X
for	B-X
the	B-X
lack	B-X
of	B-X
amide	B-X
lipid	B-X
interaction	B-X
between	B-X
the	B-X
lipopeptide	B-X
and	B-X
TLR2-TLR6	B-X
.	B-X
The	B-X
structures	B-X
of	B-X
the	B-X
TLR2-lipoteichoic	B-X
acid	B-X
and	B-X
the	B-X
TLR2-PE-DTPA	B-X
complexes	B-X
demonstrate	B-X
that	B-X
a	B-X
precise	B-X
interaction	B-X
pattern	B-X
of	B-X
the	B-X
head	B-X
group	B-X
is	B-X
essential	B-X
for	B-X
a	B-X
robust	B-X
immune	B-X
response	B-X
by	B-X
TLR2	B-X
heterodimers	B-X
.	B-X

The	O
structures	O
of	O
the	O
TLR2	B-Protein
-	O
lipoteichoic	O
acid	O
and	O
the	O
TLR2	B-Protein
-	O
PE	O
-	O
DTPA	O
complexes	O
demonstrate	O
that	O
a	O
precise	O
interaction	O
pattern	O
of	O
the	O
head	O
group	O
is	O
essential	O
for	O
a	O
robust	O
immune	O
response	O
by	O
TLR2	B-Protein
heterodimers	O
.	O

Palmitoylation	O
regulates	O
epidermal	O
homeostasis	O
and	O
hair	O
follicle	O
differentiation	O
.	O
<EOS>	B-X
Palmitoylation	B-X
is	B-X
a	B-X
key	B-X
post-translational	B-X
modification	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
DHHC-containing	B-X
palmitoyl	B-X
acyl-transferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
Unlike	B-X
other	B-X
lipid	B-X
modifications	B-X
,	B-X
palmitoylation	B-X
is	B-X
reversible	B-X
and	B-X
thus	B-X
often	B-X
regulates	B-X
dynamic	B-X
protein	B-X
interactions	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
a	B-X
key	B-X
role	B-X
for	B-X
palmitoylation	B-X
in	B-X
regulating	B-X
developmental	B-X
signals	B-X
in	B-X
mammalian	B-X
tissue	B-X
homeostasis	B-X
.	B-X

Palmitoylation	O
is	O
a	O
key	O
post	O
-	O
translational	O
modification	O
mediated	O
by	O
a	O
family	O
of	O
DHHC	O
-	O
containing	O
palmitoyl	O
acyl	O
-	O
transferases	O
(	O
PATs	O
)	O
.	O
<EOS>	B-X
Palmitoylation	B-X
serves	B-X
as	B-X
a	B-X
key	B-X
regulator	B-X
of	B-X
maturational	B-X
processing	B-X
in	B-X
other	B-X
integral	B-X
membrane	B-X
proteins	B-X
,	B-X
but	B-X
has	B-X
not	B-X
been	B-X
tested	B-X
previously	B-X
for	B-X
functional	B-X
effects	B-X
on	B-X
CFTR	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
used	B-X
metabolic	B-X
labelling	B-X
to	B-X
confirm	B-X
that	B-X
wild-type	B-X
and	B-X
F508del	B-X
CFTR	B-X
are	B-X
palmitoylated	B-X
,	B-X
and	B-X
show	B-X
that	B-X
blocking	B-X
palmitoylation	B-X
with	B-X
the	B-X
pharmacologic	B-X
inhibitor	B-X
2-BP	B-X
(	B-X
2-bromopalmitate	B-X
)	B-X
decreases	B-X
steady-state	B-X
levels	B-X
of	B-X
both	B-X
wild-type	B-X
and	B-X
low	B-X
temperature-corrected	B-X
F508del	B-X
CFTR	B-X
,	B-X
disrupts	B-X
post-ER	B-X
(	B-X
endoplasmic	B-X
reticulum	B-X
)	B-X
maturation	B-X
and	B-X
reduces	B-X
ion	B-X
channel	B-X
function	B-X
at	B-X
the	B-X
cell	B-X
surface	B-X
.	B-X
PATs	B-X
(	B-X
protein	B-X
acyl	B-X
transferases	B-X
)	B-X
comprise	B-X
a	B-X
family	B-X
of	B-X
23	B-X
gene	B-X
products	B-X
that	B-X
contain	B-X
a	B-X
DHHC	B-X
motif	B-X
and	B-X
mediate	B-X
palmitoylation	B-X
.	B-X
Recombinant	B-X
expression	B-X
of	B-X
specific	B-X
PATs	B-X
led	B-X
to	B-X
increased	B-X
levels	B-X
of	B-X
CFTR	B-X
protein	B-X
and	B-X
enhanced	B-X
palmitoylation	B-X
as	B-X
judged	B-X
by	B-X
Western	B-X
blot	B-X
and	B-X
metabolic	B-X
labelling	B-X
.	B-X
Specifically	B-X
,	B-X
we	B-X
show	B-X
that	B-X
DHHC-7	B-X
(	B-X
i	B-X
)	B-X
increases	B-X
steady-state	B-X
levels	B-X
of	B-X
wild-type	B-X
and	B-X
F508del	B-X
CFTR	B-X
band	B-X
B	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
interacts	B-X
preferentially	B-X
with	B-X
the	B-X
band	B-X
B	B-X
glycoform	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
augments	B-X
radiolabelling	B-X
by	B-X
[	B-X
3H	B-X
]	B-X
palmitic	B-X
acid	B-X
.	B-X
Interestingly	B-X
,	B-X
immunofluorescence	B-X
revealed	B-X
that	B-X
DHHC-7	B-X
also	B-X
sequesters	B-X
the	B-X
F508del	B-X
protein	B-X
to	B-X
a	B-X
post-ER	B-X
(	B-X
Golgi	B-X
)	B-X
compartment	B-X
.	B-X
Our	B-X
findings	B-X
point	B-X
to	B-X
the	B-X
importance	B-X
of	B-X
palmitoylation	B-X
during	B-X
wild-type	B-X
and	B-X
F508del	B-X
CFTR	B-X
trafficking	B-X
.	B-X

Unlike	O
other	O
lipid	O
modifications	O
,	O
palmitoylation	O
is	O
reversible	O
and	O
thus	O
often	O
regulates	O
dynamic	O
protein	O
interactions	O
.	O
<EOS>	B-X
Unlike	B-X
other	B-X
lipid	B-X
modifications	B-X
,	B-X
palmitoylation	B-X
is	B-X
reversible	B-X
and	B-X
thus	B-X
often	B-X
regulates	B-X
dynamic	B-X
protein	B-X
interactions	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
a	B-X
key	B-X
role	B-X
for	B-X
palmitoylation	B-X
in	B-X
regulating	B-X
developmental	B-X
signals	B-X
in	B-X
mammalian	B-X
tissue	B-X
homeostasis	B-X
.	B-X

We	O
find	O
that	O
the	O
mouse	O
hair	O
loss	O
mutant	O
,	O
depilated	O
,	O
(	O
dep	O
)	O
is	O
due	O
to	O
a	O
single	O
amino	O
acid	O
deletion	O
in	O
the	O
PAT	O
,	O
Zdhhc21	B-Protein
,	O
resulting	O
in	O
protein	O
mislocalization	O
and	O
loss	O
of	O
palmitoylation	O
activity	O
.	O
<EOS>	B-X
Palmitoylation	B-X
is	B-X
a	B-X
key	B-X
post-translational	B-X
modification	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
DHHC-containing	B-X
palmitoyl	B-X
acyl-transferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
Unlike	B-X
other	B-X
lipid	B-X
modifications	B-X
,	B-X
palmitoylation	B-X
is	B-X
reversible	B-X
and	B-X
thus	B-X
often	B-X
regulates	B-X
dynamic	B-X
protein	B-X
interactions	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
a	B-X
key	B-X
role	B-X
for	B-X
palmitoylation	B-X
in	B-X
regulating	B-X
developmental	B-X
signals	B-X
in	B-X
mammalian	B-X
tissue	B-X
homeostasis	B-X
.	B-X

We	O
examined	O
expression	O
of	O
Zdhhc21	B-Protein
protein	O
in	O
skin	O
and	O
find	O
it	O
restricted	O
to	O
specific	O
hair	O
lineages	O
.	O
<EOS>	B-X
Unlike	B-X
other	B-X
lipid	B-X
modifications	B-X
,	B-X
palmitoylation	B-X
is	B-X
reversible	B-X
and	B-X
thus	B-X
often	B-X
regulates	B-X
dynamic	B-X
protein	B-X
interactions	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X

Loss	O
of	O
Zdhhc21	B-Protein
function	O
results	O
in	O
delayed	O
hair	O
shaft	O
differentiation	O
,	O
at	O
the	O
site	O
of	O
expression	O
of	O
the	O
gene	O
,	O
but	O
also	O
leads	O
to	O
hyperplasia	O
of	O
the	O
interfollicular	O
epidermis	O
(	O
IFE	O
)	O
and	O
sebaceous	O
glands	O
,	O
distant	O
from	O
the	O
expression	O
site	O
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X

The	O
specific	O
delay	O
in	O
follicle	O
differentiation	O
is	O
associated	O
with	O
attenuated	O
anagen	O
propagation	O
and	O
is	O
reflected	O
by	O
decreased	O
levels	O
of	O
Lef1	B-Protein
,	O
nuclear	B-Protein
beta	I-Protein
-	I-Protein
catenin	I-Protein
,	O
and	O
Foxn1	B-Protein
in	O
hair	O
shaft	O
progenitors	O
.	O
<EOS>	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X

In	O
the	O
thickened	O
basal	O
compartment	O
of	O
mutant	O
IFE	O
,	O
phospho	O
-	O
ERK	O
and	O
cell	O
proliferation	O
are	O
increased	O
,	O
suggesting	O
increased	O
signaling	O
through	O
EGFR	B-Protein
or	O
integrin	O
-	O
related	O
receptors	O
,	O
with	O
a	O
parallel	O
reduction	O
in	O
expression	O
of	O
the	O
key	O
differentiation	O
factor	O
Gata3	B-Protein
.	O
<EOS>	B-X
Palmitoylation	B-X
is	B-X
a	B-X
key	B-X
post-translational	B-X
modification	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
DHHC-containing	B-X
palmitoyl	B-X
acyl-transferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
a	B-X
key	B-X
role	B-X
for	B-X
palmitoylation	B-X
in	B-X
regulating	B-X
developmental	B-X
signals	B-X
in	B-X
mammalian	B-X
tissue	B-X
homeostasis	B-X
.	B-X

We	O
show	O
that	O
the	O
Src	O
-	O
family	O
kinase	O
,	O
Fyn	B-Protein
,	O
involved	O
in	O
keratinocyte	O
differentiation	O
,	O
is	O
a	O
direct	O
palmitoylation	O
target	O
of	O
Zdhhc21	B-Protein
and	O
is	O
mislocalized	O
in	O
mutant	O
follicles	O
.	O
<EOS>	B-X
Palmitoylation	B-X
is	B-X
a	B-X
key	B-X
post-translational	B-X
modification	B-X
mediated	B-X
by	B-X
a	B-X
family	B-X
of	B-X
DHHC-containing	B-X
palmitoyl	B-X
acyl-transferases	B-X
(	B-X
PATs	B-X
)	B-X
.	B-X
Unlike	B-X
other	B-X
lipid	B-X
modifications	B-X
,	B-X
palmitoylation	B-X
is	B-X
reversible	B-X
and	B-X
thus	B-X
often	B-X
regulates	B-X
dynamic	B-X
protein	B-X
interactions	B-X
.	B-X
We	B-X
find	B-X
that	B-X
the	B-X
mouse	B-X
hair	B-X
loss	B-X
mutant	B-X
,	B-X
depilated	B-X
,	B-X
(	B-X
dep	B-X
)	B-X
is	B-X
due	B-X
to	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
deletion	B-X
in	B-X
the	B-X
PAT	B-X
,	B-X
Zdhhc21	B-X
,	B-X
resulting	B-X
in	B-X
protein	B-X
mislocalization	B-X
and	B-X
loss	B-X
of	B-X
palmitoylation	B-X
activity	B-X
.	B-X
We	B-X
examined	B-X
expression	B-X
of	B-X
Zdhhc21	B-X
protein	B-X
in	B-X
skin	B-X
and	B-X
find	B-X
it	B-X
restricted	B-X
to	B-X
specific	B-X
hair	B-X
lineages	B-X
.	B-X
Loss	B-X
of	B-X
Zdhhc21	B-X
function	B-X
results	B-X
in	B-X
delayed	B-X
hair	B-X
shaft	B-X
differentiation	B-X
,	B-X
at	B-X
the	B-X
site	B-X
of	B-X
expression	B-X
of	B-X
the	B-X
gene	B-X
,	B-X
but	B-X
also	B-X
leads	B-X
to	B-X
hyperplasia	B-X
of	B-X
the	B-X
interfollicular	B-X
epidermis	B-X
(	B-X
IFE	B-X
)	B-X
and	B-X
sebaceous	B-X
glands	B-X
,	B-X
distant	B-X
from	B-X
the	B-X
expression	B-X
site	B-X
.	B-X
The	B-X
specific	B-X
delay	B-X
in	B-X
follicle	B-X
differentiation	B-X
is	B-X
associated	B-X
with	B-X
attenuated	B-X
anagen	B-X
propagation	B-X
and	B-X
is	B-X
reflected	B-X
by	B-X
decreased	B-X
levels	B-X
of	B-X
Lef1	B-X
,	B-X
nuclear	B-X
beta-catenin	B-X
,	B-X
and	B-X
Foxn1	B-X
in	B-X
hair	B-X
shaft	B-X
progenitors	B-X
.	B-X
In	B-X
the	B-X
thickened	B-X
basal	B-X
compartment	B-X
of	B-X
mutant	B-X
IFE	B-X
,	B-X
phospho-ERK	B-X
and	B-X
cell	B-X
proliferation	B-X
are	B-X
increased	B-X
,	B-X
suggesting	B-X
increased	B-X
signaling	B-X
through	B-X
EGFR	B-X
or	B-X
integrin-related	B-X
receptors	B-X
,	B-X
with	B-X
a	B-X
parallel	B-X
reduction	B-X
in	B-X
expression	B-X
of	B-X
the	B-X
key	B-X
differentiation	B-X
factor	B-X
Gata3	B-X
.	B-X
We	B-X
show	B-X
that	B-X
the	B-X
Src-family	B-X
kinase	B-X
,	B-X
Fyn	B-X
,	B-X
involved	B-X
in	B-X
keratinocyte	B-X
differentiation	B-X
,	B-X
is	B-X
a	B-X
direct	B-X
palmitoylation	B-X
target	B-X
of	B-X
Zdhhc21	B-X
and	B-X
is	B-X
mislocalized	B-X
in	B-X
mutant	B-X
follicles	B-X
.	B-X
This	B-X
study	B-X
is	B-X
the	B-X
first	B-X
to	B-X
demonstrate	B-X
a	B-X
key	B-X
role	B-X
for	B-X
palmitoylation	B-X
in	B-X
regulating	B-X
developmental	B-X
signals	B-X
in	B-X
mammalian	B-X
tissue	B-X
homeostasis	B-X
.	B-X

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
a	O
key	O
role	O
for	O
palmitoylation	O
in	O
regulating	O
developmental	O
signals	O
in	O
mammalian	O
tissue	O
homeostasis	O
.	O

Rapid	O
and	O
selective	O
detection	O
of	O
fatty	O
acylated	O
proteins	O
using	O
omega	O
-	O
alkynyl	O
-	O
fatty	O
acids	O
and	O
click	O
chemistry	O
.	O
<EOS>	B-X
Progress	B-X
in	B-X
understanding	B-X
the	B-X
biology	B-X
of	B-X
protein	B-X
fatty	B-X
acylation	B-X
has	B-X
been	B-X
impeded	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
rapid	B-X
direct	B-X
detection	B-X
and	B-X
identification	B-X
methods	B-X
.	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Progress	O
in	O
understanding	O
the	O
biology	O
of	O
protein	O
fatty	O
acylation	O
has	O
been	O
impeded	O
by	O
the	O
lack	O
of	O
rapid	O
direct	O
detection	O
and	O
identification	O
methods	O
.	O
<EOS>	B-X
Progress	B-X
in	B-X
understanding	B-X
the	B-X
biology	B-X
of	B-X
protein	B-X
fatty	B-X
acylation	B-X
has	B-X
been	B-X
impeded	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
rapid	B-X
direct	B-X
detection	B-X
and	B-X
identification	B-X
methods	B-X
.	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

We	O
first	O
report	O
that	O
a	O
synthetic	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
analog	O
can	O
be	O
readily	O
and	O
specifically	O
incorporated	O
into	O
GAPDH	B-Protein
or	O
mitochondrial	O
3	B-Protein
-	I-Protein
hydroxyl	I-Protein
-	I-Protein
3	I-Protein
-	I-Protein
methylglutaryl	I-Protein
-	I-Protein
CoA	I-Protein
synthase	I-Protein
in	O
vitro	O
and	O
reacted	O
with	O
an	O
azido	O
-	O
biotin	O
probe	O
or	O
the	O
fluorogenic	O
probe	O
3	O
-	O
azido	O
-	O
7	O
-	O
hydroxycoumarin	O
using	O
click	O
chemistry	O
for	O
rapid	O
detection	O
by	O
Western	O
blotting	O
or	O
flat	O
bed	O
fluorescence	O
scanning	O
.	O
<EOS>	B-X
The	B-X
excised	B-X
tissue	B-X
of	B-X
a	B-X
single	B-X
patient	B-X
in	B-X
the	B-X
microdose	B-X
administration	B-X
group	B-X
was	B-X
imaged	B-X
with	B-X
both	B-X
a	B-X
wide-field	B-X
fluorescence	B-X
surgical	B-X
system	B-X
and	B-X
a	B-X
flat-bed	B-X
scanning	B-X
fluorescence	B-X
imaging	B-X
system	B-X
.	B-X
Here	B-X
the	B-X
resultant	B-X
fluorescence	B-X
from	B-X
a	B-X
breadloaf	B-X
section	B-X
of	B-X
the	B-X
primary	B-X
tumor	B-X
specimen	B-X
and	B-X
six	B-X
region-specific	B-X
tissue	B-X
samples	B-X
collected	B-X
from	B-X
that	B-X
breadloaf	B-X
are	B-X
compared	B-X
using	B-X
these	B-X
two	B-X
imaging	B-X
systems	B-X
-	B-X
a	B-X
flatbed	B-X
,	B-X
black-box	B-X
,	B-X
fluorescence	B-X
scanning	B-X
system	B-X
,	B-X
the	B-X
Odyssey	B-X
CLx	B-X
,	B-X
and	B-X
a	B-X
open-air	B-X
,	B-X
wide-field	B-X
,	B-X
pre-clinical	B-X
surgical	B-X
imaging	B-X
system	B-X
,	B-X
the	B-X
Solaris	B-X
.	B-X
Florescence	B-X
signal	B-X
is	B-X
compared	B-X
using	B-X
a	B-X
variety	B-X
of	B-X
methods	B-X
including	B-X
:	B-X
mean	B-X
,	B-X
standard	B-X
deviation	B-X
,	B-X
variance	B-X
,	B-X
tumor-to-background	B-X
ratio	B-X
,	B-X
biological-variance	B-X
ratio	B-X
,	B-X
and	B-X
contrast-to-noise	B-X
ratio	B-X
.	B-X
Progress	B-X
in	B-X
understanding	B-X
the	B-X
biology	B-X
of	B-X
protein	B-X
fatty	B-X
acylation	B-X
has	B-X
been	B-X
impeded	B-X
by	B-X
the	B-X
lack	B-X
of	B-X
rapid	B-X
direct	B-X
detection	B-X
and	B-X
identification	B-X
methods	B-X
.	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

The	O
acylated	O
cysteine	O
residues	O
were	O
confirmed	O
by	O
MS	O
.	O
<EOS>	B-X
Bacterial	B-X
lipoproteins	B-X
are	B-X
known	B-X
to	B-X
be	B-X
diacylated	B-X
or	B-X
triacylated	B-X
and	B-X
activate	B-X
mammalian	B-X
immune	B-X
cells	B-X
via	B-X
Toll-like	B-X
receptor	B-X
2/6	B-X
or	B-X
2/1	B-X
heterodimer	B-X
.	B-X
Because	B-X
the	B-X
genomes	B-X
of	B-X
low	B-X
G+C	B-X
content	B-X
gram-positive	B-X
bacteria	B-X
,	B-X
such	B-X
as	B-X
Staphylococcus	B-X
aureus	B-X
,	B-X
do	B-X
not	B-X
contain	B-X
Escherichia	B-X
coli-type	B-X
apolipoprotein	B-X
N-acyltransferase	B-X
,	B-X
an	B-X
enzyme	B-X
converting	B-X
diacylated	B-X
lipoproteins	B-X
into	B-X
triacylated	B-X
forms	B-X
,	B-X
it	B-X
has	B-X
been	B-X
widely	B-X
believed	B-X
that	B-X
native	B-X
lipoproteins	B-X
of	B-X
S.	B-X
aureus	B-X
are	B-X
diacylated	B-X
.	B-X
However	B-X
,	B-X
we	B-X
recently	B-X
demonstrated	B-X
that	B-X
one	B-X
lipoprotein	B-X
SitC	B-X
purified	B-X
from	B-X
S.	B-X
aureus	B-X
RN4220	B-X
strain	B-X
was	B-X
triacylated	B-X
.	B-X
Almost	B-X
simultaneously	B-X
,	B-X
another	B-X
group	B-X
reported	B-X
that	B-X
another	B-X
lipoprotein	B-X
SA2202	B-X
purified	B-X
from	B-X
S.	B-X
aureus	B-X
SA113	B-X
strain	B-X
was	B-X
diacylated	B-X
.	B-X
Toward	B-X
this	B-X
purpose	B-X
,	B-X
we	B-X
intensively	B-X
used	B-X
MS-based	B-X
analyses	B-X
.	B-X
Further	B-X
MS/MS	B-X
analysis	B-X
of	B-X
the	B-X
lipoprotein	B-X
lipase	B-X
digest	B-X
revealed	B-X
that	B-X
the	B-X
lipoprotein	B-X
lipase-resistant	B-X
fatty	B-X
acid	B-X
was	B-X
acylated	B-X
to	B-X
α-amino	B-X
group	B-X
of	B-X
the	B-X
N-terminal	B-X
cysteine	B-X
residue	B-X
of	B-X
SitC	B-X
.	B-X
Triacylated	B-X
forms	B-X
of	B-X
SitC	B-X
with	B-X
various	B-X
length	B-X
fatty	B-X
acids	B-X
were	B-X
also	B-X
confirmed	B-X
in	B-X
cell	B-X
lysate	B-X
of	B-X
the	B-X
RN4220	B-X
and	B-X
Triton	B-X
X-114	B-X
phase	B-X
in	B-X
three	B-X
other	B-X
S.	B-X
aureus	B-X
strains	B-X
,	B-X
including	B-X
SA113	B-X
strain	B-X
and	B-X
one	B-X
Staphylococcus	B-X
epidermidis	B-X
strain	B-X
.	B-X
Moreover	B-X
,	B-X
four	B-X
other	B-X
major	B-X
lipoproteins	B-X
including	B-X
SA2202	B-X
in	B-X
S.	B-X
aureus	B-X
strains	B-X
were	B-X
identified	B-X
as	B-X
N-acylated	B-X
.	B-X
These	B-X
results	B-X
strongly	B-X
suggest	B-X
that	B-X
lipoproteins	B-X
of	B-X
S.	B-X
aureus	B-X
are	B-X
mainly	B-X
in	B-X
the	B-X
N-acylated	B-X
triacyl	B-X
form	B-X
.	B-X

Second	O
,	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
is	O
preferentially	O
incorporated	O
into	O
transiently	O
expressed	O
H	B-Protein
-	I-Protein
or	O
N	B-Protein
-	I-Protein
Ras	I-Protein
proteins	O
(	O
but	O
not	O
nonpalmitoylated	O
K	B-Protein
-	I-Protein
Ras	I-Protein
)	O
,	O
compared	O
with	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
or	O
omega	O
-	O
alkynyl	O
-	O
stearate	O
,	O
via	O
an	O
alkali	O
sensitive	O
thioester	O
bond	O
.	O
<EOS>	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Third	O
,	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
is	O
specifically	O
incorporated	O
into	O
endogenous	O
co	O
-	O
and	O
posttranslationally	O
myristoylated	O
proteins	O
.	O
<EOS>	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

The	O
competitive	O
inhibitors	O
2	O
-	O
bromopalmitate	O
and	O
2	O
-	O
hydroxymyristate	O
prevented	O
incorporation	O
of	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
and	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
into	O
palmitoylated	O
and	O
myristoylated	O
proteins	O
,	O
respectively	O
.	O
<EOS>	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Labeling	O
cells	O
with	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
does	O
not	O
affect	O
membrane	O
association	O
of	O
N	B-Protein
-	I-Protein
Ras	I-Protein
.	O
<EOS>	B-X
We	B-X
first	B-X
report	B-X
that	B-X
a	B-X
synthetic	B-X
omega-alkynyl-palmitate	B-X
analog	B-X
can	B-X
be	B-X
readily	B-X
and	B-X
specifically	B-X
incorporated	B-X
into	B-X
GAPDH	B-X
or	B-X
mitochondrial	B-X
3-hydroxyl-3-methylglutaryl-CoA	B-X
synthase	B-X
in	B-X
vitro	B-X
and	B-X
reacted	B-X
with	B-X
an	B-X
azido-biotin	B-X
probe	B-X
or	B-X
the	B-X
fluorogenic	B-X
probe	B-X
3-azido-7-hydroxycoumarin	B-X
using	B-X
click	B-X
chemistry	B-X
for	B-X
rapid	B-X
detection	B-X
by	B-X
Western	B-X
blotting	B-X
or	B-X
flat	B-X
bed	B-X
fluorescence	B-X
scanning	B-X
.	B-X
The	B-X
acylated	B-X
cysteine	B-X
residues	B-X
were	B-X
confirmed	B-X
by	B-X
MS.	B-X
Second	B-X
,	B-X
omega-alkynyl-palmitate	B-X
is	B-X
preferentially	B-X
incorporated	B-X
into	B-X
transiently	B-X
expressed	B-X
H-	B-X
or	B-X
N-Ras	B-X
proteins	B-X
(	B-X
but	B-X
not	B-X
nonpalmitoylated	B-X
K-Ras	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
omega-alkynyl-myristate	B-X
or	B-X
omega-alkynyl-stearate	B-X
,	B-X
via	B-X
an	B-X
alkali	B-X
sensitive	B-X
thioester	B-X
bond	B-X
.	B-X
Third	B-X
,	B-X
omega-alkynyl-myristate	B-X
is	B-X
specifically	B-X
incorporated	B-X
into	B-X
endogenous	B-X
co-	B-X
and	B-X
posttranslationally	B-X
myristoylated	B-X
proteins	B-X
.	B-X
The	B-X
competitive	B-X
inhibitors	B-X
2-bromopalmitate	B-X
and	B-X
2-hydroxymyristate	B-X
prevented	B-X
incorporation	B-X
of	B-X
omega-alkynyl-palmitate	B-X
and	B-X
omega-alkynyl-myristate	B-X
into	B-X
palmitoylated	B-X
and	B-X
myristoylated	B-X
proteins	B-X
,	B-X
respectively	B-X
.	B-X
Labeling	B-X
cells	B-X
with	B-X
omega-alkynyl-palmitate	B-X
does	B-X
not	B-X
affect	B-X
membrane	B-X
association	B-X
of	B-X
N-Ras	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
palmitoylation	B-X
of	B-X
endogenous	B-X
proteins	B-X
including	B-X
H-	B-X
and	B-X
N-Ras	B-X
could	B-X
be	B-X
easily	B-X
detected	B-X
using	B-X
omega-alkynyl-palmitate	B-X
as	B-X
label	B-X
in	B-X
cultured	B-X
HeLa	B-X
,	B-X
Jurkat	B-X
,	B-X
and	B-X
COS-7	B-X
cells	B-X
,	B-X
and	B-X
,	B-X
promisingly	B-X
,	B-X
in	B-X
mice	B-X
.	B-X
The	B-X
omega-alkynyl-myristate	B-X
and	B-X
-palmitate	B-X
analogs	B-X
used	B-X
with	B-X
click	B-X
chemistry	B-X
and	B-X
azido-probes	B-X
will	B-X
be	B-X
invaluable	B-X
to	B-X
study	B-X
protein	B-X
acylation	B-X
in	B-X
vitro	B-X
,	B-X
in	B-X
cells	B-X
,	B-X
and	B-X
in	B-X
vivo	B-X
.	B-X

Furthermore	O
,	O
the	O
palmitoylation	O
of	O
endogenous	O
proteins	O
including	O
H	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
could	O
be	O
easily	O
detected	O
using	O
omega	O
-	O
alkynyl	O
-	O
palmitate	O
as	O
label	O
in	O
cultured	O
HeLa	O
,	O
Jurkat	O
,	O
and	O
COS	O
-	O
7	O
cells	O
,	O
and	O
,	O
promisingly	O
,	O
in	O
mice	O
.	O

The	O
omega	O
-	O
alkynyl	O
-	O
myristate	O
and	O
-	O
palmitate	O
analogs	O
used	O
with	O
click	O
chemistry	O
and	O
azido	O
-	O
probes	O
will	O
be	O
invaluable	O
to	O
study	O
protein	O
acylation	O
in	O
vitro	O
,	O
in	O
cells	O
,	O
and	O
in	O
vivo	O
.	O

Regulation	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
trafficking	O
and	O
function	O
by	O
palmitoylation	O
.	O
<EOS>	B-X
The	B-X
SNARE	B-X
(	B-X
soluble	B-X
N-ethylmaleimide-sensitive	B-X
fusion	B-X
protein-attachment	B-X
protein	B-X
receptor	B-X
)	B-X
protein	B-X
SNAP-25	B-X
(	B-X
25	B-X
kDa	B-X
synaptosome-associated	B-X
protein	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
regulated	B-X
exocytosis	B-X
in	B-X
neuronal	B-X
and	B-X
neuroendocrine	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
majority	B-X
of	B-X
SNARE	B-X
proteins	B-X
contain	B-X
transmembrane	B-X
domains	B-X
,	B-X
SNAP-25	B-X
is	B-X
instead	B-X
anchored	B-X
to	B-X
membranes	B-X
by	B-X
the	B-X
palmitoylation	B-X
of	B-X
a	B-X
central	B-X
cysteine-rich	B-X
region	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
of	B-X
SNAP-25	B-X
palmitoylation	B-X
and	B-X
how	B-X
this	B-X
modification	B-X
regulates	B-X
the	B-X
intracellular	B-X
trafficking	B-X
and	B-X
exocytotic	B-X
function	B-X
of	B-X
this	B-X
essential	B-X
protein	B-X
.	B-X
Protein	B-X
palmitoylation	B-X
plays	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
sorting	B-X
and	B-X
targeting	B-X
of	B-X
several	B-X
proteins	B-X
to	B-X
pre-	B-X
and	B-X
postsynaptic	B-X
sites	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
have	B-X
analyzed	B-X
the	B-X
role	B-X
of	B-X
palmitoylation	B-X
in	B-X
trafficking	B-X
of	B-X
synaptotagmin	B-X
I	B-X
and	B-X
its	B-X
modulation	B-X
by	B-X
synaptic	B-X
activity	B-X
.	B-X
We	B-X
found	B-X
that	B-X
palmitoylation	B-X
of	B-X
N-terminal	B-X
cysteines	B-X
contributed	B-X
to	B-X
sorting	B-X
of	B-X
synaptotagmin	B-X
I	B-X
to	B-X
an	B-X
intracellular	B-X
vesicular	B-X
compartment	B-X
at	B-X
the	B-X
presynaptic	B-X
terminal	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
palmitate	B-X
was	B-X
stably	B-X
associated	B-X
with	B-X
both	B-X
synaptotagmin	B-X
I	B-X
and	B-X
SNAP-25	B-X
and	B-X
that	B-X
rapid	B-X
neuronal	B-X
depolarization	B-X
did	B-X
not	B-X
affect	B-X
palmitate	B-X
turnover	B-X
on	B-X
these	B-X
proteins	B-X
.	B-X
However	B-X
,	B-X
long-term	B-X
treatment	B-X
with	B-X
drugs	B-X
that	B-X
either	B-X
block	B-X
synaptic	B-X
activity	B-X
or	B-X
disrupt	B-X
SNARE	B-X
complex	B-X
assembly	B-X
modulated	B-X
palmitoylation	B-X
and	B-X
accumulation	B-X
of	B-X
synaptotagmin	B-X
I	B-X
at	B-X
presynaptic	B-X
sites	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
palmitoylation	B-X
is	B-X
involved	B-X
in	B-X
trafficking	B-X
of	B-X
specific	B-X
elements	B-X
involved	B-X
in	B-X
transmitter	B-X
release	B-X
and	B-X
that	B-X
distinct	B-X
mechanisms	B-X
regulate	B-X
addition	B-X
and	B-X
removal	B-X
of	B-X
palmitate	B-X
on	B-X
select	B-X
neuronal	B-X
proteins	B-X
.	B-X

The	O
SNARE	O
(	O
soluble	O
N	O
-	O
ethylmaleimide	O
-	O
sensitive	O
fusion	O
protein	O
-	O
attachment	O
protein	O
receptor	O
)	O
protein	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
(	O
25	B-Protein
kDa	I-Protein
synaptosome	I-Protein
-	I-Protein
associated	I-Protein
protein	I-Protein
)	O
is	O
essential	O
for	O
regulated	O
exocytosis	O
in	O
neuronal	O
and	O
neuroendocrine	O
cells	O
.	O
<EOS>	B-X
The	B-X
SNARE	B-X
(	B-X
soluble	B-X
N-ethylmaleimide-sensitive	B-X
fusion	B-X
protein-attachment	B-X
protein	B-X
receptor	B-X
)	B-X
protein	B-X
SNAP-25	B-X
(	B-X
25	B-X
kDa	B-X
synaptosome-associated	B-X
protein	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
regulated	B-X
exocytosis	B-X
in	B-X
neuronal	B-X
and	B-X
neuroendocrine	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
majority	B-X
of	B-X
SNARE	B-X
proteins	B-X
contain	B-X
transmembrane	B-X
domains	B-X
,	B-X
SNAP-25	B-X
is	B-X
instead	B-X
anchored	B-X
to	B-X
membranes	B-X
by	B-X
the	B-X
palmitoylation	B-X
of	B-X
a	B-X
central	B-X
cysteine-rich	B-X
region	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
of	B-X
SNAP-25	B-X
palmitoylation	B-X
and	B-X
how	B-X
this	B-X
modification	B-X
regulates	B-X
the	B-X
intracellular	B-X
trafficking	B-X
and	B-X
exocytotic	B-X
function	B-X
of	B-X
this	B-X
essential	B-X
protein	B-X
.	B-X

Whereas	O
the	O
majority	O
of	O
SNARE	O
proteins	O
contain	O
transmembrane	O
domains	O
,	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
is	O
instead	O
anchored	O
to	O
membranes	O
by	O
the	O
palmitoylation	O
of	O
a	O
central	O
cysteine	O
-	O
rich	O
region	O
.	O
<EOS>	B-X
The	B-X
SNARE	B-X
(	B-X
soluble	B-X
N-ethylmaleimide-sensitive	B-X
fusion	B-X
protein-attachment	B-X
protein	B-X
receptor	B-X
)	B-X
protein	B-X
SNAP-25	B-X
(	B-X
25	B-X
kDa	B-X
synaptosome-associated	B-X
protein	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
regulated	B-X
exocytosis	B-X
in	B-X
neuronal	B-X
and	B-X
neuroendocrine	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
majority	B-X
of	B-X
SNARE	B-X
proteins	B-X
contain	B-X
transmembrane	B-X
domains	B-X
,	B-X
SNAP-25	B-X
is	B-X
instead	B-X
anchored	B-X
to	B-X
membranes	B-X
by	B-X
the	B-X
palmitoylation	B-X
of	B-X
a	B-X
central	B-X
cysteine-rich	B-X
region	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
of	B-X
SNAP-25	B-X
palmitoylation	B-X
and	B-X
how	B-X
this	B-X
modification	B-X
regulates	B-X
the	B-X
intracellular	B-X
trafficking	B-X
and	B-X
exocytotic	B-X
function	B-X
of	B-X
this	B-X
essential	B-X
protein	B-X
.	B-X

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
SNAP	B-Protein
-	I-Protein
25	I-Protein
palmitoylation	O
and	O
how	O
this	O
modification	O
regulates	O
the	O
intracellular	O
trafficking	O
and	O
exocytotic	O
function	O
of	O
this	O
essential	O
protein	O
.	O
<EOS>	B-X
The	B-X
SNARE	B-X
(	B-X
soluble	B-X
N-ethylmaleimide-sensitive	B-X
fusion	B-X
protein-attachment	B-X
protein	B-X
receptor	B-X
)	B-X
protein	B-X
SNAP-25	B-X
(	B-X
25	B-X
kDa	B-X
synaptosome-associated	B-X
protein	B-X
)	B-X
is	B-X
essential	B-X
for	B-X
regulated	B-X
exocytosis	B-X
in	B-X
neuronal	B-X
and	B-X
neuroendocrine	B-X
cells	B-X
.	B-X
Whereas	B-X
the	B-X
majority	B-X
of	B-X
SNARE	B-X
proteins	B-X
contain	B-X
transmembrane	B-X
domains	B-X
,	B-X
SNAP-25	B-X
is	B-X
instead	B-X
anchored	B-X
to	B-X
membranes	B-X
by	B-X
the	B-X
palmitoylation	B-X
of	B-X
a	B-X
central	B-X
cysteine-rich	B-X
region	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
discuss	B-X
the	B-X
mechanisms	B-X
of	B-X
SNAP-25	B-X
palmitoylation	B-X
and	B-X
how	B-X
this	B-X
modification	B-X
regulates	B-X
the	B-X
intracellular	B-X
trafficking	B-X
and	B-X
exocytotic	B-X
function	B-X
of	B-X
this	B-X
essential	B-X
protein	B-X
.	B-X

Regulation	O
of	O
synaptic	O
structure	O
and	O
function	O
by	O
palmitoylated	O
AMPA	O
receptor	O
binding	O
protein	O
.	O
<EOS>	B-X
AMPA	B-X
receptor	B-X
binding	B-X
protein	B-X
(	B-X
ABP	B-X
)	B-X
is	B-X
a	B-X
multi-PDZ	B-X
domain	B-X
scaffold	B-X
that	B-X
binds	B-X
and	B-X
stabilizes	B-X
AMPA	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
GluR2/3	B-X
subunits	B-X
at	B-X
synapses	B-X
.	B-X
A	B-X
palmitoylated	B-X
N-terminal	B-X
splice	B-X
variant	B-X
(	B-X
pABP-L	B-X
)	B-X
concentrates	B-X
in	B-X
spine	B-X
heads	B-X
,	B-X
whereas	B-X
a	B-X
non-palmitoylated	B-X
form	B-X
(	B-X
ABP-L	B-X
)	B-X
is	B-X
intracellular	B-X
.	B-X
We	B-X
show	B-X
that	B-X
postsynaptic	B-X
Sindbis	B-X
viral	B-X
expression	B-X
of	B-X
pABP-L	B-X
increased	B-X
AMPAR	B-X
mediated	B-X
mEPSC	B-X
amplitude	B-X
and	B-X
frequency	B-X
and	B-X
elevated	B-X
surface	B-X
levels	B-X
of	B-X
GluR1	B-X
and	B-X
GluR2	B-X
,	B-X
suggesting	B-X
an	B-X
increase	B-X
in	B-X
AMPA	B-X
receptors	B-X
at	B-X
individual	B-X
synapses	B-X
.	B-X
A	B-X
non-palmitoylated	B-X
pABP-L	B-X
mutant	B-X
(	B-X
C11A	B-X
)	B-X
did	B-X
not	B-X
change	B-X
spine	B-X
density	B-X
or	B-X
size	B-X
.	B-X
Thus	B-X
postsynaptic	B-X
pABP-L	B-X
induces	B-X
pre	B-X
and	B-X
postsynaptic	B-X
changes	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
palmitoylation	B-X
and	B-X
likely	B-X
achieved	B-X
through	B-X
ABP	B-X
association	B-X
with	B-X
a	B-X
multi-molecular	B-X
cell	B-X
surface	B-X
signaling	B-X
complex	B-X
.	B-X

AMPA	O
receptor	O
binding	O
protein	O
(	O
ABP	O
)	O
is	O
a	O
multi	O
-	O
PDZ	O
domain	O
scaffold	O
that	O
binds	O
and	O
stabilizes	O
AMPA	O
receptor	O
(	O
AMPAR	O
)	O
GluR2	B-Protein
/	O
3	B-Protein
subunits	O
at	O
synapses	O
.	O
<EOS>	B-X
AMPA	B-X
receptor	B-X
binding	B-X
protein	B-X
(	B-X
ABP	B-X
)	B-X
is	B-X
a	B-X
multi-PDZ	B-X
domain	B-X
scaffold	B-X
that	B-X
binds	B-X
and	B-X
stabilizes	B-X
AMPA	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
GluR2/3	B-X
subunits	B-X
at	B-X
synapses	B-X
.	B-X
A	B-X
palmitoylated	B-X
N-terminal	B-X
splice	B-X
variant	B-X
(	B-X
pABP-L	B-X
)	B-X
concentrates	B-X
in	B-X
spine	B-X
heads	B-X
,	B-X
whereas	B-X
a	B-X
non-palmitoylated	B-X
form	B-X
(	B-X
ABP-L	B-X
)	B-X
is	B-X
intracellular	B-X
.	B-X
We	B-X
show	B-X
that	B-X
postsynaptic	B-X
Sindbis	B-X
viral	B-X
expression	B-X
of	B-X
pABP-L	B-X
increased	B-X
AMPAR	B-X
mediated	B-X
mEPSC	B-X
amplitude	B-X
and	B-X
frequency	B-X
and	B-X
elevated	B-X
surface	B-X
levels	B-X
of	B-X
GluR1	B-X
and	B-X
GluR2	B-X
,	B-X
suggesting	B-X
an	B-X
increase	B-X
in	B-X
AMPA	B-X
receptors	B-X
at	B-X
individual	B-X
synapses	B-X
.	B-X
A	B-X
non-palmitoylated	B-X
pABP-L	B-X
mutant	B-X
(	B-X
C11A	B-X
)	B-X
did	B-X
not	B-X
change	B-X
spine	B-X
density	B-X
or	B-X
size	B-X
.	B-X
Exogenous	B-X
pABP-L	B-X
and	B-X
endogenous	B-X
GRIP	B-X
,	B-X
a	B-X
related	B-X
scaffold	B-X
,	B-X
colocalized	B-X
with	B-X
NPRAP	B-X
(	B-X
delta-catenin	B-X
)	B-X
,	B-X
to	B-X
which	B-X
ABP	B-X
and	B-X
GRIP	B-X
bind	B-X
,	B-X
and	B-X
with	B-X
cadherins	B-X
,	B-X
which	B-X
bind	B-X
NPRAP	B-X
.	B-X
Thus	B-X
postsynaptic	B-X
pABP-L	B-X
induces	B-X
pre	B-X
and	B-X
postsynaptic	B-X
changes	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
palmitoylation	B-X
and	B-X
likely	B-X
achieved	B-X
through	B-X
ABP	B-X
association	B-X
with	B-X
a	B-X
multi-molecular	B-X
cell	B-X
surface	B-X
signaling	B-X
complex	B-X
.	B-X

A	O
palmitoylated	O
N	O
-	O
terminal	O
splice	O
variant	O
(	O
pABP	O
-	O
L	O
)	O
concentrates	O
in	O
spine	O
heads	O
,	O
whereas	O
a	O
non	O
-	O
palmitoylated	O
form	O
(	O
ABP	O
-	O
L	O
)	O
is	O
intracellular	O
.	O
<EOS>	B-X
AMPA	B-X
receptor	B-X
binding	B-X
protein	B-X
(	B-X
ABP	B-X
)	B-X
is	B-X
a	B-X
multi-PDZ	B-X
domain	B-X
scaffold	B-X
that	B-X
binds	B-X
and	B-X
stabilizes	B-X
AMPA	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
GluR2/3	B-X
subunits	B-X
at	B-X
synapses	B-X
.	B-X
A	B-X
palmitoylated	B-X
N-terminal	B-X
splice	B-X
variant	B-X
(	B-X
pABP-L	B-X
)	B-X
concentrates	B-X
in	B-X
spine	B-X
heads	B-X
,	B-X
whereas	B-X
a	B-X
non-palmitoylated	B-X
form	B-X
(	B-X
ABP-L	B-X
)	B-X
is	B-X
intracellular	B-X
.	B-X
We	B-X
show	B-X
that	B-X
postsynaptic	B-X
Sindbis	B-X
viral	B-X
expression	B-X
of	B-X
pABP-L	B-X
increased	B-X
AMPAR	B-X
mediated	B-X
mEPSC	B-X
amplitude	B-X
and	B-X
frequency	B-X
and	B-X
elevated	B-X
surface	B-X
levels	B-X
of	B-X
GluR1	B-X
and	B-X
GluR2	B-X
,	B-X
suggesting	B-X
an	B-X
increase	B-X
in	B-X
AMPA	B-X
receptors	B-X
at	B-X
individual	B-X
synapses	B-X
.	B-X
Spines	B-X
were	B-X
enlarged	B-X
and	B-X
more	B-X
numerous	B-X
and	B-X
nerve	B-X
terminals	B-X
contacting	B-X
these	B-X
cells	B-X
displayed	B-X
enlarged	B-X
synaptophysin	B-X
puncta	B-X
.	B-X
A	B-X
non-palmitoylated	B-X
pABP-L	B-X
mutant	B-X
(	B-X
C11A	B-X
)	B-X
did	B-X
not	B-X
change	B-X
spine	B-X
density	B-X
or	B-X
size	B-X
.	B-X
Exogenous	B-X
pABP-L	B-X
and	B-X
endogenous	B-X
GRIP	B-X
,	B-X
a	B-X
related	B-X
scaffold	B-X
,	B-X
colocalized	B-X
with	B-X
NPRAP	B-X
(	B-X
delta-catenin	B-X
)	B-X
,	B-X
to	B-X
which	B-X
ABP	B-X
and	B-X
GRIP	B-X
bind	B-X
,	B-X
and	B-X
with	B-X
cadherins	B-X
,	B-X
which	B-X
bind	B-X
NPRAP	B-X
.	B-X
Thus	B-X
postsynaptic	B-X
pABP-L	B-X
induces	B-X
pre	B-X
and	B-X
postsynaptic	B-X
changes	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
palmitoylation	B-X
and	B-X
likely	B-X
achieved	B-X
through	B-X
ABP	B-X
association	B-X
with	B-X
a	B-X
multi-molecular	B-X
cell	B-X
surface	B-X
signaling	B-X
complex	B-X
.	B-X

We	O
show	O
that	O
postsynaptic	O
Sindbis	O
viral	O
expression	O
of	O
pABP	O
-	O
L	O
increased	O
AMPAR	O
mediated	O
mEPSC	O
amplitude	O
and	O
frequency	O
and	O
elevated	O
surface	O
levels	O
of	O
GluR1	B-Protein
and	O
GluR2	B-Protein
,	O
suggesting	O
an	O
increase	O
in	O
AMPA	O
receptors	O
at	O
individual	O
synapses	O
.	O
<EOS>	B-X
AMPA	B-X
receptor	B-X
binding	B-X
protein	B-X
(	B-X
ABP	B-X
)	B-X
is	B-X
a	B-X
multi-PDZ	B-X
domain	B-X
scaffold	B-X
that	B-X
binds	B-X
and	B-X
stabilizes	B-X
AMPA	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
GluR2/3	B-X
subunits	B-X
at	B-X
synapses	B-X
.	B-X
A	B-X
palmitoylated	B-X
N-terminal	B-X
splice	B-X
variant	B-X
(	B-X
pABP-L	B-X
)	B-X
concentrates	B-X
in	B-X
spine	B-X
heads	B-X
,	B-X
whereas	B-X
a	B-X
non-palmitoylated	B-X
form	B-X
(	B-X
ABP-L	B-X
)	B-X
is	B-X
intracellular	B-X
.	B-X
We	B-X
show	B-X
that	B-X
postsynaptic	B-X
Sindbis	B-X
viral	B-X
expression	B-X
of	B-X
pABP-L	B-X
increased	B-X
AMPAR	B-X
mediated	B-X
mEPSC	B-X
amplitude	B-X
and	B-X
frequency	B-X
and	B-X
elevated	B-X
surface	B-X
levels	B-X
of	B-X
GluR1	B-X
and	B-X
GluR2	B-X
,	B-X
suggesting	B-X
an	B-X
increase	B-X
in	B-X
AMPA	B-X
receptors	B-X
at	B-X
individual	B-X
synapses	B-X
.	B-X
A	B-X
non-palmitoylated	B-X
pABP-L	B-X
mutant	B-X
(	B-X
C11A	B-X
)	B-X
did	B-X
not	B-X
change	B-X
spine	B-X
density	B-X
or	B-X
size	B-X
.	B-X
Exogenous	B-X
pABP-L	B-X
and	B-X
endogenous	B-X
GRIP	B-X
,	B-X
a	B-X
related	B-X
scaffold	B-X
,	B-X
colocalized	B-X
with	B-X
NPRAP	B-X
(	B-X
delta-catenin	B-X
)	B-X
,	B-X
to	B-X
which	B-X
ABP	B-X
and	B-X
GRIP	B-X
bind	B-X
,	B-X
and	B-X
with	B-X
cadherins	B-X
,	B-X
which	B-X
bind	B-X
NPRAP	B-X
.	B-X
Thus	B-X
postsynaptic	B-X
pABP-L	B-X
induces	B-X
pre	B-X
and	B-X
postsynaptic	B-X
changes	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
palmitoylation	B-X
and	B-X
likely	B-X
achieved	B-X
through	B-X
ABP	B-X
association	B-X
with	B-X
a	B-X
multi-molecular	B-X
cell	B-X
surface	B-X
signaling	B-X
complex	B-X
.	B-X

Spines	O
were	O
enlarged	O
and	O
more	O
numerous	O
and	O
nerve	O
terminals	O
contacting	O
these	O
cells	O
displayed	O
enlarged	O
synaptophysin	B-Protein
puncta	O
.	O
<EOS>	B-X
Spines	B-X
were	B-X
enlarged	B-X
and	B-X
more	B-X
numerous	B-X
and	B-X
nerve	B-X
terminals	B-X
contacting	B-X
these	B-X
cells	B-X
displayed	B-X
enlarged	B-X
synaptophysin	B-X
puncta	B-X
.	B-X

A	O
non	O
-	O
palmitoylated	O
pABP	O
-	O
L	O
mutant	O
(	O
C11A	O
)	O
did	O
not	O
change	O
spine	O
density	O
or	O
size	O
.	O
<EOS>	B-X
Cell	B-X
size	B-X
is	B-X
tightly	B-X
controlled	B-X
in	B-X
healthy	B-X
tissues	B-X
,	B-X
but	B-X
it	B-X
is	B-X
unclear	B-X
how	B-X
deviations	B-X
in	B-X
cell	B-X
size	B-X
affect	B-X
cell	B-X
physiology	B-X
.	B-X
To	B-X
address	B-X
this	B-X
,	B-X
we	B-X
measured	B-X
how	B-X
the	B-X
cell	B-X
's	B-X
proteome	B-X
changes	B-X
with	B-X
increasing	B-X
cell	B-X
size	B-X
.	B-X
Size-dependent	B-X
protein	B-X
concentration	B-X
changes	B-X
are	B-X
widespread	B-X
and	B-X
predicted	B-X
by	B-X
subcellular	B-X
localization	B-X
,	B-X
size-dependent	B-X
mRNA	B-X
concentrations	B-X
,	B-X
and	B-X
protein	B-X
turnover	B-X
.	B-X
As	B-X
proliferating	B-X
cells	B-X
grow	B-X
larger	B-X
,	B-X
concentration	B-X
changes	B-X
typically	B-X
associated	B-X
with	B-X
cellular	B-X
senescence	B-X
are	B-X
increasingly	B-X
pronounced	B-X
,	B-X
suggesting	B-X
that	B-X
large	B-X
size	B-X
may	B-X
be	B-X
a	B-X
cause	B-X
rather	B-X
than	B-X
just	B-X
a	B-X
consequence	B-X
of	B-X
cell	B-X
senescence	B-X
.	B-X
Size-dependent	B-X
changes	B-X
to	B-X
the	B-X
proteome	B-X
,	B-X
including	B-X
those	B-X
associated	B-X
with	B-X
senescence	B-X
,	B-X
are	B-X
not	B-X
observed	B-X
when	B-X
an	B-X
increase	B-X
in	B-X
cell	B-X
size	B-X
is	B-X
accompanied	B-X
by	B-X
an	B-X
increase	B-X
in	B-X
ploidy	B-X
.	B-X
Together	B-X
,	B-X
our	B-X
findings	B-X
show	B-X
how	B-X
cell	B-X
size	B-X
could	B-X
impact	B-X
many	B-X
aspects	B-X
of	B-X
cell	B-X
physiology	B-X
by	B-X
remodeling	B-X
the	B-X
proteome	B-X
and	B-X
provide	B-X
a	B-X
rationale	B-X
for	B-X
cell	B-X
size	B-X
control	B-X
and	B-X
polyploidization	B-X
.	B-X

Exogenous	O
pABP	O
-	O
L	O
and	O
endogenous	O
GRIP	O
,	O
a	O
related	O
scaffold	O
,	O
colocalized	O
with	O
NPRAP	B-Protein
(	O
delta	O
-	O
catenin	O
)	O
,	O
to	O
which	O
ABP	O
and	O
GRIP	O
bind	O
,	O
and	O
with	O
cadherins	O
,	O
which	O
bind	O
NPRAP	B-Protein
.	O

Thus	O
postsynaptic	O
pABP	O
-	O
L	O
induces	O
pre	O
and	O
postsynaptic	O
changes	O
that	O
are	O
dependent	O
on	O
palmitoylation	O
and	O
likely	O
achieved	O
through	O
ABP	O
association	O
with	O
a	O
multi	O
-	O
molecular	O
cell	O
surface	O
signaling	O
complex	O
.	O
<EOS>	B-X
AMPA	B-X
receptor	B-X
binding	B-X
protein	B-X
(	B-X
ABP	B-X
)	B-X
is	B-X
a	B-X
multi-PDZ	B-X
domain	B-X
scaffold	B-X
that	B-X
binds	B-X
and	B-X
stabilizes	B-X
AMPA	B-X
receptor	B-X
(	B-X
AMPAR	B-X
)	B-X
GluR2/3	B-X
subunits	B-X
at	B-X
synapses	B-X
.	B-X
A	B-X
palmitoylated	B-X
N-terminal	B-X
splice	B-X
variant	B-X
(	B-X
pABP-L	B-X
)	B-X
concentrates	B-X
in	B-X
spine	B-X
heads	B-X
,	B-X
whereas	B-X
a	B-X
non-palmitoylated	B-X
form	B-X
(	B-X
ABP-L	B-X
)	B-X
is	B-X
intracellular	B-X
.	B-X
We	B-X
show	B-X
that	B-X
postsynaptic	B-X
Sindbis	B-X
viral	B-X
expression	B-X
of	B-X
pABP-L	B-X
increased	B-X
AMPAR	B-X
mediated	B-X
mEPSC	B-X
amplitude	B-X
and	B-X
frequency	B-X
and	B-X
elevated	B-X
surface	B-X
levels	B-X
of	B-X
GluR1	B-X
and	B-X
GluR2	B-X
,	B-X
suggesting	B-X
an	B-X
increase	B-X
in	B-X
AMPA	B-X
receptors	B-X
at	B-X
individual	B-X
synapses	B-X
.	B-X
Spines	B-X
were	B-X
enlarged	B-X
and	B-X
more	B-X
numerous	B-X
and	B-X
nerve	B-X
terminals	B-X
contacting	B-X
these	B-X
cells	B-X
displayed	B-X
enlarged	B-X
synaptophysin	B-X
puncta	B-X
.	B-X
A	B-X
non-palmitoylated	B-X
pABP-L	B-X
mutant	B-X
(	B-X
C11A	B-X
)	B-X
did	B-X
not	B-X
change	B-X
spine	B-X
density	B-X
or	B-X
size	B-X
.	B-X
Exogenous	B-X
pABP-L	B-X
and	B-X
endogenous	B-X
GRIP	B-X
,	B-X
a	B-X
related	B-X
scaffold	B-X
,	B-X
colocalized	B-X
with	B-X
NPRAP	B-X
(	B-X
delta-catenin	B-X
)	B-X
,	B-X
to	B-X
which	B-X
ABP	B-X
and	B-X
GRIP	B-X
bind	B-X
,	B-X
and	B-X
with	B-X
cadherins	B-X
,	B-X
which	B-X
bind	B-X
NPRAP	B-X
.	B-X
Thus	B-X
postsynaptic	B-X
pABP-L	B-X
induces	B-X
pre	B-X
and	B-X
postsynaptic	B-X
changes	B-X
that	B-X
are	B-X
dependent	B-X
on	B-X
palmitoylation	B-X
and	B-X
likely	B-X
achieved	B-X
through	B-X
ABP	B-X
association	B-X
with	B-X
a	B-X
multi-molecular	B-X
cell	B-X
surface	B-X
signaling	B-X
complex	B-X
.	B-X

DELLA	O
proteins	O
restrain	O
germination	O
and	O
elongation	O
growth	O
in	O
Arabidopsis	O
thaliana	O
COP9	O
signalosome	O
mutants	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
higher	B-X
eukaryotes	B-X
.	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
these	B-X
two	B-X
DELLA	B-X
proteins	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
elongation	B-X
defects	B-X
of	B-X
a	B-X
weak	B-X
csn5	B-X
mutant	B-X
allele	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

The	O
COP9	O
signalosome	O
(	O
CSN	O
)	O
is	O
an	O
evolutionarily	O
conserved	O
multiprotein	O
complex	O
with	O
an	O
essential	O
role	O
in	O
the	O
development	O
of	O
higher	O
eukaryotes	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
higher	B-X
eukaryotes	B-X
.	B-X
CSN	B-X
deconjugates	B-X
the	B-X
ubiquitin-related	B-X
modifier	B-X
NEDD8	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
cullin-RING	B-X
type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
,	B-X
and	B-X
CSN-mediated	B-X
cullin	B-X
deneddylation	B-X
is	B-X
required	B-X
for	B-X
full	B-X
CRL	B-X
activity	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X

CSN	O
deconjugates	O
the	O
ubiquitin	B-Protein
-	O
related	O
modifier	O
NEDD8	B-Protein
from	O
the	O
cullin	O
subunit	O
of	O
cullin	O
-	O
RING	O
type	O
E3	O
ubiquitin	B-Protein
ligases	O
(	O
CRLs	O
)	O
,	O
and	O
CSN	O
-	O
mediated	O
cullin	O
deneddylation	O
is	O
required	O
for	O
full	O
CRL	O
activity	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
higher	B-X
eukaryotes	B-X
.	B-X
CSN	B-X
deconjugates	B-X
the	B-X
ubiquitin-related	B-X
modifier	B-X
NEDD8	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
cullin-RING	B-X
type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
,	B-X
and	B-X
CSN-mediated	B-X
cullin	B-X
deneddylation	B-X
is	B-X
required	B-X
for	B-X
full	B-X
CRL	B-X
activity	B-X
.	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X

Although	O
several	O
plant	O
E3	O
CRL	O
functions	O
have	O
been	O
shown	O
to	O
be	O
compromised	O
in	O
Arabidopsis	O
csn	O
mutants	O
,	O
none	O
of	O
these	O
functions	O
have	O
so	O
far	O
been	O
shown	O
to	O
limit	O
growth	O
in	O
these	O
mutants	O
.	O
<EOS>	B-X
CSN	B-X
deconjugates	B-X
the	B-X
ubiquitin-related	B-X
modifier	B-X
NEDD8	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
cullin-RING	B-X
type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
,	B-X
and	B-X
CSN-mediated	B-X
cullin	B-X
deneddylation	B-X
is	B-X
required	B-X
for	B-X
full	B-X
CRL	B-X
activity	B-X
.	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
these	B-X
two	B-X
DELLA	B-X
proteins	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
elongation	B-X
defects	B-X
of	B-X
a	B-X
weak	B-X
csn5	B-X
mutant	B-X
allele	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

Here	O
,	O
we	O
examine	O
the	O
role	O
of	O
CSN	O
in	O
the	O
context	O
of	O
the	O
E3	O
ubiquitin	B-Protein
ligase	O
SCF	O
(	O
SLEEPY1	B-Protein
(	O
SLY1	B-Protein
)	O
)	O
,	O
which	O
promotes	O
gibberellic	O
acid	O
(	O
GA	O
)	O
-	O
dependent	O
responses	O
in	O
Arabidopsis	O
thaliana	O
.	O
<EOS>	B-X
The	B-X
COP9	B-X
signalosome	B-X
(	B-X
CSN	B-X
)	B-X
is	B-X
an	B-X
evolutionarily	B-X
conserved	B-X
multiprotein	B-X
complex	B-X
with	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
the	B-X
development	B-X
of	B-X
higher	B-X
eukaryotes	B-X
.	B-X
CSN	B-X
deconjugates	B-X
the	B-X
ubiquitin-related	B-X
modifier	B-X
NEDD8	B-X
from	B-X
the	B-X
cullin	B-X
subunit	B-X
of	B-X
cullin-RING	B-X
type	B-X
E3	B-X
ubiquitin	B-X
ligases	B-X
(	B-X
CRLs	B-X
)	B-X
,	B-X
and	B-X
CSN-mediated	B-X
cullin	B-X
deneddylation	B-X
is	B-X
required	B-X
for	B-X
full	B-X
CRL	B-X
activity	B-X
.	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

We	O
show	O
that	O
csn	O
mutants	O
are	O
impaired	O
in	O
GA	O
-	O
and	O
SCF	O
(	O
SLY1	B-Protein
)	O
-	O
dependent	O
germination	O
and	O
elongation	O
growth	O
,	O
and	O
we	O
show	O
that	O
these	O
defects	O
correlate	O
with	O
an	O
accumulation	O
and	O
reduced	O
turnover	O
of	O
an	O
SCF	O
(	O
SLY1	B-Protein
)	O
-	O
degradation	O
target	O
,	O
the	O
DELLA	O
protein	O
REPRESSOR	B-Protein
-	I-Protein
OF	I-Protein
-	I-Protein
ga1	I-Protein
-	I-Protein
3	I-Protein
(	O
RGA	B-Protein
)	O
.	O

Genetic	O
interaction	O
studies	O
between	O
csn	O
mutants	O
and	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
RGA	B-Protein
and	O
its	O
functional	O
homologue	O
GIBBERELLIC	B-Protein
ACID	I-Protein
INSENSITIVE	I-Protein
(	O
GAI	B-Protein
)	O
further	O
reveal	O
that	O
RGA	B-Protein
and	O
GAI	B-Protein
repress	O
defects	O
of	O
germination	O
in	O
strong	O
csn	O
mutants	O
.	O
<EOS>	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
these	B-X
two	B-X
DELLA	B-X
proteins	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
elongation	B-X
defects	B-X
of	B-X
a	B-X
weak	B-X
csn5	B-X
mutant	B-X
allele	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

In	O
addition	O
,	O
we	O
find	O
that	O
these	O
two	O
DELLA	O
proteins	O
are	O
largely	O
responsible	O
for	O
the	O
elongation	O
defects	O
of	O
a	O
weak	O
csn5	B-Protein
mutant	O
allele	O
.	O
<EOS>	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
these	B-X
two	B-X
DELLA	B-X
proteins	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
elongation	B-X
defects	B-X
of	B-X
a	B-X
weak	B-X
csn5	B-X
mutant	B-X
allele	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

We	O
thus	O
conclude	O
that	O
an	O
impairment	O
of	O
SCF	O
(	O
SLY1	B-Protein
)	O
is	O
at	O
least	O
in	O
part	O
causative	O
for	O
the	O
germination	O
and	O
elongation	O
defects	O
of	O
csn	O
mutants	O
,	O
and	O
suggest	O
that	O
DELLA	O
proteins	O
are	O
major	O
growth	O
repressors	O
in	O
these	O
mutants	O
.	O
<EOS>	B-X
Although	B-X
several	B-X
plant	B-X
E3	B-X
CRL	B-X
functions	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
compromised	B-X
in	B-X
Arabidopsis	B-X
csn	B-X
mutants	B-X
,	B-X
none	B-X
of	B-X
these	B-X
functions	B-X
have	B-X
so	B-X
far	B-X
been	B-X
shown	B-X
to	B-X
limit	B-X
growth	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
examine	B-X
the	B-X
role	B-X
of	B-X
CSN	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
E3	B-X
ubiquitin	B-X
ligase	B-X
SCF	B-X
(	B-X
SLEEPY1	B-X
(	B-X
SLY1	B-X
)	B-X
)	B-X
,	B-X
which	B-X
promotes	B-X
gibberellic	B-X
acid	B-X
(	B-X
GA	B-X
)	B-X
-dependent	B-X
responses	B-X
in	B-X
Arabidopsis	B-X
thaliana	B-X
.	B-X
We	B-X
show	B-X
that	B-X
csn	B-X
mutants	B-X
are	B-X
impaired	B-X
in	B-X
GA-	B-X
and	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-dependent	B-X
germination	B-X
and	B-X
elongation	B-X
growth	B-X
,	B-X
and	B-X
we	B-X
show	B-X
that	B-X
these	B-X
defects	B-X
correlate	B-X
with	B-X
an	B-X
accumulation	B-X
and	B-X
reduced	B-X
turnover	B-X
of	B-X
an	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
-degradation	B-X
target	B-X
,	B-X
the	B-X
DELLA	B-X
protein	B-X
REPRESSOR-OF-ga1-3	B-X
(	B-X
RGA	B-X
)	B-X
.	B-X
Genetic	B-X
interaction	B-X
studies	B-X
between	B-X
csn	B-X
mutants	B-X
and	B-X
loss-of-function	B-X
alleles	B-X
of	B-X
RGA	B-X
and	B-X
its	B-X
functional	B-X
homologue	B-X
GIBBERELLIC	B-X
ACID	B-X
INSENSITIVE	B-X
(	B-X
GAI	B-X
)	B-X
further	B-X
reveal	B-X
that	B-X
RGA	B-X
and	B-X
GAI	B-X
repress	B-X
defects	B-X
of	B-X
germination	B-X
in	B-X
strong	B-X
csn	B-X
mutants	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
we	B-X
find	B-X
that	B-X
these	B-X
two	B-X
DELLA	B-X
proteins	B-X
are	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
elongation	B-X
defects	B-X
of	B-X
a	B-X
weak	B-X
csn5	B-X
mutant	B-X
allele	B-X
.	B-X
We	B-X
thus	B-X
conclude	B-X
that	B-X
an	B-X
impairment	B-X
of	B-X
SCF	B-X
(	B-X
SLY1	B-X
)	B-X
is	B-X
at	B-X
least	B-X
in	B-X
part	B-X
causative	B-X
for	B-X
the	B-X
germination	B-X
and	B-X
elongation	B-X
defects	B-X
of	B-X
csn	B-X
mutants	B-X
,	B-X
and	B-X
suggest	B-X
that	B-X
DELLA	B-X
proteins	B-X
are	B-X
major	B-X
growth	B-X
repressors	B-X
in	B-X
these	B-X
mutants	B-X
.	B-X

Designed	O
semisynthetic	O
protein	O
inhibitors	O
of	O
Ub	O
/	O
Ubl	O
E1	O
activating	O
enzymes	O
.	O
<EOS>	B-X
Semisynthetic	B-X
,	B-X
mechanism-based	B-X
protein	B-X
inhibitors	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
Ubl	B-X
)	B-X
activating	B-X
enzymes	B-X
(	B-X
E1s	B-X
)	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
target	B-X
E1-catalyzed	B-X
adenylation	B-X
and	B-X
thioesterification	B-X
of	B-X
the	B-X
Ub/Ubl	B-X
C-terminus	B-X
during	B-X
the	B-X
processes	B-X
of	B-X
protein	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
The	B-X
inhibitors	B-X
were	B-X
generated	B-X
by	B-X
intein-mediated	B-X
expressed	B-X
protein	B-X
ligation	B-X
using	B-X
a	B-X
truncated	B-X
Ub/Ubl	B-X
protein	B-X
(	B-X
SUMO	B-X
residues	B-X
1-94	B-X
;	B-X
Ub	B-X
residues	B-X
1-71	B-X
)	B-X
with	B-X
a	B-X
C-terminal	B-X
thioester	B-X
and	B-X
synthetic	B-X
tripeptides	B-X
having	B-X
a	B-X
C-terminal	B-X
adenosine	B-X
analogue	B-X
and	B-X
an	B-X
N-terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
SUMO-AMSN	B-X
(	B-X
4a	B-X
)	B-X
and	B-X
Ub-AMSN	B-X
(	B-X
4b	B-X
)	B-X
contain	B-X
a	B-X
sulfamide	B-X
group	B-X
as	B-X
a	B-X
nonhydrolyzable	B-X
mimic	B-X
of	B-X
the	B-X
phosphate	B-X
group	B-X
in	B-X
the	B-X
cognate	B-X
Ub/Ubl-AMP	B-X
adenylate	B-X
intermediate	B-X
in	B-X
the	B-X
first	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
inhibit	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
SUMO-AVSN	B-X
(	B-X
5a	B-X
)	B-X
and	B-X
Ub-AVSN	B-X
(	B-X
5b	B-X
)	B-X
contain	B-X
an	B-X
electrophilic	B-X
vinyl	B-X
sulfonamide	B-X
designed	B-X
to	B-X
trap	B-X
the	B-X
incoming	B-X
E1	B-X
cysteine	B-X
nucleophile	B-X
(	B-X
Uba2	B-X
Cys173	B-X
in	B-X
SUMO	B-X
E1	B-X
;	B-X
Uba1	B-X
Cys593	B-X
in	B-X
Ub	B-X
E1	B-X
)	B-X
in	B-X
the	B-X
second	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
,	B-X
covalently	B-X
,	B-X
and	B-X
stably	B-X
cross-link	B-X
to	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
cysteine	B-X
nucleophile-dependent	B-X
manner	B-X
.	B-X
These	B-X
inhibitors	B-X
are	B-X
powerful	B-X
tools	B-X
to	B-X
probe	B-X
outstanding	B-X
mechanistic	B-X
questions	B-X
in	B-X
E1	B-X
function	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
study	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
E1	B-X
enzymes	B-X
.	B-X

Semisynthetic	O
,	O
mechanism	O
-	O
based	O
protein	O
inhibitors	O
of	O
ubiquitin	B-Protein
(	O
Ub	B-Protein
)	O
and	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
Ubl	O
)	O
activating	O
enzymes	O
(	O
E1s	O
)	O
have	O
been	O
developed	O
to	O
target	O
E1	O
-	O
catalyzed	O
adenylation	O
and	O
thioesterification	O
of	O
the	O
Ub	B-Protein
/	O
Ubl	O
C	O
-	O
terminus	O
during	O
the	O
processes	O
of	O
protein	O
SUMOylation	O
and	O
ubiquitination	O
.	O
<EOS>	B-X
Semisynthetic	B-X
,	B-X
mechanism-based	B-X
protein	B-X
inhibitors	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
Ubl	B-X
)	B-X
activating	B-X
enzymes	B-X
(	B-X
E1s	B-X
)	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
target	B-X
E1-catalyzed	B-X
adenylation	B-X
and	B-X
thioesterification	B-X
of	B-X
the	B-X
Ub/Ubl	B-X
C-terminus	B-X
during	B-X
the	B-X
processes	B-X
of	B-X
protein	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
The	B-X
inhibitors	B-X
were	B-X
generated	B-X
by	B-X
intein-mediated	B-X
expressed	B-X
protein	B-X
ligation	B-X
using	B-X
a	B-X
truncated	B-X
Ub/Ubl	B-X
protein	B-X
(	B-X
SUMO	B-X
residues	B-X
1-94	B-X
;	B-X
Ub	B-X
residues	B-X
1-71	B-X
)	B-X
with	B-X
a	B-X
C-terminal	B-X
thioester	B-X
and	B-X
synthetic	B-X
tripeptides	B-X
having	B-X
a	B-X
C-terminal	B-X
adenosine	B-X
analogue	B-X
and	B-X
an	B-X
N-terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
SUMO-AMSN	B-X
(	B-X
4a	B-X
)	B-X
and	B-X
Ub-AMSN	B-X
(	B-X
4b	B-X
)	B-X
contain	B-X
a	B-X
sulfamide	B-X
group	B-X
as	B-X
a	B-X
nonhydrolyzable	B-X
mimic	B-X
of	B-X
the	B-X
phosphate	B-X
group	B-X
in	B-X
the	B-X
cognate	B-X
Ub/Ubl-AMP	B-X
adenylate	B-X
intermediate	B-X
in	B-X
the	B-X
first	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
inhibit	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
SUMO-AVSN	B-X
(	B-X
5a	B-X
)	B-X
and	B-X
Ub-AVSN	B-X
(	B-X
5b	B-X
)	B-X
contain	B-X
an	B-X
electrophilic	B-X
vinyl	B-X
sulfonamide	B-X
designed	B-X
to	B-X
trap	B-X
the	B-X
incoming	B-X
E1	B-X
cysteine	B-X
nucleophile	B-X
(	B-X
Uba2	B-X
Cys173	B-X
in	B-X
SUMO	B-X
E1	B-X
;	B-X
Uba1	B-X
Cys593	B-X
in	B-X
Ub	B-X
E1	B-X
)	B-X
in	B-X
the	B-X
second	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
,	B-X
covalently	B-X
,	B-X
and	B-X
stably	B-X
cross-link	B-X
to	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
cysteine	B-X
nucleophile-dependent	B-X
manner	B-X
.	B-X
These	B-X
inhibitors	B-X
are	B-X
powerful	B-X
tools	B-X
to	B-X
probe	B-X
outstanding	B-X
mechanistic	B-X
questions	B-X
in	B-X
E1	B-X
function	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
study	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
E1	B-X
enzymes	B-X
.	B-X

The	O
inhibitors	O
were	O
generated	O
by	O
intein	O
-	O
mediated	O
expressed	O
protein	O
ligation	O
using	O
a	O
truncated	O
Ub	B-Protein
/	O
Ubl	O
protein	O
(	O
SUMO	O
residues	O
1	O
-	O
94	O
;	O
Ub	B-Protein
residues	O
1	O
-	O
71	O
)	O
with	O
a	O
C	O
-	O
terminal	O
thioester	O
and	O
synthetic	O
tripeptides	O
having	O
a	O
C	O
-	O
terminal	O
adenosine	O
analogue	O
and	O
an	O
N	O
-	O
terminal	O
cysteine	O
residue	O
.	O
<EOS>	B-X
Semisynthetic	B-X
,	B-X
mechanism-based	B-X
protein	B-X
inhibitors	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
Ubl	B-X
)	B-X
activating	B-X
enzymes	B-X
(	B-X
E1s	B-X
)	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
target	B-X
E1-catalyzed	B-X
adenylation	B-X
and	B-X
thioesterification	B-X
of	B-X
the	B-X
Ub/Ubl	B-X
C-terminus	B-X
during	B-X
the	B-X
processes	B-X
of	B-X
protein	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
The	B-X
inhibitors	B-X
were	B-X
generated	B-X
by	B-X
intein-mediated	B-X
expressed	B-X
protein	B-X
ligation	B-X
using	B-X
a	B-X
truncated	B-X
Ub/Ubl	B-X
protein	B-X
(	B-X
SUMO	B-X
residues	B-X
1-94	B-X
;	B-X
Ub	B-X
residues	B-X
1-71	B-X
)	B-X
with	B-X
a	B-X
C-terminal	B-X
thioester	B-X
and	B-X
synthetic	B-X
tripeptides	B-X
having	B-X
a	B-X
C-terminal	B-X
adenosine	B-X
analogue	B-X
and	B-X
an	B-X
N-terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
SUMO-AMSN	B-X
(	B-X
4a	B-X
)	B-X
and	B-X
Ub-AMSN	B-X
(	B-X
4b	B-X
)	B-X
contain	B-X
a	B-X
sulfamide	B-X
group	B-X
as	B-X
a	B-X
nonhydrolyzable	B-X
mimic	B-X
of	B-X
the	B-X
phosphate	B-X
group	B-X
in	B-X
the	B-X
cognate	B-X
Ub/Ubl-AMP	B-X
adenylate	B-X
intermediate	B-X
in	B-X
the	B-X
first	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
inhibit	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
SUMO-AVSN	B-X
(	B-X
5a	B-X
)	B-X
and	B-X
Ub-AVSN	B-X
(	B-X
5b	B-X
)	B-X
contain	B-X
an	B-X
electrophilic	B-X
vinyl	B-X
sulfonamide	B-X
designed	B-X
to	B-X
trap	B-X
the	B-X
incoming	B-X
E1	B-X
cysteine	B-X
nucleophile	B-X
(	B-X
Uba2	B-X
Cys173	B-X
in	B-X
SUMO	B-X
E1	B-X
;	B-X
Uba1	B-X
Cys593	B-X
in	B-X
Ub	B-X
E1	B-X
)	B-X
in	B-X
the	B-X
second	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
,	B-X
covalently	B-X
,	B-X
and	B-X
stably	B-X
cross-link	B-X
to	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
cysteine	B-X
nucleophile-dependent	B-X
manner	B-X
.	B-X
These	B-X
inhibitors	B-X
are	B-X
powerful	B-X
tools	B-X
to	B-X
probe	B-X
outstanding	B-X
mechanistic	B-X
questions	B-X
in	B-X
E1	B-X
function	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
study	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
E1	B-X
enzymes	B-X
.	B-X

SUMO	O
-	O
AMSN	O
(	O
4a	O
)	O
and	O
Ub	B-Protein
-	O
AMSN	O
(	O
4b	O
)	O
contain	O
a	O
sulfamide	O
group	O
as	O
a	O
nonhydrolyzable	O
mimic	O
of	O
the	O
phosphate	O
group	O
in	O
the	O
cognate	O
Ub	B-Protein
/	O
Ubl	O
-	O
AMP	O
adenylate	O
intermediate	O
in	O
the	O
first	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
inhibit	O
SUMO	O
E1	O
and	O
Ub	O
E1	O
,	O
respectively	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

SUMO	O
-	O
AVSN	O
(	O
5a	O
)	O
and	O
Ub	B-Protein
-	O
AVSN	O
(	O
5b	O
)	O
contain	O
an	O
electrophilic	O
vinyl	O
sulfonamide	O
designed	O
to	O
trap	O
the	O
incoming	O
E1	O
cysteine	O
nucleophile	O
(	O
Uba2	B-Protein
Cys173	O
in	O
SUMO	O
E1	O
;	O
Uba1	B-Protein
Cys593	O
in	O
Ub	O
E1	O
)	O
in	O
the	O
second	O
half	O
-	O
reaction	O
,	O
and	O
these	O
constructs	O
selectively	O
,	O
covalently	O
,	O
and	O
stably	O
cross	O
-	O
link	O
to	O
SUMO	O
E1	O
and	O
Ub	B-Protein
E1	O
,	O
respectively	O
,	O
in	O
a	O
cysteine	O
nucleophile	O
-	O
dependent	O
manner	O
.	O
<EOS>	B-X
Semisynthetic	B-X
,	B-X
mechanism-based	B-X
protein	B-X
inhibitors	B-X
of	B-X
ubiquitin	B-X
(	B-X
Ub	B-X
)	B-X
and	B-X
ubiquitin-like	B-X
modifier	B-X
(	B-X
Ubl	B-X
)	B-X
activating	B-X
enzymes	B-X
(	B-X
E1s	B-X
)	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
target	B-X
E1-catalyzed	B-X
adenylation	B-X
and	B-X
thioesterification	B-X
of	B-X
the	B-X
Ub/Ubl	B-X
C-terminus	B-X
during	B-X
the	B-X
processes	B-X
of	B-X
protein	B-X
SUMOylation	B-X
and	B-X
ubiquitination	B-X
.	B-X
The	B-X
inhibitors	B-X
were	B-X
generated	B-X
by	B-X
intein-mediated	B-X
expressed	B-X
protein	B-X
ligation	B-X
using	B-X
a	B-X
truncated	B-X
Ub/Ubl	B-X
protein	B-X
(	B-X
SUMO	B-X
residues	B-X
1-94	B-X
;	B-X
Ub	B-X
residues	B-X
1-71	B-X
)	B-X
with	B-X
a	B-X
C-terminal	B-X
thioester	B-X
and	B-X
synthetic	B-X
tripeptides	B-X
having	B-X
a	B-X
C-terminal	B-X
adenosine	B-X
analogue	B-X
and	B-X
an	B-X
N-terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
SUMO-AMSN	B-X
(	B-X
4a	B-X
)	B-X
and	B-X
Ub-AMSN	B-X
(	B-X
4b	B-X
)	B-X
contain	B-X
a	B-X
sulfamide	B-X
group	B-X
as	B-X
a	B-X
nonhydrolyzable	B-X
mimic	B-X
of	B-X
the	B-X
phosphate	B-X
group	B-X
in	B-X
the	B-X
cognate	B-X
Ub/Ubl-AMP	B-X
adenylate	B-X
intermediate	B-X
in	B-X
the	B-X
first	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
inhibit	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
dose-dependent	B-X
manner	B-X
.	B-X
SUMO-AVSN	B-X
(	B-X
5a	B-X
)	B-X
and	B-X
Ub-AVSN	B-X
(	B-X
5b	B-X
)	B-X
contain	B-X
an	B-X
electrophilic	B-X
vinyl	B-X
sulfonamide	B-X
designed	B-X
to	B-X
trap	B-X
the	B-X
incoming	B-X
E1	B-X
cysteine	B-X
nucleophile	B-X
(	B-X
Uba2	B-X
Cys173	B-X
in	B-X
SUMO	B-X
E1	B-X
;	B-X
Uba1	B-X
Cys593	B-X
in	B-X
Ub	B-X
E1	B-X
)	B-X
in	B-X
the	B-X
second	B-X
half-reaction	B-X
,	B-X
and	B-X
these	B-X
constructs	B-X
selectively	B-X
,	B-X
covalently	B-X
,	B-X
and	B-X
stably	B-X
cross-link	B-X
to	B-X
SUMO	B-X
E1	B-X
and	B-X
Ub	B-X
E1	B-X
,	B-X
respectively	B-X
,	B-X
in	B-X
a	B-X
cysteine	B-X
nucleophile-dependent	B-X
manner	B-X
.	B-X
These	B-X
inhibitors	B-X
are	B-X
powerful	B-X
tools	B-X
to	B-X
probe	B-X
outstanding	B-X
mechanistic	B-X
questions	B-X
in	B-X
E1	B-X
function	B-X
and	B-X
can	B-X
also	B-X
be	B-X
used	B-X
to	B-X
study	B-X
the	B-X
biological	B-X
functions	B-X
of	B-X
E1	B-X
enzymes	B-X
.	B-X

These	O
inhibitors	O
are	O
powerful	O
tools	O
to	O
probe	O
outstanding	O
mechanistic	O
questions	O
in	O
E1	O
function	O
and	O
can	O
also	O
be	O
used	O
to	O
study	O
the	O
biological	O
functions	O
of	O
E1	O
enzymes	O
.	O

Characterization	O
of	O
the	O
self	O
-	O
palmitoylation	O
activity	O
of	O
the	O
transport	O
protein	O
particle	O
component	O
Bet3	B-Protein
.	O
<EOS>	B-X
Bet3	B-X
,	B-X
a	B-X
transport	B-X
protein	B-X
particle	B-X
component	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
,	B-X
contains	B-X
a	B-X
hydrophobic	B-X
tunnel	B-X
occupied	B-X
by	B-X
a	B-X
fatty	B-X
acid	B-X
linked	B-X
to	B-X
cysteine	B-X
68	B-X
.	B-X
We	B-X
reported	B-X
that	B-X
Bet3	B-X
has	B-X
a	B-X
unique	B-X
self-palmitoylating	B-X
activity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
mutation	B-X
of	B-X
arginine	B-X
67	B-X
reduced	B-X
self-palmitoylation	B-X
of	B-X
Bet3	B-X
,	B-X
but	B-X
the	B-X
effect	B-X
was	B-X
compensated	B-X
by	B-X
increasing	B-X
the	B-X
pH	B-X
.	B-X
Thus	B-X
,	B-X
arginine	B-X
helps	B-X
to	B-X
deprotonate	B-X
cysteine	B-X
such	B-X
that	B-X
it	B-X
could	B-X
function	B-X
as	B-X
a	B-X
nucleophile	B-X
in	B-X
the	B-X
acylation	B-X
reaction	B-X
which	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
structural	B-X
analysis	B-X
of	B-X
non-acylated	B-X
Bet3	B-X
.	B-X
Using	B-X
fluorescence	B-X
spectroscopy	B-X
we	B-X
show	B-X
that	B-X
long-chain	B-X
acyl-CoAs	B-X
bind	B-X
with	B-X
micromolar	B-X
affinity	B-X
to	B-X
Bet3	B-X
,	B-X
whereas	B-X
shorter-chain	B-X
acyl-CoAs	B-X
do	B-X
not	B-X
interact	B-X
.	B-X
Bet3	B-X
contains	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
Pal-CoA	B-X
,	B-X
but	B-X
their	B-X
number	B-X
was	B-X
reduced	B-X
to	B-X
two	B-X
in	B-X
the	B-X
mutant	B-X
with	B-X
an	B-X
obstructed	B-X
tunnel	B-X
,	B-X
indicating	B-X
that	B-X
Bet3	B-X
contains	B-X
binding	B-X
sites	B-X
on	B-X
its	B-X
surface	B-X
.	B-X

Bet3	B-Protein
,	O
a	O
transport	O
protein	O
particle	O
component	O
involved	O
in	O
vesicular	O
trafficking	O
,	O
contains	O
a	O
hydrophobic	O
tunnel	O
occupied	O
by	O
a	O
fatty	O
acid	O
linked	O
to	O
cysteine	O
68	O
.	O
<EOS>	B-X
Bet3	B-X
,	B-X
a	B-X
transport	B-X
protein	B-X
particle	B-X
component	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
,	B-X
contains	B-X
a	B-X
hydrophobic	B-X
tunnel	B-X
occupied	B-X
by	B-X
a	B-X
fatty	B-X
acid	B-X
linked	B-X
to	B-X
cysteine	B-X
68	B-X
.	B-X
We	B-X
reported	B-X
that	B-X
Bet3	B-X
has	B-X
a	B-X
unique	B-X
self-palmitoylating	B-X
activity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
mutation	B-X
of	B-X
arginine	B-X
67	B-X
reduced	B-X
self-palmitoylation	B-X
of	B-X
Bet3	B-X
,	B-X
but	B-X
the	B-X
effect	B-X
was	B-X
compensated	B-X
by	B-X
increasing	B-X
the	B-X
pH	B-X
.	B-X
Thus	B-X
,	B-X
arginine	B-X
helps	B-X
to	B-X
deprotonate	B-X
cysteine	B-X
such	B-X
that	B-X
it	B-X
could	B-X
function	B-X
as	B-X
a	B-X
nucleophile	B-X
in	B-X
the	B-X
acylation	B-X
reaction	B-X
which	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
structural	B-X
analysis	B-X
of	B-X
non-acylated	B-X
Bet3	B-X
.	B-X
Using	B-X
fluorescence	B-X
spectroscopy	B-X
we	B-X
show	B-X
that	B-X
long-chain	B-X
acyl-CoAs	B-X
bind	B-X
with	B-X
micromolar	B-X
affinity	B-X
to	B-X
Bet3	B-X
,	B-X
whereas	B-X
shorter-chain	B-X
acyl-CoAs	B-X
do	B-X
not	B-X
interact	B-X
.	B-X
Mutants	B-X
with	B-X
a	B-X
deleted	B-X
acylation	B-X
site	B-X
or	B-X
a	B-X
blocked	B-X
tunnel	B-X
bind	B-X
to	B-X
Pal-CoA	B-X
,	B-X
only	B-X
the	B-X
latter	B-X
with	B-X
slightly	B-X
reduced	B-X
affinity	B-X
.	B-X
Bet3	B-X
contains	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
Pal-CoA	B-X
,	B-X
but	B-X
their	B-X
number	B-X
was	B-X
reduced	B-X
to	B-X
two	B-X
in	B-X
the	B-X
mutant	B-X
with	B-X
an	B-X
obstructed	B-X
tunnel	B-X
,	B-X
indicating	B-X
that	B-X
Bet3	B-X
contains	B-X
binding	B-X
sites	B-X
on	B-X
its	B-X
surface	B-X
.	B-X

We	O
reported	O
that	O
Bet3	B-Protein
has	O
a	O
unique	O
self	O
-	O
palmitoylating	O
activity	O
.	O

Here	O
we	O
show	O
that	O
mutation	O
of	O
arginine	O
67	O
reduced	O
self	O
-	O
palmitoylation	O
of	O
Bet3	B-Protein
,	O
but	O
the	O
effect	O
was	O
compensated	O
by	O
increasing	O
the	O
pH	O
.	O

Thus	O
,	O
arginine	O
helps	O
to	O
deprotonate	O
cysteine	O
such	O
that	O
it	O
could	O
function	O
as	O
a	O
nucleophile	O
in	O
the	O
acylation	O
reaction	O
which	O
is	O
supported	O
by	O
the	O
structural	O
analysis	O
of	O
non	O
-	O
acylated	O
Bet3	B-Protein
.	O
<EOS>	B-X
Bet3	B-X
,	B-X
a	B-X
transport	B-X
protein	B-X
particle	B-X
component	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
,	B-X
contains	B-X
a	B-X
hydrophobic	B-X
tunnel	B-X
occupied	B-X
by	B-X
a	B-X
fatty	B-X
acid	B-X
linked	B-X
to	B-X
cysteine	B-X
68	B-X
.	B-X
We	B-X
reported	B-X
that	B-X
Bet3	B-X
has	B-X
a	B-X
unique	B-X
self-palmitoylating	B-X
activity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
mutation	B-X
of	B-X
arginine	B-X
67	B-X
reduced	B-X
self-palmitoylation	B-X
of	B-X
Bet3	B-X
,	B-X
but	B-X
the	B-X
effect	B-X
was	B-X
compensated	B-X
by	B-X
increasing	B-X
the	B-X
pH	B-X
.	B-X
Thus	B-X
,	B-X
arginine	B-X
helps	B-X
to	B-X
deprotonate	B-X
cysteine	B-X
such	B-X
that	B-X
it	B-X
could	B-X
function	B-X
as	B-X
a	B-X
nucleophile	B-X
in	B-X
the	B-X
acylation	B-X
reaction	B-X
which	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
structural	B-X
analysis	B-X
of	B-X
non-acylated	B-X
Bet3	B-X
.	B-X
Using	B-X
fluorescence	B-X
spectroscopy	B-X
we	B-X
show	B-X
that	B-X
long-chain	B-X
acyl-CoAs	B-X
bind	B-X
with	B-X
micromolar	B-X
affinity	B-X
to	B-X
Bet3	B-X
,	B-X
whereas	B-X
shorter-chain	B-X
acyl-CoAs	B-X
do	B-X
not	B-X
interact	B-X
.	B-X
Mutants	B-X
with	B-X
a	B-X
deleted	B-X
acylation	B-X
site	B-X
or	B-X
a	B-X
blocked	B-X
tunnel	B-X
bind	B-X
to	B-X
Pal-CoA	B-X
,	B-X
only	B-X
the	B-X
latter	B-X
with	B-X
slightly	B-X
reduced	B-X
affinity	B-X
.	B-X
Bet3	B-X
contains	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
Pal-CoA	B-X
,	B-X
but	B-X
their	B-X
number	B-X
was	B-X
reduced	B-X
to	B-X
two	B-X
in	B-X
the	B-X
mutant	B-X
with	B-X
an	B-X
obstructed	B-X
tunnel	B-X
,	B-X
indicating	B-X
that	B-X
Bet3	B-X
contains	B-X
binding	B-X
sites	B-X
on	B-X
its	B-X
surface	B-X
.	B-X

Using	O
fluorescence	O
spectroscopy	O
we	O
show	O
that	O
long	O
-	O
chain	O
acyl	O
-	O
CoAs	O
bind	O
with	O
micromolar	O
affinity	O
to	O
Bet3	B-Protein
,	O
whereas	O
shorter	O
-	O
chain	O
acyl	O
-	O
CoAs	O
do	O
not	O
interact	O
.	O

Mutants	O
with	O
a	O
deleted	O
acylation	O
site	O
or	O
a	O
blocked	O
tunnel	O
bind	O
to	O
Pal	O
-	O
CoA	O
,	O
only	O
the	O
latter	O
with	O
slightly	O
reduced	O
affinity	O
.	O
<EOS>	B-X
Once	B-X
l-arginine	B-X
binds	B-X
to	B-X
the	B-X
active	B-X
site	B-X
positioned	B-X
above	B-X
the	B-X
heme	B-X
moiety	B-X
,	B-X
two	B-X
consecutive	B-X
monooxygenation	B-X
reactions	B-X
take	B-X
place	B-X
.	B-X
The	B-X
cysteine-269	B-X
residue	B-X
of	B-X
PP2Ac-subunit	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
site	B-X
of	B-X
covalent	B-X
modification	B-X
by	B-X
PLMs	B-X
.	B-X
Using	B-X
a	B-X
gene	B-X
(	B-X
chcA	B-X
)	B-X
from	B-X
a	B-X
set	B-X
of	B-X
CHC-CoA	B-X
biosynthesis	B-X
genes	B-X
from	B-X
Streptomyces	B-X
collinus	B-X
as	B-X
a	B-X
probe	B-X
,	B-X
a	B-X
75	B-X
kb	B-X
region	B-X
of	B-X
29	B-X
ORFs	B-X
encoding	B-X
PLM	B-X
biosynthesis	B-X
was	B-X
located	B-X
in	B-X
the	B-X
genome	B-X
of	B-X
Streptomyces	B-X
sp	B-X
.	B-X
Current	B-X
work	B-X
is	B-X
aimed	B-X
at	B-X
selective	B-X
in	B-X
vitro	B-X
acylation	B-X
of	B-X
PLM	B-X
G	B-X
with	B-X
various	B-X
carboxylic	B-X
acids	B-X
and	B-X
a	B-X
precursor-directed	B-X
biosynthesis	B-X
in	B-X
a	B-X
chcA	B-X
deletion	B-X
mutant	B-X
with	B-X
the	B-X
aim	B-X
of	B-X
generating	B-X
novel	B-X
PLM	B-X
analogs	B-X
.	B-X

Bet3	B-Protein
contains	O
three	O
binding	O
sites	O
for	O
Pal	O
-	O
CoA	O
,	O
but	O
their	O
number	O
was	O
reduced	O
to	O
two	O
in	O
the	O
mutant	O
with	O
an	O
obstructed	O
tunnel	O
,	O
indicating	O
that	O
Bet3	B-Protein
contains	O
binding	O
sites	O
on	O
its	O
surface	O
.	O
<EOS>	B-X
Bet3	B-X
,	B-X
a	B-X
transport	B-X
protein	B-X
particle	B-X
component	B-X
involved	B-X
in	B-X
vesicular	B-X
trafficking	B-X
,	B-X
contains	B-X
a	B-X
hydrophobic	B-X
tunnel	B-X
occupied	B-X
by	B-X
a	B-X
fatty	B-X
acid	B-X
linked	B-X
to	B-X
cysteine	B-X
68	B-X
.	B-X
We	B-X
reported	B-X
that	B-X
Bet3	B-X
has	B-X
a	B-X
unique	B-X
self-palmitoylating	B-X
activity	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
mutation	B-X
of	B-X
arginine	B-X
67	B-X
reduced	B-X
self-palmitoylation	B-X
of	B-X
Bet3	B-X
,	B-X
but	B-X
the	B-X
effect	B-X
was	B-X
compensated	B-X
by	B-X
increasing	B-X
the	B-X
pH	B-X
.	B-X
Thus	B-X
,	B-X
arginine	B-X
helps	B-X
to	B-X
deprotonate	B-X
cysteine	B-X
such	B-X
that	B-X
it	B-X
could	B-X
function	B-X
as	B-X
a	B-X
nucleophile	B-X
in	B-X
the	B-X
acylation	B-X
reaction	B-X
which	B-X
is	B-X
supported	B-X
by	B-X
the	B-X
structural	B-X
analysis	B-X
of	B-X
non-acylated	B-X
Bet3	B-X
.	B-X
Using	B-X
fluorescence	B-X
spectroscopy	B-X
we	B-X
show	B-X
that	B-X
long-chain	B-X
acyl-CoAs	B-X
bind	B-X
with	B-X
micromolar	B-X
affinity	B-X
to	B-X
Bet3	B-X
,	B-X
whereas	B-X
shorter-chain	B-X
acyl-CoAs	B-X
do	B-X
not	B-X
interact	B-X
.	B-X
Mutants	B-X
with	B-X
a	B-X
deleted	B-X
acylation	B-X
site	B-X
or	B-X
a	B-X
blocked	B-X
tunnel	B-X
bind	B-X
to	B-X
Pal-CoA	B-X
,	B-X
only	B-X
the	B-X
latter	B-X
with	B-X
slightly	B-X
reduced	B-X
affinity	B-X
.	B-X
Bet3	B-X
contains	B-X
three	B-X
binding	B-X
sites	B-X
for	B-X
Pal-CoA	B-X
,	B-X
but	B-X
their	B-X
number	B-X
was	B-X
reduced	B-X
to	B-X
two	B-X
in	B-X
the	B-X
mutant	B-X
with	B-X
an	B-X
obstructed	B-X
tunnel	B-X
,	B-X
indicating	B-X
that	B-X
Bet3	B-X
contains	B-X
binding	B-X
sites	B-X
on	B-X
its	B-X
surface	B-X
.	B-X

Farnesyltransferase	O
inhibitors	O
in	O
myelodysplastic	O
syndrome	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
in	B-X
active	B-X
clinical	B-X
development	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
Farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
target	B-X
multiple	B-X
pathways	B-X
including	B-X
the	B-X
Ras	B-X
pathway	B-X
implicated	B-X
in	B-X
the	B-X
pathogenesis	B-X
of	B-X
some	B-X
hematologic	B-X
malignancies	B-X
.	B-X
Anderson	B-X
Cancer	B-X
Center	B-X
have	B-X
explored	B-X
the	B-X
potential	B-X
of	B-X
these	B-X
agents	B-X
as	B-X
monotherapy	B-X
for	B-X
leukemias	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X

The	O
farnesyltransferase	O
inhibitors	O
(	O
FTIs	O
)	O
are	O
in	O
active	O
clinical	O
development	O
in	O
a	O
variety	O
of	O
human	O
malignancies	O
.	O

The	O
most	O
promising	O
activity	O
to	O
date	O
has	O
been	O
demonstrated	O
in	O
patients	O
with	O
hematologic	O
malignancies	O
,	O
in	O
particular	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
in	B-X
active	B-X
clinical	B-X
development	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
MDS	B-X
,	B-X
two	B-X
nonpeptidomimetic	B-X
agents	B-X
,	B-X
tipifarnib	B-X
(	B-X
Zarnestra	B-X
,	B-X
Johnson	B-X
&	B-X
Johnson	B-X
,	B-X
New	B-X
Brunswick	B-X
,	B-X
NJ	B-X
)	B-X
and	B-X
lonafarnib	B-X
(	B-X
Sarasar	B-X
,	B-X
Schering-Plough	B-X
,	B-X
Kenilworth	B-X
,	B-X
NJ	B-X
)	B-X
have	B-X
been	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
.	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
Clinical	B-X
response	B-X
correlation	B-X
with	B-X
documentation	B-X
of	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
and/or	B-X
evidence	B-X
of	B-X
decreased	B-X
farnesylation	B-X
of	B-X
downstream	B-X
protein	B-X
targets	B-X
has	B-X
not	B-X
been	B-X
demonstrated	B-X
with	B-X
either	B-X
agent	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
activating	B-X
Ras	B-X
mutation	B-X
has	B-X
not	B-X
predicted	B-X
response	B-X
to	B-X
therapy	B-X
with	B-X
FTIs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

In	O
patients	O
with	O
MDS	O
,	O
two	O
nonpeptidomimetic	O
agents	O
,	O
tipifarnib	O
(	O
Zarnestra	O
,	O
Johnson	O
&	O
Johnson	O
,	O
New	O
Brunswick	O
,	O
NJ	O
)	O
and	O
lonafarnib	O
(	O
Sarasar	O
,	O
Schering	O
-	O
Plough	O
,	O
Kenilworth	O
,	O
NJ	O
)	O
have	O
been	O
the	O
most	O
extensively	O
studied	O
.	O
<EOS>	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
MDS	B-X
,	B-X
two	B-X
nonpeptidomimetic	B-X
agents	B-X
,	B-X
tipifarnib	B-X
(	B-X
Zarnestra	B-X
,	B-X
Johnson	B-X
&	B-X
Johnson	B-X
,	B-X
New	B-X
Brunswick	B-X
,	B-X
NJ	B-X
)	B-X
and	B-X
lonafarnib	B-X
(	B-X
Sarasar	B-X
,	B-X
Schering-Plough	B-X
,	B-X
Kenilworth	B-X
,	B-X
NJ	B-X
)	B-X
have	B-X
been	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
.	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
activating	B-X
Ras	B-X
mutation	B-X
has	B-X
not	B-X
predicted	B-X
response	B-X
to	B-X
therapy	B-X
with	B-X
FTIs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

In	O
both	O
phase	O
I	O
and	O
phase	O
II	O
trials	O
,	O
tipifarnib	O
has	O
demonstrated	O
significant	O
efficacy	O
,	O
with	O
overall	O
response	O
rates	O
of	O
30	O
%	O
and	O
complete	O
remissions	O
in	O
about	O
15	O
%	O
.	O
<EOS>	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
MDS	B-X
,	B-X
two	B-X
nonpeptidomimetic	B-X
agents	B-X
,	B-X
tipifarnib	B-X
(	B-X
Zarnestra	B-X
,	B-X
Johnson	B-X
&	B-X
Johnson	B-X
,	B-X
New	B-X
Brunswick	B-X
,	B-X
NJ	B-X
)	B-X
and	B-X
lonafarnib	B-X
(	B-X
Sarasar	B-X
,	B-X
Schering-Plough	B-X
,	B-X
Kenilworth	B-X
,	B-X
NJ	B-X
)	B-X
have	B-X
been	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
.	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
Lonafarnib	B-X
has	B-X
been	B-X
associated	B-X
primarily	B-X
with	B-X
diarrhea	B-X
and	B-X
other	B-X
gastrointestinal	B-X
toxicity	B-X
,	B-X
anorexia	B-X
,	B-X
and	B-X
nausea	B-X
,	B-X
which	B-X
has	B-X
limited	B-X
its	B-X
efficacy	B-X
.	B-X
Clinical	B-X
response	B-X
correlation	B-X
with	B-X
documentation	B-X
of	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
and/or	B-X
evidence	B-X
of	B-X
decreased	B-X
farnesylation	B-X
of	B-X
downstream	B-X
protein	B-X
targets	B-X
has	B-X
not	B-X
been	B-X
demonstrated	B-X
with	B-X
either	B-X
agent	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
activating	B-X
Ras	B-X
mutation	B-X
has	B-X
not	B-X
predicted	B-X
response	B-X
to	B-X
therapy	B-X
with	B-X
FTIs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

Dose	O
-	O
limiting	O
adverse	O
effects	O
have	O
been	O
primarily	O
myelosuppression	O
,	O
although	O
fatigue	O
,	O
neurotoxicity	O
,	O
and	O
occasional	O
renal	O
dysfunction	O
have	O
required	O
dose	O
reductions	O
.	O
<EOS>	B-X
Dose-limiting	B-X
adverse	B-X
effects	B-X
have	B-X
been	B-X
primarily	B-X
myelosuppression	B-X
,	B-X
although	B-X
fatigue	B-X
,	B-X
neurotoxicity	B-X
,	B-X
and	B-X
occasional	B-X
renal	B-X
dysfunction	B-X
have	B-X
required	B-X
dose	B-X
reductions	B-X
.	B-X
Lonafarnib	B-X
has	B-X
been	B-X
associated	B-X
primarily	B-X
with	B-X
diarrhea	B-X
and	B-X
other	B-X
gastrointestinal	B-X
toxicity	B-X
,	B-X
anorexia	B-X
,	B-X
and	B-X
nausea	B-X
,	B-X
which	B-X
has	B-X
limited	B-X
its	B-X
efficacy	B-X
.	B-X

Lonafarnib	O
in	O
patients	O
with	O
MDS	O
has	O
also	O
resulted	O
in	O
clinical	O
responses	O
in	O
approximately	O
30	O
%	O
,	O
including	O
significant	O
improvements	O
in	O
platelet	O
counts	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
in	B-X
active	B-X
clinical	B-X
development	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
MDS	B-X
,	B-X
two	B-X
nonpeptidomimetic	B-X
agents	B-X
,	B-X
tipifarnib	B-X
(	B-X
Zarnestra	B-X
,	B-X
Johnson	B-X
&	B-X
Johnson	B-X
,	B-X
New	B-X
Brunswick	B-X
,	B-X
NJ	B-X
)	B-X
and	B-X
lonafarnib	B-X
(	B-X
Sarasar	B-X
,	B-X
Schering-Plough	B-X
,	B-X
Kenilworth	B-X
,	B-X
NJ	B-X
)	B-X
have	B-X
been	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
.	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
Lonafarnib	B-X
has	B-X
been	B-X
associated	B-X
primarily	B-X
with	B-X
diarrhea	B-X
and	B-X
other	B-X
gastrointestinal	B-X
toxicity	B-X
,	B-X
anorexia	B-X
,	B-X
and	B-X
nausea	B-X
,	B-X
which	B-X
has	B-X
limited	B-X
its	B-X
efficacy	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
activating	B-X
Ras	B-X
mutation	B-X
has	B-X
not	B-X
predicted	B-X
response	B-X
to	B-X
therapy	B-X
with	B-X
FTIs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

Lonafarnib	O
has	O
been	O
associated	O
primarily	O
with	O
diarrhea	O
and	O
other	O
gastrointestinal	O
toxicity	O
,	O
anorexia	O
,	O
and	O
nausea	O
,	O
which	O
has	O
limited	O
its	O
efficacy	O
.	O
<EOS>	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Dose-limiting	B-X
adverse	B-X
effects	B-X
have	B-X
been	B-X
primarily	B-X
myelosuppression	B-X
,	B-X
although	B-X
fatigue	B-X
,	B-X
neurotoxicity	B-X
,	B-X
and	B-X
occasional	B-X
renal	B-X
dysfunction	B-X
have	B-X
required	B-X
dose	B-X
reductions	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
Lonafarnib	B-X
has	B-X
been	B-X
associated	B-X
primarily	B-X
with	B-X
diarrhea	B-X
and	B-X
other	B-X
gastrointestinal	B-X
toxicity	B-X
,	B-X
anorexia	B-X
,	B-X
and	B-X
nausea	B-X
,	B-X
which	B-X
has	B-X
limited	B-X
its	B-X
efficacy	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

Clinical	O
response	O
correlation	O
with	O
documentation	O
of	O
inhibition	O
of	O
farnesyltransferase	O
and	O
/	O
or	O
evidence	O
of	O
decreased	O
farnesylation	O
of	O
downstream	O
protein	O
targets	O
has	O
not	O
been	O
demonstrated	O
with	O
either	O
agent	O
.	O
<EOS>	B-X
These	B-X
processes	B-X
all	B-X
require	B-X
dynamic	B-X
protein-protein	B-X
interactions	B-X
at	B-X
cell	B-X
membranes	B-X
.	B-X
Lipid	B-X
modifications	B-X
target	B-X
proteins	B-X
to	B-X
membranes	B-X
by	B-X
increasing	B-X
substrate	B-X
hydrophobicity	B-X
by	B-X
the	B-X
addition	B-X
of	B-X
a	B-X
fatty	B-X
acid	B-X
or	B-X
isoprenyl	B-X
moiety	B-X
,	B-X
and	B-X
recent	B-X
evidence	B-X
suggests	B-X
that	B-X
dysregulated	B-X
posttranslational	B-X
lipid	B-X
modifications	B-X
may	B-X
play	B-X
a	B-X
role	B-X
in	B-X
multiple	B-X
neuropsychiatric	B-X
disorders	B-X
,	B-X
including	B-X
schizophrenia	B-X
.	B-X
Consistent	B-X
with	B-X
these	B-X
emerging	B-X
findings	B-X
,	B-X
we	B-X
have	B-X
recently	B-X
reported	B-X
decreased	B-X
protein	B-X
S-palmitoylation	B-X
in	B-X
schizophrenia	B-X
.	B-X
Protein	B-X
prenylation	B-X
is	B-X
a	B-X
lipid	B-X
modification	B-X
that	B-X
occurs	B-X
upstream	B-X
of	B-X
S-palmitoylation	B-X
on	B-X
many	B-X
protein	B-X
substrates	B-X
,	B-X
facilitating	B-X
membrane	B-X
localization	B-X
and	B-X
activity	B-X
of	B-X
key	B-X
intracellular	B-X
signaling	B-X
proteins	B-X
.	B-X
Accordingly	B-X
,	B-X
we	B-X
hypothesized	B-X
that	B-X
,	B-X
in	B-X
addition	B-X
to	B-X
palmitoylation	B-X
,	B-X
protein	B-X
prenylation	B-X
may	B-X
be	B-X
abnormal	B-X
in	B-X
schizophrenia	B-X
.	B-X
To	B-X
test	B-X
this	B-X
,	B-X
we	B-X
assayed	B-X
protein	B-X
expression	B-X
of	B-X
the	B-X
five	B-X
prenyltransferase	B-X
subunits	B-X
(	B-X
FNTA	B-X
,	B-X
FNTB	B-X
,	B-X
PGGT1B	B-X
,	B-X
RABGGTA	B-X
,	B-X
and	B-X
RABGGTB	B-X
)	B-X
in	B-X
postmortem	B-X
dorsolateral	B-X
prefrontal	B-X
cortex	B-X
from	B-X
patients	B-X
with	B-X
schizophrenia	B-X
and	B-X
paired	B-X
comparison	B-X
subjects	B-X
(	B-X
n	B-X
=	B-X
13	B-X
pairs	B-X
)	B-X
.	B-X
We	B-X
found	B-X
decreased	B-X
levels	B-X
of	B-X
FNTA	B-X
(	B-X
14	B-X
%	B-X
)	B-X
,	B-X
PGGT1B	B-X
(	B-X
13	B-X
%	B-X
)	B-X
,	B-X
and	B-X
RABGGTB	B-X
(	B-X
8	B-X
%	B-X
)	B-X
in	B-X
schizophrenia	B-X
.	B-X
To	B-X
determine	B-X
whether	B-X
upstream	B-X
or	B-X
downstream	B-X
factors	B-X
may	B-X
be	B-X
driving	B-X
these	B-X
changes	B-X
,	B-X
we	B-X
also	B-X
assayed	B-X
protein	B-X
expression	B-X
of	B-X
the	B-X
isoprenoid	B-X
synthases	B-X
FDPS	B-X
and	B-X
GGPS1	B-X
and	B-X
prenylation-dependent	B-X
processing	B-X
enzymes	B-X
RCE	B-X
and	B-X
ICMT	B-X
.	B-X
We	B-X
found	B-X
these	B-X
upstream	B-X
and	B-X
downstream	B-X
enzymes	B-X
to	B-X
have	B-X
normal	B-X
protein	B-X
expression	B-X
.	B-X
To	B-X
rule	B-X
out	B-X
effects	B-X
from	B-X
chronic	B-X
antipsychotic	B-X
treatment	B-X
,	B-X
we	B-X
assayed	B-X
FNTA	B-X
,	B-X
PGGT1B	B-X
,	B-X
and	B-X
RABGGTB	B-X
in	B-X
the	B-X
cortex	B-X
from	B-X
rats	B-X
treated	B-X
long-term	B-X
with	B-X
haloperidol	B-X
decanoate	B-X
and	B-X
found	B-X
no	B-X
change	B-X
in	B-X
the	B-X
expression	B-X
of	B-X
these	B-X
proteins	B-X
.	B-X
Given	B-X
the	B-X
role	B-X
prenylation	B-X
plays	B-X
in	B-X
localization	B-X
of	B-X
key	B-X
signaling	B-X
proteins	B-X
found	B-X
at	B-X
the	B-X
synapse	B-X
,	B-X
these	B-X
data	B-X
offer	B-X
a	B-X
potential	B-X
mechanism	B-X
underlying	B-X
abnormal	B-X
protein-protein	B-X
interactions	B-X
and	B-X
protein	B-X
localization	B-X
in	B-X
schizophrenia	B-X
.	B-X

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
activating	O
Ras	O
mutation	O
has	O
not	O
predicted	O
response	O
to	O
therapy	O
with	O
FTIs	O
in	O
MDS	O
and	O
AML	O
.	O
<EOS>	B-X
Instead	B-X
,	B-X
in	B-X
most	B-X
tumours	B-X
the	B-X
Warburg	B-X
effect	B-X
is	B-X
an	B-X
essential	B-X
part	B-X
of	B-X
a	B-X
'selfish	B-X
'	B-X
metabolic	B-X
reprogramming	B-X
,	B-X
which	B-X
results	B-X
from	B-X
the	B-X
interplay	B-X
between	B-X
(	B-X
normoxic/hypoxic	B-X
)	B-X
hypoxia-inducible	B-X
factor-1	B-X
(	B-X
HIF-1	B-X
)	B-X
overexpression	B-X
,	B-X
oncogene	B-X
activation	B-X
(	B-X
cMyc	B-X
,	B-X
Ras	B-X
)	B-X
,	B-X
loss	B-X
of	B-X
function	B-X
of	B-X
tumour	B-X
suppressors	B-X
(	B-X
mutant	B-X
p53	B-X
,	B-X
mutant	B-X
phosphatase	B-X
and	B-X
tensin	B-X
homologue	B-X
(	B-X
PTEN	B-X
)	B-X
,	B-X
microRNAs	B-X
and	B-X
sirtuins	B-X
with	B-X
suppressor	B-X
functions	B-X
)	B-X
,	B-X
activated	B-X
(	B-X
PI3K-Akt-mTORC1	B-X
,	B-X
Ras-Raf-MEK-ERK-cMyc	B-X
,	B-X
Jak-Stat3	B-X
)	B-X
or	B-X
deactivated	B-X
(	B-X
LKB1-AMPK	B-X
)	B-X
signalling	B-X
pathways	B-X
,	B-X
components	B-X
of	B-X
the	B-X
tumour	B-X
microenvironment	B-X
,	B-X
and	B-X
HIF-1	B-X
cooperation	B-X
with	B-X
epigenetic	B-X
mechanisms	B-X
.	B-X
Molecular	B-X
and	B-X
functional	B-X
processes	B-X
of	B-X
the	B-X
Warburg	B-X
effect	B-X
include	B-X
:	B-X
(	B-X
a	B-X
)	B-X
considerable	B-X
acceleration	B-X
of	B-X
glycolytic	B-X
fluxes	B-X
;	B-X
(	B-X
b	B-X
)	B-X
adequate	B-X
ATP	B-X
generation	B-X
per	B-X
unit	B-X
time	B-X
to	B-X
maintain	B-X
energy	B-X
homeostasis	B-X
and	B-X
electrochemical	B-X
gradients	B-X
;	B-X
(	B-X
c	B-X
)	B-X
backup	B-X
and	B-X
diversion	B-X
of	B-X
glycolytic	B-X
intermediates	B-X
facilitating	B-X
the	B-X
biosynthesis	B-X
of	B-X
nucleotides	B-X
,	B-X
non-essential	B-X
amino	B-X
acids	B-X
,	B-X
lipids	B-X
and	B-X
hexosamines	B-X
;	B-X
(	B-X
d	B-X
)	B-X
inhibition	B-X
of	B-X
pyruvate	B-X
entry	B-X
into	B-X
mitochondria	B-X
;	B-X
(	B-X
e	B-X
)	B-X
excessive	B-X
formation	B-X
and	B-X
accumulation	B-X
of	B-X
lactate	B-X
,	B-X
which	B-X
stimulates	B-X
tumour	B-X
growth	B-X
and	B-X
suppression	B-X
of	B-X
anti-tumour	B-X
immunity	B-X
-	B-X
in	B-X
addition	B-X
,	B-X
lactate	B-X
can	B-X
serve	B-X
as	B-X
an	B-X
energy	B-X
source	B-X
for	B-X
normoxic	B-X
cancer	B-X
cells	B-X
and	B-X
drives	B-X
malignant	B-X
progression	B-X
and	B-X
resistances	B-X
to	B-X
conventional	B-X
therapies	B-X
;	B-X
(	B-X
f	B-X
)	B-X
cytosolic	B-X
lactate	B-X
being	B-X
mainly	B-X
exported	B-X
through	B-X
upregulated	B-X
lactate-proton	B-X
symporters	B-X
(	B-X
MCT4	B-X
)	B-X
,	B-X
working	B-X
together	B-X
with	B-X
other	B-X
H	B-X
Pancreatic	B-X
ductal	B-X
adenocarcinoma	B-X
(	B-X
PDAC	B-X
)	B-X
is	B-X
predicted	B-X
to	B-X
be	B-X
the	B-X
second	B-X
most	B-X
common	B-X
cause	B-X
of	B-X
death	B-X
within	B-X
the	B-X
next	B-X
10	B-X
years	B-X
.	B-X
The	B-X
oncogenic	B-X
KRAS	B-X
mutation	B-X
is	B-X
the	B-X
major	B-X
event	B-X
in	B-X
pancreatic	B-X
cancer	B-X
;	B-X
it	B-X
confers	B-X
permanent	B-X
activation	B-X
of	B-X
the	B-X
KRAS	B-X
protein	B-X
,	B-X
which	B-X
acts	B-X
as	B-X
a	B-X
molecular	B-X
switch	B-X
to	B-X
activate	B-X
various	B-X
intracellular	B-X
signalling	B-X
pathways	B-X
and	B-X
transcription	B-X
factors	B-X
inducing	B-X
cell	B-X
proliferation	B-X
,	B-X
migration	B-X
,	B-X
transformation	B-X
and	B-X
survival	B-X
.	B-X
Several	B-X
laboratory	B-X
methods	B-X
have	B-X
been	B-X
developed	B-X
to	B-X
detect	B-X
KRAS	B-X
mutations	B-X
in	B-X
biological	B-X
samples	B-X
,	B-X
including	B-X
digital	B-X
droplet	B-X
PCR	B-X
(	B-X
which	B-X
displays	B-X
high	B-X
sensitivity	B-X
)	B-X
.	B-X
Clinical	B-X
studies	B-X
have	B-X
revealed	B-X
that	B-X
a	B-X
KRAS	B-X
mutation	B-X
assay	B-X
in	B-X
fine-needle	B-X
aspiration	B-X
material	B-X
combined	B-X
with	B-X
cytopathology	B-X
increases	B-X
the	B-X
sensitivity	B-X
,	B-X
accuracy	B-X
and	B-X
negative	B-X
predictive	B-X
value	B-X
of	B-X
cytopathology	B-X
for	B-X
a	B-X
positive	B-X
diagnosis	B-X
of	B-X
pancreatic	B-X
cancer	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
KRAS	B-X
mutations	B-X
in	B-X
serum	B-X
and	B-X
plasma	B-X
(	B-X
liquid	B-X
biopsies	B-X
)	B-X
correlates	B-X
with	B-X
a	B-X
worse	B-X
prognosis	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
mutated	B-X
KRAS	B-X
can	B-X
also	B-X
have	B-X
therapeutic	B-X
implications	B-X
,	B-X
whether	B-X
at	B-X
the	B-X
gene	B-X
level	B-X
per	B-X
se	B-X
,	B-X
during	B-X
its	B-X
post-translational	B-X
maturation	B-X
,	B-X
interaction	B-X
with	B-X
nucleotides	B-X
and	B-X
after	B-X
activation	B-X
of	B-X
the	B-X
various	B-X
oncogenic	B-X
signals	B-X
.	B-X

Despite	O
this	O
lack	O
of	O
evidence	O
,	O
significant	O
clinical	O
efficacy	O
of	O
the	O
FTIs	O
has	O
been	O
observed	O
in	O
MDS	O
,	O
on	O
a	O
par	O
with	O
the	O
efficacy	O
of	O
currently	O
available	O
chemotherapeutic	O
agents	O
,	O
leading	O
to	O
further	O
development	O
of	O
this	O
new	O
class	O
of	O
drugs	O
in	O
MDS	O
and	O
AML	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
inhibitors	B-X
(	B-X
FTIs	B-X
)	B-X
are	B-X
in	B-X
active	B-X
clinical	B-X
development	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
human	B-X
malignancies	B-X
.	B-X
The	B-X
most	B-X
promising	B-X
activity	B-X
to	B-X
date	B-X
has	B-X
been	B-X
demonstrated	B-X
in	B-X
patients	B-X
with	B-X
hematologic	B-X
malignancies	B-X
,	B-X
in	B-X
particular	B-X
acute	B-X
myeloid	B-X
leukemia	B-X
(	B-X
AML	B-X
)	B-X
and	B-X
myelodysplastic	B-X
syndrome	B-X
(	B-X
MDS	B-X
)	B-X
.	B-X
In	B-X
patients	B-X
with	B-X
MDS	B-X
,	B-X
two	B-X
nonpeptidomimetic	B-X
agents	B-X
,	B-X
tipifarnib	B-X
(	B-X
Zarnestra	B-X
,	B-X
Johnson	B-X
&	B-X
Johnson	B-X
,	B-X
New	B-X
Brunswick	B-X
,	B-X
NJ	B-X
)	B-X
and	B-X
lonafarnib	B-X
(	B-X
Sarasar	B-X
,	B-X
Schering-Plough	B-X
,	B-X
Kenilworth	B-X
,	B-X
NJ	B-X
)	B-X
have	B-X
been	B-X
the	B-X
most	B-X
extensively	B-X
studied	B-X
.	B-X
In	B-X
both	B-X
phase	B-X
I	B-X
and	B-X
phase	B-X
II	B-X
trials	B-X
,	B-X
tipifarnib	B-X
has	B-X
demonstrated	B-X
significant	B-X
efficacy	B-X
,	B-X
with	B-X
overall	B-X
response	B-X
rates	B-X
of	B-X
30	B-X
%	B-X
and	B-X
complete	B-X
remissions	B-X
in	B-X
about	B-X
15	B-X
%	B-X
.	B-X
Lonafarnib	B-X
in	B-X
patients	B-X
with	B-X
MDS	B-X
has	B-X
also	B-X
resulted	B-X
in	B-X
clinical	B-X
responses	B-X
in	B-X
approximately	B-X
30	B-X
%	B-X
,	B-X
including	B-X
significant	B-X
improvements	B-X
in	B-X
platelet	B-X
counts	B-X
.	B-X
Lonafarnib	B-X
has	B-X
been	B-X
associated	B-X
primarily	B-X
with	B-X
diarrhea	B-X
and	B-X
other	B-X
gastrointestinal	B-X
toxicity	B-X
,	B-X
anorexia	B-X
,	B-X
and	B-X
nausea	B-X
,	B-X
which	B-X
has	B-X
limited	B-X
its	B-X
efficacy	B-X
.	B-X
Clinical	B-X
response	B-X
correlation	B-X
with	B-X
documentation	B-X
of	B-X
inhibition	B-X
of	B-X
farnesyltransferase	B-X
and/or	B-X
evidence	B-X
of	B-X
decreased	B-X
farnesylation	B-X
of	B-X
downstream	B-X
protein	B-X
targets	B-X
has	B-X
not	B-X
been	B-X
demonstrated	B-X
with	B-X
either	B-X
agent	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
activating	B-X
Ras	B-X
mutation	B-X
has	B-X
not	B-X
predicted	B-X
response	B-X
to	B-X
therapy	B-X
with	B-X
FTIs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X
Despite	B-X
this	B-X
lack	B-X
of	B-X
evidence	B-X
,	B-X
significant	B-X
clinical	B-X
efficacy	B-X
of	B-X
the	B-X
FTIs	B-X
has	B-X
been	B-X
observed	B-X
in	B-X
MDS	B-X
,	B-X
on	B-X
a	B-X
par	B-X
with	B-X
the	B-X
efficacy	B-X
of	B-X
currently	B-X
available	B-X
chemotherapeutic	B-X
agents	B-X
,	B-X
leading	B-X
to	B-X
further	B-X
development	B-X
of	B-X
this	B-X
new	B-X
class	B-X
of	B-X
drugs	B-X
in	B-X
MDS	B-X
and	B-X
AML	B-X
.	B-X

An	O
S	O
-	O
acylation	O
switch	O
of	O
conserved	O
G	O
domain	O
cysteines	O
is	O
required	O
for	O
polarity	O
signaling	O
by	O
ROP	O
GTPases	O
.	O

Rho	O
GTPases	O
are	O
master	O
regulators	O
of	O
cell	O
polarity	O
.	O
<EOS>	B-X
Cdc42	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Rho	B-X
family	B-X
of	B-X
small	B-X
GTPases	B-X
and	B-X
a	B-X
master	B-X
regulator	B-X
of	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
,	B-X
controlling	B-X
cell	B-X
motility	B-X
,	B-X
polarity	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
.	B-X
This	B-X
small	B-X
G	B-X
protein	B-X
and	B-X
its	B-X
regulators	B-X
have	B-X
been	B-X
the	B-X
subject	B-X
of	B-X
many	B-X
years	B-X
of	B-X
fruitful	B-X
investigation	B-X
and	B-X
the	B-X
advent	B-X
of	B-X
functional	B-X
genomics	B-X
and	B-X
proteomics	B-X
has	B-X
opened	B-X
up	B-X
new	B-X
avenues	B-X
of	B-X
exploration	B-X
including	B-X
how	B-X
it	B-X
functions	B-X
at	B-X
specific	B-X
locations	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
This	B-X
has	B-X
coincided	B-X
with	B-X
the	B-X
introduction	B-X
of	B-X
new	B-X
structural	B-X
techniques	B-X
with	B-X
the	B-X
ability	B-X
to	B-X
study	B-X
small	B-X
GTPases	B-X
in	B-X
the	B-X
context	B-X
of	B-X
the	B-X
membrane	B-X
.	B-X
Given	B-X
the	B-X
challenges	B-X
encountered	B-X
with	B-X
targeting	B-X
small	B-X
G	B-X
proteins	B-X
directly	B-X
therapeutically	B-X
,	B-X
it	B-X
is	B-X
arguably	B-X
the	B-X
regulators	B-X
of	B-X
Cdc42	B-X
and	B-X
the	B-X
effector	B-X
signalling	B-X
pathways	B-X
downstream	B-X
of	B-X
the	B-X
small	B-X
G	B-X
protein	B-X
which	B-X
will	B-X
be	B-X
the	B-X
most	B-X
tractable	B-X
targets	B-X
for	B-X
therapeutic	B-X
intervention	B-X
.	B-X

For	O
their	O
function	O
,	O
Rhos	O
must	O
associate	O
with	O
discrete	O
plasma	O
membrane	O
domains	O
.	O
<EOS>	B-X
For	B-X
their	B-X
function	B-X
,	B-X
Rhos	B-X
must	B-X
associate	B-X
with	B-X
discrete	B-X
plasma	B-X
membrane	B-X
domains	B-X
.	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X

Rho	O
of	O
Plants	O
(	O
ROPs	O
)	O
or	O
RACs	O
comprise	O
a	O
single	O
family	O
.	O
<EOS>	B-X
In	B-X
eukaryotes	B-X
the	B-X
RHO	B-X
family	B-X
of	B-X
small	B-X
G	B-X
proteins	B-X
have	B-X
emerged	B-X
as	B-X
central	B-X
regulators	B-X
of	B-X
cell	B-X
polarity	B-X
signaling	B-X
.	B-X
It	B-X
is	B-X
by	B-X
now	B-X
well	B-X
established	B-X
that	B-X
ROPs	B-X
,	B-X
the	B-X
plant	B-X
specific	B-X
RHO	B-X
subfamily	B-X
members	B-X
,	B-X
affect	B-X
cell	B-X
polarization	B-X
.	B-X
Work	B-X
carried	B-X
out	B-X
over	B-X
the	B-X
last	B-X
several	B-X
years	B-X
is	B-X
beginning	B-X
to	B-X
reveal	B-X
how	B-X
ROPs	B-X
are	B-X
activated	B-X
,	B-X
how	B-X
their	B-X
activity	B-X
is	B-X
spatially	B-X
regulated	B-X
,	B-X
through	B-X
which	B-X
effectors	B-X
they	B-X
regulate	B-X
cell	B-X
polarity	B-X
and	B-X
how	B-X
they	B-X
interact	B-X
with	B-X
hormonal	B-X
signaling	B-X
and	B-X
other	B-X
polarity	B-X
determinants	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
provide	B-X
an	B-X
updated	B-X
view	B-X
of	B-X
polarity	B-X
signaling	B-X
in	B-X
plants	B-X
,	B-X
primarily	B-X
focusing	B-X
on	B-X
the	B-X
function	B-X
of	B-X
ROPs	B-X
and	B-X
how	B-X
they	B-X
interact	B-X
with	B-X
and	B-X
coordinate	B-X
different	B-X
polarity	B-X
determinants	B-X
.	B-X

Prenylation	O
and	O
S	O
-	O
acylation	O
of	O
hypervariable	O
domain	O
cysteines	O
of	O
Ras	O
and	O
Rho	O
GTPases	O
are	O
required	O
for	O
their	O
function	O
;	O
however	O
,	O
lipid	O
modifications	O
in	O
the	O
G	O
domain	O
have	O
never	O
been	O
reported	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
master	B-X
regulators	B-X
of	B-X
cell	B-X
polarity	B-X
.	B-X
For	B-X
their	B-X
function	B-X
,	B-X
Rhos	B-X
must	B-X
associate	B-X
with	B-X
discrete	B-X
plasma	B-X
membrane	B-X
domains	B-X
.	B-X
Rho	B-X
of	B-X
Plants	B-X
(	B-X
ROPs	B-X
)	B-X
or	B-X
RACs	B-X
comprise	B-X
a	B-X
single	B-X
family	B-X
.	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Reversible	B-X
S-acylation	B-X
involves	B-X
the	B-X
attachment	B-X
of	B-X
palmitate	B-X
(	B-X
C16:0	B-X
)	B-X
or	B-X
other	B-X
saturated	B-X
lipids	B-X
to	B-X
cysteines	B-X
through	B-X
a	B-X
thioester	B-X
linkage	B-X
and	B-X
was	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transient	B-X
S-acylation	B-X
of	B-X
Arabidopsis	B-X
AtROP6	B-X
takes	B-X
place	B-X
on	B-X
two	B-X
conserved	B-X
G	B-X
domain	B-X
cysteine	B-X
residues	B-X
,	B-X
C21	B-X
and	B-X
C156	B-X
.	B-X
C21	B-X
is	B-X
relatively	B-X
exposed	B-X
and	B-X
is	B-X
accessible	B-X
for	B-X
modification	B-X
,	B-X
but	B-X
C156	B-X
is	B-X
not	B-X
,	B-X
implying	B-X
that	B-X
its	B-X
S-acylation	B-X
involves	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X
Site-specific	B-X
acylation-deficient	B-X
AtROP6	B-X
mutants	B-X
can	B-X
bind	B-X
and	B-X
hydrolyze	B-X
GTP	B-X
but	B-X
display	B-X
compromised	B-X
effects	B-X
on	B-X
polar	B-X
cell	B-X
growth	B-X
,	B-X
endocytic	B-X
uptake	B-X
of	B-X
the	B-X
tracer	B-X
dye	B-X
FM4-64	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
an	B-X
S-acylation	B-X
switch	B-X
that	B-X
regulates	B-X
Rho	B-X
signaling	B-X
.	B-X

Reversible	O
S	O
-	O
acylation	O
involves	O
the	O
attachment	O
of	O
palmitate	O
(	O
C16	O
:	O
0	O
)	O
or	O
other	O
saturated	O
lipids	O
to	O
cysteines	O
through	O
a	O
thioester	O
linkage	O
and	O
was	O
implicated	O
in	O
the	O
regulation	O
of	O
signaling	O
.	O
<EOS>	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Reversible	B-X
S-acylation	B-X
involves	B-X
the	B-X
attachment	B-X
of	B-X
palmitate	B-X
(	B-X
C16:0	B-X
)	B-X
or	B-X
other	B-X
saturated	B-X
lipids	B-X
to	B-X
cysteines	B-X
through	B-X
a	B-X
thioester	B-X
linkage	B-X
and	B-X
was	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transient	B-X
S-acylation	B-X
of	B-X
Arabidopsis	B-X
AtROP6	B-X
takes	B-X
place	B-X
on	B-X
two	B-X
conserved	B-X
G	B-X
domain	B-X
cysteine	B-X
residues	B-X
,	B-X
C21	B-X
and	B-X
C156	B-X
.	B-X
C21	B-X
is	B-X
relatively	B-X
exposed	B-X
and	B-X
is	B-X
accessible	B-X
for	B-X
modification	B-X
,	B-X
but	B-X
C156	B-X
is	B-X
not	B-X
,	B-X
implying	B-X
that	B-X
its	B-X
S-acylation	B-X
involves	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X
Site-specific	B-X
acylation-deficient	B-X
AtROP6	B-X
mutants	B-X
can	B-X
bind	B-X
and	B-X
hydrolyze	B-X
GTP	B-X
but	B-X
display	B-X
compromised	B-X
effects	B-X
on	B-X
polar	B-X
cell	B-X
growth	B-X
,	B-X
endocytic	B-X
uptake	B-X
of	B-X
the	B-X
tracer	B-X
dye	B-X
FM4-64	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
an	B-X
S-acylation	B-X
switch	B-X
that	B-X
regulates	B-X
Rho	B-X
signaling	B-X
.	B-X

Here	O
we	O
show	O
that	O
transient	O
S	O
-	O
acylation	O
of	O
Arabidopsis	O
AtROP6	B-Protein
takes	O
place	O
on	O
two	O
conserved	O
G	O
domain	O
cysteine	O
residues	O
,	O
C21	O
and	O
C156	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
master	B-X
regulators	B-X
of	B-X
cell	B-X
polarity	B-X
.	B-X
For	B-X
their	B-X
function	B-X
,	B-X
Rhos	B-X
must	B-X
associate	B-X
with	B-X
discrete	B-X
plasma	B-X
membrane	B-X
domains	B-X
.	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Reversible	B-X
S-acylation	B-X
involves	B-X
the	B-X
attachment	B-X
of	B-X
palmitate	B-X
(	B-X
C16:0	B-X
)	B-X
or	B-X
other	B-X
saturated	B-X
lipids	B-X
to	B-X
cysteines	B-X
through	B-X
a	B-X
thioester	B-X
linkage	B-X
and	B-X
was	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transient	B-X
S-acylation	B-X
of	B-X
Arabidopsis	B-X
AtROP6	B-X
takes	B-X
place	B-X
on	B-X
two	B-X
conserved	B-X
G	B-X
domain	B-X
cysteine	B-X
residues	B-X
,	B-X
C21	B-X
and	B-X
C156	B-X
.	B-X
C21	B-X
is	B-X
relatively	B-X
exposed	B-X
and	B-X
is	B-X
accessible	B-X
for	B-X
modification	B-X
,	B-X
but	B-X
C156	B-X
is	B-X
not	B-X
,	B-X
implying	B-X
that	B-X
its	B-X
S-acylation	B-X
involves	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X
Site-specific	B-X
acylation-deficient	B-X
AtROP6	B-X
mutants	B-X
can	B-X
bind	B-X
and	B-X
hydrolyze	B-X
GTP	B-X
but	B-X
display	B-X
compromised	B-X
effects	B-X
on	B-X
polar	B-X
cell	B-X
growth	B-X
,	B-X
endocytic	B-X
uptake	B-X
of	B-X
the	B-X
tracer	B-X
dye	B-X
FM4-64	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
an	B-X
S-acylation	B-X
switch	B-X
that	B-X
regulates	B-X
Rho	B-X
signaling	B-X
.	B-X

C21	O
is	O
relatively	O
exposed	O
and	O
is	O
accessible	O
for	O
modification	O
,	O
but	O
C156	O
is	O
not	O
,	O
implying	O
that	O
its	O
S	O
-	O
acylation	O
involves	O
a	O
conformational	O
change	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
beam	O
-	O
size	O
analysis	O
shows	O
that	O
S	O
-	O
acylation	O
of	O
AtROP6	B-Protein
regulates	O
its	O
membrane	O
-	O
association	O
dynamics	O
,	O
and	O
detergent	O
-	O
solubilization	O
studies	O
indicate	O
that	O
it	O
regulates	O
AtROP6	B-Protein
association	O
with	O
lipid	O
rafts	O
.	O
<EOS>	B-X
For	B-X
their	B-X
function	B-X
,	B-X
Rhos	B-X
must	B-X
associate	B-X
with	B-X
discrete	B-X
plasma	B-X
membrane	B-X
domains	B-X
.	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Reversible	B-X
S-acylation	B-X
involves	B-X
the	B-X
attachment	B-X
of	B-X
palmitate	B-X
(	B-X
C16:0	B-X
)	B-X
or	B-X
other	B-X
saturated	B-X
lipids	B-X
to	B-X
cysteines	B-X
through	B-X
a	B-X
thioester	B-X
linkage	B-X
and	B-X
was	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transient	B-X
S-acylation	B-X
of	B-X
Arabidopsis	B-X
AtROP6	B-X
takes	B-X
place	B-X
on	B-X
two	B-X
conserved	B-X
G	B-X
domain	B-X
cysteine	B-X
residues	B-X
,	B-X
C21	B-X
and	B-X
C156	B-X
.	B-X
C21	B-X
is	B-X
relatively	B-X
exposed	B-X
and	B-X
is	B-X
accessible	B-X
for	B-X
modification	B-X
,	B-X
but	B-X
C156	B-X
is	B-X
not	B-X
,	B-X
implying	B-X
that	B-X
its	B-X
S-acylation	B-X
involves	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X
Site-specific	B-X
acylation-deficient	B-X
AtROP6	B-X
mutants	B-X
can	B-X
bind	B-X
and	B-X
hydrolyze	B-X
GTP	B-X
but	B-X
display	B-X
compromised	B-X
effects	B-X
on	B-X
polar	B-X
cell	B-X
growth	B-X
,	B-X
endocytic	B-X
uptake	B-X
of	B-X
the	B-X
tracer	B-X
dye	B-X
FM4-64	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
an	B-X
S-acylation	B-X
switch	B-X
that	B-X
regulates	B-X
Rho	B-X
signaling	B-X
.	B-X

Site	O
-	O
specific	O
acylation	O
-	O
deficient	O
AtROP6	B-Protein
mutants	O
can	O
bind	O
and	O
hydrolyze	O
GTP	O
but	O
display	O
compromised	O
effects	O
on	O
polar	O
cell	O
growth	O
,	O
endocytic	O
uptake	O
of	O
the	O
tracer	O
dye	O
FM4	O
-	O
64	O
,	O
and	O
distribution	O
of	O
reactive	O
oxygen	O
species	O
.	O
<EOS>	B-X
Rho	B-X
GTPases	B-X
are	B-X
master	B-X
regulators	B-X
of	B-X
cell	B-X
polarity	B-X
.	B-X
Prenylation	B-X
and	B-X
S-acylation	B-X
of	B-X
hypervariable	B-X
domain	B-X
cysteines	B-X
of	B-X
Ras	B-X
and	B-X
Rho	B-X
GTPases	B-X
are	B-X
required	B-X
for	B-X
their	B-X
function	B-X
;	B-X
however	B-X
,	B-X
lipid	B-X
modifications	B-X
in	B-X
the	B-X
G	B-X
domain	B-X
have	B-X
never	B-X
been	B-X
reported	B-X
.	B-X
Reversible	B-X
S-acylation	B-X
involves	B-X
the	B-X
attachment	B-X
of	B-X
palmitate	B-X
(	B-X
C16:0	B-X
)	B-X
or	B-X
other	B-X
saturated	B-X
lipids	B-X
to	B-X
cysteines	B-X
through	B-X
a	B-X
thioester	B-X
linkage	B-X
and	B-X
was	B-X
implicated	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
signaling	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
transient	B-X
S-acylation	B-X
of	B-X
Arabidopsis	B-X
AtROP6	B-X
takes	B-X
place	B-X
on	B-X
two	B-X
conserved	B-X
G	B-X
domain	B-X
cysteine	B-X
residues	B-X
,	B-X
C21	B-X
and	B-X
C156	B-X
.	B-X
C21	B-X
is	B-X
relatively	B-X
exposed	B-X
and	B-X
is	B-X
accessible	B-X
for	B-X
modification	B-X
,	B-X
but	B-X
C156	B-X
is	B-X
not	B-X
,	B-X
implying	B-X
that	B-X
its	B-X
S-acylation	B-X
involves	B-X
a	B-X
conformational	B-X
change	B-X
.	B-X
Fluorescence	B-X
recovery	B-X
after	B-X
photobleaching	B-X
beam-size	B-X
analysis	B-X
shows	B-X
that	B-X
S-acylation	B-X
of	B-X
AtROP6	B-X
regulates	B-X
its	B-X
membrane-association	B-X
dynamics	B-X
,	B-X
and	B-X
detergent-solubilization	B-X
studies	B-X
indicate	B-X
that	B-X
it	B-X
regulates	B-X
AtROP6	B-X
association	B-X
with	B-X
lipid	B-X
rafts	B-X
.	B-X
Site-specific	B-X
acylation-deficient	B-X
AtROP6	B-X
mutants	B-X
can	B-X
bind	B-X
and	B-X
hydrolyze	B-X
GTP	B-X
but	B-X
display	B-X
compromised	B-X
effects	B-X
on	B-X
polar	B-X
cell	B-X
growth	B-X
,	B-X
endocytic	B-X
uptake	B-X
of	B-X
the	B-X
tracer	B-X
dye	B-X
FM4-64	B-X
,	B-X
and	B-X
distribution	B-X
of	B-X
reactive	B-X
oxygen	B-X
species	B-X
.	B-X
These	B-X
data	B-X
reveal	B-X
an	B-X
S-acylation	B-X
switch	B-X
that	B-X
regulates	B-X
Rho	B-X
signaling	B-X
.	B-X

These	O
data	O
reveal	O
an	O
S	O
-	O
acylation	O
switch	O
that	O
regulates	O
Rho	O
signaling	O
.	O

Simultaneous	O
C7	O
-	O
and	O
N1	O
-	O
prenylation	O
of	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
catalyzed	O
by	O
a	O
prenyltransferase	O
from	O
Aspergillus	O
oryzae	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
prenyltransferase	B-X
gene	B-X
cTrpPT	B-X
was	B-X
amplified	B-X
from	B-X
Aspergillus	B-X
oryzae	B-X
DSM1147	B-X
,	B-X
cloned	B-X
into	B-X
pQE70	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
was	B-X
monitored	B-X
with	B-X
HPLC	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
This	B-X
enzyme	B-X
showed	B-X
higher	B-X
substrate	B-X
specificity	B-X
towards	B-X
aromatic	B-X
substrates	B-X
,	B-X
but	B-X
lower	B-X
regioselectivity	B-X
regarding	B-X
the	B-X
prenylation	B-X
position	B-X
than	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
.	B-X
Cyclo-L-Trp-L-Trp	B-X
was	B-X
much	B-X
better	B-X
accepted	B-X
than	B-X
other	B-X
cyclic	B-X
dipeptides	B-X
tested	B-X
in	B-X
this	B-X
study	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
and	B-X
(	B-X
13	B-X
)	B-X
C-NMR	B-X
analyses	B-X
,	B-X
including	B-X
long-range	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
(	B-X
13	B-X
)	B-X
C	B-X
connectivities	B-X
in	B-X
Heteronuclear	B-X
Multiple-Bond	B-X
Correlation	B-X
(	B-X
HMBC	B-X
)	B-X
and	B-X
Nuclear	B-X
Overhauser	B-X
Effect	B-X
Spectroscopy	B-X
(	B-X
NOESY	B-X
)	B-X
,	B-X
proved	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
as	B-X
C7-	B-X
and	B-X
N1-prenylated	B-X
derivatives	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
1:1.2	B-X
using	B-X
cyclo-L-Trp-L-Trp	B-X
as	B-X
substrate	B-X
.	B-X
The	B-X
K	B-X
(	B-X
M	B-X
)	B-X
values	B-X
were	B-X
determined	B-X
at	B-X
about	B-X
2.5	B-X
mM	B-X
for	B-X
dimethylallyl	B-X
diphosphate	B-X
and	B-X
0.3	B-X
mM	B-X
for	B-X
cyclo-L-Trp-L-Trp	B-X
with	B-X
a	B-X
turnover	B-X
number	B-X
of	B-X
0.33	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
.	B-X

A	O
putative	O
prenyltransferase	O
gene	O
cTrpPT	B-Protein
was	O
amplified	O
from	O
Aspergillus	O
oryzae	O
DSM1147	O
,	O
cloned	O
into	O
pQE70	O
and	O
overexpressed	O
in	O
Escherichia	O
coli	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
prenyltransferase	B-X
gene	B-X
cTrpPT	B-X
was	B-X
amplified	B-X
from	B-X
Aspergillus	B-X
oryzae	B-X
DSM1147	B-X
,	B-X
cloned	B-X
into	B-X
pQE70	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
This	B-X
enzyme	B-X
showed	B-X
higher	B-X
substrate	B-X
specificity	B-X
towards	B-X
aromatic	B-X
substrates	B-X
,	B-X
but	B-X
lower	B-X
regioselectivity	B-X
regarding	B-X
the	B-X
prenylation	B-X
position	B-X
than	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X

The	O
overproduced	O
His	O
(	O
6	O
)	O
-	O
CTrpPT	B-Protein
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
incubated	O
with	O
L	O
-	O
tryptophan	O
or	O
tryptophan	O
-	O
containing	O
cyclic	O
dipeptides	O
in	O
the	O
presence	O
of	O
dimethylallyl	O
diphosphate	O
.	O
<EOS>	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
was	B-X
monitored	B-X
with	B-X
HPLC	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
Cyclo-L-Trp-L-Trp	B-X
was	B-X
much	B-X
better	B-X
accepted	B-X
than	B-X
other	B-X
cyclic	B-X
dipeptides	B-X
tested	B-X
in	B-X
this	B-X
study	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
and	B-X
(	B-X
13	B-X
)	B-X
C-NMR	B-X
analyses	B-X
,	B-X
including	B-X
long-range	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
(	B-X
13	B-X
)	B-X
C	B-X
connectivities	B-X
in	B-X
Heteronuclear	B-X
Multiple-Bond	B-X
Correlation	B-X
(	B-X
HMBC	B-X
)	B-X
and	B-X
Nuclear	B-X
Overhauser	B-X
Effect	B-X
Spectroscopy	B-X
(	B-X
NOESY	B-X
)	B-X
,	B-X
proved	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
as	B-X
C7-	B-X
and	B-X
N1-prenylated	B-X
derivatives	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
1:1.2	B-X
using	B-X
cyclo-L-Trp-L-Trp	B-X
as	B-X
substrate	B-X
.	B-X
The	B-X
K	B-X
(	B-X
M	B-X
)	B-X
values	B-X
were	B-X
determined	B-X
at	B-X
about	B-X
2.5	B-X
mM	B-X
for	B-X
dimethylallyl	B-X
diphosphate	B-X
and	B-X
0.3	B-X
mM	B-X
for	B-X
cyclo-L-Trp-L-Trp	B-X
with	B-X
a	B-X
turnover	B-X
number	B-X
of	B-X
0.33	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
.	B-X

The	O
formation	O
of	O
the	O
enzyme	O
products	O
was	O
monitored	O
with	O
HPLC	O
.	O
<EOS>	B-X
However	B-X
,	B-X
using	B-X
HPLC-based	B-X
assays	B-X
,	B-X
2-OH-E	B-X
(	B-X
+	B-X
)	B-X
and	B-X
analogous	B-X
hydroxylated	B-X
products	B-X
can	B-X
be	B-X
easily	B-X
detected	B-X
and	B-X
quickly	B-X
separated	B-X
from	B-X
other	B-X
oxidation	B-X
products	B-X
.	B-X
Reactive	B-X
oxygen	B-X
species	B-X
(	B-X
ROS	B-X
)	B-X
are	B-X
a	B-X
group	B-X
of	B-X
unstable	B-X
and	B-X
highly	B-X
reactive	B-X
molecules	B-X
or	B-X
free	B-X
radicals	B-X
typically	B-X
generated	B-X
as	B-X
by-products	B-X
of	B-X
cellular	B-X
processes	B-X
involving	B-X
molecular	B-X
oxygen	B-X
.	B-X
The	B-X
protocol	B-X
includes	B-X
preparation	B-X
of	B-X
frozen	B-X
aortic	B-X
tissue	B-X
sections	B-X
,	B-X
monitoring	B-X
DHE	B-X
oxidation-derived	B-X
fluorescence	B-X
by	B-X
fluorescence	B-X
microscopy	B-X
,	B-X
and	B-X
high-performance	B-X
liquid	B-X
chromatograph-based	B-X
analysis	B-X
of	B-X
MitoSOX	B-X
and	B-X
its	B-X
oxidation	B-X
products	B-X
.	B-X
In	B-X
this	B-X
report	B-X
,	B-X
an	B-X
enzyme	B-X
cascade	B-X
strategy	B-X
was	B-X
proposed	B-X
and	B-X
a	B-X
high-efficiency	B-X
fluorescence	B-X
assay	B-X
was	B-X
established	B-X
for	B-X
rapid	B-X
and	B-X
convenient	B-X
phenylalanine	B-X
quantification	B-X
.	B-X
The	B-X
assay	B-X
involves	B-X
phenylalanine	B-X
dehydrogenase	B-X
for	B-X
the	B-X
quantitative	B-X
metabolization	B-X
of	B-X
phenylalanine	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
NADH	B-X
,	B-X
as	B-X
well	B-X
as	B-X
nitroreductase	B-X
combining	B-X
a	B-X
nitroaromatic	B-X
substrate	B-X
for	B-X
the	B-X
fluorescent	B-X
quantification	B-X
of	B-X
NADH	B-X
and	B-X
subsequently	B-X
phenylalanine	B-X
.	B-X
The	B-X
phenylalanine	B-X
levels	B-X
in	B-X
clinical	B-X
serum	B-X
determined	B-X
by	B-X
this	B-X
fluorescence	B-X
assay	B-X
are	B-X
consistent	B-X
with	B-X
those	B-X
from	B-X
HPLC	B-X
.	B-X

It	O
was	O
shown	O
that	O
CTrpPT	B-Protein
differed	O
clearly	O
from	O
other	O
known	O
indole	O
prenyltransferases	O
in	O
several	O
aspects	O
.	O
<EOS>	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
This	B-X
enzyme	B-X
showed	B-X
higher	B-X
substrate	B-X
specificity	B-X
towards	B-X
aromatic	B-X
substrates	B-X
,	B-X
but	B-X
lower	B-X
regioselectivity	B-X
regarding	B-X
the	B-X
prenylation	B-X
position	B-X
than	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X

This	O
enzyme	O
showed	O
higher	O
substrate	O
specificity	O
towards	O
aromatic	O
substrates	O
,	O
but	O
lower	O
regioselectivity	O
regarding	O
the	O
prenylation	O
position	O
than	O
other	O
indole	O
prenyltransferases	O
.	O
<EOS>	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
was	B-X
monitored	B-X
with	B-X
HPLC	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
This	B-X
enzyme	B-X
showed	B-X
higher	B-X
substrate	B-X
specificity	B-X
towards	B-X
aromatic	B-X
substrates	B-X
,	B-X
but	B-X
lower	B-X
regioselectivity	B-X
regarding	B-X
the	B-X
prenylation	B-X
position	B-X
than	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
and	B-X
(	B-X
13	B-X
)	B-X
C-NMR	B-X
analyses	B-X
,	B-X
including	B-X
long-range	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
(	B-X
13	B-X
)	B-X
C	B-X
connectivities	B-X
in	B-X
Heteronuclear	B-X
Multiple-Bond	B-X
Correlation	B-X
(	B-X
HMBC	B-X
)	B-X
and	B-X
Nuclear	B-X
Overhauser	B-X
Effect	B-X
Spectroscopy	B-X
(	B-X
NOESY	B-X
)	B-X
,	B-X
proved	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
as	B-X
C7-	B-X
and	B-X
N1-prenylated	B-X
derivatives	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
1:1.2	B-X
using	B-X
cyclo-L-Trp-L-Trp	B-X
as	B-X
substrate	B-X
.	B-X

Cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
was	O
much	O
better	O
accepted	O
than	O
other	O
cyclic	O
dipeptides	O
tested	O
in	O
this	O
study	O
.	O
<EOS>	B-X
A	B-X
putative	B-X
prenyltransferase	B-X
gene	B-X
cTrpPT	B-X
was	B-X
amplified	B-X
from	B-X
Aspergillus	B-X
oryzae	B-X
DSM1147	B-X
,	B-X
cloned	B-X
into	B-X
pQE70	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
was	B-X
monitored	B-X
with	B-X
HPLC	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
Cyclo-L-Trp-L-Trp	B-X
was	B-X
much	B-X
better	B-X
accepted	B-X
than	B-X
other	B-X
cyclic	B-X
dipeptides	B-X
tested	B-X
in	B-X
this	B-X
study	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
and	B-X
(	B-X
13	B-X
)	B-X
C-NMR	B-X
analyses	B-X
,	B-X
including	B-X
long-range	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
(	B-X
13	B-X
)	B-X
C	B-X
connectivities	B-X
in	B-X
Heteronuclear	B-X
Multiple-Bond	B-X
Correlation	B-X
(	B-X
HMBC	B-X
)	B-X
and	B-X
Nuclear	B-X
Overhauser	B-X
Effect	B-X
Spectroscopy	B-X
(	B-X
NOESY	B-X
)	B-X
,	B-X
proved	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
as	B-X
C7-	B-X
and	B-X
N1-prenylated	B-X
derivatives	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
1:1.2	B-X
using	B-X
cyclo-L-Trp-L-Trp	B-X
as	B-X
substrate	B-X
.	B-X
The	B-X
K	B-X
(	B-X
M	B-X
)	B-X
values	B-X
were	B-X
determined	B-X
at	B-X
about	B-X
2.5	B-X
mM	B-X
for	B-X
dimethylallyl	B-X
diphosphate	B-X
and	B-X
0.3	B-X
mM	B-X
for	B-X
cyclo-L-Trp-L-Trp	B-X
with	B-X
a	B-X
turnover	B-X
number	B-X
of	B-X
0.33	B-X
s	B-X
(	B-X
-1	B-X
)	B-X
.	B-X

In	O
comparison	O
to	O
other	O
indole	O
prenyltransferases	O
with	O
one	O
dominant	O
enzyme	O
product	O
,	O
at	O
least	O
two	O
product	O
peaks	O
were	O
detected	O
in	O
the	O
reaction	O
mixtures	O
of	O
CTrpPT	B-Protein
.	O
<EOS>	B-X
A	B-X
putative	B-X
prenyltransferase	B-X
gene	B-X
cTrpPT	B-X
was	B-X
amplified	B-X
from	B-X
Aspergillus	B-X
oryzae	B-X
DSM1147	B-X
,	B-X
cloned	B-X
into	B-X
pQE70	B-X
and	B-X
overexpressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
.	B-X
The	B-X
overproduced	B-X
His	B-X
(	B-X
6	B-X
)	B-X
-CTrpPT	B-X
was	B-X
purified	B-X
to	B-X
near	B-X
homogeneity	B-X
and	B-X
incubated	B-X
with	B-X
L-tryptophan	B-X
or	B-X
tryptophan-containing	B-X
cyclic	B-X
dipeptides	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
dimethylallyl	B-X
diphosphate	B-X
.	B-X
The	B-X
formation	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
was	B-X
monitored	B-X
with	B-X
HPLC	B-X
.	B-X
It	B-X
was	B-X
shown	B-X
that	B-X
CTrpPT	B-X
differed	B-X
clearly	B-X
from	B-X
other	B-X
known	B-X
indole	B-X
prenyltransferases	B-X
in	B-X
several	B-X
aspects	B-X
.	B-X
This	B-X
enzyme	B-X
showed	B-X
higher	B-X
substrate	B-X
specificity	B-X
towards	B-X
aromatic	B-X
substrates	B-X
,	B-X
but	B-X
lower	B-X
regioselectivity	B-X
regarding	B-X
the	B-X
prenylation	B-X
position	B-X
than	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
.	B-X
In	B-X
comparison	B-X
to	B-X
other	B-X
indole	B-X
prenyltransferases	B-X
with	B-X
one	B-X
dominant	B-X
enzyme	B-X
product	B-X
,	B-X
at	B-X
least	B-X
two	B-X
product	B-X
peaks	B-X
were	B-X
detected	B-X
in	B-X
the	B-X
reaction	B-X
mixtures	B-X
of	B-X
CTrpPT	B-X
.	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
and	B-X
(	B-X
13	B-X
)	B-X
C-NMR	B-X
analyses	B-X
,	B-X
including	B-X
long-range	B-X
(	B-X
1	B-X
)	B-X
H-	B-X
(	B-X
13	B-X
)	B-X
C	B-X
connectivities	B-X
in	B-X
Heteronuclear	B-X
Multiple-Bond	B-X
Correlation	B-X
(	B-X
HMBC	B-X
)	B-X
and	B-X
Nuclear	B-X
Overhauser	B-X
Effect	B-X
Spectroscopy	B-X
(	B-X
NOESY	B-X
)	B-X
,	B-X
proved	B-X
the	B-X
structures	B-X
of	B-X
the	B-X
enzyme	B-X
products	B-X
as	B-X
C7-	B-X
and	B-X
N1-prenylated	B-X
derivatives	B-X
with	B-X
a	B-X
ratio	B-X
of	B-X
1:1.2	B-X
using	B-X
cyclo-L-Trp-L-Trp	B-X
as	B-X
substrate	B-X
.	B-X

(	O
1	O
)	O
H	O
-	O
and	O
(	O
13	O
)	O
C	O
-	O
NMR	O
analyses	O
,	O
including	O
long	O
-	O
range	O
(	O
1	O
)	O
H	O
-	O
(	O
13	O
)	O
C	O
connectivities	O
in	O
Heteronuclear	O
Multiple	O
-	O
Bond	O
Correlation	O
(	O
HMBC	O
)	O
and	O
Nuclear	O
Overhauser	O
Effect	O
Spectroscopy	O
(	O
NOESY	O
)	O
,	O
proved	O
the	O
structures	O
of	O
the	O
enzyme	O
products	O
as	O
C7	O
-	O
and	O
N1	O
-	O
prenylated	O
derivatives	O
with	O
a	O
ratio	O
of	O
1	O
:	O
1	O
.	O
2	O
using	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
as	O
substrate	O
.	O

The	O
K	O
(	O
M	O
)	O
values	O
were	O
determined	O
at	O
about	O
2	O
.	O
5	O
mM	O
for	O
dimethylallyl	O
diphosphate	O
and	O
0	O
.	O
3	O
mM	O
for	O
cyclo	O
-	O
L	O
-	O
Trp	O
-	O
L	O
-	O
Trp	O
with	O
a	O
turnover	O
number	O
of	O
0	O
.	O
33	O
s	O
(	O
-	O
1	O
)	O
.	O

The	O
lipoatrophic	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
deficient	O
mouse	O
model	O
reveals	O
autophagy	O
in	O
mature	O
adipocytes	O
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
pathological	B-X
situation	B-X
with	B-X
autophagy	B-X
as	B-X
an	B-X
adaptative	B-X
response	B-X
to	B-X
adipocyte	B-X
failure	B-X
.	B-X

Adipose	O
tissue	O
lipoatrophy	O
caused	O
by	O
caveolin	O
gene	O
deletion	O
in	O
mice	O
is	O
not	O
linked	O
to	O
defective	O
adipocyte	O
differentiation	O
.	O

We	O
show	O
that	O
adipose	O
tissue	O
development	O
cannot	O
be	O
rescued	O
by	O
endothelial	O
specific	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
re	O
-	O
expression	O
,	O
indicating	O
primordial	O
role	O
of	O
caveolin	O
in	O
mature	O
adipocytes	O
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X

Partial	O
or	O
total	O
caveolin	O
deficiency	O
in	O
adipocytes	O
induced	O
broad	O
protein	O
expression	O
defects	O
,	O
including	O
but	O
not	O
limited	O
to	O
previously	O
described	O
downregulation	O
of	O
insulin	B-Protein
receptor	I-Protein
.	O
<EOS>	B-X
The	B-X
measures	B-X
are	B-X
broadly	B-X
consistent	B-X
in	B-X
indicating	B-X
that	B-X
harmonics	B-X
with	B-X
numbers	B-X
up	B-X
to	B-X
about	B-X
five	B-X
are	B-X
well	B-X
resolved	B-X
,	B-X
but	B-X
that	B-X
resolution	B-X
decreases	B-X
for	B-X
higher	B-X
harmonics	B-X
.	B-X
Categorical	B-X
perception	B-X
is	B-X
used	B-X
extensively	B-X
in	B-X
music	B-X
performance	B-X
for	B-X
the	B-X
purpose	B-X
of	B-X
musical	B-X
expression	B-X
because	B-X
without	B-X
violating	B-X
the	B-X
score	B-X
,	B-X
the	B-X
singer	B-X
may	B-X
sharpen	B-X
or	B-X
flatten	B-X
and	B-X
lengthen	B-X
or	B-X
shorten	B-X
the	B-X
tones	B-X
,	B-X
thereby	B-X
creating	B-X
musical	B-X
expression	B-X
.	B-X
This	B-X
review	B-X
attempts	B-X
to	B-X
collect	B-X
,	B-X
organize	B-X
,	B-X
summarize	B-X
,	B-X
and	B-X
analyze	B-X
the	B-X
most	B-X
up	B-X
to	B-X
date	B-X
research	B-X
linked	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
AMX	B-X
by	B-X
different	B-X
advanced	B-X
oxidation	B-X
process	B-X
systems	B-X
including	B-X
photocatalytic	B-X
,	B-X
ultrasonic	B-X
,	B-X
electro-oxidation	B-X
,	B-X
and	B-X
advanced	B-X
oxidation	B-X
process-based	B-X
on	B-X
partials	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
characterized	B-X
expression	B-X
dynamics	B-X
throughout	B-X
a	B-X
dehydration-rehydration	B-X
time-course	B-X
in	B-X
six	B-X
diverse	B-X
genotypes	B-X
of	B-X
the	B-X
dioecious	B-X
liverwort	B-X
Marchantia	B-X
inflexa	B-X
.	B-X
We	B-X
identified	B-X
classical	B-X
signatures	B-X
of	B-X
stress	B-X
response	B-X
in	B-X
M.	B-X
inflexa	B-X
,	B-X
including	B-X
major	B-X
changes	B-X
in	B-X
transcripts	B-X
related	B-X
to	B-X
metabolism	B-X
,	B-X
expression	B-X
of	B-X
LEA	B-X
and	B-X
ELIP	B-X
genes	B-X
,	B-X
and	B-X
evidence	B-X
of	B-X
cell	B-X
wall	B-X
remodeling	B-X
.	B-X
However	B-X
,	B-X
we	B-X
detected	B-X
very	B-X
little	B-X
temporal	B-X
synchronization	B-X
of	B-X
these	B-X
responses	B-X
across	B-X
different	B-X
genotypes	B-X
of	B-X
M.	B-X
inflexa	B-X
,	B-X
which	B-X
may	B-X
be	B-X
related	B-X
to	B-X
genotypic	B-X
variation	B-X
among	B-X
samples	B-X
,	B-X
constitutive	B-X
expression	B-X
of	B-X
dehydration-associated	B-X
transcripts	B-X
,	B-X
the	B-X
sequestration	B-X
of	B-X
mRNAs	B-X
in	B-X
ribonucleoprotein	B-X
partials	B-X
prior	B-X
to	B-X
drying	B-X
,	B-X
or	B-X
the	B-X
lower	B-X
tolerance	B-X
of	B-X
M.	B-X
inflexa	B-X
relative	B-X
to	B-X
most	B-X
bryophytes	B-X
studied	B-X
to	B-X
date	B-X
.	B-X
Our	B-X
characterization	B-X
of	B-X
intraspecific	B-X
variation	B-X
in	B-X
expression	B-X
dynamics	B-X
suggests	B-X
that	B-X
differences	B-X
in	B-X
the	B-X
timing	B-X
of	B-X
transcriptional	B-X
adjustments	B-X
contribute	B-X
to	B-X
variation	B-X
among	B-X
genotypes	B-X
,	B-X
and	B-X
that	B-X
developmental	B-X
differences	B-X
impact	B-X
the	B-X
relative	B-X
tolerance	B-X
of	B-X
meristematic	B-X
and	B-X
differentiated	B-X
tissues	B-X
.	B-X

Global	O
alterations	O
in	O
protein	O
turnover	O
,	O
and	O
accelerated	O
degradation	O
of	O
long	O
-	O
lived	O
proteins	O
were	O
found	O
in	O
caveolin	O
-	O
deficient	O
adipocytes	O
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X

Lipidation	O
of	O
endogenous	O
LC3	O
autophagy	O
marker	O
and	O
distribution	O
of	O
GFP	B-Protein
-	O
LC3	O
into	O
aggregates	O
demonstrated	O
activated	O
autophagy	O
in	O
the	O
absence	O
of	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
in	O
adipocytes	O
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
pathological	B-X
situation	B-X
with	B-X
autophagy	B-X
as	B-X
an	B-X
adaptative	B-X
response	B-X
to	B-X
adipocyte	B-X
failure	B-X
.	B-X

Furthermore	O
,	O
electron	O
microscopy	O
revealed	O
autophagic	O
vacuoles	O
in	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
deficient	O
but	O
not	O
control	O
adipocytes	O
.	O

Surprisingly	O
,	O
significant	O
levels	O
of	O
lipidated	O
LC3	B-Protein
-	I-Protein
II	I-Protein
were	O
found	O
around	O
lipid	O
droplets	O
of	O
normal	O
adipocytes	O
,	O
maintained	O
in	O
nutrient	O
-	O
rich	O
conditions	O
or	O
isolated	O
from	O
fed	O
mice	O
,	O
which	O
do	O
not	O
display	O
autophagy	O
.	O
<EOS>	B-X
Host	B-X
defense	B-X
peptides	B-X
(	B-X
HDPs	B-X
)	B-X
are	B-X
key	B-X
regulators	B-X
of	B-X
gut	B-X
homeostasis	B-X
and	B-X
generally	B-X
malfunctioning	B-X
in	B-X
above-mentioned	B-X
conditions	B-X
.	B-X
We	B-X
hypothesized	B-X
that	B-X
high-intensity	B-X
interval	B-X
training	B-X
(	B-X
HIIT	B-X
)	B-X
would	B-X
counteract	B-X
high-fat	B-X
diet	B-X
(	B-X
HFD	B-X
)	B-X
-induced	B-X
changes	B-X
in	B-X
the	B-X
microbiota	B-X
without	B-X
altering	B-X
obesity	B-X
in	B-X
mice	B-X
.	B-X
Compared	B-X
with	B-X
chow-fed	B-X
mice	B-X
,	B-X
an	B-X
obesity-causing	B-X
HFD	B-X
decreased	B-X
the	B-X
Bacteroidetes-to-Firmicutes	B-X
ratio	B-X
and	B-X
decreased	B-X
the	B-X
genetic	B-X
capacity	B-X
in	B-X
the	B-X
fecal	B-X
microbiota	B-X
for	B-X
metabolic	B-X
pathways	B-X
such	B-X
as	B-X
the	B-X
tricarboxylic	B-X
acid	B-X
(	B-X
TCA	B-X
)	B-X
cycle	B-X
.	B-X
After	B-X
HFD-induced	B-X
obesity	B-X
was	B-X
established	B-X
,	B-X
a	B-X
subset	B-X
of	B-X
mice	B-X
were	B-X
HIIT	B-X
for	B-X
6	B-X
wk	B-X
,	B-X
which	B-X
increased	B-X
host	B-X
aerobic	B-X
capacity	B-X
but	B-X
did	B-X
not	B-X
alter	B-X
body	B-X
or	B-X
adipose	B-X
tissue	B-X
mass	B-X
.	B-X
HIIT	B-X
increased	B-X
the	B-X
alpha	B-X
diversity	B-X
and	B-X
Bacteroidetes/Firmicutes	B-X
ratio	B-X
of	B-X
the	B-X
distal	B-X
gut	B-X
and	B-X
fecal	B-X
microbiota	B-X
during	B-X
diet-induced	B-X
obesity	B-X
.	B-X
Strikingly	B-X
,	B-X
the	B-X
same	B-X
microbial	B-X
metabolism	B-X
indexes	B-X
that	B-X
were	B-X
increased	B-X
by	B-X
exercise	B-X
were	B-X
all	B-X
decreased	B-X
in	B-X
HFD-fed	B-X
vs.	B-X
chow	B-X
diet-fed	B-X
mice	B-X
.	B-X

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
caveolin	O
deficiency	O
induce	O
autophagy	O
in	O
adipocytes	O
,	O
a	O
feature	O
that	O
is	O
not	O
a	O
physiological	O
response	O
to	O
fasting	O
in	O
normal	O
fat	O
cells	O
.	O

This	O
likely	O
resulted	O
from	O
defective	O
insulin	B-Protein
and	O
lipolytic	O
responses	O
that	O
converge	O
in	O
chronic	O
nutrient	O
shortage	O
in	O
adipocytes	O
lacking	O
caveolin	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X

This	O
is	O
the	O
first	O
report	O
of	O
a	O
pathological	O
situation	O
with	O
autophagy	O
as	O
an	O
adaptative	O
response	O
to	O
adipocyte	O
failure	O
.	O
<EOS>	B-X
Adipose	B-X
tissue	B-X
lipoatrophy	B-X
caused	B-X
by	B-X
caveolin	B-X
gene	B-X
deletion	B-X
in	B-X
mice	B-X
is	B-X
not	B-X
linked	B-X
to	B-X
defective	B-X
adipocyte	B-X
differentiation	B-X
.	B-X
We	B-X
show	B-X
that	B-X
adipose	B-X
tissue	B-X
development	B-X
can	B-X
not	B-X
be	B-X
rescued	B-X
by	B-X
endothelial	B-X
specific	B-X
caveolin-1	B-X
re-expression	B-X
,	B-X
indicating	B-X
primordial	B-X
role	B-X
of	B-X
caveolin	B-X
in	B-X
mature	B-X
adipocytes	B-X
.	B-X
Partial	B-X
or	B-X
total	B-X
caveolin	B-X
deficiency	B-X
in	B-X
adipocytes	B-X
induced	B-X
broad	B-X
protein	B-X
expression	B-X
defects	B-X
,	B-X
including	B-X
but	B-X
not	B-X
limited	B-X
to	B-X
previously	B-X
described	B-X
downregulation	B-X
of	B-X
insulin	B-X
receptor	B-X
.	B-X
Global	B-X
alterations	B-X
in	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
accelerated	B-X
degradation	B-X
of	B-X
long-lived	B-X
proteins	B-X
were	B-X
found	B-X
in	B-X
caveolin-deficient	B-X
adipocytes	B-X
.	B-X
Lipidation	B-X
of	B-X
endogenous	B-X
LC3	B-X
autophagy	B-X
marker	B-X
and	B-X
distribution	B-X
of	B-X
GFP-LC3	B-X
into	B-X
aggregates	B-X
demonstrated	B-X
activated	B-X
autophagy	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
caveolin-1	B-X
in	B-X
adipocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
electron	B-X
microscopy	B-X
revealed	B-X
autophagic	B-X
vacuoles	B-X
in	B-X
caveolin-1	B-X
deficient	B-X
but	B-X
not	B-X
control	B-X
adipocytes	B-X
.	B-X
Surprisingly	B-X
,	B-X
significant	B-X
levels	B-X
of	B-X
lipidated	B-X
LC3-II	B-X
were	B-X
found	B-X
around	B-X
lipid	B-X
droplets	B-X
of	B-X
normal	B-X
adipocytes	B-X
,	B-X
maintained	B-X
in	B-X
nutrient-rich	B-X
conditions	B-X
or	B-X
isolated	B-X
from	B-X
fed	B-X
mice	B-X
,	B-X
which	B-X
do	B-X
not	B-X
display	B-X
autophagy	B-X
.	B-X
Altogether	B-X
,	B-X
these	B-X
data	B-X
indicate	B-X
that	B-X
caveolin	B-X
deficiency	B-X
induce	B-X
autophagy	B-X
in	B-X
adipocytes	B-X
,	B-X
a	B-X
feature	B-X
that	B-X
is	B-X
not	B-X
a	B-X
physiological	B-X
response	B-X
to	B-X
fasting	B-X
in	B-X
normal	B-X
fat	B-X
cells	B-X
.	B-X
This	B-X
likely	B-X
resulted	B-X
from	B-X
defective	B-X
insulin	B-X
and	B-X
lipolytic	B-X
responses	B-X
that	B-X
converge	B-X
in	B-X
chronic	B-X
nutrient	B-X
shortage	B-X
in	B-X
adipocytes	B-X
lacking	B-X
caveolin-1	B-X
.	B-X
This	B-X
is	B-X
the	B-X
first	B-X
report	B-X
of	B-X
a	B-X
pathological	B-X
situation	B-X
with	B-X
autophagy	B-X
as	B-X
an	B-X
adaptative	B-X
response	B-X
to	B-X
adipocyte	B-X
failure	B-X
.	B-X

Regulation	O
of	O
the	O
p53	B-Protein
pathway	O
by	O
ubiquitin	B-Protein
and	O
related	O
proteins	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
,	B-X
such	B-X
as	B-X
phosphorylation	B-X
,	B-X
ubiquitination	B-X
and	B-X
acetylation	B-X
,	B-X
play	B-X
crucial	B-X
roles	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
autophagy	B-X
.	B-X
Recent	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
acetylation	B-X
occurs	B-X
on	B-X
the	B-X
key	B-X
proteins	B-X
participating	B-X
in	B-X
autophagic	B-X
cargo	B-X
assembly	B-X
and	B-X
autophagosome-lysosome	B-X
fusion	B-X
,	B-X
such	B-X
as	B-X
SQSTM1/p62	B-X
and	B-X
STX17	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
current	B-X
knowledge	B-X
on	B-X
acetylation	B-X
of	B-X
autophagy	B-X
proteins	B-X
and	B-X
their	B-X
regulations	B-X
and	B-X
functions	B-X
in	B-X
the	B-X
autophagy	B-X
pathway	B-X
with	B-X
focus	B-X
on	B-X
recent	B-X
findings	B-X
.	B-X
To	B-X
date	B-X
,	B-X
the	B-X
PINK1-PRKN-dependent	B-X
and	B-X
receptors	B-X
(	B-X
including	B-X
proteins	B-X
and	B-X
lipids	B-X
)	B-X
-dependent	B-X
pathways	B-X
have	B-X
been	B-X
characterized	B-X
to	B-X
determine	B-X
the	B-X
mitophagy	B-X
in	B-X
mammalian	B-X
cells	B-X
.	B-X

The	O
p53	B-Protein
tumour	O
suppressor	O
protein	O
is	O
subject	O
to	O
many	O
levels	O
of	O
control	O
,	O
including	O
modification	O
with	O
ubiquitin	B-Protein
and	O
related	O
proteins	O
such	O
as	O
SUMO	O
and	O
NEDD8	B-Protein
.	O
<EOS>	B-X
The	B-X
p53	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
subject	B-X
to	B-X
many	B-X
levels	B-X
of	B-X
control	B-X
,	B-X
including	B-X
modification	B-X
with	B-X
ubiquitin	B-X
and	B-X
related	B-X
proteins	B-X
such	B-X
as	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
.	B-X
These	B-X
modifications	B-X
regulate	B-X
p53	B-X
at	B-X
a	B-X
number	B-X
of	B-X
levels	B-X
,	B-X
including	B-X
control	B-X
of	B-X
protein	B-X
turnover	B-X
,	B-X
alterations	B-X
in	B-X
sub-cellular	B-X
localization	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Numerous	B-X
E3	B-X
ligases	B-X
that	B-X
can	B-X
mediate	B-X
these	B-X
modifications	B-X
of	B-X
p53	B-X
have	B-X
been	B-X
described	B-X
,	B-X
some	B-X
of	B-X
which	B-X
promote	B-X
conjugation	B-X
with	B-X
more	B-X
than	B-X
one	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Understanding	B-X
the	B-X
complexity	B-X
of	B-X
this	B-X
mechanism	B-X
of	B-X
p53	B-X
regulation	B-X
will	B-X
help	B-X
in	B-X
the	B-X
development	B-X
of	B-X
therapeutic	B-X
drugs	B-X
that	B-X
function	B-X
to	B-X
modulate	B-X
these	B-X
events	B-X
.	B-X

These	O
modifications	O
regulate	O
p53	B-Protein
at	O
a	O
number	O
of	O
levels	O
,	O
including	O
control	O
of	O
protein	O
turnover	O
,	O
alterations	O
in	O
sub	O
-	O
cellular	O
localization	O
and	O
changes	O
in	O
the	O
ability	O
to	O
regulate	O
gene	O
expression	O
.	O

Numerous	O
E3	O
ligases	O
that	O
can	O
mediate	O
these	O
modifications	O
of	O
p53	B-Protein
have	O
been	O
described	O
,	O
some	O
of	O
which	O
promote	O
conjugation	O
with	O
more	O
than	O
one	O
ubiquitin	B-Protein
-	O
like	O
protein	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
subject	B-X
to	B-X
many	B-X
levels	B-X
of	B-X
control	B-X
,	B-X
including	B-X
modification	B-X
with	B-X
ubiquitin	B-X
and	B-X
related	B-X
proteins	B-X
such	B-X
as	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
.	B-X
These	B-X
modifications	B-X
regulate	B-X
p53	B-X
at	B-X
a	B-X
number	B-X
of	B-X
levels	B-X
,	B-X
including	B-X
control	B-X
of	B-X
protein	B-X
turnover	B-X
,	B-X
alterations	B-X
in	B-X
sub-cellular	B-X
localization	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Numerous	B-X
E3	B-X
ligases	B-X
that	B-X
can	B-X
mediate	B-X
these	B-X
modifications	B-X
of	B-X
p53	B-X
have	B-X
been	B-X
described	B-X
,	B-X
some	B-X
of	B-X
which	B-X
promote	B-X
conjugation	B-X
with	B-X
more	B-X
than	B-X
one	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Understanding	B-X
the	B-X
complexity	B-X
of	B-X
this	B-X
mechanism	B-X
of	B-X
p53	B-X
regulation	B-X
will	B-X
help	B-X
in	B-X
the	B-X
development	B-X
of	B-X
therapeutic	B-X
drugs	B-X
that	B-X
function	B-X
to	B-X
modulate	B-X
these	B-X
events	B-X
.	B-X

Understanding	O
the	O
complexity	O
of	O
this	O
mechanism	O
of	O
p53	B-Protein
regulation	O
will	O
help	O
in	O
the	O
development	O
of	O
therapeutic	O
drugs	O
that	O
function	O
to	O
modulate	O
these	O
events	O
.	O
<EOS>	B-X
The	B-X
p53	B-X
tumour	B-X
suppressor	B-X
protein	B-X
is	B-X
subject	B-X
to	B-X
many	B-X
levels	B-X
of	B-X
control	B-X
,	B-X
including	B-X
modification	B-X
with	B-X
ubiquitin	B-X
and	B-X
related	B-X
proteins	B-X
such	B-X
as	B-X
SUMO	B-X
and	B-X
NEDD8	B-X
.	B-X
These	B-X
modifications	B-X
regulate	B-X
p53	B-X
at	B-X
a	B-X
number	B-X
of	B-X
levels	B-X
,	B-X
including	B-X
control	B-X
of	B-X
protein	B-X
turnover	B-X
,	B-X
alterations	B-X
in	B-X
sub-cellular	B-X
localization	B-X
and	B-X
changes	B-X
in	B-X
the	B-X
ability	B-X
to	B-X
regulate	B-X
gene	B-X
expression	B-X
.	B-X
Numerous	B-X
E3	B-X
ligases	B-X
that	B-X
can	B-X
mediate	B-X
these	B-X
modifications	B-X
of	B-X
p53	B-X
have	B-X
been	B-X
described	B-X
,	B-X
some	B-X
of	B-X
which	B-X
promote	B-X
conjugation	B-X
with	B-X
more	B-X
than	B-X
one	B-X
ubiquitin-like	B-X
protein	B-X
.	B-X
Understanding	B-X
the	B-X
complexity	B-X
of	B-X
this	B-X
mechanism	B-X
of	B-X
p53	B-X
regulation	B-X
will	B-X
help	B-X
in	B-X
the	B-X
development	B-X
of	B-X
therapeutic	B-X
drugs	B-X
that	B-X
function	B-X
to	B-X
modulate	B-X
these	B-X
events	B-X
.	B-X

Interplay	O
of	O
palmitoylation	O
and	O
phosphorylation	O
in	O
the	O
trafficking	O
and	O
localization	O
of	O
phosphodiesterase	B-Protein
10A	I-Protein
:	O
implications	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Phosphodiesterase	B-Protein
10A	I-Protein
(	O
PDE10A	B-Protein
)	O
is	O
a	O
striatum	O
-	O
enriched	O
,	O
dual	O
-	O
specific	O
cyclic	O
nucleotide	O
phosphodiesterase	O
that	O
has	O
gained	O
considerable	O
attention	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
psychiatric	O
disorders	O
such	O
as	O
schizophrenia	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

As	O
such	O
,	O
a	O
PDE10A	B-Protein
-	O
selective	O
inhibitor	O
compound	O
,	O
MP	O
-	O
10	O
,	O
has	O
recently	O
entered	O
clinical	O
testing	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Since	O
little	O
is	O
known	O
about	O
the	O
cellular	O
regulation	O
of	O
PDE10A	B-Protein
,	O
we	O
sought	O
to	O
elucidate	O
the	O
mechanisms	O
that	O
govern	O
its	O
subcellular	O
localization	O
in	O
striatal	O
medium	O
spiny	O
neurons	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Previous	O
reports	O
suggest	O
that	O
PDE10A	B-Protein
is	O
primarily	O
membrane	O
bound	O
and	O
is	O
transported	O
throughout	O
medium	O
spiny	O
neuron	O
axons	O
and	O
dendrites	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Moreover	O
,	O
it	O
has	O
been	O
shown	O
in	O
PC12	O
cells	O
that	O
the	O
localization	O
of	O
the	O
major	O
splice	O
form	O
,	O
PDE10A2	B-Protein
,	O
may	O
be	O
regulated	O
by	O
protein	O
kinase	O
A	O
phosphorylation	O
at	O
threonine	O
16	O
(	O
Thr	O
-	O
16	O
)	O
.	O
<EOS>	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Using	O
an	O
antibody	O
that	O
specifically	O
recognizes	O
phosphorylated	O
Thr	O
-	O
16	O
(	O
pThr	O
-	O
16	O
)	O
of	O
PDE10A2	B-Protein
,	O
we	O
provide	O
evidence	O
that	O
phosphorylation	O
at	O
Thr	O
-	O
16	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
PDE10A	B-Protein
subcellular	O
localization	O
in	O
vivo	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Furthermore	O
,	O
we	O
demonstrate	O
in	O
primary	O
mouse	O
striatal	O
neuron	O
cultures	O
that	O
PDE10A	B-Protein
membrane	O
association	O
and	O
transport	O
throughout	O
dendritic	O
processes	O
requires	O
palmitoylation	O
of	O
cysteine	O
11	O
(	O
Cys	O
-	O
11	O
)	O
of	O
PDE10A2	B-Protein
,	O
likely	O
by	O
the	O
palmitoyl	O
acyltransferases	O
DHHC	B-Protein
-	I-Protein
7	I-Protein
and	O
-	B-Protein
19	I-Protein
.	O

Finally	O
,	O
we	O
show	O
that	O
Thr	O
-	O
16	O
phosphorylation	O
regulates	O
PDE10A	B-Protein
trafficking	O
and	O
localization	O
by	O
preventing	O
palmitoylation	O
of	O
Cys	O
-	O
11	O
rather	O
than	O
by	O
interfering	O
with	O
palmitate	O
-	O
lipid	O
interactions	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

These	O
data	O
support	O
a	O
model	O
whereby	O
PDE10A	B-Protein
trafficking	O
and	O
localization	O
can	O
be	O
regulated	O
in	O
response	O
to	O
local	O
fluctuations	O
in	O
cAMP	O
levels	O
.	O

Given	O
this	O
,	O
we	O
propose	O
that	O
excessive	O
striatal	O
dopamine	O
release	O
,	O
as	O
occurs	O
in	O
schizophrenia	O
,	O
might	O
exert	O
differential	O
effects	O
on	O
the	O
regulation	O
of	O
PDE10A	B-Protein
localization	O
in	O
the	O
two	O
striatal	O
output	O
pathways	O
.	O
<EOS>	B-X
Phosphodiesterase	B-X
10A	B-X
(	B-X
PDE10A	B-X
)	B-X
is	B-X
a	B-X
striatum-enriched	B-X
,	B-X
dual-specific	B-X
cyclic	B-X
nucleotide	B-X
phosphodiesterase	B-X
that	B-X
has	B-X
gained	B-X
considerable	B-X
attention	B-X
as	B-X
a	B-X
potential	B-X
therapeutic	B-X
target	B-X
for	B-X
psychiatric	B-X
disorders	B-X
such	B-X
as	B-X
schizophrenia	B-X
.	B-X
As	B-X
such	B-X
,	B-X
a	B-X
PDE10A-selective	B-X
inhibitor	B-X
compound	B-X
,	B-X
MP-10	B-X
,	B-X
has	B-X
recently	B-X
entered	B-X
clinical	B-X
testing	B-X
.	B-X
Since	B-X
little	B-X
is	B-X
known	B-X
about	B-X
the	B-X
cellular	B-X
regulation	B-X
of	B-X
PDE10A	B-X
,	B-X
we	B-X
sought	B-X
to	B-X
elucidate	B-X
the	B-X
mechanisms	B-X
that	B-X
govern	B-X
its	B-X
subcellular	B-X
localization	B-X
in	B-X
striatal	B-X
medium	B-X
spiny	B-X
neurons	B-X
.	B-X
Previous	B-X
reports	B-X
suggest	B-X
that	B-X
PDE10A	B-X
is	B-X
primarily	B-X
membrane	B-X
bound	B-X
and	B-X
is	B-X
transported	B-X
throughout	B-X
medium	B-X
spiny	B-X
neuron	B-X
axons	B-X
and	B-X
dendrites	B-X
.	B-X
Moreover	B-X
,	B-X
it	B-X
has	B-X
been	B-X
shown	B-X
in	B-X
PC12	B-X
cells	B-X
that	B-X
the	B-X
localization	B-X
of	B-X
the	B-X
major	B-X
splice	B-X
form	B-X
,	B-X
PDE10A2	B-X
,	B-X
may	B-X
be	B-X
regulated	B-X
by	B-X
protein	B-X
kinase	B-X
A	B-X
phosphorylation	B-X
at	B-X
threonine	B-X
16	B-X
(	B-X
Thr-16	B-X
)	B-X
.	B-X
Using	B-X
an	B-X
antibody	B-X
that	B-X
specifically	B-X
recognizes	B-X
phosphorylated	B-X
Thr-16	B-X
(	B-X
pThr-16	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
we	B-X
provide	B-X
evidence	B-X
that	B-X
phosphorylation	B-X
at	B-X
Thr-16	B-X
is	B-X
critical	B-X
for	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
subcellular	B-X
localization	B-X
in	B-X
vivo	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
demonstrate	B-X
in	B-X
primary	B-X
mouse	B-X
striatal	B-X
neuron	B-X
cultures	B-X
that	B-X
PDE10A	B-X
membrane	B-X
association	B-X
and	B-X
transport	B-X
throughout	B-X
dendritic	B-X
processes	B-X
requires	B-X
palmitoylation	B-X
of	B-X
cysteine	B-X
11	B-X
(	B-X
Cys-11	B-X
)	B-X
of	B-X
PDE10A2	B-X
,	B-X
likely	B-X
by	B-X
the	B-X
palmitoyl	B-X
acyltransferases	B-X
DHHC-7	B-X
and	B-X
-19	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
show	B-X
that	B-X
Thr-16	B-X
phosphorylation	B-X
regulates	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
by	B-X
preventing	B-X
palmitoylation	B-X
of	B-X
Cys-11	B-X
rather	B-X
than	B-X
by	B-X
interfering	B-X
with	B-X
palmitate-lipid	B-X
interactions	B-X
.	B-X
These	B-X
data	B-X
support	B-X
a	B-X
model	B-X
whereby	B-X
PDE10A	B-X
trafficking	B-X
and	B-X
localization	B-X
can	B-X
be	B-X
regulated	B-X
in	B-X
response	B-X
to	B-X
local	B-X
fluctuations	B-X
in	B-X
cAMP	B-X
levels	B-X
.	B-X
Given	B-X
this	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
excessive	B-X
striatal	B-X
dopamine	B-X
release	B-X
,	B-X
as	B-X
occurs	B-X
in	B-X
schizophrenia	B-X
,	B-X
might	B-X
exert	B-X
differential	B-X
effects	B-X
on	B-X
the	B-X
regulation	B-X
of	B-X
PDE10A	B-X
localization	B-X
in	B-X
the	B-X
two	B-X
striatal	B-X
output	B-X
pathways	B-X
.	B-X

Characterization	O
of	O
an	O
acyltransferase	O
acting	O
on	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
protein	O
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

We	O
have	O
identified	O
a	O
protein	O
-	O
acyltransferase	O
activity	O
in	O
membranes	O
from	O
mouse	O
fibroblasts	O
which	O
transfers	O
palmitate	O
from	O
palmitoyl	O
-	O
CoA	O
to	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
protein-acyltransferase	B-X
activity	B-X
in	B-X
membranes	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
which	B-X
transfers	B-X
palmitate	B-X
from	B-X
palmitoyl-CoA	B-X
to	B-X
p21N-ras	B-X
.	B-X
Specificity	B-X
of	B-X
acylation	B-X
has	B-X
been	B-X
confirmed	B-X
by	B-X
linkage	B-X
analysis	B-X
using	B-X
hydroxylamine	B-X
and	B-X
by	B-X
peptide	B-X
mapping	B-X
of	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
acylated	B-X
p21N-ras	B-X
.	B-X
The	B-X
acylation	B-X
was	B-X
temperature-	B-X
and	B-X
time-dependent	B-X
,	B-X
and	B-X
prevented	B-X
by	B-X
prior	B-X
boiling	B-X
of	B-X
membranes	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
enzymatic	B-X
process	B-X
.	B-X
The	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
membranes	B-X
,	B-X
but	B-X
not	B-X
cytosol	B-X
,	B-X
and	B-X
co-fractionated	B-X
on	B-X
Percoll	B-X
gradients	B-X
with	B-X
Golgi	B-X
markers	B-X
.	B-X
Cytosolic	B-X
p21N-ras	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
,	B-X
which	B-X
is	B-X
C-terminally	B-X
modified	B-X
at	B-X
its	B-X
CAAX	B-X
sequence	B-X
,	B-X
was	B-X
a	B-X
better	B-X
substrate	B-X
for	B-X
the	B-X
enzyme	B-X
that	B-X
recombinant	B-X
bacterially	B-X
expressed	B-X
,	B-X
unmodified	B-X
p21N-ras	B-X
.	B-X
The	B-X
activity	B-X
could	B-X
be	B-X
solubilised	B-X
in	B-X
non-ionic	B-X
detergents	B-X
,	B-X
making	B-X
it	B-X
amenable	B-X
to	B-X
purification	B-X
.	B-X

Specificity	O
of	O
acylation	O
has	O
been	O
confirmed	O
by	O
linkage	O
analysis	O
using	O
hydroxylamine	O
and	O
by	O
peptide	O
mapping	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
acylated	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
protein-acyltransferase	B-X
activity	B-X
in	B-X
membranes	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
which	B-X
transfers	B-X
palmitate	B-X
from	B-X
palmitoyl-CoA	B-X
to	B-X
p21N-ras	B-X
.	B-X
Specificity	B-X
of	B-X
acylation	B-X
has	B-X
been	B-X
confirmed	B-X
by	B-X
linkage	B-X
analysis	B-X
using	B-X
hydroxylamine	B-X
and	B-X
by	B-X
peptide	B-X
mapping	B-X
of	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
acylated	B-X
p21N-ras	B-X
.	B-X
The	B-X
acylation	B-X
was	B-X
temperature-	B-X
and	B-X
time-dependent	B-X
,	B-X
and	B-X
prevented	B-X
by	B-X
prior	B-X
boiling	B-X
of	B-X
membranes	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
enzymatic	B-X
process	B-X
.	B-X
Cytosolic	B-X
p21N-ras	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
,	B-X
which	B-X
is	B-X
C-terminally	B-X
modified	B-X
at	B-X
its	B-X
CAAX	B-X
sequence	B-X
,	B-X
was	B-X
a	B-X
better	B-X
substrate	B-X
for	B-X
the	B-X
enzyme	B-X
that	B-X
recombinant	B-X
bacterially	B-X
expressed	B-X
,	B-X
unmodified	B-X
p21N-ras	B-X
.	B-X

The	O
acylation	O
was	O
temperature	O
-	O
and	O
time	O
-	O
dependent	O
,	O
and	O
prevented	O
by	O
prior	O
boiling	O
of	O
membranes	O
,	O
consistent	O
with	O
an	O
enzymatic	O
process	O
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
protein-acyltransferase	B-X
activity	B-X
in	B-X
membranes	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
which	B-X
transfers	B-X
palmitate	B-X
from	B-X
palmitoyl-CoA	B-X
to	B-X
p21N-ras	B-X
.	B-X
Specificity	B-X
of	B-X
acylation	B-X
has	B-X
been	B-X
confirmed	B-X
by	B-X
linkage	B-X
analysis	B-X
using	B-X
hydroxylamine	B-X
and	B-X
by	B-X
peptide	B-X
mapping	B-X
of	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
acylated	B-X
p21N-ras	B-X
.	B-X
The	B-X
acylation	B-X
was	B-X
temperature-	B-X
and	B-X
time-dependent	B-X
,	B-X
and	B-X
prevented	B-X
by	B-X
prior	B-X
boiling	B-X
of	B-X
membranes	B-X
,	B-X
consistent	B-X
with	B-X
an	B-X
enzymatic	B-X
process	B-X
.	B-X
The	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
membranes	B-X
,	B-X
but	B-X
not	B-X
cytosol	B-X
,	B-X
and	B-X
co-fractionated	B-X
on	B-X
Percoll	B-X
gradients	B-X
with	B-X
Golgi	B-X
markers	B-X
.	B-X

The	O
activity	O
was	O
detected	O
in	O
membranes	O
,	O
but	O
not	O
cytosol	O
,	O
and	O
co	O
-	O
fractionated	O
on	O
Percoll	O
gradients	O
with	O
Golgi	O
markers	O
.	O
<EOS>	B-X
The	B-X
nasal	B-X
tissues	B-X
have	B-X
the	B-X
main	B-X
consecutive	B-X
roles	B-X
of	B-X
moistening	B-X
and	B-X
heating	B-X
the	B-X
air	B-X
entering	B-X
the	B-X
respiratory	B-X
tract	B-X
and	B-X
detecting	B-X
odor	B-X
The	B-X
catecholamines	B-X
epinephrine	B-X
,	B-X
norepinephrine	B-X
and	B-X
dopamine	B-X
are	B-X
present	B-X
in	B-X
or	B-X
have	B-X
access	B-X
to	B-X
mucous	B-X
membranes	B-X
in	B-X
the	B-X
digestive	B-X
,	B-X
respiratory	B-X
and	B-X
genitourinary	B-X
tracts	B-X
,	B-X
which	B-X
represent	B-X
the	B-X
first	B-X
sites	B-X
of	B-X
microbial	B-X
colonization	B-X
and	B-X
infection	B-X
within	B-X
the	B-X
body	B-X
.	B-X
Epithelial	B-X
cells	B-X
at	B-X
mucosal	B-X
surfaces	B-X
establish	B-X
and	B-X
maintain	B-X
symbiotic	B-X
microbial	B-X
communities	B-X
and	B-X
serve	B-X
as	B-X
the	B-X
initial	B-X
cellular	B-X
point	B-X
of	B-X
contact	B-X
for	B-X
pathogens	B-X
with	B-X
the	B-X
animal	B-X
host	B-X
.	B-X
These	B-X
cells	B-X
express	B-X
receptors	B-X
that	B-X
are	B-X
capable	B-X
of	B-X
detecting	B-X
and	B-X
responding	B-X
to	B-X
microbe-associated	B-X
molecular	B-X
patterns	B-X
and	B-X
in	B-X
most	B-X
host	B-X
species	B-X
express	B-X
G	B-X
protein-coupled	B-X
receptors	B-X
for	B-X
catecholamines	B-X
.	B-X
Although	B-X
it	B-X
is	B-X
increasingly	B-X
recognized	B-X
that	B-X
substances	B-X
produced	B-X
and	B-X
released	B-X
from	B-X
nerves	B-X
and	B-X
endocrine	B-X
cells	B-X
can	B-X
exert	B-X
immuno-modulatory	B-X
actions	B-X
at	B-X
mucosal	B-X
sites	B-X
,	B-X
there	B-X
have	B-X
been	B-X
few	B-X
investigations	B-X
focused	B-X
specifically	B-X
on	B-X
the	B-X
catecholaminergic	B-X
modulation	B-X
of	B-X
interactions	B-X
between	B-X
the	B-X
mucosal	B-X
epithelium	B-X
and	B-X
bacteria	B-X
or	B-X
other	B-X
mucosa-associated	B-X
microorganisms	B-X
.	B-X
For	B-X
example	B-X
,	B-X
psychological	B-X
stress	B-X
or	B-X
other	B-X
conditions	B-X
that	B-X
activate	B-X
the	B-X
sympathetic	B-X
nervous	B-X
system	B-X
to	B-X
release	B-X
epinephrine	B-X
and	B-X
norepinephrine	B-X
may	B-X
act	B-X
to	B-X
produce	B-X
short-term	B-X
changes	B-X
in	B-X
luminal	B-X
and	B-X
mucosal	B-X
microbial	B-X
communities	B-X
or	B-X
alter	B-X
the	B-X
course	B-X
of	B-X
a	B-X
bacterial	B-X
infection	B-X
.	B-X
This	B-X
chapter	B-X
will	B-X
briefly	B-X
review	B-X
this	B-X
developing	B-X
and	B-X
important	B-X
research	B-X
area	B-X
of	B-X
mucosa-microbe	B-X
interactions	B-X
with	B-X
a	B-X
focus	B-X
on	B-X
intestinal	B-X
host	B-X
defense	B-X
.	B-X

Cytosolic	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
from	O
mouse	O
fibroblasts	O
,	O
which	O
is	O
C	O
-	O
terminally	O
modified	O
at	O
its	O
CAAX	O
sequence	O
,	O
was	O
a	O
better	O
substrate	O
for	O
the	O
enzyme	O
that	O
recombinant	O
bacterially	O
expressed	O
,	O
unmodified	O
p21N	B-Protein
-	I-Protein
ras	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
protein-acyltransferase	B-X
activity	B-X
in	B-X
membranes	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
which	B-X
transfers	B-X
palmitate	B-X
from	B-X
palmitoyl-CoA	B-X
to	B-X
p21N-ras	B-X
.	B-X
Specificity	B-X
of	B-X
acylation	B-X
has	B-X
been	B-X
confirmed	B-X
by	B-X
linkage	B-X
analysis	B-X
using	B-X
hydroxylamine	B-X
and	B-X
by	B-X
peptide	B-X
mapping	B-X
of	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
acylated	B-X
p21N-ras	B-X
.	B-X
Cytosolic	B-X
p21N-ras	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
,	B-X
which	B-X
is	B-X
C-terminally	B-X
modified	B-X
at	B-X
its	B-X
CAAX	B-X
sequence	B-X
,	B-X
was	B-X
a	B-X
better	B-X
substrate	B-X
for	B-X
the	B-X
enzyme	B-X
that	B-X
recombinant	B-X
bacterially	B-X
expressed	B-X
,	B-X
unmodified	B-X
p21N-ras	B-X
.	B-X

The	O
activity	O
could	O
be	O
solubilised	O
in	O
non	O
-	O
ionic	O
detergents	O
,	O
making	O
it	O
amenable	O
to	O
purification	O
.	O
<EOS>	B-X
We	B-X
have	B-X
identified	B-X
a	B-X
protein-acyltransferase	B-X
activity	B-X
in	B-X
membranes	B-X
from	B-X
mouse	B-X
fibroblasts	B-X
which	B-X
transfers	B-X
palmitate	B-X
from	B-X
palmitoyl-CoA	B-X
to	B-X
p21N-ras	B-X
.	B-X
The	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
membranes	B-X
,	B-X
but	B-X
not	B-X
cytosol	B-X
,	B-X
and	B-X
co-fractionated	B-X
on	B-X
Percoll	B-X
gradients	B-X
with	B-X
Golgi	B-X
markers	B-X
.	B-X
The	B-X
activity	B-X
could	B-X
be	B-X
solubilised	B-X
in	B-X
non-ionic	B-X
detergents	B-X
,	B-X
making	B-X
it	B-X
amenable	B-X
to	B-X
purification	B-X
.	B-X

Survival	O
defects	O
of	O
Cryptococcus	O
neoformans	O
mutants	O
exposed	O
to	O
human	O
cerebrospinal	O
fluid	O
result	O
in	O
attenuated	O
virulence	O
in	O
an	O
experimental	O
model	O
of	O
meningitis	O
.	O

Cryptococcus	O
neoformans	O
is	O
a	O
fungal	O
pathogen	O
that	O
encounters	O
various	O
microenvironments	O
during	O
growth	O
in	O
the	O
mammalian	O
host	O
,	O
including	O
intracellular	O
vacuoles	O
,	O
blood	O
,	O
and	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

Because	O
the	O
CSF	O
is	O
isolated	O
by	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
we	O
hypothesize	O
that	O
CSF	O
presents	O
unique	O
stresses	O
that	O
C	O
.	O
neoformans	O
must	O
overcome	O
to	O
establish	O
an	O
infection	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

We	O
assayed	O
1	O
,	O
201	O
mutants	O
for	O
survival	O
defects	O
in	O
growth	O
media	O
,	O
saline	O
,	O
and	O
human	O
CSF	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
The	B-X
mutations	B-X
of	B-X
three	B-X
of	B-X
these	B-X
mutants	B-X
were	B-X
recreated	B-X
in	B-X
the	B-X
clinical	B-X
serotype	B-X
A	B-X
strain	B-X
H99	B-X
:	B-X
deletions	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
a	B-X
cation	B-X
ATPase	B-X
transporter	B-X
(	B-X
ena1Δ	B-X
)	B-X
,	B-X
a	B-X
putative	B-X
NEDD8	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
rub1Δ	B-X
)	B-X
,	B-X
and	B-X
a	B-X
phosphatidylinositol	B-X
4-kinase	B-X
(	B-X
pik1Δ	B-X
)	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

We	O
assessed	O
CSF	O
-	O
specific	O
mutants	O
for	O
(	O
i	O
)	O
mutant	O
survival	O
in	O
both	O
human	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluid	O
and	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
(	O
ii	O
)	O
survival	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
virulence	O
using	O
both	O
Caenorhabditis	O
elegans	O
and	O
rabbit	O
models	O
of	O
cryptococcosis	O
.	O

Thirteen	O
mutants	O
exhibited	O
significant	O
survival	O
defects	O
unique	O
to	O
CSF	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
The	B-X
mutations	B-X
of	B-X
three	B-X
of	B-X
these	B-X
mutants	B-X
were	B-X
recreated	B-X
in	B-X
the	B-X
clinical	B-X
serotype	B-X
A	B-X
strain	B-X
H99	B-X
:	B-X
deletions	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
a	B-X
cation	B-X
ATPase	B-X
transporter	B-X
(	B-X
ena1Δ	B-X
)	B-X
,	B-X
a	B-X
putative	B-X
NEDD8	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
rub1Δ	B-X
)	B-X
,	B-X
and	B-X
a	B-X
phosphatidylinositol	B-X
4-kinase	B-X
(	B-X
pik1Δ	B-X
)	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

The	O
mutations	O
of	O
three	O
of	O
these	O
mutants	O
were	O
recreated	O
in	O
the	O
clinical	O
serotype	O
A	O
strain	O
H99	O
:	O
deletions	O
of	O
the	O
genes	O
for	O
a	O
cation	O
ATPase	O
transporter	O
(	O
ena1	B-Protein
Delta	O
)	O
,	O
a	O
putative	O
NEDD8	B-Protein
ubiquitin	B-Protein
-	O
like	O
protein	O
(	O
rub1	B-Protein
Delta	O
)	O
,	O
and	O
a	O
phosphatidylinositol	B-Protein
4	I-Protein
-	I-Protein
kinase	I-Protein
(	O
pik1	B-Protein
Delta	O
)	O
.	O

Mutant	O
survival	O
rates	O
in	O
yeast	O
media	O
,	O
saline	O
,	O
and	O
BAL	O
fluid	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
type	O
;	O
however	O
,	O
survival	O
in	O
FBS	O
was	O
reduced	O
but	O
not	O
to	O
the	O
levels	O
in	O
CSF	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
The	B-X
mutations	B-X
of	B-X
three	B-X
of	B-X
these	B-X
mutants	B-X
were	B-X
recreated	B-X
in	B-X
the	B-X
clinical	B-X
serotype	B-X
A	B-X
strain	B-X
H99	B-X
:	B-X
deletions	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
a	B-X
cation	B-X
ATPase	B-X
transporter	B-X
(	B-X
ena1Δ	B-X
)	B-X
,	B-X
a	B-X
putative	B-X
NEDD8	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
rub1Δ	B-X
)	B-X
,	B-X
and	B-X
a	B-X
phosphatidylinositol	B-X
4-kinase	B-X
(	B-X
pik1Δ	B-X
)	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

These	O
mutant	O
strains	O
also	O
exhibited	O
decreased	O
intracellular	O
survival	O
in	O
macrophages	O
,	O
various	O
degrees	O
of	O
virulence	O
in	O
nematodes	O
,	O
and	O
severe	O
attenuation	O
of	O
survival	O
in	O
a	O
rabbit	O
meningitis	O
model	O
.	O

We	O
analyzed	O
the	O
CSF	O
by	O
mass	O
spectrometry	O
for	O
candidate	O
compounds	O
responsible	O
for	O
the	O
survival	O
defect	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

Our	O
findings	O
indicate	O
that	O
the	O
genes	O
required	O
for	O
C	O
.	O
neoformans	O
survival	O
in	O
CSF	O
ex	O
vivo	O
are	O
necessary	O
for	O
survival	O
and	O
infection	O
in	O
this	O
unique	O
host	O
environment	O
.	O
<EOS>	B-X
Cryptococcus	B-X
neoformans	B-X
is	B-X
a	B-X
fungal	B-X
pathogen	B-X
that	B-X
encounters	B-X
various	B-X
microenvironments	B-X
during	B-X
growth	B-X
in	B-X
the	B-X
mammalian	B-X
host	B-X
,	B-X
including	B-X
intracellular	B-X
vacuoles	B-X
,	B-X
blood	B-X
,	B-X
and	B-X
cerebrospinal	B-X
fluid	B-X
(	B-X
CSF	B-X
)	B-X
.	B-X
Because	B-X
the	B-X
CSF	B-X
is	B-X
isolated	B-X
by	B-X
the	B-X
blood-brain	B-X
barrier	B-X
,	B-X
we	B-X
hypothesize	B-X
that	B-X
CSF	B-X
presents	B-X
unique	B-X
stresses	B-X
that	B-X
C.	B-X
neoformans	B-X
must	B-X
overcome	B-X
to	B-X
establish	B-X
an	B-X
infection	B-X
.	B-X
We	B-X
assayed	B-X
1,201	B-X
mutants	B-X
for	B-X
survival	B-X
defects	B-X
in	B-X
growth	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
human	B-X
CSF	B-X
.	B-X
We	B-X
assessed	B-X
CSF-specific	B-X
mutants	B-X
for	B-X
(	B-X
i	B-X
)	B-X
mutant	B-X
survival	B-X
in	B-X
both	B-X
human	B-X
bronchoalveolar	B-X
lavage	B-X
(	B-X
BAL	B-X
)	B-X
fluid	B-X
and	B-X
fetal	B-X
bovine	B-X
serum	B-X
(	B-X
FBS	B-X
)	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
and	B-X
(	B-X
iii	B-X
)	B-X
virulence	B-X
using	B-X
both	B-X
Caenorhabditis	B-X
elegans	B-X
and	B-X
rabbit	B-X
models	B-X
of	B-X
cryptococcosis	B-X
.	B-X
Thirteen	B-X
mutants	B-X
exhibited	B-X
significant	B-X
survival	B-X
defects	B-X
unique	B-X
to	B-X
CSF	B-X
.	B-X
The	B-X
mutations	B-X
of	B-X
three	B-X
of	B-X
these	B-X
mutants	B-X
were	B-X
recreated	B-X
in	B-X
the	B-X
clinical	B-X
serotype	B-X
A	B-X
strain	B-X
H99	B-X
:	B-X
deletions	B-X
of	B-X
the	B-X
genes	B-X
for	B-X
a	B-X
cation	B-X
ATPase	B-X
transporter	B-X
(	B-X
ena1Δ	B-X
)	B-X
,	B-X
a	B-X
putative	B-X
NEDD8	B-X
ubiquitin-like	B-X
protein	B-X
(	B-X
rub1Δ	B-X
)	B-X
,	B-X
and	B-X
a	B-X
phosphatidylinositol	B-X
4-kinase	B-X
(	B-X
pik1Δ	B-X
)	B-X
.	B-X
Mutant	B-X
survival	B-X
rates	B-X
in	B-X
yeast	B-X
media	B-X
,	B-X
saline	B-X
,	B-X
and	B-X
BAL	B-X
fluid	B-X
were	B-X
similar	B-X
to	B-X
those	B-X
of	B-X
the	B-X
wild	B-X
type	B-X
;	B-X
however	B-X
,	B-X
survival	B-X
in	B-X
FBS	B-X
was	B-X
reduced	B-X
but	B-X
not	B-X
to	B-X
the	B-X
levels	B-X
in	B-X
CSF	B-X
.	B-X
These	B-X
mutant	B-X
strains	B-X
also	B-X
exhibited	B-X
decreased	B-X
intracellular	B-X
survival	B-X
in	B-X
macrophages	B-X
,	B-X
various	B-X
degrees	B-X
of	B-X
virulence	B-X
in	B-X
nematodes	B-X
,	B-X
and	B-X
severe	B-X
attenuation	B-X
of	B-X
survival	B-X
in	B-X
a	B-X
rabbit	B-X
meningitis	B-X
model	B-X
.	B-X
We	B-X
analyzed	B-X
the	B-X
CSF	B-X
by	B-X
mass	B-X
spectrometry	B-X
for	B-X
candidate	B-X
compounds	B-X
responsible	B-X
for	B-X
the	B-X
survival	B-X
defect	B-X
.	B-X
Our	B-X
findings	B-X
indicate	B-X
that	B-X
the	B-X
genes	B-X
required	B-X
for	B-X
C.	B-X
neoformans	B-X
survival	B-X
in	B-X
CSF	B-X
ex	B-X
vivo	B-X
are	B-X
necessary	B-X
for	B-X
survival	B-X
and	B-X
infection	B-X
in	B-X
this	B-X
unique	B-X
host	B-X
environment	B-X
.	B-X

miR	B-Protein
-	I-Protein
148a	I-Protein
is	O
an	O
androgen	O
-	O
responsive	O
microRNA	O
that	O
promotes	O
LNCaP	O
prostate	O
cell	O
growth	O
by	O
repressing	O
its	O
target	O
CAND1	B-Protein
expression	O
.	O
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
cancer	B-X
biology	B-X
reveal	B-X
that	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cancer-related	B-X
genes	B-X
,	B-X
or	B-X
they	B-X
function	B-X
as	B-X
tumor	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
.	B-X
In	B-X
prostate	B-X
cancer	B-X
,	B-X
evidence	B-X
has	B-X
accumulated	B-X
for	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
androgen-dependent	B-X
gene	B-X
network	B-X
to	B-X
tumor	B-X
growth	B-X
,	B-X
although	B-X
the	B-X
precise	B-X
functions	B-X
of	B-X
miRNAs	B-X
in	B-X
prostate	B-X
cancer	B-X
remain	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
androgen-responsive	B-X
miRNAs	B-X
by	B-X
the	B-X
short	B-X
RNA	B-X
sequencing	B-X
analysis	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Among	B-X
10	B-X
miRNAs	B-X
with	B-X
known	B-X
sequences	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
miR-148a	B-X
reduces	B-X
the	B-X
expression	B-X
of	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
SKP1-Cullin1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
CAND1	B-X
mRNA	B-X
.	B-X
CAND1	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
promoted	B-X
the	B-X
proliferation	B-X
of	B-X
LNCaP	B-X
cells	B-X
.	B-X
Our	B-X
study	B-X
indicates	B-X
the	B-X
potential	B-X
contribution	B-X
of	B-X
miR-148a	B-X
to	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X

Recent	O
advances	O
in	O
cancer	O
biology	O
reveal	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cancer	O
-	O
related	O
genes	O
,	O
or	O
they	O
function	O
as	O
tumor	O
suppressors	O
or	O
oncogenes	O
.	O
<EOS>	B-X
Breast	B-X
cancer	B-X
progression	B-X
involves	B-X
multiple	B-X
genetic	B-X
events	B-X
,	B-X
which	B-X
can	B-X
activate	B-X
dominant-acting	B-X
oncogenes	B-X
and	B-X
disrupt	B-X
the	B-X
function	B-X
of	B-X
specific	B-X
tumor	B-X
suppressor	B-X
genes	B-X
.	B-X
This	B-X
article	B-X
describes	B-X
several	B-X
key	B-X
oncogene	B-X
and	B-X
tumor	B-X
suppressor	B-X
signaling	B-X
networks	B-X
that	B-X
have	B-X
been	B-X
implicated	B-X
in	B-X
breast	B-X
cancer	B-X
progression	B-X
.	B-X
Among	B-X
the	B-X
tumor	B-X
suppressors	B-X
,	B-X
the	B-X
article	B-X
emphasizes	B-X
BRCA1/2	B-X
and	B-X
p53	B-X
tumor	B-X
suppressors	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
these	B-X
well	B-X
characterized	B-X
tumor	B-X
suppressors	B-X
,	B-X
the	B-X
article	B-X
highlights	B-X
the	B-X
importance	B-X
of	B-X
PTEN	B-X
tumor	B-X
suppressor	B-X
in	B-X
counteracting	B-X
PI3K	B-X
signaling	B-X
from	B-X
activated	B-X
oncogenes	B-X
such	B-X
as	B-X
ErbB2	B-X
.	B-X
This	B-X
article	B-X
discusses	B-X
the	B-X
use	B-X
of	B-X
mouse	B-X
models	B-X
of	B-X
human	B-X
breast	B-X
that	B-X
recapitulate	B-X
the	B-X
key	B-X
genetic	B-X
events	B-X
involved	B-X
in	B-X
the	B-X
initiation	B-X
and	B-X
progression	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
therapeutic	B-X
potential	B-X
of	B-X
targeting	B-X
these	B-X
key	B-X
tumor	B-X
suppressor	B-X
and	B-X
oncogene	B-X
signaling	B-X
networks	B-X
is	B-X
discussed	B-X
.	B-X

In	O
prostate	O
cancer	O
,	O
evidence	O
has	O
accumulated	O
for	O
the	O
contribution	O
of	O
the	O
androgen	O
-	O
dependent	O
gene	O
network	O
to	O
tumor	O
growth	O
,	O
although	O
the	O
precise	O
functions	O
of	O
miRNAs	O
in	O
prostate	O
cancer	O
remain	O
to	O
be	O
investigated	O
.	O
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
cancer	B-X
biology	B-X
reveal	B-X
that	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cancer-related	B-X
genes	B-X
,	B-X
or	B-X
they	B-X
function	B-X
as	B-X
tumor	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
.	B-X
In	B-X
prostate	B-X
cancer	B-X
,	B-X
evidence	B-X
has	B-X
accumulated	B-X
for	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
androgen-dependent	B-X
gene	B-X
network	B-X
to	B-X
tumor	B-X
growth	B-X
,	B-X
although	B-X
the	B-X
precise	B-X
functions	B-X
of	B-X
miRNAs	B-X
in	B-X
prostate	B-X
cancer	B-X
remain	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
androgen-responsive	B-X
miRNAs	B-X
by	B-X
the	B-X
short	B-X
RNA	B-X
sequencing	B-X
analysis	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Among	B-X
10	B-X
miRNAs	B-X
with	B-X
known	B-X
sequences	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
miR-148a	B-X
reduces	B-X
the	B-X
expression	B-X
of	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
SKP1-Cullin1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
CAND1	B-X
mRNA	B-X
.	B-X
Our	B-X
study	B-X
indicates	B-X
the	B-X
potential	B-X
contribution	B-X
of	B-X
miR-148a	B-X
to	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X

Here	O
,	O
we	O
identified	O
androgen	O
-	O
responsive	O
miRNAs	O
by	O
the	O
short	O
RNA	O
sequencing	O
analysis	O
in	O
LNCaP	O
prostate	O
cancer	O
cells	O
.	O
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
cancer	B-X
biology	B-X
reveal	B-X
that	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cancer-related	B-X
genes	B-X
,	B-X
or	B-X
they	B-X
function	B-X
as	B-X
tumor	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
.	B-X
In	B-X
prostate	B-X
cancer	B-X
,	B-X
evidence	B-X
has	B-X
accumulated	B-X
for	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
androgen-dependent	B-X
gene	B-X
network	B-X
to	B-X
tumor	B-X
growth	B-X
,	B-X
although	B-X
the	B-X
precise	B-X
functions	B-X
of	B-X
miRNAs	B-X
in	B-X
prostate	B-X
cancer	B-X
remain	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
androgen-responsive	B-X
miRNAs	B-X
by	B-X
the	B-X
short	B-X
RNA	B-X
sequencing	B-X
analysis	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Among	B-X
10	B-X
miRNAs	B-X
with	B-X
known	B-X
sequences	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
miR-148a	B-X
reduces	B-X
the	B-X
expression	B-X
of	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
SKP1-Cullin1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
CAND1	B-X
mRNA	B-X
.	B-X
CAND1	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
promoted	B-X
the	B-X
proliferation	B-X
of	B-X
LNCaP	B-X
cells	B-X
.	B-X
Our	B-X
study	B-X
indicates	B-X
the	B-X
potential	B-X
contribution	B-X
of	B-X
miR-148a	B-X
to	B-X
the	B-X
growth	B-X
of	B-X
human	B-X
prostate	B-X
cancer	B-X
.	B-X

Among	O
10	O
miRNAs	O
with	O
known	O
sequences	O
,	O
we	O
have	O
determined	O
that	O
miR	B-Protein
-	I-Protein
148a	I-Protein
reduces	O
the	O
expression	O
of	O
cullin	B-Protein
-	I-Protein
associated	I-Protein
and	I-Protein
neddylation	I-Protein
-	I-Protein
dissociated	I-Protein
1	I-Protein
(	O
CAND1	B-Protein
)	O
,	O
a	O
negative	O
regulator	O
of	O
SKP1	B-Protein
-	O
Cullin1	B-Protein
-	O
F	O
-	O
box	O
(	O
SCF	O
)	O
ubiquitin	B-Protein
ligases	O
,	O
by	O
binding	O
to	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
CAND1	B-Protein
mRNA	O
.	O

CAND1	B-Protein
knockdown	O
by	O
small	O
interfering	O
RNA	O
promoted	O
the	O
proliferation	O
of	O
LNCaP	O
cells	O
.	O
<EOS>	B-X
Recent	B-X
advances	B-X
in	B-X
cancer	B-X
biology	B-X
reveal	B-X
that	B-X
microRNAs	B-X
(	B-X
miRNAs	B-X
)	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
cancer-related	B-X
genes	B-X
,	B-X
or	B-X
they	B-X
function	B-X
as	B-X
tumor	B-X
suppressors	B-X
or	B-X
oncogenes	B-X
.	B-X
In	B-X
prostate	B-X
cancer	B-X
,	B-X
evidence	B-X
has	B-X
accumulated	B-X
for	B-X
the	B-X
contribution	B-X
of	B-X
the	B-X
androgen-dependent	B-X
gene	B-X
network	B-X
to	B-X
tumor	B-X
growth	B-X
,	B-X
although	B-X
the	B-X
precise	B-X
functions	B-X
of	B-X
miRNAs	B-X
in	B-X
prostate	B-X
cancer	B-X
remain	B-X
to	B-X
be	B-X
investigated	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
identified	B-X
androgen-responsive	B-X
miRNAs	B-X
by	B-X
the	B-X
short	B-X
RNA	B-X
sequencing	B-X
analysis	B-X
in	B-X
LNCaP	B-X
prostate	B-X
cancer	B-X
cells	B-X
.	B-X
Among	B-X
10	B-X
miRNAs	B-X
with	B-X
known	B-X
sequences	B-X
,	B-X
we	B-X
have	B-X
determined	B-X
that	B-X
miR-148a	B-X
reduces	B-X
the	B-X
expression	B-X
of	B-X
cullin-associated	B-X
and	B-X
neddylation-dissociated	B-X
1	B-X
(	B-X
CAND1	B-X
)	B-X
,	B-X
a	B-X
negative	B-X
regulator	B-X
of	B-X
SKP1-Cullin1-F-box	B-X
(	B-X
SCF	B-X
)	B-X
ubiquitin	B-X
ligases	B-X
,	B-X
by	B-X
binding	B-X
to	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
CAND1	B-X
mRNA	B-X
.	B-X
CAND1	B-X
knockdown	B-X
by	B-X
small	B-X
interfering	B-X
RNA	B-X
promoted	B-X
the	B-X
proliferation	B-X
of	B-X
LNCaP	B-X
cells	B-X
.	B-X

Our	O
study	O
indicates	O
the	O
potential	O
contribution	O
of	O
miR	B-Protein
-	I-Protein
148a	I-Protein
to	O
the	O
growth	O
of	O
human	O
prostate	O
cancer	O
.	O

A	O
mechanistic	O
view	O
of	O
the	O
role	O
of	O
E3	O
in	O
sumoylation	O
.	O
<EOS>	B-X
In	B-X
sumoylation	B-X
,	B-X
E2	B-X
ligase	B-X
Ubc9	B-X
can	B-X
function	B-X
without	B-X
E3	B-X
enzymes	B-X
,	B-X
albeit	B-X
with	B-X
lower	B-X
reaction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
study	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
E3	B-X
ligase	B-X
RanBP2	B-X
triggers	B-X
target	B-X
recognition	B-X
and	B-X
catalysis	B-X
by	B-X
E2	B-X
Ubc9	B-X
.	B-X
Two	B-X
mechanisms	B-X
were	B-X
proposed	B-X
for	B-X
sumoylation	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Using	B-X
dynamic	B-X
correlations	B-X
obtained	B-X
from	B-X
explicit	B-X
solvent	B-X
molecular	B-X
dynamic	B-X
simulations	B-X
we	B-X
illustrate	B-X
the	B-X
key	B-X
roles	B-X
played	B-X
by	B-X
allostery	B-X
in	B-X
both	B-X
mechanisms	B-X
.	B-X
Pre-existence	B-X
of	B-X
conformational	B-X
states	B-X
explains	B-X
the	B-X
experimental	B-X
observations	B-X
that	B-X
sumoylation	B-X
can	B-X
occur	B-X
without	B-X
E3	B-X
,	B-X
even	B-X
though	B-X
at	B-X
a	B-X
reduced	B-X
rate	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
for	B-X
enhancement	B-X
of	B-X
sumoylation	B-X
by	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

Sumoylation	O
,	O
the	O
covalent	O
attachment	O
of	O
SUMO	O
(	O
Small	O
Ubiquitin	B-Protein
-	O
Like	O
Modifier	O
)	O
to	O
proteins	O
,	O
differs	O
from	O
other	O
Ubl	O
(	O
Ubiquitin	B-Protein
-	O
like	O
)	O
pathways	O
.	O
<EOS>	B-X
Sumoylation	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
SUMO	B-X
(	B-X
Small	B-X
Ubiquitin-Like	B-X
Modifier	B-X
)	B-X
to	B-X
proteins	B-X
,	B-X
differs	B-X
from	B-X
other	B-X
Ubl	B-X
(	B-X
Ubiquitin-like	B-X
)	B-X
pathways	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X

In	O
sumoylation	O
,	O
E2	O
ligase	O
Ubc9	B-Protein
can	O
function	O
without	O
E3	O
enzymes	O
,	O
albeit	O
with	O
lower	O
reaction	O
efficiency	O
.	O
<EOS>	B-X
In	B-X
sumoylation	B-X
,	B-X
E2	B-X
ligase	B-X
Ubc9	B-X
can	B-X
function	B-X
without	B-X
E3	B-X
enzymes	B-X
,	B-X
albeit	B-X
with	B-X
lower	B-X
reaction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
study	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
E3	B-X
ligase	B-X
RanBP2	B-X
triggers	B-X
target	B-X
recognition	B-X
and	B-X
catalysis	B-X
by	B-X
E2	B-X
Ubc9	B-X
.	B-X
Two	B-X
mechanisms	B-X
were	B-X
proposed	B-X
for	B-X
sumoylation	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Pre-existence	B-X
of	B-X
conformational	B-X
states	B-X
explains	B-X
the	B-X
experimental	B-X
observations	B-X
that	B-X
sumoylation	B-X
can	B-X
occur	B-X
without	B-X
E3	B-X
,	B-X
even	B-X
though	B-X
at	B-X
a	B-X
reduced	B-X
rate	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
for	B-X
enhancement	B-X
of	B-X
sumoylation	B-X
by	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

Here	O
,	O
we	O
study	O
the	O
mechanism	O
through	O
which	O
E3	O
ligase	O
RanBP2	B-Protein
triggers	O
target	O
recognition	O
and	O
catalysis	O
by	O
E2	O
Ubc9	B-Protein
.	O

Two	O
mechanisms	O
were	O
proposed	O
for	O
sumoylation	O
.	O
<EOS>	B-X
Several	B-X
anti-CSC	B-X
strategies	B-X
and	B-X
associated	B-X
targets	B-X
have	B-X
been	B-X
proposed	B-X
and	B-X
validated	B-X
till	B-X
date	B-X
.	B-X
Other	B-X
issues	B-X
governing	B-X
the	B-X
choice	B-X
of	B-X
small-	B-X
versus	B-X
macromolecules	B-X
include	B-X
druggability	B-X
of	B-X
the	B-X
target	B-X
,	B-X
ease	B-X
of	B-X
its	B-X
modulation	B-X
and	B-X
the	B-X
presence	B-X
of	B-X
compensatory	B-X
mechanisms	B-X
.	B-X
Among	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
PTMs	B-X
,	B-X
sumoylation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
important	B-X
modifications	B-X
due	B-X
to	B-X
its	B-X
known	B-X
cellular	B-X
functions	B-X
which	B-X
include	B-X
transcriptional	B-X
regulation	B-X
,	B-X
protein	B-X
stability	B-X
,	B-X
and	B-X
protein	B-X
subcellular	B-X
localization	B-X
.	B-X
Despite	B-X
its	B-X
importance	B-X
,	B-X
determining	B-X
sumoylation	B-X
sites	B-X
via	B-X
experimental	B-X
methods	B-X
is	B-X
time-consuming	B-X
and	B-X
costly	B-X
.	B-X
This	B-X
has	B-X
led	B-X
to	B-X
a	B-X
great	B-X
demand	B-X
for	B-X
the	B-X
development	B-X
of	B-X
fast	B-X
computational	B-X
methods	B-X
able	B-X
to	B-X
accurately	B-X
determine	B-X
sumoylation	B-X
sites	B-X
in	B-X
proteins	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
present	B-X
a	B-X
new	B-X
machine	B-X
learning-based	B-X
method	B-X
for	B-X
predicting	B-X
sumoylation	B-X
sites	B-X
called	B-X
SumSec	B-X
.	B-X
As	B-X
a	B-X
result	B-X
,	B-X
our	B-X
proposed	B-X
method	B-X
is	B-X
able	B-X
to	B-X
enhance	B-X
the	B-X
sumoylation	B-X
site	B-X
prediction	B-X
task	B-X
,	B-X
outperforming	B-X
previously	B-X
proposed	B-X
methods	B-X
in	B-X
the	B-X
literature	B-X
.	B-X

While	O
in	O
both	O
the	O
first	O
step	O
involves	O
Ubc9	B-Protein
conjugation	O
to	O
SUMO	O
,	O
the	O
subsequent	O
sequence	O
of	O
events	O
differs	O
:	O
in	O
the	O
first	O
E2	O
-	O
SUMO	O
forms	O
a	O
complex	O
with	O
the	O
target	O
and	O
E3	O
,	O
followed	O
by	O
SUMO	O
transfer	O
to	O
the	O
target	O
.	O

In	O
the	O
second	O
,	O
Ubc9	B-Protein
-	O
SUMO	O
binds	O
to	O
the	O
target	O
and	O
facilitates	O
SUMO	O
transfer	O
without	O
E3	O
.	O

Using	O
dynamic	O
correlations	O
obtained	O
from	O
explicit	O
solvent	O
molecular	O
dynamic	O
simulations	O
we	O
illustrate	O
the	O
key	O
roles	O
played	O
by	O
allostery	O
in	O
both	O
mechanisms	O
.	O
<EOS>	B-X
Two	B-X
mechanisms	B-X
were	B-X
proposed	B-X
for	B-X
sumoylation	B-X
.	B-X
Using	B-X
dynamic	B-X
correlations	B-X
obtained	B-X
from	B-X
explicit	B-X
solvent	B-X
molecular	B-X
dynamic	B-X
simulations	B-X
we	B-X
illustrate	B-X
the	B-X
key	B-X
roles	B-X
played	B-X
by	B-X
allostery	B-X
in	B-X
both	B-X
mechanisms	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

Pre	O
-	O
existence	O
of	O
conformational	O
states	O
explains	O
the	O
experimental	O
observations	O
that	O
sumoylation	O
can	O
occur	O
without	O
E3	O
,	O
even	O
though	O
at	O
a	O
reduced	O
rate	O
.	O

Furthermore	O
,	O
we	O
propose	O
a	O
mechanism	O
for	O
enhancement	O
of	O
sumoylation	O
by	O
E3	O
.	O
<EOS>	B-X
In	B-X
sumoylation	B-X
,	B-X
E2	B-X
ligase	B-X
Ubc9	B-X
can	B-X
function	B-X
without	B-X
E3	B-X
enzymes	B-X
,	B-X
albeit	B-X
with	B-X
lower	B-X
reaction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
study	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
E3	B-X
ligase	B-X
RanBP2	B-X
triggers	B-X
target	B-X
recognition	B-X
and	B-X
catalysis	B-X
by	B-X
E2	B-X
Ubc9	B-X
.	B-X
Two	B-X
mechanisms	B-X
were	B-X
proposed	B-X
for	B-X
sumoylation	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Using	B-X
dynamic	B-X
correlations	B-X
obtained	B-X
from	B-X
explicit	B-X
solvent	B-X
molecular	B-X
dynamic	B-X
simulations	B-X
we	B-X
illustrate	B-X
the	B-X
key	B-X
roles	B-X
played	B-X
by	B-X
allostery	B-X
in	B-X
both	B-X
mechanisms	B-X
.	B-X
Pre-existence	B-X
of	B-X
conformational	B-X
states	B-X
explains	B-X
the	B-X
experimental	B-X
observations	B-X
that	B-X
sumoylation	B-X
can	B-X
occur	B-X
without	B-X
E3	B-X
,	B-X
even	B-X
though	B-X
at	B-X
a	B-X
reduced	B-X
rate	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
for	B-X
enhancement	B-X
of	B-X
sumoylation	B-X
by	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

Analysis	O
of	O
the	O
conformational	O
ensembles	O
of	O
the	O
complex	O
of	O
E2	O
conjugated	O
to	O
SUMO	O
illustrates	O
that	O
the	O
E2	O
enzyme	O
is	O
already	O
largely	O
pre	O
-	O
organized	O
for	O
target	O
binding	O
and	O
catalysis	O
;	O
E3	O
binding	O
shifts	O
the	O
equilibrium	O
and	O
enhances	O
these	O
pre	O
-	O
existing	O
populations	O
.	O
<EOS>	B-X
Sumoylation	B-X
,	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
SUMO	B-X
(	B-X
Small	B-X
Ubiquitin-Like	B-X
Modifier	B-X
)	B-X
to	B-X
proteins	B-X
,	B-X
differs	B-X
from	B-X
other	B-X
Ubl	B-X
(	B-X
Ubiquitin-like	B-X
)	B-X
pathways	B-X
.	B-X
In	B-X
sumoylation	B-X
,	B-X
E2	B-X
ligase	B-X
Ubc9	B-X
can	B-X
function	B-X
without	B-X
E3	B-X
enzymes	B-X
,	B-X
albeit	B-X
with	B-X
lower	B-X
reaction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
study	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
E3	B-X
ligase	B-X
RanBP2	B-X
triggers	B-X
target	B-X
recognition	B-X
and	B-X
catalysis	B-X
by	B-X
E2	B-X
Ubc9	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Pre-existence	B-X
of	B-X
conformational	B-X
states	B-X
explains	B-X
the	B-X
experimental	B-X
observations	B-X
that	B-X
sumoylation	B-X
can	B-X
occur	B-X
without	B-X
E3	B-X
,	B-X
even	B-X
though	B-X
at	B-X
a	B-X
reduced	B-X
rate	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
for	B-X
enhancement	B-X
of	B-X
sumoylation	B-X
by	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

We	O
further	O
observe	O
that	O
E3	O
binding	O
regulates	O
allosterically	O
the	O
key	O
residues	O
in	O
E2	O
,	O
Ubc9	B-Protein
Asp100	O
/	O
Lys101	O
E2	O
,	O
for	O
the	O
target	O
recognition	O
.	O
<EOS>	B-X
In	B-X
sumoylation	B-X
,	B-X
E2	B-X
ligase	B-X
Ubc9	B-X
can	B-X
function	B-X
without	B-X
E3	B-X
enzymes	B-X
,	B-X
albeit	B-X
with	B-X
lower	B-X
reaction	B-X
efficiency	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
study	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
E3	B-X
ligase	B-X
RanBP2	B-X
triggers	B-X
target	B-X
recognition	B-X
and	B-X
catalysis	B-X
by	B-X
E2	B-X
Ubc9	B-X
.	B-X
While	B-X
in	B-X
both	B-X
the	B-X
first	B-X
step	B-X
involves	B-X
Ubc9	B-X
conjugation	B-X
to	B-X
SUMO	B-X
,	B-X
the	B-X
subsequent	B-X
sequence	B-X
of	B-X
events	B-X
differs	B-X
:	B-X
in	B-X
the	B-X
first	B-X
E2-SUMO	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
the	B-X
target	B-X
and	B-X
E3	B-X
,	B-X
followed	B-X
by	B-X
SUMO	B-X
transfer	B-X
to	B-X
the	B-X
target	B-X
.	B-X
In	B-X
the	B-X
second	B-X
,	B-X
Ubc9-SUMO	B-X
binds	B-X
to	B-X
the	B-X
target	B-X
and	B-X
facilitates	B-X
SUMO	B-X
transfer	B-X
without	B-X
E3	B-X
.	B-X
Using	B-X
dynamic	B-X
correlations	B-X
obtained	B-X
from	B-X
explicit	B-X
solvent	B-X
molecular	B-X
dynamic	B-X
simulations	B-X
we	B-X
illustrate	B-X
the	B-X
key	B-X
roles	B-X
played	B-X
by	B-X
allostery	B-X
in	B-X
both	B-X
mechanisms	B-X
.	B-X
Pre-existence	B-X
of	B-X
conformational	B-X
states	B-X
explains	B-X
the	B-X
experimental	B-X
observations	B-X
that	B-X
sumoylation	B-X
can	B-X
occur	B-X
without	B-X
E3	B-X
,	B-X
even	B-X
though	B-X
at	B-X
a	B-X
reduced	B-X
rate	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
propose	B-X
a	B-X
mechanism	B-X
for	B-X
enhancement	B-X
of	B-X
sumoylation	B-X
by	B-X
E3	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
conformational	B-X
ensembles	B-X
of	B-X
the	B-X
complex	B-X
of	B-X
E2	B-X
conjugated	B-X
to	B-X
SUMO	B-X
illustrates	B-X
that	B-X
the	B-X
E2	B-X
enzyme	B-X
is	B-X
already	B-X
largely	B-X
pre-organized	B-X
for	B-X
target	B-X
binding	B-X
and	B-X
catalysis	B-X
;	B-X
E3	B-X
binding	B-X
shifts	B-X
the	B-X
equilibrium	B-X
and	B-X
enhances	B-X
these	B-X
pre-existing	B-X
populations	B-X
.	B-X
We	B-X
further	B-X
observe	B-X
that	B-X
E3	B-X
binding	B-X
regulates	B-X
allosterically	B-X
the	B-X
key	B-X
residues	B-X
in	B-X
E2	B-X
,	B-X
Ubc9	B-X
Asp100/Lys101	B-X
E2	B-X
,	B-X
for	B-X
the	B-X
target	B-X
recognition	B-X
.	B-X

Human	O
stanniocalcin	B-Protein
-	I-Protein
1	I-Protein
interacts	O
with	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
and	O
acts	O
as	O
a	O
SUMO	O
E3	O
ligase	O
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
was	B-X
mapped	B-X
to	B-X
be	B-X
the	B-X
region	B-X
that	B-X
mediates	B-X
the	B-X
interaction	B-X
with	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
nuclear	B-X
proteins	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Human	O
stanniocalcin	B-Protein
-	I-Protein
1	I-Protein
(	O
STC1	B-Protein
)	O
is	O
a	O
glycoprotein	O
that	O
has	O
been	O
implicated	O
in	O
different	O
physiological	O
process	O
,	O
including	O
angiogenesis	O
,	O
apoptosis	O
and	O
carcinogenesis	O
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Here	O
we	O
identified	O
STC1	B-Protein
as	O
a	O
putative	O
molecular	O
marker	O
for	O
the	O
leukemic	O
bone	O
marrow	O
microenvironment	O
and	O
identified	O
new	O
interacting	O
protein	O
partners	O
for	O
STC1	B-Protein
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
was	B-X
mapped	B-X
to	B-X
be	B-X
the	B-X
region	B-X
that	B-X
mediates	B-X
the	B-X
interaction	B-X
with	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
nuclear	B-X
proteins	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Seven	O
selected	O
interactions	O
retrieved	O
from	O
yeast	O
two	O
-	O
hybrid	O
screens	O
were	O
confirmed	O
by	O
GST	B-Protein
-	O
pull	O
down	O
assays	O
in	O
vitro	O
.	O
<EOS>	B-X
Seven	B-X
selected	B-X
interactions	B-X
retrieved	B-X
from	B-X
yeast	B-X
two-hybrid	B-X
screens	B-X
were	B-X
confirmed	B-X
by	B-X
GST-pull	B-X
down	B-X
assays	B-X
in	B-X
vitro	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X

The	O
N	O
-	O
terminal	O
region	O
was	O
mapped	O
to	O
be	O
the	O
region	O
that	O
mediates	O
the	O
interaction	O
with	O
cytoplasmic	O
,	O
mitochondrial	O
and	O
nuclear	O
proteins	O
.	O

STC1	B-Protein
interacts	O
with	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
several	O
proteins	O
that	O
have	O
been	O
shown	O
to	O
be	O
SUMOylated	O
and	O
localized	O
to	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
was	B-X
mapped	B-X
to	B-X
be	B-X
the	B-X
region	B-X
that	B-X
mediates	B-X
the	B-X
interaction	B-X
with	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
nuclear	B-X
proteins	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Although	O
STC1	B-Protein
interacts	O
with	O
SUMO	B-Protein
-	I-Protein
1	I-Protein
and	O
has	O
a	O
high	O
theoretical	O
prediction	O
score	O
for	O
a	O
SUMOylation	O
site	O
,	O
endogenous	O
co	O
-	O
immunoprecipitation	O
and	O
in	O
vitro	O
SUMOylation	O
assays	O
with	O
the	O
purified	O
recombinant	O
protein	O
could	O
not	O
detect	O
STC1	B-Protein
SUMOylation	O
.	O

However	O
,	O
when	O
we	O
tested	O
STC1	B-Protein
for	O
SUMO	O
E3	O
ligase	O
activity	O
,	O
we	O
found	O
in	O
an	O
in	O
vitro	O
assay	O
,	O
that	O
it	O
significantly	O
increases	O
the	O
SUMOylation	O
of	O
two	O
other	O
proteins	O
.	O

Confocal	O
microscopic	O
subcellular	O
localization	O
studies	O
using	O
both	O
transfected	O
cells	O
and	O
specific	O
antibodies	O
for	O
endogenous	O
STC1	B-Protein
revealed	O
a	O
cytoplasmic	O
and	O
nuclear	O
deposition	O
,	O
the	O
latter	O
in	O
the	O
form	O
of	O
some	O
specific	O
dot	O
-	O
like	O
substructure	O
resembling	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
was	B-X
mapped	B-X
to	B-X
be	B-X
the	B-X
region	B-X
that	B-X
mediates	B-X
the	B-X
interaction	B-X
with	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
nuclear	B-X
proteins	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Together	O
,	O
these	O
findings	O
suggest	O
a	O
new	O
role	O
for	O
STC1	B-Protein
in	O
SUMOylation	O
pathways	O
,	O
in	O
nuclear	O
bodies	O
.	O
<EOS>	B-X
Human	B-X
stanniocalcin-1	B-X
(	B-X
STC1	B-X
)	B-X
is	B-X
a	B-X
glycoprotein	B-X
that	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
different	B-X
physiological	B-X
process	B-X
,	B-X
including	B-X
angiogenesis	B-X
,	B-X
apoptosis	B-X
and	B-X
carcinogenesis	B-X
.	B-X
Here	B-X
we	B-X
identified	B-X
STC1	B-X
as	B-X
a	B-X
putative	B-X
molecular	B-X
marker	B-X
for	B-X
the	B-X
leukemic	B-X
bone	B-X
marrow	B-X
microenvironment	B-X
and	B-X
identified	B-X
new	B-X
interacting	B-X
protein	B-X
partners	B-X
for	B-X
STC1	B-X
.	B-X
The	B-X
N-terminal	B-X
region	B-X
was	B-X
mapped	B-X
to	B-X
be	B-X
the	B-X
region	B-X
that	B-X
mediates	B-X
the	B-X
interaction	B-X
with	B-X
cytoplasmic	B-X
,	B-X
mitochondrial	B-X
and	B-X
nuclear	B-X
proteins	B-X
.	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
several	B-X
proteins	B-X
that	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
SUMOylated	B-X
and	B-X
localized	B-X
to	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Although	B-X
STC1	B-X
interacts	B-X
with	B-X
SUMO-1	B-X
and	B-X
has	B-X
a	B-X
high	B-X
theoretical	B-X
prediction	B-X
score	B-X
for	B-X
a	B-X
SUMOylation	B-X
site	B-X
,	B-X
endogenous	B-X
co-immunoprecipitation	B-X
and	B-X
in	B-X
vitro	B-X
SUMOylation	B-X
assays	B-X
with	B-X
the	B-X
purified	B-X
recombinant	B-X
protein	B-X
could	B-X
not	B-X
detect	B-X
STC1	B-X
SUMOylation	B-X
.	B-X
However	B-X
,	B-X
when	B-X
we	B-X
tested	B-X
STC1	B-X
for	B-X
SUMO	B-X
E3	B-X
ligase	B-X
activity	B-X
,	B-X
we	B-X
found	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
assay	B-X
,	B-X
that	B-X
it	B-X
significantly	B-X
increases	B-X
the	B-X
SUMOylation	B-X
of	B-X
two	B-X
other	B-X
proteins	B-X
.	B-X
Confocal	B-X
microscopic	B-X
subcellular	B-X
localization	B-X
studies	B-X
using	B-X
both	B-X
transfected	B-X
cells	B-X
and	B-X
specific	B-X
antibodies	B-X
for	B-X
endogenous	B-X
STC1	B-X
revealed	B-X
a	B-X
cytoplasmic	B-X
and	B-X
nuclear	B-X
deposition	B-X
,	B-X
the	B-X
latter	B-X
in	B-X
the	B-X
form	B-X
of	B-X
some	B-X
specific	B-X
dot-like	B-X
substructure	B-X
resembling	B-X
SUMOylation	B-X
related	B-X
nuclear	B-X
bodies	B-X
.	B-X
Together	B-X
,	B-X
these	B-X
findings	B-X
suggest	B-X
a	B-X
new	B-X
role	B-X
for	B-X
STC1	B-X
in	B-X
SUMOylation	B-X
pathways	B-X
,	B-X
in	B-X
nuclear	B-X
bodies	B-X
.	B-X

Experimental	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
and	O
activation	O
of	O
protein	O
degradation	O
pathways	O
in	O
corporal	O
tissue	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
priapism	B-X
lasting	B-X
more	B-X
than	B-X
24	B-X
h	B-X
in	B-X
patients	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
44-90	B-X
%	B-X
rate	B-X
of	B-X
ED	B-X
.	B-X
In	B-X
this	B-X
investigation	B-X
,	B-X
we	B-X
determined	B-X
in	B-X
two	B-X
animal	B-X
models	B-X
of	B-X
priapism	B-X
(	B-X
opiorphin-induced	B-X
priapism	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
priapism	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
)	B-X
if	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
In	B-X
both	B-X
animal	B-X
models	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
results	B-X
in	B-X
increased	B-X
levels	B-X
of	B-X
lipid	B-X
peroxidation	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
activity	B-X
and	B-X
oxidatively	B-X
damaged	B-X
proteins	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
Using	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
we	B-X
demonstrated	B-X
there	B-X
is	B-X
upregulation	B-X
of	B-X
the	B-X
ubiquitination	B-X
ligase	B-X
proteins	B-X
,	B-X
Nedd-4	B-X
and	B-X
Mdm-2	B-X
,	B-X
and	B-X
the	B-X
lysosomal	B-X
autophage	B-X
protein	B-X
,	B-X
LC3	B-X
.	B-X
The	B-X
antiapoptotic	B-X
protein	B-X
,	B-X
Bcl-2	B-X
,	B-X
was	B-X
also	B-X
upregulated	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
protein	B-X
degradation	B-X
pathways	B-X
.	B-X
As	B-X
oxidative	B-X
stress	B-X
is	B-X
known	B-X
to	B-X
mediate	B-X
the	B-X
development	B-X
of	B-X
ED	B-X
resulting	B-X
from	B-X
several	B-X
etiologies	B-X
(	B-X
for	B-X
example	B-X
,	B-X
ED	B-X
resulting	B-X
from	B-X
diabetes	B-X
and	B-X
aging	B-X
)	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
damage	B-X
to	B-X
erectile	B-X
tissue	B-X
resulting	B-X
from	B-X
priapism	B-X
might	B-X
be	B-X
prevented	B-X
by	B-X
treatments	B-X
targeting	B-X
oxidative	B-X
stress	B-X
.	B-X

Priapism	O
is	O
a	O
debilitating	O
disease	O
for	O
which	O
there	O
is	O
at	O
present	O
no	O
clinically	O
accepted	O
pharmacological	O
intervention	O
.	O
<EOS>	B-X
Priapism	B-X
is	B-X
a	B-X
debilitating	B-X
disease	B-X
for	B-X
which	B-X
there	B-X
is	B-X
at	B-X
present	B-X
no	B-X
clinically	B-X
accepted	B-X
pharmacological	B-X
intervention	B-X
.	B-X
In	B-X
this	B-X
investigation	B-X
,	B-X
we	B-X
determined	B-X
in	B-X
two	B-X
animal	B-X
models	B-X
of	B-X
priapism	B-X
(	B-X
opiorphin-induced	B-X
priapism	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
priapism	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
)	B-X
if	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X

It	O
has	O
been	O
estimated	O
that	O
priapism	O
lasting	O
more	O
than	O
24	O
h	O
in	O
patients	O
is	O
associated	O
with	O
a	O
44	O
-	O
90	O
%	O
rate	O
of	O
ED	O
.	O

In	O
this	O
investigation	O
,	O
we	O
determined	O
in	O
two	O
animal	O
models	O
of	O
priapism	O
(	O
opiorphin	B-Protein
-	O
induced	O
priapism	O
in	O
the	O
rat	O
and	O
priapism	O
in	O
a	O
mouse	O
model	O
of	O
sickle	O
cell	O
disease	O
)	O
if	O
there	O
is	O
evidence	O
for	O
an	O
increase	O
in	O
markers	O
of	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
.	O

In	O
both	O
animal	O
models	O
,	O
we	O
demonstrate	O
that	O
priapism	O
results	O
in	O
increased	O
levels	O
of	O
lipid	O
peroxidation	O
,	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
activity	O
and	O
oxidatively	O
damaged	O
proteins	O
in	O
corporal	O
tissue	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
priapism	B-X
lasting	B-X
more	B-X
than	B-X
24	B-X
h	B-X
in	B-X
patients	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
44-90	B-X
%	B-X
rate	B-X
of	B-X
ED	B-X
.	B-X
In	B-X
this	B-X
investigation	B-X
,	B-X
we	B-X
determined	B-X
in	B-X
two	B-X
animal	B-X
models	B-X
of	B-X
priapism	B-X
(	B-X
opiorphin-induced	B-X
priapism	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
priapism	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
)	B-X
if	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
In	B-X
both	B-X
animal	B-X
models	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
results	B-X
in	B-X
increased	B-X
levels	B-X
of	B-X
lipid	B-X
peroxidation	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
activity	B-X
and	B-X
oxidatively	B-X
damaged	B-X
proteins	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
Using	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
we	B-X
demonstrated	B-X
there	B-X
is	B-X
upregulation	B-X
of	B-X
the	B-X
ubiquitination	B-X
ligase	B-X
proteins	B-X
,	B-X
Nedd-4	B-X
and	B-X
Mdm-2	B-X
,	B-X
and	B-X
the	B-X
lysosomal	B-X
autophage	B-X
protein	B-X
,	B-X
LC3	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
protein	B-X
degradation	B-X
pathways	B-X
.	B-X
As	B-X
oxidative	B-X
stress	B-X
is	B-X
known	B-X
to	B-X
mediate	B-X
the	B-X
development	B-X
of	B-X
ED	B-X
resulting	B-X
from	B-X
several	B-X
etiologies	B-X
(	B-X
for	B-X
example	B-X
,	B-X
ED	B-X
resulting	B-X
from	B-X
diabetes	B-X
and	B-X
aging	B-X
)	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
damage	B-X
to	B-X
erectile	B-X
tissue	B-X
resulting	B-X
from	B-X
priapism	B-X
might	B-X
be	B-X
prevented	B-X
by	B-X
treatments	B-X
targeting	B-X
oxidative	B-X
stress	B-X
.	B-X

Using	O
western	O
blot	O
analysis	O
,	O
we	O
demonstrated	O
there	O
is	O
upregulation	O
of	O
the	O
ubiquitination	O
ligase	O
proteins	O
,	O
Nedd	B-Protein
-	I-Protein
4	I-Protein
and	O
Mdm	B-Protein
-	I-Protein
2	I-Protein
,	O
and	O
the	O
lysosomal	O
autophage	O
protein	O
,	O
LC3	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
priapism	B-X
lasting	B-X
more	B-X
than	B-X
24	B-X
h	B-X
in	B-X
patients	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
44-90	B-X
%	B-X
rate	B-X
of	B-X
ED	B-X
.	B-X
In	B-X
both	B-X
animal	B-X
models	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
results	B-X
in	B-X
increased	B-X
levels	B-X
of	B-X
lipid	B-X
peroxidation	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
activity	B-X
and	B-X
oxidatively	B-X
damaged	B-X
proteins	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
Using	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
we	B-X
demonstrated	B-X
there	B-X
is	B-X
upregulation	B-X
of	B-X
the	B-X
ubiquitination	B-X
ligase	B-X
proteins	B-X
,	B-X
Nedd-4	B-X
and	B-X
Mdm-2	B-X
,	B-X
and	B-X
the	B-X
lysosomal	B-X
autophage	B-X
protein	B-X
,	B-X
LC3	B-X
.	B-X
The	B-X
antiapoptotic	B-X
protein	B-X
,	B-X
Bcl-2	B-X
,	B-X
was	B-X
also	B-X
upregulated	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
protein	B-X
degradation	B-X
pathways	B-X
.	B-X

The	O
antiapoptotic	O
protein	O
,	O
Bcl	B-Protein
-	I-Protein
2	I-Protein
,	O
was	O
also	O
upregulated	O
.	O
<EOS>	B-X
Nuclear	B-X
transcription	B-X
factor	B-X
Nrf2	B-X
regulates	B-X
the	B-X
expression	B-X
and	B-X
coordinated	B-X
induction	B-X
of	B-X
a	B-X
battery	B-X
of	B-X
genes	B-X
encoding	B-X
cytoprotective	B-X
and	B-X
drug	B-X
transporter	B-X
proteins	B-X
in	B-X
response	B-X
to	B-X
chemical	B-X
and	B-X
radiation	B-X
stress	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
the	B-X
role	B-X
of	B-X
Nrf2	B-X
in	B-X
up-regulation	B-X
of	B-X
antiapoptotic	B-X
protein	B-X
Bcl-2	B-X
and	B-X
its	B-X
contribution	B-X
to	B-X
stress-induced	B-X
apoptosis	B-X
and	B-X
cell	B-X
survival	B-X
.	B-X
Exposure	B-X
of	B-X
mouse	B-X
hepatoma	B-X
(	B-X
Hepa-1	B-X
)	B-X
and	B-X
human	B-X
hepatoblastoma	B-X
(	B-X
HepG2	B-X
)	B-X
cells	B-X
to	B-X
antioxidant	B-X
tert-butylhydroquinone	B-X
led	B-X
to	B-X
induction	B-X
of	B-X
Bcl-2	B-X
.	B-X
Mutagenesis	B-X
and	B-X
transfection	B-X
assays	B-X
identified	B-X
an	B-X
antioxidant	B-X
response	B-X
element	B-X
between	B-X
nucleotides	B-X
-3148	B-X
and	B-X
-3140	B-X
on	B-X
the	B-X
reverse	B-X
strand	B-X
of	B-X
the	B-X
Bcl-2	B-X
gene	B-X
promoter	B-X
that	B-X
was	B-X
essential	B-X
for	B-X
activation	B-X
of	B-X
Bcl-2	B-X
gene	B-X
expression	B-X
.	B-X
Band/supershift	B-X
and	B-X
ChIP	B-X
assays	B-X
demonstrated	B-X
binding	B-X
of	B-X
Nrf2	B-X
to	B-X
Bcl-2	B-X
antioxidant	B-X
response	B-X
element	B-X
.	B-X
Alterations	B-X
in	B-X
Nrf2	B-X
led	B-X
to	B-X
altered	B-X
Bcl-2	B-X
induction	B-X
and	B-X
cellular	B-X
apoptosis	B-X
.	B-X
Moreover	B-X
,	B-X
dysfunctional/mutant	B-X
inhibitor	B-X
of	B-X
Nrf2	B-X
(	B-X
INrf2	B-X
)	B-X
in	B-X
human	B-X
lung	B-X
cancer	B-X
cells	B-X
failed	B-X
to	B-X
degrade	B-X
Nrf2	B-X
,	B-X
resulting	B-X
in	B-X
an	B-X
increased	B-X
Bcl-2	B-X
level	B-X
and	B-X
decreased	B-X
etoposide-	B-X
and	B-X
UV/γ	B-X
radiation-mediated	B-X
DNA	B-X
fragmentation	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
siRNA-mediated	B-X
down-regulation	B-X
of	B-X
Nrf2	B-X
also	B-X
led	B-X
to	B-X
decreased	B-X
apoptosis	B-X
and	B-X
increased	B-X
cell	B-X
survival	B-X
.	B-X
Furthermore	B-X
,	B-X
the	B-X
specific	B-X
knockdown	B-X
of	B-X
Bcl-2	B-X
in	B-X
Nrf2-activated	B-X
tumor	B-X
cells	B-X
led	B-X
to	B-X
increased	B-X
etoposide-induced	B-X
apoptosis	B-X
and	B-X
decreased	B-X
cell	B-X
survival	B-X
and	B-X
growth/proliferation	B-X
.	B-X
These	B-X
data	B-X
provide	B-X
the	B-X
first	B-X
evidence	B-X
of	B-X
Nrf2	B-X
in	B-X
control	B-X
of	B-X
Bcl-2	B-X
expression	B-X
and	B-X
apoptotic	B-X
cell	B-X
death	B-X
with	B-X
implications	B-X
in	B-X
antioxidant	B-X
protection	B-X
,	B-X
survival	B-X
of	B-X
cancer	B-X
cells	B-X
,	B-X
and	B-X
drug	B-X
resistance	B-X
.	B-X

Overall	O
,	O
we	O
demonstrate	O
that	O
priapism	O
is	O
associated	O
with	O
increased	O
oxidative	O
stress	O
in	O
corporal	O
tissue	O
and	O
the	O
activation	O
of	O
protein	O
degradation	O
pathways	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
priapism	B-X
lasting	B-X
more	B-X
than	B-X
24	B-X
h	B-X
in	B-X
patients	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
44-90	B-X
%	B-X
rate	B-X
of	B-X
ED	B-X
.	B-X
In	B-X
this	B-X
investigation	B-X
,	B-X
we	B-X
determined	B-X
in	B-X
two	B-X
animal	B-X
models	B-X
of	B-X
priapism	B-X
(	B-X
opiorphin-induced	B-X
priapism	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
priapism	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
)	B-X
if	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
In	B-X
both	B-X
animal	B-X
models	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
results	B-X
in	B-X
increased	B-X
levels	B-X
of	B-X
lipid	B-X
peroxidation	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
activity	B-X
and	B-X
oxidatively	B-X
damaged	B-X
proteins	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
Using	B-X
western	B-X
blot	B-X
analysis	B-X
,	B-X
we	B-X
demonstrated	B-X
there	B-X
is	B-X
upregulation	B-X
of	B-X
the	B-X
ubiquitination	B-X
ligase	B-X
proteins	B-X
,	B-X
Nedd-4	B-X
and	B-X
Mdm-2	B-X
,	B-X
and	B-X
the	B-X
lysosomal	B-X
autophage	B-X
protein	B-X
,	B-X
LC3	B-X
.	B-X
The	B-X
antiapoptotic	B-X
protein	B-X
,	B-X
Bcl-2	B-X
,	B-X
was	B-X
also	B-X
upregulated	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
protein	B-X
degradation	B-X
pathways	B-X
.	B-X
As	B-X
oxidative	B-X
stress	B-X
is	B-X
known	B-X
to	B-X
mediate	B-X
the	B-X
development	B-X
of	B-X
ED	B-X
resulting	B-X
from	B-X
several	B-X
etiologies	B-X
(	B-X
for	B-X
example	B-X
,	B-X
ED	B-X
resulting	B-X
from	B-X
diabetes	B-X
and	B-X
aging	B-X
)	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
damage	B-X
to	B-X
erectile	B-X
tissue	B-X
resulting	B-X
from	B-X
priapism	B-X
might	B-X
be	B-X
prevented	B-X
by	B-X
treatments	B-X
targeting	B-X
oxidative	B-X
stress	B-X
.	B-X

As	O
oxidative	O
stress	O
is	O
known	O
to	O
mediate	O
the	O
development	O
of	O
ED	O
resulting	O
from	O
several	O
etiologies	O
(	O
for	O
example	O
,	O
ED	O
resulting	O
from	O
diabetes	O
and	O
aging	O
)	O
,	O
we	O
suggest	O
that	O
damage	O
to	O
erectile	O
tissue	O
resulting	O
from	O
priapism	O
might	O
be	O
prevented	O
by	O
treatments	O
targeting	O
oxidative	O
stress	O
.	O
<EOS>	B-X
It	B-X
has	B-X
been	B-X
estimated	B-X
that	B-X
priapism	B-X
lasting	B-X
more	B-X
than	B-X
24	B-X
h	B-X
in	B-X
patients	B-X
is	B-X
associated	B-X
with	B-X
a	B-X
44-90	B-X
%	B-X
rate	B-X
of	B-X
ED	B-X
.	B-X
In	B-X
this	B-X
investigation	B-X
,	B-X
we	B-X
determined	B-X
in	B-X
two	B-X
animal	B-X
models	B-X
of	B-X
priapism	B-X
(	B-X
opiorphin-induced	B-X
priapism	B-X
in	B-X
the	B-X
rat	B-X
and	B-X
priapism	B-X
in	B-X
a	B-X
mouse	B-X
model	B-X
of	B-X
sickle	B-X
cell	B-X
disease	B-X
)	B-X
if	B-X
there	B-X
is	B-X
evidence	B-X
for	B-X
an	B-X
increase	B-X
in	B-X
markers	B-X
of	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
In	B-X
both	B-X
animal	B-X
models	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
results	B-X
in	B-X
increased	B-X
levels	B-X
of	B-X
lipid	B-X
peroxidation	B-X
,	B-X
glutathione	B-X
S-transferase	B-X
activity	B-X
and	B-X
oxidatively	B-X
damaged	B-X
proteins	B-X
in	B-X
corporal	B-X
tissue	B-X
.	B-X
Overall	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
priapism	B-X
is	B-X
associated	B-X
with	B-X
increased	B-X
oxidative	B-X
stress	B-X
in	B-X
corporal	B-X
tissue	B-X
and	B-X
the	B-X
activation	B-X
of	B-X
protein	B-X
degradation	B-X
pathways	B-X
.	B-X
As	B-X
oxidative	B-X
stress	B-X
is	B-X
known	B-X
to	B-X
mediate	B-X
the	B-X
development	B-X
of	B-X
ED	B-X
resulting	B-X
from	B-X
several	B-X
etiologies	B-X
(	B-X
for	B-X
example	B-X
,	B-X
ED	B-X
resulting	B-X
from	B-X
diabetes	B-X
and	B-X
aging	B-X
)	B-X
,	B-X
we	B-X
suggest	B-X
that	B-X
damage	B-X
to	B-X
erectile	B-X
tissue	B-X
resulting	B-X
from	B-X
priapism	B-X
might	B-X
be	B-X
prevented	B-X
by	B-X
treatments	B-X
targeting	B-X
oxidative	B-X
stress	B-X
.	B-X

The	O
steady	O
-	O
state	O
repertoire	O
of	O
human	O
SCF	O
Ubiquitin	B-Protein
ligase	O
complexes	O
does	O
not	O
require	O
ongoing	O
Nedd8	B-Protein
conjugation	O
.	O

The	O
human	O
genome	O
encodes	O
69	O
different	O
F	O
-	O
box	O
proteins	O
(	O
FBPs	O
)	O
,	O
each	O
of	O
which	O
can	O
potentially	O
assemble	O
with	O
Skp1	B-Protein
-	O
Cul1	B-Protein
-	O
RING	O
to	O
serve	O
as	O
the	O
substrate	O
specificity	O
subunit	O
of	O
an	O
SCF	O
ubiquitin	B-Protein
ligase	O
complex	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

SCF	O
activity	O
is	O
switched	O
on	O
by	O
conjugation	O
of	O
the	O
ubiquitin	B-Protein
-	O
like	O
protein	O
Nedd8	B-Protein
to	O
Cul1	B-Protein
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Cycles	O
of	O
Nedd8	B-Protein
conjugation	O
and	O
deconjugation	O
acting	O
in	O
conjunction	O
with	O
the	O
Cul1	B-Protein
-	O
sequestering	O
factor	O
Cand1	B-Protein
are	O
thought	O
to	O
control	O
dynamic	O
cycles	O
of	O
SCF	O
assembly	O
and	O
disassembly	O
,	O
which	O
would	O
enable	O
a	O
dynamic	O
equilibrium	O
between	O
the	O
Cul1	B-Protein
-	O
RING	O
catalytic	O
core	O
of	O
SCF	O
and	O
the	O
cellular	O
repertoire	O
of	O
FBPs	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
the	O
cellular	O
composition	O
of	O
SCF	O
complexes	O
and	O
evaluated	O
the	O
impact	O
of	O
Nedd8	B-Protein
conjugation	O
on	O
this	O
steady	O
-	O
state	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

At	O
least	O
42	O
FBPs	O
assembled	O
with	O
Cul1	B-Protein
in	O
HEK	O
293	O
cells	O
,	O
and	O
the	O
levels	O
of	O
Cul1	B-Protein
-	O
bound	O
FBPs	O
varied	O
by	O
over	O
two	O
orders	O
of	O
magnitude	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X

Unexpectedly	O
,	O
quantitative	O
mass	O
spectrometry	O
revealed	O
that	O
blockade	O
of	O
Nedd8	B-Protein
conjugation	O
led	O
to	O
a	O
modest	O
increase	O
,	O
rather	O
than	O
a	O
decrease	O
,	O
in	O
the	O
overall	O
level	O
of	O
most	O
SCF	O
complexes	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

We	O
suggest	O
that	O
multiple	O
mechanisms	O
including	O
FBP	O
dissociation	O
and	O
turnover	O
cooperate	O
to	O
maintain	O
the	O
cellular	O
pool	O
of	O
SCF	O
ubiquitin	B-Protein
ligases	O
.	O
<EOS>	B-X
The	B-X
human	B-X
genome	B-X
encodes	B-X
69	B-X
different	B-X
F-box	B-X
proteins	B-X
(	B-X
FBPs	B-X
)	B-X
,	B-X
each	B-X
of	B-X
which	B-X
can	B-X
potentially	B-X
assemble	B-X
with	B-X
Skp1-Cul1-RING	B-X
to	B-X
serve	B-X
as	B-X
the	B-X
substrate	B-X
specificity	B-X
subunit	B-X
of	B-X
an	B-X
SCF	B-X
ubiquitin	B-X
ligase	B-X
complex	B-X
.	B-X
SCF	B-X
activity	B-X
is	B-X
switched	B-X
on	B-X
by	B-X
conjugation	B-X
of	B-X
the	B-X
ubiquitin-like	B-X
protein	B-X
Nedd8	B-X
to	B-X
Cul1	B-X
.	B-X
Cycles	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
and	B-X
deconjugation	B-X
acting	B-X
in	B-X
conjunction	B-X
with	B-X
the	B-X
Cul1-sequestering	B-X
factor	B-X
Cand1	B-X
are	B-X
thought	B-X
to	B-X
control	B-X
dynamic	B-X
cycles	B-X
of	B-X
SCF	B-X
assembly	B-X
and	B-X
disassembly	B-X
,	B-X
which	B-X
would	B-X
enable	B-X
a	B-X
dynamic	B-X
equilibrium	B-X
between	B-X
the	B-X
Cul1-RING	B-X
catalytic	B-X
core	B-X
of	B-X
SCF	B-X
and	B-X
the	B-X
cellular	B-X
repertoire	B-X
of	B-X
FBPs	B-X
.	B-X
To	B-X
test	B-X
this	B-X
hypothesis	B-X
,	B-X
we	B-X
determined	B-X
the	B-X
cellular	B-X
composition	B-X
of	B-X
SCF	B-X
complexes	B-X
and	B-X
evaluated	B-X
the	B-X
impact	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
on	B-X
this	B-X
steady-state	B-X
.	B-X
At	B-X
least	B-X
42	B-X
FBPs	B-X
assembled	B-X
with	B-X
Cul1	B-X
in	B-X
HEK	B-X
293	B-X
cells	B-X
,	B-X
and	B-X
the	B-X
levels	B-X
of	B-X
Cul1-bound	B-X
FBPs	B-X
varied	B-X
by	B-X
over	B-X
two	B-X
orders	B-X
of	B-X
magnitude	B-X
.	B-X
Unexpectedly	B-X
,	B-X
quantitative	B-X
mass	B-X
spectrometry	B-X
revealed	B-X
that	B-X
blockade	B-X
of	B-X
Nedd8	B-X
conjugation	B-X
led	B-X
to	B-X
a	B-X
modest	B-X
increase	B-X
,	B-X
rather	B-X
than	B-X
a	B-X
decrease	B-X
,	B-X
in	B-X
the	B-X
overall	B-X
level	B-X
of	B-X
most	B-X
SCF	B-X
complexes	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
multiple	B-X
mechanisms	B-X
including	B-X
FBP	B-X
dissociation	B-X
and	B-X
turnover	B-X
cooperate	B-X
to	B-X
maintain	B-X
the	B-X
cellular	B-X
pool	B-X
of	B-X
SCF	B-X
ubiquitin	B-X
ligases	B-X
.	B-X

Crystal	O
structure	O
of	O
UBA2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
:	O
insights	O
into	O
E1	O
-	O
E2	O
interactions	O
in	O
Sumo	O
pathways	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Canonical	O
ubiquitin	B-Protein
-	O
like	O
proteins	O
(	O
UBLs	O
)	O
such	O
as	O
ubiquitin	B-Protein
,	O
Sumo	O
,	O
NEDD8	B-Protein
,	O
and	O
ISG15	B-Protein
are	O
ligated	O
to	O
targets	O
by	O
E1	O
-	O
E2	O
-	O
E3	O
multienzyme	O
cascades	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

The	O
Sumo	O
cascade	O
,	O
conserved	O
among	O
all	O
eukaryotes	O
,	O
regulates	O
numerous	O
biological	O
processes	O
including	O
protein	O
localization	O
,	O
transcription	O
,	O
DNA	O
replication	O
,	O
and	O
mitosis	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Sumo	O
conjugation	O
is	O
initiated	O
by	O
the	O
heterodimeric	O
Aos1	B-Protein
-	O
Uba2	B-Protein
E1	O
enzyme	O
(	O
in	O
humans	O
called	O
Sae1	B-Protein
-	O
Uba2	B-Protein
)	O
,	O
which	O
activates	O
Sumo	O
'	O
s	O
C	O
-	O
terminus	O
,	O
binds	O
the	O
dedicated	O
E2	O
enzyme	O
Ubc9	B-Protein
,	O
and	O
promotes	O
Sumo	O
C	O
-	O
terminal	O
transfer	O
between	O
the	O
Uba2	B-Protein
and	O
Ubc9	B-Protein
catalytic	O
cysteines	O
.	O

To	O
gain	O
insights	O
into	O
details	O
of	O
E1	O
-	O
E2	O
interactions	O
in	O
the	O
Sumo	O
pathway	O
,	O
we	O
determined	O
crystal	O
structures	O
of	O
the	O
C	O
-	O
terminal	O
ubiquitin	B-Protein
fold	O
domain	O
(	O
ufd	O
)	O
from	O
yeast	O
Uba2	B-Protein
(	O
Uba2	B-Protein
(	O
ufd	O
)	O
)	O
,	O
alone	O
and	O
in	O
complex	O
with	O
Ubc9	B-Protein
.	O

The	O
overall	O
structures	O
of	O
both	O
yeast	O
Uba2	B-Protein
(	O
ufd	O
)	O
and	O
Ubc9	B-Protein
superimpose	O
well	O
on	O
their	O
individual	O
human	O
counterparts	O
,	O
suggesting	O
conservation	O
of	O
fundamental	O
features	O
of	O
Sumo	O
conjugation	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Docking	O
the	O
Uba2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
and	O
prior	O
full	O
-	O
length	O
human	O
Uba2	B-Protein
structures	O
allows	O
generation	O
of	O
models	O
for	O
steps	O
in	O
Sumo	O
transfer	O
from	O
Uba2	B-Protein
to	O
Ubc9	B-Protein
,	O
and	O
supports	O
the	O
notion	O
that	O
Uba2	B-Protein
undergoes	O
remarkable	O
conformational	O
changes	O
during	O
the	O
reaction	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Comparisons	O
to	O
previous	O
structures	O
from	O
the	O
NEDD8	B-Protein
cascade	O
demonstrate	O
that	O
UBL	O
cascades	O
generally	O
utilize	O
some	O
parallel	O
E1	O
-	O
E2	O
interaction	O
surfaces	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

In	O
addition	O
,	O
the	O
structure	O
of	O
the	O
Uba2	B-Protein
(	O
ufd	O
)	O
-	O
Ubc9	B-Protein
complex	O
reveals	O
interactions	O
unique	O
to	O
Sumo	O
E1	O
and	O
E2	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Comparison	O
with	O
a	O
previous	O
Ubc9	B-Protein
-	O
E3	O
complex	O
structure	O
demonstrates	O
overlap	O
between	O
Uba2	B-Protein
and	O
E3	O
binding	O
sites	O
on	O
Ubc9	B-Protein
,	O
indicating	O
that	O
loading	O
with	O
Sumo	O
and	O
E3	O
-	O
catalyzed	O
transfer	O
to	O
substrates	O
are	O
strictly	O
separate	O
steps	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

The	O
results	O
suggest	O
mechanisms	O
establishing	O
specificity	O
and	O
order	O
in	O
Sumo	O
conjugation	O
cascades	O
.	O
<EOS>	B-X
Canonical	B-X
ubiquitin-like	B-X
proteins	B-X
(	B-X
UBLs	B-X
)	B-X
such	B-X
as	B-X
ubiquitin	B-X
,	B-X
Sumo	B-X
,	B-X
NEDD8	B-X
,	B-X
and	B-X
ISG15	B-X
are	B-X
ligated	B-X
to	B-X
targets	B-X
by	B-X
E1-E2-E3	B-X
multienzyme	B-X
cascades	B-X
.	B-X
The	B-X
Sumo	B-X
cascade	B-X
,	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
,	B-X
regulates	B-X
numerous	B-X
biological	B-X
processes	B-X
including	B-X
protein	B-X
localization	B-X
,	B-X
transcription	B-X
,	B-X
DNA	B-X
replication	B-X
,	B-X
and	B-X
mitosis	B-X
.	B-X
Sumo	B-X
conjugation	B-X
is	B-X
initiated	B-X
by	B-X
the	B-X
heterodimeric	B-X
Aos1-Uba2	B-X
E1	B-X
enzyme	B-X
(	B-X
in	B-X
humans	B-X
called	B-X
Sae1-Uba2	B-X
)	B-X
,	B-X
which	B-X
activates	B-X
Sumo	B-X
's	B-X
C-terminus	B-X
,	B-X
binds	B-X
the	B-X
dedicated	B-X
E2	B-X
enzyme	B-X
Ubc9	B-X
,	B-X
and	B-X
promotes	B-X
Sumo	B-X
C-terminal	B-X
transfer	B-X
between	B-X
the	B-X
Uba2	B-X
and	B-X
Ubc9	B-X
catalytic	B-X
cysteines	B-X
.	B-X
To	B-X
gain	B-X
insights	B-X
into	B-X
details	B-X
of	B-X
E1-E2	B-X
interactions	B-X
in	B-X
the	B-X
Sumo	B-X
pathway	B-X
,	B-X
we	B-X
determined	B-X
crystal	B-X
structures	B-X
of	B-X
the	B-X
C-terminal	B-X
ubiquitin	B-X
fold	B-X
domain	B-X
(	B-X
ufd	B-X
)	B-X
from	B-X
yeast	B-X
Uba2	B-X
(	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
)	B-X
,	B-X
alone	B-X
and	B-X
in	B-X
complex	B-X
with	B-X
Ubc9	B-X
.	B-X
The	B-X
overall	B-X
structures	B-X
of	B-X
both	B-X
yeast	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
and	B-X
Ubc9	B-X
superimpose	B-X
well	B-X
on	B-X
their	B-X
individual	B-X
human	B-X
counterparts	B-X
,	B-X
suggesting	B-X
conservation	B-X
of	B-X
fundamental	B-X
features	B-X
of	B-X
Sumo	B-X
conjugation	B-X
.	B-X
Docking	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
and	B-X
prior	B-X
full-length	B-X
human	B-X
Uba2	B-X
structures	B-X
allows	B-X
generation	B-X
of	B-X
models	B-X
for	B-X
steps	B-X
in	B-X
Sumo	B-X
transfer	B-X
from	B-X
Uba2	B-X
to	B-X
Ubc9	B-X
,	B-X
and	B-X
supports	B-X
the	B-X
notion	B-X
that	B-X
Uba2	B-X
undergoes	B-X
remarkable	B-X
conformational	B-X
changes	B-X
during	B-X
the	B-X
reaction	B-X
.	B-X
Comparisons	B-X
to	B-X
previous	B-X
structures	B-X
from	B-X
the	B-X
NEDD8	B-X
cascade	B-X
demonstrate	B-X
that	B-X
UBL	B-X
cascades	B-X
generally	B-X
utilize	B-X
some	B-X
parallel	B-X
E1-E2	B-X
interaction	B-X
surfaces	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
Uba2	B-X
(	B-X
ufd	B-X
)	B-X
-Ubc9	B-X
complex	B-X
reveals	B-X
interactions	B-X
unique	B-X
to	B-X
Sumo	B-X
E1	B-X
and	B-X
E2	B-X
.	B-X
Comparison	B-X
with	B-X
a	B-X
previous	B-X
Ubc9-E3	B-X
complex	B-X
structure	B-X
demonstrates	B-X
overlap	B-X
between	B-X
Uba2	B-X
and	B-X
E3	B-X
binding	B-X
sites	B-X
on	B-X
Ubc9	B-X
,	B-X
indicating	B-X
that	B-X
loading	B-X
with	B-X
Sumo	B-X
and	B-X
E3-catalyzed	B-X
transfer	B-X
to	B-X
substrates	B-X
are	B-X
strictly	B-X
separate	B-X
steps	B-X
.	B-X
The	B-X
results	B-X
suggest	B-X
mechanisms	B-X
establishing	B-X
specificity	B-X
and	B-X
order	B-X
in	B-X
Sumo	B-X
conjugation	B-X
cascades	B-X
.	B-X

Farnesyl	O
cysteine	O
C	O
-	O
terminal	O
methyltransferase	O
activity	O
is	O
dependent	O
upon	O
the	O
STE14	B-Protein
gene	O
product	O
in	O
Saccharomyces	O
cerevisiae	O
.	O
<EOS>	B-X
Membrane	B-X
extracts	B-X
of	B-X
sterile	B-X
Saccharomyces	B-X
cerevisiae	B-X
strains	B-X
containing	B-X
the	B-X
a-specific	B-X
ste14	B-X
mutation	B-X
lack	B-X
a	B-X
farnesyl	B-X
cysteine	B-X
C-terminal	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
that	B-X
is	B-X
present	B-X
in	B-X
wild-type	B-X
a	B-X
and	B-X
alpha	B-X
cells	B-X
.	B-X
Other	B-X
a-specific	B-X
sterile	B-X
strains	B-X
with	B-X
ste6	B-X
and	B-X
ste16	B-X
mutations	B-X
also	B-X
have	B-X
wild-type	B-X
levels	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
.	B-X
This	B-X
enzyme	B-X
activity	B-X
,	B-X
detected	B-X
by	B-X
using	B-X
a	B-X
synthetic	B-X
peptide	B-X
sequence	B-X
based	B-X
on	B-X
the	B-X
C-terminus	B-X
of	B-X
a	B-X
ras	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
responsible	B-X
not	B-X
only	B-X
for	B-X
the	B-X
essential	B-X
methylation	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
residue	B-X
of	B-X
a	B-X
mating	B-X
factor	B-X
,	B-X
but	B-X
also	B-X
for	B-X
the	B-X
methylation	B-X
of	B-X
yeast	B-X
RAS1	B-X
and	B-X
RAS2	B-X
proteins	B-X
and	B-X
possibly	B-X
other	B-X
polypeptides	B-X
with	B-X
similar	B-X
C-terminal	B-X
structures	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
farnesylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
in	B-X
the	B-X
peptide	B-X
is	B-X
required	B-X
for	B-X
the	B-X
methyltransferase	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
methyl	B-X
esterification	B-X
follows	B-X
the	B-X
lipidation	B-X
reaction	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
To	B-X
show	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
methyltransferase	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
result	B-X
of	B-X
the	B-X
ste14	B-X
mutation	B-X
,	B-X
we	B-X
transformed	B-X
ste14	B-X
mutant	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
complementing	B-X
the	B-X
mating	B-X
defect	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
found	B-X
that	B-X
active	B-X
enzyme	B-X
was	B-X
produced	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
a	B-X
similar	B-X
transformation	B-X
of	B-X
cells	B-X
possessing	B-X
the	B-X
wild-type	B-X
STE14	B-X
gene	B-X
resulted	B-X
in	B-X
sixfold	B-X
overproduction	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Although	B-X
more	B-X
complicated	B-X
possibilities	B-X
can	B-X
not	B-X
be	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
STE14	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
the	B-X
structural	B-X
gene	B-X
for	B-X
a	B-X
methyltransferase	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
isoprenylated	B-X
cysteine	B-X
alpha-methyl	B-X
ester	B-X
C-terminal	B-X
structures	B-X
.	B-X

Membrane	O
extracts	O
of	O
sterile	O
Saccharomyces	O
cerevisiae	O
strains	O
containing	O
the	O
a	O
-	O
specific	O
ste14	B-Protein
mutation	O
lack	O
a	O
farnesyl	O
cysteine	O
C	O
-	O
terminal	O
carboxyl	O
methyltransferase	O
activity	O
that	O
is	O
present	O
in	O
wild	O
-	O
type	O
a	O
and	O
alpha	O
cells	O
.	O

Other	O
a	O
-	O
specific	O
sterile	O
strains	O
with	O
ste6	B-Protein
and	O
ste16	B-Protein
mutations	O
also	O
have	O
wild	O
-	O
type	O
levels	O
of	O
the	O
farnesyl	O
cysteine	O
carboxyl	O
methyltransferase	O
activity	O
.	O

This	O
enzyme	O
activity	O
,	O
detected	O
by	O
using	O
a	O
synthetic	O
peptide	O
sequence	O
based	O
on	O
the	O
C	O
-	O
terminus	O
of	O
a	O
ras	O
protein	O
,	O
may	O
be	O
responsible	O
not	O
only	O
for	O
the	O
essential	O
methylation	O
of	O
the	O
farnesyl	O
cysteine	O
residue	O
of	O
a	O
mating	O
factor	O
,	O
but	O
also	O
for	O
the	O
methylation	O
of	O
yeast	O
RAS1	B-Protein
and	O
RAS2	B-Protein
proteins	O
and	O
possibly	O
other	O
polypeptides	O
with	O
similar	O
C	O
-	O
terminal	O
structures	O
.	O

We	O
demonstrate	O
that	O
the	O
farnesylation	O
of	O
the	O
cysteine	O
residue	O
in	O
the	O
peptide	O
is	O
required	O
for	O
the	O
methyltransferase	O
activity	O
,	O
suggesting	O
that	O
methyl	O
esterification	O
follows	O
the	O
lipidation	O
reaction	O
in	O
the	O
cell	O
.	O
<EOS>	B-X
Membrane	B-X
extracts	B-X
of	B-X
sterile	B-X
Saccharomyces	B-X
cerevisiae	B-X
strains	B-X
containing	B-X
the	B-X
a-specific	B-X
ste14	B-X
mutation	B-X
lack	B-X
a	B-X
farnesyl	B-X
cysteine	B-X
C-terminal	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
that	B-X
is	B-X
present	B-X
in	B-X
wild-type	B-X
a	B-X
and	B-X
alpha	B-X
cells	B-X
.	B-X
Other	B-X
a-specific	B-X
sterile	B-X
strains	B-X
with	B-X
ste6	B-X
and	B-X
ste16	B-X
mutations	B-X
also	B-X
have	B-X
wild-type	B-X
levels	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
.	B-X
This	B-X
enzyme	B-X
activity	B-X
,	B-X
detected	B-X
by	B-X
using	B-X
a	B-X
synthetic	B-X
peptide	B-X
sequence	B-X
based	B-X
on	B-X
the	B-X
C-terminus	B-X
of	B-X
a	B-X
ras	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
responsible	B-X
not	B-X
only	B-X
for	B-X
the	B-X
essential	B-X
methylation	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
residue	B-X
of	B-X
a	B-X
mating	B-X
factor	B-X
,	B-X
but	B-X
also	B-X
for	B-X
the	B-X
methylation	B-X
of	B-X
yeast	B-X
RAS1	B-X
and	B-X
RAS2	B-X
proteins	B-X
and	B-X
possibly	B-X
other	B-X
polypeptides	B-X
with	B-X
similar	B-X
C-terminal	B-X
structures	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
farnesylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
in	B-X
the	B-X
peptide	B-X
is	B-X
required	B-X
for	B-X
the	B-X
methyltransferase	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
methyl	B-X
esterification	B-X
follows	B-X
the	B-X
lipidation	B-X
reaction	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
To	B-X
show	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
methyltransferase	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
result	B-X
of	B-X
the	B-X
ste14	B-X
mutation	B-X
,	B-X
we	B-X
transformed	B-X
ste14	B-X
mutant	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
complementing	B-X
the	B-X
mating	B-X
defect	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
found	B-X
that	B-X
active	B-X
enzyme	B-X
was	B-X
produced	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
a	B-X
similar	B-X
transformation	B-X
of	B-X
cells	B-X
possessing	B-X
the	B-X
wild-type	B-X
STE14	B-X
gene	B-X
resulted	B-X
in	B-X
sixfold	B-X
overproduction	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Although	B-X
more	B-X
complicated	B-X
possibilities	B-X
can	B-X
not	B-X
be	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
STE14	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
the	B-X
structural	B-X
gene	B-X
for	B-X
a	B-X
methyltransferase	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
isoprenylated	B-X
cysteine	B-X
alpha-methyl	B-X
ester	B-X
C-terminal	B-X
structures	B-X
.	B-X

To	O
show	O
that	O
the	O
loss	O
of	O
methyltransferase	O
activity	O
is	O
a	O
direct	O
result	O
of	O
the	O
ste14	B-Protein
mutation	O
,	O
we	O
transformed	O
ste14	B-Protein
mutant	O
cells	O
with	O
a	O
plasmid	O
complementing	O
the	O
mating	O
defect	O
of	O
this	O
strain	O
and	O
found	O
that	O
active	O
enzyme	O
was	O
produced	O
.	O
<EOS>	B-X
Membrane	B-X
extracts	B-X
of	B-X
sterile	B-X
Saccharomyces	B-X
cerevisiae	B-X
strains	B-X
containing	B-X
the	B-X
a-specific	B-X
ste14	B-X
mutation	B-X
lack	B-X
a	B-X
farnesyl	B-X
cysteine	B-X
C-terminal	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
that	B-X
is	B-X
present	B-X
in	B-X
wild-type	B-X
a	B-X
and	B-X
alpha	B-X
cells	B-X
.	B-X
Other	B-X
a-specific	B-X
sterile	B-X
strains	B-X
with	B-X
ste6	B-X
and	B-X
ste16	B-X
mutations	B-X
also	B-X
have	B-X
wild-type	B-X
levels	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
.	B-X
This	B-X
enzyme	B-X
activity	B-X
,	B-X
detected	B-X
by	B-X
using	B-X
a	B-X
synthetic	B-X
peptide	B-X
sequence	B-X
based	B-X
on	B-X
the	B-X
C-terminus	B-X
of	B-X
a	B-X
ras	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
responsible	B-X
not	B-X
only	B-X
for	B-X
the	B-X
essential	B-X
methylation	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
residue	B-X
of	B-X
a	B-X
mating	B-X
factor	B-X
,	B-X
but	B-X
also	B-X
for	B-X
the	B-X
methylation	B-X
of	B-X
yeast	B-X
RAS1	B-X
and	B-X
RAS2	B-X
proteins	B-X
and	B-X
possibly	B-X
other	B-X
polypeptides	B-X
with	B-X
similar	B-X
C-terminal	B-X
structures	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
farnesylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
in	B-X
the	B-X
peptide	B-X
is	B-X
required	B-X
for	B-X
the	B-X
methyltransferase	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
methyl	B-X
esterification	B-X
follows	B-X
the	B-X
lipidation	B-X
reaction	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
To	B-X
show	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
methyltransferase	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
result	B-X
of	B-X
the	B-X
ste14	B-X
mutation	B-X
,	B-X
we	B-X
transformed	B-X
ste14	B-X
mutant	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
complementing	B-X
the	B-X
mating	B-X
defect	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
found	B-X
that	B-X
active	B-X
enzyme	B-X
was	B-X
produced	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
a	B-X
similar	B-X
transformation	B-X
of	B-X
cells	B-X
possessing	B-X
the	B-X
wild-type	B-X
STE14	B-X
gene	B-X
resulted	B-X
in	B-X
sixfold	B-X
overproduction	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Although	B-X
more	B-X
complicated	B-X
possibilities	B-X
can	B-X
not	B-X
be	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
STE14	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
the	B-X
structural	B-X
gene	B-X
for	B-X
a	B-X
methyltransferase	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
isoprenylated	B-X
cysteine	B-X
alpha-methyl	B-X
ester	B-X
C-terminal	B-X
structures	B-X
.	B-X

Finally	O
,	O
we	O
demonstrated	O
that	O
a	O
similar	O
transformation	O
of	O
cells	O
possessing	O
the	O
wild	O
-	O
type	O
STE14	B-Protein
gene	O
resulted	O
in	O
sixfold	O
overproduction	O
of	O
the	O
enzyme	O
.	O
<EOS>	B-X
Membrane	B-X
extracts	B-X
of	B-X
sterile	B-X
Saccharomyces	B-X
cerevisiae	B-X
strains	B-X
containing	B-X
the	B-X
a-specific	B-X
ste14	B-X
mutation	B-X
lack	B-X
a	B-X
farnesyl	B-X
cysteine	B-X
C-terminal	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
that	B-X
is	B-X
present	B-X
in	B-X
wild-type	B-X
a	B-X
and	B-X
alpha	B-X
cells	B-X
.	B-X
Other	B-X
a-specific	B-X
sterile	B-X
strains	B-X
with	B-X
ste6	B-X
and	B-X
ste16	B-X
mutations	B-X
also	B-X
have	B-X
wild-type	B-X
levels	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
.	B-X
This	B-X
enzyme	B-X
activity	B-X
,	B-X
detected	B-X
by	B-X
using	B-X
a	B-X
synthetic	B-X
peptide	B-X
sequence	B-X
based	B-X
on	B-X
the	B-X
C-terminus	B-X
of	B-X
a	B-X
ras	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
responsible	B-X
not	B-X
only	B-X
for	B-X
the	B-X
essential	B-X
methylation	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
residue	B-X
of	B-X
a	B-X
mating	B-X
factor	B-X
,	B-X
but	B-X
also	B-X
for	B-X
the	B-X
methylation	B-X
of	B-X
yeast	B-X
RAS1	B-X
and	B-X
RAS2	B-X
proteins	B-X
and	B-X
possibly	B-X
other	B-X
polypeptides	B-X
with	B-X
similar	B-X
C-terminal	B-X
structures	B-X
.	B-X
To	B-X
show	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
methyltransferase	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
result	B-X
of	B-X
the	B-X
ste14	B-X
mutation	B-X
,	B-X
we	B-X
transformed	B-X
ste14	B-X
mutant	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
complementing	B-X
the	B-X
mating	B-X
defect	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
found	B-X
that	B-X
active	B-X
enzyme	B-X
was	B-X
produced	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
a	B-X
similar	B-X
transformation	B-X
of	B-X
cells	B-X
possessing	B-X
the	B-X
wild-type	B-X
STE14	B-X
gene	B-X
resulted	B-X
in	B-X
sixfold	B-X
overproduction	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Although	B-X
more	B-X
complicated	B-X
possibilities	B-X
can	B-X
not	B-X
be	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
STE14	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
the	B-X
structural	B-X
gene	B-X
for	B-X
a	B-X
methyltransferase	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
isoprenylated	B-X
cysteine	B-X
alpha-methyl	B-X
ester	B-X
C-terminal	B-X
structures	B-X
.	B-X

Although	O
more	O
complicated	O
possibilities	O
cannot	O
be	O
ruled	O
out	O
,	O
these	O
results	O
suggest	O
that	O
STE14	B-Protein
is	O
a	O
candidate	O
for	O
the	O
structural	O
gene	O
for	O
a	O
methyltransferase	O
involved	O
in	O
the	O
formation	O
of	O
isoprenylated	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
C	O
-	O
terminal	O
structures	O
.	O
<EOS>	B-X
Membrane	B-X
extracts	B-X
of	B-X
sterile	B-X
Saccharomyces	B-X
cerevisiae	B-X
strains	B-X
containing	B-X
the	B-X
a-specific	B-X
ste14	B-X
mutation	B-X
lack	B-X
a	B-X
farnesyl	B-X
cysteine	B-X
C-terminal	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
that	B-X
is	B-X
present	B-X
in	B-X
wild-type	B-X
a	B-X
and	B-X
alpha	B-X
cells	B-X
.	B-X
Other	B-X
a-specific	B-X
sterile	B-X
strains	B-X
with	B-X
ste6	B-X
and	B-X
ste16	B-X
mutations	B-X
also	B-X
have	B-X
wild-type	B-X
levels	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
carboxyl	B-X
methyltransferase	B-X
activity	B-X
.	B-X
This	B-X
enzyme	B-X
activity	B-X
,	B-X
detected	B-X
by	B-X
using	B-X
a	B-X
synthetic	B-X
peptide	B-X
sequence	B-X
based	B-X
on	B-X
the	B-X
C-terminus	B-X
of	B-X
a	B-X
ras	B-X
protein	B-X
,	B-X
may	B-X
be	B-X
responsible	B-X
not	B-X
only	B-X
for	B-X
the	B-X
essential	B-X
methylation	B-X
of	B-X
the	B-X
farnesyl	B-X
cysteine	B-X
residue	B-X
of	B-X
a	B-X
mating	B-X
factor	B-X
,	B-X
but	B-X
also	B-X
for	B-X
the	B-X
methylation	B-X
of	B-X
yeast	B-X
RAS1	B-X
and	B-X
RAS2	B-X
proteins	B-X
and	B-X
possibly	B-X
other	B-X
polypeptides	B-X
with	B-X
similar	B-X
C-terminal	B-X
structures	B-X
.	B-X
We	B-X
demonstrate	B-X
that	B-X
the	B-X
farnesylation	B-X
of	B-X
the	B-X
cysteine	B-X
residue	B-X
in	B-X
the	B-X
peptide	B-X
is	B-X
required	B-X
for	B-X
the	B-X
methyltransferase	B-X
activity	B-X
,	B-X
suggesting	B-X
that	B-X
methyl	B-X
esterification	B-X
follows	B-X
the	B-X
lipidation	B-X
reaction	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
To	B-X
show	B-X
that	B-X
the	B-X
loss	B-X
of	B-X
methyltransferase	B-X
activity	B-X
is	B-X
a	B-X
direct	B-X
result	B-X
of	B-X
the	B-X
ste14	B-X
mutation	B-X
,	B-X
we	B-X
transformed	B-X
ste14	B-X
mutant	B-X
cells	B-X
with	B-X
a	B-X
plasmid	B-X
complementing	B-X
the	B-X
mating	B-X
defect	B-X
of	B-X
this	B-X
strain	B-X
and	B-X
found	B-X
that	B-X
active	B-X
enzyme	B-X
was	B-X
produced	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
demonstrated	B-X
that	B-X
a	B-X
similar	B-X
transformation	B-X
of	B-X
cells	B-X
possessing	B-X
the	B-X
wild-type	B-X
STE14	B-X
gene	B-X
resulted	B-X
in	B-X
sixfold	B-X
overproduction	B-X
of	B-X
the	B-X
enzyme	B-X
.	B-X
Although	B-X
more	B-X
complicated	B-X
possibilities	B-X
can	B-X
not	B-X
be	B-X
ruled	B-X
out	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
STE14	B-X
is	B-X
a	B-X
candidate	B-X
for	B-X
the	B-X
structural	B-X
gene	B-X
for	B-X
a	B-X
methyltransferase	B-X
involved	B-X
in	B-X
the	B-X
formation	B-X
of	B-X
isoprenylated	B-X
cysteine	B-X
alpha-methyl	B-X
ester	B-X
C-terminal	B-X
structures	B-X
.	B-X

cDNA	O
sequence	O
,	O
in	O
vitro	O
synthesis	O
,	O
and	O
intramitochondrial	O
lipoylation	O
of	O
H	B-Protein
-	I-Protein
protein	I-Protein
of	O
the	O
glycine	O
cleavage	O
system	O
.	O
<EOS>	B-X
H-protein	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
and	B-X
has	B-X
lipoic	B-X
acid	B-X
as	B-X
a	B-X
prosthetic	B-X
group	B-X
.	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
result	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
two	B-X
adenylation	B-X
signals	B-X
in	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
the	B-X
cDNA	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
Bovine	B-X
liver	B-X
H-protein	B-X
precursor	B-X
has	B-X
no	B-X
lipoic	B-X
acid	B-X
prosthetic	B-X
group	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

H	B-Protein
-	I-Protein
protein	I-Protein
is	O
a	O
component	O
of	O
the	O
glycine	O
cleavage	O
system	O
loosely	O
associated	O
with	O
the	O
mitochondrial	O
inner	O
membrane	O
and	O
has	O
lipoic	O
acid	O
as	O
a	O
prosthetic	O
group	O
.	O
<EOS>	B-X
The	B-X
glycine	B-X
cleavage	B-X
system	B-X
catalyzes	B-X
the	B-X
following	B-X
reversible	B-X
reaction	B-X
:	B-X
Glycine	B-X
+	B-X
H	B-X
(	B-X
4	B-X
)	B-X
folate	B-X
+	B-X
NAD	B-X
(	B-X
+	B-X
)	B-X
<	B-X
==	B-X
>	B-X
5,10-methylene-H	B-X
(	B-X
4	B-X
)	B-X
folate	B-X
+	B-X
CO	B-X
(	B-X
2	B-X
)	B-X
+	B-X
NH	B-X
(	B-X
3	B-X
)	B-X
+	B-X
NADH	B-X
+	B-X
H	B-X
(	B-X
+	B-X
)	B-X
The	B-X
glycine	B-X
cleavage	B-X
system	B-X
is	B-X
widely	B-X
distributed	B-X
in	B-X
animals	B-X
,	B-X
plants	B-X
and	B-X
bacteria	B-X
and	B-X
consists	B-X
of	B-X
three	B-X
intrinsic	B-X
and	B-X
one	B-X
common	B-X
components	B-X
:	B-X
those	B-X
are	B-X
i	B-X
)	B-X
P-protein	B-X
,	B-X
a	B-X
pyridoxal	B-X
phosphate-containing	B-X
protein	B-X
,	B-X
ii	B-X
)	B-X
T-protein	B-X
,	B-X
a	B-X
protein	B-X
required	B-X
for	B-X
the	B-X
tetrahydrofolate-dependent	B-X
reaction	B-X
,	B-X
iii	B-X
)	B-X
H-protein	B-X
,	B-X
a	B-X
protein	B-X
that	B-X
carries	B-X
the	B-X
aminomethyl	B-X
intermediate	B-X
and	B-X
then	B-X
hydrogen	B-X
through	B-X
the	B-X
prosthetic	B-X
lipoyl	B-X
moiety	B-X
,	B-X
and	B-X
iv	B-X
)	B-X
L-protein	B-X
,	B-X
a	B-X
common	B-X
lipoamide	B-X
dehydrogenase	B-X
.	B-X
In	B-X
animals	B-X
and	B-X
plants	B-X
,	B-X
the	B-X
proteins	B-X
form	B-X
an	B-X
enzyme	B-X
complex	B-X
loosely	B-X
associating	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
.	B-X
In	B-X
the	B-X
enzymatic	B-X
reaction	B-X
,	B-X
H-protein	B-X
converts	B-X
P-protein	B-X
,	B-X
which	B-X
is	B-X
by	B-X
itself	B-X
a	B-X
potential	B-X
alpha-amino	B-X
acid	B-X
decarboxylase	B-X
,	B-X
to	B-X
an	B-X
active	B-X
enzyme	B-X
,	B-X
and	B-X
also	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
T-protein	B-X
.	B-X
In	B-X
both	B-X
glycine	B-X
cleavage	B-X
and	B-X
synthesis	B-X
,	B-X
aminomethyl	B-X
moiety	B-X
bound	B-X
to	B-X
lipoic	B-X
acid	B-X
of	B-X
H-protein	B-X
represents	B-X
the	B-X
intermediate	B-X
that	B-X
is	B-X
degraded	B-X
to	B-X
or	B-X
can	B-X
be	B-X
formed	B-X
from	B-X
N	B-X
(	B-X
5	B-X
)	B-X
,	B-X
N	B-X
(	B-X
10	B-X
)	B-X
-methylene-H	B-X
(	B-X
4	B-X
)	B-X
folate	B-X
and	B-X
ammonia	B-X
by	B-X
the	B-X
action	B-X
of	B-X
T-protein	B-X
.	B-X
N	B-X
(	B-X
5	B-X
)	B-X
,	B-X
N	B-X
(	B-X
10	B-X
)	B-X
-Methylene-H	B-X
(	B-X
4	B-X
)	B-X
folate	B-X
is	B-X
used	B-X
for	B-X
the	B-X
biosynthesis	B-X
of	B-X
various	B-X
cellular	B-X
substances	B-X
such	B-X
as	B-X
purines	B-X
,	B-X
thymidylate	B-X
and	B-X
methionine	B-X
that	B-X
is	B-X
the	B-X
major	B-X
methyl	B-X
group	B-X
donor	B-X
through	B-X
S-adenosyl-methionine	B-X
.	B-X
This	B-X
accounts	B-X
for	B-X
the	B-X
physiological	B-X
importance	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
as	B-X
the	B-X
most	B-X
prominent	B-X
pathway	B-X
in	B-X
serine	B-X
and	B-X
glycine	B-X
catabolism	B-X
in	B-X
various	B-X
vertebrates	B-X
including	B-X
humans	B-X
.	B-X
Nonketotic	B-X
hyperglycinemia	B-X
,	B-X
a	B-X
congenital	B-X
metabolic	B-X
disorder	B-X
in	B-X
human	B-X
infants	B-X
,	B-X
results	B-X
from	B-X
defective	B-X
glycine	B-X
cleavage	B-X
activity	B-X
.	B-X
The	B-X
majority	B-X
of	B-X
patients	B-X
with	B-X
nonketotic	B-X
hyperglycinemia	B-X
had	B-X
lesions	B-X
in	B-X
the	B-X
P-protein	B-X
gene	B-X
,	B-X
whereas	B-X
some	B-X
had	B-X
mutant	B-X
T-protein	B-X
genes	B-X
.	B-X
The	B-X
only	B-X
patient	B-X
classified	B-X
into	B-X
the	B-X
degenerative	B-X
type	B-X
of	B-X
nonketotic	B-X
hyperglycinemia	B-X
had	B-X
an	B-X
H-protein	B-X
devoid	B-X
of	B-X
the	B-X
prosthetic	B-X
lipoyl	B-X
residue	B-X
.	B-X
The	B-X
crystallography	B-X
of	B-X
normal	B-X
T-protein	B-X
as	B-X
well	B-X
as	B-X
biochemical	B-X
characterization	B-X
of	B-X
recombinants	B-X
of	B-X
the	B-X
normal	B-X
and	B-X
mutant	B-X
T-proteins	B-X
confirmed	B-X
why	B-X
the	B-X
mutant	B-X
T-proteins	B-X
had	B-X
lost	B-X
enzyme	B-X
activity	B-X
.	B-X
Putative	B-X
mechanisms	B-X
of	B-X
cellular	B-X
injuries	B-X
including	B-X
those	B-X
in	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
of	B-X
patients	B-X
with	B-X
nonketotic	B-X
hyperglycinemia	B-X
are	B-X
discussed	B-X
.	B-X

cDNA	O
clones	O
encoding	O
H	B-Protein
-	I-Protein
protein	I-Protein
were	O
isolated	O
from	O
a	O
bovine	O
liver	O
cDNA	O
library	O
with	O
an	O
oligonucleotide	O
probe	O
from	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
NH2	O
-	O
terminal	O
region	O
.	O
<EOS>	B-X
H-protein	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
and	B-X
has	B-X
lipoic	B-X
acid	B-X
as	B-X
a	B-X
prosthetic	B-X
group	B-X
.	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
result	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
two	B-X
adenylation	B-X
signals	B-X
in	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
the	B-X
cDNA	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
Bovine	B-X
liver	B-X
H-protein	B-X
precursor	B-X
has	B-X
no	B-X
lipoic	B-X
acid	B-X
prosthetic	B-X
group	B-X
.	B-X
When	B-X
incubated	B-X
with	B-X
isolated	B-X
bovine	B-X
liver	B-X
mitochondria	B-X
,	B-X
the	B-X
precursor	B-X
was	B-X
imported	B-X
into	B-X
mitochondria	B-X
,	B-X
processed	B-X
to	B-X
its	B-X
mature	B-X
form	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
14	B-X
kDa	B-X
,	B-X
and	B-X
lipoylated	B-X
at	B-X
lysine	B-X
59	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

DNA	O
sequence	O
analysis	O
and	O
deduced	O
amino	O
acid	O
sequence	O
showed	O
that	O
the	O
cDNAs	O
encoded	O
an	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
of	O
173	O
amino	O
acids	O
including	O
a	O
48	O
-	O
amino	O
acid	O
presequence	O
.	O

Calculated	O
molecular	O
mass	O
of	O
the	O
precursor	O
and	O
mature	O
protein	O
without	O
lipoic	O
acid	O
were	O
18	O
,	O
790	O
and	O
13	O
,	O
846	O
,	O
respectively	O
.	O
<EOS>	B-X
H-protein	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
and	B-X
has	B-X
lipoic	B-X
acid	B-X
as	B-X
a	B-X
prosthetic	B-X
group	B-X
.	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
Bovine	B-X
liver	B-X
H-protein	B-X
precursor	B-X
has	B-X
no	B-X
lipoic	B-X
acid	B-X
prosthetic	B-X
group	B-X
.	B-X
When	B-X
incubated	B-X
with	B-X
isolated	B-X
bovine	B-X
liver	B-X
mitochondria	B-X
,	B-X
the	B-X
precursor	B-X
was	B-X
imported	B-X
into	B-X
mitochondria	B-X
,	B-X
processed	B-X
to	B-X
its	B-X
mature	B-X
form	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
14	B-X
kDa	B-X
,	B-X
and	B-X
lipoylated	B-X
at	B-X
lysine	B-X
59	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

Northern	O
blot	O
analysis	O
indicated	O
a	O
major	O
mRNA	O
component	O
of	O
1	O
.	O
1	O
kilobases	O
and	O
a	O
minor	O
component	O
of	O
0	O
.	O
6	O
kilobase	O
.	O

The	O
result	O
is	O
consistent	O
with	O
the	O
presence	O
of	O
two	O
adenylation	O
signals	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
cDNA	O
.	O
<EOS>	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
result	B-X
is	B-X
consistent	B-X
with	B-X
the	B-X
presence	B-X
of	B-X
two	B-X
adenylation	B-X
signals	B-X
in	B-X
the	B-X
3'-untranslated	B-X
region	B-X
of	B-X
the	B-X
cDNA	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
H	B-Protein
-	I-Protein
protein	I-Protein
cDNA	O
produced	O
a	O
19	O
-	O
kDa	O
protein	O
recognized	O
by	O
antibody	O
raised	O
to	O
chicken	O
H	B-Protein
-	I-Protein
protein	I-Protein
.	O

Bovine	O
liver	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
has	O
no	O
lipoic	O
acid	O
prosthetic	O
group	O
.	O
<EOS>	B-X
H-protein	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
and	B-X
has	B-X
lipoic	B-X
acid	B-X
as	B-X
a	B-X
prosthetic	B-X
group	B-X
.	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
Bovine	B-X
liver	B-X
H-protein	B-X
precursor	B-X
has	B-X
no	B-X
lipoic	B-X
acid	B-X
prosthetic	B-X
group	B-X
.	B-X
When	B-X
incubated	B-X
with	B-X
isolated	B-X
bovine	B-X
liver	B-X
mitochondria	B-X
,	B-X
the	B-X
precursor	B-X
was	B-X
imported	B-X
into	B-X
mitochondria	B-X
,	B-X
processed	B-X
to	B-X
its	B-X
mature	B-X
form	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
14	B-X
kDa	B-X
,	B-X
and	B-X
lipoylated	B-X
at	B-X
lysine	B-X
59	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

When	O
incubated	O
with	O
isolated	O
bovine	O
liver	O
mitochondria	O
,	O
the	O
precursor	O
was	O
imported	O
into	O
mitochondria	O
,	O
processed	O
to	O
its	O
mature	O
form	O
with	O
a	O
molecular	O
mass	O
of	O
14	O
kDa	O
,	O
and	O
lipoylated	O
at	O
lysine	O
59	O
.	O
<EOS>	B-X
H-protein	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
glycine	B-X
cleavage	B-X
system	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
mitochondrial	B-X
inner	B-X
membrane	B-X
and	B-X
has	B-X
lipoic	B-X
acid	B-X
as	B-X
a	B-X
prosthetic	B-X
group	B-X
.	B-X
cDNA	B-X
clones	B-X
encoding	B-X
H-protein	B-X
were	B-X
isolated	B-X
from	B-X
a	B-X
bovine	B-X
liver	B-X
cDNA	B-X
library	B-X
with	B-X
an	B-X
oligonucleotide	B-X
probe	B-X
from	B-X
the	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
the	B-X
NH2-terminal	B-X
region	B-X
.	B-X
DNA	B-X
sequence	B-X
analysis	B-X
and	B-X
deduced	B-X
amino	B-X
acid	B-X
sequence	B-X
showed	B-X
that	B-X
the	B-X
cDNAs	B-X
encoded	B-X
an	B-X
H-protein	B-X
precursor	B-X
of	B-X
173	B-X
amino	B-X
acids	B-X
including	B-X
a	B-X
48-amino	B-X
acid	B-X
presequence	B-X
.	B-X
Calculated	B-X
molecular	B-X
mass	B-X
of	B-X
the	B-X
precursor	B-X
and	B-X
mature	B-X
protein	B-X
without	B-X
lipoic	B-X
acid	B-X
were	B-X
18,790	B-X
and	B-X
13,846	B-X
,	B-X
respectively	B-X
.	B-X
In	B-X
vitro	B-X
transcription	B-X
and	B-X
translation	B-X
of	B-X
the	B-X
H-protein	B-X
cDNA	B-X
produced	B-X
a	B-X
19-kDa	B-X
protein	B-X
recognized	B-X
by	B-X
antibody	B-X
raised	B-X
to	B-X
chicken	B-X
H-protein	B-X
.	B-X
Bovine	B-X
liver	B-X
H-protein	B-X
precursor	B-X
has	B-X
no	B-X
lipoic	B-X
acid	B-X
prosthetic	B-X
group	B-X
.	B-X
When	B-X
incubated	B-X
with	B-X
isolated	B-X
bovine	B-X
liver	B-X
mitochondria	B-X
,	B-X
the	B-X
precursor	B-X
was	B-X
imported	B-X
into	B-X
mitochondria	B-X
,	B-X
processed	B-X
to	B-X
its	B-X
mature	B-X
form	B-X
with	B-X
a	B-X
molecular	B-X
mass	B-X
of	B-X
14	B-X
kDa	B-X
,	B-X
and	B-X
lipoylated	B-X
at	B-X
lysine	B-X
59	B-X
.	B-X
These	B-X
results	B-X
indicate	B-X
that	B-X
lipoylation	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
import	B-X
of	B-X
H-protein	B-X
precursor	B-X
into	B-X
mitochondria	B-X
and	B-X
H-protein	B-X
is	B-X
lipoylated	B-X
in	B-X
mitochondria	B-X
which	B-X
probably	B-X
contain	B-X
the	B-X
physiologically	B-X
active	B-X
form	B-X
of	B-X
lipoic	B-X
acid	B-X
as	B-X
well	B-X
as	B-X
the	B-X
enzyme	B-X
(	B-X
s	B-X
)	B-X
responsible	B-X
for	B-X
the	B-X
attachment	B-X
.	B-X

These	O
results	O
indicate	O
that	O
lipoylation	O
is	O
not	O
required	O
for	O
the	O
import	O
of	O
H	B-Protein
-	I-Protein
protein	I-Protein
precursor	O
into	O
mitochondria	O
and	O
H	B-Protein
-	I-Protein
protein	I-Protein
is	O
lipoylated	O
in	O
mitochondria	O
which	O
probably	O
contain	O
the	O
physiologically	O
active	O
form	O
of	O
lipoic	O
acid	O
as	O
well	O
as	O
the	O
enzyme	O
(	O
s	O
)	O
responsible	O
for	O
the	O
attachment	O
.	O
<EOS>	B-X
Cuproptosis	B-X
is	B-X
a	B-X
recently	B-X
discovered	B-X
mechanism	B-X
of	B-X
programmed	B-X
cell	B-X
death	B-X
caused	B-X
by	B-X
intracellular	B-X
aggregation	B-X
of	B-X
mitochondrial	B-X
lipoylated	B-X
proteins	B-X
and	B-X
destabilization	B-X
of	B-X
iron-sulfur	B-X
proteins	B-X
triggered	B-X
by	B-X
copper	B-X
.	B-X
Hepatocellular	B-X
carcinoma	B-X
(	B-X
HCC	B-X
)	B-X
is	B-X
a	B-X
common	B-X
malignant	B-X
tumor	B-X
with	B-X
a	B-X
poor	B-X
prognosis	B-X
.	B-X
We	B-X
aimed	B-X
to	B-X
predict	B-X
the	B-X
survival	B-X
of	B-X
patients	B-X
with	B-X
HCC	B-X
using	B-X
the	B-X
cuproptosis-related	B-X
gene	B-X
(	B-X
CRG	B-X
)	B-X
expression	B-X
.	B-X
Cuproptosis	B-X
,	B-X
a	B-X
newly	B-X
identified	B-X
form	B-X
of	B-X
regulated	B-X
cell	B-X
death	B-X
that	B-X
is	B-X
copper-dependent	B-X
,	B-X
offers	B-X
great	B-X
opportunities	B-X
for	B-X
exploring	B-X
the	B-X
use	B-X
of	B-X
copper-based	B-X
nanomaterials	B-X
inducing	B-X
cuproptosis	B-X
for	B-X
cancer	B-X
treatment	B-X
.	B-X
Here	B-X
,	B-X
a	B-X
glucose	B-X
oxidase	B-X
(	B-X
GOx	B-X
)	B-X
-engineered	B-X
nonporous	B-X
copper	B-X
(	B-X
I	B-X
)	B-X
1,2,4-triazolate	B-X
(	B-X
[	B-X
Cu	B-X
(	B-X
tz	B-X
)	B-X
]	B-X
)	B-X
coordination	B-X
polymer	B-X
(	B-X
CP	B-X
)	B-X
nanoplatform	B-X
,	B-X
denoted	B-X
as	B-X
GOx	B-X
@	B-X
[	B-X
Cu	B-X
(	B-X
tz	B-X
)	B-X
]	B-X
,	B-X
for	B-X
starvation-augmented	B-X
cuproptosis	B-X
and	B-X
photodynamic	B-X
synergistic	B-X
therapy	B-X
is	B-X
developed	B-X
.	B-X
Importantly	B-X
,	B-X
the	B-X
catalytic	B-X
activity	B-X
of	B-X
GOx	B-X
is	B-X
shielded	B-X
in	B-X
the	B-X
nonporous	B-X
scaffold	B-X
but	B-X
can	B-X
be	B-X
``	B-X
turned	B-X
on	B-X
''	B-X
for	B-X
efficient	B-X
glucose	B-X
depletion	B-X
only	B-X
upon	B-X
glutathione	B-X
(	B-X
GSH	B-X
)	B-X
stimulation	B-X
in	B-X
cancer	B-X
cells	B-X
,	B-X
thereby	B-X
proceeding	B-X
cancer	B-X
starvation	B-X
therapy	B-X
.	B-X
The	B-X
depletion	B-X
of	B-X
glucose	B-X
and	B-X
GSH	B-X
sensitizes	B-X
cancer	B-X
cells	B-X
to	B-X
the	B-X
GOx	B-X
@	B-X
[	B-X
Cu	B-X
(	B-X
tz	B-X
)	B-X
]	B-X
-mediated	B-X
cuproptosis	B-X
,	B-X
producing	B-X
aggregation	B-X
of	B-X
lipoylated	B-X
mitochondrial	B-X
proteins	B-X
,	B-X
the	B-X
target	B-X
of	B-X
copper-induced	B-X
toxicity	B-X
.	B-X
The	B-X
increased	B-X
intracellular	B-X
hydrogen	B-X
peroxide	B-X
(	B-X
H	B-X

Post	O
-	O
translational	O
modification	O
of	O
bovine	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
.	O
<EOS>	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
Peptides	B-X
were	B-X
purified	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
reversed-phase	B-X
and	B-X
ion-exchange	B-X
batch	B-X
extraction	B-X
procedures	B-X
followed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X

Tyrosine	O
sulfation	O
and	O
pyroglutamate	O
formation	O
,	O
a	O
mass	O
spectrometric	O
study	O
.	O
<EOS>	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X

The	O
amino	O
-	O
terminal	O
fragment	O
of	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
i	O
.	O
e	O
.	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
)	O
and	O
joining	O
peptide	O
portions	O
of	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
have	O
been	O
purified	O
from	O
extracts	O
of	O
bovine	O
posterior	O
pituitaries	O
.	O

Peptides	O
were	O
purified	O
using	O
a	O
combination	O
of	O
reversed	O
-	O
phase	O
and	O
ion	O
-	O
exchange	O
batch	O
extraction	O
procedures	O
followed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O
<EOS>	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
Peptides	B-X
were	B-X
purified	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
reversed-phase	B-X
and	B-X
ion-exchange	B-X
batch	B-X
extraction	B-X
procedures	B-X
followed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Pyroglutamate	B-X
is	B-X
normally	B-X
formed	B-X
through	B-X
the	B-X
cyclization	B-X
of	B-X
glutamine	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X

beta	B-Protein
-	I-Protein
Lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
consist	O
of	O
four	O
major	O
components	O
while	O
joining	O
peptide	O
was	O
found	O
to	O
consist	O
of	O
two	O
major	O
components	O
.	O
<EOS>	B-X
The	B-X
amino-terminal	B-X
fragment	B-X
of	B-X
beta-lipotropin	B-X
(	B-X
i.e	B-X
.	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
four	B-X
major	B-X
components	B-X
while	B-X
joining	B-X
peptide	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
two	B-X
major	B-X
components	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
be	B-X
sulfated	B-X
at	B-X
tyrosine	B-X
residue	B-X
28	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

Fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
fragments	O
of	O
both	O
peptides	O
revealed	O
that	O
the	O
observed	O
heterogeneity	O
could	O
be	O
explained	O
in	O
terms	O
of	O
post	O
-	O
translational	O
modifications	O
.	O
<EOS>	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

beta	B-Protein
-	I-Protein
Lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
be	O
sulfated	O
at	O
tyrosine	O
residue	O
28	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
tyrosine	O
residue	O
in	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
is	O
situated	O
within	O
an	O
amino	O
acid	O
sequence	O
with	O
a	O
preponderance	O
of	O
glutamate	O
residues	O
.	O
<EOS>	B-X
The	B-X
amino-terminal	B-X
fragment	B-X
of	B-X
beta-lipotropin	B-X
(	B-X
i.e	B-X
.	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
four	B-X
major	B-X
components	B-X
while	B-X
joining	B-X
peptide	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
two	B-X
major	B-X
components	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
be	B-X
sulfated	B-X
at	B-X
tyrosine	B-X
residue	B-X
28	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Pyroglutamate	B-X
is	B-X
normally	B-X
formed	B-X
through	B-X
the	B-X
cyclization	B-X
of	B-X
glutamine	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

Sulfation	O
of	O
this	O
amino	O
acid	O
residue	O
is	O
entirely	O
compatible	O
with	O
the	O
known	O
primary	O
structure	O
requirements	O
of	O
the	O
sulfotransferase	O
enzyme	O
located	O
in	O
the	O
trans	O
-	O
Golgi	O
fraction	O
.	O
<EOS>	B-X
The	B-X
amino-terminal	B-X
fragment	B-X
of	B-X
beta-lipotropin	B-X
(	B-X
i.e	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
be	B-X
sulfated	B-X
at	B-X
tyrosine	B-X
residue	B-X
28	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

Both	O
beta	B-Protein
-	I-Protein
lipotropin	I-Protein
(	O
1	O
-	O
40	O
)	O
and	O
joining	O
peptide	O
were	O
found	O
to	O
have	O
pyroglutamate	O
at	O
their	O
amino	O
termini	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
cDNA	O
sequence	O
for	O
bovine	O
pro	B-Protein
-	I-Protein
opiomelanocortin	I-Protein
predicts	O
the	O
presence	O
of	O
glutamic	O
acid	O
at	O
position	O
1	O
of	O
both	O
peptides	O
.	O
<EOS>	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
Peptides	B-X
were	B-X
purified	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
reversed-phase	B-X
and	B-X
ion-exchange	B-X
batch	B-X
extraction	B-X
procedures	B-X
followed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
four	B-X
major	B-X
components	B-X
while	B-X
joining	B-X
peptide	B-X
was	B-X
found	B-X
to	B-X
consist	B-X
of	B-X
two	B-X
major	B-X
components	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
beta-Lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
was	B-X
found	B-X
to	B-X
be	B-X
sulfated	B-X
at	B-X
tyrosine	B-X
residue	B-X
28	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

Pyroglutamate	O
is	O
normally	O
formed	O
through	O
the	O
cyclization	O
of	O
glutamine	O
.	O
<EOS>	B-X
Pyroglutamate	B-X
is	B-X
normally	B-X
formed	B-X
through	B-X
the	B-X
cyclization	B-X
of	B-X
glutamine	B-X
.	B-X

This	O
reaction	O
is	O
thought	O
to	O
be	O
catalyzed	O
by	O
a	O
pyroglutamate	O
forming	O
enzyme	O
located	O
within	O
the	O
secretory	O
granule	O
fraction	O
.	O
<EOS>	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

Under	O
certain	O
circumstances	O
peptides	O
with	O
glutamate	O
at	O
their	O
amino	O
termini	O
may	O
act	O
as	O
substrates	O
for	O
this	O
enzyme	O
.	O
<EOS>	B-X
The	B-X
amino-terminal	B-X
fragment	B-X
of	B-X
beta-lipotropin	B-X
(	B-X
i.e	B-X
.	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
portions	B-X
of	B-X
pro-opiomelanocortin	B-X
have	B-X
been	B-X
purified	B-X
from	B-X
extracts	B-X
of	B-X
bovine	B-X
posterior	B-X
pituitaries	B-X
.	B-X
Peptides	B-X
were	B-X
purified	B-X
using	B-X
a	B-X
combination	B-X
of	B-X
reversed-phase	B-X
and	B-X
ion-exchange	B-X
batch	B-X
extraction	B-X
procedures	B-X
followed	B-X
by	B-X
reversed-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Fast	B-X
atom	B-X
bombardment-mass	B-X
spectrometric	B-X
analysis	B-X
of	B-X
the	B-X
tryptic	B-X
fragments	B-X
of	B-X
both	B-X
peptides	B-X
revealed	B-X
that	B-X
the	B-X
observed	B-X
heterogeneity	B-X
could	B-X
be	B-X
explained	B-X
in	B-X
terms	B-X
of	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
tyrosine	B-X
residue	B-X
in	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
is	B-X
situated	B-X
within	B-X
an	B-X
amino	B-X
acid	B-X
sequence	B-X
with	B-X
a	B-X
preponderance	B-X
of	B-X
glutamate	B-X
residues	B-X
.	B-X
Sulfation	B-X
of	B-X
this	B-X
amino	B-X
acid	B-X
residue	B-X
is	B-X
entirely	B-X
compatible	B-X
with	B-X
the	B-X
known	B-X
primary	B-X
structure	B-X
requirements	B-X
of	B-X
the	B-X
sulfotransferase	B-X
enzyme	B-X
located	B-X
in	B-X
the	B-X
trans-Golgi	B-X
fraction	B-X
.	B-X
Both	B-X
beta-lipotropin	B-X
(	B-X
1-40	B-X
)	B-X
and	B-X
joining	B-X
peptide	B-X
were	B-X
found	B-X
to	B-X
have	B-X
pyroglutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
to	B-X
an	B-X
extent	B-X
of	B-X
about	B-X
50	B-X
%	B-X
.	B-X
The	B-X
cDNA	B-X
sequence	B-X
for	B-X
bovine	B-X
pro-opiomelanocortin	B-X
predicts	B-X
the	B-X
presence	B-X
of	B-X
glutamic	B-X
acid	B-X
at	B-X
position	B-X
1	B-X
of	B-X
both	B-X
peptides	B-X
.	B-X
Pyroglutamate	B-X
is	B-X
normally	B-X
formed	B-X
through	B-X
the	B-X
cyclization	B-X
of	B-X
glutamine	B-X
.	B-X
This	B-X
reaction	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
catalyzed	B-X
by	B-X
a	B-X
pyroglutamate	B-X
forming	B-X
enzyme	B-X
located	B-X
within	B-X
the	B-X
secretory	B-X
granule	B-X
fraction	B-X
.	B-X
Under	B-X
certain	B-X
circumstances	B-X
peptides	B-X
with	B-X
glutamate	B-X
at	B-X
their	B-X
amino	B-X
termini	B-X
may	B-X
act	B-X
as	B-X
substrates	B-X
for	B-X
this	B-X
enzyme	B-X
.	B-X

ADP	O
-	O
ribosylation	O
of	O
proteins	O
in	O
brain	O
regions	O
of	O
rats	O
during	O
postnatal	O
development	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
of	B-X
chromatin-bound	B-X
proteins	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
eukaryotic	B-X
gene	B-X
expression	B-X
.	B-X
Processes	B-X
such	B-X
as	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
and	B-X
ADP-ribosylation	B-X
may	B-X
alter	B-X
the	B-X
interaction	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
DNA	B-X
and	B-X
consequently	B-X
affect	B-X
chromatin	B-X
conformation	B-X
and	B-X
the	B-X
binding	B-X
of	B-X
enzymes	B-X
and	B-X
other	B-X
molecules	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
chromosomal	B-X
proteins	B-X
(	B-X
histone	B-X
and	B-X
non-histone	B-X
proteins	B-X
)	B-X
in	B-X
some	B-X
rat	B-X
brain	B-X
regions	B-X
during	B-X
postnatal	B-X
development	B-X
was	B-X
investigated	B-X
;	B-X
also	B-X
the	B-X
effect	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
on	B-X
this	B-X
process	B-X
in	B-X
fetal	B-X
brain	B-X
slices	B-X
was	B-X
studied	B-X
.	B-X
It	B-X
has	B-X
been	B-X
found	B-X
that	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
extracted	B-X
from	B-X
rat	B-X
cerebral	B-X
cortex	B-X
and	B-X
cerebellum	B-X
at	B-X
1	B-X
,	B-X
10	B-X
and	B-X
30	B-X
days	B-X
of	B-X
age	B-X
,	B-X
increases	B-X
from	B-X
1	B-X
to	B-X
10	B-X
days	B-X
of	B-X
age	B-X
(	B-X
i.e	B-X
.	B-X
the	B-X
period	B-X
of	B-X
maximal	B-X
cell	B-X
proliferation	B-X
)	B-X
and	B-X
decreases	B-X
thereafter	B-X
,	B-X
while	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
non-histone	B-X
proteins	B-X
(	B-X
NHPs	B-X
)	B-X
sharply	B-X
decreases	B-X
during	B-X
the	B-X
same	B-X
developmental	B-X
period	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
EGF	B-X
to	B-X
fetal	B-X
brain	B-X
slices	B-X
causes	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
(	B-X
particularly	B-X
of	B-X
the	B-X
histone	B-X
H1	B-X
fraction	B-X
)	B-X
and	B-X
also	B-X
of	B-X
NHPs	B-X
and	B-X
microsomal	B-X
proteins	B-X
.	B-X

Post	O
-	O
translational	O
modifications	O
of	O
chromatin	O
-	O
bound	O
proteins	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O
<EOS>	B-X
DOT1L	B-X
,	B-X
the	B-X
only	B-X
H3K79	B-X
methyltransferase	B-X
in	B-X
human	B-X
cells	B-X
and	B-X
a	B-X
homolog	B-X
of	B-X
the	B-X
yeast	B-X
Dot1	B-X
,	B-X
normally	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
AF10	B-X
,	B-X
AF17	B-X
,	B-X
and	B-X
ENL	B-X
or	B-X
AF9	B-X
,	B-X
is	B-X
dysregulated	B-X
in	B-X
most	B-X
cases	B-X
of	B-X
mixed-lineage	B-X
leukemia	B-X
(	B-X
MLLr	B-X
)	B-X
,	B-X
and	B-X
has	B-X
been	B-X
believed	B-X
to	B-X
regulate	B-X
transcriptional	B-X
elongation	B-X
on	B-X
the	B-X
basis	B-X
of	B-X
its	B-X
colocalization	B-X
with	B-X
RNA	B-X
polymerase	B-X
II	B-X
(	B-X
Pol	B-X
II	B-X
)	B-X
,	B-X
the	B-X
sharing	B-X
of	B-X
subunits	B-X
(	B-X
AF9	B-X
and	B-X
ENL	B-X
)	B-X
between	B-X
the	B-X
DOT1L	B-X
and	B-X
super	B-X
elongation	B-X
complexes	B-X
,	B-X
and	B-X
the	B-X
distribution	B-X
of	B-X
H3K79	B-X
methylation	B-X
on	B-X
both	B-X
promoters	B-X
and	B-X
transcribed	B-X
regions	B-X
of	B-X
active	B-X
genes	B-X
.	B-X
Here	B-X
we	B-X
show	B-X
that	B-X
DOT1L	B-X
depletion	B-X
in	B-X
erythroleukemic	B-X
cells	B-X
reduces	B-X
its	B-X
global	B-X
occupancy	B-X
without	B-X
affecting	B-X
the	B-X
traveling	B-X
ratio	B-X
or	B-X
the	B-X
elongation	B-X
rate	B-X
(	B-X
assessed	B-X
by	B-X
4sUDRB-seq	B-X
)	B-X
of	B-X
Pol	B-X
II	B-X
,	B-X
suggesting	B-X
that	B-X
DOT1L	B-X
does	B-X
not	B-X
play	B-X
a	B-X
major	B-X
role	B-X
in	B-X
elongation	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
analyses	B-X
of	B-X
transcription	B-X
initiation	B-X
factor	B-X
binding	B-X
reveal	B-X
that	B-X
DOT1L	B-X
and	B-X
ENL	B-X
depletions	B-X
each	B-X
result	B-X
in	B-X
reduced	B-X
TATA	B-X
binding	B-X
protein	B-X
(	B-X
TBP	B-X
)	B-X
occupancies	B-X
on	B-X
thousands	B-X
of	B-X
genes	B-X
.	B-X
More	B-X
importantly	B-X
,	B-X
DOT1L	B-X
and	B-X
ENL	B-X
depletions	B-X
concomitantly	B-X
reduce	B-X
TBP	B-X
and	B-X
Pol	B-X
II	B-X
occupancies	B-X
on	B-X
a	B-X
significant	B-X
fraction	B-X
of	B-X
direct	B-X
(	B-X
DOT1L-bound	B-X
)	B-X
target	B-X
genes	B-X
,	B-X
indicating	B-X
a	B-X
role	B-X
for	B-X
the	B-X
DOT1L	B-X
complex	B-X
in	B-X
transcription	B-X
initiation	B-X
.	B-X
These	B-X
results	B-X
advance	B-X
our	B-X
understanding	B-X
of	B-X
roles	B-X
of	B-X
the	B-X
DOT1L	B-X
complex	B-X
in	B-X
transcriptional	B-X
regulation	B-X
and	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
MLLr	B-X
leukemias	B-X
.	B-X

Processes	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
may	O
alter	O
the	O
interaction	O
of	O
these	O
proteins	O
with	O
DNA	O
and	O
consequently	O
affect	O
chromatin	O
conformation	O
and	O
the	O
binding	O
of	O
enzymes	O
and	O
other	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
of	B-X
chromatin-bound	B-X
proteins	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
eukaryotic	B-X
gene	B-X
expression	B-X
.	B-X
Processes	B-X
such	B-X
as	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
and	B-X
ADP-ribosylation	B-X
may	B-X
alter	B-X
the	B-X
interaction	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
DNA	B-X
and	B-X
consequently	B-X
affect	B-X
chromatin	B-X
conformation	B-X
and	B-X
the	B-X
binding	B-X
of	B-X
enzymes	B-X
and	B-X
other	B-X
molecules	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
chromosomal	B-X
proteins	B-X
(	B-X
histone	B-X
and	B-X
non-histone	B-X
proteins	B-X
)	B-X
in	B-X
some	B-X
rat	B-X
brain	B-X
regions	B-X
during	B-X
postnatal	B-X
development	B-X
was	B-X
investigated	B-X
;	B-X
also	B-X
the	B-X
effect	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
on	B-X
this	B-X
process	B-X
in	B-X
fetal	B-X
brain	B-X
slices	B-X
was	B-X
studied	B-X
.	B-X
It	B-X
has	B-X
been	B-X
found	B-X
that	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
extracted	B-X
from	B-X
rat	B-X
cerebral	B-X
cortex	B-X
and	B-X
cerebellum	B-X
at	B-X
1	B-X
,	B-X
10	B-X
and	B-X
30	B-X
days	B-X
of	B-X
age	B-X
,	B-X
increases	B-X
from	B-X
1	B-X
to	B-X
10	B-X
days	B-X
of	B-X
age	B-X
(	B-X
i.e	B-X
.	B-X
the	B-X
period	B-X
of	B-X
maximal	B-X
cell	B-X
proliferation	B-X
)	B-X
and	B-X
decreases	B-X
thereafter	B-X
,	B-X
while	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
non-histone	B-X
proteins	B-X
(	B-X
NHPs	B-X
)	B-X
sharply	B-X
decreases	B-X
during	B-X
the	B-X
same	B-X
developmental	B-X
period	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
EGF	B-X
to	B-X
fetal	B-X
brain	B-X
slices	B-X
causes	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
(	B-X
particularly	B-X
of	B-X
the	B-X
histone	B-X
H1	B-X
fraction	B-X
)	B-X
and	B-X
also	B-X
of	B-X
NHPs	B-X
and	B-X
microsomal	B-X
proteins	B-X
.	B-X

In	O
the	O
present	O
study	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
chromosomal	O
proteins	O
(	O
histone	B-Protein
and	O
non	O
-	O
histone	O
proteins	O
)	O
in	O
some	O
rat	O
brain	O
regions	O
during	O
postnatal	O
development	O
was	O
investigated	O
;	O
also	O
the	O
effect	O
of	O
epidermal	B-Protein
growth	I-Protein
factor	I-Protein
(	O
EGF	B-Protein
)	O
on	O
this	O
process	O
in	O
fetal	O
brain	O
slices	O
was	O
studied	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-Protein
extracted	O
from	O
rat	O
cerebral	O
cortex	O
and	O
cerebellum	O
at	O
1	O
,	O
10	O
and	O
30	O
days	O
of	O
age	O
,	O
increases	O
from	O
1	O
to	O
10	O
days	O
of	O
age	O
(	O
i	O
.	O
e	O
.	O
the	O
period	O
of	O
maximal	O
cell	O
proliferation	O
)	O
and	O
decreases	O
thereafter	O
,	O
while	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
non	O
-	O
histone	O
proteins	O
(	O
NHPs	O
)	O
sharply	O
decreases	O
during	O
the	O
same	O
developmental	O
period	O
.	O

The	O
addition	O
of	O
EGF	B-Protein
to	O
fetal	O
brain	O
slices	O
causes	O
a	O
significant	O
increase	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	B-Protein
(	O
particularly	O
of	O
the	O
histone	B-Protein
H1	I-Protein
fraction	O
)	O
and	O
also	O
of	O
NHPs	O
and	O
microsomal	O
proteins	O
.	O
<EOS>	B-X
Post-translational	B-X
modifications	B-X
of	B-X
chromatin-bound	B-X
proteins	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
eukaryotic	B-X
gene	B-X
expression	B-X
.	B-X
Processes	B-X
such	B-X
as	B-X
acetylation	B-X
,	B-X
methylation	B-X
,	B-X
phosphorylation	B-X
and	B-X
ADP-ribosylation	B-X
may	B-X
alter	B-X
the	B-X
interaction	B-X
of	B-X
these	B-X
proteins	B-X
with	B-X
DNA	B-X
and	B-X
consequently	B-X
affect	B-X
chromatin	B-X
conformation	B-X
and	B-X
the	B-X
binding	B-X
of	B-X
enzymes	B-X
and	B-X
other	B-X
molecules	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
gene	B-X
expression	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
chromosomal	B-X
proteins	B-X
(	B-X
histone	B-X
and	B-X
non-histone	B-X
proteins	B-X
)	B-X
in	B-X
some	B-X
rat	B-X
brain	B-X
regions	B-X
during	B-X
postnatal	B-X
development	B-X
was	B-X
investigated	B-X
;	B-X
also	B-X
the	B-X
effect	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
on	B-X
this	B-X
process	B-X
in	B-X
fetal	B-X
brain	B-X
slices	B-X
was	B-X
studied	B-X
.	B-X
It	B-X
has	B-X
been	B-X
found	B-X
that	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
extracted	B-X
from	B-X
rat	B-X
cerebral	B-X
cortex	B-X
and	B-X
cerebellum	B-X
at	B-X
1	B-X
,	B-X
10	B-X
and	B-X
30	B-X
days	B-X
of	B-X
age	B-X
,	B-X
increases	B-X
from	B-X
1	B-X
to	B-X
10	B-X
days	B-X
of	B-X
age	B-X
(	B-X
i.e	B-X
.	B-X
the	B-X
period	B-X
of	B-X
maximal	B-X
cell	B-X
proliferation	B-X
)	B-X
and	B-X
decreases	B-X
thereafter	B-X
,	B-X
while	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
non-histone	B-X
proteins	B-X
(	B-X
NHPs	B-X
)	B-X
sharply	B-X
decreases	B-X
during	B-X
the	B-X
same	B-X
developmental	B-X
period	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
EGF	B-X
to	B-X
fetal	B-X
brain	B-X
slices	B-X
causes	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
(	B-X
particularly	B-X
of	B-X
the	B-X
histone	B-X
H1	B-X
fraction	B-X
)	B-X
and	B-X
also	B-X
of	B-X
NHPs	B-X
and	B-X
microsomal	B-X
proteins	B-X
.	B-X
This	B-X
result	B-X
is	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
EGF	B-X
as	B-X
a	B-X
mitogen	B-X
factor	B-X
,	B-X
previously	B-X
shown	B-X
in	B-X
astroglial	B-X
cell	B-X
cultures	B-X
.	B-X

This	O
result	O
is	O
in	O
agreement	O
with	O
the	O
effect	O
of	O
EGF	B-Protein
as	O
a	O
mitogen	O
factor	O
,	O
previously	O
shown	O
in	O
astroglial	O
cell	O
cultures	O
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
chromosomal	B-X
proteins	B-X
(	B-X
histone	B-X
and	B-X
non-histone	B-X
proteins	B-X
)	B-X
in	B-X
some	B-X
rat	B-X
brain	B-X
regions	B-X
during	B-X
postnatal	B-X
development	B-X
was	B-X
investigated	B-X
;	B-X
also	B-X
the	B-X
effect	B-X
of	B-X
epidermal	B-X
growth	B-X
factor	B-X
(	B-X
EGF	B-X
)	B-X
on	B-X
this	B-X
process	B-X
in	B-X
fetal	B-X
brain	B-X
slices	B-X
was	B-X
studied	B-X
.	B-X
the	B-X
period	B-X
of	B-X
maximal	B-X
cell	B-X
proliferation	B-X
)	B-X
and	B-X
decreases	B-X
thereafter	B-X
,	B-X
while	B-X
the	B-X
process	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
non-histone	B-X
proteins	B-X
(	B-X
NHPs	B-X
)	B-X
sharply	B-X
decreases	B-X
during	B-X
the	B-X
same	B-X
developmental	B-X
period	B-X
.	B-X
The	B-X
addition	B-X
of	B-X
EGF	B-X
to	B-X
fetal	B-X
brain	B-X
slices	B-X
causes	B-X
a	B-X
significant	B-X
increase	B-X
of	B-X
ADP-ribosylation	B-X
of	B-X
total	B-X
histones	B-X
(	B-X
particularly	B-X
of	B-X
the	B-X
histone	B-X
H1	B-X
fraction	B-X
)	B-X
and	B-X
also	B-X
of	B-X
NHPs	B-X
and	B-X
microsomal	B-X
proteins	B-X
.	B-X
This	B-X
result	B-X
is	B-X
in	B-X
agreement	B-X
with	B-X
the	B-X
effect	B-X
of	B-X
EGF	B-X
as	B-X
a	B-X
mitogen	B-X
factor	B-X
,	B-X
previously	B-X
shown	B-X
in	B-X
astroglial	B-X
cell	B-X
cultures	B-X
.	B-X

Characterization	O
of	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
:	O
phosphorylation	O
,	O
kinase	O
activity	O
,	O
acylation	O
,	O
and	O
kinetics	O
of	O
complex	O
formation	O
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

The	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
of	O
three	O
isolates	O
of	O
feline	O
sarcoma	O
virus	O
(	O
ST	O
-	O
FeSV	O
,	O
GA	O
-	O
FeSV	O
,	O
TP1	O
-	O
FeSV	O
)	O
from	O
a	O
stable	O
noncovalent	O
complex	O
with	O
two	O
cellular	O
phosphoproteins	O
,	O
pp90	B-Protein
and	O
pp50	B-Protein
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

These	O
two	O
phosphoproteins	O
are	O
the	O
same	O
phosphoproteins	O
which	O
have	O
been	O
shown	O
to	O
complex	O
with	O
the	O
transforming	O
proteins	O
of	O
Rous	O
sarcoma	O
virus	O
,	O
Fujinami	O
sarcoma	O
virus	O
,	O
Yamaguchi	O
73	O
virus	O
(	O
Lipsich	O
et	O
al	O
.	O
,	O
1982	O
)	O
,	O
and	O
PRCII	O
avian	O
sarcoma	O
virus	O
(	O
Adkins	O
et	O
al	O
.	O
,	O
1982	O
)	O
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
gag	B-Protein
-	O
onc	O
fusion	O
proteins	O
are	O
phosphorylated	O
on	O
serine	O
,	O
threonine	O
,	O
and	O
tyrosine	O
;	O
however	O
,	O
quantitative	O
and	O
/	O
or	O
qualitative	O
differences	O
in	O
phosphorylation	O
of	O
the	O
two	O
species	O
were	O
apparent	O
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

Only	O
the	O
monomeric	O
form	O
of	O
the	O
gag	B-Protein
-	O
onc	O
proteins	O
was	O
able	O
to	O
undergo	O
tyrosine	O
specific	O
autophosphorylation	O
in	O
an	O
in	O
vitro	O
kinase	O
reaction	O
.	O

Both	O
the	O
monomeric	O
and	O
complex	O
-	O
associated	O
forms	O
of	O
the	O
proteins	O
were	O
acylated	O
,	O
the	O
complex	O
-	O
associated	O
molecules	O
to	O
a	O
greater	O
degree	O
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
newly	O
synthesized	O
gag	B-Protein
-	O
onc	O
molecules	O
become	O
rapidly	O
incorporated	O
into	O
the	O
complex	O
and	O
that	O
a	O
significant	O
amount	O
of	O
these	O
molecules	O
remained	O
associated	O
with	O
the	O
complex	O
for	O
more	O
than	O
20	O
hr	O
.	O
<EOS>	B-X
The	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
of	B-X
three	B-X
isolates	B-X
of	B-X
feline	B-X
sarcoma	B-X
virus	B-X
(	B-X
ST-FeSV	B-X
,	B-X
GA-FeSV	B-X
,	B-X
TP1-FeSV	B-X
)	B-X
from	B-X
a	B-X
stable	B-X
noncovalent	B-X
complex	B-X
with	B-X
two	B-X
cellular	B-X
phosphoproteins	B-X
,	B-X
pp90	B-X
and	B-X
pp50	B-X
.	B-X
These	B-X
two	B-X
phosphoproteins	B-X
are	B-X
the	B-X
same	B-X
phosphoproteins	B-X
which	B-X
have	B-X
been	B-X
shown	B-X
to	B-X
complex	B-X
with	B-X
the	B-X
transforming	B-X
proteins	B-X
of	B-X
Rous	B-X
sarcoma	B-X
virus	B-X
,	B-X
Fujinami	B-X
sarcoma	B-X
virus	B-X
,	B-X
Yamaguchi	B-X
73	B-X
virus	B-X
(	B-X
Lipsich	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
,	B-X
and	B-X
PRCII	B-X
avian	B-X
sarcoma	B-X
virus	B-X
(	B-X
Adkins	B-X
et	B-X
al.	B-X
,	B-X
1982	B-X
)	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
gag-onc	B-X
fusion	B-X
proteins	B-X
are	B-X
phosphorylated	B-X
on	B-X
serine	B-X
,	B-X
threonine	B-X
,	B-X
and	B-X
tyrosine	B-X
;	B-X
however	B-X
,	B-X
quantitative	B-X
and/or	B-X
qualitative	B-X
differences	B-X
in	B-X
phosphorylation	B-X
of	B-X
the	B-X
two	B-X
species	B-X
were	B-X
apparent	B-X
.	B-X
Only	B-X
the	B-X
monomeric	B-X
form	B-X
of	B-X
the	B-X
gag-onc	B-X
proteins	B-X
was	B-X
able	B-X
to	B-X
undergo	B-X
tyrosine	B-X
specific	B-X
autophosphorylation	B-X
in	B-X
an	B-X
in	B-X
vitro	B-X
kinase	B-X
reaction	B-X
.	B-X
Both	B-X
the	B-X
monomeric	B-X
and	B-X
complex-associated	B-X
forms	B-X
of	B-X
the	B-X
proteins	B-X
were	B-X
acylated	B-X
,	B-X
the	B-X
complex-associated	B-X
molecules	B-X
to	B-X
a	B-X
greater	B-X
degree	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
newly	B-X
synthesized	B-X
gag-onc	B-X
molecules	B-X
become	B-X
rapidly	B-X
incorporated	B-X
into	B-X
the	B-X
complex	B-X
and	B-X
that	B-X
a	B-X
significant	B-X
amount	B-X
of	B-X
these	B-X
molecules	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
complex	B-X
for	B-X
more	B-X
than	B-X
20	B-X
hr	B-X
.	B-X

Autoacylation	O
of	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
with	O
acyl	O
coenzyme	O
A	O
.	O
<EOS>	B-X
Rat	B-X
brain	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
known	B-X
to	B-X
contain	B-X
long	B-X
chain	B-X
,	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
demonstrated	B-X
that	B-X
the	B-X
protein	B-X
acts	B-X
as	B-X
both	B-X
an	B-X
acylating	B-X
enzyme	B-X
and	B-X
an	B-X
acceptor	B-X
.	B-X
Thus	B-X
,	B-X
acylation	B-X
occurs	B-X
by	B-X
an	B-X
autocatalytic	B-X
process	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
a	B-X
separate	B-X
acyltransferase	B-X
that	B-X
copurifies	B-X
with	B-X
PLP	B-X
was	B-X
essentially	B-X
excluded	B-X
by	B-X
adding	B-X
brain	B-X
subcellular	B-X
fractions	B-X
to	B-X
the	B-X
reaction	B-X
mixtures	B-X
and	B-X
by	B-X
changing	B-X
the	B-X
isolation	B-X
procedure	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
the	B-X
reaction	B-X
entails	B-X
net	B-X
addition	B-X
of	B-X
acyl	B-X
groups	B-X
.	B-X
Denaturation	B-X
of	B-X
the	B-X
protein	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
or	B-X
heat	B-X
inhibits	B-X
the	B-X
reaction	B-X
,	B-X
whereas	B-X
cerulenin	B-X
has	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

Rat	O
brain	O
myelin	B-Protein
proteolipid	I-Protein
protein	I-Protein
(	O
PLP	B-Protein
)	O
is	O
known	O
to	O
contain	O
long	O
chain	O
,	O
covalently	O
bound	O
fatty	O
acids	O
.	O
<EOS>	B-X
Rat	B-X
brain	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
known	B-X
to	B-X
contain	B-X
long	B-X
chain	B-X
,	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
demonstrated	B-X
that	B-X
the	B-X
protein	B-X
acts	B-X
as	B-X
both	B-X
an	B-X
acylating	B-X
enzyme	B-X
and	B-X
an	B-X
acceptor	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
a	B-X
separate	B-X
acyltransferase	B-X
that	B-X
copurifies	B-X
with	B-X
PLP	B-X
was	B-X
essentially	B-X
excluded	B-X
by	B-X
adding	B-X
brain	B-X
subcellular	B-X
fractions	B-X
to	B-X
the	B-X
reaction	B-X
mixtures	B-X
and	B-X
by	B-X
changing	B-X
the	B-X
isolation	B-X
procedure	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
Although	B-X
fatty	B-X
acids	B-X
are	B-X
bound	B-X
via	B-X
an	B-X
O-ester	B-X
linkage	B-X
,	B-X
free	B-X
SH	B-X
groups	B-X
are	B-X
required	B-X
in	B-X
the	B-X
reaction	B-X
.	B-X
Denaturation	B-X
of	B-X
the	B-X
protein	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
or	B-X
heat	B-X
inhibits	B-X
the	B-X
reaction	B-X
,	B-X
whereas	B-X
cerulenin	B-X
has	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X

In	O
the	O
course	O
of	O
characterizing	O
the	O
mechanism	O
of	O
acylation	O
,	O
we	O
found	O
that	O
the	O
isolated	O
PLP	B-Protein
,	O
in	O
the	O
absence	O
of	O
any	O
membrane	O
fraction	O
,	O
was	O
esterified	O
after	O
incubation	O
with	O
[	O
3H	O
]	O
palmitoyl	O
coenzyme	O
A	O
(	O
CoA	O
)	O
.	O
<EOS>	B-X
Rat	B-X
brain	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
known	B-X
to	B-X
contain	B-X
long	B-X
chain	B-X
,	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
acylation	B-X
occurs	B-X
by	B-X
an	B-X
autocatalytic	B-X
process	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
a	B-X
separate	B-X
acyltransferase	B-X
that	B-X
copurifies	B-X
with	B-X
PLP	B-X
was	B-X
essentially	B-X
excluded	B-X
by	B-X
adding	B-X
brain	B-X
subcellular	B-X
fractions	B-X
to	B-X
the	B-X
reaction	B-X
mixtures	B-X
and	B-X
by	B-X
changing	B-X
the	B-X
isolation	B-X
procedure	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

This	O
observation	O
demonstrated	O
that	O
the	O
protein	O
acts	O
as	O
both	O
an	O
acylating	O
enzyme	O
and	O
an	O
acceptor	O
.	O

Thus	O
,	O
acylation	O
occurs	O
by	O
an	O
autocatalytic	O
process	O
.	O
<EOS>	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
acylation	B-X
occurs	B-X
by	B-X
an	B-X
autocatalytic	B-X
process	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

The	O
possibility	O
of	O
a	O
separate	O
acyltransferase	O
that	O
copurifies	O
with	O
PLP	B-Protein
was	O
essentially	O
excluded	O
by	O
adding	O
brain	O
subcellular	O
fractions	O
to	O
the	O
reaction	O
mixtures	O
and	O
by	O
changing	O
the	O
isolation	O
procedure	O
.	O

After	O
deacylation	O
,	O
the	O
protein	O
was	O
acylated	O
at	O
a	O
4	O
-	O
fold	O
greater	O
rate	O
,	O
suggesting	O
that	O
the	O
original	O
sites	O
were	O
reacylated	O
.	O

The	O
palmitoyl	O
-	O
CoA	O
concentration	O
followed	O
Michaelis	O
kinetics	O
,	O
confirming	O
that	O
spontaneous	O
acylation	O
was	O
not	O
occurring	O
.	O

Pulse	O
-	O
chase	O
experiments	O
indicated	O
that	O
the	O
reaction	O
entails	O
net	O
addition	O
of	O
acyl	O
groups	O
.	O
<EOS>	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
demonstrated	B-X
that	B-X
the	B-X
protein	B-X
acts	B-X
as	B-X
both	B-X
an	B-X
acylating	B-X
enzyme	B-X
and	B-X
an	B-X
acceptor	B-X
.	B-X
Thus	B-X
,	B-X
acylation	B-X
occurs	B-X
by	B-X
an	B-X
autocatalytic	B-X
process	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
a	B-X
separate	B-X
acyltransferase	B-X
that	B-X
copurifies	B-X
with	B-X
PLP	B-X
was	B-X
essentially	B-X
excluded	B-X
by	B-X
adding	B-X
brain	B-X
subcellular	B-X
fractions	B-X
to	B-X
the	B-X
reaction	B-X
mixtures	B-X
and	B-X
by	B-X
changing	B-X
the	B-X
isolation	B-X
procedure	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
the	B-X
reaction	B-X
entails	B-X
net	B-X
addition	B-X
of	B-X
acyl	B-X
groups	B-X
.	B-X
Although	B-X
fatty	B-X
acids	B-X
are	B-X
bound	B-X
via	B-X
an	B-X
O-ester	B-X
linkage	B-X
,	B-X
free	B-X
SH	B-X
groups	B-X
are	B-X
required	B-X
in	B-X
the	B-X
reaction	B-X
.	B-X
Denaturation	B-X
of	B-X
the	B-X
protein	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
or	B-X
heat	B-X
inhibits	B-X
the	B-X
reaction	B-X
,	B-X
whereas	B-X
cerulenin	B-X
has	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

Although	O
fatty	O
acids	O
are	O
bound	O
via	O
an	O
O	O
-	O
ester	O
linkage	O
,	O
free	O
SH	O
groups	O
are	O
required	O
in	O
the	O
reaction	O
.	O

Denaturation	O
of	O
the	O
protein	O
by	O
sodium	O
dodecyl	O
sulfate	O
or	O
heat	O
inhibits	O
the	O
reaction	O
,	O
whereas	O
cerulenin	O
has	O
little	O
or	O
no	O
effect	O
.	O
<EOS>	B-X
Most	B-X
analytical	B-X
electrophoreses	B-X
of	B-X
proteins	B-X
are	B-X
achieved	B-X
by	B-X
separation	B-X
in	B-X
polyacrylamide	B-X
gels	B-X
under	B-X
conditions	B-X
that	B-X
ensure	B-X
dissociation	B-X
of	B-X
proteins	B-X
into	B-X
individual	B-X
polypeptide	B-X
subunits	B-X
and	B-X
minimize	B-X
aggregation	B-X
.	B-X
Most	B-X
commonly	B-X
,	B-X
the	B-X
anionic	B-X
detergent	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
(	B-X
SDS	B-X
)	B-X
is	B-X
used	B-X
in	B-X
combination	B-X
with	B-X
a	B-X
reducing	B-X
agent	B-X
(	B-X
β-mercaptoethanol	B-X
or	B-X
dithiothreitol	B-X
)	B-X
and	B-X
with	B-X
heating	B-X
to	B-X
dissociate	B-X
proteins	B-X
before	B-X
loading	B-X
onto	B-X
the	B-X
gel	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
migration	B-X
of	B-X
SDS-polypeptide	B-X
complexes	B-X
in	B-X
an	B-X
electric	B-X
field	B-X
is	B-X
proportional	B-X
to	B-X
the	B-X
relative	B-X
size	B-X
of	B-X
the	B-X
polypeptide	B-X
chain	B-X
,	B-X
and	B-X
its	B-X
molecular	B-X
weight	B-X
can	B-X
be	B-X
estimated	B-X
by	B-X
comparison	B-X
to	B-X
protein	B-X
markers	B-X
of	B-X
known	B-X
molecular	B-X
weight	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
apparent	B-X
molecular	B-X
weight	B-X
of	B-X
modified	B-X
proteins	B-X
does	B-X
not	B-X
always	B-X
accurately	B-X
reflect	B-X
the	B-X
mass	B-X
of	B-X
the	B-X
polypeptide	B-X
chain	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
preparation	B-X
and	B-X
running	B-X
of	B-X
SDS-PAGE	B-X
gels	B-X
,	B-X
followed	B-X
by	B-X
staining	B-X
to	B-X
detect	B-X
proteins	B-X
using	B-X
Coomassie	B-X
Brilliant	B-X
Blue	B-X
.	B-X

PO	B-Protein
,	O
the	O
major	O
protein	O
in	O
peripheral	O
nerve	O
myelin	O
,	O
is	O
also	O
an	O
acylated	O
protein	O
,	O
but	O
it	O
was	O
not	O
labeled	O
upon	O
incubation	O
of	O
either	O
peripheral	O
myelin	O
or	O
the	O
isolated	O
protein	O
with	O
[	O
3H	O
]	O
palmitoyl	O
-	O
CoA	O
,	O
demonstrating	O
that	O
it	O
is	O
acylated	O
by	O
a	O
different	O
route	O
.	O
<EOS>	B-X
Rat	B-X
brain	B-X
myelin	B-X
proteolipid	B-X
protein	B-X
(	B-X
PLP	B-X
)	B-X
is	B-X
known	B-X
to	B-X
contain	B-X
long	B-X
chain	B-X
,	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
.	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
This	B-X
observation	B-X
demonstrated	B-X
that	B-X
the	B-X
protein	B-X
acts	B-X
as	B-X
both	B-X
an	B-X
acylating	B-X
enzyme	B-X
and	B-X
an	B-X
acceptor	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
Denaturation	B-X
of	B-X
the	B-X
protein	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
or	B-X
heat	B-X
inhibits	B-X
the	B-X
reaction	B-X
,	B-X
whereas	B-X
cerulenin	B-X
has	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

Several	O
synthetic	O
peptides	O
derived	O
from	O
PLP	B-Protein
sequences	O
with	O
sites	O
known	O
to	O
be	O
acylated	O
in	O
vivo	O
as	O
well	O
as	O
a	O
series	O
of	O
deacylated	O
PLP	B-Protein
tryptic	O
peptides	O
were	O
not	O
labeled	O
,	O
indicating	O
that	O
integrity	O
of	O
the	O
protein	O
is	O
required	O
for	O
acylation	O
.	O

Limited	O
proteolysis	O
and	O
peptide	O
mapping	O
showed	O
that	O
the	O
same	O
sites	O
are	O
acylated	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
suggesting	O
that	O
the	O
autocatalytic	O
acylation	O
reaction	O
is	O
physiological	O
.	O
<EOS>	B-X
In	B-X
the	B-X
course	B-X
of	B-X
characterizing	B-X
the	B-X
mechanism	B-X
of	B-X
acylation	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
isolated	B-X
PLP	B-X
,	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
any	B-X
membrane	B-X
fraction	B-X
,	B-X
was	B-X
esterified	B-X
after	B-X
incubation	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl	B-X
coenzyme	B-X
A	B-X
(	B-X
CoA	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
acylation	B-X
occurs	B-X
by	B-X
an	B-X
autocatalytic	B-X
process	B-X
.	B-X
The	B-X
possibility	B-X
of	B-X
a	B-X
separate	B-X
acyltransferase	B-X
that	B-X
copurifies	B-X
with	B-X
PLP	B-X
was	B-X
essentially	B-X
excluded	B-X
by	B-X
adding	B-X
brain	B-X
subcellular	B-X
fractions	B-X
to	B-X
the	B-X
reaction	B-X
mixtures	B-X
and	B-X
by	B-X
changing	B-X
the	B-X
isolation	B-X
procedure	B-X
.	B-X
After	B-X
deacylation	B-X
,	B-X
the	B-X
protein	B-X
was	B-X
acylated	B-X
at	B-X
a	B-X
4-fold	B-X
greater	B-X
rate	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
original	B-X
sites	B-X
were	B-X
reacylated	B-X
.	B-X
The	B-X
palmitoyl-CoA	B-X
concentration	B-X
followed	B-X
Michaelis	B-X
kinetics	B-X
,	B-X
confirming	B-X
that	B-X
spontaneous	B-X
acylation	B-X
was	B-X
not	B-X
occurring	B-X
.	B-X
Pulse-chase	B-X
experiments	B-X
indicated	B-X
that	B-X
the	B-X
reaction	B-X
entails	B-X
net	B-X
addition	B-X
of	B-X
acyl	B-X
groups	B-X
.	B-X
Although	B-X
fatty	B-X
acids	B-X
are	B-X
bound	B-X
via	B-X
an	B-X
O-ester	B-X
linkage	B-X
,	B-X
free	B-X
SH	B-X
groups	B-X
are	B-X
required	B-X
in	B-X
the	B-X
reaction	B-X
.	B-X
Denaturation	B-X
of	B-X
the	B-X
protein	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate	B-X
or	B-X
heat	B-X
inhibits	B-X
the	B-X
reaction	B-X
,	B-X
whereas	B-X
cerulenin	B-X
has	B-X
little	B-X
or	B-X
no	B-X
effect	B-X
.	B-X
PO	B-X
,	B-X
the	B-X
major	B-X
protein	B-X
in	B-X
peripheral	B-X
nerve	B-X
myelin	B-X
,	B-X
is	B-X
also	B-X
an	B-X
acylated	B-X
protein	B-X
,	B-X
but	B-X
it	B-X
was	B-X
not	B-X
labeled	B-X
upon	B-X
incubation	B-X
of	B-X
either	B-X
peripheral	B-X
myelin	B-X
or	B-X
the	B-X
isolated	B-X
protein	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitoyl-CoA	B-X
,	B-X
demonstrating	B-X
that	B-X
it	B-X
is	B-X
acylated	B-X
by	B-X
a	B-X
different	B-X
route	B-X
.	B-X
Several	B-X
synthetic	B-X
peptides	B-X
derived	B-X
from	B-X
PLP	B-X
sequences	B-X
with	B-X
sites	B-X
known	B-X
to	B-X
be	B-X
acylated	B-X
in	B-X
vivo	B-X
as	B-X
well	B-X
as	B-X
a	B-X
series	B-X
of	B-X
deacylated	B-X
PLP	B-X
tryptic	B-X
peptides	B-X
were	B-X
not	B-X
labeled	B-X
,	B-X
indicating	B-X
that	B-X
integrity	B-X
of	B-X
the	B-X
protein	B-X
is	B-X
required	B-X
for	B-X
acylation	B-X
.	B-X
Limited	B-X
proteolysis	B-X
and	B-X
peptide	B-X
mapping	B-X
showed	B-X
that	B-X
the	B-X
same	B-X
sites	B-X
are	B-X
acylated	B-X
in	B-X
vitro	B-X
or	B-X
in	B-X
vivo	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
autocatalytic	B-X
acylation	B-X
reaction	B-X
is	B-X
physiological	B-X
.	B-X

Posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
spp	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
for	B-X
``	B-X
NH4+	B-X
switch-off/on	B-X
''	B-X
of	B-X
nitrogenase	B-X
activity	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
correlation	B-X
was	B-X
established	B-X
between	B-X
the	B-X
in	B-X
vivo	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
activity	B-X
by	B-X
NH4Cl	B-X
or	B-X
glutamine	B-X
and	B-X
the	B-X
reversible	B-X
covalent	B-X
modification	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
.	B-X
Dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DRAT	B-X
)	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
of	B-X
A.	B-X
brasilense	B-X
with	B-X
NAD	B-X
as	B-X
the	B-X
donor	B-X
molecule	B-X
.	B-X
Dinitrogenase	B-X
reductase-activating	B-X
glycohydrolase	B-X
(	B-X
DRAG	B-X
)	B-X
activity	B-X
was	B-X
present	B-X
in	B-X
extracts	B-X
of	B-X
both	B-X
A.	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
.	B-X
The	B-X
DRAG	B-X
activity	B-X
in	B-X
A.	B-X
lipoferum	B-X
was	B-X
membrane	B-X
associated	B-X
,	B-X
and	B-X
it	B-X
catalyzed	B-X
the	B-X
activation	B-X
of	B-X
inactive	B-X
nitrogenase	B-X
(	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
)	B-X
from	B-X
both	B-X
A.	B-X
lipoferum	B-X
and	B-X
Rhodospirillum	B-X
rubrum	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
a	B-X
posttranslational	B-X
regulatory	B-X
system	B-X
for	B-X
nitrogenase	B-X
activity	B-X
is	B-X
present	B-X
in	B-X
A.	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
and	B-X
that	B-X
it	B-X
operates	B-X
via	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
as	B-X
it	B-X
does	B-X
in	B-X
R.	B-X
rubrum	B-X
.	B-X

The	O
mechanism	O
for	O
"	O
NH4	O
+	O
switch	O
-	O
off	O
/	O
on	O
"	O
of	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
was	O
investigated	O
.	O

A	O
correlation	O
was	O
established	O
between	O
the	O
in	O
vivo	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
NH4Cl	O
or	O
glutamine	O
and	O
the	O
reversible	O
covalent	O
modification	O
of	O
dinitrogenase	O
reductase	O
.	O
<EOS>	B-X
The	B-X
photosynthetic	B-X
bacteria	B-X
can	B-X
evolve	B-X
H2	B-X
in	B-X
the	B-X
light	B-X
through	B-X
a	B-X
nitrogenase-mediated	B-X
reaction	B-X
.	B-X
The	B-X
nitrogenase	B-X
enzyme	B-X
in	B-X
the	B-X
photosynthetic	B-X
bacteria	B-X
is	B-X
similar	B-X
to	B-X
other	B-X
nitrogenases	B-X
.	B-X
It	B-X
is	B-X
made	B-X
of	B-X
two	B-X
soluble	B-X
components	B-X
:	B-X
a	B-X
)	B-X
the	B-X
Fe	B-X
protein	B-X
(	B-X
dinitrogenase	B-X
reductase	B-X
or	B-X
Component	B-X
II	B-X
)	B-X
which	B-X
receives	B-X
electrons	B-X
from	B-X
ferredoxin	B-X
,	B-X
and	B-X
b	B-X
)	B-X
the	B-X
Mo-Fe	B-X
protein	B-X
(	B-X
dinitrogenase	B-X
or	B-X
Component	B-X
I	B-X
)	B-X
on	B-X
which	B-X
the	B-X
substrates	B-X
(	B-X
including	B-X
protons	B-X
)	B-X
are	B-X
reduced	B-X
.	B-X
In	B-X
photosynthetic	B-X
bacteria	B-X
,	B-X
the	B-X
physiological	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
activity	B-X
involves	B-X
inactivation	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
the	B-X
nitrogenase	B-X
Fe	B-X
protein	B-X
.	B-X
After	B-X
an	B-X
ammonia	B-X
shock	B-X
,	B-X
both	B-X
the	B-X
Fe	B-X
protein	B-X
of	B-X
nitrogenase	B-X
,	B-X
and	B-X
the	B-X
glutamine	B-X
synthetase	B-X
,	B-X
become	B-X
adenylylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
the	B-X
adenylylation	B-X
state	B-X
,	B-X
glutamine	B-X
synthetase	B-X
has	B-X
AMP	B-X
moieties	B-X
bound	B-X
to	B-X
the	B-X
protein	B-X
by	B-X
phosphate	B-X
linkage	B-X
.	B-X
In	B-X
toluene-treated	B-X
cells	B-X
of	B-X
Rhodopseudomas	B-X
capsulata	B-X
preincubated	B-X
with	B-X
radioactive	B-X
ATP	B-X
,	B-X
labelled	B-X
either	B-X
by	B-X
14C	B-X
on	B-X
the	B-X
adenine	B-X
or	B-X
by	B-X
32P	B-X
on	B-X
the	B-X
P	B-X
alpha	B-X
of	B-X
ATP	B-X
and	B-X
then	B-X
submitted	B-X
to	B-X
an	B-X
ammonia	B-X
shock	B-X
,	B-X
the	B-X
Fe	B-X
protein	B-X
becomes	B-X
covalently	B-X
labelled	B-X
only	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
ATP	B-X
ad	B-X
not	B-X
with	B-X
[	B-X
32P	B-X
]	B-X
alpha	B-X
ATP	B-X
,	B-X
while	B-X
glutamine	B-X
synthetase	B-X
becomes	B-X
labelled	B-X
with	B-X
both	B-X
radioactive	B-X
ATP	B-X
molecules	B-X
.	B-X
This	B-X
indicates	B-X
that	B-X
a	B-X
different	B-X
type	B-X
of	B-X
linkage	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
binding	B-X
of	B-X
the	B-X
modifying	B-X
group	B-X
to	B-X
Fe	B-X
protein	B-X
and	B-X
to	B-X
glutamine	B-X
synthetase	B-X
.	B-X
It	B-X
functions	B-X
physiologically	B-X
as	B-X
an	B-X
uptake-hydrogenase	B-X
and	B-X
may	B-X
contribute	B-X
to	B-X
the	B-X
recycling	B-X
of	B-X
electrons	B-X
to	B-X
nitrogenase	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
excess	B-X
carbon	B-X
compounds	B-X
,	B-X
its	B-X
main	B-X
role	B-X
may	B-X
be	B-X
to	B-X
maintain	B-X
an	B-X
anaerobic	B-X
microenvironment	B-X
for	B-X
the	B-X
nitrogenase	B-X
.	B-X
Reduced	B-X
Fd	B-X
I	B-X
from	B-X
R.	B-X
capsulata	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
donate	B-X
its	B-X
electrons	B-X
to	B-X
nitrogenase	B-X
.	B-X

Dinitrogenase	B-Protein
reductase	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
(	O
DRAT	B-Protein
)	O
activity	O
was	O
detected	O
in	O
extracts	O
of	O
A	O
.	O
brasilense	O
with	O
NAD	O
as	O
the	O
donor	O
molecule	O
.	O
<EOS>	B-X
The	B-X
mechanism	B-X
for	B-X
``	B-X
NH4+	B-X
switch-off/on	B-X
''	B-X
of	B-X
nitrogenase	B-X
activity	B-X
in	B-X
Azospirillum	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
was	B-X
investigated	B-X
.	B-X
A	B-X
correlation	B-X
was	B-X
established	B-X
between	B-X
the	B-X
in	B-X
vivo	B-X
regulation	B-X
of	B-X
nitrogenase	B-X
activity	B-X
by	B-X
NH4Cl	B-X
or	B-X
glutamine	B-X
and	B-X
the	B-X
reversible	B-X
covalent	B-X
modification	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
.	B-X
Dinitrogenase	B-X
reductase	B-X
ADP-ribosyltransferase	B-X
(	B-X
DRAT	B-X
)	B-X
activity	B-X
was	B-X
detected	B-X
in	B-X
extracts	B-X
of	B-X
A.	B-X
brasilense	B-X
with	B-X
NAD	B-X
as	B-X
the	B-X
donor	B-X
molecule	B-X
.	B-X
Dinitrogenase	B-X
reductase-activating	B-X
glycohydrolase	B-X
(	B-X
DRAG	B-X
)	B-X
activity	B-X
was	B-X
present	B-X
in	B-X
extracts	B-X
of	B-X
both	B-X
A.	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
.	B-X
The	B-X
DRAG	B-X
activity	B-X
in	B-X
A.	B-X
lipoferum	B-X
was	B-X
membrane	B-X
associated	B-X
,	B-X
and	B-X
it	B-X
catalyzed	B-X
the	B-X
activation	B-X
of	B-X
inactive	B-X
nitrogenase	B-X
(	B-X
by	B-X
covalent	B-X
modification	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
)	B-X
from	B-X
both	B-X
A.	B-X
lipoferum	B-X
and	B-X
Rhodospirillum	B-X
rubrum	B-X
.	B-X
A	B-X
region	B-X
homologous	B-X
to	B-X
R.	B-X
rubrum	B-X
draT	B-X
and	B-X
draG	B-X
was	B-X
identified	B-X
in	B-X
the	B-X
genomic	B-X
DNA	B-X
of	B-X
A.	B-X
brasilense	B-X
as	B-X
a	B-X
12-kilobase	B-X
EcoRI	B-X
fragment	B-X
and	B-X
in	B-X
A.	B-X
lipoferum	B-X
as	B-X
a	B-X
7-kilobase	B-X
EcoRI	B-X
fragment	B-X
.	B-X
It	B-X
is	B-X
concluded	B-X
that	B-X
a	B-X
posttranslational	B-X
regulatory	B-X
system	B-X
for	B-X
nitrogenase	B-X
activity	B-X
is	B-X
present	B-X
in	B-X
A.	B-X
brasilense	B-X
and	B-X
A.	B-X
lipoferum	B-X
and	B-X
that	B-X
it	B-X
operates	B-X
via	B-X
ADP-ribosylation	B-X
of	B-X
dinitrogenase	B-X
reductase	B-X
as	B-X
it	B-X
does	B-X
in	B-X
R.	B-X
rubrum	B-X
.	B-X

Dinitrogenase	B-Protein
reductase	I-Protein
-	I-Protein
activating	I-Protein
glycohydrolase	I-Protein
(	O
DRAG	B-Protein
)	O
activity	O
was	O
present	O
in	O
extracts	O
of	O
both	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
.	O

The	O
DRAG	B-Protein
activity	O
in	O
A	O
.	O
lipoferum	O
was	O
membrane	O
associated	O
,	O
and	O
it	O
catalyzed	O
the	O
activation	O
of	O
inactive	O
nitrogenase	O
(	O
by	O
covalent	O
modification	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
)	O
from	O
both	O
A	O
.	O
lipoferum	O
and	O
Rhodospirillum	O
rubrum	O
.	O

A	O
region	O
homologous	O
to	O
R	O
.	O
rubrum	O
draT	B-Protein
and	O
draG	B-Protein
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
A	O
.	O
brasilense	O
as	O
a	O
12	O
-	O
kilobase	O
EcoRI	B-Protein
fragment	O
and	O
in	O
A	O
.	O
lipoferum	O
as	O
a	O
7	O
-	O
kilobase	O
EcoRI	B-Protein
fragment	O
.	O

It	O
is	O
concluded	O
that	O
a	O
posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
is	O
present	O
in	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
and	O
that	O
it	O
operates	O
via	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-Protein
reductase	I-Protein
as	O
it	O
does	O
in	O
R	O
.	O
rubrum	O
.	O

The	O
membrane	O
binding	O
domain	O
of	O
rod	O
cGMP	O
phosphodiesterase	O
is	O
posttranslationally	O
modified	O
by	O
methyl	O
esterification	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
.	O

Retinal	O
rod	O
cGMP	O
phosphodiesterase	O
(	O
3	O
'	O
,	O
5	O
'	O
-	O
cyclic	O
-	O
GMP	O
phosphodiesterase	O
;	O
EC	O
3	O
.	O
1	O
.	O
4	O
.	O
35	O
;	O
PDE	O
)	O
,	O
a	O
key	O
regulatory	O
enzyme	O
involved	O
in	O
visual	O
excitation	O
,	O
is	O
one	O
of	O
several	O
outer	O
segment	O
membrane	O
proteins	O
that	O
are	O
carboxyl	O
methylated	O
in	O
the	O
presence	O
of	O
the	O
methyl	O
donor	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
[	O
3H	O
-	O
methyl	O
]	O
methionine	O
.	O
<EOS>	B-X
We	B-X
have	B-X
established	B-X
earlier	B-X
that	B-X
rod	B-X
photoreceptor	B-X
cGMP-phosphodiesterase	B-X
(	B-X
PDE6	B-X
)	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
are	B-X
equally	B-X
represented	B-X
in	B-X
the	B-X
retina	B-X
at	B-X
the	B-X
protein	B-X
level	B-X
and	B-X
have	B-X
similar	B-X
turnover	B-X
rates	B-X
.	B-X
mRNA	B-X
quantification	B-X
revealed	B-X
five	B-X
PDE6beta	B-X
messages	B-X
for	B-X
every	B-X
PDE6alpha	B-X
transcript	B-X
pointing	B-X
at	B-X
post-transcriptional	B-X
regulation	B-X
of	B-X
PDE6alpha	B-X
and	B-X
PDE6beta	B-X
expression	B-X
.	B-X
Indeed	B-X
,	B-X
the	B-X
wild-type	B-X
PDE6alpha	B-X
mRNA	B-X
was	B-X
translated	B-X
5-fold	B-X
more	B-X
efficiently	B-X
than	B-X
that	B-X
of	B-X
PDE6beta	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
extend	B-X
our	B-X
study	B-X
of	B-X
translational	B-X
regulation	B-X
of	B-X
PDE6	B-X
subunits	B-X
and	B-X
present	B-X
a	B-X
detailed	B-X
analysis	B-X
of	B-X
the	B-X
role	B-X
of	B-X
PDE6alpha	B-X
and	B-X
PDE6beta	B-X
5'-	B-X
and	B-X
3'-UTRs	B-X
(	B-X
untranslated	B-X
regions	B-X
)	B-X
in	B-X
this	B-X
process	B-X
.	B-X
We	B-X
showed	B-X
that	B-X
both	B-X
the	B-X
short	B-X
and	B-X
long	B-X
PDE6beta	B-X
5'-UTRs	B-X
lead	B-X
to	B-X
more	B-X
efficient	B-X
protein	B-X
synthesis	B-X
than	B-X
the	B-X
PDE6alpha	B-X
5'-UTR	B-X
.	B-X
The	B-X
3'-UTRs	B-X
of	B-X
PDE6alpha	B-X
and	B-X
PDE6beta	B-X
stimulated	B-X
translation	B-X
by	B-X
approximately	B-X
2-	B-X
and	B-X
3-fold	B-X
,	B-X
respectively	B-X
.	B-X
However	B-X
,	B-X
the	B-X
positive	B-X
effect	B-X
of	B-X
the	B-X
PDE6alpha	B-X
or	B-X
PDE6beta	B-X
3'-UTRs	B-X
was	B-X
not	B-X
observed	B-X
when	B-X
these	B-X
regions	B-X
were	B-X
placed	B-X
in	B-X
constructs	B-X
containing	B-X
the	B-X
5'-UTR	B-X
of	B-X
the	B-X
corresponding	B-X
PDE6	B-X
subunit	B-X
.	B-X
Furthermore	B-X
,	B-X
it	B-X
appears	B-X
that	B-X
PDE6alpha	B-X
5'-	B-X
and	B-X
3'-UTRs	B-X
may	B-X
be	B-X
involved	B-X
in	B-X
a	B-X
base	B-X
pairing	B-X
interaction	B-X
that	B-X
reduces	B-X
the	B-X
efficiency	B-X
of	B-X
protein	B-X
synthesis	B-X
.	B-X
Finally	B-X
,	B-X
using	B-X
progressive	B-X
deletion	B-X
analysis	B-X
of	B-X
the	B-X
PDE6alpha	B-X
5'-UTR	B-X
,	B-X
we	B-X
have	B-X
identified	B-X
several	B-X
regions	B-X
that	B-X
have	B-X
significant	B-X
contribution	B-X
in	B-X
regulation	B-X
of	B-X
protein	B-X
synthesis	B-X
.	B-X
Based	B-X
on	B-X
these	B-X
and	B-X
earlier	B-X
published	B-X
data	B-X
,	B-X
it	B-X
can	B-X
be	B-X
stated	B-X
that	B-X
an	B-X
equimolar	B-X
level	B-X
of	B-X
PDE6alpha	B-X
and	B-X
PDE6beta	B-X
synthesized	B-X
from	B-X
different	B-X
amounts	B-X
of	B-X
mRNA	B-X
(	B-X
ratio	B-X
of	B-X
PDE6alpha	B-X
to	B-X
PDE6beta	B-X
mRNA	B-X
in	B-X
the	B-X
retina	B-X
is	B-X
1:5	B-X
)	B-X
is	B-X
achieved	B-X
as	B-X
a	B-X
result	B-X
of	B-X
combinatorial	B-X
effects	B-X
of	B-X
5'-UTRs	B-X
and	B-X
coding	B-X
regions	B-X
of	B-X
PDE6alpha	B-X
and	B-X
PDE6beta	B-X
mRNAs	B-X
on	B-X
translational	B-X
regulation	B-X
.	B-X

By	O
chromatographic	O
analyses	O
of	O
the	O
3H	O
-	O
methyl	O
amino	O
acid	O
generated	O
by	O
exhaustive	O
proteolysis	O
of	O
purified	O
PDE	O
,	O
followed	O
by	O
performic	O
acid	O
oxidation	O
of	O
the	O
digest	O
,	O
we	O
have	O
shown	O
that	O
this	O
modification	O
occurs	O
at	O
a	O
C	O
-	O
terminal	O
cysteine	O
residue	O
of	O
the	O
alpha	O
subunit	O
of	O
this	O
enzyme	O
.	O

When	O
PDE	O
is	O
subjected	O
to	O
limited	O
proteolysis	O
with	O
trypsin	O
,	O
a	O
3H	O
-	O
methylated	O
fragment	O
of	O
1000	O
daltons	O
or	O
less	O
is	O
rapidly	O
removed	O
prior	O
to	O
the	O
degradation	O
of	O
its	O
inhibitory	O
gamma	O
subunit	O
.	O
<EOS>	B-X
Retinal	B-X
rod	B-X
cGMP	B-X
phosphodiesterase	B-X
(	B-X
3',5'-cyclic-GMP	B-X
phosphodiesterase	B-X
;	B-X
EC	B-X
3.1.4.35	B-X
;	B-X
PDE	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulatory	B-X
enzyme	B-X
involved	B-X
in	B-X
visual	B-X
excitation	B-X
,	B-X
is	B-X
one	B-X
of	B-X
several	B-X
outer	B-X
segment	B-X
membrane	B-X
proteins	B-X
that	B-X
are	B-X
carboxyl	B-X
methylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
3H-methyl	B-X
]	B-X
methionine	B-X
.	B-X
By	B-X
chromatographic	B-X
analyses	B-X
of	B-X
the	B-X
3H-methyl	B-X
amino	B-X
acid	B-X
generated	B-X
by	B-X
exhaustive	B-X
proteolysis	B-X
of	B-X
purified	B-X
PDE	B-X
,	B-X
followed	B-X
by	B-X
performic	B-X
acid	B-X
oxidation	B-X
of	B-X
the	B-X
digest	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
at	B-X
a	B-X
C-terminal	B-X
cysteine	B-X
residue	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
When	B-X
PDE	B-X
is	B-X
subjected	B-X
to	B-X
limited	B-X
proteolysis	B-X
with	B-X
trypsin	B-X
,	B-X
a	B-X
3H-methylated	B-X
fragment	B-X
of	B-X
1000	B-X
daltons	B-X
or	B-X
less	B-X
is	B-X
rapidly	B-X
removed	B-X
prior	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
its	B-X
inhibitory	B-X
gamma	B-X
subunit	B-X
.	B-X
This	B-X
small	B-X
fragment	B-X
remains	B-X
membrane	B-X
bound	B-X
,	B-X
whereas	B-X
the	B-X
bulk	B-X
of	B-X
the	B-X
enzyme	B-X
is	B-X
released	B-X
,	B-X
indicating	B-X
that	B-X
a	B-X
domain	B-X
responsible	B-X
for	B-X
anchoring	B-X
PDE	B-X
to	B-X
the	B-X
membrane	B-X
is	B-X
located	B-X
near	B-X
the	B-X
C	B-X
terminus	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
C-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Cys-Cys-Val-Gln	B-X
predicted	B-X
from	B-X
the	B-X
alpha	B-X
cDNA	B-X
sequence	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
PDE	B-X
undergoes	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
the	B-X
proteolytic	B-X
removal	B-X
of	B-X
two	B-X
or	B-X
three	B-X
terminal	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
methyl	B-X
esterification	B-X
of	B-X
the	B-X
alpha-carboxyl	B-X
group	B-X
of	B-X
the	B-X
terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
the	B-X
sulfhydryl	B-X
group	B-X
of	B-X
the	B-X
methylated	B-X
cysteine	B-X
is	B-X
also	B-X
lipidated	B-X
to	B-X
mediate	B-X
membrane	B-X
binding	B-X
.	B-X
These	B-X
modifications	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
delivering	B-X
the	B-X
nascent	B-X
PDE	B-X
chains	B-X
to	B-X
the	B-X
membrane	B-X
and	B-X
in	B-X
correctly	B-X
positioning	B-X
the	B-X
PDE	B-X
molecule	B-X
in	B-X
the	B-X
rod	B-X
disks	B-X
for	B-X
phototransduction	B-X
.	B-X

This	O
small	O
fragment	O
remains	O
membrane	O
bound	O
,	O
whereas	O
the	O
bulk	O
of	O
the	O
enzyme	O
is	O
released	O
,	O
indicating	O
that	O
a	O
domain	O
responsible	O
for	O
anchoring	O
PDE	O
to	O
the	O
membrane	O
is	O
located	O
near	O
the	O
C	O
terminus	O
.	O

Based	O
on	O
the	O
C	O
-	O
terminal	O
amino	O
acid	O
sequence	O
of	O
Cys	O
-	O
Cys	O
-	O
Val	O
-	O
Gln	O
predicted	O
from	O
the	O
alpha	O
cDNA	O
sequence	O
,	O
we	O
conclude	O
that	O
PDE	O
undergoes	O
posttranslational	O
modifications	O
,	O
including	O
the	O
proteolytic	O
removal	O
of	O
two	O
or	O
three	O
terminal	O
amino	O
acids	O
,	O
and	O
methyl	O
esterification	O
of	O
the	O
alpha	O
-	O
carboxyl	O
group	O
of	O
the	O
terminal	O
cysteine	O
residue	O
.	O
<EOS>	B-X
The	B-X
gamma	B-X
polypeptide	B-X
of	B-X
brain	B-X
G-proteins	B-X
is	B-X
carboxyl	B-X
methylated	B-X
when	B-X
the	B-X
purified	B-X
beta	B-X
gamma	B-X
subunit	B-X
complex	B-X
is	B-X
reconstituted	B-X
with	B-X
S-adenosyl-	B-X
[	B-X
3H-methyl	B-X
]	B-X
-L-methionine	B-X
and	B-X
a	B-X
methyltransferase	B-X
present	B-X
in	B-X
detergent-stripped	B-X
brain	B-X
membranes	B-X
.	B-X
By	B-X
chromatographic	B-X
analysis	B-X
of	B-X
the	B-X
3H-amino	B-X
acid	B-X
generated	B-X
by	B-X
exhaustive	B-X
proteolysis	B-X
and	B-X
performic	B-X
acid	B-X
oxidation	B-X
of	B-X
the	B-X
3H-methylated	B-X
beta	B-X
gamma	B-X
complex	B-X
,	B-X
we	B-X
show	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
on	B-X
the	B-X
alpha-carboxyl	B-X
group	B-X
of	B-X
a	B-X
C-terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
Our	B-X
result	B-X
suggests	B-X
that	B-X
brain	B-X
G-protein	B-X
may	B-X
undergo	B-X
multiple	B-X
covalent	B-X
modification	B-X
steps	B-X
,	B-X
including	B-X
proteolytic	B-X
removal	B-X
of	B-X
the	B-X
three	B-X
terminal	B-X
amino	B-X
acids	B-X
from	B-X
the	B-X
predicted	B-X
common	B-X
C-terminal	B-X
Cys-Xaa-Xaa-Xaa	B-X
sequence	B-X
,	B-X
and	B-X
the	B-X
methyl	B-X
esterification	B-X
of	B-X
the	B-X
resulting	B-X
terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
This	B-X
modification	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
associated	B-X
with	B-X
lipidation	B-X
at	B-X
the	B-X
sulfhydryl	B-X
group	B-X
of	B-X
the	B-X
same	B-X
cysteine	B-X
,	B-X
which	B-X
would	B-X
explain	B-X
the	B-X
tight	B-X
membrane	B-X
binding	B-X
property	B-X
of	B-X
the	B-X
brain	B-X
beta	B-X
gamma	B-X
complex	B-X
.	B-X

We	O
speculate	O
that	O
the	O
sulfhydryl	O
group	O
of	O
the	O
methylated	O
cysteine	O
is	O
also	O
lipidated	O
to	O
mediate	O
membrane	O
binding	O
.	O
<EOS>	B-X
Retinal	B-X
rod	B-X
cGMP	B-X
phosphodiesterase	B-X
(	B-X
3',5'-cyclic-GMP	B-X
phosphodiesterase	B-X
;	B-X
EC	B-X
3.1.4.35	B-X
;	B-X
PDE	B-X
)	B-X
,	B-X
a	B-X
key	B-X
regulatory	B-X
enzyme	B-X
involved	B-X
in	B-X
visual	B-X
excitation	B-X
,	B-X
is	B-X
one	B-X
of	B-X
several	B-X
outer	B-X
segment	B-X
membrane	B-X
proteins	B-X
that	B-X
are	B-X
carboxyl	B-X
methylated	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
methyl	B-X
donor	B-X
S-adenosyl-L-	B-X
[	B-X
3H-methyl	B-X
]	B-X
methionine	B-X
.	B-X
By	B-X
chromatographic	B-X
analyses	B-X
of	B-X
the	B-X
3H-methyl	B-X
amino	B-X
acid	B-X
generated	B-X
by	B-X
exhaustive	B-X
proteolysis	B-X
of	B-X
purified	B-X
PDE	B-X
,	B-X
followed	B-X
by	B-X
performic	B-X
acid	B-X
oxidation	B-X
of	B-X
the	B-X
digest	B-X
,	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
this	B-X
modification	B-X
occurs	B-X
at	B-X
a	B-X
C-terminal	B-X
cysteine	B-X
residue	B-X
of	B-X
the	B-X
alpha	B-X
subunit	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
When	B-X
PDE	B-X
is	B-X
subjected	B-X
to	B-X
limited	B-X
proteolysis	B-X
with	B-X
trypsin	B-X
,	B-X
a	B-X
3H-methylated	B-X
fragment	B-X
of	B-X
1000	B-X
daltons	B-X
or	B-X
less	B-X
is	B-X
rapidly	B-X
removed	B-X
prior	B-X
to	B-X
the	B-X
degradation	B-X
of	B-X
its	B-X
inhibitory	B-X
gamma	B-X
subunit	B-X
.	B-X
This	B-X
small	B-X
fragment	B-X
remains	B-X
membrane	B-X
bound	B-X
,	B-X
whereas	B-X
the	B-X
bulk	B-X
of	B-X
the	B-X
enzyme	B-X
is	B-X
released	B-X
,	B-X
indicating	B-X
that	B-X
a	B-X
domain	B-X
responsible	B-X
for	B-X
anchoring	B-X
PDE	B-X
to	B-X
the	B-X
membrane	B-X
is	B-X
located	B-X
near	B-X
the	B-X
C	B-X
terminus	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
C-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
of	B-X
Cys-Cys-Val-Gln	B-X
predicted	B-X
from	B-X
the	B-X
alpha	B-X
cDNA	B-X
sequence	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
PDE	B-X
undergoes	B-X
posttranslational	B-X
modifications	B-X
,	B-X
including	B-X
the	B-X
proteolytic	B-X
removal	B-X
of	B-X
two	B-X
or	B-X
three	B-X
terminal	B-X
amino	B-X
acids	B-X
,	B-X
and	B-X
methyl	B-X
esterification	B-X
of	B-X
the	B-X
alpha-carboxyl	B-X
group	B-X
of	B-X
the	B-X
terminal	B-X
cysteine	B-X
residue	B-X
.	B-X
We	B-X
speculate	B-X
that	B-X
the	B-X
sulfhydryl	B-X
group	B-X
of	B-X
the	B-X
methylated	B-X
cysteine	B-X
is	B-X
also	B-X
lipidated	B-X
to	B-X
mediate	B-X
membrane	B-X
binding	B-X
.	B-X
These	B-X
modifications	B-X
may	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
delivering	B-X
the	B-X
nascent	B-X
PDE	B-X
chains	B-X
to	B-X
the	B-X
membrane	B-X
and	B-X
in	B-X
correctly	B-X
positioning	B-X
the	B-X
PDE	B-X
molecule	B-X
in	B-X
the	B-X
rod	B-X
disks	B-X
for	B-X
phototransduction	B-X
.	B-X

These	O
modifications	O
may	O
play	O
an	O
important	O
role	O
in	O
delivering	O
the	O
nascent	O
PDE	O
chains	O
to	O
the	O
membrane	O
and	O
in	O
correctly	O
positioning	O
the	O
PDE	O
molecule	O
in	O
the	O
rod	O
disks	O
for	O
phototransduction	O
.	O

Purification	O
of	O
bacteriorhodopsin	B-Protein
and	O
characterization	O
of	O
mature	O
and	O
partially	O
processed	O
forms	O
.	O
<EOS>	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X

Bacteriorhodopsin	B-Protein
(	O
BR	B-Protein
)	O
essentially	O
free	O
of	O
native	O
lipids	O
has	O
been	O
prepared	O
in	O
a	O
highly	O
stable	O
state	O
.	O

Purple	O
membrane	O
was	O
solubilized	O
in	O
Triton	O
X	O
-	O
100	O
and	O
BR	B-Protein
was	O
purified	O
by	O
size	O
exclusion	O
chromatography	O
using	O
3	O
-	O
[	O
cholamidopropyl	O
)	O
dimethylammonio	O
]	O
-	O
2	O
-	O
hydroxyl	O
-	O
1	O
-	O
propanesulfonic	O
acid	O
(	O
CHAPSO	O
)	O
detergent	O
at	O
pH	O
5	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

Molar	O
ratios	O
of	O
phospholipid	O
/	O
BR	B-Protein
ranged	O
from	O
0	O
.	O
4	O
to	O
0	O
.	O
05	O
corresponding	O
to	O
94	O
-	O
98	O
%	O
phospholipid	O
removal	O
.	O

Purified	O
BR	B-Protein
has	O
an	O
absorbance	O
ratio	O
(	O
A280nm	O
/	O
A548nm	O
)	O
of	O
1	O
.	O
5	O
-	O
1	O
.	O
6	O
in	O
the	O
dark	O
-	O
adapted	O
state	O
which	O
is	O
the	O
highest	O
purified	O
BR	B-Protein
/	O
protein	O
ratio	O
reported	O
to	O
date	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

The	O
purified	O
BR	B-Protein
in	O
CHAPSO	O
shows	O
maximum	O
stability	O
in	O
the	O
pH	O
range	O
5	O
.	O
0	O
-	O
5	O
.	O
5	O
.	O

Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
profiles	O
of	O
native	O
purple	O
membrane	O
and	O
solubilized	O
BR	B-Protein
from	O
most	O
Halobacterium	O
halobium	O
JW	O
-	O
3	O
cultures	O
show	O
3	O
higher	O
molecular	O
weight	O
bands	O
in	O
addition	O
to	O
BR	B-Protein
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

Immunological	O
staining	O
and	O
amino	O
acid	O
sequencing	O
indicates	O
that	O
these	O
additional	O
proteins	O
are	O
partially	O
processed	O
forms	O
of	O
the	O
BR	B-Protein
precursor	O
protein	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

The	O
BR	B-Protein
preprotein	O
contains	O
13	O
additional	O
amino	O
acids	O
on	O
the	O
NH2	O
terminus	O
which	O
are	O
removed	O
by	O
post	O
-	O
translational	O
processing	O
in	O
at	O
least	O
four	O
steps	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

Isoelectric	O
focusing	O
separated	O
most	O
delipidated	O
and	O
non	O
-	O
delipidated	O
BR	O
samples	O
into	O
8	O
bands	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

Incomplete	O
BR	O
post	O
-	O
translational	O
processing	O
BR	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
multiplicity	O
of	O
isoelectric	O
BR	O
species	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

The	O
principal	O
components	O
have	O
pI	O
values	O
of	O
5	O
.	O
20	O
and	O
5	O
.	O
24	O
and	O
both	O
have	O
absorption	O
maxima	O
at	O
550	O
nm	O
,	O
characteristic	O
of	O
detergent	O
-	O
solubilized	O
BR	O
.	O
<EOS>	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

BR	B-Protein
in	O
Triton	O
X	O
-	O
100	O
or	O
nonylglucoside	O
,	O
delipidated	O
BR	O
in	O
CHAPSO	O
,	O
and	O
BR	B-Protein
in	O
intact	O
purple	O
membrane	O
all	O
have	O
a	O
dark	O
-	O
adapted	O
ratio	O
of	O
13	O
-	O
cis	O
to	O
all	O
-	O
trans	O
-	O
retinal	O
of	O
1	O
.	O
9	O
:	O
1	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
small	B-X
amounts	B-X
of	B-X
endotoxin	B-X
in	B-X
recombinant	B-X
protein	B-X
preparations	B-X
can	B-X
cause	B-X
side	B-X
effects	B-X
in	B-X
host	B-X
organism	B-X
such	B-X
as	B-X
endotoxin	B-X
shock	B-X
,	B-X
tissue	B-X
injury	B-X
,	B-X
and	B-X
even	B-X
death	B-X
.	B-X
Bacteriorhodopsin	B-X
(	B-X
BR	B-X
)	B-X
essentially	B-X
free	B-X
of	B-X
native	B-X
lipids	B-X
has	B-X
been	B-X
prepared	B-X
in	B-X
a	B-X
highly	B-X
stable	B-X
state	B-X
.	B-X
Purple	B-X
membrane	B-X
was	B-X
solubilized	B-X
in	B-X
Triton	B-X
X-100	B-X
and	B-X
BR	B-X
was	B-X
purified	B-X
by	B-X
size	B-X
exclusion	B-X
chromatography	B-X
using	B-X
3-	B-X
[	B-X
cholamidopropyl	B-X
)	B-X
dimethylammonio	B-X
]	B-X
-2-hydroxyl-1-propanesulfonic	B-X
acid	B-X
(	B-X
CHAPSO	B-X
)	B-X
detergent	B-X
at	B-X
pH	B-X
5	B-X
.	B-X
Molar	B-X
ratios	B-X
of	B-X
phospholipid/BR	B-X
ranged	B-X
from	B-X
0.4	B-X
to	B-X
0.05	B-X
corresponding	B-X
to	B-X
94-98	B-X
%	B-X
phospholipid	B-X
removal	B-X
.	B-X
Purified	B-X
BR	B-X
has	B-X
an	B-X
absorbance	B-X
ratio	B-X
(	B-X
A280nm/A548nm	B-X
)	B-X
of	B-X
1.5-1.6	B-X
in	B-X
the	B-X
dark-adapted	B-X
state	B-X
which	B-X
is	B-X
the	B-X
highest	B-X
purified	B-X
BR/protein	B-X
ratio	B-X
reported	B-X
to	B-X
date	B-X
.	B-X
The	B-X
purified	B-X
BR	B-X
in	B-X
CHAPSO	B-X
shows	B-X
maximum	B-X
stability	B-X
in	B-X
the	B-X
pH	B-X
range	B-X
5.0-5.5	B-X
.	B-X
Sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
profiles	B-X
of	B-X
native	B-X
purple	B-X
membrane	B-X
and	B-X
solubilized	B-X
BR	B-X
from	B-X
most	B-X
Halobacterium	B-X
halobium	B-X
JW-3	B-X
cultures	B-X
show	B-X
3	B-X
higher	B-X
molecular	B-X
weight	B-X
bands	B-X
in	B-X
addition	B-X
to	B-X
BR	B-X
.	B-X
Immunological	B-X
staining	B-X
and	B-X
amino	B-X
acid	B-X
sequencing	B-X
indicates	B-X
that	B-X
these	B-X
additional	B-X
proteins	B-X
are	B-X
partially	B-X
processed	B-X
forms	B-X
of	B-X
the	B-X
BR	B-X
precursor	B-X
protein	B-X
.	B-X
The	B-X
BR	B-X
preprotein	B-X
contains	B-X
13	B-X
additional	B-X
amino	B-X
acids	B-X
on	B-X
the	B-X
NH2	B-X
terminus	B-X
which	B-X
are	B-X
removed	B-X
by	B-X
post-translational	B-X
processing	B-X
in	B-X
at	B-X
least	B-X
four	B-X
steps	B-X
.	B-X
Isoelectric	B-X
focusing	B-X
separated	B-X
most	B-X
delipidated	B-X
and	B-X
non-delipidated	B-X
BR	B-X
samples	B-X
into	B-X
8	B-X
bands	B-X
.	B-X
Incomplete	B-X
BR	B-X
post-translational	B-X
processing	B-X
BR	B-X
is	B-X
thought	B-X
to	B-X
be	B-X
largely	B-X
responsible	B-X
for	B-X
the	B-X
multiplicity	B-X
of	B-X
isoelectric	B-X
BR	B-X
species	B-X
.	B-X
The	B-X
principal	B-X
components	B-X
have	B-X
pI	B-X
values	B-X
of	B-X
5.20	B-X
and	B-X
5.24	B-X
and	B-X
both	B-X
have	B-X
absorption	B-X
maxima	B-X
at	B-X
550	B-X
nm	B-X
,	B-X
characteristic	B-X
of	B-X
detergent-solubilized	B-X
BR	B-X
.	B-X
BR	B-X
in	B-X
Triton	B-X
X-100	B-X
or	B-X
nonylglucoside	B-X
,	B-X
delipidated	B-X
BR	B-X
in	B-X
CHAPSO	B-X
,	B-X
and	B-X
BR	B-X
in	B-X
intact	B-X
purple	B-X
membrane	B-X
all	B-X
have	B-X
a	B-X
dark-adapted	B-X
ratio	B-X
of	B-X
13-cis	B-X
to	B-X
all-trans-retinal	B-X
of	B-X
1.9:1	B-X
.	B-X

In	O
vivo	O
characterization	O
of	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
SV40	O
chromatin	O
and	O
large	B-Protein
T	I-Protein
antigen	I-Protein
by	O
immunofractionation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
confirmed	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribosylation	B-X
)	B-X
of	B-X
large	B-X
T	B-X
antigen	B-X
of	B-X
SV40	B-X
by	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
and	B-X
consequently	B-X
have	B-X
begun	B-X
to	B-X
characterize	B-X
how	B-X
this	B-X
post-translational	B-X
nuclear	B-X
modification	B-X
of	B-X
the	B-X
viral	B-X
protein	B-X
modulates	B-X
its	B-X
biological	B-X
functions	B-X
.	B-X
SV40	B-X
minichromosomal	B-X
subpopulation	B-X
containing	B-X
replicative	B-X
intermediate	B-X
DNA	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
significantly	B-X
higher	B-X
affinity	B-X
for	B-X
anti-poly	B-X
(	B-X
ADP-Rib	B-X
)	B-X
-Sepharose	B-X
than	B-X
viral	B-X
chromatin	B-X
fractions	B-X
containing	B-X
mature	B-X
minichromosomal	B-X
DNA	B-X
.	B-X
An	B-X
anti-large	B-X
T-Sepharose	B-X
column	B-X
was	B-X
used	B-X
to	B-X
isolate	B-X
T	B-X
antigen	B-X
from	B-X
crude	B-X
extracts	B-X
by	B-X
two	B-X
different	B-X
approaches	B-X
:	B-X
(	B-X
1	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
was	B-X
labeled	B-X
with	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
in	B-X
vivo	B-X
and	B-X
the	B-X
infected	B-X
cell	B-X
extract	B-X
was	B-X
immunofractionated	B-X
to	B-X
isolate	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
(	B-X
2	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cell	B-X
extracts	B-X
was	B-X
immunofractionated	B-X
followed	B-X
by	B-X
immunostaining	B-X
.	B-X
Using	B-X
these	B-X
techniques	B-X
,	B-X
1-10	B-X
%	B-X
of	B-X
the	B-X
total	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
.	B-X
Minichromosome	B-X
preparations	B-X
per	B-X
se	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
immunofractionation	B-X
on	B-X
anti-large	B-X
T-Sepharose	B-X
.	B-X
The	B-X
high	B-X
level	B-X
of	B-X
retention	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
species	B-X
of	B-X
minichromosomes	B-X
on	B-X
this	B-X
matrix	B-X
suggested	B-X
that	B-X
this	B-X
post-translational	B-X
modification	B-X
of	B-X
viral	B-X
chromatin	B-X
may	B-X
be	B-X
related	B-X
to	B-X
those	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
and	B-X
transcription	B-X
under	B-X
regulation	B-X
by	B-X
large	B-X
T	B-X
antigen	B-X
.	B-X

We	O
have	O
confirmed	O
the	O
poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
large	B-Protein
T	I-Protein
antigen	I-Protein
of	O
SV40	O
by	O
using	O
antibodies	O
to	O
both	O
large	B-Protein
T	I-Protein
antigen	I-Protein
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
and	O
consequently	O
have	O
begun	O
to	O
characterize	O
how	O
this	O
post	O
-	O
translational	O
nuclear	O
modification	O
of	O
the	O
viral	O
protein	O
modulates	O
its	O
biological	O
functions	O
.	O
<EOS>	B-X
We	B-X
have	B-X
confirmed	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribosylation	B-X
)	B-X
of	B-X
large	B-X
T	B-X
antigen	B-X
of	B-X
SV40	B-X
by	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
and	B-X
consequently	B-X
have	B-X
begun	B-X
to	B-X
characterize	B-X
how	B-X
this	B-X
post-translational	B-X
nuclear	B-X
modification	B-X
of	B-X
the	B-X
viral	B-X
protein	B-X
modulates	B-X
its	B-X
biological	B-X
functions	B-X
.	B-X
SV40	B-X
minichromosomal	B-X
subpopulation	B-X
containing	B-X
replicative	B-X
intermediate	B-X
DNA	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
significantly	B-X
higher	B-X
affinity	B-X
for	B-X
anti-poly	B-X
(	B-X
ADP-Rib	B-X
)	B-X
-Sepharose	B-X
than	B-X
viral	B-X
chromatin	B-X
fractions	B-X
containing	B-X
mature	B-X
minichromosomal	B-X
DNA	B-X
.	B-X
An	B-X
anti-large	B-X
T-Sepharose	B-X
column	B-X
was	B-X
used	B-X
to	B-X
isolate	B-X
T	B-X
antigen	B-X
from	B-X
crude	B-X
extracts	B-X
by	B-X
two	B-X
different	B-X
approaches	B-X
:	B-X
(	B-X
1	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
was	B-X
labeled	B-X
with	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
in	B-X
vivo	B-X
and	B-X
the	B-X
infected	B-X
cell	B-X
extract	B-X
was	B-X
immunofractionated	B-X
to	B-X
isolate	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
(	B-X
2	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cell	B-X
extracts	B-X
was	B-X
immunofractionated	B-X
followed	B-X
by	B-X
immunostaining	B-X
.	B-X
Using	B-X
these	B-X
techniques	B-X
,	B-X
1-10	B-X
%	B-X
of	B-X
the	B-X
total	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
.	B-X
Minichromosome	B-X
preparations	B-X
per	B-X
se	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
immunofractionation	B-X
on	B-X
anti-large	B-X
T-Sepharose	B-X
.	B-X
The	B-X
high	B-X
level	B-X
of	B-X
retention	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
species	B-X
of	B-X
minichromosomes	B-X
on	B-X
this	B-X
matrix	B-X
suggested	B-X
that	B-X
this	B-X
post-translational	B-X
modification	B-X
of	B-X
viral	B-X
chromatin	B-X
may	B-X
be	B-X
related	B-X
to	B-X
those	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
and	B-X
transcription	B-X
under	B-X
regulation	B-X
by	B-X
large	B-X
T	B-X
antigen	B-X
.	B-X

SV40	O
minichromosomal	O
subpopulation	O
containing	O
replicative	O
intermediate	O
DNA	O
was	O
shown	O
to	O
have	O
a	O
significantly	O
higher	O
affinity	O
for	O
anti	O
-	O
poly	O
(	O
ADP	O
-	O
Rib	O
)	O
-	O
Sepharose	O
than	O
viral	O
chromatin	O
fractions	O
containing	O
mature	O
minichromosomal	O
DNA	O
.	O
<EOS>	B-X
We	B-X
have	B-X
confirmed	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribosylation	B-X
)	B-X
of	B-X
large	B-X
T	B-X
antigen	B-X
of	B-X
SV40	B-X
by	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
and	B-X
consequently	B-X
have	B-X
begun	B-X
to	B-X
characterize	B-X
how	B-X
this	B-X
post-translational	B-X
nuclear	B-X
modification	B-X
of	B-X
the	B-X
viral	B-X
protein	B-X
modulates	B-X
its	B-X
biological	B-X
functions	B-X
.	B-X
SV40	B-X
minichromosomal	B-X
subpopulation	B-X
containing	B-X
replicative	B-X
intermediate	B-X
DNA	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
significantly	B-X
higher	B-X
affinity	B-X
for	B-X
anti-poly	B-X
(	B-X
ADP-Rib	B-X
)	B-X
-Sepharose	B-X
than	B-X
viral	B-X
chromatin	B-X
fractions	B-X
containing	B-X
mature	B-X
minichromosomal	B-X
DNA	B-X
.	B-X
An	B-X
anti-large	B-X
T-Sepharose	B-X
column	B-X
was	B-X
used	B-X
to	B-X
isolate	B-X
T	B-X
antigen	B-X
from	B-X
crude	B-X
extracts	B-X
by	B-X
two	B-X
different	B-X
approaches	B-X
:	B-X
(	B-X
1	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
was	B-X
labeled	B-X
with	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
in	B-X
vivo	B-X
and	B-X
the	B-X
infected	B-X
cell	B-X
extract	B-X
was	B-X
immunofractionated	B-X
to	B-X
isolate	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
(	B-X
2	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cell	B-X
extracts	B-X
was	B-X
immunofractionated	B-X
followed	B-X
by	B-X
immunostaining	B-X
.	B-X
Using	B-X
these	B-X
techniques	B-X
,	B-X
1-10	B-X
%	B-X
of	B-X
the	B-X
total	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
.	B-X
Minichromosome	B-X
preparations	B-X
per	B-X
se	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
immunofractionation	B-X
on	B-X
anti-large	B-X
T-Sepharose	B-X
.	B-X
The	B-X
high	B-X
level	B-X
of	B-X
retention	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
species	B-X
of	B-X
minichromosomes	B-X
on	B-X
this	B-X
matrix	B-X
suggested	B-X
that	B-X
this	B-X
post-translational	B-X
modification	B-X
of	B-X
viral	B-X
chromatin	B-X
may	B-X
be	B-X
related	B-X
to	B-X
those	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
and	B-X
transcription	B-X
under	B-X
regulation	B-X
by	B-X
large	B-X
T	B-X
antigen	B-X
.	B-X

An	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
column	O
was	O
used	O
to	O
isolate	O
T	B-Protein
antigen	I-Protein
from	O
crude	O
extracts	O
by	O
two	O
different	O
approaches	O
:	O
(	O
1	O
)	O
large	B-Protein
T	I-Protein
antigen	I-Protein
was	O
labeled	O
with	O
[	O
35S	O
]	O
methionine	O
in	O
vivo	O
and	O
the	O
infected	O
cell	O
extract	O
was	O
immunofractionated	O
to	O
isolate	O
large	B-Protein
T	I-Protein
antigen	I-Protein
and	O
(	O
2	O
)	O
large	B-Protein
T	I-Protein
antigen	I-Protein
from	O
infected	O
cell	O
extracts	O
was	O
immunofractionated	O
followed	O
by	O
immunostaining	O
.	O

Using	O
these	O
techniques	O
,	O
1	O
-	O
10	O
%	O
of	O
the	O
total	O
T	B-Protein
antigen	I-Protein
from	O
infected	O
cells	O
was	O
found	O
to	O
be	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
confirmed	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribosylation	B-X
)	B-X
of	B-X
large	B-X
T	B-X
antigen	B-X
of	B-X
SV40	B-X
by	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
and	B-X
consequently	B-X
have	B-X
begun	B-X
to	B-X
characterize	B-X
how	B-X
this	B-X
post-translational	B-X
nuclear	B-X
modification	B-X
of	B-X
the	B-X
viral	B-X
protein	B-X
modulates	B-X
its	B-X
biological	B-X
functions	B-X
.	B-X
SV40	B-X
minichromosomal	B-X
subpopulation	B-X
containing	B-X
replicative	B-X
intermediate	B-X
DNA	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
significantly	B-X
higher	B-X
affinity	B-X
for	B-X
anti-poly	B-X
(	B-X
ADP-Rib	B-X
)	B-X
-Sepharose	B-X
than	B-X
viral	B-X
chromatin	B-X
fractions	B-X
containing	B-X
mature	B-X
minichromosomal	B-X
DNA	B-X
.	B-X
An	B-X
anti-large	B-X
T-Sepharose	B-X
column	B-X
was	B-X
used	B-X
to	B-X
isolate	B-X
T	B-X
antigen	B-X
from	B-X
crude	B-X
extracts	B-X
by	B-X
two	B-X
different	B-X
approaches	B-X
:	B-X
(	B-X
1	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
was	B-X
labeled	B-X
with	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
in	B-X
vivo	B-X
and	B-X
the	B-X
infected	B-X
cell	B-X
extract	B-X
was	B-X
immunofractionated	B-X
to	B-X
isolate	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
(	B-X
2	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cell	B-X
extracts	B-X
was	B-X
immunofractionated	B-X
followed	B-X
by	B-X
immunostaining	B-X
.	B-X
Using	B-X
these	B-X
techniques	B-X
,	B-X
1-10	B-X
%	B-X
of	B-X
the	B-X
total	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
.	B-X
The	B-X
high	B-X
level	B-X
of	B-X
retention	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
species	B-X
of	B-X
minichromosomes	B-X
on	B-X
this	B-X
matrix	B-X
suggested	B-X
that	B-X
this	B-X
post-translational	B-X
modification	B-X
of	B-X
viral	B-X
chromatin	B-X
may	B-X
be	B-X
related	B-X
to	B-X
those	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
and	B-X
transcription	B-X
under	B-X
regulation	B-X
by	B-X
large	B-X
T	B-X
antigen	B-X
.	B-X

Minichromosome	O
preparations	O
per	O
se	O
were	O
also	O
subjected	O
to	O
immunofractionation	O
on	O
anti	O
-	O
large	O
T	O
-	O
Sepharose	O
.	O

The	O
high	O
level	O
of	O
retention	O
of	O
poly	O
(	O
ADP	O
-	O
ribosylated	O
)	O
species	O
of	O
minichromosomes	O
on	O
this	O
matrix	O
suggested	O
that	O
this	O
post	O
-	O
translational	O
modification	O
of	O
viral	O
chromatin	O
may	O
be	O
related	O
to	O
those	O
steps	O
in	O
viral	O
replication	O
and	O
transcription	O
under	O
regulation	O
by	O
large	B-Protein
T	I-Protein
antigen	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
confirmed	B-X
the	B-X
poly	B-X
(	B-X
ADP-ribosylation	B-X
)	B-X
of	B-X
large	B-X
T	B-X
antigen	B-X
of	B-X
SV40	B-X
by	B-X
using	B-X
antibodies	B-X
to	B-X
both	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
poly	B-X
(	B-X
ADP-ribose	B-X
)	B-X
and	B-X
consequently	B-X
have	B-X
begun	B-X
to	B-X
characterize	B-X
how	B-X
this	B-X
post-translational	B-X
nuclear	B-X
modification	B-X
of	B-X
the	B-X
viral	B-X
protein	B-X
modulates	B-X
its	B-X
biological	B-X
functions	B-X
.	B-X
SV40	B-X
minichromosomal	B-X
subpopulation	B-X
containing	B-X
replicative	B-X
intermediate	B-X
DNA	B-X
was	B-X
shown	B-X
to	B-X
have	B-X
a	B-X
significantly	B-X
higher	B-X
affinity	B-X
for	B-X
anti-poly	B-X
(	B-X
ADP-Rib	B-X
)	B-X
-Sepharose	B-X
than	B-X
viral	B-X
chromatin	B-X
fractions	B-X
containing	B-X
mature	B-X
minichromosomal	B-X
DNA	B-X
.	B-X
An	B-X
anti-large	B-X
T-Sepharose	B-X
column	B-X
was	B-X
used	B-X
to	B-X
isolate	B-X
T	B-X
antigen	B-X
from	B-X
crude	B-X
extracts	B-X
by	B-X
two	B-X
different	B-X
approaches	B-X
:	B-X
(	B-X
1	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
was	B-X
labeled	B-X
with	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
in	B-X
vivo	B-X
and	B-X
the	B-X
infected	B-X
cell	B-X
extract	B-X
was	B-X
immunofractionated	B-X
to	B-X
isolate	B-X
large	B-X
T	B-X
antigen	B-X
and	B-X
(	B-X
2	B-X
)	B-X
large	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cell	B-X
extracts	B-X
was	B-X
immunofractionated	B-X
followed	B-X
by	B-X
immunostaining	B-X
.	B-X
Using	B-X
these	B-X
techniques	B-X
,	B-X
1-10	B-X
%	B-X
of	B-X
the	B-X
total	B-X
T	B-X
antigen	B-X
from	B-X
infected	B-X
cells	B-X
was	B-X
found	B-X
to	B-X
be	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
.	B-X
Minichromosome	B-X
preparations	B-X
per	B-X
se	B-X
were	B-X
also	B-X
subjected	B-X
to	B-X
immunofractionation	B-X
on	B-X
anti-large	B-X
T-Sepharose	B-X
.	B-X
The	B-X
high	B-X
level	B-X
of	B-X
retention	B-X
of	B-X
poly	B-X
(	B-X
ADP-ribosylated	B-X
)	B-X
species	B-X
of	B-X
minichromosomes	B-X
on	B-X
this	B-X
matrix	B-X
suggested	B-X
that	B-X
this	B-X
post-translational	B-X
modification	B-X
of	B-X
viral	B-X
chromatin	B-X
may	B-X
be	B-X
related	B-X
to	B-X
those	B-X
steps	B-X
in	B-X
viral	B-X
replication	B-X
and	B-X
transcription	B-X
under	B-X
regulation	B-X
by	B-X
large	B-X
T	B-X
antigen	B-X
.	B-X

The	O
human	O
receptor	O
for	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
.	O

Evidence	O
for	O
variable	O
post	O
-	O
translational	O
processing	O
,	O
phosphorylation	O
,	O
sulfation	O
,	O
and	O
the	O
ability	O
of	O
precursor	O
forms	O
of	O
the	O
receptor	O
to	O
bind	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
.	O

The	O
T	B-Protein
-	I-Protein
cell	I-Protein
growth	I-Protein
factor	I-Protein
(	I-Protein
TCGF	I-Protein
)	I-Protein
receptor	I-Protein
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
peripheral	O
blood	O
T	O
-	O
cells	O
is	O
characterized	O
as	O
a	O
glycoprotein	O
with	O
an	O
apparent	O
Mr	O
=	O
55	O
,	O
000	O
that	O
contains	O
N	O
-	O
linked	O
and	O
O	O
-	O
linked	O
carbohydrate	O
with	O
only	O
approximately	O
33	O
,	O
000	O
daltons	O
of	O
peptide	O
structure	O
(	O
p33	B-Protein
)	O
as	O
evaluated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

There	O
are	O
two	O
N	O
-	O
linked	O
glycosylated	O
intermediate	O
precursor	O
forms	O
(	O
apparent	O
Mr	O
=	O
35	O
,	O
000	O
(	O
p35	B-Protein
)	O
and	O
37	O
,	O
000	O
(	O
p37	B-Protein
]	O
.	O
<EOS>	B-X
The	B-X
T-cell	B-X
growth	B-X
factor	B-X
(	B-X
TCGF	B-X
)	B-X
receptor	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
peripheral	B-X
blood	B-X
T-cells	B-X
is	B-X
characterized	B-X
as	B-X
a	B-X
glycoprotein	B-X
with	B-X
an	B-X
apparent	B-X
Mr	B-X
=	B-X
55,000	B-X
that	B-X
contains	B-X
N-linked	B-X
and	B-X
O-linked	B-X
carbohydrate	B-X
with	B-X
only	B-X
approximately	B-X
33,000	B-X
daltons	B-X
of	B-X
peptide	B-X
structure	B-X
(	B-X
p33	B-X
)	B-X
as	B-X
evaluated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
There	B-X
are	B-X
two	B-X
N-linked	B-X
glycosylated	B-X
intermediate	B-X
precursor	B-X
forms	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
35,000	B-X
(	B-X
p35	B-X
)	B-X
and	B-X
37,000	B-X
(	B-X
p37	B-X
]	B-X
.	B-X
This	B-X
receptor	B-X
differs	B-X
from	B-X
the	B-X
TCGF	B-X
receptor	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
50,000	B-X
)	B-X
because	B-X
of	B-X
differences	B-X
in	B-X
post-translational	B-X
processing	B-X
.	B-X
Experiments	B-X
with	B-X
the	B-X
carboxylic	B-X
ionophore	B-X
monensin	B-X
demonstrate	B-X
blockade	B-X
of	B-X
the	B-X
transition	B-X
of	B-X
the	B-X
p35	B-X
and	B-X
p37	B-X
receptor	B-X
precursor	B-X
forms	B-X
to	B-X
the	B-X
mature	B-X
receptor	B-X
,	B-X
presumably	B-X
secondary	B-X
to	B-X
inhibition	B-X
of	B-X
Golgi-associated	B-X
receptor	B-X
processing	B-X
.	B-X
We	B-X
identify	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
of	B-X
TCGF	B-X
receptor	B-X
mRNA	B-X
as	B-X
intermediate	B-X
in	B-X
size	B-X
between	B-X
the	B-X
p33	B-X
and	B-X
the	B-X
p35/p37	B-X
forms	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
p33	B-X
,	B-X
p35	B-X
,	B-X
and	B-X
p37	B-X
precursor	B-X
forms	B-X
,	B-X
but	B-X
not	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
,	B-X
are	B-X
all	B-X
capable	B-X
of	B-X
binding	B-X
TCGF	B-X
.	B-X

This	O
receptor	O
differs	O
from	O
the	O
TCGF	B-Protein
receptor	I-Protein
on	O
HUT	O
-	O
102B2	O
cells	O
(	O
apparent	O
Mr	O
=	O
50	O
,	O
000	O
)	O
because	O
of	O
differences	O
in	O
post	O
-	O
translational	O
processing	O
.	O
<EOS>	B-X
The	B-X
T-cell	B-X
growth	B-X
factor	B-X
(	B-X
TCGF	B-X
)	B-X
receptor	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
peripheral	B-X
blood	B-X
T-cells	B-X
is	B-X
characterized	B-X
as	B-X
a	B-X
glycoprotein	B-X
with	B-X
an	B-X
apparent	B-X
Mr	B-X
=	B-X
55,000	B-X
that	B-X
contains	B-X
N-linked	B-X
and	B-X
O-linked	B-X
carbohydrate	B-X
with	B-X
only	B-X
approximately	B-X
33,000	B-X
daltons	B-X
of	B-X
peptide	B-X
structure	B-X
(	B-X
p33	B-X
)	B-X
as	B-X
evaluated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
There	B-X
are	B-X
two	B-X
N-linked	B-X
glycosylated	B-X
intermediate	B-X
precursor	B-X
forms	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
35,000	B-X
(	B-X
p35	B-X
)	B-X
and	B-X
37,000	B-X
(	B-X
p37	B-X
]	B-X
.	B-X
This	B-X
receptor	B-X
differs	B-X
from	B-X
the	B-X
TCGF	B-X
receptor	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
50,000	B-X
)	B-X
because	B-X
of	B-X
differences	B-X
in	B-X
post-translational	B-X
processing	B-X
.	B-X
Experiments	B-X
with	B-X
the	B-X
carboxylic	B-X
ionophore	B-X
monensin	B-X
demonstrate	B-X
blockade	B-X
of	B-X
the	B-X
transition	B-X
of	B-X
the	B-X
p35	B-X
and	B-X
p37	B-X
receptor	B-X
precursor	B-X
forms	B-X
to	B-X
the	B-X
mature	B-X
receptor	B-X
,	B-X
presumably	B-X
secondary	B-X
to	B-X
inhibition	B-X
of	B-X
Golgi-associated	B-X
receptor	B-X
processing	B-X
.	B-X
We	B-X
identify	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
of	B-X
TCGF	B-X
receptor	B-X
mRNA	B-X
as	B-X
intermediate	B-X
in	B-X
size	B-X
between	B-X
the	B-X
p33	B-X
and	B-X
the	B-X
p35/p37	B-X
forms	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
p33	B-X
,	B-X
p35	B-X
,	B-X
and	B-X
p37	B-X
precursor	B-X
forms	B-X
,	B-X
but	B-X
not	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
,	B-X
are	B-X
all	B-X
capable	B-X
of	B-X
binding	B-X
TCGF	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and/or	B-X
conformational	B-X
changes	B-X
of	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
are	B-X
necessary	B-X
for	B-X
ligand	B-X
binding	B-X
;	B-X
however	B-X
,	B-X
the	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
are	B-X
not	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
at	B-X
least	B-X
some	B-X
TCGF	B-X
receptors	B-X
are	B-X
phosphorylated	B-X
and	B-X
sulfated	B-X
,	B-X
and	B-X
that	B-X
TCGF	B-X
receptors	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
T-cells	B-X
are	B-X
more	B-X
heavily	B-X
sulfated	B-X
than	B-X
those	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
.	B-X

Experiments	O
with	O
the	O
carboxylic	O
ionophore	O
monensin	O
demonstrate	O
blockade	O
of	O
the	O
transition	O
of	O
the	O
p35	B-Protein
and	O
p37	B-Protein
receptor	O
precursor	O
forms	O
to	O
the	O
mature	O
receptor	O
,	O
presumably	O
secondary	O
to	O
inhibition	O
of	O
Golgi	O
-	O
associated	O
receptor	O
processing	O
.	O

We	O
identify	O
the	O
primary	O
translation	O
product	O
of	O
TCGF	B-Protein
receptor	I-Protein
mRNA	O
as	O
intermediate	O
in	O
size	O
between	O
the	O
p33	B-Protein
and	O
the	O
p35	B-Protein
/	O
p37	B-Protein
forms	O
.	O
<EOS>	B-X
The	B-X
T-cell	B-X
growth	B-X
factor	B-X
(	B-X
TCGF	B-X
)	B-X
receptor	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
peripheral	B-X
blood	B-X
T-cells	B-X
is	B-X
characterized	B-X
as	B-X
a	B-X
glycoprotein	B-X
with	B-X
an	B-X
apparent	B-X
Mr	B-X
=	B-X
55,000	B-X
that	B-X
contains	B-X
N-linked	B-X
and	B-X
O-linked	B-X
carbohydrate	B-X
with	B-X
only	B-X
approximately	B-X
33,000	B-X
daltons	B-X
of	B-X
peptide	B-X
structure	B-X
(	B-X
p33	B-X
)	B-X
as	B-X
evaluated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
There	B-X
are	B-X
two	B-X
N-linked	B-X
glycosylated	B-X
intermediate	B-X
precursor	B-X
forms	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
35,000	B-X
(	B-X
p35	B-X
)	B-X
and	B-X
37,000	B-X
(	B-X
p37	B-X
]	B-X
.	B-X
This	B-X
receptor	B-X
differs	B-X
from	B-X
the	B-X
TCGF	B-X
receptor	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
50,000	B-X
)	B-X
because	B-X
of	B-X
differences	B-X
in	B-X
post-translational	B-X
processing	B-X
.	B-X
Experiments	B-X
with	B-X
the	B-X
carboxylic	B-X
ionophore	B-X
monensin	B-X
demonstrate	B-X
blockade	B-X
of	B-X
the	B-X
transition	B-X
of	B-X
the	B-X
p35	B-X
and	B-X
p37	B-X
receptor	B-X
precursor	B-X
forms	B-X
to	B-X
the	B-X
mature	B-X
receptor	B-X
,	B-X
presumably	B-X
secondary	B-X
to	B-X
inhibition	B-X
of	B-X
Golgi-associated	B-X
receptor	B-X
processing	B-X
.	B-X
We	B-X
identify	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
of	B-X
TCGF	B-X
receptor	B-X
mRNA	B-X
as	B-X
intermediate	B-X
in	B-X
size	B-X
between	B-X
the	B-X
p33	B-X
and	B-X
the	B-X
p35/p37	B-X
forms	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
p33	B-X
,	B-X
p35	B-X
,	B-X
and	B-X
p37	B-X
precursor	B-X
forms	B-X
,	B-X
but	B-X
not	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
,	B-X
are	B-X
all	B-X
capable	B-X
of	B-X
binding	B-X
TCGF	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
removal	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and/or	B-X
conformational	B-X
changes	B-X
of	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
are	B-X
necessary	B-X
for	B-X
ligand	B-X
binding	B-X
;	B-X
however	B-X
,	B-X
the	B-X
extensive	B-X
post-translational	B-X
modifications	B-X
are	B-X
not	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
at	B-X
least	B-X
some	B-X
TCGF	B-X
receptors	B-X
are	B-X
phosphorylated	B-X
and	B-X
sulfated	B-X
,	B-X
and	B-X
that	B-X
TCGF	B-X
receptors	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
T-cells	B-X
are	B-X
more	B-X
heavily	B-X
sulfated	B-X
than	B-X
those	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
.	B-X

We	O
further	O
demonstrate	O
that	O
the	O
p33	B-Protein
,	O
p35	B-Protein
,	O
and	O
p37	B-Protein
precursor	O
forms	O
,	O
but	O
not	O
the	O
primary	O
translation	O
product	O
,	O
are	O
all	O
capable	O
of	O
binding	O
TCGF	B-Protein
.	O

Thus	O
,	O
the	O
removal	O
of	O
the	O
signal	O
peptide	O
and	O
/	O
or	O
conformational	O
changes	O
of	O
the	O
primary	O
translation	O
product	O
are	O
necessary	O
for	O
ligand	O
binding	O
;	O
however	O
,	O
the	O
extensive	O
post	O
-	O
translational	O
modifications	O
are	O
not	O
.	O
<EOS>	B-X
The	B-X
signal	B-X
peptidase	B-X
complex	B-X
(	B-X
SPC	B-X
)	B-X
is	B-X
an	B-X
essential	B-X
membrane	B-X
complex	B-X
in	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
(	B-X
ER	B-X
)	B-X
,	B-X
where	B-X
it	B-X
removes	B-X
signal	B-X
peptides	B-X
(	B-X
SPs	B-X
)	B-X
from	B-X
a	B-X
large	B-X
variety	B-X
of	B-X
secretory	B-X
pre-proteins	B-X
with	B-X
exquisite	B-X
specificity	B-X
.	B-X
Although	B-X
the	B-X
determinants	B-X
of	B-X
this	B-X
process	B-X
have	B-X
been	B-X
established	B-X
empirically	B-X
,	B-X
the	B-X
molecular	B-X
details	B-X
of	B-X
SP	B-X
recognition	B-X
and	B-X
removal	B-X
remain	B-X
elusive	B-X
.	B-X
The	B-X
removal	B-X
of	B-X
a	B-X
hydrophobic	B-X
signal	B-X
peptide	B-X
and	B-X
covalent	B-X
attachment	B-X
of	B-X
GPI	B-X
at	B-X
the	B-X
new	B-X
carboxyl	B-X
terminus	B-X
are	B-X
catalyzed	B-X
by	B-X
an	B-X
endoplasmic	B-X
reticulum	B-X
membrane	B-X
GPI	B-X
transamidase	B-X
complex	B-X
(	B-X
GPI-T	B-X
)	B-X
conserved	B-X
among	B-X
all	B-X
eukaryotes	B-X
.	B-X
Translocation	B-X
of	B-X
a	B-X
nascent	B-X
protein	B-X
from	B-X
the	B-X
cytosol	B-X
into	B-X
the	B-X
ER	B-X
mediated	B-X
by	B-X
its	B-X
signal	B-X
peptide	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
protein	B-X
secretion	B-X
.	B-X
The	B-X
aim	B-X
of	B-X
this	B-X
work	B-X
was	B-X
to	B-X
develop	B-X
a	B-X
platform	B-X
technology	B-X
to	B-X
optimize	B-X
the	B-X
signal	B-X
peptides	B-X
for	B-X
high	B-X
level	B-X
production	B-X
of	B-X
therapeutic	B-X
antibodies	B-X
in	B-X
CHO	B-X
cells	B-X
.	B-X
A	B-X
database	B-X
of	B-X
signal	B-X
peptides	B-X
from	B-X
a	B-X
large	B-X
number	B-X
of	B-X
human	B-X
immunoglobulin	B-X
(	B-X
Ig	B-X
)	B-X
heavy	B-X
chain	B-X
(	B-X
HC	B-X
)	B-X
and	B-X
kappa	B-X
light	B-X
chain	B-X
(	B-X
LC	B-X
)	B-X
was	B-X
generated	B-X
.	B-X
Most	B-X
of	B-X
the	B-X
HC	B-X
signal	B-X
peptides	B-X
contain	B-X
19	B-X
amino	B-X
acids	B-X
which	B-X
can	B-X
be	B-X
divided	B-X
into	B-X
three	B-X
domains	B-X
and	B-X
the	B-X
LC	B-X
signal	B-X
peptides	B-X
contain	B-X
22	B-X
amino	B-X
acids	B-X
.	B-X
The	B-X
signal	B-X
peptides	B-X
were	B-X
then	B-X
clustered	B-X
according	B-X
to	B-X
sequence	B-X
similarity	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
clustering	B-X
,	B-X
8	B-X
HC	B-X
and	B-X
2	B-X
LC	B-X
signal	B-X
peptides	B-X
were	B-X
analyzed	B-X
for	B-X
their	B-X
impacts	B-X
on	B-X
the	B-X
production	B-X
of	B-X
5-top	B-X
selling	B-X
antibody	B-X
therapeutics	B-X
,	B-X
namely	B-X
,	B-X
Herceptin	B-X
,	B-X
Avastin	B-X
,	B-X
Remicade	B-X
,	B-X
Rituxan	B-X
,	B-X
and	B-X
Humira	B-X
.	B-X
The	B-X
best	B-X
HC	B-X
and	B-X
LC	B-X
signal	B-X
peptides	B-X
for	B-X
producing	B-X
these	B-X
5	B-X
antibodies	B-X
were	B-X
identified	B-X
.	B-X
The	B-X
optimized	B-X
signal	B-X
peptides	B-X
for	B-X
Rituxan	B-X
is	B-X
2-fold	B-X
better	B-X
compared	B-X
to	B-X
its	B-X
native	B-X
signal	B-X
peptides	B-X
which	B-X
are	B-X
available	B-X
in	B-X
the	B-X
public	B-X
database	B-X
.	B-X
Substitution	B-X
of	B-X
a	B-X
single	B-X
amino	B-X
acid	B-X
in	B-X
the	B-X
optimized	B-X
HC	B-X
signal	B-X
peptide	B-X
for	B-X
Avastin	B-X
reduced	B-X
its	B-X
production	B-X
significantly	B-X
.	B-X
Mass	B-X
spectrometry	B-X
analyses	B-X
revealed	B-X
that	B-X
all	B-X
optimized	B-X
signal	B-X
peptides	B-X
are	B-X
accurately	B-X
removed	B-X
in	B-X
the	B-X
mature	B-X
antibodies	B-X
.	B-X
The	B-X
results	B-X
presented	B-X
in	B-X
this	B-X
report	B-X
are	B-X
particularly	B-X
important	B-X
for	B-X
the	B-X
production	B-X
of	B-X
these	B-X
5	B-X
antibodies	B-X
as	B-X
biosimilar	B-X
drugs	B-X
.	B-X
They	B-X
also	B-X
have	B-X
the	B-X
potential	B-X
to	B-X
be	B-X
the	B-X
best	B-X
signal	B-X
peptides	B-X
for	B-X
the	B-X
production	B-X
of	B-X
new	B-X
antibodies	B-X
in	B-X
CHO	B-X
cells	B-X
.	B-X

Lastly	O
,	O
we	O
demonstrate	O
that	O
at	O
least	O
some	O
TCGF	B-Protein
receptors	I-Protein
are	O
phosphorylated	O
and	O
sulfated	O
,	O
and	O
that	O
TCGF	B-Protein
receptors	I-Protein
on	O
phytohemagglutinin	O
-	O
activated	O
normal	O
T	O
-	O
cells	O
are	O
more	O
heavily	O
sulfated	O
than	O
those	O
on	O
HUT	O
-	O
102B2	O
cells	O
.	O
<EOS>	B-X
The	B-X
T-cell	B-X
growth	B-X
factor	B-X
(	B-X
TCGF	B-X
)	B-X
receptor	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
peripheral	B-X
blood	B-X
T-cells	B-X
is	B-X
characterized	B-X
as	B-X
a	B-X
glycoprotein	B-X
with	B-X
an	B-X
apparent	B-X
Mr	B-X
=	B-X
55,000	B-X
that	B-X
contains	B-X
N-linked	B-X
and	B-X
O-linked	B-X
carbohydrate	B-X
with	B-X
only	B-X
approximately	B-X
33,000	B-X
daltons	B-X
of	B-X
peptide	B-X
structure	B-X
(	B-X
p33	B-X
)	B-X
as	B-X
evaluated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
This	B-X
receptor	B-X
differs	B-X
from	B-X
the	B-X
TCGF	B-X
receptor	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
(	B-X
apparent	B-X
Mr	B-X
=	B-X
50,000	B-X
)	B-X
because	B-X
of	B-X
differences	B-X
in	B-X
post-translational	B-X
processing	B-X
.	B-X
Experiments	B-X
with	B-X
the	B-X
carboxylic	B-X
ionophore	B-X
monensin	B-X
demonstrate	B-X
blockade	B-X
of	B-X
the	B-X
transition	B-X
of	B-X
the	B-X
p35	B-X
and	B-X
p37	B-X
receptor	B-X
precursor	B-X
forms	B-X
to	B-X
the	B-X
mature	B-X
receptor	B-X
,	B-X
presumably	B-X
secondary	B-X
to	B-X
inhibition	B-X
of	B-X
Golgi-associated	B-X
receptor	B-X
processing	B-X
.	B-X
We	B-X
identify	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
of	B-X
TCGF	B-X
receptor	B-X
mRNA	B-X
as	B-X
intermediate	B-X
in	B-X
size	B-X
between	B-X
the	B-X
p33	B-X
and	B-X
the	B-X
p35/p37	B-X
forms	B-X
.	B-X
We	B-X
further	B-X
demonstrate	B-X
that	B-X
the	B-X
p33	B-X
,	B-X
p35	B-X
,	B-X
and	B-X
p37	B-X
precursor	B-X
forms	B-X
,	B-X
but	B-X
not	B-X
the	B-X
primary	B-X
translation	B-X
product	B-X
,	B-X
are	B-X
all	B-X
capable	B-X
of	B-X
binding	B-X
TCGF	B-X
.	B-X
Lastly	B-X
,	B-X
we	B-X
demonstrate	B-X
that	B-X
at	B-X
least	B-X
some	B-X
TCGF	B-X
receptors	B-X
are	B-X
phosphorylated	B-X
and	B-X
sulfated	B-X
,	B-X
and	B-X
that	B-X
TCGF	B-X
receptors	B-X
on	B-X
phytohemagglutinin-activated	B-X
normal	B-X
T-cells	B-X
are	B-X
more	B-X
heavily	B-X
sulfated	B-X
than	B-X
those	B-X
on	B-X
HUT-102B2	B-X
cells	B-X
.	B-X

The	O
effects	O
of	O
processing	O
inhibitors	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
the	O
intracellular	O
migration	O
of	O
glycoprotein	B-Protein
E2	I-Protein
of	O
mouse	O
hepatitis	O
virus	O
and	O
the	O
maturation	O
of	O
coronavirus	O
particles	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
tunicamycin	O
and	O
inhibitors	O
of	O
the	O
processing	O
of	O
N	O
-	O
linked	O
glycans	O
including	O
N	O
-	O
methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
,	O
castanospermine	O
,	O
mannodeoxynojirimycin	O
,	O
and	O
swainsonine	O
on	O
the	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
and	O
the	O
intracellular	O
maturation	O
of	O
the	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
A59	O
.	O

Indirect	O
immunofluorescence	O
staining	O
with	O
monoclonal	O
antibodies	O
revealed	O
that	O
glycoprotein	B-Protein
E2	I-Protein
exhibits	O
different	O
antigenic	O
properties	O
depending	O
on	O
the	O
presence	O
and	O
on	O
the	O
structure	O
of	O
the	O
N	O
-	O
linked	O
oligosaccharides	O
and	O
that	O
efficient	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
to	O
the	O
plasma	O
membrane	O
requires	O
the	O
removal	O
of	O
glucose	O
residues	O
.	O

In	O
the	O
presence	O
of	O
tunicamycin	O
in	O
the	O
nonglycosylated	O
E2	B-Protein
apoprotein	O
was	O
synthesized	O
in	O
normal	O
amounts	O
and	O
readily	O
acylated	O
throughout	O
the	O
infectious	O
cycle	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
tunicamycin	B-X
and	B-X
inhibitors	B-X
of	B-X
the	B-X
processing	B-X
of	B-X
N-linked	B-X
glycans	B-X
including	B-X
N-methyl-1-deoxynojirimycin	B-X
,	B-X
castanospermine	B-X
,	B-X
mannodeoxynojirimycin	B-X
,	B-X
and	B-X
swainsonine	B-X
on	B-X
the	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
and	B-X
the	B-X
intracellular	B-X
maturation	B-X
of	B-X
the	B-X
coronavirus	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
A59	B-X
.	B-X
Indirect	B-X
immunofluorescence	B-X
staining	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
revealed	B-X
that	B-X
glycoprotein	B-X
E2	B-X
exhibits	B-X
different	B-X
antigenic	B-X
properties	B-X
depending	B-X
on	B-X
the	B-X
presence	B-X
and	B-X
on	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
N-linked	B-X
oligosaccharides	B-X
and	B-X
that	B-X
efficient	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
requires	B-X
the	B-X
removal	B-X
of	B-X
glucose	B-X
residues	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
tunicamycin	B-X
in	B-X
the	B-X
nonglycosylated	B-X
E2	B-X
apoprotein	B-X
was	B-X
synthesized	B-X
in	B-X
normal	B-X
amounts	B-X
and	B-X
readily	B-X
acylated	B-X
throughout	B-X
the	B-X
infectious	B-X
cycle	B-X
.	B-X
This	B-X
E2-species	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
A59-infected	B-X
cells	B-X
with	B-X
indirect	B-X
immunofluorescence	B-X
staining	B-X
or	B-X
lactoperoxidase	B-X
labeling	B-X
.	B-X
N-Methyl-1-deoxynojirimycin	B-X
and	B-X
castanospermine	B-X
,	B-X
both	B-X
of	B-X
which	B-X
selectively	B-X
inhibited	B-X
the	B-X
processing	B-X
glucosidases	B-X
,	B-X
caused	B-X
a	B-X
drop	B-X
in	B-X
virion	B-X
formation	B-X
by	B-X
two	B-X
log	B-X
steps	B-X
and	B-X
a	B-X
drastic	B-X
delay	B-X
in	B-X
the	B-X
surface	B-X
expression	B-X
of	B-X
glycoprotein	B-X
E2	B-X
.	B-X
The	B-X
E2	B-X
species	B-X
synthesized	B-X
under	B-X
such	B-X
conditions	B-X
was	B-X
acylated	B-X
but	B-X
accumulated	B-X
intracellularly	B-X
in	B-X
a	B-X
compartment	B-X
distinct	B-X
from	B-X
the	B-X
Golgi	B-X
.	B-X
Mannodeoxynojirimycin	B-X
and	B-X
swainsonine	B-X
,	B-X
which	B-X
block	B-X
later	B-X
stages	B-X
of	B-X
the	B-X
processing	B-X
pathway	B-X
,	B-X
had	B-X
less	B-X
or	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
virus	B-X
particles	B-X
.	B-X

This	O
E2	B-Protein
-	O
species	O
could	O
not	O
be	O
detected	O
on	O
the	O
surface	O
of	O
mouse	O
hepatitis	O
virus	O
A59	O
-	O
infected	O
cells	O
with	O
indirect	O
immunofluorescence	O
staining	O
or	O
lactoperoxidase	B-Protein
labeling	O
.	O
<EOS>	B-X
Human	B-X
embryonic	B-X
kidney	B-X
cells	B-X
have	B-X
been	B-X
transformed	B-X
by	B-X
exposing	B-X
cells	B-X
to	B-X
sheared	B-X
fragments	B-X
of	B-X
adenovirus	B-X
type	B-X
5	B-X
DNA	B-X
.	B-X
The	B-X
transformed	B-X
cells	B-X
(	B-X
designated	B-X
293	B-X
cells	B-X
)	B-X
exhibited	B-X
many	B-X
of	B-X
the	B-X
characteristics	B-X
of	B-X
transformation	B-X
including	B-X
the	B-X
elaboration	B-X
of	B-X
a	B-X
virus-specific	B-X
tumour	B-X
antigen	B-X
.	B-X
Analysis	B-X
of	B-X
the	B-X
polypeptides	B-X
synthesized	B-X
in	B-X
the	B-X
293	B-X
cells	B-X
by	B-X
labelling	B-X
with	B-X
35S-methionine	B-X
and	B-X
SDS	B-X
PAGE	B-X
showed	B-X
a	B-X
variable	B-X
pattern	B-X
of	B-X
synthesis	B-X
,	B-X
different	B-X
in	B-X
a	B-X
number	B-X
of	B-X
respects	B-X
from	B-X
that	B-X
seen	B-X
in	B-X
otheruman	B-X
cells	B-X
.	B-X
On	B-X
labelling	B-X
the	B-X
surface	B-X
of	B-X
cells	B-X
by	B-X
lactoperoxidase	B-X
catalysed	B-X
radio-iodination	B-X
,	B-X
the	B-X
absence	B-X
of	B-X
a	B-X
labelled	B-X
polypeptide	B-X
analogous	B-X
to	B-X
the	B-X
250	B-X
K	B-X
(	B-X
LETS	B-X
)	B-X
glycoprotein	B-X
was	B-X
noted	B-X
.	B-X
Hybridization	B-X
of	B-X
labelled	B-X
cellular	B-X
RNA	B-X
with	B-X
restriction	B-X
fragments	B-X
of	B-X
adenovirus	B-X
type	B-X
5	B-X
DNA	B-X
indicated	B-X
transcription	B-X
of	B-X
a	B-X
portion	B-X
of	B-X
the	B-X
adenovirus	B-X
genome	B-X
at	B-X
the	B-X
conventional	B-X
left	B-X
hand	B-X
end	B-X
.	B-X

N	O
-	O
Methyl	O
-	O
1	O
-	O
deoxynojirimycin	O
and	O
castanospermine	O
,	O
both	O
of	O
which	O
selectively	O
inhibited	O
the	O
processing	O
glucosidases	O
,	O
caused	O
a	O
drop	O
in	O
virion	O
formation	O
by	O
two	O
log	O
steps	O
and	O
a	O
drastic	O
delay	O
in	O
the	O
surface	O
expression	O
of	O
glycoprotein	B-Protein
E2	I-Protein
.	O

The	O
E2	B-Protein
species	O
synthesized	O
under	O
such	O
conditions	O
was	O
acylated	O
but	O
accumulated	O
intracellularly	O
in	O
a	O
compartment	O
distinct	O
from	O
the	O
Golgi	O
.	O

Concomitantly	O
,	O
synthesis	O
of	O
the	O
matrix	O
glycoprotein	B-Protein
E1	I-Protein
of	O
mouse	O
hepatitis	O
virus	O
A59	O
was	O
drastically	O
impaired	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
the	B-X
effects	B-X
of	B-X
tunicamycin	B-X
and	B-X
inhibitors	B-X
of	B-X
the	B-X
processing	B-X
of	B-X
N-linked	B-X
glycans	B-X
including	B-X
N-methyl-1-deoxynojirimycin	B-X
,	B-X
castanospermine	B-X
,	B-X
mannodeoxynojirimycin	B-X
,	B-X
and	B-X
swainsonine	B-X
on	B-X
the	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
and	B-X
the	B-X
intracellular	B-X
maturation	B-X
of	B-X
the	B-X
coronavirus	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
A59	B-X
.	B-X
Indirect	B-X
immunofluorescence	B-X
staining	B-X
with	B-X
monoclonal	B-X
antibodies	B-X
revealed	B-X
that	B-X
glycoprotein	B-X
E2	B-X
exhibits	B-X
different	B-X
antigenic	B-X
properties	B-X
depending	B-X
on	B-X
the	B-X
presence	B-X
and	B-X
on	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
N-linked	B-X
oligosaccharides	B-X
and	B-X
that	B-X
efficient	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
to	B-X
the	B-X
plasma	B-X
membrane	B-X
requires	B-X
the	B-X
removal	B-X
of	B-X
glucose	B-X
residues	B-X
.	B-X
This	B-X
E2-species	B-X
could	B-X
not	B-X
be	B-X
detected	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
A59-infected	B-X
cells	B-X
with	B-X
indirect	B-X
immunofluorescence	B-X
staining	B-X
or	B-X
lactoperoxidase	B-X
labeling	B-X
.	B-X
N-Methyl-1-deoxynojirimycin	B-X
and	B-X
castanospermine	B-X
,	B-X
both	B-X
of	B-X
which	B-X
selectively	B-X
inhibited	B-X
the	B-X
processing	B-X
glucosidases	B-X
,	B-X
caused	B-X
a	B-X
drop	B-X
in	B-X
virion	B-X
formation	B-X
by	B-X
two	B-X
log	B-X
steps	B-X
and	B-X
a	B-X
drastic	B-X
delay	B-X
in	B-X
the	B-X
surface	B-X
expression	B-X
of	B-X
glycoprotein	B-X
E2	B-X
.	B-X
Concomitantly	B-X
,	B-X
synthesis	B-X
of	B-X
the	B-X
matrix	B-X
glycoprotein	B-X
E1	B-X
of	B-X
mouse	B-X
hepatitis	B-X
virus	B-X
A59	B-X
was	B-X
drastically	B-X
impaired	B-X
.	B-X
Mannodeoxynojirimycin	B-X
and	B-X
swainsonine	B-X
,	B-X
which	B-X
block	B-X
later	B-X
stages	B-X
of	B-X
the	B-X
processing	B-X
pathway	B-X
,	B-X
had	B-X
less	B-X
or	B-X
no	B-X
effect	B-X
on	B-X
the	B-X
transport	B-X
of	B-X
glycoprotein	B-X
E2	B-X
and	B-X
the	B-X
formation	B-X
of	B-X
virus	B-X
particles	B-X
.	B-X

Mannodeoxynojirimycin	O
and	O
swainsonine	O
,	O
which	O
block	O
later	O
stages	O
of	O
the	O
processing	O
pathway	O
,	O
had	O
less	O
or	O
no	O
effect	O
on	O
the	O
transport	O
of	O
glycoprotein	B-Protein
E2	I-Protein
and	O
the	O
formation	O
of	O
virus	O
particles	O
.	O
<EOS>	B-X
The	B-X
glycans	B-X
in	B-X
some	B-X
proteins	B-X
play	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
protein	B-X
folding	B-X
,	B-X
oligomerization	B-X
,	B-X
quality	B-X
control	B-X
,	B-X
sorting	B-X
,	B-X
and	B-X
transport	B-X
so	B-X
the	B-X
hindering	B-X
of	B-X
N-linked	B-X
glycosylation	B-X
of	B-X
glycoproteins	B-X
will	B-X
prevent	B-X
assembly	B-X
of	B-X
the	B-X
virion	B-X
.	B-X
Our	B-X
study	B-X
aimed	B-X
to	B-X
find	B-X
out	B-X
the	B-X
mechanism	B-X
action	B-X
of	B-X
tunicamycin	B-X
on	B-X
the	B-X
viral	B-X
glycoproteins	B-X
.	B-X
The	B-X
growth	B-X
of	B-X
coronavirus	B-X
in	B-X
the	B-X
presence	B-X
inhibitor	B-X
tunicamycin	B-X
resulted	B-X
in	B-X
the	B-X
production	B-X
of	B-X
spikeless	B-X
,	B-X
non-infectious	B-X
virions	B-X
which	B-X
were	B-X
devoid	B-X
of	B-X
S	B-X
protein	B-X
.	B-X
We	B-X
concluded	B-X
that	B-X
tunicamycin	B-X
inhibits	B-X
E2	B-X
,	B-X
S	B-X
,	B-X
and	B-X
M	B-X
glycoproteins	B-X
of	B-X
coronaviruses	B-X
.	B-X

Purification	O
and	O
postsynthetic	O
modifications	O
of	O
Friend	O
erythroleukemic	O
cell	O
high	O
mobility	O
group	O
protein	O
HMG	B-Protein
-	I-Protein
I	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
detected	B-X
and	B-X
purified	B-X
a	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
nonhistone	B-X
chromatin	B-X
protein	B-X
having	B-X
extraction	B-X
and	B-X
acid-solubility	B-X
properties	B-X
like	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
``	B-X
high	B-X
mobility	B-X
group	B-X
''	B-X
(	B-X
HMG	B-X
)	B-X
nuclear	B-X
proteins	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
electrophoretic	B-X
properties	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
this	B-X
mouse	B-X
cell	B-X
``	B-X
HMG-like	B-X
''	B-X
protein	B-X
is	B-X
comparable	B-X
to	B-X
those	B-X
of	B-X
the	B-X
HMG-I	B-X
proteins	B-X
isolated	B-X
from	B-X
human	B-X
HeLa	B-X
S3	B-X
cells	B-X
,	B-X
African	B-X
green	B-X
monkey	B-X
cells	B-X
,	B-X
Ehrlich	B-X
ascites	B-X
mouse	B-X
cells	B-X
,	B-X
and	B-X
rat	B-X
fibroblast	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
also	B-X
designated	B-X
the	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
protein	B-X
as	B-X
HMG-I	B-X
.	B-X
In	B-X
common	B-X
with	B-X
the	B-X
other	B-X
HMG	B-X
proteins	B-X
the	B-X
Friend	B-X
cell	B-X
HMG-I	B-X
protein	B-X
can	B-X
undergo	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
biochemical	B-X
modifications	B-X
including	B-X
acetylation	B-X
,	B-X
ADP-ribosylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
these	B-X
studies	B-X
we	B-X
found	B-X
that	B-X
in	B-X
vivo	B-X
radiolabeling	B-X
experiments	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
minor	B-X
HMG-14	B-X
subspecies	B-X
(	B-X
and/or	B-X
possibly	B-X
a	B-X
minor	B-X
HMG-I	B-X
subspecies	B-X
)	B-X
are	B-X
phosphorylated	B-X
whereas	B-X
HMG-1	B-X
,	B-X
-2	B-X
,	B-X
-17	B-X
,	B-X
and	B-X
the	B-X
major	B-X
HMG-14	B-X
are	B-X
not	B-X
heavily	B-X
phosphorylated	B-X
.	B-X

We	O
have	O
previously	O
detected	O
and	O
purified	O
a	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
nonhistone	O
chromatin	O
protein	O
having	O
extraction	O
and	O
acid	O
-	O
solubility	O
properties	O
like	O
the	O
low	O
molecular	O
weight	O
"	O
high	O
mobility	O
group	O
"	O
(	O
HMG	O
)	O
nuclear	O
proteins	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
detected	B-X
and	B-X
purified	B-X
a	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
nonhistone	B-X
chromatin	B-X
protein	B-X
having	B-X
extraction	B-X
and	B-X
acid-solubility	B-X
properties	B-X
like	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
``	B-X
high	B-X
mobility	B-X
group	B-X
''	B-X
(	B-X
HMG	B-X
)	B-X
nuclear	B-X
proteins	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
electrophoretic	B-X
properties	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
this	B-X
mouse	B-X
cell	B-X
``	B-X
HMG-like	B-X
''	B-X
protein	B-X
is	B-X
comparable	B-X
to	B-X
those	B-X
of	B-X
the	B-X
HMG-I	B-X
proteins	B-X
isolated	B-X
from	B-X
human	B-X
HeLa	B-X
S3	B-X
cells	B-X
,	B-X
African	B-X
green	B-X
monkey	B-X
cells	B-X
,	B-X
Ehrlich	B-X
ascites	B-X
mouse	B-X
cells	B-X
,	B-X
and	B-X
rat	B-X
fibroblast	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
also	B-X
designated	B-X
the	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
protein	B-X
as	B-X
HMG-I	B-X
.	B-X
In	B-X
common	B-X
with	B-X
the	B-X
other	B-X
HMG	B-X
proteins	B-X
the	B-X
Friend	B-X
cell	B-X
HMG-I	B-X
protein	B-X
can	B-X
undergo	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
biochemical	B-X
modifications	B-X
including	B-X
acetylation	B-X
,	B-X
ADP-ribosylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
these	B-X
studies	B-X
we	B-X
found	B-X
that	B-X
in	B-X
vivo	B-X
radiolabeling	B-X
experiments	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
minor	B-X
HMG-14	B-X
subspecies	B-X
(	B-X
and/or	B-X
possibly	B-X
a	B-X
minor	B-X
HMG-I	B-X
subspecies	B-X
)	B-X
are	B-X
phosphorylated	B-X
whereas	B-X
HMG-1	B-X
,	B-X
-2	B-X
,	B-X
-17	B-X
,	B-X
and	B-X
the	B-X
major	B-X
HMG-14	B-X
are	B-X
not	B-X
heavily	B-X
phosphorylated	B-X
.	B-X

We	O
show	O
here	O
that	O
the	O
electrophoretic	O
properties	O
and	O
the	O
amino	O
acid	O
composition	O
of	O
this	O
mouse	O
cell	O
"	O
HMG	O
-	O
like	O
"	O
protein	O
is	O
comparable	O
to	O
those	O
of	O
the	O
HMG	B-Protein
-	I-Protein
I	I-Protein
proteins	O
isolated	O
from	O
human	O
HeLa	O
S3	O
cells	O
,	O
African	O
green	O
monkey	O
cells	O
,	O
Ehrlich	O
ascites	O
mouse	O
cells	O
,	O
and	O
rat	O
fibroblast	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
detected	B-X
and	B-X
purified	B-X
a	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
nonhistone	B-X
chromatin	B-X
protein	B-X
having	B-X
extraction	B-X
and	B-X
acid-solubility	B-X
properties	B-X
like	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
``	B-X
high	B-X
mobility	B-X
group	B-X
''	B-X
(	B-X
HMG	B-X
)	B-X
nuclear	B-X
proteins	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
electrophoretic	B-X
properties	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
this	B-X
mouse	B-X
cell	B-X
``	B-X
HMG-like	B-X
''	B-X
protein	B-X
is	B-X
comparable	B-X
to	B-X
those	B-X
of	B-X
the	B-X
HMG-I	B-X
proteins	B-X
isolated	B-X
from	B-X
human	B-X
HeLa	B-X
S3	B-X
cells	B-X
,	B-X
African	B-X
green	B-X
monkey	B-X
cells	B-X
,	B-X
Ehrlich	B-X
ascites	B-X
mouse	B-X
cells	B-X
,	B-X
and	B-X
rat	B-X
fibroblast	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
also	B-X
designated	B-X
the	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
protein	B-X
as	B-X
HMG-I	B-X
.	B-X
In	B-X
common	B-X
with	B-X
the	B-X
other	B-X
HMG	B-X
proteins	B-X
the	B-X
Friend	B-X
cell	B-X
HMG-I	B-X
protein	B-X
can	B-X
undergo	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
biochemical	B-X
modifications	B-X
including	B-X
acetylation	B-X
,	B-X
ADP-ribosylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
these	B-X
studies	B-X
we	B-X
found	B-X
that	B-X
in	B-X
vivo	B-X
radiolabeling	B-X
experiments	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
minor	B-X
HMG-14	B-X
subspecies	B-X
(	B-X
and/or	B-X
possibly	B-X
a	B-X
minor	B-X
HMG-I	B-X
subspecies	B-X
)	B-X
are	B-X
phosphorylated	B-X
whereas	B-X
HMG-1	B-X
,	B-X
-2	B-X
,	B-X
-17	B-X
,	B-X
and	B-X
the	B-X
major	B-X
HMG-14	B-X
are	B-X
not	B-X
heavily	B-X
phosphorylated	B-X
.	B-X

Therefore	O
,	O
we	O
have	O
also	O
designated	O
the	O
Friend	O
erythroleukemic	O
mouse	O
cell	O
protein	O
as	O
HMG	B-Protein
-	I-Protein
I	I-Protein
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
detected	B-X
and	B-X
purified	B-X
a	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
nonhistone	B-X
chromatin	B-X
protein	B-X
having	B-X
extraction	B-X
and	B-X
acid-solubility	B-X
properties	B-X
like	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
``	B-X
high	B-X
mobility	B-X
group	B-X
''	B-X
(	B-X
HMG	B-X
)	B-X
nuclear	B-X
proteins	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
electrophoretic	B-X
properties	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
this	B-X
mouse	B-X
cell	B-X
``	B-X
HMG-like	B-X
''	B-X
protein	B-X
is	B-X
comparable	B-X
to	B-X
those	B-X
of	B-X
the	B-X
HMG-I	B-X
proteins	B-X
isolated	B-X
from	B-X
human	B-X
HeLa	B-X
S3	B-X
cells	B-X
,	B-X
African	B-X
green	B-X
monkey	B-X
cells	B-X
,	B-X
Ehrlich	B-X
ascites	B-X
mouse	B-X
cells	B-X
,	B-X
and	B-X
rat	B-X
fibroblast	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
also	B-X
designated	B-X
the	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
protein	B-X
as	B-X
HMG-I	B-X
.	B-X
In	B-X
common	B-X
with	B-X
the	B-X
other	B-X
HMG	B-X
proteins	B-X
the	B-X
Friend	B-X
cell	B-X
HMG-I	B-X
protein	B-X
can	B-X
undergo	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
biochemical	B-X
modifications	B-X
including	B-X
acetylation	B-X
,	B-X
ADP-ribosylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
these	B-X
studies	B-X
we	B-X
found	B-X
that	B-X
in	B-X
vivo	B-X
radiolabeling	B-X
experiments	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
minor	B-X
HMG-14	B-X
subspecies	B-X
(	B-X
and/or	B-X
possibly	B-X
a	B-X
minor	B-X
HMG-I	B-X
subspecies	B-X
)	B-X
are	B-X
phosphorylated	B-X
whereas	B-X
HMG-1	B-X
,	B-X
-2	B-X
,	B-X
-17	B-X
,	B-X
and	B-X
the	B-X
major	B-X
HMG-14	B-X
are	B-X
not	B-X
heavily	B-X
phosphorylated	B-X
.	B-X

In	O
common	O
with	O
the	O
other	O
HMG	O
proteins	O
the	O
Friend	O
cell	O
HMG	B-Protein
-	I-Protein
I	I-Protein
protein	O
can	O
undergo	O
a	O
variety	O
of	O
post	O
-	O
translational	O
biochemical	O
modifications	O
including	O
acetylation	O
,	O
ADP	O
-	O
ribosylation	O
,	O
glycosylation	O
,	O
and	O
phosphorylation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
detected	B-X
and	B-X
purified	B-X
a	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
nonhistone	B-X
chromatin	B-X
protein	B-X
having	B-X
extraction	B-X
and	B-X
acid-solubility	B-X
properties	B-X
like	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
``	B-X
high	B-X
mobility	B-X
group	B-X
''	B-X
(	B-X
HMG	B-X
)	B-X
nuclear	B-X
proteins	B-X
.	B-X
We	B-X
show	B-X
here	B-X
that	B-X
the	B-X
electrophoretic	B-X
properties	B-X
and	B-X
the	B-X
amino	B-X
acid	B-X
composition	B-X
of	B-X
this	B-X
mouse	B-X
cell	B-X
``	B-X
HMG-like	B-X
''	B-X
protein	B-X
is	B-X
comparable	B-X
to	B-X
those	B-X
of	B-X
the	B-X
HMG-I	B-X
proteins	B-X
isolated	B-X
from	B-X
human	B-X
HeLa	B-X
S3	B-X
cells	B-X
,	B-X
African	B-X
green	B-X
monkey	B-X
cells	B-X
,	B-X
Ehrlich	B-X
ascites	B-X
mouse	B-X
cells	B-X
,	B-X
and	B-X
rat	B-X
fibroblast	B-X
cells	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
have	B-X
also	B-X
designated	B-X
the	B-X
Friend	B-X
erythroleukemic	B-X
mouse	B-X
cell	B-X
protein	B-X
as	B-X
HMG-I	B-X
.	B-X
In	B-X
common	B-X
with	B-X
the	B-X
other	B-X
HMG	B-X
proteins	B-X
the	B-X
Friend	B-X
cell	B-X
HMG-I	B-X
protein	B-X
can	B-X
undergo	B-X
a	B-X
variety	B-X
of	B-X
post-translational	B-X
biochemical	B-X
modifications	B-X
including	B-X
acetylation	B-X
,	B-X
ADP-ribosylation	B-X
,	B-X
glycosylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Surprisingly	B-X
,	B-X
in	B-X
the	B-X
course	B-X
of	B-X
these	B-X
studies	B-X
we	B-X
found	B-X
that	B-X
in	B-X
vivo	B-X
radiolabeling	B-X
experiments	B-X
revealed	B-X
that	B-X
only	B-X
two	B-X
minor	B-X
HMG-14	B-X
subspecies	B-X
(	B-X
and/or	B-X
possibly	B-X
a	B-X
minor	B-X
HMG-I	B-X
subspecies	B-X
)	B-X
are	B-X
phosphorylated	B-X
whereas	B-X
HMG-1	B-X
,	B-X
-2	B-X
,	B-X
-17	B-X
,	B-X
and	B-X
the	B-X
major	B-X
HMG-14	B-X
are	B-X
not	B-X
heavily	B-X
phosphorylated	B-X
.	B-X

Surprisingly	O
,	O
in	O
the	O
course	O
of	O
these	O
studies	O
we	O
found	O
that	O
in	O
vivo	O
radiolabeling	O
experiments	O
revealed	O
that	O
only	O
two	O
minor	O
HMG	B-Protein
-	I-Protein
14	I-Protein
subspecies	O
(	O
and	O
/	O
or	O
possibly	O
a	O
minor	O
HMG	B-Protein
-	I-Protein
I	I-Protein
subspecies	O
)	O
are	O
phosphorylated	O
whereas	O
HMG	B-Protein
-	I-Protein
1	I-Protein
,	O
-	B-Protein
2	I-Protein
,	I-Protein
-	B-Protein
17	I-Protein
,	O
and	O
the	O
major	O
HMG	B-Protein
-	I-Protein
14	I-Protein
are	O
not	O
heavily	O
phosphorylated	O
.	O

In	O
vitro	O
sulfation	O
of	O
pulmonary	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

Surfactant	O
-	O
associated	O
protein	O
-	O
35	O
consists	O
of	O
a	O
group	O
of	O
phospholipid	O
-	O
associated	O
proteins	O
of	O
26	O
-	O
36	O
kDa	O
isolated	O
from	O
pulmonary	O
alveolar	O
surfactant	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

In	O
the	O
rat	O
,	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
synthesized	O
from	O
26	O
-	O
kDa	O
primary	O
translation	O
products	O
which	O
are	O
cotranslationally	O
acetylated	O
and	O
glycosylated	O
to	O
heterogeneous	O
30	O
and	O
34	O
kDa	O
forms	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

High	O
-	O
mannose	O
oligosaccharide	O
-	O
containing	O
precursors	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
are	O
processed	O
in	O
the	O
rough	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
to	O
complex	O
-	O
type	O
oligosaccharides	O
,	O
resulting	O
in	O
a	O
mature	O
glycoprotein	O
which	O
exhibits	O
extensive	O
charge	O
heterogeneity	O
in	O
two	O
-	O
dimensional	O
isoelectric	O
focusing	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Much	O
of	O
this	O
charge	O
heterogeneity	O
is	O
related	O
to	O
terminal	O
sialylation	O
of	O
the	O
two	O
asparagine	O
-	O
linked	O
oligosaccharides	O
.	O
<EOS>	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Much	B-X
of	B-X
this	B-X
charge	B-X
heterogeneity	B-X
is	B-X
related	B-X
to	B-X
terminal	B-X
sialylation	B-X
of	B-X
the	B-X
two	B-X
asparagine-linked	B-X
oligosaccharides	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
is	O
also	O
sulfated	O
.	O
<EOS>	B-X
We	B-X
have	B-X
previously	B-X
reported	B-X
that	B-X
a	B-X
46-kDa	B-X
protein	B-X
present	B-X
in	B-X
an	B-X
outer	B-X
membrane	B-X
protein	B-X
preparation	B-X
seemed	B-X
to	B-X
be	B-X
a	B-X
species-specific	B-X
antigen	B-X
of	B-X
Serpulina	B-X
hyodysenteriae	B-X
(	B-X
Z.	B-X
S.	B-X
Li	B-X
,	B-X
N.	B-X
S.	B-X
Jensen	B-X
,	B-X
M.	B-X
Bélanger	B-X
,	B-X
M.-C.	B-X
L'Espérance	B-X
,	B-X
and	B-X
M.	B-X
Jacques	B-X
,	B-X
J.	B-X
Clin	B-X
.	B-X
The	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
further	B-X
characterize	B-X
this	B-X
antigen	B-X
.	B-X
A	B-X
Western	B-X
blot	B-X
(	B-X
immunoblot	B-X
)	B-X
analysis	B-X
and	B-X
immunogold	B-X
labeling	B-X
with	B-X
a	B-X
monospecific	B-X
antiserum	B-X
against	B-X
this	B-X
protein	B-X
confirmed	B-X
that	B-X
the	B-X
protein	B-X
was	B-X
present	B-X
in	B-X
all	B-X
S.	B-X
hyodysenteriae	B-X
reference	B-X
strains	B-X
but	B-X
not	B-X
in	B-X
the	B-X
nonpathogenic	B-X
organism	B-X
Serpulina	B-X
innocens	B-X
.	B-X
The	B-X
immunogold	B-X
labeling	B-X
results	B-X
also	B-X
indicated	B-X
that	B-X
the	B-X
protein	B-X
was	B-X
associated	B-X
with	B-X
the	B-X
periplasmic	B-X
flagella	B-X
of	B-X
S.	B-X
hyodysenteriae	B-X
.	B-X
N-terminal	B-X
amino	B-X
acid	B-X
sequencing	B-X
confirmed	B-X
that	B-X
the	B-X
protein	B-X
was	B-X
in	B-X
fact	B-X
a	B-X
periplasmic	B-X
flagellar	B-X
sheath	B-X
protein	B-X
.	B-X
The	B-X
molecular	B-X
mass	B-X
of	B-X
this	B-X
protein	B-X
,	B-X
first	B-X
estimated	B-X
to	B-X
be	B-X
46	B-X
kDa	B-X
by	B-X
Western	B-X
blotting	B-X
,	B-X
was	B-X
determined	B-X
to	B-X
be	B-X
44	B-X
kDa	B-X
when	B-X
the	B-X
protein	B-X
was	B-X
evaluated	B-X
more	B-X
precisely	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
,	B-X
and	B-X
the	B-X
protein	B-X
was	B-X
glycosylated	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
glycoprotein	B-X
staining	B-X
and	B-X
also	B-X
by	B-X
N-glycosidase	B-X
F	B-X
treatment	B-X
.	B-X
Five	B-X
other	B-X
periplasmic	B-X
flagellar	B-X
proteins	B-X
of	B-X
S.	B-X
hyodysenteriae	B-X
,	B-X
which	B-X
may	B-X
have	B-X
been	B-X
the	B-X
core	B-X
proteins	B-X
and	B-X
had	B-X
molecular	B-X
masses	B-X
of	B-X
39	B-X
,	B-X
35	B-X
,	B-X
32	B-X
,	B-X
30	B-X
,	B-X
and	B-X
29	B-X
kDa	B-X
,	B-X
were	B-X
antigenically	B-X
related	B-X
and	B-X
cross-reacted	B-X
with	B-X
the	B-X
periplasmic	B-X
flagellar	B-X
proteins	B-X
of	B-X
S.	B-X
innocens	B-X
.	B-X
Finally	B-X
,	B-X
serum	B-X
from	B-X
a	B-X
pig	B-X
experimentally	B-X
infected	B-X
with	B-X
S.	B-X
hyodysenteriae	B-X
recognized	B-X
the	B-X
44-kDa	B-X
periplasmic	B-X
flagellar	B-X
sheath	B-X
protein	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
44-kDa	B-X
periplasmic	B-X
flagellar	B-X
sheath	B-X
protein	B-X
of	B-X
S.	B-X
hyodysenteriae	B-X
is	B-X
a	B-X
species-specific	B-X
glycoprotein	B-X
antigen	B-X
.	B-X

Sulfation	O
of	O
the	O
30	O
and	O
34	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
was	O
clearly	O
detected	O
in	O
primary	O
cultures	O
of	O
rat	O
Type	O
II	O
epithelial	O
cells	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

These	O
sulfated	O
isoforms	O
were	O
sensitive	O
to	O
endoglycosidase	O
F	O
digestion	O
,	O
but	O
resistant	O
to	O
neuraminidase	O
,	O
suggesting	O
that	O
sulfation	O
occurred	O
at	O
oligosaccharide	O
residues	O
other	O
than	O
sialic	O
acid	O
.	O
<EOS>	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Much	B-X
of	B-X
this	B-X
charge	B-X
heterogeneity	B-X
is	B-X
related	B-X
to	B-X
terminal	B-X
sialylation	B-X
of	B-X
the	B-X
two	B-X
asparagine-linked	B-X
oligosaccharides	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

The	O
lack	O
of	O
sulfation	O
of	O
the	O
26	O
kDa	O
forms	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
and	O
the	O
resistance	O
of	O
the	O
sulfated	O
isoforms	O
to	O
endoglycosidase	B-Protein
H	I-Protein
digestion	O
are	O
consistent	O
with	O
Golgi	O
-	O
associated	O
sulfation	O
of	O
the	O
complex	O
type	O
oligosaccharides	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Much	B-X
of	B-X
this	B-X
charge	B-X
heterogeneity	B-X
is	B-X
related	B-X
to	B-X
terminal	B-X
sialylation	B-X
of	B-X
the	B-X
two	B-X
asparagine-linked	B-X
oligosaccharides	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

Thus	O
,	O
sulfation	O
is	O
another	O
component	O
of	O
the	O
complex	O
post	O
-	O
translational	O
processing	O
of	O
surfactant	O
-	O
associated	O
protein	O
-	O
35	O
,	O
which	O
includes	O
acetylation	O
,	O
hydroxylation	O
,	O
glycosylation	O
,	O
sialylation	O
,	O
sulfhydryl	O
-	O
dependent	O
oligomerization	O
and	O
sulfation	O
.	O
<EOS>	B-X
Surfactant-associated	B-X
protein-35	B-X
consists	B-X
of	B-X
a	B-X
group	B-X
of	B-X
phospholipid-associated	B-X
proteins	B-X
of	B-X
26-36	B-X
kDa	B-X
isolated	B-X
from	B-X
pulmonary	B-X
alveolar	B-X
surfactant	B-X
.	B-X
In	B-X
the	B-X
rat	B-X
,	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
synthesized	B-X
from	B-X
26-kDa	B-X
primary	B-X
translation	B-X
products	B-X
which	B-X
are	B-X
cotranslationally	B-X
acetylated	B-X
and	B-X
glycosylated	B-X
to	B-X
heterogeneous	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
.	B-X
High-mannose	B-X
oligosaccharide-containing	B-X
precursors	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
are	B-X
processed	B-X
in	B-X
the	B-X
rough	B-X
endoplasmic	B-X
reticulum	B-X
and	B-X
Golgi	B-X
to	B-X
complex-type	B-X
oligosaccharides	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
mature	B-X
glycoprotein	B-X
which	B-X
exhibits	B-X
extensive	B-X
charge	B-X
heterogeneity	B-X
in	B-X
two-dimensional	B-X
isoelectric	B-X
focusing	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Much	B-X
of	B-X
this	B-X
charge	B-X
heterogeneity	B-X
is	B-X
related	B-X
to	B-X
terminal	B-X
sialylation	B-X
of	B-X
the	B-X
two	B-X
asparagine-linked	B-X
oligosaccharides	B-X
.	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
report	B-X
that	B-X
surfactant-associated	B-X
protein-35	B-X
is	B-X
also	B-X
sulfated	B-X
.	B-X
Sulfation	B-X
of	B-X
the	B-X
30	B-X
and	B-X
34	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
was	B-X
clearly	B-X
detected	B-X
in	B-X
primary	B-X
cultures	B-X
of	B-X
rat	B-X
Type	B-X
II	B-X
epithelial	B-X
cells	B-X
.	B-X
These	B-X
sulfated	B-X
isoforms	B-X
were	B-X
sensitive	B-X
to	B-X
endoglycosidase	B-X
F	B-X
digestion	B-X
,	B-X
but	B-X
resistant	B-X
to	B-X
neuraminidase	B-X
,	B-X
suggesting	B-X
that	B-X
sulfation	B-X
occurred	B-X
at	B-X
oligosaccharide	B-X
residues	B-X
other	B-X
than	B-X
sialic	B-X
acid	B-X
.	B-X
The	B-X
lack	B-X
of	B-X
sulfation	B-X
of	B-X
the	B-X
26	B-X
kDa	B-X
forms	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
and	B-X
the	B-X
resistance	B-X
of	B-X
the	B-X
sulfated	B-X
isoforms	B-X
to	B-X
endoglycosidase	B-X
H	B-X
digestion	B-X
are	B-X
consistent	B-X
with	B-X
Golgi-associated	B-X
sulfation	B-X
of	B-X
the	B-X
complex	B-X
type	B-X
oligosaccharides	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
.	B-X
Thus	B-X
,	B-X
sulfation	B-X
is	B-X
another	B-X
component	B-X
of	B-X
the	B-X
complex	B-X
post-translational	B-X
processing	B-X
of	B-X
surfactant-associated	B-X
protein-35	B-X
,	B-X
which	B-X
includes	B-X
acetylation	B-X
,	B-X
hydroxylation	B-X
,	B-X
glycosylation	B-X
,	B-X
sialylation	B-X
,	B-X
sulfhydryl-dependent	B-X
oligomerization	B-X
and	B-X
sulfation	B-X
.	B-X

Effect	O
of	O
propeptide	O
mutations	O
on	O
post	O
-	O
translational	O
processing	O
of	O
factor	B-Protein
IX	I-Protein
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
mutations	B-X
on	B-X
proteolytic	B-X
processing	B-X
,	B-X
gamma-carboxylation	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
were	B-X
assessed	B-X
by	B-X
direct	B-X
structural	B-X
analysis	B-X
.	B-X
After	B-X
purification	B-X
,	B-X
the	B-X
molecular	B-X
weight	B-X
of	B-X
each	B-X
of	B-X
the	B-X
recombinant	B-X
Factor	B-X
IX	B-X
species	B-X
and	B-X
its	B-X
NH2-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

Evidence	O
that	O
beta	O
-	O
hydroxylation	O
and	O
gamma	O
-	O
carboxylation	O
are	O
independent	O
events	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
mutations	B-X
on	B-X
proteolytic	B-X
processing	B-X
,	B-X
gamma-carboxylation	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
were	B-X
assessed	B-X
by	B-X
direct	B-X
structural	B-X
analysis	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

Post	O
-	O
translational	O
processing	O
of	O
Factor	B-Protein
IX	I-Protein
includes	O
glycosylation	O
,	O
cleavage	O
of	O
the	O
signal	O
peptide	O
and	O
propeptide	O
,	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
specific	O
glutamic	O
acid	O
residues	O
to	O
form	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
and	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
at	O
residue	O
64	O
to	O
form	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
mutations	B-X
on	B-X
proteolytic	B-X
processing	B-X
,	B-X
gamma-carboxylation	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
were	B-X
assessed	B-X
by	B-X
direct	B-X
structural	B-X
analysis	B-X
.	B-X
After	B-X
purification	B-X
,	B-X
the	B-X
molecular	B-X
weight	B-X
of	B-X
each	B-X
of	B-X
the	B-X
recombinant	B-X
Factor	B-X
IX	B-X
species	B-X
and	B-X
its	B-X
NH2-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

The	O
human	O
Factor	B-Protein
IX	I-Protein
cDNA	O
coding	O
sequence	O
was	O
modified	O
in	O
the	O
propeptide	O
region	O
(	O
residue	O
-	O
18	O
to	O
-	O
1	O
)	O
using	O
oligonucleotide	O
-	O
directed	O
site	O
-	O
specific	O
mutagenesis	O
,	O
and	O
the	O
altered	O
Factor	B-Protein
IX	I-Protein
cDNA	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
After	B-X
purification	B-X
,	B-X
the	B-X
molecular	B-X
weight	B-X
of	B-X
each	B-X
of	B-X
the	B-X
recombinant	B-X
Factor	B-X
IX	B-X
species	B-X
and	B-X
its	B-X
NH2-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

The	O
effects	O
of	O
the	O
mutations	O
on	O
proteolytic	O
processing	O
,	O
gamma	O
-	O
carboxylation	O
,	O
and	O
beta	O
-	O
hydroxylation	O
were	O
assessed	O
by	O
direct	O
structural	O
analysis	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
mutations	B-X
on	B-X
proteolytic	B-X
processing	B-X
,	B-X
gamma-carboxylation	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
were	B-X
assessed	B-X
by	B-X
direct	B-X
structural	B-X
analysis	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

After	O
purification	O
,	O
the	O
molecular	O
weight	O
of	O
each	O
of	O
the	O
recombinant	O
Factor	B-Protein
IX	I-Protein
species	O
and	O
its	O
NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
were	O
shown	O
to	O
be	O
identical	O
to	O
those	O
of	O
plasma	O
Factor	B-Protein
IX	I-Protein
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
After	B-X
purification	B-X
,	B-X
the	B-X
molecular	B-X
weight	B-X
of	B-X
each	B-X
of	B-X
the	B-X
recombinant	B-X
Factor	B-X
IX	B-X
species	B-X
and	B-X
its	B-X
NH2-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

gamma	O
-	O
Carboxyglutamic	O
acid	O
and	O
beta	O
-	O
hydroxyaspartic	O
acid	O
analyses	O
revealed	O
that	O
recombinant	O
wild	O
-	O
type	O
Factor	B-Protein
IX	I-Protein
contained	O
9	O
.	O
2	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
3	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
/	O
molecule	O
compared	O
with	O
11	O
.	O
4	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
39	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
in	O
plasma	O
Factor	B-Protein
IX	I-Protein
.	O

When	O
the	O
18	O
-	O
residue	O
propeptide	O
was	O
deleted	O
or	O
when	O
the	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
sodium	O
warfarin	O
,	O
secreted	O
Factor	B-Protein
IX	I-Protein
contained	O
no	O
detectable	O
gamma	O
-	O
carboxyglutamic	O
acid	O
but	O
0	O
.	O
36	O
and	O
0	O
.	O
40	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
respectively	O
.	O
<EOS>	B-X
We	B-X
demonstrate	B-X
that	B-X
(	B-X
i	B-X
)	B-X
NisB	B-X
has	B-X
stronger	B-X
interactions	B-X
with	B-X
precursor	B-X
nisin	B-X
than	B-X
NisC	B-X
has	B-X
,	B-X
(	B-X
ii	B-X
)	B-X
deletion	B-X
of	B-X
the	B-X
propeptide	B-X
part	B-X
keeping	B-X
the	B-X
nisin	B-X
leader	B-X
intact	B-X
leads	B-X
to	B-X
a	B-X
lack	B-X
of	B-X
binding	B-X
,	B-X
(	B-X
iii	B-X
)	B-X
NisB	B-X
point	B-X
mutants	B-X
of	B-X
highly	B-X
conserved	B-X
residues	B-X
W616	B-X
,	B-X
F342A	B-X
,	B-X
Y346F	B-X
and	B-X
P639A	B-X
are	B-X
still	B-X
able	B-X
to	B-X
dehydrate	B-X
prenisin	B-X
,	B-X
(	B-X
iv	B-X
)	B-X
NisB	B-X
Δ	B-X
(	B-X
77-79	B-X
)	B-X
Y80F	B-X
mutant	B-X
decreased	B-X
the	B-X
levels	B-X
of	B-X
NisB-prenisin	B-X
interactions	B-X
and	B-X
resulted	B-X
in	B-X
unmodified	B-X
prenisin	B-X
,	B-X
(	B-X
v	B-X
)	B-X
substitution	B-X
of	B-X
an	B-X
active	B-X
site	B-X
residue	B-X
H331A	B-X
in	B-X
NisC	B-X
leads	B-X
to	B-X
higher	B-X
amounts	B-X
of	B-X
the	B-X
co-purified	B-X
complex	B-X
,	B-X
(	B-X
vi	B-X
)	B-X
NisB	B-X
is	B-X
present	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
dimer	B-X
,	B-X
and	B-X
(	B-X
vii	B-X
)	B-X
the	B-X
region	B-X
FNLD	B-X
(	B-X
-18	B-X
to	B-X
-15	B-X
)	B-X
of	B-X
the	B-X
leader	B-X
is	B-X
an	B-X
important	B-X
site	B-X
for	B-X
binding	B-X
not	B-X
only	B-X
to	B-X
NisB	B-X
,	B-X
but	B-X
also	B-X
to	B-X
NisC	B-X
.	B-X
An	B-X
important	B-X
virulence	B-X
factor	B-X
of	B-X
the	B-X
opportunistic	B-X
human	B-X
pathogen	B-X
Pseudomonas	B-X
aeruginosa	B-X
is	B-X
elastase	B-X
,	B-X
a	B-X
secreted	B-X
thermolysin-like	B-X
neutral	B-X
zinc-metalloprotease	B-X
(	B-X
TNP	B-X
)	B-X
.	B-X
Elastase	B-X
is	B-X
synthesized	B-X
as	B-X
a	B-X
larger	B-X
precursor	B-X
with	B-X
an	B-X
amino-terminal	B-X
18	B-X
kDa	B-X
propeptide	B-X
,	B-X
and	B-X
was	B-X
the	B-X
first	B-X
TNP	B-X
shown	B-X
to	B-X
require	B-X
its	B-X
propeptide	B-X
as	B-X
an	B-X
intramolecular	B-X
chaperone	B-X
(	B-X
IMC	B-X
)	B-X
for	B-X
activity	B-X
and	B-X
secretion	B-X
.	B-X
This	B-X
paper	B-X
reports	B-X
the	B-X
analysis	B-X
of	B-X
the	B-X
elastase	B-X
propeptide	B-X
to	B-X
identify	B-X
residues	B-X
conserved	B-X
among	B-X
other	B-X
TNP	B-X
precursors	B-X
that	B-X
may	B-X
be	B-X
critical	B-X
for	B-X
its	B-X
IMC	B-X
function	B-X
.	B-X
The	B-X
prosequences	B-X
of	B-X
TNP	B-X
precursors	B-X
from	B-X
both	B-X
Gram-negative	B-X
(	B-X
Vibrio	B-X
species	B-X
and	B-X
Legionella	B-X
species	B-X
)	B-X
and	B-X
Gram-positive	B-X
(	B-X
Bacillus	B-X
species	B-X
)	B-X
bacteria	B-X
were	B-X
found	B-X
to	B-X
show	B-X
homology	B-X
to	B-X
the	B-X
elastase	B-X
propeptide	B-X
.	B-X
Two	B-X
regions	B-X
of	B-X
conserved	B-X
residues	B-X
were	B-X
observed	B-X
:	B-X
a	B-X
hydrophilic	B-X
region	B-X
(	B-X
ProM	B-X
)	B-X
found	B-X
in	B-X
the	B-X
middle	B-X
of	B-X
the	B-X
elastase	B-X
propeptide	B-X
and	B-X
a	B-X
more	B-X
hydrophobic	B-X
region	B-X
(	B-X
ProC	B-X
)	B-X
located	B-X
proximal	B-X
to	B-X
the	B-X
propeptide-processing	B-X
site	B-X
.	B-X
To	B-X
test	B-X
whether	B-X
such	B-X
conserved	B-X
motifs	B-X
were	B-X
important	B-X
to	B-X
function	B-X
,	B-X
single	B-X
residue	B-X
substitutions	B-X
at	B-X
eight	B-X
conserved	B-X
amino	B-X
acids	B-X
were	B-X
introduced	B-X
within	B-X
the	B-X
full-length	B-X
pre-proelastase	B-X
precursor	B-X
by	B-X
site-specific	B-X
mutagenesis	B-X
of	B-X
lasB	B-X
,	B-X
the	B-X
gene	B-X
encoding	B-X
elastase	B-X
.	B-X
Mutant	B-X
lasB	B-X
alleles	B-X
were	B-X
expressed	B-X
from	B-X
plasmids	B-X
within	B-X
a	B-X
lasB-deleted	B-X
P.	B-X
aeruginosa	B-X
strain	B-X
,	B-X
FRD740	B-X
,	B-X
and	B-X
the	B-X
effects	B-X
of	B-X
these	B-X
propeptide	B-X
alterations	B-X
on	B-X
elastase	B-X
enzyme	B-X
activity	B-X
,	B-X
processing	B-X
,	B-X
stability	B-X
and	B-X
accumulation	B-X
inside	B-X
and	B-X
outside	B-X
of	B-X
the	B-X
cell	B-X
were	B-X
examined	B-X
.	B-X
Within	B-X
the	B-X
ProC	B-X
region	B-X
,	B-X
mutations	B-X
at	B-X
Ile181	B-X
and	B-X
Ala183	B-X
abolished	B-X
the	B-X
accumulation	B-X
of	B-X
a	B-X
stable	B-X
elastase	B-X
molecule	B-X
in	B-X
the	B-X
supernatant	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
from	B-X
this	B-X
preliminary	B-X
study	B-X
show	B-X
that	B-X
conserved	B-X
residues	B-X
within	B-X
the	B-X
elastase	B-X
propeptide	B-X
are	B-X
essential	B-X
for	B-X
its	B-X
function	B-X
and	B-X
begin	B-X
to	B-X
define	B-X
the	B-X
mechanisms	B-X
of	B-X
action	B-X
of	B-X
IMCs	B-X
in	B-X
the	B-X
TNP	B-X
family	B-X
.	B-X

Point	O
mutations	O
leading	O
to	O
substitution	O
of	O
alanine	O
for	O
phenylalanine	O
at	O
residue	O
-	O
16	O
or	O
glutamic	O
acid	O
for	O
alanine	O
at	O
residue	O
-	O
10	O
contained	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
,	O
respectively	O
,	O
and	O
0	O
.	O
2	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O
<EOS>	B-X
Post-translational	B-X
processing	B-X
of	B-X
Factor	B-X
IX	B-X
includes	B-X
glycosylation	B-X
,	B-X
cleavage	B-X
of	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
propeptide	B-X
,	B-X
vitamin	B-X
K-dependent	B-X
carboxylation	B-X
of	B-X
specific	B-X
glutamic	B-X
acid	B-X
residues	B-X
to	B-X
form	B-X
gamma-carboxyglutamic	B-X
acid	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
at	B-X
residue	B-X
64	B-X
to	B-X
form	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
The	B-X
human	B-X
Factor	B-X
IX	B-X
cDNA	B-X
coding	B-X
sequence	B-X
was	B-X
modified	B-X
in	B-X
the	B-X
propeptide	B-X
region	B-X
(	B-X
residue	B-X
-18	B-X
to	B-X
-1	B-X
)	B-X
using	B-X
oligonucleotide-directed	B-X
site-specific	B-X
mutagenesis	B-X
,	B-X
and	B-X
the	B-X
altered	B-X
Factor	B-X
IX	B-X
cDNA	B-X
was	B-X
expressed	B-X
in	B-X
Chinese	B-X
hamster	B-X
ovary	B-X
cells	B-X
.	B-X
The	B-X
effects	B-X
of	B-X
the	B-X
mutations	B-X
on	B-X
proteolytic	B-X
processing	B-X
,	B-X
gamma-carboxylation	B-X
,	B-X
and	B-X
beta-hydroxylation	B-X
were	B-X
assessed	B-X
by	B-X
direct	B-X
structural	B-X
analysis	B-X
.	B-X
After	B-X
purification	B-X
,	B-X
the	B-X
molecular	B-X
weight	B-X
of	B-X
each	B-X
of	B-X
the	B-X
recombinant	B-X
Factor	B-X
IX	B-X
species	B-X
and	B-X
its	B-X
NH2-terminal	B-X
amino	B-X
acid	B-X
sequence	B-X
were	B-X
shown	B-X
to	B-X
be	B-X
identical	B-X
to	B-X
those	B-X
of	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
gamma-Carboxyglutamic	B-X
acid	B-X
and	B-X
beta-hydroxyaspartic	B-X
acid	B-X
analyses	B-X
revealed	B-X
that	B-X
recombinant	B-X
wild-type	B-X
Factor	B-X
IX	B-X
contained	B-X
9.2	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.3	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues/molecule	B-X
compared	B-X
with	B-X
11.4	B-X
gamma-carboxyglutamic	B-X
acid	B-X
and	B-X
0.39	B-X
beta-hydroxyaspartic	B-X
acid	B-X
residues	B-X
in	B-X
plasma	B-X
Factor	B-X
IX	B-X
.	B-X
When	B-X
the	B-X
18-residue	B-X
propeptide	B-X
was	B-X
deleted	B-X
or	B-X
when	B-X
the	B-X
cells	B-X
were	B-X
grown	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
sodium	B-X
warfarin	B-X
,	B-X
secreted	B-X
Factor	B-X
IX	B-X
contained	B-X
no	B-X
detectable	B-X
gamma-carboxyglutamic	B-X
acid	B-X
but	B-X
0.36	B-X
and	B-X
0.40	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
,	B-X
respectively	B-X
.	B-X
Point	B-X
mutations	B-X
leading	B-X
to	B-X
substitution	B-X
of	B-X
alanine	B-X
for	B-X
phenylalanine	B-X
at	B-X
residue	B-X
-16	B-X
or	B-X
glutamic	B-X
acid	B-X
for	B-X
alanine	B-X
at	B-X
residue	B-X
-10	B-X
contained	B-X
0.2	B-X
and	B-X
1.7	B-X
gamma-carboxyglutamic	B-X
acid	B-X
residues	B-X
,	B-X
respectively	B-X
,	B-X
and	B-X
0.2	B-X
residues	B-X
of	B-X
beta-hydroxyaspartic	B-X
acid	B-X
.	B-X
These	B-X
data	B-X
confirm	B-X
that	B-X
the	B-X
propeptide	B-X
mutations	B-X
made	B-X
do	B-X
not	B-X
interfere	B-X
with	B-X
proteolytic	B-X
processing	B-X
and	B-X
that	B-X
the	B-X
Factor	B-X
IX	B-X
propeptide	B-X
contains	B-X
a	B-X
recognition	B-X
site	B-X
that	B-X
designates	B-X
the	B-X
adjacent	B-X
glutamic	B-X
acid-rich	B-X
domain	B-X
for	B-X
gamma-carboxylation	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
beta-hydroxylation	B-X
of	B-X
aspartic	B-X
acid	B-X
64	B-X
is	B-X
an	B-X
independent	B-X
process	B-X
which	B-X
does	B-X
not	B-X
require	B-X
vitamin	B-X
K	B-X
and	B-X
is	B-X
mediated	B-X
through	B-X
a	B-X
hydroxylation	B-X
recognition	B-X
site	B-X
in	B-X
the	B-X
mature	B-X
Factor	B-X
IX	B-X
,	B-X
not	B-X
in	B-X
the	B-X
propeptide	B-X
.	B-X

These	O
data	O
confirm	O
that	O
the	O
propeptide	O
mutations	O
made	O
do	O
not	O
interfere	O
with	O
proteolytic	O
processing	O
and	O
that	O
the	O
Factor	B-Protein
IX	I-Protein
propeptide	O
contains	O
a	O
recognition	O
site	O
that	O
designates	O
the	O
adjacent	O
glutamic	O
acid	O
-	O
rich	O
domain	O
for	O
gamma	O
-	O
carboxylation	O
.	O
<EOS>	B-X
The	B-X
mutation	B-X
causes	B-X
the	B-X
substitution	B-X
of	B-X
the	B-X
most	B-X
5	B-X
'	B-X
cysteine	B-X
residue	B-X
by	B-X
a	B-X
serine	B-X
within	B-X
a	B-X
highly	B-X
conserved	B-X
sequence	B-X
of	B-X
the	B-X
pro	B-X
(	B-X
alpha	B-X
)	B-X
1	B-X
(	B-X
V	B-X
)	B-X
C-propeptide	B-X
domain	B-X
and	B-X
causes	B-X
reduction	B-X
of	B-X
collagen	B-X
V	B-X
by	B-X
preventing	B-X
incorporation	B-X
of	B-X
the	B-X
mutant	B-X
pro	B-X
(	B-X
alpha	B-X
)	B-X
1	B-X
(	B-X
V	B-X
)	B-X
chains	B-X
in	B-X
the	B-X
collagen	B-X
V	B-X
trimers	B-X
.	B-X
These	B-X
findings	B-X
confirm	B-X
the	B-X
causal	B-X
role	B-X
of	B-X
collagen	B-X
V	B-X
in	B-X
at	B-X
least	B-X
a	B-X
subgroup	B-X
of	B-X
EDS	B-X
I	B-X
,	B-X
prove	B-X
that	B-X
EDS	B-X
I	B-X
and	B-X
II	B-X
are	B-X
allelic	B-X
conditions	B-X
,	B-X
and	B-X
represent	B-X
a	B-X
,	B-X
so	B-X
far	B-X
,	B-X
unique	B-X
example	B-X
of	B-X
a	B-X
human	B-X
collagen	B-X
disorder	B-X
caused	B-X
by	B-X
substitution	B-X
of	B-X
a	B-X
highly	B-X
conserved	B-X
cysteine	B-X
residue	B-X
in	B-X
the	B-X
C-propeptide	B-X
domain	B-X
of	B-X
a	B-X
fibrillar	B-X
collagen	B-X
.	B-X
Prohormone	B-X
convertase	B-X
2	B-X
(	B-X
PC2	B-X
)	B-X
is	B-X
a	B-X
subtilisin-like	B-X
protease	B-X
involved	B-X
in	B-X
the	B-X
intracellular	B-X
processing	B-X
of	B-X
prohormones	B-X
and	B-X
proneuropeptides	B-X
.	B-X
Like	B-X
its	B-X
substrates	B-X
,	B-X
it	B-X
is	B-X
synthesised	B-X
as	B-X
a	B-X
prepropeptide	B-X
which	B-X
undergoes	B-X
proteolysis	B-X
during	B-X
transit	B-X
through	B-X
the	B-X
regulated	B-X
secretory	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
this	B-X
further	B-X
,	B-X
we	B-X
made	B-X
a	B-X
chimeric	B-X
protein	B-X
containing	B-X
both	B-X
the	B-X
signal	B-X
peptide	B-X
and	B-X
pro-region	B-X
of	B-X
PC2	B-X
and	B-X
the	B-X
N-terminal	B-X
part	B-X
of	B-X
alpha1-antitrypsin	B-X
,	B-X
called	B-X
pro2alpha1	B-X
.	B-X
Pro2alpha1	B-X
thus	B-X
exhibits	B-X
the	B-X
membrane	B-X
association	B-X
and	B-X
aggregation	B-X
properties	B-X
of	B-X
PC2	B-X
,	B-X
confirming	B-X
the	B-X
role	B-X
of	B-X
the	B-X
pro-region	B-X
in	B-X
these	B-X
processes	B-X
.	B-X
A	B-X
series	B-X
of	B-X
deletions	B-X
were	B-X
performed	B-X
within	B-X
the	B-X
84-residue	B-X
propeptide	B-X
in	B-X
order	B-X
to	B-X
define	B-X
the	B-X
sequences	B-X
involved	B-X
.	B-X
Deletion	B-X
of	B-X
amino	B-X
acids	B-X
52-77	B-X
reduced	B-X
aggregation	B-X
but	B-X
large	B-X
deletions	B-X
in	B-X
the	B-X
pro-region	B-X
had	B-X
only	B-X
a	B-X
minimal	B-X
effect	B-X
on	B-X
membrane	B-X
association	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
several	B-X
regions	B-X
within	B-X
the	B-X
propeptide	B-X
are	B-X
important	B-X
in	B-X
these	B-X
events	B-X
.	B-X

In	O
contrast	O
,	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
64	O
is	O
an	O
independent	O
process	O
which	O
does	O
not	O
require	O
vitamin	O
K	O
and	O
is	O
mediated	O
through	O
a	O
hydroxylation	O
recognition	O
site	O
in	O
the	O
mature	O
Factor	B-Protein
IX	I-Protein
,	O
not	O
in	O
the	O
propeptide	O
.	O

(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
serves	O
as	O
high	O
-	O
affinity	O
substrate	O
for	O
tyrosylprotein	O
sulfotransferase	O
:	O
a	O
Golgi	O
enzyme	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

Tyrosylprotein	O
sulfotransferase	O
,	O
the	O
enzyme	O
catalyzing	O
the	O
sulfation	O
of	O
proteins	O
on	O
tyrosine	O
residues	O
,	O
was	O
characterized	O
by	O
using	O
the	O
acidic	O
polymer	O
containing	O
tyrosine	O
(	O
Glu62	O
,	O
Ala30	O
,	O
Tyr8	O
)	O
n	O
(	O
referred	O
to	O
as	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
)	O
as	O
exogenous	O
"	O
protein	O
"	O
substrate	O
.	O

After	O
subcellular	O
fractionation	O
of	O
a	O
bovine	O
adrenal	O
medulla	O
homogenate	O
,	O
tyrosylprotein	O
sulfotransferase	O
activity	O
was	O
found	O
to	O
be	O
highest	O
in	O
fractions	O
enriched	O
in	O
Golgi	O
membrane	O
vesicles	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

Tyrosylprotein	O
sulfotransferase	O
required	O
the	O
presence	O
of	O
a	O
nonionic	O
detergent	O
for	O
sulfation	O
of	O
exogenous	O
Glu	O
,	O
Ala	O
,	O
Tyr	O
,	O
indicating	O
an	O
orientation	O
of	O
the	O
catalytic	O
site	O
of	O
the	O
enzyme	O
toward	O
the	O
Golgi	O
lumen	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

Tyrosylprotein	O
sulfotransferase	O
was	O
solubilized	O
by	O
Triton	O
X	O
-	O
100	O
,	O
suggesting	O
that	O
the	O
enzyme	O
was	O
tightly	O
associated	O
with	O
the	O
Golgi	O
membrane	O
,	O
possibly	O
as	O
an	O
integral	O
membrane	O
protein	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

The	O
apparent	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
was	O
supported	O
by	O
the	O
observation	O
that	O
tyrosine	O
sulfation	O
of	O
proteins	O
in	O
intact	O
cells	O
was	O
blocked	O
by	O
monensin	O
and	O
was	O
in	O
line	O
with	O
previous	O
observations	O
that	O
all	O
tyrosine	O
-	O
sulfated	O
proteins	O
known	O
so	O
far	O
are	O
secretory	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

Glu	O
,	O
Ala	O
,	O
Tyr	O
was	O
found	O
to	O
have	O
a	O
very	O
high	O
affinity	O
for	O
tyrosylprotein	O
sulfotransferase	O
(	O
apparent	O
Km	O
,	O
300	O
nM	O
)	O
,	O
similar	O
to	O
that	O
reported	O
for	O
certain	O
tyrosylprotein	O
kinases	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

While	O
this	O
may	O
suggest	O
some	O
similarity	O
between	O
these	O
enzymes	O
,	O
the	O
Golgi	O
localization	O
of	O
tyrosylprotein	O
sulfotransferase	O
segregates	O
tyrosine	O
sulfation	O
from	O
the	O
sites	O
of	O
tyrosine	O
phosphorylation	O
of	O
proteins	O
in	O
the	O
intact	O
cell	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

If	O
,	O
however	O
,	O
tyrosylprotein	O
sulfotransferase	O
was	O
allowed	O
to	O
react	O
with	O
cytoplasmic	O
proteins	O
by	O
using	O
a	O
nonionic	O
detergent	O
,	O
tyrosine	O
sulfation	O
of	O
tubulin	O
was	O
observed	O
.	O
<EOS>	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
,	B-X
the	B-X
enzyme	B-X
catalyzing	B-X
the	B-X
sulfation	B-X
of	B-X
proteins	B-X
on	B-X
tyrosine	B-X
residues	B-X
,	B-X
was	B-X
characterized	B-X
by	B-X
using	B-X
the	B-X
acidic	B-X
polymer	B-X
containing	B-X
tyrosine	B-X
(	B-X
Glu62	B-X
,	B-X
Ala30	B-X
,	B-X
Tyr8	B-X
)	B-X
n	B-X
(	B-X
referred	B-X
to	B-X
as	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
)	B-X
as	B-X
exogenous	B-X
``	B-X
protein	B-X
''	B-X
substrate	B-X
.	B-X
After	B-X
subcellular	B-X
fractionation	B-X
of	B-X
a	B-X
bovine	B-X
adrenal	B-X
medulla	B-X
homogenate	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
activity	B-X
was	B-X
found	B-X
to	B-X
be	B-X
highest	B-X
in	B-X
fractions	B-X
enriched	B-X
in	B-X
Golgi	B-X
membrane	B-X
vesicles	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
required	B-X
the	B-X
presence	B-X
of	B-X
a	B-X
nonionic	B-X
detergent	B-X
for	B-X
sulfation	B-X
of	B-X
exogenous	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
,	B-X
indicating	B-X
an	B-X
orientation	B-X
of	B-X
the	B-X
catalytic	B-X
site	B-X
of	B-X
the	B-X
enzyme	B-X
toward	B-X
the	B-X
Golgi	B-X
lumen	B-X
.	B-X
Tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
solubilized	B-X
by	B-X
Triton	B-X
X-100	B-X
,	B-X
suggesting	B-X
that	B-X
the	B-X
enzyme	B-X
was	B-X
tightly	B-X
associated	B-X
with	B-X
the	B-X
Golgi	B-X
membrane	B-X
,	B-X
possibly	B-X
as	B-X
an	B-X
integral	B-X
membrane	B-X
protein	B-X
.	B-X
The	B-X
apparent	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
supported	B-X
by	B-X
the	B-X
observation	B-X
that	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
proteins	B-X
in	B-X
intact	B-X
cells	B-X
was	B-X
blocked	B-X
by	B-X
monensin	B-X
and	B-X
was	B-X
in	B-X
line	B-X
with	B-X
previous	B-X
observations	B-X
that	B-X
all	B-X
tyrosine-sulfated	B-X
proteins	B-X
known	B-X
so	B-X
far	B-X
are	B-X
secretory	B-X
.	B-X
Glu	B-X
,	B-X
Ala	B-X
,	B-X
Tyr	B-X
was	B-X
found	B-X
to	B-X
have	B-X
a	B-X
very	B-X
high	B-X
affinity	B-X
for	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
(	B-X
apparent	B-X
Km	B-X
,	B-X
300	B-X
nM	B-X
)	B-X
,	B-X
similar	B-X
to	B-X
that	B-X
reported	B-X
for	B-X
certain	B-X
tyrosylprotein	B-X
kinases	B-X
.	B-X
While	B-X
this	B-X
may	B-X
suggest	B-X
some	B-X
similarity	B-X
between	B-X
these	B-X
enzymes	B-X
,	B-X
the	B-X
Golgi	B-X
localization	B-X
of	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
segregates	B-X
tyrosine	B-X
sulfation	B-X
from	B-X
the	B-X
sites	B-X
of	B-X
tyrosine	B-X
phosphorylation	B-X
of	B-X
proteins	B-X
in	B-X
the	B-X
intact	B-X
cell	B-X
.	B-X
If	B-X
,	B-X
however	B-X
,	B-X
tyrosylprotein	B-X
sulfotransferase	B-X
was	B-X
allowed	B-X
to	B-X
react	B-X
with	B-X
cytoplasmic	B-X
proteins	B-X
by	B-X
using	B-X
a	B-X
nonionic	B-X
detergent	B-X
,	B-X
tyrosine	B-X
sulfation	B-X
of	B-X
tubulin	B-X
was	B-X
observed	B-X
.	B-X

Developmental	O
changes	O
in	O
the	O
modification	O
of	O
lysosomal	O
enzymes	O
in	O
Dictyostelium	O
discoideum	O
.	O
<EOS>	B-X
The	B-X
form	B-X
of	B-X
post-translational	B-X
modification	B-X
present	B-X
on	B-X
two	B-X
lysosomal	B-X
enzymes	B-X
--	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
--	B-X
changes	B-X
as	B-X
part	B-X
of	B-X
the	B-X
developmental	B-X
program	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
Prior	B-X
to	B-X
8	B-X
h	B-X
of	B-X
development	B-X
,	B-X
all	B-X
enzyme	B-X
molecules	B-X
are	B-X
of	B-X
a	B-X
single	B-X
modification	B-X
type	B-X
(	B-X
early	B-X
form	B-X
enzyme	B-X
)	B-X
.	B-X
Starting	B-X
at	B-X
8	B-X
h	B-X
of	B-X
development	B-X
,	B-X
enzyme	B-X
molecules	B-X
with	B-X
a	B-X
second	B-X
type	B-X
of	B-X
modification	B-X
(	B-X
late-form	B-X
enzymes	B-X
)	B-X
begin	B-X
to	B-X
appear	B-X
in	B-X
the	B-X
cell	B-X
.	B-X
We	B-X
separated	B-X
the	B-X
early	B-X
and	B-X
late	B-X
forms	B-X
of	B-X
these	B-X
enzymes	B-X
from	B-X
each	B-X
other	B-X
by	B-X
chromatography	B-X
on	B-X
DEAE-cellulose	B-X
.	B-X
We	B-X
found	B-X
that	B-X
the	B-X
change	B-X
in	B-X
protein	B-X
modification	B-X
affects	B-X
the	B-X
enzymes	B-X
'	B-X
in	B-X
vitro	B-X
properties	B-X
.	B-X
The	B-X
early	B-X
and	B-X
late	B-X
forms	B-X
of	B-X
both	B-X
of	B-X
these	B-X
enzymes	B-X
differ	B-X
in	B-X
thermostability	B-X
and	B-X
susceptibility	B-X
to	B-X
proteolytic	B-X
inactivation	B-X
.	B-X
We	B-X
suggest	B-X
that	B-X
by	B-X
synthesizing	B-X
molecules	B-X
with	B-X
a	B-X
second	B-X
form	B-X
of	B-X
modification	B-X
,	B-X
the	B-X
cell	B-X
confers	B-X
new	B-X
characteristics	B-X
to	B-X
its	B-X
lysosomal	B-X
enzymes	B-X
.	B-X

Evidence	O
has	O
been	O
found	O
for	O
a	O
generalized	O
change	O
in	O
the	O
post	O
-	O
translational	O
modification	O
of	O
lysosomal	O
enzymes	O
during	O
development	O
of	O
Dictyostelium	O
discoideum	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
Between	B-X
6	B-X
and	B-X
10	B-X
hr	B-X
of	B-X
development	B-X
,	B-X
all	B-X
activities	B-X
,	B-X
including	B-X
the	B-X
preformed	B-X
enzyme	B-X
,	B-X
become	B-X
less	B-X
negatively	B-X
charged	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
modest	B-X
but	B-X
reproducible	B-X
shift	B-X
in	B-X
the	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
All	B-X
of	B-X
the	B-X
enzymatic	B-X
activity	B-X
present	B-X
during	B-X
vegetative	B-X
growth	B-X
and	B-X
early	B-X
development	B-X
is	B-X
immunoprecipitable	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

The	O
physical	O
and	O
antigenic	O
properties	O
of	O
four	O
developmentally	O
regulated	O
lysosomal	O
enzymes	O
,	O
N	B-Protein
-	I-Protein
acetylglucosaminidase	I-Protein
,	O
beta	B-Protein
-	I-Protein
glucosidase	I-Protein
,	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
,	O
and	O
acid	B-Protein
phosphatase	I-Protein
,	O
have	O
been	O
examined	O
throughout	O
the	O
life	O
cycle	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X

In	O
vegetative	O
cells	O
,	O
a	O
single	O
major	O
isoelectric	O
species	O
is	O
detected	O
for	O
each	O
enzymatic	O
activity	O
on	O
native	O
nonequilibrium	O
isoelectric	O
focusing	O
gels	O
.	O

Between	O
6	O
and	O
10	O
hr	O
of	O
development	O
,	O
all	O
activities	O
,	O
including	O
the	O
preformed	O
enzyme	O
,	O
become	O
less	O
negatively	O
charged	O
,	O
resulting	O
in	O
a	O
modest	O
but	O
reproducible	O
shift	O
in	O
the	O
isoelectric	O
focusing	O
pattern	O
.	O

This	O
alteration	O
is	O
not	O
detected	O
by	O
native	O
gel	O
electrophoresis	O
at	O
constant	O
pH	O
.	O
<EOS>	B-X
Beyond	B-X
acute	B-X
effects	B-X
on	B-X
brain	B-X
functions	B-X
,	B-X
specific	B-X
protocols	B-X
are	B-X
suited	B-X
to	B-X
induce	B-X
long-lasting	B-X
alterations	B-X
of	B-X
cortical	B-X
excitability	B-X
and	B-X
activity	B-X
,	B-X
which	B-X
share	B-X
features	B-X
with	B-X
long-term	B-X
potentiation	B-X
and	B-X
depression	B-X
.	B-X
In	B-X
cancer	B-X
,	B-X
complex	B-X
genome	B-X
rearrangements	B-X
and	B-X
other	B-X
structural	B-X
alterations	B-X
,	B-X
including	B-X
the	B-X
amplification	B-X
of	B-X
oncogenes	B-X
on	B-X
circular	B-X
extrachromosomal	B-X
DNA	B-X
(	B-X
ecDNA	B-X
)	B-X
elements	B-X
,	B-X
drive	B-X
the	B-X
formation	B-X
and	B-X
progression	B-X
of	B-X
tumors	B-X
.	B-X
ecDNA	B-X
is	B-X
a	B-X
particularly	B-X
challenging	B-X
structural	B-X
alteration	B-X
.	B-X
Lipoxidation	B-X
is	B-X
a	B-X
well-known	B-X
reaction	B-X
between	B-X
electrophilic	B-X
carbonyl	B-X
species	B-X
,	B-X
formed	B-X
during	B-X
oxidation	B-X
of	B-X
lipids	B-X
,	B-X
and	B-X
specific	B-X
proteins	B-X
that	B-X
,	B-X
in	B-X
most	B-X
cases	B-X
,	B-X
causes	B-X
an	B-X
alteration	B-X
in	B-X
proteins	B-X
function	B-X
.	B-X
Lipoxidation	B-X
may	B-X
have	B-X
an	B-X
effect	B-X
in	B-X
cancer	B-X
development	B-X
through	B-X
their	B-X
effects	B-X
in	B-X
tumour	B-X
cells	B-X
,	B-X
as	B-X
well	B-X
as	B-X
through	B-X
the	B-X
alteration	B-X
of	B-X
immune	B-X
components	B-X
and	B-X
the	B-X
consequent	B-X
modulation	B-X
of	B-X
the	B-X
immune	B-X
response	B-X
.	B-X
Moreover	B-X
,	B-X
lipoxidation	B-X
adducts	B-X
may	B-X
alter	B-X
the	B-X
immune	B-X
response	B-X
,	B-X
consequently	B-X
causing	B-X
either	B-X
positive	B-X
or	B-X
negative	B-X
alterations	B-X
in	B-X
cancer	B-X
progression	B-X
.	B-X

As	O
development	O
continues	O
,	O
the	O
specific	O
activity	O
of	O
beta	B-Protein
-	I-Protein
glucosidase	I-Protein
,	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
,	O
and	O
acid	B-Protein
phosphatase	I-Protein
continues	O
to	O
increase	O
and	O
coincidentally	O
,	O
new	O
,	O
less	O
acidic	O
isozymic	O
bands	O
of	O
activity	O
can	O
be	O
observed	O
on	O
both	O
gel	O
systems	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
Between	B-X
6	B-X
and	B-X
10	B-X
hr	B-X
of	B-X
development	B-X
,	B-X
all	B-X
activities	B-X
,	B-X
including	B-X
the	B-X
preformed	B-X
enzyme	B-X
,	B-X
become	B-X
less	B-X
negatively	B-X
charged	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
modest	B-X
but	B-X
reproducible	B-X
shift	B-X
in	B-X
the	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
.	B-X
This	B-X
alteration	B-X
is	B-X
not	B-X
detected	B-X
by	B-X
native	B-X
gel	B-X
electrophoresis	B-X
at	B-X
constant	B-X
pH	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
All	B-X
of	B-X
the	B-X
enzymatic	B-X
activity	B-X
present	B-X
during	B-X
vegetative	B-X
growth	B-X
and	B-X
early	B-X
development	B-X
is	B-X
immunoprecipitable	B-X
.	B-X
However	B-X
,	B-X
the	B-X
less	B-X
negatively	B-X
charged	B-X
isozymes	B-X
that	B-X
accumulate	B-X
after	B-X
aggregation	B-X
are	B-X
not	B-X
recognized	B-X
by	B-X
the	B-X
antibody	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

Some	O
of	O
these	O
new	O
isozymes	O
accumulate	O
preferentially	O
in	O
anterior	O
cells	O
,	O
while	O
others	O
accumulate	O
preferentially	O
in	O
posterior	O
cells	O
of	O
migrating	O
slugs	O
.	O
<EOS>	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
However	B-X
,	B-X
the	B-X
less	B-X
negatively	B-X
charged	B-X
isozymes	B-X
that	B-X
accumulate	B-X
after	B-X
aggregation	B-X
are	B-X
not	B-X
recognized	B-X
by	B-X
the	B-X
antibody	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

N	B-Protein
-	I-Protein
Acetylglucosaminidase	I-Protein
does	O
not	O
increase	O
in	O
specific	O
activity	O
late	O
in	O
development	O
and	O
no	O
new	O
isozymic	O
species	O
appear	O
.	O
<EOS>	B-X
β-N-Acetylglucosaminidases	B-X
(	B-X
GlcNAcases	B-X
)	B-X
hydrolyse	B-X
N-acetylglucosamine-containing	B-X
oligosaccharides	B-X
and	B-X
proteins	B-X
.	B-X
These	B-X
enzymes	B-X
produce	B-X
N-acetylglucosamine	B-X
(	B-X
GlcNAc	B-X
)	B-X
and	B-X
have	B-X
a	B-X
wide	B-X
range	B-X
of	B-X
promising	B-X
applications	B-X
in	B-X
the	B-X
food	B-X
,	B-X
energy	B-X
,	B-X
and	B-X
pharmaceutical	B-X
industries	B-X
,	B-X
such	B-X
as	B-X
synergistic	B-X
degradation	B-X
of	B-X
chitin	B-X
with	B-X
endo-chitinases	B-X
and	B-X
using	B-X
GlcNAc	B-X
to	B-X
produce	B-X
sialic	B-X
acid	B-X
,	B-X
bioethanol	B-X
,	B-X
single-cell	B-X
proteins	B-X
,	B-X
and	B-X
pharmaceutical	B-X
therapeutics	B-X
.	B-X
GlcNAcases	B-X
also	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
the	B-X
dynamic	B-X
balance	B-X
of	B-X
cellular	B-X
O-linked	B-X
GlcNAc	B-X
levels	B-X
,	B-X
catabolism	B-X
of	B-X
ganglioside	B-X
storage	B-X
in	B-X
Tay-Sachs	B-X
disease	B-X
,	B-X
and	B-X
bacterial	B-X
cell	B-X
wall	B-X
recycling	B-X
and	B-X
flagellar	B-X
assembly	B-X
.	B-X
In	B-X
view	B-X
of	B-X
these	B-X
important	B-X
biological	B-X
functions	B-X
and	B-X
the	B-X
wide	B-X
range	B-X
of	B-X
industrial	B-X
applications	B-X
of	B-X
GlcNAcases	B-X
,	B-X
this	B-X
review	B-X
aims	B-X
to	B-X
provide	B-X
a	B-X
better	B-X
understanding	B-X
of	B-X
various	B-X
advances	B-X
for	B-X
these	B-X
enzymes	B-X
.	B-X
It	B-X
focuses	B-X
on	B-X
enzymatic	B-X
properties	B-X
of	B-X
GlcNAcases	B-X
,	B-X
including	B-X
substrate	B-X
specificity	B-X
,	B-X
catalytic	B-X
activity	B-X
,	B-X
pH	B-X
optimum	B-X
,	B-X
temperature	B-X
optimum	B-X
,	B-X
thermostability	B-X
,	B-X
the	B-X
effects	B-X
of	B-X
various	B-X
metal	B-X
ions	B-X
and	B-X
organic	B-X
reagents	B-X
,	B-X
and	B-X
transglycosylation	B-X
.	B-X

Using	O
a	O
monoclonal	O
antibody	O
that	O
reacts	O
with	O
sulfated	O
N	O
-	O
linked	O
oligosaccharides	O
shared	O
by	O
vegetative	O
lysosomal	O
enzymes	O
in	O
D	O
.	O
discoideum	O
,	O
the	O
antigenicity	O
of	O
the	O
developmental	O
isozymes	O
has	O
been	O
characterized	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
present	O
during	O
vegetative	O
growth	O
and	O
early	O
development	O
is	O
immunoprecipitable	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
Between	B-X
6	B-X
and	B-X
10	B-X
hr	B-X
of	B-X
development	B-X
,	B-X
all	B-X
activities	B-X
,	B-X
including	B-X
the	B-X
preformed	B-X
enzyme	B-X
,	B-X
become	B-X
less	B-X
negatively	B-X
charged	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
modest	B-X
but	B-X
reproducible	B-X
shift	B-X
in	B-X
the	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
All	B-X
of	B-X
the	B-X
enzymatic	B-X
activity	B-X
present	B-X
during	B-X
vegetative	B-X
growth	B-X
and	B-X
early	B-X
development	B-X
is	B-X
immunoprecipitable	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X

However	O
,	O
the	O
less	O
negatively	O
charged	O
isozymes	O
that	O
accumulate	O
after	O
aggregation	O
are	O
not	O
recognized	O
by	O
the	O
antibody	O
.	O

Nonantigenic	O
acid	O
phosphatase	O
and	O
alpha	B-Protein
-	I-Protein
mannosidase	I-Protein
are	O
found	O
in	O
both	O
anterior	O
and	O
posterior	O
cells	O
from	O
migrating	O
pseudoplasmodia	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

Since	O
each	O
enzyme	O
is	O
coded	O
by	O
a	O
single	O
structural	O
gene	O
,	O
these	O
results	O
suggest	O
that	O
the	O
isozymes	O
present	O
late	O
in	O
development	O
arise	O
from	O
the	O
synthesis	O
of	O
the	O
same	O
polypeptides	O
with	O
altered	O
post	O
-	O
translational	O
modifications	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
The	B-X
physical	B-X
and	B-X
antigenic	B-X
properties	B-X
of	B-X
four	B-X
developmentally	B-X
regulated	B-X
lysosomal	B-X
enzymes	B-X
,	B-X
N-acetylglucosaminidase	B-X
,	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
,	B-X
have	B-X
been	B-X
examined	B-X
throughout	B-X
the	B-X
life	B-X
cycle	B-X
.	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
Between	B-X
6	B-X
and	B-X
10	B-X
hr	B-X
of	B-X
development	B-X
,	B-X
all	B-X
activities	B-X
,	B-X
including	B-X
the	B-X
preformed	B-X
enzyme	B-X
,	B-X
become	B-X
less	B-X
negatively	B-X
charged	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
modest	B-X
but	B-X
reproducible	B-X
shift	B-X
in	B-X
the	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
All	B-X
of	B-X
the	B-X
enzymatic	B-X
activity	B-X
present	B-X
during	B-X
vegetative	B-X
growth	B-X
and	B-X
early	B-X
development	B-X
is	B-X
immunoprecipitable	B-X
.	B-X
However	B-X
,	B-X
the	B-X
less	B-X
negatively	B-X
charged	B-X
isozymes	B-X
that	B-X
accumulate	B-X
after	B-X
aggregation	B-X
are	B-X
not	B-X
recognized	B-X
by	B-X
the	B-X
antibody	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

The	O
appearance	O
of	O
anterior	O
and	O
posterior	O
specific	O
isozymes	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
cell	O
type	O
specific	O
changes	O
in	O
the	O
glycoprotein	O
modification	O
pathway	O
for	O
newly	O
synthesized	O
proteins	O
.	O
<EOS>	B-X
Evidence	B-X
has	B-X
been	B-X
found	B-X
for	B-X
a	B-X
generalized	B-X
change	B-X
in	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
lysosomal	B-X
enzymes	B-X
during	B-X
development	B-X
of	B-X
Dictyostelium	B-X
discoideum	B-X
.	B-X
In	B-X
vegetative	B-X
cells	B-X
,	B-X
a	B-X
single	B-X
major	B-X
isoelectric	B-X
species	B-X
is	B-X
detected	B-X
for	B-X
each	B-X
enzymatic	B-X
activity	B-X
on	B-X
native	B-X
nonequilibrium	B-X
isoelectric	B-X
focusing	B-X
gels	B-X
.	B-X
Between	B-X
6	B-X
and	B-X
10	B-X
hr	B-X
of	B-X
development	B-X
,	B-X
all	B-X
activities	B-X
,	B-X
including	B-X
the	B-X
preformed	B-X
enzyme	B-X
,	B-X
become	B-X
less	B-X
negatively	B-X
charged	B-X
,	B-X
resulting	B-X
in	B-X
a	B-X
modest	B-X
but	B-X
reproducible	B-X
shift	B-X
in	B-X
the	B-X
isoelectric	B-X
focusing	B-X
pattern	B-X
.	B-X
As	B-X
development	B-X
continues	B-X
,	B-X
the	B-X
specific	B-X
activity	B-X
of	B-X
beta-glucosidase	B-X
,	B-X
alpha-mannosidase	B-X
,	B-X
and	B-X
acid	B-X
phosphatase	B-X
continues	B-X
to	B-X
increase	B-X
and	B-X
coincidentally	B-X
,	B-X
new	B-X
,	B-X
less	B-X
acidic	B-X
isozymic	B-X
bands	B-X
of	B-X
activity	B-X
can	B-X
be	B-X
observed	B-X
on	B-X
both	B-X
gel	B-X
systems	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
new	B-X
isozymes	B-X
accumulate	B-X
preferentially	B-X
in	B-X
anterior	B-X
cells	B-X
,	B-X
while	B-X
others	B-X
accumulate	B-X
preferentially	B-X
in	B-X
posterior	B-X
cells	B-X
of	B-X
migrating	B-X
slugs	B-X
.	B-X
N-Acetylglucosaminidase	B-X
does	B-X
not	B-X
increase	B-X
in	B-X
specific	B-X
activity	B-X
late	B-X
in	B-X
development	B-X
and	B-X
no	B-X
new	B-X
isozymic	B-X
species	B-X
appear	B-X
.	B-X
Using	B-X
a	B-X
monoclonal	B-X
antibody	B-X
that	B-X
reacts	B-X
with	B-X
sulfated	B-X
N-linked	B-X
oligosaccharides	B-X
shared	B-X
by	B-X
vegetative	B-X
lysosomal	B-X
enzymes	B-X
in	B-X
D.	B-X
discoideum	B-X
,	B-X
the	B-X
antigenicity	B-X
of	B-X
the	B-X
developmental	B-X
isozymes	B-X
has	B-X
been	B-X
characterized	B-X
.	B-X
However	B-X
,	B-X
the	B-X
less	B-X
negatively	B-X
charged	B-X
isozymes	B-X
that	B-X
accumulate	B-X
after	B-X
aggregation	B-X
are	B-X
not	B-X
recognized	B-X
by	B-X
the	B-X
antibody	B-X
.	B-X
Nonantigenic	B-X
acid	B-X
phosphatase	B-X
and	B-X
alpha-mannosidase	B-X
are	B-X
found	B-X
in	B-X
both	B-X
anterior	B-X
and	B-X
posterior	B-X
cells	B-X
from	B-X
migrating	B-X
pseudoplasmodia	B-X
.	B-X
Since	B-X
each	B-X
enzyme	B-X
is	B-X
coded	B-X
by	B-X
a	B-X
single	B-X
structural	B-X
gene	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
isozymes	B-X
present	B-X
late	B-X
in	B-X
development	B-X
arise	B-X
from	B-X
the	B-X
synthesis	B-X
of	B-X
the	B-X
same	B-X
polypeptides	B-X
with	B-X
altered	B-X
post-translational	B-X
modifications	B-X
.	B-X
The	B-X
appearance	B-X
of	B-X
anterior	B-X
and	B-X
posterior	B-X
specific	B-X
isozymes	B-X
is	B-X
likely	B-X
to	B-X
be	B-X
the	B-X
result	B-X
of	B-X
cell	B-X
type	B-X
specific	B-X
changes	B-X
in	B-X
the	B-X
glycoprotein	B-X
modification	B-X
pathway	B-X
for	B-X
newly	B-X
synthesized	B-X
proteins	B-X
.	B-X

Sulfation	O
of	O
lutropin	O
oligosaccharides	O
with	O
a	O
cell	O
-	O
free	O
system	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
To	B-X
characterize	B-X
this	B-X
post-translational	B-X
modification	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
reconstituted	B-X
cell-free	B-X
sulfation	B-X
system	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
Thus	B-X
the	B-X
cell-free	B-X
sulfation	B-X
system	B-X
accurately	B-X
duplicates	B-X
the	B-X
in	B-X
vivo	B-X
process	B-X
.	B-X

Sulfate	O
is	O
covalently	O
linked	O
to	O
the	O
oligosaccharides	O
on	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
bovine	O
lutropin	O
(	O
luteinizing	O
hormone	O
;	O
LH	O
)	O
but	O
not	O
to	O
those	O
on	O
human	O
chorionic	O
gonadotropin	O
(	O
hCG	O
)	O
.	O

Since	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
pituitary	O
and	O
placental	O
alpha	O
subunits	O
are	O
homologous	O
,	O
comparison	O
of	O
their	O
asparagine	O
-	O
linked	O
sugars	O
can	O
provide	O
information	O
regarding	O
tissue	O
specificity	O
of	O
oligosaccharide	O
maturation	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
Since	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
the	B-X
pituitary	B-X
and	B-X
placental	B-X
alpha	B-X
subunits	B-X
are	B-X
homologous	B-X
,	B-X
comparison	B-X
of	B-X
their	B-X
asparagine-linked	B-X
sugars	B-X
can	B-X
provide	B-X
information	B-X
regarding	B-X
tissue	B-X
specificity	B-X
of	B-X
oligosaccharide	B-X
maturation	B-X
.	B-X
LH	B-X
is	B-X
sulfated	B-X
by	B-X
pituitary	B-X
and	B-X
liver	B-X
membranes	B-X
but	B-X
not	B-X
by	B-X
those	B-X
from	B-X
placenta	B-X
.	B-X
Desialylated	B-X
hCG	B-X
(	B-X
AshCG	B-X
)	B-X
is	B-X
sulfated	B-X
by	B-X
membranes	B-X
from	B-X
placenta	B-X
and	B-X
pituitary	B-X
,	B-X
but	B-X
not	B-X
liver	B-X
,	B-X
while	B-X
hCG	B-X
is	B-X
not	B-X
sulfated	B-X
by	B-X
any	B-X
of	B-X
these	B-X
membranes	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
sulfate	B-X
added	B-X
to	B-X
AshCG	B-X
is	B-X
apparently	B-X
attached	B-X
to	B-X
peptide	B-X
rather	B-X
than	B-X
oligosaccharide	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X

To	O
characterize	O
this	O
post	O
-	O
translational	O
modification	O
,	O
we	O
have	O
developed	O
a	O
reconstituted	O
cell	O
-	O
free	O
sulfation	O
system	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
this	B-X
post-translational	B-X
modification	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
reconstituted	B-X
cell-free	B-X
sulfation	B-X
system	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
Thus	B-X
the	B-X
cell-free	B-X
sulfation	B-X
system	B-X
accurately	B-X
duplicates	B-X
the	B-X
in	B-X
vivo	B-X
process	B-X
.	B-X

Sulfate	O
is	O
incorporated	O
into	O
exogenously	O
added	O
glycoproteins	O
by	O
sulfotransferases	O
from	O
Triton	O
X	O
-	O
100	O
-	O
lysed	O
Golgi	O
membranes	O
in	O
the	O
presence	O
of	O
3	O
'	O
-	O
phosphoadenosine	O
5	O
'	O
-	O
phospho	O
[	O
35S	O
]	O
sulfate	O
,	O
which	O
is	O
generated	O
from	O
[	O
35S	O
]	O
sulfate	O
by	O
a	O
ribosome	O
-	O
free	O
supernate	O
from	O
Krebs	O
ascites	O
tumor	O
cells	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
To	B-X
characterize	B-X
this	B-X
post-translational	B-X
modification	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
reconstituted	B-X
cell-free	B-X
sulfation	B-X
system	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
LH	B-X
is	B-X
sulfated	B-X
by	B-X
pituitary	B-X
and	B-X
liver	B-X
membranes	B-X
but	B-X
not	B-X
by	B-X
those	B-X
from	B-X
placenta	B-X
.	B-X
Desialylated	B-X
hCG	B-X
(	B-X
AshCG	B-X
)	B-X
is	B-X
sulfated	B-X
by	B-X
membranes	B-X
from	B-X
placenta	B-X
and	B-X
pituitary	B-X
,	B-X
but	B-X
not	B-X
liver	B-X
,	B-X
while	B-X
hCG	B-X
is	B-X
not	B-X
sulfated	B-X
by	B-X
any	B-X
of	B-X
these	B-X
membranes	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
sulfate	B-X
added	B-X
to	B-X
AshCG	B-X
is	B-X
apparently	B-X
attached	B-X
to	B-X
peptide	B-X
rather	B-X
than	B-X
oligosaccharide	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
Thus	B-X
the	B-X
cell-free	B-X
sulfation	B-X
system	B-X
accurately	B-X
duplicates	B-X
the	B-X
in	B-X
vivo	B-X
process	B-X
.	B-X

LH	O
is	O
sulfated	O
by	O
pituitary	O
and	O
liver	O
membranes	O
but	O
not	O
by	O
those	O
from	O
placenta	O
.	O

Desialylated	O
hCG	O
(	O
AshCG	O
)	O
is	O
sulfated	O
by	O
membranes	O
from	O
placenta	O
and	O
pituitary	O
,	O
but	O
not	O
liver	O
,	O
while	O
hCG	O
is	O
not	O
sulfated	O
by	O
any	O
of	O
these	O
membranes	O
.	O

Endoglycosidase	O
F	O
releases	O
all	O
the	O
incorporated	O
sulfate	O
from	O
LH	O
in	O
the	O
form	O
of	O
a	O
heterogeneous	O
mixture	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
Since	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
the	B-X
pituitary	B-X
and	B-X
placental	B-X
alpha	B-X
subunits	B-X
are	B-X
homologous	B-X
,	B-X
comparison	B-X
of	B-X
their	B-X
asparagine-linked	B-X
sugars	B-X
can	B-X
provide	B-X
information	B-X
regarding	B-X
tissue	B-X
specificity	B-X
of	B-X
oligosaccharide	B-X
maturation	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
LH	B-X
is	B-X
sulfated	B-X
by	B-X
pituitary	B-X
and	B-X
liver	B-X
membranes	B-X
but	B-X
not	B-X
by	B-X
those	B-X
from	B-X
placenta	B-X
.	B-X
Desialylated	B-X
hCG	B-X
(	B-X
AshCG	B-X
)	B-X
is	B-X
sulfated	B-X
by	B-X
membranes	B-X
from	B-X
placenta	B-X
and	B-X
pituitary	B-X
,	B-X
but	B-X
not	B-X
liver	B-X
,	B-X
while	B-X
hCG	B-X
is	B-X
not	B-X
sulfated	B-X
by	B-X
any	B-X
of	B-X
these	B-X
membranes	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
sulfate	B-X
added	B-X
to	B-X
AshCG	B-X
is	B-X
apparently	B-X
attached	B-X
to	B-X
peptide	B-X
rather	B-X
than	B-X
oligosaccharide	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X

In	O
contrast	O
,	O
the	O
sulfate	O
added	O
to	O
AshCG	O
is	O
apparently	O
attached	O
to	O
peptide	O
rather	O
than	O
oligosaccharide	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
Since	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
the	B-X
pituitary	B-X
and	B-X
placental	B-X
alpha	B-X
subunits	B-X
are	B-X
homologous	B-X
,	B-X
comparison	B-X
of	B-X
their	B-X
asparagine-linked	B-X
sugars	B-X
can	B-X
provide	B-X
information	B-X
regarding	B-X
tissue	B-X
specificity	B-X
of	B-X
oligosaccharide	B-X
maturation	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
LH	B-X
is	B-X
sulfated	B-X
by	B-X
pituitary	B-X
and	B-X
liver	B-X
membranes	B-X
but	B-X
not	B-X
by	B-X
those	B-X
from	B-X
placenta	B-X
.	B-X
Desialylated	B-X
hCG	B-X
(	B-X
AshCG	B-X
)	B-X
is	B-X
sulfated	B-X
by	B-X
membranes	B-X
from	B-X
placenta	B-X
and	B-X
pituitary	B-X
,	B-X
but	B-X
not	B-X
liver	B-X
,	B-X
while	B-X
hCG	B-X
is	B-X
not	B-X
sulfated	B-X
by	B-X
any	B-X
of	B-X
these	B-X
membranes	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
sulfate	B-X
added	B-X
to	B-X
AshCG	B-X
is	B-X
apparently	B-X
attached	B-X
to	B-X
peptide	B-X
rather	B-X
than	B-X
oligosaccharide	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X

As	O
found	O
with	O
the	O
cell	O
-	O
free	O
system	O
,	O
sulfate	O
metabolically	O
incorporated	O
into	O
LH	O
by	O
pituitary	O
cells	O
is	O
present	O
on	O
a	O
heterogeneous	O
population	O
of	O
mono	O
-	O
and	O
disulfated	O
oligosaccharides	O
.	O
<EOS>	B-X
Sulfate	B-X
is	B-X
covalently	B-X
linked	B-X
to	B-X
the	B-X
oligosaccharides	B-X
on	B-X
the	B-X
alpha	B-X
and	B-X
beta	B-X
subunits	B-X
of	B-X
bovine	B-X
lutropin	B-X
(	B-X
luteinizing	B-X
hormone	B-X
;	B-X
LH	B-X
)	B-X
but	B-X
not	B-X
to	B-X
those	B-X
on	B-X
human	B-X
chorionic	B-X
gonadotropin	B-X
(	B-X
hCG	B-X
)	B-X
.	B-X
Since	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
the	B-X
pituitary	B-X
and	B-X
placental	B-X
alpha	B-X
subunits	B-X
are	B-X
homologous	B-X
,	B-X
comparison	B-X
of	B-X
their	B-X
asparagine-linked	B-X
sugars	B-X
can	B-X
provide	B-X
information	B-X
regarding	B-X
tissue	B-X
specificity	B-X
of	B-X
oligosaccharide	B-X
maturation	B-X
.	B-X
To	B-X
characterize	B-X
this	B-X
post-translational	B-X
modification	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
reconstituted	B-X
cell-free	B-X
sulfation	B-X
system	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
LH	B-X
is	B-X
sulfated	B-X
by	B-X
pituitary	B-X
and	B-X
liver	B-X
membranes	B-X
but	B-X
not	B-X
by	B-X
those	B-X
from	B-X
placenta	B-X
.	B-X
Desialylated	B-X
hCG	B-X
(	B-X
AshCG	B-X
)	B-X
is	B-X
sulfated	B-X
by	B-X
membranes	B-X
from	B-X
placenta	B-X
and	B-X
pituitary	B-X
,	B-X
but	B-X
not	B-X
liver	B-X
,	B-X
while	B-X
hCG	B-X
is	B-X
not	B-X
sulfated	B-X
by	B-X
any	B-X
of	B-X
these	B-X
membranes	B-X
.	B-X
Endoglycosidase	B-X
F	B-X
releases	B-X
all	B-X
the	B-X
incorporated	B-X
sulfate	B-X
from	B-X
LH	B-X
in	B-X
the	B-X
form	B-X
of	B-X
a	B-X
heterogeneous	B-X
mixture	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
sulfate	B-X
added	B-X
to	B-X
AshCG	B-X
is	B-X
apparently	B-X
attached	B-X
to	B-X
peptide	B-X
rather	B-X
than	B-X
oligosaccharide	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
Thus	B-X
the	B-X
cell-free	B-X
sulfation	B-X
system	B-X
accurately	B-X
duplicates	B-X
the	B-X
in	B-X
vivo	B-X
process	B-X
.	B-X

Thus	O
the	O
cell	O
-	O
free	O
sulfation	O
system	O
accurately	O
duplicates	O
the	O
in	O
vivo	O
process	O
.	O
<EOS>	B-X
To	B-X
characterize	B-X
this	B-X
post-translational	B-X
modification	B-X
,	B-X
we	B-X
have	B-X
developed	B-X
a	B-X
reconstituted	B-X
cell-free	B-X
sulfation	B-X
system	B-X
.	B-X
Sulfate	B-X
is	B-X
incorporated	B-X
into	B-X
exogenously	B-X
added	B-X
glycoproteins	B-X
by	B-X
sulfotransferases	B-X
from	B-X
Triton	B-X
X-100-lysed	B-X
Golgi	B-X
membranes	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
3'-phosphoadenosine	B-X
5'-phospho	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
,	B-X
which	B-X
is	B-X
generated	B-X
from	B-X
[	B-X
35S	B-X
]	B-X
sulfate	B-X
by	B-X
a	B-X
ribosome-free	B-X
supernate	B-X
from	B-X
Krebs	B-X
ascites	B-X
tumor	B-X
cells	B-X
.	B-X
As	B-X
found	B-X
with	B-X
the	B-X
cell-free	B-X
system	B-X
,	B-X
sulfate	B-X
metabolically	B-X
incorporated	B-X
into	B-X
LH	B-X
by	B-X
pituitary	B-X
cells	B-X
is	B-X
present	B-X
on	B-X
a	B-X
heterogeneous	B-X
population	B-X
of	B-X
mono-	B-X
and	B-X
disulfated	B-X
oligosaccharides	B-X
.	B-X
Thus	B-X
the	B-X
cell-free	B-X
sulfation	B-X
system	B-X
accurately	B-X
duplicates	B-X
the	B-X
in	B-X
vivo	B-X
process	B-X
.	B-X

In	O
vivo	O
participation	O
of	O
a	O
high	O
potential	O
iron	O
-	O
sulfur	O
protein	O
as	O
electron	O
donor	O
to	O
the	O
photochemical	O
reaction	O
center	O
of	O
Rubrivivax	O
gelatinosus	O
.	O

We	O
have	O
found	O
that	O
the	O
only	O
high	O
redox	O
potential	O
electron	O
transfer	O
component	O
in	O
the	O
soluble	O
fraction	O
of	O
Rubrivivax	O
gelatinosus	O
TG	O
-	O
9	O
is	O
a	O
high	B-Protein
-	I-Protein
potential	I-Protein
iron	I-Protein
-	I-Protein
sulfur	I-Protein
protein	I-Protein
(	O
HiPIP	B-Protein
)	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
HiPIP	B-X
in	B-X
the	B-X
photoinduced	B-X
electron	B-X
transfer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
photooxidation	B-X
of	B-X
HiPIP	B-X
was	B-X
observed	B-X
in	B-X
intact	B-X
cells	B-X
of	B-X
Ru	B-X
.	B-X
gelatinosus	B-X
TG-9	B-X
under	B-X
anaerobic	B-X
conditions	B-X
by	B-X
EPR	B-X
and	B-X
absorption	B-X
spectroscopies	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X
The	B-X
turnover	B-X
of	B-X
a	B-X
cyt	B-X
bc1	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
slow	B-X
electrogenic	B-X
phase	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
linked	B-X
to	B-X
this	B-X
process	B-X
.	B-X

We	O
demonstrated	O
the	O
participation	O
of	O
this	O
HiPIP	B-Protein
in	O
the	O
photoinduced	O
electron	O
transfer	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
HiPIP	B-X
in	B-X
the	B-X
photoinduced	B-X
electron	B-X
transfer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
photooxidation	B-X
of	B-X
HiPIP	B-X
was	B-X
observed	B-X
in	B-X
intact	B-X
cells	B-X
of	B-X
Ru	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X

First	O
,	O
the	O
addition	O
of	O
HiPIP	B-Protein
to	O
purified	O
membranes	O
enhanced	O
the	O
rate	O
of	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
HiPIP	B-X
in	B-X
the	B-X
photoinduced	B-X
electron	B-X
transfer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
photooxidation	B-X
of	B-X
HiPIP	B-X
was	B-X
observed	B-X
in	B-X
intact	B-X
cells	B-X
of	B-X
Ru	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X
The	B-X
complete	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
is	B-X
achieved	B-X
in	B-X
tens	B-X
of	B-X
milliseconds	B-X
.	B-X
The	B-X
turnover	B-X
of	B-X
a	B-X
cyt	B-X
bc1	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
slow	B-X
electrogenic	B-X
phase	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
linked	B-X
to	B-X
this	B-X
process	B-X
.	B-X

Second	O
,	O
the	O
photooxidation	O
of	O
HiPIP	B-Protein
was	O
observed	O
in	O
intact	O
cells	O
of	O
Ru	O
.	O
gelatinosus	O
TG	O
-	O
9	O
under	O
anaerobic	O
conditions	O
by	O
EPR	O
and	O
absorption	O
spectroscopies	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
HiPIP	B-X
in	B-X
the	B-X
photoinduced	B-X
electron	B-X
transfer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
photooxidation	B-X
of	B-X
HiPIP	B-X
was	B-X
observed	B-X
in	B-X
intact	B-X
cells	B-X
of	B-X
Ru	B-X
.	B-X
gelatinosus	B-X
TG-9	B-X
under	B-X
anaerobic	B-X
conditions	B-X
by	B-X
EPR	B-X
and	B-X
absorption	B-X
spectroscopies	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X

Analysis	O
of	O
flash	O
-	O
induced	O
absorption	O
changes	O
showed	O
that	O
the	O
equilibration	O
of	O
positive	O
equivalents	O
between	O
the	O
reaction	O
center	O
and	O
HiPIP	B-Protein
occurs	O
in	O
less	O
than	O
1	O
ms	O
after	O
flash	O
excitation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
We	B-X
demonstrated	B-X
the	B-X
participation	B-X
of	B-X
this	B-X
HiPIP	B-X
in	B-X
the	B-X
photoinduced	B-X
electron	B-X
transfer	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Second	B-X
,	B-X
the	B-X
photooxidation	B-X
of	B-X
HiPIP	B-X
was	B-X
observed	B-X
in	B-X
intact	B-X
cells	B-X
of	B-X
Ru	B-X
.	B-X
gelatinosus	B-X
TG-9	B-X
under	B-X
anaerobic	B-X
conditions	B-X
by	B-X
EPR	B-X
and	B-X
absorption	B-X
spectroscopies	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X
The	B-X
complete	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
is	B-X
achieved	B-X
in	B-X
tens	B-X
of	B-X
milliseconds	B-X
.	B-X
The	B-X
turnover	B-X
of	B-X
a	B-X
cyt	B-X
bc1	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
slow	B-X
electrogenic	B-X
phase	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
linked	B-X
to	B-X
this	B-X
process	B-X
.	B-X

The	O
complete	O
re	O
-	O
reduction	O
of	O
the	O
photooxidized	O
reaction	O
center	O
is	O
achieved	O
in	O
tens	O
of	O
milliseconds	O
.	O
<EOS>	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X
The	B-X
complete	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
is	B-X
achieved	B-X
in	B-X
tens	B-X
of	B-X
milliseconds	B-X
.	B-X
The	B-X
turnover	B-X
of	B-X
a	B-X
cyt	B-X
bc1	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
slow	B-X
electrogenic	B-X
phase	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
linked	B-X
to	B-X
this	B-X
process	B-X
.	B-X

The	O
turnover	O
of	O
a	O
cyt	O
bc1	O
is	O
also	O
involved	O
in	O
this	O
reaction	O
,	O
as	O
shown	O
by	O
a	O
slow	O
electrogenic	O
phase	O
of	O
the	O
membrane	O
potential	O
linked	O
to	O
this	O
process	O
.	O
<EOS>	B-X
We	B-X
have	B-X
found	B-X
that	B-X
the	B-X
only	B-X
high	B-X
redox	B-X
potential	B-X
electron	B-X
transfer	B-X
component	B-X
in	B-X
the	B-X
soluble	B-X
fraction	B-X
of	B-X
Rubrivivax	B-X
gelatinosus	B-X
TG-9	B-X
is	B-X
a	B-X
high-potential	B-X
iron-sulfur	B-X
protein	B-X
(	B-X
HiPIP	B-X
)	B-X
.	B-X
First	B-X
,	B-X
the	B-X
addition	B-X
of	B-X
HiPIP	B-X
to	B-X
purified	B-X
membranes	B-X
enhanced	B-X
the	B-X
rate	B-X
of	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
.	B-X
Analysis	B-X
of	B-X
flash-induced	B-X
absorption	B-X
changes	B-X
showed	B-X
that	B-X
the	B-X
equilibration	B-X
of	B-X
positive	B-X
equivalents	B-X
between	B-X
the	B-X
reaction	B-X
center	B-X
and	B-X
HiPIP	B-X
occurs	B-X
in	B-X
less	B-X
than	B-X
1	B-X
ms	B-X
after	B-X
flash	B-X
excitation	B-X
.	B-X
The	B-X
complete	B-X
re-reduction	B-X
of	B-X
the	B-X
photooxidized	B-X
reaction	B-X
center	B-X
is	B-X
achieved	B-X
in	B-X
tens	B-X
of	B-X
milliseconds	B-X
.	B-X
The	B-X
turnover	B-X
of	B-X
a	B-X
cyt	B-X
bc1	B-X
is	B-X
also	B-X
involved	B-X
in	B-X
this	B-X
reaction	B-X
,	B-X
as	B-X
shown	B-X
by	B-X
a	B-X
slow	B-X
electrogenic	B-X
phase	B-X
of	B-X
the	B-X
membrane	B-X
potential	B-X
linked	B-X
to	B-X
this	B-X
process	B-X
.	B-X

Quantitation	O
of	O
procholecystokinin	B-Protein
and	O
its	O
products	O
in	O
plasma	O
by	O
processing	O
-	O
independent	O
analysis	O
.	O
<EOS>	B-X
A	B-X
procedure	B-X
for	B-X
processing-independent	B-X
quantitation	B-X
of	B-X
procholecystokinin	B-X
(	B-X
proCCK	B-X
)	B-X
and	B-X
its	B-X
products	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
plasma	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
tryptic	B-X
cleavage	B-X
after	B-X
Lys61	B-X
and	B-X
Arg71	B-X
with	B-X
subsequent	B-X
monospecific	B-X
radioimmuno-analysis	B-X
of	B-X
fragment	B-X
62-71	B-X
of	B-X
human	B-X
proCCK	B-X
,	B-X
which	B-X
again	B-X
corresponds	B-X
to	B-X
fragment	B-X
1-10	B-X
of	B-X
CCK-22	B-X
.	B-X
The	B-X
detection	B-X
limit	B-X
of	B-X
the	B-X
analysis	B-X
was	B-X
0.2	B-X
pmol/l	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
13	B-X
healthy	B-X
volunteers	B-X
the	B-X
basal	B-X
concentration	B-X
with	B-X
the	B-X
above-mentioned	B-X
radioimmunoassay	B-X
was	B-X
1.1	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
(	B-X
mean	B-X
+/-	B-X
S.E.M	B-X
.	B-X
)	B-X
Two	B-X
hours	B-X
after	B-X
ingestion	B-X
of	B-X
a	B-X
mixed	B-X
meal	B-X
,	B-X
the	B-X
plasma	B-X
concentration	B-X
was	B-X
2.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
before	B-X
,	B-X
and	B-X
21.7	B-X
+/-	B-X
1.2	B-X
pmol/l	B-X
after	B-X
tryptic	B-X
cleavage	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
37	B-X
patients	B-X
with	B-X
the	B-X
carcinoid	B-X
syndrome	B-X
,	B-X
the	B-X
basal	B-X
concentration	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
was	B-X
14.1	B-X
(	B-X
2.8-150.4	B-X
)	B-X
pmol/l	B-X
(	B-X
median	B-X
(	B-X
range	B-X
)	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
0.3	B-X
(	B-X
0-18.8	B-X
)	B-X
pmol/l	B-X
for	B-X
carboxyamidated	B-X
CCK	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
processing-independent	B-X
analysis	B-X
is	B-X
useful	B-X
for	B-X
quantitation	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
in	B-X
plasma	B-X
,	B-X
since	B-X
it	B-X
quantitates	B-X
CCK	B-X
cell	B-X
secretion	B-X
more	B-X
accurately	B-X
than	B-X
conventional	B-X
CCK	B-X
assays	B-X
.	B-X

A	O
procedure	O
for	O
processing	O
-	O
independent	O
quantitation	O
of	O
procholecystokinin	B-Protein
(	O
proCCK	B-Protein
)	O
and	O
its	O
products	O
has	O
been	O
applied	O
to	O
plasma	O
.	O
<EOS>	B-X
A	B-X
procedure	B-X
for	B-X
processing-independent	B-X
quantitation	B-X
of	B-X
procholecystokinin	B-X
(	B-X
proCCK	B-X
)	B-X
and	B-X
its	B-X
products	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
plasma	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
tryptic	B-X
cleavage	B-X
after	B-X
Lys61	B-X
and	B-X
Arg71	B-X
with	B-X
subsequent	B-X
monospecific	B-X
radioimmuno-analysis	B-X
of	B-X
fragment	B-X
62-71	B-X
of	B-X
human	B-X
proCCK	B-X
,	B-X
which	B-X
again	B-X
corresponds	B-X
to	B-X
fragment	B-X
1-10	B-X
of	B-X
CCK-22	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
13	B-X
healthy	B-X
volunteers	B-X
the	B-X
basal	B-X
concentration	B-X
with	B-X
the	B-X
above-mentioned	B-X
radioimmunoassay	B-X
was	B-X
1.1	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
(	B-X
mean	B-X
+/-	B-X
S.E.M	B-X
.	B-X
)	B-X
Two	B-X
hours	B-X
after	B-X
ingestion	B-X
of	B-X
a	B-X
mixed	B-X
meal	B-X
,	B-X
the	B-X
plasma	B-X
concentration	B-X
was	B-X
2.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
before	B-X
,	B-X
and	B-X
21.7	B-X
+/-	B-X
1.2	B-X
pmol/l	B-X
after	B-X
tryptic	B-X
cleavage	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
37	B-X
patients	B-X
with	B-X
the	B-X
carcinoid	B-X
syndrome	B-X
,	B-X
the	B-X
basal	B-X
concentration	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
was	B-X
14.1	B-X
(	B-X
2.8-150.4	B-X
)	B-X
pmol/l	B-X
(	B-X
median	B-X
(	B-X
range	B-X
)	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
0.3	B-X
(	B-X
0-18.8	B-X
)	B-X
pmol/l	B-X
for	B-X
carboxyamidated	B-X
CCK	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
processing-independent	B-X
analysis	B-X
is	B-X
useful	B-X
for	B-X
quantitation	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
in	B-X
plasma	B-X
,	B-X
since	B-X
it	B-X
quantitates	B-X
CCK	B-X
cell	B-X
secretion	B-X
more	B-X
accurately	B-X
than	B-X
conventional	B-X
CCK	B-X
assays	B-X
.	B-X

The	O
procedure	O
is	O
based	O
on	O
tryptic	O
cleavage	O
after	O
Lys61	O
and	O
Arg71	O
with	O
subsequent	O
monospecific	O
radioimmuno	O
-	O
analysis	O
of	O
fragment	O
62	O
-	O
71	O
of	O
human	O
proCCK	B-Protein
,	O
which	O
again	O
corresponds	O
to	O
fragment	O
1	O
-	O
10	O
of	O
CCK	B-Protein
-	O
22	O
.	O
<EOS>	B-X
A	B-X
procedure	B-X
for	B-X
processing-independent	B-X
quantitation	B-X
of	B-X
procholecystokinin	B-X
(	B-X
proCCK	B-X
)	B-X
and	B-X
its	B-X
products	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
plasma	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
tryptic	B-X
cleavage	B-X
after	B-X
Lys61	B-X
and	B-X
Arg71	B-X
with	B-X
subsequent	B-X
monospecific	B-X
radioimmuno-analysis	B-X
of	B-X
fragment	B-X
62-71	B-X
of	B-X
human	B-X
proCCK	B-X
,	B-X
which	B-X
again	B-X
corresponds	B-X
to	B-X
fragment	B-X
1-10	B-X
of	B-X
CCK-22	B-X
.	B-X
The	B-X
detection	B-X
limit	B-X
of	B-X
the	B-X
analysis	B-X
was	B-X
0.2	B-X
pmol/l	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
13	B-X
healthy	B-X
volunteers	B-X
the	B-X
basal	B-X
concentration	B-X
with	B-X
the	B-X
above-mentioned	B-X
radioimmunoassay	B-X
was	B-X
1.1	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
(	B-X
mean	B-X
+/-	B-X
S.E.M	B-X
.	B-X
)	B-X
before	B-X
,	B-X
and	B-X
13.7	B-X
+/-	B-X
0.6	B-X
pmol/l	B-X
after	B-X
,	B-X
incubation	B-X
with	B-X
trypsin	B-X
.	B-X
Two	B-X
hours	B-X
after	B-X
ingestion	B-X
of	B-X
a	B-X
mixed	B-X
meal	B-X
,	B-X
the	B-X
plasma	B-X
concentration	B-X
was	B-X
2.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
before	B-X
,	B-X
and	B-X
21.7	B-X
+/-	B-X
1.2	B-X
pmol/l	B-X
after	B-X
tryptic	B-X
cleavage	B-X
.	B-X
With	B-X
a	B-X
conventional	B-X
CCK	B-X
radioimmunoassay	B-X
specific	B-X
for	B-X
the	B-X
C-terminally	B-X
amidated	B-X
and	B-X
O-sulfated	B-X
bioactive	B-X
epitope	B-X
,	B-X
the	B-X
concentration	B-X
was	B-X
1.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
in	B-X
the	B-X
basal	B-X
state	B-X
and	B-X
4.2	B-X
+/-	B-X
0.4	B-X
pmol/l	B-X
2	B-X
h	B-X
after	B-X
a	B-X
meal	B-X
.	B-X
Tryptic	B-X
cleavage	B-X
did	B-X
not	B-X
increase	B-X
the	B-X
concentrations	B-X
of	B-X
amidated	B-X
,	B-X
bioactive	B-X
CCK	B-X
peptides	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
37	B-X
patients	B-X
with	B-X
the	B-X
carcinoid	B-X
syndrome	B-X
,	B-X
the	B-X
basal	B-X
concentration	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
was	B-X
14.1	B-X
(	B-X
2.8-150.4	B-X
)	B-X
pmol/l	B-X
(	B-X
median	B-X
(	B-X
range	B-X
)	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
0.3	B-X
(	B-X
0-18.8	B-X
)	B-X
pmol/l	B-X
for	B-X
carboxyamidated	B-X
CCK	B-X
.	B-X
Only	B-X
two	B-X
patients	B-X
had	B-X
significantly	B-X
elevated	B-X
CCK	B-X
concentrations	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
processing-independent	B-X
analysis	B-X
is	B-X
useful	B-X
for	B-X
quantitation	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
in	B-X
plasma	B-X
,	B-X
since	B-X
it	B-X
quantitates	B-X
CCK	B-X
cell	B-X
secretion	B-X
more	B-X
accurately	B-X
than	B-X
conventional	B-X
CCK	B-X
assays	B-X
.	B-X

The	O
detection	O
limit	O
of	O
the	O
analysis	O
was	O
0	O
.	O
2	O
pmol	O
/	O
l	O
.	O

Plasma	O
was	O
extracted	O
with	O
ethanol	O
.	O
<EOS>	B-X
In	B-X
this	B-X
study	B-X
,	B-X
a	B-X
simple	B-X
,	B-X
quick	B-X
,	B-X
sensitive	B-X
and	B-X
reliable	B-X
method	B-X
utilizing	B-X
ultra-high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
with	B-X
tandem	B-X
mass	B-X
spectrometry	B-X
method	B-X
was	B-X
validated	B-X
for	B-X
simultaneous	B-X
quantification	B-X
of	B-X
six	B-X
main	B-X
2-	B-X
(	B-X
2-phenylethyl	B-X
)	B-X
chromones	B-X
,	B-X
including	B-X
agarotetrol	B-X
,	B-X
isoagarotetrol	B-X
,	B-X
(	B-X
5S,6R,7R,8S	B-X
)	B-X
-5,6,7,8-tetrahydroxy-	B-X
(	B-X
4-methoxyphenethyl	B-X
)	B-X
-5,6,7,8-tetrahydro-4H-chromen-4-one	B-X
,	B-X
8-chloro-2-	B-X
(	B-X
2-phenyl	B-X
ethyl	B-X
)	B-X
-5,6,7-trihydroxy-5,6,7,8-tetrahydrochromone	B-X
,	B-X
6,7-dimethoxy-2-	B-X
(	B-X
2-phenylethyl	B-X
)	B-X
chromone	B-X
,	B-X
and	B-X
2-	B-X
(	B-X
2-phenylethyl	B-X
)	B-X
chromone	B-X
in	B-X
rat	B-X
plasma	B-X
after	B-X
oral	B-X
administration	B-X
of	B-X
agarwood	B-X
ethanol	B-X
extract	B-X
.	B-X
We	B-X
investigated	B-X
if	B-X
shiitake	B-X
extracts	B-X
with	B-X
a	B-X
high	B-X
lentinic	B-X
acid	B-X
content	B-X
(	B-X
Shiitake-H	B-X
)	B-X
and	B-X
without	B-X
lentinic	B-X
acid	B-X
(	B-X
Shiitake-N	B-X
)	B-X
could	B-X
suppress	B-X
the	B-X
elevation	B-X
in	B-X
plasma	B-X
ethanol	B-X
concentrations	B-X
by	B-X
accelerating	B-X
ethanol	B-X
metabolism	B-X
and	B-X
preventing	B-X
ethanol	B-X
absorption	B-X
from	B-X
the	B-X
gut	B-X
.	B-X
Shiitake-H	B-X
and	B-X
Shiitake-N	B-X
suppressed	B-X
the	B-X
elevation	B-X
in	B-X
concentrations	B-X
of	B-X
ethanol	B-X
and	B-X
acetaldehyde	B-X
in	B-X
plasma	B-X
,	B-X
and	B-X
promoted	B-X
the	B-X
activities	B-X
of	B-X
alcohol	B-X
dehydrogenase	B-X
(	B-X
ADH	B-X
)	B-X
and	B-X
aldehyde	B-X
dehydrogenase	B-X
(	B-X
ALDH	B-X
)	B-X
in	B-X
the	B-X
liver	B-X
.	B-X
We	B-X
also	B-X
examined	B-X
the	B-X
change	B-X
in	B-X
plasma	B-X
ethanol	B-X
concentration	B-X
by	B-X
injecting	B-X
Shiitake-H	B-X
or	B-X
Shiitake-N	B-X
into	B-X
the	B-X
ligated	B-X
loop	B-X
of	B-X
the	B-X
stomach	B-X
or	B-X
jejunum	B-X
together	B-X
with	B-X
an	B-X
ethanol	B-X
solution	B-X
.	B-X
Shiitake-H	B-X
suppressed	B-X
the	B-X
absorption	B-X
of	B-X
ethanol	B-X
from	B-X
the	B-X
stomach	B-X
and	B-X
jejunum	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
Shiitake-H	B-X
accelerates	B-X
ethanol	B-X
metabolism	B-X
in	B-X
the	B-X
stomach	B-X
and	B-X
liver	B-X
and	B-X
inhibits	B-X
ethanol	B-X
absorption	B-X
in	B-X
the	B-X
stomach	B-X
and	B-X
jejunum	B-X
indicating	B-X
that	B-X
lentinic	B-X
acid	B-X
is	B-X
a	B-X
functional	B-X
component	B-X
in	B-X
shiitake	B-X
.	B-X

In	O
plasma	O
from	O
13	O
healthy	O
volunteers	O
the	O
basal	O
concentration	O
with	O
the	O
above	O
-	O
mentioned	O
radioimmunoassay	O
was	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
)	O
before	O
,	O
and	O
13	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
pmol	O
/	O
l	O
after	O
,	O
incubation	O
with	O
trypsin	O
.	O

Two	O
hours	O
after	O
ingestion	O
of	O
a	O
mixed	O
meal	O
,	O
the	O
plasma	O
concentration	O
was	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
before	O
,	O
and	O
21	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
pmol	O
/	O
l	O
after	O
tryptic	O
cleavage	O
.	O

With	O
a	O
conventional	O
CCK	B-Protein
radioimmunoassay	O
specific	O
for	O
the	O
C	O
-	O
terminally	O
amidated	O
and	O
O	O
-	O
sulfated	O
bioactive	O
epitope	O
,	O
the	O
concentration	O
was	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
in	O
the	O
basal	O
state	O
and	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
pmol	O
/	O
l	O
2	O
h	O
after	O
a	O
meal	O
.	O

Tryptic	O
cleavage	O
did	O
not	O
increase	O
the	O
concentrations	O
of	O
amidated	O
,	O
bioactive	O
CCK	B-Protein
peptides	O
.	O
<EOS>	B-X
Based	B-X
on	B-X
experimental	B-X
data	B-X
with	B-X
artificial	B-X
substrates	B-X
,	B-X
peptides	B-X
,	B-X
and	B-X
protein	B-X
standards	B-X
,	B-X
ψ-trypsin	B-X
shows	B-X
altered	B-X
kinetic	B-X
properties	B-X
,	B-X
thermodynamic	B-X
stability	B-X
and	B-X
cleavage	B-X
site	B-X
preference	B-X
(	B-X
and	B-X
partly	B-X
also	B-X
cleavage	B-X
specificity	B-X
)	B-X
compared	B-X
to	B-X
the	B-X
above-mentioned	B-X
proteoforms	B-X
.	B-X
It	B-X
cleaves	B-X
predominantly	B-X
at	B-X
the	B-X
characteristic	B-X
trypsin	B-X
cleavage	B-X
sites	B-X
.	B-X
However	B-X
,	B-X
in	B-X
a	B-X
comparison	B-X
with	B-X
common	B-X
tryptic	B-X
digestion	B-X
,	B-X
non-specific	B-X
cleavages	B-X
occur	B-X
more	B-X
frequently	B-X
(	B-X
mostly	B-X
after	B-X
the	B-X
aromatic	B-X
residues	B-X
of	B-X
Tyr	B-X
and	B-X
Phe	B-X
)	B-X
and	B-X
more	B-X
missed	B-X
cleavages	B-X
are	B-X
generated	B-X
.	B-X
Because	B-X
of	B-X
the	B-X
preferential	B-X
cleavages	B-X
after	B-X
the	B-X
basic	B-X
residues	B-X
and	B-X
more	B-X
developed	B-X
side	B-X
specificity	B-X
,	B-X
which	B-X
is	B-X
not	B-X
expected	B-X
to	B-X
occur	B-X
for	B-X
the	B-X
major	B-X
trypsin	B-X
forms	B-X
(	B-X
but	B-X
may	B-X
appear	B-X
anyway	B-X
because	B-X
of	B-X
their	B-X
autolysis	B-X
)	B-X
,	B-X
ψ-trypsin	B-X
produces	B-X
valuable	B-X
information	B-X
,	B-X
which	B-X
is	B-X
complementary	B-X
in	B-X
part	B-X
to	B-X
data	B-X
based	B-X
on	B-X
a	B-X
strictly	B-X
specific	B-X
trypsin	B-X
digestion	B-X
and	B-X
thus	B-X
can	B-X
be	B-X
unnoticed	B-X
following	B-X
common	B-X
proteomics	B-X
protocols	B-X
.	B-X

In	O
plasma	O
from	O
37	O
patients	O
with	O
the	O
carcinoid	O
syndrome	O
,	O
the	O
basal	O
concentration	O
of	O
proCCK	B-Protein
and	O
its	O
products	O
was	O
14	O
.	O
1	O
(	O
2	O
.	O
8	O
-	O
150	O
.	O
4	O
)	O
pmol	O
/	O
l	O
(	O
median	O
(	O
range	O
)	O
)	O
,	O
compared	O
with	O
0	O
.	O
3	O
(	O
0	O
-	O
18	O
.	O
8	O
)	O
pmol	O
/	O
l	O
for	O
carboxyamidated	O
CCK	B-Protein
.	O

Only	O
two	O
patients	O
had	O
significantly	O
elevated	O
CCK	B-Protein
concentrations	O
.	O
<EOS>	B-X
Recently	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
genes	B-X
implicated	B-X
in	B-X
lipid	B-X
absorption	B-X
were	B-X
upregulated	B-X
in	B-X
the	B-X
duodenum	B-X
of	B-X
fasting	B-X
gastro-esophageal	B-X
reflux	B-X
disease	B-X
(	B-X
GERD	B-X
)	B-X
patients	B-X
.	B-X
ApoA-IV	B-X
may	B-X
stimulate	B-X
release	B-X
of	B-X
cholecystokinin	B-X
(	B-X
CCK	B-X
)	B-X
,	B-X
an	B-X
activator	B-X
of	B-X
vagal	B-X
afferents	B-X
.	B-X
This	B-X
study	B-X
evaluated	B-X
putative	B-X
involvement	B-X
of	B-X
abnormal	B-X
apoA-IV	B-X
and	B-X
CCK	B-X
responses	B-X
to	B-X
lipid	B-X
in	B-X
GERD	B-X
.	B-X
Plasma	B-X
concentrations	B-X
of	B-X
cholecystokinin	B-X
(	B-X
CCK	B-X
)	B-X
have	B-X
been	B-X
reported	B-X
to	B-X
be	B-X
elevated	B-X
in	B-X
patients	B-X
with	B-X
chronic	B-X
pancreatitis	B-X
.	B-X
The	B-X
elevations	B-X
are	B-X
suggested	B-X
to	B-X
be	B-X
due	B-X
to	B-X
increased	B-X
release	B-X
of	B-X
CCK	B-X
from	B-X
the	B-X
upper	B-X
small	B-X
intestine	B-X
secondary	B-X
to	B-X
the	B-X
absence	B-X
of	B-X
protease	B-X
activity	B-X
(	B-X
trypsin	B-X
and	B-X
chymotrypsin	B-X
)	B-X
in	B-X
the	B-X
intestinal	B-X
lumen	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
plasma	B-X
CCK	B-X
levels	B-X
before	B-X
and	B-X
after	B-X
liquid	B-X
as	B-X
well	B-X
as	B-X
solid	B-X
meals	B-X
in	B-X
eight	B-X
patients	B-X
with	B-X
pancreatic	B-X
insufficiency	B-X
due	B-X
to	B-X
advanced	B-X
chronic	B-X
pancreatitis	B-X
and	B-X
in	B-X
eight	B-X
healthy	B-X
controls	B-X
.	B-X
CCK	B-X
concentrations	B-X
were	B-X
measured	B-X
with	B-X
a	B-X
sensitive	B-X
and	B-X
specific	B-X
radioimmunoassay	B-X
using	B-X
an	B-X
antibody	B-X
directed	B-X
against	B-X
the	B-X
sulfated	B-X
tyrosyl	B-X
region	B-X
of	B-X
CCK	B-X
.	B-X
No	B-X
differences	B-X
in	B-X
basal	B-X
or	B-X
maximal	B-X
postprandial	B-X
plasma	B-X
CCK	B-X
levels	B-X
between	B-X
patients	B-X
and	B-X
controls	B-X
were	B-X
observed	B-X
.	B-X
In	B-X
the	B-X
liquid	B-X
meal	B-X
study	B-X
,	B-X
basal	B-X
CCK	B-X
concentrations	B-X
in	B-X
patients	B-X
and	B-X
controls	B-X
were	B-X
2.2	B-X
+/-	B-X
0.7	B-X
and	B-X
2.5	B-X
+/-	B-X
0.4	B-X
pM	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
maximal	B-X
postprandial	B-X
concentrations	B-X
of	B-X
9.6	B-X
+/-	B-X
2.2	B-X
and	B-X
11.2	B-X
+/-	B-X
1.4	B-X
pM	B-X
.	B-X
In	B-X
the	B-X
solid	B-X
meal	B-X
study	B-X
,	B-X
basal	B-X
CCK	B-X
concentrations	B-X
in	B-X
patients	B-X
and	B-X
controls	B-X
were	B-X
2.5	B-X
+/-	B-X
0.6	B-X
and	B-X
2.6	B-X
+/-	B-X
0.4	B-X
pM	B-X
,	B-X
respectively	B-X
,	B-X
with	B-X
maximal	B-X
postprandial	B-X
concentrations	B-X
of	B-X
9.4	B-X
+/-	B-X
1.6	B-X
and	B-X
8.6	B-X
+/-	B-X
1.4	B-X
pM	B-X
.	B-X
The	B-X
only	B-X
difference	B-X
observed	B-X
was	B-X
a	B-X
significantly	B-X
longer	B-X
time	B-X
interval	B-X
to	B-X
maximal	B-X
plasma	B-X
CCK	B-X
levels	B-X
in	B-X
patients	B-X
as	B-X
compared	B-X
with	B-X
controls	B-X
after	B-X
the	B-X
liquid	B-X
meal	B-X
.	B-X
Two	B-X
patients	B-X
with	B-X
no	B-X
detectable	B-X
trypsin	B-X
activity	B-X
in	B-X
the	B-X
small	B-X
intestinal	B-X
lumen	B-X
during	B-X
a	B-X
Lundh	B-X
test	B-X
meal	B-X
had	B-X
basal	B-X
CCK	B-X
levels	B-X
of	B-X
1.3	B-X
and	B-X
1.8	B-X
pM	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
present	B-X
study	B-X
does	B-X
not	B-X
support	B-X
the	B-X
hypothesis	B-X
that	B-X
trypsin	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
CCK	B-X
release	B-X
.	B-X

We	O
conclude	O
that	O
processing	O
-	O
independent	O
analysis	O
is	O
useful	O
for	O
quantitation	O
of	O
proCCK	B-Protein
and	O
its	O
products	O
in	O
plasma	O
,	O
since	O
it	O
quantitates	O
CCK	B-Protein
cell	O
secretion	O
more	O
accurately	O
than	O
conventional	O
CCK	B-Protein
assays	O
.	O
<EOS>	B-X
A	B-X
procedure	B-X
for	B-X
processing-independent	B-X
quantitation	B-X
of	B-X
procholecystokinin	B-X
(	B-X
proCCK	B-X
)	B-X
and	B-X
its	B-X
products	B-X
has	B-X
been	B-X
applied	B-X
to	B-X
plasma	B-X
.	B-X
The	B-X
procedure	B-X
is	B-X
based	B-X
on	B-X
tryptic	B-X
cleavage	B-X
after	B-X
Lys61	B-X
and	B-X
Arg71	B-X
with	B-X
subsequent	B-X
monospecific	B-X
radioimmuno-analysis	B-X
of	B-X
fragment	B-X
62-71	B-X
of	B-X
human	B-X
proCCK	B-X
,	B-X
which	B-X
again	B-X
corresponds	B-X
to	B-X
fragment	B-X
1-10	B-X
of	B-X
CCK-22	B-X
.	B-X
The	B-X
detection	B-X
limit	B-X
of	B-X
the	B-X
analysis	B-X
was	B-X
0.2	B-X
pmol/l	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
13	B-X
healthy	B-X
volunteers	B-X
the	B-X
basal	B-X
concentration	B-X
with	B-X
the	B-X
above-mentioned	B-X
radioimmunoassay	B-X
was	B-X
1.1	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
(	B-X
mean	B-X
+/-	B-X
S.E.M	B-X
.	B-X
)	B-X
Two	B-X
hours	B-X
after	B-X
ingestion	B-X
of	B-X
a	B-X
mixed	B-X
meal	B-X
,	B-X
the	B-X
plasma	B-X
concentration	B-X
was	B-X
2.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
before	B-X
,	B-X
and	B-X
21.7	B-X
+/-	B-X
1.2	B-X
pmol/l	B-X
after	B-X
tryptic	B-X
cleavage	B-X
.	B-X
With	B-X
a	B-X
conventional	B-X
CCK	B-X
radioimmunoassay	B-X
specific	B-X
for	B-X
the	B-X
C-terminally	B-X
amidated	B-X
and	B-X
O-sulfated	B-X
bioactive	B-X
epitope	B-X
,	B-X
the	B-X
concentration	B-X
was	B-X
1.0	B-X
+/-	B-X
0.1	B-X
pmol/l	B-X
in	B-X
the	B-X
basal	B-X
state	B-X
and	B-X
4.2	B-X
+/-	B-X
0.4	B-X
pmol/l	B-X
2	B-X
h	B-X
after	B-X
a	B-X
meal	B-X
.	B-X
Tryptic	B-X
cleavage	B-X
did	B-X
not	B-X
increase	B-X
the	B-X
concentrations	B-X
of	B-X
amidated	B-X
,	B-X
bioactive	B-X
CCK	B-X
peptides	B-X
.	B-X
In	B-X
plasma	B-X
from	B-X
37	B-X
patients	B-X
with	B-X
the	B-X
carcinoid	B-X
syndrome	B-X
,	B-X
the	B-X
basal	B-X
concentration	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
was	B-X
14.1	B-X
(	B-X
2.8-150.4	B-X
)	B-X
pmol/l	B-X
(	B-X
median	B-X
(	B-X
range	B-X
)	B-X
)	B-X
,	B-X
compared	B-X
with	B-X
0.3	B-X
(	B-X
0-18.8	B-X
)	B-X
pmol/l	B-X
for	B-X
carboxyamidated	B-X
CCK	B-X
.	B-X
Only	B-X
two	B-X
patients	B-X
had	B-X
significantly	B-X
elevated	B-X
CCK	B-X
concentrations	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
processing-independent	B-X
analysis	B-X
is	B-X
useful	B-X
for	B-X
quantitation	B-X
of	B-X
proCCK	B-X
and	B-X
its	B-X
products	B-X
in	B-X
plasma	B-X
,	B-X
since	B-X
it	B-X
quantitates	B-X
CCK	B-X
cell	B-X
secretion	B-X
more	B-X
accurately	B-X
than	B-X
conventional	B-X
CCK	B-X
assays	B-X
.	B-X

Synergistic	O
activation	O
of	O
rat	O
brain	O
phospholipase	B-Protein
D	I-Protein
by	O
ADP	O
-	O
ribosylation	O
factor	O
and	O
rhoA	B-Protein
p21	I-Protein
,	O
and	O
its	O
inhibition	O
by	O
Clostridium	O
botulinum	O
C3	B-Protein
exoenzyme	I-Protein
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
Inhibition	B-X
correlated	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
ADP-ribosylation	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

An	O
activator	O
of	O
rat	O
brain	O
phospholipase	B-Protein
D	I-Protein
(	O
PLD	B-Protein
)	O
that	O
is	O
distinct	O
from	O
the	O
already	O
identified	O
PLD	B-Protein
activator	O
,	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
ARF	O
)	O
,	O
was	O
partially	O
purified	O
from	O
bovine	O
brain	O
cytosol	O
by	O
a	O
series	O
of	O
chromatographic	O
steps	O
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
Inhibition	B-X
correlated	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
ADP-ribosylation	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

The	O
partially	O
purified	O
preparation	O
contained	O
a	O
22	O
-	O
kDa	O
substrate	O
for	O
Clostridium	O
botulinum	O
C3	B-Protein
exoenzyme	I-Protein
ADP	O
-	O
ribosyltransferase	O
,	O
which	O
strongly	O
reacted	O
with	O
anti	O
-	O
rhoA	B-Protein
p21	I-Protein
antibody	O
,	O
but	O
not	O
with	O
anti	O
-	O
rac1	B-Protein
p21	I-Protein
or	O
anti	O
-	O
cdc42Hs	B-Protein
p21	I-Protein
antibody	O
.	O
<EOS>	B-X
This	B-X
is	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
signal	B-X
transduction	B-X
because	B-X
inhibition	B-X
of	B-X
Ras	B-X
activation	B-X
by	B-X
anti-Ras	B-X
antibodies	B-X
or	B-X
dominant	B-X
inhibitory	B-X
Ras	B-X
mutants	B-X
blocks	B-X
many	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
these	B-X
receptors	B-X
on	B-X
cellular	B-X
function	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
the	B-X
cloning	B-X
of	B-X
complementary	B-X
DNAs	B-X
from	B-X
a	B-X
rat	B-X
brain	B-X
library	B-X
that	B-X
encode	B-X
a	B-X
approximately	B-X
140K	B-X
GRF	B-X
for	B-X
Ras	B-X
p21	B-X
(	B-X
p140Ras-GRF	B-X
)	B-X
.	B-X
This	B-X
portion	B-X
of	B-X
Ras-GRF	B-X
accelerated	B-X
the	B-X
release	B-X
of	B-X
GDP	B-X
from	B-X
RasH	B-X
and	B-X
RasN	B-X
p21	B-X
in	B-X
vitro	B-X
,	B-X
but	B-X
not	B-X
from	B-X
the	B-X
related	B-X
RalA	B-X
,	B-X
or	B-X
CDC42Hs	B-X
GTP-binding	B-X
proteins	B-X
.	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
Inhibition	B-X
correlated	B-X
with	B-X
the	B-X
extent	B-X
of	B-X
ADP-ribosylation	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

Treatment	O
of	O
the	O
partially	O
purified	O
PLD	B-Protein
-	O
activating	O
factor	O
with	O
both	O
C3	B-Protein
exoenzyme	I-Protein
and	O
NAD	O
significantly	O
inhibited	O
the	O
PLD	B-Protein
-	O
stimulating	O
activity	O
.	O
<EOS>	B-X
Phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
is	B-X
believed	B-X
to	B-X
play	B-X
an	B-X
important	B-X
role	B-X
in	B-X
cell	B-X
signal	B-X
transduction	B-X
:	B-X
PLD	B-X
catalyzes	B-X
the	B-X
hydrolysis	B-X
primarily	B-X
of	B-X
phosphatidylcholine	B-X
(	B-X
PC	B-X
)	B-X
to	B-X
produce	B-X
phosphatidic	B-X
acid	B-X
that	B-X
may	B-X
serve	B-X
as	B-X
a	B-X
lipid	B-X
second	B-X
messenger	B-X
.	B-X
Although	B-X
the	B-X
mechanism	B-X
of	B-X
PLD	B-X
activation	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
fully	B-X
understood	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
low	B-X
molecular	B-X
weight	B-X
GTP-binding	B-X
protein	B-X
(	B-X
small	B-X
G	B-X
protein	B-X
)	B-X
superfamily	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
has	B-X
been	B-X
identified	B-X
as	B-X
a	B-X
PLD-activating	B-X
factor	B-X
.	B-X
In	B-X
addition	B-X
to	B-X
ARF	B-X
,	B-X
we	B-X
found	B-X
that	B-X
RhoA	B-X
,	B-X
another	B-X
member	B-X
of	B-X
the	B-X
small	B-X
G	B-X
proteins	B-X
,	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
,	B-X
and	B-X
that	B-X
ARF	B-X
and	B-X
RhoA	B-X
synergistically	B-X
stimulated	B-X
the	B-X
enzyme	B-X
activity	B-X
.	B-X
When	B-X
proteins	B-X
of	B-X
bovine	B-X
brain	B-X
cytosol	B-X
were	B-X
subjected	B-X
to	B-X
anion	B-X
exchange	B-X
column	B-X
chromatography	B-X
and	B-X
then	B-X
reconstituted	B-X
with	B-X
rat	B-X
brain	B-X
PLD	B-X
partially	B-X
purified	B-X
from	B-X
the	B-X
membranes	B-X
,	B-X
fractions	B-X
eluted	B-X
at	B-X
60	B-X
mM	B-X
NaCl	B-X
,	B-X
where	B-X
ARF	B-X
was	B-X
not	B-X
detected	B-X
,	B-X
activated	B-X
the	B-X
enzyme	B-X
in	B-X
a	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
This	B-X
PLD-stimulating	B-X
activity	B-X
seemed	B-X
to	B-X
be	B-X
attributed	B-X
to	B-X
a	B-X
small	B-X
G	B-X
protein	B-X
RhoA	B-X
.	B-X
Evidence	B-X
provided	B-X
includes	B-X
the	B-X
findings	B-X
that	B-X
:	B-X
(	B-X
1	B-X
)	B-X
the	B-X
partially	B-X
purified	B-X
preparation	B-X
of	B-X
the	B-X
PLD-activating	B-X
factor	B-X
by	B-X
subsequent	B-X
column	B-X
chromatographies	B-X
contained	B-X
a	B-X
22	B-X
kDa	B-X
substrate	B-X
for	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
;	B-X
(	B-X
2	B-X
)	B-X
the	B-X
22	B-X
kDa	B-X
protein	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-RhoA	B-X
antibody	B-X
;	B-X
(	B-X
3	B-X
)	B-X
the	B-X
treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
together	B-X
,	B-X
but	B-X
not	B-X
individually	B-X
,	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
;	B-X
and	B-X
(	B-X
4	B-X
)	B-X
recombinant	B-X
isoprenylated	B-X
RhoA	B-X
activated	B-X
the	B-X
PLD	B-X
.	B-X
On	B-X
the	B-X
contrary	B-X
,	B-X
recombinant	B-X
nonisoprenylated	B-X
RhoA	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
Interestingly	B-X
,	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
,	B-X
and	B-X
recombinant	B-X
isoprenylated	B-X
RhoA	B-X
could	B-X
substitute	B-X
for	B-X
the	B-X
partially	B-X
purified	B-X
preparation	B-X
.	B-X
These	B-X
results	B-X
conclude	B-X
that	B-X
rat	B-X
brain	B-X
PLD	B-X
is	B-X
regulated	B-X
by	B-X
RhoA	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
the	B-X
post-translational	B-X
modification	B-X
of	B-X
RhoA	B-X
is	B-X
essential	B-X
for	B-X
its	B-X
function	B-X
as	B-X
the	B-X
PLD	B-X
activator	B-X
.	B-X

These	O
results	O
suggest	O
that	O
rhoA	B-Protein
p21	I-Protein
is	O
,	O
at	O
least	O
in	O
part	O
,	O
responsible	O
for	O
the	O
PLD	B-Protein
-	O
stimulating	O
activity	O
in	O
the	O
preparation	O
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

Recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
expressed	O
in	O
and	O
purified	O
from	O
Sf9	O
cells	O
activated	O
rat	O
brain	O
PLD	B-Protein
in	O
a	O
concentration	O
-	O
and	O
GTP	O
gamma	O
S	O
(	O
guanosine	O
5	O
'	O
-	O
O	O
-	O
(	O
3	O
-	O
thiotriphosphate	O
)	O
)	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
recombinant	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
(	O
fused	O
to	O
glutathione	B-Protein
S	I-Protein
-	I-Protein
transferase	I-Protein
)	O
expressed	O
in	O
Escherichia	O
coli	O
failed	O
to	O
activate	O
the	O
PLD	B-Protein
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

This	O
difference	O
cannot	O
be	O
explained	O
by	O
a	O
lower	O
affinity	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
for	O
GTP	O
gamma	O
S	O
,	O
as	O
the	O
rates	O
of	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
were	O
very	O
similar	O
for	O
both	O
recombinant	O
preparations	O
and	O
the	O
GTP	O
gamma	O
S	O
-	O
bound	O
form	O
of	O
non	O
-	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
did	O
not	O
induce	O
PLD	B-Protein
activation	O
.	O

Interestingly	O
,	O
recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
and	O
ARF	O
synergistically	O
activated	O
rat	O
brain	O
PLD	B-Protein
;	O
a	O
similar	O
pattern	O
was	O
seen	O
with	O
the	O
partially	O
purified	O
PLD	B-Protein
-	O
activating	O
factor	O
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

The	O
synergistic	O
activation	O
was	O
inhibited	O
by	O
C3	B-Protein
exoenzyme	I-Protein
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
recombinant	O
isoprenylated	O
rhoA	B-Protein
p21	I-Protein
in	O
a	O
NAD	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
correlated	O
with	O
the	O
extent	O
of	O
ADP	O
-	O
ribosylation	O
.	O
<EOS>	B-X
When	B-X
WBC264-9C	B-X
cells	B-X
are	B-X
preincubated	B-X
with	B-X
pertussis	B-X
toxin	B-X
,	B-X
chemotaxis	B-X
is	B-X
inhibited	B-X
and	B-X
ADP-ribosylation	B-X
of	B-X
a	B-X
membrane	B-X
protein	B-X
with	B-X
a	B-X
subunit	B-X
Mr	B-X
41,000	B-X
is	B-X
observed	B-X
.	B-X
Both	B-X
the	B-X
inhibition	B-X
of	B-X
chemotaxis	B-X
and	B-X
the	B-X
ADP-ribosylation	B-X
by	B-X
pertussis	B-X
toxin	B-X
display	B-X
a	B-X
similar	B-X
time	B-X
lag	B-X
,	B-X
temperature	B-X
dependence	B-X
,	B-X
and	B-X
pertussis	B-X
toxin-concentration	B-X
dependence	B-X
.	B-X
Although	B-X
the	B-X
inhibition	B-X
of	B-X
chemotaxis	B-X
and	B-X
the	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
membrane	B-X
protein	B-X
are	B-X
qualitatively	B-X
correlated	B-X
,	B-X
nearly	B-X
complete	B-X
inhibition	B-X
of	B-X
chemotaxis	B-X
occurs	B-X
when	B-X
there	B-X
is	B-X
only	B-X
partial	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
membrane	B-X
protein	B-X
.	B-X
Pertussis	B-X
toxin-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
the	B-X
Mr	B-X
41,000	B-X
protein	B-X
in	B-X
WBC264-9C	B-X
membranes	B-X
is	B-X
stimulated	B-X
by	B-X
GDP	B-X
,	B-X
GTP	B-X
,	B-X
and	B-X
to	B-X
a	B-X
lesser	B-X
extent	B-X
by	B-X
GMP	B-X
;	B-X
the	B-X
nonhydrolyzable	B-X
GTP	B-X
analog	B-X
guanosine	B-X
5'-	B-X
[	B-X
beta	B-X
,	B-X
gamma-imido	B-X
]	B-X
triphosphate	B-X
has	B-X
no	B-X
effect	B-X
.	B-X

These	O
findings	O
suggest	O
that	O
rhoA	B-Protein
p21	I-Protein
regulates	O
rat	O
brain	O
PLD	B-Protein
in	O
concert	O
with	O
ARF	O
,	O
and	O
that	O
isoprenylation	O
of	O
rhoA	B-Protein
p21	I-Protein
is	O
essential	O
for	O
PLD	B-Protein
regulation	O
in	O
vitro	O
.	O
<EOS>	B-X
An	B-X
activator	B-X
of	B-X
rat	B-X
brain	B-X
phospholipase	B-X
D	B-X
(	B-X
PLD	B-X
)	B-X
that	B-X
is	B-X
distinct	B-X
from	B-X
the	B-X
already	B-X
identified	B-X
PLD	B-X
activator	B-X
,	B-X
ADP-ribosylation	B-X
factor	B-X
(	B-X
ARF	B-X
)	B-X
,	B-X
was	B-X
partially	B-X
purified	B-X
from	B-X
bovine	B-X
brain	B-X
cytosol	B-X
by	B-X
a	B-X
series	B-X
of	B-X
chromatographic	B-X
steps	B-X
.	B-X
The	B-X
partially	B-X
purified	B-X
preparation	B-X
contained	B-X
a	B-X
22-kDa	B-X
substrate	B-X
for	B-X
Clostridium	B-X
botulinum	B-X
C3	B-X
exoenzyme	B-X
ADP-ribosyltransferase	B-X
,	B-X
which	B-X
strongly	B-X
reacted	B-X
with	B-X
anti-rhoA	B-X
p21	B-X
antibody	B-X
,	B-X
but	B-X
not	B-X
with	B-X
anti-rac1	B-X
p21	B-X
or	B-X
anti-cdc42Hs	B-X
p21	B-X
antibody	B-X
.	B-X
Treatment	B-X
of	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
with	B-X
both	B-X
C3	B-X
exoenzyme	B-X
and	B-X
NAD	B-X
significantly	B-X
inhibited	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
is	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
responsible	B-X
for	B-X
the	B-X
PLD-stimulating	B-X
activity	B-X
in	B-X
the	B-X
preparation	B-X
.	B-X
Recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
expressed	B-X
in	B-X
and	B-X
purified	B-X
from	B-X
Sf9	B-X
cells	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
a	B-X
concentration-	B-X
and	B-X
GTP	B-X
gamma	B-X
S	B-X
(	B-X
guanosine	B-X
5'-O-	B-X
(	B-X
3-thiotriphosphate	B-X
)	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
recombinant	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
(	B-X
fused	B-X
to	B-X
glutathione	B-X
S-transferase	B-X
)	B-X
expressed	B-X
in	B-X
Escherichia	B-X
coli	B-X
failed	B-X
to	B-X
activate	B-X
the	B-X
PLD	B-X
.	B-X
This	B-X
difference	B-X
can	B-X
not	B-X
be	B-X
explained	B-X
by	B-X
a	B-X
lower	B-X
affinity	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
for	B-X
GTP	B-X
gamma	B-X
S	B-X
,	B-X
as	B-X
the	B-X
rates	B-X
of	B-X
[	B-X
35S	B-X
]	B-X
GTP	B-X
gamma	B-X
S	B-X
binding	B-X
were	B-X
very	B-X
similar	B-X
for	B-X
both	B-X
recombinant	B-X
preparations	B-X
and	B-X
the	B-X
GTP	B-X
gamma	B-X
S-bound	B-X
form	B-X
of	B-X
non-isoprenylated	B-X
rhoA	B-X
p21	B-X
did	B-X
not	B-X
induce	B-X
PLD	B-X
activation	B-X
.	B-X
Interestingly	B-X
,	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
and	B-X
ARF	B-X
synergistically	B-X
activated	B-X
rat	B-X
brain	B-X
PLD	B-X
;	B-X
a	B-X
similar	B-X
pattern	B-X
was	B-X
seen	B-X
with	B-X
the	B-X
partially	B-X
purified	B-X
PLD-activating	B-X
factor	B-X
.	B-X
The	B-X
synergistic	B-X
activation	B-X
was	B-X
inhibited	B-X
by	B-X
C3	B-X
exoenzyme-catalyzed	B-X
ADP-ribosylation	B-X
of	B-X
recombinant	B-X
isoprenylated	B-X
rhoA	B-X
p21	B-X
in	B-X
a	B-X
NAD-dependent	B-X
manner	B-X
.	B-X
These	B-X
findings	B-X
suggest	B-X
that	B-X
rhoA	B-X
p21	B-X
regulates	B-X
rat	B-X
brain	B-X
PLD	B-X
in	B-X
concert	B-X
with	B-X
ARF	B-X
,	B-X
and	B-X
that	B-X
isoprenylation	B-X
of	B-X
rhoA	B-X
p21	B-X
is	B-X
essential	B-X
for	B-X
PLD	B-X
regulation	B-X
in	B-X
vitro	B-X
.	B-X

Farnesyltransferase	O
inhibitors	O
block	O
the	O
neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
malignant	O
phenotype	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Neurofibromatosis	O
type	O
I	O
(	O
NF1	O
)	O
is	O
a	O
hereditary	O
tumor	O
and	O
developmental	O
disorder	O
whose	O
defective	O
gene	O
was	O
cloned	O
previously	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

The	O
protein	O
product	O
of	O
the	O
NF1	B-Protein
gene	O
,	O
neurofibromin	B-Protein
,	O
contains	O
a	O
domain	O
that	O
shows	O
significant	O
sequence	O
homology	O
to	O
the	O
known	O
catalytic	O
domains	O
of	O
mammalian	O
Ras	O
GTPase	O
-	O
activating	O
proteins	O
(	O
GAP	O
)	O
and	O
the	O
yeast	O
IRA1	B-Protein
and	O
IRA2	B-Protein
proteins	O
.	O

This	O
homologous	O
region	O
of	O
neurofibromin	B-Protein
has	O
been	O
shown	O
to	O
exhibit	O
GAP	O
activity	O
toward	O
Ras	O
proteins	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Malignant	O
schwannoma	O
cell	O
lines	O
from	O
NF1	O
patients	O
contain	O
normal	O
levels	O
of	O
GAP	O
and	O
nonmutated	O
Ras	O
proteins	O
but	O
barely	O
detectable	O
levels	O
of	O
neurofibromin	B-Protein
,	O
based	O
on	O
genetic	O
mutations	O
in	O
the	O
NF1	B-Protein
gene	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Because	O
these	O
cells	O
contain	O
constitutively	O
activated	O
Ras	O
.	O
GTP	O
,	O
it	O
has	O
been	O
proposed	O
that	O
neurofibromin	B-Protein
may	O
be	O
the	O
sole	O
negative	O
regulator	O
of	O
Ras	O
in	O
these	O
cells	O
.	O

Overall	O
,	O
these	O
results	O
have	O
implied	O
an	O
important	O
role	O
of	O
the	O
Ras	O
signaling	O
pathway	O
in	O
NF1	O
malignant	O
schwannomas	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Recently	O
,	O
several	O
laboratories	O
have	O
developed	O
small	O
molecule	O
inhibitors	O
of	O
Ras	O
function	O
that	O
inhibit	O
the	O
enzyme	O
farnesyltransferase	O
(	O
FT	O
)	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

FT	O
-	O
mediated	O
post	O
-	O
translational	O
farnesylation	O
of	O
Ras	O
proteins	O
is	O
absolutely	O
necessary	O
for	O
Ras	O
function	O
since	O
this	O
modification	O
is	O
required	O
for	O
the	O
anchoring	O
of	O
Ras	O
proteins	O
to	O
the	O
plasma	O
cell	O
membrane	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
that	O
FT	O
inhibitors	O
can	O
block	O
the	O
growth	O
of	O
tumor	O
cells	O
carrying	O
mutant	O
Ras	O
proteins	O
,	O
it	O
remained	O
unclear	O
how	O
this	O
class	O
of	O
inhibitors	O
would	O
affect	O
tumor	O
cells	O
such	O
as	O
in	O
NF1	O
,	O
whose	O
malignant	O
growth	O
appears	O
to	O
be	O
mediated	O
by	O
up	O
-	O
regulation	O
of	O
wild	O
-	O
type	O
Ras	O
activity	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Thus	O
,	O
in	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
BMS	O
-	O
186511	O
,	O
a	O
bisubstrate	O
analogue	O
inhibitor	O
of	O
FT	O
,	O
would	O
inhibit	O
the	O
malignant	O
growth	O
properties	O
of	O
a	O
cell	O
line	O
established	O
from	O
malignant	O
schwannoma	O
of	O
an	O
NF1	O
patient	O
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

Our	O
results	O
indicate	O
that	O
the	O
malignant	O
growth	O
properties	O
of	O
ST88	O
-	O
14	O
cells	O
,	O
the	O
most	O
malignant	O
cell	O
line	O
among	O
several	O
well	O
-	O
characterized	O
NF1	O
cells	O
,	O
are	O
inhibited	O
by	O
BMS	O
-	O
186511	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Following	O
treatment	O
with	O
BMS	O
-	O
186511	O
,	O
ST88	O
-	O
14	O
cells	O
became	O
flat	O
,	O
nonrefractile	O
,	O
were	O
contact	O
-	O
inhibited	O
,	O
and	O
lost	O
their	O
ability	O
to	O
grow	O
in	O
soft	O
agar	O
.	O
<EOS>	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X

In	O
the	O
drug	O
-	O
exposed	O
cells	O
,	O
Ras	O
proteins	O
were	O
prevented	O
from	O
FT	O
-	O
mediated	O
membrane	O
association	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
Following	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
,	B-X
ST88-14	B-X
cells	B-X
became	B-X
flat	B-X
,	B-X
nonrefractile	B-X
,	B-X
were	B-X
contact-inhibited	B-X
,	B-X
and	B-X
lost	B-X
their	B-X
ability	B-X
to	B-X
grow	B-X
in	B-X
soft	B-X
agar	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

BMS	O
-	O
186511	O
was	O
found	O
to	O
specifically	O
inhibit	O
FT	O
,	O
but	O
not	O
geranylgeranyltransferase	O
I	O
,	O
a	O
closely	O
related	O
enzyme	O
.	O
<EOS>	B-X
We	B-X
describe	B-X
the	B-X
biological	B-X
properties	B-X
of	B-X
a	B-X
new	B-X
class	B-X
of	B-X
potent	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
inhibitors	B-X
designed	B-X
as	B-X
bisubstrate	B-X
analog	B-X
inhibitors	B-X
.	B-X
These	B-X
inhibitors	B-X
incorporate	B-X
the	B-X
structural	B-X
motifs	B-X
of	B-X
both	B-X
farnesyl	B-X
pyrophosphate	B-X
and	B-X
the	B-X
CAAX	B-X
tetrapeptide	B-X
,	B-X
the	B-X
two	B-X
substrates	B-X
of	B-X
the	B-X
reaction	B-X
catalyzed	B-X
by	B-X
FT	B-X
.	B-X
Both	B-X
the	B-X
phosphinate	B-X
inhibitor	B-X
,	B-X
BMS-185878	B-X
,	B-X
and	B-X
the	B-X
phosphonate	B-X
inhibitor	B-X
,	B-X
BMS-184467	B-X
,	B-X
exhibited	B-X
higher	B-X
in	B-X
vitro	B-X
FT	B-X
selectivity	B-X
than	B-X
some	B-X
of	B-X
the	B-X
previously	B-X
reported	B-X
CVFM	B-X
peptidomimentics	B-X
and	B-X
benzodiazepine	B-X
analogs	B-X
.	B-X
Xenopus	B-X
oocyte	B-X
maturation	B-X
induced	B-X
by	B-X
microinjected	B-X
oncogenic	B-X
Ras	B-X
proteins	B-X
was	B-X
blocked	B-X
by	B-X
coinjected	B-X
BMS-184467	B-X
and	B-X
BMS-185878	B-X
.	B-X
However	B-X
,	B-X
both	B-X
inhibitors	B-X
showed	B-X
poor	B-X
cell	B-X
activity	B-X
presumably	B-X
because	B-X
of	B-X
the	B-X
doubly	B-X
charged	B-X
nature	B-X
of	B-X
the	B-X
compounds	B-X
.	B-X
Thus	B-X
,	B-X
masking	B-X
the	B-X
charge	B-X
on	B-X
the	B-X
carboxylate	B-X
ion	B-X
markedly	B-X
improved	B-X
the	B-X
cell	B-X
permeability	B-X
of	B-X
BMS-185878	B-X
,	B-X
leading	B-X
to	B-X
BMS-186511	B-X
,	B-X
the	B-X
methyl	B-X
carboxyl	B-X
ester	B-X
prodrug	B-X
.	B-X
BMS-186511	B-X
inhibited	B-X
FT	B-X
activity	B-X
in	B-X
whole	B-X
cells	B-X
as	B-X
determined	B-X
by	B-X
inhibition	B-X
of	B-X
p21	B-X
Ras	B-X
protein	B-X
processing	B-X
,	B-X
inhibition	B-X
of	B-X
farnesylation	B-X
of	B-X
proteins	B-X
including	B-X
Ras	B-X
and	B-X
the	B-X
accumulation	B-X
of	B-X
unfarnesylated	B-X
Ras	B-X
proteins	B-X
in	B-X
the	B-X
cytosolic	B-X
fraction	B-X
.	B-X
While	B-X
the	B-X
cellular	B-X
effects	B-X
of	B-X
these	B-X
bisubstrate	B-X
analog	B-X
inhibitors	B-X
had	B-X
no	B-X
significant	B-X
effect	B-X
on	B-X
growth	B-X
of	B-X
untransformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
they	B-X
produced	B-X
pronounced	B-X
inhibition	B-X
of	B-X
Ras	B-X
transformed	B-X
cell	B-X
growth	B-X
.	B-X
Both	B-X
the	B-X
anchorage	B-X
dependent	B-X
and	B-X
independent	B-X
growth	B-X
of	B-X
ras	B-X
transformed	B-X
cells	B-X
were	B-X
severely	B-X
curtailed	B-X
by	B-X
micromolar	B-X
concentrations	B-X
of	B-X
BMS-186511	B-X
.	B-X
We	B-X
also	B-X
found	B-X
that	B-X
both	B-X
H-ras	B-X
and	B-X
K-ras	B-X
transformed	B-X
cells	B-X
are	B-X
affected	B-X
by	B-X
this	B-X
bisubstrate	B-X
inhibitor	B-X
.	B-X
The	B-X
inhibition	B-X
of	B-X
FT	B-X
activity	B-X
in	B-X
cells	B-X
and	B-X
the	B-X
ensuing	B-X
inhibition	B-X
of	B-X
ras	B-X
transformed	B-X
cell	B-X
growth	B-X
is	B-X
further	B-X
manifested	B-X
in	B-X
distinct	B-X
morphological	B-X
changes	B-X
in	B-X
cells	B-X
.	B-X
Cells	B-X
flattened	B-X
,	B-X
became	B-X
less	B-X
refractile	B-X
and	B-X
grew	B-X
in	B-X
contact	B-X
inhibited	B-X
monolayer	B-X
.	B-X
Moreover	B-X
,	B-X
the	B-X
highly	B-X
diffused	B-X
character	B-X
of	B-X
the	B-X
actin	B-X
cytoskeleton	B-X
in	B-X
the	B-X
ras	B-X
transformed	B-X
cells	B-X
was	B-X
dramatically	B-X
reverted	B-X
to	B-X
an	B-X
organized	B-X
network	B-X
of	B-X
stress	B-X
cables	B-X
crisscrossing	B-X
the	B-X
entire	B-X
cells	B-X
upon	B-X
treatment	B-X
with	B-X
BMS-186511	B-X
.	B-X
All	B-X
of	B-X
these	B-X
effects	B-X
of	B-X
BMS-186511	B-X
are	B-X
limited	B-X
to	B-X
ras	B-X
transformed	B-X
cells	B-X
that	B-X
utilize	B-X
farnesylated	B-X
Ras	B-X
,	B-X
but	B-X
are	B-X
not	B-X
seen	B-X
in	B-X
transformed	B-X
cells	B-X
that	B-X
use	B-X
geranylgeranyl	B-X
Ras	B-X
or	B-X
myristoyl	B-X
Ras	B-X
.	B-X
Significantly	B-X
,	B-X
these	B-X
FT	B-X
inhibitors	B-X
did	B-X
not	B-X
produce	B-X
any	B-X
signs	B-X
of	B-X
gross	B-X
cytotoxicity	B-X
in	B-X
untransformed	B-X
,	B-X
ras	B-X
transformed	B-X
cells	B-X
or	B-X
other	B-X
oncogene	B-X
transformed	B-X
cells	B-X
.	B-X

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
FT	O
inhibitors	O
may	O
ultimately	O
become	O
the	O
first	O
generation	O
of	O
drugs	O
against	O
the	O
malignant	O
phenotype	O
in	O
NF1	O
based	O
on	O
rational	O
insights	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
neurofibromin	B-Protein
.	O
<EOS>	B-X
Neurofibromatosis	B-X
type	B-X
I	B-X
(	B-X
NF1	B-X
)	B-X
is	B-X
a	B-X
hereditary	B-X
tumor	B-X
and	B-X
developmental	B-X
disorder	B-X
whose	B-X
defective	B-X
gene	B-X
was	B-X
cloned	B-X
previously	B-X
.	B-X
The	B-X
protein	B-X
product	B-X
of	B-X
the	B-X
NF1	B-X
gene	B-X
,	B-X
neurofibromin	B-X
,	B-X
contains	B-X
a	B-X
domain	B-X
that	B-X
shows	B-X
significant	B-X
sequence	B-X
homology	B-X
to	B-X
the	B-X
known	B-X
catalytic	B-X
domains	B-X
of	B-X
mammalian	B-X
Ras	B-X
GTPase-activating	B-X
proteins	B-X
(	B-X
GAP	B-X
)	B-X
and	B-X
the	B-X
yeast	B-X
IRA1	B-X
and	B-X
IRA2	B-X
proteins	B-X
.	B-X
This	B-X
homologous	B-X
region	B-X
of	B-X
neurofibromin	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
exhibit	B-X
GAP	B-X
activity	B-X
toward	B-X
Ras	B-X
proteins	B-X
.	B-X
Malignant	B-X
schwannoma	B-X
cell	B-X
lines	B-X
from	B-X
NF1	B-X
patients	B-X
contain	B-X
normal	B-X
levels	B-X
of	B-X
GAP	B-X
and	B-X
nonmutated	B-X
Ras	B-X
proteins	B-X
but	B-X
barely	B-X
detectable	B-X
levels	B-X
of	B-X
neurofibromin	B-X
,	B-X
based	B-X
on	B-X
genetic	B-X
mutations	B-X
in	B-X
the	B-X
NF1	B-X
gene	B-X
.	B-X
Because	B-X
these	B-X
cells	B-X
contain	B-X
constitutively	B-X
activated	B-X
Ras.GTP	B-X
,	B-X
it	B-X
has	B-X
been	B-X
proposed	B-X
that	B-X
neurofibromin	B-X
may	B-X
be	B-X
the	B-X
sole	B-X
negative	B-X
regulator	B-X
of	B-X
Ras	B-X
in	B-X
these	B-X
cells	B-X
.	B-X
Overall	B-X
,	B-X
these	B-X
results	B-X
have	B-X
implied	B-X
an	B-X
important	B-X
role	B-X
of	B-X
the	B-X
Ras	B-X
signaling	B-X
pathway	B-X
in	B-X
NF1	B-X
malignant	B-X
schwannomas	B-X
.	B-X
Recently	B-X
,	B-X
several	B-X
laboratories	B-X
have	B-X
developed	B-X
small	B-X
molecule	B-X
inhibitors	B-X
of	B-X
Ras	B-X
function	B-X
that	B-X
inhibit	B-X
the	B-X
enzyme	B-X
farnesyltransferase	B-X
(	B-X
FT	B-X
)	B-X
.	B-X
FT-mediated	B-X
post-translational	B-X
farnesylation	B-X
of	B-X
Ras	B-X
proteins	B-X
is	B-X
absolutely	B-X
necessary	B-X
for	B-X
Ras	B-X
function	B-X
since	B-X
this	B-X
modification	B-X
is	B-X
required	B-X
for	B-X
the	B-X
anchoring	B-X
of	B-X
Ras	B-X
proteins	B-X
to	B-X
the	B-X
plasma	B-X
cell	B-X
membrane	B-X
.	B-X
Although	B-X
previous	B-X
studies	B-X
have	B-X
shown	B-X
that	B-X
FT	B-X
inhibitors	B-X
can	B-X
block	B-X
the	B-X
growth	B-X
of	B-X
tumor	B-X
cells	B-X
carrying	B-X
mutant	B-X
Ras	B-X
proteins	B-X
,	B-X
it	B-X
remained	B-X
unclear	B-X
how	B-X
this	B-X
class	B-X
of	B-X
inhibitors	B-X
would	B-X
affect	B-X
tumor	B-X
cells	B-X
such	B-X
as	B-X
in	B-X
NF1	B-X
,	B-X
whose	B-X
malignant	B-X
growth	B-X
appears	B-X
to	B-X
be	B-X
mediated	B-X
by	B-X
up-regulation	B-X
of	B-X
wild-type	B-X
Ras	B-X
activity	B-X
.	B-X
Thus	B-X
,	B-X
in	B-X
the	B-X
current	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
whether	B-X
BMS-186511	B-X
,	B-X
a	B-X
bisubstrate	B-X
analogue	B-X
inhibitor	B-X
of	B-X
FT	B-X
,	B-X
would	B-X
inhibit	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
a	B-X
cell	B-X
line	B-X
established	B-X
from	B-X
malignant	B-X
schwannoma	B-X
of	B-X
an	B-X
NF1	B-X
patient	B-X
.	B-X
Our	B-X
results	B-X
indicate	B-X
that	B-X
the	B-X
malignant	B-X
growth	B-X
properties	B-X
of	B-X
ST88-14	B-X
cells	B-X
,	B-X
the	B-X
most	B-X
malignant	B-X
cell	B-X
line	B-X
among	B-X
several	B-X
well-characterized	B-X
NF1	B-X
cells	B-X
,	B-X
are	B-X
inhibited	B-X
by	B-X
BMS-186511	B-X
in	B-X
a	B-X
concentration-dependent	B-X
manner	B-X
.	B-X
In	B-X
the	B-X
drug-exposed	B-X
cells	B-X
,	B-X
Ras	B-X
proteins	B-X
were	B-X
prevented	B-X
from	B-X
FT-mediated	B-X
membrane	B-X
association	B-X
.	B-X
BMS-186511	B-X
was	B-X
found	B-X
to	B-X
specifically	B-X
inhibit	B-X
FT	B-X
,	B-X
but	B-X
not	B-X
geranylgeranyltransferase	B-X
I	B-X
,	B-X
a	B-X
closely	B-X
related	B-X
enzyme	B-X
.	B-X
Thus	B-X
,	B-X
it	B-X
is	B-X
conceivable	B-X
that	B-X
FT	B-X
inhibitors	B-X
may	B-X
ultimately	B-X
become	B-X
the	B-X
first	B-X
generation	B-X
of	B-X
drugs	B-X
against	B-X
the	B-X
malignant	B-X
phenotype	B-X
in	B-X
NF1	B-X
based	B-X
on	B-X
rational	B-X
insights	B-X
into	B-X
the	B-X
mechanism	B-X
of	B-X
action	B-X
of	B-X
neurofibromin	B-X
.	B-X

A	O
novel	O
G	O
protein	O
alpha	O
subunit	O
containing	O
atypical	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
is	O
differentially	O
expressed	O
in	O
a	O
molluscan	O
nervous	O
system	O
.	O

We	O
described	O
the	O
characterization	O
of	O
a	O
novel	O
G	O
protein	O
alpha	O
subunit	O
,	O
G	B-Protein
alpha	I-Protein
a	I-Protein
.	O

cDNA	O
encoding	O
this	O
subunit	O
was	O
cloned	O
from	O
the	O
central	O
nervous	O
system	O
of	O
the	O
mollusc	O
Lymnaea	O
stagnalis	O
.	O
<EOS>	B-X
The	B-X
central	B-X
nervous	B-X
system	B-X
of	B-X
the	B-X
pond	B-X
snail	B-X
,	B-X
Lymnaea	B-X
stagnalis	B-X
,	B-X
contains	B-X
many	B-X
large	B-X
,	B-X
identified	B-X
neurons	B-X
which	B-X
can	B-X
be	B-X
easily	B-X
manipulated	B-X
making	B-X
it	B-X
an	B-X
advantageous	B-X
model	B-X
system	B-X
to	B-X
elucidate	B-X
in	B-X
vivo	B-X
the	B-X
architecture	B-X
of	B-X
neuronal	B-X
signal	B-X
transduction	B-X
pathways	B-X
.	B-X
We	B-X
have	B-X
isolated	B-X
three	B-X
cDNA	B-X
clones	B-X
encoding	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
that	B-X
are	B-X
expressed	B-X
in	B-X
the	B-X
Lymnaea	B-X
CNS	B-X
,	B-X
i.e	B-X
.	B-X
The	B-X
strong	B-X
conservation	B-X
of	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
suggests	B-X
that	B-X
functional	B-X
insights	B-X
into	B-X
G	B-X
protein-mediated	B-X
signalling	B-X
routes	B-X
obtained	B-X
through	B-X
the	B-X
experimental	B-X
amenability	B-X
of	B-X
the	B-X
Lymnaea	B-X
CNS	B-X
will	B-X
have	B-X
relevance	B-X
for	B-X
similar	B-X
pathways	B-X
in	B-X
the	B-X
mammalian	B-X
brain	B-X
.	B-X
We	B-X
have	B-X
cloned	B-X
cDNA	B-X
encoding	B-X
a	B-X
G-protein	B-X
beta	B-X
subunit	B-X
from	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
(	B-X
CNS	B-X
)	B-X
of	B-X
the	B-X
mollusc	B-X
Lymnaea	B-X
stagnalis	B-X
.	B-X
The	B-X
deduced	B-X
protein	B-X
is	B-X
very	B-X
homologous	B-X
to	B-X
other	B-X
metazoan	B-X
beta	B-X
subunits	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
Lymnaea	B-X
CNS	B-X
can	B-X
be	B-X
used	B-X
as	B-X
a	B-X
model	B-X
system	B-X
to	B-X
study	B-X
beta	B-X
gamma	B-X
subunits	B-X
in	B-X
their	B-X
native	B-X
setting	B-X
since	B-X
its	B-X
large	B-X
neurons	B-X
can	B-X
be	B-X
manipulated	B-X
and	B-X
studied	B-X
relatively	B-X
easily	B-X
in	B-X
vivo	B-X
.	B-X

The	O
deduced	O
protein	O
contains	O
all	O
characteristic	O
guanine	O
nucleotide	O
-	O
binding	O
domains	O
of	O
G	O
alpha	O
subunits	O
but	O
shares	O
only	O
a	O
limited	O
degree	O
of	O
overall	O
sequence	O
identity	O
with	O
known	O
subtypes	O
(	O
approximately	O
30	O
%	O
)	O
.	O

Moreover	O
,	O
two	O
of	O
the	O
nucleotide	O
-	O
binding	O
domains	O
exhibit	O
salient	O
deviations	O
from	O
corresponding	O
sequences	O
in	O
other	O
G	O
protein	O
alpha	O
subunits	O
.	O
<EOS>	B-X
We	B-X
described	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
G	B-X
protein	B-X
alpha	B-X
subunit	B-X
,	B-X
G	B-X
alpha	B-X
a.	B-X
cDNA	B-X
encoding	B-X
this	B-X
subunit	B-X
was	B-X
cloned	B-X
from	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
of	B-X
the	B-X
mollusc	B-X
Lymnaea	B-X
stagnalis	B-X
.	B-X
The	B-X
deduced	B-X
protein	B-X
contains	B-X
all	B-X
characteristic	B-X
guanine	B-X
nucleotide-binding	B-X
domains	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
but	B-X
shares	B-X
only	B-X
a	B-X
limited	B-X
degree	B-X
of	B-X
overall	B-X
sequence	B-X
identity	B-X
with	B-X
known	B-X
subtypes	B-X
(	B-X
approximately	B-X
30	B-X
%	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
two	B-X
of	B-X
the	B-X
nucleotide-binding	B-X
domains	B-X
exhibit	B-X
salient	B-X
deviations	B-X
from	B-X
corresponding	B-X
sequences	B-X
in	B-X
other	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
.	B-X
The	B-X
A	B-X
domain	B-X
,	B-X
determining	B-X
kinetic	B-X
features	B-X
of	B-X
the	B-X
GTPase	B-X
cycle	B-X
,	B-X
contains	B-X
a	B-X
markedly	B-X
unique	B-X
amino	B-X
acid	B-X
sequence	B-X
(	B-X
ILIIGGPGAGK	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
C	B-X
domain	B-X
is	B-X
also	B-X
clearly	B-X
distinct	B-X
(	B-X
DVAGQRSL	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
leucine	B-X
in	B-X
this	B-X
motif	B-X
,	B-X
instead	B-X
of	B-X
glutamic	B-X
acid	B-X
,	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
hypotheses	B-X
concerning	B-X
the	B-X
GTPase	B-X
mechanism	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
G	B-X
alpha	B-X
subtypes	B-X
,	B-X
G	B-X
alpha	B-X
a	B-X
has	B-X
no	B-X
appropriate	B-X
N-terminal	B-X
residues	B-X
that	B-X
could	B-X
be	B-X
acylated	B-X
.	B-X
It	B-X
does	B-X
contain	B-X
the	B-X
strictly	B-X
conserved	B-X
arginine	B-X
residue	B-X
that	B-X
serves	B-X
as	B-X
a	B-X
cholera	B-X
toxin	B-X
substrate	B-X
in	B-X
G	B-X
alpha	B-X
s	B-X
and	B-X
G	B-X
alpha	B-X
t	B-X
but	B-X
lacks	B-X
a	B-X
site	B-X
for	B-X
ADP-ribosylation	B-X
by	B-X
pertussis	B-X
toxin	B-X
.	B-X
In	B-X
situ	B-X
hybridization	B-X
experiments	B-X
indicate	B-X
that	B-X
G	B-X
alpha	B-X
a-encoding	B-X
mRNA	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
limited	B-X
subpopulation	B-X
of	B-X
neurons	B-X
within	B-X
the	B-X
Lymnaea	B-X
brain	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
G	B-X
alpha	B-X
a	B-X
defines	B-X
a	B-X
separate	B-X
class	B-X
of	B-X
G	B-X
proteins	B-X
with	B-X
cell	B-X
type-specific	B-X
functions	B-X
.	B-X

The	O
A	O
domain	O
,	O
determining	O
kinetic	O
features	O
of	O
the	O
GTPase	O
cycle	O
,	O
contains	O
a	O
markedly	O
unique	O
amino	O
acid	O
sequence	O
(	O
ILIIGGPGAGK	O
)	O
.	O
<EOS>	B-X
The	B-X
deduced	B-X
protein	B-X
contains	B-X
all	B-X
characteristic	B-X
guanine	B-X
nucleotide-binding	B-X
domains	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
but	B-X
shares	B-X
only	B-X
a	B-X
limited	B-X
degree	B-X
of	B-X
overall	B-X
sequence	B-X
identity	B-X
with	B-X
known	B-X
subtypes	B-X
(	B-X
approximately	B-X
30	B-X
%	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
two	B-X
of	B-X
the	B-X
nucleotide-binding	B-X
domains	B-X
exhibit	B-X
salient	B-X
deviations	B-X
from	B-X
corresponding	B-X
sequences	B-X
in	B-X
other	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
.	B-X
The	B-X
A	B-X
domain	B-X
,	B-X
determining	B-X
kinetic	B-X
features	B-X
of	B-X
the	B-X
GTPase	B-X
cycle	B-X
,	B-X
contains	B-X
a	B-X
markedly	B-X
unique	B-X
amino	B-X
acid	B-X
sequence	B-X
(	B-X
ILIIGGPGAGK	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
C	B-X
domain	B-X
is	B-X
also	B-X
clearly	B-X
distinct	B-X
(	B-X
DVAGQRSL	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
leucine	B-X
in	B-X
this	B-X
motif	B-X
,	B-X
instead	B-X
of	B-X
glutamic	B-X
acid	B-X
,	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
hypotheses	B-X
concerning	B-X
the	B-X
GTPase	B-X
mechanism	B-X
.	B-X

In	O
addition	O
,	O
the	O
C	O
domain	O
is	O
also	O
clearly	O
distinct	O
(	O
DVAGQRSL	O
)	O
.	O

The	O
presence	O
of	O
a	O
leucine	O
in	O
this	O
motif	O
,	O
instead	O
of	O
glutamic	O
acid	O
,	O
has	O
important	O
implications	O
for	O
hypotheses	O
concerning	O
the	O
GTPase	O
mechanism	O
.	O
<EOS>	B-X
The	B-X
A	B-X
domain	B-X
,	B-X
determining	B-X
kinetic	B-X
features	B-X
of	B-X
the	B-X
GTPase	B-X
cycle	B-X
,	B-X
contains	B-X
a	B-X
markedly	B-X
unique	B-X
amino	B-X
acid	B-X
sequence	B-X
(	B-X
ILIIGGPGAGK	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
leucine	B-X
in	B-X
this	B-X
motif	B-X
,	B-X
instead	B-X
of	B-X
glutamic	B-X
acid	B-X
,	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
hypotheses	B-X
concerning	B-X
the	B-X
GTPase	B-X
mechanism	B-X
.	B-X

In	O
contrast	O
to	O
other	O
G	O
alpha	O
subtypes	O
,	O
G	B-Protein
alpha	I-Protein
a	I-Protein
has	O
no	O
appropriate	O
N	O
-	O
terminal	O
residues	O
that	O
could	O
be	O
acylated	O
.	O
<EOS>	B-X
We	B-X
described	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
G	B-X
protein	B-X
alpha	B-X
subunit	B-X
,	B-X
G	B-X
alpha	B-X
a.	B-X
cDNA	B-X
encoding	B-X
this	B-X
subunit	B-X
was	B-X
cloned	B-X
from	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
of	B-X
the	B-X
mollusc	B-X
Lymnaea	B-X
stagnalis	B-X
.	B-X
The	B-X
deduced	B-X
protein	B-X
contains	B-X
all	B-X
characteristic	B-X
guanine	B-X
nucleotide-binding	B-X
domains	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
but	B-X
shares	B-X
only	B-X
a	B-X
limited	B-X
degree	B-X
of	B-X
overall	B-X
sequence	B-X
identity	B-X
with	B-X
known	B-X
subtypes	B-X
(	B-X
approximately	B-X
30	B-X
%	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
two	B-X
of	B-X
the	B-X
nucleotide-binding	B-X
domains	B-X
exhibit	B-X
salient	B-X
deviations	B-X
from	B-X
corresponding	B-X
sequences	B-X
in	B-X
other	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
.	B-X
The	B-X
A	B-X
domain	B-X
,	B-X
determining	B-X
kinetic	B-X
features	B-X
of	B-X
the	B-X
GTPase	B-X
cycle	B-X
,	B-X
contains	B-X
a	B-X
markedly	B-X
unique	B-X
amino	B-X
acid	B-X
sequence	B-X
(	B-X
ILIIGGPGAGK	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
C	B-X
domain	B-X
is	B-X
also	B-X
clearly	B-X
distinct	B-X
(	B-X
DVAGQRSL	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
leucine	B-X
in	B-X
this	B-X
motif	B-X
,	B-X
instead	B-X
of	B-X
glutamic	B-X
acid	B-X
,	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
hypotheses	B-X
concerning	B-X
the	B-X
GTPase	B-X
mechanism	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
G	B-X
alpha	B-X
subtypes	B-X
,	B-X
G	B-X
alpha	B-X
a	B-X
has	B-X
no	B-X
appropriate	B-X
N-terminal	B-X
residues	B-X
that	B-X
could	B-X
be	B-X
acylated	B-X
.	B-X
It	B-X
does	B-X
contain	B-X
the	B-X
strictly	B-X
conserved	B-X
arginine	B-X
residue	B-X
that	B-X
serves	B-X
as	B-X
a	B-X
cholera	B-X
toxin	B-X
substrate	B-X
in	B-X
G	B-X
alpha	B-X
s	B-X
and	B-X
G	B-X
alpha	B-X
t	B-X
but	B-X
lacks	B-X
a	B-X
site	B-X
for	B-X
ADP-ribosylation	B-X
by	B-X
pertussis	B-X
toxin	B-X
.	B-X
In	B-X
situ	B-X
hybridization	B-X
experiments	B-X
indicate	B-X
that	B-X
G	B-X
alpha	B-X
a-encoding	B-X
mRNA	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
limited	B-X
subpopulation	B-X
of	B-X
neurons	B-X
within	B-X
the	B-X
Lymnaea	B-X
brain	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
G	B-X
alpha	B-X
a	B-X
defines	B-X
a	B-X
separate	B-X
class	B-X
of	B-X
G	B-X
proteins	B-X
with	B-X
cell	B-X
type-specific	B-X
functions	B-X
.	B-X

It	O
does	O
contain	O
the	O
strictly	O
conserved	O
arginine	O
residue	O
that	O
serves	O
as	O
a	O
cholera	O
toxin	O
substrate	O
in	O
G	B-Protein
alpha	I-Protein
s	I-Protein
and	O
G	O
alpha	O
t	O
but	O
lacks	O
a	O
site	O
for	O
ADP	O
-	O
ribosylation	O
by	O
pertussis	O
toxin	O
.	O

In	O
situ	O
hybridization	O
experiments	O
indicate	O
that	O
G	B-Protein
alpha	I-Protein
a	I-Protein
-	O
encoding	O
mRNA	O
is	O
expressed	O
in	O
a	O
limited	O
subpopulation	O
of	O
neurons	O
within	O
the	O
Lymnaea	O
brain	O
.	O

These	O
data	O
suggest	O
that	O
G	B-Protein
alpha	I-Protein
a	I-Protein
defines	O
a	O
separate	O
class	O
of	O
G	O
proteins	O
with	O
cell	O
type	O
-	O
specific	O
functions	O
.	O
<EOS>	B-X
We	B-X
described	B-X
the	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
G	B-X
protein	B-X
alpha	B-X
subunit	B-X
,	B-X
G	B-X
alpha	B-X
a.	B-X
cDNA	B-X
encoding	B-X
this	B-X
subunit	B-X
was	B-X
cloned	B-X
from	B-X
the	B-X
central	B-X
nervous	B-X
system	B-X
of	B-X
the	B-X
mollusc	B-X
Lymnaea	B-X
stagnalis	B-X
.	B-X
The	B-X
deduced	B-X
protein	B-X
contains	B-X
all	B-X
characteristic	B-X
guanine	B-X
nucleotide-binding	B-X
domains	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
but	B-X
shares	B-X
only	B-X
a	B-X
limited	B-X
degree	B-X
of	B-X
overall	B-X
sequence	B-X
identity	B-X
with	B-X
known	B-X
subtypes	B-X
(	B-X
approximately	B-X
30	B-X
%	B-X
)	B-X
.	B-X
Moreover	B-X
,	B-X
two	B-X
of	B-X
the	B-X
nucleotide-binding	B-X
domains	B-X
exhibit	B-X
salient	B-X
deviations	B-X
from	B-X
corresponding	B-X
sequences	B-X
in	B-X
other	B-X
G	B-X
protein	B-X
alpha	B-X
subunits	B-X
.	B-X
The	B-X
A	B-X
domain	B-X
,	B-X
determining	B-X
kinetic	B-X
features	B-X
of	B-X
the	B-X
GTPase	B-X
cycle	B-X
,	B-X
contains	B-X
a	B-X
markedly	B-X
unique	B-X
amino	B-X
acid	B-X
sequence	B-X
(	B-X
ILIIGGPGAGK	B-X
)	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
the	B-X
C	B-X
domain	B-X
is	B-X
also	B-X
clearly	B-X
distinct	B-X
(	B-X
DVAGQRSL	B-X
)	B-X
.	B-X
The	B-X
presence	B-X
of	B-X
a	B-X
leucine	B-X
in	B-X
this	B-X
motif	B-X
,	B-X
instead	B-X
of	B-X
glutamic	B-X
acid	B-X
,	B-X
has	B-X
important	B-X
implications	B-X
for	B-X
hypotheses	B-X
concerning	B-X
the	B-X
GTPase	B-X
mechanism	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
other	B-X
G	B-X
alpha	B-X
subtypes	B-X
,	B-X
G	B-X
alpha	B-X
a	B-X
has	B-X
no	B-X
appropriate	B-X
N-terminal	B-X
residues	B-X
that	B-X
could	B-X
be	B-X
acylated	B-X
.	B-X
It	B-X
does	B-X
contain	B-X
the	B-X
strictly	B-X
conserved	B-X
arginine	B-X
residue	B-X
that	B-X
serves	B-X
as	B-X
a	B-X
cholera	B-X
toxin	B-X
substrate	B-X
in	B-X
G	B-X
alpha	B-X
s	B-X
and	B-X
G	B-X
alpha	B-X
t	B-X
but	B-X
lacks	B-X
a	B-X
site	B-X
for	B-X
ADP-ribosylation	B-X
by	B-X
pertussis	B-X
toxin	B-X
.	B-X
In	B-X
situ	B-X
hybridization	B-X
experiments	B-X
indicate	B-X
that	B-X
G	B-X
alpha	B-X
a-encoding	B-X
mRNA	B-X
is	B-X
expressed	B-X
in	B-X
a	B-X
limited	B-X
subpopulation	B-X
of	B-X
neurons	B-X
within	B-X
the	B-X
Lymnaea	B-X
brain	B-X
.	B-X
These	B-X
data	B-X
suggest	B-X
that	B-X
G	B-X
alpha	B-X
a	B-X
defines	B-X
a	B-X
separate	B-X
class	B-X
of	B-X
G	B-X
proteins	B-X
with	B-X
cell	B-X
type-specific	B-X
functions	B-X
.	B-X

Semisynthetic	O
chemical	O
modification	O
of	O
the	O
antifungal	O
lipopeptide	O
echinocandin	O
B	O
(	O
ECB	O
)	O
:	O
structure	O
-	O
activity	O
studies	O
of	O
the	O
lipophilic	O
and	O
geometric	O
parameters	O
of	O
polyarylated	O
acyl	O
analogs	O
of	O
ECB	O
.	O
<EOS>	B-X
Echinocandin	B-X
B	B-X
(	B-X
ECB	B-X
)	B-X
is	B-X
a	B-X
lipopeptide	B-X
composed	B-X
of	B-X
a	B-X
complex	B-X
cyclic	B-X
peptide	B-X
acylated	B-X
at	B-X
the	B-X
N-terminus	B-X
by	B-X
linoleic	B-X
acid	B-X
.	B-X
Enzymatic	B-X
deacylation	B-X
of	B-X
ECB	B-X
provided	B-X
the	B-X
peptide	B-X
``	B-X
nucleus	B-X
''	B-X
as	B-X
a	B-X
biologically	B-X
inactive	B-X
substrate	B-X
from	B-X
which	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
generated	B-X
by	B-X
chemical	B-X
reacylation	B-X
at	B-X
the	B-X
N-terminus	B-X
.	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Using	B-X
these	B-X
parameters	B-X
as	B-X
a	B-X
guide	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
synthesized	B-X
which	B-X
included	B-X
arylacyl	B-X
groups	B-X
that	B-X
incorporated	B-X
biphenyl	B-X
,	B-X
terphenyl	B-X
,	B-X
tetraphenyl	B-X
,	B-X
and	B-X
arylethynyl	B-X
groups	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

Echinocandin	O
B	O
(	O
ECB	O
)	O
is	O
a	O
lipopeptide	O
composed	O
of	O
a	O
complex	O
cyclic	O
peptide	O
acylated	O
at	O
the	O
N	O
-	O
terminus	O
by	O
linoleic	O
acid	O
.	O

Enzymatic	O
deacylation	O
of	O
ECB	O
provided	O
the	O
peptide	O
"	O
nucleus	O
"	O
as	O
a	O
biologically	O
inactive	O
substrate	O
from	O
which	O
novel	O
ECB	O
analogs	O
were	O
generated	O
by	O
chemical	O
reacylation	O
at	O
the	O
N	O
-	O
terminus	O
.	O

Varying	O
the	O
acyl	O
group	O
revealed	O
that	O
the	O
structure	O
and	O
physical	O
properties	O
of	O
the	O
side	O
chain	O
,	O
particularly	O
its	O
geometry	O
and	O
lipophilicity	O
,	O
played	O
a	O
pivotal	O
role	O
in	O
determining	O
the	O
antifungal	O
potency	O
properties	O
of	O
the	O
analog	O
.	O
<EOS>	B-X
Echinocandin	B-X
B	B-X
(	B-X
ECB	B-X
)	B-X
is	B-X
a	B-X
lipopeptide	B-X
composed	B-X
of	B-X
a	B-X
complex	B-X
cyclic	B-X
peptide	B-X
acylated	B-X
at	B-X
the	B-X
N-terminus	B-X
by	B-X
linoleic	B-X
acid	B-X
.	B-X
Enzymatic	B-X
deacylation	B-X
of	B-X
ECB	B-X
provided	B-X
the	B-X
peptide	B-X
``	B-X
nucleus	B-X
''	B-X
as	B-X
a	B-X
biologically	B-X
inactive	B-X
substrate	B-X
from	B-X
which	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
generated	B-X
by	B-X
chemical	B-X
reacylation	B-X
at	B-X
the	B-X
N-terminus	B-X
.	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Using	B-X
these	B-X
parameters	B-X
as	B-X
a	B-X
guide	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
synthesized	B-X
which	B-X
included	B-X
arylacyl	B-X
groups	B-X
that	B-X
incorporated	B-X
biphenyl	B-X
,	B-X
terphenyl	B-X
,	B-X
tetraphenyl	B-X
,	B-X
and	B-X
arylethynyl	B-X
groups	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

Using	O
CLOGP	O
values	O
to	O
describe	O
and	O
compare	O
the	O
lipophilicities	O
of	O
the	O
side	O
chain	O
fragments	O
,	O
it	O
was	O
shown	O
that	O
values	O
of	O
>	O
3	O
.	O
5	O
were	O
required	O
for	O
expression	O
of	O
antifungal	O
activity	O
.	O
<EOS>	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Using	B-X
these	B-X
parameters	B-X
as	B-X
a	B-X
guide	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
synthesized	B-X
which	B-X
included	B-X
arylacyl	B-X
groups	B-X
that	B-X
incorporated	B-X
biphenyl	B-X
,	B-X
terphenyl	B-X
,	B-X
tetraphenyl	B-X
,	B-X
and	B-X
arylethynyl	B-X
groups	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

Secondly	O
,	O
a	O
linearly	O
rigid	O
geometry	O
of	O
the	O
side	O
chain	O
was	O
the	O
most	O
effective	O
shape	O
in	O
enhancing	O
the	O
antifungal	O
potency	O
.	O
<EOS>	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

Using	O
these	O
parameters	O
as	O
a	O
guide	O
,	O
a	O
variety	O
of	O
novel	O
ECB	O
analogs	O
were	O
synthesized	O
which	O
included	O
arylacyl	O
groups	O
that	O
incorporated	O
biphenyl	O
,	O
terphenyl	O
,	O
tetraphenyl	O
,	O
and	O
arylethynyl	O
groups	O
.	O

Generally	O
the	O
glucan	O
synthase	O
inhibition	O
by	O
these	O
analogs	O
correlated	O
well	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
activities	O
and	O
was	O
likewise	O
influenced	O
by	O
the	O
structure	O
of	O
the	O
side	O
chain	O
.	O
<EOS>	B-X
Enzymatic	B-X
deacylation	B-X
of	B-X
ECB	B-X
provided	B-X
the	B-X
peptide	B-X
``	B-X
nucleus	B-X
''	B-X
as	B-X
a	B-X
biologically	B-X
inactive	B-X
substrate	B-X
from	B-X
which	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
generated	B-X
by	B-X
chemical	B-X
reacylation	B-X
at	B-X
the	B-X
N-terminus	B-X
.	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Using	B-X
these	B-X
parameters	B-X
as	B-X
a	B-X
guide	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
synthesized	B-X
which	B-X
included	B-X
arylacyl	B-X
groups	B-X
that	B-X
incorporated	B-X
biphenyl	B-X
,	B-X
terphenyl	B-X
,	B-X
tetraphenyl	B-X
,	B-X
and	B-X
arylethynyl	B-X
groups	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

These	O
structural	O
variations	O
resulted	O
in	O
enhancement	O
of	O
antifungal	O
activity	O
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
.	O
<EOS>	B-X
Varying	B-X
the	B-X
acyl	B-X
group	B-X
revealed	B-X
that	B-X
the	B-X
structure	B-X
and	B-X
physical	B-X
properties	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
,	B-X
particularly	B-X
its	B-X
geometry	B-X
and	B-X
lipophilicity	B-X
,	B-X
played	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
determining	B-X
the	B-X
antifungal	B-X
potency	B-X
properties	B-X
of	B-X
the	B-X
analog	B-X
.	B-X
Using	B-X
CLOGP	B-X
values	B-X
to	B-X
describe	B-X
and	B-X
compare	B-X
the	B-X
lipophilicities	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
fragments	B-X
,	B-X
it	B-X
was	B-X
shown	B-X
that	B-X
values	B-X
of	B-X
>	B-X
3.5	B-X
were	B-X
required	B-X
for	B-X
expression	B-X
of	B-X
antifungal	B-X
activity	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
These	B-X
structural	B-X
variations	B-X
resulted	B-X
in	B-X
enhancement	B-X
of	B-X
antifungal	B-X
activity	B-X
in	B-X
both	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
assays	B-X
.	B-X

Some	O
of	O
these	O
analogs	O
,	O
including	O
LY303366	O
(	O
14a	O
)	O
,	O
were	O
effective	O
by	O
the	O
oral	O
route	O
of	O
administration	O
.	O
<EOS>	B-X
Enzymatic	B-X
deacylation	B-X
of	B-X
ECB	B-X
provided	B-X
the	B-X
peptide	B-X
``	B-X
nucleus	B-X
''	B-X
as	B-X
a	B-X
biologically	B-X
inactive	B-X
substrate	B-X
from	B-X
which	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
generated	B-X
by	B-X
chemical	B-X
reacylation	B-X
at	B-X
the	B-X
N-terminus	B-X
.	B-X
Secondly	B-X
,	B-X
a	B-X
linearly	B-X
rigid	B-X
geometry	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
was	B-X
the	B-X
most	B-X
effective	B-X
shape	B-X
in	B-X
enhancing	B-X
the	B-X
antifungal	B-X
potency	B-X
.	B-X
Using	B-X
these	B-X
parameters	B-X
as	B-X
a	B-X
guide	B-X
,	B-X
a	B-X
variety	B-X
of	B-X
novel	B-X
ECB	B-X
analogs	B-X
were	B-X
synthesized	B-X
which	B-X
included	B-X
arylacyl	B-X
groups	B-X
that	B-X
incorporated	B-X
biphenyl	B-X
,	B-X
terphenyl	B-X
,	B-X
tetraphenyl	B-X
,	B-X
and	B-X
arylethynyl	B-X
groups	B-X
.	B-X
Generally	B-X
the	B-X
glucan	B-X
synthase	B-X
inhibition	B-X
by	B-X
these	B-X
analogs	B-X
correlated	B-X
well	B-X
with	B-X
in	B-X
vitro	B-X
and	B-X
in	B-X
vivo	B-X
activities	B-X
and	B-X
was	B-X
likewise	B-X
influenced	B-X
by	B-X
the	B-X
structure	B-X
of	B-X
the	B-X
side	B-X
chain	B-X
.	B-X
Some	B-X
of	B-X
these	B-X
analogs	B-X
,	B-X
including	B-X
LY303366	B-X
(	B-X
14a	B-X
)	B-X
,	B-X
were	B-X
effective	B-X
by	B-X
the	B-X
oral	B-X
route	B-X
of	B-X
administration	B-X
.	B-X

Fatty	O
acylation	O
of	O
the	O
rat	O
asialoglycoprotein	O
receptor	O
.	O
<EOS>	B-X
Functional	B-X
rat	B-X
or	B-X
human	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomeric	B-X
integral	B-X
membrane	B-X
glycoproteins	B-X
.	B-X
Rat	B-X
ASGP-R	B-X
contains	B-X
three	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
;	B-X
human	B-X
ASGP-R	B-X
contains	B-X
two	B-X
subunits	B-X
,	B-X
HHL1	B-X
and	B-X
HHL2	B-X
.	B-X
Both	B-X
receptors	B-X
are	B-X
covalently	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
(	B-X
Zeng	B-X
,	B-X
F.-Y.	B-X
,	B-X
Kaphalia	B-X
,	B-X
B.	B-X
S.	B-X
,	B-X
Ansari	B-X
,	B-X
G.	B-X
A.	B-X
S.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
The	B-X
degree	B-X
of	B-X
acylation	B-X
is	B-X
>	B-X
/=90	B-X
%	B-X
per	B-X
subunit	B-X
.	B-X
Deacylation	B-X
of	B-X
affinity-purified	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
results	B-X
in	B-X
the	B-X
spontaneous	B-X
formation	B-X
of	B-X
dimers	B-X
through	B-X
reversible	B-X
disulfide	B-X
bonds	B-X
,	B-X
indicating	B-X
that	B-X
deacylation	B-X
concomitantly	B-X
generates	B-X
free	B-X
thiol	B-X
groups	B-X
.	B-X
Reaction	B-X
of	B-X
hydroxylamine-treated	B-X
ASGP-R	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
iodoacetamide	B-X
resulted	B-X
in	B-X
the	B-X
specific	B-X
incorporation	B-X
of	B-X
radioactivity	B-X
into	B-X
all	B-X
RHL	B-X
and	B-X
HHL	B-X
subunits	B-X
,	B-X
verifying	B-X
that	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
To	B-X
identify	B-X
the	B-X
Cys	B-X
residue	B-X
involved	B-X
in	B-X
the	B-X
thioester	B-X
linkages	B-X
,	B-X
14C-carboxyamidomethylated	B-X
RHL	B-X
subunits	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
and	B-X
digested	B-X
in-gel	B-X
with	B-X
trypsin	B-X
,	B-X
and	B-X
the	B-X
resulting	B-X
peptides	B-X
were	B-X
separated	B-X
by	B-X
reverse-phase	B-X
high	B-X
performance	B-X
liquid	B-X
chromatography	B-X
.	B-X
Amino	B-X
acid	B-X
sequence	B-X
of	B-X
radioactive	B-X
peptides	B-X
revealed	B-X
that	B-X
Cys35	B-X
in	B-X
RHL1	B-X
and	B-X
Cys54	B-X
in	B-X
RHL2	B-X
and	B-X
RHL3	B-X
were	B-X
radiolabeled	B-X
and	B-X
,	B-X
therefore	B-X
,	B-X
are	B-X
fatty	B-X
acylation	B-X
sites	B-X
.	B-X
Fatty	B-X
acylation	B-X
of	B-X
HHL	B-X
subunits	B-X
was	B-X
analyzed	B-X
by	B-X
site-directed	B-X
mutagenesis	B-X
.	B-X
Metabolic	B-X
labeling	B-X
of	B-X
Cos7	B-X
cells	B-X
transfected	B-X
with	B-X
wild	B-X
type	B-X
HHL1	B-X
cDNA	B-X
resulted	B-X
in	B-X
substantial	B-X
incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
purified	B-X
HHL1	B-X
.	B-X
Incorporation	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
into	B-X
a	B-X
C36S	B-X
mutant	B-X
of	B-X
HHL1	B-X
was	B-X
negligible	B-X
(	B-X
approximately	B-X
1	B-X
%	B-X
)	B-X
compared	B-X
with	B-X
wild	B-X
type	B-X
.	B-X

The	O
three	O
subunits	O
from	O
active	O
receptors	O
contain	O
covalently	O
bound	O
palmitate	O
and	O
stearate	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X

Rat	O
hepatic	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomers	O
composed	O
of	O
three	O
homologous	O
glycoprotein	O
subunits	O
,	O
designated	O
rat	O
hepatic	B-Protein
lectins	I-Protein
(	I-Protein
RHL	I-Protein
)	I-Protein
1	I-Protein
,	O
2	B-Protein
,	O
and	O
3	B-Protein
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
(	B-X
1993	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
268	B-X
,	B-X
27186-27190	B-X
)	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
In	B-X
the	B-X
accompanying	B-X
paper	B-X
(	B-X
Zeng	B-X
,	B-X
F-Y.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

ASGP	O
-	O
Rs	O
mediate	O
the	O
endocytosis	O
and	O
degradation	O
of	O
circulating	O
glycoconjugates	O
containing	O
terminal	O
N	O
-	O
acetylgalactosamine	O
or	O
galactose	O
,	O
including	O
desialylated	O
plasma	O
glycoproteins	O
.	O
<EOS>	B-X
Neuraminidases	B-X
(	B-X
sialidases	B-X
)	B-X
are	B-X
enzymes	B-X
that	B-X
hydrolytically	B-X
remove	B-X
sialic	B-X
acid	B-X
from	B-X
sialylated	B-X
proteins	B-X
and	B-X
lipids	B-X
.	B-X
Neuraminidases	B-X
are	B-X
encoded	B-X
by	B-X
a	B-X
range	B-X
of	B-X
human	B-X
pathogens	B-X
,	B-X
including	B-X
bacteria	B-X
,	B-X
viruses	B-X
,	B-X
fungi	B-X
,	B-X
and	B-X
protozoa	B-X
.	B-X
Many	B-X
pathogen	B-X
neuraminidases	B-X
are	B-X
virulence	B-X
factors	B-X
,	B-X
indicating	B-X
that	B-X
desialylation	B-X
of	B-X
host	B-X
glycoconjugates	B-X
can	B-X
be	B-X
a	B-X
critical	B-X
step	B-X
in	B-X
infection	B-X
.	B-X
Specifically	B-X
,	B-X
desialylation	B-X
of	B-X
host	B-X
cell	B-X
surface	B-X
glycoproteins	B-X
can	B-X
enable	B-X
these	B-X
molecules	B-X
to	B-X
function	B-X
as	B-X
pathogen	B-X
receptors	B-X
or	B-X
can	B-X
alter	B-X
signaling	B-X
through	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
combine	B-X
previously	B-X
reported	B-X
glycoproteomics	B-X
methods	B-X
with	B-X
quantitative	B-X
proteomics	B-X
analysis	B-X
to	B-X
identify	B-X
glycoproteins	B-X
whose	B-X
sialylation	B-X
changes	B-X
in	B-X
response	B-X
to	B-X
neuraminidase	B-X
treatment	B-X
.	B-X
The	B-X
two	B-X
glycoproteomics	B-X
methods-periodate	B-X
oxidation	B-X
and	B-X
aniline-catalyzed	B-X
oxime	B-X
ligation	B-X
(	B-X
PAL	B-X
)	B-X
and	B-X
galactose	B-X
oxidase	B-X
and	B-X
aniline-catalyzed	B-X
oxime	B-X
ligation	B-X
(	B-X
GAL	B-X
)	B-X
-rely	B-X
on	B-X
chemoselective	B-X
labeling	B-X
of	B-X
sialylated	B-X
and	B-X
nonsialylated	B-X
glycoproteins	B-X
,	B-X
respectively	B-X
.	B-X
Among	B-X
the	B-X
identified	B-X
substrates	B-X
were	B-X
host	B-X
glycoproteins	B-X
known	B-X
to	B-X
function	B-X
in	B-X
bacteria	B-X
adherence	B-X
and	B-X
infection	B-X
.	B-X
Functional	B-X
assays	B-X
suggest	B-X
that	B-X
multiple	B-X
desialylated	B-X
cell	B-X
surface	B-X
glycoproteins	B-X
may	B-X
act	B-X
together	B-X
as	B-X
pneumococcus	B-X
receptors	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
method	B-X
will	B-X
provide	B-X
a	B-X
powerful	B-X
approach	B-X
to	B-X
identify	B-X
glycoproteins	B-X
that	B-X
are	B-X
desialylated	B-X
by	B-X
both	B-X
purified	B-X
neuraminidases	B-X
and	B-X
intact	B-X
pathogens	B-X
.	B-X

We	O
have	O
shown	O
in	O
permeable	O
rat	O
hepatocytes	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
one	O
subpopulation	O
of	O
receptors	O
(	O
designated	O
State	O
2	O
ASGP	O
-	O
Rs	O
)	O
can	O
be	O
decreased	O
or	O
increased	O
,	O
respectively	O
,	O
by	O
ATP	O
and	O
palmitoyl	O
-	O
CoA	O
(	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
,	O
and	O
Oka	O
,	O
J	O
.	O
A	O
.	O
(	O
1993	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
27186	O
-	O
27190	O
)	O
.	O

We	O
proposed	O
that	O
a	O
reversible	O
and	O
cyclic	O
acylation	O
/	O
deacylation	O
process	O
may	O
regulate	O
ASGP	O
-	O
R	O
activity	O
during	O
endocytosis	O
,	O
receptor	O
-	O
ligand	O
dissociation	O
,	O
and	O
receptor	O
recycling	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

In	O
the	O
accompanying	O
paper	O
(	O
Zeng	O
,	O
F	O
-	O
Y	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21388	O
-	O
21395	O
)	O
,	O
we	O
show	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
affinity	O
-	O
purified	O
State	O
2	O
ASGP	O
-	O
Rs	O
is	O
decreased	O
by	O
treatment	O
with	O
hydroxylamine	O
under	O
mild	O
conditions	O
consistent	O
with	O
these	O
ASGP	O
-	O
Rs	O
being	O
fatty	O
acylated	O
in	O
vivo	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
(	B-X
1993	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
Chem	B-X
.	B-X
268	B-X
,	B-X
27186-27190	B-X
)	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
In	B-X
the	B-X
accompanying	B-X
paper	B-X
(	B-X
Zeng	B-X
,	B-X
F-Y.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

In	O
this	O
study	O
,	O
we	O
used	O
a	O
chemical	O
method	O
to	O
determine	O
the	O
presence	O
of	O
covalently	O
-	O
bound	O
fatty	O
acids	O
in	O
individual	O
ASGP	O
-	O
R	O
subunits	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

The	O
affinity	O
-	O
purified	O
ASGP	O
-	O
R	O
preparations	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
nonreducing	O
conditions	O
,	O
and	O
the	O
gel	O
slices	O
containing	O
individual	O
RHL	O
subunits	O
were	O
treated	O
with	O
alkali	O
to	O
release	O
covalently	O
bound	O
fatty	O
acids	O
,	O
which	O
were	O
subsequently	O
analyzed	O
by	O
gas	O
chromatography	O
and	O
confirmed	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
In	B-X
the	B-X
accompanying	B-X
paper	B-X
(	B-X
Zeng	B-X
,	B-X
F-Y.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

Both	O
stearic	O
and	O
palmitic	O
acids	O
were	O
detected	O
in	O
all	O
three	O
receptor	O
subunits	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X

Pretreatment	O
of	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
before	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
reduced	O
the	O
content	O
of	O
both	O
fatty	O
acids	O
by	O
66	O
-	O
80	O
%	O
,	O
indicating	O
that	O
most	O
of	O
these	O
fatty	O
acids	O
are	O
attached	O
to	O
cysteine	O
residues	O
via	O
thioester	O
linkages	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
In	B-X
the	B-X
accompanying	B-X
paper	B-X
(	B-X
Zeng	B-X
,	B-X
F-Y.	B-X
,	B-X
and	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
(	B-X
1995	B-X
)	B-X
J.	B-X
Biol	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
when	O
freshly	O
isolated	O
hepatocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
[	O
3H	O
]	O
palmitate	O
,	O
all	O
three	O
RHL	O
subunits	O
in	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
were	O
metabolically	O
labeled	O
.	O
<EOS>	B-X
Rat	B-X
hepatic	B-X
asialoglycoprotein	B-X
receptors	B-X
(	B-X
ASGP-Rs	B-X
)	B-X
are	B-X
hetero-oligomers	B-X
composed	B-X
of	B-X
three	B-X
homologous	B-X
glycoprotein	B-X
subunits	B-X
,	B-X
designated	B-X
rat	B-X
hepatic	B-X
lectins	B-X
(	B-X
RHL	B-X
)	B-X
1	B-X
,	B-X
2	B-X
,	B-X
and	B-X
3	B-X
.	B-X
ASGP-Rs	B-X
mediate	B-X
the	B-X
endocytosis	B-X
and	B-X
degradation	B-X
of	B-X
circulating	B-X
glycoconjugates	B-X
containing	B-X
terminal	B-X
N-acetylgalactosamine	B-X
or	B-X
galactose	B-X
,	B-X
including	B-X
desialylated	B-X
plasma	B-X
glycoproteins	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
in	B-X
permeable	B-X
rat	B-X
hepatocytes	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
one	B-X
subpopulation	B-X
of	B-X
receptors	B-X
(	B-X
designated	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
)	B-X
can	B-X
be	B-X
decreased	B-X
or	B-X
increased	B-X
,	B-X
respectively	B-X
,	B-X
by	B-X
ATP	B-X
and	B-X
palmitoyl-CoA	B-X
(	B-X
Weigel	B-X
,	B-X
P.	B-X
H.	B-X
,	B-X
and	B-X
Oka	B-X
,	B-X
J	B-X
.	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Both	B-X
stearic	B-X
and	B-X
palmitic	B-X
acids	B-X
were	B-X
detected	B-X
in	B-X
all	B-X
three	B-X
receptor	B-X
subunits	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
Furthermore	B-X
,	B-X
when	B-X
freshly	B-X
isolated	B-X
hepatocytes	B-X
were	B-X
cultured	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
all	B-X
three	B-X
RHL	B-X
subunits	B-X
in	B-X
affinity-purified	B-X
ASGP-Rs	B-X
were	B-X
metabolically	B-X
labeled	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

We	O
conclude	O
that	O
RHL1	B-Protein
,	O
RHL2	B-Protein
,	O
and	O
RHL3	B-Protein
are	O
modified	O
by	O
fatty	O
acylation	O
in	O
intact	O
cells	O
.	O
<EOS>	B-X
We	B-X
proposed	B-X
that	B-X
a	B-X
reversible	B-X
and	B-X
cyclic	B-X
acylation/deacylation	B-X
process	B-X
may	B-X
regulate	B-X
ASGP-R	B-X
activity	B-X
during	B-X
endocytosis	B-X
,	B-X
receptor-ligand	B-X
dissociation	B-X
,	B-X
and	B-X
receptor	B-X
recycling	B-X
.	B-X
270	B-X
,	B-X
21388-21395	B-X
)	B-X
,	B-X
we	B-X
show	B-X
that	B-X
the	B-X
ligand	B-X
binding	B-X
activity	B-X
of	B-X
affinity-purified	B-X
State	B-X
2	B-X
ASGP-Rs	B-X
is	B-X
decreased	B-X
by	B-X
treatment	B-X
with	B-X
hydroxylamine	B-X
under	B-X
mild	B-X
conditions	B-X
consistent	B-X
with	B-X
these	B-X
ASGP-Rs	B-X
being	B-X
fatty	B-X
acylated	B-X
in	B-X
vivo	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
we	B-X
used	B-X
a	B-X
chemical	B-X
method	B-X
to	B-X
determine	B-X
the	B-X
presence	B-X
of	B-X
covalently-bound	B-X
fatty	B-X
acids	B-X
in	B-X
individual	B-X
ASGP-R	B-X
subunits	B-X
.	B-X
The	B-X
affinity-purified	B-X
ASGP-R	B-X
preparations	B-X
were	B-X
separated	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
nonreducing	B-X
conditions	B-X
,	B-X
and	B-X
the	B-X
gel	B-X
slices	B-X
containing	B-X
individual	B-X
RHL	B-X
subunits	B-X
were	B-X
treated	B-X
with	B-X
alkali	B-X
to	B-X
release	B-X
covalently	B-X
bound	B-X
fatty	B-X
acids	B-X
,	B-X
which	B-X
were	B-X
subsequently	B-X
analyzed	B-X
by	B-X
gas	B-X
chromatography	B-X
and	B-X
confirmed	B-X
by	B-X
gas	B-X
chromatography-mass	B-X
spectrometry	B-X
.	B-X
Pretreatment	B-X
of	B-X
ASGP-Rs	B-X
with	B-X
hydroxylamine	B-X
before	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
reduced	B-X
the	B-X
content	B-X
of	B-X
both	B-X
fatty	B-X
acids	B-X
by	B-X
66-80	B-X
%	B-X
,	B-X
indicating	B-X
that	B-X
most	B-X
of	B-X
these	B-X
fatty	B-X
acids	B-X
are	B-X
attached	B-X
to	B-X
cysteine	B-X
residues	B-X
via	B-X
thioester	B-X
linkages	B-X
.	B-X
We	B-X
conclude	B-X
that	B-X
RHL1	B-X
,	B-X
RHL2	B-X
,	B-X
and	B-X
RHL3	B-X
are	B-X
modified	B-X
by	B-X
fatty	B-X
acylation	B-X
in	B-X
intact	B-X
cells	B-X
.	B-X

Terminal	O
marking	O
of	O
avian	O
triosephosphate	O
isomerases	O
by	O
deamidation	O
and	O
oxidation	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Triosephosphate	B-Protein
isomerase	I-Protein
(	O
TPI	B-Protein
)	O
provides	O
an	O
excellent	O
model	O
for	O
terminal	O
marking	O
and	O
protein	O
degradation	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Mammalian	O
TPI	B-Protein
is	O
terminally	O
modified	O
by	O
deamidation	O
at	O
Asn71	O
-	O
Gly	O
,	O
resulting	O
in	O
unfolding	O
,	O
dissociation	O
,	O
and	O
proteolysis	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

In	O
contrast	O
,	O
chicken	O
TPI	B-Protein
,	O
which	O
contains	O
a	O
lysine	O
at	O
position	O
71	O
,	O
is	O
terminally	O
modified	O
by	O
the	O
oxidation	O
of	O
Cys126	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Thus	O
,	O
both	O
deamidation	O
and	O
oxidation	O
initiate	O
degradation	O
of	O
TPI	B-Protein
from	O
different	O
species	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

To	O
explore	O
the	O
terminal	O
marking	O
in	O
other	O
avians	O
,	O
we	O
have	O
purified	O
the	O
turkey	O
TPI	B-Protein
to	O
homogeneity	O
and	O
determined	O
its	O
characteristics	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Although	O
the	O
molecular	O
properties	O
of	O
the	O
turkey	O
and	O
chicken	O
TPI	B-Protein
were	O
very	O
similar	O
,	O
their	O
tolerances	O
to	O
temperature	O
,	O
oxidants	O
,	O
and	O
alkaline	O
pH	O
were	O
very	O
different	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

For	O
example	O
,	O
chicken	O
TPI	B-Protein
was	O
inactivated	O
80	O
%	O
in	O
either	O
10	O
mM	O
oxidized	O
glutathione	O
or	O
H2O2	O
,	O
whereas	O
120	O
mM	O
GSSG	O
had	O
no	O
effect	O
on	O
turkey	O
TPI	B-Protein
,	O
and	O
>	O
120	O
mM	O
H2O2	O
was	O
needed	O
for	O
80	O
%	O
inactivation	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X

Under	O
alkaline	O
conditions	O
that	O
cause	O
rapid	O
deamidation	O
of	O
the	O
mammalian	O
TPI	B-Protein
,	O
neither	O
avian	O
enzyme	O
deamidated	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Chicken	O
TPI	B-Protein
,	O
however	O
,	O
aggregated	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Chicken	B-X
TPI	B-X
,	B-X
however	B-X
,	B-X
aggregated	B-X
.	B-X

Aggregation	O
was	O
reversed	O
by	O
2	O
-	O
mercaptoethanol	O
.	O
<EOS>	B-X
We	B-X
confirmed	B-X
their	B-X
data	B-X
and	B-X
found	B-X
that	B-X
70	B-X
mM	B-X
2-mercaptoethanol	B-X
was	B-X
also	B-X
active	B-X
.	B-X
DDT-induced	B-X
aggregation	B-X
was	B-X
not	B-X
associated	B-X
with	B-X
platelet	B-X
shape	B-X
change	B-X
or	B-X
secretion	B-X
of	B-X
dense	B-X
granule	B-X
contents	B-X
,	B-X
was	B-X
not	B-X
inhibited	B-X
by	B-X
tetracaine	B-X
or	B-X
metabolic	B-X
inhibitors	B-X
,	B-X
was	B-X
prevented	B-X
at	B-X
pH	B-X
6.5	B-X
,	B-X
and	B-X
prevented	B-X
,	B-X
reversed	B-X
,	B-X
or	B-X
arrested	B-X
by	B-X
EDTA	B-X
,	B-X
depending	B-X
on	B-X
when	B-X
the	B-X
EDTA	B-X
was	B-X
added	B-X
.	B-X
Platelets	B-X
stimulated	B-X
with	B-X
DTT	B-X
bound	B-X
125I-labeled	B-X
fibrinogen	B-X
.	B-X
SDS	B-X
gel	B-X
electrophoresis	B-X
of	B-X
platelet	B-X
fractions	B-X
prepared	B-X
by	B-X
use	B-X
of	B-X
Triton	B-X
X-114	B-X
showed	B-X
that	B-X
aggregating	B-X
concentrations	B-X
of	B-X
DTT	B-X
reduced	B-X
proteins	B-X
of	B-X
apparent	B-X
Mr	B-X
69,000	B-X
and	B-X
52,000	B-X
(	B-X
probably	B-X
platelet	B-X
albumin	B-X
)	B-X
and	B-X
,	B-X
to	B-X
a	B-X
variable	B-X
extent	B-X
,	B-X
glycoproteins	B-X
Ib	B-X
,	B-X
IIb	B-X
and	B-X
III	B-X
.	B-X
Exposure	B-X
of	B-X
unlabeled	B-X
or	B-X
125I-labeled	B-X
platelets	B-X
to	B-X
ADP	B-X
had	B-X
no	B-X
discernible	B-X
effect	B-X
on	B-X
the	B-X
electrophoretic	B-X
patterns	B-X
.	B-X

Under	O
prolonged	O
exposure	O
to	O
milder	O
conditions	O
the	O
turkey	O
enzyme	O
was	O
completely	O
inactivated	O
and	O
deamidated	O
at	O
Asn15	O
-	O
Gly	O
.	O
<EOS>	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
For	B-X
example	B-X
,	B-X
chicken	B-X
TPI	B-X
was	B-X
inactivated	B-X
80	B-X
%	B-X
in	B-X
either	B-X
10	B-X
mM	B-X
oxidized	B-X
glutathione	B-X
or	B-X
H2O2	B-X
,	B-X
whereas	B-X
120	B-X
mM	B-X
GSSG	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
turkey	B-X
TPI	B-X
,	B-X
and	B-X
>	B-X
120	B-X
mM	B-X
H2O2	B-X
was	B-X
needed	B-X
for	B-X
80	B-X
%	B-X
inactivation	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Under	B-X
prolonged	B-X
exposure	B-X
to	B-X
milder	B-X
conditions	B-X
the	B-X
turkey	B-X
enzyme	B-X
was	B-X
completely	B-X
inactivated	B-X
and	B-X
deamidated	B-X
at	B-X
Asn15-Gly	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Thus	O
,	O
there	O
are	O
marked	O
differences	O
in	O
the	O
susceptibility	O
of	O
these	O
two	O
avian	O
enzymes	O
to	O
oxidation	O
and	O
deamidation	O
,	O
and	O
their	O
terminal	O
marking	O
mechanisms	O
appear	O
to	O
be	O
different	O
.	O
<EOS>	B-X
Triosephosphate	B-X
isomerase	B-X
(	B-X
TPI	B-X
)	B-X
provides	B-X
an	B-X
excellent	B-X
model	B-X
for	B-X
terminal	B-X
marking	B-X
and	B-X
protein	B-X
degradation	B-X
.	B-X
Mammalian	B-X
TPI	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
deamidation	B-X
at	B-X
Asn71-Gly	B-X
,	B-X
resulting	B-X
in	B-X
unfolding	B-X
,	B-X
dissociation	B-X
,	B-X
and	B-X
proteolysis	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
chicken	B-X
TPI	B-X
,	B-X
which	B-X
contains	B-X
a	B-X
lysine	B-X
at	B-X
position	B-X
71	B-X
,	B-X
is	B-X
terminally	B-X
modified	B-X
by	B-X
the	B-X
oxidation	B-X
of	B-X
Cys126	B-X
.	B-X
Thus	B-X
,	B-X
both	B-X
deamidation	B-X
and	B-X
oxidation	B-X
initiate	B-X
degradation	B-X
of	B-X
TPI	B-X
from	B-X
different	B-X
species	B-X
.	B-X
To	B-X
explore	B-X
the	B-X
terminal	B-X
marking	B-X
in	B-X
other	B-X
avians	B-X
,	B-X
we	B-X
have	B-X
purified	B-X
the	B-X
turkey	B-X
TPI	B-X
to	B-X
homogeneity	B-X
and	B-X
determined	B-X
its	B-X
characteristics	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
properties	B-X
of	B-X
the	B-X
turkey	B-X
and	B-X
chicken	B-X
TPI	B-X
were	B-X
very	B-X
similar	B-X
,	B-X
their	B-X
tolerances	B-X
to	B-X
temperature	B-X
,	B-X
oxidants	B-X
,	B-X
and	B-X
alkaline	B-X
pH	B-X
were	B-X
very	B-X
different	B-X
.	B-X
Under	B-X
alkaline	B-X
conditions	B-X
that	B-X
cause	B-X
rapid	B-X
deamidation	B-X
of	B-X
the	B-X
mammalian	B-X
TPI	B-X
,	B-X
neither	B-X
avian	B-X
enzyme	B-X
deamidated	B-X
.	B-X
Thus	B-X
,	B-X
there	B-X
are	B-X
marked	B-X
differences	B-X
in	B-X
the	B-X
susceptibility	B-X
of	B-X
these	B-X
two	B-X
avian	B-X
enzymes	B-X
to	B-X
oxidation	B-X
and	B-X
deamidation	B-X
,	B-X
and	B-X
their	B-X
terminal	B-X
marking	B-X
mechanisms	B-X
appear	B-X
to	B-X
be	B-X
different	B-X
.	B-X

Effects	O
of	O
lovastatin	O
on	O
adenylyl	O
cyclase	O
activity	O
and	O
G	O
proteins	O
in	O
GH4C1	O
cells	O
.	O

We	O
studied	O
the	O
effect	O
of	O
lovastatin	O
,	O
a	O
cholesterol	O
lowering	O
drug	O
,	O
on	O
the	O
basal	O
state	O
of	O
G	O
-	O
proteins	O
in	O
GH4C1	O
cells	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
,	B-X
a	B-X
cholesterol	B-X
lowering	B-X
drug	B-X
,	B-X
on	B-X
the	B-X
basal	B-X
state	B-X
of	B-X
G-proteins	B-X
in	B-X
GH4C1	B-X
cells	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
the	B-X
addition	B-X
of	B-X
lovastatin	B-X
markedly	B-X
decreased	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
alpha-subunits	B-X
of	B-X
the	B-X
Gs	B-X
and	B-X
Gi-proteins	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
alpha	B-X
s	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
both	B-X
effects	B-X
were	B-X
reverted	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
mevalonate	B-X
.	B-X
As	B-X
the	B-X
attachment	B-X
of	B-X
G	B-X
protein	B-X
subunits	B-X
to	B-X
the	B-X
membrane	B-X
is	B-X
dependent	B-X
on	B-X
gamma-subunit	B-X
prenylation	B-X
,	B-X
we	B-X
assume	B-X
that	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
lovastatin	B-X
exerts	B-X
its	B-X
effects	B-X
on	B-X
G-proteins	B-X
is	B-X
the	B-X
lack	B-X
of	B-X
mevalonate	B-X
for	B-X
the	B-X
synthesis	B-X
of	B-X
prenyl	B-X
residues	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
some	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
lovastatin	B-X
are	B-X
mediated	B-X
through	B-X
changes	B-X
in	B-X
the	B-X
basal	B-X
state	B-X
of	B-X
G-protein	B-X
in	B-X
the	B-X
membrane	B-X
and	B-X
consequently	B-X
on	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
.	B-X

Our	O
data	O
show	O
that	O
the	O
addition	O
of	O
lovastatin	O
markedly	O
decreased	O
the	O
amount	O
of	O
the	O
alpha	O
-	O
subunits	O
of	O
the	O
Gs	O
and	O
Gi	O
-	O
proteins	O
in	O
the	O
plasma	O
membrane	O
.	O

The	O
decrease	O
of	O
alpha	O
s	O
was	O
correlated	O
with	O
a	O
decrease	O
in	O
adenylyl	O
cyclase	O
activity	O
,	O
and	O
both	O
effects	O
were	O
reverted	O
by	O
the	O
presence	O
of	O
mevalonate	O
.	O

As	O
the	O
attachment	O
of	O
G	O
protein	O
subunits	O
to	O
the	O
membrane	O
is	O
dependent	O
on	O
gamma	O
-	O
subunit	O
prenylation	O
,	O
we	O
assume	O
that	O
the	O
mechanism	O
through	O
which	O
lovastatin	O
exerts	O
its	O
effects	O
on	O
G	O
-	O
proteins	O
is	O
the	O
lack	O
of	O
mevalonate	O
for	O
the	O
synthesis	O
of	O
prenyl	O
residues	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
some	O
of	O
the	O
effects	O
of	O
lovastatin	O
are	O
mediated	O
through	O
changes	O
in	O
the	O
basal	O
state	O
of	O
G	O
-	O
protein	O
in	O
the	O
membrane	O
and	O
consequently	O
on	O
adenylyl	O
cyclase	O
activity	O
.	O
<EOS>	B-X
We	B-X
studied	B-X
the	B-X
effect	B-X
of	B-X
lovastatin	B-X
,	B-X
a	B-X
cholesterol	B-X
lowering	B-X
drug	B-X
,	B-X
on	B-X
the	B-X
basal	B-X
state	B-X
of	B-X
G-proteins	B-X
in	B-X
GH4C1	B-X
cells	B-X
.	B-X
Our	B-X
data	B-X
show	B-X
that	B-X
the	B-X
addition	B-X
of	B-X
lovastatin	B-X
markedly	B-X
decreased	B-X
the	B-X
amount	B-X
of	B-X
the	B-X
alpha-subunits	B-X
of	B-X
the	B-X
Gs	B-X
and	B-X
Gi-proteins	B-X
in	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
The	B-X
decrease	B-X
of	B-X
alpha	B-X
s	B-X
was	B-X
correlated	B-X
with	B-X
a	B-X
decrease	B-X
in	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
,	B-X
and	B-X
both	B-X
effects	B-X
were	B-X
reverted	B-X
by	B-X
the	B-X
presence	B-X
of	B-X
mevalonate	B-X
.	B-X
As	B-X
the	B-X
attachment	B-X
of	B-X
G	B-X
protein	B-X
subunits	B-X
to	B-X
the	B-X
membrane	B-X
is	B-X
dependent	B-X
on	B-X
gamma-subunit	B-X
prenylation	B-X
,	B-X
we	B-X
assume	B-X
that	B-X
the	B-X
mechanism	B-X
through	B-X
which	B-X
lovastatin	B-X
exerts	B-X
its	B-X
effects	B-X
on	B-X
G-proteins	B-X
is	B-X
the	B-X
lack	B-X
of	B-X
mevalonate	B-X
for	B-X
the	B-X
synthesis	B-X
of	B-X
prenyl	B-X
residues	B-X
.	B-X
In	B-X
conclusion	B-X
,	B-X
our	B-X
data	B-X
indicate	B-X
that	B-X
some	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
lovastatin	B-X
are	B-X
mediated	B-X
through	B-X
changes	B-X
in	B-X
the	B-X
basal	B-X
state	B-X
of	B-X
G-protein	B-X
in	B-X
the	B-X
membrane	B-X
and	B-X
consequently	B-X
on	B-X
adenylyl	B-X
cyclase	B-X
activity	B-X
.	B-X

The	O
neuroendocrine	O
precursor	O
7B2	B-Protein
is	O
a	O
sulfated	O
protein	O
proteolytically	O
processed	O
by	O
a	O
ubiquitous	O
furin	B-Protein
-	O
like	O
convertase	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

The	O
neuroendocrine	O
granule	O
-	O
associated	O
protein	O
7B2	B-Protein
,	O
unlike	O
many	O
other	O
neuroendocrine	O
precursor	O
proteins	O
stored	O
in	O
secretory	O
granules	O
,	O
carries	O
in	O
its	O
primary	O
structure	O
the	O
Arg	O
-	O
Xaa	O
-	O
Arg	O
/	O
Lys	O
-	O
Arg	O
processing	O
site	O
usually	O
found	O
in	O
constitutively	O
secreted	O
precursor	O
proteins	O
and	O
recognized	O
by	O
the	O
ubiquitously	O
expressed	O
convertase	O
,	O
furin	B-Protein
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
P4	B-X
Arg	B-X
to	B-X
Gly	B-X
completely	B-X
prevented	B-X
this	B-X
conversion	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

pro7B2	B-Protein
(	O
30	O
kDa	O
)	O
,	O
when	O
expressed	O
in	O
endocrine	O
(	O
AtT	O
-	O
20	O
,	O
PC12	O
,	O
and	O
GH4C1	O
)	O
or	O
non	O
-	O
endocrine	O
(	O
Ltk	O
-	O
)	O
cell	O
lines	O
using	O
recombinant	O
vaccinia	O
viruses	O
,	O
was	O
converted	O
to	O
a	O
23	O
-	O
kDa	O
form	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

Mutation	O
of	O
the	O
P4	O
Arg	O
to	O
Gly	O
completely	O
prevented	O
this	O
conversion	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
P4	B-X
Arg	B-X
to	B-X
Gly	B-X
completely	B-X
prevented	B-X
this	B-X
conversion	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X

When	O
excess	O
pro7B2	B-Protein
was	O
coexpressed	O
with	O
the	O
pro	O
-	O
protein	O
convertases	O
PC1	B-Protein
,	O
PC2	B-Protein
,	O
or	O
furin	B-Protein
,	O
only	O
furin	B-Protein
could	O
induce	O
complete	O
processing	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
Mutation	B-X
of	B-X
the	B-X
P4	B-X
Arg	B-X
to	B-X
Gly	B-X
completely	B-X
prevented	B-X
this	B-X
conversion	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

In	O
addition	O
,	O
coexpression	O
of	O
pro7B2	B-Protein
in	O
LoVo	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
endogenous	O
furin	B-Protein
activity	O
,	O
with	O
each	O
one	O
of	O
the	O
three	O
convertases	O
,	O
showed	O
that	O
only	O
furin	B-Protein
was	O
able	O
to	O
induce	O
processing	O
of	O
this	O
precursor	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

pro7B2	B-Protein
processing	O
in	O
AtT	O
-	O
20	O
was	O
completely	O
abolished	O
when	O
protein	O
transport	O
into	O
Golgi	O
compartments	O
was	O
blocked	O
by	O
cell	O
incubation	O
at	O
either	O
15	O
or	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
monensin	O
or	O
brefeldin	O
A	O
.	O
<EOS>	B-X
Golgi	B-X
membrane	B-X
dynamics	B-X
.	B-X
While	B-X
metazoan	B-X
genomes	B-X
encode	B-X
MESH1	B-X
(	B-X
Metazoan	B-X
SpoT	B-X
Homolog	B-X
1	B-X
)	B-X
with	B-X
ppGpp	B-X
hydrolase	B-X
activity	B-X
,	B-X
neither	B-X
ppGpp	B-X
nor	B-X
the	B-X
stringent	B-X
response	B-X
is	B-X
found	B-X
in	B-X
metazoa	B-X
.	B-X
To	B-X
further	B-X
understand	B-X
whether	B-X
MESH1	B-X
knockdown	B-X
triggers	B-X
a	B-X
similar	B-X
transcriptional	B-X
response	B-X
in	B-X
mammalian	B-X
cells	B-X
,	B-X
here	B-X
,	B-X
we	B-X
employed	B-X
RNA-Seq	B-X
to	B-X
analyze	B-X
the	B-X
transcriptome	B-X
response	B-X
to	B-X
MESH1	B-X
knockdown	B-X
in	B-X
human	B-X
cancer	B-X
cells	B-X
.	B-X
Furthermore	B-X
,	B-X
MESH1	B-X
knockdown	B-X
increased	B-X
ATF4	B-X
protein	B-X
,	B-X
eIF2a	B-X
phosphorylation	B-X
,	B-X
and	B-X
induction	B-X
of	B-X
ATF3	B-X
,	B-X
XBPs	B-X
,	B-X
and	B-X
CHOP	B-X
mRNA	B-X
.	B-X
Concurrent	B-X
ATF4	B-X
knockdown	B-X
re-sensitizes	B-X
MESH1-depleted	B-X
RCC4	B-X
cells	B-X
to	B-X
ferroptosis	B-X
,	B-X
suggesting	B-X
its	B-X
role	B-X
in	B-X
the	B-X
ferroptosis	B-X
protection	B-X
mediated	B-X
by	B-X
MESH1	B-X
knockdown	B-X
.	B-X
ATF3	B-X
induction	B-X
is	B-X
abolished	B-X
by	B-X
the	B-X
concurrent	B-X
knockdown	B-X
of	B-X
NADK	B-X
,	B-X
implicating	B-X
a	B-X
role	B-X
of	B-X
NADPH	B-X
accumulation	B-X
in	B-X
the	B-X
integrative	B-X
stress	B-X
response	B-X
.	B-X
Collectively	B-X
,	B-X
these	B-X
results	B-X
suggest	B-X
that	B-X
MESH1	B-X
depletion	B-X
triggers	B-X
ER	B-X
stress	B-X
and	B-X
ISR	B-X
as	B-X
a	B-X
part	B-X
of	B-X
its	B-X
overall	B-X
transcriptome	B-X
changes	B-X
to	B-X
enable	B-X
stress	B-X
survival	B-X
of	B-X
cancer	B-X
cells	B-X
.	B-X

Furthermore	O
,	O
pulse	O
-	O
chase	O
experiments	O
in	O
the	O
presence	O
of	O
Na2	O
[	O
35S	O
]	O
SO4	O
showed	O
that	O
pro7B2	B-Protein
is	O
Tyr	O
-	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
before	O
it	O
is	O
processed	O
.	O
<EOS>	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

These	O
results	O
demonstrate	O
that	O
pro7B2	B-Protein
is	O
first	O
processed	O
by	O
a	O
furin	B-Protein
-	O
like	O
enzyme	O
within	O
the	O
trans	O
-	O
Golgi	O
network	O
into	O
a	O
23	O
-	O
kDa	O
form	O
that	O
is	O
then	O
sequestered	O
into	O
secretory	O
granules	O
.	O
<EOS>	B-X
The	B-X
neuroendocrine	B-X
granule-associated	B-X
protein	B-X
7B2	B-X
,	B-X
unlike	B-X
many	B-X
other	B-X
neuroendocrine	B-X
precursor	B-X
proteins	B-X
stored	B-X
in	B-X
secretory	B-X
granules	B-X
,	B-X
carries	B-X
in	B-X
its	B-X
primary	B-X
structure	B-X
the	B-X
Arg-Xaa-Arg/Lys-Arg	B-X
processing	B-X
site	B-X
usually	B-X
found	B-X
in	B-X
constitutively	B-X
secreted	B-X
precursor	B-X
proteins	B-X
and	B-X
recognized	B-X
by	B-X
the	B-X
ubiquitously	B-X
expressed	B-X
convertase	B-X
,	B-X
furin	B-X
.	B-X
pro7B2	B-X
(	B-X
30	B-X
kDa	B-X
)	B-X
,	B-X
when	B-X
expressed	B-X
in	B-X
endocrine	B-X
(	B-X
AtT-20	B-X
,	B-X
PC12	B-X
,	B-X
and	B-X
GH4C1	B-X
)	B-X
or	B-X
non-endocrine	B-X
(	B-X
Ltk-	B-X
)	B-X
cell	B-X
lines	B-X
using	B-X
recombinant	B-X
vaccinia	B-X
viruses	B-X
,	B-X
was	B-X
converted	B-X
to	B-X
a	B-X
23-kDa	B-X
form	B-X
.	B-X
When	B-X
excess	B-X
pro7B2	B-X
was	B-X
coexpressed	B-X
with	B-X
the	B-X
pro-protein	B-X
convertases	B-X
PC1	B-X
,	B-X
PC2	B-X
,	B-X
or	B-X
furin	B-X
,	B-X
only	B-X
furin	B-X
could	B-X
induce	B-X
complete	B-X
processing	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
coexpression	B-X
of	B-X
pro7B2	B-X
in	B-X
LoVo	B-X
cells	B-X
,	B-X
which	B-X
are	B-X
devoid	B-X
of	B-X
endogenous	B-X
furin	B-X
activity	B-X
,	B-X
with	B-X
each	B-X
one	B-X
of	B-X
the	B-X
three	B-X
convertases	B-X
,	B-X
showed	B-X
that	B-X
only	B-X
furin	B-X
was	B-X
able	B-X
to	B-X
induce	B-X
processing	B-X
of	B-X
this	B-X
precursor	B-X
.	B-X
pro7B2	B-X
processing	B-X
in	B-X
AtT-20	B-X
was	B-X
completely	B-X
abolished	B-X
when	B-X
protein	B-X
transport	B-X
into	B-X
Golgi	B-X
compartments	B-X
was	B-X
blocked	B-X
by	B-X
cell	B-X
incubation	B-X
at	B-X
either	B-X
15	B-X
or	B-X
37	B-X
degrees	B-X
C	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
monensin	B-X
or	B-X
brefeldin	B-X
A	B-X
.	B-X
Furthermore	B-X
,	B-X
pulse-chase	B-X
experiments	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
Na2	B-X
[	B-X
35S	B-X
]	B-X
SO4	B-X
showed	B-X
that	B-X
pro7B2	B-X
is	B-X
Tyr-sulfated	B-X
in	B-X
the	B-X
trans-Golgi	B-X
network	B-X
before	B-X
it	B-X
is	B-X
processed	B-X
.	B-X
These	B-X
results	B-X
demonstrate	B-X
that	B-X
pro7B2	B-X
is	B-X
first	B-X
processed	B-X
by	B-X
a	B-X
furin-like	B-X
enzyme	B-X
within	B-X
the	B-X
trans-Golgi	B-X
network	B-X
into	B-X
a	B-X
23-kDa	B-X
form	B-X
that	B-X
is	B-X
then	B-X
sequestered	B-X
into	B-X
secretory	B-X
granules	B-X
.	B-X

Molecular	O
cloning	O
of	O
ras	O
and	O
rap	O
genes	O
from	O
Entamoeba	O
histolytica	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

To	O
better	O
understand	O
growth	O
regulation	O
in	O
the	O
protozoan	O
parasite	O
Entamoeba	O
histolytica	O
,	O
ameba	O
genes	O
homologous	O
to	O
the	O
ras	O
oncogene	O
and	O
rap	O
(	O
Krev	B-Protein
-	I-Protein
1	I-Protein
)	O
anti	O
-	O
oncogene	O
were	O
cloned	O
.	O

Two	O
putative	O
ameba	O
ras	O
genes	O
(	O
Ehras1	B-Protein
and	O
Ehras2	B-Protein
)	O
were	O
identified	O
,	O
which	O
contain	O
205	O
and	O
203	O
amino	O
acid	O
(	O
aa	O
)	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
respectively	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

The	O
Ehras1	B-Protein
ORF	O
shows	O
an	O
91	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehras2	B-Protein
,	O
a	O
55	O
%	O
identity	O
with	O
Dictyostelium	O
discoideum	O
(	O
Dd	O
)	O
ras	B-Protein
,	O
and	O
a	O
47	O
%	O
identity	O
with	O
human	O
(	O
Hs	O
)	O
ras	O
.	O

Two	O
ameba	O
rap	O
genes	O
(	O
Ehrap1	B-Protein
and	O
Ehrap2	B-Protein
)	O
were	O
identified	O
,	O
both	O
of	O
which	O
contain	O
184	O
-	O
aa	O
ORFs	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

The	O
Ehrap1	B-Protein
ORF	O
shows	O
a	O
93	O
%	O
positional	O
identity	O
with	O
that	O
of	O
Ehrap2	B-Protein
,	O
a	O
60	O
%	O
identity	O
with	O
Dd	O
rap	B-Protein
,	O
a	O
61	O
%	O
identity	O
with	O
Hs	O
Krev	B-Protein
-	I-Protein
1	I-Protein
,	O
and	O
a	O
45	O
%	O
identity	O
with	O
that	O
of	O
Ehras1	B-Protein
.	O

Conserved	O
aa	O
in	O
each	O
ameba	O
ras	O
and	O
rap	O
ORF	O
include	O
GTP	O
-	O
binding	O
sites	O
,	O
effector	O
site	O
,	O
site	O
of	O
ADP	O
-	O
ribosylation	O
by	O
Pseudomonas	O
exoenzyme	O
S	O
,	O
and	O
COOH	O
-	O
terminus	O
CAAX	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

As	O
all	O
Xs	O
=	O
Leu	O
or	O
Phe	O
,	O
ameba	O
ras	O
and	O
rap	O
proteins	O
may	O
be	O
gerenylgerenylated	O
and	O
not	O
farnesylated	O
.	O
<EOS>	B-X
Guidelines	B-X
for	B-X
the	B-X
use	B-X
and	B-X
interpretation	B-X
of	B-X
assays	B-X
for	B-X
monitoring	B-X
autophagy	B-X
(	B-X
3rd	B-X
edition	B-X
)	B-X
.	B-X
A	B-X
consortium	B-X
of	B-X
microorganisms	B-X
was	B-X
established	B-X
that	B-X
was	B-X
able	B-X
to	B-X
grow	B-X
with	B-X
the	B-X
beta-tripeptide	B-X
H-beta-HVal-beta-HAla-beta-HLeu-OH	B-X
,	B-X
with	B-X
the	B-X
beta-dipeptide	B-X
H-beta-HAla-beta-HLeu-OH	B-X
,	B-X
and	B-X
with	B-X
the	B-X
beta-amino	B-X
acids	B-X
H-beta-HAla-OH	B-X
,	B-X
H-beta-HVal-OH	B-X
,	B-X
and	B-X
H-beta-HLeu-OH	B-X
as	B-X
the	B-X
sole	B-X
carbon	B-X
and	B-X
energy	B-X
sources	B-X
.	B-X
During	B-X
degradation	B-X
of	B-X
the	B-X
beta-tripeptide	B-X
H-beta-HVal-beta-HAla-beta-HLeu-OH	B-X
,	B-X
the	B-X
temporary	B-X
formation	B-X
of	B-X
a	B-X
metabolite	B-X
was	B-X
observed	B-X
.	B-X
The	B-X
metabolite	B-X
was	B-X
identified	B-X
as	B-X
the	B-X
beta-dipeptide	B-X
H-beta-HAla-beta-HLeu-OH	B-X
by	B-X
nuclear	B-X
magnetic	B-X
resonance	B-X
spectroscopy	B-X
and	B-X
mass	B-X
spectrometry	B-X
.	B-X
When	B-X
a	B-X
1:1	B-X
mixture	B-X
of	B-X
the	B-X
beta-tripeptide	B-X
and	B-X
the	B-X
corresponding	B-X
alpha-tripeptide	B-X
H-Val-Ala-Leu-OH	B-X
was	B-X
added	B-X
to	B-X
the	B-X
enrichment	B-X
culture	B-X
,	B-X
the	B-X
alpha-peptide	B-X
was	B-X
completely	B-X
utilized	B-X
in	B-X
six	B-X
days	B-X
and	B-X
thereafter	B-X
growth	B-X
of	B-X
the	B-X
culture	B-X
stopped	B-X
.	B-X

Both	O
ras	O
and	O
rap	O
genes	O
are	O
transcribed	O
by	O
trophozoites	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

A	O
single	O
21	O
-	O
kDa	O
ameba	O
ras	O
protein	O
reacts	O
with	O
the	O
rat	O
Y13	O
-	O
259	O
anti	O
-	O
ras	O
monoclonal	O
antibody	O
,	O
which	O
is	O
located	O
on	O
the	O
cytosolic	O
side	O
of	O
the	O
plasma	O
membrane	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

These	O
are	O
the	O
first	O
ras	O
and	O
rap	O
genes	O
identified	O
from	O
a	O
protozoan	O
parasite	O
.	O
<EOS>	B-X
To	B-X
better	B-X
understand	B-X
growth	B-X
regulation	B-X
in	B-X
the	B-X
protozoan	B-X
parasite	B-X
Entamoeba	B-X
histolytica	B-X
,	B-X
ameba	B-X
genes	B-X
homologous	B-X
to	B-X
the	B-X
ras	B-X
oncogene	B-X
and	B-X
rap	B-X
(	B-X
Krev-1	B-X
)	B-X
anti-oncogene	B-X
were	B-X
cloned	B-X
.	B-X
Two	B-X
putative	B-X
ameba	B-X
ras	B-X
genes	B-X
(	B-X
Ehras1	B-X
and	B-X
Ehras2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
which	B-X
contain	B-X
205	B-X
and	B-X
203	B-X
amino	B-X
acid	B-X
(	B-X
aa	B-X
)	B-X
open	B-X
reading	B-X
frames	B-X
(	B-X
ORFs	B-X
)	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
Ehras1	B-X
ORF	B-X
shows	B-X
an	B-X
91	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras2	B-X
,	B-X
a	B-X
55	B-X
%	B-X
identity	B-X
with	B-X
Dictyostelium	B-X
discoideum	B-X
(	B-X
Dd	B-X
)	B-X
ras	B-X
,	B-X
and	B-X
a	B-X
47	B-X
%	B-X
identity	B-X
with	B-X
human	B-X
(	B-X
Hs	B-X
)	B-X
ras	B-X
.	B-X
Two	B-X
ameba	B-X
rap	B-X
genes	B-X
(	B-X
Ehrap1	B-X
and	B-X
Ehrap2	B-X
)	B-X
were	B-X
identified	B-X
,	B-X
both	B-X
of	B-X
which	B-X
contain	B-X
184-aa	B-X
ORFs	B-X
.	B-X
The	B-X
Ehrap1	B-X
ORF	B-X
shows	B-X
a	B-X
93	B-X
%	B-X
positional	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehrap2	B-X
,	B-X
a	B-X
60	B-X
%	B-X
identity	B-X
with	B-X
Dd	B-X
rap	B-X
,	B-X
a	B-X
61	B-X
%	B-X
identity	B-X
with	B-X
Hs	B-X
Krev-1	B-X
,	B-X
and	B-X
a	B-X
45	B-X
%	B-X
identity	B-X
with	B-X
that	B-X
of	B-X
Ehras1	B-X
.	B-X
Conserved	B-X
aa	B-X
in	B-X
each	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
ORF	B-X
include	B-X
GTP-binding	B-X
sites	B-X
,	B-X
effector	B-X
site	B-X
,	B-X
site	B-X
of	B-X
ADP-ribosylation	B-X
by	B-X
Pseudomonas	B-X
exoenzyme	B-X
S	B-X
,	B-X
and	B-X
COOH-terminus	B-X
CAAX	B-X
.	B-X
As	B-X
all	B-X
Xs	B-X
=	B-X
Leu	B-X
or	B-X
Phe	B-X
,	B-X
ameba	B-X
ras	B-X
and	B-X
rap	B-X
proteins	B-X
may	B-X
be	B-X
gerenylgerenylated	B-X
and	B-X
not	B-X
farnesylated	B-X
.	B-X
Both	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
are	B-X
transcribed	B-X
by	B-X
trophozoites	B-X
.	B-X
A	B-X
single	B-X
21-kDa	B-X
ameba	B-X
ras	B-X
protein	B-X
reacts	B-X
with	B-X
the	B-X
rat	B-X
Y13-259	B-X
anti-ras	B-X
monoclonal	B-X
antibody	B-X
,	B-X
which	B-X
is	B-X
located	B-X
on	B-X
the	B-X
cytosolic	B-X
side	B-X
of	B-X
the	B-X
plasma	B-X
membrane	B-X
.	B-X
These	B-X
are	B-X
the	B-X
first	B-X
ras	B-X
and	B-X
rap	B-X
genes	B-X
identified	B-X
from	B-X
a	B-X
protozoan	B-X
parasite	B-X
.	B-X

Isoprenylation	O
of	O
large	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
hepatitis	O
delta	O
virus	O
assembly	O
.	O
<EOS>	B-X
The	B-X
large	B-X
delta	B-X
antigen	B-X
(	B-X
LDAg	B-X
)	B-X
of	B-X
hepatitis	B-X
D	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
,	B-X
which	B-X
is	B-X
similar	B-X
to	B-X
the	B-X
small	B-X
delta	B-X
antigen	B-X
(	B-X
SDAg	B-X
)	B-X
,	B-X
except	B-X
it	B-X
has	B-X
19	B-X
additional	B-X
amino	B-X
acids	B-X
and	B-X
an	B-X
isoprenylation	B-X
signal	B-X
at	B-X
the	B-X
C-terminus	B-X
,	B-X
is	B-X
crucial	B-X
for	B-X
interacting	B-X
with	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
(	B-X
HBsAg	B-X
)	B-X
to	B-X
form	B-X
a	B-X
mature	B-X
virion	B-X
of	B-X
HDV	B-X
.	B-X
However	B-X
,	B-X
no	B-X
evidence	B-X
yet	B-X
shows	B-X
whether	B-X
the	B-X
intermolecular	B-X
interaction	B-X
of	B-X
LDAg	B-X
is	B-X
necessary	B-X
for	B-X
forming	B-X
an	B-X
empty	B-X
HDV	B-X
particle	B-X
.	B-X

Hepatitis	O
delta	O
virus	O
(	O
HDV	O
)	O
encodes	O
two	O
proteins	O
,	O
the	O
small	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
(	O
SHDAg	B-Protein
)	O
and	O
large	B-Protein
hepatitis	I-Protein
delta	I-Protein
antigen	I-Protein
(	O
LHDAg	B-Protein
)	O
.	O
<EOS>	B-X
The	B-X
hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
nucleocapsid	B-X
consists	B-X
of	B-X
a	B-X
genomic-length	B-X
RNA	B-X
of	B-X
1.7	B-X
kb	B-X
and	B-X
approximately	B-X
equimolar	B-X
amounts	B-X
of	B-X
the	B-X
small	B-X
and	B-X
large	B-X
forms	B-X
of	B-X
the	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
S-HDAg	B-X
and	B-X
L-HDAg	B-X
,	B-X
respectively	B-X
)	B-X
.	B-X
Since	B-X
HDV	B-X
RNA	B-X
particles	B-X
contain	B-X
not	B-X
only	B-X
a	B-X
genomic	B-X
RNA	B-X
species	B-X
encoding	B-X
S-HDAg	B-X
but	B-X
also	B-X
an	B-X
RNA	B-X
species	B-X
encoding	B-X
L-HDAg	B-X
,	B-X
which	B-X
is	B-X
produced	B-X
by	B-X
an	B-X
RNA-editing	B-X
process	B-X
,	B-X
the	B-X
question	B-X
arises	B-X
as	B-X
to	B-X
whether	B-X
RNAs	B-X
encoding	B-X
either	B-X
L-HDAg	B-X
or	B-X
S-HDAg	B-X
can	B-X
initiate	B-X
replication	B-X
.	B-X
To	B-X
study	B-X
this	B-X
,	B-X
two	B-X
cDNA-free	B-X
transfection	B-X
methods	B-X
were	B-X
employed	B-X
:	B-X
HDV	B-X
RNA	B-X
cotransfected	B-X
with	B-X
either	B-X
the	B-X
S-HDAg-encoding	B-X
mRNA	B-X
species	B-X
or	B-X
the	B-X
ribonucleocapsid	B-X
protein	B-X
complex	B-X
,	B-X
comprising	B-X
HDV	B-X
RNA	B-X
and	B-X
recombinant	B-X
S-HDAg	B-X
.	B-X
Results	B-X
showed	B-X
that	B-X
the	B-X
genomic-sense	B-X
RNA	B-X
encoding	B-X
S-HDAg	B-X
could	B-X
promote	B-X
HDV	B-X
replication	B-X
,	B-X
whereas	B-X
the	B-X
L-HDAg-encoding	B-X
RNA	B-X
species	B-X
was	B-X
unable	B-X
to	B-X
replicate	B-X
under	B-X
the	B-X
same	B-X
conditions	B-X
.	B-X
The	B-X
antigenomic	B-X
RNA	B-X
species	B-X
encoding	B-X
either	B-X
S-HDAg	B-X
or	B-X
L-HDAg	B-X
could	B-X
not	B-X
replicate	B-X
by	B-X
either	B-X
of	B-X
these	B-X
procedures	B-X
.	B-X
These	B-X
data	B-X
indicate	B-X
that	B-X
L-HDAg-encoding	B-X
RNA	B-X
species	B-X
are	B-X
probably	B-X
not	B-X
involved	B-X
in	B-X
the	B-X
initiation	B-X
of	B-X
HDV	B-X
RNA	B-X
synthesis	B-X
;	B-X
instead	B-X
,	B-X
their	B-X
main	B-X
function	B-X
may	B-X
be	B-X
to	B-X
serve	B-X
as	B-X
template	B-X
for	B-X
producing	B-X
L-HDAg	B-X
,	B-X
which	B-X
regulates	B-X
HDV	B-X
RNA	B-X
synthesis	B-X
and	B-X
virion	B-X
assembly	B-X
.	B-X
These	B-X
results	B-X
suggest	B-X
that	B-X
the	B-X
genomic	B-X
RNA	B-X
species	B-X
encoding	B-X
S-HDAg	B-X
is	B-X
the	B-X
only	B-X
functional	B-X
genome	B-X
for	B-X
HDV	B-X
infection	B-X
and	B-X
explain	B-X
why	B-X
the	B-X
presence	B-X
of	B-X
the	B-X
edited	B-X
HDV	B-X
RNA	B-X
encoding	B-X
L-HDAg	B-X
does	B-X
not	B-X
interfere	B-X
with	B-X
HDV	B-X
infection	B-X
.	B-X

Both	O
proteins	O
are	O
identical	O
except	O
for	O
the	O
presence	O
of	O
additional	O
19	O
amino	O
acids	O
at	O
the	O
C	O
terminus	O
of	O
LHDAg	B-Protein
.	O

While	O
SHDAg	B-Protein
is	O
required	O
for	O
HDV	O
RNA	O
replication	O
,	O
LHDAg	B-Protein
inhibits	O
replication	O
and	O
is	O
required	O
together	O
with	O
hepatitis	O
B	O
surface	O
antigen	O
for	O
the	O
assembly	O
of	O
HDV	O
.	O
<EOS>	B-X
Hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
encodes	B-X
two	B-X
proteins	B-X
,	B-X
the	B-X
small	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
SHDAg	B-X
)	B-X
and	B-X
large	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
LHDAg	B-X
)	B-X
.	B-X
Both	B-X
proteins	B-X
are	B-X
identical	B-X
except	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
19	B-X
amino	B-X
acids	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
LHDAg	B-X
.	B-X
While	B-X
SHDAg	B-X
is	B-X
required	B-X
for	B-X
HDV	B-X
RNA	B-X
replication	B-X
,	B-X
LHDAg	B-X
inhibits	B-X
replication	B-X
and	B-X
is	B-X
required	B-X
together	B-X
with	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
for	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
The	B-X
C-terminal	B-X
last	B-X
4	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
(	B-X
Cys-Arg-Pro-Gln	B-X
)	B-X
is	B-X
an	B-X
isoprenylation	B-X
motif	B-X
.	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
the	B-X
mutation	B-X
of	B-X
the	B-X
Cys	B-X
inhibited	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
In	B-X
order	B-X
to	B-X
discern	B-X
whether	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
to	B-X
change	B-X
of	B-X
amino	B-X
acid	B-X
residue	B-X
or	B-X
abolition	B-X
of	B-X
isoprenylation	B-X
,	B-X
we	B-X
constructed	B-X
several	B-X
LHDAg	B-X
mutants	B-X
of	B-X
the	B-X
terminal	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
by	B-X
cotransfection	B-X
experiments	B-X
.	B-X
We	B-X
found	B-X
that	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
substitutions	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
other	B-X
than	B-X
the	B-X
Cys	B-X
also	B-X
inhibited	B-X
isoprenylation	B-X
and	B-X
that	B-X
the	B-X
status	B-X
of	B-X
isoprenylation	B-X
of	B-X
these	B-X
mutant	B-X
proteins	B-X
correlated	B-X
well	B-X
with	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
into	B-X
virions	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
isoprenylation	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
,	B-X
is	B-X
required	B-X
for	B-X
LHDAg	B-X
packaging	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
attachment	B-X
of	B-X
an	B-X
isoprenylation	B-X
motif	B-X
to	B-X
SHDAg	B-X
did	B-X
not	B-X
enable	B-X
it	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
and	B-X
that	B-X
the	B-X
deletions	B-X
of	B-X
any	B-X
5	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
last	B-X
15	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
196	B-X
to	B-X
210	B-X
)	B-X
unique	B-X
to	B-X
the	B-X
LHDAg	B-X
abolished	B-X
the	B-X
packaging	B-X
ability	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
deletion	B-X
of	B-X
33	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
163	B-X
to	B-X
195	B-X
)	B-X
upstream	B-X
of	B-X
the	B-X
last	B-X
C-terminal	B-X
19	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
its	B-X
packaging	B-X
ability	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
15	B-X
amino	B-X
acids	B-X
upstream	B-X
of	B-X
the	B-X
isoprenylation	B-X
site	B-X
of	B-X
LHDAg	B-X
are	B-X
also	B-X
essential	B-X
for	B-X
HDV	B-X
assembly	B-X
,	B-X
and	B-X
a	B-X
large	B-X
portion	B-X
of	B-X
the	B-X
alleged	B-X
C-terminal	B-X
Pro/Gly-rich	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
146	B-X
to	B-X
195	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
process	B-X
.	B-X

The	O
C	O
-	O
terminal	O
last	O
4	O
amino	O
acids	O
of	O
LHDAg	B-Protein
(	O
Cys	O
-	O
Arg	O
-	O
Pro	O
-	O
Gln	O
)	O
is	O
an	O
isoprenylation	O
motif	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
the	O
mutation	O
of	O
the	O
Cys	O
inhibited	O
the	O
assembly	O
of	O
HDV	O
.	O
<EOS>	B-X
Hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
encodes	B-X
two	B-X
proteins	B-X
,	B-X
the	B-X
small	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
SHDAg	B-X
)	B-X
and	B-X
large	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
LHDAg	B-X
)	B-X
.	B-X
While	B-X
SHDAg	B-X
is	B-X
required	B-X
for	B-X
HDV	B-X
RNA	B-X
replication	B-X
,	B-X
LHDAg	B-X
inhibits	B-X
replication	B-X
and	B-X
is	B-X
required	B-X
together	B-X
with	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
for	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
The	B-X
C-terminal	B-X
last	B-X
4	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
(	B-X
Cys-Arg-Pro-Gln	B-X
)	B-X
is	B-X
an	B-X
isoprenylation	B-X
motif	B-X
.	B-X
It	B-X
has	B-X
previously	B-X
been	B-X
shown	B-X
that	B-X
the	B-X
mutation	B-X
of	B-X
the	B-X
Cys	B-X
inhibited	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
We	B-X
found	B-X
that	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
substitutions	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
other	B-X
than	B-X
the	B-X
Cys	B-X
also	B-X
inhibited	B-X
isoprenylation	B-X
and	B-X
that	B-X
the	B-X
status	B-X
of	B-X
isoprenylation	B-X
of	B-X
these	B-X
mutant	B-X
proteins	B-X
correlated	B-X
well	B-X
with	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
into	B-X
virions	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
15	B-X
amino	B-X
acids	B-X
upstream	B-X
of	B-X
the	B-X
isoprenylation	B-X
site	B-X
of	B-X
LHDAg	B-X
are	B-X
also	B-X
essential	B-X
for	B-X
HDV	B-X
assembly	B-X
,	B-X
and	B-X
a	B-X
large	B-X
portion	B-X
of	B-X
the	B-X
alleged	B-X
C-terminal	B-X
Pro/Gly-rich	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
146	B-X
to	B-X
195	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
process	B-X
.	B-X

In	O
order	O
to	O
discern	O
whether	O
this	O
effect	O
is	O
due	O
to	O
change	O
of	O
amino	O
acid	O
residue	O
or	O
abolition	O
of	O
isoprenylation	O
,	O
we	O
constructed	O
several	O
LHDAg	B-Protein
mutants	O
of	O
the	O
terminal	O
three	O
amino	O
acid	O
residues	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
by	O
cotransfection	O
experiments	O
.	O
<EOS>	B-X
Hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
encodes	B-X
two	B-X
proteins	B-X
,	B-X
the	B-X
small	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
SHDAg	B-X
)	B-X
and	B-X
large	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
LHDAg	B-X
)	B-X
.	B-X
Both	B-X
proteins	B-X
are	B-X
identical	B-X
except	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
19	B-X
amino	B-X
acids	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
LHDAg	B-X
.	B-X
While	B-X
SHDAg	B-X
is	B-X
required	B-X
for	B-X
HDV	B-X
RNA	B-X
replication	B-X
,	B-X
LHDAg	B-X
inhibits	B-X
replication	B-X
and	B-X
is	B-X
required	B-X
together	B-X
with	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
for	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
The	B-X
C-terminal	B-X
last	B-X
4	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
(	B-X
Cys-Arg-Pro-Gln	B-X
)	B-X
is	B-X
an	B-X
isoprenylation	B-X
motif	B-X
.	B-X
In	B-X
order	B-X
to	B-X
discern	B-X
whether	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
to	B-X
change	B-X
of	B-X
amino	B-X
acid	B-X
residue	B-X
or	B-X
abolition	B-X
of	B-X
isoprenylation	B-X
,	B-X
we	B-X
constructed	B-X
several	B-X
LHDAg	B-X
mutants	B-X
of	B-X
the	B-X
terminal	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
by	B-X
cotransfection	B-X
experiments	B-X
.	B-X
We	B-X
also	B-X
made	B-X
GST-fusion	B-X
proteins	B-X
of	B-X
these	B-X
mutants	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
isoprenylated	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
We	B-X
found	B-X
that	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
substitutions	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
other	B-X
than	B-X
the	B-X
Cys	B-X
also	B-X
inhibited	B-X
isoprenylation	B-X
and	B-X
that	B-X
the	B-X
status	B-X
of	B-X
isoprenylation	B-X
of	B-X
these	B-X
mutant	B-X
proteins	B-X
correlated	B-X
well	B-X
with	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
into	B-X
virions	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
isoprenylation	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
,	B-X
is	B-X
required	B-X
for	B-X
LHDAg	B-X
packaging	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
attachment	B-X
of	B-X
an	B-X
isoprenylation	B-X
motif	B-X
to	B-X
SHDAg	B-X
did	B-X
not	B-X
enable	B-X
it	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
and	B-X
that	B-X
the	B-X
deletions	B-X
of	B-X
any	B-X
5	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
last	B-X
15	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
196	B-X
to	B-X
210	B-X
)	B-X
unique	B-X
to	B-X
the	B-X
LHDAg	B-X
abolished	B-X
the	B-X
packaging	B-X
ability	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
deletion	B-X
of	B-X
33	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
163	B-X
to	B-X
195	B-X
)	B-X
upstream	B-X
of	B-X
the	B-X
last	B-X
C-terminal	B-X
19	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
its	B-X
packaging	B-X
ability	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
15	B-X
amino	B-X
acids	B-X
upstream	B-X
of	B-X
the	B-X
isoprenylation	B-X
site	B-X
of	B-X
LHDAg	B-X
are	B-X
also	B-X
essential	B-X
for	B-X
HDV	B-X
assembly	B-X
,	B-X
and	B-X
a	B-X
large	B-X
portion	B-X
of	B-X
the	B-X
alleged	B-X
C-terminal	B-X
Pro/Gly-rich	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
146	B-X
to	B-X
195	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
process	B-X
.	B-X

We	O
also	O
made	O
GST	O
-	O
fusion	O
proteins	O
of	O
these	O
mutants	O
and	O
tested	O
their	O
abilities	O
to	O
be	O
isoprenylated	O
in	O
rabbit	O
reticulocyte	O
lysate	O
system	O
.	O
<EOS>	B-X
Hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
encodes	B-X
two	B-X
proteins	B-X
,	B-X
the	B-X
small	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
SHDAg	B-X
)	B-X
and	B-X
large	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
LHDAg	B-X
)	B-X
.	B-X
Both	B-X
proteins	B-X
are	B-X
identical	B-X
except	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
19	B-X
amino	B-X
acids	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
LHDAg	B-X
.	B-X
In	B-X
order	B-X
to	B-X
discern	B-X
whether	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
to	B-X
change	B-X
of	B-X
amino	B-X
acid	B-X
residue	B-X
or	B-X
abolition	B-X
of	B-X
isoprenylation	B-X
,	B-X
we	B-X
constructed	B-X
several	B-X
LHDAg	B-X
mutants	B-X
of	B-X
the	B-X
terminal	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
by	B-X
cotransfection	B-X
experiments	B-X
.	B-X
We	B-X
also	B-X
made	B-X
GST-fusion	B-X
proteins	B-X
of	B-X
these	B-X
mutants	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
isoprenylated	B-X
in	B-X
rabbit	B-X
reticulocyte	B-X
lysate	B-X
system	B-X
.	B-X
We	B-X
found	B-X
that	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
substitutions	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
other	B-X
than	B-X
the	B-X
Cys	B-X
also	B-X
inhibited	B-X
isoprenylation	B-X
and	B-X
that	B-X
the	B-X
status	B-X
of	B-X
isoprenylation	B-X
of	B-X
these	B-X
mutant	B-X
proteins	B-X
correlated	B-X
well	B-X
with	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
into	B-X
virions	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
15	B-X
amino	B-X
acids	B-X
upstream	B-X
of	B-X
the	B-X
isoprenylation	B-X
site	B-X
of	B-X
LHDAg	B-X
are	B-X
also	B-X
essential	B-X
for	B-X
HDV	B-X
assembly	B-X
,	B-X
and	B-X
a	B-X
large	B-X
portion	B-X
of	B-X
the	B-X
alleged	B-X
C-terminal	B-X
Pro/Gly-rich	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
146	B-X
to	B-X
195	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
process	B-X
.	B-X

We	O
found	O
that	O
some	O
,	O
but	O
not	O
all	O
,	O
of	O
the	O
substitutions	O
of	O
the	O
amino	O
acid	O
residues	O
other	O
than	O
the	O
Cys	O
also	O
inhibited	O
isoprenylation	O
and	O
that	O
the	O
status	O
of	O
isoprenylation	O
of	O
these	O
mutant	O
proteins	O
correlated	O
well	O
with	O
their	O
abilities	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
into	O
virions	O
.	O

This	O
result	O
indicates	O
that	O
isoprenylation	O
,	O
rather	O
than	O
the	O
primary	O
amino	O
acid	O
sequence	O
,	O
is	O
required	O
for	O
LHDAg	B-Protein
packaging	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
attachment	O
of	O
an	O
isoprenylation	O
motif	O
to	O
SHDAg	B-Protein
did	O
not	O
enable	O
it	O
to	O
be	O
packaged	O
with	O
HBsAg	B-Protein
and	O
that	O
the	O
deletions	O
of	O
any	O
5	O
amino	O
acids	O
in	O
the	O
last	O
15	O
amino	O
acids	O
(	O
amino	O
acids	O
196	O
to	O
210	O
)	O
unique	O
to	O
the	O
LHDAg	B-Protein
abolished	O
the	O
packaging	O
ability	O
.	O
<EOS>	B-X
Hepatitis	B-X
delta	B-X
virus	B-X
(	B-X
HDV	B-X
)	B-X
encodes	B-X
two	B-X
proteins	B-X
,	B-X
the	B-X
small	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
SHDAg	B-X
)	B-X
and	B-X
large	B-X
hepatitis	B-X
delta	B-X
antigen	B-X
(	B-X
LHDAg	B-X
)	B-X
.	B-X
Both	B-X
proteins	B-X
are	B-X
identical	B-X
except	B-X
for	B-X
the	B-X
presence	B-X
of	B-X
additional	B-X
19	B-X
amino	B-X
acids	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
of	B-X
LHDAg	B-X
.	B-X
While	B-X
SHDAg	B-X
is	B-X
required	B-X
for	B-X
HDV	B-X
RNA	B-X
replication	B-X
,	B-X
LHDAg	B-X
inhibits	B-X
replication	B-X
and	B-X
is	B-X
required	B-X
together	B-X
with	B-X
hepatitis	B-X
B	B-X
surface	B-X
antigen	B-X
for	B-X
the	B-X
assembly	B-X
of	B-X
HDV	B-X
.	B-X
The	B-X
C-terminal	B-X
last	B-X
4	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
(	B-X
Cys-Arg-Pro-Gln	B-X
)	B-X
is	B-X
an	B-X
isoprenylation	B-X
motif	B-X
.	B-X
In	B-X
order	B-X
to	B-X
discern	B-X
whether	B-X
this	B-X
effect	B-X
is	B-X
due	B-X
to	B-X
change	B-X
of	B-X
amino	B-X
acid	B-X
residue	B-X
or	B-X
abolition	B-X
of	B-X
isoprenylation	B-X
,	B-X
we	B-X
constructed	B-X
several	B-X
LHDAg	B-X
mutants	B-X
of	B-X
the	B-X
terminal	B-X
three	B-X
amino	B-X
acid	B-X
residues	B-X
and	B-X
tested	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
by	B-X
cotransfection	B-X
experiments	B-X
.	B-X
We	B-X
found	B-X
that	B-X
some	B-X
,	B-X
but	B-X
not	B-X
all	B-X
,	B-X
of	B-X
the	B-X
substitutions	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
residues	B-X
other	B-X
than	B-X
the	B-X
Cys	B-X
also	B-X
inhibited	B-X
isoprenylation	B-X
and	B-X
that	B-X
the	B-X
status	B-X
of	B-X
isoprenylation	B-X
of	B-X
these	B-X
mutant	B-X
proteins	B-X
correlated	B-X
well	B-X
with	B-X
their	B-X
abilities	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
into	B-X
virions	B-X
.	B-X
This	B-X
result	B-X
indicates	B-X
that	B-X
isoprenylation	B-X
,	B-X
rather	B-X
than	B-X
the	B-X
primary	B-X
amino	B-X
acid	B-X
sequence	B-X
,	B-X
is	B-X
required	B-X
for	B-X
LHDAg	B-X
packaging	B-X
.	B-X
Furthermore	B-X
,	B-X
we	B-X
found	B-X
that	B-X
the	B-X
attachment	B-X
of	B-X
an	B-X
isoprenylation	B-X
motif	B-X
to	B-X
SHDAg	B-X
did	B-X
not	B-X
enable	B-X
it	B-X
to	B-X
be	B-X
packaged	B-X
with	B-X
HBsAg	B-X
and	B-X
that	B-X
the	B-X
deletions	B-X
of	B-X
any	B-X
5	B-X
amino	B-X
acids	B-X
in	B-X
the	B-X
last	B-X
15	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
196	B-X
to	B-X
210	B-X
)	B-X
unique	B-X
to	B-X
the	B-X
LHDAg	B-X
abolished	B-X
the	B-X
packaging	B-X
ability	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
the	B-X
deletion	B-X
of	B-X
33	B-X
amino	B-X
acids	B-X
(	B-X
amino	B-X
acids	B-X
163	B-X
to	B-X
195	B-X
)	B-X
upstream	B-X
of	B-X
the	B-X
last	B-X
C-terminal	B-X
19	B-X
amino	B-X
acids	B-X
of	B-X
LHDAg	B-X
did	B-X
not	B-X
interfere	B-X
with	B-X
its	B-X
packaging	B-X
ability	B-X
.	B-X
Therefore	B-X
,	B-X
we	B-X
conclude	B-X
that	B-X
the	B-X
15	B-X
amino	B-X
acids	B-X
upstream	B-X
of	B-X
the	B-X
isoprenylation	B-X
site	B-X
of	B-X
LHDAg	B-X
are	B-X
also	B-X
essential	B-X
for	B-X
HDV	B-X
assembly	B-X
,	B-X
and	B-X
a	B-X
large	B-X
portion	B-X
of	B-X
the	B-X
alleged	B-X
C-terminal	B-X
Pro/Gly-rich	B-X
region	B-X
(	B-X
amino	B-X
acids	B-X
146	B-X
to	B-X
195	B-X
)	B-X
is	B-X
not	B-X
required	B-X
for	B-X
the	B-X
assembly	B-X
process	B-X
.	B-X

In	O
contrast	O
,	O
the	O
deletion	O
of	O
33	O
amino	O
acids	O
(	O
amino	O
acids	O
163	O
to	O
195	O
)	O
upstream	O
of	O
the	O
last	O
C	O
-	O
terminal	O
19	O
amino	O
acids	O
of	O
LHDAg	B-Protein
did	O
not	O
interfere	O
with	O
its	O
packaging	O
ability	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
15	O
amino	O
acids	O
upstream	O
of	O
the	O
isoprenylation	O
site	O
of	O
LHDAg	B-Protein
are	O
also	O
essential	O
for	O
HDV	O
assembly	O
,	O
and	O
a	O
large	O
portion	O
of	O
the	O
alleged	O
C	O
-	O
terminal	O
Pro	O
/	O
Gly	O
-	O
rich	O
region	O
(	O
amino	O
acids	O
146	O
to	O
195	O
)	O
is	O
not	O
required	O
for	O
the	O
assembly	O
process	O
.	O

Involvement	O
of	O
lysine	O
residues	O
of	O
goat	O
serum	B-Protein
albumin	I-Protein
in	O
high	O
-	O
affinity	O
binding	O
of	O
bilirubin	O
.	O
<EOS>	B-X
Four	B-X
maleylated	B-X
derivatives	B-X
of	B-X
goat	B-X
serum	B-X
albumin	B-X
having	B-X
percent	B-X
modification	B-X
as	B-X
40	B-X
%	B-X
,	B-X
46	B-X
%	B-X
,	B-X
84	B-X
%	B-X
and	B-X
98	B-X
%	B-X
were	B-X
prepared	B-X
using	B-X
varying	B-X
molar	B-X
ratio	B-X
of	B-X
maleic	B-X
anhydride	B-X
over	B-X
protein	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X
Immunodiffusion	B-X
results	B-X
of	B-X
native	B-X
and	B-X
modified	B-X
albumins	B-X
with	B-X
anti-goat	B-X
serum	B-X
albumin	B-X
antiserum	B-X
also	B-X
suggested	B-X
significant	B-X
conformational	B-X
changes	B-X
in	B-X
serum	B-X
albumin	B-X
upon	B-X
maleylation	B-X
.	B-X
About	B-X
88	B-X
%	B-X
reduction	B-X
in	B-X
bilirubin	B-X
binding	B-X
was	B-X
observed	B-X
after	B-X
modification	B-X
of	B-X
98	B-X
%	B-X
amino	B-X
groups	B-X
of	B-X
serum	B-X
albumin	B-X
as	B-X
studied	B-X
by	B-X
visible	B-X
difference	B-X
spectroscopy	B-X
at	B-X
pH	B-X
8.0	B-X
,	B-X
and	B-X
at	B-X
0.15	B-X
ionic	B-X
strength	B-X
.	B-X
Increase	B-X
in	B-X
ionic	B-X
strength	B-X
to	B-X
1.0	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
any	B-X
significant	B-X
reversal	B-X
in	B-X
bilirubin	B-X
binding	B-X
.	B-X
These	B-X
results	B-X
prove	B-X
the	B-X
involvement	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
bilirubin-albumin	B-X
interaction	B-X
.	B-X

Four	O
maleylated	O
derivatives	O
of	O
goat	O
serum	B-Protein
albumin	I-Protein
having	O
percent	O
modification	O
as	O
40	O
%	O
,	O
46	O
%	O
,	O
84	O
%	O
and	O
98	O
%	O
were	O
prepared	O
using	O
varying	O
molar	O
ratio	O
of	O
maleic	O
anhydride	O
over	O
protein	O
.	O
<EOS>	B-X
Four	B-X
maleylated	B-X
derivatives	B-X
of	B-X
goat	B-X
serum	B-X
albumin	B-X
having	B-X
percent	B-X
modification	B-X
as	B-X
40	B-X
%	B-X
,	B-X
46	B-X
%	B-X
,	B-X
84	B-X
%	B-X
and	B-X
98	B-X
%	B-X
were	B-X
prepared	B-X
using	B-X
varying	B-X
molar	B-X
ratio	B-X
of	B-X
maleic	B-X
anhydride	B-X
over	B-X
protein	B-X
.	B-X
These	B-X
preparations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
pure	B-X
,	B-X
both	B-X
with	B-X
respect	B-X
to	B-X
size	B-X
and	B-X
charged	B-X
as	B-X
judged	B-X
by	B-X
gel	B-X
filtration	B-X
and	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X
Immunodiffusion	B-X
results	B-X
of	B-X
native	B-X
and	B-X
modified	B-X
albumins	B-X
with	B-X
anti-goat	B-X
serum	B-X
albumin	B-X
antiserum	B-X
also	B-X
suggested	B-X
significant	B-X
conformational	B-X
changes	B-X
in	B-X
serum	B-X
albumin	B-X
upon	B-X
maleylation	B-X
.	B-X
About	B-X
88	B-X
%	B-X
reduction	B-X
in	B-X
bilirubin	B-X
binding	B-X
was	B-X
observed	B-X
after	B-X
modification	B-X
of	B-X
98	B-X
%	B-X
amino	B-X
groups	B-X
of	B-X
serum	B-X
albumin	B-X
as	B-X
studied	B-X
by	B-X
visible	B-X
difference	B-X
spectroscopy	B-X
at	B-X
pH	B-X
8.0	B-X
,	B-X
and	B-X
at	B-X
0.15	B-X
ionic	B-X
strength	B-X
.	B-X
These	B-X
results	B-X
prove	B-X
the	B-X
involvement	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
bilirubin-albumin	B-X
interaction	B-X
.	B-X

These	O
preparations	O
were	O
found	O
to	O
be	O
pure	O
,	O
both	O
with	O
respect	O
to	O
size	O
and	O
charged	O
as	O
judged	O
by	O
gel	O
filtration	O
and	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O
<EOS>	B-X
These	B-X
preparations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
pure	B-X
,	B-X
both	B-X
with	B-X
respect	B-X
to	B-X
size	B-X
and	B-X
charged	B-X
as	B-X
judged	B-X
by	B-X
gel	B-X
filtration	B-X
and	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X

Maleylation	O
caused	O
significant	O
change	O
in	O
protein	O
conformation	O
as	O
revealed	O
by	O
the	O
change	O
in	O
Stokes	O
radius	O
and	O
frictional	O
ratio	O
of	O
serum	B-Protein
albumin	I-Protein
,	O
from	O
3	O
.	O
46	O
nm	O
and	O
1	O
.	O
28	O
to	O
4	O
.	O
96	O
nm	O
and	O
1	O
.	O
79	O
,	O
respectively	O
,	O
upon	O
98	O
%	O
modification	O
.	O
<EOS>	B-X
Four	B-X
maleylated	B-X
derivatives	B-X
of	B-X
goat	B-X
serum	B-X
albumin	B-X
having	B-X
percent	B-X
modification	B-X
as	B-X
40	B-X
%	B-X
,	B-X
46	B-X
%	B-X
,	B-X
84	B-X
%	B-X
and	B-X
98	B-X
%	B-X
were	B-X
prepared	B-X
using	B-X
varying	B-X
molar	B-X
ratio	B-X
of	B-X
maleic	B-X
anhydride	B-X
over	B-X
protein	B-X
.	B-X
These	B-X
preparations	B-X
were	B-X
found	B-X
to	B-X
be	B-X
pure	B-X
,	B-X
both	B-X
with	B-X
respect	B-X
to	B-X
size	B-X
and	B-X
charged	B-X
as	B-X
judged	B-X
by	B-X
gel	B-X
filtration	B-X
and	B-X
polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X
Immunodiffusion	B-X
results	B-X
of	B-X
native	B-X
and	B-X
modified	B-X
albumins	B-X
with	B-X
anti-goat	B-X
serum	B-X
albumin	B-X
antiserum	B-X
also	B-X
suggested	B-X
significant	B-X
conformational	B-X
changes	B-X
in	B-X
serum	B-X
albumin	B-X
upon	B-X
maleylation	B-X
.	B-X
About	B-X
88	B-X
%	B-X
reduction	B-X
in	B-X
bilirubin	B-X
binding	B-X
was	B-X
observed	B-X
after	B-X
modification	B-X
of	B-X
98	B-X
%	B-X
amino	B-X
groups	B-X
of	B-X
serum	B-X
albumin	B-X
as	B-X
studied	B-X
by	B-X
visible	B-X
difference	B-X
spectroscopy	B-X
at	B-X
pH	B-X
8.0	B-X
,	B-X
and	B-X
at	B-X
0.15	B-X
ionic	B-X
strength	B-X
.	B-X
Increase	B-X
in	B-X
ionic	B-X
strength	B-X
to	B-X
1.0	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
any	B-X
significant	B-X
reversal	B-X
in	B-X
bilirubin	B-X
binding	B-X
.	B-X
These	B-X
results	B-X
prove	B-X
the	B-X
involvement	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
bilirubin-albumin	B-X
interaction	B-X
.	B-X

Immunodiffusion	O
results	O
of	O
native	O
and	O
modified	O
albumins	B-Protein
with	O
anti	O
-	O
goat	O
serum	B-Protein
albumin	I-Protein
antiserum	O
also	O
suggested	O
significant	O
conformational	O
changes	O
in	O
serum	B-Protein
albumin	I-Protein
upon	O
maleylation	O
.	O
<EOS>	B-X
Four	B-X
maleylated	B-X
derivatives	B-X
of	B-X
goat	B-X
serum	B-X
albumin	B-X
having	B-X
percent	B-X
modification	B-X
as	B-X
40	B-X
%	B-X
,	B-X
46	B-X
%	B-X
,	B-X
84	B-X
%	B-X
and	B-X
98	B-X
%	B-X
were	B-X
prepared	B-X
using	B-X
varying	B-X
molar	B-X
ratio	B-X
of	B-X
maleic	B-X
anhydride	B-X
over	B-X
protein	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X
Immunodiffusion	B-X
results	B-X
of	B-X
native	B-X
and	B-X
modified	B-X
albumins	B-X
with	B-X
anti-goat	B-X
serum	B-X
albumin	B-X
antiserum	B-X
also	B-X
suggested	B-X
significant	B-X
conformational	B-X
changes	B-X
in	B-X
serum	B-X
albumin	B-X
upon	B-X
maleylation	B-X
.	B-X
About	B-X
88	B-X
%	B-X
reduction	B-X
in	B-X
bilirubin	B-X
binding	B-X
was	B-X
observed	B-X
after	B-X
modification	B-X
of	B-X
98	B-X
%	B-X
amino	B-X
groups	B-X
of	B-X
serum	B-X
albumin	B-X
as	B-X
studied	B-X
by	B-X
visible	B-X
difference	B-X
spectroscopy	B-X
at	B-X
pH	B-X
8.0	B-X
,	B-X
and	B-X
at	B-X
0.15	B-X
ionic	B-X
strength	B-X
.	B-X
Increase	B-X
in	B-X
ionic	B-X
strength	B-X
to	B-X
1.0	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
any	B-X
significant	B-X
reversal	B-X
in	B-X
bilirubin	B-X
binding	B-X
.	B-X
These	B-X
results	B-X
prove	B-X
the	B-X
involvement	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
bilirubin-albumin	B-X
interaction	B-X
.	B-X

About	O
88	O
%	O
reduction	O
in	O
bilirubin	O
binding	O
was	O
observed	O
after	O
modification	O
of	O
98	O
%	O
amino	O
groups	O
of	O
serum	B-Protein
albumin	I-Protein
as	O
studied	O
by	O
visible	O
difference	O
spectroscopy	O
at	O
pH	O
8	O
.	O
0	O
,	O
and	O
at	O
0	O
.	O
15	O
ionic	O
strength	O
.	O

Increase	O
in	O
ionic	O
strength	O
to	O
1	O
.	O
0	O
did	O
not	O
lead	O
to	O
any	O
significant	O
reversal	O
in	O
bilirubin	O
binding	O
.	O

These	O
results	O
prove	O
the	O
involvement	O
of	O
lysine	O
residues	O
in	O
bilirubin	O
-	O
albumin	B-Protein
interaction	O
.	O
<EOS>	B-X
Four	B-X
maleylated	B-X
derivatives	B-X
of	B-X
goat	B-X
serum	B-X
albumin	B-X
having	B-X
percent	B-X
modification	B-X
as	B-X
40	B-X
%	B-X
,	B-X
46	B-X
%	B-X
,	B-X
84	B-X
%	B-X
and	B-X
98	B-X
%	B-X
were	B-X
prepared	B-X
using	B-X
varying	B-X
molar	B-X
ratio	B-X
of	B-X
maleic	B-X
anhydride	B-X
over	B-X
protein	B-X
.	B-X
Maleylation	B-X
caused	B-X
significant	B-X
change	B-X
in	B-X
protein	B-X
conformation	B-X
as	B-X
revealed	B-X
by	B-X
the	B-X
change	B-X
in	B-X
Stokes	B-X
radius	B-X
and	B-X
frictional	B-X
ratio	B-X
of	B-X
serum	B-X
albumin	B-X
,	B-X
from	B-X
3.46	B-X
nm	B-X
and	B-X
1.28	B-X
to	B-X
4.96	B-X
nm	B-X
and	B-X
1.79	B-X
,	B-X
respectively	B-X
,	B-X
upon	B-X
98	B-X
%	B-X
modification	B-X
.	B-X
Immunodiffusion	B-X
results	B-X
of	B-X
native	B-X
and	B-X
modified	B-X
albumins	B-X
with	B-X
anti-goat	B-X
serum	B-X
albumin	B-X
antiserum	B-X
also	B-X
suggested	B-X
significant	B-X
conformational	B-X
changes	B-X
in	B-X
serum	B-X
albumin	B-X
upon	B-X
maleylation	B-X
.	B-X
About	B-X
88	B-X
%	B-X
reduction	B-X
in	B-X
bilirubin	B-X
binding	B-X
was	B-X
observed	B-X
after	B-X
modification	B-X
of	B-X
98	B-X
%	B-X
amino	B-X
groups	B-X
of	B-X
serum	B-X
albumin	B-X
as	B-X
studied	B-X
by	B-X
visible	B-X
difference	B-X
spectroscopy	B-X
at	B-X
pH	B-X
8.0	B-X
,	B-X
and	B-X
at	B-X
0.15	B-X
ionic	B-X
strength	B-X
.	B-X
Increase	B-X
in	B-X
ionic	B-X
strength	B-X
to	B-X
1.0	B-X
did	B-X
not	B-X
lead	B-X
to	B-X
any	B-X
significant	B-X
reversal	B-X
in	B-X
bilirubin	B-X
binding	B-X
.	B-X
These	B-X
results	B-X
prove	B-X
the	B-X
involvement	B-X
of	B-X
lysine	B-X
residues	B-X
in	B-X
bilirubin-albumin	B-X
interaction	B-X
.	B-X

Post	O
-	O
translational	O
processing	O
of	O
Schizosaccharomyces	O
pombe	O
YPT5	O
protein	O
.	O
<EOS>	B-X
SpYPT5p	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
rab/YPT	B-X
small	B-X
GTP-binding	B-X
protein	B-X
family	B-X
,	B-X
which	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
intracellular	B-X
trafficking	B-X
.	B-X
The	B-X
protein	B-X
sequence	B-X
terminates	B-X
with	B-X
a	B-X
CXC	B-X
motif	B-X
,	B-X
and	B-X
in	B-X
our	B-X
previous	B-X
report	B-X
(	B-X
Newman	B-X
,	B-X
C.	B-X
M.	B-X
H.	B-X
,	B-X
Giannakouros	B-X
,	B-X
T.	B-X
,	B-X
Hancock	B-X
,	B-X
J.	B-X
F.	B-X
,	B-X
Fawell	B-X
,	B-X
E.	B-X
H.	B-X
,	B-X
Armstrong	B-X
,	B-X
J.	B-X
,	B-X
and	B-X
Magee	B-X
,	B-X
A.	B-X
I	B-X
.	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

In	O
vitro	O
and	O
in	O
vivo	O
analysis	O
of	O
processing	O
mutants	O
.	O
<EOS>	B-X
In	B-X
TN-5B1-4	B-X
cells	B-X
,	B-X
the	B-X
ie-2	B-X
mutants	B-X
produced	B-X
more	B-X
budded	B-X
virus	B-X
and	B-X
fewer	B-X
occlusion	B-X
bodies	B-X
but	B-X
the	B-X
infection	B-X
proceeded	B-X
without	B-X
delay	B-X
.	B-X
Examination	B-X
of	B-X
the	B-X
effects	B-X
of	B-X
ie-2	B-X
and	B-X
the	B-X
respective	B-X
mutants	B-X
on	B-X
immediate-early	B-X
viral	B-X
promoters	B-X
in	B-X
transient	B-X
expression	B-X
assays	B-X
revealed	B-X
striking	B-X
differences	B-X
in	B-X
the	B-X
relative	B-X
levels	B-X
of	B-X
expression	B-X
and	B-X
differences	B-X
in	B-X
responses	B-X
to	B-X
ie-2	B-X
and	B-X
its	B-X
mutant	B-X
forms	B-X
in	B-X
different	B-X
cell	B-X
lines	B-X
.	B-X
The	B-X
infectivity	B-X
of	B-X
the	B-X
budded	B-X
form	B-X
of	B-X
ie-2	B-X
mutants	B-X
by	B-X
hemocoelic	B-X
injection	B-X
was	B-X
similar	B-X
to	B-X
that	B-X
of	B-X
wild-type	B-X
virus	B-X
in	B-X
both	B-X
species	B-X
.	B-X
Thus	B-X
,	B-X
ie-2	B-X
mutants	B-X
are	B-X
viable	B-X
but	B-X
exhibit	B-X
cell	B-X
line-specific	B-X
effects	B-X
on	B-X
temporal	B-X
regulation	B-X
of	B-X
the	B-X
infection	B-X
process	B-X
.	B-X
Due	B-X
to	B-X
its	B-X
effect	B-X
on	B-X
virion	B-X
occlusion	B-X
,	B-X
mutants	B-X
of	B-X
IE-2	B-X
were	B-X
essentially	B-X
noninfectious	B-X
by	B-X
the	B-X
normal	B-X
route	B-X
of	B-X
infection	B-X
in	B-X
both	B-X
species	B-X
tested	B-X
.	B-X

SpYPT5p	B-Protein
is	O
a	O
member	O
of	O
the	O
rab	O
/	O
YPT	O
small	O
GTP	O
-	O
binding	O
protein	O
family	O
,	O
which	O
is	O
believed	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
intracellular	O
trafficking	O
.	O
<EOS>	B-X
SpYPT5p	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
rab/YPT	B-X
small	B-X
GTP-binding	B-X
protein	B-X
family	B-X
,	B-X
which	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
intracellular	B-X
trafficking	B-X
.	B-X
The	B-X
protein	B-X
sequence	B-X
terminates	B-X
with	B-X
a	B-X
CXC	B-X
motif	B-X
,	B-X
and	B-X
in	B-X
our	B-X
previous	B-X
report	B-X
(	B-X
Newman	B-X
,	B-X
C.	B-X
M.	B-X
H.	B-X
,	B-X
Giannakouros	B-X
,	B-X
T.	B-X
,	B-X
Hancock	B-X
,	B-X
J.	B-X
F.	B-X
,	B-X
Fawell	B-X
,	B-X
E.	B-X
H.	B-X
,	B-X
Armstrong	B-X
,	B-X
J.	B-X
,	B-X
and	B-X
Magee	B-X
,	B-X
A.	B-X
I	B-X
.	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

The	O
protein	O
sequence	O
terminates	O
with	O
a	O
CXC	O
motif	O
,	O
and	O
in	O
our	O
previous	O
report	O
(	O
Newman	O
,	O
C	O
.	O
M	O
.	O
H	O
.	O
,	O
Giannakouros	O
,	O
T	O
.	O
,	O
Hancock	O
,	O
J	O
.	O
F	O
.	O
,	O
Fawell	O
,	O
E	O
.	O
H	O
.	O
,	O
Armstrong	O
,	O
J	O
.	O
,	O
and	O
Magee	O
,	O
A	O
.	O
I	O
.	O
(	O
1992	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
267	O
,	O
11329	O
-	O
11336	O
)	O
we	O
have	O
shown	O
that	O
SpYPT5p	B-Protein
is	O
prenylated	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
where	O
geranylgeranylation	O
was	O
confirmed	O
,	O
and	O
carboxyl	O
-	O
methylated	O
.	O

In	O
order	O
to	O
dissect	O
the	O
role	O
of	O
prenylation	O
of	O
each	O
cysteine	O
,	O
we	O
have	O
generated	O
C	O
-	O
terminal	O
mutants	O
where	O
either	O
one	O
or	O
both	O
cysteine	O
(	O
s	O
)	O
were	O
replaced	O
by	O
serine	O
and	O
expressed	O
them	O
in	O
vitro	O
in	O
reticulocyte	O
lysates	O
and	O
in	O
vivo	O
in	O
transfected	O
COS	O
cells	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
sequence	B-X
terminates	B-X
with	B-X
a	B-X
CXC	B-X
motif	B-X
,	B-X
and	B-X
in	B-X
our	B-X
previous	B-X
report	B-X
(	B-X
Newman	B-X
,	B-X
C.	B-X
M.	B-X
H.	B-X
,	B-X
Giannakouros	B-X
,	B-X
T.	B-X
,	B-X
Hancock	B-X
,	B-X
J.	B-X
F.	B-X
,	B-X
Fawell	B-X
,	B-X
E.	B-X
H.	B-X
,	B-X
Armstrong	B-X
,	B-X
J.	B-X
,	B-X
and	B-X
Magee	B-X
,	B-X
A.	B-X
I.	B-X
Chem	B-X
.	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
In	B-X
order	B-X
to	B-X
dissect	B-X
the	B-X
role	B-X
of	B-X
prenylation	B-X
of	B-X
each	B-X
cysteine	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
C-terminal	B-X
mutants	B-X
where	B-X
either	B-X
one	B-X
or	B-X
both	B-X
cysteine	B-X
(	B-X
s	B-X
)	B-X
were	B-X
replaced	B-X
by	B-X
serine	B-X
and	B-X
expressed	B-X
them	B-X
in	B-X
vitro	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
transfected	B-X
COS	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
cysteines	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
are	B-X
prenylated	B-X
but	B-X
that	B-X
the	B-X
rate	B-X
of	B-X
prenylation	B-X
of	B-X
the	B-X
two	B-X
cysteines	B-X
is	B-X
different	B-X
.	B-X
The	B-X
upstream	B-X
cysteine	B-X
was	B-X
found	B-X
to	B-X
be	B-X
preferentially	B-X
prenylated	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
unless	B-X
cytosol	B-X
from	B-X
COS	B-X
cells	B-X
was	B-X
added	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
upstream	B-X
cysteine	B-X
is	B-X
not	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
prenylation	B-X
of	B-X
the	B-X
other	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

Our	O
results	O
suggest	O
that	O
both	O
cysteines	O
of	O
the	O
CXC	O
motif	O
are	O
prenylated	O
but	O
that	O
the	O
rate	O
of	O
prenylation	O
of	O
the	O
two	O
cysteines	O
is	O
different	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
sequence	B-X
terminates	B-X
with	B-X
a	B-X
CXC	B-X
motif	B-X
,	B-X
and	B-X
in	B-X
our	B-X
previous	B-X
report	B-X
(	B-X
Newman	B-X
,	B-X
C.	B-X
M.	B-X
H.	B-X
,	B-X
Giannakouros	B-X
,	B-X
T.	B-X
,	B-X
Hancock	B-X
,	B-X
J.	B-X
F.	B-X
,	B-X
Fawell	B-X
,	B-X
E.	B-X
H.	B-X
,	B-X
Armstrong	B-X
,	B-X
J.	B-X
,	B-X
and	B-X
Magee	B-X
,	B-X
A.	B-X
I	B-X
.	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
In	B-X
order	B-X
to	B-X
dissect	B-X
the	B-X
role	B-X
of	B-X
prenylation	B-X
of	B-X
each	B-X
cysteine	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
C-terminal	B-X
mutants	B-X
where	B-X
either	B-X
one	B-X
or	B-X
both	B-X
cysteine	B-X
(	B-X
s	B-X
)	B-X
were	B-X
replaced	B-X
by	B-X
serine	B-X
and	B-X
expressed	B-X
them	B-X
in	B-X
vitro	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
transfected	B-X
COS	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
cysteines	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
are	B-X
prenylated	B-X
but	B-X
that	B-X
the	B-X
rate	B-X
of	B-X
prenylation	B-X
of	B-X
the	B-X
two	B-X
cysteines	B-X
is	B-X
different	B-X
.	B-X
The	B-X
upstream	B-X
cysteine	B-X
was	B-X
found	B-X
to	B-X
be	B-X
preferentially	B-X
prenylated	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
unless	B-X
cytosol	B-X
from	B-X
COS	B-X
cells	B-X
was	B-X
added	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
upstream	B-X
cysteine	B-X
is	B-X
not	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
prenylation	B-X
of	B-X
the	B-X
other	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

The	O
upstream	O
cysteine	O
was	O
found	O
to	O
be	O
preferentially	O
prenylated	O
in	O
reticulocyte	O
lysates	O
unless	O
cytosol	O
from	O
COS	O
cells	O
was	O
added	O
.	O
<EOS>	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
In	B-X
order	B-X
to	B-X
dissect	B-X
the	B-X
role	B-X
of	B-X
prenylation	B-X
of	B-X
each	B-X
cysteine	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
C-terminal	B-X
mutants	B-X
where	B-X
either	B-X
one	B-X
or	B-X
both	B-X
cysteine	B-X
(	B-X
s	B-X
)	B-X
were	B-X
replaced	B-X
by	B-X
serine	B-X
and	B-X
expressed	B-X
them	B-X
in	B-X
vitro	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
transfected	B-X
COS	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
cysteines	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
are	B-X
prenylated	B-X
but	B-X
that	B-X
the	B-X
rate	B-X
of	B-X
prenylation	B-X
of	B-X
the	B-X
two	B-X
cysteines	B-X
is	B-X
different	B-X
.	B-X
The	B-X
upstream	B-X
cysteine	B-X
was	B-X
found	B-X
to	B-X
be	B-X
preferentially	B-X
prenylated	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
unless	B-X
cytosol	B-X
from	B-X
COS	B-X
cells	B-X
was	B-X
added	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
upstream	B-X
cysteine	B-X
is	B-X
not	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
prenylation	B-X
of	B-X
the	B-X
other	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

A	O
separate	O
activity	O
could	O
therefore	O
be	O
required	O
for	O
prenylation	O
of	O
the	O
second	O
cysteine	O
,	O
or	O
the	O
presence	O
of	O
an	O
additional	O
factor	O
is	O
needed	O
to	O
allow	O
accumulation	O
of	O
doubly	O
prenylated	O
SpYPT5p	B-Protein
.	O
<EOS>	B-X
SpYPT5p	B-X
is	B-X
a	B-X
member	B-X
of	B-X
the	B-X
rab/YPT	B-X
small	B-X
GTP-binding	B-X
protein	B-X
family	B-X
,	B-X
which	B-X
is	B-X
believed	B-X
to	B-X
be	B-X
involved	B-X
in	B-X
the	B-X
regulation	B-X
of	B-X
intracellular	B-X
trafficking	B-X
.	B-X
267	B-X
,	B-X
11329-11336	B-X
)	B-X
we	B-X
have	B-X
shown	B-X
that	B-X
SpYPT5p	B-X
is	B-X
prenylated	B-X
both	B-X
in	B-X
vivo	B-X
and	B-X
in	B-X
vitro	B-X
,	B-X
where	B-X
geranylgeranylation	B-X
was	B-X
confirmed	B-X
,	B-X
and	B-X
carboxyl-methylated	B-X
.	B-X
In	B-X
order	B-X
to	B-X
dissect	B-X
the	B-X
role	B-X
of	B-X
prenylation	B-X
of	B-X
each	B-X
cysteine	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
C-terminal	B-X
mutants	B-X
where	B-X
either	B-X
one	B-X
or	B-X
both	B-X
cysteine	B-X
(	B-X
s	B-X
)	B-X
were	B-X
replaced	B-X
by	B-X
serine	B-X
and	B-X
expressed	B-X
them	B-X
in	B-X
vitro	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
transfected	B-X
COS	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
cysteines	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
are	B-X
prenylated	B-X
but	B-X
that	B-X
the	B-X
rate	B-X
of	B-X
prenylation	B-X
of	B-X
the	B-X
two	B-X
cysteines	B-X
is	B-X
different	B-X
.	B-X
The	B-X
upstream	B-X
cysteine	B-X
was	B-X
found	B-X
to	B-X
be	B-X
preferentially	B-X
prenylated	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
unless	B-X
cytosol	B-X
from	B-X
COS	B-X
cells	B-X
was	B-X
added	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
upstream	B-X
cysteine	B-X
is	B-X
not	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
prenylation	B-X
of	B-X
the	B-X
other	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

However	O
,	O
the	O
modification	O
of	O
the	O
upstream	O
cysteine	O
is	O
not	O
a	O
prerequisite	O
for	O
the	O
prenylation	O
of	O
the	O
other	O
.	O
<EOS>	B-X
Cystatin	B-X
SN	B-X
(	B-X
CST1	B-X
)	B-X
and	B-X
cystatin	B-X
SA	B-X
(	B-X
CST2	B-X
)	B-X
are	B-X
cysteine	B-X
protease	B-X
inhibitors	B-X
that	B-X
protect	B-X
against	B-X
allergen	B-X
,	B-X
viral	B-X
,	B-X
and	B-X
bacterial	B-X
proteases	B-X
.	B-X
Ubiquitin-fold	B-X
modifier	B-X
1	B-X
(	B-X
UFM1	B-X
)	B-X
is	B-X
a	B-X
recently	B-X
identified	B-X
ubiquitin-like	B-X
posttranslational	B-X
modification	B-X
with	B-X
important	B-X
biological	B-X
functions	B-X
.	B-X
However	B-X
,	B-X
the	B-X
regulatory	B-X
mechanisms	B-X
governing	B-X
UFM1	B-X
modification	B-X
of	B-X
target	B-X
proteins	B-X
(	B-X
UFMylation	B-X
)	B-X
and	B-X
the	B-X
cellular	B-X
processes	B-X
controlled	B-X
by	B-X
UFMylation	B-X
remain	B-X
largely	B-X
unknown	B-X
.	B-X
One	B-X
unique	B-X
feature	B-X
of	B-X
selenium	B-X
is	B-X
its	B-X
incorporation	B-X
as	B-X
selenocysteine	B-X
,	B-X
a	B-X
rare	B-X
21st	B-X
amino	B-X
acid	B-X
,	B-X
into	B-X
selenoproteins	B-X
.	B-X
Unlike	B-X
other	B-X
amino	B-X
acids	B-X
,	B-X
incorporation	B-X
of	B-X
selenocysteine	B-X
requires	B-X
a	B-X
distinctive	B-X
UGA	B-X
stop	B-X
codon	B-X
recoding	B-X
mechanism	B-X
.	B-X
Although	B-X
many	B-X
studies	B-X
correlating	B-X
selenium	B-X
,	B-X
selenoproteins	B-X
,	B-X
aging	B-X
,	B-X
and	B-X
senescence	B-X
have	B-X
been	B-X
performed	B-X
,	B-X
it	B-X
has	B-X
not	B-X
yet	B-X
been	B-X
explored	B-X
if	B-X
the	B-X
upstream	B-X
events	B-X
regulating	B-X
selenoprotein	B-X
synthesis	B-X
play	B-X
a	B-X
role	B-X
in	B-X
senescence-associated	B-X
pathologies	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
review	B-X
the	B-X
potential	B-X
role	B-X
of	B-X
epitranscriptomic	B-X
marks	B-X
that	B-X
govern	B-X
selenocysteine	B-X
utilization	B-X
in	B-X
regulating	B-X
the	B-X
senescence	B-X
program	B-X
.	B-X

Furthermore	O
,	O
gene	O
replacement	O
in	O
Schizosaccharomyces	O
pombe	O
revealed	O
that	O
each	O
cysteine	O
of	O
the	O
CXC	O
motif	O
can	O
individually	O
support	O
function	O
.	O
<EOS>	B-X
The	B-X
protein	B-X
sequence	B-X
terminates	B-X
with	B-X
a	B-X
CXC	B-X
motif	B-X
,	B-X
and	B-X
in	B-X
our	B-X
previous	B-X
report	B-X
(	B-X
Newman	B-X
,	B-X
C.	B-X
M.	B-X
H.	B-X
,	B-X
Giannakouros	B-X
,	B-X
T.	B-X
,	B-X
Hancock	B-X
,	B-X
J.	B-X
F.	B-X
,	B-X
Fawell	B-X
,	B-X
E.	B-X
H.	B-X
,	B-X
Armstrong	B-X
,	B-X
J.	B-X
,	B-X
and	B-X
Magee	B-X
,	B-X
A.	B-X
I	B-X
.	B-X
In	B-X
order	B-X
to	B-X
dissect	B-X
the	B-X
role	B-X
of	B-X
prenylation	B-X
of	B-X
each	B-X
cysteine	B-X
,	B-X
we	B-X
have	B-X
generated	B-X
C-terminal	B-X
mutants	B-X
where	B-X
either	B-X
one	B-X
or	B-X
both	B-X
cysteine	B-X
(	B-X
s	B-X
)	B-X
were	B-X
replaced	B-X
by	B-X
serine	B-X
and	B-X
expressed	B-X
them	B-X
in	B-X
vitro	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
and	B-X
in	B-X
vivo	B-X
in	B-X
transfected	B-X
COS	B-X
cells	B-X
.	B-X
Our	B-X
results	B-X
suggest	B-X
that	B-X
both	B-X
cysteines	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
are	B-X
prenylated	B-X
but	B-X
that	B-X
the	B-X
rate	B-X
of	B-X
prenylation	B-X
of	B-X
the	B-X
two	B-X
cysteines	B-X
is	B-X
different	B-X
.	B-X
The	B-X
upstream	B-X
cysteine	B-X
was	B-X
found	B-X
to	B-X
be	B-X
preferentially	B-X
prenylated	B-X
in	B-X
reticulocyte	B-X
lysates	B-X
unless	B-X
cytosol	B-X
from	B-X
COS	B-X
cells	B-X
was	B-X
added	B-X
.	B-X
A	B-X
separate	B-X
activity	B-X
could	B-X
therefore	B-X
be	B-X
required	B-X
for	B-X
prenylation	B-X
of	B-X
the	B-X
second	B-X
cysteine	B-X
,	B-X
or	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
factor	B-X
is	B-X
needed	B-X
to	B-X
allow	B-X
accumulation	B-X
of	B-X
doubly	B-X
prenylated	B-X
SpYPT5p	B-X
.	B-X
However	B-X
,	B-X
the	B-X
modification	B-X
of	B-X
the	B-X
upstream	B-X
cysteine	B-X
is	B-X
not	B-X
a	B-X
prerequisite	B-X
for	B-X
the	B-X
prenylation	B-X
of	B-X
the	B-X
other	B-X
.	B-X
Furthermore	B-X
,	B-X
gene	B-X
replacement	B-X
in	B-X
Schizosaccharomyces	B-X
pombe	B-X
revealed	B-X
that	B-X
each	B-X
cysteine	B-X
of	B-X
the	B-X
CXC	B-X
motif	B-X
can	B-X
individually	B-X
support	B-X
function	B-X
.	B-X
Carboxyl	B-X
methylation	B-X
occurred	B-X
only	B-X
on	B-X
protein	B-X
which	B-X
had	B-X
been	B-X
prenylated	B-X
on	B-X
the	B-X
C-terminal	B-X
cysteine	B-X
and	B-X
was	B-X
required	B-X
for	B-X
efficient	B-X
membrane	B-X
binding	B-X
in	B-X
vitro	B-X
.	B-X

Carboxyl	O
methylation	O
occurred	O
only	O
on	O
protein	O
which	O
had	O
been	O
prenylated	O
on	O
the	O
C	O
-	O
terminal	O
cysteine	O
and	O
was	O
required	O
for	O
efficient	O
membrane	O
binding	O
in	O
vitro	O
.	O

Bet2p	B-Protein
and	O
Mad2p	B-Protein
are	O
components	O
of	O
a	O
prenyltransferase	O
that	O
adds	O
geranylgeranyl	O
onto	O
Ypt1p	B-Protein
and	O
Sec4p	B-Protein
.	O
<EOS>	B-X
Three	B-X
different	B-X
prenyltransferases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
cells	B-X
,	B-X
the	B-X
farnesyltransferase	B-X
and	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
geranylgeranyltransferases	B-X
(	B-X
GGTase	B-X
)	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Mad2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
Bet2p	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
Mad2p	B-X
that	B-X
appears	B-X
to	B-X
bind	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
efficient	B-X
transfer	B-X
of	B-X
geranylgeranyl	B-X
onto	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
requires	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
activity	B-X
.	B-X

Three	O
different	O
prenyltransferases	O
have	O
been	O
identified	O
in	O
yeast	O
and	O
higher	O
cells	O
,	O
the	O
farnesyltransferase	O
and	O
the	O
type	O
I	O
and	O
type	O
II	O
geranylgeranyltransferases	O
(	O
GGTase	O
)	O
.	O
<EOS>	B-X
Three	B-X
different	B-X
prenyltransferases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
cells	B-X
,	B-X
the	B-X
farnesyltransferase	B-X
and	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
geranylgeranyltransferases	B-X
(	B-X
GGTase	B-X
)	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
and	B-X
GGTase-I	B-X
modify	B-X
peptides	B-X
in	B-X
vitro	B-X
with	B-X
the	B-X
CAAX	B-X
(	B-X
C	B-X
,	B-X
Cys	B-X
;	B-X
A	B-X
,	B-X
aliphatic	B-X
residue	B-X
;	B-X
X	B-X
,	B-X
terminal	B-X
amino	B-X
acid	B-X
)	B-X
consensus	B-X
motif	B-X
.	B-X
These	B-X
enzymes	B-X
are	B-X
heterodimers	B-X
that	B-X
have	B-X
different	B-X
beta-subunits	B-X
and	B-X
a	B-X
shared	B-X
alpha-subunit	B-X
.	B-X
In	B-X
yeast	B-X
,	B-X
the	B-X
RAM2	B-X
gene	B-X
encodes	B-X
this	B-X
alpha-subunit	B-X
.	B-X
RAM2	B-X
is	B-X
also	B-X
homologous	B-X
to	B-X
MAD2	B-X
,	B-X
a	B-X
yeast	B-X
gene	B-X
whose	B-X
product	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
feedback	B-X
control	B-X
of	B-X
mitosis	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X

The	O
farnesyltransferase	O
and	O
GGTase	O
-	O
I	O
modify	O
peptides	O
in	O
vitro	O
with	O
the	O
CAAX	O
(	O
C	O
,	O
Cys	O
;	O
A	O
,	O
aliphatic	O
residue	O
;	O
X	O
,	O
terminal	O
amino	O
acid	O
)	O
consensus	O
motif	O
.	O
<EOS>	B-X
Three	B-X
different	B-X
prenyltransferases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
cells	B-X
,	B-X
the	B-X
farnesyltransferase	B-X
and	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
geranylgeranyltransferases	B-X
(	B-X
GGTase	B-X
)	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
and	B-X
GGTase-I	B-X
modify	B-X
peptides	B-X
in	B-X
vitro	B-X
with	B-X
the	B-X
CAAX	B-X
(	B-X
C	B-X
,	B-X
Cys	B-X
;	B-X
A	B-X
,	B-X
aliphatic	B-X
residue	B-X
;	B-X
X	B-X
,	B-X
terminal	B-X
amino	B-X
acid	B-X
)	B-X
consensus	B-X
motif	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X

These	O
enzymes	O
are	O
heterodimers	O
that	O
have	O
different	O
beta	O
-	O
subunits	O
and	O
a	O
shared	O
alpha	O
-	O
subunit	O
.	O

In	O
yeast	O
,	O
the	O
RAM2	B-Protein
gene	O
encodes	O
this	O
alpha	O
-	O
subunit	O
.	O
<EOS>	B-X
The	B-X
RAM2	B-X
gene	B-X
encodes	B-X
the	B-X
common	B-X
alpha-subunit	B-X
of	B-X
two	B-X
PTFs	B-X
,	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
and	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
.	B-X
In	B-X
this	B-X
study	B-X
,	B-X
the	B-X
RAM2	B-X
gene	B-X
of	B-X
the	B-X
prenylation	B-X
pathway	B-X
in	B-X
the	B-X
opportunistic	B-X
pathogen	B-X
Candida	B-X
albicans	B-X
was	B-X
analysed	B-X
.	B-X
The	B-X
heterozygote	B-X
trisomy	B-X
test	B-X
was	B-X
used	B-X
to	B-X
demonstrate	B-X
that	B-X
RAM2	B-X
is	B-X
essential	B-X
to	B-X
the	B-X
viability	B-X
of	B-X
C.	B-X
albicans	B-X
.	B-X
RAM2	B-X
mRNA	B-X
in	B-X
the	B-X
yeast	B-X
and	B-X
hyphae	B-X
growth	B-X
states	B-X
was	B-X
not	B-X
detected	B-X
by	B-X
Northern	B-X
blot	B-X
analysis	B-X
,	B-X
but	B-X
was	B-X
detected	B-X
by	B-X
RT-PCR	B-X
.	B-X
The	B-X
data	B-X
from	B-X
genetic	B-X
studies	B-X
and	B-X
cell-free	B-X
enzyme	B-X
assays	B-X
suggest	B-X
that	B-X
the	B-X
drugs	B-X
may	B-X
not	B-X
have	B-X
access	B-X
to	B-X
the	B-X
Candida	B-X
cytoplasm	B-X
.	B-X
The	B-X
regulation	B-X
of	B-X
PTF	B-X
subunits	B-X
was	B-X
also	B-X
examined	B-X
in	B-X
a	B-X
strain	B-X
in	B-X
which	B-X
RAM2	B-X
was	B-X
under	B-X
the	B-X
control	B-X
of	B-X
a	B-X
regulable	B-X
promoter	B-X
.	B-X
Overall	B-X
,	B-X
this	B-X
study	B-X
demonstrated	B-X
that	B-X
RAM2	B-X
is	B-X
essential	B-X
to	B-X
C.	B-X
albicans	B-X
,	B-X
indicating	B-X
that	B-X
protein	B-X
prenylation	B-X
is	B-X
an	B-X
indispensable	B-X
cellular	B-X
process	B-X
in	B-X
this	B-X
yeast	B-X
.	B-X

RAM2	B-Protein
is	O
also	O
homologous	O
to	O
MAD2	B-Protein
,	O
a	O
yeast	O
gene	O
whose	O
product	O
has	O
been	O
implicated	O
in	O
the	O
feedback	O
control	O
of	O
mitosis	O
.	O
<EOS>	B-X
Three	B-X
different	B-X
prenyltransferases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
cells	B-X
,	B-X
the	B-X
farnesyltransferase	B-X
and	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
geranylgeranyltransferases	B-X
(	B-X
GGTase	B-X
)	B-X
.	B-X
In	B-X
yeast	B-X
,	B-X
the	B-X
RAM2	B-X
gene	B-X
encodes	B-X
this	B-X
alpha-subunit	B-X
.	B-X
RAM2	B-X
is	B-X
also	B-X
homologous	B-X
to	B-X
MAD2	B-X
,	B-X
a	B-X
yeast	B-X
gene	B-X
whose	B-X
product	B-X
has	B-X
been	B-X
implicated	B-X
in	B-X
the	B-X
feedback	B-X
control	B-X
of	B-X
mitosis	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X

We	O
have	O
shown	O
that	O
Bet2p	B-Protein
is	O
a	O
component	O
of	O
the	O
yeast	O
GGTase	O
-	O
II	O
(	O
refs	O
6	O
,	O
12	O
)	O
that	O
geranylgeranylates	O
Ypt1p	B-Protein
,	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
that	O
mediates	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
complex	O
.	O

Here	O
we	O
report	O
that	O
Mad2p	B-Protein
is	O
a	O
component	O
of	O
this	O
enzyme	O
.	O
<EOS>	B-X
These	B-X
enzymes	B-X
are	B-X
heterodimers	B-X
that	B-X
have	B-X
different	B-X
beta-subunits	B-X
and	B-X
a	B-X
shared	B-X
alpha-subunit	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Mad2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
this	B-X
enzyme	B-X
.	B-X
Bet2p	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
Mad2p	B-X
that	B-X
appears	B-X
to	B-X
bind	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X

Bet2p	B-Protein
forms	O
a	O
complex	O
with	O
Mad2p	B-Protein
that	O
appears	O
to	O
bind	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
farnesyl	O
pyrophosphate	O
.	O

The	O
efficient	O
transfer	O
of	O
geranylgeranyl	O
onto	O
small	O
GTP	O
-	O
binding	O
proteins	O
requires	O
the	O
presence	O
of	O
an	O
additional	O
activity	O
.	O
<EOS>	B-X
Three	B-X
different	B-X
prenyltransferases	B-X
have	B-X
been	B-X
identified	B-X
in	B-X
yeast	B-X
and	B-X
higher	B-X
cells	B-X
,	B-X
the	B-X
farnesyltransferase	B-X
and	B-X
the	B-X
type	B-X
I	B-X
and	B-X
type	B-X
II	B-X
geranylgeranyltransferases	B-X
(	B-X
GGTase	B-X
)	B-X
.	B-X
The	B-X
farnesyltransferase	B-X
and	B-X
GGTase-I	B-X
modify	B-X
peptides	B-X
in	B-X
vitro	B-X
with	B-X
the	B-X
CAAX	B-X
(	B-X
C	B-X
,	B-X
Cys	B-X
;	B-X
A	B-X
,	B-X
aliphatic	B-X
residue	B-X
;	B-X
X	B-X
,	B-X
terminal	B-X
amino	B-X
acid	B-X
)	B-X
consensus	B-X
motif	B-X
.	B-X
We	B-X
have	B-X
shown	B-X
that	B-X
Bet2p	B-X
is	B-X
a	B-X
component	B-X
of	B-X
the	B-X
yeast	B-X
GGTase-II	B-X
(	B-X
refs	B-X
6	B-X
,	B-X
12	B-X
)	B-X
that	B-X
geranylgeranylates	B-X
Ypt1p	B-X
,	B-X
a	B-X
small	B-X
GTP-binding	B-X
protein	B-X
that	B-X
mediates	B-X
transport	B-X
from	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
to	B-X
the	B-X
Golgi	B-X
complex	B-X
.	B-X
Bet2p	B-X
forms	B-X
a	B-X
complex	B-X
with	B-X
Mad2p	B-X
that	B-X
appears	B-X
to	B-X
bind	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
,	B-X
but	B-X
not	B-X
farnesyl	B-X
pyrophosphate	B-X
.	B-X
The	B-X
efficient	B-X
transfer	B-X
of	B-X
geranylgeranyl	B-X
onto	B-X
small	B-X
GTP-binding	B-X
proteins	B-X
requires	B-X
the	B-X
presence	B-X
of	B-X
an	B-X
additional	B-X
activity	B-X
.	B-X

Vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
activity	O
,	O
prothrombin	B-Protein
mRNA	O
,	O
and	O
prothrombin	B-Protein
production	O
in	O
two	O
cultured	O
rat	O
hepatoma	O
cell	O
lines	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
under-gamma-carboxylated	B-X
forms	B-X
of	B-X
plasma	B-X
prothrombin	B-X
is	B-X
a	B-X
marker	B-X
for	B-X
human	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
A	B-X
rat	B-X
hepatoma	B-X
cell	B-X
line	B-X
(	B-X
7777	B-X
)	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
secrete	B-X
undercarboxylated	B-X
prothrombin	B-X
when	B-X
grown	B-X
as	B-X
a	B-X
solid	B-X
tumor	B-X
has	B-X
now	B-X
been	B-X
grown	B-X
in	B-X
monolayer	B-X
culture	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
has	B-X
a	B-X
decreased	B-X
activity	B-X
of	B-X
the	B-X
microsomal	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
when	B-X
compared	B-X
to	B-X
a	B-X
control	B-X
(	B-X
H4IIEC3	B-X
)	B-X
hepatoma	B-X
line	B-X
,	B-X
does	B-X
not	B-X
increase	B-X
intracellular	B-X
prothrombin	B-X
concentrations	B-X
in	B-X
response	B-X
to	B-X
vitamin	B-X
K	B-X
depletion	B-X
,	B-X
and	B-X
secretes	B-X
undercarboxylated	B-X
prothrombin	B-X
even	B-X
when	B-X
grown	B-X
in	B-X
vitamin	B-X
K	B-X
supplemented	B-X
media	B-X
.	B-X
Prothrombin	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
prothrombin	B-X
mRNA	B-X
levels	B-X
,	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
model	B-X
for	B-X
assessing	B-X
the	B-X
cellular	B-X
alterations	B-X
responsible	B-X
for	B-X
undercarboxylated	B-X
prothrombin	B-X
excretion	B-X
by	B-X
human	B-X
hepatocellular	B-X
tumors	B-X
.	B-X

The	O
presence	O
of	O
under	O
-	O
gamma	O
-	O
carboxylated	O
forms	O
of	O
plasma	O
prothrombin	B-Protein
is	O
a	O
marker	O
for	O
human	O
primary	O
hepatocellular	O
carcinoma	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
under-gamma-carboxylated	B-X
forms	B-X
of	B-X
plasma	B-X
prothrombin	B-X
is	B-X
a	B-X
marker	B-X
for	B-X
human	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
A	B-X
rat	B-X
hepatoma	B-X
cell	B-X
line	B-X
(	B-X
7777	B-X
)	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
secrete	B-X
undercarboxylated	B-X
prothrombin	B-X
when	B-X
grown	B-X
as	B-X
a	B-X
solid	B-X
tumor	B-X
has	B-X
now	B-X
been	B-X
grown	B-X
in	B-X
monolayer	B-X
culture	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
has	B-X
a	B-X
decreased	B-X
activity	B-X
of	B-X
the	B-X
microsomal	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
when	B-X
compared	B-X
to	B-X
a	B-X
control	B-X
(	B-X
H4IIEC3	B-X
)	B-X
hepatoma	B-X
line	B-X
,	B-X
does	B-X
not	B-X
increase	B-X
intracellular	B-X
prothrombin	B-X
concentrations	B-X
in	B-X
response	B-X
to	B-X
vitamin	B-X
K	B-X
depletion	B-X
,	B-X
and	B-X
secretes	B-X
undercarboxylated	B-X
prothrombin	B-X
even	B-X
when	B-X
grown	B-X
in	B-X
vitamin	B-X
K	B-X
supplemented	B-X
media	B-X
.	B-X
Prothrombin	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
prothrombin	B-X
mRNA	B-X
levels	B-X
,	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
model	B-X
for	B-X
assessing	B-X
the	B-X
cellular	B-X
alterations	B-X
responsible	B-X
for	B-X
undercarboxylated	B-X
prothrombin	B-X
excretion	B-X
by	B-X
human	B-X
hepatocellular	B-X
tumors	B-X
.	B-X

A	O
rat	O
hepatoma	O
cell	O
line	O
(	O
7777	O
)	O
which	O
was	O
previously	O
shown	O
to	O
secrete	O
undercarboxylated	O
prothrombin	B-Protein
when	O
grown	O
as	O
a	O
solid	O
tumor	O
has	O
now	O
been	O
grown	O
in	O
monolayer	O
culture	O
.	O
<EOS>	B-X
The	B-X
presence	B-X
of	B-X
under-gamma-carboxylated	B-X
forms	B-X
of	B-X
plasma	B-X
prothrombin	B-X
is	B-X
a	B-X
marker	B-X
for	B-X
human	B-X
primary	B-X
hepatocellular	B-X
carcinoma	B-X
.	B-X
A	B-X
rat	B-X
hepatoma	B-X
cell	B-X
line	B-X
(	B-X
7777	B-X
)	B-X
which	B-X
was	B-X
previously	B-X
shown	B-X
to	B-X
secrete	B-X
undercarboxylated	B-X
prothrombin	B-X
when	B-X
grown	B-X
as	B-X
a	B-X
solid	B-X
tumor	B-X
has	B-X
now	B-X
been	B-X
grown	B-X
in	B-X
monolayer	B-X
culture	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
has	B-X
a	B-X
decreased	B-X
activity	B-X
of	B-X
the	B-X
microsomal	B-X
vitamin	B-X
K-dependent	B-X
carboxylase	B-X
when	B-X
compared	B-X
to	B-X
a	B-X
control	B-X
(	B-X
H4IIEC3	B-X
)	B-X
hepatoma	B-X
line	B-X
,	B-X
does	B-X
not	B-X
increase	B-X
intracellular	B-X
prothrombin	B-X
concentrations	B-X
in	B-X
response	B-X
to	B-X
vitamin	B-X
K	B-X
depletion	B-X
,	B-X
and	B-X
secretes	B-X
undercarboxylated	B-X
prothrombin	B-X
even	B-X
when	B-X
grown	B-X
in	B-X
vitamin	B-X
K	B-X
supplemented	B-X
media	B-X
.	B-X
Prothrombin	B-X
gene	B-X
expression	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
,	B-X
as	B-X
measured	B-X
by	B-X
prothrombin	B-X
mRNA	B-X
levels	B-X
,	B-X
was	B-X
not	B-X
altered	B-X
in	B-X
the	B-X
7777	B-X
cell	B-X
line	B-X
.	B-X
This	B-X
cell	B-X
line	B-X
appears	B-X
to	B-X
be	B-X
a	B-X
model	B-X
for	B-X
assessing	B-X
the	B-X
cellular	B-X
alterations	B-X
responsible	B-X
for	B-X
undercarboxylated	B-X
prothrombin	B-X
excretion	B-X
by	B-X
human	B-X
hepatocellular	B-X
tumors	B-X
.	B-X

This	O
cell	O
line	O
has	O
a	O
decreased	O
activity	O
of	O
the	O
microsomal	O
vitamin	B-Protein
K	I-Protein
-	I-Protein
dependent	I-Protein
carboxylase	I-Protein
when	O
compared	O
to	O
a	O
control	O
(	O
H4IIEC3	O
)	O
hepatoma	O
line	O
,	O
does	O
not	O
increase	O
intracellular	O
prothrombin	B-Protein
concentrations	O
in	O
response	O
to	O
vitamin	O
K	O
depletion	O
,	O
and	O
secretes	O
undercarboxylated	O
prothrombin	B-Protein
even	O
when	O
grown	O
in	O
vitamin	O
K	O
supplemented	O
media	O
.	O

Prothrombin	B-Protein
gene	O
expression	O
in	O
the	O
7777	O
cell	O
line	O
,	O
as	O
measured	O
by	O
prothrombin	B-Protein
mRNA	O
levels	O
,	O
was	O
not	O
altered	O
in	O
the	O
7777	O
cell	O
line	O
.	O

This	O
cell	O
line	O
appears	O
to	O
be	O
a	O
model	O
for	O
assessing	O
the	O
cellular	O
alterations	O
responsible	O
for	O
undercarboxylated	O
prothrombin	B-Protein
excretion	O
by	O
human	O
hepatocellular	O
tumors	O
.	O

A	O
novel	O
N	O
-	O
terminal	O
motif	O
for	O
palmitoylation	O
of	O
G	O
-	O
protein	O
alpha	O
subunits	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
post-translational	B-X
processing	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
expressed	B-X
endogenously	B-X
in	B-X
rat	B-X
PC12	B-X
and	B-X
NG108-15	B-X
rat/mouse	B-X
hybrid	B-X
cells	B-X
,	B-X
and	B-X
after	B-X
transfection	B-X
of	B-X
cDNA	B-X
expression	B-X
constructs	B-X
into	B-X
COS	B-X
cells	B-X
.	B-X
Thioester-linked	B-X
palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
,	B-X
alpha	B-X
s	B-X
,	B-X
alpha	B-X
q/alpha	B-X
11	B-X
and	B-X
alpha	B-X
12	B-X
has	B-X
been	B-X
detected	B-X
by	B-X
metabolic	B-X
labelling	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
and	B-X
immunoprecipitation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
occurs	B-X
post-translationally	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
protein-synthesis	B-X
inhibitors	B-X
,	B-X
suggesting	B-X
possible	B-X
dynamic	B-X
acylation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
the	B-X
C-terminal	B-X
CAAX	B-X
motif	B-X
has	B-X
been	B-X
excluded	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
alpha	B-X
o	B-X
has	B-X
been	B-X
used	B-X
to	B-X
implicate	B-X
the	B-X
site	B-X
of	B-X
modification	B-X
as	B-X
a	B-X
cysteine	B-X
residue	B-X
next	B-X
to	B-X
the	B-X
N-terminal	B-X
myristoylated	B-X
glycine	B-X
,	B-X
in	B-X
a	B-X
novel	B-X
protein-lipid	B-X
modification	B-X
motif	B-X
Met-Gly-Cys	B-X
.	B-X
The	B-X
non-palmitoylated	B-X
alpha	B-X
o	B-X
mutant	B-X
is	B-X
still	B-X
myristoylated	B-X
but	B-X
shows	B-X
reduced	B-X
membrane	B-X
binding	B-X
,	B-X
suggesting	B-X
that	B-X
reversible	B-X
palmitoylation	B-X
may	B-X
regulate	B-X
G	B-X
alpha	B-X
localization	B-X
and	B-X
function	B-X
.	B-X

We	O
have	O
examined	O
the	O
post	O
-	O
translational	O
processing	O
of	O
G	O
alpha	O
subunits	O
expressed	O
endogenously	O
in	O
rat	O
PC12	O
and	O
NG108	O
-	O
15	O
rat	O
/	O
mouse	O
hybrid	O
cells	O
,	O
and	O
after	O
transfection	O
of	O
cDNA	O
expression	O
constructs	O
into	O
COS	O
cells	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
post-translational	B-X
processing	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
expressed	B-X
endogenously	B-X
in	B-X
rat	B-X
PC12	B-X
and	B-X
NG108-15	B-X
rat/mouse	B-X
hybrid	B-X
cells	B-X
,	B-X
and	B-X
after	B-X
transfection	B-X
of	B-X
cDNA	B-X
expression	B-X
constructs	B-X
into	B-X
COS	B-X
cells	B-X
.	B-X
Thioester-linked	B-X
palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
,	B-X
alpha	B-X
s	B-X
,	B-X
alpha	B-X
q/alpha	B-X
11	B-X
and	B-X
alpha	B-X
12	B-X
has	B-X
been	B-X
detected	B-X
by	B-X
metabolic	B-X
labelling	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
and	B-X
immunoprecipitation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
occurs	B-X
post-translationally	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
protein-synthesis	B-X
inhibitors	B-X
,	B-X
suggesting	B-X
possible	B-X
dynamic	B-X
acylation	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
alpha	B-X
o	B-X
has	B-X
been	B-X
used	B-X
to	B-X
implicate	B-X
the	B-X
site	B-X
of	B-X
modification	B-X
as	B-X
a	B-X
cysteine	B-X
residue	B-X
next	B-X
to	B-X
the	B-X
N-terminal	B-X
myristoylated	B-X
glycine	B-X
,	B-X
in	B-X
a	B-X
novel	B-X
protein-lipid	B-X
modification	B-X
motif	B-X
Met-Gly-Cys	B-X
.	B-X
The	B-X
non-palmitoylated	B-X
alpha	B-X
o	B-X
mutant	B-X
is	B-X
still	B-X
myristoylated	B-X
but	B-X
shows	B-X
reduced	B-X
membrane	B-X
binding	B-X
,	B-X
suggesting	B-X
that	B-X
reversible	B-X
palmitoylation	B-X
may	B-X
regulate	B-X
G	B-X
alpha	B-X
localization	B-X
and	B-X
function	B-X
.	B-X

Thioester	O
-	O
linked	O
palmitoylation	O
of	O
alpha	B-Protein
o	I-Protein
,	O
alpha	B-Protein
s	I-Protein
,	O
alpha	B-Protein
q	I-Protein
/	O
alpha	B-Protein
11	I-Protein
and	O
alpha	B-Protein
12	I-Protein
has	O
been	O
detected	O
by	O
metabolic	O
labelling	O
with	O
[	O
3H	O
]	O
palmitate	O
and	O
immunoprecipitation	O
.	O

Palmitoylation	O
of	O
alpha	B-Protein
o	I-Protein
occurs	O
post	O
-	O
translationally	O
in	O
cells	O
treated	O
with	O
protein	O
-	O
synthesis	O
inhibitors	O
,	O
suggesting	O
possible	O
dynamic	O
acylation	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
post-translational	B-X
processing	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
expressed	B-X
endogenously	B-X
in	B-X
rat	B-X
PC12	B-X
and	B-X
NG108-15	B-X
rat/mouse	B-X
hybrid	B-X
cells	B-X
,	B-X
and	B-X
after	B-X
transfection	B-X
of	B-X
cDNA	B-X
expression	B-X
constructs	B-X
into	B-X
COS	B-X
cells	B-X
.	B-X
Thioester-linked	B-X
palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
,	B-X
alpha	B-X
s	B-X
,	B-X
alpha	B-X
q/alpha	B-X
11	B-X
and	B-X
alpha	B-X
12	B-X
has	B-X
been	B-X
detected	B-X
by	B-X
metabolic	B-X
labelling	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
and	B-X
immunoprecipitation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
occurs	B-X
post-translationally	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
protein-synthesis	B-X
inhibitors	B-X
,	B-X
suggesting	B-X
possible	B-X
dynamic	B-X
acylation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
the	B-X
C-terminal	B-X
CAAX	B-X
motif	B-X
has	B-X
been	B-X
excluded	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
alpha	B-X
o	B-X
has	B-X
been	B-X
used	B-X
to	B-X
implicate	B-X
the	B-X
site	B-X
of	B-X
modification	B-X
as	B-X
a	B-X
cysteine	B-X
residue	B-X
next	B-X
to	B-X
the	B-X
N-terminal	B-X
myristoylated	B-X
glycine	B-X
,	B-X
in	B-X
a	B-X
novel	B-X
protein-lipid	B-X
modification	B-X
motif	B-X
Met-Gly-Cys	B-X
.	B-X
The	B-X
non-palmitoylated	B-X
alpha	B-X
o	B-X
mutant	B-X
is	B-X
still	B-X
myristoylated	B-X
but	B-X
shows	B-X
reduced	B-X
membrane	B-X
binding	B-X
,	B-X
suggesting	B-X
that	B-X
reversible	B-X
palmitoylation	B-X
may	B-X
regulate	B-X
G	B-X
alpha	B-X
localization	B-X
and	B-X
function	B-X
.	B-X

Palmitoylation	O
of	O
the	O
C	O
-	O
terminal	O
CAAX	O
motif	O
has	O
been	O
excluded	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
alpha	B-Protein
o	I-Protein
has	O
been	O
used	O
to	O
implicate	O
the	O
site	O
of	O
modification	O
as	O
a	O
cysteine	O
residue	O
next	O
to	O
the	O
N	O
-	O
terminal	O
myristoylated	O
glycine	O
,	O
in	O
a	O
novel	O
protein	O
-	O
lipid	O
modification	O
motif	O
Met	O
-	O
Gly	O
-	O
Cys	O
.	O

The	O
non	O
-	O
palmitoylated	O
alpha	B-Protein
o	I-Protein
mutant	O
is	O
still	O
myristoylated	O
but	O
shows	O
reduced	O
membrane	O
binding	O
,	O
suggesting	O
that	O
reversible	O
palmitoylation	O
may	O
regulate	O
G	O
alpha	O
localization	O
and	O
function	O
.	O
<EOS>	B-X
We	B-X
have	B-X
examined	B-X
the	B-X
post-translational	B-X
processing	B-X
of	B-X
G	B-X
alpha	B-X
subunits	B-X
expressed	B-X
endogenously	B-X
in	B-X
rat	B-X
PC12	B-X
and	B-X
NG108-15	B-X
rat/mouse	B-X
hybrid	B-X
cells	B-X
,	B-X
and	B-X
after	B-X
transfection	B-X
of	B-X
cDNA	B-X
expression	B-X
constructs	B-X
into	B-X
COS	B-X
cells	B-X
.	B-X
Thioester-linked	B-X
palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
,	B-X
alpha	B-X
s	B-X
,	B-X
alpha	B-X
q/alpha	B-X
11	B-X
and	B-X
alpha	B-X
12	B-X
has	B-X
been	B-X
detected	B-X
by	B-X
metabolic	B-X
labelling	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
and	B-X
immunoprecipitation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
alpha	B-X
o	B-X
occurs	B-X
post-translationally	B-X
in	B-X
cells	B-X
treated	B-X
with	B-X
protein-synthesis	B-X
inhibitors	B-X
,	B-X
suggesting	B-X
possible	B-X
dynamic	B-X
acylation	B-X
.	B-X
Site-directed	B-X
mutagenesis	B-X
of	B-X
alpha	B-X
o	B-X
has	B-X
been	B-X
used	B-X
to	B-X
implicate	B-X
the	B-X
site	B-X
of	B-X
modification	B-X
as	B-X
a	B-X
cysteine	B-X
residue	B-X
next	B-X
to	B-X
the	B-X
N-terminal	B-X
myristoylated	B-X
glycine	B-X
,	B-X
in	B-X
a	B-X
novel	B-X
protein-lipid	B-X
modification	B-X
motif	B-X
Met-Gly-Cys	B-X
.	B-X
The	B-X
non-palmitoylated	B-X
alpha	B-X
o	B-X
mutant	B-X
is	B-X
still	B-X
myristoylated	B-X
but	B-X
shows	B-X
reduced	B-X
membrane	B-X
binding	B-X
,	B-X
suggesting	B-X
that	B-X
reversible	B-X
palmitoylation	B-X
may	B-X
regulate	B-X
G	B-X
alpha	B-X
localization	B-X
and	B-X
function	B-X
.	B-X

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
Rab	O
geranylgeranyl	O
transferase	O
and	O
demonstration	O
of	O
its	O
role	O
as	O
a	O
Rab	O
escort	O
protein	O
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
biochemical	B-X
assays	B-X
we	B-X
demonstrate	B-X
that	B-X
component	B-X
A	B-X
binds	B-X
unprenylated	B-X
Rab1A	B-X
,	B-X
presents	B-X
it	B-X
to	B-X
the	B-X
catalytic	B-X
component	B-X
B	B-X
,	B-X
and	B-X
remains	B-X
bound	B-X
to	B-X
it	B-X
after	B-X
the	B-X
geranylgeranyl	B-X
transfer	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
detergents	B-X
,	B-X
the	B-X
reaction	B-X
terminates	B-X
when	B-X
all	B-X
of	B-X
component	B-X
A	B-X
is	B-X
occupied	B-X
with	B-X
prenylated	B-X
Rab	B-X
.	B-X
Detergents	B-X
allow	B-X
multiple	B-X
rounds	B-X
of	B-X
catalysis	B-X
,	B-X
apparently	B-X
by	B-X
dissociating	B-X
the	B-X
component	B-X
A-Rab	B-X
complex	B-X
and	B-X
thus	B-X
allowing	B-X
recycling	B-X
of	B-X
component	B-X
A	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
component	B-X
A	B-X
may	B-X
be	B-X
regenerated	B-X
by	B-X
transferring	B-X
its	B-X
prenylated	B-X
Rab	B-X
to	B-X
a	B-X
protein	B-X
acceptor	B-X
,	B-X
such	B-X
as	B-X
Rab3A	B-X
GDI	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X

cDNA	O
cloning	O
of	O
component	O
A	O
of	O
rat	O
Rab	O
geranylgeranyl	O
transferase	O
confirms	O
identity	O
of	O
the	O
protein	O
with	O
the	O
human	O
choroideremia	B-Protein
gene	O
product	O
and	O
its	O
resemblance	O
to	O
Rab3A	B-Protein
guanine	I-Protein
nucleotide	I-Protein
dissociation	I-Protein
inhibitor	I-Protein
(	O
GDI	B-Protein
)	O
,	O
which	O
binds	O
prenylated	O
Rabs	O
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
biochemical	B-X
assays	B-X
we	B-X
demonstrate	B-X
that	B-X
component	B-X
A	B-X
binds	B-X
unprenylated	B-X
Rab1A	B-X
,	B-X
presents	B-X
it	B-X
to	B-X
the	B-X
catalytic	B-X
component	B-X
B	B-X
,	B-X
and	B-X
remains	B-X
bound	B-X
to	B-X
it	B-X
after	B-X
the	B-X
geranylgeranyl	B-X
transfer	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
detergents	B-X
,	B-X
the	B-X
reaction	B-X
terminates	B-X
when	B-X
all	B-X
of	B-X
component	B-X
A	B-X
is	B-X
occupied	B-X
with	B-X
prenylated	B-X
Rab	B-X
.	B-X
Detergents	B-X
allow	B-X
multiple	B-X
rounds	B-X
of	B-X
catalysis	B-X
,	B-X
apparently	B-X
by	B-X
dissociating	B-X
the	B-X
component	B-X
A-Rab	B-X
complex	B-X
and	B-X
thus	B-X
allowing	B-X
recycling	B-X
of	B-X
component	B-X
A	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
component	B-X
A	B-X
may	B-X
be	B-X
regenerated	B-X
by	B-X
transferring	B-X
its	B-X
prenylated	B-X
Rab	B-X
to	B-X
a	B-X
protein	B-X
acceptor	B-X
,	B-X
such	B-X
as	B-X
Rab3A	B-X
GDI	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X
A	B-X
genetic	B-X
defect	B-X
in	B-X
REP	B-X
underlies	B-X
human	B-X
choroideremia	B-X
,	B-X
a	B-X
disease	B-X
of	B-X
retinal	B-X
degeneration	B-X
.	B-X

In	O
biochemical	O
assays	O
we	O
demonstrate	O
that	O
component	O
A	O
binds	O
unprenylated	O
Rab1A	B-Protein
,	O
presents	O
it	O
to	O
the	O
catalytic	O
component	O
B	O
,	O
and	O
remains	O
bound	O
to	O
it	O
after	O
the	O
geranylgeranyl	O
transfer	O
reaction	O
.	O

In	O
the	O
absence	O
of	O
detergents	O
,	O
the	O
reaction	O
terminates	O
when	O
all	O
of	O
component	O
A	O
is	O
occupied	O
with	O
prenylated	O
Rab	O
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
biochemical	B-X
assays	B-X
we	B-X
demonstrate	B-X
that	B-X
component	B-X
A	B-X
binds	B-X
unprenylated	B-X
Rab1A	B-X
,	B-X
presents	B-X
it	B-X
to	B-X
the	B-X
catalytic	B-X
component	B-X
B	B-X
,	B-X
and	B-X
remains	B-X
bound	B-X
to	B-X
it	B-X
after	B-X
the	B-X
geranylgeranyl	B-X
transfer	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
detergents	B-X
,	B-X
the	B-X
reaction	B-X
terminates	B-X
when	B-X
all	B-X
of	B-X
component	B-X
A	B-X
is	B-X
occupied	B-X
with	B-X
prenylated	B-X
Rab	B-X
.	B-X
Detergents	B-X
allow	B-X
multiple	B-X
rounds	B-X
of	B-X
catalysis	B-X
,	B-X
apparently	B-X
by	B-X
dissociating	B-X
the	B-X
component	B-X
A-Rab	B-X
complex	B-X
and	B-X
thus	B-X
allowing	B-X
recycling	B-X
of	B-X
component	B-X
A	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
component	B-X
A	B-X
may	B-X
be	B-X
regenerated	B-X
by	B-X
transferring	B-X
its	B-X
prenylated	B-X
Rab	B-X
to	B-X
a	B-X
protein	B-X
acceptor	B-X
,	B-X
such	B-X
as	B-X
Rab3A	B-X
GDI	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X

Detergents	O
allow	O
multiple	O
rounds	O
of	O
catalysis	O
,	O
apparently	O
by	O
dissociating	O
the	O
component	O
A	O
-	O
Rab	O
complex	O
and	O
thus	O
allowing	O
recycling	O
of	O
component	O
A	O
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
biochemical	B-X
assays	B-X
we	B-X
demonstrate	B-X
that	B-X
component	B-X
A	B-X
binds	B-X
unprenylated	B-X
Rab1A	B-X
,	B-X
presents	B-X
it	B-X
to	B-X
the	B-X
catalytic	B-X
component	B-X
B	B-X
,	B-X
and	B-X
remains	B-X
bound	B-X
to	B-X
it	B-X
after	B-X
the	B-X
geranylgeranyl	B-X
transfer	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
detergents	B-X
,	B-X
the	B-X
reaction	B-X
terminates	B-X
when	B-X
all	B-X
of	B-X
component	B-X
A	B-X
is	B-X
occupied	B-X
with	B-X
prenylated	B-X
Rab	B-X
.	B-X
Detergents	B-X
allow	B-X
multiple	B-X
rounds	B-X
of	B-X
catalysis	B-X
,	B-X
apparently	B-X
by	B-X
dissociating	B-X
the	B-X
component	B-X
A-Rab	B-X
complex	B-X
and	B-X
thus	B-X
allowing	B-X
recycling	B-X
of	B-X
component	B-X
A	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
component	B-X
A	B-X
may	B-X
be	B-X
regenerated	B-X
by	B-X
transferring	B-X
its	B-X
prenylated	B-X
Rab	B-X
to	B-X
a	B-X
protein	B-X
acceptor	B-X
,	B-X
such	B-X
as	B-X
Rab3A	B-X
GDI	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X

Within	O
the	O
cell	O
,	O
component	O
A	O
may	O
be	O
regenerated	O
by	O
transferring	O
its	O
prenylated	O
Rab	O
to	O
a	O
protein	O
acceptor	O
,	O
such	O
as	O
Rab3A	B-Protein
GDI	I-Protein
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
biochemical	B-X
assays	B-X
we	B-X
demonstrate	B-X
that	B-X
component	B-X
A	B-X
binds	B-X
unprenylated	B-X
Rab1A	B-X
,	B-X
presents	B-X
it	B-X
to	B-X
the	B-X
catalytic	B-X
component	B-X
B	B-X
,	B-X
and	B-X
remains	B-X
bound	B-X
to	B-X
it	B-X
after	B-X
the	B-X
geranylgeranyl	B-X
transfer	B-X
reaction	B-X
.	B-X
In	B-X
the	B-X
absence	B-X
of	B-X
detergents	B-X
,	B-X
the	B-X
reaction	B-X
terminates	B-X
when	B-X
all	B-X
of	B-X
component	B-X
A	B-X
is	B-X
occupied	B-X
with	B-X
prenylated	B-X
Rab	B-X
.	B-X
Detergents	B-X
allow	B-X
multiple	B-X
rounds	B-X
of	B-X
catalysis	B-X
,	B-X
apparently	B-X
by	B-X
dissociating	B-X
the	B-X
component	B-X
A-Rab	B-X
complex	B-X
and	B-X
thus	B-X
allowing	B-X
recycling	B-X
of	B-X
component	B-X
A	B-X
.	B-X
Within	B-X
the	B-X
cell	B-X
,	B-X
component	B-X
A	B-X
may	B-X
be	B-X
regenerated	B-X
by	B-X
transferring	B-X
its	B-X
prenylated	B-X
Rab	B-X
to	B-X
a	B-X
protein	B-X
acceptor	B-X
,	B-X
such	B-X
as	B-X
Rab3A	B-X
GDI	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X

In	O
view	O
of	O
its	O
function	O
in	O
escorting	O
Rab	O
proteins	O
during	O
and	O
presumably	O
after	O
the	O
prenyl	O
transfer	O
reaction	O
,	O
we	O
propose	O
to	O
rename	O
component	O
A	O
as	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
.	O

A	O
genetic	O
defect	O
in	O
REP	O
underlies	O
human	O
choroideremia	B-Protein
,	O
a	O
disease	O
of	O
retinal	O
degeneration	O
.	O
<EOS>	B-X
cDNA	B-X
cloning	B-X
of	B-X
component	B-X
A	B-X
of	B-X
rat	B-X
Rab	B-X
geranylgeranyl	B-X
transferase	B-X
confirms	B-X
identity	B-X
of	B-X
the	B-X
protein	B-X
with	B-X
the	B-X
human	B-X
choroideremia	B-X
gene	B-X
product	B-X
and	B-X
its	B-X
resemblance	B-X
to	B-X
Rab3A	B-X
guanine	B-X
nucleotide	B-X
dissociation	B-X
inhibitor	B-X
(	B-X
GDI	B-X
)	B-X
,	B-X
which	B-X
binds	B-X
prenylated	B-X
Rabs	B-X
.	B-X
In	B-X
view	B-X
of	B-X
its	B-X
function	B-X
in	B-X
escorting	B-X
Rab	B-X
proteins	B-X
during	B-X
and	B-X
presumably	B-X
after	B-X
the	B-X
prenyl	B-X
transfer	B-X
reaction	B-X
,	B-X
we	B-X
propose	B-X
to	B-X
rename	B-X
component	B-X
A	B-X
as	B-X
Rab	B-X
escort	B-X
protein	B-X
(	B-X
REP	B-X
)	B-X
.	B-X
A	B-X
genetic	B-X
defect	B-X
in	B-X
REP	B-X
underlies	B-X
human	B-X
choroideremia	B-X
,	B-X
a	B-X
disease	B-X
of	B-X
retinal	B-X
degeneration	B-X
.	B-X

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
:	O
glycoprotein	B-Protein
IX	I-Protein
is	O
primarily	O
myristoylated	O
while	O
glycoprotein	O
Ib	O
is	O
palmitoylated	O
.	O
<EOS>	B-X
The	B-X
acylation	B-X
of	B-X
megakaryocyte	B-X
proteins	B-X
was	B-X
studied	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
complex	B-X
.	B-X
Guinea	B-X
pig	B-X
megakaryocytes	B-X
were	B-X
purified	B-X
and	B-X
separated	B-X
into	B-X
subpopulations	B-X
at	B-X
different	B-X
phases	B-X
of	B-X
maturation	B-X
.	B-X
Cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
or	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
to	B-X
study	B-X
endogenous	B-X
protein	B-X
acylation	B-X
.	B-X
Cycloheximide	B-X
was	B-X
used	B-X
to	B-X
distinguish	B-X
between	B-X
cotranslational	B-X
and	B-X
posttranslational	B-X
acylation	B-X
and	B-X
hydroxylamine	B-X
to	B-X
distinguish	B-X
between	B-X
thioester	B-X
and	B-X
amide	B-X
linkages	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
was	O
studied	O
with	O
special	O
emphasis	O
on	O
the	O
myristoylation	O
and	O
palmitoylation	O
of	O
the	O
glycoprotein	O
(	O
GP	O
)	O
Ib	O
complex	O
.	O
<EOS>	B-X
The	B-X
acylation	B-X
of	B-X
megakaryocyte	B-X
proteins	B-X
was	B-X
studied	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
complex	B-X
.	B-X
Guinea	B-X
pig	B-X
megakaryocytes	B-X
were	B-X
purified	B-X
and	B-X
separated	B-X
into	B-X
subpopulations	B-X
at	B-X
different	B-X
phases	B-X
of	B-X
maturation	B-X
.	B-X
Cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
or	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
to	B-X
study	B-X
endogenous	B-X
protein	B-X
acylation	B-X
.	B-X
Cycloheximide	B-X
was	B-X
used	B-X
to	B-X
distinguish	B-X
between	B-X
cotranslational	B-X
and	B-X
posttranslational	B-X
acylation	B-X
and	B-X
hydroxylamine	B-X
to	B-X
distinguish	B-X
between	B-X
thioester	B-X
and	B-X
amide	B-X
linkages	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

Guinea	O
pig	O
megakaryocytes	O
were	O
purified	O
and	O
separated	O
into	O
subpopulations	O
at	O
different	O
phases	O
of	O
maturation	O
.	O
<EOS>	B-X
We	B-X
introduce	B-X
a	B-X
new	B-X
method	B-X
for	B-X
preparing	B-X
subpopulations	B-X
of	B-X
guinea	B-X
pig	B-X
megakaryocytes	B-X
(	B-X
MK	B-X
)	B-X
.	B-X
MK	B-X
,	B-X
partially	B-X
purified	B-X
by	B-X
a	B-X
density	B-X
gradient	B-X
,	B-X
were	B-X
separated	B-X
according	B-X
to	B-X
size	B-X
by	B-X
sedimentation	B-X
,	B-X
starting	B-X
as	B-X
a	B-X
monolayer	B-X
,	B-X
in	B-X
an	B-X
albumin	B-X
gradient	B-X
at	B-X
unit	B-X
gravity	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
method	B-X
can	B-X
isolate	B-X
MK	B-X
subpopulations	B-X
that	B-X
are	B-X
viable	B-X
and	B-X
can	B-X
be	B-X
used	B-X
to	B-X
investigate	B-X
the	B-X
biochemical	B-X
characteristics	B-X
of	B-X
MK	B-X
at	B-X
different	B-X
phases	B-X
of	B-X
maturation	B-X
.	B-X
Guinea	B-X
pig	B-X
megakaryocytes	B-X
were	B-X
purified	B-X
and	B-X
separated	B-X
into	B-X
subpopulations	B-X
at	B-X
different	B-X
phases	B-X
of	B-X
maturation	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

Cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
[	O
3H	O
]	O
palmitate	O
,	O
or	O
[	O
3H	O
]	O
acetate	O
to	O
study	O
endogenous	O
protein	O
acylation	O
.	O
<EOS>	B-X
Thus	B-X
,	B-X
the	B-X
objective	B-X
of	B-X
this	B-X
study	B-X
was	B-X
to	B-X
evaluate	B-X
the	B-X
effect	B-X
of	B-X
PA	B-X
on	B-X
NET	B-X
release	B-X
and	B-X
the	B-X
underlying	B-X
mechanism	B-X
in	B-X
vitro	B-X
.	B-X
Phorbol-12-myristate-13-acetate	B-X
(	B-X
PMA	B-X
;	B-X
100	B-X
ng/mL	B-X
,	B-X
3	B-X
h	B-X
)	B-X
was	B-X
used	B-X
to	B-X
induce	B-X
the	B-X
release	B-X
of	B-X
NET	B-X
in	B-X
vitro	B-X
.	B-X
Cells	B-X
were	B-X
maintained	B-X
in	B-X
RPMI-1640	B-X
basic	B-X
medium	B-X
without	B-X
phenol	B-X
red	B-X
,	B-X
treated	B-X
with	B-X
600	B-X
μM	B-X
PA	B-X
for	B-X
different	B-X
times	B-X
(	B-X
4	B-X
,	B-X
5	B-X
,	B-X
6	B-X
,	B-X
and	B-X
7	B-X
h	B-X
)	B-X
in	B-X
the	B-X
presence	B-X
or	B-X
absence	B-X
of	B-X
PMA	B-X
.	B-X
Exogenous	B-X
PA	B-X
led	B-X
to	B-X
accumulation	B-X
of	B-X
sequestosome-1	B-X
and	B-X
microtubule-associated	B-X
protein	B-X
1	B-X
light	B-X
chain	B-X
3-II	B-X
,	B-X
and	B-X
no	B-X
further	B-X
accumulation	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
chloroquine	B-X
,	B-X
all	B-X
of	B-X
which	B-X
suggested	B-X
an	B-X
impairment	B-X
of	B-X
autophagic	B-X
flux	B-X
.	B-X

Cycloheximide	O
was	O
used	O
to	O
distinguish	O
between	O
cotranslational	O
and	O
posttranslational	O
acylation	O
and	O
hydroxylamine	O
to	O
distinguish	O
between	O
thioester	O
and	O
amide	O
linkages	O
.	O
<EOS>	B-X
The	B-X
acylation	B-X
of	B-X
megakaryocyte	B-X
proteins	B-X
was	B-X
studied	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
complex	B-X
.	B-X
Cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
or	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
to	B-X
study	B-X
endogenous	B-X
protein	B-X
acylation	B-X
.	B-X
Cycloheximide	B-X
was	B-X
used	B-X
to	B-X
distinguish	B-X
between	B-X
cotranslational	B-X
and	B-X
posttranslational	B-X
acylation	B-X
and	B-X
hydroxylamine	B-X
to	B-X
distinguish	B-X
between	B-X
thioester	B-X
and	B-X
amide	B-X
linkages	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X

After	O
incubations	O
,	O
delipidated	O
proteins	O
or	O
GPIb	O
complex	O
subunits	O
,	O
immunoprecipitated	O
with	O
PG	O
-	O
1	O
,	O
AN	O
-	O
51	O
or	O
FMC	O
-	O
25	O
monoclonal	O
antibody	O
,	O
were	O
separated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
assessed	O
by	O
fluorography	O
.	O
<EOS>	B-X
The	B-X
membrane	B-X
contacts	B-X
MscS	B-X
at	B-X
sensor	B-X
paddles	B-X
,	B-X
but	B-X
lipids	B-X
also	B-X
leave	B-X
the	B-X
membrane	B-X
and	B-X
move	B-X
along	B-X
grooves	B-X
between	B-X
the	B-X
paddles	B-X
to	B-X
reside	B-X
as	B-X
far	B-X
as	B-X
15	B-X
Å	B-X
away	B-X
from	B-X
the	B-X
membrane	B-X
in	B-X
hydrophobic	B-X
pockets	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
show	B-X
that	B-X
MscS	B-X
opens	B-X
when	B-X
it	B-X
is	B-X
sufficiently	B-X
delipidated	B-X
by	B-X
incubation	B-X
with	B-X
the	B-X
detergent	B-X
dodecyl-β-maltoside	B-X
or	B-X
the	B-X
branched	B-X
detergent	B-X
lauryl	B-X
maltose	B-X
neopentyl	B-X
glycol	B-X
.	B-X
Based	B-X
on	B-X
the	B-X
distribution	B-X
of	B-X
the	B-X
aliphatic	B-X
chains	B-X
in	B-X
the	B-X
open	B-X
and	B-X
closed	B-X
conformation	B-X
,	B-X
we	B-X
propose	B-X
that	B-X
during	B-X
gating	B-X
,	B-X
lipids	B-X
leave	B-X
the	B-X
complex	B-X
on	B-X
the	B-X
cytosolic	B-X
leaflet	B-X
at	B-X
the	B-X
height	B-X
of	B-X
highest	B-X
lateral	B-X
tension	B-X
,	B-X
while	B-X
on	B-X
the	B-X
periplasmic	B-X
side	B-X
,	B-X
lipids	B-X
flow	B-X
into	B-X
gaps	B-X
,	B-X
which	B-X
open	B-X
between	B-X
transmembrane	B-X
helices	B-X
.	B-X
Conditions	B-X
were	B-X
developed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
for	B-X
purification	B-X
,	B-X
delipidation	B-X
,	B-X
and	B-X
long	B-X
term	B-X
stabilization	B-X
of	B-X
octaethylene	B-X
glycol	B-X
monododecyl	B-X
ether	B-X
(	B-X
C	B-X
(	B-X
12	B-X
)	B-X
E	B-X
(	B-X
8	B-X
)	B-X
)	B-X
-solubilized	B-X
sarcoplasmic	B-X
reticulum	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-ATPase	B-X
with	B-X
tightly	B-X
bound	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
and	B-X
F	B-X
(	B-X
-	B-X
)	B-X
,	B-X
an	B-X
analog	B-X
for	B-X
the	B-X
phosphoenzyme	B-X
intermediate	B-X
without	B-X
bound	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
.	B-X
The	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-ATPase	B-X
activity	B-X
to	B-X
monitor	B-X
denaturation	B-X
was	B-X
assessed	B-X
after	B-X
treatment	B-X
with	B-X
20	B-X
mm	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
to	B-X
release	B-X
tightly	B-X
bound	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
/F	B-X
(	B-X
-	B-X
)	B-X
.	B-X
The	B-X
solubilized	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
/F	B-X
(	B-X
-	B-X
)	B-X
-bound	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-ATPase	B-X
was	B-X
very	B-X
rapidly	B-X
denatured	B-X
at	B-X
pH	B-X
8	B-X
,	B-X
but	B-X
was	B-X
perfectly	B-X
stabilized	B-X
at	B-X
pH	B-X
6	B-X
against	B-X
denaturation	B-X
for	B-X
over	B-X
20	B-X
days	B-X
at	B-X
4	B-X
degrees	B-X
C	B-X
even	B-X
without	B-X
exogenously	B-X
added	B-X
phospholipid	B-X
and	B-X
at	B-X
a	B-X
high	B-X
C	B-X
(	B-X
12	B-X
)	B-X
E	B-X
(	B-X
8	B-X
)	B-X
/enzyme	B-X
weight	B-X
ratio	B-X
(	B-X
10:1	B-X
)	B-X
.	B-X
The	B-X
perfect	B-X
stability	B-X
was	B-X
attained	B-X
with	B-X
or	B-X
without	B-X
0.1	B-X
mm	B-X
dithiothreitol	B-X
,	B-X
but	B-X
inactivation	B-X
occurred	B-X
with	B-X
a	B-X
half-life	B-X
of	B-X
10	B-X
days	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
1	B-X
mm	B-X
dithiothreitol	B-X
,	B-X
possibly	B-X
due	B-X
to	B-X
reduction	B-X
of	B-X
a	B-X
specific	B-X
disulfide	B-X
bond	B-X
(	B-X
s	B-X
)	B-X
.	B-X
The	B-X
present	B-X
study	B-X
thus	B-X
reveals	B-X
an	B-X
essential	B-X
property	B-X
of	B-X
the	B-X
Mg	B-X
(	B-X
2+	B-X
)	B-X
/F	B-X
(	B-X
-	B-X
)	B-X
/Ca	B-X
(	B-X
2+	B-X
)	B-X
-ATPase	B-X
complex	B-X
,	B-X
which	B-X
will	B-X
likely	B-X
provide	B-X
clues	B-X
to	B-X
understanding	B-X
structure	B-X
of	B-X
the	B-X
Ca	B-X
(	B-X
2+	B-X
)	B-X
-released	B-X
form	B-X
of	B-X
phosphoenzyme	B-X
intermediate	B-X
at	B-X
an	B-X
atomic	B-X
level	B-X
.	B-X

Radiolabeled	O
fatty	O
acids	O
bound	O
to	O
GPIX	B-Protein
and	O
GPIb	O
were	O
also	O
analyzed	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
scintillation	O
spectrometry	O
.	O
<EOS>	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

With	O
[	O
3H	O
]	O
myristic	O
acid	O
and	O
[	O
3H	O
]	O
acetate	O
,	O
GPIX	B-Protein
was	O
found	O
to	O
be	O
a	O
major	O
myristoylated	O
protein	O
in	O
megakaryocytes	O
and	O
CHRF	O
-	O
288	O
cells	O
.	O

Myristic	O
acid	O
was	O
linked	O
to	O
GPIX	B-Protein
by	O
an	O
amide	O
bond	O
,	O
and	O
this	O
process	O
occurred	O
cotranslationally	O
.	O
<EOS>	B-X
Cycloheximide	B-X
was	B-X
used	B-X
to	B-X
distinguish	B-X
between	B-X
cotranslational	B-X
and	B-X
posttranslational	B-X
acylation	B-X
and	B-X
hydroxylamine	B-X
to	B-X
distinguish	B-X
between	B-X
thioester	B-X
and	B-X
amide	B-X
linkages	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X

With	O
[	O
3H	O
]	O
acetate	O
,	O
GPIb	O
was	O
primarily	O
palmitoylated	O
,	O
but	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
GPIb	O
was	O
acylated	O
with	O
about	O
equal	O
mounts	O
of	O
myristic	O
acid	O
and	O
palmitic	O
acids	O
.	O
<EOS>	B-X
Cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
or	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
to	B-X
study	B-X
endogenous	B-X
protein	B-X
acylation	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

Both	O
fatty	O
acids	O
were	O
linked	O
to	O
GPIb	O
by	O
thioester	O
bonds	O
,	O
and	O
acylation	O
was	O
posttranslational	O
.	O
<EOS>	B-X
The	B-X
acylation	B-X
of	B-X
megakaryocyte	B-X
proteins	B-X
was	B-X
studied	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
complex	B-X
.	B-X
Cells	B-X
were	B-X
incubated	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
,	B-X
or	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
to	B-X
study	B-X
endogenous	B-X
protein	B-X
acylation	B-X
.	B-X
Cycloheximide	B-X
was	B-X
used	B-X
to	B-X
distinguish	B-X
between	B-X
cotranslational	B-X
and	B-X
posttranslational	B-X
acylation	B-X
and	B-X
hydroxylamine	B-X
to	B-X
distinguish	B-X
between	B-X
thioester	B-X
and	B-X
amide	B-X
linkages	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

The	O
myristoylation	O
of	O
GPIX	B-Protein
while	O
the	O
palmitoylation	O
of	O
GPIb	O
occurred	O
throughout	O
megakaryocyte	O
maturation	O
.	O
<EOS>	B-X
The	B-X
acylation	B-X
of	B-X
megakaryocyte	B-X
proteins	B-X
was	B-X
studied	B-X
with	B-X
special	B-X
emphasis	B-X
on	B-X
the	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
of	B-X
the	B-X
glycoprotein	B-X
(	B-X
GP	B-X
)	B-X
Ib	B-X
complex	B-X
.	B-X
Guinea	B-X
pig	B-X
megakaryocytes	B-X
were	B-X
purified	B-X
and	B-X
separated	B-X
into	B-X
subpopulations	B-X
at	B-X
different	B-X
phases	B-X
of	B-X
maturation	B-X
.	B-X
After	B-X
incubations	B-X
,	B-X
delipidated	B-X
proteins	B-X
or	B-X
GPIb	B-X
complex	B-X
subunits	B-X
,	B-X
immunoprecipitated	B-X
with	B-X
PG-1	B-X
,	B-X
AN-51	B-X
or	B-X
FMC-25	B-X
monoclonal	B-X
antibody	B-X
,	B-X
were	B-X
separated	B-X
by	B-X
sodium	B-X
dodecyl	B-X
sulfate-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
(	B-X
SDS-PAGE	B-X
)	B-X
and	B-X
assessed	B-X
by	B-X
fluorography	B-X
.	B-X
Radiolabeled	B-X
fatty	B-X
acids	B-X
bound	B-X
to	B-X
GPIX	B-X
and	B-X
GPIb	B-X
were	B-X
also	B-X
analyzed	B-X
by	B-X
high	B-X
pressure	B-X
liquid	B-X
chromatography	B-X
(	B-X
HPLC	B-X
)	B-X
and	B-X
scintillation	B-X
spectrometry	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
myristic	B-X
acid	B-X
and	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIX	B-X
was	B-X
found	B-X
to	B-X
be	B-X
a	B-X
major	B-X
myristoylated	B-X
protein	B-X
in	B-X
megakaryocytes	B-X
and	B-X
CHRF-288	B-X
cells	B-X
.	B-X
Myristic	B-X
acid	B-X
was	B-X
linked	B-X
to	B-X
GPIX	B-X
by	B-X
an	B-X
amide	B-X
bond	B-X
,	B-X
and	B-X
this	B-X
process	B-X
occurred	B-X
cotranslationally	B-X
.	B-X
With	B-X
[	B-X
3H	B-X
]	B-X
acetate	B-X
,	B-X
GPIb	B-X
was	B-X
primarily	B-X
palmitoylated	B-X
,	B-X
but	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
myristate	B-X
,	B-X
GPIb	B-X
was	B-X
acylated	B-X
with	B-X
about	B-X
equal	B-X
mounts	B-X
of	B-X
myristic	B-X
acid	B-X
and	B-X
palmitic	B-X
acids	B-X
.	B-X
Both	B-X
fatty	B-X
acids	B-X
were	B-X
linked	B-X
to	B-X
GPIb	B-X
by	B-X
thioester	B-X
bonds	B-X
,	B-X
and	B-X
acylation	B-X
was	B-X
posttranslational	B-X
.	B-X
The	B-X
myristoylation	B-X
of	B-X
GPIX	B-X
while	B-X
the	B-X
palmitoylation	B-X
of	B-X
GPIb	B-X
occurred	B-X
throughout	B-X
megakaryocyte	B-X
maturation	B-X
.	B-X
Myristoylation	B-X
and	B-X
palmitoylation	B-X
may	B-X
have	B-X
different	B-X
functions	B-X
relevant	B-X
to	B-X
the	B-X
assembly	B-X
of	B-X
the	B-X
GPIb	B-X
complex	B-X
in	B-X
megakaryocytes	B-X
.	B-X

Myristoylation	O
and	O
palmitoylation	O
may	O
have	O
different	O
functions	O
relevant	O
to	O
the	O
assembly	O
of	O
the	O
GPIb	O
complex	O
in	O
megakaryocytes	O
.	O

The	O
inhibition	O
of	O
phosphoenolpyruvate	B-Protein
carboxykinase	I-Protein
following	O
in	O
vivo	O
chronic	O
phenobarbital	O
treatment	O
in	O
the	O
rat	O
is	O
due	O
to	O
a	O
post	O
-	O
translational	O
event	O
.	O
<EOS>	B-X
Chronic	B-X
treatment	B-X
of	B-X
rats	B-X
with	B-X
phenobarbital	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
decrease	B-X
gluconeogenesis	B-X
in	B-X
rat	B-X
hepatocytes	B-X
by	B-X
a	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
phosphoenolpyruvate	B-X
(	B-X
P-pyruvate	B-X
)	B-X
carboxykinase	B-X
activity	B-X
[	B-X
Argaud	B-X
,	B-X
D.	B-X
,	B-X
Halimi	B-X
,	B-X
S.	B-X
,	B-X
Catelloni	B-X
,	B-X
F.	B-X
&	B-X
Leverve	B-X
,	B-X
X	B-X
.	B-X
Contrary	B-X
to	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
regulation	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
find	B-X
a	B-X
diminution	B-X
of	B-X
either	B-X
P-pyruvate	B-X
carboxykinase	B-X
protein	B-X
(	B-X
by	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
)	B-X
or	B-X
P-pyruvate	B-X
carboxykinase	B-X
mRNA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
phenobarbital	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Kinetic	B-X
studies	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
,	B-X
measured	B-X
by	B-X
either	B-X
carboxylation	B-X
of	B-X
P-pyruvate	B-X
or	B-X
decarboxylation	B-X
of	B-X
oxaloacetate	B-X
,	B-X
revealed	B-X
a	B-X
decrease	B-X
in	B-X
both	B-X
V	B-X
(	B-X
max	B-X
)	B-X
and	B-X
Km	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
nutritional	B-X
state	B-X
affected	B-X
only	B-X
the	B-X
V	B-X
(	B-X
max	B-X
)	B-X
,	B-X
as	B-X
expected	B-X
.	B-X
Assessment	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
specificity	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
full	B-X
inhibition	B-X
of	B-X
the	B-X
enzyme	B-X
with	B-X
its	B-X
specific	B-X
inhibitor	B-X
3-mercaptopicolinate	B-X
in	B-X
the	B-X
micromolar	B-X
range	B-X
.	B-X
P-Pyruvate	B-X
carboxykinase	B-X
,	B-X
purified	B-X
either	B-X
by	B-X
ammonium	B-X
sulfate	B-X
fractionation	B-X
or	B-X
by	B-X
immunoprecipitation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
decrease	B-X
in	B-X
affinity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
mass	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
altered	B-X
,	B-X
the	B-X
pH	B-X
sensitivity	B-X
to	B-X
3-mercaptopicolinate	B-X
inhibition	B-X
and	B-X
the	B-X
enzyme	B-X
recovery	B-X
after	B-X
immunoprecipitation	B-X
both	B-X
seemed	B-X
to	B-X
be	B-X
affected	B-X
.	B-X
This	B-X
leads	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
chronic	B-X
phenobarbital	B-X
treatment	B-X
on	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
transcriptional	B-X
regulation	B-X
but	B-X
is	B-X
exerted	B-X
at	B-X
the	B-X
post-translational	B-X
level	B-X
.	B-X

Chronic	O
treatment	O
of	O
rats	O
with	O
phenobarbital	O
has	O
been	O
reported	O
to	O
decrease	O
gluconeogenesis	O
in	O
rat	O
hepatocytes	O
by	O
a	O
50	O
%	O
inhibition	O
of	O
phosphoenolpyruvate	B-Protein
(	I-Protein
P	I-Protein
-	I-Protein
pyruvate	I-Protein
)	I-Protein
carboxykinase	I-Protein
activity	O
[	O
Argaud	O
,	O
D	O
.	O
,	O
Halimi	O
,	O
S	O
.	O
,	O
Catelloni	O
,	O
F	O
.	O
&	O
Leverve	O
,	O
X	O
.	O
(	O
1991	O
)	O
Biochem	O
.	O
J	O
.	O
280	O
,	O
663	O
-	O
669	O
]	O
.	O
<EOS>	B-X
Chronic	B-X
treatment	B-X
of	B-X
rats	B-X
with	B-X
phenobarbital	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
decrease	B-X
gluconeogenesis	B-X
in	B-X
rat	B-X
hepatocytes	B-X
by	B-X
a	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
phosphoenolpyruvate	B-X
(	B-X
P-pyruvate	B-X
)	B-X
carboxykinase	B-X
activity	B-X
[	B-X
Argaud	B-X
,	B-X
D.	B-X
,	B-X
Halimi	B-X
,	B-X
S.	B-X
,	B-X
Catelloni	B-X
,	B-X
F.	B-X
&	B-X
Leverve	B-X
,	B-X
X	B-X
.	B-X
(	B-X
1991	B-X
)	B-X
Biochem	B-X
.	B-X
J	B-X
.	B-X
280	B-X
,	B-X
663-669	B-X
]	B-X
.	B-X
Contrary	B-X
to	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
regulation	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
find	B-X
a	B-X
diminution	B-X
of	B-X
either	B-X
P-pyruvate	B-X
carboxykinase	B-X
protein	B-X
(	B-X
by	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
)	B-X
or	B-X
P-pyruvate	B-X
carboxykinase	B-X
mRNA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
phenobarbital	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Kinetic	B-X
studies	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
,	B-X
measured	B-X
by	B-X
either	B-X
carboxylation	B-X
of	B-X
P-pyruvate	B-X
or	B-X
decarboxylation	B-X
of	B-X
oxaloacetate	B-X
,	B-X
revealed	B-X
a	B-X
decrease	B-X
in	B-X
both	B-X
V	B-X
(	B-X
max	B-X
)	B-X
and	B-X
Km	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
nutritional	B-X
state	B-X
affected	B-X
only	B-X
the	B-X
V	B-X
(	B-X
max	B-X
)	B-X
,	B-X
as	B-X
expected	B-X
.	B-X
Assessment	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
specificity	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
full	B-X
inhibition	B-X
of	B-X
the	B-X
enzyme	B-X
with	B-X
its	B-X
specific	B-X
inhibitor	B-X
3-mercaptopicolinate	B-X
in	B-X
the	B-X
micromolar	B-X
range	B-X
.	B-X
P-Pyruvate	B-X
carboxykinase	B-X
,	B-X
purified	B-X
either	B-X
by	B-X
ammonium	B-X
sulfate	B-X
fractionation	B-X
or	B-X
by	B-X
immunoprecipitation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
decrease	B-X
in	B-X
affinity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
mass	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
altered	B-X
,	B-X
the	B-X
pH	B-X
sensitivity	B-X
to	B-X
3-mercaptopicolinate	B-X
inhibition	B-X
and	B-X
the	B-X
enzyme	B-X
recovery	B-X
after	B-X
immunoprecipitation	B-X
both	B-X
seemed	B-X
to	B-X
be	B-X
affected	B-X
.	B-X
This	B-X
leads	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
chronic	B-X
phenobarbital	B-X
treatment	B-X
on	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
transcriptional	B-X
regulation	B-X
but	B-X
is	B-X
exerted	B-X
at	B-X
the	B-X
post-translational	B-X
level	B-X
.	B-X

Contrary	O
to	O
the	O
current	O
knowledge	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
regulation	O
,	O
we	O
failed	O
to	O
find	O
a	O
diminution	O
of	O
either	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
protein	O
(	O
by	O
using	O
a	O
polyclonal	O
antibody	O
)	O
or	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
mRNA	O
,	O
in	O
the	O
liver	O
of	O
rats	O
treated	O
with	O
phenobarbital	O
for	O
2	O
weeks	O
.	O
<EOS>	B-X
Chronic	B-X
treatment	B-X
of	B-X
rats	B-X
with	B-X
phenobarbital	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
decrease	B-X
gluconeogenesis	B-X
in	B-X
rat	B-X
hepatocytes	B-X
by	B-X
a	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
phosphoenolpyruvate	B-X
(	B-X
P-pyruvate	B-X
)	B-X
carboxykinase	B-X
activity	B-X
[	B-X
Argaud	B-X
,	B-X
D.	B-X
,	B-X
Halimi	B-X
,	B-X
S.	B-X
,	B-X
Catelloni	B-X
,	B-X
F.	B-X
&	B-X
Leverve	B-X
,	B-X
X	B-X
.	B-X
280	B-X
,	B-X
663-669	B-X
]	B-X
.	B-X
Contrary	B-X
to	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
regulation	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
find	B-X
a	B-X
diminution	B-X
of	B-X
either	B-X
P-pyruvate	B-X
carboxykinase	B-X
protein	B-X
(	B-X
by	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
)	B-X
or	B-X
P-pyruvate	B-X
carboxykinase	B-X
mRNA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
phenobarbital	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Kinetic	B-X
studies	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
,	B-X
measured	B-X
by	B-X
either	B-X
carboxylation	B-X
of	B-X
P-pyruvate	B-X
or	B-X
decarboxylation	B-X
of	B-X
oxaloacetate	B-X
,	B-X
revealed	B-X
a	B-X
decrease	B-X
in	B-X
both	B-X
V	B-X
(	B-X
max	B-X
)	B-X
and	B-X
Km	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
nutritional	B-X
state	B-X
affected	B-X
only	B-X
the	B-X
V	B-X
(	B-X
max	B-X
)	B-X
,	B-X
as	B-X
expected	B-X
.	B-X
Assessment	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
specificity	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
full	B-X
inhibition	B-X
of	B-X
the	B-X
enzyme	B-X
with	B-X
its	B-X
specific	B-X
inhibitor	B-X
3-mercaptopicolinate	B-X
in	B-X
the	B-X
micromolar	B-X
range	B-X
.	B-X
P-Pyruvate	B-X
carboxykinase	B-X
,	B-X
purified	B-X
either	B-X
by	B-X
ammonium	B-X
sulfate	B-X
fractionation	B-X
or	B-X
by	B-X
immunoprecipitation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
decrease	B-X
in	B-X
affinity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X
This	B-X
leads	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
chronic	B-X
phenobarbital	B-X
treatment	B-X
on	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
transcriptional	B-X
regulation	B-X
but	B-X
is	B-X
exerted	B-X
at	B-X
the	B-X
post-translational	B-X
level	B-X
.	B-X

Kinetic	O
studies	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
activity	O
,	O
measured	O
by	O
either	O
carboxylation	O
of	O
P	O
-	O
pyruvate	O
or	O
decarboxylation	O
of	O
oxaloacetate	O
,	O
revealed	O
a	O
decrease	O
in	O
both	O
V	O
(	O
max	O
)	O
and	O
Km	O
after	O
phenobarbital	O
treatment	O
,	O
whereas	O
the	O
nutritional	O
state	O
affected	O
only	O
the	O
V	O
(	O
max	O
)	O
,	O
as	O
expected	O
.	O

Assessment	O
of	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
specificity	O
was	O
confirmed	O
by	O
the	O
full	O
inhibition	O
of	O
the	O
enzyme	O
with	O
its	O
specific	O
inhibitor	O
3	O
-	O
mercaptopicolinate	O
in	O
the	O
micromolar	O
range	O
.	O
<EOS>	B-X
Chronic	B-X
treatment	B-X
of	B-X
rats	B-X
with	B-X
phenobarbital	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
decrease	B-X
gluconeogenesis	B-X
in	B-X
rat	B-X
hepatocytes	B-X
by	B-X
a	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
phosphoenolpyruvate	B-X
(	B-X
P-pyruvate	B-X
)	B-X
carboxykinase	B-X
activity	B-X
[	B-X
Argaud	B-X
,	B-X
D.	B-X
,	B-X
Halimi	B-X
,	B-X
S.	B-X
,	B-X
Catelloni	B-X
,	B-X
F.	B-X
&	B-X
Leverve	B-X
,	B-X
X	B-X
.	B-X
280	B-X
,	B-X
663-669	B-X
]	B-X
.	B-X
Contrary	B-X
to	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
regulation	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
find	B-X
a	B-X
diminution	B-X
of	B-X
either	B-X
P-pyruvate	B-X
carboxykinase	B-X
protein	B-X
(	B-X
by	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
)	B-X
or	B-X
P-pyruvate	B-X
carboxykinase	B-X
mRNA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
phenobarbital	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Kinetic	B-X
studies	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
,	B-X
measured	B-X
by	B-X
either	B-X
carboxylation	B-X
of	B-X
P-pyruvate	B-X
or	B-X
decarboxylation	B-X
of	B-X
oxaloacetate	B-X
,	B-X
revealed	B-X
a	B-X
decrease	B-X
in	B-X
both	B-X
V	B-X
(	B-X
max	B-X
)	B-X
and	B-X
Km	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
nutritional	B-X
state	B-X
affected	B-X
only	B-X
the	B-X
V	B-X
(	B-X
max	B-X
)	B-X
,	B-X
as	B-X
expected	B-X
.	B-X
Assessment	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
specificity	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
full	B-X
inhibition	B-X
of	B-X
the	B-X
enzyme	B-X
with	B-X
its	B-X
specific	B-X
inhibitor	B-X
3-mercaptopicolinate	B-X
in	B-X
the	B-X
micromolar	B-X
range	B-X
.	B-X
P-Pyruvate	B-X
carboxykinase	B-X
,	B-X
purified	B-X
either	B-X
by	B-X
ammonium	B-X
sulfate	B-X
fractionation	B-X
or	B-X
by	B-X
immunoprecipitation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
decrease	B-X
in	B-X
affinity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
mass	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
altered	B-X
,	B-X
the	B-X
pH	B-X
sensitivity	B-X
to	B-X
3-mercaptopicolinate	B-X
inhibition	B-X
and	B-X
the	B-X
enzyme	B-X
recovery	B-X
after	B-X
immunoprecipitation	B-X
both	B-X
seemed	B-X
to	B-X
be	B-X
affected	B-X
.	B-X
This	B-X
leads	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
chronic	B-X
phenobarbital	B-X
treatment	B-X
on	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
transcriptional	B-X
regulation	B-X
but	B-X
is	B-X
exerted	B-X
at	B-X
the	B-X
post-translational	B-X
level	B-X
.	B-X

P	B-Protein
-	I-Protein
Pyruvate	I-Protein
carboxykinase	I-Protein
,	O
purified	O
either	O
by	O
ammonium	O
sulfate	O
fractionation	O
or	O
by	O
immunoprecipitation	O
,	O
exhibited	O
a	O
similar	O
decrease	O
in	O
affinity	O
after	O
phenobarbital	O
treatment	O
.	O
<EOS>	B-X
Chronic	B-X
treatment	B-X
of	B-X
rats	B-X
with	B-X
phenobarbital	B-X
has	B-X
been	B-X
reported	B-X
to	B-X
decrease	B-X
gluconeogenesis	B-X
in	B-X
rat	B-X
hepatocytes	B-X
by	B-X
a	B-X
50	B-X
%	B-X
inhibition	B-X
of	B-X
phosphoenolpyruvate	B-X
(	B-X
P-pyruvate	B-X
)	B-X
carboxykinase	B-X
activity	B-X
[	B-X
Argaud	B-X
,	B-X
D.	B-X
,	B-X
Halimi	B-X
,	B-X
S.	B-X
,	B-X
Catelloni	B-X
,	B-X
F.	B-X
&	B-X
Leverve	B-X
,	B-X
X	B-X
.	B-X
Contrary	B-X
to	B-X
the	B-X
current	B-X
knowledge	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
regulation	B-X
,	B-X
we	B-X
failed	B-X
to	B-X
find	B-X
a	B-X
diminution	B-X
of	B-X
either	B-X
P-pyruvate	B-X
carboxykinase	B-X
protein	B-X
(	B-X
by	B-X
using	B-X
a	B-X
polyclonal	B-X
antibody	B-X
)	B-X
or	B-X
P-pyruvate	B-X
carboxykinase	B-X
mRNA	B-X
,	B-X
in	B-X
the	B-X
liver	B-X
of	B-X
rats	B-X
treated	B-X
with	B-X
phenobarbital	B-X
for	B-X
2	B-X
weeks	B-X
.	B-X
Kinetic	B-X
studies	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
,	B-X
measured	B-X
by	B-X
either	B-X
carboxylation	B-X
of	B-X
P-pyruvate	B-X
or	B-X
decarboxylation	B-X
of	B-X
oxaloacetate	B-X
,	B-X
revealed	B-X
a	B-X
decrease	B-X
in	B-X
both	B-X
V	B-X
(	B-X
max	B-X
)	B-X
and	B-X
Km	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
,	B-X
whereas	B-X
the	B-X
nutritional	B-X
state	B-X
affected	B-X
only	B-X
the	B-X
V	B-X
(	B-X
max	B-X
)	B-X
,	B-X
as	B-X
expected	B-X
.	B-X
Assessment	B-X
of	B-X
P-pyruvate	B-X
carboxykinase	B-X
specificity	B-X
was	B-X
confirmed	B-X
by	B-X
the	B-X
full	B-X
inhibition	B-X
of	B-X
the	B-X
enzyme	B-X
with	B-X
its	B-X
specific	B-X
inhibitor	B-X
3-mercaptopicolinate	B-X
in	B-X
the	B-X
micromolar	B-X
range	B-X
.	B-X
P-Pyruvate	B-X
carboxykinase	B-X
,	B-X
purified	B-X
either	B-X
by	B-X
ammonium	B-X
sulfate	B-X
fractionation	B-X
or	B-X
by	B-X
immunoprecipitation	B-X
,	B-X
exhibited	B-X
a	B-X
similar	B-X
decrease	B-X
in	B-X
affinity	B-X
after	B-X
phenobarbital	B-X
treatment	B-X
.	B-X
Although	B-X
the	B-X
molecular	B-X
mass	B-X
does	B-X
not	B-X
appear	B-X
to	B-X
be	B-X
altered	B-X
,	B-X
the	B-X
pH	B-X
sensitivity	B-X
to	B-X
3-mercaptopicolinate	B-X
inhibition	B-X
and	B-X
the	B-X
enzyme	B-X
recovery	B-X
after	B-X
immunoprecipitation	B-X
both	B-X
seemed	B-X
to	B-X
be	B-X
affected	B-X
.	B-X
This	B-X
leads	B-X
us	B-X
to	B-X
propose	B-X
that	B-X
the	B-X
effect	B-X
of	B-X
chronic	B-X
phenobarbital	B-X
treatment	B-X
on	B-X
P-pyruvate	B-X
carboxykinase	B-X
activity	B-X
is	B-X
not	B-X
the	B-X
result	B-X
of	B-X
transcriptional	B-X
regulation	B-X
but	B-X
is	B-X
exerted	B-X
at	B-X
the	B-X
post-translational	B-X
level	B-X
.	B-X

Although	O
the	O
molecular	O
mass	O
does	O
not	O
appear	O
to	O
be	O
altered	O
,	O
the	O
pH	O
sensitivity	O
to	O
3	O
-	O
mercaptopicolinate	O
inhibition	O
and	O
the	O
enzyme	O
recovery	O
after	O
immunoprecipitation	O
both	O
seemed	O
to	O
be	O
affected	O
.	O
<EOS>	B-X
The	B-X
amount	B-X
of	B-X
SDS	B-X
bound	B-X
is	B-X
generally	B-X
sequence-independent	B-X
and	B-X
proportional	B-X
to	B-X
molecular	B-X
weight	B-X
;	B-X
at	B-X
saturation	B-X
,	B-X
approximately	B-X
one	B-X
SDS	B-X
molecule	B-X
is	B-X
bound	B-X
per	B-X
two	B-X
amino	B-X
acids	B-X
,	B-X
or	B-X
∼1.4	B-X
g	B-X
of	B-X
SDS	B-X
per	B-X
gram	B-X
of	B-X
polypeptide	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
migration	B-X
of	B-X
SDS-polypeptide	B-X
complexes	B-X
in	B-X
an	B-X
electric	B-X
field	B-X
is	B-X
proportional	B-X
to	B-X
the	B-X
relative	B-X
size	B-X
of	B-X
the	B-X
polypeptide	B-X
chain	B-X
,	B-X
and	B-X
its	B-X
molecular	B-X
weight	B-X
can	B-X
be	B-X
estimated	B-X
by	B-X
comparison	B-X
to	B-X
protein	B-X
markers	B-X
of	B-X
known	B-X
molecular	B-X
weight	B-X
.	B-X
Thus	B-X
,	B-X
the	B-X
apparent	B-X
molecular	B-X
weight	B-X
of	B-X
modified	B-X
proteins	B-X
does	B-X
not	B-X
always	B-X
accurately	B-X
reflect	B-X
the	B-X
mass	B-X
of	B-X
the	B-X
polypeptide	B-X
chain	B-X
.	B-X
This	B-X
protocol	B-X
describes	B-X
preparation	B-X
and	B-X
running	B-X
of	B-X
SDS-PAGE	B-X
gels	B-X
,	B-X
followed	B-X
by	B-X
staining	B-X
to	B-X
detect	B-X
proteins	B-X
using	B-X
Coomassie	B-X
Brilliant	B-X
Blue	B-X
.	B-X

This	O
leads	O
us	O
to	O
propose	O
that	O
the	O
effect	O
of	O
chronic	O
phenobarbital	O
treatment	O
on	O
P	B-Protein
-	I-Protein
pyruvate	I-Protein
carboxykinase	I-Protein
activity	O
is	O
not	O
the	O
result	O
of	O
transcriptional	O
regulation	O
but	O
is	O
exerted	O
at	O
the	O
post	O
-	O
translational	O
level	O
.	O

Regulation	O
by	O
cAMP	O
of	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
endothelial	B-Protein
nitric	I-Protein
-	I-Protein
oxide	I-Protein
synthase	I-Protein
(	O
type	O
3	O
)	O
in	O
cardiac	O
myocytes	O
.	O
<EOS>	B-X
Cardiac	B-X
myocytes	B-X
express	B-X
the	B-X
nitric-oxide	B-X
synthase	B-X
isoform	B-X
originally	B-X
identified	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
termed	B-X
eNOS	B-X
or	B-X
NOS3	B-X
,	B-X
where	B-X
it	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
both	B-X
adrenergic	B-X
and	B-X
muscarinic	B-X
cholinergic	B-X
autonomic	B-X
nervous	B-X
system	B-X
agonists	B-X
.	B-X
eNOS	B-X
in	B-X
endothelial	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
processing	B-X
,	B-X
and	B-X
in	B-X
cardiac	B-X
myocytes	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
plasmalemmal	B-X
caveolae	B-X
,	B-X
a	B-X
process	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Other	B-X
post-translational	B-X
modifications	B-X
essential	B-X
for	B-X
the	B-X
correct	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
have	B-X
not	B-X
been	B-X
described	B-X
previously	B-X
.	B-X
We	B-X
demonstrate	B-X
,	B-X
using	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
that	B-X
native	B-X
eNOS	B-X
in	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
is	B-X
initially	B-X
translated	B-X
as	B-X
a	B-X
nonpalmitoylated	B-X
150-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cytosolic	B-X
and	B-X
intracellular	B-X
membrane-enriched	B-X
fractions	B-X
.	B-X
This	B-X
is	B-X
subsequently	B-X
processed	B-X
to	B-X
a	B-X
palmitoylated	B-X
135-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
a	B-X
sarcolemma-enriched	B-X
membrane	B-X
fraction	B-X
.	B-X
Forskolin	B-X
,	B-X
an	B-X
agent	B-X
that	B-X
elevates	B-X
intracellular	B-X
cAMP	B-X
,	B-X
rapidly	B-X
inhibited	B-X
processing	B-X
of	B-X
the	B-X
150-kDa	B-X
isoform	B-X
to	B-X
the	B-X
135-kDa	B-X
isoform	B-X
and	B-X
transport	B-X
of	B-X
eNOS	B-X
to	B-X
the	B-X
sarcolemma	B-X
,	B-X
effects	B-X
paralleled	B-X
by	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
phosphorylation	B-X
of	B-X
the	B-X
larger	B-X
eNOS	B-X
isoform	B-X
.	B-X
Forskolin	B-X
also	B-X
decreased	B-X
palmitoylation	B-X
of	B-X
the	B-X
135-kDa	B-X
isoform	B-X
,	B-X
although	B-X
it	B-X
did	B-X
not	B-X
accelerate	B-X
depalmitoylation	B-X
of	B-X
sarcolemmal	B-X
eNOS	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
pulse-chase	B-X
experiments	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
.	B-X
Thus	B-X
,	B-X
post-translational	B-X
processing	B-X
of	B-X
a	B-X
150-kDa	B-X
isoform	B-X
of	B-X
myocyte	B-X
eNOS	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
intracellular	B-X
trafficking	B-X
of	B-X
the	B-X
enzyme	B-X
to	B-X
sarcolemmal	B-X
caveolae	B-X
.	B-X
Both	B-X
the	B-X
post-translational	B-X
processing	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
appear	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
changes	B-X
in	B-X
intracellular	B-X
cAMP	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
may	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
cardiac	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
autonomic	B-X
agonists	B-X
in	B-X
vivo	B-X
.	B-X

Cardiac	O
myocytes	O
express	O
the	O
nitric	O
-	O
oxide	O
synthase	O
isoform	O
originally	O
identified	O
in	O
endothelial	O
cells	O
,	O
termed	O
eNOS	B-Protein
or	O
NOS3	B-Protein
,	O
where	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
myocyte	O
responsiveness	O
to	O
both	O
adrenergic	O
and	O
muscarinic	O
cholinergic	O
autonomic	O
nervous	O
system	O
agonists	O
.	O
<EOS>	B-X
Endothelium-derived	B-X
nitric	B-X
oxide	B-X
(	B-X
NO	B-X
)	B-X
is	B-X
a	B-X
key	B-X
determinant	B-X
of	B-X
blood	B-X
pressure	B-X
homeostasis	B-X
and	B-X
platelet	B-X
aggregation	B-X
and	B-X
is	B-X
synthesized	B-X
by	B-X
the	B-X
endothelial	B-X
isoform	B-X
of	B-X
nitric	B-X
oxide	B-X
synthase	B-X
(	B-X
eNOS	B-X
)	B-X
.	B-X
In	B-X
the	B-X
vascular	B-X
wall	B-X
,	B-X
eNOS	B-X
is	B-X
activated	B-X
by	B-X
diverse	B-X
cell-surface	B-X
receptors	B-X
and	B-X
by	B-X
increases	B-X
in	B-X
blood	B-X
flow	B-X
,	B-X
and	B-X
the	B-X
consequent	B-X
generation	B-X
of	B-X
NO	B-X
leads	B-X
to	B-X
vascular	B-X
smooth-muscle	B-X
relaxation	B-X
.	B-X
Endothelium-dependent	B-X
vasorelaxation	B-X
is	B-X
deranged	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
disease	B-X
states	B-X
,	B-X
including	B-X
hypertension	B-X
,	B-X
diabetes	B-X
,	B-X
and	B-X
atherosclerosis	B-X
,	B-X
but	B-X
the	B-X
roles	B-X
of	B-X
eNOS	B-X
in	B-X
endothelial	B-X
dysfunction	B-X
remain	B-X
to	B-X
be	B-X
clearly	B-X
defined	B-X
.	B-X
The	B-X
past	B-X
several	B-X
years	B-X
have	B-X
witnessed	B-X
important	B-X
advances	B-X
in	B-X
understanding	B-X
the	B-X
molecular	B-X
and	B-X
cellular	B-X
biology	B-X
of	B-X
eNOS	B-X
regulation	B-X
.	B-X
In	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
undergoes	B-X
a	B-X
complex	B-X
series	B-X
of	B-X
covalent	B-X
modifications	B-X
,	B-X
including	B-X
myristoylation	B-X
,	B-X
palmitoylation	B-X
,	B-X
and	B-X
phosphorylation	B-X
.	B-X
Palmitoylation	B-X
of	B-X
eNOS	B-X
dynamically	B-X
targets	B-X
the	B-X
enzyme	B-X
to	B-X
distinct	B-X
domains	B-X
of	B-X
the	B-X
endothelial	B-X
plasma	B-X
membrane	B-X
termed	B-X
caveolae	B-X
;	B-X
caveolae	B-X
may	B-X
serve	B-X
as	B-X
sites	B-X
for	B-X
the	B-X
sequestration	B-X
of	B-X
signal-transducing	B-X
proteins	B-X
and	B-X
are	B-X
themselves	B-X
subject	B-X
to	B-X
dynamic	B-X
regulation	B-X
by	B-X
ligands	B-X
and	B-X
lipids	B-X
.	B-X
Originally	B-X
thought	B-X
to	B-X
be	B-X
expressed	B-X
only	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
is	B-X
now	B-X
known	B-X
to	B-X
be	B-X
expressed	B-X
in	B-X
a	B-X
variety	B-X
of	B-X
tissues	B-X
,	B-X
including	B-X
blood	B-X
platelets	B-X
,	B-X
cardiac	B-X
myocytes	B-X
,	B-X
and	B-X
brain	B-X
hippocampus	B-X
.	B-X
Paradigms	B-X
established	B-X
in	B-X
endothelial	B-X
cells	B-X
for	B-X
the	B-X
molecular	B-X
regulation	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
are	B-X
being	B-X
extended	B-X
to	B-X
the	B-X
investigation	B-X
of	B-X
eNOS	B-X
expressed	B-X
in	B-X
nonendothelial	B-X
tissues	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
recent	B-X
advances	B-X
in	B-X
understanding	B-X
the	B-X
molecular	B-X
regulation	B-X
of	B-X
eNOS	B-X
and	B-X
the	B-X
other	B-X
NOS	B-X
isoforms	B-X
and	B-X
identifies	B-X
important	B-X
parallels	B-X
between	B-X
eNOS	B-X
and	B-X
other	B-X
cell-signaling	B-X
molecules	B-X
.	B-X

eNOS	B-Protein
in	O
endothelial	O
cells	O
has	O
been	O
shown	O
to	O
undergo	O
extensive	O
post	O
-	O
translational	O
processing	O
,	O
and	O
in	O
cardiac	O
myocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
,	O
eNOS	B-Protein
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
plasmalemmal	O
caveolae	O
,	O
a	O
process	O
that	O
is	O
dependent	O
on	O
myristoylation	O
and	O
palmitoylation	O
.	O
<EOS>	B-X
Cardiac	B-X
myocytes	B-X
express	B-X
the	B-X
nitric-oxide	B-X
synthase	B-X
isoform	B-X
originally	B-X
identified	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
termed	B-X
eNOS	B-X
or	B-X
NOS3	B-X
,	B-X
where	B-X
it	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
both	B-X
adrenergic	B-X
and	B-X
muscarinic	B-X
cholinergic	B-X
autonomic	B-X
nervous	B-X
system	B-X
agonists	B-X
.	B-X
eNOS	B-X
in	B-X
endothelial	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
processing	B-X
,	B-X
and	B-X
in	B-X
cardiac	B-X
myocytes	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
plasmalemmal	B-X
caveolae	B-X
,	B-X
a	B-X
process	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Other	B-X
post-translational	B-X
modifications	B-X
essential	B-X
for	B-X
the	B-X
correct	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
have	B-X
not	B-X
been	B-X
described	B-X
previously	B-X
.	B-X
We	B-X
demonstrate	B-X
,	B-X
using	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
that	B-X
native	B-X
eNOS	B-X
in	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
is	B-X
initially	B-X
translated	B-X
as	B-X
a	B-X
nonpalmitoylated	B-X
150-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cytosolic	B-X
and	B-X
intracellular	B-X
membrane-enriched	B-X
fractions	B-X
.	B-X
This	B-X
is	B-X
subsequently	B-X
processed	B-X
to	B-X
a	B-X
palmitoylated	B-X
135-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
a	B-X
sarcolemma-enriched	B-X
membrane	B-X
fraction	B-X
.	B-X
Forskolin	B-X
,	B-X
an	B-X
agent	B-X
that	B-X
elevates	B-X
intracellular	B-X
cAMP	B-X
,	B-X
rapidly	B-X
inhibited	B-X
processing	B-X
of	B-X
the	B-X
150-kDa	B-X
isoform	B-X
to	B-X
the	B-X
135-kDa	B-X
isoform	B-X
and	B-X
transport	B-X
of	B-X
eNOS	B-X
to	B-X
the	B-X
sarcolemma	B-X
,	B-X
effects	B-X
paralleled	B-X
by	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
phosphorylation	B-X
of	B-X
the	B-X
larger	B-X
eNOS	B-X
isoform	B-X
.	B-X
Forskolin	B-X
also	B-X
decreased	B-X
palmitoylation	B-X
of	B-X
the	B-X
135-kDa	B-X
isoform	B-X
,	B-X
although	B-X
it	B-X
did	B-X
not	B-X
accelerate	B-X
depalmitoylation	B-X
of	B-X
sarcolemmal	B-X
eNOS	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
pulse-chase	B-X
experiments	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
.	B-X
Thus	B-X
,	B-X
post-translational	B-X
processing	B-X
of	B-X
a	B-X
150-kDa	B-X
isoform	B-X
of	B-X
myocyte	B-X
eNOS	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
intracellular	B-X
trafficking	B-X
of	B-X
the	B-X
enzyme	B-X
to	B-X
sarcolemmal	B-X
caveolae	B-X
.	B-X
Both	B-X
the	B-X
post-translational	B-X
processing	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
appear	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
changes	B-X
in	B-X
intracellular	B-X
cAMP	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
may	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
cardiac	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
autonomic	B-X
agonists	B-X
in	B-X
vivo	B-X
.	B-X

Other	O
post	O
-	O
translational	O
modifications	O
essential	O
for	O
the	O
correct	O
subcellular	O
targeting	O
of	O
eNOS	B-Protein
have	O
not	O
been	O
described	O
previously	O
.	O

We	O
demonstrate	O
,	O
using	O
[	O
35S	O
]	O
methionine	O
pulse	O
-	O
chase	O
experiments	O
,	O
that	O
native	O
eNOS	B-Protein
in	O
adult	O
rat	O
ventricular	O
myocytes	O
is	O
initially	O
translated	O
as	O
a	O
nonpalmitoylated	O
150	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
associated	O
with	O
cytosolic	O
and	O
intracellular	O
membrane	O
-	O
enriched	O
fractions	O
.	O
<EOS>	B-X
Cardiac	B-X
myocytes	B-X
express	B-X
the	B-X
nitric-oxide	B-X
synthase	B-X
isoform	B-X
originally	B-X
identified	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
termed	B-X
eNOS	B-X
or	B-X
NOS3	B-X
,	B-X
where	B-X
it	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
both	B-X
adrenergic	B-X
and	B-X
muscarinic	B-X
cholinergic	B-X
autonomic	B-X
nervous	B-X
system	B-X
agonists	B-X
.	B-X
eNOS	B-X
in	B-X
endothelial	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
processing	B-X
,	B-X
and	B-X
in	B-X
cardiac	B-X
myocytes	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
plasmalemmal	B-X
caveolae	B-X
,	B-X
a	B-X
process	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Other	B-X
post-translational	B-X
modifications	B-X
essential	B-X
for	B-X
the	B-X
correct	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
have	B-X
not	B-X
been	B-X
described	B-X
previously	B-X
.	B-X
We	B-X
demonstrate	B-X
,	B-X
using	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
that	B-X
native	B-X
eNOS	B-X
in	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
is	B-X
initially	B-X
translated	B-X
as	B-X
a	B-X
nonpalmitoylated	B-X
150-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cytosolic	B-X
and	B-X
intracellular	B-X
membrane-enriched	B-X
fractions	B-X
.	B-X
This	B-X
is	B-X
subsequently	B-X
processed	B-X
to	B-X
a	B-X
palmitoylated	B-X
135-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
a	B-X
sarcolemma-enriched	B-X
membrane	B-X
fraction	B-X
.	B-X
Forskolin	B-X
,	B-X
an	B-X
agent	B-X
that	B-X
elevates	B-X
intracellular	B-X
cAMP	B-X
,	B-X
rapidly	B-X
inhibited	B-X
processing	B-X
of	B-X
the	B-X
150-kDa	B-X
isoform	B-X
to	B-X
the	B-X
135-kDa	B-X
isoform	B-X
and	B-X
transport	B-X
of	B-X
eNOS	B-X
to	B-X
the	B-X
sarcolemma	B-X
,	B-X
effects	B-X
paralleled	B-X
by	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
phosphorylation	B-X
of	B-X
the	B-X
larger	B-X
eNOS	B-X
isoform	B-X
.	B-X
Forskolin	B-X
also	B-X
decreased	B-X
palmitoylation	B-X
of	B-X
the	B-X
135-kDa	B-X
isoform	B-X
,	B-X
although	B-X
it	B-X
did	B-X
not	B-X
accelerate	B-X
depalmitoylation	B-X
of	B-X
sarcolemmal	B-X
eNOS	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
pulse-chase	B-X
experiments	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
.	B-X
Thus	B-X
,	B-X
post-translational	B-X
processing	B-X
of	B-X
a	B-X
150-kDa	B-X
isoform	B-X
of	B-X
myocyte	B-X
eNOS	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
intracellular	B-X
trafficking	B-X
of	B-X
the	B-X
enzyme	B-X
to	B-X
sarcolemmal	B-X
caveolae	B-X
.	B-X
Both	B-X
the	B-X
post-translational	B-X
processing	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
appear	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
changes	B-X
in	B-X
intracellular	B-X
cAMP	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
may	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
cardiac	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
autonomic	B-X
agonists	B-X
in	B-X
vivo	B-X
.	B-X

This	O
is	O
subsequently	O
processed	O
to	O
a	O
palmitoylated	O
135	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
found	O
only	O
in	O
a	O
sarcolemma	O
-	O
enriched	O
membrane	O
fraction	O
.	O

Forskolin	O
,	O
an	O
agent	O
that	O
elevates	O
intracellular	O
cAMP	O
,	O
rapidly	O
inhibited	O
processing	O
of	O
the	O
150	O
-	O
kDa	O
isoform	O
to	O
the	O
135	O
-	O
kDa	O
isoform	O
and	O
transport	O
of	O
eNOS	B-Protein
to	O
the	O
sarcolemma	O
,	O
effects	O
paralleled	O
by	O
protein	O
kinase	O
A	O
-	O
dependent	O
phosphorylation	O
of	O
the	O
larger	O
eNOS	B-Protein
isoform	O
.	O

Forskolin	O
also	O
decreased	O
palmitoylation	O
of	O
the	O
135	O
-	O
kDa	O
isoform	O
,	O
although	O
it	O
did	O
not	O
accelerate	O
depalmitoylation	O
of	O
sarcolemmal	O
eNOS	B-Protein
,	O
as	O
determined	O
by	O
pulse	O
-	O
chase	O
experiments	O
with	O
[	O
3H	O
]	O
palmitate	O
.	O

Thus	O
,	O
post	O
-	O
translational	O
processing	O
of	O
a	O
150	O
-	O
kDa	O
isoform	O
of	O
myocyte	O
eNOS	B-Protein
appears	O
to	O
be	O
necessary	O
for	O
intracellular	O
trafficking	O
of	O
the	O
enzyme	O
to	O
sarcolemmal	O
caveolae	O
.	O
<EOS>	B-X
Cardiac	B-X
myocytes	B-X
express	B-X
the	B-X
nitric-oxide	B-X
synthase	B-X
isoform	B-X
originally	B-X
identified	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
termed	B-X
eNOS	B-X
or	B-X
NOS3	B-X
,	B-X
where	B-X
it	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
both	B-X
adrenergic	B-X
and	B-X
muscarinic	B-X
cholinergic	B-X
autonomic	B-X
nervous	B-X
system	B-X
agonists	B-X
.	B-X
eNOS	B-X
in	B-X
endothelial	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
processing	B-X
,	B-X
and	B-X
in	B-X
cardiac	B-X
myocytes	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
plasmalemmal	B-X
caveolae	B-X
,	B-X
a	B-X
process	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Other	B-X
post-translational	B-X
modifications	B-X
essential	B-X
for	B-X
the	B-X
correct	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
have	B-X
not	B-X
been	B-X
described	B-X
previously	B-X
.	B-X
We	B-X
demonstrate	B-X
,	B-X
using	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
that	B-X
native	B-X
eNOS	B-X
in	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
is	B-X
initially	B-X
translated	B-X
as	B-X
a	B-X
nonpalmitoylated	B-X
150-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cytosolic	B-X
and	B-X
intracellular	B-X
membrane-enriched	B-X
fractions	B-X
.	B-X
This	B-X
is	B-X
subsequently	B-X
processed	B-X
to	B-X
a	B-X
palmitoylated	B-X
135-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
found	B-X
only	B-X
in	B-X
a	B-X
sarcolemma-enriched	B-X
membrane	B-X
fraction	B-X
.	B-X
Forskolin	B-X
,	B-X
an	B-X
agent	B-X
that	B-X
elevates	B-X
intracellular	B-X
cAMP	B-X
,	B-X
rapidly	B-X
inhibited	B-X
processing	B-X
of	B-X
the	B-X
150-kDa	B-X
isoform	B-X
to	B-X
the	B-X
135-kDa	B-X
isoform	B-X
and	B-X
transport	B-X
of	B-X
eNOS	B-X
to	B-X
the	B-X
sarcolemma	B-X
,	B-X
effects	B-X
paralleled	B-X
by	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
phosphorylation	B-X
of	B-X
the	B-X
larger	B-X
eNOS	B-X
isoform	B-X
.	B-X
Forskolin	B-X
also	B-X
decreased	B-X
palmitoylation	B-X
of	B-X
the	B-X
135-kDa	B-X
isoform	B-X
,	B-X
although	B-X
it	B-X
did	B-X
not	B-X
accelerate	B-X
depalmitoylation	B-X
of	B-X
sarcolemmal	B-X
eNOS	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
pulse-chase	B-X
experiments	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
.	B-X
Thus	B-X
,	B-X
post-translational	B-X
processing	B-X
of	B-X
a	B-X
150-kDa	B-X
isoform	B-X
of	B-X
myocyte	B-X
eNOS	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
intracellular	B-X
trafficking	B-X
of	B-X
the	B-X
enzyme	B-X
to	B-X
sarcolemmal	B-X
caveolae	B-X
.	B-X
Both	B-X
the	B-X
post-translational	B-X
processing	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
appear	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
changes	B-X
in	B-X
intracellular	B-X
cAMP	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
may	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
cardiac	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
autonomic	B-X
agonists	B-X
in	B-X
vivo	B-X
.	B-X

Both	O
the	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
eNOS	B-Protein
appear	O
to	O
be	O
modified	O
by	O
changes	O
in	O
intracellular	O
cAMP	O
,	O
an	O
effect	O
that	O
may	O
have	O
important	O
implications	O
for	O
cardiac	O
myocyte	O
responsiveness	O
to	O
autonomic	O
agonists	O
in	O
vivo	O
.	O
<EOS>	B-X
Cardiac	B-X
myocytes	B-X
express	B-X
the	B-X
nitric-oxide	B-X
synthase	B-X
isoform	B-X
originally	B-X
identified	B-X
in	B-X
endothelial	B-X
cells	B-X
,	B-X
termed	B-X
eNOS	B-X
or	B-X
NOS3	B-X
,	B-X
where	B-X
it	B-X
plays	B-X
a	B-X
role	B-X
in	B-X
regulating	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
both	B-X
adrenergic	B-X
and	B-X
muscarinic	B-X
cholinergic	B-X
autonomic	B-X
nervous	B-X
system	B-X
agonists	B-X
.	B-X
eNOS	B-X
in	B-X
endothelial	B-X
cells	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
undergo	B-X
extensive	B-X
post-translational	B-X
processing	B-X
,	B-X
and	B-X
in	B-X
cardiac	B-X
myocytes	B-X
as	B-X
well	B-X
as	B-X
endothelial	B-X
cells	B-X
,	B-X
eNOS	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
targeted	B-X
to	B-X
plasmalemmal	B-X
caveolae	B-X
,	B-X
a	B-X
process	B-X
that	B-X
is	B-X
dependent	B-X
on	B-X
myristoylation	B-X
and	B-X
palmitoylation	B-X
.	B-X
Other	B-X
post-translational	B-X
modifications	B-X
essential	B-X
for	B-X
the	B-X
correct	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
have	B-X
not	B-X
been	B-X
described	B-X
previously	B-X
.	B-X
We	B-X
demonstrate	B-X
,	B-X
using	B-X
[	B-X
35S	B-X
]	B-X
methionine	B-X
pulse-chase	B-X
experiments	B-X
,	B-X
that	B-X
native	B-X
eNOS	B-X
in	B-X
adult	B-X
rat	B-X
ventricular	B-X
myocytes	B-X
is	B-X
initially	B-X
translated	B-X
as	B-X
a	B-X
nonpalmitoylated	B-X
150-kDa	B-X
isoform	B-X
,	B-X
which	B-X
is	B-X
associated	B-X
with	B-X
cytosolic	B-X
and	B-X
intracellular	B-X
membrane-enriched	B-X
fractions	B-X
.	B-X
Forskolin	B-X
,	B-X
an	B-X
agent	B-X
that	B-X
elevates	B-X
intracellular	B-X
cAMP	B-X
,	B-X
rapidly	B-X
inhibited	B-X
processing	B-X
of	B-X
the	B-X
150-kDa	B-X
isoform	B-X
to	B-X
the	B-X
135-kDa	B-X
isoform	B-X
and	B-X
transport	B-X
of	B-X
eNOS	B-X
to	B-X
the	B-X
sarcolemma	B-X
,	B-X
effects	B-X
paralleled	B-X
by	B-X
protein	B-X
kinase	B-X
A-dependent	B-X
phosphorylation	B-X
of	B-X
the	B-X
larger	B-X
eNOS	B-X
isoform	B-X
.	B-X
Forskolin	B-X
also	B-X
decreased	B-X
palmitoylation	B-X
of	B-X
the	B-X
135-kDa	B-X
isoform	B-X
,	B-X
although	B-X
it	B-X
did	B-X
not	B-X
accelerate	B-X
depalmitoylation	B-X
of	B-X
sarcolemmal	B-X
eNOS	B-X
,	B-X
as	B-X
determined	B-X
by	B-X
pulse-chase	B-X
experiments	B-X
with	B-X
[	B-X
3H	B-X
]	B-X
palmitate	B-X
.	B-X
Thus	B-X
,	B-X
post-translational	B-X
processing	B-X
of	B-X
a	B-X
150-kDa	B-X
isoform	B-X
of	B-X
myocyte	B-X
eNOS	B-X
appears	B-X
to	B-X
be	B-X
necessary	B-X
for	B-X
intracellular	B-X
trafficking	B-X
of	B-X
the	B-X
enzyme	B-X
to	B-X
sarcolemmal	B-X
caveolae	B-X
.	B-X
Both	B-X
the	B-X
post-translational	B-X
processing	B-X
and	B-X
subcellular	B-X
targeting	B-X
of	B-X
eNOS	B-X
appear	B-X
to	B-X
be	B-X
modified	B-X
by	B-X
changes	B-X
in	B-X
intracellular	B-X
cAMP	B-X
,	B-X
an	B-X
effect	B-X
that	B-X
may	B-X
have	B-X
important	B-X
implications	B-X
for	B-X
cardiac	B-X
myocyte	B-X
responsiveness	B-X
to	B-X
autonomic	B-X
agonists	B-X
in	B-X
vivo	B-X
.	B-X

Direct	O
demonstration	O
of	O
geranylgeranylation	O
and	O
farnesylation	O
of	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
in	O
vivo	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
protein	O
can	O
be	O
modified	O
in	O
vitro	O
by	O
farnesylation	O
or	O
geranylgeranylation	O
.	O
<EOS>	B-X
Thirty	B-X
years	B-X
of	B-X
research	B-X
have	B-X
uncovered	B-X
supportive	B-X
roles	B-X
for	B-X
the	B-X
mevalonate	B-X
pathway	B-X
in	B-X
numerous	B-X
cellular	B-X
processes	B-X
that	B-X
support	B-X
oncogenesis	B-X
,	B-X
most	B-X
recently	B-X
macropinocytosis	B-X
.	B-X
Central	B-X
to	B-X
the	B-X
diverse	B-X
mechanisms	B-X
of	B-X
statin	B-X
sensitivity	B-X
is	B-X
an	B-X
acquired	B-X
dependence	B-X
on	B-X
one	B-X
mevalonate	B-X
pathway	B-X
output	B-X
,	B-X
protein	B-X
geranylgeranylation	B-X
.	B-X
The	B-X
protein	B-X
prenylation	B-X
is	B-X
one	B-X
of	B-X
the	B-X
essential	B-X
post-translational	B-X
protein	B-X
modifications	B-X
,	B-X
which	B-X
extensively	B-X
exists	B-X
in	B-X
the	B-X
eukaryocyte	B-X
.	B-X
It	B-X
includes	B-X
protein	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
,	B-X
using	B-X
farnesyl	B-X
pyrophosphate	B-X
(	B-X
FPP	B-X
)	B-X
or	B-X
geranylgeranyl	B-X
pyrophosphate	B-X
(	B-X
GGPP	B-X
)	B-X
as	B-X
the	B-X
substrate	B-X
,	B-X
respectively	B-X
.	B-X
The	B-X
prenylation	B-X
occurs	B-X
by	B-X
covalent	B-X
addition	B-X
of	B-X
these	B-X
two	B-X
types	B-X
of	B-X
isoprenoids	B-X
to	B-X
cysteine	B-X
residues	B-X
at	B-X
or	B-X
near	B-X
the	B-X
carboxyl	B-X
terminus	B-X
of	B-X
the	B-X
proteins	B-X
that	B-X
possess	B-X
CaaX	B-X
motif	B-X
,	B-X
such	B-X
as	B-X
Ras	B-X
small	B-X
GTPase	B-X
family	B-X
.	B-X
The	B-X
attachment	B-X
of	B-X
hydrophobic	B-X
prenyl	B-X
groups	B-X
can	B-X
anchor	B-X
the	B-X
proteins	B-X
to	B-X
intracellular	B-X
membranes	B-X
and	B-X
trigger	B-X
downstream	B-X
cell	B-X
signaling	B-X
pathway	B-X
.	B-X
The	B-X
abnormal	B-X
expression	B-X
of	B-X
this	B-X
enzyme	B-X
will	B-X
affect	B-X
the	B-X
relative	B-X
content	B-X
of	B-X
FPP	B-X
and	B-X
GGPP	B-X
,	B-X
and	B-X
thus	B-X
disrupts	B-X
the	B-X
balance	B-X
between	B-X
protein	B-X
farnesylation	B-X
and	B-X
geranylgeranylation	B-X
,	B-X
which	B-X
participates	B-X
into	B-X
various	B-X
aspects	B-X
of	B-X
cellular	B-X
physiology	B-X
and	B-X
pathology	B-X
.	B-X
In	B-X
this	B-X
paper	B-X
,	B-X
we	B-X
mainly	B-X
review	B-X
the	B-X
property	B-X
of	B-X
this	B-X
important	B-X
protein	B-X
post-translational	B-X
modification	B-X
and	B-X
research	B-X
progress	B-X
in	B-X
its	B-X
regulation	B-X
of	B-X
cigarette	B-X
smoke	B-X
induced	B-X
pulmonary	B-X
disease	B-X
,	B-X
adipocyte	B-X
insulin	B-X
sensitivity	B-X
,	B-X
the	B-X
inflammation	B-X
response	B-X
of	B-X
Sertoli	B-X
cells	B-X
,	B-X
the	B-X
hepatic	B-X
lipogenesis	B-X
and	B-X
the	B-X
cardiac	B-X
hypertrophy	B-X
.	B-X

However	O
,	O
a	O
previous	O
analysis	O
of	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
in	O
vivo	O
found	O
only	O
farnesylated	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
.	O
<EOS>	B-X
It	B-X
has	B-X
recently	B-X
been	B-X
reported	B-X
that	B-X
Ki-Ras	B-X
protein	B-X
can	B-X
be	B-X
modified	B-X
in	B-X
vitro	B-X
by	B-X
farnesylation	B-X
or	B-X
geranylgeranylation	B-X
.	B-X
However	B-X
,	B-X
a	B-X
previous	B-X
analysis	B-X
of	B-X
Ki-Ras	B-X
prenylation	B-X
in	B-X
vivo	B-X
found	B-X
only	B-X
farnesylated	B-X
Ki-Ras	B-X
.	B-X
In	B-X
this	B-X
report	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
under	B-X
normal	B-X
conditions	B-X
,	B-X
Ki-Ras	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
and	B-X
when	B-X
cells	B-X
are	B-X
treated	B-X
with	B-X
the	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
B956	B-X
or	B-X
B957	B-X
,	B-X
farnesylation	B-X
is	B-X
inhibited	B-X
and	B-X
Ki-Ras	B-X
becomes	B-X
geranylgeranylated	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X
These	B-X
results	B-X
have	B-X
strong	B-X
implications	B-X
in	B-X
the	B-X
design	B-X
of	B-X
anticancer	B-X
drugs	B-X
based	B-X
on	B-X
inhibition	B-X
of	B-X
prenylation	B-X
.	B-X

In	O
this	O
report	O
it	O
is	O
shown	O
that	O
under	O
normal	O
conditions	O
,	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
is	O
farnesylated	O
in	O
vivo	O
and	O
when	O
cells	O
are	O
treated	O
with	O
the	O
farnesyl	O
transferase	O
inhibitors	O
B956	O
or	O
B957	O
,	O
farnesylation	O
is	O
inhibited	O
and	O
Ki	B-Protein
-	I-Protein
Ras	I-Protein
becomes	O
geranylgeranylated	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O
<EOS>	B-X
It	B-X
has	B-X
recently	B-X
been	B-X
reported	B-X
that	B-X
Ki-Ras	B-X
protein	B-X
can	B-X
be	B-X
modified	B-X
in	B-X
vitro	B-X
by	B-X
farnesylation	B-X
or	B-X
geranylgeranylation	B-X
.	B-X
However	B-X
,	B-X
a	B-X
previous	B-X
analysis	B-X
of	B-X
Ki-Ras	B-X
prenylation	B-X
in	B-X
vivo	B-X
found	B-X
only	B-X
farnesylated	B-X
Ki-Ras	B-X
.	B-X
In	B-X
this	B-X
report	B-X
it	B-X
is	B-X
shown	B-X
that	B-X
under	B-X
normal	B-X
conditions	B-X
,	B-X
Ki-Ras	B-X
is	B-X
farnesylated	B-X
in	B-X
vivo	B-X
and	B-X
when	B-X
cells	B-X
are	B-X
treated	B-X
with	B-X
the	B-X
farnesyl	B-X
transferase	B-X
inhibitors	B-X
B956	B-X
or	B-X
B957	B-X
,	B-X
farnesylation	B-X
is	B-X
inhibited	B-X
and	B-X
Ki-Ras	B-X
becomes	B-X
geranylgeranylated	B-X
in	B-X
a	B-X
dose	B-X
dependent	B-X
manner	B-X
.	B-X

These	O
results	O
have	O
strong	O
implications	O
in	O
the	O
design	O
of	O
anticancer	O
drugs	O
based	O
on	O
inhibition	O
of	O
prenylation	O
.	O
<EOS>	B-X
However	B-X
,	B-X
a	B-X
previous	B-X
analysis	B-X
of	B-X
Ki-Ras	B-X
prenylation	B-X
in	B-X
vivo	B-X
found	B-X
only	B-X
farnesylated	B-X
Ki-Ras	B-X
.	B-X
These	B-X
results	B-X
have	B-X
strong	B-X
implications	B-X
in	B-X
the	B-X
design	B-X
of	B-X
anticancer	B-X
drugs	B-X
based	B-X
on	B-X
inhibition	B-X
of	B-X
prenylation	B-X
.	B-X

The	O
alpha	B-Protein
7	I-Protein
integrin	I-Protein
as	O
a	O
target	O
protein	O
for	O
cell	O
surface	O
mono	O
-	O
ADP	O
-	O
ribosylation	O
in	O
muscle	O
cells	O
.	O
<EOS>	B-X
A	B-X
membrane-associated	B-X
arginine-specific	B-X
mono-ADP-ribosyltransferase	B-X
was	B-X
purified	B-X
215,000-fold	B-X
from	B-X
rabbit	B-X
skeletal	B-X
muscle	B-X
and	B-X
its	B-X
gene	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
skeletal	B-X
muscle	B-X
cDNA	B-X
library	B-X
.	B-X
The	B-X
enzyme	B-X
was	B-X
a	B-X
glycosylphosphatidyl-inositol-linked	B-X
protein	B-X
,	B-X
present	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
differentiated	B-X
skeletal	B-X
muscle	B-X
myoblasts	B-X
(	B-X
myotubes	B-X
)	B-X
.	B-X
Following	B-X
incubation	B-X
of	B-X
cultured	B-X
,	B-X
intact	B-X
myotubes	B-X
with	B-X
[	B-X
adenylate-32P	B-X
]	B-X
NAD	B-X
and	B-X
analysis	B-X
by	B-X
SDS-PAGE	B-X
,	B-X
a	B-X
major	B-X
radiolabeled	B-X
protein	B-X
of	B-X
97/140	B-X
kDa	B-X
(	B-X
reduced/nonreduced	B-X
conditions	B-X
)	B-X
was	B-X
observed	B-X
.	B-X
It	B-X
was	B-X
identified	B-X
as	B-X
integrin	B-X
alpha	B-X
7	B-X
based	B-X
on	B-X
its	B-X
size	B-X
,	B-X
binding	B-X
to	B-X
a	B-X
laminin	B-X
affinity	B-X
column	B-X
,	B-X
immunoprecipitation	B-X
with	B-X
a	B-X
monoclonal	B-X
antibody	B-X
,	B-X
and	B-X
partial	B-X
amino	B-X
acid	B-X
sequencing	B-X
.	B-X
Since	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
cleavage	B-X
of	B-X
the	B-X
ADP-ribosylarginine	B-X
bond	B-X
and	B-X
a	B-X
component	B-X
with	B-X
the	B-X
transferase	B-X
of	B-X
a	B-X
putative	B-X
ADP-ribosylation	B-X
cycle	B-X
,	B-X
is	B-X
cytosolic	B-X
,	B-X
whereas	B-X
the	B-X
transferase	B-X
is	B-X
attached	B-X
via	B-X
a	B-X
GPI-anchor	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
the	B-X
processing	B-X
of	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
investigated	B-X
.	B-X
32P	B-X
label	B-X
was	B-X
rapidly	B-X
removed	B-X
from	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
,	B-X
a	B-X
process	B-X
inhibited	B-X
by	B-X
free	B-X
ADP-ribose	B-X
or	B-X
p-nitrophenylthymidine-5'-monophosphate	B-X
,	B-X
alternative	B-X
substrates	B-X
for	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
The	B-X
processed	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
not	B-X
susceptible	B-X
to	B-X
subsequent	B-X
ADP-ribosylation	B-X
,	B-X
although	B-X
the	B-X
amount	B-X
of	B-X
surface	B-X
integrin	B-X
alpha	B-X
7	B-X
remained	B-X
constant	B-X
.	B-X
During	B-X
the	B-X
processing	B-X
,	B-X
no	B-X
loss	B-X
of	B-X
label	B-X
was	B-X
observed	B-X
from	B-X
integrin	B-X
alpha	B-X
7	B-X
radiolabeled	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
NAD	B-X
,	B-X
containing	B-X
14C	B-X
in	B-X
the	B-X
nicotinamide-proximal	B-X
ribose	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
degradation	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
by	B-X
a	B-X
cell	B-X
surface	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
Thus	B-X
,	B-X
cell	B-X
surface	B-X
ADP-ribosylation	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
intracellular	B-X
ADP-ribosylation	B-X
,	B-X
is	B-X
not	B-X
readily	B-X
reversed	B-X
by	B-X
the	B-X
presently	B-X
known	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
and	B-X
seems	B-X
to	B-X
operate	B-X
outside	B-X
the	B-X
postulated	B-X
ADP-ribosylation	B-X
cycle	B-X
.	B-X

A	O
membrane	B-Protein
-	I-Protein
associated	I-Protein
arginine	I-Protein
-	I-Protein
specific	I-Protein
mono	I-Protein
-	I-Protein
ADP	I-Protein
-	I-Protein
ribosyltransferase	I-Protein
was	O
purified	O
215	O
,	O
000	O
-	O
fold	O
from	O
rabbit	O
skeletal	O
muscle	O
and	O
its	O
gene	O
was	O
isolated	O
from	O
a	O
skeletal	O
muscle	O
cDNA	O
library	O
.	O
<EOS>	B-X
Mono-ADP-ribosylation	B-X
is	B-X
a	B-X
reversible	B-X
modification	B-X
of	B-X
proteins	B-X
,	B-X
with	B-X
NAD	B-X
:	B-X
arginine	B-X
ADP-ribosyltransferases	B-X
(	B-X
EC	B-X
2.4.2.31	B-X
)	B-X
and	B-X
ADP-ribosylarginine	B-X
hydrolases	B-X
(	B-X
EC	B-X
3.2.2.19	B-X
)	B-X
catalyzing	B-X
the	B-X
opposing	B-X
reactions	B-X
in	B-X
an	B-X
ADP-ribosylation	B-X
cycle	B-X
.	B-X
A	B-X
membrane-associated	B-X
arginine-specific	B-X
(	B-X
mono	B-X
)	B-X
-ADP-ribosyltransferase	B-X
was	B-X
purified	B-X
215,000-fold	B-X
from	B-X
rabbit	B-X
skeletal	B-X
muscle	B-X
.	B-X
On	B-X
the	B-X
basis	B-X
of	B-X
the	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
HPLC-purified	B-X
tryptic	B-X
peptides	B-X
,	B-X
degenerate	B-X
oligonucleotide	B-X
primers	B-X
were	B-X
synthesized	B-X
and	B-X
used	B-X
in	B-X
a	B-X
polymerase	B-X
chain	B-X
reaction	B-X
(	B-X
PCR	B-X
)	B-X
-based	B-X
procedure	B-X
to	B-X
generate	B-X
cDNA	B-X
.	B-X
A	B-X
specific	B-X
probe	B-X
,	B-X
based	B-X
on	B-X
PCR-generated	B-X
sequence	B-X
,	B-X
was	B-X
used	B-X
to	B-X
screen	B-X
a	B-X
rabbit	B-X
skeletal	B-X
muscle	B-X
cDNA	B-X
library	B-X
.	B-X
A	B-X
composite	B-X
cDNA	B-X
sequence	B-X
,	B-X
obtained	B-X
from	B-X
library	B-X
screening	B-X
and	B-X
rapid	B-X
amplification	B-X
of	B-X
the	B-X
5	B-X
'	B-X
end	B-X
of	B-X
the	B-X
cDNA	B-X
,	B-X
contained	B-X
a	B-X
981-base-pair	B-X
open	B-X
reading	B-X
frame	B-X
,	B-X
encoding	B-X
a	B-X
36,134-Da	B-X
protein	B-X
.	B-X
Escherichia	B-X
coli	B-X
cells	B-X
transformed	B-X
with	B-X
an	B-X
expression	B-X
vector	B-X
containing	B-X
transferase-specific	B-X
sequence	B-X
expressed	B-X
ADP-ribosyltransferase	B-X
activity	B-X
.	B-X
A	B-X
transferase-specific	B-X
oligonucleotide	B-X
probe	B-X
recognized	B-X
a	B-X
4-kilobase	B-X
mRNA	B-X
expressed	B-X
primarily	B-X
in	B-X
rabbit	B-X
skeletal	B-X
and	B-X
cardiac	B-X
muscle	B-X
.	B-X
There	B-X
was	B-X
no	B-X
extended	B-X
similarity	B-X
in	B-X
deduced	B-X
amino	B-X
acid	B-X
sequences	B-X
of	B-X
the	B-X
muscle	B-X
transferase	B-X
and	B-X
several	B-X
bacterial	B-X
ADP-ribosylating	B-X
toxins	B-X
.	B-X

The	O
enzyme	O
was	O
a	O
glycosylphosphatidyl	O
-	O
inositol	O
-	O
linked	O
protein	O
,	O
present	O
on	O
the	O
surface	O
of	O
differentiated	O
skeletal	O
muscle	O
myoblasts	O
(	O
myotubes	O
)	O
.	O
<EOS>	B-X
A	B-X
membrane-associated	B-X
arginine-specific	B-X
mono-ADP-ribosyltransferase	B-X
was	B-X
purified	B-X
215,000-fold	B-X
from	B-X
rabbit	B-X
skeletal	B-X
muscle	B-X
and	B-X
its	B-X
gene	B-X
was	B-X
isolated	B-X
from	B-X
a	B-X
skeletal	B-X
muscle	B-X
cDNA	B-X
library	B-X
.	B-X
The	B-X
enzyme	B-X
was	B-X
a	B-X
glycosylphosphatidyl-inositol-linked	B-X
protein	B-X
,	B-X
present	B-X
on	B-X
the	B-X
surface	B-X
of	B-X
differentiated	B-X
skeletal	B-X
muscle	B-X
myoblasts	B-X
(	B-X
myotubes	B-X
)	B-X
.	B-X
Following	B-X
incubation	B-X
of	B-X
cultured	B-X
,	B-X
intact	B-X
myotubes	B-X
with	B-X
[	B-X
adenylate-32P	B-X
]	B-X
NAD	B-X
and	B-X
analysis	B-X
by	B-X
SDS-PAGE	B-X
,	B-X
a	B-X
major	B-X
radiolabeled	B-X
protein	B-X
of	B-X
97/140	B-X
kDa	B-X
(	B-X
reduced/nonreduced	B-X
conditions	B-X
)	B-X
was	B-X
observed	B-X
.	B-X
Since	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
cleavage	B-X
of	B-X
the	B-X
ADP-ribosylarginine	B-X
bond	B-X
and	B-X
a	B-X
component	B-X
with	B-X
the	B-X
transferase	B-X
of	B-X
a	B-X
putative	B-X
ADP-ribosylation	B-X
cycle	B-X
,	B-X
is	B-X
cytosolic	B-X
,	B-X
whereas	B-X
the	B-X
transferase	B-X
is	B-X
attached	B-X
via	B-X
a	B-X
GPI-anchor	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
the	B-X
processing	B-X
of	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
investigated	B-X
.	B-X
The	B-X
processed	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
not	B-X
susceptible	B-X
to	B-X
subsequent	B-X
ADP-ribosylation	B-X
,	B-X
although	B-X
the	B-X
amount	B-X
of	B-X
surface	B-X
integrin	B-X
alpha	B-X
7	B-X
remained	B-X
constant	B-X
.	B-X
During	B-X
the	B-X
processing	B-X
,	B-X
no	B-X
loss	B-X
of	B-X
label	B-X
was	B-X
observed	B-X
from	B-X
integrin	B-X
alpha	B-X
7	B-X
radiolabeled	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
NAD	B-X
,	B-X
containing	B-X
14C	B-X
in	B-X
the	B-X
nicotinamide-proximal	B-X
ribose	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
degradation	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
by	B-X
a	B-X
cell	B-X
surface	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
Thus	B-X
,	B-X
cell	B-X
surface	B-X
ADP-ribosylation	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
intracellular	B-X
ADP-ribosylation	B-X
,	B-X
is	B-X
not	B-X
readily	B-X
reversed	B-X
by	B-X
the	B-X
presently	B-X
known	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
and	B-X
seems	B-X
to	B-X
operate	B-X
outside	B-X
the	B-X
postulated	B-X
ADP-ribosylation	B-X
cycle	B-X
.	B-X

Following	O
incubation	O
of	O
cultured	O
,	O
intact	O
myotubes	O
with	O
[	O
adenylate	O
-	O
32P	O
]	O
NAD	O
and	O
analysis	O
by	O
SDS	O
-	O
PAGE	O
,	O
a	O
major	O
radiolabeled	O
protein	O
of	O
97	O
/	O
140	O
kDa	O
(	O
reduced	O
/	O
nonreduced	O
conditions	O
)	O
was	O
observed	O
.	O

It	O
was	O
identified	O
as	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
based	O
on	O
its	O
size	O
,	O
binding	O
to	O
a	O
laminin	O
affinity	O
column	O
,	O
immunoprecipitation	O
with	O
a	O
monoclonal	O
antibody	O
,	O
and	O
partial	O
amino	O
acid	O
sequencing	O
.	O
<EOS>	B-X
Following	B-X
incubation	B-X
of	B-X
cultured	B-X
,	B-X
intact	B-X
myotubes	B-X
with	B-X
[	B-X
adenylate-32P	B-X
]	B-X
NAD	B-X
and	B-X
analysis	B-X
by	B-X
SDS-PAGE	B-X
,	B-X
a	B-X
major	B-X
radiolabeled	B-X
protein	B-X
of	B-X
97/140	B-X
kDa	B-X
(	B-X
reduced/nonreduced	B-X
conditions	B-X
)	B-X
was	B-X
observed	B-X
.	B-X
It	B-X
was	B-X
identified	B-X
as	B-X
integrin	B-X
alpha	B-X
7	B-X
based	B-X
on	B-X
its	B-X
size	B-X
,	B-X
binding	B-X
to	B-X
a	B-X
laminin	B-X
affinity	B-X
column	B-X
,	B-X
immunoprecipitation	B-X
with	B-X
a	B-X
monoclonal	B-X
antibody	B-X
,	B-X
and	B-X
partial	B-X
amino	B-X
acid	B-X
sequencing	B-X
.	B-X
Since	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
cleavage	B-X
of	B-X
the	B-X
ADP-ribosylarginine	B-X
bond	B-X
and	B-X
a	B-X
component	B-X
with	B-X
the	B-X
transferase	B-X
of	B-X
a	B-X
putative	B-X
ADP-ribosylation	B-X
cycle	B-X
,	B-X
is	B-X
cytosolic	B-X
,	B-X
whereas	B-X
the	B-X
transferase	B-X
is	B-X
attached	B-X
via	B-X
a	B-X
GPI-anchor	B-X
to	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
the	B-X
processing	B-X
of	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
investigated	B-X
.	B-X
32P	B-X
label	B-X
was	B-X
rapidly	B-X
removed	B-X
from	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
,	B-X
a	B-X
process	B-X
inhibited	B-X
by	B-X
free	B-X
ADP-ribose	B-X
or	B-X
p-nitrophenylthymidine-5'-monophosphate	B-X
,	B-X
alternative	B-X
substrates	B-X
for	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
The	B-X
processed	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
not	B-X
susceptible	B-X
to	B-X
subsequent	B-X
ADP-ribosylation	B-X
,	B-X
although	B-X
the	B-X
amount	B-X
of	B-X
surface	B-X
integrin	B-X
alpha	B-X
7	B-X
remained	B-X
constant	B-X
.	B-X
During	B-X
the	B-X
processing	B-X
,	B-X
no	B-X
loss	B-X
of	B-X
label	B-X
was	B-X
observed	B-X
from	B-X
integrin	B-X
alpha	B-X
7	B-X
radiolabeled	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
NAD	B-X
,	B-X
containing	B-X
14C	B-X
in	B-X
the	B-X
nicotinamide-proximal	B-X
ribose	B-X
,	B-X
consistent	B-X
with	B-X
a	B-X
degradation	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
by	B-X
a	B-X
cell	B-X
surface	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X

Since	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
,	O
the	O
enzyme	O
responsible	O
for	O
cleavage	O
of	O
the	O
ADP	O
-	O
ribosylarginine	O
bond	O
and	O
a	O
component	O
with	O
the	O
transferase	O
of	O
a	O
putative	O
ADP	O
-	O
ribosylation	O
cycle	O
,	O
is	O
cytosolic	O
,	O
whereas	O
the	O
transferase	O
is	O
attached	O
via	O
a	O
GPI	O
-	O
anchor	O
to	O
the	O
cell	O
surface	O
,	O
the	O
processing	O
of	O
ADP	O
-	O
ribosylated	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
was	O
investigated	O
.	O

32P	O
label	O
was	O
rapidly	O
removed	O
from	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylated	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
,	O
a	O
process	O
inhibited	O
by	O
free	O
ADP	O
-	O
ribose	O
or	O
p	O
-	O
nitrophenylthymidine	O
-	O
5	O
'	O
-	O
monophosphate	O
,	O
alternative	O
substrates	O
for	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O
<EOS>	B-X
Integrin	B-X
alpha	B-X
7	B-X
is	B-X
a	B-X
major	B-X
substrate	B-X
in	B-X
skeletal	B-X
muscle	B-X
cells	B-X
for	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
glycosylphosphatidylinositol-anchored	B-X
,	B-X
arginine-specific	B-X
ADP-ribosyltransferase	B-X
.	B-X
Since	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
cleavage	B-X
of	B-X
the	B-X
ADP-ribosylarginine	B-X
bond	B-X
and	B-X
a	B-X
component	B-X
with	B-X
the	B-X
transferase	B-X
of	B-X
a	B-X
putative	B-X
ADP-ribosylation	B-X
cycle	B-X
,	B-X
is	B-X
cytosolic	B-X
,	B-X
the	B-X
processing	B-X
of	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
investigated	B-X
.	B-X
Following	B-X
incubation	B-X
of	B-X
differentiated	B-X
mouse	B-X
C2C12	B-X
myoblasts	B-X
with	B-X
[	B-X
adenylate-32P	B-X
]	B-X
NAD	B-X
and	B-X
analysis	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
two	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
forms	B-X
of	B-X
integrin	B-X
alpha	B-X
7	B-X
were	B-X
resolved	B-X
.	B-X
By	B-X
pulse-chase	B-X
and	B-X
purification	B-X
of	B-X
the	B-X
radiolabeled	B-X
proteins	B-X
on	B-X
a	B-X
laminin	B-X
affinity	B-X
column	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
a	B-X
105-kDa	B-X
ADP-ribosylated	B-X
form	B-X
originated	B-X
from	B-X
a	B-X
mono-ADP-ribosylated	B-X
102-kDa	B-X
form	B-X
and	B-X
represented	B-X
integrin	B-X
alpha	B-X
7	B-X
modified	B-X
at	B-X
more	B-X
than	B-X
one	B-X
site	B-X
.	B-X
The	B-X
additional	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
modification	B-X
,	B-X
utilized	B-X
at	B-X
higher	B-X
NAD	B-X
concentrations	B-X
,	B-X
were	B-X
located	B-X
in	B-X
the	B-X
63-kDa	B-X
N-terminal	B-X
segment	B-X
of	B-X
integrin	B-X
alpha	B-X
7	B-X
.	B-X
Both	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrins	B-X
were	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
cytoskeleton	B-X
,	B-X
bound	B-X
to	B-X
laminin	B-X
affinity	B-X
columns	B-X
,	B-X
and	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
to	B-X
integrin	B-X
beta	B-X
1	B-X
.	B-X
32P	B-X
label	B-X
was	B-X
rapidly	B-X
removed	B-X
from	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
at	B-X
either	B-X
site	B-X
of	B-X
modification	B-X
,	B-X
a	B-X
process	B-X
inhibited	B-X
by	B-X
free	B-X
ADP-ribose	B-X
or	B-X
p-nitrophenylthymidine-5'-monophosphate	B-X
,	B-X
an	B-X
alternative	B-X
substrate	B-X
of	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
The	B-X
processed	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
unavailable	B-X
for	B-X
subsequent	B-X
ADP-ribosylation	B-X
,	B-X
although	B-X
the	B-X
amount	B-X
of	B-X
surface	B-X
integrin	B-X
alpha	B-X
7	B-X
remained	B-X
constant	B-X
.	B-X
During	B-X
the	B-X
processing	B-X
,	B-X
no	B-X
loss	B-X
of	B-X
label	B-X
was	B-X
observed	B-X
from	B-X
integrin	B-X
alpha	B-X
7	B-X
radiolabeled	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
NAD	B-X
,	B-X
containing	B-X
14C	B-X
in	B-X
the	B-X
nicotinamide	B-X
proximal	B-X
ribose	B-X
,	B-X
consistent	B-X
with	B-X
degradation	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
by	B-X
a	B-X
cell	B-X
surface	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
Thus	B-X
,	B-X
cell	B-X
surface	B-X
ADP-ribosylation	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
intracellular	B-X
ADP-ribosylation	B-X
,	B-X
is	B-X
not	B-X
readily	B-X
reversed	B-X
by	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
and	B-X
seems	B-X
to	B-X
operate	B-X
outside	B-X
the	B-X
postulated	B-X
ADP-ribosylation	B-X
cycle	B-X
.	B-X

The	O
processed	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
was	O
not	O
susceptible	O
to	O
subsequent	O
ADP	O
-	O
ribosylation	O
,	O
although	O
the	O
amount	O
of	O
surface	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
remained	O
constant	O
.	O
<EOS>	B-X
Injury	B-X
causes	B-X
the	B-X
release	B-X
of	B-X
factors	B-X
that	B-X
contribute	B-X
to	B-X
repair	B-X
mechanisms	B-X
including	B-X
members	B-X
of	B-X
the	B-X
epidermal	B-X
growth	B-X
factor	B-X
and	B-X
fibroblast	B-X
growth	B-X
factor	B-X
families	B-X
(	B-X
TGF-alpha	B-X
,	B-X
KGF	B-X
,	B-X
HGF	B-X
)	B-X
,	B-X
chemokines	B-X
(	B-X
MCP-1	B-X
)	B-X
,	B-X
interleukins	B-X
(	B-X
IL-1beta	B-X
,	B-X
IL-2	B-X
,	B-X
IL-4	B-X
,	B-X
IL-13	B-X
)	B-X
,	B-X
and	B-X
prostaglandins	B-X
(	B-X
PGE	B-X
(	B-X
2	B-X
)	B-X
)	B-X
,	B-X
for	B-X
example	B-X
.	B-X
These	B-X
factors	B-X
coordinate	B-X
processes	B-X
involving	B-X
integrins	B-X
,	B-X
matrix	B-X
materials	B-X
(	B-X
fibronectin	B-X
,	B-X
collagen	B-X
,	B-X
laminin	B-X
)	B-X
,	B-X
matrix	B-X
metalloproteinases	B-X
(	B-X
MMP-1	B-X
,	B-X
MMP-7	B-X
,	B-X
MMP-9	B-X
)	B-X
,	B-X
focal	B-X
adhesions	B-X
,	B-X
and	B-X
cytoskeletal	B-X
structures	B-X
to	B-X
promote	B-X
cell	B-X
spreading	B-X
and	B-X
migration	B-X
.	B-X
Mechanistically	B-X
,	B-X
this	B-X
process	B-X
is	B-X
mediated	B-X
through	B-X
activation	B-X
of	B-X
the	B-X
LPA	B-X
receptors	B-X
(	B-X
LPAR1	B-X
and	B-X
PPARG/PPARγ	B-X
)	B-X
-DDIT4-macroautophagy/autophagy	B-X
axis	B-X
,	B-X
and	B-X
further	B-X
upregulation	B-X
of	B-X
multiple	B-X
adhesion	B-X
factors	B-X
(	B-X
e.g.	B-X
,	B-X
cadherins	B-X
and	B-X
selectins	B-X
)	B-X
in	B-X
a	B-X
CLDN7	B-X
(	B-X
claudin	B-X
7	B-X
)	B-X
-dependent	B-X
manner	B-X
.	B-X
Integrins	B-X
are	B-X
heterodimeric	B-X
transmembrane	B-X
cell	B-X
adhesion	B-X
molecules	B-X
made	B-X
up	B-X
of	B-X
alpha	B-X
(	B-X
α	B-X
)	B-X
and	B-X
beta	B-X
(	B-X
β	B-X
)	B-X
subunits	B-X
arranged	B-X
in	B-X
numerous	B-X
dimeric	B-X
pairings	B-X
.	B-X
This	B-X
review	B-X
presents	B-X
current	B-X
evidence	B-X
from	B-X
human	B-X
and	B-X
animal	B-X
studies	B-X
on	B-X
integrin	B-X
structure	B-X
and	B-X
molecular	B-X
signaling	B-X
,	B-X
with	B-X
particular	B-X
emphasis	B-X
on	B-X
signal	B-X
transduction	B-X
in	B-X
infants	B-X
.	B-X
This	B-X
review	B-X
summarizes	B-X
current	B-X
evidence	B-X
from	B-X
human	B-X
and	B-X
animal	B-X
studies	B-X
on	B-X
integrin	B-X
structure	B-X
and	B-X
molecular	B-X
signaling	B-X
and	B-X
promising	B-X
role	B-X
in	B-X
diseases	B-X
of	B-X
inflammation	B-X
,	B-X
infection	B-X
,	B-X
and	B-X
angiogenesis	B-X
in	B-X
infants	B-X
.	B-X
This	B-X
review	B-X
shows	B-X
that	B-X
integrin	B-X
receptors	B-X
and	B-X
ligands	B-X
are	B-X
novel	B-X
therapeutic	B-X
targets	B-X
of	B-X
clinical	B-X
interest	B-X
and	B-X
hold	B-X
promise	B-X
as	B-X
novel	B-X
therapeutic	B-X
targets	B-X
in	B-X
the	B-X
management	B-X
of	B-X
several	B-X
neonatal	B-X
diseases	B-X
.	B-X

During	O
the	O
processing	O
,	O
no	O
loss	O
of	O
label	O
was	O
observed	O
from	O
integrin	B-Protein
alpha	I-Protein
7	I-Protein
radiolabeled	O
with	O
[	O
14C	O
]	O
NAD	O
,	O
containing	O
14C	O
in	O
the	O
nicotinamide	O
-	O
proximal	O
ribose	O
,	O
consistent	O
with	O
a	O
degradation	O
of	O
the	O
ADP	O
-	O
ribose	O
moiety	O
by	O
a	O
cell	O
surface	O
5	O
'	O
-	O
nucleotide	O
phosphodiesterase	O
.	O
<EOS>	B-X
Integrin	B-X
alpha	B-X
7	B-X
is	B-X
a	B-X
major	B-X
substrate	B-X
in	B-X
skeletal	B-X
muscle	B-X
cells	B-X
for	B-X
the	B-X
cell	B-X
surface	B-X
,	B-X
glycosylphosphatidylinositol-anchored	B-X
,	B-X
arginine-specific	B-X
ADP-ribosyltransferase	B-X
.	B-X
Since	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
,	B-X
the	B-X
enzyme	B-X
responsible	B-X
for	B-X
cleavage	B-X
of	B-X
the	B-X
ADP-ribosylarginine	B-X
bond	B-X
and	B-X
a	B-X
component	B-X
with	B-X
the	B-X
transferase	B-X
of	B-X
a	B-X
putative	B-X
ADP-ribosylation	B-X
cycle	B-X
,	B-X
is	B-X
cytosolic	B-X
,	B-X
the	B-X
processing	B-X
of	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
investigated	B-X
.	B-X
Following	B-X
incubation	B-X
of	B-X
differentiated	B-X
mouse	B-X
C2C12	B-X
myoblasts	B-X
with	B-X
[	B-X
adenylate-32P	B-X
]	B-X
NAD	B-X
and	B-X
analysis	B-X
by	B-X
SDS-polyacrylamide	B-X
gel	B-X
electrophoresis	B-X
under	B-X
reducing	B-X
conditions	B-X
,	B-X
two	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
forms	B-X
of	B-X
integrin	B-X
alpha	B-X
7	B-X
were	B-X
resolved	B-X
.	B-X
By	B-X
pulse-chase	B-X
and	B-X
purification	B-X
of	B-X
the	B-X
radiolabeled	B-X
proteins	B-X
on	B-X
a	B-X
laminin	B-X
affinity	B-X
column	B-X
,	B-X
it	B-X
was	B-X
demonstrated	B-X
that	B-X
a	B-X
105-kDa	B-X
ADP-ribosylated	B-X
form	B-X
originated	B-X
from	B-X
a	B-X
mono-ADP-ribosylated	B-X
102-kDa	B-X
form	B-X
and	B-X
represented	B-X
integrin	B-X
alpha	B-X
7	B-X
modified	B-X
at	B-X
more	B-X
than	B-X
one	B-X
site	B-X
.	B-X
The	B-X
additional	B-X
site	B-X
(	B-X
s	B-X
)	B-X
of	B-X
modification	B-X
,	B-X
utilized	B-X
at	B-X
higher	B-X
NAD	B-X
concentrations	B-X
,	B-X
were	B-X
located	B-X
in	B-X
the	B-X
63-kDa	B-X
N-terminal	B-X
segment	B-X
of	B-X
integrin	B-X
alpha	B-X
7	B-X
.	B-X
Both	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrins	B-X
were	B-X
loosely	B-X
associated	B-X
with	B-X
the	B-X
cytoskeleton	B-X
,	B-X
bound	B-X
to	B-X
laminin	B-X
affinity	B-X
columns	B-X
,	B-X
and	B-X
immunoprecipitated	B-X
with	B-X
antibodies	B-X
to	B-X
integrin	B-X
beta	B-X
1	B-X
.	B-X
32P	B-X
label	B-X
was	B-X
rapidly	B-X
removed	B-X
from	B-X
[	B-X
32P	B-X
]	B-X
ADP-ribosylated	B-X
integrin	B-X
alpha	B-X
7	B-X
at	B-X
either	B-X
site	B-X
of	B-X
modification	B-X
,	B-X
a	B-X
process	B-X
inhibited	B-X
by	B-X
free	B-X
ADP-ribose	B-X
or	B-X
p-nitrophenylthymidine-5'-monophosphate	B-X
,	B-X
an	B-X
alternative	B-X
substrate	B-X
of	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
The	B-X
processed	B-X
integrin	B-X
alpha	B-X
7	B-X
was	B-X
unavailable	B-X
for	B-X
subsequent	B-X
ADP-ribosylation	B-X
,	B-X
although	B-X
the	B-X
amount	B-X
of	B-X
surface	B-X
integrin	B-X
alpha	B-X
7	B-X
remained	B-X
constant	B-X
.	B-X
During	B-X
the	B-X
processing	B-X
,	B-X
no	B-X
loss	B-X
of	B-X
label	B-X
was	B-X
observed	B-X
from	B-X
integrin	B-X
alpha	B-X
7	B-X
radiolabeled	B-X
with	B-X
[	B-X
14C	B-X
]	B-X
NAD	B-X
,	B-X
containing	B-X
14C	B-X
in	B-X
the	B-X
nicotinamide	B-X
proximal	B-X
ribose	B-X
,	B-X
consistent	B-X
with	B-X
degradation	B-X
of	B-X
the	B-X
ADP-ribose	B-X
moiety	B-X
by	B-X
a	B-X
cell	B-X
surface	B-X
5'-nucleotide	B-X
phosphodiesterase	B-X
.	B-X
Thus	B-X
,	B-X
cell	B-X
surface	B-X
ADP-ribosylation	B-X
,	B-X
in	B-X
contrast	B-X
to	B-X
intracellular	B-X
ADP-ribosylation	B-X
,	B-X
is	B-X
not	B-X
readily	B-X
reversed	B-X
by	B-X
ADP-ribosylarginine	B-X
hydrolase	B-X
and	B-X
seems	B-X
to	B-X
operate	B-X
outside	B-X
the	B-X
postulated	B-X
ADP-ribosylation	B-X
cycle	B-X
.	B-X

Thus	O
,	O
cell	O
surface	O
ADP	O
-	O
ribosylation	O
,	O
in	O
contrast	O
to	O
intracellular	O
ADP	O
-	O
ribosylation	O
,	O
is	O
not	O
readily	O
reversed	O
by	O
the	O
presently	O
known	O
ADP	B-Protein
-	I-Protein
ribosylarginine	I-Protein
hydrolase	I-Protein
and	O
seems	O
to	O
operate	O
outside	O
the	O
postulated	O
ADP	O
-	O
ribosylation	O
cycle	O
.	O
<EOS>	B-X
Mammalian	B-X
ecto	B-X
ADP-ribosyltransferases	B-X
(	B-X
ARTs	B-X
)	B-X
constitute	B-X
a	B-X
family	B-X
of	B-X
structurally	B-X
related	B-X
proteins	B-X
expressed	B-X
on	B-X
the	B-X
cell	B-X
surface	B-X
or	B-X
secreted	B-X
in	B-X
the	B-X
extracellular	B-X
compartment	B-X
.	B-X
Using	B-X
NAD+	B-X
as	B-X
substrate	B-X
,	B-X
they	B-X
transfer	B-X
ADP-ribose	B-X
groups	B-X
onto	B-X
target	B-X
proteins	B-X
.	B-X
In	B-X
contrast	B-X
to	B-X
intracellular	B-X
poly	B-X
(	B-X
ADP-ribosyl	B-X
)	B-X
transferases	B-X
(	B-X
PARPs	B-X
)	B-X
,	B-X
these	B-X
enzymes	B-X
transfer	B-X
a	B-X
single	B-X
ADPR	B-X
and	B-X
are	B-X
thus	B-X
mono-ARTs	B-X
.	B-X
ADP-ribosylation	B-X
of	B-X
target	B-X
proteins	B-X
on	B-X
cell	B-X
surfaces	B-X
or	B-X
circulating	B-X
in	B-X
body	B-X
fluids	B-X
leads	B-X
to	B-X
reversible	B-X
post-translational	B-X
modifications	B-X
which	B-X
can	B-X
inhibit	B-X
the	B-X
targets	B-X
,	B-X
as	B-X
known	B-X
for	B-X
bacterial	B-X
ARTs	B-X
,	B-X
or	B-X
activate	B-X
them	B-X
,	B-X
as	B-X
in	B-X
the	B-X
crosstalk	B-X
between	B-X
mouse	B-X
ART2	B-X
and	B-X
the	B-X
cytolytic	B-X
P2X7	B-X
receptor	B-X
on	B-X
T	B-X
lymphocytes	B-X
.	B-X
ART	B-X
activity	B-X
in	B-X
the	B-X
extracellular	B-X
compartment	B-X
provides	B-X
sophisticated	B-X
regulatory	B-X
mechanisms	B-X
for	B-X
cell	B-X
communication	B-X
.	B-X

[	O
Isoprenylated	O
proteins	O
and	O
cell	O
proliferation	O
:	O
regulators	O
and	O
effectors	O
of	O
Ras	O
proteins	O
]	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Several	B-X
effectors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
mediate	B-X
the	B-X
biological	B-X
effects	B-X
of	B-X
Ras	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Ras	O
proteins	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
cellular	O
proliferation	O
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
crucial	B-X
role	B-X
as	B-X
a	B-X
central	B-X
component	B-X
of	B-X
the	B-X
cellular	B-X
networks	B-X
controlling	B-X
a	B-X
variety	B-X
of	B-X
signaling	B-X
pathways	B-X
that	B-X
regulate	B-X
growth	B-X
,	B-X
proliferation	B-X
,	B-X
survival	B-X
,	B-X
differentiation	B-X
,	B-X
adhesion	B-X
,	B-X
cytoskeletal	B-X
rearrangements	B-X
and	B-X
motility	B-X
of	B-X
a	B-X
cell	B-X
.	B-X
Almost	B-X
,	B-X
4	B-X
decades	B-X
passed	B-X
since	B-X
Ras	B-X
research	B-X
was	B-X
started	B-X
and	B-X
ras	B-X
genes	B-X
were	B-X
originally	B-X
discovered	B-X
as	B-X
retroviral	B-X
oncogenes	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
pioneering	B-X
works	B-X
which	B-X
allowed	B-X
the	B-X
discovery	B-X
of	B-X
RAS	B-X
oncogenes	B-X
,	B-X
the	B-X
finding	B-X
of	B-X
frequent	B-X
mutations	B-X
of	B-X
RAS	B-X
in	B-X
various	B-X
human	B-X
cancers	B-X
,	B-X
the	B-X
role	B-X
of	B-X
these	B-X
mutations	B-X
in	B-X
tumorigenesis	B-X
and	B-X
mutation-activated	B-X
signaling	B-X
networks	B-X
.	B-X
Cancer	B-X
is	B-X
a	B-X
multi-step	B-X
process	B-X
during	B-X
which	B-X
cells	B-X
acquire	B-X
mutations	B-X
that	B-X
eventually	B-X
lead	B-X
to	B-X
uncontrolled	B-X
cell	B-X
growth	B-X
and	B-X
division	B-X
and	B-X
evasion	B-X
of	B-X
programmed	B-X
cell	B-X
death	B-X
.	B-X
The	B-X
oncogenes	B-X
such	B-X
as	B-X
Ras	B-X
and	B-X
c-Myc	B-X
may	B-X
be	B-X
responsible	B-X
in	B-X
all	B-X
three	B-X
major	B-X
stages	B-X
of	B-X
cancer	B-X
i.e.	B-X
,	B-X
early	B-X
,	B-X
intermediate	B-X
,	B-X
and	B-X
late	B-X
.	B-X
The	B-X
NF-κB	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
control	B-X
the	B-X
expression	B-X
of	B-X
genes	B-X
linked	B-X
with	B-X
tumor	B-X
pathways	B-X
such	B-X
as	B-X
chronic	B-X
inflammation	B-X
,	B-X
tumor	B-X
cell	B-X
survival	B-X
,	B-X
anti-apoptosis	B-X
,	B-X
proliferation	B-X
,	B-X
invasion	B-X
,	B-X
and	B-X
angiogenesis	B-X
.	B-X
In	B-X
the	B-X
last	B-X
few	B-X
decades	B-X
,	B-X
various	B-X
biomarker	B-X
pathways	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
play	B-X
a	B-X
critical	B-X
role	B-X
in	B-X
carcinogenesis	B-X
such	B-X
as	B-X
Ras	B-X
,	B-X
NF-κB	B-X
and	B-X
DNA	B-X
damage	B-X
.	B-X

They	O
are	O
189	O
amino	O
acid	O
monomeric	O
GTP	O
-	O
binding	O
proteins	O
that	O
cycle	O
between	O
an	O
inactive	O
GDP	O
-	O
bound	O
and	O
the	O
active	O
GTP	O
-	O
bound	O
state	O
,	O
and	O
carry	O
a	O
slow	O
intrinsic	O
GTPase	O
activity	O
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Ras	O
proteins	O
are	O
activated	O
by	O
growth	O
promoting	O
signals	O
incoming	O
from	O
receptor	O
tyrosine	O
kinases	O
via	O
SH2	O
domain	O
and	O
SH3	O
domain	O
containing	O
adapter	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Sos	O
,	O
as	O
well	O
as	O
from	O
serpentine	O
receptors	O
via	O
the	O
beta	O
gamma	O
subunits	O
of	O
heterotrimeric	O
G	O
proteins	O
and	O
the	O
Ras	O
exchange	O
factor	O
Ras	B-Protein
-	I-Protein
GRF	I-Protein
(	O
or	O
Cdc25	B-Protein
)	O
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Several	B-X
effectors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
mediate	B-X
the	B-X
biological	B-X
effects	B-X
of	B-X
Ras	B-X
.	B-X
The	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
closely	B-X
related	B-X
protein	B-X
B-Raf	B-X
,	B-X
elicit	B-X
the	B-X
ERK	B-X
cascade	B-X
of	B-X
MAP	B-X
kinases	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Proteins	O
that	O
can	O
stimulate	O
the	O
GTPase	O
activity	O
of	O
Ras	O
(	O
GAPs	O
)	O
ensure	O
that	O
following	O
mitogenic	O
stimulations	O
,	O
they	O
return	O
to	O
their	O
inactive	O
GDP	O
-	O
bound	O
state	O
;	O
amongst	O
these	O
proteins	O
are	O
p120	B-Protein
-	I-Protein
GAP	I-Protein
,	O
neurofibomin	B-Protein
(	O
the	O
product	O
of	O
the	O
susceptibility	O
gene	O
to	O
type	O
I	O
neurofibromatosis	O
)	O
,	O
as	O
well	O
as	O
the	O
inositol	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
tetrakisphosphate	O
-	O
dependent	O
GAPIP4BF	B-Protein
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Several	B-X
effectors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
mediate	B-X
the	B-X
biological	B-X
effects	B-X
of	B-X
Ras	B-X
.	B-X
The	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
closely	B-X
related	B-X
protein	B-X
B-Raf	B-X
,	B-X
elicit	B-X
the	B-X
ERK	B-X
cascade	B-X
of	B-X
MAP	B-X
kinases	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Several	O
effectors	O
have	O
been	O
identified	O
that	O
mediate	O
the	O
biological	O
effects	O
of	O
Ras	O
.	O
<EOS>	B-X
STK19	B-X
phosphorylates	B-X
NRAS	B-X
to	B-X
enhance	B-X
its	B-X
binding	B-X
to	B-X
its	B-X
downstream	B-X
effectors	B-X
and	B-X
promotes	B-X
oncogenic	B-X
NRAS-mediated	B-X
melanocyte	B-X
malignant	B-X
transformation	B-X
.	B-X
A	B-X
recurrent	B-X
D89N	B-X
substitution	B-X
in	B-X
STK19	B-X
whose	B-X
alterations	B-X
were	B-X
identified	B-X
in	B-X
25	B-X
%	B-X
of	B-X
human	B-X
melanomas	B-X
represents	B-X
a	B-X
gain-of-function	B-X
mutation	B-X
that	B-X
interacts	B-X
better	B-X
with	B-X
NRAS	B-X
to	B-X
enhance	B-X
melanocyte	B-X
transformation	B-X
.	B-X
The	B-X
expression	B-X
of	B-X
RAS	B-X
components	B-X
and	B-X
the	B-X
elevation	B-X
of	B-X
angiotensin	B-X
converting	B-X
enzyme	B-X
in	B-X
a	B-X
number	B-X
of	B-X
interstitial	B-X
lung	B-X
diseases	B-X
suggests	B-X
the	B-X
existence	B-X
of	B-X
a	B-X
pulmonary	B-X
RAS	B-X
and	B-X
that	B-X
angiotensin	B-X
II	B-X
could	B-X
mediate	B-X
,	B-X
at	B-X
least	B-X
in	B-X
part	B-X
,	B-X
the	B-X
response	B-X
to	B-X
lung	B-X
injury	B-X
.	B-X
Complexes	B-X
of	B-X
molecules	B-X
are	B-X
assembled	B-X
through	B-X
structural	B-X
motifs	B-X
that	B-X
mediate	B-X
phosphotyrosine-SH2	B-X
domain	B-X
and	B-X
SH3-proline-rich	B-X
domain	B-X
interactions	B-X
.	B-X
These	B-X
interactions	B-X
lead	B-X
to	B-X
activation	B-X
of	B-X
signaling	B-X
molecules	B-X
,	B-X
especially	B-X
activation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
that	B-X
in	B-X
turn	B-X
mediate	B-X
downstream	B-X
effects	B-X
on	B-X
gene	B-X
regulation	B-X
,	B-X
vesicle	B-X
movement	B-X
,	B-X
and	B-X
cytoskeletal	B-X
reorganizations	B-X
.	B-X
The	B-X
most	B-X
rapid	B-X
are	B-X
of	B-X
growth	B-X
in	B-X
recent	B-X
years	B-X
has	B-X
been	B-X
the	B-X
realization	B-X
that	B-X
signaling	B-X
through	B-X
both	B-X
G-protein	B-X
coupled	B-X
receptors	B-X
and	B-X
adhesion	B-X
receptors	B-X
is	B-X
dependent	B-X
on	B-X
tyrosine	B-X
kinase	B-X
activation	B-X
,	B-X
recruitment	B-X
of	B-X
complexes	B-X
of	B-X
SH2	B-X
,	B-X
SH3	B-X
,	B-X
and	B-X
proline-rich	B-X
signaling	B-X
molecules	B-X
to	B-X
appropriate	B-X
locations	B-X
in	B-X
the	B-X
cell	B-X
,	B-X
and	B-X
on	B-X
activation	B-X
of	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
of	B-X
proteins	B-X
.	B-X
The	B-X
challenge	B-X
in	B-X
future	B-X
years	B-X
will	B-X
be	B-X
to	B-X
identity	B-X
the	B-X
way	B-X
in	B-X
which	B-X
the	B-X
activation	B-X
of	B-X
tyrosine	B-X
kinase	B-X
(	B-X
s	B-X
)	B-X
is	B-X
induced	B-X
by	B-X
receptor	B-X
activation	B-X
,	B-X
identify	B-X
the	B-X
tyrosine	B-X
kinase	B-X
(	B-X
s	B-X
)	B-X
involved	B-X
,	B-X
and	B-X
identify	B-X
the	B-X
way	B-X
in	B-X
which	B-X
specific	B-X
members	B-X
of	B-X
the	B-X
Ras	B-X
superfamily	B-X
activate	B-X
downstream	B-X
effectors	B-X
to	B-X
induce	B-X
the	B-X
responses	B-X
of	B-X
platelets	B-X
to	B-X
activation	B-X
.	B-X

The	O
serine	O
/	O
threonine	O
kinase	O
Raf	B-Protein
-	I-Protein
1	I-Protein
,	O
as	O
well	O
as	O
the	O
closely	O
related	O
protein	O
B	B-Protein
-	I-Protein
Raf	I-Protein
,	O
elicit	O
the	O
ERK	O
cascade	O
of	O
MAP	O
kinases	O
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
The	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
closely	B-X
related	B-X
protein	B-X
B-Raf	B-X
,	B-X
elicit	B-X
the	B-X
ERK	B-X
cascade	B-X
of	B-X
MAP	B-X
kinases	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Phosphatidylinositol	O
-	O
3	O
-	O
OH	O
kinase	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
family	O
proteins	O
that	O
play	O
a	O
role	O
in	O
the	O
control	O
of	O
actin	O
polymerisation	O
,	O
as	O
well	O
as	O
in	O
growth	O
control	O
,	O
RalGDS	B-Protein
,	O
RGL	O
and	O
Rlf	B-Protein
,	O
are	O
responsible	O
for	O
the	O
activation	O
of	O
the	O
Ras	O
-	O
related	O
protein	O
Ral	B-Protein
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Several	B-X
effectors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
mediate	B-X
the	B-X
biological	B-X
effects	B-X
of	B-X
Ras	B-X
.	B-X
The	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
closely	B-X
related	B-X
protein	B-X
B-Raf	B-X
,	B-X
elicit	B-X
the	B-X
ERK	B-X
cascade	B-X
of	B-X
MAP	B-X
kinases	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Recent	O
evidence	O
,	O
using	O
effector	O
domain	O
mutants	O
of	O
Ras	O
,	O
demonstrates	O
that	O
these	O
pathways	O
cooperate	O
to	O
elicit	O
the	O
growth	O
promoting	O
effects	O
of	O
Ras	O
proteins	O
.	O
<EOS>	B-X
Ras	B-X
proteins	B-X
play	B-X
a	B-X
central	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
cellular	B-X
proliferation	B-X
.	B-X
They	B-X
are	B-X
189	B-X
amino	B-X
acid	B-X
monomeric	B-X
GTP-binding	B-X
proteins	B-X
that	B-X
cycle	B-X
between	B-X
an	B-X
inactive	B-X
GDP-bound	B-X
and	B-X
the	B-X
active	B-X
GTP-bound	B-X
state	B-X
,	B-X
and	B-X
carry	B-X
a	B-X
slow	B-X
intrinsic	B-X
GTPase	B-X
activity	B-X
.	B-X
Ras	B-X
proteins	B-X
are	B-X
activated	B-X
by	B-X
growth	B-X
promoting	B-X
signals	B-X
incoming	B-X
from	B-X
receptor	B-X
tyrosine	B-X
kinases	B-X
via	B-X
SH2	B-X
domain	B-X
and	B-X
SH3	B-X
domain	B-X
containing	B-X
adapter	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Sos	B-X
,	B-X
as	B-X
well	B-X
as	B-X
from	B-X
serpentine	B-X
receptors	B-X
via	B-X
the	B-X
beta	B-X
gamma	B-X
subunits	B-X
of	B-X
heterotrimeric	B-X
G	B-X
proteins	B-X
and	B-X
the	B-X
Ras	B-X
exchange	B-X
factor	B-X
Ras-GRF	B-X
(	B-X
or	B-X
Cdc25	B-X
)	B-X
.	B-X
Proteins	B-X
that	B-X
can	B-X
stimulate	B-X
the	B-X
GTPase	B-X
activity	B-X
of	B-X
Ras	B-X
(	B-X
GAPs	B-X
)	B-X
ensure	B-X
that	B-X
following	B-X
mitogenic	B-X
stimulations	B-X
,	B-X
they	B-X
return	B-X
to	B-X
their	B-X
inactive	B-X
GDP-bound	B-X
state	B-X
;	B-X
amongst	B-X
these	B-X
proteins	B-X
are	B-X
p120-GAP	B-X
,	B-X
neurofibomin	B-X
(	B-X
the	B-X
product	B-X
of	B-X
the	B-X
susceptibility	B-X
gene	B-X
to	B-X
type	B-X
I	B-X
neurofibromatosis	B-X
)	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
inositol	B-X
1,3,4,5-tetrakisphosphate-dependent	B-X
GAPIP4BF	B-X
.	B-X
Several	B-X
effectors	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
mediate	B-X
the	B-X
biological	B-X
effects	B-X
of	B-X
Ras	B-X
.	B-X
The	B-X
serine/threonine	B-X
kinase	B-X
Raf-1	B-X
,	B-X
as	B-X
well	B-X
as	B-X
the	B-X
closely	B-X
related	B-X
protein	B-X
B-Raf	B-X
,	B-X
elicit	B-X
the	B-X
ERK	B-X
cascade	B-X
of	B-X
MAP	B-X
kinases	B-X
.	B-X
Phosphatidylinositol-3-OH	B-X
kinase	B-X
is	B-X
involved	B-X
in	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Rac/Rho	B-X
family	B-X
proteins	B-X
that	B-X
play	B-X
a	B-X
role	B-X
in	B-X
the	B-X
control	B-X
of	B-X
actin	B-X
polymerisation	B-X
,	B-X
as	B-X
well	B-X
as	B-X
in	B-X
growth	B-X
control	B-X
,	B-X
RalGDS	B-X
,	B-X
RGL	B-X
and	B-X
Rlf	B-X
,	B-X
are	B-X
responsible	B-X
for	B-X
the	B-X
activation	B-X
of	B-X
the	B-X
Ras-related	B-X
protein	B-X
Ral	B-X
.	B-X
Recent	B-X
evidence	B-X
,	B-X
using	B-X
effector	B-X
domain	B-X
mutants	B-X
of	B-X
Ras	B-X
,	B-X
demonstrates	B-X
that	B-X
these	B-X
pathways	B-X
cooperate	B-X
to	B-X
elicit	B-X
the	B-X
growth	B-X
promoting	B-X
effects	B-X
of	B-X
Ras	B-X
proteins	B-X
.	B-X

Inhibition	O
of	O
the	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
but	O
not	O
H	B-Protein
-	I-Protein
or	O
N	B-Protein
-	I-Protein
Ras	I-Protein
,	O
is	O
highly	O
resistant	O
to	O
CAAX	O
peptidomimetics	O
and	O
requires	O
both	O
a	O
farnesyltransferase	O
and	O
a	O
geranylgeranyltransferase	O
I	O
inhibitor	O
in	O
human	O
tumor	O
cell	O
lines	O
.	O
<EOS>	B-X
KRAS	B-X
is	B-X
one	B-X
of	B-X
the	B-X
most	B-X
commonly	B-X
mutated	B-X
oncogene	B-X
and	B-X
a	B-X
negative	B-X
predictive	B-X
factor	B-X
for	B-X
a	B-X
number	B-X
of	B-X
targeted	B-X
therapies	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
development	B-X
of	B-X
targeting	B-X
strategies	B-X
against	B-X
mutant	B-X
KRAS	B-X
is	B-X
urgently	B-X
needed	B-X
.	B-X
One	B-X
potential	B-X
strategy	B-X
involves	B-X
disruption	B-X
of	B-X
K-Ras	B-X
membrane	B-X
localization	B-X
,	B-X
which	B-X
is	B-X
necessary	B-X
for	B-X
its	B-X
proper	B-X
function	B-X
.	B-X
In	B-X
this	B-X
review	B-X
,	B-X
we	B-X
summarize	B-X
the	B-X
current	B-X
data	B-X
about	B-X
the	B-X
importance	B-X
of	B-X
membrane-anchorage	B-X
of	B-X
K-Ras	B-X
and	B-X
provide	B-X
a	B-X
critical	B-X
evaluation	B-X
of	B-X
this	B-X
targeting	B-X
paradigm	B-X
focusing	B-X
mainly	B-X
on	B-X
prenylation	B-X
inhibition	B-X
.	B-X
Additionally	B-X
,	B-X
we	B-X
performed	B-X
a	B-X
RAS	B-X
mutation-specific	B-X
analysis	B-X
of	B-X
prenylation-related	B-X
drug	B-X
sensitivity	B-X
data	B-X
from	B-X
a	B-X
publicly	B-X
available	B-X
database	B-X
(	B-X
https	B-X
:	B-X
//depmap.org/repurposing/	B-X
)	B-X
of	B-X
three	B-X
classes	B-X
of	B-X
prenylation	B-X
inhibitors	B-X
:	B-X
statins	B-X
,	B-X
N-bisphosphonates	B-X
,	B-X
and	B-X
farnesyl-transferase	B-X
inhibitors	B-X
.	B-X
We	B-X
observed	B-X
significant	B-X
differences	B-X
in	B-X
sensitivity	B-X
to	B-X
N-bisphosphonates	B-X
and	B-X
farnesyl-transferase	B-X
inhibitors	B-X
depending	B-X
on	B-X
KRAS	B-X
mutational	B-X
status	B-X
and	B-X
tissue	B-X
of	B-X
origin	B-X
.	B-X
These	B-X
observations	B-X
emphasize	B-X
the	B-X
importance	B-X
of	B-X
factors	B-X
affecting	B-X
efficacy	B-X
of	B-X
prenylation	B-X
inhibition	B-X
,	B-X
like	B-X
distinct	B-X
features	B-X
of	B-X
different	B-X
KRAS	B-X
mutations	B-X
,	B-X
tissue-specific	B-X
mutational	B-X
patterns	B-X
,	B-X
K-Ras	B-X
turnover	B-X
,	B-X
and	B-X
changes	B-X
in	B-X
regulation	B-X
of	B-X
prenylation	B-X
process	B-X
.	B-X
Finally	B-X
,	B-X
we	B-X
enlist	B-X
the	B-X
factors	B-X
that	B-X
might	B-X
be	B-X
responsible	B-X
for	B-X
the	B-X
large	B-X
discrepancy	B-X
between	B-X
the	B-X
outcomes	B-X
in	B-X
preclinical	B-X
and	B-X
clinical	B-X
studies	B-X
including	B-X
methodological	B-X
pitfalls	B-X
,	B-X
the	B-X
incomplete	B-X
understanding	B-X
of	B-X
K-Ras	B-X
protein	B-X
turnover	B-X
,	B-X
and	B-X
the	B-X
variation	B-X
of	B-X
KRAS	B-X
dependency	B-X
in	B-X
KRAS	B-X
mutant	B-X
tumors	B-X
.	B-X

The	O
farnesyltransferase	O
(	O
FTase	O
)	O
inhibitor	O
FTI	O
-	O
277	O
is	O
highly	O
effective	O
at	O
blocking	O
oncogenic	O
H	B-Protein
-	I-Protein
Ras	I-Protein
but	O
not	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
processing	O
and	O
signaling	O
.	O

While	O
inhibition	O
of	O
processing	O
and	O
signaling	O
of	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
is	O
more	O
sensitive	O
to	O
the	O
geranylgeranyltransferase	O
I	O
(	O
GGTase	O
I	O
)	O
inhibitor	O
GGTI	O
-	O
286	O
than	O
it	O
is	O
to	O
FTI	O
-	O
277	O
in	O
K	B-Protein
-	I-Protein
Ras4B	I-Protein
-	O
transformed	O
NIH3T3	O
cells	O
,	O
the	O
sensitivity	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
as	O
well	O
as	O
H	B-Protein
-	I-Protein
and	O
N	B-Protein
-	I-Protein
Ras	I-Protein
to	O
the	O
CAAX	O
peptidomimetics	O
in	O
human	O
tumor	O
cell	O
lines	O
is	O
not	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
panel	O
of	O
five	O
human	O
carcinoma	O
cell	O
lines	O
from	O
pancreatic	O
,	O
pulmonary	O
,	O
and	O
bladder	O
origins	O
all	O
express	O
H	B-Protein
-	I-Protein
,	O
N	B-Protein
-	I-Protein
,	O
and	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
and	O
their	O
respective	O
prenylation	O
sensitivities	O
to	O
the	O
FTase	O
and	O
GGTase	O
I	O
inhibitors	O
is	O
variable	O
.	O

In	O
all	O
of	O
the	O
cell	O
lines	O
investigated	O
,	O
the	O
prenylation	O
of	O
N	B-Protein
-	I-Protein
Ras	I-Protein
was	O
highly	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
and	O
in	O
two	O
of	O
the	O
cell	O
lines	O
,	O
N	B-Protein
-	I-Protein
Ras	I-Protein
showed	O
slight	O
sensitivity	O
to	O
GGTI	O
-	O
298	O
,	O
an	O
analog	O
of	O
GGTI	O
-	O
286	O
.	O

Although	O
the	O
prenylation	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
was	O
also	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
complete	O
inhibition	O
of	O
H	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
even	O
at	O
high	O
concentrations	O
of	O
FTI	O
-	O
277	O
and	O
/	O
or	O
GGTI	O
-	O
298	O
was	O
never	O
achieved	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
inhibitor	B-X
FTI-277	B-X
is	B-X
highly	B-X
effective	B-X
at	B-X
blocking	B-X
oncogenic	B-X
H-Ras	B-X
but	B-X
not	B-X
K-Ras4B	B-X
processing	B-X
and	B-X
signaling	B-X
.	B-X
While	B-X
inhibition	B-X
of	B-X
processing	B-X
and	B-X
signaling	B-X
of	B-X
oncogenic	B-X
K-Ras4B	B-X
is	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
inhibitor	B-X
GGTI-286	B-X
than	B-X
it	B-X
is	B-X
to	B-X
FTI-277	B-X
in	B-X
K-Ras4B-transformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
K-Ras	B-X
as	B-X
well	B-X
as	B-X
H-	B-X
and	B-X
N-Ras	B-X
to	B-X
the	B-X
CAAX	B-X
peptidomimetics	B-X
in	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
panel	B-X
of	B-X
five	B-X
human	B-X
carcinoma	B-X
cell	B-X
lines	B-X
from	B-X
pancreatic	B-X
,	B-X
pulmonary	B-X
,	B-X
and	B-X
bladder	B-X
origins	B-X
all	B-X
express	B-X
H-	B-X
,	B-X
N-	B-X
,	B-X
and	B-X
K-Ras	B-X
,	B-X
and	B-X
their	B-X
respective	B-X
prenylation	B-X
sensitivities	B-X
to	B-X
the	B-X
FTase	B-X
and	B-X
GGTase	B-X
I	B-X
inhibitors	B-X
is	B-X
variable	B-X
.	B-X
In	B-X
all	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
investigated	B-X
,	B-X
the	B-X
prenylation	B-X
of	B-X
N-Ras	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
and	B-X
in	B-X
two	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
,	B-X
N-Ras	B-X
showed	B-X
slight	B-X
sensitivity	B-X
to	B-X
GGTI-298	B-X
,	B-X
an	B-X
analog	B-X
of	B-X
GGTI-286	B-X
.	B-X
Although	B-X
the	B-X
prenylation	B-X
of	B-X
H-Ras	B-X
was	B-X
also	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
complete	B-X
inhibition	B-X
of	B-X
H-Ras	B-X
processing	B-X
even	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
FTI-277	B-X
and/or	B-X
GGTI-298	B-X
was	B-X
never	B-X
achieved	B-X
.	B-X
The	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
highly	B-X
resistant	B-X
to	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
.	B-X
Most	B-X
significantly	B-X
,	B-X
treatment	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
with	B-X
both	B-X
inhibitors	B-X
was	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
.	B-X
In	B-X
one	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
A-549	B-X
,	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
was	B-X
highly	B-X
resistant	B-X
even	B-X
when	B-X
co-treated	B-X
with	B-X
both	B-X
inhibitors	B-X
.	B-X
Furthermore	B-X
,	B-X
soft	B-X
agar	B-X
experiments	B-X
demonstrated	B-X
that	B-X
in	B-X
all	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
tested	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
was	B-X
not	B-X
necessary	B-X
for	B-X
inhibition	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
GGTI-298	B-X
had	B-X
very	B-X
little	B-X
effect	B-X
on	B-X
soft	B-X
agar	B-X
growth	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
resulted	B-X
in	B-X
significant	B-X
growth	B-X
inhibition	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
while	B-X
FTI-277	B-X
inhibits	B-X
N-Ras	B-X
and	B-X
H-Ras	B-X
processing	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
evaluated	B-X
,	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
processing	B-X
requires	B-X
both	B-X
an	B-X
FTase	B-X
inhibitor	B-X
as	B-X
well	B-X
as	B-X
a	B-X
GGTase	B-X
I	B-X
inhibitor	B-X
,	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
human	B-X
tumor	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
does	B-X
not	B-X
require	B-X
inhibition	B-X
of	B-X
oncogenic	B-X
K-Ras	B-X
processing	B-X
.	B-X

The	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
highly	O
resistant	O
to	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
inhibitor	B-X
FTI-277	B-X
is	B-X
highly	B-X
effective	B-X
at	B-X
blocking	B-X
oncogenic	B-X
H-Ras	B-X
but	B-X
not	B-X
K-Ras4B	B-X
processing	B-X
and	B-X
signaling	B-X
.	B-X
While	B-X
inhibition	B-X
of	B-X
processing	B-X
and	B-X
signaling	B-X
of	B-X
oncogenic	B-X
K-Ras4B	B-X
is	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
inhibitor	B-X
GGTI-286	B-X
than	B-X
it	B-X
is	B-X
to	B-X
FTI-277	B-X
in	B-X
K-Ras4B-transformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
K-Ras	B-X
as	B-X
well	B-X
as	B-X
H-	B-X
and	B-X
N-Ras	B-X
to	B-X
the	B-X
CAAX	B-X
peptidomimetics	B-X
in	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
panel	B-X
of	B-X
five	B-X
human	B-X
carcinoma	B-X
cell	B-X
lines	B-X
from	B-X
pancreatic	B-X
,	B-X
pulmonary	B-X
,	B-X
and	B-X
bladder	B-X
origins	B-X
all	B-X
express	B-X
H-	B-X
,	B-X
N-	B-X
,	B-X
and	B-X
K-Ras	B-X
,	B-X
and	B-X
their	B-X
respective	B-X
prenylation	B-X
sensitivities	B-X
to	B-X
the	B-X
FTase	B-X
and	B-X
GGTase	B-X
I	B-X
inhibitors	B-X
is	B-X
variable	B-X
.	B-X
In	B-X
all	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
investigated	B-X
,	B-X
the	B-X
prenylation	B-X
of	B-X
N-Ras	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
and	B-X
in	B-X
two	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
,	B-X
N-Ras	B-X
showed	B-X
slight	B-X
sensitivity	B-X
to	B-X
GGTI-298	B-X
,	B-X
an	B-X
analog	B-X
of	B-X
GGTI-286	B-X
.	B-X
Although	B-X
the	B-X
prenylation	B-X
of	B-X
H-Ras	B-X
was	B-X
also	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
complete	B-X
inhibition	B-X
of	B-X
H-Ras	B-X
processing	B-X
even	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
FTI-277	B-X
and/or	B-X
GGTI-298	B-X
was	B-X
never	B-X
achieved	B-X
.	B-X
The	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
highly	B-X
resistant	B-X
to	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
.	B-X
Most	B-X
significantly	B-X
,	B-X
treatment	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
with	B-X
both	B-X
inhibitors	B-X
was	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
.	B-X
In	B-X
one	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
A-549	B-X
,	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
was	B-X
highly	B-X
resistant	B-X
even	B-X
when	B-X
co-treated	B-X
with	B-X
both	B-X
inhibitors	B-X
.	B-X
Furthermore	B-X
,	B-X
soft	B-X
agar	B-X
experiments	B-X
demonstrated	B-X
that	B-X
in	B-X
all	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
tested	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
was	B-X
not	B-X
necessary	B-X
for	B-X
inhibition	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
GGTI-298	B-X
had	B-X
very	B-X
little	B-X
effect	B-X
on	B-X
soft	B-X
agar	B-X
growth	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
resulted	B-X
in	B-X
significant	B-X
growth	B-X
inhibition	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
while	B-X
FTI-277	B-X
inhibits	B-X
N-Ras	B-X
and	B-X
H-Ras	B-X
processing	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
evaluated	B-X
,	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
processing	B-X
requires	B-X
both	B-X
an	B-X
FTase	B-X
inhibitor	B-X
as	B-X
well	B-X
as	B-X
a	B-X
GGTase	B-X
I	B-X
inhibitor	B-X
,	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
human	B-X
tumor	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
does	B-X
not	B-X
require	B-X
inhibition	B-X
of	B-X
oncogenic	B-X
K-Ras	B-X
processing	B-X
.	B-X

Most	O
significantly	O
,	O
treatment	O
of	O
human	O
tumor	O
cell	O
lines	O
with	O
both	O
inhibitors	O
was	O
required	O
for	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
inhibitor	B-X
FTI-277	B-X
is	B-X
highly	B-X
effective	B-X
at	B-X
blocking	B-X
oncogenic	B-X
H-Ras	B-X
but	B-X
not	B-X
K-Ras4B	B-X
processing	B-X
and	B-X
signaling	B-X
.	B-X
While	B-X
inhibition	B-X
of	B-X
processing	B-X
and	B-X
signaling	B-X
of	B-X
oncogenic	B-X
K-Ras4B	B-X
is	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
inhibitor	B-X
GGTI-286	B-X
than	B-X
it	B-X
is	B-X
to	B-X
FTI-277	B-X
in	B-X
K-Ras4B-transformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
K-Ras	B-X
as	B-X
well	B-X
as	B-X
H-	B-X
and	B-X
N-Ras	B-X
to	B-X
the	B-X
CAAX	B-X
peptidomimetics	B-X
in	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
panel	B-X
of	B-X
five	B-X
human	B-X
carcinoma	B-X
cell	B-X
lines	B-X
from	B-X
pancreatic	B-X
,	B-X
pulmonary	B-X
,	B-X
and	B-X
bladder	B-X
origins	B-X
all	B-X
express	B-X
H-	B-X
,	B-X
N-	B-X
,	B-X
and	B-X
K-Ras	B-X
,	B-X
and	B-X
their	B-X
respective	B-X
prenylation	B-X
sensitivities	B-X
to	B-X
the	B-X
FTase	B-X
and	B-X
GGTase	B-X
I	B-X
inhibitors	B-X
is	B-X
variable	B-X
.	B-X
In	B-X
all	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
investigated	B-X
,	B-X
the	B-X
prenylation	B-X
of	B-X
N-Ras	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
and	B-X
in	B-X
two	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
,	B-X
N-Ras	B-X
showed	B-X
slight	B-X
sensitivity	B-X
to	B-X
GGTI-298	B-X
,	B-X
an	B-X
analog	B-X
of	B-X
GGTI-286	B-X
.	B-X
Although	B-X
the	B-X
prenylation	B-X
of	B-X
H-Ras	B-X
was	B-X
also	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
complete	B-X
inhibition	B-X
of	B-X
H-Ras	B-X
processing	B-X
even	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
FTI-277	B-X
and/or	B-X
GGTI-298	B-X
was	B-X
never	B-X
achieved	B-X
.	B-X
The	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
highly	B-X
resistant	B-X
to	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
.	B-X
Most	B-X
significantly	B-X
,	B-X
treatment	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
with	B-X
both	B-X
inhibitors	B-X
was	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
.	B-X
In	B-X
one	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
A-549	B-X
,	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
was	B-X
highly	B-X
resistant	B-X
even	B-X
when	B-X
co-treated	B-X
with	B-X
both	B-X
inhibitors	B-X
.	B-X
Furthermore	B-X
,	B-X
soft	B-X
agar	B-X
experiments	B-X
demonstrated	B-X
that	B-X
in	B-X
all	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
tested	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
was	B-X
not	B-X
necessary	B-X
for	B-X
inhibition	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
GGTI-298	B-X
had	B-X
very	B-X
little	B-X
effect	B-X
on	B-X
soft	B-X
agar	B-X
growth	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
resulted	B-X
in	B-X
significant	B-X
growth	B-X
inhibition	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
while	B-X
FTI-277	B-X
inhibits	B-X
N-Ras	B-X
and	B-X
H-Ras	B-X
processing	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
evaluated	B-X
,	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
processing	B-X
requires	B-X
both	B-X
an	B-X
FTase	B-X
inhibitor	B-X
as	B-X
well	B-X
as	B-X
a	B-X
GGTase	B-X
I	B-X
inhibitor	B-X
,	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
human	B-X
tumor	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
does	B-X
not	B-X
require	B-X
inhibition	B-X
of	B-X
oncogenic	B-X
K-Ras	B-X
processing	B-X
.	B-X

In	O
one	O
cell	O
line	O
,	O
the	O
human	O
lung	O
adenocarcinoma	O
A	O
-	O
549	O
,	O
prenylation	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
was	O
highly	O
resistant	O
even	O
when	O
co	O
-	O
treated	O
with	O
both	O
inhibitors	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
inhibitor	B-X
FTI-277	B-X
is	B-X
highly	B-X
effective	B-X
at	B-X
blocking	B-X
oncogenic	B-X
H-Ras	B-X
but	B-X
not	B-X
K-Ras4B	B-X
processing	B-X
and	B-X
signaling	B-X
.	B-X
While	B-X
inhibition	B-X
of	B-X
processing	B-X
and	B-X
signaling	B-X
of	B-X
oncogenic	B-X
K-Ras4B	B-X
is	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
inhibitor	B-X
GGTI-286	B-X
than	B-X
it	B-X
is	B-X
to	B-X
FTI-277	B-X
in	B-X
K-Ras4B-transformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
K-Ras	B-X
as	B-X
well	B-X
as	B-X
H-	B-X
and	B-X
N-Ras	B-X
to	B-X
the	B-X
CAAX	B-X
peptidomimetics	B-X
in	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
is	B-X
not	B-X
known	B-X
.	B-X
Here	B-X
,	B-X
we	B-X
report	B-X
that	B-X
a	B-X
panel	B-X
of	B-X
five	B-X
human	B-X
carcinoma	B-X
cell	B-X
lines	B-X
from	B-X
pancreatic	B-X
,	B-X
pulmonary	B-X
,	B-X
and	B-X
bladder	B-X
origins	B-X
all	B-X
express	B-X
H-	B-X
,	B-X
N-	B-X
,	B-X
and	B-X
K-Ras	B-X
,	B-X
and	B-X
their	B-X
respective	B-X
prenylation	B-X
sensitivities	B-X
to	B-X
the	B-X
FTase	B-X
and	B-X
GGTase	B-X
I	B-X
inhibitors	B-X
is	B-X
variable	B-X
.	B-X
In	B-X
all	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
investigated	B-X
,	B-X
the	B-X
prenylation	B-X
of	B-X
N-Ras	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
and	B-X
in	B-X
two	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
,	B-X
N-Ras	B-X
showed	B-X
slight	B-X
sensitivity	B-X
to	B-X
GGTI-298	B-X
,	B-X
an	B-X
analog	B-X
of	B-X
GGTI-286	B-X
.	B-X
Although	B-X
the	B-X
prenylation	B-X
of	B-X
H-Ras	B-X
was	B-X
also	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
complete	B-X
inhibition	B-X
of	B-X
H-Ras	B-X
processing	B-X
even	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
FTI-277	B-X
and/or	B-X
GGTI-298	B-X
was	B-X
never	B-X
achieved	B-X
.	B-X
The	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
highly	B-X
resistant	B-X
to	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
.	B-X
Most	B-X
significantly	B-X
,	B-X
treatment	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
with	B-X
both	B-X
inhibitors	B-X
was	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
.	B-X
In	B-X
one	B-X
cell	B-X
line	B-X
,	B-X
the	B-X
human	B-X
lung	B-X
adenocarcinoma	B-X
A-549	B-X
,	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
was	B-X
highly	B-X
resistant	B-X
even	B-X
when	B-X
co-treated	B-X
with	B-X
both	B-X
inhibitors	B-X
.	B-X
Furthermore	B-X
,	B-X
soft	B-X
agar	B-X
experiments	B-X
demonstrated	B-X
that	B-X
in	B-X
all	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
tested	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
was	B-X
not	B-X
necessary	B-X
for	B-X
inhibition	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
GGTI-298	B-X
had	B-X
very	B-X
little	B-X
effect	B-X
on	B-X
soft	B-X
agar	B-X
growth	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
resulted	B-X
in	B-X
significant	B-X
growth	B-X
inhibition	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
while	B-X
FTI-277	B-X
inhibits	B-X
N-Ras	B-X
and	B-X
H-Ras	B-X
processing	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
evaluated	B-X
,	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
processing	B-X
requires	B-X
both	B-X
an	B-X
FTase	B-X
inhibitor	B-X
as	B-X
well	B-X
as	B-X
a	B-X
GGTase	B-X
I	B-X
inhibitor	B-X
,	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
human	B-X
tumor	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
does	B-X
not	B-X
require	B-X
inhibition	B-X
of	B-X
oncogenic	B-X
K-Ras	B-X
processing	B-X
.	B-X

Furthermore	O
,	O
soft	O
agar	O
experiments	O
demonstrated	O
that	O
in	O
all	O
the	O
human	O
tumor	O
cell	O
lines	O
tested	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
prenylation	O
was	O
not	O
necessary	O
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
.	O

In	O
addition	O
,	O
although	O
GGTI	O
-	O
298	O
had	O
very	O
little	O
effect	O
on	O
soft	O
agar	O
growth	O
,	O
the	O
combination	O
of	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
.	O
<EOS>	B-X
The	B-X
farnesyltransferase	B-X
(	B-X
FTase	B-X
)	B-X
inhibitor	B-X
FTI-277	B-X
is	B-X
highly	B-X
effective	B-X
at	B-X
blocking	B-X
oncogenic	B-X
H-Ras	B-X
but	B-X
not	B-X
K-Ras4B	B-X
processing	B-X
and	B-X
signaling	B-X
.	B-X
While	B-X
inhibition	B-X
of	B-X
processing	B-X
and	B-X
signaling	B-X
of	B-X
oncogenic	B-X
K-Ras4B	B-X
is	B-X
more	B-X
sensitive	B-X
to	B-X
the	B-X
geranylgeranyltransferase	B-X
I	B-X
(	B-X
GGTase	B-X
I	B-X
)	B-X
inhibitor	B-X
GGTI-286	B-X
than	B-X
it	B-X
is	B-X
to	B-X
FTI-277	B-X
in	B-X
K-Ras4B-transformed	B-X
NIH3T3	B-X
cells	B-X
,	B-X
the	B-X
sensitivity	B-X
of	B-X
K-Ras	B-X
as	B-X
well	B-X
as	B-X
H-	B-X
and	B-X
N-Ras	B-X
to	B-X
the	B-X
CAAX	B-X
peptidomimetics	B-X
in	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
is	B-X
not	B-X
known	B-X
.	B-X
In	B-X
all	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
investigated	B-X
,	B-X
the	B-X
prenylation	B-X
of	B-X
N-Ras	B-X
was	B-X
highly	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
and	B-X
in	B-X
two	B-X
of	B-X
the	B-X
cell	B-X
lines	B-X
,	B-X
N-Ras	B-X
showed	B-X
slight	B-X
sensitivity	B-X
to	B-X
GGTI-298	B-X
,	B-X
an	B-X
analog	B-X
of	B-X
GGTI-286	B-X
.	B-X
Although	B-X
the	B-X
prenylation	B-X
of	B-X
H-Ras	B-X
was	B-X
also	B-X
sensitive	B-X
to	B-X
FTI-277	B-X
,	B-X
complete	B-X
inhibition	B-X
of	B-X
H-Ras	B-X
processing	B-X
even	B-X
at	B-X
high	B-X
concentrations	B-X
of	B-X
FTI-277	B-X
and/or	B-X
GGTI-298	B-X
was	B-X
never	B-X
achieved	B-X
.	B-X
The	B-X
prenylation	B-X
of	B-X
K-Ras	B-X
,	B-X
on	B-X
the	B-X
other	B-X
hand	B-X
,	B-X
was	B-X
highly	B-X
resistant	B-X
to	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
.	B-X
Most	B-X
significantly	B-X
,	B-X
treatment	B-X
of	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
with	B-X
both	B-X
inhibitors	B-X
was	B-X
required	B-X
for	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
.	B-X
Furthermore	B-X
,	B-X
soft	B-X
agar	B-X
experiments	B-X
demonstrated	B-X
that	B-X
in	B-X
all	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
tested	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
prenylation	B-X
was	B-X
not	B-X
necessary	B-X
for	B-X
inhibition	B-X
of	B-X
anchorage-independent	B-X
growth	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
although	B-X
GGTI-298	B-X
had	B-X
very	B-X
little	B-X
effect	B-X
on	B-X
soft	B-X
agar	B-X
growth	B-X
,	B-X
the	B-X
combination	B-X
of	B-X
FTI-277	B-X
and	B-X
GGTI-298	B-X
resulted	B-X
in	B-X
significant	B-X
growth	B-X
inhibition	B-X
.	B-X
Therefore	B-X
,	B-X
the	B-X
results	B-X
demonstrate	B-X
that	B-X
while	B-X
FTI-277	B-X
inhibits	B-X
N-Ras	B-X
and	B-X
H-Ras	B-X
processing	B-X
in	B-X
the	B-X
human	B-X
tumor	B-X
cell	B-X
lines	B-X
evaluated	B-X
,	B-X
inhibition	B-X
of	B-X
K-Ras	B-X
processing	B-X
requires	B-X
both	B-X
an	B-X
FTase	B-X
inhibitor	B-X
as	B-X
well	B-X
as	B-X
a	B-X
GGTase	B-X
I	B-X
inhibitor	B-X
,	B-X
and	B-X
that	B-X
inhibition	B-X
of	B-X
human	B-X
tumor	B-X
growth	B-X
in	B-X
soft	B-X
agar	B-X
does	B-X
not	B-X
require	B-X
inhibition	B-X
of	B-X
oncogenic	B-X
K-Ras	B-X
processing	B-X
.	B-X

Therefore	O
,	O
the	O
results	O
demonstrate	O
that	O
while	O
FTI	O
-	O
277	O
inhibits	O
N	B-Protein
-	I-Protein
Ras	I-Protein
and	O
H	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
in	O
the	O
human	O
tumor	O
cell	O
lines	O
evaluated	O
,	O
inhibition	O
of	O
K	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
requires	O
both	O
an	O
FTase	O
inhibitor	O
as	O
well	O
as	O
a	O
GGTase	O
I	O
inhibitor	O
,	O
and	O
that	O
inhibition	O
of	O
human	O
tumor	O
growth	O
in	O
soft	O
agar	O
does	O
not	O
require	O
inhibition	O
of	O
oncogenic	O
K	B-Protein
-	I-Protein
Ras	I-Protein
processing	O
.	O

Pro108	O
is	O
important	O
for	O
folding	O
and	O
stabilization	O
of	O
adrenal	B-Protein
ferredoxin	I-Protein
,	O
but	O
does	O
not	O
influence	O
the	O
functional	O
properties	O
of	O
the	O
protein	O
.	O

The	O
truncated	O
mutant	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
of	O
bovine	O
adrenal	B-Protein
ferredoxin	I-Protein
was	O
expressed	O
as	O
apoprotein	O
in	O
Escherichia	O
coli	O
BL21	O
and	O
could	O
be	O
reconstituted	O
to	O
the	O
holoform	O
by	O
chemical	O
or	O
enzymatic	O
methods	O
.	O
<EOS>	B-X
Furthermore	B-X
,	B-X
a	B-X
suitable	B-X
extraction	B-X
method	B-X
is	B-X
required	B-X
ensuring	B-X
complete	B-X
extraction	B-X
of	B-X
metabolites	B-X
from	B-X
the	B-X
cells	B-X
and	B-X
inactivation	B-X
of	B-X
enzymatic	B-X
activity	B-X
,	B-X
with	B-X
minimal	B-X
degradation	B-X
of	B-X
labile	B-X
compounds	B-X
.	B-X
Attempts	B-X
to	B-X
remove	B-X
the	B-X
extracellular	B-X
metabolites	B-X
with	B-X
dedicated	B-X
quenching	B-X
methods	B-X
often	B-X
induce	B-X
release	B-X
of	B-X
intracellular	B-X
metabolites	B-X
into	B-X
the	B-X
quenching	B-X
solution	B-X
.	B-X
Here	B-X
we	B-X
present	B-X
an	B-X
overview	B-X
of	B-X
different	B-X
sampling	B-X
,	B-X
quenching	B-X
,	B-X
and	B-X
extraction	B-X
methods	B-X
developed	B-X
for	B-X
microbial	B-X
metabolomics	B-X
,	B-X
described	B-X
in	B-X
the	B-X
literature	B-X
.	B-X
Soticlestat	B-X
,	B-X
a	B-X
first-in-class	B-X
inhibitor	B-X
of	B-X
cholesterol	B-X
24-hydroxylase	B-X
(	B-X
also	B-X
known	B-X
as	B-X
cytochrome	B-X
P450	B-X
46A1	B-X
)	B-X
,	B-X
is	B-X
currently	B-X
in	B-X
development	B-X
for	B-X
the	B-X
treatment	B-X
of	B-X
developmental	B-X
and	B-X
epileptic	B-X
encephalopathies	B-X
.	B-X

The	O
reconstituted	O
protein	O
had	O
spectroscopic	O
,	O
functional	O
and	O
redox	O
properties	O
similar	O
to	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
of	O
adrenal	B-Protein
ferredoxin	I-Protein
,	O
into	O
which	O
the	O
cluster	O
was	O
inserted	O
upon	O
expression	O
in	O
the	O
same	O
Escherichia	O
coli	O
strain	O
.	O

Rate	O
of	O
in	O
vitro	O
cluster	O
insertion	O
into	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
apoprotein	O
was	O
much	O
lower	O
than	O
for	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
apoprotein	O
under	O
identical	O
conditions	O
.	O

Comparative	O
thermodynamic	O
studies	O
with	O
the	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
-	O
peptide	O
indicated	O
that	O
removal	O
of	O
Pro108	O
resulted	O
in	O
an	O
extensive	O
decrease	O
of	O
the	O
overall	O
stability	O
of	O
the	O
protein	O
in	O
either	O
oxidation	O
state	O
.	O

The	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
107	O
)	O
-	O
peptide	O
showed	O
a	O
higher	O
sensitivity	O
to	O
urea	O
denaturation	O
and	O
had	O
a	O
sensibly	O
lower	O
denaturation	O
temperature	O
,	O
44	O
.	O
8	O
degrees	O
C	O
,	O
compared	O
with	O
51	O
.	O
7	O
degrees	O
C	O
for	O
mutant	O
Met	O
-	O
adrenodoxin	B-Protein
-	O
(	O
4	O
-	O
108	O
)	O
.	O

The	O
stability	O
of	O
the	O
reduced	O
state	O
of	O
both	O
mutants	O
is	O
slightly	O
lower	O
than	O
that	O
of	O
the	O
oxidized	O
state	O
indicating	O
that	O
this	O
protein	O
region	O
does	O
not	O
undergo	O
major	O
structural	O
changes	O
upon	O
reduction	O
.	O

A	O
novel	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
monoclonal	O
antibody	O
recognizes	O
an	O
epitope	O
within	O
the	O
tyrosine	O
sulfate	O
motif	O
of	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
and	O
blocks	O
recognition	O
of	O
both	O
P	B-Protein
-	I-Protein
and	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
P	B-Protein
-	I-Protein
selectin	I-Protein
glycoprotein	I-Protein
ligand	I-Protein
-	I-Protein
1	I-Protein
(	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
)	O
mediate	O
the	O
earliest	O
"	O
rolling	O
"	O
of	O
leukocytes	O
on	O
the	O
lumenal	O
surface	O
of	O
endothelial	O
cells	O
at	O
sites	O
of	O
inflammation	O
.	O

Previously	O
,	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
has	O
been	O
shown	O
to	O
be	O
the	O
primary	O
mediator	O
of	O
interactions	O
between	O
neutrophils	O
and	O
P	B-Protein
-	I-Protein
selectin	I-Protein
,	O
but	O
studies	O
on	O
the	O
ability	O
of	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
to	O
mediate	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
other	O
subsets	O
of	O
leukocytes	O
have	O
yielded	O
variable	O
and	O
conflicting	O
results	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
Previously	B-X
,	B-X
PSGL-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
mediator	B-X
of	B-X
interactions	B-X
between	B-X
neutrophils	B-X
and	B-X
P-selectin	B-X
,	B-X
but	B-X
studies	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
PSGL-1	B-X
to	B-X
mediate	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
other	B-X
subsets	B-X
of	B-X
leukocytes	B-X
have	B-X
yielded	B-X
variable	B-X
and	B-X
conflicting	B-X
results	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

A	O
novel	O
IgG	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
to	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
was	O
generated	O
,	O
and	O
the	O
specificity	O
of	O
this	O
MoAb	O
was	O
confirmed	O
by	O
both	O
flow	O
cytometric	O
analysis	O
and	O
Western	O
blotting	O
of	O
cells	O
transfected	O
with	O
human	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
Previously	B-X
,	B-X
PSGL-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
mediator	B-X
of	B-X
interactions	B-X
between	B-X
neutrophils	B-X
and	B-X
P-selectin	B-X
,	B-X
but	B-X
studies	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
PSGL-1	B-X
to	B-X
mediate	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
other	B-X
subsets	B-X
of	B-X
leukocytes	B-X
have	B-X
yielded	B-X
variable	B-X
and	B-X
conflicting	B-X
results	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

This	O
newly	O
developed	O
MoAb	O
,	O
KPL1	O
,	O
inhibited	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
expressing	O
COS	O
cells	O
and	O
either	O
HL60	O
cells	O
,	O
neutrophils	O
,	O
or	O
lymphocytes	O
.	O
<EOS>	B-X
T	B-X
cell	B-X
dysfunction	B-X
is	B-X
a	B-X
hallmark	B-X
of	B-X
many	B-X
cancers	B-X
,	B-X
but	B-X
the	B-X
basis	B-X
for	B-X
T	B-X
cell	B-X
dysfunction	B-X
and	B-X
the	B-X
mechanisms	B-X
by	B-X
which	B-X
antibody	B-X
blockade	B-X
of	B-X
the	B-X
inhibitory	B-X
receptor	B-X
PD-1	B-X
(	B-X
anti-PD-1	B-X
)	B-X
reinvigorates	B-X
T	B-X
cells	B-X
are	B-X
not	B-X
fully	B-X
understood	B-X
.	B-X
Tumor	B-X
infiltrating	B-X
lymphocytes	B-X
(	B-X
TIL	B-X
)	B-X
play	B-X
an	B-X
essential	B-X
role	B-X
in	B-X
mediating	B-X
response	B-X
to	B-X
chemotherapy	B-X
and	B-X
improving	B-X
clinical	B-X
outcomes	B-X
in	B-X
all	B-X
subtypes	B-X
of	B-X
breast	B-X
cancer	B-X
.	B-X
Specific	B-X
chemokines	B-X
and	B-X
adhesion	B-X
molecules	B-X
appeared	B-X
to	B-X
target	B-X
and	B-X
attract	B-X
immune	B-X
effector	B-X
T	B-X
cells	B-X
to	B-X
the	B-X
tumor	B-X
microenvironment	B-X
and	B-X
to	B-X
specific	B-X
regions	B-X
within	B-X
the	B-X
tumor	B-X
.	B-X
Decreased	B-X
IL15	B-X
expression	B-X
also	B-X
affected	B-X
the	B-X
local	B-X
proliferation	B-X
of	B-X
B	B-X
and	B-X
T	B-X
lymphocytes	B-X
.	B-X

Furthermore	O
,	O
KPL1	O
completely	O
inhibited	O
interactions	O
between	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
either	O
purified	O
CD4	B-Protein
T	O
cells	O
or	O
neutrophils	O
in	O
a	O
flow	O
assay	O
under	O
physiological	O
conditions	O
,	O
but	O
had	O
no	O
effect	O
on	O
interactions	O
of	O
T	O
cells	O
or	O
neutrophils	O
with	O
E	B-Protein
-	I-Protein
selectin	I-Protein
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
Previously	B-X
,	B-X
PSGL-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
mediator	B-X
of	B-X
interactions	B-X
between	B-X
neutrophils	B-X
and	B-X
P-selectin	B-X
,	B-X
but	B-X
studies	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
PSGL-1	B-X
to	B-X
mediate	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
other	B-X
subsets	B-X
of	B-X
leukocytes	B-X
have	B-X
yielded	B-X
variable	B-X
and	B-X
conflicting	B-X
results	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

In	O
addition	O
,	O
KPL1	O
blocked	O
interactions	O
between	O
lymphoid	O
cells	O
transfected	O
with	O
L	B-Protein
-	I-Protein
selectin	I-Protein
and	O
COS	O
cells	O
expressing	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
.	O

The	O
KPL1	O
epitope	O
was	O
mapped	O
to	O
a	O
site	O
within	O
a	O
consensus	O
tyrosine	O
sulfation	O
motif	O
of	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
,	O
previously	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
P	B-Protein
-	I-Protein
selectin	I-Protein
and	O
now	O
shown	O
to	O
be	O
essential	O
for	O
interaction	O
with	O
L	B-Protein
-	I-Protein
selectin	I-Protein
,	O
and	O
to	O
be	O
distinct	O
from	O
the	O
epitope	O
identified	O
by	O
the	O
PL1	O
function	O
blocking	O
anti	O
-	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
MoAb	O
.	O

Two	O
-	O
color	O
flow	O
cytometry	O
of	O
normal	O
leukocytes	O
showed	O
that	O
while	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
(	O
CD16	O
(	O
+	O
)	O
)	O
,	O
monocytes	O
,	O
CD4	B-Protein
and	O
CD8	O
T	O
cells	O
,	O
and	O
alpha	O
/	O
beta	O
and	O
gamma	O
/	O
delta	O
T	O
cells	O
were	O
uniformly	O
positive	O
for	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
,	O
B	O
cells	O
expressed	O
low	O
levels	O
of	O
the	O
KPL1	O
epitope	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
Previously	B-X
,	B-X
PSGL-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
mediator	B-X
of	B-X
interactions	B-X
between	B-X
neutrophils	B-X
and	B-X
P-selectin	B-X
,	B-X
but	B-X
studies	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
PSGL-1	B-X
to	B-X
mediate	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
other	B-X
subsets	B-X
of	B-X
leukocytes	B-X
have	B-X
yielded	B-X
variable	B-X
and	B-X
conflicting	B-X
results	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

This	O
low	O
level	O
of	O
KPL1	O
staining	O
was	O
also	O
observed	O
immunohistologically	O
in	O
germinal	O
centers	O
,	O
which	O
had	O
no	O
detectable	O
KPL1	O
staining	O
,	O
whereas	O
T	O
-	O
cell	O
areas	O
(	O
interfollicular	O
region	O
)	O
were	O
positive	O
for	O
KPL1	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

Interestingly	O
,	O
plasma	O
cells	O
in	O
situ	O
and	O
interleukin	B-Protein
-	I-Protein
6	I-Protein
-	O
dependent	O
myeloma	O
cell	O
lines	O
were	O
KPL1	O
(	O
+	O
)	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

Thus	O
,	O
PSGL	B-Protein
-	I-Protein
1	I-Protein
is	O
expressed	O
on	O
essentially	O
all	O
blood	O
neutrophils	O
,	O
NK	O
cells	O
,	O
B	O
cells	O
,	O
T	O
cells	O
,	O
and	O
monocytes	O
.	O
<EOS>	B-X
Interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
P-selectin	B-X
glycoprotein	B-X
ligand-1	B-X
(	B-X
PSGL-1	B-X
)	B-X
mediate	B-X
the	B-X
earliest	B-X
``	B-X
rolling	B-X
''	B-X
of	B-X
leukocytes	B-X
on	B-X
the	B-X
lumenal	B-X
surface	B-X
of	B-X
endothelial	B-X
cells	B-X
at	B-X
sites	B-X
of	B-X
inflammation	B-X
.	B-X
Previously	B-X
,	B-X
PSGL-1	B-X
has	B-X
been	B-X
shown	B-X
to	B-X
be	B-X
the	B-X
primary	B-X
mediator	B-X
of	B-X
interactions	B-X
between	B-X
neutrophils	B-X
and	B-X
P-selectin	B-X
,	B-X
but	B-X
studies	B-X
on	B-X
the	B-X
ability	B-X
of	B-X
PSGL-1	B-X
to	B-X
mediate	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
other	B-X
subsets	B-X
of	B-X
leukocytes	B-X
have	B-X
yielded	B-X
variable	B-X
and	B-X
conflicting	B-X
results	B-X
.	B-X
A	B-X
novel	B-X
IgG	B-X
monoclonal	B-X
antibody	B-X
(	B-X
MoAb	B-X
)	B-X
to	B-X
human	B-X
PSGL-1	B-X
was	B-X
generated	B-X
,	B-X
and	B-X
the	B-X
specificity	B-X
of	B-X
this	B-X
MoAb	B-X
was	B-X
confirmed	B-X
by	B-X
both	B-X
flow	B-X
cytometric	B-X
analysis	B-X
and	B-X
Western	B-X
blotting	B-X
of	B-X
cells	B-X
transfected	B-X
with	B-X
human	B-X
PSGL-1	B-X
.	B-X
This	B-X
newly	B-X
developed	B-X
MoAb	B-X
,	B-X
KPL1	B-X
,	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
expressing	B-X
COS	B-X
cells	B-X
and	B-X
either	B-X
HL60	B-X
cells	B-X
,	B-X
neutrophils	B-X
,	B-X
or	B-X
lymphocytes	B-X
.	B-X
Furthermore	B-X
,	B-X
KPL1	B-X
completely	B-X
inhibited	B-X
interactions	B-X
between	B-X
P-selectin	B-X
and	B-X
either	B-X
purified	B-X
CD4	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
in	B-X
a	B-X
flow	B-X
assay	B-X
under	B-X
physiological	B-X
conditions	B-X
,	B-X
but	B-X
had	B-X
no	B-X
effect	B-X
on	B-X
interactions	B-X
of	B-X
T	B-X
cells	B-X
or	B-X
neutrophils	B-X
with	B-X
E-selectin	B-X
.	B-X
In	B-X
addition	B-X
,	B-X
KPL1	B-X
blocked	B-X
interactions	B-X
between	B-X
lymphoid	B-X
cells	B-X
transfected	B-X
with	B-X
L-selectin	B-X
and	B-X
COS	B-X
cells	B-X
expressing	B-X
PSGL-1	B-X
.	B-X
The	B-X
KPL1	B-X
epitope	B-X
was	B-X
mapped	B-X
to	B-X
a	B-X
site	B-X
within	B-X
a	B-X
consensus	B-X
tyrosine	B-X
sulfation	B-X
motif	B-X
of	B-X
PSGL-1	B-X
,	B-X
previously	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
P-selectin	B-X
and	B-X
now	B-X
shown	B-X
to	B-X
be	B-X
essential	B-X
for	B-X
interaction	B-X
with	B-X
L-selectin	B-X
,	B-X
and	B-X
to	B-X
be	B-X
distinct	B-X
from	B-X
the	B-X
epitope	B-X
identified	B-X
by	B-X
the	B-X
PL1	B-X
function	B-X
blocking	B-X
anti-PSGL-1	B-X
MoAb	B-X
.	B-X
Two-color	B-X
flow	B-X
cytometry	B-X
of	B-X
normal	B-X
leukocytes	B-X
showed	B-X
that	B-X
while	B-X
natural	B-X
killer	B-X
(	B-X
NK	B-X
)	B-X
cells	B-X
(	B-X
CD16	B-X
(	B-X
+	B-X
)	B-X
)	B-X
,	B-X
monocytes	B-X
,	B-X
CD4	B-X
and	B-X
CD8	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
alpha/beta	B-X
and	B-X
gamma/delta	B-X
T	B-X
cells	B-X
were	B-X
uniformly	B-X
positive	B-X
for	B-X
PSGL-1	B-X
,	B-X
B	B-X
cells	B-X
expressed	B-X
low	B-X
levels	B-X
of	B-X
the	B-X
KPL1	B-X
epitope	B-X
.	B-X
This	B-X
low	B-X
level	B-X
of	B-X
KPL1	B-X
staining	B-X
was	B-X
also	B-X
observed	B-X
immunohistologically	B-X
in	B-X
germinal	B-X
centers	B-X
,	B-X
which	B-X
had	B-X
no	B-X
detectable	B-X
KPL1	B-X
staining	B-X
,	B-X
whereas	B-X
T-cell	B-X
areas	B-X
(	B-X
interfollicular	B-X
region	B-X
)	B-X
were	B-X
positive	B-X
for	B-X
KPL1	B-X
.	B-X
Interestingly	B-X
,	B-X
plasma	B-X
cells	B-X
in	B-X
situ	B-X
and	B-X
interleukin-6-dependent	B-X
myeloma	B-X
cell	B-X
lines	B-X
were	B-X
KPL1	B-X
(	B-X
+	B-X
)	B-X
.	B-X
Thus	B-X
,	B-X
PSGL-1	B-X
is	B-X
expressed	B-X
on	B-X
essentially	B-X
all	B-X
blood	B-X
neutrophils	B-X
,	B-X
NK	B-X
cells	B-X
,	B-X
B	B-X
cells	B-X
,	B-X
T	B-X
cells	B-X
,	B-X
and	B-X
monocytes	B-X
.	B-X
Variation	B-X
in	B-X
tyrosine	B-X
sulfation	B-X
during	B-X
B-cell	B-X
differentiation	B-X
may	B-X
affect	B-X
the	B-X
ability	B-X
of	B-X
B	B-X
cells	B-X
to	B-X
interact	B-X
with	B-X
P-	B-X
and	B-X
L-selectin	B-X
.	B-X

Variation	O
in	O
tyrosine	O
sulfation	O
during	O
B	O
-	O
cell	O
differentiation	O
may	O
affect	O
the	O
ability	O
of	O
B	O
cells	O
to	O
interact	O
with	O
P	B-Protein
-	I-Protein
and	O
L	B-Protein
-	I-Protein
selectin	I-Protein
.	O

Modification	O
of	O
yeast	O
Cdc53p	B-Protein
by	O
the	O
ubiquitin	B-Protein
-	O
related	O
protein	O
rub1p	B-Protein
affects	O
function	O
of	O
the	O
SCFCdc4	B-Protein
complex	O
.	O
<EOS>	B-X
The	B-X
RUB1/NEDD-8	B-X
family	B-X
of	B-X
ubiquitin-related	B-X
genes	B-X
is	B-X
widely	B-X
represented	B-X
among	B-X
eukaryotes	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Cdc53p	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Cullin	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
is	B-X
stably	B-X
modified	B-X
by	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
a	B-X
single	B-X
Rub1p	B-X
molecule	B-X
.	B-X
Two	B-X
genes	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
are	B-X
required	B-X
for	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
.	B-X
The	B-X
first	B-X
gene	B-X
,	B-X
designated	B-X
ENR2	B-X
,	B-X
encodes	B-X
a	B-X
protein	B-X
with	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
amino-terminal	B-X
half	B-X
of	B-X
the	B-X
ubiquitin-activating	B-X
enzyme	B-X
.	B-X
By	B-X
analogy	B-X
with	B-X
Aos1p	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
Enr2p	B-X
functions	B-X
in	B-X
a	B-X
bipartite	B-X
Rub1p-activating	B-X
enzyme	B-X
.	B-X
The	B-X
second	B-X
gene	B-X
is	B-X
SKP1	B-X
,	B-X
shown	B-X
previously	B-X
to	B-X
be	B-X
required	B-X
for	B-X
some	B-X
ubiquitin-conjugation	B-X
events	B-X
.	B-X
A	B-X
deletion	B-X
allele	B-X
of	B-X
ENR2	B-X
is	B-X
lethal	B-X
with	B-X
temperature-sensitive	B-X
alleles	B-X
of	B-X
cdc34	B-X
and	B-X
enhances	B-X
the	B-X
phenotypes	B-X
of	B-X
cdc4	B-X
,	B-X
cdc53	B-X
,	B-X
and	B-X
skp1	B-X
,	B-X
strongly	B-X
implying	B-X
that	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
assembly	B-X
or	B-X
function	B-X
of	B-X
the	B-X
E3	B-X
complex	B-X
SCFCdc4	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
model	B-X
,	B-X
both	B-X
enr2delta	B-X
and	B-X
an	B-X
allele	B-X
of	B-X
Cdc53p	B-X
that	B-X
is	B-X
not	B-X
Rub1p	B-X
modified	B-X
,	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
alterations	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
Cdc4p	B-X
,	B-X
Cdc34p	B-X
,	B-X
and	B-X
Cdc53p	B-X
.	B-X

The	O
RUB1	B-Protein
/	O
NEDD	B-Protein
-	I-Protein
8	I-Protein
family	O
of	O
ubiquitin	B-Protein
-	O
related	O
genes	O
is	O
widely	O
represented	O
among	O
eukaryotes	O
.	O

Here	O
we	O
report	O
that	O
Cdc53p	B-Protein
in	O
Saccharomyces	O
cerevisiae	O
,	O
a	O
member	O
of	O
the	O
Cullin	O
family	O
of	O
proteins	O
,	O
is	O
stably	O
modified	O
by	O
the	O
covalent	O
attachment	O
of	O
a	O
single	O
Rub1p	B-Protein
molecule	O
.	O
<EOS>	B-X
The	B-X
RUB1/NEDD-8	B-X
family	B-X
of	B-X
ubiquitin-related	B-X
genes	B-X
is	B-X
widely	B-X
represented	B-X
among	B-X
eukaryotes	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Cdc53p	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Cullin	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
is	B-X
stably	B-X
modified	B-X
by	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
a	B-X
single	B-X
Rub1p	B-X
molecule	B-X
.	B-X
Two	B-X
genes	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
are	B-X
required	B-X
for	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
.	B-X
By	B-X
analogy	B-X
with	B-X
Aos1p	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
Enr2p	B-X
functions	B-X
in	B-X
a	B-X
bipartite	B-X
Rub1p-activating	B-X
enzyme	B-X
.	B-X
A	B-X
deletion	B-X
allele	B-X
of	B-X
ENR2	B-X
is	B-X
lethal	B-X
with	B-X
temperature-sensitive	B-X
alleles	B-X
of	B-X
cdc34	B-X
and	B-X
enhances	B-X
the	B-X
phenotypes	B-X
of	B-X
cdc4	B-X
,	B-X
cdc53	B-X
,	B-X
and	B-X
skp1	B-X
,	B-X
strongly	B-X
implying	B-X
that	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
assembly	B-X
or	B-X
function	B-X
of	B-X
the	B-X
E3	B-X
complex	B-X
SCFCdc4	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
model	B-X
,	B-X
both	B-X
enr2delta	B-X
and	B-X
an	B-X
allele	B-X
of	B-X
Cdc53p	B-X
that	B-X
is	B-X
not	B-X
Rub1p	B-X
modified	B-X
,	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
alterations	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
Cdc4p	B-X
,	B-X
Cdc34p	B-X
,	B-X
and	B-X
Cdc53p	B-X
.	B-X

Two	O
genes	O
have	O
been	O
identified	O
that	O
are	O
required	O
for	O
Rub1p	B-Protein
conjugation	O
to	O
Cdc53p	B-Protein
.	O
<EOS>	B-X
The	B-X
RUB1/NEDD-8	B-X
family	B-X
of	B-X
ubiquitin-related	B-X
genes	B-X
is	B-X
widely	B-X
represented	B-X
among	B-X
eukaryotes	B-X
.	B-X
Here	B-X
we	B-X
report	B-X
that	B-X
Cdc53p	B-X
in	B-X
Saccharomyces	B-X
cerevisiae	B-X
,	B-X
a	B-X
member	B-X
of	B-X
the	B-X
Cullin	B-X
family	B-X
of	B-X
proteins	B-X
,	B-X
is	B-X
stably	B-X
modified	B-X
by	B-X
the	B-X
covalent	B-X
attachment	B-X
of	B-X
a	B-X
single	B-X
Rub1p	B-X
molecule	B-X
.	B-X
Two	B-X
genes	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
are	B-X
required	B-X
for	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
.	B-X
By	B-X
analogy	B-X
with	B-X
Aos1p	B-X
,	B-X
we	B-X
infer	B-X
that	B-X
Enr2p	B-X
functions	B-X
in	B-X
a	B-X
bipartite	B-X
Rub1p-activating	B-X
enzyme	B-X
.	B-X
The	B-X
second	B-X
gene	B-X
is	B-X
SKP1	B-X
,	B-X
shown	B-X
previously	B-X
to	B-X
be	B-X
required	B-X
for	B-X
some	B-X
ubiquitin-conjugation	B-X
events	B-X
.	B-X
A	B-X
deletion	B-X
allele	B-X
of	B-X
ENR2	B-X
is	B-X
lethal	B-X
with	B-X
temperature-sensitive	B-X
alleles	B-X
of	B-X
cdc34	B-X
and	B-X
enhances	B-X
the	B-X
phenotypes	B-X
of	B-X
cdc4	B-X
,	B-X
cdc53	B-X
,	B-X
and	B-X
skp1	B-X
,	B-X
strongly	B-X
implying	B-X
that	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
assembly	B-X
or	B-X
function	B-X
of	B-X
the	B-X
E3	B-X
complex	B-X
SCFCdc4	B-X
.	B-X
Consistent	B-X
with	B-X
this	B-X
model	B-X
,	B-X
both	B-X
enr2delta	B-X
and	B-X
an	B-X
allele	B-X
of	B-X
Cdc53p	B-X
that	B-X
is	B-X
not	B-X
Rub1p	B-X
modified	B-X
,	B-X
render	B-X
cells	B-X
sensitive	B-X
to	B-X
alterations	B-X
in	B-X
the	B-X
levels	B-X
of	B-X
Cdc4p	B-X
,	B-X
Cdc34p	B-X
,	B-X
and	B-X
Cdc53p	B-X
.	B-X

The	O
first	O
gene	O
,	O
designated	O
ENR2	B-Protein
,	O
encodes	O
a	O
protein	O
with	O
sequence	O
similarity	O
to	O
the	O
amino	O
-	O
terminal	O
half	O
of	O
the	O
ubiquitin	B-Protein
-	O
activating	O
enzyme	O
.	O

By	O
analogy	O
with	O
Aos1p	B-Protein
,	O
we	O
infer	O
that	O
Enr2p	B-Protein
functions	O
in	O
a	O
bipartite	O
Rub1p	B-Protein
-	O
activating	O
enzyme	O
.	O

The	O
second	O
gene	O
is	O
SKP1	B-Protein
,	O
shown	O
previously	O
to	O
be	O
required	O
for	O
some	O
ubiquitin	B-Protein
-	O
conjugation	O
events	O
.	O
<EOS>	B-X
The	B-X
RUB1/NEDD-8	B-X
family	B-X
of	B-X
ubiquitin-related	B-X
genes	B-X
is	B-X
widely	B-X
represented	B-X
among	B-X
eukaryotes	B-X
.	B-X
Two	B-X
genes	B-X
have	B-X
been	B-X
identified	B-X
that	B-X
are	B-X
required	B-X
for	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
.	B-X
The	B-X
first	B-X
gene	B-X
,	B-X
designated	B-X
ENR2	B-X
,	B-X
encodes	B-X
a	B-X
protein	B-X
with	B-X
sequence	B-X
similarity	B-X
to	B-X
the	B-X
amino-terminal	B-X
half	B-X
of	B-X
the	B-X
ubiquitin-activating	B-X
enzyme	B-X
.	B-X
The	B-X
second	B-X
gene	B-X
is	B-X
SKP1	B-X
,	B-X
shown	B-X
previously	B-X
to	B-X
be	B-X
required	B-X
for	B-X
some	B-X
ubiquitin-conjugation	B-X
events	B-X
.	B-X
A	B-X
deletion	B-X
allele	B-X
of	B-X
ENR2	B-X
is	B-X
lethal	B-X
with	B-X
temperature-sensitive	B-X
alleles	B-X
of	B-X
cdc34	B-X
and	B-X
enhances	B-X
the	B-X
phenotypes	B-X
of	B-X
cdc4	B-X
,	B-X
cdc53	B-X
,	B-X
and	B-X
skp1	B-X
,	B-X
strongly	B-X
implying	B-X
that	B-X
Rub1p	B-X
conjugation	B-X
to	B-X
Cdc53p	B-X
is	B-X
required	B-X
for	B-X
optimal	B-X
assembly	B-X
or	B-X
function	B-X
of	B-X
the	B-X
E3	B-X
complex	B-X
SCFCdc4	B-X
.	B-X

A	O
deletion	O
allele	O
of	O
ENR2	B-Protein
is	O
lethal	O
with	O
temperature	O
-	O
sensitive	O
alleles	O
of	O
cdc34	B-Protein
and	O
enhances	O
the	O
phenotypes	O
of	O
cdc4	B-Protein
,	O
cdc53	B-Protein
,	O
and	O
skp1	B-Protein
,	O
strongly	O
implying	O
that	O
Rub1p	B-Protein
conjugation	O
to	O
Cdc53p	B-Protein
is	O
required	O
for	O
optimal	O
assembly	O
or	O
function	O
of	O
the	O
E3	O
complex	O
SCFCdc4	B-Protein
.	O
<EOS>	B-X
In	B-X
the	B-X
present	B-X
study	B-X
,	B-X
we	B-X
investigated	B-X
if	B-X
phosphorylation	B-X
regulates	B-X
Cdc34	B-X
function	B-X
.	B-X
We	B-X
mapped	B-X
the	B-X
in	B-X
vivo	B-X
phosphorylation	B-X
sites	B-X
on	B-X
budding	B-X
yeast	B-X
Cdc34	B-X
(	B-X
yCdc34	B-X
;	B-X
Ser207	B-X
and	B-X
Ser216	B-X
)	B-X
and	B-X
human	B-X
Cdc34	B-X
(	B-X
hCdc34	B-X
Ser203	B-X
,	B-X
Ser222	B-X
and	B-X
Ser231	B-X
)	B-X
to	B-X
serine	B-X
residues	B-X
in	B-X
the	B-X
acidic	B-X
tail	B-X
domain	B-X
,	B-X
a	B-X
region	B-X
that	B-X
is	B-X
critical	B-X
for	B-X
Cdc34	B-X
's	B-X
cell	B-X
cycle	B-X
function	B-X
.	B-X
CK2-mediated	B-X
phosphorylation	B-X
increased	B-X
yCdc34	B-X
ubiquitination	B-X
activity	B-X
towards	B-X
the	B-X
yeast	B-X
Saccharomyces	B-X
cerevisiae	B-X
Sic1	B-X
in	B-X
vitro	B-X
,	B-X
when	B-X
assayed	B-X
in	B-X
the	B-X
presence	B-X
of	B-X
its	B-X
cognate	B-X
SCFCdc4	B-X
E3	B-X
ligase	B-X
[	B-X
where	B-X
SCF	B-X
is	B-X
Skp1	B-X
(	B-X
S-phase	B-X
kinase-associated	B-X
protein	B-X
1	B-X
)	B-X
/cullin/F-box	B-X
]	B-X
.	B-X
Similarly	B-X
,	B-X
mutation	B-X
of	B-X
the	B-X
yCdc34	B-X
phosphorylation	B-X
sites	B-X
to	B-X
alanine	B-X
,	B-X
aspartate	B-X
or	B-X
glutamate	B-X
residues	B-X
altered	B-X
Cdc34-SCFCdc4-mediated	B-X
Sic1	B-X
ubiquitination	B-X
activity	B-X
.	B-X
Similar	B-X
results	B-X
were	B-X
obtained	B-X
when	B-X
yCdc34	B-X
's	B-X
ubiquitination	B-X
activity	B-X
was	B-X
assayed	B-X
in	B-X
the	B-X
absence	B-X
of	B-X
SCFCdc4	B-X
,	B-X
indicating	B-X
that	B-X
phosphorylation	B-X
regulates	B-X
the	B-X
intrinsic	B-X
catalytic	B-X
activity	B-X
of	B-X
Cdc34	B-X
.	B-X
To	B-X
evaluate	B-X
the	B-X
in	B-X
vivo	B-X
consequences	B-X
of	B-X
altered	B-X
Cdc34	B-X
activity	B-X
,	B-X
wild-type	B-X
yCdc34	B-X
and	B-X
the	B-X
phosphosite	B-X
mutants	B-X
were	B-X
introduced	B-X
into	B-X
an	B-X
S.	B-X
cerevisiae	B-X
cdc34	B-X
deletion	B-X
strain	B-X
and	B-X
,	B-X
following	B-X
synchronization	B-X
in	B-X
G1-phase	B-X
,	B-X
progression	B-X
through	B-X
the	B-X
cell	B-X
cycle	B-X
was	B-X
monitored	B-X
.	B-X
These	B-X
studies	B-X
demonstrate	B-X
that	B-X
CK2-mediated	B-X
phosphorylation	B-X
of	B-X
Cdc34	B-X
on	B-X
the	B-X
acidic	B-X
tail	B-X
domain	B-X
stimulates	B-X
Cdc34-SCFCdc4	B-X
ubiquitination	B-X
activity	B-X
and	B-X
cell	B-X
cycle	B-X
progression	B-X
.	B-X

Consistent	O
with	O
this	O
model	O
,	O
both	O
enr2delta	B-Protein
and	O
an	O
allele	O
of	O
Cdc53p	B-Protein
that	O
is	O
not	O
Rub1p	B-Protein
modified	O
,	O
render	O
cells	O
sensitive	O
to	O
alterations	O
in	O
the	O
levels	O
of	O
Cdc4p	B-Protein
,	O
Cdc34p	B-Protein
,	O
and	O
Cdc53p	B-Protein
.	O

A	O
novel	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
,	O
that	O
is	O
prenylated	O
and	O
contains	O
homology	O
to	O
cPLA2	B-Protein
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
membrane-bound	B-X
,	B-X
calcium-independent	B-X
PLA2	B-X
,	B-X
named	B-X
cPLA2-gamma	B-X
.	B-X
The	B-X
sequence	B-X
encodes	B-X
a	B-X
541-amino	B-X
acid	B-X
protein	B-X
containing	B-X
a	B-X
domain	B-X
with	B-X
significant	B-X
homology	B-X
to	B-X
the	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
85-kDa	B-X
cPLA2	B-X
(	B-X
cPLA2-alpha	B-X
)	B-X
.	B-X
cPLA2-gamma	B-X
does	B-X
not	B-X
contain	B-X
the	B-X
regulatory	B-X
calcium-dependent	B-X
lipid	B-X
binding	B-X
(	B-X
CaLB	B-X
)	B-X
domain	B-X
found	B-X
in	B-X
cPLA2-alpha	B-X
.	B-X
However	B-X
,	B-X
cPLA2-gamma	B-X
does	B-X
contain	B-X
two	B-X
consensus	B-X
motifs	B-X
for	B-X
lipid	B-X
modification	B-X
,	B-X
a	B-X
prenylation	B-X
motif	B-X
(	B-X
-CCLA	B-X
)	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
and	B-X
a	B-X
myristoylation	B-X
site	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
is	B-X
incorporated	B-X
into	B-X
the	B-X
prenylation	B-X
motif	B-X
of	B-X
cPLA2-gamma	B-X
.	B-X
Interestingly	B-X
,	B-X
cPLA2-gamma	B-X
demonstrates	B-X
a	B-X
preference	B-X
for	B-X
arachidonic	B-X
acid	B-X
at	B-X
the	B-X
sn-2	B-X
position	B-X
of	B-X
phosphatidylcholine	B-X
as	B-X
compared	B-X
with	B-X
palmitic	B-X
acid	B-X
.	B-X
cPLA2-gamma	B-X
encodes	B-X
a	B-X
3-kilobase	B-X
message	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X
Identification	B-X
of	B-X
cPLA2-gamma	B-X
reveals	B-X
a	B-X
newly	B-X
defined	B-X
family	B-X
of	B-X
phospholipases	B-X
A2	B-X
with	B-X
homology	B-X
to	B-X
cPLA2-alpha	B-X
.	B-X

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
membrane	O
-	O
bound	O
,	O
calcium	O
-	O
independent	O
PLA2	O
,	O
named	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
membrane-bound	B-X
,	B-X
calcium-independent	B-X
PLA2	B-X
,	B-X
named	B-X
cPLA2-gamma	B-X
.	B-X
The	B-X
sequence	B-X
encodes	B-X
a	B-X
541-amino	B-X
acid	B-X
protein	B-X
containing	B-X
a	B-X
domain	B-X
with	B-X
significant	B-X
homology	B-X
to	B-X
the	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
85-kDa	B-X
cPLA2	B-X
(	B-X
cPLA2-alpha	B-X
)	B-X
.	B-X
cPLA2-gamma	B-X
does	B-X
not	B-X
contain	B-X
the	B-X
regulatory	B-X
calcium-dependent	B-X
lipid	B-X
binding	B-X
(	B-X
CaLB	B-X
)	B-X
domain	B-X
found	B-X
in	B-X
cPLA2-alpha	B-X
.	B-X
However	B-X
,	B-X
cPLA2-gamma	B-X
does	B-X
contain	B-X
two	B-X
consensus	B-X
motifs	B-X
for	B-X
lipid	B-X
modification	B-X
,	B-X
a	B-X
prenylation	B-X
motif	B-X
(	B-X
-CCLA	B-X
)	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
and	B-X
a	B-X
myristoylation	B-X
site	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
is	B-X
incorporated	B-X
into	B-X
the	B-X
prenylation	B-X
motif	B-X
of	B-X
cPLA2-gamma	B-X
.	B-X
Interestingly	B-X
,	B-X
cPLA2-gamma	B-X
demonstrates	B-X
a	B-X
preference	B-X
for	B-X
arachidonic	B-X
acid	B-X
at	B-X
the	B-X
sn-2	B-X
position	B-X
of	B-X
phosphatidylcholine	B-X
as	B-X
compared	B-X
with	B-X
palmitic	B-X
acid	B-X
.	B-X
cPLA2-gamma	B-X
encodes	B-X
a	B-X
3-kilobase	B-X
message	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X
Identification	B-X
of	B-X
cPLA2-gamma	B-X
reveals	B-X
a	B-X
newly	B-X
defined	B-X
family	B-X
of	B-X
phospholipases	B-X
A2	B-X
with	B-X
homology	B-X
to	B-X
cPLA2-alpha	B-X
.	B-X

The	O
sequence	O
encodes	O
a	O
541	O
-	O
amino	O
acid	O
protein	O
containing	O
a	O
domain	O
with	O
significant	O
homology	O
to	O
the	O
catalytic	O
domain	O
of	O
the	O
85	O
-	O
kDa	O
cPLA2	B-Protein
(	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
)	O
.	O

cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
does	O
not	O
contain	O
the	O
regulatory	O
calcium	O
-	O
dependent	O
lipid	O
binding	O
(	O
CaLB	O
)	O
domain	O
found	O
in	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
Polymerase	B-X
I	B-X
and	B-X
transcript	B-X
release	B-X
factor	B-X
(	B-X
PTRF	B-X
)	B-X
plays	B-X
a	B-X
pivotal	B-X
role	B-X
in	B-X
regulating	B-X
cellular	B-X
senescence	B-X
,	B-X
glucose	B-X
intolerance	B-X
,	B-X
lipid	B-X
metabolism	B-X
,	B-X
and	B-X
mitochondrial	B-X
bioenergetics	B-X
,	B-X
but	B-X
its	B-X
mechanism	B-X
,	B-X
characteristics	B-X
,	B-X
and	B-X
functions	B-X
in	B-X
neuronal	B-X
cells	B-X
following	B-X
the	B-X
cerebral	B-X
ischemia-reperfusion	B-X
(	B-X
I/R	B-X
)	B-X
injury	B-X
remain	B-X
to	B-X
be	B-X
determined	B-X
.	B-X
Based	B-X
on	B-X
Western	B-X
blotting	B-X
,	B-X
immunofluorescence	B-X
,	B-X
enzyme-linked	B-X
immunosorbent	B-X
assay	B-X
,	B-X
and	B-X
liquid	B-X
chromatography-mass	B-X
spectrometry	B-X
(	B-X
LC-MS	B-X
)	B-X
analysis	B-X
results	B-X
,	B-X
we	B-X
found	B-X
that	B-X
LMP	B-X
was	B-X
presented	B-X
in	B-X
the	B-X
ischemic	B-X
distal	B-X
portion	B-X
of	B-X
random-pattern	B-X
skin	B-X
flaps	B-X
,	B-X
which	B-X
leads	B-X
to	B-X
disruption	B-X
of	B-X
lysosomal	B-X
function	B-X
and	B-X
macroautophagic/autophagic	B-X
flux	B-X
,	B-X
increased	B-X
necroptosis	B-X
,	B-X
and	B-X
aggravated	B-X
necrosis	B-X
of	B-X
the	B-X
ischemic	B-X
flaps	B-X
.	B-X
Moreover	B-X
,	B-X
bioinformatics	B-X
analysis	B-X
of	B-X
the	B-X
LC-MS	B-X
results	B-X
enabled	B-X
us	B-X
to	B-X
focus	B-X
on	B-X
the	B-X
role	B-X
of	B-X
PLA2G4E/cPLA2	B-X
(	B-X
phospholipase	B-X
A2	B-X
,	B-X
group	B-X
IVE	B-X
)	B-X
in	B-X
LMP	B-X
of	B-X
the	B-X
ischemic	B-X
flaps	B-X
.	B-X
The	B-X
activation	B-X
of	B-X
calcium-dependent	B-X
cytosolic	B-X
phospholipase	B-X
A	B-X

However	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
does	O
contain	O
two	O
consensus	O
motifs	O
for	O
lipid	O
modification	O
,	O
a	O
prenylation	O
motif	O
(	O
-	O
CCLA	O
)	O
at	O
the	O
C	O
terminus	O
and	O
a	O
myristoylation	O
site	O
at	O
the	O
N	O
terminus	O
.	O

We	O
present	O
evidence	O
that	O
the	O
isoprenoid	O
precursor	O
[	O
3H	O
]	O
mevalonolactone	O
is	O
incorporated	O
into	O
the	O
prenylation	O
motif	O
of	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
membrane-bound	B-X
,	B-X
calcium-independent	B-X
PLA2	B-X
,	B-X
named	B-X
cPLA2-gamma	B-X
.	B-X
The	B-X
sequence	B-X
encodes	B-X
a	B-X
541-amino	B-X
acid	B-X
protein	B-X
containing	B-X
a	B-X
domain	B-X
with	B-X
significant	B-X
homology	B-X
to	B-X
the	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
85-kDa	B-X
cPLA2	B-X
(	B-X
cPLA2-alpha	B-X
)	B-X
.	B-X
cPLA2-gamma	B-X
does	B-X
not	B-X
contain	B-X
the	B-X
regulatory	B-X
calcium-dependent	B-X
lipid	B-X
binding	B-X
(	B-X
CaLB	B-X
)	B-X
domain	B-X
found	B-X
in	B-X
cPLA2-alpha	B-X
.	B-X
However	B-X
,	B-X
cPLA2-gamma	B-X
does	B-X
contain	B-X
two	B-X
consensus	B-X
motifs	B-X
for	B-X
lipid	B-X
modification	B-X
,	B-X
a	B-X
prenylation	B-X
motif	B-X
(	B-X
-CCLA	B-X
)	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
and	B-X
a	B-X
myristoylation	B-X
site	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
is	B-X
incorporated	B-X
into	B-X
the	B-X
prenylation	B-X
motif	B-X
of	B-X
cPLA2-gamma	B-X
.	B-X
Interestingly	B-X
,	B-X
cPLA2-gamma	B-X
demonstrates	B-X
a	B-X
preference	B-X
for	B-X
arachidonic	B-X
acid	B-X
at	B-X
the	B-X
sn-2	B-X
position	B-X
of	B-X
phosphatidylcholine	B-X
as	B-X
compared	B-X
with	B-X
palmitic	B-X
acid	B-X
.	B-X
cPLA2-gamma	B-X
encodes	B-X
a	B-X
3-kilobase	B-X
message	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X
Identification	B-X
of	B-X
cPLA2-gamma	B-X
reveals	B-X
a	B-X
newly	B-X
defined	B-X
family	B-X
of	B-X
phospholipases	B-X
A2	B-X
with	B-X
homology	B-X
to	B-X
cPLA2-alpha	B-X
.	B-X

Interestingly	O
,	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
demonstrates	O
a	O
preference	O
for	O
arachidonic	O
acid	O
at	O
the	O
sn	O
-	O
2	O
position	O
of	O
phosphatidylcholine	O
as	O
compared	O
with	O
palmitic	O
acid	O
.	O

cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
encodes	O
a	O
3	O
-	O
kilobase	O
message	O
,	O
which	O
is	O
highly	O
expressed	O
in	O
heart	O
and	O
skeletal	O
muscle	O
,	O
suggesting	O
a	O
specific	O
role	O
in	O
these	O
tissues	O
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
membrane-bound	B-X
,	B-X
calcium-independent	B-X
PLA2	B-X
,	B-X
named	B-X
cPLA2-gamma	B-X
.	B-X
The	B-X
sequence	B-X
encodes	B-X
a	B-X
541-amino	B-X
acid	B-X
protein	B-X
containing	B-X
a	B-X
domain	B-X
with	B-X
significant	B-X
homology	B-X
to	B-X
the	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
85-kDa	B-X
cPLA2	B-X
(	B-X
cPLA2-alpha	B-X
)	B-X
.	B-X
cPLA2-gamma	B-X
does	B-X
not	B-X
contain	B-X
the	B-X
regulatory	B-X
calcium-dependent	B-X
lipid	B-X
binding	B-X
(	B-X
CaLB	B-X
)	B-X
domain	B-X
found	B-X
in	B-X
cPLA2-alpha	B-X
.	B-X
However	B-X
,	B-X
cPLA2-gamma	B-X
does	B-X
contain	B-X
two	B-X
consensus	B-X
motifs	B-X
for	B-X
lipid	B-X
modification	B-X
,	B-X
a	B-X
prenylation	B-X
motif	B-X
(	B-X
-CCLA	B-X
)	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
and	B-X
a	B-X
myristoylation	B-X
site	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
is	B-X
incorporated	B-X
into	B-X
the	B-X
prenylation	B-X
motif	B-X
of	B-X
cPLA2-gamma	B-X
.	B-X
Interestingly	B-X
,	B-X
cPLA2-gamma	B-X
demonstrates	B-X
a	B-X
preference	B-X
for	B-X
arachidonic	B-X
acid	B-X
at	B-X
the	B-X
sn-2	B-X
position	B-X
of	B-X
phosphatidylcholine	B-X
as	B-X
compared	B-X
with	B-X
palmitic	B-X
acid	B-X
.	B-X
cPLA2-gamma	B-X
encodes	B-X
a	B-X
3-kilobase	B-X
message	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X
Identification	B-X
of	B-X
cPLA2-gamma	B-X
reveals	B-X
a	B-X
newly	B-X
defined	B-X
family	B-X
of	B-X
phospholipases	B-X
A2	B-X
with	B-X
homology	B-X
to	B-X
cPLA2-alpha	B-X
.	B-X

Identification	O
of	O
cPLA2	B-Protein
-	I-Protein
gamma	I-Protein
reveals	O
a	O
newly	O
defined	O
family	O
of	O
phospholipases	O
A2	O
with	O
homology	O
to	O
cPLA2	B-Protein
-	I-Protein
alpha	I-Protein
.	O
<EOS>	B-X
We	B-X
report	B-X
the	B-X
cloning	B-X
and	B-X
characterization	B-X
of	B-X
a	B-X
novel	B-X
membrane-bound	B-X
,	B-X
calcium-independent	B-X
PLA2	B-X
,	B-X
named	B-X
cPLA2-gamma	B-X
.	B-X
The	B-X
sequence	B-X
encodes	B-X
a	B-X
541-amino	B-X
acid	B-X
protein	B-X
containing	B-X
a	B-X
domain	B-X
with	B-X
significant	B-X
homology	B-X
to	B-X
the	B-X
catalytic	B-X
domain	B-X
of	B-X
the	B-X
85-kDa	B-X
cPLA2	B-X
(	B-X
cPLA2-alpha	B-X
)	B-X
.	B-X
cPLA2-gamma	B-X
does	B-X
not	B-X
contain	B-X
the	B-X
regulatory	B-X
calcium-dependent	B-X
lipid	B-X
binding	B-X
(	B-X
CaLB	B-X
)	B-X
domain	B-X
found	B-X
in	B-X
cPLA2-alpha	B-X
.	B-X
However	B-X
,	B-X
cPLA2-gamma	B-X
does	B-X
contain	B-X
two	B-X
consensus	B-X
motifs	B-X
for	B-X
lipid	B-X
modification	B-X
,	B-X
a	B-X
prenylation	B-X
motif	B-X
(	B-X
-CCLA	B-X
)	B-X
at	B-X
the	B-X
C	B-X
terminus	B-X
and	B-X
a	B-X
myristoylation	B-X
site	B-X
at	B-X
the	B-X
N	B-X
terminus	B-X
.	B-X
We	B-X
present	B-X
evidence	B-X
that	B-X
the	B-X
isoprenoid	B-X
precursor	B-X
[	B-X
3H	B-X
]	B-X
mevalonolactone	B-X
is	B-X
incorporated	B-X
into	B-X
the	B-X
prenylation	B-X
motif	B-X
of	B-X
cPLA2-gamma	B-X
.	B-X
Interestingly	B-X
,	B-X
cPLA2-gamma	B-X
demonstrates	B-X
a	B-X
preference	B-X
for	B-X
arachidonic	B-X
acid	B-X
at	B-X
the	B-X
sn-2	B-X
position	B-X
of	B-X
phosphatidylcholine	B-X
as	B-X
compared	B-X
with	B-X
palmitic	B-X
acid	B-X
.	B-X
cPLA2-gamma	B-X
encodes	B-X
a	B-X
3-kilobase	B-X
message	B-X
,	B-X
which	B-X
is	B-X
highly	B-X
expressed	B-X
in	B-X
heart	B-X
and	B-X
skeletal	B-X
muscle	B-X
,	B-X
suggesting	B-X
a	B-X
specific	B-X
role	B-X
in	B-X
these	B-X
tissues	B-X
.	B-X
Identification	B-X
of	B-X
cPLA2-gamma	B-X
reveals	B-X
a	B-X
newly	B-X
defined	B-X
family	B-X
of	B-X
phospholipases	B-X
A2	B-X
with	B-X
homology	B-X
to	B-X
cPLA2-alpha	B-X
.	B-X

A	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X
In	B-X
recent	B-X
years	B-X
,	B-X
technological	B-X
advances	B-X
have	B-X
increased	B-X
the	B-X
accessibility	B-X
of	B-X
genetic	B-X
testing	B-X
for	B-X
mutations	B-X
in	B-X
the	B-X
gene	B-X
that	B-X
lead	B-X
to	B-X
this	B-X
disorder	B-X
.	B-X
The	B-X
disorder	B-X
itself	B-X
,	B-X
approaches	B-X
for	B-X
its	B-X
detection	B-X
and	B-X
the	B-X
steps	B-X
and	B-X
the	B-X
rationale	B-X
behind	B-X
testing	B-X
are	B-X
outlined	B-X
in	B-X
this	B-X
review	B-X
.	B-X
All	B-X
mutations	B-X
in	B-X
the	B-X
choroideremia	B-X
gene	B-X
result	B-X
in	B-X
the	B-X
truncation	B-X
or	B-X
absence	B-X
of	B-X
the	B-X
normal	B-X
protein	B-X
product	B-X
Rab	B-X
escort	B-X
protein-1	B-X
,	B-X
which	B-X
is	B-X
a	B-X
component	B-X
of	B-X
Rab	B-X
geranylgeranyltransferase	B-X
,	B-X
an	B-X
enzyme	B-X
complex	B-X
that	B-X
mediates	B-X
correct	B-X
intracellular	B-X
vesicular	B-X
transport	B-X
.	B-X
Sequence	B-X
analysis	B-X
of	B-X
the	B-X
15	B-X
exons	B-X
of	B-X
the	B-X
choroideremia	B-X
gene	B-X
and	B-X
adjacent	B-X
splice	B-X
sites	B-X
is	B-X
a	B-X
primary	B-X
method	B-X
of	B-X
mutation	B-X
detection	B-X
used	B-X
by	B-X
the	B-X
authors	B-X
'	B-X
laboratory	B-X
,	B-X
through	B-X
which	B-X
a	B-X
variety	B-X
of	B-X
mutations	B-X
including	B-X
nonsense	B-X
mutations	B-X
,	B-X
insertions	B-X
,	B-X
deletions	B-X
and	B-X
splice	B-X
site	B-X
alterations	B-X
have	B-X
been	B-X
detected	B-X
.	B-X
Alternatively	B-X
,	B-X
if	B-X
no	B-X
mutations	B-X
are	B-X
revealed	B-X
using	B-X
this	B-X
approach	B-X
,	B-X
reverse	B-X
transcription	B-X
PCR	B-X
,	B-X
northern	B-X
blot	B-X
analysis	B-X
or	B-X
a	B-X
protein	B-X
truncation	B-X
test	B-X
can	B-X
be	B-X
employed	B-X
to	B-X
detect	B-X
aberrantly	B-X
spliced	B-X
products	B-X
.	B-X
Deletions	B-X
create	B-X
a	B-X
practical	B-X
problem	B-X
in	B-X
assessing	B-X
the	B-X
carrier	B-X
status	B-X
of	B-X
females	B-X
;	B-X
linkage	B-X
analysis	B-X
with	B-X
closely	B-X
linked	B-X
markers	B-X
is	B-X
the	B-X
most	B-X
practical	B-X
approach	B-X
in	B-X
these	B-X
cases	B-X
.	B-X

OBJECTIVE	O
:	O
This	O
study	O
aimed	O
to	O
establish	O
a	O
practical	O
diagnostic	O
test	O
for	O
choroideremia	O
(	O
CHM	O
)	O
and	O
to	O
show	O
its	O
application	O
in	O
a	O
family	O
with	O
the	O
clinical	O
diagnosis	O
of	O
choroideremia	O
.	O

DESIGN	O
:	O
Case	O
series	O
.	O
<EOS>	B-X
A	B-X
case	B-X
series	B-X
is	B-X
a	B-X
descriptive	B-X
study	B-X
that	B-X
follows	B-X
a	B-X
group	B-X
of	B-X
patients	B-X
who	B-X
have	B-X
a	B-X
similar	B-X
diagnosis	B-X
or	B-X
who	B-X
are	B-X
undergoing	B-X
the	B-X
same	B-X
procedure	B-X
over	B-X
a	B-X
certain	B-X
period	B-X
of	B-X
time	B-X
.	B-X
Results	B-X
of	B-X
case	B-X
series	B-X
can	B-X
generate	B-X
hypotheses	B-X
that	B-X
are	B-X
useful	B-X
in	B-X
designing	B-X
further	B-X
studies	B-X
,	B-X
including	B-X
randomized	B-X
controlled	B-X
trials	B-X
.	B-X
However	B-X
,	B-X
no	B-X
causal	B-X
inferences	B-X
should	B-X
be	B-X
made	B-X
from	B-X
case	B-X
series	B-X
regarding	B-X
the	B-X
efficacy	B-X
of	B-X
the	B-X
investigated	B-X
treatment	B-X
.	B-X
This	B-X
article	B-X
will	B-X
provide	B-X
principles	B-X
for	B-X
the	B-X
design	B-X
,	B-X
analysis	B-X
,	B-X
and	B-X
reporting	B-X
of	B-X
case	B-X
series	B-X
,	B-X
illustrated	B-X
by	B-X
examples	B-X
from	B-X
the	B-X
orthopaedic	B-X
surgical	B-X
literature	B-X
.	B-X

PARTICIPANTS	O
:	O
Sixteen	O
males	O
from	O
13	O
families	O
with	O
clinically	O
documented	O
CHM	O
and	O
unaffected	O
normal	O
males	O
were	O
enrolled	O
in	O
this	O
study	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X

METHODS	O
:	O
Protein	O
extracted	O
from	O
either	O
leukocytes	O
or	O
Epstein	O
-	O
Barr	O
virus	O
-	O
transformed	O
lymphocytes	O
was	O
subjected	O
to	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O
<EOS>	B-X
Proteins	B-X
with	B-X
bioactive	B-X
effects	B-X
include	B-X
lectins	B-X
,	B-X
fungal	B-X
immunomodulatory	B-X
proteins	B-X
(	B-X
FIPs	B-X
)	B-X
,	B-X
ribosome	B-X
inactivating	B-X
proteins	B-X
(	B-X
RIPs	B-X
)	B-X
,	B-X
ribonucleases	B-X
,	B-X
laccases	B-X
,	B-X
among	B-X
others	B-X
.	B-X
The	B-X
original	B-X
Intra-Spin	B-X
L-PRF	B-X
showed	B-X
a	B-X
strongly	B-X
polymerized	B-X
thick	B-X
fibrin	B-X
matrix	B-X
and	B-X
all	B-X
cells	B-X
appeared	B-X
alive	B-X
with	B-X
a	B-X
normal	B-X
shape	B-X
,	B-X
including	B-X
the	B-X
textured	B-X
surface	B-X
aspect	B-X
of	B-X
activated	B-X
lymphocytes	B-X
.	B-X
The	B-X
A-PRF	B-X
,	B-X
Salvin	B-X
and	B-X
LW	B-X
PRF-like	B-X
membranes	B-X
presented	B-X
a	B-X
lightly	B-X
polymerized	B-X
slim	B-X
fibrin	B-X
gel	B-X
and	B-X
most	B-X
of	B-X
the	B-X
visible	B-X
cell	B-X
bodies	B-X
appeared	B-X
destroyed	B-X
(	B-X
squashed	B-X
or	B-X
shrunk	B-X
)	B-X
.	B-X
Finally	B-X
,	B-X
the	B-X
comparison	B-X
between	B-X
the	B-X
total	B-X
released	B-X
amounts	B-X
and	B-X
the	B-X
initial	B-X
content	B-X
of	B-X
the	B-X
membrane	B-X
(	B-X
after	B-X
forcible	B-X
extraction	B-X
)	B-X
highlighted	B-X
that	B-X
the	B-X
leukocytes	B-X
living	B-X
in	B-X
the	B-X
fibrin	B-X
matrix	B-X
are	B-X
involved	B-X
in	B-X
the	B-X
production	B-X
of	B-X
significant	B-X
amounts	B-X
of	B-X
growth	B-X
factors	B-X
.	B-X

Immunoblot	O
analysis	O
of	O
the	O
protein	O
was	O
performed	O
with	O
two	O
monoclonal	O
antibodies	O
,	O
one	O
against	O
the	O
CHM	B-Protein
gene	O
product	O
,	O
Rab	B-Protein
escort	I-Protein
protein	I-Protein
-	I-Protein
1	I-Protein
(	O
REP	B-Protein
-	I-Protein
1	I-Protein
)	O
,	O
and	O
the	O
other	O
against	O
the	O
alpha	O
-	O
subunit	O
of	O
farnesyl	O
transferase	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X

DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
and	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
-	O
single	O
stranded	O
conformation	O
polymorphism	O
analysis	O
using	O
primers	O
for	O
the	O
exons	O
of	O
the	O
CHM	B-Protein
gene	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X

Where	O
altered	O
mobility	O
of	O
the	O
DNA	O
fragments	O
was	O
detected	O
,	O
direct	O
sequencing	O
of	O
that	O
exon	O
was	O
compared	O
with	O
the	O
published	O
normal	O
sequence	O
.	O

RESULTS	O
:	O
The	O
authors	O
detected	O
REP	B-Protein
-	I-Protein
1	I-Protein
in	O
protein	O
samples	O
extracted	O
from	O
lymphoblastoid	O
cell	O
lines	O
from	O
female	O
carriers	O
but	O
not	O
from	O
CHM	O
males	O
.	O

The	O
authors	O
also	O
showed	O
the	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
in	O
the	O
peripheral	O
leukocytes	O
of	O
males	O
affected	O
with	O
CHM	O
.	O

In	O
one	O
male	O
who	O
lacked	O
REP	B-Protein
-	I-Protein
1	I-Protein
,	O
direct	O
sequencing	O
of	O
exon	O
7	O
showed	O
a	O
cytosine	O
-	O
to	O
-	O
thymine	O
transition	O
mutation	O
(	O
Arg293X	O
)	O
in	O
the	O
CHM	B-Protein
gene	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X

CONCLUSIONS	O
:	O
The	O
clinical	O
diagnosis	O
of	O
CHM	O
can	O
be	O
confirmed	O
simply	O
by	O
immunoblot	O
analysis	O
with	O
anti	O
-	O
REP	B-Protein
-	I-Protein
1	I-Protein
antibody	O
,	O
showing	O
the	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
protein	O
in	O
peripheral	O
blood	O
samples	O
.	O
<EOS>	B-X
This	B-X
study	B-X
aimed	B-X
to	B-X
establish	B-X
a	B-X
practical	B-X
diagnostic	B-X
test	B-X
for	B-X
choroideremia	B-X
(	B-X
CHM	B-X
)	B-X
and	B-X
to	B-X
show	B-X
its	B-X
application	B-X
in	B-X
a	B-X
family	B-X
with	B-X
the	B-X
clinical	B-X
diagnosis	B-X
of	B-X
choroideremia	B-X
.	B-X

Because	O
all	O
known	O
mutations	O
in	O
the	O
CHM	B-Protein
gene	O
create	O
stop	O
codons	O
that	O
truncate	O
the	O
protein	O
product	O
and	O
result	O
in	O
absence	O
of	O
REP	B-Protein
-	I-Protein
1	I-Protein
,	O
the	O
authors	O
predict	O
that	O
most	O
patients	O
with	O
CHM	O
can	O
be	O
diagnosed	O
by	O
this	O
procedure	O
.	O

Mutations	O
in	O
orthologous	O
genes	O
in	O
human	O
spondyloepimetaphyseal	O
dysplasia	O
and	O
the	O
brachymorphic	O
mouse	O
.	O
<EOS>	B-X
The	B-X
osteochondrodysplasias	B-X
are	B-X
a	B-X
genetically	B-X
heterogeneous	B-X
group	B-X
of	B-X
disorders	B-X
affecting	B-X
skeletal	B-X
development	B-X
,	B-X
linear	B-X
growth	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cartilage	B-X
and	B-X
bone	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
large	B-X
inbred	B-X
Pakistani	B-X
family	B-X
with	B-X
a	B-X
distinct	B-X
form	B-X
of	B-X
recessively	B-X
inherited	B-X
spondyloepimetaphyseal	B-X
dysplasia	B-X
(	B-X
SEMD	B-X
)	B-X
and	B-X
mapped	B-X
a	B-X
gene	B-X
associated	B-X
with	B-X
this	B-X
dwarfing	B-X
condition	B-X
to	B-X
chromosome	B-X
10q23-24	B-X
,	B-X
a	B-X
region	B-X
syntenic	B-X
with	B-X
the	B-X
locus	B-X
for	B-X
the	B-X
brachymorphic	B-X
mutation	B-X
on	B-X
mouse	B-X
chromosome	B-X
19	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
orthologous	B-X
genes	B-X
,	B-X
ATPSK2	B-X
and	B-X
Atpsk2	B-X
,	B-X
encoding	B-X
novel	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
orthologues	B-X
in	B-X
the	B-X
respective	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
genomes	B-X
.	B-X
We	B-X
characterized	B-X
a	B-X
nonsense	B-X
mutation	B-X
in	B-X
ATPSK2	B-X
in	B-X
the	B-X
SEMD	B-X
family	B-X
and	B-X
a	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
region	B-X
of	B-X
Atpsk2	B-X
encoding	B-X
the	B-X
APS	B-X
kinase	B-X
activity	B-X
in	B-X
the	B-X
brachymorphic	B-X
mouse	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

The	O
osteochondrodysplasias	O
are	O
a	O
genetically	O
heterogeneous	O
group	O
of	O
disorders	O
affecting	O
skeletal	O
development	O
,	O
linear	O
growth	O
and	O
the	O
maintenance	O
of	O
cartilage	O
and	O
bone	O
.	O
<EOS>	B-X
In	B-X
brain	B-X
and	B-X
skin	B-X
PAPSS1	B-X
is	B-X
the	B-X
major	B-X
expressed	B-X
isoform	B-X
,	B-X
whereas	B-X
in	B-X
liver	B-X
,	B-X
cartilage	B-X
and	B-X
adrenal	B-X
glands	B-X
PAPSS2	B-X
isoform	B-X
expression	B-X
predominates	B-X
and	B-X
in	B-X
various	B-X
other	B-X
tissues	B-X
the	B-X
proportions	B-X
of	B-X
the	B-X
isoform	B-X
expressions	B-X
is	B-X
purported	B-X
to	B-X
vary	B-X
.	B-X
The	B-X
deficiency	B-X
of	B-X
PAPSS2	B-X
results	B-X
in	B-X
osteochondrodysplasias	B-X
.	B-X
Osteochondrodysplasias	B-X
are	B-X
genetically	B-X
heterogeneous	B-X
group	B-X
of	B-X
disorders	B-X
that	B-X
affects	B-X
skeletal	B-X
development	B-X
,	B-X
linear	B-X
growth	B-X
,	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cartilage	B-X
and	B-X
bone	B-X
.	B-X
The	B-X
osteochondrodysplasias	B-X
are	B-X
a	B-X
genetically	B-X
heterogeneous	B-X
group	B-X
of	B-X
disorders	B-X
affecting	B-X
skeletal	B-X
development	B-X
,	B-X
linear	B-X
growth	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cartilage	B-X
and	B-X
bone	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

We	O
have	O
studied	O
a	O
large	O
inbred	O
Pakistani	O
family	O
with	O
a	O
distinct	O
form	O
of	O
recessively	O
inherited	O
spondyloepimetaphyseal	O
dysplasia	O
(	O
SEMD	O
)	O
and	O
mapped	O
a	O
gene	O
associated	O
with	O
this	O
dwarfing	O
condition	O
to	O
chromosome	O
10q23	O
-	O
24	O
,	O
a	O
region	O
syntenic	O
with	O
the	O
locus	O
for	O
the	O
brachymorphic	O
mutation	O
on	O
mouse	O
chromosome	O
19	O
.	O
<EOS>	B-X
The	B-X
osteochondrodysplasias	B-X
are	B-X
a	B-X
genetically	B-X
heterogeneous	B-X
group	B-X
of	B-X
disorders	B-X
affecting	B-X
skeletal	B-X
development	B-X
,	B-X
linear	B-X
growth	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cartilage	B-X
and	B-X
bone	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
large	B-X
inbred	B-X
Pakistani	B-X
family	B-X
with	B-X
a	B-X
distinct	B-X
form	B-X
of	B-X
recessively	B-X
inherited	B-X
spondyloepimetaphyseal	B-X
dysplasia	B-X
(	B-X
SEMD	B-X
)	B-X
and	B-X
mapped	B-X
a	B-X
gene	B-X
associated	B-X
with	B-X
this	B-X
dwarfing	B-X
condition	B-X
to	B-X
chromosome	B-X
10q23-24	B-X
,	B-X
a	B-X
region	B-X
syntenic	B-X
with	B-X
the	B-X
locus	B-X
for	B-X
the	B-X
brachymorphic	B-X
mutation	B-X
on	B-X
mouse	B-X
chromosome	B-X
19	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
orthologous	B-X
genes	B-X
,	B-X
ATPSK2	B-X
and	B-X
Atpsk2	B-X
,	B-X
encoding	B-X
novel	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
orthologues	B-X
in	B-X
the	B-X
respective	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
genomes	B-X
.	B-X
We	B-X
characterized	B-X
a	B-X
nonsense	B-X
mutation	B-X
in	B-X
ATPSK2	B-X
in	B-X
the	B-X
SEMD	B-X
family	B-X
and	B-X
a	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
region	B-X
of	B-X
Atpsk2	B-X
encoding	B-X
the	B-X
APS	B-X
kinase	B-X
activity	B-X
in	B-X
the	B-X
brachymorphic	B-X
mouse	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

We	O
identified	O
two	O
orthologous	O
genes	O
,	O
ATPSK2	B-Protein
and	O
Atpsk2	B-Protein
,	O
encoding	O
novel	O
ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
orthologues	O
in	O
the	O
respective	O
regions	O
of	O
the	O
human	O
and	O
mouse	O
genomes	O
.	O
<EOS>	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
large	B-X
inbred	B-X
Pakistani	B-X
family	B-X
with	B-X
a	B-X
distinct	B-X
form	B-X
of	B-X
recessively	B-X
inherited	B-X
spondyloepimetaphyseal	B-X
dysplasia	B-X
(	B-X
SEMD	B-X
)	B-X
and	B-X
mapped	B-X
a	B-X
gene	B-X
associated	B-X
with	B-X
this	B-X
dwarfing	B-X
condition	B-X
to	B-X
chromosome	B-X
10q23-24	B-X
,	B-X
a	B-X
region	B-X
syntenic	B-X
with	B-X
the	B-X
locus	B-X
for	B-X
the	B-X
brachymorphic	B-X
mutation	B-X
on	B-X
mouse	B-X
chromosome	B-X
19	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
orthologous	B-X
genes	B-X
,	B-X
ATPSK2	B-X
and	B-X
Atpsk2	B-X
,	B-X
encoding	B-X
novel	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
orthologues	B-X
in	B-X
the	B-X
respective	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
genomes	B-X
.	B-X
We	B-X
characterized	B-X
a	B-X
nonsense	B-X
mutation	B-X
in	B-X
ATPSK2	B-X
in	B-X
the	B-X
SEMD	B-X
family	B-X
and	B-X
a	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
region	B-X
of	B-X
Atpsk2	B-X
encoding	B-X
the	B-X
APS	B-X
kinase	B-X
activity	B-X
in	B-X
the	B-X
brachymorphic	B-X
mouse	B-X
.	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
catalyses	B-X
the	B-X
metabolic	B-X
activation	B-X
of	B-X
inorganic	B-X
sulfate	B-X
to	B-X
PAPS	B-X
,	B-X
the	B-X
universal	B-X
donor	B-X
for	B-X
post-translational	B-X
protein	B-X
sulfation	B-X
in	B-X
all	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

We	O
characterized	O
a	O
nonsense	O
mutation	O
in	O
ATPSK2	B-Protein
in	O
the	O
SEMD	O
family	O
and	O
a	O
missense	O
mutation	O
in	O
the	O
region	O
of	O
Atpsk2	B-Protein
encoding	O
the	O
APS	O
kinase	O
activity	O
in	O
the	O
brachymorphic	O
mouse	O
.	O

ATP	O
sulfurylase	O
/	O
APS	O
kinase	O
catalyses	O
the	O
metabolic	O
activation	O
of	O
inorganic	O
sulfate	O
to	O
PAPS	O
,	O
the	O
universal	O
donor	O
for	O
post	O
-	O
translational	O
protein	O
sulfation	O
in	O
all	O
cell	O
types	O
.	O
<EOS>	B-X
We	B-X
identified	B-X
two	B-X
orthologous	B-X
genes	B-X
,	B-X
ATPSK2	B-X
and	B-X
Atpsk2	B-X
,	B-X
encoding	B-X
novel	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
orthologues	B-X
in	B-X
the	B-X
respective	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
genomes	B-X
.	B-X
We	B-X
characterized	B-X
a	B-X
nonsense	B-X
mutation	B-X
in	B-X
ATPSK2	B-X
in	B-X
the	B-X
SEMD	B-X
family	B-X
and	B-X
a	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
region	B-X
of	B-X
Atpsk2	B-X
encoding	B-X
the	B-X
APS	B-X
kinase	B-X
activity	B-X
in	B-X
the	B-X
brachymorphic	B-X
mouse	B-X
.	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
catalyses	B-X
the	B-X
metabolic	B-X
activation	B-X
of	B-X
inorganic	B-X
sulfate	B-X
to	B-X
PAPS	B-X
,	B-X
the	B-X
universal	B-X
donor	B-X
for	B-X
post-translational	B-X
protein	B-X
sulfation	B-X
in	B-X
all	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

The	O
cartilage	O
-	O
specificity	O
of	O
the	O
human	O
and	O
mouse	O
phenotypes	O
provides	O
further	O
evidence	O
of	O
the	O
critical	O
role	O
of	O
sulfate	O
activation	O
in	O
the	O
maturation	O
of	O
cartilage	O
extracellular	O
matrix	O
molecules	O
and	O
the	O
effect	O
of	O
defects	O
in	O
this	O
process	O
on	O
the	O
architecture	O
of	O
cartilage	O
and	O
skeletogenesis	O
.	O
<EOS>	B-X
The	B-X
osteochondrodysplasias	B-X
are	B-X
a	B-X
genetically	B-X
heterogeneous	B-X
group	B-X
of	B-X
disorders	B-X
affecting	B-X
skeletal	B-X
development	B-X
,	B-X
linear	B-X
growth	B-X
and	B-X
the	B-X
maintenance	B-X
of	B-X
cartilage	B-X
and	B-X
bone	B-X
.	B-X
We	B-X
have	B-X
studied	B-X
a	B-X
large	B-X
inbred	B-X
Pakistani	B-X
family	B-X
with	B-X
a	B-X
distinct	B-X
form	B-X
of	B-X
recessively	B-X
inherited	B-X
spondyloepimetaphyseal	B-X
dysplasia	B-X
(	B-X
SEMD	B-X
)	B-X
and	B-X
mapped	B-X
a	B-X
gene	B-X
associated	B-X
with	B-X
this	B-X
dwarfing	B-X
condition	B-X
to	B-X
chromosome	B-X
10q23-24	B-X
,	B-X
a	B-X
region	B-X
syntenic	B-X
with	B-X
the	B-X
locus	B-X
for	B-X
the	B-X
brachymorphic	B-X
mutation	B-X
on	B-X
mouse	B-X
chromosome	B-X
19	B-X
.	B-X
We	B-X
identified	B-X
two	B-X
orthologous	B-X
genes	B-X
,	B-X
ATPSK2	B-X
and	B-X
Atpsk2	B-X
,	B-X
encoding	B-X
novel	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
orthologues	B-X
in	B-X
the	B-X
respective	B-X
regions	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
genomes	B-X
.	B-X
We	B-X
characterized	B-X
a	B-X
nonsense	B-X
mutation	B-X
in	B-X
ATPSK2	B-X
in	B-X
the	B-X
SEMD	B-X
family	B-X
and	B-X
a	B-X
missense	B-X
mutation	B-X
in	B-X
the	B-X
region	B-X
of	B-X
Atpsk2	B-X
encoding	B-X
the	B-X
APS	B-X
kinase	B-X
activity	B-X
in	B-X
the	B-X
brachymorphic	B-X
mouse	B-X
.	B-X
ATP	B-X
sulfurylase/APS	B-X
kinase	B-X
catalyses	B-X
the	B-X
metabolic	B-X
activation	B-X
of	B-X
inorganic	B-X
sulfate	B-X
to	B-X
PAPS	B-X
,	B-X
the	B-X
universal	B-X
donor	B-X
for	B-X
post-translational	B-X
protein	B-X
sulfation	B-X
in	B-X
all	B-X
cell	B-X
types	B-X
.	B-X
The	B-X
cartilage-specificity	B-X
of	B-X
the	B-X
human	B-X
and	B-X
mouse	B-X
phenotypes	B-X
provides	B-X
further	B-X
evidence	B-X
of	B-X
the	B-X
critical	B-X
role	B-X
of	B-X
sulfate	B-X
activation	B-X
in	B-X
the	B-X
maturation	B-X
of	B-X
cartilage	B-X
extracellular	B-X
matrix	B-X
molecules	B-X
and	B-X
the	B-X
effect	B-X
of	B-X
defects	B-X
in	B-X
this	B-X
process	B-X
on	B-X
the	B-X
architecture	B-X
of	B-X
cartilage	B-X
and	B-X
skeletogenesis	B-X
.	B-X

Apoprotein	B-Protein
B100	I-Protein
has	O
a	O
prolonged	O
interaction	O
with	O
the	O
translocon	O
during	O
which	O
its	O
lipidation	O
and	O
translocation	O
change	O
from	O
dependence	O
on	O
the	O
microsomal	O
triglyceride	O
transfer	O
protein	O
to	O
independence	O
.	O

When	O
lipid	O
synthesis	O
is	O
limited	O
in	O
HepG2	O
cells	O
,	O
apoprotein	B-Protein
B100	I-Protein
(	O
apoB100	B-Protein
)	O
is	O
not	O
secreted	O
but	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
pathway	O
.	O
<EOS>	B-X
When	B-X
human	B-X
hepatoma	B-X
cells	B-X
(	B-X
HepG2	B-X
)	B-X
were	B-X
incubated	B-X
with	B-X
4	B-X
mM	B-X
homocysteine	B-X
,	B-X
enhancements	B-X
in	B-X
the	B-X
production	B-X
of	B-X
cholesterol	B-X
and	B-X
secretion	B-X
of	B-X
apolipoprotein	B-X
B-100	B-X
were	B-X
observed	B-X
.	B-X
The	B-X
stimulatory	B-X
effect	B-X
on	B-X
cholesterol	B-X
synthesis	B-X
was	B-X
mediated	B-X
via	B-X
the	B-X
enhancement	B-X
of	B-X
HMG-CoA	B-X
reductase	B-X
,	B-X
which	B-X
catalyzes	B-X
the	B-X
rate-limiting	B-X
step	B-X
in	B-X
cholesterol	B-X
biosynthesis	B-X
.	B-X

To	O
investigate	O
apoB100	B-Protein
biosynthesis	O
and	O
secretion	O
further	O
,	O
the	O
physical	O
and	O
functional	O
states	O
of	O
apoB100	B-Protein
destined	O
for	O
either	O
degradation	O
or	O
lipoprotein	O
assembly	O
were	O
studied	O
under	O
conditions	O
in	O
which	O
lipid	O
synthesis	O
,	O
proteasomal	O
activity	O
,	O
and	O
microsomal	O
triglyceride	O
transfer	O
protein	O
(	O
MTP	O
)	O
lipid	O
-	O
transfer	O
activity	O
were	O
varied	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
Cells	B-X
were	B-X
pretreated	B-X
with	B-X
a	B-X
proteasomal	B-X
inhibitor	B-X
(	B-X
which	B-X
remained	B-X
with	B-X
the	B-X
cells	B-X
throughout	B-X
the	B-X
experiment	B-X
)	B-X
and	B-X
radiolabeled	B-X
for	B-X
15	B-X
min	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
seems	B-X
to	B-X
be	B-X
necessary	B-X
only	B-X
for	B-X
early	B-X
translocation	B-X
and	B-X
lipidation	B-X
events	B-X
.	B-X

Cells	O
were	O
pretreated	O
with	O
a	O
proteasomal	O
inhibitor	O
(	O
which	O
remained	O
with	O
the	O
cells	O
throughout	O
the	O
experiment	O
)	O
and	O
radiolabeled	O
for	O
15	O
min	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
Cells	B-X
were	B-X
pretreated	B-X
with	B-X
a	B-X
proteasomal	B-X
inhibitor	B-X
(	B-X
which	B-X
remained	B-X
with	B-X
the	B-X
cells	B-X
throughout	B-X
the	B-X
experiment	B-X
)	B-X
and	B-X
radiolabeled	B-X
for	B-X
15	B-X
min	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X

During	O
the	O
chase	O
period	O
,	O
labeled	O
apoB100	B-Protein
remained	O
associated	O
with	O
the	O
microsomes	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
Cells	B-X
were	B-X
pretreated	B-X
with	B-X
a	B-X
proteasomal	B-X
inhibitor	B-X
(	B-X
which	B-X
remained	B-X
with	B-X
the	B-X
cells	B-X
throughout	B-X
the	B-X
experiment	B-X
)	B-X
and	B-X
radiolabeled	B-X
for	B-X
15	B-X
min	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X

Furthermore	O
,	O
by	O
crosslinking	O
sec61beta	B-Protein
to	O
apoB100	B-Protein
,	O
we	O
showed	O
that	O
apoB100	B-Protein
remained	O
close	O
to	O
the	O
translocon	O
at	O
the	O
same	O
time	O
apoB100	B-Protein
-	O
ubiquitin	B-Protein
conjugates	O
could	O
be	O
detected	O
.	O

When	O
lipid	O
synthesis	O
and	O
lipoprotein	O
assembly	O
/	O
secretion	O
were	O
stimulated	O
by	O
adding	O
oleic	O
acid	O
(	O
OA	O
)	O
to	O
the	O
chase	O
medium	O
,	O
apoB100	B-Protein
was	O
deubiquitinated	O
,	O
and	O
its	O
interaction	O
with	O
sec61beta	B-Protein
was	O
disrupted	O
,	O
signifying	O
completion	O
of	O
translocation	O
concomitant	O
with	O
the	O
formation	O
of	O
lipoprotein	O
particles	O
.	O

MTP	O
participates	O
in	O
apoB100	B-Protein
translocation	O
and	O
lipoprotein	O
assembly	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
seems	B-X
to	B-X
be	B-X
necessary	B-X
only	B-X
for	B-X
early	B-X
translocation	B-X
and	B-X
lipidation	B-X
events	B-X
.	B-X

In	O
the	O
presence	O
of	O
OA	O
,	O
when	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
was	O
inhibited	O
at	O
the	O
end	O
of	O
pulse	O
labeling	O
,	O
apoB100	B-Protein
secretion	O
was	O
abolished	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
seems	B-X
to	B-X
be	B-X
necessary	B-X
only	B-X
for	B-X
early	B-X
translocation	B-X
and	B-X
lipidation	B-X
events	B-X
.	B-X

In	O
contrast	O
,	O
when	O
the	O
labeled	O
apoB100	B-Protein
was	O
allowed	O
to	O
accumulate	O
in	O
the	O
cell	O
for	O
60	O
min	O
before	O
adding	O
OA	O
and	O
the	O
inhibitor	O
,	O
apoB100	B-Protein
lipidation	O
and	O
secretion	O
were	O
no	O
longer	O
impaired	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
Cells	B-X
were	B-X
pretreated	B-X
with	B-X
a	B-X
proteasomal	B-X
inhibitor	B-X
(	B-X
which	B-X
remained	B-X
with	B-X
the	B-X
cells	B-X
throughout	B-X
the	B-X
experiment	B-X
)	B-X
and	B-X
radiolabeled	B-X
for	B-X
15	B-X
min	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X
Furthermore	B-X
,	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
seems	B-X
to	B-X
be	B-X
necessary	B-X
only	B-X
for	B-X
early	B-X
translocation	B-X
and	B-X
lipidation	B-X
events	B-X
.	B-X

Overall	O
,	O
the	O
data	O
imply	O
that	O
during	O
most	O
of	O
its	O
association	O
with	O
the	O
endoplasmic	O
reticulum	O
,	O
apoB100	B-Protein
is	O
close	O
to	O
or	O
within	O
the	O
translocon	O
and	O
is	O
accessible	O
to	O
both	O
the	O
ubiquitin	B-Protein
-	O
proteasome	O
and	O
lipoprotein	O
-	O
assembly	O
pathways	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
During	B-X
the	B-X
chase	B-X
period	B-X
,	B-X
labeled	B-X
apoB100	B-X
remained	B-X
associated	B-X
with	B-X
the	B-X
microsomes	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Overall	B-X
,	B-X
the	B-X
data	B-X
imply	B-X
that	B-X
during	B-X
most	B-X
of	B-X
its	B-X
association	B-X
with	B-X
the	B-X
endoplasmic	B-X
reticulum	B-X
,	B-X
apoB100	B-X
is	B-X
close	B-X
to	B-X
or	B-X
within	B-X
the	B-X
translocon	B-X
and	B-X
is	B-X
accessible	B-X
to	B-X
both	B-X
the	B-X
ubiquitin-proteasome	B-X
and	B-X
lipoprotein-assembly	B-X
pathways	B-X
.	B-X

Furthermore	O
,	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
seems	O
to	O
be	O
necessary	O
only	O
for	O
early	O
translocation	O
and	O
lipidation	O
events	O
.	O
<EOS>	B-X
When	B-X
lipid	B-X
synthesis	B-X
is	B-X
limited	B-X
in	B-X
HepG2	B-X
cells	B-X
,	B-X
apoprotein	B-X
B100	B-X
(	B-X
apoB100	B-X
)	B-X
is	B-X
not	B-X
secreted	B-X
but	B-X
rapidly	B-X
degraded	B-X
by	B-X
the	B-X
ubiquitin-proteasome	B-X
pathway	B-X
.	B-X
To	B-X
investigate	B-X
apoB100	B-X
biosynthesis	B-X
and	B-X
secretion	B-X
further	B-X
,	B-X
the	B-X
physical	B-X
and	B-X
functional	B-X
states	B-X
of	B-X
apoB100	B-X
destined	B-X
for	B-X
either	B-X
degradation	B-X
or	B-X
lipoprotein	B-X
assembly	B-X
were	B-X
studied	B-X
under	B-X
conditions	B-X
in	B-X
which	B-X
lipid	B-X
synthesis	B-X
,	B-X
proteasomal	B-X
activity	B-X
,	B-X
and	B-X
microsomal	B-X
triglyceride	B-X
transfer	B-X
protein	B-X
(	B-X
MTP	B-X
)	B-X
lipid-transfer	B-X
activity	B-X
were	B-X
varied	B-X
.	B-X
Furthermore	B-X
,	B-X
by	B-X
crosslinking	B-X
sec61beta	B-X
to	B-X
apoB100	B-X
,	B-X
we	B-X
showed	B-X
that	B-X
apoB100	B-X
remained	B-X
close	B-X
to	B-X
the	B-X
translocon	B-X
at	B-X
the	B-X
same	B-X
time	B-X
apoB100-ubiquitin	B-X
conjugates	B-X
could	B-X
be	B-X
detected	B-X
.	B-X
When	B-X
lipid	B-X
synthesis	B-X
and	B-X
lipoprotein	B-X
assembly/secretion	B-X
were	B-X
stimulated	B-X
by	B-X
adding	B-X
oleic	B-X
acid	B-X
(	B-X
OA	B-X
)	B-X
to	B-X
the	B-X
chase	B-X
medium	B-X
,	B-X
apoB100	B-X
was	B-X
deubiquitinated	B-X
,	B-X
and	B-X
its	B-X
interaction	B-X
with	B-X
sec61beta	B-X
was	B-X
disrupted	B-X
,	B-X
signifying	B-X
completion	B-X
of	B-X
translocation	B-X
concomitant	B-X
with	B-X
the	B-X
formation	B-X
of	B-X
lipoprotein	B-X
particles	B-X
.	B-X
MTP	B-X
participates	B-X
in	B-X
apoB100	B-X
translocation	B-X
and	B-X
lipoprotein	B-X
assembly	B-X
.	B-X
In	B-X
the	B-X
presence	B-X
of	B-X
OA	B-X
,	B-X
when	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
was	B-X
inhibited	B-X
at	B-X
the	B-X
end	B-X
of	B-X
pulse	B-X
labeling	B-X
,	B-X
apoB100	B-X
secretion	B-X
was	B-X
abolished	B-X
.	B-X
In	B-X
contrast	B-X
,	B-X
when	B-X
the	B-X
labeled	B-X
apoB100	B-X
was	B-X
allowed	B-X
to	B-X
accumulate	B-X
in	B-X
the	B-X
cell	B-X
for	B-X
60	B-X
min	B-X
before	B-X
adding	B-X
OA	B-X
and	B-X
the	B-X
inhibitor	B-X
,	B-X
apoB100	B-X
lipidation	B-X
and	B-X
secretion	B-X
were	B-X
no	B-X
longer	B-X
impaired	B-X
.	B-X
Furthermore	B-X
,	B-X
MTP	B-X
lipid-transfer	B-X
activity	B-X
seems	B-X
to	B-X
be	B-X
necessary	B-X
only	B-X
for	B-X
early	B-X
translocation	B-X
and	B-X
lipidation	B-X
events	B-X
.	B-X

